PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Amieux, PS; Cummings, DE; Motamed, K; Brandon, EP; Wailes, LA; Le, K; Idzerda, RL; McKnight, GS				Amieux, PS; Cummings, DE; Motamed, K; Brandon, EP; Wailes, LA; Le, K; Idzerda, RL; McKnight, GS			Compensatory regulation of RI alpha protein levels in protein kinase A mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CYCLIC-AMP; CELLS; EXPRESSION; DIFFERENTIATION; MONOPHOSPHATE; TISSUES; BINDING; BRAIN	The cAMP-dependent protein kinase holoenzyme is assembled from regulatory (R) and catalytic (C) subunits that are expressed in tissue-specific patterns, Despite the dispersion of the R and C subunit genes to different chromosomal loci, mechanisms exist that coordinately regulate the intracellular levels of R and C protein such that cAMP-dependent regulation is preserved, We have created null mutations in the RI beta and RII beta regulatory subunit genes in mice, and find that both result in an increase in the level of RI alpha protein in tissues that normally express the beta isoforms. Examination of RI alpha mRNA levels and the rates of RI alpha protein synthesis in wild type and RII beta mutant mice reveals that the mechanism of this biochemical compensation by RI alpha does not involve transcriptional or translational control, These in vivo findings are consistent with observations made in cell culture, where we demonstrate that the overexpression of C alpha in NIH 3T3 cells results in increased RI alpha protein without increases in the rate of RI alpha synthesis or the level of RI alpha mRNA. Pulse-chase experiments reveal a 4-5-fold increase in the half-life of RI alpha protein as it becomes incorporated into the holoenzyme, Compensation by RI alpha stabilization may represent an important biological mechanism that safeguards cells hom unregulated catalytic subunit activity.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Amieux, Paul/AAG-4102-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIEUX PS, UNPUB; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BUSS JE, 1979, J CYCLIC NUCL PROT, V5, P225; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORBIN JD, 1975, J BIOL CHEM, V250, P218; CORBIN JD, 1977, J BIOL CHEM, V252, P910; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DOSKELAND SO, 1977, BIOCHEM J, V165, P561, DOI 10.1042/bj1650561; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; LIU AYC, 1982, J BIOL CHEM, V257, P298; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; RICHARDS JS, 1980, J BIOL CHEM, V255, P5481; ROGERS JE, 1985, J BIOL CHEM, V260, P8002; ROGERS KV, 1992, MOL ENDOCRINOL, V6, P1756, DOI 10.1210/me.6.10.1756; SANBORN BM, 1973, J BIOL CHEM, V248, P4713; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCHWECHHEIMER K, 1977, J BIOL CHEM, V252, P7690; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202	28	191	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3993	3998		10.1074/jbc.272.7.3993	http://dx.doi.org/10.1074/jbc.272.7.3993			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020105	hybrid			2022-12-25	WOS:A1997WH01900021
J	Sharma, J; Panico, M; Barber, J; Morris, HR				Sharma, J; Panico, M; Barber, J; Morris, HR			Characterization of the low molecular weight photosystem II reaction center subunits and their light-induced modifications by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; NUCLEOTIDE-SEQUENCE; CHLOROPLAST GENOME; SINGLET OXYGEN; ALPHA-SUBUNIT; PHOTOINHIBITION; PROTEIN; CYTOCHROME-B-559; POLYPEPTIDES; DEGRADATION	A sensitive and simple reverse phase HPLC purification scheme was developed for the rapid separation of the small protein subunits hom photosystem II reaction center preparations, The precise molecular masses of the alpha- and beta-subunits of cytochrome b(559) and the psbI gene product from pea plants, found to be 4394.6 +/- 0.6, 9283.6 +/- 0.7, and 4209.5 +/- 0.5 Da, respectively, were then successfully determined for the first time by electrospray- and fast atom bombardment-mass spectrometry, Discrepancies between the molecular weights assigned and those calculated from the respective DNA sequences were observed for alpha- and beta-subunits of cytochrome b(559). Currently, the nucleotide sequence of the psbI gene product from pea plants is not available. Application of novel mapping and sequencing strategies has assured the elucidation of full primary structures of all of the purified subunits, The modifications identified here include the post-translational processing of the initiating methionine on both subunits of cytochrome b(559), NH2-terminal acetylation and an mRNA editing site at residue 26 (Ser --> Phe) on the beta-subunit, and retention of the NH2-terminal formyl-Met on the psbI gene product. In addition, specific oxidation of a single amino acid residue was identified on the psbI gene product and the beta-subunit purified from Light-treated reaction center preparations, Overall, these studies provide the first detailed primary structural characterization of the small subunits of the reaction center complex and their associated light-induced modifications.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, WOLFSON LABS, LONDON SW7 2AY, ENGLAND	Imperial College London			choudhary, jyoti/S-1232-2017	choudhary, jyoti/0000-0003-0881-5477	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSSON B, 1992, MOL MECHANISMS BIOEN, P121; BARBATO R, 1995, J BIOL CHEM, V270, P24032, DOI 10.1074/jbc.270.41.24032; BARBATO R, 1992, FEBS LETT, V309, P165, DOI 10.1016/0014-5793(92)81087-3; BLEIS J, 1993, CURR OPIN CELL BIOL, V5, P984; BOCK R, 1993, MOL GEN GENET, V240, P238, DOI 10.1007/BF00277062; BOCK R, 1994, EMBO J, V13, P4623, DOI 10.1002/j.1460-2075.1994.tb06784.x; CHAPMAN DJ, 1991, BIOCHIM BIOPHYS ACTA, V1057, P391, DOI 10.1016/S0005-2728(05)80153-7; CHAPMAN DJ, 1990, METHODS PLANT BIOCH, V5, P171; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DELASRIVAS J, 1992, FEBS LETT, V301, P246, DOI 10.1016/0014-5793(92)80250-K; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; FINDLAY JBC, 1989, PROTEIN SEQUENCING P, P68; HOWE CJ, 1988, CURR GENET, V13, P343, DOI 10.1007/BF00424430; IKEUCHI M, 1988, FEBS LETT, V241, P99, DOI 10.1016/0014-5793(88)81039-1; IRRGANG KD, 1995, J BIOL CHEM, V270, P17588, DOI 10.1074/jbc.270.29.17588; KUNSTNER P, 1995, J BIOL CHEM, V270, P9651; MACPHERSON AN, 1993, BIOCHIM BIOPHYS ACTA, V1143, P301, DOI 10.1016/0005-2728(93)90201-P; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MORRIS HR, 1981, BIOCHEM BIOPH RES CO, V101, P623, DOI 10.1016/0006-291X(81)91304-8; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NEUHAUS H, 1990, NUCLEIC ACIDS RES, V18, P368, DOI 10.1093/nar/18.2.368; RIVAS JD, 1993, BIOCHEMISTRY-US, V32, P6944, DOI 10.1021/bi00078a019; RUTHERFORD AW, 1981, BIOCHIM BIOPHYS ACTA, V635, P205, DOI 10.1016/0005-2728(81)90020-7; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; SUGINO Y, 1980, J BIOCHEM-TOKYO, V87, P351, DOI 10.1093/oxfordjournals.jbchem.a132746; TELFER A, 1994, J BIOL CHEM, V269, P13244; TELFER A, 1989, FEBS LETT, V246, P223, DOI 10.1016/0014-5793(89)80287-X; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; WEBBER AN, 1989, FEBS LETT, V242, P259, DOI 10.1016/0014-5793(89)80481-8; WILLEY DL, 1989, CURR GENET, V15, P213, DOI 10.1007/BF00435508; WOLD F, 1981, ANNU REV BIOCHEM, V50, P783, DOI 10.1146/annurev.bi.50.070181.004031	36	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3935	3943		10.1074/jbc.272.7.3935	http://dx.doi.org/10.1074/jbc.272.7.3935			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020097	hybrid			2022-12-25	WOS:A1997WH01900013
J	Stancato, LF; Silverstein, AM; OwensGrillo, JK; Chow, YH; Jove, R; Pratt, WB				Stancato, LF; Silverstein, AM; OwensGrillo, JK; Chow, YH; Jove, R; Pratt, WB			The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of raf kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; VIRUS TRANSFORMING PROTEIN; GLUCOCORTICOID RECEPTOR; SERINE PHOSPHORYLATION; CELLULAR PROTEINS; STEROID-RECEPTOR; IN-VITRO; TYROSINE; HSP90; HETEROCOMPLEX	We have expressed the mitogenic signaling proteins Src, Pus, Raf-l, Mek (MAP kinase kinase), and Erk (MAP kinase) in baculovirus-infected Sf9 insect cells in order to study a potential role for the chaperone hsp90 in formation of multiprotein complexes. One such complex obtained by immunoadsorption with anti-Pas antibody of cytosol prepared fi om cells simultaneously expressing Pas, Raf, Mek, and Erk contained Pas, Raf, and Erk. To detect directly the protein-protein interactions involved in forming multiprotein complexes, we combined cytosols from single infections in vitro in all possible combinations of protein pairs, We detected complexes between Ras Raf, Ras Src, Raf Mek, and Raf Src, but no complex containing Erk was obtained by mixing cytosols. Thus, cellular factors appear to be required for assembly of the Erk-containing multiprotein complex, One cellular factor thought to be involved in signaling protein complex formation is the chaperone hsp90, and we show that Src, Raf, and Mek are each complexed with insect hsp90. Treatment of Sf9 cells with geldanamycin, a benzoquinone ansamycin that binds to hsp90 and disrupts its function, did not decrease coadsorption of either Raf or Erk with Pas, although it did decrease the level of cytosolic Raf. To study geldanamycin action, we treated rat 3Y1 fibroblasts expressing v-Raf and showed that the antibiotic blocked assembly of Raf-hsp90 complexes at an intermediate stage of assembly where Raf is still bound to the p60 and hsp70 components of the assembly mechanism. As in Sf9 cells, Raf levels decline with geldanamycin treatment of 3Y1 cells. To determine if geldanamycin affects mitogenic response, we treated HeLa cells with epidermal growth factor (EGF) and showed that geldanamycin treatment decreased EGF signaling and decreased the level of Raf protein without affecting the EGF-mediated increase in Raf kinase activity. We conclude that hsp90 is not required for forming complexes between the mitogenic signaling proteins or for Raf kinase activity and that EGF signaling is decreased indirectly by geldanamycin because the antibiotic increases degradation of Raf and perhaps other components of the signaling pathway.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; MOFFITT CANC CTR,MOL ONCOL PROGRAM,TAMPA,FL 33612	University of Michigan System; University of Michigan; H Lee Moffitt Cancer Center & Research Institute					NATIONAL CANCER INSTITUTE [R01CA055652, R01CA028010] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL S, 1995, ONCOGENE, V11, P427; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CHOW YH, 1995, J BIOL CHEM, V270, P14100, DOI 10.1074/jbc.270.23.14100; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ERHART JC, 1988, ONCOGENE, V3, P595; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; PARK S, 1992, J BIOL CHEM, V267, P11612; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; STANCATO LF, 1994, J BIOL CHEM, V269, P22157; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITESELL L, 1992, CANCER RES, V52, P1721; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	44	180	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4013	4020		10.1074/jbc.272.7.4013	http://dx.doi.org/10.1074/jbc.272.7.4013			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020108	hybrid			2022-12-25	WOS:A1997WH01900024
J	Balkovetz, DF; Pollack, AL; Mostov, KE				Balkovetz, DF; Pollack, AL; Mostov, KE			Hepatocyte growth factor alters the polarity of Madin-Darby canine kidney cell monolayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; BETA-CATENIN; E-CADHERIN; ADHESION MOLECULE; EPITHELIAL-CELLS; TIGHT JUNCTION; SCATTER FACTOR; ALPHA-CATENIN; COMPLEX; PROTEIN	Hepatocyte growth factor (HGF) and E-cadherin are important for epithelial morphogenetic events. We examined the effects of HGF on E-cadherin localization and interaction with beta-catenin in polarized Madin-Darby canine kidney (MDCK) cell monolayers grown on filters. Surface biotinylation experiments showed that HGF increases apically accessible E-cadherin. Confocal immunofluorescence microscopy of HGF-treated cells showed localization of E-cadherin at membrane domains contacting the apical compartment and an increase in accessibility of apically applied antibodies to lateral E-cadherin below the tight junction. Coimmunoprecipitation of beta-catenin/E-cadherin complexes showed that the amount of E-cadherin associated with beta-catenin increased during the first 24 h of HGF treatment with a return to baseline values after 48 and 72 h. Metabolic labeling showed that HGF increased the synthetic rate of beta-catenin and the amount of newly synthesized E-cadherin associated with immunoprecipitated beta-catenin, with the peak effect occurring after 12 h of treatment and returning to baseline after 24 h. HGF treatment inhibited transcytosis of immunoglobulin A by the polymeric immunoglobulin receptor. We conclude that HGF treatment of polarized MDCK cells grown on filters decreases cell polarity and alters E-cadherin/beta-catenin interaction and synthesis.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco				mostov, keith/0000-0002-8123-6247	NIAID NIH HHS [R01 AI 36953, R01 AI25144] Funding Source: Medline; NIDDK NIH HHS [5-T32-DK07219] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144, R01AI036953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007219] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; APODACA G, 1991, J CLIN INVEST, V87, P1877, DOI 10.1172/JCI115211; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; CARONE FA, 1995, KIDNEY INT, V47, P861, DOI 10.1038/ki.1995.129; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; FISH EM, 1994, NEW ENGL J MED, V330, P1580; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUMBINER BM, 1993, J CELL SCI, P155; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; MATSUMOTO K, 1994, GANN MONOGR, V42, P91; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKEICHI M, 1989, CIBA F SYMP, V144, P243; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZURZOLO C, 1992, EMBO J, V11, P2337, DOI 10.1002/j.1460-2075.1992.tb05293.x	35	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3471	3477		10.1074/jbc.272.6.3471	http://dx.doi.org/10.1074/jbc.272.6.3471			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013593	hybrid			2022-12-25	WOS:A1997WG19200053
J	Wu, CB; Butz, S; Ying, YS; Anderson, RGW				Wu, CB; Butz, S; Ying, YS; Anderson, RGW			Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRION PROTEIN; INTERNALIZATION; FAMILY; CELLS; EPH; LOCALIZATION; ENDOCYTOSIS; MOLECULES; PATHWAY; COMPLEX	Recent evidence suggests that tyrosine kinases are highly organized in caveolae of tissue culture cells. We now report the isolation of a membrane domain from neuronal plasma membranes that has the biochemical characteristics of caveolae. A low density membrane (LDM) fraction with the same density as caveolae was highly enriched in tyrosine kinases such as insulin receptors, neurotrophin receptors, Eph family receptors, and Fyn. Grb2, Ras, heterotrimeric GTP-binding proteins, and Erk2 were also concentrated in the LDM. Incubation of the LDM fraction at 37 degrees C stimulated the phosphorylation on tyrosine of multiple, resident proteins, whereas the bulk membrane fraction was devoid of tyrosine kinase activity. The LDM, which makes up similar to 5-10% of the plasma membrane protein, appears to be organized for signal transduction.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DEPT MOL GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; ECONOMIDES AN, 1995, SCIENCE, V270, P1351, DOI 10.1126/science.270.5240.1351; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LIU P, 1995, J BIOL CHEM, V45, P27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MCDONALD NQ, 1995, J BIOL CHEM, V270, P19669, DOI 10.1074/jbc.270.34.19669; Mineo C, 1996, EXP CELL RES, V224, P237, DOI 10.1006/excr.1996.0133; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVE S, 1995, J NEUROCHEM, V65, P2307; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; POULOS AC, 1986, J ULTRA MOL STRUCT R, V96, P114, DOI 10.1016/0889-1605(86)90012-1; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RITTER TE, 1995, P NATL ACAD SCI USA, V92, P3824, DOI 10.1073/pnas.92.9.3824; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SEVERS NJ, 1983, BIOCHIM BIOPHYS ACTA, V737, P373, DOI 10.1016/0304-4157(83)90007-2; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1972, J CELL BIOL, V53, P365, DOI 10.1083/jcb.53.2.365; SIMIONESCU N, 1983, PHYSIOL REV, V63, P1536, DOI 10.1152/physrev.1983.63.4.1536; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; STAHL N, 1994, BRAZ J MED BIOL RES, V27, P297; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; WANG T, 1995, J NEUROSCI, V15, P4796; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065; ZAMORA AJ, 1984, NEUROSCIENCE, V13, P105, DOI 10.1016/0306-4522(84)90263-X	56	225	229	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3554	3559		10.1074/jbc.272.6.3554	http://dx.doi.org/10.1074/jbc.272.6.3554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013605	hybrid			2022-12-25	WOS:A1997WG19200065
J	Kaneko, Y; Nishiyama, H; Nonoguchi, K; Higashitsuji, H; Kishishita, M; Fujita, J				Kaneko, Y; Nishiyama, H; Nonoguchi, K; Higashitsuji, H; Kishishita, M; Fujita, J			A novel hsp110-related gene, apg-1, that is abundantly expressed in the testis responds to a low temperature heat shock rather than the traditional elevated temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HSP70 GENE; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; GERM-CELLS; PROTEIN; IDENTIFICATION; BINDING; CONFORMATION; SEQUENCE; INVITRO	We isolated a novel hsp110-related gene, apg-1, from a testis cDNA library. The apg-1 transcripts were constitutively expressed in the testicular germ cells and, in some degree, most tissues examined. In a mouse TAMA26 Sertoli cell line, apg-1 transcripts were induced in 2 h by a temperature shift from 32 to 39 degrees C, but not by a shift from 37 to 42 degrees C, the traditional heat stress, or a shift from 32 to 42 degrees C. The heat response pattern of hsp110 expression was similar to that of apg-1. Although induction of a hsp70 transcript was observed in 2 h by a shift from 32 to 39 degrees C, the induction was more apparent by a shift from 37 to 42 degrees C or from 32 to 42 degrees C. Essentially similar differential response patterns were observed among these genes in NIH/3T3 fibroblasts as well. The nuclear run-on assay and the native gel mobility shift assay demonstrated that, by the 32 to 39 degrees C temperature shift, the apg-1 gene was transcriptionally activated, and heat shock factor 1 bound to the heat shock elements in the 5'-flanking region of the apg-1 gene. These results demonstrated that expressions of apg-1, hsp110, and hsp70 could be heat-induced at a temperature lower than the traditional elevated temperatures in somatic cells of both testis and nontestis origin and suggest that the mechanisms regulating the transcript levels of apg-1 and hsp110 are different from those of hsp70. Furthermore, the constitutive expression in germ cells suggests that APG-1 plays a specific role in spermatogenesis as well as in stress response.	KYOTO UNIV, FAC MED, DEPT CLIN MOL BIOL, SAKYO KU, KYOTO 606, JAPAN	Kyoto University								ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; COHEN RS, 1985, CELL, V43, P737, DOI 10.1016/0092-8674(85)90247-8; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; FATHALLAH DM, 1993, J IMMUNOL, V151, P810; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; FUJITA J, 1983, JPN J CANCER RES, V74, P334; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARRISON RG, 1948, J PHYSIOL-LONDON, V107, pP48; HAY R, 1992, ATCC CELL LINES HYBR; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGUCHI T, 1995, ENDOCRINOLOGY, V136, P4973, DOI 10.1210/en.136.11.4973; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KANEKO Y, 1995, ONCOGENE, V10, P945; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KIM DH, 1995, P NATL ACAD SCI USA, V92, P2126, DOI 10.1073/pnas.92.6.2126; KOTHARY R, 1989, DEVELOPMENT, V105, P707; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIU RY, 1993, P NATL ACAD SCI USA, V90, P3078, DOI 10.1073/pnas.90.7.3078; MARUYAMA K, 1994, GENE, V138, P171; MATSUMOTO M, 1990, BIOCHEM BIOPH RES CO, V166, P43, DOI 10.1016/0006-291X(90)91909-C; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEINHARDT A, 1995, BIOL REPROD, V52, P798, DOI 10.1095/biolreprod52.4.798; Moore C. R., 1923, ANAT REC, V26, P344; OHSAKO S, 1995, J HISTOCHEM CYTOCHEM, V43, P67, DOI 10.1177/43.1.7822767; PELHAM H, 1985, TRENDS GENET, V1, P31, DOI 10.1016/0168-9525(85)90012-5; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SARGE KD, 1995, J BIOL CHEM, V270, P18745, DOI 10.1074/jbc.270.32.18745; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SUBJECK JR, 1983, J CELL BIOL, V97, P1389, DOI 10.1083/jcb.97.5.1389; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YASUDA K, 1995, J BIOL CHEM, V270, P29718, DOI 10.1074/jbc.270.50.29718; ZAKERI ZF, 1988, MOL CELL BIOL, V8, P2925, DOI 10.1128/MCB.8.7.2925	47	65	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2640	2645		10.1074/jbc.272.5.2640	http://dx.doi.org/10.1074/jbc.272.5.2640			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006898	hybrid			2022-12-25	WOS:A1997WE66700011
J	Gibbs, E; Kelman, Z; Gulbis, JM; ODonnell, M; Kuriyan, J; Burgers, PMJ; Hurwitz, J				Gibbs, E; Kelman, Z; Gulbis, JM; ODonnell, M; Kuriyan, J; Burgers, PMJ; Hurwitz, J			The influence of the proliferating cell nuclear antigen-interacting domain of p21(CIP1) on DNA synthesis catalyzed by the human and Saccharomyces cerevisiae polymerase delta holoenzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; NUCLEOTIDE EXCISION-REPAIR; CYCLIN-DEPENDENT KINASES; REPLICATION FACTOR-C; ESCHERICHIA-COLI; INVITRO REPLICATION; SV40 ORIGIN; INHIBITOR; PROTEIN; P21	In eukaryotes, processive DNA synthesis catalyzed by DNA polymerases delta and epsilon (pol delta and epsilon) requires the proliferating cell nuclear antigen (PCNA). It has recently been shown that in humans (h), the PCNA function, required for both DNA replication and nucleotide excision repair, can be inactivated by p21(CIP1) due to a specific interaction between hPCNA and the carboxyl terminus of p21(CIP1). I,this report, we show that Saccharomyces cerevisiae (S. cerevisiae) PCNA-dependent pol delta-catalyzed DNA synthesis was inhibited less efficiently than the human system by the intact p21(CIP1) protein and was unaffected by the p21(CIP1) carboxyl-terminal peptide (codons 139-160). This species-specific response of PCNA to p21(CIP1)-mediated inhibition of DNA synthesis results from a marked difference in the ability of h and S. cerevisiae PCNA to interact with p21(CIP1). AS shown by binding studies using the surface plasmon resonance technique, hPCNA hinds both full-length p21(CIP1) and the p21(CIP1) peptide-(139-160) stoichiometrically with a similar affinity (K-D similar to 2.5 nM) while S. cerevisiae PCNA binds p21(CIP1) with similar to 10-fold less affinity and does not interact with the p21(CIP1) peptide-(139-160).	CORNELL UNIV MED COLL,HOWARD HUGHES MED INST,DEPT MICROBIOL,NEW YORK,NY; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,LAB MOL BIOPHYS,NEW YORK,NY 10021; WASHINGTON UNIV,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Cornell University; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Rockefeller University; Washington University (WUSTL)	Gibbs, E (corresponding author), MEM SLOAN KETTERING CANC CTR,GRAD PROGRAM MOL BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.		Burgers, Peter M/AAW-6621-2021		NIGMS NIH HHS [GM-32431, R01 GM032431, GM-38839, GM-38559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431, R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amin NS, 1996, GENETICS, V144, P479; BAUER GA, 1988, J BIOL CHEM, V263, P917; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARPER JW, 1993, CELL, V75, P805; HERENDEEN RH, 1996, CELL, V84, P5; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Roos G, 1996, EXP CELL RES, V226, P208, DOI 10.1006/excr.1996.0220; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	46	52	52	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2373	2381						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999948				2022-12-25	WOS:A1997WD67900054
J	Tan, Z; Bruzik, KS; Shears, SB				Tan, Z; Bruzik, KS; Shears, SB			Properties of the inositol 3,4,5,6-tetrakisphosphate 1-kinase purified from rat liver - Regulation of enzyme activity by inositol 1,3,4-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACINAR-CELLS; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; CHLORIDE SECRETION; T84 CELLS; CALCIUM; 1,4,5,6-TETRAKISPHOSPHATE; 1,3,4,6-TETRAKISPHOSPHATE; POLYPHOSPHATES; PHOSPHATES; SIGNALS	Inositol 3,4,5,6-tetrakisphosphate is a novel intracellular signal that regulates calcium-dependent chloride conductance (Xie, W., Kaetzel, M. A., Bruzik, H. S., Dedman, J. R., Shears, S. B., and Nelson, D. J. (1996) J. Biol. Chem. 271, 14092-14097). The molecular mechanisms that regulate the cellular levels of this signal are not characterized. To pursue this problem we have now studied the 1-kinase that deactivates inositol 3,4,5,6-tetrakisphosphate. The enzyme was purified from rat liver 1600-fold with a 1% yield. The native molecular mass was determined to be 46 kDa by gel filtration. The K-m values for inositol 3,4,5,6-tetrakisphosphate and ATP were 0.3 and 10.6 mu M, respectively. The kinase was unaffected by either protein kinase A or protein kinase C. Increases in Ca2+ concentration from 0.1 to 1-2 mu M inhibited activity by 10-20%. Most importantly, inositol 1,3,4-trisphosphate was shown to be a potent (K-i = 0.2 mu M), specific, and competitive inhibitor of the 1-kinase. Our new kinetic data show that typical receptor-dependent adjustments in cellular levels of inositol 1,3,4-trisphosphate provide a mechanism by which the concentration of inositol 3,4,5,6-tetrakisphosphate is dependent on changes in phospholipase C activity. These conclusions also provide a new perspective to our understanding of the physiological importance of the pathway of inositol phosphate turnover initiated by the inositol 1,4,5-trisphosphate 3-kinase.	NIEHS,LAB SIGNAL TRANSDUCT,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709; UNIV ILLINOIS,COLL PHARM,DEPT MED CHEM & PHARMACOGNOSY MC781,CHICAGO,IL 60612	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916				BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; HO MWY, 1997, IN PRESS AM J PHYSL; Hughes P J, 1993, Curr Opin Neurobiol, V3, P383, DOI 10.1016/0959-4388(93)90132-I; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; KORN SJ, 1991, J PHYSIOL-LONDON, V439, P423, DOI 10.1113/jphysiol.1991.sp018674; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SOBOLL S, 1978, EUR J BIOCHEM, V113, P429; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1988, BIOCHEM J, V249, P283, DOI 10.1042/bj2490283; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092	26	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2285	2290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999935				2022-12-25	WOS:A1997WD67900041
J	Lavie, Y; Cao, HT; Volner, A; Lucci, A; Han, TY; Geffen, V; Giuliano, AE; Cabot, MC				Lavie, Y; Cao, HT; Volner, A; Lucci, A; Han, TY; Geffen, V; Giuliano, AE; Cabot, MC			Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; P-GLYCOPROTEIN; GLUCOSYLCERAMIDE SYNTHASE; BREAST-CANCER; DAUNORUBICIN RESISTANCE; SPHINGOLIPID SYNTHESIS; TUMOR PROGRESSION; LIPID-COMPOSITION; PLASMA-MEMBRANE; ACCUMULATION	We have previously shown that multidrug-resistant cancer cells display elevated levels of glucosylceramide (Lavie, Y., Cao, H., Bursten, S. L., Giuliano, A. E., and Cabot, M. C. (1996) J. Biol. Chem. 271, 19530-19536). In this study we used the multidrug-resistant human breast cancer cell. line MCF-7-Adriamycin-resistant (AdrR), which exhibits marked accumulation of glucosylceramide compared with the parental MCF-7 wild type (drug-sensitive) cell line, to define the relationship between glycolipids and multidrug resistance (MDR). Herein it is shown that clinically relevant concentrations of tamoxifen, verapamil, and cyclosporin A, all circumventors of MDR, markedly decrease glucosylceramide levels in MCF-7-AdrR cells (IC50 values, 1.0, 0.8, and 2.3 mu M, respectively). In intact cells, tamoxifen inhibited glycosphingolipid synthesis at the step of ceramide glycosylation. In cell-free assays for glucosylceramide synthase, tamoxifen (1:10 molar ratio with ceramide) inhibited glucosylceramide formation by nearly 50%. In cell cultures, inhibition of glucosylceramide synthesis by tamoxifen is correlated with its ability to sensitize MCF-7-AdrR cells to Adriamycin toxicity. Moreover, treatment of cells with 1-phenyl-2-palnitoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis, likewise sensitized MCF-7-AdrR cells to Adriamycin. It is concluded that high cellular levels of glucosylceramide are correlated with MDR, and that glycolipids are a target for the action of MDR-reversing agents such as tamoxifen. The data entertain the notion that drug resistance phenomena are aligned with cell capacity to metabolize ceramide.	ST JOHNS HOSP, JOHN WAYNE CANC INST, SANTA MONICA, CA 90404 USA	John Wayne Cancer Institute								ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; ABE A, 1995, J LIPID RES, V36, P611; Abe A, 1996, J BIOL CHEM, V271, P14383, DOI 10.1074/jbc.271.24.14383; BIEDLER JL, 1983, CANCER TREAT REP, V67, P859; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CABOT MC, 1995, BREAST CANCER RES TR, V36, P299, DOI 10.1007/BF00713401; Cabot Myles C., 1996, P43; CALLAGHAN R, 1995, BRIT J CANCER, V71, P294, DOI 10.1038/bjc.1995.59; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; Fan D., 1994, REVERSAL MULTIDRUG R, P93; FREI EI, 1993, PRINCIPLES CHEMOTHER, P631; FURUYA S, 1995, J NEUROCHEM, V65, P1551; Gupta KP, 1996, J BIOL CHEM, V271, P2102, DOI 10.1074/jbc.271.4.2102; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAREL R, 1993, J BIOL CHEM, V268, P14476; HOLLERAN WM, 1986, CANCER CHEMOTH PHARM, V17, P11, DOI 10.1007/BF00299859; INOKUCHI J, 1987, CANCER LETT, V38, P23, DOI 10.1016/0304-3835(87)90196-0; JAFFREZOU JP, 1995, BBA-MOL CELL RES, V1266, P1, DOI 10.1016/0167-4889(94)00219-5; JAFFREZOU JP, 1991, J BIOL CHEM, V266, P19858; JOHNSTON SRD, 1993, BREAST CANCER RES TR, V28, P241, DOI 10.1007/BF00666585; Kellen J. A., 1996, TAMOXIFEN ANTIESTROG; KIRK J, 1994, BIOCHEM PHARMACOL, V48, P277, DOI 10.1016/0006-2952(94)90098-1; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lavie Y., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P423; MARSH NL, 1995, J CLIN INVEST, V95, P2903, DOI 10.1172/JCI117997; MAY GL, 1988, INT J CANCER, V42, P728, DOI 10.1002/ijc.2910420517; MCCLAY EF, 1994, J CLIN ONCOL, V12, P617, DOI 10.1200/JCO.1994.12.3.617; MORTON DL, 1994, PROG BRAIN RES, V101, P251; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; NAYFIELD SG, 1995, J CELL BIOCHEM, P42; NILSSON O, 1982, J NEUROCHEM, V39, P709, DOI 10.1111/j.1471-4159.1982.tb07950.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RAMU A, 1984, CANCER TREAT REP, V68, P637; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; ROSENWALD AG, 1994, J LIPID RES, V35, P1232; SACHS CW, 1995, J BIOL CHEM, V270, P26639, DOI 10.1074/jbc.270.44.26639; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SHUKLA GS, 1990, ARCH BIOCHEM BIOPHYS, V283, P372, DOI 10.1016/0003-9861(90)90657-K; SLATER LM, 1986, BRIT J CANCER, V54, P235, DOI 10.1038/bjc.1986.167; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; SOLARY E, 1991, CANCER, V68, P1714, DOI 10.1002/1097-0142(19911015)68:8&lt;1714::AID-CNCR2820680811&gt;3.0.CO;2-2; Sweely CC, 1985, BIOCH LIPIDS MEMBRAN, P361; TANIGAWA N, 1982, CANCER RES, V42, P2159; THURIN J, 1986, FEBS LETT, V208, P17, DOI 10.1016/0014-5793(86)81522-8; TSURUO T, 1981, CANCER RES, V41, P1967; VOLM M, 1993, CANCER, V71, P3981, DOI 10.1002/1097-0142(19930615)71:12<3981::AID-CNCR2820711231>3.0.CO;2-A; WADKINS RM, 1993, BIOCHIM BIOPHYS ACTA, V1153, P225, DOI 10.1016/0005-2736(93)90409-S; WATANABE T, 1995, ACTA ONCOL, V34, P235, DOI 10.3109/02841869509093961; WELSH CJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P41, DOI 10.1006/abbi.1994.1468; WRIGHT LC, 1985, BIOCHEM BIOPH RES CO, V133, P539, DOI 10.1016/0006-291X(85)90940-4; YAN JP, 1995, J BIOL CHEM, V270, P22836, DOI 10.1074/jbc.270.39.22836; YUSA K, 1989, CANCER RES, V49, P5002	57	259	286	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1682	1687		10.1074/jbc.272.3.1682	http://dx.doi.org/10.1074/jbc.272.3.1682			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999846	hybrid, Green Published			2022-12-25	WOS:A1997WD05800044
J	vantHof, W; Blankenvoorde, MFJ; Veerman, ECI; Amerongen, AVN				vantHof, W; Blankenvoorde, MFJ; Veerman, ECI; Amerongen, AVN			The salivary lipocalin Von Ebner's Gland protein is a cysteine proteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINALLY TRUNCATED FORMS; EGG-WHITE CYSTATIN; ESCHERICHIA-COLI; TEAR FLUID; PAPAIN; SUPERFAMILY; PEPTIDES; CLONING; ALBUMIN; MEMBER	The lipocalins make up a heterogeneous superfamily of proteins. Although showing almost no sequence homology, they share very similar secondary and tertiary structures. Their ability to bind hydrophobic ligands is well established, but the physiological function of most lipocalins remains unclear. The lipocalin from the human Von Ebner's Gland of the tongue (VEGh) contains three sequence motifs corresponding with the papain-binding domains of cystatins, a family of naturally occurring cysteine proteinase inhibitors. We found that VEGh inhibited papain activity to a similar extent as salivary cystatin S. Furthermore, synthetic peptides derived from VEGh and cystatin C, comprising these three motifs, inhibited papain, too. We conclude that VEGh is a physiological inhibitor of cysteine proteinases and therefore can play a role in the control of inflammatory processes in oral and ocular tissues.			vantHof, W (corresponding author), VRIJE UNIV AMSTERDAM,ACTA,DEPT ORAL BIOCHEM,FAC MED,VAN DER BOECHORSTSTR 7,NL-1081 BT AMSTERDAM,NETHERLANDS.							AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; BARRETT AJ, 1972, ANAL BIOCHEM, V47, P280, DOI 10.1016/0003-2697(72)90302-8; BECK-SICKINGER A G, 1991, Peptide Research, V4, P88; BJORCK L, 1989, NATURE, V337, P385, DOI 10.1038/337385a0; BJORCK L, 1990, J VIROL, V64, P941; BLAKER M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P131, DOI 10.1016/0167-4781(93)90279-M; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; DELAIRE A, 1992, EXP EYE RES, V55, P645, DOI 10.1016/S0014-4835(05)80178-2; FLOWER DR, 1994, FEBS LETT, V354, P7, DOI 10.1016/0014-5793(94)01078-1; GARIBOTTI M, 1995, CHEM SENSES, V20, P69, DOI 10.1093/chemse/20.1.69; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; HALL A, 1993, BIOCHEM J, V291, P123, DOI 10.1042/bj2910123; HENSKENS YMC, 1993, J PERIODONTAL RES, V28, P43, DOI 10.1111/j.1600-0765.1993.tb01049.x; Henskens YMC, 1996, BIOL CHEM H-S, V377, P71; Henskens YMC, 1996, J PERIODONTOL, V67, P205, DOI 10.1902/jop.1996.67.3.205; JANSSEN PT, 1983, EXP EYE RES, V36, P773, DOI 10.1016/0014-4835(83)90031-3; KORANT BD, 1985, BIOCHEM BIOPH RES CO, V127, P1072, DOI 10.1016/S0006-291X(85)80054-1; LALMANACH G, 1993, J PROTEIN CHEM, V12, P23, DOI 10.1007/BF01024910; LASSAGNE H, 1993, GENOMICS, V18, P160, DOI 10.1006/geno.1993.1444; LINDAHL P, 1994, BIOCHEMISTRY-US, V33, P4384, DOI 10.1021/bi00180a036; LINDAHL P, 1992, BIOCHEM J, V286, P165, DOI 10.1042/bj2860165; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; NISHIKATA M, 1991, BIOCHEM BIOPH RES CO, V174, P625, DOI 10.1016/0006-291X(91)91463-M; RATHMAN WM, 1990, J BIOL BUCCALE, V18, P19; REDL B, 1992, J BIOL CHEM, V267, P20282; SAITOH E, 1994, J BIOCHEM-TOKYO, V116, P399, DOI 10.1093/oxfordjournals.jbchem.a124538; SCHENKELS LCPM, 1995, J DENT RES, V74, P1543, DOI 10.1177/00220345950740090701; SELSTED ME, 1982, EXP EYE RES, V34, P305, DOI 10.1016/0014-4835(82)90079-3; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9	30	108	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1837	1841						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999869				2022-12-25	WOS:A1997WD05800067
J	Walter, J; Capell, A; Hung, AY; Langen, H; Schnolzer, M; Thinakaran, G; Sisodia, SS; Selkoe, DJ; Haass, C				Walter, J; Capell, A; Hung, AY; Langen, H; Schnolzer, M; Thinakaran, G; Sisodia, SS; Selkoe, DJ; Haass, C			Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; CHONDROITIN SULFATE GLYCOSAMINOGLYCAN; NERVE GROWTH-FACTOR; ALZHEIMERS-DISEASE; ECTOPROTEIN KINASE; SECRETORY PATHWAY; PC12 CELLS; SURFACE; CLEAVAGE; PEPTIDE	The beta-amyloid precursor protein (beta APP) is a transmembrane protein that is exclusively phosphorylated on serine residues within its ectodomain. To identify the cellular site of beta APP phosphorylation, we took advantage of an antibody that specifically detects the free C terminus of beta-secretase-cleaved beta APP containing the Swedish missense mutation (APP(s)(sw)-beta). This antibody previously established the cellular location of the beta-secretase cleavage of Swedish beta APP as a post-Golgi secretory compartment (Haass, C., Lemere, C., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., and Selkoe, D. J. (1995) Nature Med. 1, 1291-1296). We have now localized the selective ectodomain phosphorylation of beta APP to the same compartment. Moreover, the phosphorylation sites of beta APP were identified at Ser(198) and Ser(206) of beta APP695 by tryptic peptide mapping, mass spectrometry, and site-directed mutagenesis. Intracellular phosphorylation of beta APP was inhibited by Brefeldin A and by incubating cells at 20 degrees C, thus excluding phosphorylation in the endoplasmic reticulum or trans-Golgi network. Ectodomain phosphorylation within a post-Golgi compartment occurred not only with mutant Swedish beta APP, but also with wild type beta APP. In addition to phosphorylation within a post-Golgi compartment, beta APP was also found to undergo phosphorylation at the cell surface by an ectoprotein kinase. Therefore, this study revealed two distinct cellular locations for beta APP phosphorylation.	ZENT INST SEEL GESUNDHEIT,MOL BIOL ABT J5,D-68159 MANNHEIM,GERMANY; F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,GENE TECHNOL,CH-4070 BASEL,SWITZERLAND; GERMAN CANC RES CTR,DEPT CELL BIOL,D-69120 HEIDELBERG,GERMANY; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,NEUROSCI PROGRAM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,BALTIMORE,MD 21205	Central Institute of Mental Health; Roche Holding; Helmholtz Association; German Cancer Research Center (DKFZ); Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Johns Hopkins University			Wang, Caihong/T-5837-2019; Walter, Jochen/B-3677-2014	Wang, Caihong/0000-0002-6808-3709; Walter, Jochen/0000-0002-4678-2912	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012749] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49552-04] Funding Source: Medline; NIA NIH HHS [AG 12749] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DAS S, 1986, MOL BIOCHEM PARASIT, V20, P143, DOI 10.1016/0166-6851(86)90026-5; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; EHRLICH YH, 1986, NATURE, V320, P67, DOI 10.1038/320067a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FRIEDBERG I, 1995, J BIOL CHEM, V270, P20560, DOI 10.1074/jbc.270.35.20560; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Henschen A., 1986, BLOOD COAGULATION, V171, P241; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KOO EH, 1994, J BIOL CHEM, V269, P17386; KREBS EG, 1993, BIOSCIENCE REP, V13, P127, DOI 10.1007/BF01149958; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; KUBLER D, 1989, J BIOL CHEM, V264, P14549; KUBLER D, 1982, J BIOL CHEM, V257, P322; LESTER DS, 1990, BIOCHIM BIOPHYS ACTA, V1052, P293, DOI 10.1016/0167-4889(90)90224-2; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NAGASHIMA K, 1991, FEBS LETT, V293, P119, DOI 10.1016/0014-5793(91)81165-5; OETTING WS, 1986, J BIOL CHEM, V261, P1649; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PAUL JI, 1984, J BIOL CHEM, V259, P3477; PAWLOWSKA Z, 1993, J NEUROCHEM, V60, P678, DOI 10.1111/j.1471-4159.1993.tb03201.x; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; ROSA P, 1992, J BIOL CHEM, V267, P12227; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; THINAKARAN G, 1994, J BIOL CHEM, V269, P22099; THINAKARAN G, 1995, J BIOL CHEM, V270, P16522, DOI 10.1074/jbc.270.28.16522; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; WALTER J, 1994, CELL MOL BIOL RES, V40, P473; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7; [No title captured]	70	59	64	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1896	1903		10.1074/jbc.272.3.1896	http://dx.doi.org/10.1074/jbc.272.3.1896			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999878	hybrid			2022-12-25	WOS:A1997WD05800076
J	Yang, M; Ellenberg, J; Bonifacino, JS; Weissman, AM				Yang, M; Ellenberg, J; Bonifacino, JS; Weissman, AM			The transmembrane domain of a carboxyl-terminal anchored protein determines localization to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREFELDIN-A; MEMBRANE-PROTEINS; GOLGI-APPARATUS; INTERLEUKIN-2 RECEPTOR; SECRETORY PATHWAY; PLASMA-MEMBRANE; KIN RECOGNITION; MANNOSIDASE-II; ER RETENTION; ZETA-CHAIN	UBC6 is a C-terminal membrane-anchored (type IV) protein, native to Saccharomyces cerevisiae, where it is found in the endoplasmic reticulum. When expressed in mammalian cells, this novel ubiquitin-conjugating enzyme also localizes to the endoplasmic reticulum. UBC6 lacks a lumenal domain and contains no known endoplasmic reticulum retention signals. Analysis of chimeric proteins in which the cytosolic domain of UBC is linked to a heterologous transmembrane domain, or in which the UBC6 transmembrane domain is appended to an unrelated soluble protein, led to the determination that the transmembrane domain of UBC6 plays a dominant role in its compartmental localization. The basis for the transmembrane domain-mediated subcellular targeting of UBC6 was evaluated by lengthening the wild type UBC6 hydrophobic segment from 17 to 21 amino acids, which resulted in re-targeting to the Golgi complex. A further increase in length to 26 amino acids allowed this modified protein to traverse the secretory pathway and gain expression at the plasma membrane. These findings are consistent with models in which, in the absence of dominant cytosolic or lumenal targeting determinants, proteins may be sorted within the secretory pathway based on interactions between their trans membrane domains and the surrounding lipid bilayer.	NCI,LAB IMMUNE CELL BIOL,DIV BASIC SCI,NIH,BETHESDA,MD 20892; NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			; Ellenberg, Jan/I-4688-2014	Bonifacino, Juan S./0000-0002-5673-6370; Ellenberg, Jan/0000-0001-5909-701X				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HIGH S, 1995, PROG BIOPHYS MOL BIO, V63, P233, DOI 10.1016/0079-6107(95)00005-8; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JENSEN JP, 1993, J IMMUNOL, V150, P122; KLAUSNER RD, 1985, PROTEINS IRON STORAG, P111; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; Lippincott-Schwartz J, 1993, Subcell Biochem, V21, P95; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SANDELIUS AS, 1986, PLANT PHYSIOL, V81, P177, DOI 10.1104/pp.81.1.177; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335	61	111	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1970	1975		10.1074/jbc.272.3.1970	http://dx.doi.org/10.1074/jbc.272.3.1970			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999888	hybrid			2022-12-25	WOS:A1997WD05800086
J	Waridel, F; Estreicher, A; Bron, L; Flaman, JM; Fontolliet, C; Monnier, P; Frebourg, T; Iggo, R				Waridel, F; Estreicher, A; Bron, L; Flaman, JM; Fontolliet, C; Monnier, P; Frebourg, T; Iggo, R			Field cancerisation and polyclonal p53 mutation in the upper aerodigestive tract	ONCOGENE			English	Article						p53 functional assay; head and neck cancer; preneoplastic lesions	SQUAMOUS-CELL CARCINOMA; GENE-MUTATIONS; FUNCTIONAL ASSAY; NECK-CANCER; HEAD; DIAGNOSIS; TUMORS	Field cancerisation of the aerodigestive tract is caused by chronic exposure to alcohol and tobacco, but the nature of the genetic alterations preceding overt malignancy is unknown. To identify potential field changes we have used a functional assay which tests the transcriptional competence of human p53 expressed in yeast, To increase the sensitivity and reliability of the technique for samples containing under 20% mutant p53, the 5' and 3'-ends of the p53 cDNA were examined separately. With this split form of the assay the tissue p53 mRNA acts as its own control for RNA quality. Mutations were detected in 87% (46/53) of tumours, reflecting the high sensitivity of the technique, Multiple biopsies of histologically normal tissue from the upper aero-digestive tract were tested and clonal p53 mutations were identified in 76% (38/50) of biopsies from patients presenting with multiple tumours compared with 32% (38/117) of biopsies from patients presenting with single tumours (P<0.000001). AU patients (16/16) presenting with multiple tumours had at least one positive biopsy, compared with only 53% (19/36) of patients presenting with single tumours (P<0.001), This defines expansion of multiple clones of mutant p53-containing cells as an important biological mechanism of field cancerisation, and provides a means to identify patients likely to benefit from intensive screening for the development of new head and neck tumours.	SWISS INST EXPT CANC RES,ONCOGENE GRP,ISREC,CH-1066 EPALINGES,SWITZERLAND; CHU VAUDOIS,UNIV HOSP,SERV OTORHINOLARYNGOL,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,UNIV HOSP,PATHOL SERV,CH-1011 LAUSANNE,SWITZERLAND; CHU ROUEN,MOL GENET UNIT,F-76031 ROUEN,FRANCE	Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU de Rouen			Flaman, Jean-Michel/K-8415-2018; Frebourg, Thierry/AAK-8390-2020; Iggo, Richard/G-3546-2014	Flaman, Jean-Michel/0000-0003-3544-0199; Estreicher, Anne/0000-0001-6828-2508				BLASZYK H, 1995, BIOTECHNIQUES, V18, P256; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; CHUNG KY, 1993, CANCER RES, V53, P1676; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; Flaman JM, 1996, ONCOGENE, V12, P813; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; MAO L, 1994, CANCER RES, V54, P1634; NEES M, 1993, CANCER RES, V53, P4189; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; SAVARY M, 1991, ADV OTO-RHINO-LARYNG, V46, P165; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306	18	148	150	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					163	169		10.1038/sj.onc.1200812	http://dx.doi.org/10.1038/sj.onc.1200812			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010218				2022-12-25	WOS:A1997WC81800004
J	Marks, JR; Huper, G; Vaughn, JP; Davis, PL; Norris, J; McDonnell, DP; Wiseman, RW; Futreal, PA; Iglehart, JD				Marks, JR; Huper, G; Vaughn, JP; Davis, PL; Norris, J; McDonnell, DP; Wiseman, RW; Futreal, PA; Iglehart, JD			BRCA1 expression is not directly responsive to estrogen	ONCOGENE			English	Article						BRCA1; estrogen response; cell cycle; antiestrogen; proliferation	BREAST-CANCER-CELLS; GROWTH-FACTOR; GENE; RECEPTOR; MUTATIONS; TISSUES; DIFFERENTIATION; TRANSCRIPTION; ANTIESTROGENS; CULTURE	Expression of the breast cancer susceptibility gene, BRCA1, is induced by 17-beta estradiol (E(2)) in estrogen receptor containing breast cancer cell lines, Our previous studies have shown that BRCA1 transcription is also regulated with the cell cycle, reaching maximal levels just before the onset of DNA synthesis, In this study, we have examined whether the estrogen induction of BRCA1 is direct or is a result of the mitogenic activity of the hormone, Four lines of evidence lead us to conclude that E(2) induces BRCA1 primarily through an increase in DNA synthesis: (1) The kinetics and magnitude of induction are different from the directly E(2) inducible gene, pS2; (2) Induction of BRCA1, but not pS2, is blocked by cycloheximide indicating that de novo protein synthesis is required; (3) Other hormonal and growth factor treatments that induce DNA synthesis have a similar effect, including IGF-1, EGF and DNA synthetic flares induced by tamoxifen and retinoic acid; (4) BRCA1 genomic fragments near the 5' end of the gene containing putative estrogen response elements fail to respond to E(2) when transfected into breast cancer cell lines, The most consistent explanation for these findings and other published studies is that BRCA1 transcription is induced as a result of the mitogenic activity of E(2) in estrogen receptor positive cells.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; NIEHS, MOL CARCINOGENESIS LAB, RES TRIANGLE PK, NC 27709 USA; DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Marks, JR (corresponding author), DUKE UNIV, MED CTR, DEPT SURG, BOX 3873, DURHAM, NC 27710 USA.			Norris, John/0000-0001-6553-8053	NATIONAL CANCER INSTITUTE [P50CA068438, R01CA061218] Funding Source: NIH RePORTER; NCI NIH HHS [CA68438, CA63786, CA61218] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; FORD D, 1995, AM J HUM GENET, V57, P1457; FREED KA, 1989, J MOL ENDOCRINOL, V3, P183, DOI 10.1677/jme.0.0030183; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; IMAI Y, 1982, CANCER RES, V42, P4394; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARKS JR, 1989, J VIROL, V63, P790, DOI 10.1128/JVI.63.2.790-797.1989; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MCDONNELL DP, 1995, ANN NY ACAD SCI, V761, P121, DOI 10.1111/j.1749-6632.1995.tb31374.x; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; RAMKUMAR T, 1995, ENDOCRINOLOGY, V136, P536, DOI 10.1210/en.136.2.536; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; ZEIMET AG, 1994, J STEROID BIOCHEM, V49, P365, DOI 10.1016/0960-0760(94)90281-X	37	99	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					115	121		10.1038/sj.onc.1200808	http://dx.doi.org/10.1038/sj.onc.1200808			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010238				2022-12-25	WOS:A1997WB76000011
J	Lander, HM; Hajjar, DP; Hempstead, BL; Mirza, UA; Chait, BT; Campbell, S; Quilliam, LA				Lander, HM; Hajjar, DP; Hempstead, BL; Mirza, UA; Chait, BT; Campbell, S; Quilliam, LA			A molecular redox switch on p21(ras) - Structural basis for the nitric oxide-p21(ras) interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENE PRODUCT P21; NF-KAPPA-B; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; GTP-BINDING; OXIDE; RAS; EXPRESSION; ACTIVATION; PROTEINS	We have identified the site of molecular interaction between nitric oxide (NO) and p21(ras) responsible for initiation of signal transduction, We found that p21(ras) was singly S-nitrosylated and localized this modification to a fragment of p21(ras) containing Cys(118). A mutant form of p21(ras), in which Cys(118) was changed to a serine residue and termed p21(ras)C118S, was not S-nitrosylated, NO-related species stimulated guanine nucleotide exchange on wild-type p21(ras), resulting in an active form, but not on p21(ras)C118S. Furthermore, in contrast to parental Jurkat T cells, NO-related species did not stimulate mitogen-activated protein kinase activity in cells transfected with p21(ras)C118S. These data indicate that Cys(118) is a critical site of redox regulation of p21(ras), and S-nitrosylation of this residue triggers guanine nucleotide exchange and downstream signaling.	CORNELL UNIV,COLL MED,DEPT PATHOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; ROCKEFELLER UNIV,LAB MASS SPECT,NEW YORK,NY 10021; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Cornell University; Cornell University; Rockefeller University; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University-Purdue University Indianapolis	Lander, HM (corresponding author), CORNELL UNIV,COLL MED,DEPT BIOCHEM,1300 YORK AVE,NEW YORK,NY 10021, USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	campbell, sharon/0000-0003-0311-409X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIAID NIH HHS [AI37637] Funding Source: Medline; NINDS NIH HHS [NS3057] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V250, P3; DAVIDGE ST, 1995, CIRC RES, V77, P274, DOI 10.1161/01.RES.77.2.274; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; JOHN J, 1989, J BIOL CHEM, V264, P13086; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MIRZA UA, 1995, J BIOL CHEM, V270, P17185, DOI 10.1074/jbc.270.29.17185; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHERER A, 1989, J MOL BIOL, V206, P257, DOI 10.1016/0022-2836(89)90540-8; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHEFFLER LA, 1995, J IMMUNOL, V155, P886; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001	30	416	426	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4323	4326		10.1074/jbc.272.7.4323	http://dx.doi.org/10.1074/jbc.272.7.4323			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020151	hybrid			2022-12-25	WOS:A1997WH01900067
J	Spijker, S; Smit, AB; Martens, GJM; Geraerts, WPM				Spijker, S; Smit, AB; Martens, GJM; Geraerts, WPM			Identification of a molluscan homologue of the neuroendocrine polypeptide 7B2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASE PC2; PROOPIOMELANOCORTIN; INHIBITION; PROTEIN; CLONING	In vertebrates, interaction of prohormone convertase 2 (PC2) with the highly conserved polypeptide 7B2 is essential for transport and maturation of proPC2 in the regulated secretory pathway. In vitro, 7B2 displays a strong inhibitory activity toward PC2, Here, we characterize a cDNA encoding the first invertebrate 7B2-related protein (L7B2) from the brain of the mollusc Lymnaea stagnalis. The overall amino acid sequence identity between L7B2 and its vertebrate counterparts is surprisingly low (29%) and is restricted to a few small stretches of amino acid residues, Of particular interest are a conserved proline-rich region in the middle portion of the L7B2 sequence and a repeated conserved region in the carboxyl-terminal domain. Synthetic peptides corresponding to the carboxyl-terminal regions inhibit Lymnaea PC2 enzyme activity in extracts of insulin-producing neurons, in which both L7B2 and Lymnaea PC2 are abundantly expressed. Moreover, the peptides inhibit mouse PC2 enzyme activity. Our cloning of invertebrate 7B2 helps to delineate residues that are important for 7B2-PC2 interaction.	CATHOLIC UNIV NIJMEGEN, DEPT ANIM PHYSIOL, NL-6525 ED NIJMEGEN, NETHERLANDS; FREE UNIV AMSTERDAM, NEUROSCI RES INST, GRAD SCH NEUROSCI AMSTERDAM, NL-1081 HV AMSTERDAM, NETHERLANDS	Radboud University Nijmegen; University of Amsterdam; Vrije Universiteit Amsterdam			Smit, August B/E-8410-2011; Martens, Gerard JM/D-1925-2010; Spijker, Sabine/F-2300-2011	Spijker, Sabine/0000-0002-6814-2019				AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; LAZURE C, 1991, INT J PEPT PROT RES, V38, P392; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; MARTENS GJM, 1988, FEBS LETT, V234, P160, DOI 10.1016/0014-5793(88)81324-3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MARTENS GJM, 1989, EUR J BIOCHEM, V181, P75, DOI 10.1111/j.1432-1033.1989.tb14695.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SIGAFOOS J, 1993, CELL MOL NEUROBIOL, V13, P271, DOI 10.1007/BF00733755; Smit AB, 1996, NEUROSCIENCE, V70, P589, DOI 10.1016/0306-4522(95)00378-9; SMIT AB, 1994, FEBS LETT, V343, P27, DOI 10.1016/0014-5793(94)80600-4; SMIT AB, 1992, FEBS LETT, V312, P213, DOI 10.1016/0014-5793(92)80938-D; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; VANMINNEN J, 1988, CELL TISSUE RES, V251, P477, DOI 10.1007/BF00215857; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1996, J BIOL CHEM, V271, P23582, DOI 10.1074/jbc.271.38.23582	24	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4116	4120		10.1074/jbc.272.7.4116	http://dx.doi.org/10.1074/jbc.272.7.4116			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020122	hybrid, Green Published			2022-12-25	WOS:A1997WH01900038
J	Xia, WL; Voellmy, R				Xia, WL; Voellmy, R			Hyperphosphorylation of heat shock transcription factor 1 is correlated with transcriptional competence and slow dissociation of active factor trimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HSP70 GENE; ACTIVATION; PROTEIN; CELLS; PHOSPHORYLATION; ELEMENT; STRESS; OLIGOMERIZATION; MECHANISMS	In the course of its activation by heat and other stresses, the inactive monomer of human heat shack transcription factor 1 (HSF1) is converted to a DNA-binding homotrimer and is hyperphosphorylated. At least four Ser/Thr residues in HSF1 appeared to be inducibly phosphorylated during heat shock, Ser/Thr protein kinase inhibitors inhibited, and protein phosphatase inhibitor calyculin A and phorbol ester enhanced, hsp70-CAT reporter gene expression but not heat shock element DNA binding activity in HeLa cells undergoing a moderate heat shock. Calyculin A (5-20 nM) caused hyperphosphorylation of HSF1, the extent of which was comparable to that produced by moderate to severe heat shock. Upon recovery from a 42 degrees C/30 min-heat shock, HSF1 trimers disassembled quantitatively within 2 h. Calyculin A interfered with the dissociation of HSF1 trimers. Thus, hyperphosphorylation increases the effective half-life of the HSF1 trimer, which may prolong factor activity subsequent to heat shock. Hyperphosphorylation also dramatically stimulated the transactivation function of HSF1: exposure to calyculin A of cells induced to form inactive HSF1 trimers resulted in the conversion of the inactive to active trimers, Given that deletion of certain sequences renders HSF1 constitutively active, these results suggested that the activation of HSF1 trimers by calyculin A was a consequence of hyperphosphorylation of HSF1 rather than of a down-stream factor.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOL BIOL, MIAMI, FL 33136 USA	University of Miami					NIGMS NIH HHS [GM31125] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUCE JL, 1993, CANCER RES, V53, P12; CHANG NT, 1993, J BIOL CHEM, V268, P1436; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; ERDOS G, 1994, BIOCHEM BIOPH RES CO, V202, P476, DOI 10.1006/bbrc.1994.1953; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOJ A, 1994, EMBO J, V13, P2617; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Newton EM, 1996, MOL CELL BIOL, V16, P839; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; YAMAMOTO N, 1994, KIDNEY INT, V45, P1093, DOI 10.1038/ki.1994.146; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	25	122	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4094	4102		10.1074/jbc.272.7.4094	http://dx.doi.org/10.1074/jbc.272.7.4094			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020119	hybrid			2022-12-25	WOS:A1997WH01900035
J	Barois, N; Forquet, F; Davoust, J				Barois, N; Forquet, F; Davoust, J			Selective modulation of the major histocompatibility complex class II antigen presentation pathway following B cell receptor ligation and protein kinase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; INVARIANT CHAIN COMPLEXES; HLA-DR MOLECULES; SURFACE EXPRESSION; CYTOPLASMIC TAIL; INTRACELLULAR-TRANSPORT; LYMPHOBLASTOID-CELLS; PEPTIDE PRESENTATION; GOLGI-APPARATUS; DOWN-REGULATION	We noticed that B cell receptor ligation or phorbol 12-myristate 13-acetate treatment induced intracellular vesicles containing major histocompatibility complex (MHC) class II and invariant chain (Ii), and increased the amount of transmembrane p12 Ii fragments coimmunoprecipitated with class II molecules. To determine the influence of protein kinase C activation on the MHC class II presentation pathway, we analyzed the subcellular distribution of Ii, the induction of SDS-stable forms of class II molecules, and their ability to present different antigens. Ii chains visualized with luminal and cytoplasmic directed antibodies appeared in early endosomal compartments accessible to transferrin in response to phorbol 12-myristate 13-acetate treatment, whereas transmembrane Ii degradation products equivalent to the p12 Ii fragments were colocalized with the B cell receptors internalized after cross-linking. Protein kinase C activation delayed in parallel the formation of SDS-stable forms of class II molecules and reduced the presentation of antigenic determinants requiring newly synthesized class II alpha beta-Ii complexes. These data indicate that B cell activation affects Ii processing and MHC class II peptide loading in endosomal compartments intersecting the biosynthetic pathway.	CNRS MARSEILLE LUMINY,INSERM,CTR IMMUNOL,F-13288 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite				Davoust, Jean/0000-0002-3098-7665				ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ALLEN PM, 1984, J IMMUNOL, V132, P1077; AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ARNESON LS, 1995, J CELL BIOL, V129, P1217, DOI 10.1083/jcb.129.5.1217; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; Busch R, 1996, CURR OPIN IMMUNOL, V8, P51, DOI 10.1016/S0952-7915(96)80105-1; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEN ZZ, 1986, J IMMUNOL, V136, P2300; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DELBRUCK R, 1994, EUR J CELL BIOL, V64, P7; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HUMBERT M, 1993, EUR J IMMUNOL, V23, P3158, DOI 10.1002/eji.1830231218; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; Kawauchi K, 1996, MOL IMMUNOL, V33, P287, DOI 10.1016/0161-5890(95)00134-4; LAMB CA, 1992, J IMMUNOL, V148, P3478; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LORENZ RG, 1988, J IMMUNOL, V141, P4124; LUCOCQ J, 1991, J CELL SCI, V100, P753; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NGUYEN QV, 1989, HUM IMMUNOL, V24, P153, DOI 10.1016/0198-8859(89)90056-6; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; PENNELL CA, 1985, P NATL ACAD SCI USA, V82, P3799, DOI 10.1073/pnas.82.11.3799; PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325; PIETERS J, 1993, J CELL SCI, V106, P831; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHOLL PR, 1994, IMMUNOL TODAY, V15, P418, DOI 10.1016/0167-5699(94)90271-2; SCHONHORN JE, 1995, J BIOL CHEM, V270, P3698, DOI 10.1074/jbc.270.8.3698; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; SORENG KM, 1994, CELL IMMUNOL, V157, P277, DOI 10.1006/cimm.1994.1222; SPIRO RC, 1989, J IMMUNOL, V143, P2589; STPIERRE Y, 1990, J IMMUNOL, V145, P812; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; XU MZ, 1994, MOL IMMUNOL, V31, P723, DOI 10.1016/0161-5890(94)90146-5; XU XX, 1995, J IMMUNOL, V155, P2984	62	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3641	3647		10.1074/jbc.272.6.3641	http://dx.doi.org/10.1074/jbc.272.6.3641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013617	hybrid			2022-12-25	WOS:A1997WG19200077
J	Dombroski, AJ				Dombroski, AJ			Recognition of the -10 promoter sequence by a partial polypeptide of sigma(70) in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TRANSCRIPTION INITIATION; BACILLUS-SUBTILIS; AMINO-ACIDS; SIGMA-70 SUBUNIT; ANT PROMOTER; DNA; REGION; SPECIFICITY	Promoter recognition by RNA polymerase depends upon its ability to bind to specific DNA sequences. The sigma (sigma) subunit provides selectivity for transcription initiation by interacting with the -10 and -35 elements of promoter DNA, Suppressor mutations in a factor that compensate for specific ''down'' substitutions in the promoter have demonstrated that sigma factor recognizes certain base pairs of the promoter, Since these suppressors were only identified for changes at the -12 and -11 positions of the -10 element (TATAAT), the role of the other base pairs of this region in specifying recognition by sigma factor remained unclear, Using a partial polypeptide of sigma(70) carrying regions 2-4, this report shows that the first three positions of the -10 element (-12, -11, -10) are important for sigma factor alone to recognize and bind to duplex DNA. The sigma polypeptide also binds to an ''extended -10'' promoter, even without a -35 element, A mismatch bubble from -10 to +3 is bound regardless of the sequence within the bubble, or the presence or absence of a -35 element, Unexpectedly, binding to a mismatch bubble that lacks a -35 hexamer is sensitive to the identity of the -11 position, but not the -12 position.			Dombroski, AJ (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL & MOL GENET, 6431 FANNIN JFB1765, HOUSTON, TX 77030 USA.				NIAID NIH HHS [5RO1AI19635-14] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019635] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIYAR SE, 1994, J BIOL CHEM, V269, P13179; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BACKENDORF C, 1983, NUCLEIC ACIDS RES, V11, P5795, DOI 10.1093/nar/11.17.5795; BRODOLIN KL, 1993, NUCLEIC ACIDS RES, V21, P5748, DOI 10.1093/nar/21.24.5748; BUCKLE M, 1994, TRANSCRIPTION MECH R; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1970, FED PROC, V29, P1164; CHAN B, 1989, GENE, V84, P227, DOI 10.1016/0378-1119(89)90496-4; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DANOT O, 1994, J MOL BIOL, V238, P643, DOI 10.1006/jmbi.1994.1324; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; Dombroski AJ, 1996, P NATL ACAD SCI USA, V93, P8858, DOI 10.1073/pnas.93.17.8858; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRANA D, 1985, GENETICS, V110, P1; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HARRISON CA, 1982, NUCLEIC ACIDS RES, V10, P2399, DOI 10.1093/nar/10.7.2399; HAWLEY DK, 1980, P NATL ACAD SCI-BIOL, V77, P6381, DOI 10.1073/pnas.77.11.6381; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HILLEL Z, 1978, BIOCHEMISTRY-US, V17, P2954, DOI 10.1021/bi00608a003; Hiratsu K, 1995, MOL MICROBIOL, V18, P841, DOI 10.1111/j.1365-2958.1995.18050841.x; INOKUCHI K, 1984, J MOL BIOL, V178, P653, DOI 10.1016/0022-2836(84)90243-2; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JONES CH, 1992, P NATL ACAD SCI USA, V89, P1958, DOI 10.1073/pnas.89.5.1958; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KENNEY TJ, 1991, J BACTERIOL, V173, P3282, DOI 10.1128/jb.173.11.3282-3290.1991; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KNAUS R, 1990, NUCLEIC ACIDS MOL BI, V4, P110; KOLB A, 1995, NUCLEIC ACIDS RES, V23, P819, DOI 10.1093/nar/23.5.819; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MAKINO K, 1993, GENE DEV, V7, P149, DOI 10.1101/gad.7.1.149; MOYLE H, 1991, J BACTERIOL, V173, P1944, DOI 10.1128/jb.173.6.1944-1950.1991; PONNAMBALAM S, 1988, MOL MICROBIOL, V2, P165, DOI 10.1111/j.1365-2958.1988.tb00018.x; PONNAMBALAM S, 1986, J BIOL CHEM, V261, P6043; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; Roberts CW, 1996, CELL, V86, P495; RONG JC, 1994, J BACTERIOL, V176, P5218, DOI 10.1128/JB.176.17.5218-5224.1994; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SAUCIER JM, 1972, NATURE-NEW BIOL, V239, P167, DOI 10.1038/newbio239167a0; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; TANAKA K, 1995, NUCLEIC ACIDS RES, V23, P827, DOI 10.1093/nar/23.5.827; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; XIONG XF, 1993, J MOL BIOL, V231, P569, DOI 10.1006/jmbi.1993.1310; YOUDERIAN P, 1982, CELL, V30, P843, DOI 10.1016/0092-8674(82)90289-6; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	58	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3487	3494						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013595				2022-12-25	WOS:A1997WG19200055
J	Daoudal, S; Tournaire, C; Halere, A; Veyssiere, G; Jean, C				Daoudal, S; Tournaire, C; Halere, A; Veyssiere, G; Jean, C			Isolation of the mouse aldose reductase promoter and identification of a tonicity-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; VAS-DEFERENS; CHLORAMPHENICOL ACETYLTRANSFERASE; GENOMIC ORGANIZATION; HYPEROSMOTIC STRESS; ANDROGEN REGULATION; RENAL-CELLS; GENE; PROTEIN; RAT	Aldose reductase (AR; EC 1.1.1.21) is an oxidoreductase that catalyzes the NADPH-dependent conversion of glucose to sorbitol, the first step of the polyol pathway. AR is of great interest due to its implication in the etiology of diabetic complications. In renal medullary cells, AR also plays an osmoregulatory role by accumulating sorbitol to maintain the intracellular osmotic balance during antidiuresis. We have previously cloned the AR cDNA from mouse kidney, and we report here the isolation of the mouse AR gene promoter. Transient transfection of chloramphenicol acetyltransferase reporter constructs containing various 5'-flanking regions of the mouse AR gene in CV1 cells led to the identification of a sequence spanning base pairs -1053 to -1040, required for an enhancer activity in hypertonic compared with isotonic cell culture conditions. This sequence is similar to the tonicity-responsive element first characterized in the betaine-gamma-aminobutyric acid transporter promoter.	UNIV CLERMONT FERRAND,LAB REPROD & DEV,EQUIPE PR C JEAN,CNRS,URA 1940,F-63177 CLERMONT FERRAN,FRANCE	Centre National de la Recherche Scientifique (CNRS)								BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; BEKHOR I, 1989, CURR EYE RES, V8, P1299, DOI 10.3109/02713688909013910; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BONDY CA, 1989, MOL ENDOCRINOL, V3, P1409, DOI 10.1210/mend-3-9-1409; COHEN DM, 1993, AM J PHYSIOL, V264, pF601, DOI 10.1152/ajprenal.1993.264.4.F601; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; DAOUDAL S, 1995, LIFE SCI ADV STEROID, V14, P45; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; FABRE S, 1994, J BIOL CHEM, V269, P5857; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FERRARETTO A, 1993, BIOCHIM BIOPHYS ACTA, V1175, P283, DOI 10.1016/0167-4889(93)90218-E; FERRARIS JD, 1994, P NATL ACAD SCI USA, V91, P10742, DOI 10.1073/pnas.91.22.10742; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GARCIAPEREZ A, 1991, J MEMBRANE BIOL, V119, P1, DOI 10.1007/BF01868535; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM A, 1991, J BIOL CHEM, V266, P6872; GRAHAM C, 1991, GENE, V107, P259, DOI 10.1016/0378-1119(91)90326-7; GUI T, 1995, EUR J BIOCHEM, V227, P448, DOI 10.1111/j.1432-1033.1995.tb20408.x; HOHMAN TC, 1990, ENZYMOLOGY MOL BIOL, V3, P139; IWATA N, 1990, ARCH BIOCHEM BIOPHYS, V282, P70, DOI 10.1016/0003-9861(90)90088-G; JEFFERY J, 1983, P NATL ACAD SCI-BIOL, V80, P901, DOI 10.1073/pnas.80.4.901; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTINEZ A, 1989, J ENDOCRINOL, V120, P67, DOI 10.1677/joe.0.1200067; MARTINEZ A, 1990, MOL CELL ENDOCRINOL, V72, P201, DOI 10.1016/0303-7207(90)90144-W; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PAILHOUX E, 1992, J STEROID BIOCHEM, V42, P561, DOI 10.1016/0960-0760(92)90445-O; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SOMERO GN, 1986, AM J PHYSIOL, V251, pR197, DOI 10.1152/ajpregu.1986.251.2.R197; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; TERADA Y, 1994, J BIOL CHEM, V269, P31296; WANG K, 1993, J BIOL CHEM, V268, P16052; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	36	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2615	2619		10.1074/jbc.272.5.2615	http://dx.doi.org/10.1074/jbc.272.5.2615			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006894	hybrid			2022-12-25	WOS:A1997WE66700007
J	Dufour, JF; Arias, IM; Turner, TJ				Dufour, JF; Arias, IM; Turner, TJ			Inositol 1,4,5-trisphosphate and calcium regulate the calcium channel function of the hepatic inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; CYTOSOLIC CA2+; TIME-COURSE; TRISPHOSPHATE; WAVES; HEPATOCYTES; MECHANISMS; CEREBELLUM; MICROSOMES; ACTIVATION	The regulation of the inositol 1,4,5-trisphosphate (IP3) receptor in liver was analyzed using a novel superfusion method. Hepatic microsomes were loaded with Ca-45(2+), and superfused at high flow rates to provide precise control over IP3 and Ca2+ concentrations ([Ca2+]) and to isolate Ca-45(2+) release from reuptake. Ca-45(2+) release was dependent on both [Ca2+] and IP3. The initial rate of Ca-45(2+) release was a biphasic function of [Ca2+], increasing as [Ca2+] approached 3 mu M but decreasing at higher concentrations, suggesting that the hepatic IP3 receptor is regulated by [Ca2+] at two sites, a high affinity potentiation site and a low affinity inhibitory site. The relationship between initial rates and IP3 concentration was steep (Hill coefficient of 3.4), suggesting that activation of the calcium channel requires binding of at least 3 IP3 molecules. IP3 concentrations above 10 mu M produced rapid decay of release rates, suggesting receptor inactivation. Superfusion with 10 mu M IP3 under conditions that minimize calcium release ([Ca2+] < 1 mM) inhibited Ca-45(2+) release in response to subsequent stimulation (400 nM Ca2+). These data suggest sequential positive and negative regulation of the hepatic IP3 receptor by cytosolic calcium and by IP3, which may underlie hepatocellular propagation of regenerative, oscillatory calcium signals.	TUFTS UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,BOSTON,MA 02111	Tufts University			Dufour, Jean Francois Jacques/AAL-9866-2020	Dufour, Jean Francois Jacques/0000-0002-8062-1346; Turner, Timothy/0000-0001-9770-2647	NIDDK NIH HHS [DK34928, DK35652] Funding Source: Medline; NINDS NIH HHS [NS28815] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035652, P30DK034928, R01DK035652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS028815, R01NS028815] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BENVENISTE M, 1990, J PHYSIOL-LONDON, V428, P333, DOI 10.1113/jphysiol.1990.sp018215; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CLAPHAM DE, 1995, ADV SEC MESS PHOSPH, V30, P1; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; COMBETTES L, 1994, SCIENCE, V265, P813, DOI 10.1126/science.8047889; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P469, DOI 10.1146/annurev.ph.57.030195.002345; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINCH EA, 1994, SCIENCE, V265, P813, DOI 10.1126/science.265.5173.813-a; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HIROSE K, 1994, NATURE, V372, P791; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; JAFRI MS, 1994, P NATL ACAD SCI USA, V91, P9485, DOI 10.1073/pnas.91.20.9485; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; WATRAS J, 1991, J NEUROSCI, V11, P3239	27	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2675	2681		10.1074/jbc.272.5.2675	http://dx.doi.org/10.1074/jbc.272.5.2675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006903	hybrid			2022-12-25	WOS:A1997WE66700016
J	Marti, A; Luo, ZJ; Cunningham, C; Ohta, Y; Hartwig, J; Stossel, TP; Kyriakis, JM; Avruch, J				Marti, A; Luo, ZJ; Cunningham, C; Ohta, Y; Hartwig, J; Stossel, TP; Kyriakis, JM; Avruch, J			Actin-binding protein-280 binds the stress-activated protein kinase (SAPK) activator SEK-1 and is required for tumor necrosis factor-alpha activation of SAPK in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; C-JUN; PHOSPHORYLATION; PLATELETS; ELEMENTS; CASCADE; FILAMIN; TARGET; GROWTH; RAF-1	SEK-1, a dual specificity protein kinase that serves as one of the immediate upstream activators of the stress-activated protein kinases (SAPKs), associates specifically with the actin-binding protein, ABP-280, in vitro and in situ. SEK-1 binds to the carboxyl-terminal rod segment of ABP-280, upstream of the ABP carboxyl-terminal dimerization domain. Activation of SEK-1 in situ increases the SEK-1 activity bound to ABP-280 without changing the amount of SEK-1 polypeptide bound. The influence of ABP-280 on SAPK regulation was evaluated in human melanoma cells that lack ABP-280 expression, and in stable transformants of these cells expressing wild type ABP, or an actin-binding but dimerization-deficient mutant ABP (ABP Delta CT109). ABP-280-deficient cells show an activation of SAPK in response to most stimuli that is comparable to that seen in ABP-280-replete cells; ABP-280-deficient cells, however, fail to show the brisk tumor necrosis factor-alpha (TNE-alpha) activation of SAPK seen in ABP-replete cells and have an 80% reduction in SAPK activation by lysophosphatidic acid. Expression of the dimerization-deficient mutant ABP-280 fails to correct the defective SAPK response to lysophosphatidic acid, but essentially normalizes the TNF-alpha activation of SAPK. Thus, a lack of ABP-280 in melanoma cells causes a defect in the regulation of SAPK that is selective for TNF-alpha and is attributable to the lack of ABP-280 polypeptide itself rather than to the disordered actin cytoskeleton that results therefrom. ABP-280 participates in TNF-alpha signal transduction to SAPKs, in part through the binding of SEK-1.	MASSACHUSETTS GEN HOSP, DIABET UNIT, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, MED SERV, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DIV EXPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; NATL INST NEUROSCI, NATL CTR NEUROL & PSYCHIAT, TOKYO 187, JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Center for Neurology & Psychiatry - Japan			Martí, Amelia/H-1192-2017; Marti, Amelia/M-2709-2019; Luo, Zhijun/AAE-9302-2019	Martí, Amelia/0000-0001-9832-7981; Marti, Amelia/0000-0001-9832-7981; Luo, Zhijun/0000-0001-8105-5289				ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; CHOI KY, 1994, CELL, V78, P499; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GEITZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARTWIG J, 1995, PROTEIN PROFILE, V2, P739; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KRYIAKIS JM, 1994, NATURE, V369, P156; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MCGILL M, 1984, THROMB HAEMOSTASIS, V52, P37; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Ohta Y, 1996, J BIOL CHEM, V271, P11858, DOI 10.1074/jbc.271.20.11858; OHTA Y, 1991, CELL, V67, P225; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SAMBROOK J, 1989, MOL CLONING LAB MANU, P756; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; UEDA M, 1992, EUR J BIOCHEM, V203, P347, DOI 10.1111/j.1432-1033.1992.tb16556.x; YADA Y, 1990, BIOCHEM BIOPH RES CO, V172, P256, DOI 10.1016/S0006-291X(05)80202-5; YAN MH, 1994, NATURE, V372, P798; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	32	144	149	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2620	2628		10.1074/jbc.272.5.2620	http://dx.doi.org/10.1074/jbc.272.5.2620			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006895	hybrid			2022-12-25	WOS:A1997WE66700008
J	Nett, JH; Denke, E; Trumpower, BL				Nett, JH; Denke, E; Trumpower, BL			Two-step processing is not essential for the import and assembly of functionally active iron-sulfur protein into the cytochrome bc(1) complex in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INTERMEDIATE PEPTIDASE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; REDUCTASE COMPLEX; C REDUCTASE; CLEAVAGE; PRESEQUENCE; SUBUNITS; MEMBRANE; GENE	The iron-sulfur protein of the cytochrome be, complex is one of a small number of proteins that are processed in two Sequential steps by matrix processing peptidase (MPP) and mitochondrial intermediate peptidase (MIP) during import into Saccharomyces cerevisiae mitochondria. To test whether two-step processing is necessary for import and assembly of the iron-sulfur protein into the cytochrome bc(1) complex, we mutagenized the presequence of the iron-sulfur protein to eliminate the original MPP site and replace the MIP site with a new MPP site. The mutated presequence is cleaved and forms mature-sized protein in a single step, and the mature-sized iron-sulfur protein is correctly targeted to the outer side of the inner mitochondrial membrane in vitro. Mutant iron-sulfur protein which is processed to mature size in one step complements the respiratory deficient phenotype of a yeast strain in which the endogenous gene for the iron-sulfur protein is deleted, These results establish that mature-sized iron-sulfur protein can be formed by single-step processing and assembled into a functionally active form in the cytochrome be, complex in S. cerevisiae.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College					NIGMS NIH HHS [GM 20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; BRANDT U, 1993, J BIOL CHEM, V268, P8387; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; FU W, 1990, J BIOL CHEM, V265, P16541; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P631; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; ISAYA G, 1994, MOL CELL BIOL, V14, P5603, DOI 10.1128/MCB.14.8.5603; ISAYA G, 1992, J BIOL CHEM, V267, P7904; JAPA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P716, DOI 10.1016/0003-9861(89)90340-8; JAPA S, 1994, ARCH BIOCHEM BIOPHYS, V312, P414, DOI 10.1006/abbi.1994.1327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Nett JH, 1996, J BIOL CHEM, V271, P26713, DOI 10.1074/jbc.271.43.26713; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; NISHIKIMI M, 1985, J BIOL CHEM, V260, P398; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; SCHMITT ME, 1991, J BIOL CHEM, V266, P14958; SZTUL ES, 1988, J BIOL CHEM, V263, P12085; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P628, DOI 10.1021/bi00053a031; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WONG F, 1995, BIOTECHNIQUES, V18, P1034	29	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2212	2217						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999925				2022-12-25	WOS:A1997WD67900031
J	Williams, KJ; Boyle, JM; Birch, JM; Norton, JD; Scott, D				Williams, KJ; Boyle, JM; Birch, JM; Norton, JD; Scott, D			Cell cycle arrest defect in Li-Fraumeni Syndrome: A mechanism of cancer predisposition?	ONCOGENE			English	Article						Li-Fraumeni; p53; transgenic; G(1) arrest	WILD-TYPE P53; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; PRONE FAMILY; G(1) ARREST; RADIOSENSITIVITY; CHECKPOINT; MUTATIONS; FIBROBLASTS; REPAIR	Cancer predisposition in approximately 60% of Li-Fraumeni Syndrome (LPS) families is associated with germline mutation of the TP53 gene. The p53 protein has been shown to mediate G(1) arrest following DNA damage, We have investigated gamma-irradiation-induced transient and permanent G(1) arrest in normal and LFS fibroblasts. The duration of transient G(1) arrest varied between strains, but there was no difference in the range between normal (2-12 h) and LFS (1-13 h) cells. However, the extent of permanent G(1) arrest was greatly reduced in LFS fibroblasts (mean 33 +/- 8% of the cell population) compared with normals (mean 67 +/- 9%) and correlated with their increased radiation survival (r = 0.97, P<0.001). This phenotype was observed in LFS fibroblasts both with (seven cases) and without (two cases) TP53 mutation. Parallel studies with fibroblasts derived from cancer-prone, p53-deficient mice revealed no radiation-induced G(1) cell cycle arrest in p53 null (-/-) cells, The p53 +/- cells were comparable to the wt p53 cells in transient G(1) arrest capacity, but showed a diminished permanent G(1) arrest. These data clearly implicate p53 function in permanent G(1) arrest, The reduced capacity for DNA damage-induced, permanent G(1) arrest in LFS may contribute significantly to cancer predisposition in this familial syndrome.	CHRISTIE HOSP NHS TRUST,CRC,PAEDIAT & FAMILIAL CANC RES GRP,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP NHS TRUST,CRC,DEPT GENE REGULAT,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Williams, KJ (corresponding author), CHRISTIE HOSP NHS TRUST,CRC,DEPT CANC GENET,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND.							BECHHANSEN NT, 1981, LANCET, V1, P1335; BIRCH JM, 1994, CANCER RES, V54, P1298; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BURNET NG, 1994, RADIOTHER ONCOL, V33, P228, DOI 10.1016/0167-8140(94)90358-1; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LALLE P, 1995, ONCOGENE, V10, P2447; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI CY, 1995, ONCOGENE, V11, P1885; LI FP, 1969, J NATL CANCER I, V43, P1365; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; NAGASAWA H, 1995, CANCER RES, V55, P1842; OCONNOR PM, 1993, CANCER RES, V53, P4776; PARSHAD R, 1993, RADIAT RES, V136, P236, DOI 10.2307/3578616; PAULES RS, 1995, CANCER RES, V55, P1763; POOT M, 1990, FLOW CYTOMETRY PRACT, P105; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Sproston ARM, 1996, INT J RADIAT BIOL, V70, P145, DOI 10.1080/095530096145139; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART N, 1995, ONCOGENE, V10, P109; WEEKS DE, 1991, RADIAT RES, V128, P90, DOI 10.2307/3578071; Williams KJ, 1996, BRIT J CANCER, V74, P698, DOI 10.1038/bjc.1996.424; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	35	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					277	282		10.1038/sj.onc.1200838	http://dx.doi.org/10.1038/sj.onc.1200838			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018113				2022-12-25	WOS:A1997WD51600003
J	Lassle, M; Blatch, GL; Kundra, V; Takatori, T; Zetter, BR				Lassle, M; Blatch, GL; Kundra, V; Takatori, T; Zetter, BR			Stress-inducible, murine protein mSTI1 - Characterization of binding domains for heat shock proteins and in vitro phosphorylation by different kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; TARGETING SEQUENCES; ESCHERICHIA-COLI; NUCLEAR IMPORT; HSP90; EXPRESSION; TPR; IDENTIFICATION; ACTIVATION	We have recently isolated the cDNA for the murine homologue of the stress-inducible phosphoprotein STI1 (also known as IEF SSP 3521 or p60). STI1 was previously shown to be a fold up-regulated in MRC-B fibro blasts upon viral transformation and to exist in a mac romolecular complex with heat shock proteins of the HSP 70 and 90 families. By peptide-sequencing we have identified the two heat shock proteins that bind to murine STI1 (mSTI1) as HSC 70 and HSP 84/86. We describe two separate binding regions within mSTI1 for the two heat shock proteins. In the presence of cell extracts, the N-terminal region of mSTI1 binds preferentially to HSC 70, whereas the C-terminal portion of the molecule promotes the binding of HSP 84/86. Heat treatment caused a strong induction of mSTI1 message without affecting the steady-state level of the protein significantly. In addition, heat treatment led to changes in the isoform-composition of mSTI1. pp70(s6k), pp90(rsk), and mitogen activated protein kinase-activated protein kinase 2 were tested as possible STI1 kinases in, vitro using recombinant mSTI1 as a substrate: only pp90(rsk) was able to phosphorylate recombinant mSTI1. In vitro kinase assays using casein kinase II suggest serine 189 to be a likely phosphorylation site in mSTI1.	HARVARD UNIV,SCH MED,DEPT CELL BIOL & SURG,BOSTON,MA 02115; CHILDRENS HOSP,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital			Blatch, Gregory/Q-5900-2019	Blatch, Gregory/0000-0003-0778-8577	NCI NIH HHS [CA39373] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; ERIKSON RL, 1995, PROTEIN KINASE FACTS, V1, P112; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Harlow E., 1988, ANTIBODIES LAB MANUA; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOHFELD J, 1995, CELL, V83, P589; HONORE B, 1992, J BIOL CHEM, V267, P8485; JANS DA, 1994, ONCOGENE, V9, P2961; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PYERIN W, 1994, ADV ENZYME REGUL, V34, P225, DOI 10.1016/0065-2571(94)90018-3; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STOKOE D, 1993, BIOCHEM J, V296, P842; TORRES JH, 1995, PLANT MOL BIOL, V27, P1221, DOI 10.1007/BF00020896; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	41	142	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1876	1884		10.1074/jbc.272.3.1876	http://dx.doi.org/10.1074/jbc.272.3.1876			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999875	hybrid			2022-12-25	WOS:A1997WD05800073
J	Ohguchi, K; Nakashima, S; Tan, ZM; Banno, Y; Dohi, S; Nozawa, Y				Ohguchi, K; Nakashima, S; Tan, ZM; Banno, Y; Dohi, S; Nozawa, Y			Increased activity of small GTP-binding protein-dependent phospholipase D during differentiation in human promyelocytic leukemic HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; D ACTIVATION; HL-60 CELLS; HUMAN NEUTROPHILS; KINASE-C; SYNERGISTIC ACTIVATION; SUPEROXIDE GENERATION; DOWNSTREAM EFFECTOR; SIGNAL-TRANSDUCTION; NADPH OXIDASE	In response to dibutyryl cyclic AMP (dbcAMP) and all-trans retinoic acid, human promyelocytic leukemic HL60 cells differentiate into granulocyte-like cells. In cell lysate and in vitro reconstitution system, phospholipase D (PLD) activity in response to guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) was up regulated by db-cAMP or all-trans retinoic acid treatment. In the present study, the mechanism(s) for increased PLD activity during differentiation was examined. Western blot analysis revealed that the contents of ADP-ribosylation factor, Rac2, and Cdc42Hs but not RhoA and Rad in the cytosolic fraction were elevated during differentiation. However, the cytosolic fraction from undifferentiated cells was almost equally potent as the cytosolic fraction from differentiated cells in the ability to stimulate membrane PLD activity. It was shown that the GTP gamma S-dependent PLD activity in membranes from differentiated cells was much higher than that in membranes from undifferentiated cells, suggesting that the increased PLD activity during differentiation was due to alterations in some membrane component(s). Clostridium botulinum ADP-ribosyltransferase C3 and C. difficile toxin B, which are known as inhibitors of RhoA and Rho family proteins, respectively, effectively suppressed PLD activity in membranes from differentiated cells. In fact, the amount of membrane-associated RhoA was increased during differentiation. Furthermore, the extent of GTP gamma S-dependent PLD activity partially purified from membranes from differentiated cells was greater than that from membranes from undifferentiated cells in the presence of recombinant ADP-ribosylation factor 1. The PLD (hPLD1) mRNA level was observed to be up-regulated during differentiation, as inferred by reverse transcription-polymerase chain reaction. Our results suggest the possibility that the increased Rho proteins in membranes and the changed level of PLD itself may be, at least in part, responsible for the increase in GTP gamma S-dependent PLD activity during granulocytic differentiation of HL60 cells.	GIFU UNIV,SCH MED,DEPT BIOCHEM,GIFU 500,JAPAN; GIFU UNIV,SCH MED,DEPT ANESTHESIOL & CRIT CARE MED,GIFU 500,JAPAN	Gifu University; Gifu University								AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; ALAM MS, 1995, BIOCHEM BIOPH RES CO, V207, P460, DOI 10.1006/bbrc.1995.1210; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BAULDRY SA, 1992, J BIOL CHEM, V267, P25141; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GELAS P, 1992, BIOCHEM J, V287, P67, DOI 10.1042/bj2870067; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HONG JX, 1994, J BIOL CHEM, V269, P9743; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; NOBES CD, 1995, J CELL SCI, V108, P225; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; OLSON SC, 1991, J BIOL CHEM, V266, P17236; OLSON SC, 1990, FEBS LETT, V272, P19, DOI 10.1016/0014-5793(90)80439-P; PERRY DK, 1992, J IMMUNOL, V149, P2749; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; SUCHARD SJ, 1994, J BIOL CHEM, V269, P8063; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TOBERT JA, 1987, CIRCULATION, V76, P534, DOI 10.1161/01.CIR.76.3.534; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; XING MZ, 1994, J BIOL CHEM, V269, P3117; XING MZ, 1992, J BIOL CHEM, V267, P6602	51	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1990	1996		10.1074/jbc.272.3.1990	http://dx.doi.org/10.1074/jbc.272.3.1990			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999891	hybrid			2022-12-25	WOS:A1997WD05800089
J	Rippe, RA; Umezawa, A; Kimball, JP; Breindl, M; Brenner, DA				Rippe, RA; Umezawa, A; Kimball, JP; Breindl, M; Brenner, DA			Binding of upstream stimulatory factor to an E-box in the 3'-flanking region stimulates alpha 1(I) collagen gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; PUTATIVE REGULATORY SEQUENCES; TISSUE-SPECIFIC EXPRESSION; 1ST INTRON CONTRIBUTE; I PROCOLLAGEN COL1A1; NUCLEAR FACTOR-I; TRANSGENIC MICE; FACTOR USF; DNA METHYLATION; MESSENGER-RNA	Since several lines of evidence implicate the 3'-flanking region in regulating alpha 1(I) collagen gene transcription, we analyzed 12.4-kilobase pairs of 3'-flanking sequence of the murine alpha 1(I) collagen gene for transcriptional elements. A region of the 3'-flanking region stimulated expression of the heterologous beta-globin gene promoter in an enhancer trap plasmid and of the alpha 1(I) collagen gene promoter in a collagen-luciferase reporter gene construct when located 3' to the luciferase reporter gene. DNase I footprinting analysis demonstrated the presence of three regions where DNA binding proteins specifically interact within this 3'-stimulatory region. Inspection of the DNA sequence revealed a consensus E-box, a binding site for basic helix-loop helix proteins, in one of the protein binding sites. Mobility shift assays demonstrated that upstream stimulatory factors (USF) USF-1 and USF-2 bind to this E-box. Mutating the E-box in the context of the 3'-flanking region confirmed that it contributes to the enhancement of transcriptional activity of the alpha 1(I) collagen gene promoter. Mutations in all three protein binding sites abolished transcriptional activation by the 3'-flanking region, suggesting a complex interaction among the trans-acting factors in enhancing transcriptional activity. Thus, a region of the 3'-flanking region of the alpha 1(I) collagen gene stimulates transcription of the alpha 1(I) collagen gene promoter, and USF-1 and USF-2 con tribute to this transcriptional stimulation.	UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOL BIOL, SAN DIEGO, CA 92182 USA	University of North Carolina; University of North Carolina Chapel Hill; California State University System; San Diego State University; California State University System; San Diego State University	Rippe, RA (corresponding author), UNIV N CAROLINA, DEPT MED, DIV DIGEST DIS, CB 7038, CHAPEL HILL, NC 27599 USA.			Brenner, David/0000-0003-2573-525X	NCI NIH HHS [CA50528] Funding Source: Medline; NIDDK NIH HHS [DK34987] Funding Source: Medline; NIGMS NIH HHS [GM41084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARSH GS, 1984, J BIOL CHEM, V259, P4906; BEDALOV A, 1995, J BONE MINER RES, V10, P1443; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BRENNER DA, 1993, HEPATOLOGY, V17, P287, DOI 10.1016/0270-9139(93)90090-A; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CHAN H, 1991, MOL CELL BIOL, V11, P47, DOI 10.1128/MCB.11.1.47; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FURTH JJ, 1991, EXP CELL RES, V192, P118, DOI 10.1016/0014-4827(91)90165-Q; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; HALLE JP, 1995, J BIOL CHEM, V270, P21307, DOI 10.1074/jbc.270.36.21307; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HU L, 1994, J BIOL CHEM, V269, P183; HYDER SM, 1994, J STEROID BIOCHEM, V48, P69, DOI 10.1016/0960-0760(94)90252-6; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; KULOZIK M, 1990, J CLIN INVEST, V86, P917, DOI 10.1172/JCI114793; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MOOSLEHNER K, 1988, NUCLEIC ACIDS RES, V16, P773, DOI 10.1093/nar/16.2.773; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NIBU Y, 1994, J BIOL CHEM, V269, P28598; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; PATERSON JM, 1995, BIOCHEM J, V310, P401, DOI 10.1042/bj3100401; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RHODES K, 1994, MOL CELL BIOL, V14, P5950, DOI 10.1128/MCB.14.9.5950; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMKEVICH CP, 1992, BIOCHEM J, V286, P179, DOI 10.1042/bj2860179; SINGH IS, 1994, MOL ENDOCRINOL, V8, P1163, DOI 10.1210/me.8.9.1163; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; SOKOLOV BP, 1995, J BIOL CHEM, V270, P9622, DOI 10.1074/jbc.270.16.9622; SOKOLOV BP, 1993, BIOCHEMISTRY-US, V32, P9242, DOI 10.1021/bi00086a033; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TSUKAMOTO H, 1986, HEPATOLOGY, V6, P814, DOI 10.1002/hep.1840060503; VARGA J, 1990, ANN INTERN MED, V112, P344, DOI 10.7326/0003-4819-112-5-344; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WONG SC, 1995, J NEUROCHEM, V65, P23; WU H, 1990, MOL CELL BIOL, V10, P1452, DOI 10.1128/MCB.10.4.1452	65	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1753	1760		10.1074/jbc.272.3.1753	http://dx.doi.org/10.1074/jbc.272.3.1753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999857	hybrid, Green Published			2022-12-25	WOS:A1997WD05800055
J	Schoenwaelder, SM; Yuan, YP; Cooray, P; Salem, HH; Jackson, SP				Schoenwaelder, SM; Yuan, YP; Cooray, P; Salem, HH; Jackson, SP			Calpain cleavage of focal adhesion proteins regulates the cytoskeletal attachment of integrin alpha(IIb)beta(3) (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin clots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLOOD-PLATELETS; TYROSINE PHOSPHORYLATION; MU-CALPAIN; EXTRACELLULAR-MATRIX; NEUTRAL PROTEASE; IIB-IIIA; ACTIVATION; ASSOCIATION; BINDING; IDENTIFICATION	The intracellular thiol protease calpain catalyzes the limited proteolysis of various focal adhesion structural proteins and signaling enzymes in adherent cells. In human platelets, calpain activation is dependent on fibrinogen binding to integrin alpha(IIb)beta(3) and subsequent platelet aggregation, suggesting a potential role for this protease in the regulation of postaggregation responses. In this study, we have examined the effects of calpain activation on several postaggregation events in human platelets, including the cytoskeletal attachment of integrin alpha(IIb)beta(3), the tyrosine phosphorylation of cytoskeletal proteins, and the cellular retraction of fibrin clots. We demonstrate that calpain activation in either washed platelets or platelet-rich plasma is associated with a marked reduction in platelet-mediated fibrin clot retraction. This relaxation of clot retraction was observed in both thrombin and ionophore A23187-stimulated platelets. Calcium dose response studies (extracellular calcium concentrations between 0.1 mu M and 1 M) revealed a strong correlation between calpain activation and relaxed clot retraction. Furthermore, pretreating platelets with the calpain inhibitors calpeptin and calpain inhibitor I prevented the calpain-mediated reduction in clot retraction. Relaxed fibrin clot retraction was associated with the cleavage of several platelet focal adhesion structural proteins and signaling enzymes, resulting in the dissociation of talin, pp60(c-scr), and integrin alpha(IIb)beta(3) from the contractile cytoskeleton and the tyrosine dephosphorylation of multiple cytoskeletal proteins. These studies suggest an important role for calpain in the regulation of multiple postaggregation events in human platelets. The ability of calpain to inhibit clot retraction is likely to be due to the cleavage of both structural and signaling proteins involved in modulating integrin-cytoskeletal interactions.	BOX HILL HOSP,DEPT PATHOL,BOX HILL,VIC 3128,AUSTRALIA	Box Hill Hospital	Schoenwaelder, SM (corresponding author), BOX HILL HOSP,MONASH MED SCH,DEPT MED,ARNOLD ST,BOX HILL,VIC 3128,AUSTRALIA.		Jackson, Shaun P/E-9633-2011; Schoenwaelder, Simone/E-9506-2011	Jackson, Shaun/0000-0002-4750-1991; Schoenwaelder, Simone/0000-0003-0465-5840				ALTMULLER A, 1995, BBA-MOL CELL RES, V1265, P61, DOI 10.1016/0167-4889(94)00194-J; ARIYOSHI H, 1995, ARTERIOSCL THROM VAS, V15, P511, DOI 10.1161/01.ATV.15.4.511; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARILLO S, 1994, ONCOGENE, V9, P1679; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1995, THROMB HAEMOSTASIS, V73, pA987; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GILMORE AP, 1995, NATURE, V373, P197, DOI 10.1038/373197a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; JAKOBSEN E, 1979, THROMB RES, V3, P145; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; ODA A, 1993, J BIOL CHEM, V268, P12603; ODA A, 1992, J BIOL CHEM, V267, P20075; OGAWA Y, 1968, J BIOCHEM-TOKYO, V64, P255, DOI 10.1093/oxfordjournals.jbchem.a128887; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLACE RW, 1987, BIOCHEMISTRY-US, V26, P2766, DOI 10.1021/bi00384a017	35	115	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1694	1702		10.1074/jbc.272.3.1694	http://dx.doi.org/10.1074/jbc.272.3.1694			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999848	hybrid			2022-12-25	WOS:A1997WD05800046
J	Gopalakrishnan, S; Fischer, RS; Quinlan, MP				Gopalakrishnan, S; Fischer, RS; Quinlan, MP			Induction of a complex between rasGAP and a novel 110 kD protein is required for immortalization of primary epithelial cells by the E1A 12S oncoprotein of adenovirus	ONCOGENE			English	Article						immortalization; adenovirus E1A 12S; protein complexes	GTPASE-ACTIVATING PROTEIN; EFFICIENT NUCLEAR-LOCALIZATION; GROWTH-FACTOR INDUCTION; C-TERMINAL REGION; TYROSINE PHOSPHORYLATION; COOPERATING ONCOGENES; CELLULAR PROTEIN; E1A-12S PROTEIN; TUMOR-ANTIGEN; EMBRYO CELLS	Although established cell lines can be transformed with oncogenic ras, primary epithelial cells cannot, but require the coexpression of an immortalizing oncogene, such as the E1A region of adenovirus. We have previously shown that immortalization of primary epithelial cells by E1A 12S requires the expression of five regions encoded by both the first and second exons of the gene, However, only three of these regions, located in the first exon, are required for cotransformation of primary cells with an activated ras oncogene, Thus, the expression of oncogenic ras is able to abrogate the need for the E1A function(s) encoded by the second exon that are required for immortalization, This suggested the possibility that the functions encoded by the second exon of E1A may involve or interact with the normal ras signal transduction pathway, The results described herein demonstrate that immortalization-competent 12S gene products induce the expression of a novel 110 kD protein, p110, that forms a stable complex with rasGAP. Failure to induce the p110-rasGAP complex results in the concomitant loss of ability of 12S to immortalize primary epithelial cells, The appearance of this complex parallels the expression of the 12S protein and is sensitive to the levels of E1A 12S, p110 induction is independent of the ability of 12S to activate the cell cycle and of the presence of adenovirus E1B and is not observed in the presence of the large T antigen of SV40, Thus, it is not a general response to proliferation or tumorigenic transformation, but rather seems to be specific to the immortalization function(s) of E1A 12S.	UNIV TENNESSEE, CTR HLTH SCI, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center				Fischer, Robert/0000-0003-0650-2696	NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER; NCI NIH HHS [CA50540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOLS BLMC, 1991, CANCER RES, V51, P1177; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1994, CELL GROWTH DIFFER, V5, P475; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Flint S. J, 1981, DNA TUMOR VIRUSES; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOTOH A, 1994, LEUKEMIA, V8, P115; GRAHAM FL, 1974, NATURE, V251, P687, DOI 10.1038/251687a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GSCHWENDT M, 1993, BIOCHEM BIOPH RES CO, V194, P571, DOI 10.1006/bbrc.1993.1858; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; PRONK GJ, 1993, ONCOGENE, V8, P2773; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1994, ONCOGENE, V9, P2639; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1993, ONCOGENE, V8, P3289; QUINLAN MP, 1993, ONCOGENE, V8, P257; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHENK T, 1991, ADV CANCER RES, V57, P47; SJOLANDER A, 1992, BIOCHEM BIOPH RES CO, V189, P1503, DOI 10.1016/0006-291X(92)90245-G; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAUB M, 1984, METHODS SERUM FREE C; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	75	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2659	2669						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000140				2022-12-25	WOS:A1996VZ65400016
J	MirShekari, SY; Ashford, DA; Harvey, DJ; Dwek, RA; Schulze, IT				MirShekari, SY; Ashford, DA; Harvey, DJ; Dwek, RA; Schulze, IT			The glycosylation of the influenza A virus hemagglutinin by mammalian cells - A site-specific study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; ENDO-BETA-GALACTOSIDASE; BINDING-PROPERTIES; CALF THYMUS; LINKED OLIGOSACCHARIDES; BACTEROIDES-FRAGILIS; SIALIC-ACID; UDP-GAL; LECTIN; RECEPTOR	We have characterized the glycans at individual sites on the hemagglutinin of three influenza A variants to obtain information on the role of cell-specific glycosylation in determining the receptor binding properties of this virus, The variants differ in whether they have a glycosylation site at residue 129 on the tip of the hemagglutinin and whether amino acid 184 (near to the receptor binding site) is His or Asn. We found that all sites on each variant are glycosylated in Madin-Darby bovine kidney cells, that the glycosylation is site-specific, and that the glycans at the same site in each variant are highly similar. One site that is buried in the hemagglutinin trimer contains only oligomannose glycans, The remaining sites carry complex glycans of increasing size as the distance of the site from the viral membrane decreases, Most of these complex glycans are terminated with alpha-galactose residues, a consequence in bovine cells of the removal of terminal sialic acids by the viral neuraminidase, Although the glycans at residue 129 are among the smallest on the molecule, they are large enough to reach the receptor binding pocket on their own and adjacent monomers. The results suggest that the reduction in receptor binding observed with Madin-Darby bovine kidney cell-grown virus is due to the combined effect of large complex glycans at the tip of the hemagglutinin and a His to Asn substitution close to the receptor binding pocket.	ST LOUIS UNIV,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,ST LOUIS,MO 63104; UNIV OXFORD,DEPT BIOCHEM,GLYCOBIOL INST,OXFORD OX1 3QU,ENGLAND	Saint Louis University; University of Oxford			Harvey, David/A-5579-2013	Harvey, David/0000-0003-0544-771X	FIC NIH HHS [FO6 TWO1561] Funding Source: Medline; NIAID NIH HHS [AI 23520] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW001561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023520] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; AYTAY S, 1991, J VIROL, V65, P3022, DOI 10.1128/JVI.65.6.3022-3028.1991; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; Blackburn P, 1982, ENZYMES, VXV, P317; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BORDOLI RS, 1994, RAPID COMMUN MASS SP, V8, P585, DOI 10.1002/rcm.1290080803; Costa J, 1996, PLANTA, V198, P221, DOI 10.1007/BF00206247; CRECELIUS DM, 1984, VIROLOGY, V139, P164, DOI 10.1016/0042-6822(84)90337-4; CRECELIUS DM, 1983, THESIS ST LOUIS U; DEOM CM, 1985, J BIOL CHEM, V260, P4771; DESHPANDE KL, 1987, P NATL ACAD SCI USA, V84, P36, DOI 10.1073/pnas.84.1.36; DOEM CM, 1986, P NATL ACAD SCI USA, V83, P3771; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; FUKUDA MN, 1978, J BIOL CHEM, V253, P6814; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GALLAGHER PJ, 1992, J VIROL, V66, P7136, DOI 10.1128/JVI.66.12.7136-7145.1992; HARLOW E, 1988, ANTIBODIES LABORATOR, P524; Harvey DJ, 1995, RAPID COMMUN MASS SP, V9, P1556, DOI 10.1002/rcm.1290091517; HARVEY DJ, 1994, ORG MASS SPECTROM, V29, P753, DOI 10.1002/oms.1210291208; HITI AL, 1981, VIROLOGY, V111, P113, DOI 10.1016/0042-6822(81)90658-9; INKSTER MD, 1993, J VIROL, V67, P7436, DOI 10.1128/JVI.67.12.7436-7443.1993; KEIL W, 1985, EMBO J, V4, P2711, DOI 10.1002/j.1460-2075.1985.tb03991.x; KEIL W, 1984, VIROLOGY, V133, P77, DOI 10.1016/0042-6822(84)90427-6; KELM S, 1992, EUR J BIOCHEM, V205, P147, DOI 10.1111/j.1432-1033.1992.tb16762.x; KEMBLE GW, 1993, J CELL BIOL, V122, P1253, DOI 10.1083/jcb.122.6.1253; KOBATA A, 1987, METHOD ENZYMOL, V138, P84; LAKSHMI MV, 1978, VIROLOGY, V88, P314, DOI 10.1016/0042-6822(78)90288-X; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIRSHEKARI SY, 1995, THESIS U OXFORE; NORONHABLOB L, 1976, VIROLOGY, V69, P314, DOI 10.1016/0042-6822(76)90218-X; PAREKH RB, 1987, EMBO J, V6, P12333; PONS MW, 1968, VIROLOGY, V34, P385, DOI 10.1016/0042-6822(68)90257-2; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SCHULZE IT, 1988, VIRUS RES S, V2, P60; SCUDDER P, 1987, EUR J BIOCHEM, V168, P585, DOI 10.1111/j.1432-1033.1987.tb13457.x; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SKEHEL JJ, 1984, P NATL ACAD SCI-BIOL, V81, P1779, DOI 10.1073/pnas.81.6.1779; VANDENEIJNDEN DH, 1983, EUR J BIOCHEM, V134, P523; VANHALBEEK H, 1983, BIOCHEM BIOPH RES CO, V110, P124, DOI 10.1016/0006-291X(83)91269-X; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	47	82	87	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4027	4036		10.1074/jbc.272.7.4027	http://dx.doi.org/10.1074/jbc.272.7.4027			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020110	hybrid			2022-12-25	WOS:A1997WH01900026
J	Molino, M; Barnathan, ES; Numerof, R; Clark, J; Dreyer, M; Cumashi, A; Hoxie, JA; Schechter, N; Woolkalis, M; Brass, LF				Molino, M; Barnathan, ES; Numerof, R; Clark, J; Dreyer, M; Cumashi, A; Hoxie, JA; Schechter, N; Woolkalis, M; Brass, LF			Interactions of mast cell tryptase with thrombin receptors and PAR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG TRYPTASE; ACTIVATED RECEPTOR; MOLECULAR-CLONING; CATHEPSIN-G; PEPTIDE; MECHANISM; PLATELET; PROTEIN; INTERNALIZATION; PURIFICATION	Tryptase is a serine protease secreted by mast cells that is able to activate other cells. In the present studies we have tested whether these responses could be mediated by thrombin receptors or PAR-2, two G-protein-coupled receptors that are activated by proteolysis. When added to a peptide corresponding to the N terminus of PAR-2, tryptase cleaved the peptide at the activating site, but at higher concentrations it also cleaved downstream, as did trypsin, a known activator of PAR-2. Thrombin, factor Xa, plasmin, urokinase, plasma kallikrein, and tissue kallikrein had no effect. Tryptase also cleaved the analogous thrombin receptor peptide at the activating site but less efficiently. When added to COS-1 cells expressing either receptor, tryptase stimulated phosphoinositide hydrolysis. With PAR-2, this response was half-maximal at 1 nM tryptase and could be inhibited by the tryptase inhibitor, APC366, or by antibodies to tryptase and PAR-2. When added to human endothelial cells, which normally express PAR-2 and thrombin receptors, or keratinocytes, which express only PAR-2, tryptase caused an increase in cytosolic Ca2+. However, when added to platelets or CHRF-288 cells, which express thrombin receptors but not PAR-2, tryptase caused neither aggregation nor increased Ca2+, These results show that 1) tryptase has the potential to activate both PAR-2 and thrombin receptors; 2) for PAR-2, this potential is realized, although cleavage at secondary sites may Limit activation, particularly at higher tryptase concentrations; and 3) in contrast, although tryptase clearly activates thrombin receptors in COS-1 cells, it does not appear to cleave endogenous thrombin receptors in platelets or CHRF-288 cells. These distinctions correlate with the observed differences in the rate of cleavage of the PAR-2 and thrombin receptor peptides by tryptase. Tryptase is the first protease other than trypsin that has been shown to activate human PAR-2. Its presence within mast cell granules places it in tissues where PAR-2 is expressed but trypsin is unlikely to reach.	UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT DERMATOL,PHILADELPHIA,PA 19104; UNIV PENN,CTR EXPT THERAPEUT,PHILADELPHIA,PA 19104; IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY; THOMAS JEFFERSON UNIV,DEPT PHYSIOL,PHILADELPHIA,PA 19107; ARRIS PHARMACEUT CORP,S SAN FRANCISCO,CA 94080	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Jefferson University				Dreyer, Mark/0000-0002-8691-9063	NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047839, P01HL040387] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16520] Funding Source: Medline; NHLBI NIH HHS [HL-40387, HL-47839] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BROWN JK, 1995, AM J RESP CELL MOL, V13, P227, DOI 10.1165/ajrcmb.13.2.7626290; BUTRUS SI, 1990, OPHTHALMOLOGY, V97, P1678; BUTTERFIELD JH, 1990, J LEUKOCYTE BIOL, V47, P409, DOI 10.1002/jlb.47.5.409; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; COMPTON SJ, 1996, AM J RESP CRIT CARE, V153, pA575; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; DEAN NM, 1989, ANAL BIOCHEM, V183, P199, DOI 10.1016/0003-2697(89)90468-5; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; HARTMANN T, 1994, AM J PHYSIOL, V267, pL113, DOI 10.1152/ajplung.1994.267.2.L113; HARTMANN T, 1992, AM J PHYSIOL, V262, pL568; HEIN L, 1994, J BIOL CHEM, V269, P27719; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Hwa JJ, 1996, CIRC RES, V78, P581, DOI 10.1161/01.RES.78.4.581; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kimura M, 1996, AM J PHYSIOL-CELL PH, V271, pC54, DOI 10.1152/ajpcell.1996.271.1.C54; KOVANEN PT, 1995, CIRCULATION, V92, P1084, DOI 10.1161/01.CIR.92.5.1084; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; MOLINO M, 1992, BIOCHEM J, V288, P741, DOI 10.1042/bj2880741; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; NORTON KJ, 1993, BLOOD, V82, P2125; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; ROZNIECKI JJ, 1995, ANN NEUROL, V37, P63, DOI 10.1002/ana.410370112; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SCHECHTER NM, 1995, BIOCHEMISTRY-US, V34, P10628, DOI 10.1021/bi00033a038; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; TANAKA T, 1983, J BIOL CHEM, V258, P3552; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868	42	519	545	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4043	4049		10.1074/jbc.272.7.4043	http://dx.doi.org/10.1074/jbc.272.7.4043			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020112	hybrid			2022-12-25	WOS:A1997WH01900028
J	Petersen, BO; Shuman, S				Petersen, BO; Shuman, S			Histidine 265 is important for covalent catalysis by vaccinia topoisomerase and is conserved in all eukaryotic type I enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; STRAND CLEAVAGE; MUTANT ALLELES; DNA CLEAVAGE; TYROSINE; IDENTIFICATION; CAMPTOTHECIN; MUTATION; SEQUENCE; BINDING	Vaccinia topoisomerase catalyzes DNA cleavage and rejoining via transesterification to pentapyrimidine recognition site 5'-(CPT)CCTT down arrow in duplex DNA. The proposed reaction mechanism involves general-base catalysis of the attack by active site nucleophile Tyr-274 on the scissile phosphodiester and general-acid catalysis of the expulsion of the 5'-deoxyribose oxygen on the leaving DNA strand, The pK(a) values suggest histidine and cysteine side chains as candidates for the roles of proton acceptor and donor, respectively, To test this, we replaced each of the eight histidines and two cysteines of the vaccinia topoisomerase with alanine, Single mutants C100A and C211A and a double mutant C100A-C211A were fully active in DNA relaxation, indicating that a cysteine is not the general acid, Only one histidine mutation, H265A, affected enzyme activity, The rates of DNA relaxation, single-turnover strand cleavage, and single-turnover religation by H265A were 2 orders of magnitude lower than the wild-type rates, Yet the H265A mutation did not alter the dependence of the cleavage rate on pH, indicating that His-265 is not the general base, Replacing His-265 with glutamine or asparagine slowed DNA relaxation and single-turnover cleavage to about one-third of the wild-type rate, All three mutations, H265A, H265N, and H265Q, skewed the cleavage-religation equilibrium in favor of the covalently bound state, His-265 is strictly conserved in every member of the eukaryotic type I topoisomerase family.			Petersen, BO (corresponding author), SLOAN KETTERING INST,PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Caron P R, 1994, Adv Pharmacol, V29B, P271; ENG WK, 1989, J BIOL CHEM, V264, P13373; GERHOLD D, 1994, NUCLEIC ACIDS RES, V22, P3773, DOI 10.1093/nar/22.18.3773; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; GUPTA M, 1994, J BIOL CHEM, V269, P573; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jensen AD, 1996, EUR J BIOCHEM, V236, P389, DOI 10.1111/j.1432-1033.1996.00389.x; KLEMPERER N, 1993, J BIOL CHEM, V268, P15887; KLEMPERER N, 1995, VIROLOGY, V206, P203, DOI 10.1016/S0042-6822(95)80035-2; LEVIN NA, 1993, GENETICS, V133, P799; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1992, CANCER RES, V52, P525; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P29760; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; TOSH K, 1995, GENE, V163, P151, DOI 10.1016/0378-1119(95)00376-H; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978	30	53	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3891	3896		10.1074/jbc.272.7.3891	http://dx.doi.org/10.1074/jbc.272.7.3891			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020090	hybrid			2022-12-25	WOS:A1997WH01900006
J	Rye, KA; Hime, NJ; Barter, PJ				Rye, KA; Hime, NJ; Barter, PJ			Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; EGG PHOSPHATIDYLCHOLINE; PLASMA-LIPOPROTEINS; BINDING; DEFICIENCY; RICH; SOLUBILIZATION; PHOSPHOLIPIDS; SUBFRACTIONS; LOCALIZATION	It is well established that cholesteryl ester transfer protein (CETP) changes the size of high density lipoproteins (HDL) during incubation in vitro. It has been suggested that HDL-CETP-HDL ternary complex formation is involved in these changes. The present results, which are consistent with CETP changing the size of spherical reconstituted HDL (rHDL) by a mechanism involving fusion, support the ternary complex hypothesis. When rHDL containing a core of cholesteryl esters and either three molecules of apolipoprotein (ape) A-I/particle, (A-I)rHDL, or six molecules of apoA-II/particle, (A-II)rHDL, were incubated individually with CETP, their respective diameters decreased from 9.4 to 7.8 nn and from 9.8 to 8.8 nm. The small (A-I)rHDL and (A-II)rHDL contained, respectively, two molecules of apoA-I/particle and four molecules of apoA-II/particle. As all of the rHDL lipids and apolipoproteins were quantitatively recovered at the end of the incubations, it was apparent that there was a 50% increase in the number of particles. This increase in the number of particles can be explained as follows: (i) sequential binding of two rHDL to CETP to generate a ternary complex, (ii) fusion of the rHDL in the ternary complex, and (iii) rearrangement of the fusion product into three small particles. Various spectroscopic techniques were used to show that the small rHDL were structurally distinct from the original rHDL. These results provide the first evidence that CETP mediates the fusion of spherical rHDL.	ROYAL ADELAIDE HOSP,DIV CARDIOVASC SERV,ADELAIDE,SA 5000,AUSTRALIA; UNIV ADELAIDE,ROYAL ADELAIDE HOSP,DEPT MED,ADELAIDE,SA 5000,AUSTRALIA	Royal Adelaide Hospital; Royal Adelaide Hospital; University of Adelaide								AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; BARTER PJ, 1982, ATHEROSCLEROSIS, V44, P27, DOI 10.1016/0021-9150(82)90050-8; BARTER PJ, 1980, J LIPID RES, V21, P238; BISGAIER CL, 1991, J LIPID RES, V32, P21; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; DUNN MJ, 1989, PROTEIN PURIFICATION, P1; Engberts JBFN, 1995, BBA-REV BIOMEMBRANES, V1241, P323, DOI 10.1016/0304-4157(95)00008-9; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; HAMILTON JA, 1991, BIOCHEMISTRY-US, V30, P2894, DOI 10.1021/bi00225a024; HAMILTON JA, 1989, BIOCHEMISTRY-US, V28, P2514, DOI 10.1021/bi00432a025; HAMILTON JA, 1981, P NATL ACAD SCI-BIOL, V78, P6878, DOI 10.1073/pnas.78.11.6878; HARTER C, 1989, J BIOL CHEM, V264, P6459; IHM J, 1982, J LIPID RES, V23, P1328; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; KOIZUMI J, 1991, ATHEROSCLEROSIS, V90, P189, DOI 10.1016/0021-9150(91)90114-I; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; LAGROST L, 1990, J LIPID RES, V31, P1569; LIANG HQ, 1994, J LIPID RES, V35, P1187; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MORRISETT JD, 1984, BIOCHEMISTRY-US, V23, P5343, DOI 10.1021/bi00317a037; POLLARD HB, 1988, MOL MECHANISMS MEMBR, P341; ROBINSON D, 1987, ARTERIOSCLEROSIS, V7, P341, DOI 10.1161/01.ATV.7.4.341; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1994, J BIOL CHEM, V269, P10298; Rye KA, 1996, J BIOL CHEM, V271, P4243; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; SAKAI N, 1991, ARTERIOSCLER THROMB, V11, P71, DOI 10.1161/01.ATV.11.1.71; SATA T, 1972, J LIPID RES, V13, P757; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1989, ATHEROSCLEROSIS, V77, P183, DOI 10.1016/0021-9150(89)90080-4; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; WANG S, 1992, J BIOL CHEM, V267, P17487; WEINBERG RB, 1994, J BIOL CHEM, V269, P29588; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803	38	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3953	3960		10.1074/jbc.272.7.3953	http://dx.doi.org/10.1074/jbc.272.7.3953			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020099	hybrid			2022-12-25	WOS:A1997WH01900015
J	Chestukhin, A; Litovchick, L; Muradov, K; Batkin, M; Shaltiel, S				Chestukhin, A; Litovchick, L; Muradov, K; Batkin, M; Shaltiel, S			Unveiling the substrate specificity of meprin beta on the basis of the site in protein kinase A cleaved by the kinase splitting membranal proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; RAT-KIDNEY; ALPHA-SUBUNIT; MICROVILLAR MEMBRANES; ASTACIN FAMILY; BRUSH-BORDER; MOUSE KIDNEY; METALLOENDOPEPTIDASES; ENDOPEPTIDASE-2; EXPRESSION	The kinase splitting membranal proteinase (KSMP) is a metalloendopeptidase that inactivates the catalytic (C) subunit of protein kinase A (PKA) by clipping off its carboxyl terminal tail. Here we show that this cleavage occurs at Glu(332)-Glu(333), within the cluster of acidic amino acids (Asp(328)-Glu(334)) of the kinase. The K-m values of KSMP and of meprin beta (which reproduces KSMP activity) for the C-subunit are below 1 mu M. The K-m for peptides containing a stretch of four Glu residues are in the micromolar range, illustrating the significant contribution of this cluster to the substrate recognition of meprin beta. This conclusion is supported by a systematic study using a series of the C-subunit mutants with deletions and mutations in the cluster of acidics. Hydrophobic amino acids vicinal to the cleavage site increase the K-eat of the proteinase. These studies unveil a new specificity for meprin beta, suggesting new substrates that are 1-2 orders of magnitude better in their K-m and K-eat than those commonly used for meprin assay. A search for substrates having such a cluster of acidics and hydrophobics, which are accessible to meprin under physiological conditions, point at gastrin as a potential target. Indeed, meprin beta is shown to cleave gastrin at its cluster of five glutamic acid residues and also at the M-D bond within its WMDF-NH2 sequence, which is indispensable for all the known biological activities of gastrins. The latter meprin cleavage will lead to the inactivation of gastrin and thus to the control of its activity.	WEIZMANN INST SCI,DEPT REGULAT BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Litovchick, Larisa/0000-0002-9540-597X				ALHANATY E, 1979, BIOCHEM BIOPH RES CO, V89, P323, DOI 10.1016/0006-291X(79)90633-8; ALHANATY E, 1981, P NATL ACAD SCI-BIOL, V78, P3492, DOI 10.1073/pnas.78.6.3492; ALHANATY E, 1985, CURR TOP CELL REGUL, V27, P267; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1986, BIOMED BIOCHIM ACTA, V45, P1515; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BOND JS, 1995, ZINC METALLOPROTEASE, P23; Chestukhin A, 1996, J BIOL CHEM, V271, P10175, DOI 10.1074/jbc.271.17.10175; Chestukhin A, 1996, J BIOL CHEM, V271, P30272, DOI 10.1074/jbc.271.47.30272; Chestukhin A, 1996, FEBS LETT, V382, P265, DOI 10.1016/0014-5793(96)00178-0; Cleland W.W., 1970, ENZYMES, P1; CORBEIL D, 1992, FEBS LETT, V309, P203, DOI 10.1016/0014-5793(92)81095-4; DUMERMUTH E, 1993, FEBS LETT, V335, P367, DOI 10.1016/0014-5793(93)80421-P; Edkins JS, 1905, P R SOC LOND B-CONTA, V76, P376, DOI 10.1098/rspb.1905.0029; GORBEA CM, 1994, MAMMALIAN BRUSH BORD, P89; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; JIANG WP, 1993, J BIOL CHEM, V268, P10380; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; JOHNSON GD, 1993, J BIOL CHEM, V268, P17647; JOHNSON LR, 1989, HDB PHYSL 6, V2, P291; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; MORLEY JS, 1965, NATURE, V207, P1356, DOI 10.1038/2071356a0; REHFELD JF, 1995, EMBO J, V14, P389, DOI 10.1002/j.1460-2075.1995.tb07013.x; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; REHFELD JF, 1993, GASTRIN, P1; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SEGER R, 1989, EMBO J, V8, P435, DOI 10.1002/j.1460-2075.1989.tb03395.x; SEGER R, 1988, J BIOL CHEM, V263, P3496; SEGER R, 1989, THESIS WEIZMANN I SC; SEGER R, 1993, INNOVATION PROTEASES, P231; SHALTIEL S, 1988, ROOTS OF MODERN BIOCHEMISTRY, P781; SHALTIEL S, 1989, MECH REGULATION INTR, P188; STEPHENSON SL, 1988, BIOCHEM J, V255, P45, DOI 10.1042/bj2550045; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; TRACY HJ, 1964, NATURE, V204, P935, DOI 10.1038/204935a0; WOLZ RL, 1991, BIOCHEMISTRY-US, V30, P8488, DOI 10.1021/bi00098a029; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; YAMAGUCHI T, 1992, EUR J BIOCHEM, V204, P547, DOI 10.1111/j.1432-1033.1992.tb16666.x; YAMAGUCHI T, 1994, LIFE SCI, V54, P381, DOI 10.1016/0024-3205(94)00795-0; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	47	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3153	3160		10.1074/jbc.272.6.3153	http://dx.doi.org/10.1074/jbc.272.6.3153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013548	hybrid			2022-12-25	WOS:A1997WG19200008
J	Foltz, IN; Lee, JC; Young, PR; Schrader, JW				Foltz, IN; Lee, JC; Young, PR; Schrader, JW			Hemopoietic growth factors with the exception of interleukin-4 activate the p38 mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; HEAT-SHOCK PROTEIN-27; MAPKAP KINASE-2; TYROSINE PHOSPHORYLATION; CELLS; CASCADE; MODULATION; RECEPTORS; REQUIRES	The mammalian mitogen-activated protein (MAP) kinase homologue p38 has been shown to be activated by pro-inflammatory cytokines as well as physical and chemical stresses. We now show that a variety of hemopoietic growth factors, including Steel locus factor, colony stimulating factor-1, granulocyte/macrophage-colony stimulating factor, and interleukin-3, activate p38 MAP kinase and the downstream kinase MAPKAP kinase-2. Furthermore, although these growth factors activate both p38 MAP kinase and Erk MAP kinases, we demonstrate using a specific inhibitor of p38 MAP kinase, SE 203580, that p38 MAP kinase activity was required for MAP kinase-activated protein kinase-2 activation. Conversely p38 MAP kinase was shown not to be required for in vivo activation of p90(rsk), known to be downstream of the Erk MAP kinases. Interleukin-4 was unique among the hemopoietic growth factors we examined in failing to induce activation of either p38 MAP kinase or MAP kinase-activated protein kinase-2. These findings demonstrate that the activation of p38 MAP kinase is involved not only in responses to stresses but also in signaling by growth factors that regulate the normal development and function of cells of the immune system.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406	University of British Columbia; GlaxoSmithKline								AHLERS A, 1994, BLOOD, V83, P1791; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAJIMA A, 1993, BLOOD, V82, P1960; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; STANLEY ER, 1994, CYTOKINE HDB, P387; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	46	147	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3296	3301		10.1074/jbc.272.6.3296	http://dx.doi.org/10.1074/jbc.272.6.3296			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013568	hybrid			2022-12-25	WOS:A1997WG19200028
J	Gremlich, S; Roduit, R; Thorens, B				Gremlich, S; Roduit, R; Thorens, B			Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells - Comparison with the effects of fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET AMYLOID POLYPEPTIDE; LONG-TERM EXPOSURE; RAT ISLETS; GENE-EXPRESSION; DIABETES-MELLITUS; NEUROPEPTIDE-Y; MESSENGER-RNA; TREATED RATS; GLUCOSE; LANGERHANS	GLUT2 expression is strongly decreased in glucose-unresponsive pancreatic beta cells of diabetic rodents. This decreased expression is due to circulating factors distinct from insulin or glucose, Here we evaluated the effect of palmitic acid and the synthetic glucocorticoid desamethasone on GLUT2 expression by in vitro cultured rat pancreatic islets. Palmitic acid induced a 40% decrease in GLUT2 mRNA levels with, however, no consistent effect on protein expression, Dexamethasone, in contrast, had no effect on GLUT2 mRNA, but decreased GLUT2 protein by about 65%. The effect of dexamethasone was more pronounced at high glucose concentrations and was inhibited by the glucocorticoid antagonist RU-486. Biosynthetic labeling experiments revealed that GLUTS translation rate was only minimally affected by dexamethasone, but that its half-life was decreased by 50%, indicating that glucocorticoids activated a posttranslational degradation mechanism. This degradation mechanism was not affecting all membrane proteins, since the alpha subunit of the Na+/K+-ATPase was unaffected, Glucose-induced insulin secretion was strongly decreased by treatment with palmitic acid and/or dexamethasone. The insulin content was decreased (similar to 55 percent) in the presence of palmitic acid, but increased (similar to 180%) in the presence of dexamethasone. We conclude that a combination of elevated fatty acids and glucocorticoids can induce two common features observed in diabetic beta cells, decreased GLUT2 expression, and loss of glucose-induced insulin secretion.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND	University of Lausanne			Roduit, Raphael/AAC-3890-2021	Roduit, Raphael/0000-0001-7440-2799				CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESPIN SR, 1973, J CLIN INVEST, V52, P1979, DOI 10.1172/JCI107382; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FERNANDEZMEJIA C, 1992, ENDOCRINOLOGY, V130, P1660, DOI 10.1210/en.130.3.1660; FERRER J, 1993, DIABETES, V42, P1273, DOI 10.2337/diabetes.42.9.1273; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; JAMAL H, 1991, ENDOCRINOLOGY, V129, P3372, DOI 10.1210/endo-129-6-3372; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KHAN A, 1995, ENDOCRINOLOGY, V136, P1934, DOI 10.1210/en.136.5.1934; KHAN A, 1992, AM J PHYSIOL, V263, pE663, DOI 10.1152/ajpendo.1992.263.4.E663; KORANYI L, 1992, DIABETOLOGIA, V35, P1125, DOI 10.1007/BF00401365; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; LENZEN S, 1984, ENDOCR REV, V5, P411, DOI 10.1210/edrv-5-3-411; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MULDER H, 1995, DIABETOLOGIA, V38, P395, DOI 10.1007/s001250050298; OBRIEN TD, 1991, DIABETES, V40, P1701, DOI 10.2337/diabetes.40.12.1701; OGAWA A, 1992, J CLIN INVEST, V90, P497, DOI 10.1172/JCI115886; OGAWA Y, 1995, DIABETES, V44, P75, DOI 10.2337/diabetes.44.1.75; OHNEDA M, 1993, J CLIN INVEST, V92, P1950, DOI 10.1172/JCI116788; ORLAND MJ, 1991, DIABETES, V40, P181, DOI 10.2337/diabetes.40.2.181; PHILIPPE J, 1990, ENDOCRINOLOGY, V127, P1640, DOI 10.1210/endo-127-4-1640; PHILIPPE J, 1992, J CLIN INVEST, V90, P2228, DOI 10.1172/JCI116108; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; ROBERTSON RP, 1973, J CLIN INVEST, V52, P870, DOI 10.1172/JCI107251; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; SHAFRIR E, 1990, DIABETES MELLITUS TH, P299; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; WAEBER G, 1994, J BIOL CHEM, V269, P26912; WANG ZL, 1994, ENDOCRINOLOGY, V135, P200, DOI 10.1210/en.135.1.200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394	45	115	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3216	3222		10.1074/jbc.272.6.3216	http://dx.doi.org/10.1074/jbc.272.6.3216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013557	hybrid			2022-12-25	WOS:A1997WG19200017
J	Pollock, VV; Barber, MJ				Pollock, VV; Barber, MJ			Biotin sulfoxide reductase - Heterologous expression and characterization of a functional molybdopterin guanine dinucleotide-containing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; MOLYBDENUM COFACTOR; METHIONINE SULFOXIDE; MOLECULAR-CLONING; SP DENITRIFICANS; SULFITE OXIDASE; PROTEIN; PURIFICATION; GENE	Rhodobacter sphaeroides f. sp. denitrificans biotin sulfoxide reductase has been heterologously expressed in Escherichia coli as a functional 106-kDa glutathione S-transferase fusion protein. Following cleavage with Factor Xa and purification to homogeneity, the soluble 83-kDa enzyme retained biotin sulfoxide reductase activity using reduced methyl viologen or reduced benzyl viologen as artificial electron donors. Initial rate kinetics indicated a specific activity at pH 8.0 of 0.9 mu mol of biotin sulfoxide reduced per min/nmol of enzyme and K-m values of 29 and 15 mu M for reduced methyl viologen and biotin sulfoxide reductase, respectively. Biotin sulfoxide reductase was also capable of reducing nicotinamide N-oxide, methionine sulfoxide, trimethylamine-N-oxide, and dimethyl sulfoxide, although with varying efficiencies, and could directly utilize NADPH as a reducing agent, both for the reduction of biotin sulfoxide and ferricyanide. The enzyme contained the prosthetic group, molybdopterin guanine dinucleotide, and did not require any accessory proteins for functionality. These results represent the first successful heterologous expression and characterization of a functional molybdopterin guanine dinucleotide-containing enzyme and the demonstration of reduced pyridine nucleotide-dependent biotin sulfoxide reductase activity.	UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,TAMPA,FL 33612	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P266, DOI 10.1016/0003-9861(95)90009-8; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BASTIAN NR, 1991, J BIOL CHEM, V266, P45; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; del Campillo-Campbell A, 1979, Methods Enzymol, V62, P379; DELCAMPILLOCAMPBELL A, 1982, J BACTERIOL, V149, P469, DOI 10.1128/JB.149.2.469-478.1982; EJIRI SI, 1980, ANAL BIOCHEM, V102, P393, DOI 10.1016/0003-2697(80)90173-6; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GARRETT RM, 1994, J BIOL CHEM, V269, P272; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HELLEBUST H, 1989, J BIOTECHNOL, V12, P275, DOI 10.1016/0168-1656(89)90047-3; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; Hilton JC, 1996, BBA-PROTEIN STRUCT M, V1294, P111, DOI 10.1016/0167-4838(96)00015-5; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; Keresztessy Z, 1996, BIOCHEM J, V314, P41, DOI 10.1042/bj3140041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISSOLO T, 1984, J BIOL CHEM, V259, P1725; MCCORMICK DB, 1970, ANAL BIOCHEM, V34, P226, DOI 10.1016/0003-2697(70)90102-8; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MENDEL RR, 1983, J CHROMATOGR, V267, P409, DOI 10.1016/S0021-9673(01)90862-3; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; PIERSON DE, 1990, J BACTERIOL, V172, P2194, DOI 10.1128/jb.172.4.2194-2198.1990; POLLOCK VV, 1995, ARCH BIOCHEM BIOPHYS, V318, P322, DOI 10.1006/abbi.1995.1236; RAHMAN MA, 1992, J BIOL CHEM, V267, P15549; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; SATOH T, 1987, J BIOCHEM-TOKYO, V102, P191, DOI 10.1093/oxfordjournals.jbchem.a122032; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; SHERMAN MY, 1992, EMBO J, V11, P71; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THORNELEY RN, 1974, BIOCHIM BIOPHYS ACTA, V333, P487, DOI 10.1016/0005-2728(74)90133-9; Trimboli AJ, 1996, ARCH BIOCHEM BIOPHYS, V331, P117, DOI 10.1006/abbi.1996.0289	33	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3355	3362		10.1074/jbc.272.6.3355	http://dx.doi.org/10.1074/jbc.272.6.3355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013576	hybrid			2022-12-25	WOS:A1997WG19200036
J	Shen, Y; Li, R; Shiosaki, K				Shen, Y; Li, R; Shiosaki, K			Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; MOLECULAR-CLONING; MULTIPLE-SCLEROSIS; TNF-ALPHA; EXPRESSION; BRAIN; DEATH; LOCALIZATION; GROWTH; 55-KD	Recent evidence indicates that tumor necrosis factor-alpha (TNF-alpha) is up-regulated following brain injury and in neurodegenerative disorders such as stroke, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. TNF-alpha elicits its biological effects through two distinct TNF receptor (TNFR) subtypes: p55 TNFR (TNFR1) and p75 TNFR (TNFR2). Studies have demonstrated that the p55 TNFR contributes to cell death, whereas the role of the p75 TNFR in neuronal viability is unclear. To better understand the role of p75 TNFR, we treated human neuronal SH-SY5Y cells with phosphorothioate-modified antisense oligonucleotides (ASO) for p75 TNFR and established that ASO inhibited p75 TNFR expression. Treatment of SH-SY5Y cells with ASO alone did not affect cell viability, whereas treatment with both ASO and human TNF-alpha significantly increased cell death relative to treatment with TNF-alpha alone. Moreover, addition of ASO significantly increased the level of cell injury observed following hypoxic conditions or exposure of beta-amyloid peptide. These results indicate that inhibition of p75 TNFR using ASO increases the vulnerability of neurotypic cells to insults and suggest that the p7B TNFR may not be required for normal neuronal cell viability but rather plays a protective role following injury.	UNIV LOUISVILLE,SCH MED,DEPT PSYCHIAT,LOUISVILLE,KY 40292	University of Louisville	Shen, Y (corresponding author), ABBOTT LABS,DEPT NEUROSCI,DIV PHARMACEUT DISCOVERY,47C-AP10,ABBOTT PK,IL 60064, USA.							AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; BRADLEY JR, 1995, AM J PATHOL, V146, P27; BRUCE AJ, 1996, NAT MED, V2, P1; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; CHAMBAUTGUERIN AM, 1995, J NEUROCHEM, V65, P537; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; FILIT H, 1991, NEUROSCI LETT, V129, P318; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; HELLER RA, 1992, CELL, V70, P47; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; KINOUCHI K, 1991, BIOCHEM BIOPH RES CO, V181, P1532, DOI 10.1016/0006-291X(91)92113-X; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Retaux S, 1996, NEURON, V16, P63, DOI 10.1016/S0896-6273(00)80024-0; SARIN A, 1995, J IMMUNOL, V155, P3716; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEIL S, 1994, INT J DEV NEUROSCI, V12, P405, DOI 10.1016/0736-5748(94)90024-8; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SHEN Y, 1995, BRAIN RES, V671, P282, DOI 10.1016/0006-8993(94)01264-I; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; VESANEN M, 1992, J GEN VIROL, V73, P1753, DOI 10.1099/0022-1317-73-7-1753; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WIESLANDER AP, 1993, CLIN NEPHROL, V39, P343; WOLVERS DAW, 1993, EUR CYTOKINE NETW, V4, P377	32	81	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3550	3553		10.1074/jbc.272.6.3550	http://dx.doi.org/10.1074/jbc.272.6.3550			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013604	hybrid			2022-12-25	WOS:A1997WG19200064
J	Sonoki, T; Nagasaki, A; Gotoh, T; Takiguchi, M; Takeya, M; Matsuzaki, H; Mori, M				Sonoki, T; Nagasaki, A; Gotoh, T; Takiguchi, M; Takeya, M; Matsuzaki, H; Mori, M			Coinduction of nitric-oxide synthase and arginase I in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-TYPE ARGINASE; UREA CYCLE ENZYMES; ARGININOSUCCINATE SYNTHETASE; L-ARGININE; NUCLEOTIDE-SEQUENCE; ENDOTHELIAL-CELLS; RELAXING FACTOR; MESSENGER-RNAS; CDNA; GENE	Nitric oxide is synthesized by nitric-oxide synthase from arginine, a common substrate of arginase. Rat peritoneal macrophages were cultured in the presence of bacterial lipopolysaccharide (LPS), and expression of the inducible isoform of nitric oxide synthase (iNOS) and liver-type arginase (arginase I) was analyzed, mRNAs for iNOS and arginase I were induced by LPS in a dose-dependent manner, iNOS mRNA appeared 2 h after LPS treatment and increased to a near maximum at 8-12 h. On the other hand, arginase I mRNA that was undetectable prior to the treatment began to increase after 4 h with a lag time and reached a maximum at 12 h. Immunoblot analysis showed that iNOS and arginase I proteins were also induced, mRNA for arginase II, an arginase isozyme, was not detected in the LPS-activated peritoneal cells, mRNA for CCAAT/enhancer-binding protein beta (C/EBP beta), a transactivator of the arginase I gene, was also induced, and the induction was more rapid than that of arginase I mRNA. Changes in iNOS and arginase I mRNAs were also examined in LPS-injected rats in vivo. iNOS mRNA increased rapidly in the lung and spleen, reached a maximum 2-6 h after the LPS treatment, and decreased thereafter. Arginase I mRNA was induced markedly and more slowly in both tissues, reaching a maximum in 12 h. Thus, arginase I appears to have an important role in down regulating nitric oxide synthesis in murine macrophages by decreasing the availability of arginine, and the induction of arginase I is mediated by C/EBP beta.	KUMAMOTO UNIV,SCH MED,DEPT MOL GENET,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 2,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT PATHOL 2,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University; Kumamoto University								BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chowdhury S, 1996, EUR J BIOCHEM, V236, P500, DOI 10.1111/j.1432-1033.1996.00500.x; CURRIE GA, 1978, NATURE, V273, P758, DOI 10.1038/273758a0; DIZIKES GJ, 1986, BIOCHEM BIOPH RES CO, V141, P53, DOI 10.1016/S0006-291X(86)80333-3; DIZIKES GJ, 1986, SOMAT CELL MOLEC GEN, V12, P375, DOI 10.1007/BF01570732; FELDMAN JD, 1974, J IMMUNOL, V113, P329; Gill DJ, 1996, J BIOL CHEM, V271, P11280, DOI 10.1074/jbc.271.19.11280; GLASS RD, 1973, J BIOL CHEM, V248, P5785; GOTOH T, 1994, J BIOCHEM-TOKYO, V115, P778, DOI 10.1093/oxfordjournals.jbchem.a124409; GOTOH T, 1996, FEBS LETT, V392, P119; HARAGUCHI Y, 1987, P NATL ACAD SCI USA, V84, P412, DOI 10.1073/pnas.84.2.412; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HATTORI Y, 1995, BIOCHEM BIOPH RES CO, V215, P148, DOI 10.1006/bbrc.1995.2445; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HERZFELD A, 1976, BIOCHEM J, V153, P469, DOI 10.1042/bj1530469; IKEMOTO M, 1990, BIOCHEM J, V270, P679; IYONAGA K, 1997, IN PRESS HISTOCHEM J; KAWAMOTO S, 1987, J BIOL CHEM, V262, P6280; KAYSEN GA, 1973, BIOCHEM J, V133, P779, DOI 10.1042/bj1330779; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KUNG JT, 1977, J EXP MED, V146, P665, DOI 10.1084/jem.146.3.665; LAMERS WH, 1985, EUR J BIOCHEM, V146, P475, DOI 10.1111/j.1432-1033.1985.tb08675.x; MITCHELL JA, 1990, EUR J PHARMACOL, V176, P253, DOI 10.1016/0014-2999(90)90541-D; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V269, P175, DOI 10.1016/0003-9861(89)90097-0; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Nagasaki A, 1996, J BIOL CHEM, V271, P2658, DOI 10.1074/jbc.271.5.2658; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NEBES VL, 1988, MOL ENDOCRINOL, V2, P444, DOI 10.1210/mend-2-5-444; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; OHTAKE A, 1988, J BIOL CHEM, V263, P2245; SATO H, 1992, J LEUKOCYTE BIOL, V52, P161, DOI 10.1002/jlb.52.2.161; SCHIMKE RT, 1962, J BIOL CHEM, V237, P459; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHINOMIYA T, 1990, J BIOCHEM, V107, P435, DOI 10.1093/oxfordjournals.jbchem.a123063; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; TAKIGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8789, DOI 10.1093/nar/16.18.8789; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; WANG WW, 1995, BIOCHEM BIOPH RES CO, V210, P1009, DOI 10.1006/bbrc.1995.1757; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045	41	197	200	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3689	3693		10.1074/jbc.272.6.3689	http://dx.doi.org/10.1074/jbc.272.6.3689			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013624	hybrid			2022-12-25	WOS:A1997WG19200084
J	Barger, PM; Kelly, DP				Barger, PM; Kelly, DP			Identification of a retinoid/chicken ovalbumin upstream promoter transcription factor response element in the human retinoid X receptor gamma 2 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN ACYL-COENZYME; A-I GENE; THYROID-HORMONE; DNA-BINDING; ACID RECEPTORS; RXR-ALPHA; SIGNALING PATHWAYS; DEHYDROGENASE GENE; NUCLEAR RECEPTORS; ORPHAN RECEPTORS	To investigate the mechanisms involved in the transcriptional control of retinoid X receptor (RXR) gene expression, the 5'-flanking region of the human RXR gamma 2 isoform was characterized. An imperfect hexamer repeat (gamma retinoid X response element; gamma RXRE) with a single nucleotide spacer (GGTTGAaAGGTCA) was identified immediately upstream of the RXR gamma 2 gene transcription start site. Cotransfection studies in CV-1 cells with expression vectors for the retinoid receptors RXR alpha and retinoic acid receptor beta (RAR beta) demonstrated that the gamma RXRE confers retinoid-mediated transcriptional activation with preferential activation by RXR in the presence of its cognate ligand, 9-cis-retinoic acid (RA). Electrophoretic mobility shift assays demonstrated that RXR homodimer binding to gamma RXRE is markedly enhanced by 9-cis-RA, whereas RAR . RXR heterodimer binding is ligand-independent. DNA binding studies and cell cotransfection experiments also demonstrated that the nuclear receptor, chicken ovalbumin upstream promoter transcription factor (COUP-TF), repressed transcription via the gamma RXRE. Cotransfection experiments revealed that COUP-TF and RXR alpha compete at the gamma RXRE to modulate transcription bidirectionally over a wide range. These results demonstrate that the human RXR gamma 2 gene promoter contains a novel imperfect repeat element capable of mediating RXR-dependent transcriptional autoactivation and COUP-TF-dependent repression.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Kelly, Daniel/ABG-2056-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007275] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07275-17] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; Castelein H, 1996, MOL CELL ENDOCRINOL, V119, P11, DOI 10.1016/0303-7207(96)03794-X; COLBERT MC, 1995, DEV DYNAM, V204, P1, DOI 10.1002/aja.1002040102; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; Disch DL, 1996, MOL CELL BIOL, V16, P4043; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; DOWHAN DH, 1994, ENDOCRINOLOGY, V135, P2595, DOI 10.1210/en.135.6.2595; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GE RW, 1994, J BIOL CHEM, V269, P13185; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUAN BF, 1992, P NATL ACAD SCI USA, V89, P9059, DOI 10.1073/pnas.89.19.9059; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEE MO, 1995, MOL CELL BIOL, V15, P4194; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LIU Q, 1993, MOL ENDOCRINOL, V7, P651, DOI 10.1210/me.7.5.651; LIU Y, 1994, NUCLEIC ACIDS RES, V22, P1079, DOI 10.1093/nar/22.6.1079; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEDIN JA, 1994, MOL CELL ENDOCRINOL, V105, P27, DOI 10.1016/0303-7207(94)90032-9; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MINTY A, 1986, MOL CELL BIOL, V6, P2121; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROWE A, 1991, DEVELOPMENT, V111, P771; SAKURAI A, 1995, MOL CELL ENDOCRINOL, V110, P103, DOI 10.1016/0303-7207(95)03522-9; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SUBAUSTE JS, 1994, J BIOL CHEM, V269, P30232; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; SUZUKI S, 1994, MOL ENDOCRINOL, V8, P305, DOI 10.1210/me.8.3.305; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	57	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2722	2728		10.1074/jbc.272.5.2722	http://dx.doi.org/10.1074/jbc.272.5.2722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006910	hybrid			2022-12-25	WOS:A1997WE66700023
J	deChaves, EIP; Bussiere, M; Vance, DE; Campenot, RB; Vance, JE				deChaves, EIP; Bussiere, M; Vance, DE; Campenot, RB; Vance, JE			Elevation of ceramide within distal neurites inhibits neurite growth in cultured rat sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; LEUKEMIA HL-60 CELLS; SHORT-CHAIN CERAMIDE; SPHINGOLIPID BIOSYNTHESIS; SPHINGOMYELIN TURNOVER; FACTOR DEPRIVATION; GANGLIOSIDE GM1; FREE SYSTEM; SPHINGOSINE	Sphingolipids are abundant constituents of neuronal membranes and have been implicated in intracellular signaling. We show that two analogs of glycosphingolipid biosynthetic intermediates, fumonisin B-1 (which inhibits dihydroceramide synthesis) and DL-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) (which inhibits glucosylceramide synthesis) decrease glycosphingolipid synthesis in rat sympathetic neurons. Although both fumonisin and PPMP inhibit glycosphingolipid synthesis, these inhibitors have differential effects on ceramide metabolism in axons. threo-PPMP, but not erythro-PPMP or fumonisin, induces an accumulation of [H-3]palmitate-labeled ceramide and impairs axonal growth. Moreover, exogenously added, cell-permeable C-6-ceramide, but not C-6-dihydroceramide, mimicks the effect of PPMP. Our studies suggest that the lipid second messenger ceramide acts in distal axons, but not cell bodies, as a negative regulator of neurite growth.	UNIV ALBERTA, LIPID & LIPOPROT RES GRP, HERITAGE MED RES CTR 315, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT ANAT & CELL BIOL, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON, AB T6G 2S2, CANADA	University of Alberta; University of Alberta; University of Alberta; University of Alberta								ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; ARITA M, 1984, J NEUROSCI RES, V12, P289, DOI 10.1002/jnr.490120216; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Campenot R B, 1979, Methods Enzymol, V58, P302; CAMPENOT RB, 1991, J NEUROSCI, V11, P1126; CAMPENOT RB, 1989, NEURON, V3, P733, DOI 10.1016/0896-6273(89)90242-0; CAMPENOT RB, 1994, J NEUROBIOL, V25, P599, DOI 10.1002/neu.480250603; CAMPENOT RB, 1982, DEV BIOL, V93, P1, DOI 10.1016/0012-1606(82)90232-9; CAMPENOT RB, 1992, CELL CELL INTERACTIO, P275; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; CUELLO AC, 1989, P NATL ACAD SCI USA, V86, P2056, DOI 10.1073/pnas.86.6.2056; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FACCI L, 1984, J NEUROCHEM, V42, P299, DOI 10.1111/j.1471-4159.1984.tb02678.x; FERRARI G, 1993, J NEUROSCI, V13, P1879; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FOLCH J, 1957, J BIOL CHEM, V226, P497; FURUYA S, 1995, J NEUROCHEM, V65, P1551; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HALL FL, 1988, J BIOL CHEM, V263, P4460; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAREL R, 1993, J BIOL CHEM, V268, P14476; Hawrot E, 1979, Methods Enzymol, V58, P574; INOKUCHI JI, 1987, J LIPID RES, V28, P565; ITO A, 1995, J NEUROCHEM, V65, P463; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; Kapfhammer Josef P., 1992, Current Opinion in Cell Biology, V4, P863, DOI 10.1016/0955-0674(92)90112-P; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; LADISCH S, 1985, ANAL BIOCHEM, V146, P220, DOI 10.1016/0003-2697(85)90419-1; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; LEE KF, 1994, SCIENCE, V263, P1447, DOI 10.1126/science.8128229; LEE KF, 1994, DEVELOPMENT, V120, P1027; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1995, J BIOL CHEM, V270, P13834, DOI 10.1074/jbc.270.23.13834; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKADA Y, 1988, FEBS LETT, V235, P25, DOI 10.1016/0014-5793(88)81227-4; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; RAHMANN H, 1992, CURRENT ASPECTS NEUR, P87; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P57, DOI 10.1016/0005-2760(95)00010-A; ROISEN J, 1984, ADV EXP MED BIOL, V174, P499; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P371; SCHWAB ME, 1994, NATURE, V371, P658, DOI 10.1038/371658a0; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SPIRMAN N, 1982, J NEUROCHEM, V39, P874, DOI 10.1111/j.1471-4159.1982.tb07974.x; SPOERRI PE, 1988, DEV BRAIN RES, V41, P71, DOI 10.1016/0165-3806(88)90170-8; SPOERRI PE, 1986, GANGLIOSIDES NEURONA, P309; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; UEMURA K, 1990, J BIOCHEM-TOKYO, V108, P525; WANG E, 1991, J BIOL CHEM, V266, P14486; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F	70	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3028	3035		10.1074/jbc.272.5.3028	http://dx.doi.org/10.1074/jbc.272.5.3028			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006952	hybrid			2022-12-25	WOS:A1997WE66700065
J	Albrecht, DE; Tidball, JG				Albrecht, DE; Tidball, JG			Platelet-derived growth factor-stimulated secretion of basement membrane proteins by skeletal muscle occurs by tyrosine kinase-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTENDINOUS JUNCTIONS; EXTRACELLULAR-MATRIX; L6 MYOBLASTS; FIBRONECTIN; COLLAGEN; LAMININ; PDGF; DIFFERENTIATION; PROLIFERATION; RECEPTOR	The basement membrane of skeletal muscle is produced by the muscle cells it ensheathes and by nonmuscle cells located in the surrounding extracellular matrix, In this study, we have shown that platelet-derived growth factor (PDGF) stimulates secretion of three basement membrane components of skeletal muscle: laminin (70% increase), fibronectin (30%), and type IV collagen (70%). Furthermore, we have found using the signal transduction inhibitors, genistein (tyrosine kinase inhibitor), phorbol 12-myristate 13-acetate (protein kinase C (PKC) inhibitor), thapsigargin (depletes intracellular Ca2+ stores), and H89 (protein kinase A inhibitor), that PDGF-stimulated secretion of these proteins occurs through distinct signaling pathways. Densitometry of Western blots of L6 myoblast supernatant indicates that the PDGF-induced increase in secretion of laminin and type IV collagen is tyrosine kinase-dependent. The increase in type IV collagen secretion also shows dependence on PKC, as well as the release of intracellular Ca2+. Inhibition of either of these pathways reduces the increase in type TV collagen secretion to 20%. In contrast, the PDGF-induced increase in laminin secretion is unaffected by inhibition of either PKC or intracellular Ca2+ release. The increase in fibronectin secretion by PDGF uses yet a third set of signals. PDGF-induced fibronectin secretion is not dependent on tyrosine kinase activity but is dependent on protein kinase A as well as the release of intracellular Ca2+. These divergent signaling pathways provide for independent regulation of basement membrane protein secretion, allowing a muscle cell to modify both the quantity and composition of its basement membrane in response to its environment.	UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles			Tidball, James/H-7970-2012	Tidball, James/0000-0003-1202-8038	NIAMS NIH HHS [AR-40343] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040343] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; BERNARD MP, 1985, BIOCHEMISTRY-US, V24, P2698, DOI 10.1021/bi00332a016; Bischoff R, 1994, MYOLOGY, P97; BOWENPOPE DF, 1984, BLOOD, V64, P458; CHIQUET M, 1981, DEV BIOL, V88, P220, DOI 10.1016/0012-1606(81)90166-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; DEBLAQUIERE J, 1994, J BIOL CHEM, V269, P4812; DUKSIN D, 1983, J BIOL CHEM, V258, P4585; FOSTER RF, 1987, DEV BIOL, V122, P11, DOI 10.1016/0012-1606(87)90327-7; Gorospe Jose Rafael M., 1992, Current Opinion in Rheumatology, V4, P794; GULATI AK, 1983, J CELL BIOL, V97, P957, DOI 10.1083/jcb.97.4.957; IVES HE, 1987, J BIOL CHEM, V262, P1950; JIN P, 1991, J BIOL CHEM, V266, P1245; JIN P, 1990, J CELL BIOL, V10, P1665; KALCHEIM C, 1982, P NATL ACAD SCI-BIOL, V79, P3077, DOI 10.1073/pnas.79.10.3077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; OWEN AJ, 1982, P NATL ACAD SCI-BIOL, V79, P3203, DOI 10.1073/pnas.79.10.3203; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; PODLESKI TR, 1979, EXP CELL RES, V122, P317, DOI 10.1016/0014-4827(79)90308-2; SANES JR, 1982, J CELL BIOL, V93, P442, DOI 10.1083/jcb.93.2.442; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SAVARESE DMF, 1992, J BIOL CHEM, V267, P21928; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SWASDISON S, 1989, CELL TISSUE RES, V257, P537, DOI 10.1007/BF00221463; TIDBALL JG, 1989, CELL TISSUE RES, V257, P77; TIDBALL JG, 1993, J CELL BIOL, V123, P627, DOI 10.1083/jcb.123.3.627; TIDBALL JG, 1994, DEV BIOL, V163, P447, DOI 10.1006/dbio.1994.1161; TURNER DC, 1983, DEV BIOL, V95, P497, DOI 10.1016/0012-1606(83)90052-0; VENKATASUBRAMANIAN K, 1984, DEV BIOL, V104, P428, DOI 10.1016/0012-1606(84)90098-8; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; YABLONKAREUVENI Z, 1993, DEV BIOL, V156, P307, DOI 10.1006/dbio.1993.1079; YABLONKAREUVENI Z, 1990, J CELL BIOL, V111, P1623, DOI 10.1083/jcb.111.4.1623	38	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2236	2244						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999929				2022-12-25	WOS:A1997WD67900035
J	Bandyopadhyay, G; Standaert, ML; Zhao, LM; Yu, BZ; Avignon, A; Galloway, L; Karnam, P; Moscat, J; Farese, RV				Bandyopadhyay, G; Standaert, ML; Zhao, LM; Yu, BZ; Avignon, A; Galloway, L; Karnam, P; Moscat, J; Farese, RV			Activation of protein kinase C (alpha, beta, and zeta) by insulin in 3T3/L1 cells - Transfection studies suggest a role for PKC-zeta in glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE; PHORBOL ESTERS; RAT ADIPOCYTES; 3T3-L1 ADIPOCYTES; TRANSLOCATION; FIBROBLASTS; DIFFERENTIATION; PHOSPHORYLATION; STIMULATION; ISOFORMS	We presently studied (a) insulin effects on protein kinase C (PKC) and (b) effects of transfection-induced, stable expression of PKC isoforms on glucose transport in 3T3/L1 cells. In both fibroblasts and adipocytes, insulin provoked increases in membrane PKC enzyme activity and membrane levels of PKC-alpha and PKC-beta. However, insulin-induced increases in PKC enzyme activity were apparent in both non-down-regulated adipocytes and adipocytes that were down-regulated by overnight treatment with 5 mu M phorbol ester, which largely depletes PKC-alpha, PKC-beta, and PKC-epsilon, but not PKC-zeta. Moreover, insulin provoked increases in the enzyme activity of immunoprecipitable PKC-zeta. In transfection studies, stable overexpression of wild-type or constitutively active forms of PKC-alpha, PKC-beta(1), and PKC-beta(2) failed to influence basal or insulin-stimulated glucose transport (2-deoxyglucose uptake) in fibroblasts and adipocytes, despite inhibiting insulin effects on glycogen synthesis. In contrast, stable overexpression of wild-type PKC-zeta increased, and a dominant-negative mutant form of PKC-zeta decreased, basal and insulin-stimulated glucose transport in fibroblasts and adipocytes. These findings suggested that: (a) insulin activates PKC-zeta, as well as PKC-alpha and beta; and (b) PKC-zeta is required for, and may contribute to, insulin effects on glucose transport in 3T3/L1 cells.	UNIV S FLORIDA,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,DEPT BIOCHEM,TAMPA,FL 33612; CHINA MED UNIV,DEPT BIOCHEM,SHENYANG 11001,LIAONING,PEOPLES R CHINA; HOP LAPEYRONIE,SERV MALAD METAB,F-34295 MONTPELLIER,FRANCE; UNIV AUTONOMA MADRID,CTR BIOL MOL SERVERO OCHOA,MADRID 28049,SPAIN	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Universite de Montpellier; CHU de Montpellier; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Moscat, Jorge/A-7011-2009; Avignon, Antoine/AAD-5441-2020; Farese, Robert/B-3605-2015		NIDDK NIH HHS [DK38079] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD Z, 1984, J BIOL CHEM, V259, P8743; AVIGNON A, 1995, BIOCHEM J, V308, P181, DOI 10.1042/bj3080181; BLACKMORE PF, 1986, BIOCHEM J, V237, P235, DOI 10.1042/bj2370235; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; FARESE RV, 1992, BIOCHEM J, V288, P319, DOI 10.1042/bj2880319; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GIBBS EM, 1991, BIOCHEM J, V275, P145, DOI 10.1042/bj2750145; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; ISHIZUKA T, 1989, FEBS LETT, V257, P337, DOI 10.1016/0014-5793(89)81565-0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P296; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KLIP A, 1988, ENDOCRINOLOGY, V123, P296, DOI 10.1210/endo-123-1-296; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MERRALL NW, 1993, BIOCHIM BIOPHYS ACTA, V1177, P191, DOI 10.1016/0167-4889(93)90040-V; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; ROACH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P7170, DOI 10.1073/pnas.80.23.7170; ROTH BL, 1989, J NEUROCHEM, V52, P215, DOI 10.1111/j.1471-4159.1989.tb10919.x; WAYS DK, 1994, CELL GROWTH DIFFER, V5, P1195; YAMADA K, 1994, ARCH BIOCHEM BIOPHYS, V312, P167, DOI 10.1006/abbi.1994.1295; YAMADA K, 1995, BIOCHEM J, V308, P177, DOI 10.1042/bj3080177	30	270	277	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2551	2558						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999972				2022-12-25	WOS:A1997WD67900078
J	Milne, JLS; Caterina, MJ; Devreotes, PN				Milne, JLS; Caterina, MJ; Devreotes, PN			Random Mutagenesis of the cAMP chemoattractant receptor, cAR1, of Dictyostelium - Evidence for multiple states of activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD CYTOPLASMIC LOOP; MUSCARINIC ACETYLCHOLINE-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; LIGAND-INDUCED PHOSPHORYLATION; PROTEIN-COUPLED RECEPTORS; FORMYL PEPTIDE RECEPTOR; BETA-GAMMA-SUBUNITS; SIGNAL-TRANSDUCTION; AMINO-ACID; INTRACELLULAR LOOP	cAMP receptor 1 (cAR1) of Dictyostelium couples to the G protein G2 to mediate activation of adenylyl and guanylyl cyclases, chemotaxis, and cell aggregation. Other cAR1-dependent events, including receptor phosphorylation and influx of extracellular Ca2+, do not require G proteins, To further characterize signal transduction through cAR1, we performed random mutagenesis of the third intracellular loop (24 amino acids), since the corresponding region of other seven helix receptors has been implicated in the coupling to G proteins. Mutant receptors were expressed in car1(-) cells and were characterized for G protein-dependent and -independent signal transduction. Our results demonstrate that cAR1 is remarkably tolerant to amino acid substitutions in the third intracellular loop. Of the 21 positions where amino acid substitutions were observed, one or more replacements were found that retained full biological function. However, certain alterations resulted in receptors with reduced ability to bind cAMP and/or transduce signals, There were specific signal transduction mutants that could undergo cAMP-dependent cAR1 phosphorylation but were impaired either in coupling to G proteins, in G protein-independent Ca2+ influx, or in both pathways. In addition, there were general activation mutants that failed to restore aggregation to car1(-) cells and displayed severe defects in all signal transduction events, including the most robust response, cAMP-dependent cAR1 phosphorylation. Certain of these mutant phenotypes were obtained in a complementary study, where the entire region of cAR1 from the third to the seventh transmembrane helices was randomly mutagenized. Considered together, these studies indicate that the activation cycle of cAR1 may involve a number of distinct receptor intermediates. A model of G protein-dependent and -independent signal transduction through cAR1 is discussed.			Milne, JLS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,725 N WOLFE ST,BALTIMORE,MD 21205, USA.				NIGMS NIH HHS [GM34933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDEN JR, 1992, BIOCHEM BIOPH RES CO, V188, P1111, DOI 10.1016/0006-291X(92)91346-R; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P402; BOONE C, 1993, P NATL ACAD SCI USA, V90, P9921, DOI 10.1073/pnas.90.21.9921; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BRECHLER V, 1994, RECEPTOR CHANNEL, V2, P89; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; CATERINA MJ, 1995, J BIOL CHEM, V270, P4418, DOI 10.1074/jbc.270.9.4418; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; CLAPHAM DE, 1994, NATURE, V371, P109, DOI 10.1038/371109a0; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COUKELL MB, 1983, DEV GENET, V3, P283; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HERELD D, 1994, J BIOL CHEM, V269, P7036; HOGGER P, 1995, J BIOL CHEM, V270, P7405; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; Kim JY, 1997, J BIOL CHEM, V272, P2060; KIM JY, 1994, J BIOL CHEM, V269, P28724; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KLEIN P, 1987, J BIOL CHEM, V262, P358; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOUIS JM, 1994, GENE DEV, V8, P2086, DOI 10.1101/gad.8.17.2086; LUI J, 1995, P NATL ACAD SCI USA, V92, P11642; Maeda M, 1996, J BIOL CHEM, V271, P3351; MILNE JL, 1993, MOL BIOL CELL, V4, P283, DOI 10.1091/mbc.4.3.283; MILNE JLS, 1995, J BIOL CHEM, V270, P5926, DOI 10.1074/jbc.270.11.5926; MORO O, 1993, J BIOL CHEM, V268, P6862; MORO O, 1993, J BIOL CHEM, V268, P22273; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; REN Q, 1993, J BIOL CHEM, V268, P16483; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAXE CL, 1991, DEV GENET, V12, P6, DOI 10.1002/dvg.1020120104; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHNITZLER GR, 1995, CELL, V81, P737, DOI 10.1016/0092-8674(95)90535-9; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SHAPIRO RA, 1993, J BIOL CHEM, V268, P21734; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; SUN TJ, 1990, J CELL BIOL, V110, P1549, DOI 10.1083/jcb.110.5.1549; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; TWITCHELL WA, 1994, MOL PHARMACOL, V46, P793; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	77	14	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2069	2076						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999904				2022-12-25	WOS:A1997WD67900010
J	Nielsen, NH; Emdin, SO; Cajander, J; Landberg, G				Nielsen, NH; Emdin, SO; Cajander, J; Landberg, G			Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein	ONCOGENE			English	Article						breast cancer; cell cycle; retinoblastoma tumour suppressor protein; cyclins and p16	TUMOR-SUPPRESSOR PROTEIN; D-CDK COMPLEXES; GENE-EXPRESSION; GROWTH-FACTOR; ECTOPIC EXPRESSION; MAMMARY CARCINOMAS; PHASE-TRANSITION; TRANSGENIC MICE; POOR PROGNOSIS; G(1) CONTROL	Inactivation of the retinoblastoma protein (pRB) by mutations or abnormal phosphorylation is a mechanism by which tumour cells can subdue normal growth control. Among molecules involved in control of pRB phosphorylation, cyclin D1 and E have been found to be deregulated and overexpressed in various types of cancers. In order to study the cell cycle regulatory mechanisms in breast cancer, we have analysed the protein expression of cyclin D1 and E in 114 tumour specimens from patients with primary breast cancer using Western blotting. Twenty-five out of 34 tumours with overexpression of cyclin E showed uniform low cyclin D1 expression, and by immunohistochemical analysis of pRB we present evidence for the existence of pRB defects in approximately 40% of these tumours in contrast to no PRE defects in the other group of tumours. This result was supported by a high protein expression of the cyclin-dependent kinase inhibitor p16 in 44% of the tumours with high cyclin E and low D1 expression, and all immunohistochemical pRB defect tumours showed a high p16 protein level. Additionally, an abnormal low pRB phosphorylation in relation to a high proliferative activity and loss of heterozygosity of the retinoblastoma susceptibility gene locus were found in all but one tumour with immunohistochemical defect pRB. Interestingly, tumours with high cyclin E and low D1 expression were generally oestrogen receptor negative suggesting a role for cell cycle regulators in the mechanisms leading to oestrogen independent tumour growth. Furthermore, the prognosis differed markedly for the patients in the various groups of tumours, indicating that the heterogeneous nature of breast cancer pathogenesis and the clinical course in part could be explained by different and distinctive sets of cell cycle defects.	UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT ONCOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT SURG,S-90187 UMEA,SWEDEN	Umea University; Umea University; Umea University								ADNANE J, 1989, ONCOGENE, V4, P1389; AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; BATES S, 1994, ONCOGENE, V9, P1633; BOOKSTEIN R, 1990, NUCLEIC ACIDS RES, V18, P1666, DOI 10.1093/nar/18.6.1666; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BOYNTON RF, 1991, CANCER RES, V51, P5766; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Geng Y, 1996, ONCOGENE, V12, P1173; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HE J, 1994, CANCER RES, V54, P5804; HENRY JA, 1993, INT J CANCER, V53, P774, DOI 10.1002/ijc.2910530512; HERMAN ME, 1994, CANCER RES, V54, P5867; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JIANG W, 1993, ONCOGENE, V8, P3447; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, CANCER RES, V55, P4818; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NEVINS JR, 1992, SCIENCE, V258, P424; NIELSEN NH, 1996, IN PRESS BR J CANC; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PIETILAINEN T, 1995, EUR J CANCER, V31A, P329, DOI 10.1016/0959-8049(94)00463-F; RENNER WA, 1995, BIOTECHNOL BIOENG, V47, P476, DOI 10.1002/bit.260470409; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SAWAN A, 1992, J PATHOL, V168, P23, DOI 10.1002/path.1711680105; SCHOTT DR, 1994, CANCER RES, V54, P1393; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; Ueki K, 1996, CANCER RES, V56, P150; VANAGTHOVEN T, 1992, CANCER RES, V52, P5082; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG NP, 1993, ONCOGENE, V8, P279; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU HJ, 1991, ONCOGENE, V6, P1139; YANDELL DW, 1989, AM J HUM GENET, V45, P547; ZHOU P, 1995, ONCOGENE, V11, P517; ZUKERBERG LR, 1995, MODERN PATHOL, V8, P560	73	128	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					295	304		10.1038/sj.onc.1200833	http://dx.doi.org/10.1038/sj.onc.1200833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018115				2022-12-25	WOS:A1997WD51600005
J	Rossel, M; Pasini, A; Chappuis, S; Geneste, O; Fournier, L; Schuffenecker, I; Takahashi, M; vanGrunsven, LA; Urdiales, JL; Rudkin, BB; Lenoir, GM; Billaud, M				Rossel, M; Pasini, A; Chappuis, S; Geneste, O; Fournier, L; Schuffenecker, I; Takahashi, M; vanGrunsven, LA; Urdiales, JL; Rudkin, BB; Lenoir, GM; Billaud, M			Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations	ONCOGENE			English	Article						MEN 2; RET proto-oncogene; tyrosine kinase; isoforms	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE; PROTOONCOGENE MUTATIONS; CELL-LINE; FMTC; EXPRESSION; RECEPTOR; DISEASE; GENE; SPECIFICITY	Germline mutations of the RET proto-oncogene, which codes for a receptor tyrosine kinase, cause multiple endocrine neoplasia type 2A (MEN 2A) and 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC). MEN 2 mutations have been shown to result in RET oncogenic activation. The RET gene encodes several isoforms whose biological properties, when altered by MEN 2 mutations, have not been thoroughly addressed yet. In this study, we have introduced a MEN 2A mutation (Cys634-->Arg) and the unique MEN 2B mutation (Met918-->Thr) in two RET isoforms of 1114 and 1072 amino acids which differ in the carboxy-terminus part, Herein, we report that each RET isoform activated by MEN 2A or MEN 2B mutation was transforming in fibroblasts and induced neuronal differentiation of pheochromocytoma PC12 cells. However, among the different RET-MEN 2 mutants, the long RET isoform activated by the MEN 2B mutation stimulated the most prominent neurite outgrowth in PC12 cells, while the short RET isoform counterpart elicited a very weak differentiation effect in PC12 cells. We further demonstrate that the morphological changes of PC12 cells caused by constitutively activated RET oncoproteins involved the engagement of a Ras-dependent pathway. These findings provide evidence that the biological properties of RET-MEN 2 mutants depend on the interplay between the RET isoforms and the nature of the activating MEN 2 mutation.	UNIV LYON 1,GENET LAB,UMR 5641 CNRS,F-69373 LYON 08,FRANCE; HOP EDOUARD HERRIOT,GENET LAB,LYON 03,FRANCE; NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,UMR 49 CNRS,F-69364 LYON,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Nagoya University; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			TAKAHASHI, Masahide/I-7244-2014; Urdiales, José Luis/K-1125-2014; van Grunsven, Leo/E-5839-2010; Takahashi, Masahide/AAN-4770-2020; Billaud, Marc N/M-6954-2013	Urdiales, José Luis/0000-0002-2519-9293; van Grunsven, Leo/0000-0002-0990-7034; Takahashi, Masahide/0000-0002-2803-2683; RUDKIN, Brian B./0000-0003-3700-1982; Rossel, Mireille/0000-0003-2275-0817				ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; BOLINO A, 1995, ONCOGENE, V10, P2415; BORELLO MG, 1995, ONCOGENE, V11, P2419; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELELLIS RA, 1995, LAB INVEST, V72, P494; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1994, HUM MOL GENET, V3, P234; FOURNIER E, 1995, ONCOGENE, V11, P921; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Iwashita T, 1996, ONCOGENE, V12, P481; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS SM, 1995, ONCOGENE, V11, P2039; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSSEL M, 1995, HUM GENET, V95, P403; RUSSO AF, IN PRESS GENETIC MEC; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanWeering DHJ, 1995, ONCOGENE, V11, P2207	55	78	78	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					265	275		10.1038/sj.onc.1200831	http://dx.doi.org/10.1038/sj.onc.1200831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018112				2022-12-25	WOS:A1997WD51600002
J	Akopian, TN; Kisselev, AF; Goldberg, AL				Akopian, TN; Kisselev, AF; Goldberg, AL			Processive degradation of proteins and other catalytic properties of the proteasome from Thermoplasma acidophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE; ESCHERICHIA-COLI; PROTEOLYTIC ACTIVITY; AMINO-ACIDS; COMPLEX; UBIQUITIN; PATHWAY; COMPONENTS; RESOLUTION; INHIBITORS	Although the structure of the 20 S proteasome from Thermoplasma acidophilum has been elucidated, its enzymatic properties have not been explored in depth. Thermoplasma proteasomes, which contain one type of active site, exhibit not only ''chymotrypsin-like'' activity (as reported), but also some ''post-glutamyl'' and ''trypsin-like'' activities. Like eukaryotic proteasomes, its activity can be stimulated by SDS, Mg2+, and also guanidine HCl, but not urea. The enzyme was strongly inhibited by novel peptide aldehydes with hydrophobic P4 residues, and was rapidly inactivated by 3,4-dichloroisocoumarin (DCI). DCI modified the N-terminal threonine of the catalytic beta-subunit, the presumed active site nucleophile. To define how proteins are degraded, casein was derivatized with fluorescein isothiocyanate to facilitate detection of released products by the proteasome. Many fluorescent peptides were generated, but the relative amounts of different peptides were independent of the duration of the reaction. The rate of disappearance of protein substrates paralleled the rate of appearance of small products. Unlike conventional proteases, proteasome degrades proteins processively without release of polypeptide intermediates. Upon activation by SDS, guanidine, heat (55 degrees C), or partial inhibition with DCI, proteasomes still functioned processively, but generated a different pattern of peptides under each condition. Thus, processivity is an inherent feature of the 20 S proteasome, not requiring all active sites or ATP hydrolysis.			Akopian, TN (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.							BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1992, EUR J BIOCHEM, V208, P789, DOI 10.1111/j.1432-1033.1992.tb17249.x; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DJABALLAH H, 1993, BIOCHEM J, V292, P857, DOI 10.1042/bj2920857; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1995, ARCH BIOCHEM BIOPHYS, V317, P69, DOI 10.1006/abbi.1995.1137; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GRANT EP, 1995, J IMMUNOL, V155, P3750; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KLEINSCHMIDT JA, 1983, EUR J CELL BIOL, V32, P143; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; RYPNIEWSKI WR, 1993, BIOCHEMISTRY-US, V32, P9851, DOI 10.1021/bi00088a041; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WILK S, 1993, ENZYME PROTEIN, V47, P187, DOI 10.1159/000468677; YU B, 1993, J BIOL CHEM, V268, P2029; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	42	167	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1791	1798		10.1074/jbc.272.3.1791	http://dx.doi.org/10.1074/jbc.272.3.1791			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999862	hybrid			2022-12-25	WOS:A1997WD05800060
J	Guttmann, RP; Elce, JS; Bell, PD; Isbell, JC; Johnson, GVW				Guttmann, RP; Elce, JS; Bell, PD; Isbell, JC; Johnson, GVW			'Oxidation inhibits substrate proteolysis by calpain I but not autolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-ACTIVATED PROTEASE; CA2+-ACTIVATED NEUTRAL PROTEASE; PAIRED HELICAL FILAMENTS; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; PROTEINASE CALPAIN; BRAIN SPECTRIN; TAU; SUBUNIT; TISSUE	In this study, the effects of oxidation on calpain I autolysis and calpain-mediated proteolysis were examined. Calpain I was incubated with increasing concentrations of free calcium in the presence or absence of oxidant, and autolytic conversion of both the 80- and 30-kDa subunits was measured by immunoblotting utilizing monoclonal antibodies which recognize both autolyzed and non-autolyzed forms of each subunit, respectively. Autolytic conversion of the 80-kDa subunit of calpain I was not detected until free calcium concentration was greater than 40 mu M, whereas autolysis of the 30-kDa subunit did not occur until the free calcium concentration was greater than 100 mu M. In addition, autolytic conversion of either the 80- or 30-kDa subunit was not inhibited by the presence of oxidant. Calpain I activity was measured using the fluorescent peptide N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosine-7-amido-4-methylcoumarin or the microtubule-associated protein tau as substrate. Calpain I was found to have proteolytic activity at free calcium concentrations below that required for autolysis. Calpain I activity was strongly inhibited by oxidant at all calcium concentrations studied, suggesting that proteolytic activity of both the non-autolyzed 80-kDa and autolyzed 76-kDa forms was susceptible to oxidation. Interestingly, whereas oxidation did not inhibit autolytic conversion, the presence of high substrate concentrations did result in a significant reduction of autolysis without altering calpain proteolytic activity. Calpain I activity that had been inhibited by the presence of oxidant was recovered immediately by addition of the reducing agent dithiothreitol.	UNIV ALABAMA, DEPT PSYCHIAT, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Queens University - Canada			Johnson, Gail V.W./K-4723-2012; guttmann, rodney/AAN-8880-2021	Johnson, Gail V.W./0000-0003-3464-0404; guttmann, rodney/0000-0001-5553-3099	NIA NIH HHS [AG06569, AG12396] Funding Source: Medline; NINDS NIH HHS [NS27538] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027538, R01NS027538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569, R01AG012396] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; BENUCK M, 1993, LIFE SCI, V52, P877, DOI 10.1016/0024-3205(93)90517-7; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BLOMGREN K, 1995, BRAIN RES, V684, P143, DOI 10.1016/0006-8993(95)00399-B; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; CHOI BH, 1995, NEUROBIOL AGING, V16, P675, DOI 10.1016/0197-4580(95)00065-M; CONG JY, 1989, J BIOL CHEM, V264, P10096; COTTIN P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P139, DOI 10.1016/0167-4838(91)90118-J; GLASER T, 1994, P NATL ACAD SCI USA, V91, P7879, DOI 10.1073/pnas.91.17.7879; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; GRAHAMSIEGENTHALER K, 1994, J BIOL CHEM, V269, P30457; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTTMANN RP, 1995, J NEUROCHEM, V64, P1209; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; JOHNSON P, 1994, FREE RADICAL RES, V21, P27, DOI 10.3109/10715769409056552; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MELLGREN RL, 1982, J BIOL CHEM, V257, P7203; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLONI E, 1985, P NATL ACAD SCI USA, V82, P6435, DOI 10.1073/pnas.82.19.6435; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; Neumann N P, 1972, Methods Enzymol, V25, P393, DOI 10.1016/S0076-6879(72)25034-0; Neumar RW, 1996, J NEUROCHEM, V66, P421; NILSSON E, 1990, NEUROBIOL AGING, V11, P425, DOI 10.1016/0197-4580(90)90009-O; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; NIXON RA, 1989, ANN NY ACAD SCI, V568, P198; OHNO S, 1990, CYTOGENET CELL GENET, V53, P225, DOI 10.1159/000132937; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PETERSON C, 1991, NEUROSCI LETT, V121, P239, DOI 10.1016/0304-3940(91)90694-O; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; SAIDO TC, 1994, FEBS LETT, V346, P263, DOI 10.1016/0014-5793(94)00487-0; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SAMIS JA, 1987, BIOCHEM J, V246, P481, DOI 10.1042/bj2460481; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P275, DOI 10.1093/oxfordjournals.jbchem.a133463; SUZUKI K, 1987, PROGR CLIN BIOCH MED, V5, P43; TALLANT EA, 1988, BIOCHEMISTRY-US, V27, P2205, DOI 10.1021/bi00406a059; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; ZIMMERMAN UJP, 1982, BIOCHEMISTRY-US, V21, P3977, DOI 10.1021/bi00260a012	60	83	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					2005	2012		10.1074/jbc.272.3.2005	http://dx.doi.org/10.1074/jbc.272.3.2005			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999893	hybrid			2022-12-25	WOS:A1997WD05800091
J	Irigoyen, JP; Besser, D; Nagamine, Y				Irigoyen, JP; Besser, D; Nagamine, Y			Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracellular signal-regulated kinase (ERK) signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED ENDOTHELIAL-CELLS; DOMINANT-NEGATIVE MUTANT; PROTEIN-KINASE; SHEAR-STRESS; C-JUN; MESSENGER-RNA; MAP KINASE; LLC-PK1 CELLS; EXPRESSION; PHOSPHORYLATION	Urokinase-type plasminogen activator (uPA) expression is induced upon cytoskeletal reorganization (CSR) by a mechanism independent of protein kinase C and cAMP protein kinase in nontransformed renal epithelial (LLC-PK1) cells. This CSR-dependent uPA gene activation is mediated by an AP-1-recognizing element located 2 kilobases upstream of the transcription initiation site. The phosphorylation of c-Jun, a component of AP-1, is induced by CSR, which seems to increase both the activity and stability of c-Jun (Lee, J. S., von der Ahe, D., Kiefer, B., and Nagamine, Y. (1993) Nucleic Acids Res. 21, 3365-3372). It has been shown that c-Jun is phosphorylated by members of the mitogen-activated protein kinase family, i.e. ERKs and JNKs. ERKs are activated through a growth factor coupled Ras/Raf-dependent signaling pathway, while JNKs are activated through a stress-induced signaling pathway. Although CSR induces both ERK-2 and JNK activity, JNK does not seem to be involved in the uPA gene induction because UV irradiation, which activates JNK as efficiently as CSR, does not activate the uPA promoter. Further analysis showed the involvement of SOS, Ras, and Raf-1 in the pathway induced by CSR. Our results suggest that cells sense changes in cell morphology using the cytoskeleton as a sensor and respond by activating the ERK-involving signaling pathway from within the cell.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ANDRUS L, 1988, J BIOL CHEM, V263, P6183; BARBEE KA, 1994, CIRC RES, V74, P163, DOI 10.1161/01.RES.74.1.163; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; BENZEEV A, 1984, BIOCHIM BIOPHYS ACTA, V780, P197, DOI 10.1016/0304-419X(85)90003-4; BERNAL SD, 1985, CRC CR REV ONCOL-HEM, V3, P191, DOI 10.1016/S1040-8428(85)80026-3; Besser D, 1995, ONCOGENE, V11, P2383; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COAN DE, 1993, J CELL SCI, V104, P1145; CONNOLLY JA, 1985, EUR J CELL BIOL, V37, P191; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DELMAS V, 1994, REV PHYSIOL BIOCH P, V124, P1, DOI 10.1007/BFb0031030; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; FRIXEN UH, 1993, CANCER RES, V53, P3618; GEIGER B, 1984, J CELL BIOL, V99, pS83, DOI 10.1083/jcb.99.1.83s; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HASUI Y, 1989, CANCER RES, V49, P1067; HESKETH J, 1994, MOL BIOL REP, V19, P233, DOI 10.1007/BF00986965; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKUN J, 1991, CANCER RES, V51, P1221; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVESQUE MJ, 1985, J BIOMECH ENG-T ASME, V107, P341, DOI 10.1115/1.3138567; LEWIS L, 1987, DIFFERENTIATION, V36, P228, DOI 10.1111/j.1432-0436.1987.tb00197.x; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MALEK AM, 1994, J HYPERTENS, V12, P989; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Oliver J M, 1979, Symp Soc Exp Biol, V33, P277; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYKE C, 1991, AM J PATHOL, V138, P1059; ROSEN EM, 1990, J CELL SCI, V96, P639; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAPPINO AP, 1987, CANCER RES, V47, P4043; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHINOHARAGOTOH Y, 1991, EXP CELL RES, V193, P161, DOI 10.1016/0014-4827(91)90551-5; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSENG H, 1993, CIRCULATION, V88, P184; VALINSKY JE, 1985, EMBO J, V4, P1403, DOI 10.1002/j.1460-2075.1985.tb03793.x; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; VRIESSMITS AMM, 1992, NATURE, V357, P602; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WECHEZAK AR, 1989, J CELL PHYSIOL, V139, P136, DOI 10.1002/jcp.1041390120; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273; ZIEGLER A, 1991, J BIOL CHEM, V266, P21067	73	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1904	1909		10.1074/jbc.272.3.1904	http://dx.doi.org/10.1074/jbc.272.3.1904			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999879	hybrid			2022-12-25	WOS:A1997WD05800077
J	Mahe, D; Mahl, P; Gattoni, R; Fischer, N; Mattei, MG; Stevenin, J; Fuchs, JP				Mahe, D; Mahl, P; Gattoni, R; Fischer, N; Mattei, MG; Stevenin, J; Fuchs, JP			Cloning of human 2H9 heterogeneous nuclear ribonucleoproteins - Relation with splicing and early heat shock-induced splicing arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; MAMMALIAN NUCLEI; COILED BODY; HNRNP A1; NASCENT TRANSCRIPTS; PREMESSENGER RNA; CDNA CLONING; HELA-CELLS; IN-VIVO; LOCALIZATION	Using antibody 2H9 from our heterogeneous nuclear ribonucleoproteins (anti-hnRNP) monoclonal antibody library, we previously showed in HeLa cells that a 35-37-kDa protein doublet switches from the hnRNP complexes to the nuclear matrix following a 10-min heat shock at 45 degrees C (1 Lutz, Y., Jacob, M., and Fuchs, J. P. (1988) Exp. Cell Res. 175, 109-124). cDNA cloning and sequencing revealed an hnRNP protein (2H9) which is a new member of the hnRNP F, H/H' family. Protein 2H9 displays two consensus sequence-type RNA binding do mains (CS-RBD) showing 80-90% homology with two of the three CS-RBDs of hnRNP F and H/H'. Another common feature is the presence of two glycine/tyrosine-rich auxiliary domains located at the C terminus and between the two CS-RBDs. At the functional level we show that specific anti-2H9 peptide antibodies can directly inhibit an in vitro splicing system. Moreover, the 2H9 protein doublet is no more present in nuclear extracts from such briefly stressed cells, which interestingly correlates with the inability of these extracts to catalyze in vitro splicing reactions. Taken together, our data suggest that these proteins are involved in the splicing process and also participate in early heat shock-induced splicing arrest by transiently leaving the hnRNP complexes. These 2H9 proteins, which are encoded by a single gene located on human chromosome 10, were also found to be associated with nuclear bodies in situ.	ULP, INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE, CU STRASBOURG, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; GRP HOSP TIMONE, HOP ENFANTS, F-13385 MARSEILLE 5, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			MAHE, Dominique MD/I-7316-2015					ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; AST G, 1991, EMBO J, V10, P425, DOI 10.1002/j.1460-2075.1991.tb07964.x; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BOND U, 1988, EMBO J, V7, P3509, DOI 10.1002/j.1460-2075.1988.tb03227.x; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1993, J CELL BIOL, V120, P841, DOI 10.1083/jcb.120.4.841; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DATAR KV, 1993, NUCLEIC ACIDS RES, V21, P439, DOI 10.1093/nar/21.3.439; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fakan Stanislav, 1994, Trends in Cell Biology, V4, P86, DOI 10.1016/0962-8924(94)90180-5; GALLINARO H, 1983, EMBO J, V2, P953, DOI 10.1002/j.1460-2075.1983.tb01527.x; Gattoni R, 1996, NUCLEIC ACIDS RES, V24, P2535, DOI 10.1093/nar/24.13.2535; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HONORE B, 1995, J BIOL CHEM, V270, P28780; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; Huang S, 1996, J CELL BIOL, V133, P719, DOI 10.1083/jcb.133.4.719; JACOB M, 1981, CELL NUCLEUS, V8, P193; KLOETZEL PM, 1986, BIOCHIM BIOPHYS ACTA, V867, P9, DOI 10.1016/0167-4781(86)90023-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; LUTZ Y, 1988, EXP CELL RES, V175, P109, DOI 10.1016/0014-4827(88)90259-5; MAHE D, 1995, EXP CELL RES, V216, P1, DOI 10.1006/excr.1995.1001; MAHL P, 1989, J CELL BIOL, V109, P1921, DOI 10.1083/jcb.109.5.1921; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; MICHAEL WM, 1995, CELL, V83, P415; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Moore MJ, 1993, RNA WORLD, P1; Nickerson JA, 1995, INT REV CYTOL, V162A, P67; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; Puvion E, 1981, CELL NUCLEUS, P59; RIO D C, 1992, Current Opinion in Cell Biology, V4, P444, DOI 10.1016/0955-0674(92)90010-A; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SPECTOR DL, 1993, COLD SPRING HARB SYM, V58, P799, DOI 10.1101/SQB.1993.058.01.087; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111; ZHANG GH, 1994, NATURE, V372, P809	64	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1827	1836		10.1074/jbc.272.3.1827	http://dx.doi.org/10.1074/jbc.272.3.1827			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999868	hybrid			2022-12-25	WOS:A1997WD05800066
J	Noiri, E; Hu, Y; Bahou, WF; Keese, CR; Giaever, I; Goligorsky, MS				Noiri, E; Hu, Y; Bahou, WF; Keese, CR; Giaever, I; Goligorsky, MS			Permissive role of nitric oxide in endothelin-induced migration of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN UMBILICAL VEIN; MAMMALIAN-CELLS; DEPENDENT RELAXATION; CORONARY-ARTERIES; EXPRESSION; RECEPTOR; HYPOXIA; ANGIOGENESIS; GROWTH; DNA	Endothelin (ET) synthesis is enhanced at sites of ischemia or in injured vessels. The purpose of this study was to explore the possibility of autocrine stimulation of endothelial cell migration by members of the endothelin family. Experiments with microvascular endothelial cell transmigration in a Boyden chemotactic apparatus showed that endothelins 1 and 3, as well as a selective agonist of ET(B) receptor IRL-1620, equipotently stimulated migration. Endothelial cell migration was unaffected by the blockade of ET(A) receptor, but it was inhibited by ET(B) receptor antagonism. Based on our previous demonstration of signaling from the occupied ET(B) receptor to constitutive nitric oxide (NO) synthase (Tsukahara, H., Ende, H., Magazine, H. I., Bahou, W. F., and Goligorsky, M. S. (1994) J. Biol. Chem. 269, 21778-21785), we next examined the contribution of ET-stimulated NO production to endothelial cell migration. In three independent cellular systems, 1) migration and wound healing by microvascular endothelial cells, 2) wound healing by Chinese hamster ovary cells stably expressing ET(B) receptor with or without endothelial NO synthase, and 3) application of antisense oligodeoxynucleotides targeting endothelial NO synthase in human umbilical vein endothelial cells, an absolute requirement for the functional NO synthase in cell migration has been demonstrated. These findings establish the permissive role of NO synthesis in endothelin stimulated migration of en dothelial cells.	SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794; RENSSELAER POLYTECH INST,TROY,NY 12180	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rensselaer Polytechnic Institute				NOIRI, Eisei/0000-0002-9515-7582	NIDDK NIH HHS [DK45695, DK45462] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045462, R01DK045695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOSSALLER C, 1987, J CLIN INVEST, V79, P170, DOI 10.1172/JCI112779; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; DOUGLAS SA, 1994, CIRC RES, V75, P190, DOI 10.1161/01.RES.75.1.190; FUJITANI Y, 1992, FEBS LETT, V298, P79, DOI 10.1016/0014-5793(92)80026-D; GHOSH PM, 1993, BIOPHYS J, V64, P1602, DOI 10.1016/S0006-3495(93)81531-5; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; HARIK SI, 1995, J PHYSIOL-LONDON, V485, P525, DOI 10.1113/jphysiol.1995.sp020748; ICHIMORI K, 1994, REV SCI INSTRUM, V65, P1; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; LEIBOVICH SJ, 1994, P NATL ACAD SCI USA, V91, P4190, DOI 10.1073/pnas.91.10.4190; LERMAN A, 1993, CIRCULATION, V88, P2923, DOI 10.1161/01.CIR.88.6.2923; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; MORBIDELLI L, 1995, AM J PHYSIOL-HEART C, V269, pH686, DOI 10.1152/ajpheart.1995.269.2.H686; Noiri E, 1996, AM J PHYSIOL-CELL PH, V270, pC794, DOI 10.1152/ajpcell.1996.270.3.C794; PU LQ, 1993, CIRCULATION, V88, P208, DOI 10.1161/01.CIR.88.1.208; RAKUGI H, 1990, BIOCHEM BIOPH RES CO, V169, P973, DOI 10.1016/0006-291X(90)91989-6; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SHIMONAKA M, 1994, J BIOL CHEM, V269, P14284; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKAGI Y, 1990, BIOCHEM BIOPH RES CO, V168, P537, DOI 10.1016/0006-291X(90)92354-3; TAKAYANAGI R, 1991, FEBS LETT, V282, P103, DOI 10.1016/0014-5793(91)80454-B; TSUKAHARA H, 1994, J BIOL CHEM, V269, P21778; TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WINKLES JA, 1993, BIOCHEM BIOPH RES CO, V191, P1081, DOI 10.1006/bbrc.1993.1327; WREN AD, 1993, BIOCHEM BIOPH RES CO, V196, P369, DOI 10.1006/bbrc.1993.2258; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	33	132	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1747	1752		10.1074/jbc.272.3.1747	http://dx.doi.org/10.1074/jbc.272.3.1747			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999856	hybrid			2022-12-25	WOS:A1997WD05800054
J	Stover, PJ; Chen, LH; Suh, JR; Stover, DM; Keyomarsi, K; Shane, B				Stover, PJ; Chen, LH; Suh, JR; Stover, DM; Keyomarsi, K; Shane, B			Molecular cloning, characterization, and regulation of the human mitochondrial serine hydroxymethyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; MAMMALIAN-CELLS; PROTEINS; LOCALIZATION; SYNTHETASE; EXPRESSION; PROMOTER; GLYCINE; FOLATE	The human mitochondrial serine hydroxymethyltransferase (mSHMT) gene was isolated, sequenced, and characterized. The 4.5-kilobase gene contains 10 introns and 11 exons, with all splice junctions conforming to the GT/AG rule. The 5' promoter region contains consensus motifs for several regulatory proteins including PEA-3, Sp-1, AP-2, and a CCCTCCC motif common to many genes expressed in liver. Consensus TATA or CAAT sequence motifs are not present, and primer extension and 5'-rapid amplification of cDNA ends studies suggest that transcription initiation occurs at multiple sites. The mitochondrial leader sequence region of the deduced mRNA contains two potential ATG start sites, which are encoded by separate exons. The intervening 891-base pair intron contains consensus promoter elements suggesting that mSHMT may be transcribed from alternate promoters. 5'-Rapid amplification of cDNA ends analysis demonstrated that the first ATG is transcribed in human MCF-7 cells. However, transfection of Chinese hamster ovary cells deficient in mSHMT activity with the human mSHMT gene lacking exon 1 overcame the cell's glycine auxotrophy and restored intra cellular glycine concentrations to that observed in wildtype cells, showing that exon 1 is not essential for mSHMT localization or activity and that translation initiation from the second ATG is sufficient for mSHMT import into the mitochondria. Mitochondrial SHMT mRNA levels in MCF-7 cells did not vary during the cell cycle and were not affected by the absence of glycine, serine, folate, thymidylate, or purines from the media.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA; CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA	University of California System; University of California Berkeley; Cornell University; State University of New York (SUNY) System; Wadsworth Center			Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [CA41991] Funding Source: Medline; NIDDK NIH HHS [DK42033, DK49621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049621, R01DK042033] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURNS RA, 1982, COMP BIOCHEM PHYS B, V71, P351, DOI 10.1016/0305-0491(82)90394-7; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; CHRISTEN P, 1990, ANN NY ACAD SCI, V585, P331, DOI 10.1111/j.1749-6632.1990.tb28065.x; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; DASGUPTA P, 1982, J NEUROCHEM, V39, P743, DOI 10.1111/j.1471-4159.1982.tb07955.x; ELSEA SH, 1995, AM J HUM GENET, V57, P1342; GARROW TA, 1993, J BIOL CHEM, V268, P11910; GLICK B, 1991, ANNU REV GENET, V25, P21; HASHIMOTO A, 1992, J CHROMATOGR-BIOMED, V582, P41, DOI 10.1016/0378-4347(92)80300-F; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MARTINI F, 1989, J BIOL CHEM, V264, P8509; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; Narkewicz MR, 1996, BIOCHEM J, V313, P991, DOI 10.1042/bj3130991; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PFENDNER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P503, DOI 10.1016/0003-9861(80)90382-3; PRZYBYLA AE, 1979, J BIOL CHEM, V254, P2154; RASSIN DK, 1981, J NEUROCHEM, V36, P1263, DOI 10.1111/j.1471-4159.1981.tb01726.x; SANBORN TA, 1975, ENDOCRINOLOGY, V97, P1000, DOI 10.1210/endo-97-4-1000; SETOYAMA C, 1990, J BIOL CHEM, V265, P1293; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; SNELL K, 1988, BRIT J CANCER, V57, P87, DOI 10.1038/bjc.1988.15; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2155, DOI 10.1021/bi00122a037; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; WANG YB, 1994, J BIOL CHEM, V269, P9137	31	101	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1842	1848		10.1074/jbc.272.3.1842	http://dx.doi.org/10.1074/jbc.272.3.1842			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999870	hybrid			2022-12-25	WOS:A1997WD05800068
J	Zarkowska, T; U, S; Harlow, E; Mittnacht, S				Zarkowska, T; U, S; Harlow, E; Mittnacht, S			Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs	ONCOGENE			English	Article						pRB; epitope mapping; cyclin D1-CDK4 kinase; phosphorylation site; cell cycle	SUSCEPTIBILITY GENE-PRODUCT; MAP KINASE; PROGRESSION; PHOSPHATASE; FAMILY	The growth suppressive activity of the retinoblastoma tumour suppressor protein is controlled by cell cycle dependent phosphorylation, However, while many in vivo phosphorylation sites have been mapped, the identities of those residues whose phosphorylation is regulated remain elusive, We have mapped the epitopes of three independent monoclonal antibodies that recognise a distinction between differentially phosphorylated pRB sub-populations. All three antibodies recognise an identical epitope which encompasses an essential serine positioned within a consensus site for proline directed kinase phosphorylation, We provide evidence that this residue, serine 608 of pRB, is an authentic phosphorylation site that can be phosphorylated in vitro by cyclin A-CDK2 and cyclin D1-CDK4 kinases but not by cyclin E-CDK2 kinase or the mitogen activated kinase ERK2. Phosphorylation at this residue seems to be cell cycle regulated, occurring prior to entry into the S phase.	INST CANC RES,DEPT CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND; MASSACHUSETTS GEN HOSP,ONCOL MOL LAB,CHARLESTOWN,MA 02129	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Harvard University; Massachusetts General Hospital								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Belbrahem A, 1996, EXP CELL RES, V225, P286, DOI 10.1006/excr.1996.0178; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; HAMEL PA, 1992, ONCOGENE, V7, P693; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Possee RD., 1992, BACULOVIRUS EXPRESSI; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	22	55	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					249	254		10.1038/sj.onc.1200824	http://dx.doi.org/10.1038/sj.onc.1200824			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010227				2022-12-25	WOS:A1997WC81800013
J	Broome, MA; Hunter, T				Broome, MA; Hunter, T			The PDGF receptor phosphorylates Tyr 138 in the c-Src SH3 domain in vivo reducing peptide ligand binding	ONCOGENE			English	Article						PDGF receptors; c-Src; SH3 domain; tyrosine phosphorylation	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; PROLINE-RICH PEPTIDES; MUTANT MICE; BACULOVIRUS EXPRESSION; CRYSTAL-STRUCTURE; SARCOMA VIRUS; BETA-RECEPTOR; CELL-CYCLE; 3T3 CELLS	Treatment of quiescent NIH3T3 cells with PDGF BE results in the transient activation and hyperphosphorylation of the protein-tyrosine kinase, c-Src. These effects correlate with novel serine and tyrosine phosphorylations in the N-terminal non-catalytic region of the molecule, which contains an SH3 and SH2 domain. In this study, a site of PDGF-induced tyrosine phosphorylation was mapped to Tyr 138 in the SH3 domain; Tyr 138 is exposed on the SH3 peptide binding surface. This same site is phosphorylated in vitro by the PDGF receptor when purified baculovirus-expressed c-Src is complexed with the activated receptor. Phosphorylation of Tyr 138 required association of c-Src with the PDGF receptor via its SH2 domain. When a c-Src Phe 138 mutant was stably expressed in Src(-) mouse fibroblasts, it was activated to the same extent as wild type c-Src following PDGF stimulation, indicating that phosphorylation of this site is not required for PDGF-mediated activation. However, Tyr 138 phosphorylation was found to diminish SH3 domain peptide ligand binding ability in vitro.	SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Salk Institute; University of California System; University of California San Diego					NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GARTNER T, 1992, EUR J BIOCHEM, V208, P91, DOI 10.1111/j.1432-1033.1992.tb17162.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Ishino M, 1995, ONCOGENE, V11, P2331; KARN J, 1989, ONCOGENE, V4, P773; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LIU XQ, 1993, ONCOGENE, V8, P1119; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSTELIN T, 1994, SRC FAMILY TYROSINE; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OKADA M, 1993, J BIOL CHEM, V268, P18070; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENG ZY, 1995, ONCOGENE, V11, P1955; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Possee RD., 1992, BACULOVIRUS EXPRESSI; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; Summers MD, 1987, MANUAL METHODS BACUL; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALKER F, 1993, J BIOL CHEM, V268, P19552; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YU KT, 1985, J BIOL CHEM, V260, P5838; ZHANG S, 1991, Cellular Physiology and Biochemistry, V1, P24, DOI 10.1159/000154590	83	41	41	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					17	34		10.1038/sj.onc.1200798	http://dx.doi.org/10.1038/sj.onc.1200798			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010229				2022-12-25	WOS:A1997WB76000002
J	Costello, PS; Turner, M; Walters, AE; Cunningham, CN; Bauer, PH; Downward, J; Tybulewicz, VLJ				Costello, PS; Turner, M; Walters, AE; Cunningham, CN; Bauer, PH; Downward, J; Tybulewicz, VLJ			Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells	ONCOGENE			English	Article						Syk; Fc epsilon RI; mast cell; signal transduction; allergy	BASOPHILIC LEUKEMIA-CELLS; FC-EPSILON-RI; SEVERE COMBINED IMMUNODEFICIENCY; IMMUNOGLOBULIN-E RECEPTOR; ANTIGEN RECEPTOR; MICE LACKING; TRANSCRIPTION FACTOR; GAMMA-CHAIN; T-CELLS; PHOSPHOLIPASE C-GAMMA-1	Activation of the high affinity IgE receptor (Fc epsilon RI) of mast cells, a member of the antigen receptor family, leads to the release of allergic mediators, a critical event in the onset of immediate hypersensitivity. Stimulation of Fc epsilon RI results in the rapid association and activation of the Syk tyrosine kinase. Using Syk-deficient mast cells we show that they fail to degranulate, synthesize leukotrienes and secrete cytokines when stimulated through Fc epsilon RI, conclusively demonstrating an essential role for Syk in Fc epsilon Phi RI signalling, Furthermore, our data strongly supports a model of Fc epsilon RI engagement leading to the sequential activation of the tyrosine kinases Lyn and then Syk, A similar mechanism is likely to apply to signal transduction through all members of the antigen receptor family.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	MRC National Institute for Medical Research; Cancer Research UK			Turner, Martin/N-9976-2014	Turner, Martin/0000-0002-3801-9896; Downward, Julian/0000-0002-2331-4729				Adachi M, 1996, CELL, V85, P15; ALBER G, 1991, J BIOL CHEM, V266, P22613; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; Choi OH, 1996, NATURE, V380, P634; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DAI TN, 1995, ONCOGENE, V10, P849; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EISEMAN E, 1992, NATURE, V355, P78; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; GRAND DG, 1994, J EXP MED, V180, P673; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HO AM, 1994, J BIOL CHEM, V269, P28181; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kimura T, 1996, MOL CELL BIOL, V16, P1471; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; OHNO H, 1994, J EXP MED, V179, P365, DOI 10.1084/jem.179.1.365; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; ORTEGA E, 1989, EUR J IMMUNOL, V19, P2251, DOI 10.1002/eji.1830191211; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK SY, 1995, EUR J IMMUNOL, V25, P2107, DOI 10.1002/eji.1830250746; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; Schultz Leonard D., 1993, Cell, V73, P1445; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; WADHWA M, 1991, QUANTITATIVE BIOL AS, P309; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	73	263	269	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2595	2605						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000133				2022-12-25	WOS:A1996VZ65400009
J	Chen, YQE; Drucker, DJ				Chen, YQE; Drucker, DJ			Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; GUINEA-PIG PANCREAS; GENE-EXPRESSION; MESSENGER-RNA; PREPROGLUCAGON CONTAINS; DISPERSED ACINI; RAT; INTESTINE; SEQUENCES; CELLS	Glucagon-like peptide 1 stimulates insulin secretion and inhibits glucagon secretion, gastric emptying, and feeding, suggesting it may be biologically useful for the treatment of diabetes, A lizard glucagon-like peptide 1 (GLP-1)-related peptide, exendin 4, binds to the GLP-1 receptor and mimics the actions of GLP-1 in vivo, To determine the genetic relationship between exendin 4 and GLP-1, we analyzed the structure and expression of pancreatic and intestinal proglucagon mRNAs in the reptile Heloderma suspectum, Two different proglucagon cDNAs (lizard proglucagon I (LPI) and lizard proglucagon II (LPII)), with unique 3'-untranslated regions were identified, Two LPI mRNA transcripts, similar to 1.6 and 2.1 kilobases, encoded glucagon and GLP-1 but not GLP-2 and were restricted in expression to the pancreas, In contrast, a 1.1-kilobase LPII mRNA transcript, encoding glucagon, GLP-1, and GLP-2 utilized a different 3'-untranslated region and was expressed in both pancreas and intestine, Lizard proglucagon mRNA transcripts were not detectable by reverse transcription-polymerase chain reaction or Northern blotting in salivary gland. A single class of lizard salivary gland proexendin cDNAs encoded the sequence of exendin 4 and a 45- amino acid exendin NH2-terminal peptide, Exendin mRNA transcripts were expressed in the salivary gland, but not pancreas or intestine, These data demonstrate that GLP-1 and exendin 4 represent related yet distinct peptides encoded by different genes in the lizard.	UNIV TORONTO,TORONTO GEN HOSP,BANTING & BEST DIABET CTR,DEPT MED,TORONTO,ON M5G 2C4,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital			Drucker, Daniel J/A-4092-2010					BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAlessio DA, 1996, J CLIN INVEST, V97, P133, DOI 10.1172/JCI118380; Dhanvantari S, 1996, MOL ENDOCRINOL, V10, P342, DOI 10.1210/me.10.4.342; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GOKE R, 1993, J BIOL CHEM, V268, P19650; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HEINRICH G, 1984, ENDOCRINOLOGY, V115, P2176, DOI 10.1210/endo-115-6-2176; IRWIN DM, 1995, MOL ENDOCRINOL, V9, P267, DOI 10.1210/me.9.3.267; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE YC, 1990, MOL ENDOCRINOL, V4, P800, DOI 10.1210/mend-4-6-800; LEE YC, 1990, ENDOCRINOLOGY, V127, P2217, DOI 10.1210/endo-127-5-2217; LOPEZ LC, 1983, P NATL ACAD SCI-BIOL, V80, P5485, DOI 10.1073/pnas.80.18.5485; LUND PK, 1981, J BIOL CHEM, V256, P6515; LUND PK, 1983, J BIOL CHEM, V258, P3280; LUND PK, 1982, P NATL ACAD SCI-BIOL, V79, P345, DOI 10.1073/pnas.79.2.345; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; NOVAK U, 1987, EUR J BIOCHEM, V164, P553, DOI 10.1111/j.1432-1033.1987.tb11162.x; ORSKOV C, 1987, DIABETOLOGIA, V30, P874; ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467, DOI 10.1210/endo-119-4-1467; PHILIPPE J, 1988, DIABETES, V37, P1647, DOI 10.2337/diabetes.37.12.1647; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; Raufman JP, 1996, REGUL PEPTIDES, V61, P1, DOI 10.1016/0167-0115(96)00135-8; RAUFMAN JP, 1992, J BIOL CHEM, V267, P21432; ROTHENBERG ME, 1995, J BIOL CHEM, V270, P10136, DOI 10.1074/jbc.270.17.10136; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; WANG ZL, 1995, J CLIN INVEST, V95, P417, DOI 10.1172/JCI117671	34	139	183	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4108	4115		10.1074/jbc.272.7.4108	http://dx.doi.org/10.1074/jbc.272.7.4108			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020121	hybrid			2022-12-25	WOS:A1997WH01900037
J	Majello, B; DeLuca, P; Lania, L				Majello, B; DeLuca, P; Lania, L			Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; DNA-BINDING; FAMILY; PROMOTER; CLONING; GENE; MEMBERS; ELEMENT; KRUPPEL; INVIVO	Sp3 is a member of the Sp family of transcription factors and binds to DNA with affinity and specificity comparable to that of Spl. We demonstrate that Sp3 is a bifunctional transcription factor that can both activate and repress transcription, Gene fusion experiments in mammalian cells demonstrate that the Sp3 activation potential is distributed over an extensive glutamine-rich N-terminal region, whereas the repressor activity has been mapped in a 72-amino acid region located at the 5' of the zinc finger DNA-binding domain, We demonstrated that the repression activity is strictly dependent on the context of the DNA-binding sites bound by Sp3. We found that Sp3 represses transcription of promoters bearing multiple GAL4 DNA-binding sites, whereas it activates isogenic reporters containing a single GAL4-binding site, Transfection experiments in Drosophila cells that lack endogenous Sp activity demonstrated that Sp3 does not possess an active repression domain that can function in insect cells, rather it is a weak transcriptional activator of the c-myc promoter. Our results strongly suggest that Sp3 is a dual-function regulator whose activity is dependent upon both the promoter and the cellular context.	UNIV NAPLES,DEPT GENET MOL & GEN BIOL,I-80134 NAPLES,ITALY; CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			De Luca, Pasquale/AAL-5673-2021	De Luca, Pasquale/0000-0003-4289-6784; Majello, Barbara/0000-0003-2789-3585				COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LATCHMAN DE, 1995, EUCARYOTIC TRANSCRIP; LILLIE JW, 1989, NATURE, V338, P38; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; UM M, 1995, MOL CELL BIOL, V15, P5007	26	256	261	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4021	4026		10.1074/jbc.272.7.4021	http://dx.doi.org/10.1074/jbc.272.7.4021			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020109	hybrid			2022-12-25	WOS:A1997WH01900025
J	Yokoyama, K; Zimmerman, K; Scholten, J; Gelb, MH				Yokoyama, K; Zimmerman, K; Scholten, J; Gelb, MH			Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-I and protein farnesyltransferase and its consequence on the specificity of protein prenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC MECHANISM; METAL REQUIREMENTS; PEPTIDE-BINDING; GAMMA-SUBUNITS; ALPHA-SUBUNIT; CDNA CLONING; TRANSFERASE; FARNESYL; RAS; EXPRESSION	Protein geranylgeranyltransferase-I (PGGT-I) and protein farnesyltransferase (PFT) attach geranylgeranyl and farnesyl groups, respectively, to the C termini of eukaryotic cell proteins, In vitro, PGGT-I and PFT can transfer both geranylgeranyl and farnesyl groups from geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) to their protein or peptide prenyl acceptor substrates. In the present study it is shown that PGGT-I binds GGPP 330-fold tighter than FPP and that PFT binds FPP 15-fold tighter than GGPP, Therefore, in vivo, where both GGPP and FPP compete for the binding to prenyltransferases, PGGT-I and PFT will likely be bound predominantly to GGPP and FPP, respectively. Previous studies have shown that K-Ras4B and the Ras-related GTPase TC21 are substrates for both PGGT-I and PFT in vitro, It is shown that TC21 can compete with the C-terminal peptide of the gamma subunit of heterotrimeric G proteins and with the C-terminal peptide of lamin B for geranylgeranylation by PGGT-I and for farnesylation by PFT, respectively, K-Ras4B competes in both cases but is almost exclusively farnesylated by PFT in the presence of the lamin B peptide competitor. Rapid and single turnover kinetic studies indicate that the rate constant for the PGGT-I-catalyzed geranylgeranyl transfer step of the reaction cycle is 14-fold larger than the steady-state turnover number, which indicates that the rate of the overall reaction is limited by a step subsequent to prenyl transfer such as release of products from the enzyme, PGGT-I-catalyzed farnesylation is 37-fold slower than geranylgeranylation and is limited by the farnesyl transfer step, These results together with earlier studies provide a paradigm for the substrate specificity of PGGT-I and PFT and provide information that is critical for the design of prenyltransferase inhibitors as anti-cancer agents.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; WARNER LAMBERT PARKE DAVIS,ANN ARBOR,MI 48106	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pfizer				gelb, michael/0000-0001-7000-5219	NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER; NCI NIH HHS [CA52874] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BUKHTIYAROV YE, 1995, J BIOL CHEM, V270, P19035, DOI 10.1074/jbc.270.32.19035; BUSS J, 1996, CHEM BIOL, V2, P787; CARBONI JM, 1995, ONCOGENE, V10, P1905; CASEY PJ, 1992, J LIPID RES, V33, P1731; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; Dolence JM, 1995, BIOCHEMISTRY-US, V34, P16687, DOI 10.1021/bi00051a017; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KALMAN VK, 1995, J BIOL CHEM, V270, P14835, DOI 10.1074/jbc.270.24.14835; MAGEE AI, 1992, BIOCHEM SOC T, V20, P497, DOI 10.1042/bst0200497; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINE J, 1990, New Biologist, V2, P219; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; YOKOYAMA K, 1992, BIOCHEM SOC T, V20, P479; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; ZHANG FL, 1994, J BIOL CHEM, V269, P23465	47	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3944	3952		10.1074/jbc.272.7.3944	http://dx.doi.org/10.1074/jbc.272.7.3944			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020098	hybrid			2022-12-25	WOS:A1997WH01900014
J	Brakebusch, C; Jallal, B; Fusco, O; Iacobelli, S; Ullrich, A				Brakebusch, C; Jallal, B; Fusco, O; Iacobelli, S; Ullrich, A			Expression of the 90K immunostimulator gene is controlled by a promoter with unique features	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-ASSOCIATED ANTIGEN; REGULATORY FACTOR-I; TRANSCRIPTION FACTOR IRF-1; CYSTEINE-RICH DOMAIN; BREAST-CANCER; INSITU HYBRIDIZATION; PROGNOSTIC VALUE; PROTEIN; DNA	90K is a secreted glycoprotein with tumor suppressive functions, which is up-regulated in various types of cancer and in AIDS. In order to understand the regulation of its expression, the mouse 90K gene was isolated and analyzed. The gene spans about 8.8-kilobase pairs and consists of 6 exons and was localized on chromosome 11, region E. RNase protection identified one major transcription st-art site (+1) and three minor ones (-3, +32, +34). The mouse 90K gene was found to have a TATAless promoter of unusual structure. The 2.3-kilobase pair 5'-flanking region exhibited strong promoter activity in NIH. 3T3 cells; however, it contained neither a TATA-box nor a SP1 site and was not GC-rich. No known initiator motif was found around the transcription start site. 5'- and 3'-deletions defined a minimal promoter of 51 base pairs (-66 --> -16), not including the start site, essential and sufficient for promoter activity. This minimal promoter showed increased activity after stimulation with interferon-gamma or poly (I . C), a substance mimicking viral infection. Essential for both inductions was the integrity of an interferon regulatory factor element within this sequence,a potential binding site for the anti-oncogenic transcription factor interferon regulatory factor-1.	MAX PLANCK INST BIOCHEM,DEPT MOL BIOL,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063; UNIV G DANNUNZIO,CATTEDRA ONCOL MED,I-66100 CHIETI,ITALY	Max Planck Society; G d'Annunzio University of Chieti-Pescara				Brakebusch, Cord/0000-0002-9342-1634				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAILLY A, 1986, EMBO J, V5, P3235, DOI 10.1002/j.1460-2075.1986.tb04634.x; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; CALABRESE G, 1995, CYTOGENET CELL GENET, V69, P223, DOI 10.1159/000133969; CHICHEPORTICHE Y, 1994, J BIOL CHEM, V269, P5512; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FENG GS, 1994, ONCOGENE, V9, P1745; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HUANG DH, 1988, J BIOL CHEM, V263, P12596; IACOBELLI S, 1994, BRIT J CANCER, V69, P172, DOI 10.1038/bjc.1994.29; IACOBELLI S, 1986, CANCER RES, V46, P3005; IACOBELLI S, 1988, INT J CANCER, V42, P182, DOI 10.1002/ijc.2910420207; JALLAL B, 1995, CANCER RES, V55, P3223; KOTHS K, 1993, J BIOL CHEM, V268, P14245; LAMOND AI, 1993, BIOESSAYS, V15, P595, DOI 10.1002/bies.950150905; LONGO G, 1993, BRIT J HAEMATOL, V85, P207, DOI 10.1111/j.1365-2141.1993.tb08674.x; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; MARTH C, 1994, INT J CANCER, V59, P808, DOI 10.1002/ijc.2910590617; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAGOE Y, 1994, J BIOL CHEM, V269, P8268; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NATOLI C, 1991, J INFECT DIS, V164, P616, DOI 10.1093/infdis/164.3.616; NATOLI C, 1993, J ACQ IMMUN DEF SYND, V6, P370; PAL SK, 1991, MOL CELL BIOL, V11, P5190, DOI 10.1128/MCB.11.10.5190; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; ULLRICH A, 1994, J BIOL CHEM, V269, P18401; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; VILCEK J, 1990, HDB EXPT PHARM, P3; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	52	12	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3674	3682		10.1074/jbc.272.6.3674	http://dx.doi.org/10.1074/jbc.272.6.3674			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013622	hybrid			2022-12-25	WOS:A1997WG19200082
J	Cuevo, RS; Garrett, S; Horowitz, JM				Cuevo, RS; Garrett, S; Horowitz, JM			Detection and functional characterization of p180, a novel cell cycle regulated yeast transcription factor that binds retinoblastoma control elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; SP1-MEDIATED TRANSCRIPTION; SUSCEPTIBILITY GENE; NEGATIVE REGULATION; AMINO-TERMINUS; RB PROTEIN; EXPRESSION; PROMOTER	In recent years it has become apparent that the cellular machinery governing cell cycle progression and transcription control are often homologous in yeast and mammalian cells, We and others have previously shown that the SP family of mammalian transcription factors regulates the transcription of a number of genes whose activities are governed by the product of the retinoblastoma (Rb) susceptibility gene, including c-FOS, c-MYC, TGF beta-1, IGF-II, and c-JUN, To determine whether a similar pathway of transcriptional regulation may function in yeast, we explored the possibility that transcription factors with nucleotide-binding specificities akin to those of the SP family are expressed in Saccharomyces cerevisiae and Schizosaccharomyces pombe, Here we report the detection of novel yeast proteins (S. cerevisiae, p180; S. pombe, p200) that specifically bind Rb-regulated promoter elements in vitro dependent on nucleotides that are also required for binding and trans-activation by SP family members in vivo. Our results indicate that the S. cerevisiae retinoblastoma control element-binding activity 1) requires zinc for association with DNA; 2) does not bind to SCB, MCB, or E2F sites in vitro; 3) is cell cycle-regulated in a SWI6-independent fashion; and 4) maximally stimulates retinoblastoma control element-mediated transcription in early- to mid-S phase. Taken together, these data suggest that p180 may regulate the transcription of a subset of yeast genes whose expression is coincident with the onset and/or progression of DNA replication.	DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University					NCI NIH HHS [CA01694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS BJ, 1993, SCIENCE, V261, P1543, DOI 10.1126/science.8372349; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURKE DJ, 1991, MOL CELL BIOL, V11, P3691, DOI 10.1128/MCB.11.7.3691; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chellappan Srikumar P., 1994, Molecular and Cellular Differentiation, V2, P201; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROSS SL, 1983, MOL CELL BIOL, V8, P945; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; FINLEY RL, 1990, MOL CELL BIOL, V10, P5663, DOI 10.1128/MCB.10.11.5663; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; Horowitz Jonathan M., 1995, Molecular and Cellular Differentiation, V3, P275; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MALHOTRA P, 1993, J BIOL CHEM, V268, P20392; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; POON D, 1994, J BIOL CHEM, V269, P23135; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sambrook J., 2002, MOL CLONING LAB MANU; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH MM, 1983, J MOL BIOL, V169, P663, DOI 10.1016/S0022-2836(83)80164-8; SONI R, 1995, PLANT CELL, V7, P85, DOI 10.1105/tpc.7.1.85; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Sterner JM, 1996, CELL GROWTH DIFFER, V7, P53; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VEMU S, 1995, J BIOL CHEM, V270, P20724, DOI 10.1074/jbc.270.35.20724; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIE Q, 1995, EMBO J, V14, P4073, DOI 10.1002/j.1460-2075.1995.tb00079.x; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220; [No title captured]	61	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3813	3822		10.1074/jbc.272.6.3813	http://dx.doi.org/10.1074/jbc.272.6.3813			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013640	hybrid			2022-12-25	WOS:A1997WG19200100
J	Hirano, K; Phan, BC; Hartshorne, DJ				Hirano, K; Phan, BC; Hartshorne, DJ			Interactions of the subunits of smooth muscle myosin phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; TYPE-1 CATALYTIC SUBUNIT; LIGHT-CHAIN PHOSPHATASE; PURIFICATION; INVOLVEMENT; KINASE; RHO; INHIBITION; SYSTEM; ACID	Myosin phosphatase from smooth muscle consists of a catalytic subunit (PP1c) and two non-catalytic subunits, M130 and M20, Interactions among PP1c, M20, and various mutants of M130 were investigated. Using the yeast two hybrid system, PP1c was shown to bind to the NH2-terminal sequence of M130, 1-511. Other interactions were detected, i.e. PP1c to PP1c, M20 to the COOH-terminal fragment of M130, and dimerization of the COOH-terminal fragment of M130. Mutants of M130 were constructed to localize the PP1c and light chain binding regions, Results from the two-hybrid system indicated two binding sites for PP1c on M130: one site in the NH2-terminal 38 residues and a weaker site(s) in the ankyrin repeats region, Inhibition of PP1c activity with phosphorylase a by the M130 mutants also was consistent with the assignment of these two sites. Overlay assays showed binding of phosphorylated light chain to the ankyrin repeats, probably in the COOH-terminal repeats. Activation of PP1c with phosphorylated light chain required binding sites for PP1c and substrate, plus an additional sequence COOH-terminal to the ankyrin repeats. Thus, activation of phosphatase and binding of PP1c and substrate are properties of the NH2-terminal one-third of M130.	UNIV ARIZONA,MUSCLE BIOL GRP,TUCSON,AZ 85721	University of Arizona			Hirano, Katsuya/B-2785-2008	Hirano, Katsuya/0000-0003-0164-1283	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984, R01HL023615] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20984, HL07249, HL23615] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BRAUTIGAN DL, 1989, ARCH BIOCHEM BIOPHYS, V275, P44, DOI 10.1016/0003-9861(89)90348-2; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUJITA A, 1995, J PHARMACOL EXP THER, V274, P555; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; GONG MC, 1995, J PHYSIOL-LONDON, V486, P113, DOI 10.1113/jphysiol.1995.sp020795; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; Haystead CMM, 1995, FEBS LETT, V377, P123, DOI 10.1016/0014-5793(95)01318-0; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; HIRANO K, 1995, J BIOL CHEM, V270, P19786, DOI 10.1074/jbc.270.34.19786; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ichikawa K, 1996, BIOCHEMISTRY-US, V35, P6313, DOI 10.1021/bi960208q; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1987, J BIOL CHEM, V262, P13828; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; MARTIN BI, 1994, PROTEIN EXPRES PURIF, V5, P211, DOI 10.1006/prep.1994.1033; MITSUI T, 1992, J BIOL CHEM, V267, P16727; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; OKUBO S, 1993, ADV PROTEIN PHOSPHAT, V7, P295; SHIESTL RH, 1989, CURR GENET, V16, P339; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; YOSHIDA M, 1988, J BIOCHEM-TOKYO, V103, P380, DOI 10.1093/oxfordjournals.jbchem.a122278	38	83	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3683	3688		10.1074/jbc.272.6.3683	http://dx.doi.org/10.1074/jbc.272.6.3683			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013623	hybrid			2022-12-25	WOS:A1997WG19200083
J	Lobau, S; Weber, J; WilkeMounts, S; Senior, AE				Lobau, S; Weber, J; WilkeMounts, S; Senior, AE			F-1-ATPase, roles of three catalytic site residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; SYNTHASE BETA-SUBUNIT; NUCLEOTIDE-BINDING; ATP SYNTHASE; RAS P21; HYDROLYSIS; MUTATIONS; MECHANISM; TRIPHOSPHATE; MUTAGENESIS	Three critical residues, beta-Lys-155, beta-Asp-242, and beta-GLu-181, situated close to the gamma-phosphate of MgATP in F-1-ATPase catalytic sites, were investigated. The mutations beta K155Q, beta D242N, and beta E181Q were each combined with the beta Y331W mutation; the fluorescence signal of beta-Trp-331 was used to determine MgATP, MgADP, ATP, and ADP binding parameters for the three catalytic sites of the enzyme. The quantitative contribution of side chains to binding energy at all three catalytic sites was calculated. The following conclusions were made. The major functional interaction of beta-Lys-155 is with the gamma-phosphate of MgATP and is of primary importance at site 1 (the site of highest affinity) and site 2. Release of MgATP during oxidative phosphorylation requires conformational re-positioning of this residue. The major functional interaction of beta-Asp-242 is with the magnesium of the magnesium nucleotide at site 1; it has little or no influence at site 2 or 3. In steady-state turnover, the MgATP hydrolysis reaction occurs at site 1. beta-Glu-181 contributes little to nucleotide binding; its major catalytic effect derives apparently from a role in reaction chemistry per se. This work also emphasizes that nucleotide binding cooperativity shown by the three catalytic sites toward MgATP and MgADP is absolutely dependent on the presence of magnesium.			Lobau, S (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; Amano T, 1996, J BIOL CHEM, V271, P18128, DOI 10.1074/jbc.271.30.18128; AMANO T, 1994, FEBS LETT, V348, P93, DOI 10.1016/0014-5793(94)00588-5; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; LANGEN R, 1992, BIOCHEMISTRY-US, V31, P8691, DOI 10.1021/bi00152a002; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PARK MY, 1994, J BIOCHEM-TOKYO, V116, P1139, DOI 10.1093/oxfordjournals.jbchem.a124640; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; RAO R, 1988, J BIOL CHEM, V263, P5569; Rayment I, 1996, J BIOL CHEM, V271, P15850, DOI 10.1074/jbc.271.27.15850; Sato K, 1996, J BIOL CHEM, V271, P17439, DOI 10.1074/jbc.271.29.17439; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SENIOR AE, 1993, J BIOL CHEM, V268, P6989; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SOUID AK, 1995, J BIOL CHEM, V270, P9074, DOI 10.1074/jbc.270.16.9074; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1996, J BIOL CHEM, V271, P3474; WEBER J, 1997, IN PRESS BIOCH BIOPH; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343	35	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3648	3656		10.1074/jbc.272.6.3648	http://dx.doi.org/10.1074/jbc.272.6.3648			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013618	hybrid			2022-12-25	WOS:A1997WG19200078
J	Pfeiffer, S; Gorren, ACF; Schmidt, K; Werner, ER; Hansert, B; Bohle, DS; Mayer, B				Pfeiffer, S; Gorren, ACF; Schmidt, K; Werner, ER; Hansert, B; Bohle, DS; Mayer, B			Metabolic fate of peroxynitrite in aqueous solution - Reaction with nitric oxide and pH-dependent decomposition to nitrite and oxygen in a 2:1 stoichiometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYL RADICAL PRODUCTION; SUPEROXIDE-DISMUTASE; ASCORBIC-ACID; OXIDATION; KINETICS; NITRATION; ATHEROSCLEROSIS; PEROXONITRITE; CHEMISTRY; TYROSINE	Peroxynitrite, the reaction product of nitric oxide (NO) and superoxide (0(2)(-.)) is assumed to decompose upon protonation in a first order process via intramolecular rearrangement to NO3-. The present study was carried out to elucidate the origin of NO-2 found in decomposed peroxynitrite solutions. As revealed by stopped-flow spectroscopy, the decay of peroxynitrite followed first-order kinetics and exhibited a pK(a) of 6.8 +/- 0.1. The reaction of peroxynitrite with NO was considered as one possible source of NO2- but the calculated second order rate constant of 9.1 x 10(4) M(-1) s(-1) is probably too small to explain NO2- formation under physiological conditions. Moreover, pure peroxynitrite decomposed to NO-2 without apparent release of NO. Determination of NO-2 and NO3- in solutions of decomposed peroxynitrite showed that the relative amount of NO2- increased with increasing pH, with NO2- accounting for about 30% of decomposition products at pH 7.5 and NO3- being the sole metabolite at pH 3.0. Formation of NO2- was accompanied by release of stoichiometric amounts of O-2 (0.495 mol/mol of NO2-). The two reactions yielding NO2- and NO3- showed distinct temperature dependences from which a difference in E(act) of 26.2 +/- 0.9 kJ mol(-1) was calculated. The present results demonstrate that peroxynitrite decomposes with significant rates to NO2- plus O-2 at physiological pH. Through formation of biologically active intermediates, this novel pathway of peroxynitrite decomposition may contribute to the physiology and/or cytotoxicity of NO and superoxide.	GRAZ UNIV, INST PHARMAKOL & TOXIKOL, A-8010 GRAZ, AUSTRIA; UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA; UNIV WYOMING, DEPT CHEM, LARAMIE, WY 82071 USA	University of Graz; University of Innsbruck; University of Wyoming			Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494; Werner, Ernst R./0000-0003-1948-3391; Gorren, Antonius Cornelis Franciscus/0000-0003-3476-6162				AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BOHLE DS, 1994, J AM CHEM SOC, V116, P7423, DOI 10.1021/ja00095a062; Crow J P, 1995, Adv Pharmacol, V34, P17; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; EDWARDS JO, 1994, PROG INORG CHEM, V41, P599, DOI 10.1002/9780470166420.ch8; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HOGG N, 1993, BIOCHEM SOC T, V21, P358, DOI 10.1042/bst0210358; HOGG N, 1994, ARCH BIOCHEM BIOPHYS, V314, P153, DOI 10.1006/abbi.1994.1423; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; HUGHES MN, 1970, J CHEM SOC A, P925, DOI 10.1039/j19700000925; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KHAN AU, 1995, J BIOLUM CHEMILUM, V10, P329, DOI 10.1002/bio.1170100604; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUKOVETZ WR, 1989, J CARDIOVASC PHARM, V14, pS40, DOI 10.1097/00005344-198914110-00008; Laurent M, 1996, BIOCHEM J, V314, P109, DOI 10.1042/bj3140109; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; LIU S, 1994, J PHARMACOL EXP THER, V268, P1114; LOGAGER T, 1993, J PHYS CHEM-US, V97, P6664; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; PAPEE HM, 1964, NATURE, V204, P142, DOI 10.1038/204142a0; PLUMB RC, 1992, ANALYST, V117, P1639, DOI 10.1039/an9921701639; POU S, 1995, BBA-GEN SUBJECTS, V1244, P62, DOI 10.1016/0304-4165(94)00197-6; Pryor WA, 1996, J AM CHEM SOC, V118, P3125, DOI 10.1021/ja9529955; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; SCHMIDT K, 1994, BIOCHEM J, V301, P645, DOI 10.1042/bj3010645; SQUADRITO GL, 1995, ARCH BIOCHEM BIOPHYS, V322, P53, DOI 10.1006/abbi.1995.1435; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; VasquezVivar J, 1996, BIOCHEM J, V314, P869, DOI 10.1042/bj3140869; WERNERFELMAYER G, 1993, FEBS LETT, V322, P223, DOI 10.1016/0014-5793(93)81574-J; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	47	303	305	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3465	3470		10.1074/jbc.272.6.3465	http://dx.doi.org/10.1074/jbc.272.6.3465			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013592	hybrid			2022-12-25	WOS:A1997WG19200052
J	Stellrecht, CMM; DeMayo, FJ; Finegold, MJ; Tsai, MJ				Stellrecht, CMM; DeMayo, FJ; Finegold, MJ; Tsai, MJ			Tissue-specific and developmental regulation of the rat insulin II gene enhancer, RIPE3, in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; 5'-FLANKING REGION; BINDING PROTEINS; BETA-CELLS; TRANSCRIPTION; ELEMENTS; SEQUENCES; COMPLEXES; PROMOTER; NEURONS	The rat insulin II gene enhancer, RIPE3 (-126 to -86), mediates beta-islet cell-specific activity in transfection assays, To investigate the in vivo activity of RIPE3, we generated mice carrying a transgene consisting of three copies of RIPE3 linked to a minimal chicken ovalbumin promoter in conjunction with sequences encoding the human growth hormone gene. 13 transgenic mice were obtained, 11 of which expressed the transgene, as determined by serum radioimmunoassay for human growth hormone. Expression of the transgene was assessed for cell specificity by immunocytochemistry. The pancreatic islet cells invariably stained for growth hormone, while the acinar and ductal cells did not. Staining of adjacent sections for insulin, glucagon, and somatostatin revealed that growth hormone was expressed in the beta-cell in all of the mice analyzed, but in some mice alpha-cells also contained growth hormone. RNase protection analysis revealed that the tissues that consistently express the transgene in these animals are the pancreas and brain. Developmental analysis revealed that the transgene was expressed in the pancreatic bud at embryonic day 9.5, corresponding to the temporal expression pattern of the insulin gene. These results signify that an element as small as 41 base pairs is capable of regulating pancreatic temporal and spatial gene expression in vivo.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017379, R01HD017379] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17379] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BORDONARO M, 1994, BIOTECHNIQUES, V16, P428; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; CORDLE SR, 1991, MOL CELL BIOL, V11, P2881, DOI 10.1128/MCB.11.5.2881; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; DELTOUR L, 1993, P NATL ACAD SCI USA, V90, P527, DOI 10.1073/pnas.90.2.527; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EPISKOPOU V, 1984, P NATL ACAD SCI-BIOL, V81, P4657, DOI 10.1073/pnas.81.15.4657; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GIDDINGS SJ, 1988, J BIOL CHEM, V263, P3845; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HOGAN BLM, 1988, MANIPULATING MOUSE E; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; JETTON TL, 1994, J BIOL CHEM, V269, P3641; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; Peyton M, 1996, MOL CELL BIOL, V16, P626; PEYTON M, 1994, J BIOL CHEM, V269, P25936; RAY MK, 1995, J BIOL CHEM, V270, P2689, DOI 10.1074/jbc.270.6.2689; SEPULEVEDA AR, 1989, CANCER RES, V49, P6180; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SHIEH SY, 1995, J BIOL CHEM, V270, P21503, DOI 10.1074/jbc.270.37.21503; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155	33	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3567	3572		10.1074/jbc.272.6.3567	http://dx.doi.org/10.1074/jbc.272.6.3567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013607	hybrid			2022-12-25	WOS:A1997WG19200067
J	Yu, XC; Sturrock, ED; Wu, ZC; Biemann, K; Ehlers, MRW; Riordan, JF				Yu, XC; Sturrock, ED; Wu, ZC; Biemann, K; Ehlers, MRW; Riordan, JF			Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCANS; SECRETION; SEQUENCE; BINDING; CELLS; CHAIN	The sites of glycosylation of Chinese hamster ovary cell expressed testicular angiotensin-converting enzyme (tACE) have been determined by matrix-assisted laser desorption ionization/time of flight/mass spectrometry of peptides generated by proteolytic and cyanogen bromide digestion. Two of the seven potential N-linked glycosylation sites, Asn(90) and Asn(109), were found to be fully glycosylated by analysis of peptides before and after treatment with a series of glycosidases and with endoproteinase Asp-N, The mass spectra of the glycopeptides exhibit characteristic clusters of peaks which indicate the N-linked glycans in tACE to be mostly of the biantennary, fucosylated complex type, This structural information was used to demonstrate that three other sites, Asn(155), Asn(337), and Asn(586) are partially glycosylated, whereas Asn(72) appears to be fully glycosylated, The only potential site that was not modified is Asn(620), Sequence analysis of tryptic peptides obtained from somatic ACE (human kidney) identified six glycosylated and one unglycosylated Asn. Only one of these glycosylation sites had a counterpart in tACE, Comparison of the two proteins reveals a pattern in which amino-terminal N-linked sites are preferred. The functional significance of glycosylation was examined with a tACE mutant lacking the O-glycan-rich first amino-terminal 36 residues and truncated at Ser(625). When expressed in the presence of the alpha-glucosidase I inhibitor N-butyldeoxynojirimycin and treated with endoglycosidase H to remove all but the terminal N-acetylglucosamine residues, it retained full enzymatic activity, was electrophoretically homogeneous, and is a good candidate for crystallographic studies.	HARVARD UNIV,SCH MED,CTR BIOCHEM & BIOPHYS SCI & MED,BOSTON,MA 02115; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; UNIV CAPE TOWN,SCH MED,DEPT BIOCHEM MED,ZA-7925 CAPE TOWN,SOUTH AFRICA	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); University of Cape Town					NHLBI NIH HHS [HL34704] Funding Source: Medline; NIGMS NIH HHS [GM05472] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM005472, R01GM005472] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; CONROY JM, 1978, BIOCHIM BIOPHYS ACTA, V524, P403, DOI 10.1016/0005-2744(78)90177-8; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; DAVIS SJ, 1995, J BIOL CHEM, V270, P369, DOI 10.1074/jbc.270.1.369; Ehlers M R, 1991, Protein Expr Purif, V2, P1, DOI 10.1016/1046-5928(91)90001-Y; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1992, BIOCHEM BIOPH RES CO, V183, P199, DOI 10.1016/0006-291X(92)91628-4; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; KARLSSON GB, 1993, J BIOL CHEM, V268, P570; KASTURI S, 1994, BIOCHEMISTRY-US, V33, P6228, DOI 10.1021/bi00186a024; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; NAIM HY, 1993, BIOCHEM J, V296, P607, DOI 10.1042/bj2960607; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; RIPKA JE, 1993, BIOCHEM BIOPH RES CO, V196, P503, DOI 10.1006/bbrc.1993.2278; Sadhukhan R, 1996, J BIOL CHEM, V271, P6429, DOI 10.1074/jbc.271.11.6429; SARENEVA T, 1995, BIOCHEM J, V308, P9, DOI 10.1042/bj3080009; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Sturrock ED, 1996, BIOCHEMISTRY-US, V35, P9560, DOI 10.1021/bi960243x	24	64	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3511	3519		10.1074/jbc.272.6.3511	http://dx.doi.org/10.1074/jbc.272.6.3511			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013598	hybrid, Green Published			2022-12-25	WOS:A1997WG19200058
J	Margana, RK; Boggaram, V				Margana, RK; Boggaram, V			Functional analysis of surfactant protein B (SP-B) promoter - Sp1, Sp3, TTF-1, and HNF-3 alpha transcription factors are necessary for lung cell-specific activation of SP-B gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; RABBIT FETAL LUNG; FACTOR-I; INSITU HYBRIDIZATION; EXPRESSION PATTERNS; RECOGNITION SITE; MESSENGER-RNA; SP-A; DNA; FAMILY	Surfactant protein B (SP-B) is essential for maintenance of biophysical properties and physiological function of pulmonary surfactant. SP-B mRNA expression is restricted to alveolar type II epithelial cells and bronchiolar epithelial cells (Clara cells) of adult lung. We previously (Margana, R. K., and Boggaram, V. (1996) Am. J. Physiol. 270, L601-L612) found that a minimal promoter region (-236 to +39) of rabbit SP-B gene is sufficient for high level expression of chloramphenicol acetyltransferase reporter gene in NCI-H441 cells, a cell line with characteristics of Clara cells. In the present study we used mutational analysis, electrophoretic mobility shift assays, and DNase I footprinting to identify cis-DNA regulatory elements and trans-acting protein factors required for lung cell-specific expression of SP-B gene. We found that in addition to thyroid transcription factor 1 (TTF-1) and hepatocyte nuclear factor 3 alpha (HNF-3 alpha) binding sites, two spatially separate DNA sequences that bind Spl and Sp3 factors are necessary for the maintenance of SP-B promoter activity. Mutation of any one of the transcription factor binding sites caused a significant reduction in SP-B promoter activity suggesting that Sp1, Sp3, and TTF-1 and HNF-3 alpha interact cooperatively with SP-B promoter to activate gene transcription.	UNIV TEXAS,HLTH SCI CTR,DEPT MOL BIOL,TYLER,TX 75710	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048048, R01HL048048] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48048] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAM J, 1991, BIOTECHNIQUES, V10, P423; Ausubel F., 1993, CURRENT PROTOCOLS; BOGGARAMV, 1996, FASEB J, V10, pA1122; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNO MA, 1995, AM J PHYSIOL-LUNG C, V268, pL381; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLOROS J, 1991, AM J RESP CELL MOL, V4, P449, DOI 10.1165/ajrcmb/4.5.449; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LAKIN ND, 1993, TRANSCRIPTION FACTOR; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LILEY HG, 1989, J CLIN INVEST, V83, P1191, DOI 10.1172/JCI114000; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Margana RK, 1996, AM J PHYSIOL-LUNG C, V270, pL601, DOI 10.1152/ajplung.1996.270.4.L601; MARGANA RK, 1995, AM J PHYSIOL-LUNG C, V268, pL481, DOI 10.1152/ajplung.1995.268.3.L481; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V970, P194, DOI 10.1016/0167-4889(88)90179-6; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; PILOTMATIAS TJ, 1989, DNA-J MOLEC CELL BIO, V8, P75, DOI 10.1089/dna.1.1989.8.75; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; VENKATESH VC, 1995, AM J PHYSIOL-LUNG C, V268, pL674, DOI 10.1152/ajplung.1995.268.4.L674; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V7, P335, DOI 10.1165/ajrcmb/7.3.335; XU JJ, 1993, BIOCHIM BIOPHYS ACTA, V1169, P146, DOI 10.1016/0005-2760(93)90199-J; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	46	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3083	3090		10.1074/jbc.272.5.3083	http://dx.doi.org/10.1074/jbc.272.5.3083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006959	hybrid			2022-12-25	WOS:A1997WE66700072
J	Tomaska, L; Nosek, J; Fukuhara, H				Tomaska, L; Nosek, J; Fukuhara, H			Identification of a putative mitochondrial telomere-binding protein of the yeast Candida parapsilosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUADRUPLEX NUCLEIC-ACIDS; SACCHAROMYCES-CEREVISIAE; TETRAHYMENA-THERMOPHILA; PHYSARUM-POLYCEPHALUM; SPECIFICALLY BINDS; GENE-PRODUCT; DNA; RAP1; AFFINITY; REPEATS	Terminal segments (telomeres) of linear mitochondrial DNA (mtDNA) molecules of the yeast Candida parapsilosis consist of large sequence units repeated in tandem. The extreme ends of mtDNA terminate with a 5' single-stranded overhang of about 110 nucleotides. We identified and purified a mitochondrial telomere-binding protein (mtTBP) that specifically recognizes a synthetic oligonucleotide derived from the extreme end of this linear mtDNA. MtTBP is highly resistant to protease and heat treatments, and it protects the telomeric probe hom degradation by various DNA-modifying enzymes. Resistance of the complex to bacterial alkaline phosphatase suggests that mtTBP binds the very end of the molecule. We purified mtTBP to near homogeneity using DNA affinity chromatography based on the telomeric oligonucleotide covalently bound to Sepharose. Sodium dodecyl sulfate-polyacrylamide gel electrophoretic analysis of the purified fractions revealed the presence of a protein with an apparent molecular mass of similar to 15 kDa. UV cross-linking and gel filtration chromatography experiments suggested that native mtTBP is probably a homo-oligomer. MtTBP of C. parapsilosis is the first identified protein that specifically binds to telomeres of Linear mitochondrial DNA.	COMENIUS UNIV BRATISLAVA, FAC NAT SCI, DEPT BIOCHEM, BRATISLAVA 84215, SLOVAKIA; CTR UNIV PARIS 11, INST CURIE, SECT RECH, F-91405 ORSAY, FRANCE	Comenius University Bratislava; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Tomaska, L (corresponding author), COMENIUS UNIV BRATISLAVA, FAC NAT SCI, DEPT GENET, MLYNSKA DOLINA B-1, BRATISLAVA 84215, SLOVAKIA.		Nosek, Jozef/A-7581-2008; Tomaska, Lubomir/I-3071-2014	Nosek, Jozef/0000-0002-1020-5451; Tomaska, Lubomir/0000-0003-4886-1910				BENDICH AJ, 1993, CURR GENET, V24, P279, DOI 10.1007/BF00336777; BIESSMANN H, 1992, ADV GENET, V30, P185, DOI 10.1016/S0065-2660(08)60321-1; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGATI C, 1993, MOL CELL BIOL, V13, P1306, DOI 10.1128/MCB.13.2.1306; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COREN JS, 1991, MOL CELL BIOL, V11, P2282, DOI 10.1128/MCB.11.4.2282; COREN JS, 1992, BIOCHIM BIOPHYS ACTA, V1171, P162, DOI 10.1016/0167-4781(92)90116-H; DARLEYUSMAR VM, 1987, MITOCHONDRIA PRACTIC, P113; DINOUEL N, 1993, MOL CELL BIOL, V13, P2315, DOI 10.1128/MCB.13.4.2315; FANG G, 1995, TELOMERES, P69; FANG GW, 1991, NUCLEIC ACIDS RES, V19, P5515, DOI 10.1093/nar/19.20.5515; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; FUKUHARA H, 1993, MOL CELL BIOL, V13, P2309, DOI 10.1128/MCB.13.4.2309; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HICKE B, 1995, NUCLEIC ACIDS RES, V23, P1887, DOI 10.1093/nar/23.11.1887; HUBBARD K, 1995, EXP CELL RES, V218, P241, DOI 10.1006/excr.1995.1152; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KIPLING D, 1995, TELOMERE, P1; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; KOVAC L, 1984, MOL GEN GENET, V197, P420, DOI 10.1007/BF00329938; KUROIWA T, 1994, MICROSC RES TECHNIQ, V27, P220, DOI 10.1002/jemt.1070270304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JJ, 1993, BIOESSAYS, V15, P555, DOI 10.1002/bies.950150809; LIU ZP, 1991, GENE DEV, V5, P49, DOI 10.1101/gad.5.1.49; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MIYAKAWA I, 1987, J CELL SCI, V88, P431; MIYAKAWA I, 1993, PLANT CELL PHYSIOL, V34, P151; MORIN GB, 1986, CELL, V46, P873, DOI 10.1016/0092-8674(86)90069-3; MORIN GB, 1988, CELL, V52, P367, DOI 10.1016/S0092-8674(88)80029-1; NOSEK J, 1995, MOL GEN GENET, V247, P61, DOI 10.1007/BF00425822; NOSEK J, 1994, P 11 YEAST JOINT S F, P97; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SHENG H, 1995, MOL CELL BIOL, V15, P1144; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; WANG WL, 1992, NUCLEIC ACIDS RES, V20, P6621, DOI 10.1093/nar/20.24.6621; WESOLOWSKI M, 1981, MOL CELL BIOL, V1, P387, DOI 10.1128/MCB.1.5.387; WILLIAMS M, 1992, NUCLEIC ACIDS RES, V20, P4935, DOI 10.1093/nar/20.18.4935; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZENTGRAF U, 1995, PLANT MOL BIOL, V27, P467, DOI 10.1007/BF00019314; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	59	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3049	3056		10.1074/jbc.272.5.3049	http://dx.doi.org/10.1074/jbc.272.5.3049			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006955	hybrid			2022-12-25	WOS:A1997WE66700068
J	Afonina, E; Neumann, M; Pavlakis, GN				Afonina, E; Neumann, M; Pavlakis, GN			Preferential binding of poly(A)-binding protein 1 to an inhibitory RNA element in the human immunodeficiency virus type 1 gag mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL MESSENGER-RNA; REV GENE-PRODUCT; EXPRESSION; YEAST; TRANSLATION; SEQUENCES; HIV-1; DEADENYLATION; STABILITY; CELLS	Human immunodeficiency virus type 1 (HIV-1) mRNAs encoding structural proteins contain multiple inhibitory/instability elements (INS), which decrease the efficiency of viral protein expression. We have previously identified a strong INS element (INS-I) within the p17(gag) coding region. Here we show that poly(A)binding protein 1 (PABP1) binds preferentially to INS-1 within the p17(gag) mRNA, but not to a mutated mRNA in which INS-1 function is eliminated. Competition experiments performed in the presence of different nucleic acids and homoribopolymers demonstrated preferential binding of PABP1 to the INS-1-containing RNA. In contrast to HeLa cells and several lymphoid cell lines, certain human glioma cell lines exhibit high levels of gag expression in the absence of Rev upon transient transfection with wild type gag expression vectors. We analyzed extracts of different cell lines and found that the binding of PABP1 to INS-1 RNA is significantly diminished in glial cell extracts. The expression levels of gag correlate with the absence of binding of PABP1 to the INS-1 RNA in cellular extracts. These results suggest a role for PABP1 in the inhibition of gag expression mediated through INS-1.	NCI, FCRDC, ABL BASIC RES PROGRAM, HUMAN RETROVIRUS SECT, D-85764 MUNICH, GERMANY									ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BELOSTOTSKY DA, 1993, P NATL ACAD SCI USA, V90, P6686, DOI 10.1073/pnas.90.14.6686; BENKO D M, 1990, New Biologist, V2, P1111; BRACKWERNER R, 1992, AIDS, V6, P273, DOI 10.1097/00002030-199203000-00003; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CAMPBELL LH, 1994, J VIROL, V68, P5433, DOI 10.1128/JVI.68.9.5433-5438.1994; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; LAWRENCE JB, 1991, NEW BIOL, V3, P1220; MALDARELLI F, 1991, J VIROL, V65, P5732, DOI 10.1128/JVI.65.11.5732-5743.1991; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MOORE SP, 1990, J BIOL CHEM, V265, P11108; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; NEUMANN M, 1995, J VIROL, V69, P2159, DOI 10.1128/JVI.69.4.2159-2167.1995; PAVLAKIS GN, 1996, AIDS ETIOLOGY DIAGNO, V4; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SCHWARTZ S, 1992, MOL CELL BIOL, V12, P207, DOI 10.1128/MCB.12.1.207; SOLOMIN L, 1990, J VIROL, V64, P6010, DOI 10.1128/JVI.64.12.6010-6017.1990; STAVROU D, 1987, J NEUROL SCI, V80, P205, DOI 10.1016/0022-510X(87)90155-9; Symensma TL, 1996, J VIROL, V70, P179, DOI 10.1128/JVI.70.1.179-187.1996; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	38	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2307	2311						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999938	hybrid			2022-12-25	WOS:A1997WD67900044
J	Chen, BB; Lim, RW				Chen, BB; Lim, RW			Physical and functional interactions between the transcriptional inhibitors Id3 and ITF-2b - Evidence toward a novel mechanisms regulating muscle-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING PROTEINS; ENHANCER; SEQUENCE; DISTINCT; SKELETAL; ELEMENTS; E2A	We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF-2 transcription factor, ITF-2b, that interacts with the transcriptional inhibitor Id3/HLH462. The interaction was confirmed in vitro, and inside intact myogenic C2C12 cells, As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD. However, when overexpressed simultaneously, ITF-2b and Id3/HLH462 counteracted each other's inhibitory effect to produce a reduced over-all inhibition. Moreover, while ITF-2b inhibited the creatine kinase promoter, it acted as a weak transactivator on an artificial promoter consisting of three tandem copies of the consensus myogenic factor DNA binding site, Further investigation indicated that the ITF-2b/MyoD heterodimer bound to its specific DNA binding site in vitro, and the DNA binding was effectively blocked by Id3/HLH462, Additional analysis revealed the presence of transcripts for both the activating (ITF-2a) and inhibitory (ITF-2b) isoforms in differentiating C2C12 cultures, suggesting that both isoforms might participate in regulating the differentiation process, Taken together, this study reveals a more complex pattern of regulatory interactions involving the helix-loop-helix proteins than was previously anticipated.	UNIV MISSOURI,SCH MED,DEPT PHARMACOL,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NIAMS NIH HHS [AR40562] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P678, DOI 10.1093/nar/18.3.678; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIM RW, 1995, BBA-MOL CELL RES, V1266, P91, DOI 10.1016/0167-4889(94)00226-5; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; Peyton M, 1996, MOL CELL BIOL, V16, P626; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Titus DE, 1991, PROMEGA PROTOCOLS AP; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YOON SO, 1994, J BIOL CHEM, V269, P18453	25	20	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2459	2463						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999959	hybrid			2022-12-25	WOS:A1997WD67900065
J	Hirayama, BA; Loo, DDF; Wright, EM				Hirayama, BA; Loo, DDF; Wright, EM			Cation effects on protein conformation and transport in the Na+/glucose cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; ESCHERICHIA-COLI; DIALKYLGLYCINE DECARBOXYLASE; ELECTROGENIC PROPERTIES; ACTIVE-SITE	Cation-driven cotransporters are essential membrane proteins in procaryotes and eucaryotes, which use the energy of the transmembrane electrochemical gradient to drive transport of a substrate against its concentration gradient. Do they share a common mechanism? Cation selectivity of the rabbit isoform of the Na+/glucose cotransporter (SGLT1) was examined using the two-electrode voltage clamp and the Xenopus oocyte expression system. The effect of H+, Li+, and Na+ on kinetics of SGLT1 was compared to the effects of these cations on the bacterial melibiose. In SGLT1, substitution of H+ or Li+ for Na+ caused a kinetic penalty in that the apparent affinity for suger (K-0.5(sugar)) decreased by a order of magnitude or more (from 0.2 to 30 nM) depending on the membrane potential and cation. The effect of the cation on the K-0.5(sugar)/V profiles was independent of the sugar for glucose and alpha-methyl-beta-D-glucose; this profile was maintained for galactose in Li+ and Na+, but was 2 orders of magnitude higher in H+, but the I-max for glucose, galactose, and alpha-methyl-beta-D-glucose in a given cation were identical. Li+ supported a lower maximal rate of transport (I-max) than Na+ (similar to 80% of I-max(Na), while the I-max in H+ was higher than Na+ (greater than or equal to 180% of I-max(Na). Our interpretation of these results and simulations using a six-state mathematical model, are as follows. 1) Binding of the cation causes a conformational being determined by the specific cation. 2) Once the sugar is bound, it is transported at a characteristic rate determined by the cation. 3) Mathematical simulations suggest that the largest contribution to the kinetic variability of both cation and sugar transport is associated with cation binding. Similarity to the effects of cation substitution in MelB suggests that the mechanism of energy coupling has been evolutionarily conserved.			Hirayama, BA (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,10833 LE CONTE AVE,LOS ANGELES,CA 90095, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM052094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS025554] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41301] Funding Source: Medline; NIGMS NIH HHS [GM52094] Funding Source: Medline; NINDS NIH HHS [NS25554] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASSILANA M, 1985, BIOCHEM BIOPH RES CO, V129, P626, DOI 10.1016/0006-291X(85)91937-0; BIHLER I, 1967, BIOCHIM BIOPHYS ACTA, V135, P466, DOI 10.1016/0005-2736(67)90036-3; BIHLER I, 1962, BIOCHIM BIOPHYS ACTA, V59, P78, DOI 10.1016/0006-3002(62)90699-6; BIRNIR B, 1987, J MEMBRANE BIOL, V100, P221, DOI 10.1007/BF02209153; BOSACKOV.J, 1965, BIOCHIM BIOPHYS ACTA, V102, P423, DOI 10.1016/0926-6585(65)90132-9; GIORDANA B, 1989, AM J PHYSIOL, V257, pR494, DOI 10.1152/ajpregu.1989.257.3.R494; GOLDNER AM, 1969, J GEN PHYSIOL, V53, P362, DOI 10.1085/jgp.53.3.362; HENDERSON PJF, 1992, INT REV CYTOL, V137A, P149; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; HOHENESTER E, 1994, BIOCHEMISTRY-US, V33, P13561, DOI 10.1021/bi00250a008; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MACKENZIE B, 1995, FASEB J, V9, pA1505; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PEERCE BE, 1986, P NATL ACAD SCI USA, V83, P8092, DOI 10.1073/pnas.83.21.8092; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; STEVENS BR, 1988, BIOCHIM BIOPHYS ACTA, V942, P205, DOI 10.1016/0005-2736(88)90290-8; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6	22	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2110	2115						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999910				2022-12-25	WOS:A1997WD67900016
J	Ratnam, K; Shiraishi, N; Campbell, WH; Hille, R				Ratnam, K; Shiraishi, N; Campbell, WH; Hille, R			Spectroscopic and kinetic characterization of the recombinant cytochrome C reductase fragment of nitrate reductase - Identification of the rate-limiting catalytic step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-CYTOCHROME-B5 REDUCTASE; ESCHERICHIA-COLI; HEME; EXPRESSION; CYSTEINE; DOMAIN; MUTAGENESIS; MOLYBDENUM; RESOLUTION; BINDING	The recombinant NADH-cytochrome c reductase fragment of spinach NADH-nitrate reductase (EC 1.6.6.1), consisting of the contiguous heme containing cytochrome b domain and flavin-containing NADH-cytochrome b reductase fragment, has been characterized spectroscopically and kinetically. Reductive titration with sodium dithionite indicates heme reduction takes place prior to flavin reduction, which correlates web with the reduction potentials for enzyme-bound heme (15 mV) and FAD (-280 mV). Reductive titration with NADH also indicates that the reduced enzyme forms a charge-transfer complex with NAD(+). The circular dichroism spectrum of the oxidized fragment is primarily due to the flavin, whereas the ferrous heme dominates the circular dichroism spectrum of reduced enzyme. Three kinetic phases are observed in the course of the reaction of the enzyme with NADH, each with a distinct spectral signature. The fast phase represents flavin reduction, concomitant with the formation of a charge-transfer complex between reduced flavin and NAD(+), and exhibits hyperbolic dependence on NADH concentration with a K-d of 3 mu M and a limiting rate constant of 560 s(-1). Electron transfer from reduced flavin to heme with a rate constant of 12 s(-1) is the intermediate phase, which is rate-limited by breakdown of the charge-transfer complex between NAD(+) and reduced flavin. The slow phase is dismutation of a pair of molecules of two-electron reduced enzyme (generated at the end of the second phase of the reaction) to give one molecule each of one- and three- electron reduced enzyme, with a second order rate constant of 2 x 10(6) M(-1) s(-1). In the presence of excess NADH, this dismutation reaction is followed by the rapid reaction of the one-electron reduced enzyme with a second equivalent of NADH to generate fully reduced enzyme. On the basis of this work, it appears that dissociation of NAD(+) from the reduced flavin site rate limits electron transfer to the cytochrome and likely represents the overall rate-limiting step of catalysis.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; MICHIGAN TECHNOL UNIV,PHYTOTECHNOL RES CTR,HOUGHTON,MI 49931; MICHIGAN TECHNOL UNIV,DEPT BIOL SCI,HOUGHTON,MI 49931	Ohio State University; Michigan Technological University; Michigan Technological University				Campbell, Wilbur/0000-0001-6432-7537				ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; BARBER MJ, 1990, J BIOL CHEM, V265, P20912; BARBER MJ, 1989, PLANT PHYSIOL, V90, P70, DOI 10.1104/pp.90.1.70; BURLEIGH BD, 1969, ANAL BIOCHEM, V84, P75; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CAMPBELL WH, 1992, PLANT PHYSIOL, V99, P693, DOI 10.1104/pp.99.2.693; CAMPBELL WH, 1989, MOL GENETIC ASPECTS, P123; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; CLARK WM, 1972, OXIDATION REDUCTION, P415; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V83, P8073; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; DWIVEDI UN, 1994, J BIOL CHEM, V269, P13785; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; HYDE GE, 1991, J BIOL CHEM, V266, P23542; IYANAGI T, 1984, BIOCHEMISTRY-US, V23, P1418, DOI 10.1021/bi00302a013; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; KAY CJ, 1986, J BIOL CHEM, V261, P5799; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KAY CJ, 1989, BIOCHEM J, V263, P285, DOI 10.1042/bj2630285; KOBAYASHI K, 1995, BIOCHEMISTRY-US, V34, P12932, DOI 10.1021/bi00040a003; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; MEYER TE, 1995, ARCH BIOCHEM BIOPHYS, V318, P457, DOI 10.1006/abbi.1995.1254; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; MOORE JW, 1981, KINETICS MECH, P19; RATNAM K, 1995, J BIOL CHEM, V270, P24067, DOI 10.1074/jbc.270.41.24067; ROUZE P, 1992, SOC EXP BIOL SEMIN S, V49, P45, DOI 10.1017/CBO9780511600395.004; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SOLOMONSON LP, 1984, FLAVINS FLAVOPROTEIN, P47; WILLIAMS CH, 1976, ENZYMES, V8, P154; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M	33	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2122	2128						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999912				2022-12-25	WOS:A1997WD67900018
J	Cacace, AM; Ueffing, M; Philipp, A; Han, EKH; Kolch, W; Weinstein, IB				Cacace, AM; Ueffing, M; Philipp, A; Han, EKH; Kolch, W; Weinstein, IB			PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase	ONCOGENE			English	Article						PKC epsilon; Raf; oncogene	MITOGENIC SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MAP KINASE; IN-VITRO; C FAMILY; TYROSINE PHOSPHORYLATION; 3T3 CELLS; GROWTH; FIBROBLASTS; PATHWAY	Previous studies have indicated that PKC epsilon behaves as an oncogene when overproduced in rodent fibroblasts (Cacace ef al., 1993; Mishak et al., 1993), In the present study, Western blot analysis revealed that the hyperphosphorylated form of Raf kinase was present at a high level in PKC epsilon overproducing R6 rat fibroblasts but not in R6 fibroblasts overproducing PKC alpha or beta 1. Extracts from the PKC epsilon overproducing cells also exhibited a marked increase in Raf-l kinase and MAP-kinase activity, To investigate the significance of these findings, dominant negative mutants of ras (N17) or raf (301-1) were stably expressed in early passage control and PKC epsilon-transformed R6 fibroblasts, by transduction using retrovirus-derived constructs, Dominant negative mf expressing clones exhibited a flat morphology, a decreased saturation density, and decreased growth in soft agar, In addition, these reverted clones exhibited decreased Raf kinase activity, In contrast, dominant negative ras expressing clones remained highly transformed, In addition, PKC epsilon was detected in Raf-l immunoprecipitates indicating that PKC epsilon forms a complex with Raf-l in vivo, Taken together, these results suggest that PKC epsilon functions as an oncogene in R6 cells by enhancing activation of the Raf-l kinase.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; GSF MUNICH,INST KLIN MOL BIOL & TUMORGENET,HAMATOLOGIKUM,D-81377 MUNICH,GERMANY	Columbia University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Kolch, Walter/0000-0001-5777-5016	NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEE KS, 1993, MCB, V13, P3167; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LU X, 1993, CELL, V73, P571; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRIS JDH, 1989, ONCOGENE, V4, P27; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; RAPP UR, 1991, ONCOGENE, V6, P495; SOZERI O, 1992, ONCOGENE, V7, P2259; SZEBERENYI J, 1990, MOL CELL BIOL, V12, P5329; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARNER LC, 1993, ONCOGENE, V8, P3249; WEINSTEIN IB, 1990, ORIGINS HUMAN CANC C, P113; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	54	144	145	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2517	2526						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000126				2022-12-25	WOS:A1996VZ65400002
J	GalvinParton, PA; Chen, XH; Moxham, CM; Malbon, CC				GalvinParton, PA; Chen, XH; Moxham, CM; Malbon, CC			Induction of G alpha(q)-specific antisense RNA in vivo causes increased body mass and hyperadiposity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BROWN ADIPOSE-TISSUE; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; TRANSGENIC MICE; GROWTH; CELLS; GQ; PURIFICATION; ACTIVATION	Transgenic BDF-1 mice harboring an inducible, tissue-specific transgene for RNA antisense to G alpha(q) provide a model in which to study a loss-of-function mutant of G alpha(q) in vivo. G alpha(q) deficiency induced in liver and white adipose tissue at birth produced increased body mass and hyperadiposity within 5 weeks of birth that persisted throughout adult life. G alpha(q)-deficient adipocytes display reduced lipolytic responses, shown to reflect a newly discovered, alpha(1)-adrenergic regulation of lipolysis. This alpha(1)-adrenergic response via phosphoinositide hydrolysis and activation of protein kinase C is lacking in the G alpha(q) loss-of-function mutants in vivo and provides a basis for the increased fat accumulation.	SUNY STONY BROOK, MED CTR, DEPT MOL PHARMACOL, DMDRP, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, MED CTR, DEPT PEDIAT, DMDRP, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020		NIDDK NIH HHS [T32 DK50732] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KAWABE J, 1994, J BIOL CHEM, V269, P16554; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1994, BIOCHEM J, V299, P593, DOI 10.1042/bj2990593; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; XIE RP, 1995, DEV BRAIN RES, V87, P77, DOI 10.1016/0165-3806(95)00061-H	28	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4335	4341		10.1074/jbc.272.7.4335	http://dx.doi.org/10.1074/jbc.272.7.4335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020153	hybrid			2022-12-25	WOS:A1997WH01900069
J	Janknecht, R; Hunter, T				Janknecht, R; Hunter, T			Activation of the Sap-1a transcription factor by the c-Jun N-terminal kinase (JNK) mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ELEMENTS; SERUM RESPONSE ELEMENT; COMPLEX FACTOR ELK-1; FOS EXPRESSION; MAP KINASE; INDUCTION; PROMOTER; INTEGRATION; PATHWAYS; INVIVO	Ternary complex factors (TCFs) bind to the serum response element in the c-fos promoter and mediate its activation by many extracellular stimuli. Some of these stimuli activate the ERR subclass of mitogen-activated protein kinases (MAPKs) that target the TCF Sap-1a. We show that Sap-1a is also phosphorylated by the stress-activated JNK subclass of MAPKs leading to stimulation of both c-fos serum response element and E74-site-dependent transcription in RK13 cells. Several JNK-1 phosphorylation sites were mapped within Sap-1a, and mutation of these sites affected the transactivation mediated by Sap-1a and JNK-1. The impact of these phosphorylation sites varied at different promoters and was dependent on whether Sap-1a was stimulated by ERK-1 or JNK-1. Additionally, a comparison of Sap-1a with another TCF, Elk-1, revealed that these proteins behaved differently to stimulation by ERK-1 and JNK-1. Furthermore, activation of Sap-1a by JNK-1 was inhibited by the p38(MAPK) in RK13 cells, possibly by competition for a common upstream activator. Altogether, our data suggest that Sap-1a plays an important role in the nuclear response elicited by cellular stress.			Janknecht, R (corresponding author), SALK INST BIOL STUDIES,MOL BIOL & VIROL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Janknecht, Ralf/0000-0003-1741-1562	NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Janknecht R, 1996, ONCOGENE, V12, P1961; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; VANDERGEER P, 1994, CELL BIOL LAB HDB, V3, P422; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	32	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4219	4224		10.1074/jbc.272.7.4219	http://dx.doi.org/10.1074/jbc.272.7.4219			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020136	hybrid			2022-12-25	WOS:A1997WH01900052
J	Lanzilotta, WN; Fisher, K; Seefeldt, LC				Lanzilotta, WN; Fisher, K; Seefeldt, LC			Evidence for electron transfer-dependent formation of a nitrogenase iron protein molybdenum-iron protein tight complex - The role of aspartate 39	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; NUCLEAR-MAGNETIC-RESONANCE; AZOTOBACTER-VINELANDII; CLOSTRIDIUM-PASTEURIANUM; KLEBSIELLA-PNEUMONIAE; CRYSTALLOGRAPHIC STRUCTURE; NUCLEOTIDE BINDING; MOFE PROTEIN; FE PROTEIN; REDUCTION	Nitrogenase-catalyzed substrate reduction reactions require the association of the iron (Fe) protein and the molybdenum-iron (MoFe) protein, electron transfer from the Fe protein to the MoFe protein coupled to the hydrolysis of MgATP, followed by protein-protein complex dissociation. This work examines the role of MgATP hydrolysis and electron transfer in the dissociation of the Fe protein-MoFe protein complex. Alteration of aspartate 39 to asparagine (D39N) in the nucleotide binding site of Azotobacter vinelandii Fe protein by site-directed mutagenesis resulted in an Fe protein-MoFe protein complex that did not dissociate after electron transfer. While the D39N Fe protein-MoFe protein complex was inactive in all substrate reduction reactions, the complex catalyzed both reductant-dependent and reductant-independent MgATP hydrolysis, Once docked to the MoFe protein, the D39N Fe protein was found to transfer one electron to the MoFe protein requiring MgATP hydrolysis, with an apparent first order rate constant of 0.02 s(-1) compared with 140 s(-1) for the wildtype Fe protein. Only following electron transfer to the MoFe protein did the D39N Fe protein form a tight complex with the MoFe protein, with no detectable dissociation rate. This was in contrast with the dissociation rate constant of the wild-type Fe protein from the MoFe protein following electron transfer of 5 s(-1). Chemically oxidized D39N Pe protein with MgADP-bound did not form a tight complex with the MoFe protein, showing a dissociation rate similar to chemically oxidized wildtype Fe protein (3 s(-1) for D39N Fe protein and 6 s(-1) for wild-type Fe protein), These results suggest that electron transfer from the Fe protein to the MoFe protein within the protein-protein complex normally induces conformational changes which increase the affinity of the Pe protein for the MoFe protein. A model is presented in which Asp-39 participates in a nucleotide signal transduction pathway involved in component protein-protein dissociation.	VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA; UTAH STATE UNIV, DEPT CHEM & BIOCHEM, LOGAN, UT 84322 USA	Virginia Polytechnic Institute & State University; Utah System of Higher Education; Utah State University			Fisher, Karl/A-5956-2013	Fisher, Karl/0000-0003-3539-8939; Seefeldt, Lance/0000-0002-6457-9504	NIDDK NIH HHS [DK-37255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLIN JT, 1993, P NATL ACAD SCI USA, V90, P1078, DOI 10.1073/pnas.90.3.1078; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BUI PT, 1969, BIOCHEMISTRY-US, V8, P2462, DOI 10.1021/bi00834a031; CHEN L, 1994, J BIOL CHEM, V269, P3290; CHROMY V, 1974, CLIN CHEM, V20, P1362; CORDEWENER J, 1988, EUR J BIOCHEM, V172, P739, DOI 10.1111/j.1432-1033.1988.tb13951.x; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; Hathaway G M, 1979, Methods Enzymol, V60, P495; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; KAR L, 1994, J BIOMOL STRUCT DYN, V12, P527, DOI 10.1080/07391102.1994.10508758; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LANZILOTTA WN, 1995, BIOCHEMISTRY-US, V34, P15646, DOI 10.1021/bi00048a007; LANZILOTTA WN, 1995, BIOCHEMISTRY-US, V34, P10713, DOI 10.1021/bi00034a003; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; LARSEN C, 1995, ARCH BIOCHEM BIOPHYS, V323, P215, DOI 10.1006/abbi.1995.9972; LINDAHL PA, 1987, INORG CHEM, V26, P3912, DOI 10.1021/ic00270a018; Lowe D. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P103; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; MENSINK RE, 1992, EUR J BIOCHEM, V208, P289, DOI 10.1111/j.1432-1033.1992.tb17185.x; MEYER J, 1988, BIOCHEMISTRY-US, V27, P6150, DOI 10.1021/bi00416a048; MIURA S, 1991, J BIOL CHEM, V266, P6252; MORTENSON LE, 1993, ADV ENZYMOL RAMB, V67, P299; PETERS JW, 1994, J BIOL CHEM, V269, P28076; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; Romero A, 1996, EUR J BIOCHEM, V239, P190, DOI 10.1111/j.1432-1033.1996.0190u.x; Ryle MJ, 1996, J BIOL CHEM, V271, P1551, DOI 10.1074/jbc.271.3.1551; RYLE MJ, 1995, J BIOL CHEM, V270, P13112, DOI 10.1074/jbc.270.22.13112; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x; ZUMFT WG, 1972, BIOCHEM BIOPH RES CO, V48, P1525, DOI 10.1016/0006-291X(72)90887-X	45	36	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4157	4165		10.1074/jbc.272.7.4157	http://dx.doi.org/10.1074/jbc.272.7.4157			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020128	hybrid			2022-12-25	WOS:A1997WH01900044
J	Lee, HC; Aarhus, R; Gee, KR; Kestner, T				Lee, HC; Aarhus, R; Gee, KR; Kestner, T			Caged nicotinic acid adenine dinucleotide phosphate - Synthesis and use	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; INDUCED CALCIUM-RELEASE; SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; CA2+ RELEASE; CALMODULIN	Nicotinic acid adenine dinucleotide phosphate (NAADP) is a metabolite of NADP with Ca2+ mobilizing activity. The Ca2+ release mechanism activated by NAADP as well as the Ca2+ stores that it acts on are different from those activated by either cyclic ADP-ribose or inositol 1,4,5-trisphosphate (IP3) (Lee, H. C., and Aarhus, R. (1995) J. Biol. Chem. 270, 2152-2157). In order to demonstrate unambiguously that NAADP can mobilize Ca2+ stores in live cells, a caged analog was synthesized by reacting NAADP with 1-(2-nitrophenyl)diazoethane. Anion exchange high pressure liquid chromatography (HPLC) was used to purify one particular caged form from the mixture of products. Phosphate analyses following specific enzymatic cleavage indicate that the caging group is on the 2'-phosphate. This is confirmed by P-31 NMR spectroscopy, showing that the 2'-phosphate of the caged compound exhibits an altered chemical shift of -2.6 ppm as compared with 2.3 ppm determined for the 2'-phosphate of NAADP. Caged NAADP had no Ca2+ releasing activity at a concentration as high as 1 mu M when tested on sea urchin egg microsomes. After photolysis, it released Ca2+, was effective in nanomolar range, and was indistinguishable from authentic NAADP. The regeneration of NAADP after photolysis was also confirmed by HPLC analyses. The analog is particularly susceptible to UV and can be efficiently photolyzed using a spectrofluorimeter. To demonstrate its utility in live cells, caged NAADP was microinjected into sea urchin eggs. Photolysis effectively regenerated NAADP and activated Ca2+ oscillations in the eggs. Removal of external Ca2+ did not prevent the Ca2+ oscillations but only delayed the second Ca2+ peak by about 45 s, indicating that the oscillations are due to release from internal stores and not caused by Ca-2+ influx. A mechanism based on sensitization of the Ca2+ release by Ca2+ loading is proposed to account for the Ca2+ oscillation observed.	3M CO,ST PAUL,MN 55144; MOL PROBES INC,EUGENE,OR 97402	3M	Lee, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,LYON LAB 6182,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484, R01HD032040] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32040, HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; AARHUS R, 1995, J BIOL CHEM, V270, P7745, DOI 10.1074/jbc.270.13.7745; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; GRAEFF RM, 1995, BIOCHEM BIOPH RES CO, V206, P786, DOI 10.1006/bbrc.1995.1111; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1995, CRC SERIES PHARM TOX, P31; LEE HC, 1996, RECENT PROG HORMONE, V52, P357; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WILCOX M, 1990, J ORG CHEM, V55, P1585, DOI 10.1021/jo00292a038; Willmott N, 1996, J BIOL CHEM, V271, P3699	25	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4172	4178		10.1074/jbc.272.7.4172	http://dx.doi.org/10.1074/jbc.272.7.4172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020130	hybrid			2022-12-25	WOS:A1997WH01900046
J	Ramos, JL; Duque, E; RodriguezHerva, JJ; Godoy, P; Haidour, A; Reyes, F; FernandezBarrero, A				Ramos, JL; Duque, E; RodriguezHerva, JJ; Godoy, P; Haidour, A; Reyes, F; FernandezBarrero, A			Mechanisms for solvent tolerance ill bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE LIPIDS; FATTY-ACIDS; PSEUDOMONAS; ADAPTATION; TOLUENE; HYDROCARBONS; TOXICITY; PLASMID; STRAIN	The development of tolerance in Pseudomonas putida DOT-T1 to toluene and related highly toxic compounds involves short- and long-term responses, The short-term response is based on an increase in the rigidity of the cell membrane by rapid transformation of the fatty acid cis-9,10-methylene hexadecanoic acid (C17:cyclopropane) to unsaturated 9-cis-hexadecenoic acid (C16:1,9 cis) and subsequent transformation to the trans isomer. The long-term response involves in addition to the changes in fatty acids, alterations in the level of the phospholipid polar head groups: cardiolipin increases and phosphatidylethanolamine decreases. The two alterations lead to increased cell membrane rigidity and should be regarded as physical mechanisms that prevent solvent penetrance. Biochemical mechanisms that decrease the concentration of toluene in the cell membrane also take place and involve: (i) a solvent exclusion system and (ii) metabolic removal of toluene via oxidation. Mutants unable to carry out cis --> trans isomerization of unsaturated lipids, that exhibit altered cell envelopes because of the lack of the OprL protein, or that are unable to exclude toluene from cell membranes are hypersensitive to toluene.	UNIV GRANADA,DEPT ORGAN CHEM,GRANADA 18012,SPAIN; CSIC,ESTAC EXPT ZAIDIN,DEPT BIOCHEM,GRANADA 18012,SPAIN	University of Granada; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)			Alejandro, Barrero F/G-8243-2015; Rodriguez-Herva, Jose J/A-7827-2012; Benamin, Ali Haidour/ABG-1909-2020; Reyes, Fernando/G-4027-2013	Alejandro, Barrero F/0000-0002-3058-8760; Rodriguez-Herva, Jose J/0000-0001-9962-2261; Benamin, Ali Haidour/0000-0003-3401-1878; Reyes, Fernando/0000-0003-1607-5106; Duque, Estrella/0000-0002-4857-8974; Ramos, Juan L./0000-0002-8731-7435				AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN Q, 1995, J BACTERIOL, V177, P6894, DOI 10.1128/jb.177.23.6894-6901.1995; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; CRUDEN DL, 1992, APPL ENVIRON MICROB, V58, P2723, DOI 10.1128/AEM.58.9.2723-2729.1992; DESMET MJ, 1978, BIOCHIM BIOPHYS ACTA, V506, P64, DOI 10.1016/0005-2736(78)90435-2; Gibson D. T., 1984, MICROBIAL DEGRADATIO, P181; HEIPIEPER HJ, 1992, APPL ENVIRON MICROB, V58, P1847, DOI 10.1128/AEM.58.6.1847-1852.1992; INGRAM LO, 1976, J BACTERIOL, V125, P670, DOI 10.1128/JB.125.2.670-678.1976; INOUE A, 1989, NATURE, V338, P264, DOI 10.1038/338264a0; LADBROOKE BD, 1969, CHEM PHYS LIPIDS, V3, P304, DOI 10.1016/0009-3084(69)90040-1; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MORRISON WR, 1964, J LIPID RES, V5, P600; MOSS CW, 1992, J CLIN MICROBIOL, V30, P2511, DOI 10.1128/JCM.30.9.2511-2512.1992; RAMOS JL, 1995, J BACTERIOL, V177, P3911, DOI 10.1128/jb.177.14.3911-3916.1995; RodriguezHerva JJ, 1996, J BACTERIOL, V178, P5836, DOI 10.1128/jb.178.19.5836-5840.1996; SAITO H, 1993, CHEMOSPHERE, V26, P1015, DOI 10.1016/0045-6535(93)90374-E; SELVARAJ G, 1983, J BACTERIOL, V156, P1292, DOI 10.1128/JB.156.3.1292-1300.1983; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SINENSKY M, 1974, P NATL ACAD SCI USA, V71, P522, DOI 10.1073/pnas.71.2.522; WEBER FJ, 1994, MICROBIOL-UK, V140, P2013, DOI 10.1099/13500872-140-8-2013; WEBER FJ, 1993, APPL ENVIRON MICROB, V59, P3502, DOI 10.1128/AEM.59.10.3502-3504.1993; WEBER FJ, 1995, THESIS U WAGENINGEN; WORSEY MJ, 1975, J BACTERIOL, V124, P7, DOI 10.1128/JB.124.1.7-13.1975	24	218	230	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3887	3890		10.1074/jbc.272.7.3887	http://dx.doi.org/10.1074/jbc.272.7.3887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020089	hybrid			2022-12-25	WOS:A1997WH01900005
J	Yang, HY; Cromley, D; Wang, HX; Billheimer, JT; Sturley, SL				Yang, HY; Cromley, D; Wang, HX; Billheimer, JT; Sturley, SL			Functional expression of a cDNA to human acyl-coenzyme A:Cholesterol acyltransferase in yeast - Species-dependent substrate specificity and inhibitor sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; RAT-LIVER; COA; ATHEROSCLEROSIS; METABOLISM; CELLS; ACAT	We have identified two yeast genes with similarity to a human cDNA encoding acyl-coenzyme A:cholesterol acyltransferase (ACAT), Deletion of both yeast genes results in a viable cell with undetectable esterified sterol (Yang, H., Bard, M., Bruner, D. A., Gleeson, A., Deckelbaum, R. J., Aljinovic, G., Pohl, T., Rothstein, R., and Sturley, S. L. (1996) Science 272, 1353-1356). Here, we expressed the human cDNA in the yeast double mutant, resulting in high level production of ACAT protein, but low in vivo esterification of ergosterol, the predominant yeast sterol, The activity of the human enzyme was increased by incubation of these cells with 25-hydroxy, cholesterol, an established positive regulator of mammalian sterol esterification. In contrast, the yeast enzymes were unaffected by this reagent. In vitro microsomal assays indicated no sterol esterification in extracts from the double mutant. However, significant activity was detected from strains expressing human ACAT when cholesterol was equilibrated with the microsomal membranes, The human enzyme in yeast uti lized cholesterol as the preferred sterol and was sensitive to competitive (S58035) and non-competitive (DuP 128) ACAT inhibitors, The yeast esterifying enzymes exhibited a diminished sterol substrate preference and were sensitive only to S58035, Human ACAT had a broad acyl-CoA substrate specificity, the other substrate for this reaction. By contrast, the yeast enzymes had a marked preference for specific acyl-CoAs, particularly unsaturated C-18 forms. These results confirm the yeast genes as functional homologs of the human gene and demonstrate that the enzymes confer substrate specificity to the esterification reaction in both organisms.	COLUMBIA UNIV COLL PHYS & SURG, INST HUMAN NUTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PEDIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MOL BIOPHYS, NEW YORK, NY 10032 USA; DUPONT CO INC, MERCK RES LABS, EXPT STN, WILMINGTON, DE 19880 USA	Columbia University; Columbia University; Columbia University; Columbia University; DuPont; Merck & Company			Yang, Hongyuan/AAR-1326-2020	Yang, Hongyuan/0000-0002-8482-6031				Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BILLHEIMER J, 1991, ANTIATHEROSLEROTIC A, pB5; BILLHEIMER JT, 1981, ANAL BIOCHEM, V111, P331, DOI 10.1016/0003-2697(81)90570-4; BILLHEIMER JT, 1992, ADV CHOLESTEROL RES; BILLHEIMER JT, 1991, 9TH INT S ATH ROS, V184, pA94; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1275; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1994, TRENDS CARDIOVAS MED, V4, P223, DOI 10.1016/1050-1738(94)90038-8; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; FIELD FJ, 1990, GASTROENTEROLOGY, V99, P539, DOI 10.1016/0016-5085(90)91040-D; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; HAINER JW, 1994, CLIN PHARMACOL THER, V56, P65, DOI 10.1038/clpt.1994.102; HIGLEY C, 1994, J MED CHEM, V87, P3511; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYASTHA P, 1969, BIOCHIM BIOPHYS ACTA, V176, P858; NAKAYA N, 1994, ATHEROSCLEROSIS, V109, P253; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SGOUTAS DS, 1970, BIOCHEMISTRY-US, V9, P1826, DOI 10.1021/bi00810a024; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SLISKOVIC DR, 1991, TRENDS PHARMACOL SCI, V12, P194, DOI 10.1016/0165-6147(91)90546-5; SUCKLING KE, 1985, J LIPID RES, V26, P647; TAKETANI S, 1978, BIOCHIM BIOPHYS ACTA, V528, P416, DOI 10.1016/0005-2760(78)90031-0; TAVANI DM, 1982, J LIPID RES, V23, P774; TAYLOR FR, 1981, J BIOL CHEM, V256, P3048; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Wang HX, 1996, ARTERIOSCL THROM VAS, V16, P809, DOI 10.1161/01.ATV.16.6.809; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; YUKAWA S, 1986, GENDAI IRYO, V18, P2837	36	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3980	3985		10.1074/jbc.272.7.3980	http://dx.doi.org/10.1074/jbc.272.7.3980			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020103	hybrid			2022-12-25	WOS:A1997WH01900019
J	Bessho, T; Sancar, A; Thompson, LH; Thelen, MP				Bessho, T; Sancar, A; Thompson, LH; Thelen, MP			Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; REPAIR PROTEINS; FACTOR TFIIH; DNA; PURIFICATION; ERCC1; XPA; BINDING	The human XPF-ERCC1 protein complex is one of several factors known to be required for general nucleotide excision repair, Genetic data indicate that both proteins of this complex are necessary for the repair of interstrand cross-links, perhaps via recombination, To determine whether XPF-ERCC1 completes a set of six proteins that are sufficient to carry out excision repair, the human XPF and ERCC1 cDNAs were coexpressed in SF21 insect cells from a baculovirus vector, The purified complex contained the anticipated 5' junction-specific endonuclease activity that is stimulated through a direct interaction between XPF and replication protein A (RPA), The recombinant complex also complemented extracts of XP-F cells and Chinese hamster ovary mutants assigned to complementation groups 1, 4, and 11, Furthermore, reconstitution of the human excision nuclease was observed with a mixture of five repair factors (XPA, XPC, XPG, TFIIH, and RPA) and the recombinant XPF-ERCC1, thus verifying that no additional protein factors are needed for the specific dual incisions characteristic of human excision repair.	LAWRENCE LIVERMORE NATL LAB,BIOL & BIOTECHNOL RES PROGRAM,LIVERMORE,CA 94551; UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Thelen, Michael P/G-2032-2014; Thelen, Michael/C-6834-2008	Thelen, Michael P/0000-0002-2479-5480; Thelen, Michael/0000-0002-2479-5480	NIGMS NIH HHS [GM32833, GM52120] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833, R01GM052120] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; CLUGSTON CK, 1992, CANCER RES, V52, P6375; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HATA H, 1991, CANCER RES, V51, P195; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; OREILLY DR, 1994, LAB MANUAL BACULOVIR; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1993, NUCLEIC ACIDS RES, V21, P5110, DOI 10.1093/nar/21.22.5110; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SUNG P, 1993, J BIOL CHEM, V268, P26391; THOMPSON LH, 1994, P NATL ACAD SCI USA, V91, P6855, DOI 10.1073/pnas.91.15.6855; THOMPSON LH, 1997, IN PRESS DNA DAMAGE; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	31	151	152	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3833	3837		10.1074/jbc.272.6.3833	http://dx.doi.org/10.1074/jbc.272.6.3833			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013642	hybrid, Green Published			2022-12-25	WOS:A1997WG19200102
J	Cooper, AD; Chen, J; BotelhoYetkinler, MJ; Cao, YC; Taniguchi, T; LevyWilson, B				Cooper, AD; Chen, J; BotelhoYetkinler, MJ; Cao, YC; Taniguchi, T; LevyWilson, B			Characterization of hepatic-specific regulatory elements in the promoter region of the human cholesterol 7 alpha-hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B GENE; ENRICHED TRANSCRIPTION FACTOR; BILE-ACID BIOSYNTHESIS; HYDROXYLASE GENE; MESSENGER-RNA; RECEPTOR SUPERFAMILY; MONOLAYER-CULTURES; RAT HEPATOCYTES; MAMMALIAN-CELLS; CLONING	Cholesterol 7 alpha-hydroxylase is the rate-limiting enzyme in the degradation of cholesterol to bile salts and plays a central role in regulating cholesterol homeostasis. The mechanisms involved in the transcriptional control of the human gene are largely unknown. HepG2 cells represent an appropriate model system for the study of the regulation of the gene. To identify liver-specific DNA sequences in the promoter of the human CYP7 gene, we first examined the DNase I hypersensitivity in the 5'-region of the gene. An area of hypersensitivity was observed in the region from -50 to -200 of the human gene in nuclei from transcriptionally active HepG2 cells, but was absent. in transcriptionally inactive HeLa cell nuclei or in free DNA. Various 5'-promoter deletion constructs were made and transfected into HepG2 cells. About 300 base pairs of upstream sequence are required for high level promoter activity of the human CYP7 gene in HepG2 cells. DNase I footprinting of the hypersensitive region revealed nine protected sequences. Gel retardation experiments demonstrated binding of HNF-3 to the segment from -80 to -70 and of hepatocyte nuclear factor HNF-4 (and ARP-1) to the segment from -148 to -127 of the human CYP7 promoter. Deletion of either of these sites depressed promoter activity in HepG2 cells. A third region from -313 to -285 is bound by members of the HNF-3 family and acts as an enhancer. Additionally, the segment from -197 to -173 binds a negative regulatory protein that is present in Chinese hamster ovary cell extracts and in HepG2 cell extracts. These experiments define the key control elements responsible for basal transcription of the human CYP7 gene in HepG2 cells.	PALO ALTO MED FDN,RES INST,PALO ALTO,CA 94301; STANFORD UNIV,DEPT MED,SCH MED,DIV GASTROENTEROL,STANFORD,CA 94304	Palo Alto Medical Foundation Research Institute; Stanford University					NHLBI NIH HHS [HL-54775] Funding Source: Medline; NIDDK NIH HHS [DK-38318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROOKS AR, 1991, J BIOL CHEM, V266, P7848; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; CHIANG JYL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P337, DOI 10.1016/0167-4781(92)90175-Y; COHEN JC, 1992, GENOMICS, V14, P153, DOI 10.1016/S0888-7543(05)80298-8; CRESTANI M, 1993, ARCH BIOCHEM BIOPHYS, V306, P451, DOI 10.1006/abbi.1993.1537; CRESTANI M, 1995, J LIPID RES, V36, P2419; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARNISH DC, 1994, J BIOL CHEM, V269, P28220; JELINEK DF, 1990, BIOCHEMISTRY-US, V29, P7781, DOI 10.1021/bi00486a001; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEE YH, 1994, J BIOL CHEM, V269, P14681; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; LEVYWILSON B, 1988, MOL CELL BIOL, V8, P71, DOI 10.1128/MCB.8.1.71; LI YC, 1990, J BIOL CHEM, V265, P12012; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PRINCEN HMG, 1989, BIOCHEM J, V262, P341, DOI 10.1042/bj2620341; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TANIGUCHI T, 1994, J BIOL CHEM, V269, P10071; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TWISK J, 1993, BIOCHEM J, V290, P685, DOI 10.1042/bj2900685; TZUNG KW, 1994, GENOMICS, V16, P244; WAND DP, 1993, GENOMICS, V20, P320; Wang DP, 1996, J LIPID RES, V37, P1831	35	54	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3444	3452		10.1074/jbc.272.6.3444	http://dx.doi.org/10.1074/jbc.272.6.3444			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013589	hybrid			2022-12-25	WOS:A1997WG19200049
J	Liu, YY; Collins, ED; Norma, AW; Peleg, S				Liu, YY; Collins, ED; Norma, AW; Peleg, S			Differential interaction of 1 alpha,25-dihydroxyvitamin D-3 analogues and their 20-epi homologues with the vitamin D receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; LIGAND-BINDING DOMAIN; DEPENDENT TRANSCRIPTIONAL ACTIVATION; HUMAN PROGESTERONE-RECEPTOR; STEROID-HORMONE RECEPTORS; D-RESPONSIVE ELEMENT; GLUCOCORTICOID RECEPTOR; FUNCTIONAL DOMAINS; OSTEOCALCIN GENE; CONFORMATIONAL-CHANGES	An important focus of structure-function studies of synthetic ligands for the vitamin D receptor (VDR) concerns the chiral center at carbon 20 of the steroid side chain; 20-epi analogues are 100-10,000 times more potent transcriptionally than the natural hormone 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,2S-(OH)(2)D-3). We have compared the binding properties of three pairs of analogues either with a natural (N) or 20-epi (E) orientation. In intact cells, 45-60% of VDR . N-analogue complexes, but only 5-20% of VDR . E-analogue complexes, dissociated over a 8-h interval, The two groups of ligands induced distinct changes in VDR conformation as revealed by protease clipping assays, Mapping of ligand-VDR binding activity by deletions indicated that amino acids 420-427 were important for high affinity of VDR . N-analogue complexes, but not for VDR . E-analogue complexes, Site-directed mutagenesis revealed that residues 421 and 422 were essential far 1 alpha,25-(OH)(2)D-3-induced conformational changes, high affinity of 1 alpha,25-(OH)(2)D-3 for VDR, and transcriptional activity, but not for binding of its 20-epi analogue, In contrast, deletion of residues 396-427 abolished binding of 1 alpha,25-(OH)(2)D-3, but binding of its 20-epi analogue was still detectable. The results suggest that the ligand-binding domain of VDR has multiple and different contact sites for the two families of side chain-modified ligands, resulting in VDR ligand complexes with different half-lives and transcriptional activities.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MED SPECIALTIES, ENDOCRINOL SECT, HOUSTON, TX 77030 USA; UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Riverside					NCI NIH HHS [CA-16672] Funding Source: Medline; NIDDK NIH HHS [DK-09012] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009012, R01DK009012] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; BANIAHMAD A, 1993, J CELL BIOCHEM, V51, P151, DOI 10.1002/jcb.240510206; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1569, DOI 10.1016/0006-2952(91)90426-6; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BORIS C, 1994, MOL CELL BIOL, V14, P3329; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1991, MOL ENDOCRINOL, V5, P1815, DOI 10.1210/mend-5-12-1815; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; OZONO K, 1990, J BIOL CHEM, V265, P21881; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; REESE JC, 1992, J BIOL CHEM, V267, P9868; REESE JC, 1992, MOL ENDOCRINOL, V6, P2160, DOI 10.1210/me.6.12.2160; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SONE T, 1991, J BIOL CHEM, V266, P23296; STROMSTEDT PE, 1990, J BIOL CHEM, V265, P12973; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WECKSLER WR, 1980, METHOD ENZYMOL, V67, P448; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; [No title captured]	34	93	94	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3336	3345		10.1074/jbc.272.6.3336	http://dx.doi.org/10.1074/jbc.272.6.3336			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013574	hybrid			2022-12-25	WOS:A1997WG19200034
J	Monsonego, A; Shani, Y; Friedmann, I; Paas, Y; Eizenberg, O; Schwartz, M				Monsonego, A; Shani, Y; Friedmann, I; Paas, Y; Eizenberg, O; Schwartz, M			Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; NERVE GROWTH-FACTOR; RETINOIC ACID; PERIPHERAL-NERVE; CROSS-LINKING; ERYTHROCYTE PROTEIN-4.2; BINDING PROTEIN; MESSENGER-RNA; CDNA CLONES; MACROPHAGES	Tissue-type transglutaminases (TGases) were recently shown to exert dual enzymatic activities; they catalyze the posttranslational modification of proteins by transamidation, and they also act as guanosine triphosphatase (GTPase). Here we show that a tissue-type TGase is expressed in rat brain astrocytes in vitro, and is induced by the inflammation-associated cytokines interleukin-1 beta and to a lesser extent by tumor necrosis factor-alpha. Induction is accompanied by overexpression and appearance of an additional shorter clone, which does not contain the long 3'-untranslated region and encodes for a novel TGase enzyme whose C terminus lacks a site that affects the enzyme's interaction with guanosine triphosphate (GTP), Expression of two clones revealed that the long form is inhibited noncompetitively by GTP, but the short form significantly less so, The different affinities for GTP may account for the difference in physiological function between these two enzymes.	WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAMPISI A, 1992, NEUROCHEM RES, V17, P1201, DOI 10.1007/BF00968400; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FACCHIANO F, 1993, TRENDS BIOCHEM SCI, V18, P327, DOI 10.1016/0968-0004(93)90066-V; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GENTILE V, 1991, J BIOL CHEM, V266, P478; GILAD GM, 1985, J NEUROCHEM, V45, P1522, DOI 10.1111/j.1471-4159.1985.tb07222.x; GILBERT SF, 1991, DEV BIOL, pCH13; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HAND D, 1993, J NEUROCHEM, V61, P1064, DOI 10.1111/j.1471-4159.1993.tb03621.x; HAND D, 1993, INT J DEV NEUROSCI, V11, P709, DOI 10.1016/0736-5748(93)90060-Q; HAYNES L W, 1992, Biochemical Society Transactions, V20, p159S; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; HIRSCHBERG DL, 1995, J NEUROIMMUNOL, V61, P89, DOI 10.1016/0165-5728(95)00087-I; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; KIM HC, 1991, J BIOL CHEM, V266, P536; KORNER G, 1987, J CELL PHYSIOL, V130, P44, DOI 10.1002/jcp.1041300108; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MATESZ K, 1991, EUR J NEUROSCI, V4, P290; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; MOORE WT, 1984, J BIOL CHEM, V259, P2794; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PERRY MJM, 1993, INT J DEV NEUROSCI, V11, P325, DOI 10.1016/0736-5748(93)90004-W; PERRY MJM, 1990, COMM DEV NEUROBIOL, V1, P85; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; REICHELT KL, 1992, J NEUROCHEM, V59, P500, DOI 10.1111/j.1471-4159.1992.tb09398.x; RYBICKI AC, 1994, MAMM GENOME, V5, P438, DOI 10.1007/BF00357005; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH16; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; Steinberg Roy H., 1994, Current Opinion in Neurobiology, V4, P515, DOI 10.1016/0959-4388(94)90052-3; SUNG LPA, 1992, BLOOD, V79, P2763; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; VIGE X, 1992, BRAIN RES, V591, P345, DOI 10.1016/0006-8993(92)91718-T	49	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3724	3732		10.1074/jbc.272.6.3724	http://dx.doi.org/10.1074/jbc.272.6.3724			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013629	hybrid			2022-12-25	WOS:A1997WG19200089
J	Stigson, M; Lofberg, J; Kjellen, L				Stigson, M; Lofberg, J; Kjellen, L			PG-M/versican-like proteoglycans are components of large disulfide-stabilized complexes in the axolotl embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CREST CELL-MIGRATION; EXTRACELLULAR-MATRIX; AMBYSTOMA-MEXICANUM; NEURITE OUTGROWTH; HYALURONIC-ACID; SCIATIC-NERVE; WHITE AXOLOTL; CORE PROTEIN; CDNA CLONING	Large disulfide-stabilized proteoglycan complexes were previously shown to be synthesized by the epidermis of axolotl embryos during stages crucial to subepidermal migration of neural crest cells. We now show that the complexes contain PG-M/versican-like monomers in addition to some other component with low buoyant density. Metabolically S-35-labeled proteoglycans mere extracted from epidermal explants and separated by size exclusion chromatography and density equilibrium gradient centrifugation. The complexes, which elute in the void volume on Sepharose CL-2B, were recovered at buoyant density 1.42 g/ml in CsCl gradients, whereas the monomer proteoglycans, which could only be liberated from the complexes by reduction, had a higher buoyant density (1.45 g/ml). The native complexes did not aggregate with hyaluronan. The purified complexes reacted with antibodies against a portion of a cloned PG-M/versican-like axolotl proteoglycan. These antibodies were found to stain the subepidermal matrix of axolotl embryos, suggesting that the proteoglycan complexes are encountered by neural crest cells during subepidermal migration. From Western blot analysis, the core protein of the PG-M/versican-like monomers was found to be of similar size (approximate to 500 kDa) as those of PG-M/versican variants of other species, Another chondroitin sulfate proteoglycan that was present in small amounts in the epidermal extracts was found to be distinctly different from the similarly sized PG-M/versican-like monomers.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN; UPPSALA UNIV,DEPT ENVIRONM & DEV BIOL,S-75236 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences; Uppsala University			Kjellen, Lena/F-1362-2011					ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bordzilovskaya N. P., 1989, DEV BIOL AXOLOTL, P201; BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P792, DOI 10.1111/j.1460-9568.1995.tb00682.x; BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P805, DOI 10.1111/j.1460-9568.1995.tb00683.x; CARLSON SS, 1987, J CELL BIOL, V105, P3075, DOI 10.1083/jcb.105.6.3075; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; ERNST H, 1995, J CELL SCI, V108, P3807; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FUNDERBURG FM, 1986, J CELL BIOL, V103, P2475, DOI 10.1083/jcb.103.6.2475; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; HEYMAN I, 1995, DEV DYNAM, V204, P301, DOI 10.1002/aja.1002040308; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; IWATA M, 1991, J BIOL CHEM, V266, P323; KELLER RE, 1982, DEV BIOL, V89, P179, DOI 10.1016/0012-1606(82)90306-2; KINSELLA MG, 1986, J CELL BIOL, V102, P679, DOI 10.1083/jcb.102.3.679; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LANE MC, 1991, DEV BIOL, V143, P389, DOI 10.1016/0012-1606(91)90089-L; LANE MC, 1988, DEV BIOL, V127, P78, DOI 10.1016/0012-1606(88)90190-X; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LI H, 1993, J BIOL CHEM, V268, P23504; LOFBERG J, 1989, DEV BIOL, V131, P168, DOI 10.1016/S0012-1606(89)80048-X; LOFBERG J, 1985, DEV BIOL, V107, P442, DOI 10.1016/0012-1606(85)90326-4; LOFBERG J, 1989, DEV BIOL AXOLOTL, P83; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; MORRISSKAY G, 1989, DEVELOPMENT, V106, P787; Olsson L, 1996, PIGM CELL RES, V9, P18, DOI 10.1111/j.1600-0749.1996.tb00082.x; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; PERRIS R, 1990, DEVELOPMENT, V109, P533; PERRIS R, 1987, J CELL BIOL, V105, P2511, DOI 10.1083/jcb.105.6.2511; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SHINOMURA T, 1995, J BIOL CHEM, V270, P10328, DOI 10.1074/jbc.270.17.10328; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SOLURSH M, 1986, DEV BIOL, V118, P325, DOI 10.1016/0012-1606(86)90001-1; SOLURSH M, 1982, DEV BIOL, V94, P326, DOI 10.1016/0012-1606(82)90351-7; SPIETH J, 1984, J EXP ZOOL, V229, P91, DOI 10.1002/jez.1402290112; STIGSON M, 1991, ARCH BIOCHEM BIOPHYS, V290, P391, DOI 10.1016/0003-9861(91)90557-Y; SUGIURA N, 1993, J BIOL CHEM, V268, P15779; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; UJITA M, 1994, J BIOL CHEM, V269, P27603; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1994, J CELL SCI, V107, P2581; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; ZACKSON SL, 1986, DEV BIOL, V117, P342, DOI 10.1016/0012-1606(86)90304-0; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	54	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3246	3253		10.1074/jbc.272.6.3246	http://dx.doi.org/10.1074/jbc.272.6.3246			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013561	hybrid			2022-12-25	WOS:A1997WG19200021
J	UhlinHansen, L; KuscheGullberg, M; Berg, E; Eriksson, I; Kjellen, L				UhlinHansen, L; KuscheGullberg, M; Berg, E; Eriksson, I; Kjellen, L			Mouse mastocytoma cells synthesize undersulfated heparin and chondroitin sulfate in the presence of brefeldin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMER-MODIFICATION REACTIONS; N-SULFOTRANSFERASE; BIOSYNTHESIS; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; PROTEINS; GLUCURONOSYLTRANSFERASE; DEPOLYMERIZATION; TRANSPORT; CLONING	In order to study the subcellular localization and organization of the enzymes involved in the glycosylation of the hybrid proteoglycan serglycin, mouse mastocytoma cells were metabolically labeled with [S-35]sulfate or [H-3]glucosamine in the absence or presence of brefeldin A. This drug is known to induce a disassembly of the proximal part of the Golgi complex, resulting in a redistribution of cis-, medial-, and trans-Golgi resident enzymes back to the endoplasmic reticulum, and to block the anterograde transport of proteins to the trans-Golgi network. Although the total incorporation of [H-3]glucosamine into glycosaminoglycan chains was reduced to about 25% in brefeldin A-treated cells compared to control cells, both control cells and cells treated with brefeldin A synthesized heparin as well as chondroitin sulfate chains. Therefore, enzymes involved ill the biosynthesis of both types of glycosaminoglycan chains seem to be present proximal to the trans-Golgi network in these cells. Chondroitin sulfate and heparin synthesized in cells exposed to brefeldin A were undersulfated, as demonstrated by ion-exchange chromatography, compositional analyses of disaccharides, as well as by a lower [S-35]sulfate/[H-3]glucosamine ratio compared to controls. In heparin biosynthesis, both N- and O-sulfation reactions were impaired, with a larger relative decrease in 2-O-sulfation than in 6-O-sulfation. Despite undersulfation, the heparin chains synthesized in the presence of brefeldin A were larger (30 kDa) than the heparin synthesized by control cells (20 kDa), The reduced [H-3]glucosamine incorporation hi brefeldin A-treated cells was partly due to decreased number of glycosaminoglycan chains synthesized, but also to the biosynthesis of chondroitin sulfate chains of smaller molecular size (8 versus 15 kDa in control cells). Brefeldin A had no effect on the glycosaminoglycan synthesis when used in a cell-free, microsomal fraction, indicating that brefeldin A does not interfere directly with the enzymes involved in the biosynthesis of glycosaminoglycans.	UNIV UPPSALA,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN; SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN	Uppsala University; Swedish University of Agricultural Sciences	UhlinHansen, L (corresponding author), UNIV TROMSO,INST MED BIOL,DEPT BIOCHEM,POB 977,N-9037 TROMSO,NORWAY.		Kjellen, Lena/F-1362-2011; Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				BAME KJ, 1991, J BIOL CHEM, V266, P10287; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FURTH J, 1957, P SOC EXP BIOL MED, V95, P824; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; KUSCHE M, 1988, BIOCHEM J, V253, P885, DOI 10.1042/bj2530885; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIDHOLT K, 1995, BIOCHEM J, V311, P233, DOI 10.1042/bj3110233; LIDHOLT K, 1992, BIOCHEM J, V289, P21; LIND T, 1993, J BIOL CHEM, V268, P20705; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RIESENFELD J, 1982, J BIOL CHEM, V257, P421; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGUMARAN G, 1992, BIOCHEM BIOPH RES CO, V183, P357, DOI 10.1016/0006-291X(92)90488-7; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370	32	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3200	3206		10.1074/jbc.272.6.3200	http://dx.doi.org/10.1074/jbc.272.6.3200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013555	hybrid			2022-12-25	WOS:A1997WG19200015
J	Becq, F; Hamon, Y; Bajetto, A; Gola, M; Verrier, B; Chimini, G				Becq, F; Hamon, Y; Bajetto, A; Gola, M; Verrier, B; Chimini, G			ABC1, an ATP binding cassette transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RESISTANCE P-GLYCOPROTEIN; CFTR CHLORIDE CHANNEL; CYSTIC-FIBROSIS GENE; HAMSTER OVARY CELLS; PHOSPHORYLATION; IDENTIFICATION; HYDROLYSIS; SEQUENCES; MEMBRANE	The ATP binding cassette transporter ABC1 is a 220-kDa glycoprotein expressed by macrophages and required for engulfment of cells undergoing programmed cell death. Since members of this family of proteins such as P-glycoprotein and cystic fibrosis transmembrane conductance regulator share the ability to transport anions, we have investigated the transport capability of ABC1 expressed in Xenopus oocytes using iodide efflux and voltage-clamp techniques. We report here that ABC1 generates an anion flux sensitive to glibenclamide, sulfobromophthalein, and blockers of anion transporters. The anion flux generated by ABC1 is upregulated by orthovanadate, cAMP, protein kinase A, and okadaic acid. In other ABC transporters, mutating the conserved lysine in the nucleotide binding folds was found to severely reduce or abolish hydrolysis of ATP, which in turn altered the activity of the transporter. In ABC1, replacement of the conserved lysine 1892 in the Walker A motif of the second nucleotide binding fold increased the basal ionic flux, did not alter the pharmacological inhibitory profile, but abolished the response to orthovanadate and cAMP agonists. Therefore, we conclude that ABC1 is a cAMP-dependent and sulfonylurea-sensitive anion transporter.	CNRS MARSEILLE LUMINY,CTR IMMUNOL,INSERM,F-13288 MARSEILLE 9,FRANCE; CNRS,LAB NEUROBIOL CELLULAIRE,F-13402 MARSEILLE 20,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)			Becq, Frederic/P-9233-2016; HAMON, Yannick YH/N-5372-2016; HAMON, Yannick/S-3118-2019	Becq, Frederic/0000-0003-3915-0973; HAMON, Yannick YH/0000-0002-7636-2310; HAMON, Yannick/0000-0002-7636-2310				AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; Becq F, 1996, J BIOL CHEM, V271, P16171, DOI 10.1074/jbc.271.27.16171; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN M, 1992, ANNU REV BIOCHEM, V62, P385; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; HANRAHAN JW, 1995, SOC GEN PHY, V50, P125; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KEMP PJ, 1993, PFLUG ARCH EUR J PHY, V425, P28, DOI 10.1007/BF00374500; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Muller M, 1996, J BIOL CHEM, V271, P1877; OHRUI T, 1994, AM J PHYSIOL, V266, pC1586; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUAST U, 1989, J PHARMACOL EXP THER, V250, P261; REUSS L, 1984, J GEN PHYSIOL, V83, P801, DOI 10.1085/jgp.83.6.801; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	38	118	126	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2695	2699		10.1074/jbc.272.5.2695	http://dx.doi.org/10.1074/jbc.272.5.2695			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006906	hybrid			2022-12-25	WOS:A1997WE66700019
J	Gow, AJ; Buerk, DG; Ischiropoulos, H				Gow, AJ; Buerk, DG; Ischiropoulos, H			A novel reaction mechanism for the formation of S-nitrosothiol in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL GUANYLATE-CYCLASE; NITRIC-OXIDE; SERUM-ALBUMIN; CYCLIC-GMP; NITROSATION; ACTIVATION; PEROXYNITRITE; ACCUMULATION; STIMULATION; GLUTATHIONE	The objective of this study was to investigate the mechanism of S-nitrosothiol formation under physiological conditions. A mechanism is proposed by which nitric oxide ((NO)-N-.) reacts directly with reduced thiol to produce a radical intermediate, R-S-N-.-O-H. This intermediate reduces an electron acceptor to produce S-nitrosothiol. Under aerobic conditions O-2 acts as the electron acceptor and is reduced to produce superoxide (O-2(radical anion)). The following experimental evidence is provided in support of this mechanism. Cysteine accelerates the consumption of (NO)-N-. by 2.5-fold under physiological conditions. The consumption of O-2 in the presence of (NO)-N-. and cysteine is increased by 2.4-fold. The reaction orders of (NO)-N-. and cysteine are second and first order, respectively. The second order of reaction for (NO)-N-. may result from interaction between (NO)-N-. and O-2(radical anion) to form peroxynitrite. In the presence of Cu,Zn-superoxide dismutase, the reaction of (NO)-N-. with cysteine generates hydrogen peroxide, indicating that the reaction generates O-2(radical anion). Finally, the formation of S-nitrosothiol is demonstrated in an anaerobic environment and, as predicted by the mechanism, is dependent on the presence of an electron acceptor. These results demonstrate that under physiological conditions (NO)-N-. reacts directly with thiols to form S-nitrosothiol in the presence of an electron acceptor.	UNIV PENN,INST ENVIRONM MED,SCH MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHYSIOL & BIOENGN,SCH MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOCHEM BIOPHYS,SCH MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Buerk, Donald G/F-6888-2014; Gow, Andrew/AAR-2309-2020; Gow, Andrew/N-8566-2013	Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158	NATIONAL EYE INSTITUTE [R01EY009269] Funding Source: NIH RePORTER; NEI NIH HHS [EY09269] Funding Source: Medline; NHLBI NIH HHS [HL07748] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; BUERK DG, 1993, BIOSNESORS THEORY AP, P95; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; GRUETTER DY, 1980, BIOCHEM PHARMACOL, V29, P2943, DOI 10.1016/0006-2952(80)90042-8; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; MELLION BT, 1983, MOL PHARMACOL, V23, P653; PADGETT CM, 1995, AM J PHYSIOL-CELL PH, V269, pC739, DOI 10.1152/ajpcell.1995.269.3.C739; Perutz MF, 1996, NATURE, V380, P205, DOI 10.1038/380205b0; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; TULLETT JM, 1996, BIOCH MOL BIOL NITRI, pA95; WADE RS, 1990, CHEM RES TOXICOL, V3, P289, DOI 10.1021/tx00016a002; WHALEN WJ, 1967, J APPL PHYSIOL, V23, P798, DOI 10.1152/jappl.1967.23.5.798; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; [No title captured]	26	258	266	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2841	2845		10.1074/jbc.272.5.2841	http://dx.doi.org/10.1074/jbc.272.5.2841			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006926	hybrid			2022-12-25	WOS:A1997WE66700039
J	Shifrin, VI; Davis, RJ; Neel, BG				Shifrin, VI; Davis, RJ; Neel, BG			Phosphorylation of protein-tyrosine phosphatase PTP-1B on identical sites suggests activation of a common signaling pathway during mitosis and stress response in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; FISSION YEAST; C-JUN; TRANSDUCTION PATHWAY; GENE-EXPRESSION; HUMAN-PLACENTA; GROWTH-FACTOR; INTERLEUKIN-1; INHIBITOR; CASCADE	PTP-1B is a widely expressed non-transmembrane tyrosine-specific phosphatase. Previous studies indicated that, at mitosis, PTP-1B undergoes phosphorylation on two sites, (352)Ser-Pro-Leu-Asn and (386)Ser-Pro-Ala-Lys. Although the Ser-386 site can be phosphorylated by Cyclin B/Cdc2 in vitro, the kinase for the Ser-352 site is unknown. known. We have found that these phosphorylation events are not unique to normal mitosis. Instead, treatment with many, but not all, stress stimuli, in particular osmotic shock and certain phosphatase and protein synthesis inhibitors, leads to phosphorylation of PTP-1B. Tryptic phosphopeptide and mutant analysis reveals that, as in mitosis, stress-induced PTP-1B phosphorylation involves both Ser-352 and Ser-386. Activation of the proline-directed kinases Erk1/2, JNKs, and p38 was neither necessary nor sufficient for stress-induced PTP-1B phosphorylation. Our data suggest the existence of a novel mitogen-activated protein kinase pathway in mammalian cells, which is activated at mitosis and in response to osmotic shock and other stresses and results in PTP-1B phosphorylation. This pathway may be similar to the recently described Spc1/Sty1 pathway in Schizosaccharomyces pombe.	BETH ISRAEL HOSP, DEPT MED, CANC BIOL PROGRAM, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA; HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute					NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA49152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; GUY GR, 1992, J BIOL CHEM, V267, P1846; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNIG G, 1993, YEAST, V9, P1039, DOI 10.1002/yea.320091002; HANNIG G, 1994, P NATL ACAD SCI USA, V91, P10084, DOI 10.1073/pnas.91.21.10084; Harlow E., 1988, ANTIBODIES LAB MANUA; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; OTTILIE S, 1992, MOL CELL BIOL, V12, P5571, DOI 10.1128/MCB.12.12.5571; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; TERADA Y, 1994, J BIOL CHEM, V269, P31296; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722	43	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2957	2962		10.1074/jbc.272.5.2957	http://dx.doi.org/10.1074/jbc.272.5.2957			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006942	hybrid			2022-12-25	WOS:A1997WE66700055
J	Ardini, E; Tagliabue, E; Magnifico, A; Buto, S; Castronovo, V; Colnaghi, MI; Menard, S				Ardini, E; Tagliabue, E; Magnifico, A; Buto, S; Castronovo, V; Colnaghi, MI; Menard, S			Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha 6 beta 4 integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; BINDING PROTEIN; CELL-SURFACE; GENE-PRODUCT; EXPRESSION; METASTASIS; MODULATION; CARCINOMAS; PRECURSOR; ADHESION	The interactions between tumor cells and laminin or other components of the extracellular matrix have been shown to play an important role in tumor invasion and metastasis. However, the role of the monomeric 67-kDa laminin receptor (67LR) remains unclear. me analyzed the regulation of 67LR expression under different culture conditions with respect to the expression of other well characterized laminin receptors. In A431 cells treated with laminin for different time periods, the regulation of 67LR expression correlated with expression of the alpha 6 integrin subunit but not with the expression of other laminin receptors. Moreover, cytokine treatment resulted in down-modulated expression of the alpha 6 integrin subunit and the 67LR. Co-regulation of the expression of the two receptors was further suggested by the observation that specific down-modulation of the alpha 6-chain by antisense oligonucleotides was accompanied by a proportional decrease in the cell surface expression of 67LR. Biochemical analyses indicated co-immunoprecipitation of 67LR and the alpha 6 subunit with an anti-alpha 6 but not an anti-beta 1 monoclonal antibody. Co-regulation of 67LR and alpha 6 subunit expression, together with the physical association between the two receptors, supports the hypothesis that 67LR is an auxiliary molecule involved in regulating or stabilizing the interaction of laminin with the alpha 6 beta 4 integrin.	IST NAZL TUMORI,DIV EXPT ONCOL E,I-20133 MILAN,ITALY; UNIV LIEGE,METASTASIS RES LAB,B-400 LIEGE 1,BELGIUM	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Liege			Tagliabue, Elda/B-9377-2017	Tagliabue, Elda/0000-0001-9877-2903				BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; CASSIMAN JJ, 1989, CANCER GENET CYTOGEN, V41, P19, DOI 10.1016/0165-4608(89)90104-0; CASTRONOVO V, 1993, INVAS METAST, V13, P1; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; DEFILIPPI P, 1992, J BIOL CHEM, V267, P18303; FRIDMAN R, 1990, P NATL ACAD SCI USA, V87, P6698, DOI 10.1073/pnas.87.17.6698; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KALTHOFF H, 1993, P NATL ACAD SCI USA, V90, P8972, DOI 10.1073/pnas.90.19.8972; KUMAR R, 1994, ANTICANCER RES, V14, P1001; LANDOWSKI TH, 1995, BIOCHEMISTRY-US, V34, P11276, DOI 10.1021/bi00035a037; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MARTIGNONE S, 1992, CLIN EXP METASTAS, V10, P379, DOI 10.1007/BF00133466; MARTIGNONE S, 1993, J NATL CANCER I, V85, P398, DOI 10.1093/jnci/85.5.398; PELLEGRINI R, 1992, TUMORI, V78, P1; PELLEGRINI R, 1994, INT J CANCER S, V8, P116; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAO CN, 1983, BIOCHEM BIOPH RES CO, V111, P804; ROMANOV V, 1994, CELL ADHES COMMUN, V2, P201, DOI 10.3109/15419069409004438; ROMANOV VI, 1995, BIOCHEM BIOPH RES CO, V208, P637, DOI 10.1006/bbrc.1995.1386; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SEDLAK J, 1994, CHEMOTHERAPY, V40, P51, DOI 10.1159/000239170; SOBEL ME, 1993, SEMIN CANCER BIOL, V4, P311; SONNENBERG A, 1990, J CELL SCI, V96, P207; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; VANVALEN F, 1994, EUR J CANCER, V30A, P2119, DOI 10.1016/0959-8049(94)00346-7	26	83	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2342	2345						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999943				2022-12-25	WOS:A1997WD67900049
J	Bohm, SK; Khitin, LM; Smeekens, SP; Grady, EF; Payan, DG; Bunnett, NW				Bohm, SK; Khitin, LM; Smeekens, SP; Grady, EF; Payan, DG; Bunnett, NW			Identification of potential tyrosine-containing endocytic motifs in the carboxyl-tail and seventh transmembrane domain of the neurokinin 1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED INTERNALIZATION; PROTEIN-COUPLED RECEPTOR; ANGIOTENSIN-II RECEPTOR; SUBSTANCE-P RECEPTOR; BETA-ADRENERGIC-RECEPTOR; GROWTH-FACTOR RECEPTORS; BETA-2-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; NK1 RECEPTOR; PHOSPHORYLATION SITES	Although agonist-induced endocytosis of G-protein-coupled receptors is critical for receptor desensitization and resensitization, receptor motifs that interact with the endocytic apparatus have not been adequately characterized, We examined the effects of mutating the rat neurokinin-1 receptor on endocytosis using I-125-substance P, fluorescent substance P, and receptor antibodies, Substance P induced rapid internalization of wildtype receptors that were targeted to perinuclear endosomes, Truncation of the C-tail at residues 324, 342, and 354 reduced internalization up to 60% and caused retention of receptors at the cell surface and in superficial endosomes, Mutation of Tyr-341 and Tyr-349 in potential tyrosine-containing endocytic motifs of the C-tail also impaired internalization. A Y305A mutant within the putative NPX(2-3)Y endocytic motif of the seventh transmembrane domain showed impaired signaling and was minimally expressed at the plasma membrane but was found in cytoplasmic vesicles, In contrast, a Y305F mutant signaled normally and was normally expressed at the plasma membrane but showed impaired internalization, Thus, endocytosis of the neurokinin 1 receptor relies on several tyrosine-containing sequences in the C-tail and seventh transmembrane domain.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; KHEPRI PHARMACEUT INC,S SAN FRANCISCO,CA 94080	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Bunnett, Nigel W./0000-0003-3367-0644	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043207, R56DK043207, R01DK039957, R37DK039957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021710] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43207, DK39957] Funding Source: Medline; NINDS NIH HHS [NS21710] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BUNNETT NW, 1995, PEPTIDES, V16, P733, DOI 10.1016/0196-9781(95)00042-I; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; FONG TM, 1992, MOL PHARMACOL, V41, P24; FONG TM, 1993, NATURE, V362, P350; Garland AM, 1996, MOL PHARMACOL, V49, P438; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Grady EF, 1996, NEUROSCIENCE, V75, P1239, DOI 10.1016/0306-4522(96)00357-0; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; KAGE R, 1993, J NEUROCHEM, V60, P347, DOI 10.1111/j.1471-4159.1993.tb05857.x; KONG GH, 1994, J BIOL CHEM, V269, P13084; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; MORO O, 1993, J BIOL CHEM, V268, P6862; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; PACCAUD JP, 1993, J BIOL CHEM, V268, P23191; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; SASAKAWA N, 1994, FEBS LETT, V347, P181, DOI 10.1016/0014-5793(94)00532-X; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VIGNA SR, 1994, J NEUROSCI, V14, P834; YU SS, 1993, J BIOL CHEM, V268, P337	55	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2363	2372						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999947				2022-12-25	WOS:A1997WD67900053
J	deGroot, RP; vanDijk, TB; Caldenhoven, E; Coffer, PJ; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L				deGroot, RP; vanDijk, TB; Caldenhoven, E; Coffer, PJ; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L			Activation of 12-O-tetradecanoylphorbol-13-acetate response element- and dyad symmetry element-dependent transcription by interleukin-5 is mediated by Jun N-terminal kinase stress-activated protein kinase kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH SIGNAL-TRANSDUCTION; COMMON BETA-SUBUNIT; RECEPTOR-ALPHA CHAIN; GM-CSF RECEPTOR; HUMAN EOSINOPHILS; TYROSINE PHOSPHORYLATION; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS	Interleukin-5 (IL-5) is one of the major regulators of eosinophilic granulocytes in vivo. IL-5 exerts its pleiotropic effects by binding to the IL-5 receptor, which is composed of an IL-5-specific alpha chain and a common beta c chain shared with the receptors for IL-5 and granulocyte-macrophage colony-stimulating factor, Previous studies have shown that binding of IL-5 to its receptor triggers the activation of multiple signaling cascades, including the Ras/mitogen-activated protein kinase, the phosphatidyl -3'-kinase, and the Janus kinase/signal transducer and activator of transcription pathways. Here we describe that IL-5 activates the serine/threonine protein kinase Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) pathway. We show that IL-5 activates TPA response element (TRE)-dependent transcription in transfection experiments. TRE activation by IL-5 is mediated by a region of the beta c (577-581) that is also responsible for activation of JNK/SAPK and for activation of dyad symmetry element (DSE)-dependent transcription. Dominant-negative SAPK or ERH kinase-1 was used to demonstrate that JNK/SAPK activation is necessary for induction of DSE- and TRE-dependent transcription by IL-5, whereas extracellular signal-regulated kinase 2 was not essential for TRE- and DSE-dependent transcription, By contrast, IL-5-induced activation of the tyrosine kinase Janus kinase 2 seems to be a prerequisite for TRE- and DSE-dependent transcription. Taken together, we show for the first time that IL-5 activates kinases of the JNK/SAPK family, and that this activation is linked to IL-5-induced TRE- and DSE-dependent transcription.			deGroot, RP (corresponding author), UNIV UTRECHT HOSP,DEPT PULM DIS,G03-550,HEIDELBERGLAAN 100,NL-3584 CX UTRECHT,NETHERLANDS.		Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Koenderman, Leo/0000-0002-5636-6453				ANDERSON SM, 1995, J IMMUNOL, V155, P1660; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1995, J CELL SCI, V108, P3599; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; INGLEY E, 1991, BLOOD, V78, P339; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; JUCKER M, 1995, J BIOL CHEM, V270, P27817; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; OGAWA M, 1993, BLOOD, V81, P2844; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDERBRUGGEN T, 1994, J IMMUNOL, V153, P2729; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WATANABE S, 1995, MOL BIOL CELL, V6, P627, DOI 10.1091/mbc.6.6.627; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; YAN MH, 1994, NATURE, V372, P798; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	58	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2319	2325						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999940				2022-12-25	WOS:A1997WD67900046
J	Desrivieres, S; Volarevic, S; Mercep, L; Ferrari, S				Desrivieres, S; Volarevic, S; Mercep, L; Ferrari, S			Evidence for different mechanisms of growth inhibition of T-cell lymphoma by phorbol esters and concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; RETINOBLASTOMA PROTEIN; MONOCLONAL-ANTIBODIES; DEPENDENT KINASE; GENE-PRODUCT; P34CDC2 PHOSPHORYLATION; RECEPTOR COMPLEX; MAMMALIAN-CELLS; CYCLE BLOCK; TGF-BETA	Stimuli that are mitogenic for mature T-cells induce cell cycle arrest in some T-cell tumors and T-cell hybridomas. The molecular mechanism of this growth inhibition is poorly understood,In this report, we show that in EL4, a murine T-lymphoma cell line, stimulation with concanavalin A or treatment with phorbol 13-myristate 12-acetate (PMA) inhibit growth, due to cell cycle arrest at both the G(1) and the G(2)/M phases. The block at the G(1) phase is accompanied by the appearance of a hypophosphorylated form of the retinoblastoma protein (pRb), due to the inhibition of G(1) cyclin-Cdk complexes. However, the molecular mechanisms leading to this G(1) cell cycle arrest differ between concanavalin A and PMA: concanavalin A inhibits both cyclin E-Cdk2 and cyclin D-Cdk4 complexes, while PMA inhibits only cyclin E-Cdk2. We demonstrate that concanavalin A inhibits cyclin D-Cdk4 activity by decreasing the amount of cyclin D. The inhibition of cyclin E-Cdk2 by both concanavalin A and PMA is due to increased binding of the Cdk inhibitor p21 to this complex. However, while stimulation of the cells with concanavalin A did not result in an evident increase of the total Level of p21, treatment of the cells with PMA increased p21 levels significantly. Our results indicate, furthermore, that the G(2)/m block results from the inhibition of cyclin A- and cyclin B1-associated kinase activities. As for cycIin E-Cdk2, the inhibition of the cyclin A-Cdk2 complex is due to increased binding of the p21 inhibitor.	TUMOR BIOL CTR, INST EXPT CANC RES, D-79011 FREIBURG, GERMANY				Volarevic, Sinisa/O-4349-2018; Ferrari, Stefano/I-7357-2016; Desrivieres, Sylvane/B-7399-2011; Desrivières, Sylvane/ABC-4336-2021	Volarevic, Sinisa/0000-0003-4893-389X; Ferrari, Stefano/0000-0002-6607-215X; Desrivieres, Sylvane/0000-0002-9120-7060; Desrivières, Sylvane/0000-0002-9120-7060				AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BREITMEYER JB, 1978, J IMMUNOL, V138, P726; BRUNET A, 1994, ONCOGENE, V9, P3379; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FERRARI S, 1991, METHOD ENZYMOL, V200, P159; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FODETAR R, 1995, MOL CELL BIOL, V15, P932; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; IMBODEN J, 1987, J IMMUNOL, V138, P1322; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; KATO J, 1993, GENE DEV, V7, P331; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MERCEP M, 1988, J IMMUNOL, V140, P324; MERCEP M, 1989, J IMMUNOL, V142, P4085; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NEVINS JR, 1992, SCIENCE, V258, P424; OEHLEN B, 1994, CURR OPIN CELL BIOL, V6, P836, DOI 10.1016/0955-0674(94)90053-1; OFLYNN K, 1985, EUR J IMMUNOL, V15, P7, DOI 10.1002/eji.1830150103; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sasaguri T, 1996, J BIOL CHEM, V271, P8345, DOI 10.1074/jbc.271.14.8345; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; UCKER DS, 1989, J IMMUNOL, V143, P3461; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808	65	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2470	2476						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999961				2022-12-25	WOS:A1997WD67900067
J	Fu, DX; Maloney, PC				Fu, DX; Maloney, PC			Evaluation of secondary structure of OxlT, the oxalate transporter of Oxalobacter formigenes, by circular dichroism spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; TRANSMEMBRANE HELICES; GLUCOSE TRANSPORTER; ESCHERICHIA-COLI; ANION-EXCHANGE; PURIFICATION; RECONSTITUTION; ANTIPORT; CARRIER; DECONVOLUTION	OxlT, the oxalate/formate exchange transporter of Oxalobacter formigenes, was purified as a histidine-tagged variant, OxlTHis, using Ni2+-linked affinity chromatography. OxlTHis was readily obtained in high purity (greater than or equal to 95%) and reasonable yield (greater than or equal to 60%), and showed kinetic and biochemical features characteristic of its parent, OxlT, including an unusually high maximal velocity (60 mu mol/min per mg of protein at 4 degrees C). Circular dichroism spectroscopy of purified OxlTHis identified the a-helix as its dominant secondary structural unit, encompassing 60-70% of OxlTHis residues and consistent with a model suggesting 60% of OxlT (OxlTHis) residues are involved in the construction of 12 transmembrane alpha-helices (Abe, K., Ruan, Z.-S., and Maloney, P. C. (1996) J. Biol. Chem. 271, 6789-6793). In either octyl glucoside/lipid or dodecylmaltoside/lipid micelles, solubilized OxlTHis showed a striking substrate-induced stabilization of function, and at saturating levels of substrate (1000 x K-D) activity recoverable by reconstitution disappeared with a half-life of 7 days at 23 degrees C. Measurement of changes of ellipticity at 222 nm as a function of time and substrate concentration showed that maintenance of function was attributable to a substrate-induced stabilization of the alpha-helical ensemble with a K-D of 10 mu M for the 1:1 binding of oxalate to OxlTHis.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University				Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024195, R56GM024195] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24195] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 1996, J BIOL CHEM, V271, P6789, DOI 10.1074/jbc.271.12.6789; ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; CHIN JJ, 1986, J BIOL CHEM, V261, P7101; Crowe J, 1994, Methods Mol Biol, V31, P371; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FASMAN GD, 1995, BIOPOLYMERS, V37, P339, DOI 10.1002/bip.360370505; FOSTER DL, 1983, J BIOL CHEM, V258, P31; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; JOHNSON WC, 1990, PROTEIN-STRUCT FUNCT, V7, P204; KABACK HR, 1988, ANNU REV PHYSIOL, V50, P243; KRAMER R, 1994, BBA-BIOENERGETICS, V1185, P1, DOI 10.1016/0005-2728(94)90189-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MALONEY PC, 1996, ESCHERICHIA COLI SAL, P1130; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MIELKE DL, 1988, J BIOL CHEM, V263, P3177; PARK K, 1992, PROTEIN SCI, V1, P1032, DOI 10.1002/pro.5560010809; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POPOT JL, 1993, CURR OPIN STRUC BIOL, V3, P532, DOI 10.1016/0959-440X(93)90079-Z; POS KM, 1994, FEBS LETT, V347, P37, DOI 10.1016/0014-5793(94)00502-8; POURCHER T, 1995, BIOCHEMISTRY-US, V34, P4412, DOI 10.1021/bi00013a033; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VARADHACHARY A, 1990, MOL MICROBIOL, V4, P1407, DOI 10.1111/j.1365-2958.1990.tb00720.x; Voss J, 1995, P NATL ACAD SCI USA, V92, P12300, DOI 10.1073/pnas.92.26.12300; WALMSLEY AR, 1988, TRENDS BIOCHEM SCI, V13, P226, DOI 10.1016/0968-0004(88)90089-8; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; YANG JT, 1986, METHOD ENZYMOL, V130, P208	36	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2129	2135						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999913				2022-12-25	WOS:A1997WD67900019
J	Jucker, M; McKenna, K; daSilva, AJ; Rudd, CE; Feldman, RA				Jucker, M; McKenna, K; daSilva, AJ; Rudd, CE; Feldman, RA			The fes protein-tyrosine kinase phosphorylates a subset of macrophage proteins that are involved in cell adhesion and cell-cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FPS FES; SH2 DOMAIN; TRANSFORMING ACTIVITY; EXPRESSION; RECEPTOR; ONCOGENE; DIFFERENTIATION; TRANSDUCTION; SRC	The c-fps/fes proto-oncogene encodes a 92-kDa protein-tyrosine kinase that is expressed at high levels in macrophages. We have previously shown that overexpression of c-fps/fes in a CSF-1-dependent macrophage cell line (BAC1.2F5) partially released these cells from their factor dependence and that this correlated with the tyrosine phosphorylation of a subset of proteins in a tissue-specific manner. me have now identified one of the macrophage substrates of Fes as the crk-associated substrate (Cas) and a second substrate as a 130-kDa protein that has been previously described as a T cell activation-dependent substrate and is unrelated to Cas. Both of these proteins, which have optimal consensus sequences for phosphorylation by Fes, were tightly associated with this kinase through its SH2 domain, suggesting that they were direct substrates of Fes. Remarkably, when the Fes SH2 domain was used as an affinity reagent to identify potential substrates of endogenous Fes in control BAC1.2F5 cells, the phosphotyrosyl proteins that were recognized were the same as those that were specifically phosphorylated when Fes was overexpressed in the same cells. We conclude that the substrates we identified may be structurally related or identical to the physiological targets of this kinase in macrophages. The known functions of Cas and p130 suggest that Fes kinase may play a role in signaling triggered by cell adhesion and cell cell interactions during immune responses of macrophages.	UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, INST BIOTECHNOL, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022	Rudd, Christopher E/0000-0001-5295-9019; Feldman, Ricardo A./0000-0001-6090-0439	NATIONAL CANCER INSTITUTE [R29CA055293] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA 55293] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; CARE A, 1994, ONCOGENE, V9, P739; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DASILVA AJ, 1997, IN PRESS J IMMUNOL; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1990, ONCOGENE RES, V5, P187; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1987, ONCOGENE RES, V1, P441; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HANAFUSA H, 1988, ONCOGENE HDB, P39; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KIM JW, 1990, J BIOL CHEM, V265, P3940; Law SF, 1996, MOL CELL BIOL, V16, P3327; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MARU Y, 1995, MOL CELL BIOL, V15, P835; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STANLEY ER, 1994, CYTOKINE HDB, V21, P387; Vuori K, 1996, MOL CELL BIOL, V16, P2606; YU G, 1989, J BIOL CHEM, V264, P10276	43	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2104	2109						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999909				2022-12-25	WOS:A1997WD67900015
J	Pettit, DK; Bonnert, TP; Eisenman, J; Srinivasan, S; Paxton, R; Beers, C; Lynch, D; Miller, B; Yost, J; Grabstein, KH; Gombotz, WR				Pettit, DK; Bonnert, TP; Eisenman, J; Srinivasan, S; Paxton, R; Beers, C; Lynch, D; Miller, B; Yost, J; Grabstein, KH; Gombotz, WR			Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CELL GROWTH-FACTOR; IL-2 RECEPTOR; RECOMBINANT INTERLEUKIN-2; ALPHA-CHAIN; 3-DIMENSIONAL STRUCTURE; PSEUDOMONAS EXOTOXIN; BETA-CHAIN; BINDING; PROTEINS	Interleukin (IL)-15 is a multifunctional cytokine that shares many biological activities with IL-2. This functional overlap, as well as receptor binding subunits shared by IL-15 and IL-2, suggests tertiary structural similarities between these two cytokines. In this study, recombinant human IL-15 was PEGylated via lysine-specific conjugation chemistry in order to extend the circulation half-life of this cytokine. Although PEGylation did extend the beta-elimination circulation half-life of IL-15 by greater than 50-fold, the biological activity of polyethylene glycol (PEG)-IL-15 was significantly altered. Specifically, PEG-IL-15 lost its ability to stimulate the proliferation of CTLL but took on the properties of a specific IL-15 antagonist in vitro. In comparing sequence alignments and molecular models for IL-2 and IL-15, it was noted that lysine residues resided in regions of IL-15 that may have selectively disrupted receptor subunit binding. We hypothesized that PEGylation of IL-15 interferes with beta but not alpha receptor subunit binding, resulting in the IL-15 antagonist activity observed in vitro. The validity of this hypothesis was tested by engineering site-specific mutants of human IL-15 as suggested by the IL-15 model (IL-15D8S and IL-15Q108S block beta and gamma receptor subunit binding, respectively). As with PEG-IL-15, these mutants were unable to stimulate CTLL proliferation but were able to specifically inhibit the proliferation of CTLL in response to unmodified IL-15. These results supported our model of IL-15 and confirmed that interference of beta receptor subunit binding by adjacent PEGylation could be responsible for the altered biological activity observed for PEG-IL-IB.	IMMUNEX RES & DEV CORP,DEPT PROT CHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT IMMUNOBIOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT PROD RECOVERY,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101		Pettit, DK (corresponding author), IMMUNEX RES & DEV CORP,DEPT ANALYT CHEM & FORMULAT,51 UNIV ST,SEATTLE,WA 98101, USA.							AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BENHAR I, 1994, J BIOL CHEM, V269, P13398; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; DELGADO C, 1992, CRIT REV THER DRUG, V9, P249; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GILLIS S, 1978, J IMMUNOL, V120, P2027; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GIRI JG, 1996, HDB BASIC CLIN RES, V2, P135; GOODSON RJ, 1990, BIO-TECHNOL, V8, P343, DOI 10.1038/nbt0490-343; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; JANIN J, 1976, J MOL BIOL, V100, P197, DOI 10.1016/S0022-2836(76)80148-9; JU G, 1987, J BIOL CHEM, V262, P5723; KATRE NV, 1987, P NATL ACAD SCI USA, V84, P1487, DOI 10.1073/pnas.84.6.1487; KATRE NV, 1990, J IMMUNOL, V144, P209; Kennedy MK, 1996, J CLIN IMMUNOL, V16, P134, DOI 10.1007/BF01540911; KNAUF MJ, 1988, J BIOL CHEM, V263, P15064; KNUSLI C, 1992, BRIT J HAEMATOL, V82, P654, DOI 10.1111/j.1365-2141.1992.tb06940.x; LIANG SM, 1986, J BIOL CHEM, V261, P334; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; PRICE V, 1987, GENE, V55, P287, DOI 10.1016/0378-1119(87)90288-5; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; SRINIVASAN S, 1993, PROTEIN SCI, V2, P277; SUDARSANAM S, 1994, J MOL BIOL, V241, P143, DOI 10.1006/jmbi.1994.1484; SUZUKI T, 1984, BIOCHIM BIOPHYS ACTA, V788, P248, DOI 10.1016/0167-4838(84)90268-1; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; WANG QC, 1993, CANCER RES, V53, P4588; WEIGEL U, 1989, EUR J BIOCHEM, V180, P295, DOI 10.1111/j.1432-1033.1989.tb14647.x; WEIR MP, 1988, BIOCHEMISTRY-US, V27, P6883, DOI 10.1021/bi00418a034; WLODAWER A, 1993, PROTEIN SCI, V2, P1373, DOI 10.1002/pro.5560020902; ZIMMERMAN RJ, 1989, CANCER RES, V49, P6521; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	38	90	154	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2312	2318						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999939				2022-12-25	WOS:A1997WD67900045
J	Skjaerbaek, N; Nielsen, KJ; Lewis, RJ; Alewood, P; Craik, DJ				Skjaerbaek, N; Nielsen, KJ; Lewis, RJ; Alewood, P; Craik, DJ			Determination of the solution structures of conantokin-G and conantokin-T by CD and NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-D-ASPARTATE; GAMMA-CARBOXYGLUTAMATE; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; COUPLING-CONSTANTS; CONUS PEPTIDES; ACID RESIDUES; ANTAGONIST; CONFORMATION; PROTHROMBIN	Conantokin-G and conantokin-T are two paralytic polypeptide toxins originally isolated from the venom of the fish-hunting cone snails of the genus Conus. Conantokin-G and conantokin-T are the only naturally occurring peptidic compounds which possess N-methyl-D-aspartate receptor antagonist activity, produced by a selective non-competitive antagonism of polyamine responses, They are also structurally unusual in that they contain a disproportionately large number of acid labile post-translational gamma-carboxyglutamic acid (Gla) residues, Although no precise structural information has previously been published for these peptides, early spectroscopic measurements have indicated that both conantokin-G and conantokin-T form alpha-helical structures, although there is some debate whether the presence of calcium ions is required for these peptides to adopt this fold, We now report a detailed structural study of synthetic conantokin-G and conantokin-T in a range of solution conditions using CD and H-1 NMR spec troscopy. The three-dimensional structures of conantokin-T and conantokin-G were calculated from H-1 NMR-derived distance and dihedral restraints. Both conantokins were found to contain a mixture of alpha- and 3(10) helix, that give rise to curved and straight helical conformers. Conantokin-G requires the presence of divalent cations (Zn2+, Ca2+, Cu2+, Or Mg2+) to form a stable iv-helix, while conantokin-T adopts a stable alpha-helical structure in aqueous conditions, in the presence or absence of divalent cations (Zn2+, Ca2+, Cu2+, Or Mg2+).	UNIV QUEENSLAND,CTR DRUG DESIGN & DEV,BRISBANE,QLD 4072,AUSTRALIA	University of Queensland			Lewis, Richard J/E-8674-2013; Craik, David/B-1695-2010; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Craik, David/0000-0003-0007-6796; Lewis, Richard/0000-0003-3470-923X				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; COLPITTS TL, 1995, BIOCHEMISTRY-US, V34, P2424, DOI 10.1021/bi00008a004; CRUZ LJ, 1985, J TOXICOL-TOXIN REV, V4, P107, DOI 10.3109/15569548509014416; CRUZ LJ, 1992, BIOL BULL, V183, P159, DOI 10.2307/1542418; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jones A, 1996, RAPID COMMUN MASS SP, V10, P138, DOI 10.1002/(SICI)1097-0231(19960115)10:1<138::AID-RCM442>3.0.CO;2-3; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MCLEISH MJ, 1994, BIOCHEMISTRY-US, V33, P11174, DOI 10.1021/bi00203a013; MENA EE, 1990, NEUROSCI LETT, V118, P241, DOI 10.1016/0304-3940(90)90637-O; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; Nielsen KJ, 1996, BIOCHEMISTRY-US, V35, P369, DOI 10.1021/bi952228i; NISHIUCHI Y, 1993, INT J PEPT PROT RES, V42, P533; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PASTORE A, 1990, J MAGN RESON, V90, P165, DOI 10.1016/0022-2364(90)90375-J; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; RIVIER J, 1987, BIOCHEMISTRY-US, V26, P8508, DOI 10.1021/bi00400a002; SAACAN AI, 1990, MOL PHARMACOL, V38, P705; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SEIDEMANN R, 1986, MAKROMOL CHEM, V187, P2545; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; SMYTHE ML, 1995, J AM CHEM SOC, V117, P10555, DOI 10.1021/ja00147a018; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Zhou LM, 1996, J NEUROCHEM, V66, P620	37	81	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2291	2299						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999936				2022-12-25	WOS:A1997WD67900042
J	Kashanchi, F; Araujo, J; Doniger, J; Muralidhar, S; Hoch, R; Khleif, S; Mendelson, E; Thompson, J; Azumi, N; Brady, JN; Luppi, M; Torelli, G; Rosenthal, LJ				Kashanchi, F; Araujo, J; Doniger, J; Muralidhar, S; Hoch, R; Khleif, S; Mendelson, E; Thompson, J; Azumi, N; Brady, JN; Luppi, M; Torelli, G; Rosenthal, LJ			Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53	ONCOGENE			English	Article						p53 binding; p53-activated transcription; HHV-6 transformation gene	POLYMERASE CHAIN-REACTION; VIRUS HUMAN HERPESVIRUS-6; EXANTHEM-SUBITUM; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC TRANSFORMATION; HUMAN CYTOMEGALOVIRUS; TRANSGENIC MICE; HUMAN LYMPHOMAS; LYMPHOCYTES-T; CELL-LINES	The 357 amino acid open reading frame 1 (OFF-1), also designated DR7, within the SalI-L fragment of human herpesvirus 6 (HHV-6) exhibited transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter and increased HIV-1 replication (Kashanchi et al., Virology, 201, 95-106, 1994). Tn the current study, the SalI-L transforming region was localized to the SalI-L-SH subfragment, Several ORFs identified in SalI-L-SH by sequence analysis were cloned into a selectable mammalian expression vector, pBK-CMV, Only pBK/ORF1 transformed NIH3T3 cells. Furthermore, cells expressing ORF-1 protein produced fibrosarcomas when injected into nude mice, whereas control cells, expressing either no ORF-1 protein or C-terminal truncated (after residue 172) ORF-1 protein, were not tumorigenic, Western blot analysis of proteins extracted from the tumors revealed ORF-1 protein. Additional studies indicated that ORF-1 was expressed in HHV-6-infected human T-cells by 18 h. Co-immunoprecipitation experiments showed that ORF-1 protein bound to tumor suppressor protein p53, and the OFF-1 binding domain on p53 was located between residues 28 and 187 of p53, overlapping with the specific DNA binding domain. Functional studies showed that p53-activated transcription was inhibited in ORF-1, but not in truncated OFF-1, expressing cells. Importantly, the truncated ORF-1 mutant also failed to cause transformation. Analysis of several human tumors by PCR revealed OFF-1 DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkin's and non-Hodgkin's lymphomas and glioblastomas. The detection of OFF-1 sequences in human tumors, while not proof per se, is a prerequisite for establishing its role in tumor development. Taken together, the results demonstrate that OFF-1 is an HHV-6 oncogene that binds to and affects p53. The identification of both transforming and transactivating activities within ORF-1 is a characteristic of other viral oncogenes and is the first reported for HHV-6.	GEORGETOWN UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PATHOL,WASHINGTON,DC 20007; NCI,MOL VIROL LAB,NIH,BETHESDA,MD 20892; NCI,NAVY MED ONCOL BRANCH,BETHESDA,MD 20892; UNIV MODENA,CTR EXPT HEMATOL,I-41100 MODENA,ITALY	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universita di Modena e Reggio Emilia			Luppi, Mario/J-3668-2016	Luppi, Mario/0000-0002-0373-1154; Hoch, Renee/0000-0003-0042-3751	NATIONAL CANCER INSTITUTE [R55CA060577, R01CA060577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ABLASHI DV, 1988, INT J CANCER, V42, P787, DOI 10.1002/ijc.2910420526; ABLASHI DV, 1995, TRENDS MICROBIOL, V3, P324, DOI 10.1016/S0966-842X(00)88964-7; ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; BERTRAM G, 1991, In Vivo (Attiki), V5, P271; BLAZQUEZ MV, 1995, J ACQ IMMUN DEF SYND, V9, P389; BOVENZI P, 1993, LANCET, V341, P1288, DOI 10.1016/0140-6736(93)91198-U; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; CHEN M, 1994, J VIROL, V68, P1173, DOI 10.1128/JVI.68.2.1173-1178.1994; CLANTON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P3826, DOI 10.1073/pnas.80.12.3826; CONE RW, 1993, J CLIN MICROBIOL, V31, P1262, DOI 10.1128/JCM.31.5.1262-1267.1993; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; FUJITA M, 1995, ONCOGENE, V11, P15; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; Hansen R, 1995, ONCOGENE, V11, P2535; HORVAT RT, 1991, J VIROL, V65, P2895, DOI 10.1128/JVI.65.6.2895-2902.1991; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; JOSEPHS SF, 1988, LEUKEMIA, V2, P132; KASHANCHI F, 1994, VIROLOGY, V201, P95, DOI 10.1006/viro.1994.1269; KASHANCHI F, 1993, J VIROL, V67, P2894, DOI 10.1128/JVI.67.5.2894-2902.1993; Kikuchi M, 1992, HUMAN HERPESVIRUS, VDV, P175; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KO Y, 1995, MOL CELL PROBE, V9, P215, DOI 10.1016/S0890-8508(95)90070-5; Krueger G R, 1991, In Vivo, V5, P217; Krueger G R, 1994, In Vivo, V8, P501; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE PH, 1992, J INFECT DIS, V166, P291, DOI 10.1093/infdis/166.2.291; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; LUPPI M, 1993, J INFECT DIS, V168, P1074, DOI 10.1093/infdis/168.4.1074; LUPPI M, 1995, J MED VIROL, V47, P105, DOI 10.1002/jmv.1890470119; LUPPI M, 1993, LEUKEMIA RES, V17, P1003, DOI 10.1016/0145-2126(93)90049-Q; LUSSO P, 1995, J EXP MED, V181, P1303, DOI 10.1084/jem.181.4.1303; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MANSUR CP, 1995, ONCOGENE, V10, P457; MARTIN MED, 1991, J VIROL, V65, P5381, DOI 10.1128/JVI.65.10.5381-5390.1991; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; NIEDERMAN JC, 1988, LANCET, V2, P817; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PELLETT PE, 1996, FIELDS VIROLOGY, P2587; QAVI HB, 1995, INVEST OPHTH VIS SCI, V36, P2040; RAZZAQUE A, 1993, VIROLOGY, V195, P113, DOI 10.1006/viro.1993.1351; RAZZAQUE A, 1990, ONCOGENE, V5, P1365; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SAITO Y, 1995, J NEUROVIROL, V1, P30, DOI 10.3109/13550289509111008; SIECZKOWSKI L, 1995, VIROLOGY, V211, P544, DOI 10.1006/viro.1995.1436; SOUSSI T, 1990, ONCOGENE, V5, P945; STEEPER TA, 1990, AM J CLIN PATHOL, V93, P776, DOI 10.1093/ajcp/93.6.776; TAKAHASHI K, 1988, LANCET, V1, P1463; TAKAHASHI K, 1989, J VIROL, V63, P3161, DOI 10.1128/JVI.63.7.3161-3163.1989; Target Lusso P, 1992, HUMAN HERPESVIRUS, P25; THOMPSON J, 1994, ONCOGENE, V9, P1167; TLSTY TD, 1994, COLD SPRING HARB SYM, V59, P265, DOI 10.1101/SQB.1994.059.01.031; TORELLI G, 1995, J MED VIROL, V46, P178, DOI 10.1002/jmv.1890460303; TORELLI G, 1991, BLOOD, V77, P2251, DOI 10.1182/blood.V77.10.2251.2251; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; YAMANISHI K, 1988, LANCET, V1, P1065	68	70	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					359	367		10.1038/sj.onc.1200840	http://dx.doi.org/10.1038/sj.onc.1200840			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018122				2022-12-25	WOS:A1997WD51600012
J	Kandror, O; Sherman, M; Moerschell, R; Goldberg, AL				Kandror, O; Sherman, M; Moerschell, R; Goldberg, AL			Trigger factor associates with GroEl in vivo and promotes its binding to certain polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HEAT-SHOCK; CHAPERONE PROTEINS; UNFOLDED PROTEINS; PHOSPHORYLATION; DEGRADATION; MEMBRANE; ALTERS; FORM; CELL	Trigger factor (TF) is a putative molecular chaperone recently found to function together with GroEL in the degradation of the fusion protein, CRAG. TF overproduction enhanced the ability of GroEL to form complexes with CRAG, as well as fetuin or histone. To define further this effect on GroEL binding, affinity columns containing a variety of denatured proteins were used. When cell extracts were applied onto a fetuin column, both TF and GroEL bound but not GroES. Upon ATP addition, TF and GroEL were eluted together and remained tightly associated (even in presence of GroES) in complexes containing one TF per GroEL 14-mer. Overproduction of TF enhanced the capacity of GroEL to bind to many denatured proteins. Moreover, GroEL TF complexes isolated from such cells showed much greater binding capacity than GroEL from TF-deficient cells. Furthermore, the addition of pure TF to pure GroEL also enhanced markedly its binding capacity. The affinity of GroEL for CRAG also rises during heat shock due to GroEL phosphorylation. TF expression, however, did not promote GroEL phosphorylation. Moreover, heat shock and TF overproduction affected GroEL binding to other denatured polypeptides in distinct ways; only TF promoted binding to certain polypeptides, whereas only phosphorylation increased binding to others. Thus, association with TF and phosphorylation are independent regulators of GroEL function. This enhanced affinity of TF-GroEL complexes for unfolded proteins may also be important in protein folding, because TF has prolyl isomerase activity and associates with nascent polypeptides.			Kandror, O (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.							BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CALLEBAUT I, 1995, FEBS LETT, V374, P211, DOI 10.1016/0014-5793(95)01109-R; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; SHERMAN M, 1994, J BIOL CHEM, V269, P31479; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; [No title captured]	18	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1730	1734		10.1074/jbc.272.3.1730	http://dx.doi.org/10.1074/jbc.272.3.1730			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999853	hybrid			2022-12-25	WOS:A1997WD05800051
J	Kelkar, HS; Skloss, TW; Haw, JF; Keller, NP; Adams, TH				Kelkar, HS; Skloss, TW; Haw, JF; Keller, NP; Adams, TH			Aspergillus nidulans stcL encodes a putative cytochrome P-450 monooxygenase required for bisfuran desaturation during aflatoxin/sterigmatocystin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFLATOXIN BIOSYNTHESIS; POLYKETIDE SYNTHASE; VERSICOLORIN-A; GENE; STERIGMATOCYSTIN; PARASITICUS; CLONING; CONVERSION; FLAVUS	The Aspergillus nidulans stcL gene is predicted to encode a cytochrome P-450 monooxygenase and is located within a cluster of other genes that are required for synthesis of sterigmatocystin. Inactivation of stcL resulted in strains that accumulate dihydrosterigmatocystin, a tetrahydrobisfuran containing molecule that is very similar to the unsaturated product of the wild-type pathway, sterigmatocystin. This observation led us to hypothesize that the A. nidulans sterigmatocystin biosynthetic pathway is branched similarly to the aflatoxin pathway in Aspergillus parasiticus and Aspergillus flavus and that StcL is required for the desaturation of the bisfuran moiety in the sterigmatocystin/aflatoxin precursor versicolorin B. This prediction was confirmed by feeding the stcL mutant with the subsequent pathway intermediate, versicolorin A, which resulted in accumulation of both sterigmatocystin and dihydrosterigmatocystin, indicating that StcL functions before versicolorin A synthesis. A. nidulans stcU was shown previously to encode a ketoreductase required to convert versicolorin A to demethylsterigmatocystin and an stcL, stcU double mutant strain was shown here to accumulate only versicolorin E. These results indicate that both versicolorin A and versicolorin B can serve as substrates for StcU, resulting in a branched pathway. The final product of each branch are sterigmatocystin and dihydrosterigmatocystin, respectively.	TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT PLANT PATHOL,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station								ASHLEY DL, 1987, J AGR FOOD CHEM, V35, P782, DOI 10.1021/jf00077a034; BENNETT JW, 1983, ADV APPL MICROBIOL, V29, P53, DOI 10.1016/S0065-2164(08)70354-X; BERSE B, 1983, GENE, V25, P109, DOI 10.1016/0378-1119(83)90173-7; Bhatnagar D., 1992, Handbook of applied mycology. Volume 5: Mycotoxins in ecological systems., P255; BHATNAGAR D, 1991, BIOCHEMISTRY-US, V30, P4343, DOI 10.1021/bi00231a033; BHATNAGAR D, 1993, FASEB J, V7, pA1234; Brown DW, 1996, P NATL ACAD SCI USA, V93, P14873, DOI 10.1073/pnas.93.25.14873; Brown DW, 1996, P NATL ACAD SCI USA, V93, P1418, DOI 10.1073/pnas.93.4.1418; Busby W. F., 1985, CHEM CARCINOGENS, P945; Cary JW, 1996, APPL ENVIRON MICROB, V62, P360, DOI 10.1128/AEM.62.2.360-366.1996; CHANG PK, 1995, MOL GEN GENET, V248, P270, DOI 10.1007/BF02191593; CHANG PK, 1993, APPL ENVIRON MICROB, V59, P3273, DOI 10.1128/AEM.59.10.3273-3279.1993; CHANG PK, 1992, CURR GENET, V21, P231, DOI 10.1007/BF00336846; COLE RJ, 1981, HDB FUNGAL METABOLIT, P73; CULLEN D, 1987, GENE, V57, P21, DOI 10.1016/0378-1119(87)90172-7; DEMONTELLANO PRO, 1989, TRENDS PHARMACOL SCI, V10, P354, DOI 10.1016/0165-6147(89)90007-2; HATSUDA Y, 1972, AGR BIOL CHEM TOKYO, V36, P521, DOI 10.1080/00021369.1972.10860285; Kafer E, 1977, Adv Genet, V19, P33, DOI 10.1016/S0065-2660(08)60245-X; Kelkar HS, 1996, APPL ENVIRON MICROB, V62, P4296, DOI 10.1128/AEM.62.11.4296-4298.1996; KELLER NP, 1994, APPL ENVIRON MICROB, V60, P1444, DOI 10.1128/AEM.60.5.1444-1450.1994; KELLER NP, 1995, APPL ENVIRON MICROB, V61, P3628, DOI 10.1128/AEM.61.10.3628-3632.1995; Mahanti N, 1996, APPL ENVIRON MICROB, V62, P191, DOI 10.1128/AEM.62.1.191-195.1996; MCGUIRE SM, 1989, J AM CHEM SOC, V111, P8308, DOI 10.1021/ja00203a058; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; PAPA KE, 1977, MYCOLOGIA, V69, P556, DOI 10.2307/3758559; PAYNE GA, 1993, APPL ENVIRON MICROB, V59, P156, DOI 10.1128/AEM.59.1.156-162.1993; ROEBUCK BD, 1994, TOXICOLOGY AFLATOXIN, P27; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; SKORY CD, 1992, APPL ENVIRON MICROB, V58, P3527, DOI 10.1128/AEM.58.11.3527-3537.1992; STACK M, 1971, J ASSOC OFF ANA CHEM, V54, P86; STEYN P S, 1992, Journal of Environmental Pathology Toxicology and Oncology, V11, P47; TRAIL F, 1995, APPL ENVIRON MICROB, V61, P2665, DOI 10.1128/AEM.61.7.2665-2673.1995; YABE K, 1988, APPL ENVIRON MICROB, V54, P2101, DOI 10.1128/AEM.54.8.2101-2106.1988; YABE K, 1991, AGR BIOL CHEM TOKYO, V55, P1907, DOI 10.1080/00021369.1991.10870849; Yu JH, 1996, CURR GENET, V29, P549, DOI 10.1007/s002940050084; YU JH, 1995, J BACTERIOL, V177, P4792, DOI 10.1128/jb.177.16.4792-4800.1995; YU JJ, 1995, APPL ENVIRON MICROB, V61, P2365, DOI 10.1128/AEM.61.6.2365-2371.1995; YU JJ, 1996, IN PRESS APPL ENV MI	38	45	52	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1589	1594		10.1074/jbc.272.3.1589	http://dx.doi.org/10.1074/jbc.272.3.1589			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999832	hybrid			2022-12-25	WOS:A1997WD05800030
J	Liu, LB; Freedman, J; Hornstein, A; Fenton, JW; Song, YQ; Ofosu, FA				Liu, LB; Freedman, J; Hornstein, A; Fenton, JW; Song, YQ; Ofosu, FA			Binding of thrombin to the G-protein-linked receptor, and not to glycoprotein Ib, precedes thrombin-mediated platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER SYNDROME; ALPHA-THROMBIN; VONWILLEBRAND-FACTOR; PROTEOLYTIC MECHANISM; MONOCLONAL-ANTIBODY; IX COMPLEX; CLONING; DOMAINS; INTERNALIZATION; LOCALIZATION	The roles of the G protein-linked thrombin receptor and platelet glycoprotein Ib (GPIb) as alpha-thrombin-binding sites on platelets remain controversial. alpha-Thrombin has been proposed to bind to both GPIb and the hirudin-like like domain of the G-protein-linked receptor (from which it cleaves the NH2-terminal extracellular domain to release a 41-mer peptide (TR-(1-41), where TR is alpha-thrombin receptor)) to initiate platelet activation. Using affinity-purified rabbit anti-human TR-(1-41) IgG and immunoblotting, we demonstrated TR-(1-41) release from platelets suspended in Tyrode's buffer containing 2 mM CaCl2 and incubated with greater than or equal to 0.5 nM alpha-thrombin for 10-60 s at 37 degrees C. As quantified by enzyme-linked immunosorbent assay, 0.32-0.59 nM TR-(1-41) was released from washed platelets (5 x 10(11) platelets/liter) after their incubation with 10 nM alpha-thrombin for 10 s. Parallel binding of alpha-thrombin to and activation of the platelets were confirmed by flow cytometry. A monoclonal antibody against the hirudin-like domain of the G-protein linked receptor abrogated alpha-thrombin binding to platelets, cleavage of TR-(1-41), and platelet activation by less than or equal to 1.0 nM (but not 10 nM) alpha-thrombin. Proteolysis of platelet GPIb with Serratia marcescens protease or O-sialoglycoprotein endopeptidase had no effect on cu-thrombin binding to platelets or their subsequent activation. In contrast, chymotrypsin, which cleaves both GPIb and the G-protein linked receptor, abrogated alpha-thrombin binding to platelets, TR-(1-41) release, and platelet activation. Furthermore, monoclonal antibodies directed against the reported alpha-thrombin-binding site on GPIb inhibited neither alpha-thrombin binding to nor activation of the platelets. Thus, alpha-thrombin binds to and cleaves the G-protein-linked receptor when it activates platelets, and GPIb does not appear to serve as an important binding site when alpha-thrombin activates platelets.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA; CANADIAN RED CROSS BLOOD TRANSFUS SERV,HAMILTON,ON L8N 1H8,CANADA; UNIV TORONTO,ST MICHAELS HOSP,DEPT MED,TORONTO,ON M5B 1W8,CANADA; NEW YORK STATE DEPT HLTH,ALBANY,NY 12201	McMaster University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; State University of New York (SUNY) System								BOUTON MC, 1995, BIOCHEM J, V305, P635, DOI 10.1042/bj3050635; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1995, THROMB HAEMOSTASIS, V74, P499; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BRASS LF, 1992, J BIOL CHEM, V267, P13795; COLLER BS, 1983, BLOOD, V61, P99; COOPER HA, 1982, P NATL ACAD SCI-BIOL, V79, P1433, DOI 10.1073/pnas.79.5.1433; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; COUGHLIN SR, 1992, SEMIN THROMB HEMOST, V18, P161, DOI 10.1055/s-2007-1002422; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GASSMANN M, 1990, FASEB J, V4, P2529; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; GRALNICK HR, 1992, BLOOD, V80, pA265; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P915, DOI 10.1021/bi951504q; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P906, DOI 10.1021/bi951503y; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HARMON JT, 1988, BIOCHEMISTRY-US, V27, P2151, DOI 10.1021/bi00406a050; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; JANDROTPERRUS M, 1988, EUR J BIOCHEM, V174, P359, DOI 10.1111/j.1432-1033.1988.tb14106.x; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; LIU LB, 1994, BRIT J HAEMATOL, V88, P592, DOI 10.1111/j.1365-2141.1994.tb05078.x; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MAZUROV AV, 1991, THROMB RES, V62, P673, DOI 10.1016/0049-3848(91)90371-3; MCGOWAN EB, 1986, J BIOL CHEM, V261, P739; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NORTON KJ, 1993, BLOOD, V82, P2125; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; TAM SW, 1980, J BIOL CHEM, V255, P6626; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; YAMAMOTO N, 1991, BLOOD, V77, P1740	44	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1997	2004		10.1074/jbc.272.3.1997	http://dx.doi.org/10.1074/jbc.272.3.1997			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999892	hybrid			2022-12-25	WOS:A1997WD05800090
J	Mossi, R; Jonsson, ZO; Allen, BL; Hardin, SH; Hubscher, U				Mossi, R; Jonsson, ZO; Allen, BL; Hardin, SH; Hubscher, U			Replication factor C interacts with the C-terminal side of proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; POLYMERASE-DELTA; ESCHERICHIA-COLI; SLIDING CLAMPS; SACCHAROMYCES-CEREVISIAE; TRIMERIC STRUCTURE; LARGE SUBUNIT; CALF THYMUS; RF-C; INVITRO	Replication factor C (RF-C) is a heteropentameric protein essential for DNA replication and repair. It is a molecular matchmaker required for loading of proliferating cell nuclear antigen (PCNA) onto double-stranded DNA and, thus, for PCNA-dependent DNA elongation by DNA polymerases delta and epsilon. To elucidate the mode of RF-C binding to the PCNA clamp, modified forms of human PCNA were used that could be P-32-labeled in vitro either at the C or the N terminus. Using a kinase protection assay, we show that the heteropentameric calf thymus RF-C was able to protect the C-terminal region but not the N-terminal region of human PCNA from phosphorylation, suggesting that RF C interacts with the PCNA face at which the C termini are located (C-side). A similar protection profile was obtained with the recently identified PCNA binding region (residues 478-712), but not with the DNA binding region (residues 366-477), of the human RF-C large subunit (Fotedar, R., Mossi, R., Fitzgerald, P., Rousselle, T., Maga, G., Brickner, H., Messner, H., Khastilba, S., Hubscher, U., and Fotedar, A., (1996) EMBO J., 15, 4423-4433). Furthermore, we show that the RF-C 36 kDa subunit of human RF-C could interact independently with the C side of PCNA. The RF-C large subunit from a third species, namely Drosophila melanogaster, interacted similarly with the modified human PCNA, indicating that the interaction between RF C and PCNA is conserved through eukaryotic evolution.	UNIV HOUSTON,INST MOL BIOL,DEPT BIOCHEM & BIOPHYS SCI,DEPT BIOL,HOUSTON,TX 77204; TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77843	University of Houston System; University of Houston; Texas A&M University System; Texas A&M University College Station	Mossi, R (corresponding author), UNIV ZURICH,INST VET BIOCHEM,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.		Jónsson, Zophonías/E-1960-2015; Jónsson, Zophonías Oddur/AAO-1354-2020	Jónsson, Zophonías Oddur/0000-0001-5798-9647	NIGMS NIH HHS [GM123451-02] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAND SR, 1994, J IMMUNOL, V153, P3070; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; HUBSCHER U, 1996, DNA REPLICATION EUKA, P525; JONSSON ZO, 1995, EMBO J, V14, P5745, DOI 10.1002/j.1460-2075.1995.tb00261.x; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LU Y, 1993, BIOCHEM BIOPH RES CO, V193, P779, DOI 10.1006/bbrc.1993.1693; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; NG L, 1990, J BIOL CHEM, V265, P11948; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1992, CHROMOSOMA, V102, P133; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SPICER EK, 1984, J BIOL CHEM, V259, P17790; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; THORBJARNARDOTTIR SH, 1995, GENE, V161, P1, DOI 10.1016/0378-1119(95)00286-F; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WEISER T, 1991, J BIOL CHEM, V266, P10420; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YIN KC, 1986, NUCLEIC ACIDS RES, V14, P6541, DOI 10.1093/nar/14.16.6541	40	68	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1769	1776		10.1074/jbc.272.3.1769	http://dx.doi.org/10.1074/jbc.272.3.1769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999859	hybrid			2022-12-25	WOS:A1997WD05800057
J	Rajarathnam, K; Kay, CM; Dewald, B; Wolf, M; Baggiolini, M; ClarkLewis, I; Sykes, BD				Rajarathnam, K; Kay, CM; Dewald, B; Wolf, M; Baggiolini, M; ClarkLewis, I; Sykes, BD			Neutrophil-activating peptide-2 and melanoma growth-stimulatory activity are functional as monomers for neutrophil activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; INTERLEUKIN-8 RECEPTORS; 3-DIMENSIONAL STRUCTURE; H-1-NMR SPECTROSCOPY; AMINO TERMINUS; HIGH-AFFINITY; CHEMOKINES; BINDING; RESOLUTION; IL-8	Neutrophil-activating peptide-2 (NAP-2) and melanoma growth stimulatory activity (MGSA) are members of the chemokine family of inflammatory proteins. The structures of NAP-2, determined by x-ray crystallography, and MGSA, elucidated by NMR spectroscopy, revealed a tetramer and dimer, respectively. In order to address the relevance of multimeric species to their activities on neutrophils, analogs of NAP-2 and MGSA were synthesized in which the backbone amide proton of Leu-22 in NAP-2, and Val-26 in MGSA, was substituted with the bulky methyl group (NH --> NCH3). These analogs were shown to be monomeric by sedimentation equilibrium ultracentrifugation studies and were similar to the corresponding native protein in assays for neutrophil elastase release and Ca2+ mobilization from IL-8R1 and IL-8R2 transformed cells. Sedimentation equilibrium studies of the native NAP-2 and MGSA were also carried out to address the association behavior. For NAP-2, there was no evidence for the tetramer, but an equilibrium between monomers and dimers and the dissociation constant was calculated to be 50-100 mu M. Similarly, MGSA showed a monomer-dimer equilibrium with a K-d of similar to-5 mu M. The data from the monomeric analogs and also the calculation of dissociation constants indicate that NAP-2 and MGSA have a tendency to associate above the concentrations required for maximal activity or for receptor activation, but at functional concentrations they are predominantly monomers.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA; UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN,SWITZERLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER,BC V6T 1Z3,CANADA	University of Alberta; University of Bern; University of British Columbia; University of British Columbia	Rajarathnam, K (corresponding author), UNIV ALBERTA,PENCE,713 HERITAGE BLVD,EDMONTON,AB T6G 2S2,CANADA.		Sawant, Kirti V/H-3778-2013	Wolf, Marlene/0000-0002-7283-4683				BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CREIGHTON TE, 1992, PROTEINS STRUCTURE M, P141; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; FURIE MB, 1995, AM J PATHOL, V146, P1287; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GROSS V, 1992, EUR J CLIN INVEST, V22, P200, DOI 10.1111/j.1365-2362.1992.tb01826.x; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; IDA N, 1992, J IMMUNOL METHODS, V156, P27, DOI 10.1016/0022-1759(92)90007-G; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KIM KS, 1994, J BIOL CHEM, V269, P32909; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; PATEL SR, 1993, BIOCHEMISTRY-US, V32, P5466, DOI 10.1021/bi00071a024; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RAJARATHNAM K, 1995, BIOCHEMISTRY-US, V34, P12983, DOI 10.1021/bi00040a008; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; ROT A, 1992, CYTOKINE, V4, P346; SCHNITZEL W, 1994, J LEUKOCYTE BIOL, V55, P763, DOI 10.1002/jlb.55.6.763; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; YAN ZQ, 1994, BLOOD, V84, P2329; YANG YQ, 1994, J BIOL CHEM, V269, P20110; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025	43	42	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1725	1729		10.1074/jbc.272.3.1725	http://dx.doi.org/10.1074/jbc.272.3.1725			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999852	hybrid			2022-12-25	WOS:A1997WD05800050
J	Selby, CP; Sancar, A				Selby, CP; Sancar, A			Human transcription-repair coupling factor CSB/ERCC6 is a DNA-stimulated ATPase but is not a helicase and does not disrupt the ternary transcription complex of stalled RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; COCKAYNE-SYNDROME; EXCISION-REPAIR; FACTOR TFIIE; DHFR GENE; PROTEIN; SEQUENCE; SUBUNIT; STRAND; EFFICIENT	Transcription is coupled to repair in Escherichia coli and in humans. Proteins encoded by the mfd gene in E. coli and by the ERCC6/CSB gene in humans, both of which possess the so-called helicase motifs, are required for the coupling reaction. It has been shown that the Mfd protein is an ATPase but not a helicase and accomplishes coupling, in part, by disrupting the ternary complex of E. coli RNA polymerase stalled at the site of DNA damage. In this study we overproduced the human CSB protein using the baculovirus vector and purified and characterized the recombinant protein. CSB has an ATPase activity that is stimulated strongly by DNA; however, it neither acts as a helicase nor does it dissociate stalled RNA polymerase II, suggesting a coupling mechanism in humans different from that in prokaryotes. CSB is a DNA-binding protein, and it also binds to XPA, TFIIH, and the p34 subunit of TFIIE. These interactions are likely to play a role in recruiting repair proteins to ternary complexes formed at damage sites.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYORA S, 1996, J MOL BIOL, V256, P301; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; JOHNSON RE, 1994, J BIOL CHEM, V269, P28259; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PETERSON MG, 1991, NATURE, V354, P369; Satoh MS, 1996, NUCLEIC ACIDS RES, V24, P3576, DOI 10.1093/nar/24.18.3576; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VANGOOL AJ, 1996, THESIS ERASMUS U; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	37	210	212	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1885	1890		10.1074/jbc.272.3.1885	http://dx.doi.org/10.1074/jbc.272.3.1885			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999876	Green Published, hybrid			2022-12-25	WOS:A1997WD05800074
J	Tjernberg, LO; Naslund, J; Thyberg, J; Gandy, SE; Terenius, L; Nordstedt, C				Tjernberg, LO; Naslund, J; Thyberg, J; Gandy, SE; Terenius, L; Nordstedt, C			Generation of Alzheimer amyloid beta peptide through nonspecific proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; DISEASE; CELLS; FIBRILS; IDENTIFICATION; ACCUMULATION; BIOGENESIS; RESISTANCE; LYSOSOMES; FRAGMENTS	Polymerization of Alzheimer amyloid beta peptide (A beta) into amyloid fibrils is associated with resistance to proteolysis and tissue deposition. Here, it was investigated whether A beta might be generated as a protease resistant core from a polymerized precursor. A 100-amino acid C-terminal fragment of the Alzheimer beta-amyloid precursor protein (C100), containing the A beta and cytoplasmic domains, polymerized both when inserted into membranes and after purification. When subjected to digestion using the nonspecific enzyme proteinase K, the cytoplasmic domain of C100 was degraded, whereas the A beta domain remained intact. In contrast, dissociated C100 polymers were almost completely degraded by proteinase K. Mammalian cells transfected with the human Alzheimer beta-amyloid precursor gene contained a fragment corresponding to C100, which needed similar harsh conditions to be dissolved, as did polymers formed by purified C100. Hence, it was concluded that C100 polymers are formed in mammalian cells. These results suggest that the C terminus of A beta can be generated by nonspecific proteases, acting on a polymerized substrate, rather than a specific gamma-secretase. This offers an explanation of how the A beta peptide can be formed in organelles containing proteases capable of cleaving most peptide bonds.	KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOL BIOL,S-17177 STOCKHOLM,SWEDEN; CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021	Karolinska Institutet; Cornell University	Tjernberg, LO (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT CLIN NEUROSCI,SECT EXPTL ALCOHOL & DRUG ADDICT RES,S-17177 STOCKHOLM,SWEDEN.				NATIONAL INSTITUTE ON AGING [R01AG011508, R55AG011508] Funding Source: NIH RePORTER; NIA NIH HHS [AG11508] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; NASLUND J, 1994, BIOCHEM BIOPH RES CO, V204, P780, DOI 10.1006/bbrc.1994.2527; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786	32	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1870	1875		10.1074/jbc.272.3.1870	http://dx.doi.org/10.1074/jbc.272.3.1870			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999874	hybrid			2022-12-25	WOS:A1997WD05800072
J	Gallagher, WM; Cairney, M; Schott, B; Roninson, IB; Brown, R				Gallagher, WM; Cairney, M; Schott, B; Roninson, IB; Brown, R			Identification of p53 genetic suppressor elements which confer resistance to cisplatin	ONCOGENE			English	Article						cisplatin; resistance; p53; cell cycle arrest; apoptosis	DNA-BINDING FUNCTION; CELL-LINES; ANTISENSE RNA; EXPRESSION SELECTION; STRUCTURAL ASPECTS; DRUG-RESISTANCE; OVARIAN-CANCER; PROTEIN; DEPENDENCE; SEQUENCES	Loss of p53 function is associated with the acquisition of cisplatin resistance in the human ovarian adenocarcinoma A2780 cell line, Selection for cisplatin resistance of A2780 cells was used to isolate genetic suppressor elements (GSEs) from a retroviral library expressing random fragments of human or murine TP53 cDNA. Six GSEs were identified, encoding either dominant negative mutant peptides or antisense RNA molecules which corresponded to various regions within the TP53 gene, Both types of GSE induced cisplatin resistance when introduced individually into A2780 cells, Expression of antisense GSEs led to decreased intracellular levels of p53 protein, One sense GSE induced loss of p53-mediated activities such as DNA damage induced cell cycle arrest and apoptosis, A synthetic peptide, representing the predicted amino acid sequence of this GSE, conferred resistance to cisplatin when introduced into A2780 cells and inhibited the sequence specific DNA binding activity of p53 protein in vitro. Overall, these results directly indicate that inactivation of p53 function confers cisplatin resistance in these human ovarian tumour cells. We have identified short structural domains of p53 which are capable of independent functional interactions and highlighted the efficacy of this approach to discriminate biologically active GSEs from a random fragment library.	CRC, BEATSON LABS, DEPT MED ONCOL, GLASGOW G61 1BD, LANARK, SCOTLAND; UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60612 USA	Beatson Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327; Gallagher, William/0000-0002-4307-5999	NATIONAL CANCER INSTITUTE [R01CA056736, R01CA062099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA56736, R01 CA62099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON ME, 1995, BIOESSAYS, V17, P3, DOI 10.1002/bies.950170103; Anthoney DA, 1996, CANCER RES, V56, P1374; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BAYEVER E, 1994, LEUKEMIA LYMPHOMA, V12, P223, DOI 10.3109/10428199409059593; BI SC, 1994, CANCER RES, V54, P582; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bishop MR, 1996, J CLIN ONCOL, V14, P1320, DOI 10.1200/JCO.1996.14.4.1320; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BROWN R, 1993, ANN ONCOL, V4, P623, DOI 10.1093/oxfordjournals.annonc.a058614; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Coffin J. M., 1990, VIROLOGY, P1437; DENHARDT DT, 1992, ANN NY ACAD SCI, V660, P70, DOI 10.1111/j.1749-6632.1992.tb21059.x; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FAN SJ, 1995, CANCER RES, V55, P1649; GORCZYCA W, 1993, CANCER RES, V53, P3186; GUDKOV AV, 1993, P NATL ACAD SCI USA, V90, P3231, DOI 10.1073/pnas.90.8.3231; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HAMAGUCHI K, 1993, CANCER RES, V53, P5225; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOLZMAYER TA, 1992, NUCLEIC ACIDS RES, V20, P711, DOI 10.1093/nar/20.4.711; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MCLAUGHLIN K, 1991, CANCER RES, V51, P2242; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; OSSOVSKAYA V, IN PRESS P NATL ACAD; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PLUMB JA, 1989, CANCER RES, V49, P4435; RONINSON IB, 1995, CANCER RES, V55, P4023; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; Shimamura A, 1996, CLIN CANCER RES, V2, P435; SORENSON CM, 1988, CANCER RES, V48, P4484; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; VASEY PA, 1996, IN PRESS MOL PHARM; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	49	78	82	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	1997	14	2					185	193						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010220				2022-12-25	WOS:A1997WC81800006
J	Guillot, C; Falette, N; Paperin, MP; Courtois, S; GentilPerret, A; Treilleux, I; Ozturk, M; Puisieux, A				Guillot, C; Falette, N; Paperin, MP; Courtois, S; GentilPerret, A; Treilleux, I; Ozturk, M; Puisieux, A			P21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours	ONCOGENE			English	Article						breast cancer; p53; functional inactivation; p21(WAF1/CIP1)	P53-MEDIATED G(1) ARREST; P53 MUTATIONS; P53-INDEPENDENT PATHWAY; MONOCLONAL-ANTIBODIES; SUPPRESSOR GENE; HUMAN CANCER; CELL-LINES; PROTEIN; TUMORS; P21	Functional inactivation of the wild-type p53 protein has been described in different human cancers. Since a significant proportion of breast tumours express wildtype TP53, the p53 antiproliferative activity could be inactivated in transformed mammary epithelial cells by a mechanism independent on structural alteration of the gene, To test this hypothesis, we analysed the p53 activity in primary breast tumour cells. As a preliminary study, we demonstrated in breast adenocarcinoma cell lines that the nuclear accumulation of the inhibitor of cyclin dependent kinase p21(WAF1/CIP1), in response to adriamycin treatment, specifically reflected the activity of a functional wild-type p53 protein. Then, we used this strategy to study the p53 activity in 23 primary breast tumours. p21(WAF1/CIP1) accumulation was detected in all tumours expressing wild-type TP53. In contrast, no p21(WAF1/CIP1) response was detected in cells harboring a mutant TP53 gene. This report is the first functional study of p53 in primary breast tumours. The results demonstrate that TP53 mutation represents the only common mechanism leading to an irreversible inactivation of p53 functions in this cancer type.	INSERM U453,F-69008 LYON,FRANCE; CTR LEON BERARD,DEPT ANAT & CYTOL PATHOL,F-69008 LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard			OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; PUISIEUX, Alain/0000-0002-9938-3798				BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DIELLA F, 1993, LIFE SCI ADV BIOCH, V12, P47; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOMAGALA W, 1993, AM J PATHOL, V142, P669; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; GUILLOT C, IN PRESS CLIN CANC R; Hecker D, 1996, ONCOGENE, V12, P953; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACQUEMIER J, 1994, BRIT J CANCER, V69, P846, DOI 10.1038/bjc.1994.164; JAIYESIMI IA, 1992, J CLIN ONCOL, V10, P1014, DOI 10.1200/JCO.1992.10.6.1014; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CANCER RES, V53, P2231; LEGROS Y, 1993, B CANCER, V80, P102; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MAZARS R, 1992, CANCER RES, V52, P3918; MICHIELI P, 1994, CANCER RES, V54, P3391; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ozcelik H, 1995, CLIN CANCER RES, V1, P907; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; SOULE HD, 1990, CANCER RES, V50, P6075; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	47	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					45	52		10.1038/sj.onc.1200803	http://dx.doi.org/10.1038/sj.onc.1200803			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010231				2022-12-25	WOS:A1997WB76000004
J	Qin, XQ; Barsoum, J				Qin, XQ; Barsoum, J			Differential cell cycle effects induced by E2F1 mutants	ONCOGENE			English	Article						restriction point; cell cycle withdrawal; E2F1; mutants; cell survival	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F-1; SUSCEPTIBILITY GENE; GROWTH SUPPRESSION; S-PHASE; DOWNSTREAM TARGET; FIBROBLASTS LEADS; BINDING PROTEIN; DNA-SYNTHESIS; EXPRESSION	Expression of two types of transactivation-defective E2F1 mutants in human Rb--/- tumor cells led to an increase in the proportion of cells in the G(1) phase of the cell cycle as determined by FAGS analysis. Experiments revealed two different mechanisms of action. One mutant type induced a G(1) arrest after the restriction point, with cells phenotypically at a cell cycle stage later than G(1). The action of this mutant was, at least in part, dependent on specific DNA binding and was over-ridden by coexpression of its wild-type counterpart. The other mutant type, which is defective in DNA binding, slowed the G(1) progression and restored a checkpoint for cell cycle withdrawal. The G(1) phase withdrawal of these tumor cells allowed the initiation of skeletal muscle cell differentiation. Thus, E2F1 appears to have two different functions before and after the cell cycle restriction point. This report also may provide a basis for a gene therapy approach for certain human cancers.			Qin, XQ (corresponding author), BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANERJEE A, 1992, CANCER RES, V5, P6297; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3028; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KOFF A, 1992, SCIENCE, V257, P1989; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1995, TRANSCRIPTIONAL CONT; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU HJ, 1991, CANCER RES, V51, P4481; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	8	8	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					53	62		10.1038/sj.onc.1200809	http://dx.doi.org/10.1038/sj.onc.1200809			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010232				2022-12-25	WOS:A1997WB76000005
J	Verkerk, AJMH; Ariel, I; Dekker, MC; Schneider, T; vanGurp, RJHLM; deGroot, N; Gillis, AJM; Oosterhuis, JW; Hochberg, AA; Looijenga, LHJ				Verkerk, AJMH; Ariel, I; Dekker, MC; Schneider, T; vanGurp, RJHLM; deGroot, N; Gillis, AJM; Oosterhuis, JW; Hochberg, AA; Looijenga, LHJ			Unique expression patterns of H19 in human testicular cancers of different etiology	ONCOGENE			English	Article						testis; germ cell tumors; non-germ cell tumors; H19 expression; genomic imprinting; germ cell development	GERM-CELL TUMORS; SPERMATOCYTIC SEMINOMA; IMPRINTED GENES; WILMS-TUMOR; IMMUNOHISTOCHEMICAL MARKERS; BIALLELIC EXPRESSION; ALLELIC METHYLATION; BLADDER-CARCINOMA; IGF2 EXPRESSION; HUMAN-DISEASES	The expression pattern of the imprinted human H19 gene was investigated in testicular cancers of different etiology, as well as in normal testicular parenchyma, parenchyma without germ cells, and adjacent to testicular germ cell tumors of adolescents and adults (TGCTs), using RNase protection analysis, mRNA in situ hybridization and reverse-transcription polymerase chain reaction. While different total expression levels were detected in spermatocytic seminomas, lymphomas, a Sertoli cell tumor and Leydig cell tumors, none showed a disturbance of monoallelic expression. Strikingly, the majority of invasive TGCTs revealed expression of both parental alleles. The total level of expression highly correlated with differentiation lineage and stage of maturation, similar to that as reported during early normal embryogenesis. Biallelic expression could also be determined specifically in testis parenchyma containing the preinvasive lesion of this cancer. We therefore conclude that within the adult testis, biallelic H19 expression is specific for TGCTs, and that the level of expression is dependent on differentiation lineage and maturation stage. This is in agreement with the proposed primordial germ cell-origin of this cancer, and might be related to retention of embryonic characteristics in TGCTs. In addition, our data argue against H19 being a tumor suppressor gene.	UNIV ROTTERDAM HOSP,LAB EXPT PATHOONCOL,DR DANIEL DEN HOED CANC CTR,ROTTERDAM,NETHERLANDS; HADASSAH UNIV HOSP,DEPT PATHOL,MT SCOPUS,ISRAEL; HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Hebrew University of Jerusalem; Hebrew University of Jerusalem			Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911; Verkerk, Annemieke JMH/0000-0002-7523-3656				ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; ARIEL I, 1995, UROLOGY, V45, P335, DOI 10.1016/0090-4295(95)80030-1; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BARTON SC, 1991, DEVELOPMENT, V113, P679; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BOSMAN FT, 1993, INT J DEV BIOL, V37, P203; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; Burke A, 1993, J UROL PATHOL, V1, P21; COOPER MJ, 1996, IN PRESS J UROL; CUMMINGS OW, 1994, HUM PATHOL, V25, P54, DOI 10.1016/0046-8177(94)90171-6; DEGROOT N, 1993, MOL REPROD DEV, V36, P390, DOI 10.1002/mrd.1080360316; DEKKER I, 1992, CANCER, V69, P993, DOI 10.1002/1097-0142(19920215)69:4<993::AID-CNCR2820690427>3.0.CO;2-8; Donjacour A A, 1991, Cancer Treat Res, V53, P335; DoucRasy S, 1996, ONCOGENE, V12, P423; DUGIMONT T, 1995, MOL CELL, V85, P117; EBLE JN, 1994, HUM PATHOL, V25, P1035, DOI 10.1016/0046-8177(94)90062-0; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FEIL R, 1994, DEVELOPMENT, V120, P2933; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FUNDELE RH, 1994, DEV GENET, V15, P515, DOI 10.1002/dvg.1020150610; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GOODFELLOW PN, 1982, NATURE, V300, P107, DOI 10.1038/300107a0; HALL JG, 1990, AM J HUM GENET, V46, P857; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hibi K, 1996, CANCER RES, V56, P480; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; JORGENSEN N, 1995, LAB INVEST, V72, P223; JORGENSEN N, 1993, HISTOPATHOLOGY, V22, P373; KONDO M, 1995, ONCOGENE, V10, P1193; Latham KE, 1995, DIFFERENTIATION, V59, P269; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LOTHE RA, 1993, GENE CHROMOSOME CANC, V7, P96, DOI 10.1002/gcc.2870070206; LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Meyts E. Rajpert-De, 1994, International Journal of Andrology, V17, P85, DOI 10.1111/j.1365-2605.1994.tb01225.x; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; MOSTOFI FK, 1987, SEMIN DIAGN PATHOL, V4, P320; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MUTTER GL, 1993, AM J HUM GENET, V53, P1096; NAKASHIMA N, 1988, HUM PATHOL, V19, P1144, DOI 10.1016/S0046-8177(88)80145-X; OHLSSON R, 1994, DEVELOPMENT, V120, P361; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; ROMANENKO AM, 1983, VOP ONKOL, V19, P61; ROSENBERG SA, 1982, CANCER, V49, P2112; ROSSANT J, 1993, CURR BIOL, V3, P47, DOI 10.1016/0960-9822(93)90148-H; Sasaki H, 1995, DEVELOPMENT, V121, P4195; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SOLTER D, 1988, ANNU REV GENET, V22, P127; Solter Davor, 1992, Current Opinion in Biotechnology, V3, P632, DOI 10.1016/0958-1669(92)90007-6; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SVENSSON K, 1995, MECH DEVELOP, V51, P31, DOI 10.1016/0925-4773(94)00345-N; SZABO P, 1994, DEVELOPMENT, V120, P1651; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; TALERMAN A, 1984, LAB INVEST, V51, P343; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; WALSH C, 1995, CANCER RES, V55, P1111; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	68	58	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					95	107		10.1038/sj.onc.1200802	http://dx.doi.org/10.1038/sj.onc.1200802			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010236				2022-12-25	WOS:A1997WB76000009
J	Gath, I; Closs, EI; GodtelArmbrust, U; Schmitt, S; Nakane, M; Wessler, I; Forstermann, U				Gath, I; Closs, EI; GodtelArmbrust, U; Schmitt, S; Nakane, M; Wessler, I; Forstermann, U			Inducible NO synthase II and neuronal NO synthase I are constitutively expressed in different structures of guinea pig skeletal muscle: Implications for contractile function	FASEB JOURNAL			English	Article						NO synthase mRNA; anti-NO synthase antibodies; Ca2+-dependent and -independent NO synthase activity; muscle contraction; N-G-nitro-L-arginine; S-nitroso-N-acetyl-D,L-penicillamine	NITRIC-OXIDE SYNTHASE; NITROPRUSSIDE; SARCOLEMMA; INHIBITION; ISOFORMS; RELEASE; FIBERS; CELLS	The expression of NOS isoforms was studied in guinea pig skeletal muscle at the mRNA and protein level, and the effect of NO on contractile response was examined, Ribonuclease protection analyses demonstrated NOS I and NOS II mRNAs in diaphragm and gastrocnemius muscle, In Western blots, NOS I and NOS II immunoreactivities were found in the particulate but not the soluble fraction of skeletal muscle, NOS activity was found almost exclusively in the particulate fraction, About 50% of this activity was Ca2+ independent, In immunohistochemistry, the anti-NOS I antibody stained distinct membrane regions of muscle fibers, The most intense staining was seen in neuromuscular endplates identified by labeling with a-bungarotoxin, The anti-NOS II antibody labeled muscle fibers that contained alkalilabile myosin ATPase (type I fibers), NOS II was located to intracellular structures and was also seen in ''specific pathogen-free'' animals. Pretreatment of guinea pigs with bacterial lipopolysaccharide (LPS) markedly intensified NOS II staining, Significant NOS III immunoreactivity was detected only in vascular endothelium. In functional experiments, tetanic muscle contractions were induced in diaphragm and gastrocnemius muscle by electrical stimulation of the innervating nerves, Pretreatment of guinea pigs with LPS or addition of S-nitroso-N-acetyl-D,L-penicillamine to the organ bath markedly decreased tetanic contractions, N-G-nitro-L-arginine, on the other hand, increased contractile force and reversed the effect of LPS, Our data indicate that NOS II and NOS I are expressed in different structures of skeletal muscle and are involved in the regulation of contractile response.	UNIV MAINZ,DEPT PHARMACOL,D-55101 MAINZ,GERMANY; ABBOTT LABS,DEPT 4NB,ABBOTT PK,IL 60064	Johannes Gutenberg University of Mainz; Abbott Laboratories			Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; Forstermann U, 1996, METHOD ENZYMOL, V268, P334; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FORSTERMANN U, 1995, BIOCHEM PHARMACOL, V50, P1321, DOI 10.1016/0006-2952(95)00181-6; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; GROZDANOVIC Z, 1995, CELL TISSUE RES, V281, P493; ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598; KING CE, 1994, J APPL PHYSIOL, V76, P1166, DOI 10.1152/jappl.1994.76.3.1166; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LINDGREN CA, 1994, NEUROREPORT, V5, P2205, DOI 10.1097/00001756-199410270-00054; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MORRISSEY JJ, 1994, KIDNEY INT, V45, P998, DOI 10.1038/ki.1994.135; MURRANT CL, 1994, CAN J PHYSIOL PHARM, V72, P1089, DOI 10.1139/y94-152; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; PADYKULA HA, 1955, J HISTOCHEM CYTOCHEM, V3, P161, DOI 10.1177/3.3.161; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Sambrook J., 1989, MOL CLONING; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; STEVENS DL, 1994, HARRISONS PRINCIPLES, P561; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WESSLER I, 1986, N-S ARCH PHARMACOL, V334, P365, DOI 10.1007/BF00569371	27	115	117	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1614	1620		10.1096/fasebj.10.14.9002553	http://dx.doi.org/10.1096/fasebj.10.14.9002553			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002553				2022-12-25	WOS:A1996WC86900007
J	Hall, RA; Soderling, TR				Hall, RA; Soderling, TR			Differential surface expression and phosphorylation of the N-methyl-D-aspartate receptor subunits NR1 and NR2 in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMERIC NMDA RECEPTORS; TYROSINE PHOSPHORYLATION; GLUTAMATE RECEPTORS; SYNAPTIC PLASTICITY; RAT-BRAIN; PROTEIN; DOMAIN	The trafficking and phosphorylation of the NR1 and NR2 subunits of the N-methyl-D-aspartate-type glutamate receptor complex were studied in cultured rat hippocampal neurons. Surface expression was examined by modifying surface receptors via treatment of intact neurons with either the protease chymotrypsin or the crosslinking reagent bis(sulfosuccinimidyl)suberate, followed by quantification of anti-NR1 and anti-NR2B Western blot immunostaining. These studies revealed that only 40-50% of total NR1 immunoreactivity is found at the cell surface, as compared to more than 90% of total NR2B immunoreactivity. Metabolic labeling of the cultures with P-32 revealed that NR2 subunits are highly phosphorylated under basal conditions, whereas basal phosphorylation of NR1 subunits is barely detectable. Following stimulation of the cultures with glutamate/ glycine or phorbol esters, NR1 phosphorylation was found to be enhanced by 3-5-fold, whereas phosphorylation of NR2 subunits was enhanced by less than 2-fold. To determine whether the difference in the basal NR1 versus NR2 phosphorylation could be due to tyrosine phosphorylation of NR2, phosphoamino acid analyses of NR2 were performed. These analyses revealed phosphorylation on serine but not on threonine or tyrosine; immunoprecipitation and deglycosylation experiments using anti-phosphotyrosine antibodies confirmed that NR2 subunits in the primary hippocampal cultures are not detectably phosphorylated on tyrosine residues. These results demonstrate that the NR1 and NR2 subunits, which assemble into heteromeric complexes to form functional N-methyl-D-aspartate receptors, are trafficked in neurons with differential efficiency to the plasma membrane and exhibit different levels of basal versus stimulated serine phosphorylation.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	Oregon Health & Science University				Hall, Randy/0000-0002-8318-8728	NINDS NIH HHS [NS07381, NS27037] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027037] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHOI DW, 1994, PROG BRAIN RES, V100, P47; CUDMORE SB, 1991, J NEUROCHEM, V57, P1240, DOI 10.1111/j.1471-4159.1991.tb08285.x; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; HALL RA, 1997, IN PRESS NEUROSCIENC; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; McIlhinney RAJ, 1996, NEUROSCIENCE, V70, P989, DOI 10.1016/0306-4522(95)00419-X; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K	26	129	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4135	4140		10.1074/jbc.272.7.4135	http://dx.doi.org/10.1074/jbc.272.7.4135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020125	hybrid			2022-12-25	WOS:A1997WH01900041
J	MartinezEsparza, M; JimenezCervantes, C; Beermann, F; Aparicio, P; Lozano, JA; GarciaBorron, JC				MartinezEsparza, M; JimenezCervantes, C; Beermann, F; Aparicio, P; Lozano, JA; GarciaBorron, JC			Transforming growth factor-beta 1 inhibits basal melanogenesis in B16/F10 mouse melanoma cells by increasing the rate of degradation of tyrosinase and tyrosinase-related protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN MELANOCYTES; DOPACHROME TAUTOMERASE; STIMULATING HORMONE; FACTOR-BETA; 5,6-DIHYDROXYINDOLE-2-CARBOXYLIC ACID; MAMMALIAN MELANOGENESIS; GENE-EXPRESSION; ULTRAVIOLET-B; PROLIFERATION; SKIN	Current evidence suggests that melanogenesis is controlled by epidermal paracrine modulators. We have analyzed the effects of transforming growth factor-beta 1 (TGF-beta 1) on the basal melanogenic activities of B16/F10 mouse melanoma cells. TGF-beta 1 treatment (48 h) elicited a concentration-dependent decrease in basal tyrosine hydroxylase and 3,4-dihydroxyphenylalanine (Dopa) oxidase activities, to less than 30% of the control values but had no effect on dopachrome tautomerase activity (TRP-2). The inhibition affected to similar extents the Dopa oxidase activity associated to tyrosinase-related protein-1 (TRP-1) and tyrosinase. This inhibition was noticeable between 1 and 3 h after the addition of the cytokine, and maximal after 6 h of treatment. The decrease in the enzymatic activity was paralleled by a decrease in the abundance of the TRP-1 and tyrosinase proteins. TGF-beta 1 mediated this effect by increasing the rate of degradation of tyrosinase and TRP-1. Conversely, after 48 h of treatment, the expression of the tyrosinase gene decreased only slightly, while TRP-1 and TRP-2 gene expression was not affected. An increased rate of proteolytic degradation of TRP-1 and tyrosinase seems the main mechanism accounting for the inhibitory effect of TGF-beta 1 on the melanogenic activity of B16/F10 cells.	UNIV MURCIA, SCH MED, DEPT BIOCHEM & MOL BIOL, E-30100 MURCIA, SPAIN; SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	University of Murcia; Swiss Institute Experimental Cancer Research			Martínez-Esparza, María/R-9646-2019; Jimenez-Cervantes, Celia/H-1953-2015; Garcia-Borron, Jose Carlos/H-2247-2015	Martínez-Esparza, María/0000-0001-5765-8231; Jimenez-Cervantes, Celia/0000-0002-5821-9510; Garcia-Borron, Jose Carlos/0000-0002-9192-588X; Aparicio, Pedro/0000-0001-9162-1563				ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; AROCA P, 1992, EUR J BIOCHEM, V208, P155, DOI 10.1111/j.1432-1033.1992.tb17169.x; Battey, 1986, BASIC METHODS MOL BI; CHAKRABORTY A, 1995, J INVEST DERMATOL, V105, P655, DOI 10.1111/1523-1747.ep12324134; Chakraborty AK, 1996, EUR J BIOCHEM, V236, P180, DOI 10.1111/j.1432-1033.1996.t01-1-00180.x; DEVOS S, 1994, J INVEST DERMATOL, V103, P92, DOI 10.1111/1523-1747.ep12391818; DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213; Dixon M., 1979, ENZYMES, P47; FAROOQUI JZ, 1993, ANN NY ACAD SCI, V680, P508, DOI 10.1111/j.1749-6632.1993.tb19723.x; Frank R, 1996, J INVEST DERMATOL, V106, P36, DOI 10.1111/1523-1747.ep12327182; GAILIT J, 1994, J INVEST DERMATOL, V103, P221, DOI 10.1111/1523-1747.ep12393176; HARLOW E, 1988, ANTIBODIES LAB MANUA, P509; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1982, J INVEST DERMATOL, V79, P16, DOI 10.1111/1523-1747.ep12510422; HEARING VJ, 1993, PIGMENTATION PIGMENT, P3; JACKSON IJ, 1990, GENETICS, V126, P451; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JARA JR, 1988, PIGM CELL RES, V1, P332, DOI 10.1111/j.1600-0749.1988.tb00128.x; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; JIMENEZCERVANTES C, 1993, EUR J BIOCHEM, V217, P549, DOI 10.1111/j.1432-1033.1993.tb18276.x; JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993; JIMENEZCERVANTES C, 1993, PIGM CELL RES, V6, P394, DOI 10.1111/j.1600-0749.1993.tb00621.x; KIKUCHI K, 1995, J INVEST DERMATOL, V105, P128, DOI 10.1111/1523-1747.ep12313452; KILGUS O, 1993, J INVEST DERMATOL, V100, P674, DOI 10.1111/1523-1747.ep12472339; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee ZH, 1996, J INVEST DERMATOL, V106, P605, DOI 10.1111/1523-1747.ep12345163; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LUGER TA, 1989, ACTA DERM-VENER S151, V29, P61; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; PAWELEK JM, 1990, BIOCHEM BIOPH RES CO, V166, P1328, DOI 10.1016/0006-291X(90)91011-G; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POMERANTZ SH, 1964, BIOCHEM BIOPH RES CO, V16, P188, DOI 10.1016/0006-291X(64)90359-6; Prota G., 1992, MELANINS MELANOGENES, P1; QUAGLINO D, 1991, J INVEST DERMATOL, V97, P34; Sachsenmeier KF, 1996, J BIOL CHEM, V271, P5, DOI 10.1074/jbc.271.1.5; SCHMIDT A, 1994, P NATL ACAD SCI USA, V91, P4756, DOI 10.1073/pnas.91.11.4756; SHIN I, 1993, J INVEST DERMATOL, V100, P1965; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Slominski A, 1996, BBA-GEN SUBJECTS, V1289, P247, DOI 10.1016/0304-4165(95)00159-X; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; SWOPE VB, 1994, J INVEST DERMATOL, V102, P749, DOI 10.1111/1523-1747.ep12376970; SWOPE VB, 1989, J IMMUNOL, V142, P1943; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; VALVERDE P, 1993, EUR J BIOCHEM, V217, P541, DOI 10.1111/j.1432-1033.1993.tb18275.x; WAKAMATSU K, 1988, ANAL BIOCHEM, V170, P335, DOI 10.1016/0003-2697(88)90639-2; WILMER JL, 1994, J INVEST DERMATOL, V102, P915, DOI 10.1111/1523-1747.ep12383512; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Wintzen M, 1996, J INVEST DERMATOL, V106, P673, DOI 10.1111/1523-1747.ep12345496; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0	56	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3967	3972		10.1074/jbc.272.7.3967	http://dx.doi.org/10.1074/jbc.272.7.3967			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020101	hybrid			2022-12-25	WOS:A1997WH01900017
J	Yano, T; Chu, SS; Sled, VD; Ohnishi, T; Yagi, T				Yano, T; Chu, SS; Sled, VD; Ohnishi, T; Yagi, T			The proton-translocating NADH-quinone oxidoreductase (NDH-1) of thermophilic bacterium Thermus thermophilus HB-8 - Complete DNA sequence of the gene cluster and thermostable properties of the expressed NQ02 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; UBIQUINONE OXIDOREDUCTASE; PARACOCCUS-DENITRIFICANS; MITOCHONDRIAL NADH; ESCHERICHIA-COLI; 25-KILODALTON SUBUNIT; EXTREME THERMOPHILE; CRYSTAL-STRUCTURE; DEHYDROGENASE; PROTEINS	The genes encoding the proton-translocating NADH-quinone oxidoreductase (NDH-1) of a thermophilic bacterium Thermus thermophilus HB-8 were cloned and sequenced, They constitute a cluster that is composed of 14 structural genes and contains no unidentified reading frames, All of the 14 structural genes, which are designated NQO1-14, encode subunits homologous to those of Paracoccus denitrificans NDH-1, respectively, and are arranged in the same order as other bacterial NDH-1 genes, T. thermophilus NDH-1 contains at most nine putative iron-sulfur cluster binding sites, eight of which are commonly found in other organisms. The T. thermophilus NQO2 subunit was expressed in Escherichia coli, The expressed subunit bears a single [2Fe-2S] cluster whose optical and EPR properties are very similar to those of N1a cluster in the P. denitrificans NQO2 subunit (Yano, T., Sled', V.D., Ohnishi, T., and Yagi, T. (1994) Biochemistry 33, 494-499), These results strongly suggest that the T. thermophilus NDH-1 is similar to other NDH-1 enzyme complexes in terms of subunit and cofactor composition. The T. thermophilus NQO2 subunit displayed much higher stability than the mesophilic equivalent and its iron-sulfur cluster remained intact even after incubation for 3 h at 65 degrees C under anaerobic conditions. With the advantage of thermostability, the T. thermophilus NDH-1 provides a great model system to investigate the structure-function relationship of the NDH-1 enzyme complexes.	Scripps Res Inst, DEPT MOL & EXPT MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, JOHNSON RES FDN, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030376, R01GM033712] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIGMS NIH HHS [R01GM33712, R01GM30376] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; ARCHER CD, 1993, P NATL ACAD SCI USA, V90, P9877, DOI 10.1073/pnas.90.21.9877; ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; COLLINS MD, 1980, J APPL BACTERIOL, V48, P277, DOI 10.1111/j.1365-2672.1980.tb01227.x; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; CROUSE BR, 1994, J BIOL CHEM, V269, P21030; DENG PSK, 1990, BIOCHEMISTRY-US, V29, P1094, DOI 10.1021/bi00456a036; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOEG KA, 1962, ARCH BIOCHEM BIOPHYS, V97, P37, DOI 10.1016/0003-9861(62)90041-3; Dupuis A, 1995, GENE, V167, P99, DOI 10.1016/0378-1119(95)00693-1; FARALDO MM, 1992, J BACTERIOL, V174, P7458, DOI 10.1128/jb.174.22.7458-7462.1992; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; Golinelli MP, 1996, BIOCHEMISTRY-US, V35, P8995, DOI 10.1021/bi9604284; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAN AL, 1988, ARCH BIOCHEM BIOPHYS, V267, P490, DOI 10.1016/0003-9861(88)90055-0; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; HONNAMI K, 1977, J BIOCHEM, V82, P769, DOI 10.1093/oxfordjournals.jbchem.a131753; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; KAGAWA Y, 1984, J BIOL CHEM, V259, P2956; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUI R, 1991, J BIOCHEM-TOKYO, V110, P575, DOI 10.1093/oxfordjournals.jbchem.a123622; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MCKAY A, 1982, ARCH MICROBIOL, V131, P43, DOI 10.1007/BF00451497; MEINHARDT SW, 1990, J BIOL CHEM, V265, P1360; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; OHNISHI T, 1985, J BIOL CHEM, V260, P2782; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; PAPP T, 1995, TRENDS GENET, V11, P169, DOI 10.1016/S0168-9525(00)89036-8; RUNSWICK MJ, 1989, BIOCHEMISTRY-US, V28, P9452, DOI 10.1021/bi00450a031; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SLED VD, 1993, J BIOENERG BIOMEMBR, V25, P347, DOI 10.1007/BF00762460; STEINMULLER K, 1992, PLANT MOL BIOL, V18, P135, DOI 10.1007/BF00018466; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; TRANBETCKE A, 1990, J BACTERIOL, V172, P2920, DOI 10.1128/jb.172.6.2920-2929.1990; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WALKER JE, 1980, EUR J BIOCHEM, V108, P581, DOI 10.1111/j.1432-1033.1980.tb04753.x; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; XU XM, 1992, BIOCHEMISTRY-US, V31, P6925, DOI 10.1021/bi00145a009; XU XM, 1992, ARCH BIOCHEM BIOPHYS, V296, P40, DOI 10.1016/0003-9861(92)90542-5; XU XM, 1993, BIOCHEMISTRY-US, V32, P968, DOI 10.1021/bi00054a030; XU XM, 1991, BIOCHEMISTRY-US, V30, P8678, DOI 10.1021/bi00099a027; XU XM, 1991, BIOCHEMISTRY-US, V30, P6422, DOI 10.1021/bi00240a012; XU XM, 1991, BIOCHEM BIOPH RES CO, V174, P667, DOI 10.1016/0006-291X(91)91469-S; YAGI T, 1993, J BIOENERG BIOMEMBR, V25, P339, DOI 10.1007/BF00762459; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; YAGI T, 1988, BIOCHEMISTRY-US, V27, P2008, DOI 10.1021/bi00406a030; YAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P1, DOI 10.1016/0005-2728(93)90182-F; YAGI T, 1991, J BIOENERG BIOMEMBR, V23, P211, DOI 10.1007/BF00762218; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1995, J BIOL CHEM, V270, P18264, DOI 10.1074/jbc.270.31.18264; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014; Yano T., 1993, Biological Chemistry Hoppe-Seyler, V374, P820; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; YOSHIDA M, 1977, P NATL ACAD SCI USA, V74, P936, DOI 10.1073/pnas.74.3.936	66	80	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4201	4211		10.1074/jbc.272.7.4201	http://dx.doi.org/10.1074/jbc.272.7.4201			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020134	hybrid			2022-12-25	WOS:A1997WH01900050
J	Ma, DQ; Russell, DG; Beverley, SM; Turco, SJ				Ma, DQ; Russell, DG; Beverley, SM; Turco, SJ			Golgi GDP-mannose uptake requires Leishmania LPG2 - A member of a eukaryotic family of putative nucleotide-sugar transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED ACID-PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; GUANOSINE DIPHOSPHATASE; FLAGELLAR POCKET; LIPOPHOSPHOGLYCAN; GLYCOSYLATION; DONOVANI; BIOSYNTHESIS; VIRULENCE; PROTEIN	The synthesis of glycoconjugates within the secretory pathway of eukaryotes requires the provision of lumenal nucleotide-sugar substrates. This is particularly important for eukaryotic microbes such as Leishmania because they must synthesize considerable amounts of extracellular and cell surface glycoconjugates that play significant roles in the infectious cycle. Here we used properly oriented sealed microsomes to characterize lumenal uptake of GDP-Man in Leishmania donovani. In this system, GDP-Man uptake was saturable with an apparent K-m for GDP-Man of 0.3 mu M and facilitated its use as a donor substrate for lipophosphoglycan (LPG) synthesis, A lpg2(-) deletion mutant showed loss of GDP-Man but not UDP-Gal uptake, which was restored by introduction of the gene LPG2, Immunoelectron microscopy localized an active, epitope-tagged LPG2 protein to the Golgi apparatus. Thus, LPG2 is required for nucleotide-sugar transport activity and probably encodes this Golgi transporter. LPG2 belongs to a large family of eukaryotic genes that potentially encode transporters with different substrate specificities and/or cellular locations. In the future, the amenability of the Leishmania system to biochemical and genetic manipulation will assist in functional characterization of nucleotide-sugar transports from this and other eukaryotes. Furthermore, since LPG2 plays an important role in the Leishmania infectious cycle and mammalian cells lack a Golgi GDP-Man transporter, this activity may offer a new target for chemotherapy.	UNIV KENTUCKY, MED CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; WASHINGTON UNIV, SCH MED, DEPT MOL MICROBIOL & MOL GENET, ST LOUIS, MO 63110 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02130 USA	University of Kentucky; Washington University (WUSTL); Harvard University; Harvard Medical School			Russell, David G/N-5280-2019; Russell, David G/D-4533-2009	Russell, David G/0000-0002-9748-750X; Russell, David G/0000-0002-9748-750X; Beverley, Stephen/0000-0001-5319-0811; ma, deqin/0000-0002-8581-6345	NIAID NIH HHS [AI31078] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abeijon C, 1996, J BIOL CHEM, V271, P8851, DOI 10.1074/jbc.271.15.8851; ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; ANET EFLJ, 1954, NATURE, V174, P930, DOI 10.1038/174930a0; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; CARVER MA, 1991, J BIOL CHEM, V266, P10974; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; Fleischer B, 1974, Methods Enzymol, V31, P180; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; HIGGINS DG, 1989, CABIOS, V5, P131; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; ILG T, 1994, J BIOL CHEM, V269, P24073; KANIKENNULAT C, 1995, GENETICS, V140, P933; KAPLER GM, 1990, NUCLEIC ACIDS RES, V18, P6399, DOI 10.1093/nar/18.21.6399; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCNEELY T B, 1990, Glycobiology, V1, P63, DOI 10.1093/glycob/1.1.63; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; Poster JB, 1996, J BIOL CHEM, V271, P3837; RUSH JS, 1995, ANAL BIOCHEM, V224, P494, DOI 10.1006/abio.1995.1078; RUSSELL DG, 1994, METHOD CELL BIOL, V45, P277; RUSSELL DG, 1992, J CELL SCI, V103, P1193; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x	35	138	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3799	3805		10.1074/jbc.272.6.3799	http://dx.doi.org/10.1074/jbc.272.6.3799			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013638	hybrid			2022-12-25	WOS:A1997WG19200098
J	Melander, Y; Holmberg, L; Nygard, O				Melander, Y; Holmberg, L; Nygard, O			Structure of 18 S ribosomal RNA in native 40 S ribosomal subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-3; RAT-LIVER RIBOSOMES; ESCHERICHIA-COLI; CROSS-LINKING; PROTEIN-SYNTHESIS; MESSENGER-RNA; 16S; BINDING; SITES; CROSSLINKING	We have analyzed the structure of 18 S rRNA in native 40 S subunits using chemical modification followed by primer extension. The native subunits were modified using the single-stranded specific reagents dimethyl sulfate and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenssulfonate. The modification pattern of the 18 S rRNA was compared to that obtained from derived 40 S subunits prepared by dissociation of unprogrammed 80 S ribosomes. Eighteen nucleotides showed different accessibility to the chemical probes in derived and native subunits. Half of these nucleotides were found in the central domain of the rRNA between the 1060 loop and the central pseudoknot. The remaining nucleotides were located in two clusters in the 5'- and 3'-domains of the 18 S rRNA. Derived 40 S subunits are free from non-ribosomal proteins. In contrast, native subunits are intermediates in protein synthesis initiation and contain stoichiometric amounts of initiation factor 3 (Sundkvist, I. C., and Staehelin, T. (1975) J. Mol. Biol. 99, 401-418). The possible role of this factor in altering the structure of 18 S rRNA in the native 40 S subunits is discussed.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI E5,WENNER GREN INST,DEPT ZOOL CELL BIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University								BrakierGingras L, 1995, BIOCHEM CELL BIOL, V73, P907, DOI 10.1139/o95-098; BRAWERMAN G, 1972, BIOCHEMISTRY-US, V11, P637, DOI 10.1021/bi00754a027; BRIMACOMBE R, 1992, BIOCHIMIE, V74, P319, DOI 10.1016/0300-9084(92)90109-R; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BRINK MF, 1993, EMBO J, V12, P3987, DOI 10.1002/j.1460-2075.1993.tb06076.x; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; EHRESMANN C, 1986, NUCLEIC ACIDS RES, V14, P4803, DOI 10.1093/nar/14.12.4803; EMANUILOV I, 1978, P NATL ACAD SCI USA, V75, P1389, DOI 10.1073/pnas.75.3.1389; ERICSON G, 1989, J BIOL CHEM, V264, P540; GRAIFER DM, 1994, BIOCHEMISTRY-US, V33, P6201, DOI 10.1021/bi00186a020; GROSS B, 1983, EMBO J, V2, P255, DOI 10.1002/j.1460-2075.1983.tb01414.x; GUTELL RR, 1994, NUCLEIC ACIDS RES, V22, P3502, DOI 10.1093/nar/22.17.3502; HOLMBERG L, 1994, NUCLEIC ACIDS RES, V22, P1374, DOI 10.1093/nar/22.8.1374; HOLMBERG L, 1994, NUCLEIC ACIDS RES, V22, P2776, DOI 10.1093/nar/22.14.2776; HOLMBERG L, 1994, BIOCHEMISTRY-US, V33, P15159, DOI 10.1021/bi00254a027; HOLMBERG L, 1992, J BIOL CHEM, V267, P21906; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1995, J MOL BIOL, V248, P207, DOI 10.1016/S0022-2836(95)80042-5; MURALIKRISHNA P, 1989, BIOCHEMISTRY-US, V28, P7505, DOI 10.1021/bi00445a002; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NYGARD O, 1982, BIOCHIM BIOPHYS ACTA, V697, P263, DOI 10.1016/0167-4781(82)90088-4; NYGARD O, 1982, NUCLEIC ACIDS RES, V10, P1327, DOI 10.1093/nar/10.4.1327; NYGARD O, 1982, EMBO J, V1, P357, DOI 10.1002/j.1460-2075.1982.tb01174.x; SCHREIER MH, 1973, J MOL BIOL, V73, P329, DOI 10.1016/0022-2836(73)90346-X; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SUNDKVIST IC, 1975, J MOL BIOL, V99, P401, DOI 10.1016/S0022-2836(75)80135-5; SVOBODA AJ, 1978, BIOCHEM BIOPH RES CO, V81, P1145, DOI 10.1016/0006-291X(78)91256-1; SZEKELY M, 1980, DNA PROTEIN TRANSFER, P239; TAPPRICH WE, 1989, P NATL ACAD SCI USA, V86, P4927, DOI 10.1073/pnas.86.13.4927; TOLAN DR, 1983, BIOCHIMIE, V65, P427, DOI 10.1016/S0300-9084(83)80062-5; UCHIUMI T, 1986, J BIOL CHEM, V261, P9663; Verschoor A, 1996, J CELL BIOL, V133, P495, DOI 10.1083/jcb.133.3.495; WESTERMANN P, 1984, NUCLEIC ACIDS RES, V12, P8887, DOI 10.1093/nar/12.23.8887; WESTERMANN P, 1986, STRUCTURE FUNCTION G, P642; ZAMIR A, 1969, FEBS LETT, V3, P85, DOI 10.1016/0014-5793(69)80103-1; ZAMIR A, 1971, J MOL BIOL, V60, P347, DOI 10.1016/0022-2836(71)90299-3	39	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3254	3258		10.1074/jbc.272.6.3254	http://dx.doi.org/10.1074/jbc.272.6.3254			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013562	hybrid			2022-12-25	WOS:A1997WG19200022
J	Takahashi, M; Pischetsrieder, M; Monnier, VM				Takahashi, M; Pischetsrieder, M; Monnier, VM			Isolation, purification, and characterization of amadoriase isoenzymes (fructosyl amine-oxygen oxidoreductase EC 1.5.3) from Aspergillus sp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP SOIL STRAIN; DIABETIC NEPHROPATHY; SEQUENCE-ANALYSIS; GLYCATED ALBUMIN; ACID OXIDASE; MOLECULAR-CLONING; PROTEINS; PENTOSIDINE; GLUCOSE; BINDING	Four ''amadoriase'' enzyme fractions, which oxidatively degrade glycated low molecular weight amines and amino acids under formation of hydrogen peroxide and glucosone, were isolated from an Aspergillus sp. soil strain selected on fructosyl adamantanamine as sole carbon source. The enzymes were purified to homogeneity using a combination of ion exchange, hydroxyapatite, gel filtration, and Mono & column chromatography. Molecular masses of amadoriase enzymes Ia, Ib, and Ic were 51 kDa, and 49 kDa for amadoriase II. Apparent kinetic constants for N-epsilon-fructosyl N-alpha-t-butoxycarbonyl lysine and fructosyl adamantanamine were almost identical for enzymes Ia, Ib, and Ic, but corresponding values for enzyme II were significantly different. FAD was identified in all enzymes based on its typical absorption spectrum. N terminal sequence was identical for enzymes Ia and Ib (Ala-Pro-Ser-Ile-Leu-Ser-Thr-Glu-Ser-Ser-Ile-Ile-Val-Ile-Gly-Ala- Gly-Thr-Trp-Gly-) and Ic except that the first 5 amino acids were truncated. The sequence of enzyme II was different (Ala-Val-Thr-Lys-Ser-Ser-Ser-Leu-Leu-Ile-Val-Gly-Ala-Gly- Thr-Trp-Gly-Thr-Ser-Thr-). All enzymes had the FAD cofactor-binding consensus sequence Gly-X-Gly-X-X-Gly within the N-terminal sequence. In summary, these data show the presence of two distinct amadoriase enzymes in the Aspergillus sp. soil strain selected on fructosyl adamantanamine and induced by fructosyl propylamine. In contrast to previous described enzymes, these novel amadoriase enzymes can deglycate both glycated amines and amino acids.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Monnier, Vincent M/B-1371-2009; Takahashi, Motoko/I-3154-2013	Takahashi, Motoko/0000-0002-2112-6142	NEI NIH HHS [EY07099] Funding Source: Medline; NIA NIH HHS [AG05601] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; BAYNE S, 1963, METHODS CARBOHYDR CH, V2, P421; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BEISSWENGER PJ, 1993, J CLIN INVEST, V92, P212, DOI 10.1172/JCI116552; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1983, J EXP MED, V158, P1739, DOI 10.1084/jem.158.5.1739; CHOI GH, 1990, J BACTERIOL, V172, P4522, DOI 10.1128/jb.172.8.4522-4528.1990; COHEN MP, 1995, J CLIN INVEST, V95, P2338, DOI 10.1172/JCI117926; DYER DG, 1991, J BIOL CHEM, V266, P11654; Elgawish A, 1996, J BIOL CHEM, V271, P12964, DOI 10.1074/jbc.271.22.12964; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FINOT PA, 1969, HELV CHIM ACTA, V52, P1488, DOI 10.1002/hlca.19690520609; FUKUI K, 1987, BIOCHEMISTRY-US, V26, P3612, DOI 10.1021/bi00386a054; GERHARDINGER C, 1995, J BIOL CHEM, V270, P218, DOI 10.1074/jbc.270.1.218; GERHARDINGER C, 1994, J BIOL CHEM, V269, P27297; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; HODGE JE, 1953, J AM CHEM SOC, V75, P316, DOI 10.1021/ja01098a019; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; HORIUCHI T, 1989, AGR BIOL CHEM TOKYO, V53, P103, DOI 10.1080/00021369.1989.10869245; KAWAKISHI S, 1994, MAILLARD REACTIONS C, P281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBEC G, 1989, CLIN CHEM, V35, P2254; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MOMOI K, 1988, FEBS LETT, V238, P180, DOI 10.1016/0014-5793(88)80252-7; MONNIER VM, 1983, CLIN CHEM, V29, P1997; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; RICHTMYER NK, 1963, METHODS CARBOHYDRATE, V2, P127; SAKAI Y, 1995, BIOSCI BIOTECH BIOCH, V59, P487, DOI 10.1271/bbb.59.487; SALAZAR R, 1995, BBA-MOL CELL RES, V1266, P57, DOI 10.1016/0167-4889(94)00221-Y; Saxena AK, 1996, J BIOL CHEM, V271, P32803, DOI 10.1074/jbc.271.51.32803; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; STANIFORD JM, 1993, Patent No. 526150; STEVENS CW, 1988, P NATL ACAD SCI USA, V85, P3875, DOI 10.1073/pnas.85.11.3875; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; WATANABE N, 1990, AGR BIOL CHEM TOKYO, V54, P1063, DOI 10.1080/00021369.1990.10870059; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WU VY, 1994, BIOCHEM BIOPH RES CO, V198, P734, DOI 10.1006/bbrc.1994.1106; ZIYADEH FN, 1993, MOL CELL BIOCHEM, V125, P19, DOI 10.1007/BF00926830	39	77	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3437	3443		10.1074/jbc.272.6.3437	http://dx.doi.org/10.1074/jbc.272.6.3437			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013588	hybrid			2022-12-25	WOS:A1997WG19200048
J	vanLeeuwen, HC; Rensen, M; vanderVliet, PC				vanLeeuwen, HC; Rensen, M; vanderVliet, PC			The Oct-1 POU homeodomain stabilizes the adenovirus preinitiation complex via a direct interaction with the priming protein and is displaced when the replication fork passes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; NUCLEAR FACTOR-I; DOMAIN TRANSCRIPTION FACTORS; DOUBLE-STRANDED DNA; TERMINAL PROTEIN; SYNERGISTIC INTERACTION; CRYSTAL-STRUCTURE; GENE-EXPRESSION; ORIGIN; INITIATION	Initiation of adenovirus DNA replication is strongly enhanced by two cellular transcription factors, NFI and Oct-1, which bind to the auxiliary origin and tether the viral precursor terminal protein-DNA polymerase (pTP . pol) complex to the core origin. NFI acts through a direct contact with the DNA polymerase, but the mode of action of Oct 1 is unknown. Employing glutathione S-transferase-POU pull-down assays and protein affinity chromatography, we have established that the POU domain contacts pTP rather than pol. The POU homeodomain is responsible for this interaction. The protein-protein contacts lead to increased binding of pTP-pol to the core origin, which is caused by a reduced off-rate. The enhanced formation of a pTP . pol . POU complex on the origin correlates with stimulation of replication. Using an immobilized replication system, we have studied the kinetics of dissociation of the Oct-1 POU domain during replication. In contrast to NFI, which dissociates very early in initiation, Oct-1 dissociates only when the binding site is rendered single-stranded upon translocation of the replication fork. Our data indicate that NFI and Oct-1 enhance initiation synergistically by touching different targets in the preinitiation complex and dissociate independently after initiation.	UNIV UTRECHT, PHYSIOL CHEM LAB, NL-3508 TA UTRECHT, NETHERLANDS	Utrecht University			van Leeuwen, Hans/A-2371-2014					ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; BOSHER J, 1990, New Biologist, V2, P1083; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CHEN M, 1990, J BIOL CHEM, V265, P18634; CLEAT PH, 1989, EMBO J, V8, P1841, DOI 10.1002/j.1460-2075.1989.tb03579.x; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; COENJAERTS FEJ, 1994, NUCLEIC ACIDS RES, V22, P5235, DOI 10.1093/nar/22.24.5235; Coenjaerts FEJ, 1995, METHOD ENZYMOL, V262, P548; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GRUDA MC, 1991, J VIROL, V65, P3553, DOI 10.1128/JVI.65.7.3553-3558.1991; HATFIELD L, 1993, J VIROL, V67, P3931, DOI 10.1128/JVI.67.7.3931-3939.1993; Hay R T, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P31; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; IGUCHIARIGA SMM, 1993, BIOCHIM BIOPHYS ACTA, V1172, P73, DOI 10.1016/0167-4781(93)90271-E; KENNY MK, 1988, J BIOL CHEM, V263, P9801; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; MUL YM, 1992, EMBO J, V11, P751, DOI 10.1002/j.1460-2075.1992.tb05108.x; MUL YM, 1993, NUCLEIC ACIDS RES, V21, P641, DOI 10.1093/nar/21.3.641; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; PRONK R, 1993, NUCLEIC ACIDS RES, V21, P2293, DOI 10.1093/nar/21.10.2293; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SJOBLOM A, 1995, J GEN VIROL, V76, P2679, DOI 10.1099/0022-1317-76-11-2679; STUIVER MH, 1992, J MOL BIOL, V225, P999, DOI 10.1016/0022-2836(92)90100-X; STUIVER MH, 1990, J VIROL, V64, P379, DOI 10.1128/JVI.64.1.379-386.1990; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; TODD A, 1995, J CELL BIOCHEM, V57, P280, DOI 10.1002/jcb.240570212; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; Van der Vliet P C, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P1; VANLEEUWEN HC, 1995, NUCLEIC ACIDS RES, V23, P3189; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VERRIJZER CP, 1992, NUCLEIC ACIDS RES, V20, P6369, DOI 10.1093/nar/20.23.6369; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; ZHOU DX, 1991, MOL CELL BIOL, V11, P1353, DOI 10.1128/MCB.11.3.1353; ZORBAS H, 1989, NUCLEIC ACIDS RES, V17, P7735, DOI 10.1093/nar/17.19.7735	43	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3398	3405		10.1074/jbc.272.6.3398	http://dx.doi.org/10.1074/jbc.272.6.3398			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013582	hybrid			2022-12-25	WOS:A1997WG19200042
J	Berger, AL; Cerione, RA; Erickson, JW				Berger, AL; Cerione, RA; Erickson, JW			Real time conformation changes in the retinal phosphodiesterase gamma subunit monitored by resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD CGMP PHOSPHODIESTERASE; NUCLEOTIDE-BINDING-PROTEIN; TRANSDUCIN ALPHA-SUBUNIT; INHIBITORY SUBUNIT; INTRINSIC FLUORESCENCE; EGF RECEPTOR; ACTIVATION; SITE; MACROMOLECULES	The gamma subunits of the retinal cGMP phosphodiesterase (gamma(PDE)) acts as an inhibitor of phosphodiesterase (PDE) catalytic activity and mediates enzyme regulation by the alpha subunit of the GTP-binding protein transducin (alpha(T)). In order to characterize conformational changes in the 87-amino acid gamma(PDE) subunit that may accompany the activation of the holoenzyme, gamma(PDE) was labeled with the fluorescent probes 5-iodoacetamideofluorescein and eosin-5-isothiocyanate for use in resonance energy transfer measurements. 5-Iodoacetamidofluorescein specifically labeled a cystein residue at position 68 and served as a resonance energy transfer donor. The site of modification of eosin-5-isothiocyanate, which served as the resonance energy transfer acceptor, was determined to be within the first seven residues of the amino terminus of gamma(PDE). Energy transfer between the labeled sites on free, unbound gamma(PDE) indicated that they were separated by a distance of 63 Angstrom, consistent with a random conformation. Upon binding that catalytic alpha beta subunits of the PDE, the distance between the two probes on gamma(PDE) increased to 77 Angstrom. Binding of the labeled gamma(PDE) by alpha(T) . guanosine 5'-3'-O-(thio)triphosphate did not affect the distance between the probes under conditions where the PDE was activated. These activated alpha(T) to gamma(PDE), which is essential for the stimulation of PDE activity, does not impart significant alterations in the tertiary structure of the gamma(PDE) molecule. They also support a model for PDE activation that places active alpha(T) in a complex with the holoenzyme.			Berger, AL (corresponding author), CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853, USA.				NEI NIH HHS [EY06429] Funding Source: Medline; PHS HHS [06204] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; CARRAWAY KL, 1990, BIOCHEMISTRY-US, V29, P8741, DOI 10.1021/bi00489a034; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHERRY RJ, 1976, BIOCHEMISTRY-US, V15, P3653, DOI 10.1021/bi00662a001; CLERC A, 1992, J BIOL CHEM, V267, P6620; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; EPE B, 1983, P NATL ACAD SCI-BIOL, V80, P2579, DOI 10.1073/pnas.80.9.2579; ERICKSON JW, 1993, J BIOL CHEM, V268, P3328; ERICKSON JW, 1991, BIOCHEMISTRY-US, V30, P7112, DOI 10.1021/bi00243a011; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HASS E, 1978, BIOCHEMISTRY-US, V17, P5064; HAUGLAND RP, 1994, MOL PROBES HDB FLUOR; KROLL S, 1989, J BIOL CHEM, V264, P4490; LADOWICZ JR, 1983, PRINCIPLES FLUORESCE; LAMBRIGHT DG, 1994, NATURE, V369, P611; MITTAL R, 1994, BIOCHEMISTRY-US, V33, P10178, DOI 10.1021/bi00199a046; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; YEE R, 1978, J BIOL CHEM, V253, P8902	28	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2714	2721		10.1074/jbc.272.5.2714	http://dx.doi.org/10.1074/jbc.272.5.2714			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006909	hybrid			2022-12-25	WOS:A1997WE66700022
J	Carey, DJ; Conner, K; Asundi, VK; OMahony, DJ; Stahl, RC; Showalter, LJ; CizmeciSmith, G; Hartman, J; Rothblum, LI				Carey, DJ; Conner, K; Asundi, VK; OMahony, DJ; Stahl, RC; Showalter, LJ; CizmeciSmith, G; Hartman, J; Rothblum, LI			cDNA cloning, genomic organization, and in vivo expression of rat N-syndecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; HEPARAN-SULFATE PROTEOGLYCANS; GROWTH-ASSOCIATED MOLECULE; SMOOTH-MUSCLE CELLS; CORE PROTEIN; FACTOR-BETA; FAMILY; TISSUE; DOMAIN	The amino acid sequence of rat N-syndecan core protein was deduced from the cloned cDNA sequence. The sequence predicts a core protein of 442 amino acids with six structural domains: an NH2-terminal signal peptide, a membrane distal glycosaminoglycan attachment domain, a mucin homology domain, a membrane proximal glycosaminoglycan attachment domain, a single transmembrane domain, and a noncatalytic COOH-terminal cytoplasmic domain. Transfection of human 293 cells resulted in the expression of N-syndecan that was modified by heparan sulfate chain addition. Heparitinase digestion of the expressed proteoglycan produced a core protein that migrated on SDS-polyacrylamide gels at an apparent molecular weight of 120,000, identical to N-syndecan synthesized by neonatal rat brain or Schwann cells. Rat genomic DNA coding for N-syndecan was isolated by hybridization screening. The rat N-syndecan gene is comprised of five exons. Each exon corresponds to a specific core protein structural domain, with the exception of the fifth exon, which contains the coding information for both the transmembrane and cytoplasmic domains as well as the 3'-untranslated region of the mRNA. The first intron is large, with a length of 22 kilobases. The expression of N-syndecan was investigated in late embryonic, neonatal, and adult rats by immunoblotting and Northern blotting analysis. Among the tissues and developmental stages studied, high levels of N-syndecan expression were restricted to the early postnatal nervous system. N-syndecan was expressed in all regions of the nervous system, including cortex, midbrain, spinal cord, and peripheral nerve. Immunohistochemical staining revealed high levels of N-syndecan expression in all brain regions and fiber tract areas.			Carey, DJ (corresponding author), WEIS CTR RES,GEISINGER CLIN,DANVILLE,PA 17822, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47638] Funding Source: Medline; NIGMS NIH HHS [GM40098] Funding Source: Medline; NINDS NIH HHS [NS21925] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BANSAL R, 1994, DEV BIOL, V162, P511, DOI 10.1006/dbio.1994.1105; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; CAREY DJ, 1994, EXP CELL RES, V214, P12, DOI 10.1006/excr.1994.1228; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; Chernousov MA, 1996, J BIOL CHEM, V271, P13844, DOI 10.1074/jbc.271.23.13844; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; CIZMECISMITH G, 1993, J BIOL CHEM, V268, P18740; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; GARD AL, 1993, DEV BIOL, V159, P618, DOI 10.1006/dbio.1993.1269; GOULD SE, 1995, DEV BIOL, V168, P438, DOI 10.1006/dbio.1995.1093; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HINKES MT, 1993, J BIOL CHEM, V268, P11440; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RASMUSSEN S, 1988, J CELL BIOL, V107, P1959, DOI 10.1083/jcb.107.5.1959; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAULO E, 1992, J BIOL CHEM, V267, P11408; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YEAMAN C, 1993, J CELL BIOL, V122, P941, DOI 10.1083/jcb.122.4.941	32	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2873	2879		10.1074/jbc.272.5.2873	http://dx.doi.org/10.1074/jbc.272.5.2873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006931	hybrid			2022-12-25	WOS:A1997WE66700044
J	Ciriolo, MR; Palamara, AT; Incerpi, S; Lafavia, E; Bue, MC; DeVito, P; Garaci, E; Rotilio, G				Ciriolo, MR; Palamara, AT; Incerpi, S; Lafavia, E; Bue, MC; DeVito, P; Garaci, E; Rotilio, G			Loss of GSH, oxidative stress, and decrease of intracellular pH as sequential steps in viral infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENDAI VIRUS; KAPPA-B; TRANSCRIPTION FACTOR; EUKARYOTIC CELLS; OXYGEN RADICALS; GLUTATHIONE; INHIBITION; HEMAGGLUTININ; BIOCHEMISTRY; LYMPHOCYTES	Madin-Darby canine kidney cells infected with Sendai virus rapidly lose GSH without increase in the oxidized products. The reduced tripeptide was quantitatively recovered in the culture medium of the cells. Since the GSH loss in infected cells was not blocked by methionine, a known inhibitor of hepatocyte GSH transport, a nonspecific leakage through the plasma membrane is proposed. UV-irradiated Sendai virus gave the same results, confirming that the major loss of GSH was due to membrane perturbation upon virus fusion. Consequent to the loss of the tripeptide, an intracellular pH decrease occurred, which was due to a reversible impairment of the Na+/H+ antiporter, the main system responsible for maintaining unaltered pH(i) in those cells. At the end of the infection period, a rise in both pH, value and GSH content was observed, with a complete recovery in the activity of the antiporter. However, a secondary set up of oxidative stress was observed after 24 h from infection, which is the time necessary for virus budding from cells. In this case, the GSH decrease was partly due to preferential incorporation of the cysteine residue in the viral proteins and partly engaged in mixed disulfides with intracellular proteins. In conclusion, under our conditions of viral infection, oxidative stress is imposed by GSH depletion, occurring in two steps and following direct virus challenge of the cell membrane without the intervention of reactive oxygen species. These results provide a rationale for the reported, and often contradictory, mutual effects of GSH and viral infection.	UNIV ROMA TOR VERGATA, DEPT BIOL, I-00133 ROME, ITALY; UNIV ROMA TOR VERGATA, DEPT EXPT MED & BIOCHEM SCI, I-00133 ROME, ITALY; UNIV CHIETI, INST BIOCHEM SCI, I-66100 CHIETI, ITALY	University of Rome Tor Vergata; University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara			Ciriolo, Maria Rosa/K-6572-2016; GARACI, ENRICO/AAB-3349-2021	Ciriolo, Maria Rosa/0000-0002-7863-9029; PALAMARA, ANNA TERESA/0000-0001-8330-4381				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; AUKRUST P, 1995, BLOOD, V86, P258, DOI 10.1182/blood.V86.1.258.bloodjournal861258; AW TY, 1984, J BIOL CHEM, V259, P9355; BRIGELIUS R, 1982, BIOCHEM PHARMACOL, V31, P1637, DOI 10.1016/0006-2952(82)90393-8; BUHL R, 1989, LANCET, V2, P1294; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CHEESEMAN KH, 1993, BRIT MED BULL, V49, P481, DOI 10.1093/oxfordjournals.bmb.a072625; CLERICI C, 1992, AM J PHYSIOL, V262, pL542, DOI 10.1152/ajplung.1992.262.5.L542; CUTAIA M, 1994, AM J PHYSIOL-LUNG C, V267, pL649, DOI 10.1152/ajplung.1994.267.6.L649; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DELIMA MCP, 1991, BIOCHIM BIOPHYS ACTA, V1070, P446; DELIMA MDP, 1992, EUR J BIOCHEM, V205, P181; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ELLIOTT SJ, 1992, AM J PHYSIOL, V263, pH96, DOI 10.1152/ajpheart.1992.263.1.H96; GARACI E, 1992, BIOCHEM BIOPH RES CO, V188, P1090, DOI 10.1016/0006-291X(92)91343-O; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V188, P1090; GRINSTEIN S, 1989, METHOD ENZYMOL, V173, P777; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HENNET T, 1992, J GEN VIROL, V73, P39, DOI 10.1099/0022-1317-73-1-39; Incerpi S, 1996, AM J PHYSIOL-CELL PH, V270, pC841, DOI 10.1152/ajpcell.1996.270.3.C841; INCERPI S, 1994, J CELL PHYSIOL, V159, P205, DOI 10.1002/jcp.1041590203; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADSHUS IH, 1988, BIOCHEM J, V250, P1, DOI 10.1042/bj2500001; May B.V.J., 1991, VIROLOGY PRACTICAL A, P119; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; OZAWA M, 1976, FEBS LETT, V70, P145, DOI 10.1016/0014-5793(76)80745-4; PALAMARA AT, 1995, ANTIVIR RES, V27, P237, DOI 10.1016/0166-3542(95)00008-A; PEREZ L, 1994, J GEN VIROL, V75, P2595, DOI 10.1099/0022-1317-75-10-2595; Pirmohamed M, 1996, AIDS, V10, P501, DOI 10.1097/00002030-199605000-00008; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSENBERG SO, 1991, AM J PHYSIOL, V260, pC868, DOI 10.1152/ajpcell.1991.260.4.C868; ROTILIO G, 1994, MCBU, P143; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; TERRADEZ P, 1993, BIOCHEM J, V292, P477, DOI 10.1042/bj2920477; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VILELLA S, 1992, PFLUG ARCH EUR J PHY, V420, P275, DOI 10.1007/BF00374459; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053	44	119	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2700	2708		10.1074/jbc.272.5.2700	http://dx.doi.org/10.1074/jbc.272.5.2700			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006907	hybrid			2022-12-25	WOS:A1997WE66700020
J	Galas, MC; Helms, JB; Vitale, N; Thierse, D; Aunis, D; Bader, MF				Galas, MC; Helms, JB; Vitale, N; Thierse, D; Aunis, D; Bader, MF			Regulated exocytosis in chromaffin cells - A potential role for a secretory granule-associated ARF6 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; GOLGI MEMBRANES; CHOLERA-TOXIN; ENDOPLASMIC-RETICULUM; SYNTHETIC PEPTIDE; BREFELDIN-A; BETA-COP; TRANSPORT; SUBUNIT	The ADP-ribosylation factor (ARF) GTP-binding proteins are believed to function as regulators of vesicular budding and fusion along the secretory pathway. To investigate the role of ARF in regulated exocytosis, we have examined its intracellular distribution in cultured chromaffin cells by subcellular fractionation and immunoreplica analysis. We found that ARF6 is specifically associated with the membrane of purified secretory chromaffin granules. Chemical cross-linking and immunoprecipitation experiments suggested that ARF6 may be part of a complex with beta gamma subunits of trimeric G proteins. Stimulation of intact chromaffin cells or direct elevation of cytosolic calcium in permeabilized cells triggered the rapid dissociation of ARF6 from secretory granules. This effect could be inhibited by AlF4- which selectively activates trimeric G proteins. Furthermore, a synthetic myristoylated peptide corresponding to the N-terminal domain of ARF6 strongly inhibited calcium-evoked secretion in streptolysin-O-permeabilized chromaffin cells. The possibility that ARF6 plays a role in the effector pathway by which trimeric G proteins control exocytosis in chromaffin cells is discussed.	INSERM,U338,F-67084 STRASBOURG,FRANCE; UNIV HEIDELBERG,D-69120 HEIDELBERG,GERMANY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Ruprecht Karls University Heidelberg			Vitale, Nicolas/G-5967-2014; Bader, Marie-France/O-2098-2016; Galas, Marie-Christine/AAL-9812-2020; Dominique, Aunis/W-1419-2019	Vitale, Nicolas/0000-0002-4752-4907; Galas, Marie-Christine/0000-0002-3766-7103				AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; BADER MF, 1986, J BIOL CHEM, V261, P5777; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1992, J BIOL CHEM, V267, P13053; Barr FA, 1996, FEBS LETT, V384, P65, DOI 10.1016/0014-5793(96)00285-2; BON S, 1990, EUR J BIOCHEM, V190, P221, DOI 10.1111/j.1432-1033.1990.tb15567.x; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; FRANCO M, 1995, FEBS LETT, V362, P286, DOI 10.1016/0014-5793(95)00258-B; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LANG J, 1995, EMBO J, V14, P3636; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MORGAN A, 1993, FEBS LETT, V329, P121, DOI 10.1016/0014-5793(93)80206-A; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUPNIK M, 1995, NEUROREPORT, V6, P853, DOI 10.1097/00001756-199504190-00007; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSAI SC, 1991, BIOCHEMISTRY-US, V30, P3697, DOI 10.1021/bi00229a015; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; VITALE N, 1993, J BIOL CHEM, V268, P14715; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WELSH CF, 1994, MOL CELL BIOCHEM, V138, P157, DOI 10.1007/BF00928458	44	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2788	2793		10.1074/jbc.272.5.2788	http://dx.doi.org/10.1074/jbc.272.5.2788			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006918	hybrid			2022-12-25	WOS:A1997WE66700031
J	Nakanishi, M; Matsuura, K; Kaibe, H; Tanaka, N; Nonaka, T; Mitsui, Y; Hara, A				Nakanishi, M; Matsuura, K; Kaibe, H; Tanaka, N; Nonaka, T; Mitsui, Y; Hara, A			Switch of coenzyme specificity of mouse lung carbonyl reductase by substitution of threonine 38 with aspartic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-CHAIN DEHYDROGENASES; SITE-DIRECTED MUTAGENESIS; DROSOPHILA ALCOHOL-DEHYDROGENASE; COFACTOR SPECIFICITY; GUINEA-PIG; 20-BETA-HYDROXYSTEROID DEHYDROGENASE; DIHYDROPTERIDINE REDUCTASE; CDNA CLONING; BINDING; PROTEINS	Mouse lung carbonyl reductase, a member of the short-chain dehydrogenase/reductase (SDR) family, exhibits coenzyme specificity for NADP(H) over NAD(H). Crystal structure of the enzyme-NADPH complex shows that Thr-38 interacts with the 2'-phosphate of NADPH and occupies the position spatially similar to an Asp residue of the NAD(H)-dependent SDRs that hydrogen-bonds to the hydroxyl groups of the adenine ribose of the coenzymes. Using site-directed mutagenesis, me constructed a mutant mouse lung carbonyl reductase in which Thr-38 was replaced by Asp (T38D), and we compared kinetic properties of the mutant and wild-type enzymes in both forward and reverse reactions. The mutation resulted in increases of more than 200-fold in the K-m values for NADP(H) and decreases of more than 7-fold in those for NAD(H), but few changes in the K-m values for substrates or in the k(cat) values of the reactions. NAD(H) provided maximal protection against thermal and urea denaturation of T38D, in contrast to the effective protection by NADP(H) for the wild-type enzyme. Thus, the single mutation converted the coenzyme specificity from NADP(H) to NAD(H). Calculation of free energy changes showed that the 2'-phosphate of NADP(H) contributes to its interaction with the wildtype enzyme. Changing Thr-38 to Asp destabilized the binding energies of NADP(H) by 3.9-4.5 kcal/mol and stabilized those of NAD(H) by 1.2-1.4 kcal/mol, These results indicate a significant role of Thr-38 in NADP(H) binding for the mouse lung enzyme and provide further evidence for the key role of Asp at this position in NAD(H) specificity of the SDR family proteins.	GIFU PHARMACEUT UNIV, BIOCHEM LAB, GIFU 502, JAPAN; NAGAOKA UNIV TECHNOL, DEPT BIOENGN, NAGAOKA, NIIGATA 94021, JAPAN	Gifu Pharmaceutical University; Nagaoka University of Technology				Tanaka, Nobutada/0000-0001-5365-4698				BAKER ME, 1994, BIOCHEM J, V300, P605; BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN Z, 1994, FEBS LETT, V356, P81, DOI 10.1016/0014-5793(94)01234-2; CHEN Z, 1991, EUR J BIOCHEM, V202, P263, DOI 10.1111/j.1432-1033.1991.tb16371.x; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLERMONT S, 1993, BIOCHEMISTRY-US, V32, P10178, DOI 10.1021/bi00089a038; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME, P105; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; GRIMSHAW CE, 1992, J BIOL CHEM, V267, P15334; HARA A, 1982, J BIOCHEM, V92, P1753, DOI 10.1093/oxfordjournals.jbchem.a134105; HIROSE A, 1990, BIOCHIM BIOPHYS ACTA, V1049, P346, DOI 10.1016/0167-4781(90)90109-F; Horton R. M., 1993, PCR PROTOCOLS, P251; HUANG SM, 1990, BIOCHEMISTRY-US, V29, P8063, DOI 10.1021/bi00487a011; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KUBISESKI TJ, 1995, J BIOL CHEM, V270, P16911, DOI 10.1074/jbc.270.28.16911; KUMAR A, 1992, P NATL ACAD SCI USA, V89, P10188, DOI 10.1073/pnas.89.21.10188; LABESSE G, 1994, BIOCHEM J, V304, P95, DOI 10.1042/bj3040095; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUVERGEAT V, 1995, BIOCHEMISTRY-US, V34, P12426, DOI 10.1021/bi00038a041; LOEBER G, 1991, J BIOL CHEM, V266, P3016; MAREKOV L, 1990, FEBS LETT, V266, P51, DOI 10.1016/0014-5793(90)81504-H; MATSUURA K, 1990, J HISTOCHEM CYTOCHEM, V38, P217, DOI 10.1177/38.2.1688897; MATSUURA K, 1988, BIOCHEM J, V252, P17, DOI 10.1042/bj2520017; MATSUURA K, 1989, ENZYMOLOGY MOL BIOL, V2, P335; METZGER MH, 1995, EUR J BIOCHEM, V228, P50, DOI 10.1111/j.1432-1033.1995.tb20227.x; NAKAJIMA K, 1993, P NATL ACAD SCI USA, V90, P9591, DOI 10.1073/pnas.90.20.9591; NAKANISHI M, 1995, EUR J BIOCHEM, V228, P381, DOI 10.1111/j.1432-1033.1995.tb20274.x; NAKANISHI M, 1993, BIOCHEM BIOPH RES CO, V194, P1311, DOI 10.1006/bbrc.1993.1967; Nakanishi M, 1996, J BIOCHEM, V120, P257, DOI 10.1093/oxfordjournals.jbchem.a021407; NAKAYAMA T, 1986, BIOCHIM BIOPHYS ACTA, V882, P220, DOI 10.1016/0304-4165(86)90158-3; NAKAYAMA T, 1982, ARCH BIOCHEM BIOPHYS, V217, P564, DOI 10.1016/0003-9861(82)90538-0; NEIDLE E, 1992, EUR J BIOCHEM, V204, P113, DOI 10.1111/j.1432-1033.1992.tb16612.x; ORITANI H, 1992, ARCH BIOCHEM BIOPHYS, V292, P539, DOI 10.1016/0003-9861(92)90028-U; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; VARUGHESE KI, 1994, P NATL ACAD SCI USA, V91, P5582, DOI 10.1073/pnas.91.12.5582; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YIN SJ, 1991, EUR J BIOCHEM, V197, P359, DOI 10.1111/j.1432-1033.1991.tb15919.x	44	54	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2218	2222		10.1074/jbc.272.4.2218	http://dx.doi.org/10.1074/jbc.272.4.2218			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999926	hybrid			2022-12-25	WOS:A1997WD67900032
J	Shiratsuchi, A; Umeda, M; Ohba, Y; Nakanishi, Y				Shiratsuchi, A; Umeda, M; Ohba, Y; Nakanishi, Y			Recognition of phosphatidylserine on the surface of apoptotic spermatogenic cells and subsequent phagocytosis by sertoli cells of the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; LOW-DENSITY-LIPOPROTEIN; MEMBRANE PHOSPHATIDYLSERINE; TESTIS; PHOSPHOLIPIDS; RECEPTOR; EXPOSURE; DEATH; INVITRO; CD36	In a primary co-culture of spermatogenic and Sertoli cells of the rat, many spermatogenic cells die by apoptosis and are subsequently engulfed by Sertoli cells. me investigated the mechanism of this phagocytosis reaction. Testicular cells from 20-day-old rats were cultured, and spermatogenic cells and Sertoli cells were separated. When the recovered spermatogenic cells were maintained without Sertoli cells, the viability of the cells decreased and they became more susceptible to phagocytosis by Sertoli cells. Phagocytosis was severely impaired when liposomes containing acidic phospholipids, such as phosphatidylserine, phosphatidylinositol, and cardiolipin, were included in the reaction, whereas those consisting of neutral phospholipids showed little effect. Such anionic liposomes were more efficiently engulfed by Sertoli cells than were the other neutral liposomes. Also, the number of spermatogenic cells that exposed phosphatidylserine to the surface increased when cells were maintained in single culture. The results indicate that upon induction of spermatogenic cell apoptosis, phosphatidylserine and probably other acidic phospholipids, which are normally localized in the inner leaflet of the plasma membrane, translocate to the outer leaflet and serve as a signal for phagocytosis by Sertoli cells.	KANAZAWA UNIV,GRAD SCH NAT SCI & TECHNOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,FAC PHARMACEUT SCI,KANAZAWA,ISHIKAWA 920,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT INFLAMMAT RES,BUNKYO KU,TOKYO 113,JAPAN	Kanazawa University; Kanazawa University; Tokyo Metropolitan Institute of Medical Science			Shiratsuchi, Akiko/D-8391-2015; Nakanishi, Yoshinobu/D-4602-2014	Shiratsuchi, Akiko/0000-0002-7811-4409; Nakanishi, Yoshinobu/0000-0002-8767-3587				Allan D.J., 1987, P229; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; Byers S., 1993, SERTOLI CELL, P461; CasciolaRosen L, 1996, P NATL ACAD SCI USA, V93, P1624, DOI 10.1073/pnas.93.4.1624; CHEMES H, 1986, ENDOCRINOLOGY, V119, P1673, DOI 10.1210/endo-119-4-1673; CONNOR J, 1994, J BIOL CHEM, V269, P2399; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; HUCKINS C, 1978, ANAT REC, V190, P905, DOI 10.1002/ar.1091900410; KERR JB, 1993, ANAT REC, V235, P547, DOI 10.1002/ar.1092350407; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Martin Seamus J., 1996, P107; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATHER JP, 1990, ENDOCRINOLOGY, V127, P3206, DOI 10.1210/endo-127-6-3206; MIETHING A, 1992, CELL TISSUE RES, V267, P583, DOI 10.1007/BF00319381; Mizuno K, 1996, CELL DEATH DIFFER, V3, P119; NAGAO Y, 1989, IN VITRO CELL DEV B, V25, P1088, DOI 10.1007/BF02621259; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PINEAU C, 1991, CELL TISSUE RES, V264, P589, DOI 10.1007/BF00319048; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RUSSELL LD, 1977, ANAT RECORD, V187, P347, DOI 10.1002/ar.1091870307; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; TAMARU M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P331, DOI 10.1016/0167-4781(90)90106-C; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	33	124	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2354	2358						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999945	hybrid			2022-12-25	WOS:A1997WD67900051
J	Withers, DJ; Seufferlein, T; Mann, D; Garcia, B; Jones, N; Rozengurt, E				Withers, DJ; Seufferlein, T; Mann, D; Garcia, B; Jones, N; Rozengurt, E			Rapamycin dissociates p70S6K activation from DNA synthesis stimulated by bombesin and insulin in swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PROTEIN-KINASE-C; S6 KINASE; IMMUNOSUPPRESSANT RAPAMYCIN; GENE-EXPRESSION; PHOSPHORYLATION; PROLIFERATION; MITOGEN; P70(S6K); INACTIVATION	Phosphorylation and subsequent activation of p70 S6 kinase (S6K) are events that are highly conserved in the cellular response to mitogens, The neuropeptide bombesin, which is a potent mitogen for Swiss 3T3 cells, stimulated a time- and dose-dependent activation of p70(S6K) as determined by gel mobility shift and immune complex kinase assays, This effect was inhibited by the immunosuppressant rapamycin at 10 nM, which also completely abolished bombesin-stimulated DNA synthesis at identical concentrations, In striking contrast, the combination of bombesin and insulin in synergy stimulated maximum DNA synthesis in these cells despite persistent inhibition of p70(S6K) by rapamycin throughout G(1). These results indicate that activation of p70(S6K) is not required for the transition of quiescent cells to the S phase of the cell cycle, The inhibitory effects of rapamycin on bombesin-stimulated cell cycle progression did not involve accumulation of the cyclin-dependent kinase inhibitor p27(kip1) but a striking inhibition of the expression of cyclin D1, This effect was circumvented by bombesin with insulin, suggesting that a rapamycin-insensitive pathway stimulated by this combination leads to cyclin D1 expression, Thus, these findings, dissociating the mitogenic effects of bombesin in synergy with insulin from activation of p70(S6K), support the hypothesis that this kinase is a component of one of the parallel pathways that can lead to DNA synthesis rather than an obligatory point of convergence in mitogenic signaling.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Withers, Dominic J/D-7671-2014; Seufferlein, Thomas TW/P-7147-2018	Withers, Dominic J/0000-0002-8009-7521; 				CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FRANCAVILLA A, 1992, HEPATOLOGY, V15, P871, DOI 10.1002/hep.1840150520; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P945, DOI 10.1101/SQB.1988.053.01.109; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	35	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2509	2514						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999966				2022-12-25	WOS:A1997WD67900072
J	Mukhopadhyay, T; Roth, JA				Mukhopadhyay, T; Roth, JA			Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol	ONCOGENE			English	Article						p53; lung cancer; apoptosis; methoxyestradiol; gene expression	TUMOR-SUPPRESSOR PROTEIN; BINDING-SITE; CYCLE; EXPRESSION; ESTROGEN; METABOLITE; CARCINOMA; GROWTH; DEATH; MCF-7	2-methoxyestradiol (2-MeOE(2)) treatment caused significant growth inhibition of H460 and A549 human lung cancer cell lines which contain wild-type p53, However, 2-MeOE(2) had a little effect on the p53 negative H358 and p53 mutated H322 cell lines, Western blot analysis indicated that 2-MeOE(2) treatment resulted in an eightfold increase in the endogenous wild-type p53 protein, while the level of the mutant p53 protein remained unchanged, TdT staining indicated that following 2-MeOE(2)-mediated increases in wildtype p53 protein, cells bypass the G(1)-S checkpoint of the cell cycle with 30 to 40% undergoing apoptosis. Introduction of anti-sense wt-p53 into wt-p53 cells abrogated the 2-MeOE(2) effect, A significant portion of lung cancer retains the wild-type p53 gene therefore, 2-MeOE(2) may have therapeutic application.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,SECT THORAC MOL ONCOL,DEPT THORAC & CARDIOVASC SURG,BOX 109,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIZUYOKOTA E, 1995, CANCER RES, V55, P1863; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; CANVER CC, 1994, J THORAC CARDIOV SUR, V108, P153; CUSHMAN M, 1995, J MED CHEM, V38, P2041, DOI 10.1021/jm00012a003; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FUJIWARA T, 1994, CANCER RES, V54, P2287; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HERMEKING H, 1995, CELL BIOL INT, V19, P705; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOTTERING ML, 1992, CANCER RES, V52, P5926; MAXWELL SA, 1996, IN PRESS ELECTROPHOR; MILNER J, 1990, ONCOGENE, V5, P1683; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; THOMPSON AM, 1990, BRIT J CANCER, V62, P78, DOI 10.1038/bjc.1990.233; TISHLER RB, 1995, CANCER RES, V55, P6021; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG TTY, 1995, CANCER RES, V55, P2487; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; Zamai L, 1996, CYTOMETRY, V23, P303, DOI 10.1002/(SICI)1097-0320(19960401)23:4<303::AID-CYTO6>3.3.CO;2-B	27	133	144	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					379	384		10.1038/sj.onc.1200835	http://dx.doi.org/10.1038/sj.onc.1200835			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018125				2022-12-25	WOS:A1997WD51600015
J	Wang, HY; Goligorsky, MS; Malbon, CC				Wang, HY; Goligorsky, MS; Malbon, CC			Temporal activation of Ca2+-calmodulin-sensitive protein kinase type II is obligate for adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL LINE; GROWTH FACTOR-I; ADIPOCYTE DIFFERENTIATION; LEUCINE-ZIPPER; CALMODULIN; FIBROBLASTS; EXPRESSION; INHIBITOR; INSULIN; CALCIUM	Differentiation of 3T3-L1 embryonic fibroblasts to adipocytes in response to induction by dexamethasone and isobutylmethylxanthine is blocked by inhibitors of Ca2+-calmodulin-sensitive protein kinase type II, but not by inhibitors of protein kinase A or protein kinase C. CaM kinase II displays a biphasic increase in autonomous activity, rising after an initial transient peak from 1 to 15 h, declining at 24 h, followed by a sustained rise from 24 to 48 h, which is 2.5-fold greater than basal values at induction of adipogenesis. Adipogenesis was blocked effectively by CaM kinase II inhibitors, either KN-62 or KN-93, if the inhibitors are introduced at 6 h and maintained until 12 h of induction of adipogenesis. Equally effective, however, is inhibition of CaM kinase II activity at 24-48 h after induction, during the later phase of autonomous CaM kinase activity. Inhibition of cultures with KN-62 or KN-93 either for 0 to 6 h or for 12 to 24 h failed to influence adipogenesis. Two temporally-distinct phases of CaM kinase II activation, either 6 to 12 h or 24 to 48 h, if inhibited with either KN-62 or KN-93, blocked the conversion to adipocytes. Thus, a biphasic activation of CaM kinase II is obligate for the progression of the embryonic fibroblasts to adipocytes. Inhibition of either phase of CaM kinase activity blocks adipogenesis and expression of several intermediate early gene products.	SUNY STONY BROOK, UNIV MED CTR, DIABET & METAB DIS RES PROGRAM, DEPT MED, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, UNIV MED CTR, DIABET & METAB DIS RES PROGRAM, DEPT MOL PHARMACOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Wang, HY (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, UNIV MED CTR, DMDRP, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA.		malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LIAO K, 1995, J BIOL CHEM, V270, P12123, DOI 10.1074/jbc.270.20.12123; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; PORRAS A, 1994, J BIOL CHEM, V269, P12741; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SU HL, 1993, AM J PHYSIOL, V265, pC1729, DOI 10.1152/ajpcell.1993.265.6.C1729; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Wang HY, 1996, INT J OBESITY, V20, pS26; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	30	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1817	1821		10.1074/jbc.272.3.1817	http://dx.doi.org/10.1074/jbc.272.3.1817			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999866	hybrid			2022-12-25	WOS:A1997WD05800064
J	Pu, MY; Akhand, AA; Kato, M; Hamaguchi, M; Koike, T; Iwata, H; Sabe, H; Suzuki, H; Nakashima, I				Pu, MY; Akhand, AA; Kato, M; Hamaguchi, M; Koike, T; Iwata, H; Sabe, H; Suzuki, H; Nakashima, I			Evidence of a novel redox-linked activation mechanism for the Src kinase which is independent of tyrosine 527-mediated regulation	ONCOGENE			English	Article						Src kinase; redox regulation; Hg2+ (Mercuric ions)	HERBIMYCIN-A; T-CELLS; V-SRC; PHOSPHORYLATION; PP60C-SRC; BINDING; SITE; IDENTIFICATION; AUTOIMMUNITY; ASSOCIATION	The kinase activity of p60(c-src) has been shown to be basically regulated through phosphorylation and dephosphorylation of Y527. We found that catalytic activity of the immunoprecipitated c-Src kinase from NIH3T3 cells was elevated several folds by exposure to 0.5-50 mu M of sulfhydryl-reactive Hg2+. V-max of the kinase was increased whereas K-m was decreased. N-acetylcysteine neutralized this Hg2+ effect, suggesting a critical role of the Hg2+-mediated sulfhydryl modification of the kinase in the mechanism. Addition of protein tyrosine phosphatase inhibitor Na3VO4 into the reaction mixture did not inhibit the Hg2+-mediated activation. Further study revealed that Hg2+ was capable of activating the v-Src kinase lacking Y527 and the c-Src kinase from mutant cells defective of the Y527-phosphorylating Csk kinase. Cyanogen bromide cleavage maps of radiolabeled Src proteins showed that Hg2+ selectively promoted the autophosphorylation at Y416 and that the previously in vivo radiolabeled phosphorous on Y527 was not deleted during the promotion of Y416 autophosphorylation by Hg2+, Phosphoamino acid analysis demonstrated selective promotion of phosphorylation at tyrosine but not at serine/threonine. Not like bivalent Hg2+, monovalent p-chloromercuribenzenesulfonic acid was incapable of activating c-Src kinase. These results suggest a novel Y416 phosphorylation-linked activation pathway for Src kinases which is initially triggered independent of Y527-mediated or serine/threonine phosphorylation-linked regulation, possibly through sulfhydryl-based protein structural modification for functional alteration.	NAGOYA UNIV, SCH MED, DEPT IMMUNOL, SHOWA KU, NAGOYA, AICHI 466, JAPAN; NAGOYA UNIV, SCH MED, DIS MECHANISM & CONTROL RES INST, SHOWA KU, NAGOYA, AICHI 466, JAPAN; NAGOYA UNIV, SCH MED, DIV MED, RADIOISOTOPE CTR, SHOWA KU, NAGOYA, AICHI 466, JAPAN; KYOTO UNIV, JRDC, PRESTO, INST VIRUS RES, KYOTO 60601, JAPAN	Nagoya University; Nagoya University; Nagoya University; Japan Science & Technology Agency (JST); Kyoto University			KATO, Masashi/I-7250-2014; Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ATEN J, 1991, EUR J IMMUNOL, V21, P611, DOI 10.1002/eji.1830210312; ATKINSON TP, 1993, J IMMUNOL, V151, P1448; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAWSON DC, 1995, HANDB EXP PHARMACOL, V115, P53; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; GEORGE RJ, 1990, J CELL BIOCHEM, V42, P71, DOI 10.1002/jcb.240420203; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; LANDER HM, 1992, CELL IMMUNOL, V145, P146, DOI 10.1016/0008-8749(92)90319-K; LANDER HM, 1993, J IMMUNOL, V150, P1509; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; OKADA M, 1989, J BIOL CHEM, V264, P20886; RAHMAN SMJ, 1993, FEBS LETT, V317, P35, DOI 10.1016/0014-5793(93)81486-J; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SCHUHMANN D, 1990, J IMMUNOL, V145, P2132; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMPSON RB, 1961, J AM CHEM SOC, V83, P4711, DOI 10.1021/ja01484a005; SPERLING R, 1969, BIOCHEMISTRY-US, V8, P3810, DOI 10.1021/bi00837a047; STEER ML, 1974, BIOCHIM BIOPHYS ACTA, V334, P389, DOI 10.1016/0005-2744(74)90182-X; STRICKS W, 1953, J AM CHEM SOC, V75, P5673, DOI 10.1021/ja01118a060; TAKAFUJI S, 1989, CIBA F SYMP, V147, P188; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	42	65	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2615	2622						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000135				2022-12-25	WOS:A1996VZ65400011
J	Rader, JS; Kamarasova, T; Huettner, PC; Li, L; Li, Y; Gerhard, DS				Rader, JS; Kamarasova, T; Huettner, PC; Li, L; Li, Y; Gerhard, DS			Allelotyping of all chromosomal arms in invasive cervical cancer	ONCOGENE			English	Article						cervical cancer; allelotyping; chromosomes; tumor suppressor genes; loss of heterozygosity	COMPARATIVE GENOMIC HYBRIDIZATION; POLYMERASE CHAIN-REACTION; TUMOR-SUPPRESSOR GENE; CELL-LINE SIHA; MICROSATELLITE POLYMORPHISMS; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX; CARCINOMA; HETEROZYGOSITY; DELETION	The best characterized factor in the development of cervical cancer is the integration, of human papillomavirus into cervical cell chromosomes, Tn addition to HPV integration, the neoplastic process probably requires the activation of cellular protooncogenes and loss of tumor suppressor gene function, Loss of heterozygosity analysis in a large sample is used to identify regions which harbor putative tumor suppressor genes (TSG) since the deletion of normal alleles unmask mutated alleles, We evaluated tumor tissue from invasive cervical carcinomas, carefully microdissected to eliminate normal stroma and lymphocytes, for LOH at all 41 chromosomal arms with 50 polymorphic markers, We have evaluated tumor and normal DNA pairs from 48 invasive cervical cancers of which 85% of the tumors are confined to the cervix, The mean loss for all chromosomal arms was 12%. Three regions exhibited LOH two standard deviations above the mean: 3p14.1-12 (40%), 11q23.3 (36%), and 6p22-21.3 (32%), Three regions showed loss one standard deviation above the mean: 19q13.4 (30%), 6q21-23.33 (25%), and 2q33-37 (24%). Our results indicate that a significant number of invasive cervical cancers have lost specific chromsomal regions, thereby suggesting that genes involved in the cell cycle regulation or the suppression of tumor development are located in these regions.	WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Rader, JS (corresponding author), WASHINGTON UNIV, SCH MED, DEPT OBSTET & GYNECOL, ST LOUIS, MO 63110 USA.							APPLE RJ, 1994, NAT GENET, V6, P157, DOI 10.1038/ng0294-157; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; BENTZ M, 1995, BLOOD, V85, P3610, DOI 10.1182/blood.V85.12.3610.bloodjournal85123610; CHUNG GTY, 1992, ANTICANCER RES, V12, P1485; *FOG, 1987, INT J GYNECOL OBSTET, V25, P87; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HANADA R, 1995, ONCOGENE, V11, P1829; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JONES MH, 1992, ONCOGENE, V7, P1631; JONES MH, 1994, GENE CHROMOSOME CANC, V9, P119, DOI 10.1002/gcc.2870090207; Kirkwood B., 1988, BR K ESSENTIALS MED; KLITZ W, 1994, AM J HUM GENET, V54, P497; KNOWLES JA, 1994, HUM MOL GENET, V3, P1401, DOI 10.1093/hmg/3.8.1401; KOHNO T, 1993, ONCOGENE, V8, P1825; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; KOUTSKY LA, 1988, EPIDEMIOL REV, V10, P122, DOI 10.1093/oxfordjournals.epirev.a036020; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MITRA AB, 1994, CANCER RES, V54, P4481; Muliokandov MR, 1996, CANCER RES, V56, P197; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; PETRO R, 1986, VIRAL ETIOLOGY CERVI, P3; RADFORD DM, 1990, CANCER RES, V50, P6529; RUBIO MP, 1994, CANCER RES, V54, P4760; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHENGJING L, 1990, NATURE, V346, P470; SHIBATA D, 1992, AM J PATHOL, V141, P539; SMITS PHM, 1990, VIROLOGY, V176, P158, DOI 10.1016/0042-6822(90)90240-R; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOOK AK, 1991, AM J PREV MED, V7, P208; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; SYRJANEN K, 1990, SCAND J INFECT DIS, P7; TARKKANEN M, 1995, CANCER RES, V55, P1334; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208; WALKER GJ, 1994, INT J CANCER, V59, P771, DOI 10.1002/ijc.2910590611; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; YOKOTA J, 1989, CANCER RES, V49, P3598	43	89	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2737	2741						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000149				2022-12-25	WOS:A1996VZ65400025
J	Fischer, N; Kremmer, E; Lautscham, G; MuellerLantzsch, N; Grasser, FA				Fischer, N; Kremmer, E; Lautscham, G; MuellerLantzsch, N; Grasser, FA			Epstein-Barr virus nuclear antigen 1 forms a complex with the nuclear transporter karyopherin alpha 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 RNA-POLYMERASE; DNA-BINDING; PROTEIN; EXPRESSION; REPLICATION; ORIGIN; GENES; ANTIBODIES; INTERACTS; SEQUENCE	The Epstein-Barr virus (EBV) is implicated in the induction of several malignancies, The nuclear antigen 1 (EBNA1) is the only viral protein that is expressed consistently in all EBV-associated tumors. EBNA1 is involved in the replication and maintenance of the viral episome in the infected cell and exhibits oncogenic activity in transgenic mice, Here we report the identification of the nuclear transporter karyopherin alpha 2 as a cellular partner of EBNA1 using the yeast ''two-hybrid system.'' Karyopherin alpha 2 is also called importin alpha or Rch1. The binding to karyopherin alpha 2 was mediated through a C-terminal region of EBNA1 encompassing the nuclear localization signal, whereas clones of EBNA1 devoid of the nuclear localization signal failed to bind to karyopherin alpha 2. The interaction was biochemically confirmed by far-Western analysis using bacterially expressed karyopherin alpha 2 and karyopherin alpha 2-specific monoclonal antibodies. The nuclear transport of EBNA1 was impaired by expression of N-terminally truncated karyopherin alpha 2. Zone velocity sedimentation in a sucrose gradient indicated that: (i) EBNA1 and Rch1 colocalize; and (ii) the association of karyopherin alpha 2 with high molecular weight protein complexes might be impeded by the presence of EBNA1.	UNIV SAARLANDES KLINIKEN, ABT VIROL, INST MIKROBIOL & HYG, D-66421 HOMBURG, GERMANY; GSF MUNICH, RES CTR, INST IMMUNOL, D-81377 MUNICH, GERMANY	Universitatsklinikum des Saarlandes; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Lautscham, Georg/AAC-1364-2021					ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; AUSUBEL FM, 1994, CURR PROT MOL BIOL, V1; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRASSER FA, 1994, BLOOD, V84, P3792, DOI 10.1182/blood.V84.11.3792.bloodjournal84113792; GRASSER FA, 1993, VIROLOGY, V195, P550, DOI 10.1006/viro.1993.1406; GRASSER FA, 1991, J VIROL, V65, P3779; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HEARING JC, 1985, VIROLOGY, V145, P105; HILLE A, 1993, J MED VIROL, V39, P233, DOI 10.1002/jmv.1890390311; Hurt EC, 1996, CELL, V84, P509, DOI 10.1016/S0092-8674(00)81026-0; KIEFF E, 1995, FIELDS, V2, P2343; KIMBALL AS, 1989, MOL CELL BIOL, V9, P2738, DOI 10.1128/MCB.9.6.2738; KLEIN G, 1974, P NATL ACAD SCI USA, V85, P955; KNUDSON DL, 1974, J VIROL, V14, P934, DOI 10.1128/JVI.14.4.934-944.1974; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KREMMER E, 1995, VIROLOGY, V208, P336, DOI 10.1006/viro.1995.1157; Lenoir G M, 1985, IARC Sci Publ, P309; Lenoir GM, 1987, ADV VIRAL ONCOL, V7, P173; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MASUCCI MG, 1992, INT IMMUNOL, V4, P1283, DOI 10.1093/intimm/4.11.1283; MIDDLETON T, 1991, ADV VIRUS RES, V40, P19; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; OHNO S, 1977, P NATL ACAD SCI USA, V74, P1605, DOI 10.1073/pnas.74.4.1605; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; RICKINSON AB, 1995, FIELDS, V2, P2397; Roemer K, 1996, ONCOGENE, V12, P2069; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	57	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3999	4005		10.1074/jbc.272.7.3999	http://dx.doi.org/10.1074/jbc.272.7.3999			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020106	hybrid			2022-12-25	WOS:A1997WH01900022
J	Hammond, SM; Jenco, JM; Nakashima, S; Cadwallader, K; Gu, QM; Cook, S; Nozawa, Y; Prestwich, GD; Frohman, MA; Morris, AJ				Hammond, SM; Jenco, JM; Nakashima, S; Cadwallader, K; Gu, QM; Cook, S; Nozawa, Y; Prestwich, GD; Frohman, MA; Morris, AJ			Characterization of two alternately spliced forms of phospholipase D1 - Activation of the purified enzymes by phosphatidylinositol 4,5-bisphosphate, ADP-ribosylation factor, and RHO family monomeric GTP-binding proteins and protein kinase C-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIAL-PURIFICATION; GROWTH-FACTOR; ARF; MEMBRANE; BRAIN; CELLS; RAS; PHOSPHORYLATION; STIMULATION	We previously reported the cloning of a cDNA encoding human phosphatidylcholine-specific phospholipase D1 (PLD1), an ADP-ribosylation factor (ARF)-activated phosphatidylcholine-specific phospholipase D (Hammond, S. M., Tsung, S., Autschuller, Y., Rudge, S. A., Rose, K., Engebrecht, J., Morris, A. J., and Frohman, M. A. (1995) J. Biol. Chem. 270, 29640-29643), We have now identified an evolutionarily conserved shorter splice variant of PLD1 lacking 38 amino acids (residues 585-624) that arises from regulated splicing of an alternate exon, Both forms of PLD1 (PLD1a and 1b) have been expressed in Sf9 cells using baculovirus vectors and purified to homogeneity by detergent extraction and immunoaffinity chromatography, PLD1a and 1b have very similar properties, PLD1a and 1b activity is Mg2+- dependent but insensitive to changes in free Ca2+ concentration. Phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate activate PLD1a and 1b but a range of other acidic phospholipids are ineffective, PLD1a and 1b are highly responsive to activation by GTP-gamma S-liganded ADP-ribosylation factor-1 (ARF-1) and can also be activated to a lesser extent by three purified RHO family monomeric GTP-binding proteins, RHO A, RAC-1, and CDC42, Activation of PLD1a and 1b by the RHO family monomeric GTP-binding proteins is GTP-dependent and synergistic with ARF-1, Purified protein kinase C-alpha activates PLD1a and 1b in a manner that is stimulated by phorbol esters and does not require ATP, Activation of PLD1a and 1b by protein kinase C-alpha is synergistic with ARF and with the RHO family monomeric GTP-binding proteins, suggesting that these three classes of regulators interact with different sites an the enzyme.	SUNY STONY BROOK,HLTH SCI CTR,INST CELL & DEV BIOL,STONY BROOK,NY 11794; SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL SCI,STONY BROOK,NY 11794; GIFU UNIV,SCH MED,DEPT BIOCHEM,GIFU 500,JAPAN; SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794; ONYX PHARMACEUT,RICHMOND,CA 94806	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Gifu University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Morris, Andrew/B-7869-2010		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29758] Funding Source: Medline; NIGMS NIH HHS [GM50388] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARNERO A, 1994, ONCOGENE, V9, P1387; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; Gu QM, 1996, J ORG CHEM, V61, P8642, DOI 10.1021/jo961226g; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Han JS, 1996, J BIOL CHEM, V271, P11163, DOI 10.1074/jbc.271.19.11163; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; KISTASKIS NT, 1996, J CELL BIOL, V134, P295; Kitano T, 1986, Methods Enzymol, V124, P349; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LEE YH, 1994, J BIOL CHEM, V269, P26842; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORRIS AJ, 1996, TRENDS PHARMACOL SCI, V201, P177; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P107; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; POINTING CP, 1996, PROTEIN SCI, V5, P914; RANDAZZO PA, 1995, METHOD ENZYMOL, V257, P128; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; WANG XM, 1994, J BIOL CHEM, V269, P20312; YEO EJ, 1994, J BIOL CHEM, V269, P27823	49	494	504	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3860	3868		10.1074/jbc.272.6.3860	http://dx.doi.org/10.1074/jbc.272.6.3860			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013646	hybrid			2022-12-25	WOS:A1997WG19200106
J	Leung, SM; Hightower, LE				Leung, SM; Hightower, LE			A 16-kDa protein functions as a new regulatory protein for Hsc70 molecular chaperone and is identified as a member of the Nm23/nucleoside diphosphate kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI DNAJ; COGNATE PROTEIN; STRESS PROTEINS; UNCOATING ATPASE; MAST-CELLS; SACCHAROMYCES-CEREVISIAE; KARYOPHILIC PROTEINS; POLYPEPTIDE-CHAINS; EUKARYOTIC ENZYMES	Cytoplasmic Hsc70 is a multifunctional molecular chaperone. It is hypothesized that accessory proteins are used to specify the diverse chaperone activities of Hsc70. A 16-kDa cytosolic protein (p16) co-purified with Hsc70 obtained from a fish hepatocyte cell line, PLHC-1. Hsc70 also co-immunoprecipitated with p16 from PLHC-1 cells and fish liver. p16 was identified as a member of the Nm23/nucleoside diphosphate (NDP) kinase family based on its amino acid sequence similarity, NDP kinase activity, and recognition by anti-human NDP kinase-A antibody. This antibody also co-immunoprecipitated Hsc70 and NDP kinase from human HepG2 cells. p16 monomerized Hsc70 and released Hsc70 from pigeon cytochrome c peptide (Pc) but not from FYQLALT, a peptide specifically designed for high affinity binding. Therefore, p16 may modulate Hsc70 function by maintaining Hsc70 in a monomeric state and by dissociating unfolded proteins from Hsc70 either through protein-protein interactions or by supplying ATP indirectly through phosphate transfer. p16 did not affect basal or unfolded protein-stimulated ATPase activity of bovine brain Hsc70 using in vitro assays. Interestingly, bovine liver MDP kinase did not dissociate the Hsc70 Pe complex. In addition, two nonconservative amino acid subsitutions were found near the amino terminus of p16. Therefore, p16 may be a unique Nm23/NDP kinase that functions as an accessory protein for cytosolic Hsc70 in eukaryotes.	UNIV CONNECTICUT, DEPT MOL & CELL BIOL, STORRS, CT 06269 USA	University of Connecticut								ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; Barouch W., 1993, Molecular Biology of the Cell, V4, p95A; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BULGER AJ, 1979, EVOLUTION, V33, P848, DOI 10.1111/j.1558-5646.1979.tb04739.x; BULGER AJ, 1982, EVOLUTION, V36, P1041, DOI 10.1111/j.1558-5646.1982.tb05472.x; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1992, BIOCHEM BIOPH RES CO, V189, P1150, DOI 10.1016/0006-291X(92)92324-Q; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CIAVARRA RP, 1994, P NATL ACAD SCI USA, V91, P1751, DOI 10.1073/pnas.91.5.1751; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GAO BC, 1993, J BIOL CHEM, V268, P8507; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; GUIDON PT, 1986, BIOCHEMISTRY-US, V25, P3231, DOI 10.1021/bi00359a023; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HARRINGTON HM, 1994, AUST J PLANT PHYSIOL, V21, P843, DOI 10.1071/PP9940843; HARRIS N, 1994, PLANT MOL BIOL, V25, P739, DOI 10.1007/BF00029611; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4574, DOI 10.1021/bi00134a006; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGHTOWER LE, 1988, J EXP ZOOL, V248, P290, DOI 10.1002/jez.1402480307; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; HOHFELD J, 1995, CELL, V83, P589; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; INOUE A, 1995, J BIOL CHEM, V270, P22571, DOI 10.1074/jbc.270.38.22571; KIM DH, 1992, J CELL PHYSIOL, V153, P353, DOI 10.1002/jcp.1041530215; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KIMURA N, 1988, BIOCHEM BIOPH RES CO, V151, P248, DOI 10.1016/0006-291X(88)90586-4; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; KLINKER JF, 1994, BIOCHEM J, V304, P377, DOI 10.1042/bj3040377; KLINKER JF, 1995, BIOCHEM BIOPH RES CO, V209, P575, DOI 10.1006/bbrc.1995.1539; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MARTIN MW, 1995, BRIT J PHARMACOL, V115, P1080, DOI 10.1111/j.1476-5381.1995.tb15921.x; Mehta A., 1995, Molecular Biology of the Cell, V6, p67A; MOISYADI S, 1994, PLANT PHYSIOL, V104, P1401, DOI 10.1104/pp.104.4.1401; NAGAI N, 1995, BIOCHEM BIOPH RES CO, V208, P1099, DOI 10.1006/bbrc.1995.1447; NAYLOR DJ, 1995, BBA-PROTEIN STRUCT M, V1248, P75, DOI 10.1016/0167-4838(95)00007-H; NUNES SL, 1996, BIOCHEM BIOPH RES CO, V213, P1; OHBA M, 1994, FEBS LETT, V351, P263; OKABEKADO J, 1995, FEBS LETT, V363, P311, DOI 10.1016/0014-5793(95)00338-A; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; PRASAD K, 1993, J BIOL CHEM, V268, P23758; Prasad K., 1994, Molecular Biology of the Cell, V5, p329A; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCHULTZ ME, 1985, EXP MOL PATHOL, V42, P320, DOI 10.1016/0014-4800(85)90082-6; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALTON GM, 1975, BIOCHIM BIOPHYS ACTA, V390, P231, DOI 10.1016/0005-2787(75)90344-5; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; ZIEMIENOWICZ A, 1995, J BIOL CHEM, V270, P15479, DOI 10.1074/jbc.270.26.15479; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; [No title captured]	97	76	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2607	2614		10.1074/jbc.272.5.2607	http://dx.doi.org/10.1074/jbc.272.5.2607			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006893	hybrid			2022-12-25	WOS:A1997WE66700006
J	Lidholt, K; Fjelstad, M				Lidholt, K; Fjelstad, M			Biosynthesis of the Escherichia coli K4 capsule polysaccharide - A parallel system for studies of glycosyltransferases in chondroitin formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE BIOSYNTHESIS; K5 POLYSACCHARIDE; HEPARAN-SULFATE; POLYMERIZATION; GLUCURONOSYLTRANSFERASE; HYALURONATE; ANTIGEN; CELLS	Escherichia coli K4 bacteria synthesize a capsule polysaccharide (GalNAc-GlcA(fructose))(n) with the carbohydrate backbone identical to chondroitin. GlcA- and GalNAc-transferase activities from the bacterial mem brane were assayed with accepters derived from the capsule polysaccharide and radiolabeled UDP-[C-14]GlcA and UDP-[H-3]GalNAc, respectively. It was shown that defructosylated oligosaccharides (chondroitin) could serve as substrates for both the GlcA- and the GalNAc-transferases. The radiolabeled products were completely degraded with chondroitinase AC; the [C-14]GlcA unit could be removed by beta-D-glucuronidase, and the [H-3]GalNAc could be removed by beta-N-acetylhexosaminidase. A fructosylated oligosaccharide acceptor tested for GlcA-transferase activity was found to be inactive. These results indicate that the chain elongation reaction of the K4 polysaccharide proceeds in the same way as the polymerization of the chondroitin chain, by the addition of the monosaccharide units one by one to the nonreducing end of the polymer. This makes the biosynthesis of the K4 polysaccharide an interesting parallel system for studies of chondroitin sulfate biosynthesis. In the biosynthesis of capsule polysaccharides from E. coli, a similar mechanism has earlier been demonstrated for polysialic acid (NeuNAc)(n) (Rohr, T. E., and Troy, F. A. (1980) J. Biol. Chem. 255, 2332-2342) and for the K5 polysaccharide (GlcA beta 1-4GlcNAc alpha 1-4)(n) (Lidholt, K., Fjelstad, M., Jann, K., and Lindahl, U. (1994) Carbohydr. Res. 255, 87-101). In contrast, chain elongation of hyaluronan (GlcA beta 1-3GlcNAc beta 1-4)(n) is claimed to occur at the reducing end (Prehm, P. (1983) Biochem. J. 211, 181-189).			Lidholt, K (corresponding author), UNIV UPPSALA, CTR BIOMED, DEPT MED & PHYSIOL CHEM, BOX 575, S-75123 UPPSALA, SWEDEN.							BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRONNER D, 1993, J BACTERIOL, V175, P5984, DOI 10.1128/JB.175.18.5984-5992.1993; FINKE A, 1991, J BACTERIOL, V173, P4088, DOI 10.1128/jb.173.13.4088-4094.1991; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; JANN B, 1990, CURR TOP MICROBIOL, V150, P19; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1994, CARBOHYD RES, V255, P87, DOI 10.1016/S0008-6215(00)90972-8; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LIDHOLT K, 1988, BIOCHEM J, V254, P571, DOI 10.1042/bj2540571; LIND T, 1993, J BIOL CHEM, V268, P20705; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; RICHMOND ME, 1973, BIOCHEMISTRY-US, V12, P3904, DOI 10.1021/bi00744a018; RICHMOND ME, 1973, BIOCHEMISTRY-US, V12, P3898, DOI 10.1021/bi00744a017; RODRIGUEZ ML, 1988, EUR J BIOCHEM, V177, P117, DOI 10.1111/j.1432-1033.1988.tb14351.x; ROHR TE, 1980, J BIOL CHEM, V255, P2332; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SILBERT JE, 1963, J BIOL CHEM, V238, P3542; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; SUGUMARAN G, 1990, J BIOL CHEM, V265, P18284; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x	23	37	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2682	2687		10.1074/jbc.272.5.2682	http://dx.doi.org/10.1074/jbc.272.5.2682			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006904	hybrid			2022-12-25	WOS:A1997WE66700017
J	Spyrou, G; Enmark, E; MirandaVizuete, A; Gustafsson, JA				Spyrou, G; Enmark, E; MirandaVizuete, A; Gustafsson, JA			Cloning and expression of a novel mammalian thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; DNA-BINDING ACTIVITY; REDOX REGULATION; FREE-RADICALS; REDUCTION; CELLS; IDENTIFICATION; SECRETION; INVITRO; PURIFICATION	We have isolated a 1276-base pair cDNA from a rat heart cDNA library that encodes a novel thioredoxin (Trx2) of 166 amino acid residues with a calculated molecular mass of 18.2 kDa. Trx2 possesses the conserved thioredoxin-active site, Trp-Cys-Gly-Pro-Cys, but lacks structural cysteines present in all mammalian thioredoxins. Trx2 also differs from the previously described rat thioredoxin (Trx1) by the presence of a 60-amino acid extension at the N terminus. This extension has properties characteristic for a mitochondrial translocation signal, and the cleavage at a putative mitochondrial peptidase cleavage site would give a mature protein of 12.2 kDa. Western blot analysis from cytosolic, peroxisomal, and mitochondrial rat liver cell fractions confirmed mitochondrial localization of Trx2. Northern blot and reverse transcriptase-polymerase chain reaction analyses revealed that Trx2 hybridized to a 1.3-kilobase message, and it was expressed in several tissues with the highest expression levels in heart, muscle, kidney, and adrenal gland. N-terminally truncated recombinant protein was expressed in bacteria and characterized biochemically. Trx2 possessed a dithiol-reducing enzymatic activity and, with mammalian thioredoxin reductase and NADPH, was able to reduce the interchain disulfide bridges of insulin. Furthermore, Trx2 was more resistant to oxidation than Trx1.			Spyrou, G (corresponding author), KAROLINSKA INST,NOVUM,DEPT BIOSCI,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN.		Miranda-Vizuete, Antonio/D-6927-2012; IBIS, REDOX/J-7473-2017	Miranda-Vizuete, Antonio/0000-0002-6856-5396; 				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BODENSTEIN J, 1991, Z NATURFORSCH C, V46, P270; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE FM, 1991, J REPROD FERTIL, V93, P525, DOI 10.1530/jrf.0.0930525; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; FUJII S, 1991, VIRCHOWS ARCH A, V419, P317, DOI 10.1007/BF01606523; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1988, PLASMA MEMBRANE OXID, P295; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MARTIN H, 1991, BIOCHEM BIOPH RES CO, V175, P123, DOI 10.1016/S0006-291X(05)81209-4; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MULLER EGD, 1992, YEAST, V8, P117, DOI 10.1002/yea.320080206; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; NEUPERT W, 1994, CLIN INVESTIGATOR, V72, P251; NEWMAN GW, 1994, J EXP MED, V180, P359, DOI 10.1084/jem.180.1.359; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; OKUNO H, 1993, ONCOGENE, V8, P695; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; RUBARTELLI A, 1995, CANCER RES, V55, P675; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; SCHALLREUTER KU, 1986, BIOCHEM BIOPH RES CO, V136, P630, DOI 10.1016/0006-291X(86)90487-0; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TONISSEN KF, 1991, GENE, V102, P221, DOI 10.1016/0378-1119(91)90081-L; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282	41	319	334	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2936	2941		10.1074/jbc.272.5.2936	http://dx.doi.org/10.1074/jbc.272.5.2936			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006939	hybrid			2022-12-25	WOS:A1997WE66700052
J	Seluanov, A; Bibi, E				Seluanov, A; Bibi, E			FtsY, the prokaryotic signal recognition particle receptor homologue, is essential for biogenesis of membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; SEQUENCE; GENE	In mammalian cells, many secretory proteins are targeted to the endoplasmic reticulum co-translationally, by the signal recognition particle (SRP) and its receptor. In Escherichia coli, the targeting of secretory proteins to the inner membrane can be accomplished post-translationally. Unexpectedly, despite this variance, E. coli contains essential genes encoding Ffh and FtsY with a significant similarity to proteins of the eukaryotic SRP machinery. In this study, we investigated the possibility that the prokaryotic SRP-like machinery is involved in biogenesis of membrane proteins in E. coli. The data presented here demonstrate that the SRP-receptor homologue, FtsY, is indeed essential for expression of integral membrane proteins in E. coli, indicating that, in the case of this group of proteins, FtsY and the mammalian SRP receptor have similar functions.	WEIZMANN INST SCI,DEPT BIOCHEM,DR SAMUEL O FREEDMAN CAREER DEV CHAIR LIFE SCI,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Seluanov, Andrei/0000-0003-3400-538X; Bibi, Eitan/0000-0003-3700-2707				ARKOWITZ RA, 1994, BBA-REV BIOMEMBRANES, V1197, P311; Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; GILL DR, 1987, MOL GEN GENET, V210, P504, DOI 10.1007/BF00327204; GILL DR, 1990, MOL MICROBIOL, V4, P575; HOHFELD J, 1994, CURR OPIN CELL BIOL, V6, P499, DOI 10.1016/0955-0674(94)90068-X; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MEYER DI, 1982, NATURE, V297, P503; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; TRAXLER B, 1996, J BIOL CHEM, V271, P12392; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WEIDMANN M, 1987, NATURE, V328, P830; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	17	140	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2053	2055						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999901				2022-12-25	WOS:A1997WD67900007
J	Kerangueven, F; Eisinger, F; Noguchi, T; Allione, F; Wargniez, V; Eng, C; Padberg, G; Theillet, C; Jacquemier, J; Longy, M; Sobol, H; Birnbaum, D				Kerangueven, F; Eisinger, F; Noguchi, T; Allione, F; Wargniez, V; Eng, C; Padberg, G; Theillet, C; Jacquemier, J; Longy, M; Sobol, H; Birnbaum, D			Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions	ONCOGENE			English	Article						ataxia telangiectasia; BRCA1; breast cancer; chromosome 10; chromosome 11; chromosome 17	SUSCEPTIBILITY GENE; CERVICAL-CARCINOMA; MALIGNANT-MELANOMA; CHROMOSOME 11Q23; CANCER; TUMORS; IDENTIFICATION; AMPLIFICATION; INVOLVEMENT; LOCUS	To appreciate the involvement of known or potential susceptibility genes in sporadic breast tumors, we have searched for chromosomal deletions by studying loss of heterozygosity (LOH) at 43 microsatellite (CA)(n) markers from human chromosomes 10, 11 and 17, in 115 unselected consecutive samples of breast carcinoma with particular emphasis on specific regions. No site of consistent LOH was identified on chromosome 10. Five regions of LOH were contained within bands q22-24 of chromosome 11 for which nearly 50% of the tumors had LOH at at least one marker. This region is thus a major site of deletion in breast cancer and several tumor suppressor genes seem to be involved. One of them may be the ataxia telangiectasia (ATM) gene which is located in one of the affected regions. Five regions of LOH, one of which is within the BRCA1 gene area, were recognized along chromosome 17. LOH at three of these regions were found in highly proliferative tumors, When combined with a previous study of chromosome 13 with emphasis on BRCA2 and Rb1 genes, this work allowed to distinguish a total of 12 regions of LOH, variably affected in breast tumors and correlated with prognostic parameters.	INST J PAOLI I CALMETTES,LAB BIOL TUMEURS,F-13009 MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,DEPT ONCOGENET,F-13009 MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,DEPT NUCL MED,F-13009 MARSEILLE,FRANCE; UNIV NIJMEGEN HOSP,NIJMEGEN,NETHERLANDS; IGGM,CNRS URA 9942,MONTPELLIER,FRANCE; INST J PAOLI I CALMETTES,DEPT PATHOL ANAT,F-13009 MARSEILLE,FRANCE; FDN BERGONIE,F-33076 BORDEAUX,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE	UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Radboud University Nijmegen; Universite de Montpellier; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Bergonie; Institut National de la Sante et de la Recherche Medicale (Inserm)			Padberg, G.W.A.M./H-8079-2014; Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Eisinger, Francois/0000-0002-8794-0681; Eng, Charis/0000-0002-3693-5145				AGRESTI A, 1990, J AM STAT ASSOC, V85, P543; Baffa R, 1996, CANCER RES, V56, P268; BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CARTER SL, 1994, CANCER RES, V54, P6270; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; CROPP CS, 1993, CANCER RES, V53, P5617; Davis M, 1996, CANCER RES, V56, P741; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eisinger F, 1996, CANCER RES, V56, P471; FERTIPASSANTONOPOULOU A, 1991, CANCER GENET CYTOGEN, V51, P183, DOI 10.1016/0165-4608(91)90130-M; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GRAY IC, 1995, CANCER RES, V55, P4800; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; Hollander M., 1973, NONPARAMETRIC STAT M, P115; HUI A, 1996, ONCOGENE, V56, P3225; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; Ittmann M, 1996, CANCER RES, V56, P2143; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kerangueven F, 1996, INT J ONCOL, V8, P1155; KERANGUEVEN F, 1995, ONCOL REP, V2, P89; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P271; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; LINDBLOM A, 1994, AM J HUM GENET, V54, P871; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; NAGAI MA, 1995, ONCOLOGY, V52, P448; NEGRINI M, 1995, CANCER RES, V55, P3003; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Phillips KK, 1996, CANCER RES, V56, P1222; RASIO D, 1995, CANCER RES, V55, P3988; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; SANCHEZ Y, 1996, CANCER RES, V93, P2551; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schultz DC, 1996, CANCER RES, V56, P1997; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; SOBOL H, 1994, LANCET, V344, P1151, DOI 10.1016/S0140-6736(94)90655-6; STARINK TM, 1986, CLIN GENET, V29, P222; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; THEILLET C, 1989, ONCOGENE, V4, P915; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; WINQVIST R, 1995, CANCER RES, V55, P2660; ZHUANG ZP, 1995, CANCER RES, V55, P467	54	61	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					339	347		10.1038/sj.onc.1200818	http://dx.doi.org/10.1038/sj.onc.1200818			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018120	Green Published			2022-12-25	WOS:A1997WD51600010
J	Kavanaugh, MP; Bendahan, A; Zerangue, N; Zhang, YM; Kanner, BI				Kavanaugh, MP; Bendahan, A; Zerangue, N; Zhang, YM; Kanner, BI			Mutation of an amino acid residue influencing potassium coupling in the glutamate transporter GET-1 induces obligate exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MEMBRANE-VESICLES; GLIAL-CELLS; ION FLUXES; EXPRESSION; CLONING; SODIUM; GLT-1; RECONSTITUTION; PURIFICATION	Glutamate transporters maintain low synaptic concentrations of neurotransmitter by coupling uptake to flux of other ions. After cotransport of glutamic acid with Na+, the cycle is completed by countertransport of K+. We have identified an amino acid residue (glutamate 404) influencing ion coupling in a domain of the transporter implicated previously in kainate binding. Mutation of this residue to aspartate (E404D) prevents both forward and reverse transport induced by K+. Sodium dependent transmitter exchange and a transporter-mediated chloride conductance are unaffected by the mutation, indicating that this residue selectively influences potassium flux coupling. The results support a kinetic model in which sodium and potassium are translocated in distinct steps and suggest that this highly conserved region of the transporter is intimately associated with the ion permeation pathway.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91120 JERUSALEM,ISRAEL; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Hebrew University of Jerusalem; Oregon Health & Science University					NIGMS NIH HHS [GM 48709] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Billups B, 1996, J NEUROSCI, V16, P6722; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KANAI Y, 1992, NATURE, V360, P464; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; NELSON PJ, 1983, BIOCHEMISTRY-US, V22, P5459, DOI 10.1021/bi00292a030; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1985, J BIOL CHEM, V260, P1859; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	36	151	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1703	1708		10.1074/jbc.272.3.1703	http://dx.doi.org/10.1074/jbc.272.3.1703			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999849	Green Published, hybrid			2022-12-25	WOS:A1997WD05800047
J	ZrihanLicht, S; Lim, J; Keydar, I; Sliwkowski, MX; Groopman, JE; Avraham, H				ZrihanLicht, S; Lim, J; Keydar, I; Sliwkowski, MX; Groopman, JE; Avraham, H			Association of Csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; PROTEIN-TYROSINE KINASE; PHOSPHOLIPASE-C-GAMMA; GTPASE-ACTIVATING PROTEIN; FACTOR RECEPTOR FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	Protein-tyrosine kinases, such as HER-2/ErbE-2, have been specifically linked to breast cancer. The Csk-homologous kinase (CHK), formerly MATK, is a tyrosine kinase that contains the Src homology 2 and 3 (SH2 and SH3) domains and demonstrates homology (similar to 50%) to the Csk tyrosine kinase. Like Csk, CHK is able 60 phosphorylate and inactivate Src family kinases. In this report, we investigated whether CHK is expressed in breast cancer tissues and whether it participates in the ErbB-2 signaling pathway in T47D and MCF-7 breast cancer cell lines. Immunostaining of the CHK protein in breast tissues demonstrated that primary invasive ductal carcinomas, stage II (13 of 15 cases) and stage I (8 of 15 cases), expressed the CHK protein, while this protein was not detected in the adjacent normal tissues from the same patients. To study the role of CHK in the ErbB-2 signaling pathway, glutathione S-transferase fusion proteins containing the SH2 and SH3 domains of CHK were generated. CHK-SH2 and CHK-SH3-SH2, but not CHK-SH3 or CHK-NH2-SH3, precipitated the tyrosine-phosphorylated ErbB-2 upon stimulation with heregulin. EGF or interleukin-6 stimulation of T47D cells failed to induce CHK-SH2 association with ErbB-2, the EGF-receptor, or the interleukin-6 receptor. In vivo association of the tyrosine phosphorylated ErbB-2 with CHK was observed in co-immunoprecipitation studies with anti-CHK antibodies. EGF-R, ErbB-3, and ErbB-4 were not detected in the CHK immunoprecipitates or in the precipitates of the GST-SH2 fusion proteins of CHK, suggesting that the association of CHK with ErbB-2 upon heregulin stimulation is receptor-specific (ErbB-2) and ligand-specific (heregulin). These results indicate that CHK might participate in signaling in breast cancer cells by associating, via its SH2 domain, with ErbB-2 following heregulin stimulation.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215; TEL AVIV UNIV,DEPT CELL RES & IMMUNOL,IL-69978 RAMAT AVIV,ISRAEL; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tel Aviv University; Roche Holding; Genentech				Avraham, Hava/0000-0002-7545-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51456-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; Bougeret C, 1996, J BIOL CHEM, V271, P7465, DOI 10.1074/jbc.271.13.7465; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HAMAGUCHI I, 1994, ONCOGENE, V9, P3371; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JHUN BH, 1995, J BIOL CHEM, V270, P9661, DOI 10.1074/jbc.270.16.9661; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KIM HH, 1994, J BIOL CHEM, V269, P24747; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MUSSO T, 1994, J EXP MED, V180, P2383, DOI 10.1084/jem.180.6.2383; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRICE DJ, 1995, BLOOD, V86, P122; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Riese DJ, 1996, ONCOGENE, V12, P345; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKANO S, 1994, ONCOGENE, V9, P1155; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1993, ONCOGENE, V8, P2105; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	76	56	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1856	1863		10.1074/jbc.272.3.1856	http://dx.doi.org/10.1074/jbc.272.3.1856			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999872	hybrid			2022-12-25	WOS:A1997WD05800070
J	Huff, SY; Quilliam, LA; Cox, AD; Der, CJ				Huff, SY; Quilliam, LA; Cox, AD; Der, CJ			R-Ras is regulated by activators and effectors distinct from those that control Ras function	ONCOGENE			English	Article						GDP; GTP regulation; Raf kinases; dominant negative mutants	NUCLEOTIDE EXCHANGE FACTORS; SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE KINASE; PROTEIN-KINASE; TYPE-1 NEUROFIBROMATOSIS; CELL-TRANSFORMATION; MAMMALIAN-CELLS; GENE-PRODUCT; GROWTH; EXPRESSION	Like Ras, constitutively activated mutants of the Ras-related protein R-Ras cause tumorigenic transformation of NIH3T3 cells. However, since R-Ras causes a transformed phenotype distinct from that induced by Ras, it is likely that R-Ras controls signaling pathways and cellular processes distinct from those regulated by Ras. To address this possibility, we determined if R-Ras is regulated by activators and effecters distinct from those that regulate Ras function, We observed that Ras guanine nucleotide exchange factors failed to activate R-Ras in vivo, indicating that R-Ras is activated by distinct GEFs. Consistent with this, mutants of R-Ras with mutations analogous to the Ras(15A)/(17N) dominant negative proteins did not antagonize Ras GEF function and lacked the growth inhibitory activity seen with these mutant Ras proteins, Thus, R-Ras, but not Ras, is dispensable for the viability of MIH3T3 cells. Finally, whereas constitutively activated Ras can overcome the growth inhibitory action of the Ras(17N) dominant negative protein via Raf-dependent and -independent activities, transforming mutants of R-Ras failed to do so. This inability was consistent with our observation that Ras-, but not R-Ras-transformed, NIH3T3 cells possessed constitutively upregulated Raf kinase activities. Thus, R-Ras and Ras are regulators of distinct signaling pathways and cellular processes.	UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT RADIAT ONCOL, CHAPEL HILL, NC 27599 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute			Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA052072, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA52072, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHEN SY, 1994, ONCOGENE, V9, P2691; Clark GJ, 1996, ONCOGENE, V12, P169; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1994, ONCOGENE, V9, P3281; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GRAHAM SM, 1996, IN PRESS MOL CELL BI; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MOODIE SA, 1994, TRENDS GENET, V10, P14; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	77	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	1997	14	2					133	143		10.1038/sj.onc.1200815	http://dx.doi.org/10.1038/sj.onc.1200815			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010215				2022-12-25	WOS:A1997WC81800001
J	ElRouby, S; Newcomb, EW				ElRouby, S; Newcomb, EW			Identification of Bcd a novel proto-oncogene expressed in B-cells	ONCOGENE			English	Article						transfection; transforming activity; chronic lymphocytic leukemia; B-cell differentiation	CHRONIC LYMPHOCYTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; TRANSFORMING GENES; SEQUENCES; VAV; DNA; ACTIVATION; LYMPHOMAS; CLONING; DOMAINS	A novel B-cell derived (Bcd) oncogene has been isolated from the peripheral blood lymphocytes of one B-cell chronic lymphocytic leukemia (B-CLL) patient using DNA transfer and a mouse tumorigenicity assay. The Bcd proto-oncogene was activated by a truncation in the 5' UTR, It predicts for two open reading frames (ORFs). ORF1 consists of 240 bp that would encode 80 amino acids, while the major ORF2 consists of 648 bp capable of coding for 216 amino acids, Predicted peptide sequence of ORF2 contained a zinc finger domain which showed significant homology to GC box binding proteins BTEB2 and SP1. Transfection of an expression vector containing ORF2 but not full length cDNA was able to transform NIH3T3 cells and induce tumors in nude mice. Bcd mRNA transcripts of less than or equal to 2.6 kb were selectively expressed in PBL and testis of healthy individuals. Within the PBL, Bcd gene expression was restricted to CD19(+) B-cells and absent from CD14(+) monocytes and T-cells. Bcd transcripts were detected in all normal PBL samples tested but not in several malignant human B-cell lines and not in 50% of B-cells from B-CLL patients, However, stimulation of B-cells from B-CLL patients under conditions which induced differentiation into plasma cells was associated with induction of Bcd gene expression, The Bcd gene may therefore play an important role in B-cell growth and development.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; KAPLAN CANC CTR,NEW YORK,NY 10016	New York University					NCI NIH HHS [P30-CA16087, CA53572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016087, R01CA053572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNSTEIN JM, 1994, HDB MUCOSAL IMMUNOLO, P625; BLAIR DG, 1982, SCIENCE, V28, P1122; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER GM, 1980, NATURE, V284, P418, DOI 10.1038/284418a0; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; ELROUBY S, 1993, BLOOD, V82, P3452; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORDON J, 1984, J IMMUNOL, V132, P541; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIPPS TJ, 1988, BLOOD, V72, P422; KODONAGA JT, 1987, CELL, V51, P1079; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NEWCOMB EW, 1988, CANCER RES, V48, P5514; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	34	14	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2623	2630						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000136				2022-12-25	WOS:A1996VZ65400012
J	Yatsula, BA; Plachy, J; Mikhailik, A; DavidPfeuty, T; Lecoq, O; Yatsula, V; Geryk, J; Svoboda, J; Calothy, G; Dezelee, P				Yatsula, BA; Plachy, J; Mikhailik, A; DavidPfeuty, T; Lecoq, O; Yatsula, V; Geryk, J; Svoboda, J; Calothy, G; Dezelee, P			Phenotypic changes induced by wild type and variant c-src genes carrying C-terminal sequence alterations	ONCOGENE			English	Article						c-src; avian sarcoma virus; oncogene activation; neuroretina	ROUS-SARCOMA VIRUS; NEURORETINAL CELL-PROLIFERATION; NIH 3T3 CELLS; TRANSFORMATION DEFECTIVE MUTANT; TYROSINE KINASE-ACTIVITY; V-SRC; TRANSFECTED DNA; GROWTH-FACTOR; PP60C-SRC; ACTIVATION	We previously reported the isolation of PR2257, a novel avian sarcoma retrovirus which transduced the c-src protooncogene. The v-src gene of PR2257 differs from the c-src gene by a sequence change after amino acid 525, resulting in the replacement of tyrosine 527 by a valine, and an extension of the open reading frame into the non coding region of c-src. We investigated the respective roles of Tyr527 mutation and of the C-terminal extension in activating the oncogenic properties of c-src. Therefore we overexpressed the wild type c-src gene and c-src variants, carrying either a substitution of tyrosine 527 or an extension of the C-terminus or both modifications in combination, in chicken embryo fibroblasts and post mitotic neuroretina (NR) cells, using replication defective retroviruses. We also used in vivo inoculation of plasmid DNA to assess the tumorigenicity of the various c-src genes, We report that, in contrast to previous results, overexpression of c-src is sufficient to induce NR cell division, While mutation of tyrosine 527 alone significantly activates c-src transforming and tumorigenic properties, its combination with the C-terminal extension of PR2257 confers to this gene full oncogenic properties and increased metastatic potential as compared to the v-src of Rous sarcoma virus strains.	INST CURIE,UMR 146 CNRS,F-91405 ORSAY,FRANCE; ACAD SCI CZECH REPUBL,INST MOL GENET,CR-16637 PRAGUE 6,CZECH REPUBLIC	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences			Josef, Geryk/I-8729-2014; Plachy, Jiri/G-4381-2014; Geryk, Josef/G-3548-2014	Josef, Geryk/0000-0002-3992-2980; 				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; CALOS MP, 1983, P NATL ACAD SCI-BIOL, V80, P3015, DOI 10.1073/pnas.80.10.3015; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DEZELEE P, 1992, VIROLOGY, V189, P556, DOI 10.1016/0042-6822(92)90579-E; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; GERYK J, 1989, J VIROL, V63, P481, DOI 10.1128/JVI.63.2.481-492.1989; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IBA H, 1985, MOL CELL BIOL, V5, P2856, DOI 10.1128/MCB.5.10.2856; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEBKOWSKI JS, 1984, MOL CELL BIOL, V4, P1951, DOI 10.1128/MCB.4.10.1951; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIN PH, 1995, ONCOGENE, V10, P401; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLACHY J, 1994, IMMUNOGENETICS, V40, P257, DOI 10.1007/BF00189970; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REDDY S, 1988, MOL CELL BIOL, V8, P704, DOI 10.1128/MCB.8.2.704; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SVOBODA J, 1992, IMMUNOGENETICS, V35, P309, DOI 10.1007/BF00189893; SVOBODA J, 1984, FOLIA BIOL-PRAGUE, V31, P135; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; WAKE CT, 1984, MOL CELL BIOL, V4, P387, DOI 10.1128/MCB.4.3.387; YATSULA BA, 1994, BBA-GENE STRUCT EXPR, V1218, P473, DOI 10.1016/0167-4781(94)90210-0; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298	45	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2717	2725						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000146				2022-12-25	WOS:A1996VZ65400022
J	Ridsdale, RA; Beniac, DR; Tompkins, TA; Moscarello, MA; Harauz, G				Ridsdale, RA; Beniac, DR; Tompkins, TA; Moscarello, MA; Harauz, G			Three-dimensional structure of myelin basic protein .2. Molecular modeling and considerations of predicted structures in multiple sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; AMINO ACID SEQUENCE; SECONDARY STRUCTURE; NEURAL NETWORKS; HOLY PROTEINS; F-ACTIN; MEMBRANE; BILAYERS; BINDING; DOMAINS	A computational model of myelin basic protein (MBP) has been constructed based on the premise of a phylogenetically conserved beta-sheet backbone and on electron microscopical three-dimensional reconstructions. Many residues subject to post-translational modification (phosphorylation, methylation, or conversion of arginines to citrullines) were located in loop regions and thus accessible to modifying enzymes. The triproline segment (residues 99-101) is fully exposed on the back surface of the protein in a long crossover connection between two parallel beta-strands. The proximity of this region to the underlying beta-sheet suggests that posttranslational modifications here might have potential synergistic effects on the entire structure. Post-translational modifications that lead to a reduced surface charge could result first in a weakened attachment to the myelin membrane rather than in a gross conformational change of the protein itself. Such mechanisms could be operative in demyelinating diseases such as multiple sclerosis.	UNIV GUELPH,DEPT MOL BIOL & GENET,GUELPH,ON N1G 2W1,CANADA; HOSP SICK CHILDREN,DEPT BIOCHEM RES,TORONTO,ON M5G 1X8,CANADA	University of Guelph; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Tompkins, Thomas A./0000-0002-2990-2265				BARYLKO B, 1984, EUR J CELL BIOL, V35, P327; Beniac DR, 1997, J BIOL CHEM, V272, P4261, DOI 10.1074/jbc.272.7.4261; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CARNEGIE PR, 1971, BIOCHEM J, V123, P57, DOI 10.1042/bj1230057; CHOU FCH, 1976, J BIOL CHEM, V251, P2671; DEBER CM, 1991, CLIN BIOCHEM, V24, P113, DOI 10.1016/0009-9120(91)90421-A; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DIJKSTRA BW, 1994, CURR OPIN STRUC BIOL, V4, P810, DOI 10.1016/0959-440X(94)90261-5; DOBROWOLSKI Z, 1986, EUR J CELL BIOL, V42, P17; EICHINGER L, 1992, BIOCHEMISTRY-US, V31, P4779, DOI 10.1021/bi00135a006; EYLAR EH, 1971, J BIOL CHEM, V246, P5770; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; GOLUBOVICH V P, 1989, Biophysics (English Translation of Biofizika), V34, P395; HOFSTEENGE J, 1994, CURR OPIN STRUC BIOL, V4, P807, DOI 10.1016/0959-440X(94)90260-7; INOUYE H, 1991, J NEUROSCI RES, V28, P1, DOI 10.1002/jnr.490280102; KARTHIGASAN J, 1995, MED HYPOTHESES, V45, P245; KIRSCHNER DA, 1989, J NEUROCHEM, V53, P1599, DOI 10.1111/j.1471-4159.1989.tb08558.x; Lees M., 1984, MYELIN, P197; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LESK AM, 1988, COMPUTATIONAL MOL BI, P192; MARTENSON RE, 1986, J NEUROCHEM, V46, P1612, DOI 10.1111/j.1471-4159.1986.tb01784.x; MARTENSON RE, 1981, J NEUROCHEM, V36, P1543, DOI 10.1111/j.1471-4159.1981.tb00598.x; MARTENSON RE, 1971, NATURE-NEW BIOL, V234, P87, DOI 10.1038/newbio234087a0; Mateu L, 1996, J MOL BIOL, V256, P319, DOI 10.1006/jmbi.1996.0088; MENDZ GL, 1995, EUR J BIOCHEM, V231, P659, DOI 10.1111/j.1432-1033.1995.0659d.x; MOSCARELLO MA, 1994, J CLIN INVEST, V94, P146, DOI 10.1172/JCI117300; MOSCARELLO MA, 1996, CELL BIOL PATHOLOGY; Neil KJ, 1996, NUCLEIC ACIDS RES, V24, P1472, DOI 10.1093/nar/24.8.1472; PEREZGIL J, 1994, J THEOR BIOL, V169, P221, DOI 10.1006/jtbi.1994.1143; RAMWANI JJ, 1989, BIOCHEMISTRY-US, V28, P6538, DOI 10.1021/bi00442a002; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; ROTH GA, 1993, NEUROCHEM INT, V23, P459, DOI 10.1016/0197-0186(93)90130-W; SAAVEDRA RA, 1989, J MOL EVOL, V29, P149, DOI 10.1007/BF02100113; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SEDZIK J, 1992, NEUROCHEM RES, V17, P157, DOI 10.1007/BF00966794; SHAW SY, 1986, FEBS LETT, V207, P266, DOI 10.1016/0014-5793(86)81502-2; SMITH R, 1992, J NEUROCHEM, V59, P1589, DOI 10.1111/j.1471-4159.1992.tb10989.x; Staugaitis SM, 1996, BIOESSAYS, V18, P13, DOI 10.1002/bies.950180106; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; STONER GL, 1984, J NEUROCHEM, V43, P433, DOI 10.1111/j.1471-4159.1984.tb00919.x; STONER GL, 1990, J NEUROCHEM, V55, P1404, DOI 10.1111/j.1471-4159.1990.tb03153.x; Stuart BH, 1996, BIOCHEM MOL BIOL INT, V38, P839; SUREWICZ WK, 1987, BIOCHEMISTRY-US, V26, P3881, DOI 10.1021/bi00387a021; WOD DD, 1996, MOL BIOL MULTIPLE SC; WOOD DD, 1989, J BIOL CHEM, V264, P5121; Wood DD, 1996, ANN NEUROL, V40, P18, DOI 10.1002/ana.410400106	49	81	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4269	4275		10.1074/jbc.272.7.4269	http://dx.doi.org/10.1074/jbc.272.7.4269			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020143	hybrid			2022-12-25	WOS:A1997WH01900059
J	Burton, JL; Slepnev, V; DeCamilli, PV				Burton, JL; Slepnev, V; DeCamilli, PV			An evolutionarily conserved domain in a subfamily of Rabs is crucial for the interaction with the guanyl nucleotide exchange factor Mss4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS; PROTEIN; RESIDUES; IDENTIFICATION; SWITCH; SEC4	Mss4 is a guanine nucleotide exchange factor that specifically binds to, and promotes GDP-GTP exchange on, a subset of the Rab GTPases (Burton, J. L., Burns, M. E., Gatti, E., Augustine, G. J., and De Camilli, P. (1994) EMBO J. 13, 5547-5558), In order to identify the domain(s) of the GTPase that is important for this interaction, protein chimeras were constructed between Rab3a, which binds Mss4, and Rab5a, which does not bind Mss4. We have identified the amino-terminal portion of Rab3a as the Mss4-binding region, with the effector domain being critically required for binding and the flanking regions further enhancing the interaction. Sequence comparisons have revealed that Mss4-binding Rabs share more homology with each other than with Rabs that do not bind Mss4. The region of highest homology between these Rabs, which defines them as members of the same evolutionary branch within the Rab subfamily, coincides with the domain shown here to be critical for Mss4 binding. A mutation in the zinc-binding domain of Mss4 (Mss4 D96H), a region that is highly conserved between Mss4 and its yeast homologue Dss4, completely abolished its property to bind to, and promote GDP-GTP exchange on, Rab3a. Thus, the preservation of the Mss4/Dss4-GTPase interaction appears to have been a critical factor in the evolution of this subset of Rab proteins.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University					NCI NIH HHS [CA46128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERANGER F, 1994, J BIOL CHEM, V269, P13637; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; BURTON JL, 1994, METHOD ENZYMOL, V257, P93; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CHEVALLIERMULTON MC, 1993, J BIOL CHEM, V268, P11113; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MIYAZAKI A, 1994, FEBS LETT, V350, P333, DOI 10.1016/0014-5793(94)00804-3; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	28	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3663	3668		10.1074/jbc.272.6.3663	http://dx.doi.org/10.1074/jbc.272.6.3663			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013620	hybrid			2022-12-25	WOS:A1997WG19200080
J	Desseyn, JL; GuyonnetDuperat, V; Porchet, N; Aubert, JP; Laine, A				Desseyn, JL; GuyonnetDuperat, V; Porchet, N; Aubert, JP; Laine, A			Human mucin gene MUC5B, the 10.7-kb large central exon encodes various alternate subdomains resulting in a super-repeat - Structural evidence for a 11p15.5 gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; HUMAN GASTRIC MUCIN; MOLECULAR-CLONING; INTESTINAL MUCIN; TANDEM REPEATS; EXPRESSION; CDNA; AIRWAY; IDENTIFICATION; PEPTIDES	Human mucin gene MUC5B is mapped clustered with MUC6, MUC2, and MUC5AC on chromosome 11p15.5. We report here the isolation of three overlapping genomic clones of human MUC5B spanning approximately 40 kilobases. We have determined their partial restriction maps and the intron-exon boundaries of the central region encoding a single open reading frame. This coding region has been completely sequenced. Its length is 10,713 base pairs, and it encodes a 3570-amino acid peptide. Nineteen subdomains have been individualized. Some subdomains show similarity to each other, creating larger composite repeat units that we have called super-repeats. Four super-repeats of 528 amino acid residues are thus observed within the central exon. Each comprises (i) a subdomain composed of 11 repeats of the irregular repeat of 29 amino acid residues, (ii) a unique conserved subdomain with no typical repeat, and (iii) a cysteine-rich subdomain. This latter subdomain has high sequence similarity to the cysteine-rich domains described in MUC2 and MUC5AC. Sequence data of these three genes, together with their clustered organization, lead us to suggest that they may be a part of a multigene family. The super-repeat present in MUC5B is the largest ever determined in mucin genes and the central exon of this gene is, by far, the largest reported for a vertebrate gene.	INSERM, U377, LAB GERARD BISERTE, F-59045 LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, HOP HURIEZ, LAB BIOCHIM & BIOL MOL, F-59037 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille			Desseyn, Jean-Luc/M-5070-2018	Desseyn, Jean-Luc/0000-0001-6876-8049				AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; AUDIE JP, 1995, HUM REPROD, V10, P98, DOI 10.1093/humrep/10.1.98; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BICKMORE WA, 1992, METHOD ENZYMOL, V216, P224; BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; Bobek LA, 1996, GENOMICS, V31, P277, DOI 10.1006/geno.1996.0049; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BROWN WRA, 1986, NATURE, V322, P477, DOI 10.1038/322477a0; Buisine MP, 1996, GASTROENTEROLOGY, V110, P84, DOI 10.1053/gast.1996.v110.pm8536891; CAMPION JP, 1995, HEPATOLOGY, V21, P223, DOI 10.1002/hep.1840210135; CREPIN M, 1990, BIORHEOLOGY, V27, P471; Denny PC, 1996, GLYCOBIOLOGY, V6, P43, DOI 10.1093/glycob/6.1.43; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; GUYONNETDUPERAT V, 1993, THESIS U LILLE FRANC; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HO JJL, 1995, INT J ONCOL, V7, P913; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; LESUFFLEUR T, 1994, CRIT REV ONCOL HEMAT, V17, P153, DOI 10.1016/1040-8428(94)90053-1; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; OHMORI H, 1994, J BIOL CHEM, V269, P17833; SHANKAR V, 1994, BIOCHEM J, V300, P295, DOI 10.1042/bj3000295; SHEEHAN JK, 1986, BIOCHEM J, V239, P147, DOI 10.1042/bj2390147; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; SLAYTER HS, 1984, EUR J BIOCHEM, V142, P209, DOI 10.1111/j.1432-1033.1984.tb08273.x; SMITH BF, 1985, J CLIN INVEST, V76, P439, DOI 10.1172/JCI111991; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Troxler RF, 1995, BIOCHEM BIOPH RES CO, V217, P1112, DOI 10.1006/bbrc.1995.2884; TURNER BS, 1995, BIOCHEM J, V308, P89, DOI 10.1042/bj3080089; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160	44	154	161	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3168	3178		10.1074/jbc.272.6.3168	http://dx.doi.org/10.1074/jbc.272.6.3168			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013550	hybrid			2022-12-25	WOS:A1997WG19200010
J	Liu, JQ; Kurihara, T; Miyagi, M; Tsunasawa, S; Nishihara, M; Esaki, N; Soda, K				Liu, JQ; Kurihara, T; Miyagi, M; Tsunasawa, S; Nishihara, M; Esaki, N; Soda, K			Paracatalytic inactivation of L-2-haloacid dehalogenase from Pseudomonas sp. YL by hydroxylamine - Evidence for the formation of an ester intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SP STRAIN-YL; HALOALKANE DEHALOGENASE; CATALYTIC MECHANISM; ACID DEHALOGENASE	Asp(10) of L-2-haloacid dehalogenase from Pseudomonas sp. YL was proposed to act as a nucleophile to attack the alpha-carbon of L-2-haloalkanoic acids to form an ester intermediate, which is hydrolyzed by nucleophilic attack of a water molecule on the carbonyl carbon (Liu, J.-Q, Kurihara, T., Miyagi, M., Esaki, N., and Soda, K. (1995) J. Biol. Chem. 270, 18309-18312). We have found that the enzyme is paracatalytically inactivated by hydroxylamine in the presence of the substrates monochloroacetate and L-2-chloropropionate. Ion spray mass spectrometry demonstrated that the molecular mass of the enzyme inactivated by hydroxylamine during the dechlorination of monochloroacetate is about 74 Da greater than that of the native enzyme. To determine the increase of the molecular mass more precisely, we digested the inactivated enzyme with lysyl endopeptidase and measured the molecular masses of the peptide fragments. The molecular mass of the hexapeptide Gly(6)-Lys(11) was shown to increase by 73 Da. Tandem mass spectrometric analysis of this peptide revealed that the increase is due to a modification of Asp(10). When the enzyme was paracatalytically inactivated by hydroxylamine during the dechlorination of L-2-chloropropionate, the molecular mass of the hexapeptide was 87 Da higher. Hydroxylamine is proposed to attack the carbonyl carbon of the ester intermediate and form a stable aspartate beta-hydroxamate carboxyalkyl ester residue in the inactivated enzyme.	KYOTO UNIV,MICROBIAL BIOCHEM LAB,INST CHEM RES,UJI,KYOTO 611,JAPAN; TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,OTSU,SHIGA 52021,JAPAN	Kyoto University; Takara Holdings Inc.								BURDETTE RA, 1986, J BIOL CHEM, V261, P2016; CAPLOW M, 1964, J BIOL CHEM, V239, P164; Christen P, 1977, Methods Enzymol, V46, P48; CROOKS GP, 1995, J AM CHEM SOC, V117, P10791, DOI 10.1021/ja00149a001; DAGNOLO G, 1975, J BIOL CHEM, V250, P5283; HARDMAN DJ, 1991, CRIT REV BIOTECHNOL, V11, P1, DOI 10.3109/07388559109069182; IWASAKI I, 1956, B CHEM SOC JPN, V29, P860, DOI 10.1246/bcsj.29.860; JANSSEN DB, 1994, ANNU REV MICROBIOL, V48, P163, DOI 10.1146/annurev.mi.48.100194.001115; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; NARDIDEI V, 1994, APPL ENVIRON MICROB, V60, P3375, DOI 10.1128/AEM.60.9.3375-3380.1994; NISHINO T, 1977, J BIOL CHEM, V252, P2934; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WOODS MJ, 1979, BIOCHIM BIOPHYS ACTA, V567, P225, DOI 10.1016/0005-2744(79)90189-X; YANG G, 1994, BIOCHEMISTRY-US, V33, P8527, DOI 10.1021/bi00194a018	19	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3363	3368		10.1074/jbc.272.6.3363	http://dx.doi.org/10.1074/jbc.272.6.3363			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013577	hybrid			2022-12-25	WOS:A1997WG19200037
J	Radebaugh, CA; Gong, XL; Bartholomew, B; Paule, MR				Radebaugh, CA; Gong, XL; Bartholomew, B; Paule, MR			Identification of previously unrecognized common elements in eukaryotic promoters - A ribosomal RNA gene initiator element for RNA polymerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; ACANTHAMOEBA-CASTELLANII; BINDING; DNA; SITE; COMPLEXES; TBP	A new ribosomal RNA promoter element with a functional role similar to the RNA polymerase II initiator (Inr) was identified, This sequence, which we dub the ribosomal Inr (rInr) is unusually conserved, even in normally divergent RNA polymerase I promoters. It functions in the recruitment of the fundamental, TATA-binding protein (TBP)-containing transcription factor, TIF-IB. All upstream elements of the exceptionally strong Acanthamoeba castellanii ribosomal RNA core promoter, to within 6 base pairs of the transcription initiation site (tis), can be deleted without loss of specific transcription initiation, Thus, the A. castellanii promoter can function in a manner similar to RNA polymerase II TATA-less promoters, Sequence-specific photo-cross-linking localizes a 96-kDa subunit of TIF-IB and the second largest RNA polymerase I subunit (A(133)) to the rInr sequence. A(185) also photo-cross-links when polymerase is stalled at +7.	COLORADO STATE UNIV, DEPT BIOCHEM & MOL BIOL, FT COLLINS, CO 80523 USA; SO ILLINOIS UNIV, DEPT MED BIOCHEM, CARBONDALE, IL 62901 USA	Colorado State University; Southern Illinois University System; Southern Illinois University								BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BATEMAN E, 1985, P NATL ACAD SCI USA, V82, P8004, DOI 10.1073/pnas.82.23.8004; DALESSIO JM, 1979, J BIOL CHEM, V254, P1282; DOELLING JH, 1995, PLANT J, V8, P683, DOI 10.1046/j.1365-313X.1995.08050683.x; GONG XL, 1995, MOL CELL BIOL, V15, P4956; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; IIDA CT, 1985, P NATL ACAD SCI USA, V82, P1668, DOI 10.1073/pnas.82.6.1668; IMBODEN MA, 1992, J BIOL CHEM, V267, P24601; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KOWNIN P, 1985, NUCLEIC ACIDS RES, V13, P6237, DOI 10.1093/nar/13.17.6237; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; LIDA CT, 1992, NUCLEIC ACIDS RES, V20, P3211, DOI 10.1093/nar/20.12.3211; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MEMET S, 1988, J BIOL CHEM, V263, P10048; PAULE MR, 1984, BIOCHEMISTRY-US, V23, P4167, DOI 10.1021/bi00313a025; PAULE MR, 1990, NATURE, V344, P819, DOI 10.1038/344819a0; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; Perna Peter J., 1992, Gene Expression, V2, P71; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SPINDLER SR, 1978, J BIOL CHEM, V253, P4669; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WHITE RJ, 1994, RNA POLYM 3 TRANSCRI; WINDLE J, 1986, MOL CELL BIOL, V6, P1228, DOI 10.1128/MCB.6.4.1228; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	28	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3141	3144		10.1074/jbc.272.6.3141	http://dx.doi.org/10.1074/jbc.272.6.3141			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013545	hybrid			2022-12-25	WOS:A1997WG19200005
J	Yang, D; Hayashi, H; Takii, T; Mizutani, Y; Inukai, Y; Onozaki, K				Yang, D; Hayashi, H; Takii, T; Mizutani, Y; Inukai, Y; Onozaki, K			Interleukin-1-induced growth inhibition of human melanoma cells - Interleukin-1-induced antizyme expression is responsible for ornithine decarboxylase activity down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RAT MESANGIAL CELLS; GENE-EXPRESSION; SIGNAL TRANSDUCTION; T-CELLS; IL-1 RECEPTOR; LYMPHOCYTES-T; PROTEIN; ACTIVATION; CLONING	Interleukin (IL)-1 is a multi-functional cytokine and regulates cell growth either positively or negatively. Previous studies have shown that IL-1-induced ornithine decarboxylase (ODC) activity down-regulation is involved in the anti-proliferative effect of IL-1 on human A375 melanoma cells. In this study, we examined the IL-1 alpha-induced molecular events resulting in ODC activity down-regulation in C2-1, a A375 cell. Line stably transfected with human type I IL-1 receptor, Recombinant human (rh) IL-1 alpha inhibited the growth and down-regulated the ODC activity of C2-1 cells in a dose-dependent manner. Kinetics studies showed that both the DNA synthesis and ODC activity of C2-1 cells progressively decreased horn 12 h after IL-1 addition, Northern hybridization showed that IL-1 had no influence on ODC mRNA level. However, rhIL-1 induced both a decrease of ODC protein and an ODC-inhibiting activity in IL-1-treated C2-1 cells. IL-1 specifically up-modulated the mRNA level of antizyme, a protein essential for ODC regulation, but had little effect on its stability. IL-1-induced antizyme up-modulation preceded IL-1-induced down-regulation of ODC protein, ODC activity, and DNA synthesis in C2-1 cells. Run-on transcription analysis confirmed that the increased antizyme mRNA expression was due to elevated antizyme gene transcription. Furthermore, the action of IL-1 to inhibit the ODC activity and growth of C2-1 cells was blocked by expressing the antisense RNA of human antizyme in C2-1 cells. These results suggest that IL-1-induced antizyme expression is responsible for IL-1-induced ODC activity down-regulation in human melanoma cells.	NAGOYA CITY UNIV, FAC PHARMACEUT SCI, DEPT HYG CHEM, MIZUHO KU, NAGOYA, AICHI 467, JAPAN	Nagoya City University			Mizutani, Yasuhisa/B-3809-2009					ARAKI M, 1994, INT J CANCER, V56, P275, DOI 10.1002/ijc.2910560222; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BRISTOL LA, 1991, J IMMUNOL, V146, P1509; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CELANO P, 1989, J BIOL CHEM, V264, P8922; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; Cominelli F., 1993, Lymphokine and Cytokine Research, V12, P340; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; ENDO Y, 1986, IMMUNOBIOLOGY, V172, P316, DOI 10.1016/S0171-2985(86)80113-9; ENDO Y, 1988, J IMMUNOL, V141, P2342; FREDLUND JO, 1995, EXP CELL RES, V216, P86, DOI 10.1006/excr.1995.1011; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRYLING C, 1989, CANCER RES, V49, P3333; GAFFNEY EV, 1986, CANCER RES, V46, P3834; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HEGUY A, 1993, J BIOL CHEM, V268, P10490; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KILIAN PL, 1991, CANCER RES, V51, P1823; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MAMROUDKIDRON E, 1994, FEBS LETT, V356, P162, DOI 10.1016/0014-5793(94)01260-1; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCDONALD VL, 1993, GROWTH FACTORS, V9, P167; MCKEAN DJ, 1993, J IMMUNOL, V151, P3500; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIYAZAKI Y, 1992, GENE, V113, P191, DOI 10.1016/0378-1119(92)90395-6; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MORINAGA Y, 1990, BIOCHEM BIOPH RES CO, V173, P186, DOI 10.1016/S0006-291X(05)81039-3; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; MUNOZ E, 1990, J IMMUNOL, V144, P964; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; ONOZAKI K, 1988, J IMMUNOL, V140, P112; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; OSANTO S, 1992, EUR J CANCER, V28A, P1622, DOI 10.1016/0959-8049(92)90055-7; OYA K, 1995, CANCER LETT, V91, P101, DOI 10.1016/0304-3835(94)03726-Y; PENA A, 1993, J BIOL CHEM, V268, P27277; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SEELY JE, 1983, METHOD ENZYMOL, V94, P158; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; TAKII T, 1994, LYMPHOKINE CYTOK RES, V13, P213; TALOR CW, 1984, ANNU REV BIOCHEM, V53, P749; Yang D, 1996, BIOCHEM MOL BIOL INT, V38, P957; YANG D, 1995, J BIOCHEM, V118, P802, DOI 10.1093/oxfordjournals.jbchem.a124983	63	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3376	3383		10.1074/jbc.272.6.3376	http://dx.doi.org/10.1074/jbc.272.6.3376			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013579	hybrid			2022-12-25	WOS:A1997WG19200039
J	Zawalich, WS; Zawalich, KC				Zawalich, WS; Zawalich, KC			Influence of pyruvic acid methyl ester on rat pancreatic islets - Effects on insulin secretion phosphoinositide hydrolysis, and sensitization of the beta cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSSIBLE INVOLVEMENT; PROTEIN-KINASE; MOUSE PANCREAS; B-CELL; RELEASE; GLUCOSE; INOSITOL; MECHANISMS; METABOLISM; CALCIUM	The methyl ester of pyruvic acid (methyl pyruvate) stimulated a dose-dependent increase in insulin secretion from isolated perifused rat islets. The threshold level for release was about 10 mM, and at 20 mM the addition of MP to perifused islets resulted in a large first phase of secretion followed by an insulin-secretory response that was sustained for at least 40 min. When compared to the effects of 20 mM glucose, peak first-phase release rates in response to 20 mM methyl pyruvate were comparable, but the second phase of release was only about 10-15% of that observed with an equimolar level of the hexose, The stimulatory effects of 20 mM methyl pyruvate on secretion were abolished by the K1+-ATP channel blocker diazoxide (200 mu M) and by the calcium channel antagonist nitrendipine (500 nM). The glucokinase inhibitor mannoheptulose (20 mM) had no adverse effect on the secretory response to 20 mM methyl pyruvate, whereas 10 mu M forskolin amplified the insulinotropic action of MP. Sodium pyruvate alone or in combination with 10 mu M forskolin had no insulinotropic effect, In additional experiments islet phosphoinositide pools were labeled with myo-2-[H-3]inositol, and the subsequent accumulation of labeled inositol phosphates was used to monitor the activation of phospholipase C. Methyl pyruvate stimulated a dose-dependent increase in inositol phosphate levels when measured after a 30-min incubation period with a maximal increase of about 300% at 20 mM methyl pyruvate. The increase in phosphoinositide hydrolysis caused by methyl pyruvate (20 mM) was, like insulin secretion, reduced by both diazoxide and nitrendipine but was immune to inhibition by mannoheptulose. Pyruvate (20 mM) had no effect on inositol phosphate accumulation. Prior short-term exposure to methyl pyruvate sensitized islets to subsequent stimulation with 15 mM glucose. Sodium pyruvate did not sensitize islets. These findings support the concept that the mitochondrial metabolism of nutrient molecules is an event sufficient to acutely augment insulin release from the beta cell, to increase phospholipase C-mediated phosphoinositide hydrolysis, and to induce time-dependent potentiation of insulin secretion.			Zawalich, WS (corresponding author), YALE UNIV,SCH NURSING,100 CHURCH ST,POB 9740,NEW HAVEN,CT 06536, USA.				NIDDK NIH HHS [NIDDK 41230] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041230] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERGLUND O, 1987, J ENDOCRINOL, V114, P185, DOI 10.1677/joe.0.1140185; BERGLUND O, 1980, ACTA ENDOCRINOL-COP, V93, P54, DOI 10.1530/acta.0.0930054; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BEST L, 1986, BIOCHEM J, V238, P773, DOI 10.1042/bj2380773; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; GRILL V, 1978, J CLIN INVEST, V61, P1034, DOI 10.1172/JCI109002; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HELLMAN B, 1974, ARCH BIOCHEM BIOPHYS, V162, P448, DOI 10.1016/0003-9861(74)90204-5; HENQUIN JC, 1982, DIABETES, V31, P776, DOI 10.2337/diab.31.9.776; HUGH H, 1993, BIOCHEM J, V291, P329; KELLEY GG, 1994, ENDOCRINOLOGY, V134, P1648, DOI 10.1210/en.134.4.1648; LENZEN S, 1980, BIOCHEM J, V186, P135, DOI 10.1042/bj1860135; LENZEN S, 1979, AM J PHYSIOL, V236, pE391, DOI 10.1152/ajpendo.1979.236.4.E391; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; MA MYH, 1995, EUR J ENDOCRINOL, V132, P370; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MALAISSE WJ, 1980, DIABETES, V29, P431, DOI 10.2337/diabetes.29.6.431; MALAISSE WJ, 1968, METABOLISM, V17, P126, DOI 10.1016/0026-0495(68)90138-8; MALAISSE WJ, 1992, INT J BIOCHEM, V24, P693, DOI 10.1016/0020-711X(92)90002-I; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; NIKI I, 1988, ACTA ENDOCRINOL-COP, V118, P204, DOI 10.1530/acta.0.1180204; PANTEN U, 1975, N-S ARCH PHARMACOL, V291, P405, DOI 10.1007/BF00501798; PARIS S, 1988, J BIOL CHEM, V263, P12893; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; SORENSON RL, 1986, HORM METAB RES, V18, P353, DOI 10.1055/s-2007-1012314; WIEDENKELLER DE, 1983, ENDOCRINOLOGY, V113, P2311, DOI 10.1210/endo-113-6-2311; ZAWALICH W, 1990, DIABETES RES CLIN EX, V13, P101; ZAWALICH WS, 1988, DIABETES, V37, P816, DOI 10.2337/diabetes.37.6.816; ZAWALICH WS, 1989, BIOCHEM J, V262, P557, DOI 10.1042/bj2620557; ZAWALICH WS, 1988, AM J PHYSIOL, V254, pE609, DOI 10.1152/ajpendo.1988.254.5.E609; Zawalich WS, 1996, AM J PHYSIOL-ENDOC M, V271, pE409, DOI 10.1152/ajpendo.1996.271.3.E409; ZAWALICH WS, 1992, ENDOCRINOLOGY, V131, P649, DOI 10.1210/en.131.2.649; ZAWALICH WS, 1988, DIABETES, V37, P137, DOI 10.2337/diabetes.37.2.137; ZAWALICH WS, 1989, ENDOCRINOLOGY, V125, P2400, DOI 10.1210/endo-125-5-2400; ZAWALICH WS, 1988, DIABETOLOGIA, V31, P435, DOI 10.1007/BF00271588; ZAWALICH WS, 1995, ENDOCRINOLOGY, V136, P4903, DOI 10.1210/en.136.11.4903; ZAWALICH WS, 1978, ENDOCRINOLOGY, V103, P2027, DOI 10.1210/endo-103-6-2027; ZAWALICH WS, 1993, DIABETES, V42, P843, DOI 10.2337/diabetes.42.6.843; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1276, DOI 10.1210/endo-100-5-1276; ZAWALICH WS, 1977, J BIOL CHEM, V252, P8519; Zawalich WS, 1996, ENDOCRINOLOGY, V137, P1664, DOI 10.1210/en.137.5.1664; ZAWALICH WS, 1988, DIABETES, V37, P1478, DOI 10.2337/diabetes.37.11.1478; ZAWALICH WS, 1987, DIABETES, V36, P16; ZAWALICH WS, 1996, DIABETES REV, V4, P160	49	41	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3527	3531		10.1074/jbc.272.6.3527	http://dx.doi.org/10.1074/jbc.272.6.3527			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013600	hybrid			2022-12-25	WOS:A1997WG19200060
J	Bon, S; Massoulie, J				Bon, S; Massoulie, J			Quaternary associations of acetylcholinesterase .1. Oligomeric associations of T subunits with and without the amino-terminal domain of the collagen tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM CHOLINESTERASE; DISULFIDE BONDS; TORPEDO ACETYLCHOLINESTERASE; RAT ACETYLCHOLINESTERASE; NONAMPHIPHILIC FORMS; CATALYTIC SUBUNITS; CAUDATE-NUCLEUS; BOVINE BRAIN; EXPRESSION; SEQUENCE	We investigated the production of acetylcholinesterase of type T (AChE(T)) in COS cells during transient transfection. When expressed alone, Torpedo AChE(T) remains essentially intracellular, forming dimers and tetramers; in contrast, rat AChE(T) is secreted and produces mostly amphiphilic monomers (G(1)(a)) and dimers (G(2)(a)), together with smaller proportions of nonamphiphilic (G(4)(na)) tetramers, amphiphilic tetramers (G(4)(a)), and an unstable higher polymer (13.7 S). The latter two forms have-not been described before. We show that secreted G(1)(a) and G(2)(a) forms differ from their cellular counterparts and that proteolytic cleavage occurs at the COOH terminus of ''flagged'' subunits. The binding proteins Q(N)/H-C and Q(N)/stop are constructed by associating the NH2-terminal domain of the collagen tail (Q(N)) with a functional or truncated signal for addition of a glycolipidic anchor (glycophosphatidylinositol). Coexpression with Q(N)/stop recruits monomers and dimers to form soluble tetramers (G(4)(na)), increasing the yield of secreted rat AChE and allowing secretion of Torpedo AChE. Using antibodies against Q(N) or addition of a flag epitope, we showed that the secreted tetramers contain the attachment domain. Coexpression with Q(N)/H-c modifies the distribution of AChE(T) in subcellular compartments and allows the externalization of glycophosphatidylinositol-anchored tetramers at the cell surface.	ECOLE NORMALE SUPER,LAB NEUROBIOL MOL & CELLULAIRE,CNRS,UNITE 1857,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)								ANGLISTER L, 1978, J MOL BIOL, V125, P293, DOI 10.1016/0022-2836(78)90404-7; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; BON S, 1991, CELL MOL NEUROBIOL, V11, P157, DOI 10.1007/BF00712807; BON S, 1988, J NEUROCHEM, V51, P776, DOI 10.1111/j.1471-4159.1988.tb01812.x; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; BON S, 1988, J NEUROCHEM, V51, P786, DOI 10.1111/j.1471-4159.1988.tb01813.x; CAMP S, 1995, J CLIN INVEST, V95, P333, DOI 10.1172/JCI117661; COUSSEN F, 1995, EUR J CELL BIOL, V67, P254; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; GIBNEY G, 1990, J BIOL CHEM, V265, P12576; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZAR M, 1984, J BIOL CHEM, V259, P3703; LEE SL, 1982, J BIOL CHEM, V257, P12282; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LIAO J, 1994, J NEUROCHEM, V63, P1446; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P12945; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; MASSOULIE J, 1993, PROG BRAIN RES, V98, P139; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; RANDALL WR, 1994, J BIOL CHEM, V269, P12367; ROBERTS WL, 1991, J BIOL CHEM, V266, P7481; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3550, DOI 10.1021/bi00635a008; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; VELAN B, 1991, J BIOL CHEM, V266, P23977; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	31	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3007	3015		10.1074/jbc.272.5.3007	http://dx.doi.org/10.1074/jbc.272.5.3007			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006949	hybrid			2022-12-25	WOS:A1997WE66700062
J	Jansen, E; Ayoubi, TAY; Meulemans, SMP; VandeVen, WJM				Jansen, E; Ayoubi, TAY; Meulemans, SMP; VandeVen, WJM			Cell type-specific protein-DNA interactions at the cAMP response elements of the prohormone convertase 1 promoter - Evidence for additional transactivators distinct from CREB/ATF family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN-PROCESSING ENZYME; TRANSCRIPTION FACTOR-II; BINDING PROTEIN; HETERODIMER FORMATION; SUBTILISIN FAMILY; SOMATOSTATIN GENE; BASIC RESIDUES; JUN PROTEINS; C-JUN; FURIN	The proximal promoter region of the neuroendocrine-specific human prohormone convertase 1 (PCI) gene contains two distinct cAMP response elements (CRE-1 and CRE-2). Both elements are essential in directing the cAMP-mediated hormonal regulation of PCI gene transcription. In this study, we have demonstrated that CRE-1 binds several trans-acting factors. In electrophoretic mobility shift assay experiments with nuclear extracts prepared from neuroendocrine AtT-20 and beta-TC3 cells and non neuroendocrine COS-1 cells, three specific protein-DNA complexes (I-III) were detected. Complexes II and III were shown to contain CREB-1 and ATF-1, respectively. The most slowly migrating complex I was only detected with the neuroendocrine cell lines and appeared to comprise a c-Jun-containing heterodimer. In addition, CRE-2 was shown to bind a protein that was only detected in nuclear extracts derived from the neuroendocrine cell lines. Antibody supershift experiments indicated that both the c-Jun-interacting protein in CRE-1 complex I and the CRE-2-interacting protein are distinct from known members of the basic domain, leucine zipper family of transcription factors. UV cross-linking experiments demonstrated that these potential novel proteins are similar to 100 and 60 kDa in size, respectively. Site-specific mutagenesis experiments demonstrated that the formation of both CRE-1 and CRE-2 complexes is correlated with the transcriptional activity of the proximal PC1 promoter as has been shown in transient transfections with wild-type and mutant promoter constructs. In addition, it was shown that both CREB-1 and ATF-1 transactivate the human PC1 promoter in transient transfection experiments.	UNIV LEUVEN,CTR HUMAN GENET,ONCOL MOL LAB,B-3000 LOUVAIN,BELGIUM; FLANDERS INTERUNIV INST BIOTECHNOL,B-3000 LOUVAIN,BELGIUM	KU Leuven								AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; JANSEN E, 1995, J BIOL CHEM, V270, P15391, DOI 10.1074/jbc.270.25.15391; Johanning K, 1996, J NEUROCHEM, V66, P898; JOSHI JB, 1992, P NATL ACAD SCI USA, V89, P1006, DOI 10.1073/pnas.89.3.1006; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LIU F, 1993, J BIOL CHEM, V268, P6714; Meerabux J, 1996, CANCER RES, V56, P448; MIYAMOTO S, 1995, METHOD ENZYMOL, V254, P632; MONIA YT, 1995, MOL ENDOCRINOL, V9, P784; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; ORAHILLY S, 1995, NEW ENGL J MED, V333, P1386, DOI 10.1056/NEJM199511233332104; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VANDEVEN WJM, 1991, ENZYME, V45, P257, DOI 10.1159/000468900; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622	47	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2500	2508						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999965				2022-12-25	WOS:A1997WD67900071
J	Austen, M; Luscher, B; LuscherFirzlaff, JM				Austen, M; Luscher, B; LuscherFirzlaff, JM			Characterization of the transcriptional regulator YY1 - The bipartite transactivation domain is independent of interaction with the TATA box-binding protein, transcription factor IIB, TAF(II)55, or cAMP-responsive element-binding protein (CBP)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; C-MYC; ADENOVIRUS E1A; DNA; REPRESSION; EXPRESSION; PROMOTER; RELIEF; P300; CBP	YY1 is a multifunctional transcription factor implicated in both positive and negative regulation of gene expression as well as in initiation of transcription. We show that YY1 is ubiquitously expressed in growing, differentiated, and growth-arrested cells. The protein is phosphorylated and has a half life of 3.5 h. To define functional domains, we have generated a large panel of YY1 mutant proteins. These were used to define precisely the DNA-binding domain, the region responsible for nuclear localization, and the transactivation domain. The two acidic domains at the N terminus each provide about half of the transcriptional activating activity. Furthermore, the spacer region between the Gly/Ala-rich and zinc finger domains has accessory function in transactivation. YY1 has been shown previously to bind to TAF(II)55, TATA box binding protein, transcription factor IIB, and p300. In addition, we identified cAMP-responsive element-binding protein (CBP) binding protein as a YY1 binding partner. Surprisingly, these proteins did not bind to the domains involved in transactivation, but rather to the zinc finger and Gly/Ala-rich domains of YY1. Thus, these proteins do not explain the transcriptional activating activity of YY1, but rather may be involved in repression or in initiation.	HANNOVER MED SCH, INST MOL BIOL, D-30623 HANNOVER, GERMANY	Hannover Medical School			; Luscher, Bernhard/A-7330-2011	Luscher-Firzlaff, Juliane/0000-0001-9265-8536; Luscher, Bernhard/0000-0002-9622-8709				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FLANAGAN JR, 1995, CELL GROWTH DIFFER, V6, P185; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GASTON K, 1994, FEBS LETT, V347, P289, DOI 10.1016/0014-5793(94)00567-2; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HENRIKSSONM, 1996, ADV CANCER RES, V68, P109; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Janknecht R, 1996, ONCOGENE, V12, P1961; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LAMB BT, 1992, MOL CELL BIOL, V12, P4824, DOI 10.1128/MCB.12.11.4824; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1994, ONCOGENE, V9, P1047; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Roque MC, 1996, MOL CELL BIOL, V16, P3138; SATYAMOORTHY K, 1993, MOL CELL BIOL, V13, P6621, DOI 10.1128/MCB.13.11.6621; SHENK T, 1991, ADV CANCER RES, V57, P47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5	42	171	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1709	1717		10.1074/jbc.272.3.1709	http://dx.doi.org/10.1074/jbc.272.3.1709			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999850	hybrid			2022-12-25	WOS:A1997WD05800048
J	Ingham, KC; Brew, SA; Huff, S; Litvinovich, SV				Ingham, KC; Brew, SA; Huff, S; Litvinovich, SV			Cryptic self-association sites in type III modules of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; HUMAN FIBROBLAST-CULTURES; MATRIX-ASSEMBLY RECEPTOR; TERMINAL HEP-2 REGION; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; BINDING FRAGMENT; DOMAIN-STRUCTURE; HEPARIN-BINDING; IONIC-STRENGTH	The first type III module of fibronectin (Fn) contains a cryptic site that binds Fn and its N-terminal 29 kDa fragment and is thought to be important for fibril formation (Morla, A., Zhang, Z., and Ruoslahti, E. (1994) Nature 367, 193-196; Hocking, D. C., Sottile, J., and McKeown-Longo, P. J. (1994) J. Biol. Chem. 269, 19183-19191). A synthetic 31-mer peptide (NAPQ...TIPG) derived from the middle of domain III1 was also shown to bind Fn, but the site of its interaction was not determined (Morla, A., and Ruoslahti, E. (1992) J. Cell Biol. 118, 421-429). By affinity chromatography on peptide-agarose, we tested a set of fragments representing the entire light chain of plasma Fn. Only 40-kDa Hep-2 (III12-15) failed to bind. The concentration of urea required for peak elution of Fn and the other fragments decreased in the order Fn > 42-kDa GBF (I6II1-2I7-9) > 19-kDa Fib-2 (I-10-12) > 110-kDa CBF(III2-10) > 29-kDa Fib-1 (I-1-I-5). Neither Fn nor any of the fragments bound immobilized intact III1, confirming the cryptic nature of this activity. In an effort to detect interactions between other Fn. domains, all fragments were coupled to Sepharose, and each fragment was tested on each affinity matrix before and after denaturation. The only interaction detected was that of fluid phase III1 with immobilized denatured 110-kDa CBF and 40 kDa Hep-2, both of which contain type III domains. Analysis of subfragments revealed this activity to be dominated by domains III7 and III15. Fn itself did not bind to the denatured fragments. Thus, domain III, contains two cryptic ''self-association sites,'' one that is buried in the core of the fold but recognizes many Fn fragments when presented as a peptide and another that is concealed in Fn but exposed in the native isolated domain and recognizes cryptic sites in two other type III domains. These interactions between type III domains could play an important role in assembly of Fn multimers in the extracellular matrix.			Ingham, KC (corresponding author), AMER RED CROSS,JEROME H HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21791] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER SS, 1979, J BIOL CHEM, V254, P1501; BARRY ELR, 1988, J BIOL CHEM, V263, P10464; BENNETT MJ, 1995, PROTEIN SCI, V4, P2453; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DZAMBA BJ, 1991, J CELL SCI, V100, P605; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; HARUMIYA S, 1993, J BIOCHEM-TOKYO, V113, P710, DOI 10.1093/oxfordjournals.jbchem.a124108; HAYASHINAGAI A, 1991, J BIOCHEM-TOKYO, V109, P83; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HORMANN H, 1986, BIOPOLYMERS, V25, P947, DOI 10.1002/bip.360250513; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; Hynes RO, 1990, FIBRONECTINS; ICHIHARATANAKA K, 1995, J CELL SCI, V108, P907; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1994, ARCH BIOCHEM BIOPHYS, V314, P242, DOI 10.1006/abbi.1994.1436; LAI CS, 1993, J MOL BIOL, V230, P625, DOI 10.1006/jmbi.1993.1174; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; LITVINOVICH SV, 1995, J MOL BIOL, V248, P611, DOI 10.1006/jmbi.1995.0246; LITVINOVICH SV, 1992, BIOCHIM BIOPHYS ACTA, V1119, P57, DOI 10.1016/0167-4838(92)90234-5; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARKOVIC Z, 1983, H-S Z PHYSIOL CHEM, V364, P1795, DOI 10.1515/bchm2.1983.364.2.1795; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MOON KY, 1994, J BIOL CHEM, V269, P7651; MORGENTHALER JJ, 1982, FEBS LETT, V150, P81, DOI 10.1016/0014-5793(82)81308-2; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; MOSHER DF, 1995, THROMB HAEMOSTASIS, V74, P529; NOVOKHATNY VV, 1994, J MOL BIOL, V238, P833, DOI 10.1006/jmbi.1994.1337; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SOTTILE J, 1994, J BIOL CHEM, V269, P17192; WAGNER DD, 1979, J BIOL CHEM, V254, P6746; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447	47	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1718	1724		10.1074/jbc.272.3.1718	http://dx.doi.org/10.1074/jbc.272.3.1718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999851	hybrid			2022-12-25	WOS:A1997WD05800049
J	Kubiseski, TJ; Chook, YM; Parris, WE; RozakisAdcock, M; Pawson, T				Kubiseski, TJ; Chook, YM; Parris, WE; RozakisAdcock, M; Pawson, T			High affinity binding of the pleckstrin homology domain of mSos1 to phosphatidylinositol (4,5)-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PROTEIN-KINASE-C; TYROSINE KINASE; G(BETA-GAMMA) SUBUNITS; SIGNAL-TRANSDUCTION; INOSITOL PHOSPHATES; INSULIN-RECEPTOR; SEVENLESS GENE; FACTOR SON; PH DOMAIN	mSos1 has been implicated in coupling mammalian tyrosine kinases to the Has GTPase. Because activation of Pas induced by growth factor stimulation likely requires the localization of mSos1 to the plasma membrane, we have investigated the possibility that the PH domain of mSos1 might mediate an interaction of mSos1 with phospholipid membranes. A glutathione S-transferase fusion protein containing the pleckstrin homology (PH) domain of mSos1 bound specifically and tightly to phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) with a K-d of 1.8 +/- 0.4 mu M. This interaction was saturable and was competed away with the soluble head group of PI(4,5)P-2, inositol 1,4,5-triphosphate. Substitution of Arg(452) within the PH domain with Ala had only a slight effect on binding to PI(4,5)P-2, whereas substitution of Arg(459) severely compromised the ability of the mSos1 PH domain to bind to PI(4,5)P-2 containing vesicles. Purified full-length mSos1 and mSos1 complexed with Grb2 were also tested for binding to various phosphoinositol derivatives and demonstrated a specific interaction with PI(4,5)P-2, although these interactions were weaker (K-d = similar to 53 and similar to 69 mu M, respectively) than that of the PH domain alone. These findings suggest that the PH domain of mSos1 can interact in vitro with phospholipid vesicles containing PI(4,5)P-2 and that this interaction is facilitated by the ionic interaction of Arg(459) with the negatively charged head group of PI(4,5)P-2. The association of the mSos1 PH domain with phospholipid may therefore play a role in regulating the function of this enzyme in vivo.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAM MOL BIOL & CANC,TORONTO,ON M5G 1X5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Chook, Yuh Min/AAA-9549-2019; Pawson, Tony J/E-4578-2013	Kubiseski, Terrance/0000-0001-9388-8608				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Bradshaw JP, 1996, NAT STRUCT BIOL, V3, P125, DOI 10.1038/nsb0296-125; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	38	65	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1799	1804		10.1074/jbc.272.3.1799	http://dx.doi.org/10.1074/jbc.272.3.1799			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999863	hybrid			2022-12-25	WOS:A1997WD05800061
J	Olami, Y; Rimon, A; Gerchman, Y; Rothman, A; Padan, E				Olami, Y; Rimon, A; Gerchman, Y; Rothman, A; Padan, E			Histidine 225, a residue of the NhaA-Na+/H+ antiporter of Escherichia coli is exposed and faces the cell exterior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; GENE; ANT; IDENTIFICATION; EXPRESSION; PROTEINS; CARRIER; MUTANTS; BINDING; PH	Cysteine residues were found nonessential in the mechanism of the NhaA antiporter activity of Escherichia coli. The functional C-less NhaA has provided the groundwork to study further histidine 225 of NhaA which has previously been suggested to play an important role in the activation of NhaA at alkaline pH (Rimon, A., Gerchman, Y., Olami, Y., Schuldiner, S. and Padan, E. (1995) J. Biol. Chem. 270, 26813-26817). C-less H225C was constructed and shown to possess an antiporter activity 60% of that of C-less antiporter and a pH profile similar to that of both the C-less or wild-type antiporters. Remarkably, whereas neither the wild-type nor the C-less antiporters were affected by N-ethylmaleimide, C-less H225C was inhibited by this reagent. To determine the degree of alkylation of the antiporter protein by N-ethylmaleimide, antiporter derivatives tagged at their C termini with six histidines residues were constructed. Alkylation of C-less H225C was measured by labeling of everted membrane vesicles with [C-14]N-ethylmaleimide, affinity purification of the His-tagged antiporter, and determination of the radioactivity of the purified protein. This assay showed that H225C is alkylated to a much higher level than any of the native cysteinyl residues of NhaA reaching saturation at alkyl/NhaA stoichiometry of 1. The wild-type derivative showed at least 10-fold less alkylation even at higher concentrations, suggesting that H225C resides in a domain that is much more exposed to N-ethylmaleimide than the native cysteinyl residues of NhaA. Since H225C residues both in right-side out and in side-out membrane vesicles were quantitatively alkylated by N-ethylmaleimide this assay was used to determine the accessibility of H225C to other SH reagents by titrating the H225C left free to react with N-ethylmaleimide, following exposure of the membranes to the reagents. Furthermore, since membrane-impermeant probes can react with residues in membrane-embedded protein only if accessible to the medium containing the reagent, the assay was used to determine the membrane topology of H225C. As expected for a membrane-permeant probe, p-chloromercuribenzoate reacted with H225C as efficiently as N-ethylmaleimide in both membrane orientations. Similar results were obtained with methanethiosulfonate ethylammonium supporting the recent observations that this probe is membrane-permeant. On the other hand, both membrane-impermeant reagents p-chloromercuribenzosulfonate and methanethiosulfonate ethyl-trimethyl ammonium bromide reacted with H225C 10-fold more in right-side out than in inside-out vesicles, and p-chloromercuribenzosulfonate also blocked completely the H225C in intact cells. These results strongly suggest that H225C is exposed at the periplasmic face of the membrane.	HEBREW UNIV JERUSALEM,DIV MICROBIAL & MOL ECOL,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Gerchman, Yoram/F-5226-2015; Gerchman, Yoram/H-4698-2019	Gerchman, Yoram/0000-0002-8637-9589; 				AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMEL O, 1994, EMBO J, V13, P1981, DOI 10.1002/j.1460-2075.1994.tb06467.x; DAMIANO E, 1985, EUR J BIOCHEM, V148, P183, DOI 10.1111/j.1432-1033.1985.tb08823.x; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P3950, DOI 10.1021/bi952601m; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P5333, DOI 10.1021/bi953068d; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; PAAN E, 1994, BIOCHIM BIOPHYS ACTA, V1185, P129; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1989, J BIOL CHEM, V264, P20297; Padan E., 1996, HDB BIOL PHYS, V2, P501; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; PINNER E, 1994, J BIOL CHEM, V269, P26274; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; REENSTRA WW, 1980, BIOCHEMISTRY-US, V19, P1, DOI 10.1021/bi00542a001; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; ROTTENBERG H, 1971, FEBS LETT, V13, P41, DOI 10.1016/0014-5793(71)80659-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; WU JH, 1995, BIOCHEMISTRY-US, V34, P8257, DOI 10.1021/bi00026a007; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0	36	94	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1761	1768		10.1074/jbc.272.3.1761	http://dx.doi.org/10.1074/jbc.272.3.1761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999858	hybrid			2022-12-25	WOS:A1997WD05800056
J	Schmitt, DA; Hatton, JP; Emond, C; Chaput, D; Paris, H; Levade, T; Cazenave, JP; Schaffar, L				Schmitt, DA; Hatton, JP; Emond, C; Chaput, D; Paris, H; Levade, T; Cazenave, JP; Schaffar, L			The distribution of protein kinase C in human leukocytes is altered in microgravity	FASEB JOURNAL			English	Article						spaceflight; monocytes; signal transduction; PKC	SIGNAL-TRANSDUCTION; GRAVITY; ACTIVATION; PHORBOL; CELLS; PHOSPHORYLATION; TRANSLOCATION; FILAMENTS; ISOZYMES; FLIGHT	Protein kinase C (PKC) is an ubiquitous enzyme that mediates intracellular signal transduction in eukaryotes. Jurkat and U931 cells were exposed to microgravity during a Space Shuttle flight and stimulated with a radiolabeled phorbol ester (H-3-PDBu) that specifically activates and labels several PKC isoforms, Both the total amount of H-3-PDBu labeling per cell and the relative distribution of labeling between subcellular compartments were altered in microgravity compared to onboard and ground 1 g control samples, The amount of total phorbol ester labeling per cell was increased approximately twofold in microgravity samples when compared with onboard Ig samples for both cell lines, The subcellular distribution of PKC in the cytosol and nuclear fractions appeared to be correlated with the applied acceleration, In both cell types the relative amount of phorbol ester labeling in the nuclear fraction decreased with applied acceleration, whereas the labeling in cytosolic fraction increased with g level, No significant differences were observed between labeling levels in the membrane fraction in both cell types, Interleukin-1 beta Synthesis by U931 cells was markedly decreased in microgravity when compared to the onboard 1 g control, suggesting that the observed alterations in PKC distribution may have functional consequences, The results may have important implications for the effect of gravity on cellular signal transduction.	ETAB TRANSFUS SANGUINE STRASBOURG, INSERM U311, F-67065 STRASBOURG, FRANCE; HOP & FAC MED TOULOUSE RANGUEIL, IMMUNOL LAB, F-31054 TOULOUSE, FRANCE; CTR NATL ETUD SPATIALES, F-31055 TOULOUSE, FRANCE; CHU RANGUEIL, INSERM U317, F-31054 TOULOUSE, FRANCE; CHU RANGUEIL, INSERM CJF 9206, F-31054 TOULOUSE, FRANCE; INSERM, SERV ICAR, F-75654 PARIS 13, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Schmitt, DA (corresponding author), INT SPACE UNIV, BLVD GONTHIER ANDERNACH, STRASBOURG CENT CAMPUS, F-67400 ILLKIRCH GRAFFENSTADEN, FRANCE.		Cazenave, Jean-Pierre/AAE-2935-2019; Levade, Thierry/O-8948-2014					BJORKMAN T, 1988, ADV BOT RES, V15, P1; BRIARTY LG, 1995, BIORACK SPACELAB IML, V1, P141; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; Cogoli A, 1991, Adv Space Biol Med, V1, P183; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; FLEMING SD, 1991, J LEUKOCYTE BIOL, V50, P69, DOI 10.1002/jlb.50.1.69; GENZEL P, 1988, ESA, P21; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUGHESFULFORD M, 1993, ASGSB B, V7, P31; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KILEY SC, 1995, J CELL SCI, V108, P1003; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; LORENZI G, 1990, BIOL CELL, V68, P259, DOI 10.1016/0248-4900(90)90317-V; MAHONEY CW, 1994, PROTEIN KINASE C, P16; MALVIYA AN, 1993, RECEPTOR, V3, P257; MANDELKOW E, 1989, SCIENCE, V246, P1291, DOI 10.1126/science.2588005; MEEK DW, 1992, BIOCHEM J, V287, P1; MORRISON D, 1995, POSTFL M ESTEC NOORD; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P9146; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OKADA S, 1969, SCIENCE, V165, P698, DOI 10.1126/science.165.3894.698; PARKER PJ, 1994, PROTEIN KINASE C, P3; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; Pippia P, 1996, J BIOTECHNOL, V47, P215, DOI 10.1016/0168-1656(96)01387-9; PRIGOGINE I, 1984, ORDER OUT CHAOS, P40; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SCHMITT DA, 1993, J CELL SCI, V104, P805; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHOYAB M, 1980, NATURE, V288, P451, DOI 10.1038/288451a0; SPOONER BS, 1990, AVIAT SPACE ENVIR MD, V61, P725; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TABONY J, 1994, SCIENCE, V264, P245, DOI 10.1126/science.8146654; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; WOODS KM, 1994, EXP CELL RES, V211, P171, DOI 10.1006/excr.1994.1074	37	70	73	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1996	10	14					1627	1634		10.1096/fasebj.10.14.9002555	http://dx.doi.org/10.1096/fasebj.10.14.9002555			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002555				2022-12-25	WOS:A1996WC86900009
J	Koplin, R; Brisson, JR; Whitfield, C				Koplin, R; Brisson, JR; Whitfield, C			UDP-galactofuranose precursor required for formation of the lipopolysaccharide O antigen of Klebsiella pneumoniae serotype 01 is synthesized by the product of the rfbD(KP01) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; O1K2 NCTC-5055 LIPOPOLYSACCHARIDE; MANNOSE-TYPE OLIGOSACCHARIDES; CELL-SURFACE POLYSACCHARIDE; D-GALACTAN-I; ESCHERICHIA-COLI; STRUCTURAL-ANALYSIS; CAPSULAR POLYSACCHARIDES; CLOSTRIDIUM-THERMOCELLUM; POLYACRYLAMIDE GELS	The O-side-chain polysaccharide in the Lipopolysaccharide of Klebsiella pneumoniae O1 is based on a backbone structure of repeat units of [-->3)-beta-D-Galf-(1-->3)-alpha-D-Galp-(1-->]; this structure is termed D-galactan I. The rfb (O-antigen biosynthesis) gene cluster directs the synthesis of D-galactan I and consists of six genes termed rfbA-F-KPO1. In this paper we show that rfbD(KPO1) encodes a UDP-galactopyranose mutase (NAD(P)H-requiring) (EC 5.4.99.9), which forms uridine 5'-(trihydrogen diphosphate) P'-alpha-D-galactofuranosyl ester (UDP-Galf), the biosynthetic precursor of galactofuranosyl residues. The deduced amino acid sequence of rfbD(KPO1) shows 85% and 37.5% identity to the rfbD(KPO8) gene of K. pneumoniae serotype O8 and the glf gene of Escherichia coli, respectively. The molecular mass of the purified RfbD(KPO1) enzyme is 45 kDa as determined by SDS-polyacrylamide gel electrophoresis, while gel filtration revealed a molecular mass of 92 kDa, suggesting a dimeric structure for the native protein. The rfbD(KPO1) gene product interconverts uridine 5'-(trihydrogen diphosphate) P'-alpha-D-galactopyranosyl ester (UDP-Galp) and UDP-Galf: Unlike Glf, RfbD(KPO1) showed a requirement for NADH or NADPH, which could not be replaced by NAD or NADP. RfbD(KPO1) was used to synthesize milligram quantities of UDP-Galf, allowing this compound to be purified and fully characterized in an intact form for the first time. The structure of UDP-Galf was proven by NMR spectroscopy.	UNIV GUELPH,DEPT MICROBIOL,GUELPH,ON N1G 2W1,CANADA; UNIV GUELPH,CANADIAN BACTERIAL DIS NETWORK,GUELPH,ON N1G 2W1,CANADA; NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA,ON K1A 0R6,CANADA	University of Guelph; University of Guelph; National Research Council Canada								ABEYGUNAWARDANA C, 1990, BIOCHEMISTRY-US, V29, P234, DOI 10.1021/bi00453a032; ABEYGUNAWARDANA C, 1991, BIOCHEMISTRY-US, V30, P8568, DOI 10.1021/bi00099a012; ABEYGUNAWARDANA C, 1991, BIOCHEMISTRY-US, V30, P6528, DOI 10.1021/bi00240a025; ALTMAN E, 1988, CARBOHYD RES, V179, P245, DOI 10.1016/0008-6215(88)84122-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARR K, 1984, BIOCHEMISTRY-US, V23, P5589, DOI 10.1021/bi00318a032; BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BAX A, 1988, CARBOHYD RES, V173, P53, DOI 10.1016/S0008-6215(00)90802-4; BERST M, 1971, EUR J BIOCHEM, V18, P361, DOI 10.1111/j.1432-1033.1971.tb01251.x; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; BOCK K, 1984, ADV CARBOHYD CHEM BI, V42, P193, DOI 10.1016/S0065-2318(08)60125-0; BRONNER D, 1994, MOL MICROBIOL, V14, P505, DOI 10.1111/j.1365-2958.1994.tb02185.x; CHRISTIAN R, 1993, J BACTERIOL, V175, P1250, DOI 10.1128/JB.175.5.1250-1256.1993; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; CLARKE BR, 1992, J BACTERIOL, V174, P4614, DOI 10.1128/JB.174.14.4614-4621.1992; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; DAVIES DB, 1974, BIOCHEMISTRY-US, V13, P4417, DOI 10.1021/bi00718a027; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DMITRIEV BA, 1977, CARBOHYD RES, V56, P207, DOI 10.1016/S0008-6215(00)84257-3; DUTTON GGS, 1985, CARBOHYD RES, V140, P263, DOI 10.1016/0008-6215(85)85127-2; FUJITA K, 1993, BIOSCI BIOTECH BIOCH, V57, P1166, DOI 10.1271/bbb.57.1166; GERWIG GJ, 1989, J BIOL CHEM, V264, P1027; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; Gorenstein D.G., 1984, PHOSPHORUS 31 NMR PR, P7; GORIN PAJ, 1959, CAN J CHEM, V37, P499, DOI 10.1139/v59-066; Haworth WN, 1937, BIOCHEM J, V31, P640, DOI 10.1042/bj0310640; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; ILG T, 1992, J BIOL CHEM, V267, P6834; JANN B, 1994, CARBOHYD RES, V264, P305, DOI 10.1016/S0008-6215(05)80014-X; KELLY RF, 1995, J ENDOTOXIN RES, V0002; KELLY RF, 1993, MOL MICROBIOL, V10, P615, DOI 10.1111/j.1365-2958.1993.tb00933.x; Kelly RF, 1996, J BACTERIOL, V178, P5205, DOI 10.1128/jb.178.17.5205-5214.1996; KOL O, 1992, CARBOHYD RES, V236, P339, DOI 10.1016/0008-6215(92)85028-X; KOL O, 1991, CARBOHYD RES, V217, P117, DOI 10.1016/0008-6215(91)84122-U; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; LEE CH, 1976, BIOCHEMISTRY-US, V15, P697, DOI 10.1021/bi00648a038; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; LVOV VL, 1983, CARBOHYD RES, V124, P141, DOI 10.1016/0008-6215(83)88362-1; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; MENDELZON DH, 1986, J BIOL CHEM, V261, P2129; NAKAJIMA T, 1984, J BIOCHEM, V96, P1013, DOI 10.1093/oxfordjournals.jbchem.a134917; Nassau PM, 1996, J BACTERIOL, V178, P1047, DOI 10.1128/jb.178.4.1047-1052.1996; NEUHARD J, 1976, J BACTERIOL, V126, P999, DOI 10.1128/JB.126.2.999-1001.1976; NIKAIDO H, 1971, J BACTERIOL, V105, P1073, DOI 10.1128/JB.105.3.1073-1082.1971; OXLEY D, 1989, CARBOHYD RES, V193, P241, DOI 10.1016/0008-6215(89)85122-5; OXLEY D, 1988, CARBOHYD RES, V172, P287, DOI 10.1016/S0008-6215(00)90862-0; PALMIERI MJ, 1991, ANAL BIOCHEM, V194, P388, DOI 10.1016/0003-2697(91)90246-P; PARRA E, 1994, CARBOHYD RES, V257, P239, DOI 10.1016/0008-6215(94)80038-3; PERRY MB, 1984, CAN J BIOCHEM CELL B, V62, P108, DOI 10.1139/o84-016; PERRY MB, 1990, BIOCHEM CELL BIOL, V68, P808, DOI 10.1139/o90-117; PLACKETT P, 1964, BIOCHEM J, V90, P201, DOI 10.1042/bj0900201; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; Sambrook J., 2002, MOL CLONING LAB MANU; SARVAS M, 1971, J BACTERIOL, V105, P1063, DOI 10.1128/JB.105.3.1063-1072.1971; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; TAKAYANAGI T, 1994, CARBOHYD RES, V256, P149, DOI 10.1016/0008-6215(94)84234-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREJO AG, 1970, BIOCHEM J, V117, P637, DOI 10.1042/bj1170637; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; UHRIN D, 1994, J BIOMOL NMR, V4, P615, DOI 10.1007/BF00404273; UNKEFER CJ, 1979, J BIOL CHEM, V254, P2131; WEIKERT MJ, 1993, MOL MICROBIOL, V10, P245; WHITFIELD C, 1991, J BACTERIOL, V173, P1420, DOI 10.1128/jb.173.4.1420-1431.1991; WHITFIELD C, 1992, J BACTERIOL, V174, P4913, DOI 10.1128/JB.174.15.4913-4919.1992; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAO ZJ, 1994, J BACTERIOL, V176, P4133, DOI 10.1128/JB.176.13.4133-4143.1994	70	113	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4121	4128		10.1074/jbc.272.7.4121	http://dx.doi.org/10.1074/jbc.272.7.4121			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020123	hybrid			2022-12-25	WOS:A1997WH01900039
J	Tohgo, A; Munakata, H; Takasawa, S; Nata, K; Akiyama, T; Hayashi, N; Okamoto, H				Tohgo, A; Munakata, H; Takasawa, S; Nata, K; Akiyama, T; Hayashi, N; Okamoto, H			Lysine 129 of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) participates in the binding of ATP to inhibit the cyclic ADP-ribose hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE ANTIGEN CD38; PANCREATIC BETA-CELLS; EGG-SPECIFIC NADASE; 2ND-MESSENGER ENZYME; INSULIN-SECRETION; CA2+ RELEASE; HYDROLYSIS; PROTEIN; MECHANISM; CHANNELS	CD38 catalyzes not only the formation of cyclic ADP-ribose (cADPR) from NAD(+) but also the hydrolysis of cADPR to ADP-ribose (ADPR), and ATP inhibits the hydrolysis (Takasawa, S., Tohgo, A., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Yonekura, H., and Okamoto, Il. (1993) J. Biol. Chem. 268, 26052-26054). In the present study, using purified recombinant CD38, we showed that the cADPR hydrolase activity of CD38 was inhibited by ATP in a competitive manner with cADPR. To identify the binding site for ATP and/or cADPR, we labeled the purified CD38 with FSBA. Sequence analysis of the lysylendopeptidase-digested fragment of the labeled CD38 indicated that the FSBA-labeled residue was Lys-129. We introduced site-directed mutations to change the Lys-129 of CD38 to Ala and to Arg. Neither mutant was labeled with FSBA nor catalyzed the hydrolysis of cADPR to ADPR Furthermore, the mutants did not bind cADPR, whereas they still used NAD(+) as a substrate to form cADPR and ADPR. These results indicate that Lys-129 of CD38 participates in cADPR binding and that ATP competes with cADPR for the binding site, resulting in the inhibition of the cADPR hydrolase activity of CD38.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University								ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; BEERS KW, 1995, J CLIN INVEST, V95, P2385, DOI 10.1172/JCI117932; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Colman R F, 1977, Methods Enzymol, V46, P240; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HIGASHIDA H, 1995, J PHYSIOL-LONDON, V482, P317, DOI 10.1113/jphysiol.1995.sp020520; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JACOBSON MK, 1995, BIOCHIMIE, V77, P341, DOI 10.1016/0300-9084(96)88144-2; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; KNIGHT KL, 1985, J BIOL CHEM, V260, P177; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; NATA K, 1995, GENE, V158, P213, DOI 10.1016/0378-1119(95)00095-N; NATA K, 1997, IN PRESS GENE AMST; OKAMOTO H, 1995, BIOCHIMIE, V77, P356, DOI 10.1016/0300-9084(96)88146-6; OKAMOTO H, 1997, IN PRESS METHODS ENZ; OKAMOTO H, 1993, DIABETES, V42, P76; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; Ramaschi G, 1996, BLOOD, V87, P2308, DOI 10.1182/blood.V87.6.2308.bloodjournal8762308; REIKOFSKI J, 1992, BIOTECHNOL ADV, V10, P535, DOI 10.1016/0734-9750(92)91451-J; SCHUBER F, 1979, BIOORG CHEM, V8, P83, DOI 10.1016/0045-2068(79)90039-7; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TARNUS C, 1988, BIOORG CHEM, V16, P38, DOI 10.1016/0045-2068(88)90036-3; TOHGO A, 1994, J BIOL CHEM, V269, P28555; TOHGO A, 1994, FEBS LETT, V340, P133, DOI 10.1016/0014-5793(94)80188-6; TSUJI T, 1987, BIOCHEMISTRY-US, V26, P3129, DOI 10.1021/bi00385a028	39	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3879	3882		10.1074/jbc.272.7.3879	http://dx.doi.org/10.1074/jbc.272.7.3879			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020087	hybrid			2022-12-25	WOS:A1997WH01900003
J	Cho, S; Wensink, PC				Cho, S; Wensink, PC			DNA binding by the male and female doublesex proteins of Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR INTERACTION; TRANSCRIPTION FACTOR; GENE; SITES	Drosophila yolk protein genes are regulated by doublesex male protein (DSX(M)) in males and doublesex female protein (DSX(F)) in females. Both proteins bind to the same DNA sites from which DSX(M) represses and DSX(F) activates transcription, The proteins are identical through 397 NH2-terminal amino acids that include domains for oligomerization and DNA binding. The remaining COOH termini are sex-specific and include an essential part of a second oligomerization domain, We report here mobility shift assays that examine the DNA binding properties of purified DSX(M) and DSX(F), Dimers of DSX(M) and DSX(F) bind to a regulatory site, dsxA, with the same affinity (K-app = 0.2 nM), specificity (specific/nonspecific approximate to 1.2 x 10(4)), and dependence on monovalent and divalent cations. The DNA association rate constants also are indistinguishable (k(on) = 4.6 x 10(6) M(-1) s(-1)) as are the several terms of the dissociation reaction. Dissociation has an intrinsic rate of k(off) = 5.1 x 10(-4) s(-1) and other rate terms that depend on the free concentration of specific DNA binding sites (2.4 x 10(4) M(-1) s(-1)) or nonspecific binding sites (2.4 M(-1) s(-1)). This first order dependence on unbound DNA suggests that a direct transfer between DNAs is likely to occur when DSX proteins search for specific sites in the many short open DNA regions of chromatin. Overall, dimer binding to individual DNA sites appears to be determined by the sex-nonspecific part of the two proteins, We infer that the sex specific oligomerization domains play roles in binding cooperativity to multiple DNA sites or in other protein:protein interactions.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046237] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM46237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN W, 1995, EMBO J, V14, P101; An WQ, 1996, MOL CELL BIOL, V16, P3106; AN WQ, 1995, GENE DEV, V9, P256, DOI 10.1101/gad.9.2.256; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BURTIS KC, 1991, EMBO J, V10, P2577, DOI 10.1002/j.1460-2075.1991.tb07798.x; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Cho SY, 1996, P NATL ACAD SCI USA, V93, P2043, DOI 10.1073/pnas.93.5.2043; COSCHIGANO KT, 1993, GENE DEV, V7, P42, DOI 10.1101/gad.7.1.42; ERDMAN SE, 1993, EMBO J, V12, P527, DOI 10.1002/j.1460-2075.1993.tb05684.x; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GARABEDIAN MJ, 1985, P NATL ACAD SCI USA, V82, P1396, DOI 10.1073/pnas.82.5.1396; KMIEC EB, 1986, J CELL BIOL, V103, P673, DOI 10.1083/jcb.103.3.673; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; RECORD MT, 1981, ANNU REV BIOCHEM, V50, P997, DOI 10.1146/annurev.bi.50.070181.005025; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SCHATCHARD G, 1949, ANN NY ACAD SCI, V51, P660; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675	23	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3185	3189		10.1074/jbc.272.6.3185	http://dx.doi.org/10.1074/jbc.272.6.3185			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013552	hybrid			2022-12-25	WOS:A1997WG19200012
J	Halestrap, AP; Woodfield, KY; Connern, CP				Halestrap, AP; Woodfield, KY; Connern, CP			Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CYCLOSPORINE-A; INNER MEMBRANE; HEART-MITOCHONDRIA; ADP/ATP CARRIER; TRANSPORT ACTIVITY; PLUS PROOXIDANTS; PORE; ADP; PROTEIN	Stimulation of the mitochondrial permeability transition (MPT) is de-energized mitochondria by phenylarsine oxide (PheArs) is greater than that by diamide and t-butylhydroperoxide (TBH), yet the increase in CyP binding to the inner mitochondrial membrane (Concern, C. P. and Halestrap, A. P. (1994) Biochem. J. 302, 321-324) is less. From a range of nucleotides tested only ADP, deoxy-ADP, and ATP inhibited the MPT. ADP inhibition involved two sites with K-i values of about 1 and 25 mu M which were independent of [Ca2+] and CyP binding. Carboxyatractyloside (CAT) abolished the high affinity site. Following pretreatment of mitochondria with TBH or diamide, the K-i for ADP increased to 50-100 mu M, whereas pretreatment with PheArs or eosin maleimide increased the K-i to >500 mu M; only one inhibitory site was observed in both cases. Eosin maleimide is known to attack Cys(159) of the adenine nucleotide translocase (ANT) in a CAT-sensitive manner (Majima, E., Shinohara, Y., Yamaguchi, N., Hong, Y. M., and Terada, H. (1994) Biochemistry 33, 9530-9536), and here we demonstrate CAT-sensitive binding of the ANT to a PheArs affinity column. In adenine nucleotide-depleted mitochondria, no stimulation of the MPT by uncoupler was observed in the presence or absence of thiol reagents, suggesting that membrane potential may inhibit the MPT by increasing adenine nucleotide binding through an effect on the ANT formation. We conclude that CsA and ADP inhibit pore opening in distinct ways, CsA by displacing bound CyP and ADP by binding to the ANT. Both mechanisms act to decrease the Ca2+ sensitivity of the pore. Thiol reagents and oxidative stress may modify two thiol groups on the ANT and thus stimulate pore opening by both means.			Halestrap, AP (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND.		Halestrap, Andrew P/G-7275-2011	Halestrap, Andrew/0000-0001-5374-2778				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BOGNER W, 1986, EUR J BIOCHEM, V161, P611, DOI 10.1111/j.1432-1033.1986.tb10485.x; BOULAY F, 1984, BIOCHEMISTRY-US, V23, P4807, DOI 10.1021/bi00315a042; BRANDOLIN G, 1990, BIOCHEMISTRY-US, V29, P9720, DOI 10.1021/bi00493a030; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; CROMPTON M, 1994, BIOCHEM J, V302, P181, DOI 10.1042/bj3020181; CROMPTON M, 1988, BIOCHEM J, V255, P357; DAVIDSON AM, 1990, BIOCHEM J, V268, P147, DOI 10.1042/bj2680147; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HALESTRAP AP, 1991, BIOCHEM J, V278, P715, DOI 10.1042/bj2780715; HALESTRAP AP, 1994, MITOCHONDRIA DNA PRO, P113; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; KLINGENBERG M, 1983, EUR J BIOCHEM, V131, P647, DOI 10.1111/j.1432-1033.1983.tb07312.x; Klingenberg M, 1976, ENZYMES BIOLOGICAL M, V3, P383; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KRAMER R, 1982, BIOCHEMISTRY-US, V21, P1082; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; LEQUOC D, 1989, ARCH BIOCHEM BIOPHYS, V273, P466, DOI 10.1016/0003-9861(89)90506-7; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; Macedo Denise Vaz De, 1993, European Journal of Biochemistry, V215, P595, DOI 10.1111/j.1432-1033.1993.tb18070.x; MAJIMA E, 1994, BIOCHEMISTRY-US, V33, P9530, DOI 10.1021/bi00198a019; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; RIGOBELLO MP, 1995, ARCH BIOCHEM BIOPHYS, V319, P225, DOI 10.1006/abbi.1995.1286; SAVAGE MK, 1991, ARCH BIOCHEM BIOPHYS, V290, P51, DOI 10.1016/0003-9861(91)90590-F; SLUSE FE, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P183; SOUVERIJN JH, 1973, BIOCHIM BIOPHYS ACTA, V305, P185, DOI 10.1016/0005-2728(73)90168-0; SZABO I, 1991, J BIOL CHEM, V266, P3376; Tanveer A, 1996, EUR J BIOCHEM, V238, P166, DOI 10.1111/j.1432-1033.1996.0166q.x; VALLE VGR, 1993, ARCH BIOCHEM BIOPHYS, V307, P1, DOI 10.1006/abbi.1993.1551; VIGNAIS PV, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P133; ZAHLER WL, 1968, J BIOL CHEM, V243, P716; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739; ZWIZINSKI CW, 1992, ARCH BIOCHEM BIOPHYS, V294, P178, DOI 10.1016/0003-9861(92)90154-O	60	516	539	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3346	3354		10.1074/jbc.272.6.3346	http://dx.doi.org/10.1074/jbc.272.6.3346			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013575	hybrid			2022-12-25	WOS:A1997WG19200035
J	Muzio, M; Salvesen, GS; Dixit, VM				Muzio, M; Salvesen, GS; Dixit, VM			FLICE induced apoptosis in a cell-free system - Cleavage of caspase zymogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROTEINASE-INHIBITORS; ICE/CED-3 PROTEASE; CYSTEINE PROTEASES; DEATH DOMAIN; CRMA GENE; FAS; ENCODES; IDENTIFICATION; INVOLVEMENT	Engagement of CD95 or tumor necrosis factor 1 receptor (TNFR-1) by ligand or agonist antibodies is capable of activating the cell death program, the effector arm of which is composed of mammalian interleukin-1 beta converting enzyme (ICE)-like cysteine proteases (designated caspases) that are related to the Caenorhabditis elegans death gene, CED-3. Caspases, unlike other mammalian cysteine proteases, cleave their substrates following aspartate residues. Furthermore, proteases belonging to this family exist as zymogens that in turn require cleavage at internal aspartate residues to generate the two-subunit active enzyme. As such, family members are capable of activating each other. Remarkably, both CD95 and TNFR-1 death receptors initiate apoptosis by recruiting a novel ICE/CED-3 family member, designated FLICE/MACH, to the receptor signaling complex. Therefore, FLICE/MACH represents the apical triggering protease in the cascade. Consistent with this, recombinant FLICE was found capable of proteolytically activating downstream caspases. Furthermore, CrmA, a pox virus-encoded serpin that inhibits Fas and tumor necrosis factor-induced cell death attenuates the ability of FLICE to activate downstream caspases.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; BURNHAM INST,SAN DIEGO,CA 92037	University of Michigan System; University of Michigan			Muzio, Marta/J-9360-2018; dixit, vishva m/A-4496-2012	Muzio, Marta/0000-0002-7761-759X; dixit, vishva m/0000-0001-6983-0326				BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Hasegawa J, 1996, CANCER RES, V56, P1713; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAGAIKURATA N, 1995, EUR RESPIR J, V8, P1613; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	43	301	317	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2952	2956		10.1074/jbc.272.5.2952	http://dx.doi.org/10.1074/jbc.272.5.2952			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006941	hybrid			2022-12-25	WOS:A1997WE66700054
J	DeGray, JA; Gunther, MR; TschirretGuth, R; deMontellano, PRO; Mason, RP				DeGray, JA; Gunther, MR; TschirretGuth, R; deMontellano, PRO; Mason, RP			Peroxidation of a specific tryptophan of metmyoglobin by hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; ELECTRON-TRANSFER REACTIONS; OXIDATION; ORIENTATION; TYR-151; OXYMYOGLOBIN; PROTEINS; ENZYMES; MODEL	Globin-centered radicals at tyrosine and tryptophan residues and a peroxyl radical at an unknown location have been reported previously as products of the reaction of metmyoglobin with hydrogen peroxide. The peroxyl radical is shown here to be localized on tryptophan through the use of recombinant sperm whale myoglobin labeled with C-13 at the indole ring C-3. Peroxyl radical formation was not prevented by site-directed mutations that replaced all three tyrosines, the distal histidine, or tryptophan 7 with non-oxidizable residues. In contrast, mutation of tryptophan 14 prevents peroxyl radical formation, implicating tryptophan 14 as the specific site of the peroxidation.	NIEHS, LAB PHARMACOL & CHEM, NIH, RES TRIANGLE PK, NC 27709 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of California System; University of California San Francisco; University of California System; University of California San Francisco			Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CAVE RJ, 1986, J CHEM PHYS, V84, P3089, DOI 10.1063/1.450290; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; HUANG HS, 1995, AM J PHYSIOL-HEART C, V268, pH2114, DOI 10.1152/ajpheart.1995.268.5.H2114; HUANG HS, 1995, AM J PHYSIOL-HEART C, V269, pH888, DOI 10.1152/ajpheart.1995.269.3.H888; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KEVAN L, 1986, J PHYS CHEM-US, V90, P1998, DOI 10.1021/j100401a007; KING NK, 1963, J BIOL CHEM, V238, P1520; LOW B, 1968, P NATL ACAD SCI USA, V60, P160, DOI 10.1073/pnas.60.1.160; MAKINEN MW, 1983, SCIENCE, V222, P929, DOI 10.1126/science.6415814; MAYO SL, 1986, SCIENCE, V233, P948, DOI 10.1126/science.3016897; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; OKABE E, 1993, EUR J PHARM-ENVIRON, V248, P33, DOI 10.1016/0926-6917(93)90022-I; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; RAO SI, 1993, J BIOL CHEM, V268, P803; RIZZI M, 1993, FEBS LETT, V320, P13, DOI 10.1016/0014-5793(93)81647-I; SIDERS P, 1984, J CHEM PHYS, V81, P5613, DOI 10.1063/1.447665; SLEZAK J, 1995, AM J PATHOL, V147, P772; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Svistunenko DA, 1996, FREE RADICAL RES, V24, P269, DOI 10.3109/10715769609088024; TEW D, 1988, J BIOL CHEM, V263, P17880; Watson H.C., 1969, PROGR STEREOCHEM, V4, P229; WHITBURN KD, 1987, ARCH BIOCHEM BIOPHYS, V253, P419, DOI 10.1016/0003-9861(87)90195-0; WILKS A, 1992, J BIOL CHEM, V267, P8827; YUSA K, 1987, BIOCHEMISTRY-US, V26, P6684, DOI 10.1021/bi00395a018	30	105	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2359	2362						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999946				2022-12-25	WOS:A1997WD67900052
J	Poirel, H; Oury, C; Carron, C; Duprez, E; Laabi, Y; Tsapis, A; Romana, SP; Mauchauffe, M; LeConiat, M; Berger, R; Ghysdael, J; Bernard, OA				Poirel, H; Oury, C; Carron, C; Duprez, E; Laabi, Y; Tsapis, A; Romana, SP; Mauchauffe, M; LeConiat, M; Berger, R; Ghysdael, J; Bernard, OA			The TEL gene products: Nuclear phosphoproteins with DNA binding properties	ONCOGENE			English	Article						TEL; ETS; translocation; transcription factor; leukemia; translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTIONAL ACTIVATION; ETS-FAMILY; CHROMOSOMAL TRANSLOCATION; C-ETS-1 PROTOONCOGENE; EWS GENE; FUSION; DOMAIN; CHILDHOOD	The human TEL gene is involved in several 12p13 chromosomal abnormalities present in various human hematological malignancies, the most frequent being the t(12;21)(p13;q22), specific for childhood acute lymphoblastic leukemia, The predicted product of TEL harbours an amino acid region similar to the ETS DNA binding domain. We now report the isolation of the murine TEL cDNA and the characterization of the human TEL proteins. Human and murine TEL proteins are particularly homologous within their aminoterminal regions and their ETS domains. TEL proteins are nuclear and display specific DNA binding activity toward classical ETS binding sites. In addition, we show that TEL mRNAs initiate translation at either of the two first in-frame ATGs (codon 1 and 43) to encode 50 kDa and 57 kDa TEL proteins. In vivo, each of these primary translational products is modified by multiple phosphorylation events.	INST GENET MOL,INSERM,U301,F-75010 PARIS,FRANCE; INST GENET MOL,SD 401 301 CNRS,F-75010 PARIS,FRANCE; CTR UNIV ORSAY,INST CURIE,SECT RECH,F-91405 ORSAY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			duprez, estelle a/R-2357-2016; Carron, Clémence/AAG-6304-2021; GHYSDAEL, Jacques/F-3377-2013; Bernard, Olivier A./E-5721-2016	Carron, Clemence/0000-0002-8776-7380; Oury, Cecile/0000-0002-7561-0132; Bernard, Olivier/0000-0002-0463-9747; Romana, Serge Pierrick/0000-0003-3435-239X				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BERNARD OA, 1996, IN PRESS LEUKEMIA LY; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; CAVE H, 1995, BLOOD, V86, P3869, DOI 10.1182/blood.V86.10.3869.bloodjournal86103869; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GHYSDAEL J, 1995, PATHOL BIOL, V43, P202; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEON IS, 1995, ONCOGENE, V10, P1229; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCLEAN TW, 1996, IN PRESS BLOOD; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rabault B, 1996, ONCOGENE, V13, P877; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; Sambrook J., 2002, MOL CLONING LAB MANU; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; SETH A, 1990, ONCOGENE, V5, P1761; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; VENAUT AM, 1981, CANC GENET CYTOGENET, V3, P327; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	45	94	95	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					349	357		10.1038/sj.onc.1200829	http://dx.doi.org/10.1038/sj.onc.1200829			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018121				2022-12-25	WOS:A1997WD51600011
J	Clark, GJ; Westwick, JK; Der, CJ				Clark, GJ; Westwick, JK; Der, CJ			p120 GAP modulates Ras activation of Jun kinases and transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; NIH 3T3 CELLS; C-JUN; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; FAMILY MEMBERS; ONCOGENIC RAS; SH3 DOMAIN; HA-RAS; PATHWAY	Although recent evidence demonstrates that Ras causes transformation by activation of multiple downstream pathways, the specific role of non-Raf effector pathways is presently unknown. Although Ras causes activation of the Jun NH2-terminal kinases (JNKs) via a Raf-independent pathway, the contribution of JNK activation to Pas transformation and the effector that mediates JNK activation have not been established. We observed that a dominant negative mutant of SEK1/JNKK, an activator of JNKs, selectively inhibited oncogenic Pas activation of JNK and Pas transformation, but not Pas activation of the p42 mitogen activated protein kinase. In contrast, overexpression of wild type SEK1 enhanced Pas activation of JNK and transforming activity. Thus, JNK activation promotes Pas transformation. Furthermore, a dominant negative mutant of p120 GAP (designated N-GAP), a candidate Ras effector, blocked Ras, but not Raf, transformation and blocked Pas, but not Pac, activation of JNK. Since N-GAP overexpression reduced the association of p190 Rac/Rho GAP with endogenous p120 GAP, N-GAP may form nonproductive complexes with components critical for p120 GAP function. In summary, p120 GAP may function as an effector for Ras activation of JNK and Pas transformation.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	Clark, GJ (corresponding author), UNIV N CAROLINA,DEPT PHARMACOL,CB 7365,FLOB,CHAPEL HILL,NC 27599, USA.			Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA055008, R01CA063071] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA42978, CA63071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRYANT SS, 1995, J BIOL CHEM, V270, P17947, DOI 10.1074/jbc.270.30.17947; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOCQUE B, 1997, IN PRESS CELL SIGNAL; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU N, 1994, ONCOGENE, V5, P597; YEN A, 1994, EUR J CELL BIOL, V65, P103	58	96	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1677	1681		10.1074/jbc.272.3.1677	http://dx.doi.org/10.1074/jbc.272.3.1677			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999845	Green Published, hybrid			2022-12-25	WOS:A1997WD05800043
J	Petrov, VV; Pardo, JP; Slayman, CW				Petrov, VV; Pardo, JP; Slayman, CW			Reactive cysteines of the yeast plasma-membrane H+-ATPase (PMA1) - Mapping the sites of inactivation by N-ethylmaleimide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM ATPASE; FLUORESCENCE ENERGY-TRANSFER; PROTON-TRANSLOCATING ATPASE; ISOTHIOCYANATE-BINDING-SITE; NEUROSPORA-CRASSA; SULFHYDRYL-GROUPS; DIRECTED MUTAGENESIS; KLUYVEROMYCES-LACTIS; CATALYTIC SITE; CATION PUMPS	We have taken advantage of cysteine mutants described previously (Petrov, V. V., and Slayman, C. W. (1995) J. Biol. Chem. 270, 28535-28540) to map the sites at which N-ethylmaleimide (NEM) reacts with the plasmamembrane H+ ATPase (PMA)1 of Saccharomyces cerevisiae. When membrane vesicles containing the ATPase were incubated with NEM, six of nine mutants with single cysteine substitutions showed sensitivity similar to the wild type enzyme. By contrast, C221A and C532A were inactivated more slowly than the wild-type control, and the C221, 532A double mutant was completely resistant, indicating that Cys-221 and Cys-532 are NEM-reactive residues. In the presence of 10 mM MgADP, the wild-type ATPase was partially protected against NEM; parallel experiments with the C221A and C532A mutants showed that the protection occurred at Cys-532, located in or near the nucleotide-binding site. Unexpectedly, the inactivation of the C409A ATPase was similar to 4-fold more rapid than in the case of the wild-type enzyme. Experiments with double mutants made it clear that this resulted from an acidic shift in pK(alpha) and a consequent acceleration of the reaction rate at Cys-532. One simple interpretation is that substitution of Cys-409 leads to a local conformational change within the central hydrophilic domain. Consistent with this idea, the reaction of fluorescein 5'-isothiocyanate at Lys-474 was also stimulated similar to 3.5-fold by the C409A mutation. Taken together, the results of this study provide new information about the reactivity of individual Cys residues within the ATPase and pave the way to tag specific sites for structural and functional studies of the enzyme.	YALE UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, NEW HAVEN, CT 06510 USA	Yale University	Petrov, VV (corresponding author), YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.				NIGMS NIH HHS [GM15761] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; BAKER KJ, 1994, BBA-BIOMEMBRANES, V1192, P53, DOI 10.1016/0005-2736(94)90142-2; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BROOKER RJ, 1983, J BIOL CHEM, V258, P222; BROOKER RJ, 1982, J BIOL CHEM, V257, P2051; BROOKER RJ, 1983, J BIOL CHEM, V258, P8827; CHANG A, 1990, J BIOL CHEM, V265, P15531; COAN CR, 1977, J BIOL CHEM, V252, P3044; CORBALANGARCIA S, 1993, EUR J BIOCHEM, V217, P737, DOI 10.1111/j.1432-1033.1993.tb18300.x; DAVENPORT JW, 1988, J BIOL CHEM, V263, P16007; ESMANN M, 1982, BIOCHIM BIOPHYS ACTA, V688, P260, DOI 10.1016/0005-2736(82)90602-2; FAGAN MJ, 1994, J MOL EVOL, V38, P57; Fiske CH, 1925, J BIOL CHEM, V66, P375; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; GREEN NM, 1992, ANN NY ACAD SCI, V671, P104, DOI 10.1111/j.1749-6632.1992.tb43788.x; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GUERRA G, 1995, ARCH BIOCHEM BIOPHYS, V321, P101, DOI 10.1006/abbi.1995.1373; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KAWAKITA M, 1987, J BIOCHEM-TOKYO, V102, P103, DOI 10.1093/oxfordjournals.jbchem.a122021; KAWAKITA M, 1980, J BIOCHEM, V87, P609, DOI 10.1093/oxfordjournals.jbchem.a132785; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LE DT, 1986, BIOCHEMISTRY-US, V25, P2379, DOI 10.1021/bi00357a012; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; Mahanty SK, 1996, J BIOL CHEM, V271, P367, DOI 10.1074/jbc.271.1.367; MALDONADO AM, 1995, J BIOL CHEM, V270, P8655, DOI 10.1074/jbc.270.15.8655; MATA AM, 1993, BIOCHIM BIOPHYS ACTA, V1147, P6, DOI 10.1016/0005-2736(93)90309-N; MIKI K, 1981, J BIOL CHEM, V256, P9382; MIRANDA M, 1995, J BACTERIOL, V177, P2360, DOI 10.1128/jb.177.9.2360-2367.1995; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; Padmanabha K P, 1994, Symp Soc Exp Biol, V48, P33; PARDO JP, 1989, J BIOL CHEM, V264, P9373; PARDO JP, 1988, J BIOL CHEM, V263, P18664; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; RAO R, 1996, MYCOTA, V3, P29; SAITONAKATSUKA K, 1987, J BIOCHEM-TOKYO, V101, P365, DOI 10.1093/oxfordjournals.jbchem.a121921; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; STERNBERG MJE, 1987, NATURE, V330, P86, DOI 10.1038/330086a0; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; TAN YJ, 1995, J MOL BIOL, V254, P980, DOI 10.1006/jmbi.1995.0670; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; WINSLOW JW, 1981, J BIOL CHEM, V256, P9522	45	18	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1688	1693		10.1074/jbc.272.3.1688	http://dx.doi.org/10.1074/jbc.272.3.1688			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999847	hybrid			2022-12-25	WOS:A1997WD05800045
J	Joy, A; Moffett, J; Neary, K; Mordechai, E; Stachowiak, EK; Coons, S; RankinShapiro, J; Florkiewicz, RZ; Stachowiak, MK				Joy, A; Moffett, J; Neary, K; Mordechai, E; Stachowiak, EK; Coons, S; RankinShapiro, J; Florkiewicz, RZ; Stachowiak, MK			Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells	ONCOGENE			English	Article						growth factor; nuclear localization; astrocytes; glioma; cell proliferation	FIBROBLAST GROWTH-FACTOR; MOLECULAR-WEIGHT FORMS; MESSENGER-RNA LEVELS; HUMAN-BRAIN TUMORS; GENE-EXPRESSION; FACTOR RECEPTOR; FACTOR BFGF; IMMUNOHISTOCHEMICAL LOCALIZATION; PROGENITOR CELLS; BASIC FGF	FGF-2 has been implicated in the neoplastic transformation of glioma cells and in the transition of normal quiescent astrocytes to a proliferating, reactive state. In the present study we have observed that in human glial cells, levels and subcellular localization of FGF-2 are different in quiescent and proliferating cells. FGF-2 was detected in the cytoplasm of non-reactive astrocytes in human brain sections. In contrast FGF-2 was located within the cytoplasm and nuclei of reactive astrocytes in gliotic brain tissue and in neoplastic cells of glioma tumors. In vitro, FGF-2 was found predominantly in the nucleus of subconfluent proliferating astrocytes, but was detected only in the cytoplasm of density arrested quiescent astrocytes. Our results suggest that reduced cell contact stimulates nuclear accumulation of FGF-2, accompanying mitotic activation of reactive human astrocytes. FGF-2 was constitutively localized to the nucleus of continuously proliferating glioma cells independent of cell density. A role for intracellular FGF-2 was further suggested by the observation that glioma cells that are not stimulated to proliferate by extracellular FGF-2 proliferated faster when transfected with FGF-2 expressing vectors. This increased proliferation correlated with nuclear accumulation of FGF-2. Cell proliferation was attenuated by 5'-deoxy-5'-methylthioadenosine, a FGF-2 receptor tyrosine kinase inhibitor that acts within the cell, but was unaffected by myo-inositol hexakis [dihydrogen phosphate] that disrupts FGF-2 binding to plasma membrane receptors. Our results indicate that FGF-2 serves as a nuclear regulator of proliferation in astrocytic cells. In glioma cells, the constitutive presence of FGF-2 in the nucleus may promote proliferation that is insensitive to cell contact inhibition.	BARROW NEUROL INST, PHOENIX, AZ 85013 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Barrow Neurological Institute; Scripps Research Institute					NHLBI NIH HHS [HL49376-01A1] Funding Source: Medline; NIDDK NIH HHS [DK-18811] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; ASCH AS, 1986, P NATL ACAD SCI USA, V83, P2904, DOI 10.1073/pnas.83.9.2904; BERENS M E, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P46; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BINGER DD, 1981, J NEUROPATHOL EXP NE, V40, P201; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOYLE WT, 1985, MOL CELL BIOL, V11, P3017; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; BRIDSTOCK DR, 1991, GROWTH FACTORS, V4, P189; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; COURDEC B, 1991, CELL REGUL, V2, P709; ENG LF, 1992, PROG BRAIN RES, V94, P353; ENGELE J, 1992, DEV BIOL, V152, P363, DOI 10.1016/0012-1606(92)90143-5; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; GUALANDRIS A, 1993, GROWTH FACTORS, V8, P49, DOI 10.3109/08977199309029134; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KNISS DA, 1988, BRAIN RES, V439, P281, DOI 10.1016/0006-8993(88)91485-0; Latham KE, 1996, ONCOGENE, V12, P827; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIU HM, 1994, J NEUROPATH EXP NEUR, V53, P118, DOI 10.1097/00005072-199403000-00002; MAHER PA, 1993, J BIOL CHEM, V268, P4244; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; MOFFETT J, 1994, J INT DEV NEUROSC S1, V12, P77; MORRISON RS, 1994, CANCER RES, V54, P2794; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MORRISON RS, 1994, IN VITRO CELL DEV-AN, V30A, P783; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MURPHY PR, 1988, MOL ENDOCRINOL, V2, P591, DOI 10.1210/mend-2-7-591; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; PAULUS W, 1990, ACTA NEUROPATHOL, V79, P418, DOI 10.1007/BF00308718; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PUCHACZ E, 1993, BRAIN RES, V610, P39, DOI 10.1016/0006-8993(93)91214-D; RAY J, 1995, J NEUROCHEM, V64, P503; ROSENBLUM ML, 1978, CANCER, V41, P2305, DOI 10.1002/1097-0142(197806)41:6<2305::AID-CNCR2820410632>3.0.CO;2-U; SCHECHTER JE, 1992, TISSUE CELL, V24, P791, DOI 10.1016/0040-8166(92)90015-Y; SHERMAN L, 1993, DEVELOPMENT, V118, P131; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; VIJAYAN VK, 1993, INT J DEV NEUROSCI, V11, P257, DOI 10.1016/0736-5748(93)90084-Q; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WOODWARD WR, 1992, J NEUROSCI, V12, P142; ZAGZAG D, 1990, CANCER RES, V50, P7393	57	126	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					171	183		10.1038/sj.onc.1200823	http://dx.doi.org/10.1038/sj.onc.1200823			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010219				2022-12-25	WOS:A1997WC81800005
J	Simons, A; MelamedBessudo, C; Wolkowicz, R; Sperling, J; Sperling, R; Eisenbach, L; Rotter, V				Simons, A; MelamedBessudo, C; Wolkowicz, R; Sperling, J; Sperling, R; Eisenbach, L; Rotter, V			PACT: Cloning and characterization of a cellular p53 binding protein that interacts with Rb	ONCOGENE			English	Article						p53; Rb; SR proteins; splicing	RETINOBLASTOMA GENE-PRODUCT; WILD-TYPE P53; LARGE-T-ANTIGEN; LARGE TUMOR-ANTIGEN; RNA SPLICING FACTORS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; SUSCEPTIBILITY GENE; SV40-TRANSFORMED CELLS; EMBRYONIC LETHALITY	Cellular functions of tumor suppressor proteins can be mediated by protein-protein interactions. Using p53 as a probe to screen an expression library, a cDNA encoding a 250 kDa protein was isolated. Recombinant forms of this protein, designated PACT, bind to wild type p53 while two different mutations abolish this interaction. PACT protein can also interfere with p53 specific DNA binding. PACT contains a serine/arginine (SR) rich region and a C' terminal lysine rich domain. The 250 kDa PACT protein can be precipitated from cell lysates by a method specific for SR proteins. snRNPs can be co-immunoprecipitated from cells with anti-PACT antibodies. These antibodies stain cell nuclei in a speckled pattern reminiscent of the distribution of known splicing factors. Recently, RBQ1, a truncated human homologue of PACT was identified by virtue of Rb binding. We show that RBQ1 is truncated as a result of a possible mutational event. PACT can interact with both cellular Rb and p53.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem				Eisenbach, Lea R/0000-0002-4816-1968				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BLENCOWE BJ, 1995, RNA, V1, P852; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DEPPERT W, 1990, ONCOGENE, V5, P1701; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKIND NB, 1995, ONCOGENE, V11, P841; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FU XD, 1995, RNA, V1, P663; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; Harlow E., ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUNA RMD, 1995, NATURE, V378, P203; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MANIATIS T, MOL CLONING; MARSTON NJ, 1994, ONCOGENE, V9, P2523; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOORE MJ, SPLICING PRECURSORS, P303; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SAKAI Y, 1995, GENOMICS, V30, P98, DOI 10.1006/geno.1995.0017; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; Spector DL, 1993, CURR OPIN CELL BIOL, V5, P442, DOI 10.1016/0955-0674(93)90009-F; STEITZ JA, FUNCTIONS ABUNDANT U, P115; STEWART N, 1995, ONCOGENE, V10, P109; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929; ZHANG W, 1994, ONCOGENE, V9, P2513	74	63	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					145	155		10.1038/sj.onc.1200825	http://dx.doi.org/10.1038/sj.onc.1200825			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010216				2022-12-25	WOS:A1997WC81800002
J	Ciossek, T; Ullrich, A				Ciossek, T; Ullrich, A			Identification of Elf-1 and B61 as high affinity ligands for the receptor tyrosine kinase MDK1	ONCOGENE			English	Article						MDK1; Elf-1; B61; RAP in situ; organogenesis; midbrain	GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; EPH FAMILY; GENE; EXPRESSION; HINDBRAIN; CLONING; CELLS; PHOSPHATASES; PROTEINS	Mouse Developmental Kinase 1 (MDK1) is a receptor tyrosine kinase of the eck/eph subfamily expressed in a variety of tissues during early mouse embryogenesis. To obtain further insight into the function of MDK1, we determined identity and localisation of its physiological ligand(s). Staining whole embryos,vith fusion proteins between the extracellular domain of MDK1 and human secreted alkaline phosphatase revealed areas of high receptor binding in the caudal mesencephalon, the frontal neocortex and the limb buds. This staining was sensitive to treatment with phosphatidylinositol-specific phospholipase C. Using Scatchard analysis, high affinity binding of Elf-1 (1.7 x 10(-10) M) and B61 (2.2 x 10(-10) M) towards MDK1 could be demonstrated. However, the transmembrane ligand Lerk2 displayed no measurable affinity for MDK1. Elf-1 and B61 bind to the three full-length MDK1 isoforms with similar dissociation constants. Slightly lower affinities were observed for the two truncated receptors MDK1-T1 and MDK1-T2. The activation of MDK1 with Elf-1 or B61 leads to the rapid autophosphorylation of MDK1 as well as tyrosine phosphorylation of an unknown 62 kDa phosphoprotein in Rat1 cells. These findings implicate MDK1 in patterning processes during early mouse embryogenesis and suggest MDK1 involvement in early organogenesis and midbrain development.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society								BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen J, 1996, ONCOGENE, V12, P979; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CIOSSEK T, 1995, ONCOGENE, V10, P97; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; ELLIS J, 1995, MECH DEVELOP, V52, P319, DOI 10.1016/0925-4773(95)00411-S; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; FRIEDRICH R, 1991, VIROLOGY, V183, P343, DOI 10.1016/0042-6822(91)90147-4; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Kenny D, 1995, DEV BIOL, V172, P708, DOI 10.1006/dbio.1995.8083; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORI T, 1995, MOL BRAIN RES, V34, P154, DOI 10.1016/0169-328X(95)00154-K; Orike N, 1996, CURR BIOL, V6, P108, DOI 10.1016/S0960-9822(02)00435-9; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Patel K, 1996, DEVELOPMENT, V122, P1147; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; TAKAHASHI H, 1995, ONCOGENE, V11, P879; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UENO H, 1992, J BIOL CHEM, V267, P1470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	49	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					35	43		10.1038/sj.onc.1200800	http://dx.doi.org/10.1038/sj.onc.1200800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010230				2022-12-25	WOS:A1997WB76000003
J	DeCesare, D; Palazzolo, M; Blasi, F				DeCesare, D; Palazzolo, M; Blasi, F			Functional characterization of COM, a DNA region required for cooperation between AP-1 sites in urokinase gene transcription	ONCOGENE			English	Article						urokinase; enhancer; transcription	PLASMINOGEN-ACTIVATOR GENE; COLONY-STIMULATING FACTOR; REGULATORY ELEMENT; PHORBOL-ESTER; HMG DOMAIN; ENHANCER; INDUCTION; CELLS; INTERLEUKIN-3; EXPRESSION	The inducible uPA enhancer contains two phorbol ester responsive elements: the combined PEA3/AP-1(A) and a downstream AP-1(A) site. The integrity of all three sites is essential for enhancer activity, The interposed 74 bp long DNA region (COM, Cooperation Mediator) is in turn required for the synergistic action of the PEA3/AP-1 and AP-1 sites, Here we present a characterization of the COM sequence: our results show that COM and COM-binding proteins (UEF, Urokinase Enhancer Factors) may play a structural role in the induction of the uPA enhancer by phorbol-myristate-acetate (TPA), (1) COM has a bipartite structure (uCOM and dCOM) and each half contributes by about 50% to the COM-mediated TPA induction, (2) COM function is strictly dependent on its position, but not on its orientation and neither the entire COM nor individual UEF-binding sites can directly transactivate a test promoter, (3) The requirement for COM in TPA-induction is partly eliminated by the deletion of COM sequence, However, also in the COM-deleted enhancer, integrity of the PEA3/AP-1, and AP-1, sites is essential for enhancer function, We conclude that COM and COM-binding proteins provide a structural surface which facilitates the cooperation between the transactivator proteins bound at the PEA3/AP-1, and AP-1, sites, Sequences homologous to uCOM are found in the promoters of other inducible genes, coding for proteases, cytokines and chemokines: for example, in the promoter of the MIP1 alpha/LD78 chemokine gene, a 15/18 nucleotides identity is found in a region mediating positive and negative functions in TPA induction. Thus, COM-like elements represent a general enhancer function which, although lacking an intrinsic transactivating capacity, modulates the synergism between transcription factors bound to distant sites.	UNIV MILAN,DIPARTIMENTO GENET & BIOL MICRORGAN,I-20133 MILAN,ITALY; SAN RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY	University of Milan				Blasi, Francesco/0000-0001-9406-1784				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BERTHELSEN J, 1996, J BIOL CHEM, V272, P3822; BESSER D, 1996, IN PRESS FIBRINOLYSI; Blasi F, 1990, Semin Cancer Biol, V1, P117; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECESARE D, 1995, ONCOGENE, V11, P365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Sambrook J., 2002, MOL CLONING LAB MANU; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TIJAN R, 1994, CELL, V77, P5; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1	34	31	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2551	2562						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000129				2022-12-25	WOS:A1996VZ65400005
J	Kitsberg, DI; Leder, P				Kitsberg, DI; Leder, P			Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice	ONCOGENE			English	Article						keratinocyte growth factor; int-2; transformation; MMTV; transgenic mice; fgf	PROTO-ONCOGENE INT-2; HUMAN-BREAST CANCER; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; FACTOR RECEPTORS; NEU ONCOGENE; TUMOR VIRUS; INNER-EAR; IN-VIVO; C-MYC	The kinetics of solitary mammary tumor formation in transgenic mice bearing the MMTV-int-2 (fgf3) fusion gene suggest that several genetic events are required for tumorigenesis, In an effort to identify elements that could contribute to this oncogenic process, we used differential display PCR to identify gene products that are strongly and specifically induced in int-2 mammary tumors, Using this approach we identified a member of the FGF family, kgf (fgf7), as a gene that is strongly upregulated in an int-2-containing mammary tumor, Since int-2 and kgf strongly bind the same receptor, the IIIb isoform of FGFR2, it is possible that their joint expression, one as a transgene, the other as an activated gene, might reinforce the same mitogenic pathway, To test this possibility, we created transgenic mice that carry kgf as a transgene gene under the control of the MMTV promoter/enhancer, Female mice carrying this transgene develop a very dramatic mammary epithelial hyperplasia and go on to develop solitary, metastatic adenocarcinomas of the mammary gland, Consistent with a common signalling pathway, the MMTV-kgf-induced hyperplasia has the morphologic characteristics of that seen in the MMTV-int-2 mice, Male mice also develop hyperplasia of the male genital tract, including the seminal vesicle, the vas deferens and the prostate, Thus KGF can act as a potent proliferative inducer in mammary and specific urogenital tissue and can contribute to the development of adenocarcinoma of the mammary gland in a manner strongly reminiscent of receptor-related ligand, int-2.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute								ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; CARDIFF RD, 1993, CANCER SURV, V16, P97; CUNHA GR, 1994, BIOMED PHARMACOTHER, V48, pS9, DOI 10.1016/S0753-3322(09)80003-6; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Krane IM, 1996, ONCOGENE, V12, P1781; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIDEREAU R, 1988, BIOCHIMIE, V70, P951, DOI 10.1016/0300-9084(88)90237-4; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MANSOUR SL, 1994, MOL REPROD DEV, V39, P62, DOI 10.1002/mrd.1080390111; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; McGarvey TW, 1995, EXP MOL PATHOL, V63, P52, DOI 10.1006/exmp.1995.1030; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MORRIS DW, 1990, J VIROL, V64, P1794, DOI 10.1128/JVI.64.4.1794-1802.1990; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sambrook J., 2002, MOL CLONING LAB MANU; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; ULICH TR, 1994, AM J PATHOL, V144, P862; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILSON SE, 1994, CELL MOL BIOL RES, V40, P337; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YI ES, 1994, AM J PATHOL, V145, P1015	43	92	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2507	2515						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000125				2022-12-25	WOS:A1996VZ65400001
J	Novak, U; Nice, E; Hamilton, JA; Paradiso, L				Novak, U; Nice, E; Hamilton, JA; Paradiso, L			Requirement for Y706 of the murine (or Y708 of the human) CSF-1 receptor for STAT1 activation in response to CSF-1	ONCOGENE			English	Article						CSF-1; STAT proteins; CSF-1 receptor	STIMULATING FACTOR-I; PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; GROWTH-FACTOR RECEPTORS; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; CYTOKINE RECEPTORS; FDC-P1 CELLS	Using FDC-P1 derived cell lines which ectopically express either the wild type or mutant forms of the murine CSF-1 receptor in which individual tyrosine residues have been replaced with phenylalanine, we analysed the requirement for tyrosine residues of the receptor for the activation of STAT proteins in response to CSF-1, We found Y706 to be required for efficient activation of STAT1. The activation of STAT3 was not affected by the mutation of Y706 to phenylalanine. The addition of phosphopeptides spanning Y708 of the human CSF-1 receptor (identical with the sequence surrounding Y706 of the murine receptor) to electrophoretic mobility shift assays led to competition of the formation of STAT1 containing complexes, SIF-B and SIF-C with the DNA probe, These phosphopeptides did, however, not affect the formation of the STAT3 containing complex, SIF-A, with the probe. Replacement of Y807 with phenylalanine led to a complete block of activation of all STAT proteins in response to CSF-1, however, this phosphotyrosine does not appear to represent a STAT binding site of the receptor as a phosphopeptide spanning Y809 of the human CSF-1 receptor could not compete any STAT/DNA complex formation in electrophoretic mobility shift assays.	ROYAL MELBOURNE HOSP,TUMOUR BIOL BRANCH,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Novak, U (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA.		Nice, Edouard C/B-1026-2011	Hamilton, John A/0000-0002-9493-9224				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLSON SA, 1996, IN PRESS J BIOL CHEM; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROSNET O, 1991, ONCOGENE, V6, P1641; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	46	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2607	2613						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000134				2022-12-25	WOS:A1996VZ65400010
J	Parker, GA; Crook, T; Bain, M; Sara, EA; Farrell, PJ; Allday, MJ				Parker, GA; Crook, T; Bain, M; Sara, EA; Farrell, PJ; Allday, MJ			Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus EIA and papillomavirus E7	ONCOGENE			English	Article						growth transformation; EBV; EBNA3C; pRb; p16(INK4A)	CELL-CYCLE REGULATION; B-MYB TRANSCRIPTION; TUMOR-SUPPRESSOR; RETINOBLASTOMA-PROTEIN; GROWTH SUPPRESSION; BINDING PROTEIN; DNA-DAMAGE; P53; TRANSFORMATION; EXPRESSION	Epstein-Barr virus (EBV) requires six genes to efficiently immortalize human B cells, We have shown that one of these, EBNA3C, can cooperate with activated (Ha-)ras in co-transfection assays to immortalize and transform rat embryo fibroblasts (REFs), EBNA3C also augmented transformation by (Ha-)ras and a mutant p53 to a similar extent as human papilloma virus E7, As with E7 this effect was not inhibited by cotransfection with the cyclin-dependent kinase inhibitor (CDKI), a p16(INK4A), which can normally activate the retinoblastoma protein (pRb) and induce growth arrest, Also like E7/ras and E1A/ras transformed cells the EBNA3C/ras transformants are very susceptible to apoptotic cell death. In vitro EBNA3C binds to pRb in a manner which is dependent on the integrity of the pocket domain; this suggests that EBNA3C, even though it lacks the LXCXE pRb binding motif found in E7 and E1A, may interact with pRb in vivo. We conclude that EBNA3C functions as an oncoprotein which directs cell cycle progression through the G(1) phase restriction point when conditions might signal arrest. For the first time this demonstrates that EBV encodes a protein, functionally but not necessarily mechanistically, similar to the pRb-neutralizing nuclear antigens encoded by the 'small' DNA tumor viruses.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; INST CANC RES, HADDOW LABS, SUTTON SM2 5NG, SURREY, ENGLAND	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK			Fraser, Elizabeth/M-7049-2015	Fraser, Elizabeth/0000-0001-8420-3208; Farrell, Paul/0000-0002-6754-9351	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLDAY MJ, 1988, NUCLEIC ACIDS RES, V16, P4353, DOI 10.1093/nar/16.10.4353; ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; Bain M, 1996, J VIROL, V70, P2481, DOI 10.1128/JVI.70.4.2481-2489.1996; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DUTHU A, 1992, ONCOGENE, V7, P2161; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KIEFF E, 1996, FIELDS VIROLOGY; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; MAUNDERS MJ, 1994, J GEN VIROL, V75, P769, DOI 10.1099/0022-1317-75-4-769; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER G, 1990, VIROLOGY; NEVINS JR, 1992, SCIENCE, V258, P424; Nevins JR, 1996, FIELDS VIROLOGY, P301; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; ROBERTSON ES, 1995, J VIROL, V69, P3108, DOI 10.1128/JVI.69.5.3108-3116.1995; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; THOMAS JA, 1991, ADV CANCER RES, V57, P329; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0	39	111	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2541	2549						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000128				2022-12-25	WOS:A1996VZ65400004
J	Taglienti, CA; Wysk, M; Davis, RJ				Taglienti, CA; Wysk, M; Davis, RJ			Molecular cloning of the epidermal growth factor-stimulated protein kinase p56 KKIAMRE	ONCOGENE			English	Article						EGF; MAP kinase; signal transduction	SIGNAL-TRANSDUCTION PATHWAY; CELL-CYCLE CONTROL; MAP KINASE; C-MYC; CAENORHABDITIS-ELEGANS; PHOSPHORYLATION SITES; ACTIVATION DOMAIN; ESCHERICHIA-COLI; XENOPUS-OOCYTES; HUMAN HOMOLOG	A 56 kDa protein kinase was molecularly cloned from human fetal brain. This protein kinase (p56 KKIAMRE) shares homology with p42 KKIALRE (Meyerson et al., 1992) and is related to the proline-directed protein kinase group of signal transducing enzymes. The p56 KKIAMRE and p42 KKIALRE protein kinases exhibit mutually exclusive expression in reproductive tissues; p56 KKIAMRE in testis and p42 KKIALRE in ovary. p56 KKIAMRE and p42 KKIALRE may therefore contribute to signal transduction within these highly differentiated tissues. p56 KKIAMRE and p42 KKIALRE are activated by treatment of cells with epidermal growth factor (EGF). Although p56 KKIAMRE and p42 KKIALRE contain the MAP kinase dual phosphorylation motif Thr-Xaa-Tyr (Thr-Asp-Tyr), phosphorylation on Thr and Tyr within this motif is not required for EGF-stimulated protein kinase activity.	UNIV MASSACHUSETTS, SCH MED, PROGRAM MOL MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MOL GENET & MICROBIOL, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA65861, CA58396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065861, R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHOI KY, 1994, CELL, V78, P499; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GASKINS C, 1994, MOL CELL BIOL, V14, P6996, DOI 10.1128/MCB.14.10.6996; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1994, J CELL SCI, P115; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	63	38	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2563	2574						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000130				2022-12-25	WOS:A1996VZ65400006
J	Fleurent, M; Gingras, AC; Sonenberg, N; Meloche, S				Fleurent, M; Gingras, AC; Sonenberg, N; Meloche, S			Angiotensin II stimulates phosphorylation of the translational repressor 4E-binding protein 1 by a mitogen-activated protein kinase-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INITIATION-FACTOR 4E; MESSENGER-RNA; PHAS-I; S6 PHOSPHORYLATION; MAP KINASE; EXPRESSION; GROWTH; HYPERTROPHY; ADIPOCYTES	To investigate the molecular basis of the hypertrophic action of angiotensin II (AII) in vascular smooth muscle cells (SMC), we have examined the ability of the hormone to regulate the function of the translational re presser 4E-binding protein 1 (4E-BP1). Addition of AII to quiescent aortic SMC potently increased the phosphorylation of 4E-BP1 as revealed by a decreased electro phoretic mobility and an increased phosphate content of the protein. The stimulation of 4E-BP1 phosphorylation was maximal at 15 min and persisted up to 120 min, Results from affinity chromatography on m(7)GTP-agarose demonstrated that All-induced phosphorylation of 4E-BP1 promotes its dissociation from eIF4E in target cells, Further characterization of 4E-BP1 phosphorylation by phosphoamino acid analysis and phosphopeptide mapping revealed that 4E-BP1 is phosphorylated on eight distinct peptides containing serine and threonine residues in All-treated cells. The combination of results obtained from kinetics experiments, phosphopeptide analysis of in vitro and in vivo phosphorylated 4E-BP1, and pharmacological studies with the MAP kinase kinase inhibitor PD 98059 provided strong evidence that the MAP kinases ERK1/ERK2 are not involved in the regulation of BE-BP1 phosphorylation in aortic SMC. Together, our results demonstrate that AII treatment of vascular SMC leads to hyperphosphorylation of the translational regulator 4E-BP1 and to its dissociation from eIF4E by a MAP kinase-independent mechanism.	UNIV MONTREAL, CTR RECH, HOTEL DIEU, MONTREAL, PQ H2W 1T8, CANADA; UNIV MONTREAL, DEPT PHARMACOL, MONTREAL, PQ H2W 1T8, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, MCGILL CANC CTR, MONTREAL, PQ H3G 1Y6, CANADA	Laval University; Universite de Montreal; Universite de Montreal; McGill University; McGill University			Gingras, Anne-Claude/E-9982-2010; Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437				Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chiu A T, 1991, Receptor, V1, P133; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; DUNCAN R, 1987, J BIOL CHEM, V262, P380; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KATO H, 1991, J HYPERTENS, V9, P17; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RAO GN, 1994, J BIOL CHEM, V269, P7180; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SCOTTBURDEN T, 1990, J CARDIOVASC PHARM, V16, pS36, DOI 10.1097/00005344-199016004-00009; SCOTTBURDEN T, 1990, J CARDIOVASC PHARM, V16, pS17, DOI 10.1097/00005344-199006167-00007; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076	43	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4006	4012		10.1074/jbc.272.7.4006	http://dx.doi.org/10.1074/jbc.272.7.4006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020107	hybrid			2022-12-25	WOS:A1997WH01900023
J	Kiener, PA; Lioubin, MN; Rohrschneider, LR; Ledbetter, JA; Nadler, SG; Diegel, ML				Kiener, PA; Lioubin, MN; Rohrschneider, LR; Ledbetter, JA; Nadler, SG; Diegel, ML			Co-ligation of the antigen and Fc receptors gives rise to the selective modulation of intracellular signaling in B cells - Regulation of the association of phosphatidylinositol 3-kinase and inositol 5'-phosphatase with the antigen receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CROSS-LINKING; IG-ALPHA; MEMBRANE IMMUNOGLOBULIN; LYMPHOCYTES-B; SURFACE-IMMUNOGLOBULIN; ACTIVATION; PHOSPHORYLATION; TRANSDUCTION; CD19	Cross-linking of the Fc receptor (FcR) to surface immunoglobulin (sIg) on B cells inhibits the influx of extracellular calcium and abrogates the proliferative signal, The mechanism by which this occurs is not well understood. In this report we show that co-cross-linking the FcR to the antigen receptor gives rise to very selective modulation of signal transduction in B cells, Co-cross-linking sIg and the FcR enhanced the phosphorylation of the FcR, the adapter protein, Shc, and the inositol 5'-phosphatase Ship. Furthermore, phosphorylation of the FcR induced its association with Ship, Cross-linking of the FcR and sig decreased the tyrosine phosphorylation of CD19, which led to a reduction in the association of phosphatidylinositol 3-kinasee. In addition, the phosphorylation of several other proteins of 73, 39, and 34 kDa was reduced, Activation of the cells with either F(ab')(2) or intact anti-IgG induced very similar changes in levels of tyrosine phosphorylation of most other proteins, and no differences in the activation of several protein kinases were observed, These results indicate that the inhibitory signal that is transmitted through the FcR is not mediated by a global shutdown of tyrosine phosphorylation but is, rather, a selective mechanism involving localized changes in the interactions of adapter proteins and the enzymes Ship and phosphatidylinositol 3-kinase with the antigen receptor complex.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98125	Fred Hutchinson Cancer Center	Kiener, PA (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT IMMUNOL DIS,3005 1ST AVE,SEATTLE,WA 98121, USA.							ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; CHALUPNY NJ, 1995, EUR J IMMUNOL, V25, P2978, DOI 10.1002/eji.1830251040; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLARK EA, 1993, J IMMUNOL, V150, P4715; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; GOLD MR, 1993, J IMMUNOL, V150, P377; GOLD MR, 1994, ADV IMMUNOL, V55, P221; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; KLAUS GGB, 1984, IMMUNOLOGY, V53, P693; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; Nick JA, 1996, J IMMUNOL, V156, P4867; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; POWIS G, 1994, CANCER RES, V54, P2419; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Sarkar S, 1996, J BIOL CHEM, V271, P20182, DOI 10.1074/jbc.271.33.20182; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SIDMAN CL, 1976, J EXP MED, V144, P882, DOI 10.1084/jem.144.4.882; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; TEPPER MA, 1995, J IMMUNOL, V155, P2427; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WENG WK, 1994, J BIOL CHEM, V269, P32514; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YANO H, 1993, J BIOL CHEM, V268, P25846	51	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3838	3844		10.1074/jbc.272.6.3838	http://dx.doi.org/10.1074/jbc.272.6.3838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013643	hybrid			2022-12-25	WOS:A1997WG19200103
J	Rossi, FM; Kao, JPY				Rossi, FM; Kao, JPY			Nmoc-DBHQ, a new caged molecule for modulating sarcoplasmic/endoplasmic reticulum Ca2+ ATPase activity with light flashes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORTHO-NITROBENZYL ESTERS; CALCIUM OSCILLATIONS; POSITIVE FEEDBACK; TIME REGION; PHOTOCHEMISTRY; CA-2+; PHOTOLYSIS; ACID; THAPSIGARGIN; FIBROBLASTS	We report the synthesis and characterization of O-[o-nitromandelyloxycarbonyl]-2,5-di(tert-butyl)hydroquinone (Nmoc-DBHQ), a new ''caged'' reagent for photoreleasing DBHQ, a membrane-permeant, reversible inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). The Nmoc group is a new caging group developed for the current application, Photolysis of Nmoc-DBHQ proceeds with t(1/2) = 126 +/- 2 mu s, and t(1/2) for subsequent release of DBHQ is estimated to be similar to 5 ms. Nmoc-DBHQ thus allows rapid and reversible modulation of SERCA activity in living cells. Through its acetoxymethyl ester, Nmoc-DBHQ can be loaded into cells easily by incubation. We demonstrate the use of Nmoc DBHQ for photomodulating SERCA activity in fibroblasts and vagal sensory neurons. We further demonstrate the utility of pulsed DBHQ photorelease for probing and manipulating dynamic phenomena such as [Ca2+] oscillations in fibroblasts.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,CTR MED BIOTECHNOL,INST BIOTECHNOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore				Kao, Joseph/0000-0002-8875-2180; Rossi, Francis/0000-0002-8997-720X	NIGMS NIH HHS [GM-46956] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046956] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1988, J AM CHEM SOC, V110, P3212, DOI 10.1021/ja00218a034; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; ELLISDAVIES GCR, 1988, J ORG CHEM, V53, P1966, DOI 10.1021/jo00244a022; GEE KR, 1994, J AM CHEM SOC, V116, P8366, DOI 10.1021/ja00097a054; GEE KR, 1995, J ORG CHEM, V60, P4260, DOI 10.1021/jo00118a050; GOEGER DE, 1989, BIOCHEM PHARMACOL, V38, P3995, DOI 10.1016/0006-2952(89)90679-5; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; HAROOTUNIAN AT, 1991, CELL CALCIUM, V12, P153, DOI 10.1016/0143-4160(91)90017-9; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Jafri MS, 1996, J PHYSIOL-LONDON, V493, P157, DOI 10.1113/jphysiol.1996.sp021371; Kao J. P. Y., 1993, OPTICAL MICROSCOPY E, P27; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KASS GEN, 1989, J BIOL CHEM, V264, P15192; LIVINGSTON R, 1971, TECHNIQUES CHEM, V3, P13; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MILBURN T, 1989, BIOCHEMISTRY-US, V28, P49, DOI 10.1021/bi00427a008; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; Perrin D.D., 1981, PKA PREDICTION ORGAN; POCKER Y, 1978, J AM CHEM SOC, V100, P3564, DOI 10.1021/ja00479a045; Rabek J.F., 1982, EXPT METHODS PHOTOCH, P944; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAUERS CK, 1975, J AM CHEM SOC, V97, P5546, DOI 10.1021/ja00852a038; SCHUPP H, 1987, J PHOTOCHEM, V36, P85, DOI 10.1016/0047-2670(87)87064-8; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS D, 1994, METHOD CELL BIOL, V40, P65; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752; WIEBOLDT R, 1994, BIOCHEMISTRY-US, V33, P1526, DOI 10.1021/bi00172a032; YIP RW, 1991, J PHYS CHEM-US, V95, P6078, DOI 10.1021/j100169a009; YIP RW, 1985, J PHYS CHEM-US, V89, P5328, DOI 10.1021/j100271a002; ZHU QQ, 1987, J PHOTOCHEM, V39, P317, DOI 10.1016/0047-2670(87)80041-2	37	23	24	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3266	3271		10.1074/jbc.272.6.3266	http://dx.doi.org/10.1074/jbc.272.6.3266			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013564	hybrid			2022-12-25	WOS:A1997WG19200024
J	Xu, ZP; Saunders, GF				Xu, ZP; Saunders, GF			Transcriptional regulation of the human PAX6 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; DEVELOPING SPINAL-CORD; PAIRED DOMAIN; ANIRIDIA MUTATIONS; EYELESS GENE; EXPRESSION; REGION; DNA; EYE; CONSERVATION	PAX6, a member of the highly conserved paired-type homeobox gene family, is expressed in a spatially and temporally restricted pattern during early embryogenesis, and its mutation is responsible for human aniridia. Here pre examined the transcriptional regulation of the PAX6 gene by transient transfection assays and identified multiple cis-regulatory elements that function differently in different cell lines. The transcriptional initiation site was identified by RNase protection and primer extension assay. Examination of the genomic DNA sequence indicated that the PAX6 promoter has a TATA like-box (ATATTTT) at -26 base pairs (bp), and two CCAAT boxes are positioned at -70 and -100 bp. A 38-bp poly(CA) sequence was located 992 bp upstream from the initiation site. Transient transfection assays in glioblastoma cells and leukemia cells indicate that a 92-bp region was required for basal level PAX6 promoter activity. A negative transcriptional element, silencer (bases -1518 to -1268), functioned differently in different cell lines. The activation of the promoter is positively correlated with the expression of PAX6 transcripts in all cells tested. These results indicate that a cis-regulatory element or elements is responsible for selective activation of the PAX6 promoter in cells that can express PAX6 mRNA.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA16672] Funding Source: Medline; NEI NIH HHS [EY10608, EY09675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY010608, R01EY009675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARCIONI L, 1992, EMBO J, V11, P265, DOI 10.1002/j.1460-2075.1992.tb05049.x; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GUTJAHR T, 1993, DEVELOPMENT, V117, P609; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOGAN BLM, 1988, DEVELOPMENT, V103, P115; HU YL, 1993, J BIOL CHEM, V268, P27214; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MARTHA A, 1995, HUM MUTAT, V6, P44, DOI 10.1002/humu.1380060109; MARTHA AD, 1994, HUM MUTAT, V3, P297, DOI 10.1002/humu.1380030319; PITUELLO F, 1995, P NATL ACAD SCI USA, V92, P6952, DOI 10.1073/pnas.92.15.6952; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; TANG H, IN PRESS HUM MOL GEN; TON CCT, 1992, GENOMICS, V13, P251, DOI 10.1016/0888-7543(92)90239-O; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9	39	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3430	3436		10.1074/jbc.272.6.3430	http://dx.doi.org/10.1074/jbc.272.6.3430			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013587	hybrid			2022-12-25	WOS:A1997WG19200047
J	Armand, S; Drouillard, S; Schulein, M; Henrissat, B; Driguez, H				Armand, S; Drouillard, S; Schulein, M; Henrissat, B; Driguez, H			A bifunctionalized fluorogenic tetrasaccharide as a substrate to study cellulases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; TRICHODERMA-REESEI; GLYCOSYL HYDROLASES; CELLOBIOHYDROLASE-I; ENZYMATIC-SYNTHESIS; CLASSIFICATION; CELLULOSE; OLIGOSACCHARIDES; SPECIFICITY; HYDROLYSIS	Cellulases are usually classified as endoglucanases and cellobiohydrolases, but the heterogeneity of cellulose, in terms of particle size and crystallinity, has always represented a problem for the biochemical characterization of the enzymes. The synthesis of a bifunctionalized tetrasaccharide substrate suitable for measuring cellulase activity by resonance energy transfer is described. The substrate, which carries a 5-(2-aminoethylamino)-1-naphthalenesulfonate group on the non-reducing end and an indolethyl group on the reducing end, was prepared from beta-lactosyl fluoride and indolethyl beta-cellobioside by a chemoenzymatic approach using the transglycosylating activity of endoglucanase I of Humicola insolens as the key step. The bifunctionalized substrate has been used for the determination of the catalytic constants of H. insolens endoglucanase I and cellobiohydrolases I and II; this substrate could be of general use to measure the kinetic constants of cellulases able to act on oligomers of degree of polymerization <5. The data also provide evidence that cellobiohydrolases I and II are able to degrade an oligosaccharide substrate carrying non-carbohydrate substituents at both ends.	CNRS,CTR RECH MACROMOL VEGETALES,F-38041 GRENOBLE 9,FRANCE; NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Novo Nordisk			Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588				Armand S, 1996, EUR J BIOCHEM, V236, P706, DOI 10.1111/j.1432-1033.1996.00706.x; Barr BK, 1996, BIOCHEMISTRY-US, V35, P586, DOI 10.1021/bi9520388; BOISSET C, 1995, FEBS LETT, V376, P49, DOI 10.1016/0014-5793(95)01244-0; CHRISTAKOPOULOS P, 1994, INT J BIOL MACROMOL, V16, P331, DOI 10.1016/0141-8130(94)90065-5; CLAEYSSENS M, 1992, PROTEIN SCI, V1, P1293, DOI 10.1002/pro.5560011008; COUGHLAN MP, 1985, BIOCHEM SOC T, V13, P405, DOI 10.1042/bst0130405; DALBOGE H, 1994, MOL GEN GENET, V243, P253, DOI 10.1007/BF00301060; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; Fairclough R H, 1978, Methods Enzymol, V48, P347; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1985, BIO-TECHNOL, V3, P722, DOI 10.1038/nbt0885-722; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; KOBAYASHI S, 1991, J AM CHEM SOC, V113, P3079, DOI 10.1021/ja00008a042; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Moreau V, 1996, J CHEM SOC PERK T 1, P525, DOI 10.1039/p19960000525; OKADA G, 1979, Carbohydrate Research, V71, P287, DOI 10.1016/S0008-6215(00)86076-0; PAYRE N, 1995, ANGEW CHEM INT EDIT, V34, P1239, DOI 10.1002/anie.199512391; Rasmussen G., 1991, Patent WO, Patent No. 9117243; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; RUOHONEN L, 1993, TRICHODERMA REESEI C, V8, P87; Schmidt O. T., 1962, METHODS CARBOHYDR CH, V1, P349; SCHOU C, 1993, EUR J BIOCHEM, V217, P947, DOI 10.1111/j.1432-1033.1993.tb18325.x; SHODA S, 1993, CARBOHYD RES, V249, P127, DOI 10.1016/0008-6215(93)84066-F; VRSANSKA M, 1992, CARBOHYD RES, V227, P19, DOI 10.1016/0008-6215(92)85058-8; WOLDIKE HF, 1995, Patent No. 5457946; WOOD TM, 1972, BIOCHEM J, V128, P1183, DOI 10.1042/bj1281183; YANAHIRA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1021, DOI 10.1271/bbb.59.1021; YARON A, 1979, ANAL BIOCHEM, V95, P228, DOI 10.1016/0003-2697(79)90210-0	29	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2709	2713		10.1074/jbc.272.5.2709	http://dx.doi.org/10.1074/jbc.272.5.2709			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006908	hybrid			2022-12-25	WOS:A1997WE66700021
J	Nakao, A; Roijer, E; Imamura, T; Souchelnytskyi, S; Stenman, G; Heldin, CH; tenDijke, P				Nakao, A; Roijer, E; Imamura, T; Souchelnytskyi, S; Stenman, G; Heldin, CH; tenDijke, P			Identification of Smad2, a human mad-related protein in the transforming growth factor beta signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTORS; ACTIVIN	Transforming growth factor-beta (TGF-beta) superfamily members are multifunctional cytokines that exert their effects via heteromeric complexes of two distinct serine and threonine kinase receptors. Drosophila mothers against decapentaplegic and related genes in Caenorhabditis elegans, Xenopus, and mammals were shown to function downstream in the intracellular signaling pathways of TGF-beta superfamily members. Here we report the cloning of a Mad-related protein, termed Sma- and Mad-related protein 2 (Smad2). TGF-beta stimulated the phosphorylation and nuclear translocation of Smad2 in nontransfected Mv1Lu cells. In addition, we demonstrated that TGF-beta and activin mediated phosphorylation of Smad2 after its overexpression with appropriate type I and II receptors in COS cells. Smad2 and Smad1 were found to be broadly expressed in human tissues. Smad2 is closely linked to DPC4 on chromosome 18q21.1, a region often deleted in human cancers. Cells that lack Smad2 may escape from TGF-beta-mediated growth inhibition and promote cancer progression.	GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT PATHOL,CANC GENET LAB,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg	Nakao, A (corresponding author), LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.		Dijke, Peter ten/AAG-4660-2021; Souchelnytskyi, Serhiy/J-9446-2014; Souchelnytskyi, Serhiy/G-6491-2011	Dijke, Peter ten/0000-0002-7234-342X; Souchelnytskyi, Serhiy/0000-0001-8243-9276				Attisano L, 1996, MOL CELL BIOL, V16, P1066; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANDA S, 1996, CELL GROWTH DIFFER, V7, P385; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MARKIE D, 1992, GENOMICS, V14, P431, DOI 10.1016/S0888-7543(05)80237-X; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROIJER E, 1996, IN PRESS GENES CHROM; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940	29	133	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2896	2900		10.1074/jbc.272.5.2896	http://dx.doi.org/10.1074/jbc.272.5.2896			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006934	hybrid			2022-12-25	WOS:A1997WE66700047
J	Brown, SB; Maloney, M; Kinlaw, WB				Brown, SB; Maloney, M; Kinlaw, WB			''Spot 14'' protein functions at the pretranslational level in the regulation of hepatic metabolism by thyroid hormone and glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; S14 GENE-TRANSCRIPTION; RIBONUCLEIC-ACID S14; PYRUVATE-KINASE GENE; MESSENGER-RNA; RAT-LIVER; MOLECULAR-CLONING; RESPONSE ELEMENT; EXPRESSION; LOCALIZATION	''Spot 14'' protein appears rapidly in nuclei of hepatocytes exposed to glucose and thyroid hormone. Exposure of glucose- and T-3-treated hepatocytes to a spot 14 antisense oligonucleotide inhibited induction of mRNAs encoding malic enzyme, ATP citrate lyase, fatty acid synthase, liver-type pyruvate kinase, phosphoenolpyruvate carboxykinase, and type I deiodinase but not hydroxymethylglutaryl-CoA reductase, cytochrome c, and actin mRNAs. Induction of spot 14, ATP citrate-lyase, and fatty acid synthase polypeptides, but not propionyl-CoA carboxylase and mitochondrial pyruvate carboxylase, was inhibited. Antisense treatment of hepatocytes transfected with a reporter controlled by a glucose- and T-3-inducible fragment of the pyruvate kinase gene promoter inhibited reporter activity, as did cotransfection of the reporter and a spot 14 antisense plasmid. Spot 14 protein acts in the induction of mRNAs coding for key lipogenic (malic enzyme, ATP citrate-lyase, fatty acid synthase), glycolytic (pyruvate kinase), and gluconeogenic enzymes (phosphoenolpyruvate carboxykinase), as well as the diet responsive type I deiodinase, but not those involved in mitochondrial respiration (cytochrome c) or cholesterol synthesis (hydroxymethylglutaryl-CoA reductase). Transfection experiments indicated that these effects are mediated at the transcriptional level. The protein functions in the activation of genes involved in metabolic switching between the fasted and fed states in liver.	DARTMOUTH COLL SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,LEBANON,NH 03756	Dartmouth College					NIDDK NIH HHS [DK-43142] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043142] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BOSCH F, 1990, J BIOL CHEM, V265, P13677; CARR FE, 1984, P NATL ACAD SCI-BIOL, V81, P974, DOI 10.1073/pnas.81.3.974; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1984, J BIOL CHEM, V259, P2789; KINLAW WB, 1989, J BIOL CHEM, V264, P19779; KINLAW WB, 1988, ENDOCRINOLOGY, V123, P2255, DOI 10.1210/endo-123-5-2255; KINLAW WB, 1995, J BIOL CHEM, V270, P16615, DOI 10.1074/jbc.270.28.16615; KINLAW WB, 1992, ENDOCRINOLOGY, V131, P3120, DOI 10.1210/en.131.6.3120; KINLAW WB, 1986, J CLIN INVEST, V78, P1091, DOI 10.1172/JCI112665; KINLAW WB, 1993, ENDOCRINOLOGY, V133, P645, DOI 10.1210/en.133.2.645; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; LIU ZR, 1995, BIOCHEM J, V308, P105, DOI 10.1042/bj3080105; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P247, DOI 10.1111/j.1432-1033.1992.tb17044.x; MARIASH CN, 1984, BIOCHEM BIOPH RES CO, V123, P1122; MARIASH CN, 1981, J CLIN INVEST, V65, P1126; OMARA BA, 1993, ENDOCRINOLOGY, V133, P1715, DOI 10.1210/en.133.4.1715; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; SALAVERT A, 1982, J BIOL CHEM, V257, P13404; SCARPULLA RC, 1981, J BIOL CHEM, V256, P6480; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; STRAIT KA, 1989, J BIOL CHEM, V264, P19784; TAGAMI T, 1990, ENDOCRINOLOGY, V127, P1727, DOI 10.1210/endo-127-4-1727; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; Wilkinson L., 1992, SYSTAT STAT	32	82	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2163	2166		10.1074/jbc.272.4.2163	http://dx.doi.org/10.1074/jbc.272.4.2163			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999918	hybrid			2022-12-25	WOS:A1997WD67900024
J	McConkey, GA; Rogers, MJ; McCutchan, TF				McConkey, GA; Rogers, MJ; McCutchan, TF			Inhibition of Plasmodium falciparum protein synthesis - Targeting the plastid-like organelle with thiostrepton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT RIBOSOMAL-RNA; TOXOPLASMA-GONDII; PHYLOGENETIC ANALYSIS; MALARIA PARASITES; MOLECULAR-BASIS; GTPASE CENTER; CIRCULAR DNA; RESISTANCE; INVITRO; ANTIBIOTICS	The human malaria parasite Plasmodium falciparum has two extrachromosomal DNAs associated with organelles whose function is unclear. Both genomes encode ribosomal RNAs (rRNAs) that are distinct from the nuclear-encoded rRNAs. Secondary structure analysis of all the P. falciparum rRNAs indicates that only the large subunit (LSU) rRNA encoded by the plastid-like genome is the target for thiostrepton. Indeed we find that thiostrepton inhibits growth of the parasite in the micromolar range which is 10-fold below concentrations with observable effects on total protein synthesis. me have further examined selective effects of thiostrepton on the plastid function by comparing differential effects of the drug on cytoplasmic and organellar encoded transcripts. Treatment with either thiostrepton or rifampin, an inhibitor of organellar and eubacterial RNA polymerase, both showed disappearance of organellar-encoded RNA transcripts within 6 h of treatment while transcripts of a nuclear-encoded mRNA remained constant for at least 8 h of treatment. Hence, we show a selective effect on organelle function that is suggestive of interference in the protein synthesis apparatus of the plastid. Sensitivity of P. falciparum to thiostrepton confirms that the plastid-like genome is essential for the erythrocytic cycle and presents a novel therapeutic site for this class of antibiotics.	NIAID,GROWTH & DEV SECT,PARASIT DIS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			McConkey, Glenn A./I-4062-2019	McConkey, Glenn/0000-0001-6529-794X				BECKERS CJM, 1995, J CLIN INVEST, V95, P367, DOI 10.1172/JCI117665; CLYDE DF, 1971, J TROP MED HYG, V74, P238; CUNDLIFFE E, 1990, RIBOSOME, P479; DIVO AA, 1985, J PROTOZOOL, V32, P442, DOI 10.1111/j.1550-7408.1985.tb04041.x; DIVO AA, 1985, ANTIMICROB AGENTS CH, V27, P21, DOI 10.1128/AAC.27.1.21; FEAGIN JE, 1992, NUCLEIC ACIDS RES, V20, P879, DOI 10.1093/nar/20.4.879; FEAGIN JE, 1995, EXP PARASITOL, V80, P430, DOI 10.1006/expr.1995.1055; FEAGIN JE, 1991, J PROTOZOOL, V38, P243, DOI 10.1111/j.1550-7408.1991.tb04436.x; FROMM H, 1987, EMBO J, V6, P3233, DOI 10.1002/j.1460-2075.1987.tb02640.x; GARDNER MJ, 1991, MOL BIOCHEM PARASIT, V48, P77, DOI 10.1016/0166-6851(91)90166-4; GARDNER MJ, 1994, MOL BIOCHEM PARASIT, V66, P221, DOI 10.1016/0166-6851(94)90149-X; GARDNER MJ, 1993, NUCLEIC ACIDS RES, V21, P1067, DOI 10.1093/nar/21.5.1067; GEARY TG, 1983, AM J TROP MED HYG, V32, P221, DOI 10.4269/ajtmh.1983.32.221; GEARY TG, 1987, T ROY SOC TROP MED H, V81, P499, DOI 10.1016/0035-9203(87)90175-1; GOZAR MMG, 1995, INT J PARASITOL, V25, P929, DOI 10.1016/0020-7519(95)00022-T; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; Huang SG, 1996, J MOL BIOL, V258, P308, DOI 10.1006/jmbi.1996.0252; LI J, 1995, EXP PARASITOL, V81, P182, DOI 10.1006/expr.1995.1107; LU M, 1995, NUCLEIC ACIDS RES, V23, P3426, DOI 10.1093/nar/23.17.3426; MCCONKEY GA, 1994, P NATL ACAD SCI USA, V91, P4244, DOI 10.1073/pnas.91.10.4244; MCCUTCHAN TF, 1995, PARASITOL TODAY, V11, P134, DOI 10.1016/0169-4758(95)80132-4; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MILHOUS WK, 1985, ANTIMICROB AGENTS CH, V27, P525, DOI 10.1128/AAC.27.4.525; MONTANDON PE, 1985, NUCLEIC ACIDS RES, V13, P4299, DOI 10.1093/nar/13.12.4299; NOLLER HF, 1990, RIBOSOME, P73; PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; PFEFFERKORN ER, 1994, ANTIMICROB AGENTS CH, V38, P31, DOI 10.1128/AAC.38.1.31; RANFORDCARTWRIGHT LC, 1991, MOL BIOCHEM PARASIT, V46, P185, DOI 10.1016/0166-6851(91)90212-O; Rogers MJ, 1996, RNA, V2, P134; ROSENDAHL G, 1994, NUCLEIC ACIDS RES, V22, P357, DOI 10.1093/nar/22.3.357; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; Sambrook J., 2002, MOL CLONING LAB MANU; Steinberg B. A., 1955, ANTIBIOT ANNU, P562; STRATH M, 1993, T ROY SOC TROP MED H, V87, P211, DOI 10.1016/0035-9203(93)90497-E; THOMPSON J, 1991, BIOCHIMIE, V73, P1131, DOI 10.1016/0300-9084(91)90156-U; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; TOMAVO S, 1995, INT J PARASITOL, V25, P1293, DOI 10.1016/0020-7519(95)00066-B; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRAGER W, 1994, METHOD CELL BIOL, V45, P7; UCHIUMI T, 1995, J BIOL CHEM, V270, P29889; WARRELL DA, 1993, BRUCECHWATTS ESSENTI, P176; WATERS AP, 1995, MOL BIOCHEM PARASIT, V72, P227, DOI 10.1016/0166-6851(94)00077-Z; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449	45	153	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2046	2049						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999899	hybrid			2022-12-25	WOS:A1997WD67900005
J	Pershouse, MA; ElNaggar, AK; Hurr, K; Lin, H; Yung, WKA; Steck, PA				Pershouse, MA; ElNaggar, AK; Hurr, K; Lin, H; Yung, WKA; Steck, PA			Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma	ONCOGENE			English	Article						chromosome 4; loss of heterozygosity; carcinoma	CANCER; ALLELOTYPE; HETEROZYGOSITY; MARKERS	Genomic deletions involving chromosome 4 have recently been implicated in several human cancers. To identify and characterize genetic events associated with the development of head and neck squamous cell carinoma (HNSCC), a fine mapping of allelic losses associated with chromosome 4 was performed on DNA isolated from 27 matched primary tumor specimens and normal tissues. Loss of heterozygosity (LOH) of at least one chromosome 4 polymorphic allele was seen in the majority of tumors (92%). Alleic deletions were confined to short arm loci in four tumors and to the long arm loci in 12 tumors, suggesting the presence of two regions of common deletion. One region of frequent deletion was centered at D4S405 on 4p and included the loci D4S1546 to D4S428 in similar to 41% of the tumors. The common region of deletion on 4q was more complex and extended from D4S1571 to D4S1573, Frequent genetic alterations were observed within this region (4q25) and one marker, D4S407, exhibited a high frequency of LOH (>75%). These results indicate that alterations of chromosome 4 regions are associated with HNSCC tumorigenesis and further localizes the regions that may harbor tumor suppressor genes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BRAIN TUMOR CTR,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA056041, R01CA051148] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51148, R01 CA 56041] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; FAN JB, 1994, HUM MOL GENET, V3, P243, DOI 10.1093/hmg/3.2.243; FUJIMOTO Y, 1994, CANCER RES, V54, P281; GRANDIS JR, 1993, CANCER RES, V53, P3579; GYAPAY G, 1994, NAT GENET, V7, P268; Hong WK, 1995, CLIN CANCER RES, V1, P677; JIN YS, 1993, CANCER RES, V53, P2140; MCGOWANJORDAN IJ, 1994, CANCER RES, V54, P2568; MITRA AB, 1994, CANCER RES, V54, P4481; MURRAY JC, 1992, NAT GENET, V2, P46, DOI 10.1038/ng0992-46; NAWROZ H, 1994, CANCER RES, V54, P1152; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; POLASCIK TJ, 1995, CANCER RES, V55, P5396; SATO T, 1991, CANCER RES, V51, P5118; SHIN DM, 1994, CANCER RES, V54, P321; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SPITZ MR, 1993, CANCER EPIDEM BIOMAR, V2, P329; SREEKANTAIAH C, 1994, GENE CHROMOSOME CANC, V11, P29, DOI 10.1002/gcc.2870110106; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINBERG RA, 1991, SCIENCE, V254, P706	27	66	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					369	373		10.1038/sj.onc.1200836	http://dx.doi.org/10.1038/sj.onc.1200836			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018123				2022-12-25	WOS:A1997WD51600013
J	Handen, JS; Rosenberg, HF				Handen, JS; Rosenberg, HF			Intronic enhancer activity of the eosinophil-derived neurotoxin (RNS2) and eosinophil cationic protein (RNS3) genes is mediated by an NFAT-1 consensus binding sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFATP; T-CELLS; NF-AT; REGULATORY ELEMENTS; GRANULE DEFICIENCY; MOLECULAR-CLONING; NUCLEAR FACTOR; EXPRESSION; PROMOTER; FAMILY	The eosinophil derived neurotoxin (EDN) and eosinophil cationic protein (ECP) are both small, cationic ribonuclease toxins that are stored in and secreted by activated human eosinophilic leukocytes. We have previously shown that optimal expression of the EDN gene is dependent on an interaction between an intronic enhancer element or elements and the 5' promoter region. Here we present evidence demonstrating that the gene encoding ECP is regulated in an analogous fashion and that an intronic enhancer element functioning in both genes is a consensus binding sequence for the transcription factor NFAT-1. Our initial results demonstrate that one or more nuclear proteins isolated from human promyelocytic leukemia (HL-60) cells bind specifically at this consensus site (5'-GGAGAA-3') within the intron of the EDN gene and that disruption of this sequence reduced the characteristic 20-30-fold increase in reporter gene activity observed with the tandem EDN promoter/exon 1/intron construct to background levels. The NFAT-1 consensus site in the ECP gene differs from that found in the EDN gene by a single nucleotide (5'-GGAGAG-3'); the conversion of the 3' G to an A resulted in a further enhancement of the reporter gene activity supported by the ECP promoter/exon 1/intron construct. Interestingly, no ''supershift'' was observed in gel shift assays performed in the presence of anti NFAT-1 antiserum, suggesting that a nuclear protein other than NFAT-1 may be acting at this consensus site.	NIAID,HOST DEF LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; Ackerman Steven J., 1993, P33; BARKER RL, 1990, GENE, V86, P285, DOI 10.1016/0378-1119(90)90292-Y; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CARSANA A, 1988, NUCLEIC ACIDS RES, V1, P5491; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HO AM, 1994, J BIOL CHEM, V269, P28181; HODGE MR, 1995, J IMMUNOL, V154, P6397; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JENKINS F, 1995, J IMMUNOL, V155, P1240; JOHNSTON JJ, 1992, BLOOD, V79, P2998; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LOMAX KJ, 1989, J CLIN INVEST, V83, P514, DOI 10.1172/JCI113912; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PRIESCHL EE, 1995, J IMMUNOL, V155, P4963; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; ROSENBERG HF, 1993, BLOOD, V82, P268, DOI 10.1182/blood.V82.1.268.bloodjournal821268; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SAMUELSON LC, 1991, NUCLEIC ACIDS RES, V19, P6935, DOI 10.1093/nar/19.24.6935; SCHUBERT LA, 1995, J BIOL CHEM, V270, P29624; Spry CJ, 1988, EOSINOPHILS COMPREHE; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; Tiffany HL, 1996, J BIOL CHEM, V271, P12387, DOI 10.1074/jbc.271.21.12387; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VENKATATARAMAN L, 1994, IMMUNITY, V1, P89	37	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1665	1669		10.1074/jbc.272.3.1665	http://dx.doi.org/10.1074/jbc.272.3.1665			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999843	hybrid			2022-12-25	WOS:A1997WD05800041
J	Lu, QA; Kamps, MP				Lu, QA; Kamps, MP			Heterodimerization of Hox proteins with Pbx1 and oncoprotein E2a-Pbx1 generates unique DNA-binding specificities at nucleotides predicted to contact the N-terminal arm of the Hox homeodomain-demonstration of Hox-dependent targeting of E2a-Pbx1 in vivo	ONCOGENE			English	Article						E2a-Pbx1; oncoprotein; homeodomain; Hox	HOMEOBOX GENES; EXPRESSION; LEUKEMIA; EXTRADENTICLE; MOTIF; HOX-4.2; ELEMENT; FUSION; MICE; E2A	Hox proteins control genetic programs that orchestrate development, and a large subset of Hox proteins can bind DNA elements as heterodimers with the Pbx family of homeodomain proteins. A transcriptionally activated version of Phx1, E2a-Pbx1, is an oncoprotein in human pre-B cell leukemia that strongly suppresses differentiation and retains its ability to heterodimerize with Hox proteins. Because monomeric Hox proteins bind very similar DNA motifs, it is unclear how they activate diverse developmental programs. Here we demonstrate that heterodimers containing different Hox proteins and a common Pbx1 or E2a-Pbx1 partner bind different DNA motifs, Structural models suggest that the specificity of the Hox protein is altered by a conformation change involving residues in the N-terminal arm of the Hox homeodomain. Mutational analysis also supported the hypothesis that unique sequences in the N-terminal arm of the Hox homeodomain are at least partially responsible for mediating this specificity. lit vivo, Hox proteins directed E2a-Pbx1-mediated transactivation with moderate specificity to cognate Hox-Pbx motifs. Thus, the development specificity of individual Hox proteins may be mediated, in part, by differential targeting of cellular genes by Pbx1-Hox complexes. Likewise, through its function as a common heterodimer partner, oncoprotein E2a-Pbx1 may be able to interfere with multiple programs of development that are induced by the sequential or simultaneous expression of Hox proteins during hematopoiesis.	UNIV CALIF SAN DIEGO,DEPT PATHOL,SCH MED,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	University of California System; University of California San Diego; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA056876, P01CA050528] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876-05, 2 PO1 CA50528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; CARROLL AJ, 1984, BLOOD, V63, P721; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAWRENCE HJ, 1993, CELL GROWTH DIFFER, V4, P665; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; MATHEWS CHE, 1991, BLOOD, V78, P2248; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PETRINI M, 1992, BLOOD, V80, P185; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VIEILLEGROSJEAN I, 1992, BIOCHEM BIOPH RES CO, V183, P1124, DOI 10.1016/S0006-291X(05)80307-9; ZENG WL, 1993, DEVELOPMENT, V118, P339	39	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					75	83		10.1038/sj.onc.1200799	http://dx.doi.org/10.1038/sj.onc.1200799			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010234	Bronze			2022-12-25	WOS:A1997WB76000007
J	Bell, B; Sadowski, I				Bell, B; Sadowski, I			Ras-responsiveness of the HIV-1 LTR requires RBF-1 and RBF-2 binding sites	ONCOGENE			English	Article						HIV-1 LTR; Ras; transcription; RBF-1; RBF-2	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; NF-KAPPA-B; PROTEIN-KINASE-C; ETS DOMAIN PROTEIN; GENE-EXPRESSION; T-CELLS; TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; FAMILY PROTEINS	Lentiviruses characteristically form latent integrated proviruses whose transcription can be induced by cell regulatory signals. The HIV-1 LTR responds to multiple signals, including the Ras pathway. We report here that Ras-responsive HIV-1 transcription requires two previously undescribed factors, RBF-1 and RBF-2 in Jurkat T cells. RBF-1 binds to Ets-like motifs located between nucleotides -151 and -142, and within the NF-kappa B binding sites, but is distinct from Ets-l or Elf-1. RBF-2 binds the HIV-1 LTR at nucleotides -131 and -121 and immediately 3' of the TATA box. Both RBF-1 and RBF-2 contain DNA binding subunits of relative molecular weight 100 kilodaltons. Mutation of the RBF-1 and RBF-2 binding elements (RBEs) prevents Ras stimulation of HIV-1 LTR-directed transcription. These data define a mechanism for Ras responsiveness of HIV-1 transcription that involves the previously uncharacterized factors RBF-1 and RBF-2.	UNIV BRITISH COLUMBIA, FAC MED, DEPT BIOCHEM & MOL BIOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia								ARENZANASEISDEDOS F, 1989, ONCOGENE, V4, P1359; BALDARI CT, 1992, FEBS LETT, V304, P261, DOI 10.1016/0014-5793(92)80633-R; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CLARK NM, 1995, J VIROL, V69, P4854, DOI 10.1128/JVI.69.8.4854-4862.1995; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DEHBI M, 1994, ONCOGENE, V9, P2399; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EICHER DM, 1994, J IMMUNOL, V152, P2710; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Estable MC, 1996, J VIROL, V70, P4053, DOI 10.1128/JVI.70.6.4053-4062.1996; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; GARCIA JA, 1994, AIDS, V8, pS3; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB EI, 1990, J VIROL, V64, P3654, DOI 10.1128/JVI.64.8.3654-3660.1990; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hodge DR, 1996, ONCOGENE, V12, P11; HOHASHI N, 1995, INT IMMUNOL, V7, P1851, DOI 10.1093/intimm/7.11.1851; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KELLER A, 1992, J VIROL, V66, P3946, DOI 10.1128/JVI.66.6.3946-3949.1992; KIM JYH, 1993, J VIROL, V67, P1658, DOI 10.1128/JVI.67.3.1658-1662.1993; KINTER AL, 1990, J VIROL, V64, P4306, DOI 10.1128/JVI.64.9.4306-4312.1990; KOKEN SEC, 1992, VIROLOGY, V191, P968, DOI 10.1016/0042-6822(92)90274-S; LEE AH, 1992, J VIROL, V66, P3236, DOI 10.1128/JVI.66.5.3236-3240.1992; LEYS RD, 1990, J VIROL, V64, P1207; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; MOSES AV, 1994, J VIROL, V68, P298, DOI 10.1128/JVI.68.1.298-307.1994; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL G, 1990, NATURE, V344, P178, DOI 10.1038/344178b0; Nabel Gary J., 1993, P49; NAKANISHI Y, 1991, J VIROL, V65, P6334, DOI 10.1128/JVI.65.11.6334-6338.1991; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WILLIAMS DH, 1995, EUR J IMMUNOL, V25, P42, DOI 10.1002/eji.1830250109; Yang BS, 1996, MOL CELL BIOL, V16, P538; YI Z, 1992, J VIROL, V66, P5631, DOI 10.1128/JVI.66.9.5631-5634.1992; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991	65	26	26	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2687	2697						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000143				2022-12-25	WOS:A1996VZ65400019
J	Field, KA; Holowka, D; Baird, B				Field, KA; Holowka, D; Baird, B			Compartmentalized activation of the high affinity immunoglobulin E receptor within membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; PROTEIN-TYROSINE KINASE; GPI-ANCHORED PROTEINS; BASOPHILIC LEUKEMIA-CELLS; RBL-2H3 MAST-CELLS; IGE RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; ANTIGEN RECEPTOR; GAMMA-SUBUNITS	The earliest known step in the activation of the high affinity IgE receptor, Fc epsilon RI, is the tyrosine phosphorylation of its beta and gamma subunits by the Src family tyrosine kinase, Lyn. We report here that aggregation-dependent association of Fc epsilon RI with specialized regions of the plasma membrane precedes its tyrosine phosphorylation and appears necessary for this event. Tyrosine phosphorylation of beta and gamma occurs in intact cells only for Fc epsilon RI that associate with these detergent-resistant membrane domains, which are enriched in active Lyn. Furthermore, efficient in vitro tyrosine phosphorylation of Fc epsilon RI subunits occurs only for those associated with isolated domains. This association and in vitro phosphorylation are highly sensitive to low concentrations of detergent, suggesting that lipid-mediated interactions with Lyn are important in Fc epsilon RI activation, Participation of membrane domains accounts for previously unexplained aspects of Fc epsilon RI-mediated signaling and may be relevant to signaling by other multichain immune receptors.	CORNELL UNIV, BAKER LAB, DEPT CHEM, ITHACA, NY 14853 USA	Cornell University				Field, Kenneth/0000-0001-7417-4386	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007273] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22449] Funding Source: Medline; NIGMS NIH HHS [GM07273] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER G, 1991, J BIOL CHEM, V266, P22613; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; APGAR JR, 1990, J IMMUNOL, V145, P3814; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Draberova L, 1996, IMMUNOLOGY, V87, P141; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; FRA AM, 1994, J BIOL CHEM, V269, P30745; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Holowka D, 1996, ANNU REV BIOPH BIOM, V25, P79; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; Peters JD, 1996, J BIOL CHEM, V271, P4755; Pierini L, 1996, J CELL BIOL, V134, P1427, DOI 10.1083/jcb.134.6.1427; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Repetto B, 1996, J IMMUNOL, V156, P4876; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBERTSON D, 1986, J IMMUNOL, V136, P4565; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SCHUH SM, 1995, FASEB J, V9, pA1302; SEAGRAVE J, 1990, J CELL PHYSIOL, V144, P128, DOI 10.1002/jcp.1041440117; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; THOMAS JL, 1994, J CELL BIOL, V125, P795, DOI 10.1083/jcb.125.4.795; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; WOLDEMUSSIE E, 1986, J IMMUNOL, V137, P1674; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; Yan SR, 1996, FEBS LETT, V380, P198	47	315	318	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4276	4280		10.1074/jbc.272.7.4276	http://dx.doi.org/10.1074/jbc.272.7.4276			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020144	hybrid			2022-12-25	WOS:A1997WH01900060
J	Huang, CS; Schmid, PC; Ma, WY; Schmid, HHO; Dong, ZG				Huang, CS; Schmid, PC; Ma, WY; Schmid, HHO; Dong, ZG			Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; GROWTH-FACTOR RECEPTOR; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; C ISOENZYMES; MITOGENESIS; DISSOCIATION; ASSOCIATION; FIBROBLASTS	Phorbol esters, which activate isoforms of protein kinase C, are general activators of the transcription factor activated protein 1 (AP-1). The pathway involved in this signal transduction is not very clear. Currently, little is known about whether phosphatidylinositol-3 (PI-3) kinase plays any role in phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced signal transduction. We demonstrate here that TPA not only has markedly synergistic effects on insulin-induced PI-3 kinase activity, but it also can induce PI-3 kinase activity and the PI-3 phosphates by itself. We also found that insulin, a PI-3 kinase activator, enhanced TPA-induced AP-1 trans-activation and transformation in JB6 promotion-sensitive cells. Furthermore, wortmannin and LY294002, two PI-3 kinase inhibitors, markedly decreased AP-1 activity induced by insulin, TPA, or TPA and insulin and inhibited JB6 promotion-sensitive cell transformation induced by TPA or TPA and insulin. Most importantly, constitutive overexpression of the dominant negative PI-3 kinase P85 mutants completely blocked insulin- or TPA-induced AP-1 trans-activation and TPA-induced cell transformation. All evidence from present studies suggests that PI-3 kinase acts as a mediator in TPA-induced AP-1 activation and transformation in JB6 cells.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912	University of Minnesota System				Huang, Chuanshu/0000-0003-4133-5096				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ARNOLD RS, 1996, FEBS LETT, V380, P158; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BASERGA R, 1995, CANCER RES, V55, P249; BERENBLUM I, 1975, CANC COMPREHENSIVE T, P323; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTLEY LC, 1991, CELL, V65; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHIN JE, 1993, J BIOL CHEM, V268, P6338; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Diamond L, 1980, Adv Cancer Res, V32, P1, DOI 10.1016/S0065-230X(08)60360-7; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FUKUI Y, 1991, ONCOGENE, V6, P407; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HARE K, 1994, P NATL ACAD SCI USA, V91, P7415; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; HU Q, 1995, SCIENCE, V286, P100; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1996, INT J ONCOL, V8, P389; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Knoepp SM, 1996, J BIOL CHEM, V271, P1678, DOI 10.1074/jbc.271.3.1678; Li JJ, 1996, CANCER RES, V56, P483; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SLAGA TJ, 1982, J CELL BIOCHEM, V18, P99, DOI 10.1002/jcb.1982.240180109; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846	55	104	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4187	4194		10.1074/jbc.272.7.4187	http://dx.doi.org/10.1074/jbc.272.7.4187			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020132	hybrid			2022-12-25	WOS:A1997WH01900048
J	Muller, L; Barret, A; Picart, R; Tougard, C				Muller, L; Barret, A; Picart, R; Tougard, C			Proteolytic processing of sulfated secretogranin II in the trans-Golgi network of GH3B6 prolactin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE SECRETORY GRANULES; BREFELDIN-A; PERMEABILIZED CELLS; ENDOPROTEOLYTIC CLEAVAGE; GUANINE-NUCLEOTIDE; CHROMOGRANIN-C; MEMBRANE; PROTEINS; PROSOMATOSTATIN; SECRETONEURIN	Secretogranin II (SgII) is a protein specific to the matrix of the secretory granules in neurons and neuroendocrine cells, We have already demonstrated the precursor-product relationship between sulfated SgII and four N-terminal derived peptides in GH3B6 prolactin cells. In this study, we have investigated the subcellular compartment in which the cleavage of SgII is initiated by taking advantage of its tyrosine sulfation in the trans-Golgi network (TGN). In order to prevent export of radiosulfated SgII from the TGN, we used brefeldin A (BFA) as well as incubation at 20 degrees C. BFA completely inhibited the cleavage of SgII when added immediately post-pulse. BFA added a few minutes post-pulse or after a 20 degrees C incubation, however, permitted the cleavage of SgII in the presence of the drug. These SgII-derived peptides generated in the presence of BFA could not be released upon stimulation of the cells by either thyroliberin, a physiological secretagogue, or KCl. These results demonstrate that SgII can be cleaved in the TGN. They also evidence that the cleavage occurs in a distal compartment of the TGN different from the sulfation site. The transfer of SgII from the sulfation site to this distal compartment of the TGN involves BFA-sensitive membrane dynamics.	COLL FRANCE,GRP BIOL CELLULE NEUROENDOCRINE,CNRS,URA 1115,F-75231 PARIS 05,FRANCE; COLL FRANCE,INSERM,U36,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France			muller, laurent/S-1990-2016	muller, laurent/0000-0001-9634-4323				ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARVAN P, 1991, J BIOL CHEM, V266, P14171; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BOURDAIS J, 1990, BIOCHEM BIOPH RES CO, V170, P1263, DOI 10.1016/0006-291X(90)90530-Z; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FARQUHAR MG, 1981, J CELL BIOL, V91, P77; FISCHERCOLBRIE R, 1995, PROG NEUROBIOL, V46, P49, DOI 10.1016/0301-0082(94)00060-U; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HALBAN PA, 1994, BIOCHEM J, V299, P1; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOFLEHNER J, 1995, FEBS LETT, V360, P294, DOI 10.1016/0014-5793(95)00127-U; HUANG XF, 1994, J BIOL CHEM, V269, P20838; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTNER WB, 1991, MARKERS NEURAL ENDOC, P93; KIRCHMAIR R, 1993, NEUROSCIENCE, V53, P359, DOI 10.1016/0306-4522(93)90200-Y; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MULLER L, 1995, MOL CELL ENDOCRINOL, V112, P101, DOI 10.1016/0303-7207(95)03594-W; NASCIUTTI LE, 1992, BIOL CELL, V75, P25, DOI 10.1016/0248-4900(92)90121-G; NATORI S, 1994, BIOCHIMIE, V76, P277, DOI 10.1016/0300-9084(94)90158-9; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; OZAWA H, 1994, J HISTOCHEM CYTOCHEM, V42, P1097, DOI 10.1177/42.8.8027529; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; RAMBOURG A, 1992, ANAT RECORD, V232, P169, DOI 10.1002/ar.1092320202; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROSA P, 1992, EUR J CELL BIOL, V59, P265; ROSA P, 1992, J BIOL CHEM, V267, P12227; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARIA A, 1993, NEUROSCIENCE, V54, P1, DOI 10.1016/0306-4522(93)90377-R; SCAMMELL JG, 1986, ENDOCRINOLOGY, V119, P1543, DOI 10.1210/endo-119-4-1543; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; TOUGARD C, 1980, AM J ANAT, V158, P471, DOI 10.1002/aja.1001580409; TOUGARD C, 1989, J HISTOCHEM CYTOCHEM, V9, P1329; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; XU HX, 1994, J BIOL CHEM, V269, P22875; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; ZHOU A, 1994, J BIOL CHEM, V269, P17440	53	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3669	3673		10.1074/jbc.272.6.3669	http://dx.doi.org/10.1074/jbc.272.6.3669			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013621	hybrid			2022-12-25	WOS:A1997WG19200081
J	Petersen, CM; Nielsen, MS; Nykjaer, A; Jacobsen, L; Tommerup, N; Rasmussen, HH; Roigaard, H; Gliemann, J; Madsen, P; Moestrup, SK				Petersen, CM; Nielsen, MS; Nykjaer, A; Jacobsen, L; Tommerup, N; Rasmussen, HH; Roigaard, H; Gliemann, J; Madsen, P; Moestrup, SK			Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; FACTOR-II RECEPTOR; UDP-N-ACETYLGLUCOSAMINE; CYTOPLASMIC DOMAIN; CELL DISEASE; ALPHA-2-MACROGLOBULIN RECEPTOR; RAPID INTERNALIZATION; LYSOSOMAL-ENZYMES; AMINO-ACIDS	Receptor-associated protein (RAP) is an endoplasmic reticulum/Golgi protein involved in the processing of receptors of the low density lipoprotein receptor family. A similar to 95-kDa membrane glycoprotein, designated gp95/sortilin, was purified from human brain extracts by RAP affinity chromatography and cloned in a human cDNA library. The gene maps to chromosome Ip and encodes an 833-amino acid type I receptor containing an N-terminal furin cleavage site immediately preceding the N terminus determined in the purified protein. Gp95/sortilin is expressed in several tissues including brain, spinal cord, and testis. Gp95/sortilin is not related to the low density lipoprotein receptor family but shows intriguing homologies to established sorting receptors: a 140-amino acid lumenal segment of sortilin representing a hitherto unrecognized type of extracellular module shows extensive homology to corresponding segments in each of the two lumenal domains of yeast Vps10p, and the extreme C terminus of the cytoplasmic tail of sortilin contains the casein kinase phosphorylation consensus site and an adjacent dileucine sorting motif that mediate assembly protein-1 binding and lysosomal sorting of the mannose 6-phosphate receptors. Expression of a chimeric receptor containing the cytoplasmic tail of gp95/sortilin demonstrates evidence that the tail conveys colocalization with the cation-independent mannose-6-phosphate receptor in endosomes and the Golgi compartment.	JOHN F KENNEDY INST,DK-2600 GLOSTRUP,DENMARK		Petersen, CM (corresponding author), AARHUS UNIV,DEPT MED BIOCHEM,OLE WORMS ALLE,BLDG 170,DK-8000 AARHUS C,DENMARK.		Nielsen, Morten Schallburg/G-9498-2016; Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014; Tommerup, Niels/T-8776-2017	Nielsen, Morten Schallburg/0000-0001-9863-9694; Moestrup, Søren Kragh/0000-0003-3862-2107; Tommerup, Niels/0000-0003-2304-0112; Nykjaer, Anders/0000-0001-6422-6736; Madsen, Peder Sondergaard/0000-0002-8845-4802				BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; DUZGUNES N, 1993, METHOD ENZYMOL, V221, P303, DOI 10.1016/0076-6879(93)21025-4; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; HONORE B, 1993, J BIOCHEM BIOPH METH, V27, P39, DOI 10.1016/0165-022X(93)90066-W; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JACOBS KA, 1988, NUCLEIC ACIDS RES, V16, P4637, DOI 10.1093/nar/16.10.4637; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; JADOT M, 1992, J BIOL CHEM, V267, P11069; JENSEN PH, 1992, FEBS LETT, V305, P129, DOI 10.1016/0014-5793(92)80879-L; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; Petersen CM, 1996, EMBO J, V15, P4165, DOI 10.1002/j.1460-2075.1996.tb00791.x; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SOTTRUPJENSEN L, 1995, ANAL BIOCHEM, V225, P185; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TSUJI A, 1988, CLIN CHIM ACTA, V176, P115, DOI 10.1016/0009-8981(88)90181-7; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761	42	325	342	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3599	3605		10.1074/jbc.272.6.3599	http://dx.doi.org/10.1074/jbc.272.6.3599			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013611	hybrid			2022-12-25	WOS:A1997WG19200071
J	Soldatov, NM; Zuhlke, RD; Bouron, A; Reuter, H				Soldatov, NM; Zuhlke, RD; Bouron, A; Reuter, H			Molecular structures involved in L-type calcium channel inactivation - Role of the carboxyl-terminal region encoded by exons 40-42 in alpha(1C) subunit in the kinetics and Ca2+ dependence of inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CA2+-SENSITIVE INACTIVATION; BETA-SUBUNIT; DIVERSITY; TRANSCRIPTS; SELECTIVITY; MODULATION; SKELETAL; MUSCLE; CDNAS	The pore-forming alpha(1C) subunit is the principal component of the voltage-sensitive L-type Ca2+ channel. It has a long cytoplasmic carboxyl-terminal tail playing a critical role in channel gating. The expression of alpha(1C) subunits is characterized by alternative splicing, which generates its multiple isoforms, cDNA cloning points to a diversity of human hippocampus alpha(1C) transcripts in the region of exons 40-43 that encode a part of the 662-amino acid carboxyl terminus. We compared electrophysiological properties of the web defined 2138-amino acid alpha(1C,77) channel isoform with two splice variants, alpha(1C,72) and alpha(1C,86). They contain alterations in the carboxyl terminus due to alternative splicing of exons 40-42, The 2157-amino acid alpha(1C,72) isoform contains an insertion of 19 amino acids at position 1575. The 2139-amino acid alpha(1C,86) has 80 amino acids replaced in positions 1572-1651 of alpha(1C,77) by a non-identical sequence of 81 amino acids. When expressed in Xenopus oocytes, all three splice variants retained high sensitivity toward dihydropyridine blockers but showed large differences in gating properties. Unlike alpha(1C,77) and alpha(1C,72), Ba2+ currents (I-Ba) through alpha(1C,86) inactivated 8-10 times faster at +20 mV, and its inactivation rate was strongly voltage-dependent. Compared to alpha(1C,77), the inactivation curves of I-Ba through alpha(1C,86) and alpha(1C,72) channels were shifted toward more negative voltages by 11 and 6 mV, respectively, Unlike alpha(1C,77) and alpha(1C,72) the alpha(1C,86) channel lacks a Ca2+-dependent component of inactivation Thus the segment 1572-1651 of the cytoplasmic tail of alpha(1C) is critical for the kinetics as well as for the Ca2+ and voltage dependence of L-type Ca2+ channel gating.	UNIV BERN, DEPT PHARMACOL, CH-3010 BERN, SWITZERLAND	University of Bern				Bouron, Alexandre/0000-0003-4471-7727				Adams B, 1996, BIOPHYS J, V70, pTUAM3; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BANGALORE R, 1994, MOL PHARMACOL, V46, P660; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; Olcese R., 1996, Biophysical Journal, V70, pA186; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Schmid R, 1995, BIOPHYS J, V69, P1847, DOI 10.1016/S0006-3495(95)80055-X; SCHUURMAN R, 1991, BIOTECHNIQUES, V10, P185; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; Wang YX, 1996, BIOPHYS J, V70, pWPO38; WEI XY, 1994, J BIOL CHEM, V269, P1635; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; YATANI A, 1994, MOL CELL BIOCHEM, V140, P93, DOI 10.1007/BF00926748; You YD, 1995, BIOPHYS J, V69, P1838, DOI 10.1016/S0006-3495(95)80054-8; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; Zong XG, 1996, FEBS LETT, V378, P121, DOI 10.1016/0014-5793(95)01434-9; ZONG ZQ, 1994, BIOCHEM BIOPH RES CO, V201, P1117, DOI 10.1006/bbrc.1994.1821	46	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3560	3566		10.1074/jbc.272.6.3560	http://dx.doi.org/10.1074/jbc.272.6.3560			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013606	hybrid			2022-12-25	WOS:A1997WG19200066
J	Chung, TW; Crilly, KS; Anderson, WH; Mukherjee, JJ; Kiss, Z				Chung, TW; Crilly, KS; Anderson, WH; Mukherjee, JJ; Kiss, Z			ATP-dependent choline phosphate-induced mitogenesis in fibroblasts involves activation of pp70 S6 kinase and phosphatidylinositol 3'-kinase through an extracellular site - Synergistic mitogenic effects of choline phosphate and sphingosine 1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; EPIDERMAL GROWTH-FACTOR; C-MEDIATED HYDROLYSIS; INDUCED DNA-SYNTHESIS; PHOSPHOLIPASE-C; PHORBOL ESTER; MAP KINASE; GLUCOSE-TRANSPORT; PROTEIN-KINASES; 2ND MESSENGER	serum-starved NIH 3T3 clone 7 fibroblasts, choline phosphate (ChoP) (0.5-1 mM) and insulin synergistically stimulate DNA synthesis. Here we report that ATP also greatly enhanced the mitogenic effects of ChoP (0.1-1 mM) both in the absence and presence of insulin; maximal potentiating effects required 50-100 mu M ATP. The co-mitogenic effects of ATP were mimicked by adenosine 5'-O-(3-thiotriphosphate), adenosine 5'-0-(2-thiodiphosphate), ADP, and UTP, but not by AMP or adenosine, indicating the mediatory role of a purinergic P-2 receptor. Externally added ChoP acted on DNA synthesis without its detectable uptake into fibroblasts, indicating that ChoP can be a mitogen only if it is released from cells. Extracellular ATP (10-100 mu m) induced extensive release of ChoP from fibroblasts. ChoP had negligible effects, even in the presence of ATP or insulin, on the activity state of p42/p44 mitogen-activated protein kinases, while in combination these agents stimulated the activity of phosphatidylinositol 3'-kinase (PI 3'-kinase). Expression of a dominant negative mutant of the p85 subunit of PI 3'-kinase or treatments with the PI 3'-kinase inhibitor wortmannin only partially (similar to 40-60%) reduced the combined effects of ChoP, ATP, and insulin on DNA synthesis; in contrast, the pp70 S6 kinase inhibitor rapamycin almost completely inhibited these effects. ATP and insulin also potentiated, while rapamycin strongly inhibited, the mitogenic effects of sphingosine 1-phosphate (S1P). Furthermore, even maximally effective concentrations of ChoP and S1P synergistically stimulated DNA synthesis. The results indicate that in the presence of extracellular ATP and/or S1P, ChoP induces mitogenesis through an extracellular site by mechanisms involving the activation of pp70 S6 kinase and, to a lesser extent, PI 3'-kinase.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912	University of Minnesota System					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009292] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09292] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BIERMAN AJ, 1990, J CELL PHYSIOL, V142, P441, DOI 10.1002/jcp.1041420302; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CHANG EH, 1980, J VIROL, V35, P76, DOI 10.1128/JVI.35.1.76-92.1980; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P23147; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; CUADRADO A, 1993, ONCOGENE, V8, P2959; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; ERB L, 1993, P NATL ACAD SCI USA, V90, P10449, DOI 10.1073/pnas.90.22.10449; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FISHER GJ, 1991, J CELL PHYSIOL, V146, P309, DOI 10.1002/jcp.1041460216; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GONZALEZ FA, 1989, P NATL ACAD SCI USA, V86, P4530, DOI 10.1073/pnas.86.12.4530; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HUANG NN, 1995, J CELL PHYSIOL, V165, P667, DOI 10.1002/jcp.1041650326; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; ISHIDATE K, 1980, BIOCHEM BIOPH RES CO, V96, P946, DOI 10.1016/0006-291X(80)91446-1; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KAWAKAMI M, 1991, EXP CELL RES, V193, P120, DOI 10.1016/0014-4827(91)90545-6; KISS Z, 1995, FEBS LETT, V358, P243, DOI 10.1016/0014-5793(94)01434-3; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; KISS Z, 1995, FEBS LETT, V357, P279, DOI 10.1016/0014-5793(94)01371-7; KISS Z, 1989, J BIOL CHEM, V264, P1483; KISS Z, 1995, FEBS LETT, V371, P185, DOI 10.1016/0014-5793(95)00902-L; KISS Z, 1993, FEBS LETT, V333, P229, DOI 10.1016/0014-5793(93)80659-I; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OSADA S, 1992, FEBS LETT, V297, P271, DOI 10.1016/0014-5793(92)80554-T; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; PAULSON BK, 1989, BIOCHIM BIOPHYS ACTA, V1004, P274, DOI 10.1016/0005-2760(89)90278-6; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SU Y, 1994, J BIOL CHEM, V269, P16512; TAKUWA N, 1987, J BIOL CHEM, V262, P182; THOMAS G, 1993, BIOCHEM SOC T, V21, P901, DOI 10.1042/bst0210901; TOMONO M, 1995, BIOCHEM BIOPH RES CO, V213, P980, DOI 10.1006/bbrc.1995.2225; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	64	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3064	3072		10.1074/jbc.272.5.3064	http://dx.doi.org/10.1074/jbc.272.5.3064			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006957	hybrid			2022-12-25	WOS:A1997WE66700070
J	Cohen, HT; Bossone, SA; Zhu, GM; McDonald, GA; Sukhatme, VP				Cohen, HT; Bossone, SA; Zhu, GM; McDonald, GA; Sukhatme, VP			Sp1 is a critical regulator of the Wilms' tumor-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-FACTOR RECEPTOR; FACTOR-A-CHAIN; TRANSCRIPTION FACTOR SP1; RNA POLYMERASE-II; ZINC-FINGER GENE; DENSITY-LIPOPROTEIN RECEPTOR; DNA-BINDING SITES; HUMAN WT1 GENE; C-MYB GENE; DRASH SYNDROME	We performed deletion analysis of WT1-reporter constructs containing up to 24 kilobases of 5'-flanking and first intron WT1 sequence in stably transfected cultured cells as an unbiased approach to identify cis elements critical for WT1 transcription. Although not a tissue-specific element, a proximate 9-base pair CTC repeat accounted for similar to 80% of WT1 transcription in this assay. Enhancer activity of the element and mutated versions correlated completely with their ability to form a DNA-protein complex in gel shifts. Antibody supershift, oligonucleotide competition, and Southwestern studies indicated that the CTC-bindiug factor is the transcriptional activator Sp1. Sp1 binds the CTC repeat with an affinity, K-D = 0.37 nM, at least as high as the consensus GC box. Similar CTC repeats are found in promoters of other growth-related genes. Because Sp1 is important for WT1 expression, we examined Sp1 immunohistochemistry in fetal and adult kidney. In a pattern that precedes that of WT1 message, Sp1 immunostaining was highest in uninduced mesenchyme, early tubules, developing podocytes, and mature glomeruli, but was minimal in mature proximal tubules. This work suggests abundant Sp1 may be a prerequisite for WT1 expression, and that Sp1 may have a wider role in nephrogenesis.	BETH ISRAEL HOSP, DIV RENAL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Sukhatme, Vikas/W-2776-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002280, F32DK009263, R01DK045617] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK09263, K08 DK02280, R01 DK45617] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; ASSELIN C, 1989, ONCOGENE, V4, P549; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BEHBEHANI AM, 1982, HUM PATHOL, V13, P862, DOI 10.1016/S0046-8177(82)80083-X; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRESLOW N, 1988, CANCER RES, V48, P1653; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1994, ONCOGENE, V9, P583; CHEN HM, 1993, J BIOL CHEM, V268, P8230; COHEN HT, 1995, MOL BIOL CANC MED, P384; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DAVIES RL, 1982, CELL, V31, P521, DOI 10.1016/0092-8674(82)90308-7; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GRUBB GR, 1994, LAB INVEST, V71, P472; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABIB R, 1985, CLIN NEPHROL, V24, P269; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HENTSCHEL CC, 1982, NATURE, V295, P714, DOI 10.1038/295714a0; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HOFMANN W, 1993, ONCOGENE, V8, P3123; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JADRESIC L, 1990, J PEDIATR-US, V117, P717, DOI 10.1016/S0022-3476(05)83327-X; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MACE HAF, 1983, NATURE, V304, P555, DOI 10.1038/304555a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; MANIVEL JC, 1987, HUM PATHOL, V18, P80; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; MCGHEE JD, 1981, CELL, V27, P45, DOI 10.1016/0092-8674(81)90359-7; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MINIE ME, 1992, DEVELOPMENT, V115, P1149; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MIYAGI T, 1993, LEUKEMIA, V7, P970; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; PULLEYBLANK DE, 1985, CELL, V42, P271, DOI 10.1016/S0092-8674(85)80122-7; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROBINS DM, 1981, CELL, V23, P29, DOI 10.1016/0092-8674(81)90267-1; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SHANNON RS, 1982, ARCH DIS CHILD, V57, P685, DOI 10.1136/adc.57.9.685; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIERRA F, 1990, LAB GUIDE IN VITRO T; SIF S, 1993, ONCOGENE, V8, P2501; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; SWEET RW, 1982, CELL, V31, P347, DOI 10.1016/0092-8674(82)90128-3; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WESTIN G, 1988, NUCLEIC ACIDS RES, V16, P5771, DOI 10.1093/nar/16.13.5771; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; XU J, 1993, J BIOL CHEM, V268, P16065; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282; YU YT, 1986, CELL, V45, P743, DOI 10.1016/0092-8674(86)90788-9; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHOU J, 1993, DIFFERENTIATION, V54, P109	116	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2901	2913		10.1074/jbc.272.5.2901	http://dx.doi.org/10.1074/jbc.272.5.2901			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006935	hybrid			2022-12-25	WOS:A1997WE66700048
J	Gutierrez, LM; Viniegra, S; Rueda, J; FerrerMontiel, AV; Canaves, JM; Montal, M				Gutierrez, LM; Viniegra, S; Rueda, J; FerrerMontiel, AV; Canaves, JM; Montal, M			A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BOTULINUM NEUROTOXIN-A; SYNAPTIC VESICLE; NEUROTRANSMITTER RELEASE; MEMBRANE-PROTEIN; CATECHOLAMINE SECRETION; FUSION COMPLEX; EXOCYTOSIS; SYNAPTOBREVIN; SYNTAXIN	Excitation-secretion uncoupling peptides (ESUPs) are inhibitors of Ca2+-dependent exocytosis in neural and endocrine cells. Their mechanism of action, however, remains elusive. We report that ESUP-A, a 20-mer peptide patterned after the C terminus of SNAP-25 (synaptosomal associated protein of 25 kDa) and containing the cleavage sequence for botulinum neurotoxin A (BoNT A), abrogates the slow, ATP-dependent component of the exocytotic pathway, without affecting the fast, ATP-independent, Ca2+-mediated fusion event. Ultrastructural analysis indicates that ESUP-A induces a drastic accumulation of dense-core vesicles near the plasma membrane, mimicking the effect of BoNT A. Together, these findings argue in favor of the notion that ESUP-A inhibits ATP-primed exocytosis by blocking vesicle docking. Identification of blocking peptides which mimic sequences that bind to complementary partner domains on interacting proteins of the exocytotic machinery provides new pharmacological tools to dissect the molecular and mechanistic details of neuro secretion. Our findings may assist in developing ESUPs as substitute drugs to BoNTs for the treatment of spasmodic disorders.	UNIV ALICANTE,INST NEUROCIENCIAS,DEPT NEUROQUIM,E-03080 ALICANTE,SPAIN; UNIV ALICANTE,FAC MED,E-03080 ALICANTE,SPAIN; UNIV ALICANTE,INST NEUROCIENCIAS,DEPT HISTOL,E-03080 ALICANTE,SPAIN; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universitat d'Alacant; Universitat d'Alacant; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universitat d'Alacant; University of California System; University of California San Diego			Ferrer-Montiel, Antonio/C-3072-2015; Gutierrez, Luis/K-8633-2014; Viniegra, Salvador/K-5063-2014	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Gutierrez, Luis/0000-0002-0512-7858; Viniegra, Salvador/0000-0002-3892-8563; Rueda, Joaquin/0000-0002-3774-8763				BARK IC, 1994, P NATL ACAD SCI USA, V91, P4621, DOI 10.1073/pnas.91.11.4621; BENNETT JP, 1978, NEUROTRANSMITTER REC, P58; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BITTNER MA, 1992, J BIOL CHEM, V267, P16226; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BITTNER MA, 1993, CELL MOL NEUROBIOL, V13, P649, DOI 10.1007/BF00711564; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; Calakos N, 1996, PHYSIOL REV, V76, P1; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GOMIS A, 1994, BIOCHEM PHARMACOL, V47, P225, DOI 10.1016/0006-2952(94)90010-8; GUTIERREZ LM, 1995, EUR J CELL BIOL, V68, P88; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; GUTIERREZ LM, 1995, BIOCHEM BIOPH RES CO, V206, P1, DOI 10.1006/bbrc.1995.1001; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; Matthews G, 1996, ANNU REV NEUROSCI, V19, P219; METHA PP, 1996, P NATL ACAD SCI USA, V93, P10471; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; OTTO H, 1995, BIOCHEM BIOPH RES CO, V212, P945, DOI 10.1006/bbrc.1995.2061; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; WILIAMSON LC, 1996, J BIOL CHEM, V271, P7694; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; YAMASAKI S, 1994, BIOCHEM BIOPH RES CO, V200, P829, DOI 10.1006/bbrc.1994.1526	40	84	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2634	2639		10.1074/jbc.272.5.2634	http://dx.doi.org/10.1074/jbc.272.5.2634			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006897	hybrid			2022-12-25	WOS:A1997WE66700010
J	Leitzgen, K; Knittler, MR; Haas, IG				Leitzgen, K; Knittler, MR; Haas, IG			Assembly of immunoglobulin light chains as a prerequisite for secretion - A model for oligomerization-dependent subunit folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTION; MYELOMA CELL-LINE; PRE-B-CELLS; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; VARIABLE REGION; QUALITY-CONTROL; PLASMA-CELLS; HLA-A; ANTIBODY	Oligomeric proteins usually have to assemble into their final quartenary structure to be secreted. However, most immunoglobulin (Ig) Light (L) chains can be exported as free chains, whereas only a few Ig L chains, here referred to as export-incompetent, have to assemble with Ig heavy (H) chains into antibody molecules to be secreted. In the absence of Ig H chain expression, these export-incompetent Ig L chains remain bound to BiP as partially folded monomers with only one of the two internal disulfide bonds being formed. To understand the apparent discrepancy in Ig L chain export, we performed assembly studies with chimeric Ig chains and found that the variable (V) domain of the export-incompetent NS1 kappa chain cannot mediate homodimer formation. Conversely, the V domain of the export-competent J558L lambda(1) chain supports homodimer formation and, concordantly, these Ig L chains are secreted as noncovalently or covalently linked homodimers. We show that the export-incompetent mutant lambda(1) FS62 chain forms disulfide bonds in both domains only upon pairing with Ig H chain and is secreted as part of an antibody. Therefore, Ig L chain assembly seems to be a prerequisite for complete folding, indicating that Ig L chain secretion generally depends on either homo- or heterodimer formation. We discuss a mechanism that controls oligomerization by monitoring the conformation of individual subunits that cannot proceed in folding prior to successful assembly.	UNIV HEIDELBERG,INST BIOCHEM 1,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BAUMAL R, 1973, J IMMUNOL, V111, P448; BRINSTER RL, 1983, NATURE, V306, P332, DOI 10.1038/306332a0; BURROWS P, 1979, NATURE, V280, P838, DOI 10.1038/280838a0; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CREMER A, 1994, GLYCO CELL BIOL, P171; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DUL JL, 1992, J IMMUNOL, V149, P1927; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; HAAS IG, 1984, P NATL ACAD SCI-BIOL, V81, P7185, DOI 10.1073/pnas.81.22.7185; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KLAUSNER R D, 1989, New Biologist, V1, P3; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LILIE H, 1995, J MOL BIOL, V248, P190, DOI 10.1006/jmbi.1995.0211; MASAT L, 1994, P NATL ACAD SCI USA, V91, P893, DOI 10.1073/pnas.91.3.893; MILSTEIN C, 1965, NATURE, V205, P1171, DOI 10.1038/2051171a0; MORRISON SL, 1975, J IMMUNOL, V114, P655; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; SHAPIRO AL, 1966, NATURE, V211, P243, DOI 10.1038/211243a0; SIMON T, 1990, EMBO J, V9, P1051, DOI 10.1002/j.1460-2075.1990.tb08209.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SONENSHEIN GE, 1978, J EXP MED, V148, P301, DOI 10.1084/jem.148.1.301; STEVENS FJ, 1980, P NATL ACAD SCI-BIOL, V77, P1144, DOI 10.1073/pnas.77.2.1144; WEISS S, 1985, EUR J IMMUNOL, V15, P768, DOI 10.1002/eji.1830150806; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7	42	72	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3117	3123		10.1074/jbc.272.5.3117	http://dx.doi.org/10.1074/jbc.272.5.3117			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006964	hybrid			2022-12-25	WOS:A1997WE66700077
J	Kwon, DS; Lin, CH; Chen, SJ; Coward, JK; Walsh, CT; Bollinger, JM				Kwon, DS; Lin, CH; Chen, SJ; Coward, JK; Walsh, CT; Bollinger, JM			Dissection of glutathionylspermidine synthetase/amidase from Escherichia coli into autonomously folding and functional synthetase and amidase domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ALANINE LIGASE; GAMMA-SUBSTITUTED PHOSPHINOTHRICINS; CRITHIDIA-FASCICULATA; GLUTAMINE-SYNTHETASE; GLUTATHIONE SYNTHETASE; TRANSITION-STATE; TRYPANOTHIONE; INHIBITION; PURIFICATION; METABOLISM	The bifunctional glutathionylspermidine synthetase/amidase from Escherichia coli catalyzes both the ATP-dependent formation of an amide bond between N-1 of spermidine (N-(3-amino)propyl-1,4-diaminobutane) and the glycine carboxylate of glutathione (gamma-Glu-Cys-Gly) and the opposing hydrolysis of this amide bond (Bollinger, J. M., Jr., Kwon, D. S., Huisman, G. W., Kolter, R., and Walsh, C. T. (1995) J. Biol. Chem. 270, 14031-14041). In our previous work describing its initial characterization, we proposed that the 619-amino acid (70 kDa) protein might possess separate amidase (N-terminal) and synthetase (C-terminal) domains. In the present study, we have confirmed this hypothesis by expression of independently folding and functional amidase and synthetase modules. A fragment containing the C-terminal 431 amino acids (50 kDa) has synthetase activity only, with steady-state kinetic parameters similar to the full-length protein. A fragment containing the N-terminal 225 amino acids (25 kDa) has amidase activity only and is significantly activated relative to the full-length protein for hydrolysis of glutathionylspermidine analogs. This observation suggests that the amidase activity in the full-length protein is negatively autoregulated, The amidase active site catalyzes hydrolysis of amide and ester derivatives of glutathione (e.g. glutathione ethyl ester and glutathione amide) but lacks activity toward acetylspermidine (N-1 and N-8) and acetylspermidine (N-1), indicating that glutathione provides the primary recognition determinants for glutathionylspermidine amide bond cleavage. No metal ion is required for the amidase activity, A tetrahedral phosphonate analogue of glutathionylspermidine, designed as a mimic of the proposed tetrahedral intermediate for either reaction, inhibits the synthetase activity (K-i similar to 10 mu M) but does not inhibit the amidase activity.	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; UNIV MICHIGAN,COLL PHARM,INTDEPT PROGRAM MED CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Bollinger, Joseph/C-1425-2016		NIGMS NIH HHS [GM07306, GM20011, GM15477] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, R01GM020011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE RV, 1988, BIOCHEMISTRY-US, V27, P9062, DOI 10.1021/bi00425a027; Bartlett PA, 1996, J ORG CHEM, V61, P3433, DOI 10.1021/jo952074c; BERG CM, 1992, GENE, V113, P9, DOI 10.1016/0378-1119(92)90664-B; BOLLINGER JM, 1995, J BIOL CHEM, V270, P14031, DOI 10.1074/jbc.270.23.14031; BOVERIS A, 1980, BIOCHEM J, V188, P643, DOI 10.1042/bj1880643; CHAKRAVARTY PK, 1989, J MED CHEM, V32, P1886, DOI 10.1021/jm00128a033; COLANDUONI JA, 1986, BIOORG CHEM, V14, P163, DOI 10.1016/0045-2068(86)90026-X; DUBIN DT, 1959, BIOCHEM BIOPH RES CO, V1, P262, DOI 10.1016/0006-291X(59)90034-8; DUNCAN K, 1988, BIOCHEMISTRY-US, V27, P3709, DOI 10.1021/bi00410a028; FAIRLAMB AH, 1985, MOL BIOCHEM PARASIT, V14, P187, DOI 10.1016/0166-6851(85)90037-4; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1987, NATO ASI SER, P29; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; FUKUCHI JI, 1995, J BIOL CHEM, V270, P18831, DOI 10.1074/jbc.270.32.18831; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; HENDERSON GB, 1987, MOL BIOCHEM PARASIT, V24, P39, DOI 10.1016/0166-6851(87)90113-7; HIRATAKE J, 1994, J AM CHEM SOC, V116, P12059, DOI 10.1021/ja00105a059; ITOH M, 1969, CHEM PHARM BULL, V17, P1679; LOGUSCH EW, 1989, BIOCHEMISTRY-US, V28, P3043, DOI 10.1021/bi00433a046; LOGUSCH EW, 1990, BIOCHEMISTRY-US, V29, P366, DOI 10.1021/bi00454a009; LOSSE G, 1964, LIEBIGS ANN CHEM, V676, P222; MALACHOWSKI WP, 1994, J ORG CHEM, V59, P7625, DOI 10.1021/jo00104a017; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MCDERMOTT AE, 1990, BIOCHEMISTRY-US, V29, P5767, DOI 10.1021/bi00476a018; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Meister A., 1974, ENZYMES, V10, P671; MORGAN BP, 1991, J AM CHEM SOC, V113, P297, DOI 10.1021/ja00001a043; MULLINS LS, 1990, J BIOL CHEM, V265, P8993; PARSONS WH, 1988, J MED CHEM, V31, P1772, DOI 10.1021/jm00117a017; PENKETH PG, 1987, FEBS LETT, V221, P427, DOI 10.1016/0014-5793(87)80968-7; RADZICKA A, 1995, METHOD ENZYMOL, V249, P284; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; TABOR CW, 1970, BIOCHEM BIOPH RES CO, V41, P232, DOI 10.1016/0006-291X(70)90493-6; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1975, J BIOL CHEM, V250, P2648	36	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2429	2436						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999955				2022-12-25	WOS:A1997WD67900061
J	Muchowski, PJ; Bassuk, JA; Lubsen, NH; Clark, JI				Muchowski, PJ; Bassuk, JA; Lubsen, NH; Clark, JI			Human alpha B-crystallin - Small heat shock protein and molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS CRYSTALLINS; A-CRYSTALLIN; ALEXANDERS DISEASE; MULTIPLE-SCLEROSIS; EXPRESSION; TISSUES; GENE; FIBROBLASTS; EVOLUTION; FAMILY	The polymerase chain reaction was used to amplify a cDNA sequence encoding the human alpha beta-crystallin. The amplified cDNA fragment was cloned into the bacterial expression vector pMAL-c2 and expressed as a soluble fusion protein coupled to maltose-binding protein (MBP). After maltose affinity chromatography and cleavage from MBP by Factor Xa, the recombinant human alpha beta-crystallin was separated from MBP and Factor Xa by anion exchange chromatography. Recombinant alpha beta-crystallin was characterized by SDS-polyacrylamide electrophoresis (PAGE), Western immunoblot analysis, Edman degradation, circular dichroism spectroscopy, and size exclusion chromatography. The purified crystallin migrated on SDS-PAGE to an apparent molecular weight (M(r) similar to 22,000) that corresponded to total native human alpha-crystallin and was recognized on Western immunoblots by antiserum raised against human alpha beta-crystallin purified from lens homogenates. Chemical sequencing, circular dichroism spectroscopy, and size exclusion chromatography demonstrated that the recombinant crystallin had properties similar or identical to its native counterpart. Both recombinant alpha beta-crystallin and MBP-alpha beta fusion protein associated to form high molecular weight complexes that displayed chaperon-like function by inhibiting the aggregation of alcohol dehydrogenase at 37 degrees C and demonstrated the importance of the C-terminal domain of alpha beta-crystallin for chaperone-like activity.	UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT OPHTHALMOL,SEATTLE,WA 98195; UNIV NIJMEGEN,DEPT MOL BIOL,NL-6525 ED NIJMEGEN,NETHERLANDS	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Radboud University Nijmegen			Lubsen, Nicolette H./B-8426-2011		NATIONAL EYE INSTITUTE [R01EY004542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008437] Funding Source: NIH RePORTER; NEI NIH HHS [EY07031, EY04542, R01 EY004542] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08437] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTEYN RC, 1992, EXP EYE RES, V54, P219, DOI 10.1016/S0014-4835(05)80211-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; BRAKENHOFF RH, 1990, J MOL BIOL, V216, P519, DOI 10.1016/0022-2836(90)90380-5; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; DAS KP, 1996, J BIOL CHEM, V271, P1049; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DUBIN RA, 1990, GENOMICS, V7, P594, DOI 10.1016/0888-7543(90)90204-8; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; IWAKI A, 1992, NEUROSCI LETT, V140, P89, DOI 10.1016/0304-3940(92)90689-5; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LEE DC, 1993, J MOL BIOL, V232, P1221, DOI 10.1006/jmbi.1993.1476; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; RAO PV, 1994, J BIOL CHEM, V269, P13266; RAOPV, 1995, BIOCHIM BIOPHYS ACTA, V1245, P439; RINGENS PJ, 1982, EXP EYE RES, V34, P815, DOI 10.1016/S0014-4835(82)80041-9; RINGENS PJ, 1982, EXP EYE RES, V34, P201, DOI 10.1016/0014-4835(82)90054-9; RUSSELL P, 1987, FASEB J, V1, P32, DOI 10.1096/fasebj.1.1.3301496; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; SIEZEN RJ, 1987, P NATL ACAD SCI USA, V84, P6086; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STEINMAN L, 1995, NATURE, V375, P739, DOI 10.1038/375739b0; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; TAKEMOTO L, 1990, INVEST OPHTH VIS SCI, V31, P1348; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	46	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2578	2582						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999975				2022-12-25	WOS:A1997WD67900081
J	Zhao, XM; Horne, DA				Zhao, XM; Horne, DA			The role of cysteine residues in the rearrangement of uridine to pseudouridine catalyzed by pseudouridine synthase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; ESCHERICHIA-COLI; ACTIVE-SITE; PURIFICATION; MECHANISM; URACIL; DNA; IDENTIFICATION; NUCLEOSIDES; NUCLEOPHILE	Escherichia coli tRNA pseudouridine synthase I (PSUI) catalyzes the conversion of uridine residues to pseudouridine in positions 38, 39, and 40 of various tRNA molecules. In previous biochemical studies with this enzyme (Kammen, H. O., Marvel, C. C., Hardy, L., and Penhoet, E. E. (1988) J. Biol. Chem. 263, 2255-2263) it was reported that cysteine residues are important in maintaining the active structure of the enzyme and are possibly involved in the catalytic reaction mechanism via a covalent cysteine intermediate. In order to further investigate the biochemical properties of PSUI, a high level expression and purification system for the enzyme and its corresponding mutants was developed. PSUI has three cysteine residues among 270 amino acids. In the present investigation, each cysteine residue was individually changed to serine and alanine. In addition, a triple mutant was prepared wherein all three cysteine residues were replaced by alanine. Surprisingly, while two of the three cysteine to serine mutants were inactive, all alanine mutants exhibited near wild-type levels of activity, including the triple mutant. These results provide the first direct and unambiguous chemical evidence against a covalent cysteine intermediate in the rearrangement mechanism of uridine to pseudouridine.	COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Columbia University								CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CIAMPI MS, 1977, FEBS LETT, V77, P75, DOI 10.1016/0014-5793(77)80196-8; CORTESE R, 1974, J BIOL CHEM, V249, P1103; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IVANETICH KM, 1992, PROG NUCLEIC ACID RE, V42, P127, DOI 10.1016/S0079-6603(08)60575-9; JOHNSON L, 1970, P NATL ACAD SCI USA, V67, P943, DOI 10.1073/pnas.67.2.943; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; KEALEY JT, 1991, BIOCHEMISTRY-US, V30, P9724, DOI 10.1021/bi00104a022; KOONTZ SW, 1979, J BIOL CHEM, V254, P12277; KUNITANI MG, 1980, BIOCHEMISTRY-US, V19, P1271, DOI 10.1021/bi00548a001; LANE BG, 1995, BIOCHIMIE, V77, P7, DOI 10.1016/0300-9084(96)88098-9; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; Maniatis T., 1982, MOL CLONING; MARVEL CC, 1985, J BACTERIOL, V161, P60, DOI 10.1128/JB.161.1.60-71.1985; NURSE K, 1995, RNA, V1, P102; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; POGOLOTTI AL, 1976, BIOCHEM BIOPH RES CO, V70, P972, DOI 10.1016/0006-291X(76)90687-2; PRIOR JJ, 1984, J BIOL CHEM, V259, P2429; SAMUELSSON T, 1991, NUCLEIC ACIDS RES, V19, P6139, DOI 10.1093/nar/19.22.6139; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SANTI DV, 1978, ENZYME ACTIVATED IRR, P291; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; STARZYK RM, 1982, NATURE, V298, P136, DOI 10.1038/298136a0; THIEBE R, 1971, METHOD ENZYMOL, V20, P179; TURNBOUGH CL, 1979, J BIOL CHEM, V254, P5111; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437; WYATT JR, 1991, BIOTECHNIQUES, V11, P764	30	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1950	1955		10.1074/jbc.272.3.1950	http://dx.doi.org/10.1074/jbc.272.3.1950			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999885	hybrid			2022-12-25	WOS:A1997WD05800083
J	Bourdon, JC; DeguinChambon, V; Lelong, JC; Dessen, P; May, P; Debuire, B; May, E				Bourdon, JC; DeguinChambon, V; Lelong, JC; Dessen, P; May, P; Debuire, B; May, E			Further characterisation of the p53 responsive element - Identification of new candidate genes for trans-activation by p53	ONCOGENE			English	Article						consensus sequence; computer search; transactivation; MCK; IGF-BP3	WILD-TYPE P53; DNA-BINDING; PROMOTER; PROTEIN; TRANSACTIVATION; EXPRESSION; PATHWAY; SITE	The p53 protein is known to trans-activate a number of genes by specific binding to a consensus sequence containing two decamers of the type: PuPuPuCA/TT/AGPyPyPy. In order to identify new p53 trans-activated genes, we defined a set of criteria for computer search of p53-responsive elements, Based on experimental data, we proposed an extended consensus sequence composed of the two decamers of the El-Deiry consensus sequence flanked by two additional ones, A maximum of 3 bp substitutions was accepted for the two decamers of the El-Deiry consensus sequence, as well as for each additional decamer, except when the two decamers of the El-Deiry consensus sequence are contiguous, In this case, each additional decamer is allowed to bear one base insertion or deletion between the median C and G, This set of criteria was validated by identifying within the promoter region of the IGF-BP3 gene the existence of a novel p53-responsive element whose functional significance was verified, By limiting our computer search to Vertebrate genes involved in cell cycle regulation, cellular adhesion or metastatic processes and to gene families most often found in HOVERGEN database, 7785 gene sequences were first analysed, Among the oncogenes, kinases, proteases and structural proteins, 55 new genes were selected; six of them were retrieved in more than one species	UNITE CNRS UMS 825,INSERM SC13,SERV BIOINFORMAT VILLEJUIF,F-94801 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	Bourdon, JC (corresponding author), CNRS,CEA,UMR 217,LAB CANCEROGENESE MOL,FONTENAY ROSES,FRANCE.		JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COOK JL, 1995, ONCOGENE, V11, P723; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVRERO M, 1991, GENE, V101, P195, DOI 10.1016/0378-1119(91)90411-4; MAY E, 1992, J VIROL, V66, P3347, DOI 10.1128/JVI.66.6.3347-3354.1992; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YONISHROUACH E, 1996, BEHRING I MITT, V97, P1; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	27	128	135	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					85	94		10.1038/sj.onc.1200804	http://dx.doi.org/10.1038/sj.onc.1200804			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010235				2022-12-25	WOS:A1997WB76000008
J	Lakin, ND; Weber, P; Stankovic, T; Rottinghaus, ST; Taylor, AMR; Jackson, SP				Lakin, ND; Weber, P; Stankovic, T; Rottinghaus, ST; Taylor, AMR; Jackson, SP			Analysis of the ATM protein in wild-type and ataxia telangiectasia cells	ONCOGENE			English	Article						ataxia telangiectasia; ATM; DNA; repair; PI 3-kinase; p53	STRAND BREAK REPAIR; V(D)J RECOMBINATION; DNA-REPAIR; MAMMALIAN PROTEIN; KINASE-ACTIVITY; KU AUTOANTIGEN; GENE; COMPLEX; PRODUCT; PK	Ataxia telangiectasia (A-T) is a human disorder that results in a number of clinical symptoms, including cerebellar degeneration and increased cancer predisposition. Recently the gene that is defective in A-T has been cloned and designated ATM. Here, we describe the production of antisera raised against the similar to 350 kDa ATM protein, Antisera specificity is confirmed by them recognising a similar to 350 kDa polypeptide in wild-type cells but not in A-T cells containing mutations that truncate ATM upstream of the antibody binding sites, We show that ATM is almost exclusively nuclear and is expressed in all cell lines and tissues analysed, However, ATM levels are not regulated in response to u.v. or ionising radiation, These data are consistent with ATM being a component of the DNA damage detection apparatus rather than being an inducible downstream effector of the DNA damage response. In addition, we analyse ATM protein expression in a variety of A-T patients, Strikingly, ATM expression is reduced drastically or absent in all patients analysed, including those predicted to express proteins that should be detected by our antisera, Thus, the A-T phenotype may result not only from mutations that disrupt functional domains of ATM, but also from mutations that destabilise the ATM mRNA or protein, Finally, we report that a group of patients displaying an intermediate A-T phenotype express low levels of apparently full-length ATM, This suggests that the ATM pathway is partially active in these individuals and that there is a correlation between Levels of residual ATM expression and disease severity.	CANC RES CAMPAIGN INST,WELLCOME TRUST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1TN,ENGLAND; UNIV BIRMINGHAM,SCH MED,CANC RES CAMPAIGN,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	CRUK Cambridge Institute; Wellcome Trust Sanger Institute; University of Cambridge; University of Birmingham			Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Stankovic, Tatjana/0000-0002-3780-274X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, P130; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; Jackson S. P., 1993, Gene transcription: a practical approach., P189; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KAPPELLER R, 1994, BIOESSAYS, V16, P565; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1993, ONCOGENE, V8, P3307; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LEHMANN AR, 1995, TRENDS GENET, V11, P375, DOI 10.1016/S0168-9525(00)89112-X; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; McConville CM, 1996, AM J HUM GENET, V59, P320; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SIERRA F, 1993, GENE TRANSCRIPTION P, P125; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TELETAR M, 1996, AM J HUM GENET, V59, P40; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	48	136	142	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2707	2716						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000145				2022-12-25	WOS:A1996VZ65400021
J	Fatatis, A; Miller, RJ				Fatatis, A; Miller, RJ			Platelet-derived growth factor (PDGF)-induced Ca2+ signaling in the CG4 oligodendroglial cell line and in transformed oligodendrocytes expressing the beta-PDGF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE TUMOR-ANTIGEN; 3'-PHOSPHODIESTERASE GENE; CALCIUM REGULATION; PROGENITOR-CELL; KINASE-ACTIVITY; ACID RECEPTORS; ALPHA-RECEPTOR; GLIAL-CELLS; DIFFERENTIATION; ASTROCYTE	Ca2+ signaling induced by platelet-derived growth factor (PDGF) was investigated in the oligodendroglial cell lines CG4 and CEINGE clone 3, using fura-2 microfluorimetry and video imaging. CEINGE cia cells, immortalized with polyoma middle T antigen, were found to uniformly express the polyoma middle T antigen protein as well as 2',3'-cyclic nucleotide 3'-phosphodiesterase, a specific marker for oligodendroglia. PDGF-BB induced both oscillatory and non-oscillatory Ca2+ responses in CEINGE c13 cells as well as in CG4 cells, grown either as O-2A progenitors or differentiated oligodendrocytes However, in CG4 cells the percentage of oscillatory Ca2+ responses was higher than that observed in CEINGE c13 cells. In contrast, oscillatory Ca2+ responses were not observed in PC-12 cells transfected with beta-PDGF receptor (PDGFR) or in NIH 3T3 fibroblasts, CG4 cells expressed only the alpha-PDGFR, whereas CEINGE c13 cells expressed both alpha and beta isoforms. When CEINGE c13 cells were exposed to PDGF-AA, which binds only to the alpha-PDGFR, the percentage of oscillatory Ca2+ responses was higher than that observed after PDGF-BB stimulation We previously reported that block of the enzyme sphingosine kinase, and a consequent increase in intracellular sphingosine levels in CEINGE c13 cells caused an increase in the percentage of oscillatory Ca2+ responses induced by PDGF-BB. However, in CG4 cells block of sphingosine kinase did not increase the oscillatory Ca2+ response elicted by PDGF-BB, although the addition of exogenous sphinogosine induced an oscillatory Ca2+ response in 77% of cells studied. We hypothesize that the alpha-PDGFR is less effective than the beta-PDGFR in stimulating the activity of sphinogosine kinase. The results also suggest that alpha- and beta-PDGFRs may differently regulate sphingolipid metabolism.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	University of Chicago					NIDA NIH HHS [DA-02121] Funding Source: Medline; NIMH NIH HHS [MH-40165] Funding Source: Medline; NINDS NIH HHS [NS-33502] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH040165, R01MH040165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002121] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; ELLISON JA, 1994, J NEUROSCI RES, V37, P116, DOI 10.1002/jnr.490370116; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Fatatis A, 1996, J BIOL CHEM, V271, P295, DOI 10.1074/jbc.271.1.295; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GALLO V, 1994, GLIA, V11, P94, DOI 10.1002/glia.440110204; GROTENDORST GR, 1991, J CELL PHYSIOL, V149, P235, DOI 10.1002/jcp.1041490209; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HART IK, 1989, DEVELOPMENT, V105, P595; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MEANS AR, 1988, CELL CALCIUM, V9, P313, DOI 10.1016/0143-4160(88)90012-7; MIRSKY R, 1980, J CELL BIOL, V84, P488; MONGE M, 1986, DEV NEUROSCI-BASEL, V8, P222, DOI 10.1159/000112255; MONOH K, 1989, BIOCHEM BIOPH RES CO, V165, P1213, DOI 10.1016/0006-291X(89)92731-9; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PENDE M, 1994, P NATL ACAD SCI USA, V91, P3215, DOI 10.1073/pnas.91.8.3215; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAPTIS L, 1991, J VIROL, V65, P2691, DOI 10.1128/JVI.65.5.2691-2694.1991; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; RUSSO T, 1993, NEUROSCI LETT, V159, P159, DOI 10.1016/0304-3940(93)90823-4; SCHERER SS, 1994, NEURON, V12, P1363, DOI 10.1016/0896-6273(94)90451-0; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TAKUWA N, 1995, CELL SIGNAL, V7, P93, DOI 10.1016/0898-6568(94)00074-L; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VASSBOTN FS, 1992, J BIOL CHEM, V267, P15635; WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	50	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4351	4358		10.1074/jbc.272.7.4351	http://dx.doi.org/10.1074/jbc.272.7.4351			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020156	hybrid			2022-12-25	WOS:A1997WH01900072
J	Gotoh, T; Chowdhury, S; Takiguchi, M; Mori, M				Gotoh, T; Chowdhury, S; Takiguchi, M; Mori, M			The glucocorticoid-responsive gene cascade - Activation of the rat arginase gene through induction of C/EBP beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-ZIPPER PROTEINS; LIVER-TYPE ARGINASE; UREA CYCLE ENZYMES; BINDING-PROTEIN; NUCLEAR FACTOR; MESSENGER-RNA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; EXPRESSION NF-IL6; FAMILY	The gene for liver-type arginase, an ornithine cycle enzyme, is induced by glucocorticoids in a delayed secondary manner. An enhancer element located around intron 7 of the rat arginase gene shows delayed glucocorticoid responsiveness, and it harbors two sites binding with members of the CCAAT/enhancer binding protein (C/EBP) family, Here, we investigate the role of these C/EBP binding sites in glucocorticoid response of the arginase gene. When inserted in front of the herpes simplex virus thymidine kinase promoter, these C/EBP sites exhibited glucocorticoid responsiveness in reporter transfection assay using rat hepatoma H4IIE cells. In footprint analysis using nuclear extracts of H4IIE cells, profiles of the protected areas of the two C/EBP sites changed when cells were treated with dexamethasone. In gel shift analysis, the complex formation for the two C/EBP sites was augmented in response to dexamethasone. Antibody supershift/inhibition analysis demonstrated that a major portion of the binding proteins induced by dexamethasone is C/EBP beta. Induction of arginase mRNA by dexamethasone was preceded by augmentation of the C/EBP site-binding activities, which followed increase in C/EBP beta mRNA. These results were consistent with the notion that the glucocorticoid response of the arginase gene is mediated by C/EBP beta.	KUMAMOTO UNIV,SCH MED,DEPT MOL GENET,KUMAMOTO 862,JAPAN	Kumamoto University								ADDISON WR, 1986, MOL CELL BIOL, V6, P2334, DOI 10.1128/MCB.6.7.2334; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen C L, 1980, Ann N Y Acad Sci, V349, P28, DOI 10.1111/j.1749-6632.1980.tb29512.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chowdhury S, 1996, EUR J BIOCHEM, V236, P500, DOI 10.1111/j.1432-1033.1996.00500.x; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIZIKES GJ, 1986, SOMAT CELL MOLEC GEN, V12, P375, DOI 10.1007/BF01570732; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTOH T, 1994, J BIOCHEM-TOKYO, V115, P778, DOI 10.1093/oxfordjournals.jbchem.a124409; HERZFELD A, 1976, BIOCHEM J, V153, P469, DOI 10.1042/bj1530469; HESS P, 1992, J BIOL CHEM, V267, P3490; KAWAMOTO S, 1986, BIOCHEM BIOPH RES CO, V136, P955, DOI 10.1016/0006-291X(86)90425-0; KAWAMOTO S, 1987, J BIOL CHEM, V262, P6280; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; Matsuno F, 1996, J BIOCHEM-TOKYO, V119, P524; MIYAZAKI J, 1989, GENE, V79, P269; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; NAKAMURA T, 1987, J BIOL CHEM, V262, P727; NAWA K, 1986, J BIOL CHEM, V261, P6883; NEBES VL, 1987, BIOCHEM J, V246, P237, DOI 10.1042/bj2460237; NEBES VL, 1988, MOL ENDOCRINOL, V2, P444, DOI 10.1210/mend-2-5-444; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OHTAKE A, 1988, J BIOL CHEM, V263, P2245; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHIMKE RT, 1962, J BIOL CHEM, V237, P459; SCHIMKE RT, 1962, J BIOL CHEM, V237, P1921; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	50	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3694	3698		10.1074/jbc.272.6.3694	http://dx.doi.org/10.1074/jbc.272.6.3694			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013625	hybrid			2022-12-25	WOS:A1997WG19200085
J	Jiang, MS; Hart, GW				Jiang, MS; Hart, GW			A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-DEPENDENT PHOSPHORYLATION; NUCLEAR-PORE; CYTOPLASMIC PROTEINS; DNA-BINDING; TRANSCRIPTION FACTORS; BASIC PHOSPHOPROTEIN; TAMOXIFEN AZIRIDINE; C-MYC; GLYCOSYLATION; GLCNAC	Estrogen receptors (ER) are ligand-inducible transcription factors regulated by Ser(Thr)-O-phosphorylation. Many transcription factors and eukaryotic RNA polymerase II itself are also dynamically modified by Ser(Thr)-O-linked N-acetylglucosamine moieties (O-GlcNAc). Here we report that subpopulations of murine, bovine, and human estrogen receptors are modified by O-GlcNAc. O-GlcNAc moieties were detected on insect cell-expressed, mouse ER (mER) by probing with bovine milk galactosyltransferase, followed by structural analysis, Wheat germ agglutinin-Sepharose affinity chromatography also readily detected terminal GlcNAc residues on subpopulations of ER purified from calf uterus, from human breast cancer cells (MCF-7), or from mER produced by in. vitro translation. These data suggest that greater than 10% of these populations of estrogen receptors bear O-GlcNAc. Site mapping of insect cell expressed mER localized one major site of O-GlcNAc addition to Thr-575, within a PEST region of the carboxyl-terminal F domain, Based upon their relative resistance to both hexosaminidase and to in vitro galactosylation, O-GlcNAc moieties appear to be largely buried on native mER. This dynamic saccharide modification, like phosphorylation, may play a role in modulating the dimerization, stability, or transactivation functions of estrogen receptors.	UNIV ALABAMA, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	University of Alabama System; University of Alabama Birmingham; Johns Hopkins University				Hart, Gerald/0000-0001-7812-4351	NCI NIH HHS [CA42486] Funding Source: Medline; NIGMS NIH HHS [5T3 GM07445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; AURICCHIO F, 1990, PROG CLIN BIOL RES, V322, P133; BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; BENKO DM, 1988, P NATL ACAD SCI USA, V85, P2573, DOI 10.1073/pnas.85.8.2573; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAILLETBOUDIN ML, 1989, EUR J BIOCHEM, V184, P205, DOI 10.1111/j.1432-1033.1989.tb15008.x; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DENTON RR, 1992, J BIOL CHEM, V267, P7263; Ding M, 1996, J BIOL CHEM, V271, P12555, DOI 10.1074/jbc.271.21.12555; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DONOFRIO M, 1988, P NATL ACAD SCI USA, V85, P9595, DOI 10.1073/pnas.85.24.9595; EMMAS CE, 1992, J STEROID BIOCHEM, V41, P291, DOI 10.1016/0960-0760(92)90354-L; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; GREIS KD, 1994, J VIROL, V68, P8339, DOI 10.1128/JVI.68.12.8339-8349.1994; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; HAGMANN J, 1992, J BIOL CHEM, V267, P14424; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; HART GW, 1995, PURE APPL CHEM, V67, P1637, DOI 10.1351/pac199567101637; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOLT GD, 1985, J IMMUNOL, V135, P399; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HOLT GD, 1986, J BIOL CHEM, V261, P8049; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATZENELLENBOGEN BS, 1987, BIOCHEMISTRY-US, V26, P2364, DOI 10.1021/bi00382a043; KATZENELLENBOGEN JA, 1983, J BIOL CHEM, V258, P3487; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KEARSE KP, 1991, ARCH BIOCHEM BIOPHYS, V290, P543, DOI 10.1016/0003-9861(91)90579-8; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KING IA, 1989, J BIOL CHEM, V264, P14022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MEEK JL, 1980, P NATL ACAD SCI-BIOL, V77, P1632, DOI 10.1073/pnas.77.3.1632; MIGLIACCIO A, 1991, J STEROID BIOCHEM, V38, P407, DOI 10.1016/0960-0760(91)90328-3; MIGLIACCIO A, 1992, INT J CANCER, V51, P733, DOI 10.1002/ijc.2910510512; MULLIS KG, 1990, J VIROL, V64, P5317, DOI 10.1128/JVI.64.11.5317-5323.1990; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PAKDEL F, 1993, J STEROID BIOCHEM, V46, P663, DOI 10.1016/0960-0760(93)90307-I; PEALE FV, 1989, BIOCHEMISTRY-US, V28, P8671, DOI 10.1021/bi00448a001; PLUMMER TH, 1981, J BIOL CHEM, V256, P243; PRIVALSKY ML, 1990, J VIROL, V64, P463, DOI 10.1128/JVI.64.1.463-466.1990; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Shaw P, 1996, ONCOGENE, V12, P921; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TORRES CR, 1984, J BIOL CHEM, V259, P3308; WALLENFELS B, 1979, P NATL ACAD SCI USA, V76, P3223, DOI 10.1073/pnas.76.7.3223; WASHBURN T, 1991, MOL ENDOCRINOL, V5, P235, DOI 10.1210/mend-5-2-235; WHITEHEART SW, 1989, METHOD ENZYMOL, V179, P82; YOSHIMOTO T, 1980, J BIOL CHEM, V255, P4786	75	72	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2421	2428						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999954				2022-12-25	WOS:A1997WD67900060
J	Pandit, SD; OHare, T; DonisKeller, H; Pike, LJ				Pandit, SD; OHare, T; DonisKeller, H; Pike, LJ			Functional characterization of an epidermal growth factor receptor RET chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; FACTOR-II RECEPTOR; NEOPLASIA TYPE 2B; EGF RECEPTOR; DOPAMINERGIC-NEURONS; NEUROTROPHIC FACTOR; MOTOR-NEURONS; IN-VIVO; PROTOONCOGENE; MUTATIONS	The RET (recombined in transfection) gene encodes a receptor tyrosine kinase homolog involved in innervation of the gut and renal development, A chimeric epidermal growth factor receptor (EGFR)/RET receptor was constructed which contained the extracellular and transmembrane domains of the EGF receptor fused to the intracellular domain of RET. This construct was expressed in NIH 3T3 cells, and the functional properties of the receptor were characterized and compared with those of the wild type EGF receptor, Whereas the EGF receptor exhibited both high and low affinity binding sites for I-125-EGF, the EGFR/RET chimera exhibited only low affinity binding of I-125-EGF, The chimera was able to internalize EGF more rapidly than the wild type EGF receptor and recycled to the cell surface at twice the rate of the EGF receptor. pulse-chase experiments indicated that EGF stimulated the degradation of the wild type EGF receptor but had no effect on the rate of degradation of the EGFR/RET receptor. The combination of increased recycling and decreased degradation resulted in the relatively inefficient down-regulation of the EGFR/RET chimera. Incubation of cells expressing the wild type EGF receptor with phorbol 12-myristate 13-acetate led to a reduction in I-125-EGF binding and a loss in EGF-stimulated tyrosine phosphorylation. However, phorbol 12-myristate 13-acetate treatment had only a limited effect on EGF binding and EGF-stimulated tyrosine kinase activity in cells expressing EGFR/RET chimeras. These findings suggest that the ret tyrosine kinase is not regulated by many of the common mechanisms used to terminate signaling via growth factor receptors, Such persistent activation of the Ret tyrosine kinase may be relevant to the physiological function of Ret in cells that normally express this growth factor receptor.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,DIV HUMAN MOL GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NCI NIH HHS [P01CA5352] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAI N, 1995, MOL CELL BIOL, V15, P1613; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COCHET C, 1984, J BIOL CHEM, V259, P2553; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; JADOT M, 1992, J BIOL CHEM, V267, P11069; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYERS SM, 1995, ONCOGENE, V11, P2039; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUH SM, 1994, MOL BIOL CELL, V5, P739, DOI 10.1091/mbc.5.7.739; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOMAC A, 1995, P NATL ACAD SCI USA, V92, P8274, DOI 10.1073/pnas.92.18.8274; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	49	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2199	2206						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999923				2022-12-25	WOS:A1997WD67900029
J	Grosenbach, DW; Ulaeto, DO; Hruby, DE				Grosenbach, DW; Ulaeto, DO; Hruby, DE			Palmitylation of the vaccinia virus 37-kDa major envelope antigen - Identification of a conserved acceptor motif and biological relevance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR VIRUS; POLYACRYLAMIDE GELS; PROTEIN; PALMITOYLATION; LOCALIZATION; EGRESS; HEMAGGLUTININ; POLYPEPTIDE; COMPONENT; CAVEOLAE	Computer-assisted alignment of known palmitylproteins was used to identify a potential peptide motif, TMDX(1-12)AAC(C)A (TMD, transmembrane domain; X, any amino acid; C, cysteine acceptor residues; A, aliphatic residue) responsible for directing internal palmitylation of the vaccinia virus 37-kDa major envelope antigen, p37. Site-directed mutagenesis was used to confirm this motif as the site of modification and to produce a nonpalmitylated version of the p37 protein. Comparative phenotypic analysis of the wild-type and mutant p37 alleles confirmed that the p37 protein is involved in viral envelopment and egress, and suggested that attachment of the palmitate moiety was essential for correct intracellular targeting and protein function.	OREGON STATE UNIV, CTR GENE RES & BIOTECHNOL, DEPT MICROBIOL, CORVALLIS, OR 97331 USA	Oregon State University					NIAID NIH HHS [AI-21335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021335] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIZZOZERO OA, 1994, NEUROCHEM RES, V19, P923, DOI 10.1007/BF00968702; BLASCO R, 1992, J VIROL, V66, P4170, DOI 10.1128/JVI.66.7.4170-4179.1992; BLASCO R, 1991, J VIROL, V65, P5910, DOI 10.1128/JVI.65.11.5910-5920.1991; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHILD SJ, 1992, VIROLOGY, V191, P262, DOI 10.1016/0042-6822(92)90188-U; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUNCAN SA, 1992, J VIROL, V66, P1610, DOI 10.1128/JVI.66.3.1610-1621.1992; ENGELSTAD M, 1993, VIROLOGY, V194, P627, DOI 10.1006/viro.1993.1302; Goebel S.J., 1990, VIROLOGY, V179, P517; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HILLER G, 1985, J VIROL, V55, P651, DOI 10.1128/JVI.55.3.651-659.1985; HIRT P, 1986, J VIROL, V58, P757, DOI 10.1128/JVI.58.3.757-764.1986; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HRUBY DE, 1979, J VIROL, V29, P705, DOI 10.1128/JVI.29.2.705-715.1979; Hruby Dennis E., 1993, Trends in Microbiology, V1, P20, DOI 10.1016/0966-842X(93)90020-R; ISAACS SN, 1992, J VIROL, V66, P7217, DOI 10.1128/JVI.66.12.7217-7224.1992; Jin H, 1996, J VIROL, V70, P1406, DOI 10.1128/JVI.70.3.1406-1414.1996; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; OIE M, 1990, VIROLOGY, V176, P494, DOI 10.1016/0042-6822(90)90019-N; PARKINSON JE, 1994, VIROLOGY, V204, P376, DOI 10.1006/viro.1994.1542; PAYNE L, 1978, J VIROL, V27, P28, DOI 10.1128/JVI.27.1.28-37.1978; PAYNE LG, 1992, VIROLOGY, V187, P251, DOI 10.1016/0042-6822(92)90313-E; PONIMASKIN E, 1995, BIOCHEM SOC T, V23, P565, DOI 10.1042/bst0230565; RAVANELLO MP, 1994, J GEN VIROL, V75, P1479, DOI 10.1099/0022-1317-75-6-1479; RODRIGUEZ JF, 1990, NUCLEIC ACIDS RES, V18, P5347, DOI 10.1093/nar/18.18.5347; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHMUTZ C, 1995, VIROLOGY, V213, P19, DOI 10.1006/viro.1995.1542; SCHMUTZ C, 1991, J VIROL, V65, P3435, DOI 10.1128/JVI.65.7.3435-3442.1991; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULAETO D, 1995, J GEN VIROL, V76, P103, DOI 10.1099/0022-1317-76-1-103; VANSLYKE JK, 1990, CURR TOP MICROBIOL, V163, P185; WATKIN S, 1991, CURRENT PROTOCOLS MO; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; YANG CL, 1995, P NATL ACAD SCI USA, V92, P9871, DOI 10.1073/pnas.92.21.9871; ZURCHER T, 1994, J VIROL, V68, P5748, DOI 10.1128/JVI.68.9.5748-5754.1994; [No title captured]	47	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1956	1964		10.1074/jbc.272.3.1956	http://dx.doi.org/10.1074/jbc.272.3.1956			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999886	hybrid			2022-12-25	WOS:A1997WD05800084
J	Hilchey, SP; Koudelka, GB				Hilchey, SP; Koudelka, GB			DNA-based loss of specificity mutations - Effects of DNA sequence on the contacted and non-contacted base preferences of bacteriophage P22 repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							434 REPRESSOR; NONCONTACTED BASES; BINDING PROTEINS; OPERATOR; AFFINITY; COMPLEXES	Although the two central bases of the P22 operator are not contacted by the P22 repressor, changes in these bases alter the affinity of operator for repressor. Previous studies (Wu, L., and Koudelka, G. B. (1993) J. Biol. Chem. 268, 18975-18981) show that the structure of the P22 repressor-operator complex varies with central base sequence. Here we show that central base sequence composition affects the strength of two, and likely all, specific amino acid-base pair contacts between synthetic P22 operators and P22 repressor. However, alter ing a specific protein-DNA contact via a loss-of-contact mutation in repressor results in a loss of specificity at only one contacted position. Thus, only changing the sequence of non-contacted bases affects repressor's global base specificity. The observed effects of ionic concentration on the affinities of various operators for repressor and the DNase I patterns of protein complexes with these binding sites indicate certain central base sequences facilitate optimal juxtaposition of repressor with its contacted bases, while others prevent it. The existence of different structural forms of the repressor-operator complexes explains how the relative energetic importance of specific amino acid-base pair edge contacts is modulated.	SUNY BUFFALO,DEPT SCI BIOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837	NIGMS NIH HHS [GM42138] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042138, R29GM042138] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL AC, 1993, J MOL BIOL, V234, P542, DOI 10.1006/jmbi.1993.1610; BELL AC, 1995, J BIOL CHEM, V270, P1205, DOI 10.1074/jbc.270.3.1205; DEANDA J, 1983, J BIOL CHEM, V258, P536; EBRIGHT RH, 1996, METHOD ENZYMOL, V208, P620; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P20; POTEETE AR, 1980, J MOL BIOL, V137, P81, DOI 10.1016/0022-2836(80)90158-8; Ptashne M., 1986, A GENETIC SWITCH; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SANGER F, 1973, P NATL ACAD SCI USA, V70, P1209, DOI 10.1073/pnas.70.4.1209; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; WU L, 1993, J BIOL CHEM, V268, P18975; WU L, 1992, J BIOL CHEM, V267, P9134	19	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1646	1653		10.1074/jbc.272.3.1646	http://dx.doi.org/10.1074/jbc.272.3.1646			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999840	hybrid			2022-12-25	WOS:A1997WD05800038
J	MacCallum, DE; Hupp, TR; Midgley, CA; Stuart, D; Campbell, SJ; Harper, A; Walsh, FS; Wright, EG; Balmain, A; Lane, DP; Hall, PA				MacCallum, DE; Hupp, TR; Midgley, CA; Stuart, D; Campbell, SJ; Harper, A; Walsh, FS; Wright, EG; Balmain, A; Lane, DP; Hall, PA			The p53 response to ionising radiation in adult and developing murine tissues	ONCOGENE			English	Article						p53; radiation; apoptosis; development; heterogeneity; immunochemistry; teratogenesis; transgenesis	CELLULAR TUMOR-ANTIGEN; P53-DEFICIENT MICE; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; GASTROINTESTINAL-TRACT; P53-MEDIATED APOPTOSIS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; GAMMA-IRRADIATION; HELA-CELLS	The induction of the p53 response to ionising radiation has been studied during murine development and in the adult animal. The response has been assessed by precise quantitative assay of p53 protein levels in tissues and by immunohistochemistry. Newly developed transgenic mice in which a lacZ transgene is driven by a p53 response element have also been used to directly assess the transcriptional activity of the induced protein, There is striking developmental control of the p53 response so that in early development all tissues accumulate high levels of p53 following radiation and indeed p53 is present at elevated levels in some unirradiated tissues, Later in development clear heterogeneity of the p53 response becomes apparent, both in terms of the responses of individual tissues and of cell populations, within those tissues, The study of lacZ transgene expression and the occurrence of apoptosis in different tissues that accumulate p53 protein point to a further level of control regulating the nature and degree of the downstream response to elevated levels of p53 in cells, These findings have important implications for the susceptibility of different tissue types to carcinogenic and other insults, The early expression of the p53 response is consistent with novel models of p53 function that suggest it may have evolved principally as a defense against teratogenic insult that permits plasticity of development.	UNIV DUNDEE, DEPT MOL & CELLULAR PATHOL, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, CRC, CELL TRANSFORMAT GRP, DEPT BIOCHEM, DUNDEE DD1 9SY, SCOTLAND; BEATSON INST CANC RES, CRC, DEPT MED ONCOL, GLASGOW G61 1BD, LANARK, SCOTLAND; UNITED MED & DENT SCH, TRANSGEN UNIT, LONDON SE1 9RT, ENGLAND; UNITED MED & DENT SCH, DEPT EXPT PATHOL, LONDON SE1 9RT, ENGLAND; MRC, RADIAT & GENOME STABIL UNIT, DIDCOT OX11 0RD, OXON, ENGLAND; UNIV DUNDEE, CTR BIOMED RES, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee; Beatson Institute; University of London; King's College London; University of London; King's College London; MRC Harwell; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BELLAMY COC, 1996, UNPUB; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAMPBELL SF, IN PRESS J CELL SCI; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Ferreira A, 1996, J CELL SCI, V109, P1509; FORBES RM, 1953, J BIOL CHEM, V203, P359; FREBOURG T, 1992, CANCER RES, V52, P6976; GOTTLIEB ER, UNPUB; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALL PA, 1994, J CELL SCI, V107, P3569; Hall PA, 1996, J PATHOL, V180, P1; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HALL PA, 1993, ONCOGENE, V8, P203; HALL PA, 1994, EUR J CANCER, V30A, P2001, DOI 10.1016/0959-8049(94)00394-K; HANSEN S, 1996, IN PRESS J BIOL CHEM; Harlow E., 1988, ANTIBODIES LAB MANUA; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOEVER M, 1994, ONCOGENE, V9, P109; Hogan B, 1994, MANIPULATING MOUSE E; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kitada S, 1996, ONCOGENE, V12, P187; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOMAROVA EA, UNPUB; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNA RMD, 1995, NATURE, V378, P203; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCCORMICK D, 1993, HISTOPATHOLOGY, V22, P543, DOI 10.1111/j.1365-2559.1993.tb00174.x; MCKEE PH, 1993, HISTOPATHOLOGY, V23, P377, DOI 10.1111/j.1365-2559.1993.tb01223.x; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MERRICK BA, 1995, BIOTECHNIQUES, V18, P292; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; RUGH R, 1963, AMER J ROENTGENOL RA, V89, P182; RUSSELL LB, 1957, P SOC EXP BIOL MED, V95, P174; RUSSELL LB, 1954, J CELL COMPAR PHYSL, V43, pA103, DOI 10.1002/jcp.1030430407; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WEINBERG WC, 1995, ONCOGENE, V10, P2271; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WIRNITZER U, 1995, CARCINOGENESIS, V16, P697, DOI 10.1093/carcin/16.4.697; Wubah JA, 1996, CURR BIOL, V6, P60, DOI 10.1016/S0960-9822(02)00422-0	66	187	192	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2575	2587						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000131				2022-12-25	WOS:A1996VZ65400007
J	Cebolla, A; Sousa, C; deLorenzo, V				Cebolla, A; Sousa, C; deLorenzo, V			Effector specificity mutants of the transcriptional activator NahR of naphthalene degrading Pseudomonas define protein sites involved in binding of aromatic inducers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; CATABOLIC REPORTER BACTERIUM; SALICYLATE BIOAVAILABILITY; CHROMOSOMAL INSERTION; MUTATIONAL ANALYSIS; FUNCTIONAL DOMAINS; NODD GENES; RHIZOBIUM; VECTORS; MUTAGENESIS	This work reports a genetic analysis of the interactions between NahR, the LysR-type regulator of the NAH operons for biodegradation of naphthalene in Pseudomonas, and its aromatic effecters, Six mutants encoding NahR variants responsive to salicylate analogs such as benzoate, which is not an inducer for the wild type regulator, were isolated with a polymerase chain reaction-based saturation mutagenesis protocol, Most mutants displaying a specific change of effector profile bore single amino acid substitutions within a short protein segment of 60 residues located at the central portion of the NahR sequence, Some of the protein variants exhibited an increased affinity for salicylate and also for otherwise suboptimal effecters, with apparent K-s' values 5-100-fold lower than those of the wild type NahR protein, In addition, all mutants were activated by inducers bearing novel substituents at positions 1 or 2 of the aromatic ring and displayed also an enhanced tolerance to changes at positions 3 and 4, Correlation between mutations in NahR, and the structures of the new effecters suggested that protein sites Met(116), Arg(132), Asn(169), and Arg(248) are involved in effector recognition and binding during the earlier steps of the process leading to transcriptional activation of cognate NAH promoters.	CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)				de Lorenzo, Victor/0000-0002-6041-2731; Sousa Martin, Carolina/0000-0002-9235-9496				APPELBAUM ER, 1988, J BACTERIOL, V170, P12, DOI 10.1128/jb.170.1.12-20.1988; BURN J, 1987, GENE DEV, V1, P456, DOI 10.1101/gad.1.5.456; CHO KY, 1993, J BACTERIOL, V175, P7715, DOI 10.1128/JB.175.23.7715-7719.1993; COLYER TE, 1994, MOL MICROBIOL, V13, P797, DOI 10.1111/j.1365-2958.1994.tb00472.x; deLorenzo V, 1996, MOL MICROBIOL, V19, P1177; DELORENZO V, 1993, GENE, V130, P41, DOI 10.1016/0378-1119(93)90344-3; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; GYORGYPAL Z, 1991, MOL GEN GENET, V226, P337, DOI 10.1007/BF00273624; HEITZER A, 1994, APPL ENVIRON MICROB, V60, P1487, DOI 10.1128/AEM.60.5.1487-1494.1994; HEITZER A, 1992, APPL ENVIRON MICROB, V58, P1839, DOI 10.1128/AEM.58.6.1839-1846.1992; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HORVATH B, 1987, EMBO J, V6, P841, DOI 10.1002/j.1460-2075.1987.tb04829.x; HUANG JZ, 1991, J BIOL CHEM, V266, P10830; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEHRBACH PR, 1984, J BACTERIOL, V158, P1025, DOI 10.1128/JB.158.3.1025-1032.1984; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; RAMOS JL, 1990, J MOL BIOL, V211, P373, DOI 10.1016/0022-2836(90)90358-S; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SCHELL MA, 1990, J BIOL CHEM, V265, P3844; SCHELL MA, 1989, J BACTERIOL, V171, P837, DOI 10.1128/jb.171.2.837-846.1989; SPAINK HP, 1989, PLANT MOL BIOL, V12, P59, DOI 10.1007/BF00017448; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YEN KM, 1991, J BACTERIOL, V173, P5328, DOI 10.1128/jb.173.17.5328-5335.1991	30	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3986	3992		10.1074/jbc.272.7.3986	http://dx.doi.org/10.1074/jbc.272.7.3986			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020104	hybrid, Green Published			2022-12-25	WOS:A1997WH01900020
J	Hopkins, PCR; Chang, WSW; Wardell, MR; Stone, SR				Hopkins, PCR; Chang, WSW; Wardell, MR; Stone, SR			Inhibitory mechanism of serpins - Mobility of the c-terminal region of the reactive-site loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-INHIBITORS; STRUCTURAL BASIS; HINGE REGION; ANTITHROMBIN; SUBSTRATE; COMPLEX; CONFORMATION; MUTATIONS	The reactive-site loops of serpins are characterized by a defined mobility where the loop adopts a new secondary structure as an essential part of the inhibitory process. While the importance of mobility in the N-terminal region of the reactive-site loop has been well studied, the role of mobility in the C-terminal portion has not been investigated. The requirements for mobility of the C-terminal portion of the reactive-site loop of alpha(1)-antitrypsin were investigated by creating a disulfide bridge between the P'(3) residue and residue 283 near the top of strand 2C; this disulfide would restrict the mobility of the C-terminal portion of the reactive-site loop by locking together strands 1 and 2 of the C beta-sheet. The engineered disulfide bond had no effect on the inhibitory activity of alpha(1)-antitrypsin, indicating that there is no requirement for mobility in this region of the molecule. Moreover, these results, coupled with those from molecular modeling, indicate that insertion into the A beta-sheet of the intact reactive-loop beyond P-12 is not rate-limiting for the formation of the stable complex. The engineered disulfide bond should also prove useful in the creation of more stable serpin variants; for example, such a bond in plasminogen activator inhibitor-1 would prevent it from becoming latent by locking strand 1C onto the C beta-sheet.	UNIV CAMBRIDGE,DEPT HAEMATOL,MRC CTR,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge			Chang, Wun-Shaing Wayne/C-1202-2010; Hopkins, Paul/E-5215-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1992, J BIOL CHEM, V267, P19047; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; LANE DA, 1992, J CLIN INVEST, V90, P2422, DOI 10.1172/JCI116133; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LOBERMANN H, 1984, J MOL BIOL, V177, P531; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PERONA JJ, 1993, J MOL BIOL, V230, P919, DOI 10.1006/jmbi.1993.1210; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WHISSTOCK JC, 1995, IN PRESS PROTEINS ST; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	30	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3905	3909		10.1074/jbc.272.7.3905	http://dx.doi.org/10.1074/jbc.272.7.3905			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020092	hybrid			2022-12-25	WOS:A1997WH01900008
J	Zhang, N; Peng, KC; Chen, L; Puett, D; Pierce, M				Zhang, N; Peng, KC; Chen, L; Puett, D; Pierce, M			Circular dichroic spectroscopy of N-acetylglucosaminyltransferase V and its substrate interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; ALPHA-LACTALBUMIN; KINETIC MECHANISM; GENE-TRANSFER; BHK CELLS; GALACTOSYLTRANSFERASE; CDNA; PURIFICATION; SEQUENCE; AGAROSE	beta-1,6-N-Acetylglucosaminyltransferase V (EC 2.4.1.155) catalyzes the transfer of N-acetylglucosamine (GlcNAc) from UDP-GlcNAc in beta(1,6)-linkage to the alpha(1,6)-linked mannose of N-linked oligosaccharides. Circular dichroism (CD) was used to investigate the secondary structure of a recombinant, soluble form of the enzyme and its interaction with UDP-GlcNAc and an inhibitory substrate analog. The CD spectrum of the apoenzyme indicated the presence of small amounts of beta-structure and substantial amounts (>50%) of alpha-helicity. The CD spectra of solutions containing UDP-GlcNAc and different ratios of UDP-GlcNAc:enzyme were measured. Interestingly, the spectrum of each mixture could not be accounted for by simple additivity of the two individual spectra, indicating a change in environment of the chromophores and/or a conformational change of the substrate or protein concomitant with binding. Similar results were obtained with mixtures of UDP and the enzyme, Analysis of the CD difference spectra at three wavelengths yielded an estimated average K-d of 4.4 mM for UDP-GlcNAc and 3.8 mM for UDP. By contrast, addition of the CD spectrum of an inhibitory substrate analog of its oligosaccharide acceptor substrate and the CD spectrum of the enzyme could account for that observed of an inhibitor-enzyme mixture; moreover, addition of the inhibitor to a mixture of UDP-GlcNAc and enzyme did not alter the K-d associated with UDP-GlcNAc binding to the enzyme. These results and kinetic studies reported herein suggest an ordered reaction in which UDP-GlcNAc binds first to the enzyme, followed by the sequential binding of the trisaccharide substrate.	UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30602 USA; UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia								ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BARKER R, 1972, J BIOL CHEM, V247, P7135; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BELL JE, 1976, J BIOL CHEM, V251, P3003; BENDIAK B, 1987, J BIOL CHEM, V262, P5784; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; CHEN L, 1995, GLYCOCONJUGATE J, V12, P813, DOI 10.1007/BF00731243; Cleland W. W, 1970, ENZYMES, V2, P1; CRAWLEY S, 1993, THESIS U ALBERTA EDM; GEREN CR, 1975, BIOCHEMISTRY-US, V14, P1461, DOI 10.1021/bi00678a017; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERNG GS, 1994, GLYCOBIOLOGY, V4, P867, DOI 10.1093/glycob/4.6.867; PIERCE M, 1986, J BIOL CHEM, V261, P772; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SRIVASTAVA OP, 1988, CARBOHYD RES, V179, P137, DOI 10.1016/0008-6215(88)84115-6; YADAV SP, 1991, J BIOL CHEM, V266, P698; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; ZU HY, 1995, BIOCHEM BIOPH RES CO, V206, P362, DOI 10.1006/bbrc.1995.1050	28	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4225	4229		10.1074/jbc.272.7.4225	http://dx.doi.org/10.1074/jbc.272.7.4225			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020137	hybrid			2022-12-25	WOS:A1997WH01900053
J	Blunt, AG; Lawshe, A; Cunningham, ML; Seto, ML; Ornitz, DM; MacArthur, CA				Blunt, AG; Lawshe, A; Cunningham, ML; Seto, ML; Ornitz, DM; MacArthur, CA			Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROUZON-SYNDROME; MOUSE DEVELOPMENT; MUTATIONS; GENE; CLONING; FAMILY; BINDING; ACHONDROPLASIA; GASTRULATION; SPECIFICITY	FGF-8 is a member of the family of fibroblast growth factors and is expressed during vertebrate embryo development, Eight potential FGF-8 isoforms are generated by alternative splicing in mice, several of which are expressed during embryogenesis in epithelial locations, The significance of the multiple isoforms is currently unknown, In this report, we investigate the expression patterns and the specificity of the FGF-8 isoforms for known fibroblast growth factor (FGF) receptors, RNAs for seven of the eight potential isoforms are present at multiple sites of embryonic Fgf8 expression, None of the FGF-8 isoforms exhibited activity when assayed with BaF3 cells expressing the ''b'' splice forms of FGF receptors 1-3, which are mostly expressed in epithelial tissues, Mesenchymally expressed ''c'' splice forms of FGF receptors 2 and 3 and FGF receptor 4 were activated by several FGF-8 isoforms. These findings are consistent with the hypothesis that the multiple FGF-8 isoforms are functionally redundant and function to signal in paracrine (epithelial to mesenchymal) contexts.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; UNIV WASHINGTON, SCH MED, DEPT PEDIAT, DIV CONGENITAL DEFECTS, SEATTLE, WA 98195 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Washington; University of Washington Seattle				Ornitz, David/0000-0003-1592-7629	NCI NIH HHS [R01 CA70601, R01 CA60673] Funding Source: Medline; NICHD NIH HHS [K11 HD-01054] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K11HD001054] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Harlow E., 1988, ANTIBODIES LAB MANUA; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kaufman M.H., 1992, ATLAS MOUSE DEV; KOUHARA H, 1994, ONCOGENE, V9, P455; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Payson RA, 1996, ONCOGENE, V13, P47; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WHITE RA, 1995, GENOMICS, V30, P109, DOI 10.1006/geno.1995.0020; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	41	59	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3733	3738		10.1074/jbc.272.6.3733	http://dx.doi.org/10.1074/jbc.272.6.3733			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013630	hybrid			2022-12-25	WOS:A1997WG19200090
J	Campbell, RE; Sala, RF; vandeRijn, IV; Tanner, ME				Campbell, RE; Sala, RF; vandeRijn, IV; Tanner, ME			Properties and kinetic analysis of UDP-glucose dehydrogenase from group a streptococci - Irreversible inhibition by UDP-chloroacetol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; CONSERVED CYSTEINE RESIDUES; SITE-DIRECTED MUTAGENESIS; HYALURONIC-ACID SYNTHESIS; HISTIDINOL DEHYDROGENASE; BOVINE LIVER; MOLECULAR CHARACTERIZATION; ALDEHYDE DEHYDROGENASE; CAPSULE; PNEUMONIAE	UDP-glucuronic acid is used by many pathogenic bacteria in the construction of an antiphagocytic capsule that is required for virulence. The enzyme UDP-glucose dehydrogenase catalyzes the NAD(+)-dependent 2-fold oxidation of UDP-glucose and provides a source of the acid. In the present study the recombinant dehydrogenase from group A streptococci has been purified and found to be active as a monomer. The enzyme contains no chromophoric cofactors, and its activity is unaffected by the presence of EDTA or carbonyl-trapping reagents. Initial velocity and product inhibition kinetic patterns are consistent with a bi-uni-uni-bi ping-pong mechanism in which UDP-glucose is bound first and UDP-glucuronate is released last. UDP-xylose was found to be a competitive inhibitor (K-i, 2.7 mu M) of the enzyme. The enzyme is irreversibly inactivated by uridine 5'-diphosphate chloroacetol due to the alkylation of an active site cysteine thiol. The apparent second order rate constant for the inhibition (k(i)/K-i) was found to be 2 x 10(3) mM(-1) min(-1). Incubation with the truncated compound, chloroacetol phosphate, resulted in no detectable inactivation when tested under comparable conditions. This supports the notion that uridine 5'-diphosphate-chloroacetol is bound in the place of UDP-glucose and is not simply acting as a nonspecific alkylating agent.	UNIV BRITISH COLUMBIA, DEPT CHEM, VANCOUVER, BC V6T 1Z1, CANADA; WAKE FOREST UNIV, MED CTR, WINSTON SALEM, NC 27157 USA	University of British Columbia; Wake Forest University				Campbell, Robert E./0000-0003-0604-092X	NIAID NIH HHS [AI37320] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037320] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arrecubieta C, 1996, J BACTERIOL, V178, P2971, DOI 10.1128/jb.178.10.2971-2974.1996; ARRECUBIETA C, 1994, J BACTERIOL, V176, P6375, DOI 10.1128/jb.176.20.6375-6383.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGER E, 1981, EUR J BIOCHEM, V116, P137, DOI 10.1111/j.1432-1033.1981.tb05311.x; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CORBIER C, 1992, BIOCHEMISTRY-US, V31, P12532, DOI 10.1021/bi00164a033; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; CROSS AS, 1990, CURR TOP MICROBIOL, V150, P87; DeLuca C, 1996, BIOORGAN MED CHEM, V4, P131, DOI 10.1016/0968-0896(95)00159-X; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; ECCLESTON ED, 1979, J BIOL CHEM, V254, P1399; FARRES J, 1995, BIOCHEMISTRY-US, V34, P2592, DOI 10.1021/bi00008a025; FLENTKE GR, 1990, BIOCHEMISTRY-US, V29, P2430, DOI 10.1021/bi00461a029; FRANZEN B, 1981, BIOCHEM J, V199, P599, DOI 10.1042/bj1990599; FRANZEN JS, 1978, BIOCHEM J, V173, P701, DOI 10.1042/bj1730701; FRANZEN JS, 1980, BIOCHIM BIOPHYS ACTA, V614, P242, DOI 10.1016/0005-2744(80)90214-4; FRANZEN JS, 1980, BIOCHEMISTRY-US, V19, P6080, DOI 10.1021/bi00567a021; FRANZEN JS, 1976, BIOCHEMISTRY-US, V15, P5665, DOI 10.1021/bi00670a036; GAINEY PA, 1972, BIOCHEM J, V129, P821, DOI 10.1042/bj1290821; GORISCH H, 1979, BIOCHEM J, V181, P153, DOI 10.1042/bj1810153; GRUBMEYER CT, 1986, BIOCHEMISTRY-US, V25, P4778, DOI 10.1021/bi00365a009; Harrison J., 1976, P1; HARTMAN FC, 1970, BIOCHEMISTRY-US, V9, P1776, DOI 10.1021/bi00810a017; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; KHEIROLOMOOM A, 1994, ARCH BIOCHEM BIOPHYS, V312, P493, DOI 10.1006/abbi.1994.1337; LEE CJ, 1991, CRIT REV MICROBIOL, V18, P89, DOI 10.3109/10408419109113510; MOXON ER, 1990, CURR TOP MICROBIOL, V150, P65; NAGAI A, 1993, J BIOCHEM-TOKYO, V114, P856, DOI 10.1093/oxfordjournals.jbchem.a124268; NELSESTUEN GL, 1971, J BIOL CHEM, V246, P3828; Oppenheimer N. J., 1992, ENZYMES, P453; ORDMAN AB, 1977, BIOCHIM BIOPHYS ACTA, V481, P25, DOI 10.1016/0005-2744(77)90133-4; ORDMAN AB, 1977, J BIOL CHEM, V252, P1320; PETIT C, 1995, MOL MICROBIOL, V17, P611, DOI 10.1111/j.1365-2958.1995.mmi_17040611.x; RIDLEY WP, 1975, J BIOL CHEM, V250, P8761; SCHILLER JG, 1972, CARBOHYD RES, V25, P403, DOI 10.1016/S0008-6215(00)81651-1; SCHILLER JG, 1976, BIOCHIM BIOPHYS ACTA, V453, P418, DOI 10.1016/0005-2795(76)90137-9; SCHILLER JG, 1973, BIOCHIM BIOPHYS ACTA, V293, P1, DOI 10.1016/0005-2744(73)90369-0; SIEBERTH V, 1995, J BACTERIOL, V177, P4562, DOI 10.1128/jb.177.15.4562-4565.1995; STROMINGER JL, 1957, J BIOL CHEM, V224, P79; TENG H, 1993, J BIOL CHEM, V268, P14182; vandeRijn I, 1995, DEV BIOL STAND, V85, P219; Vedadi M, 1995, BIOCHEMISTRY-US, V34, P16725, DOI 10.1021/bi00051a022; WATSON DA, 1990, INFECT IMMUN, V58, P3135, DOI 10.1128/IAI.58.9.3135-3138.1990; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; WIMER FB, 1972, THESIS OHIO STATE U; WONG YHH, 1979, BIOCHEMISTRY-US, V18, P5332, DOI 10.1021/bi00591a011	48	73	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3416	3422		10.1074/jbc.272.6.3416	http://dx.doi.org/10.1074/jbc.272.6.3416			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013585	hybrid			2022-12-25	WOS:A1997WG19200045
J	Campbell, GS; Yu, CL; Jove, R; CarterSu, C				Campbell, GS; Yu, CL; Jove, R; CarterSu, C			Constitutive activation of JAK1 in Src-transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; NIH 3T3 CELLS; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GROWTH-FACTORS; RECEPTOR; FAMILY; PP60C-SRC; MEMBERS	We have previously found that the signal transducer and activator of transcription (Stat) 3 is constitutively activated in cells stably transformed by the v-Src oncoprotein. While activation of Stat proteins has also been observed following epidermal growth factor or platelet-derived growth factor stimulation, Stat3 activation is more commonly associated with signaling through cytokine receptors and activation of the Janus family tyrosine kinases JAK1 or JAK2. We therefore investigated whether JAK1 or JAK2 were activated in Src-transformed cells. In three v-Src-transformed fibroblast cell lines (NIH3T3, Balb/c, and 3Y1), JAK1 displayed increased tyrosyl phosphorylation compared to non-transformed cells. The level of tyrosyl phosphorylation of JAK1 was significantly greater in NIH3T3 cells transformed by expression of v-Src or high levels of a constitutively active mutant of c-Src (Y527F) than in cells overexpressing the less transforming normal c-Src. Enzymatic activity of JAK1 was assessed using autophosphorylation assays. In anti-JAK1 immunoprecipitates from v-Src-transformed NIH3T3 cells, a protein with the same migration as JAK1 showed substantially increased levels of P-32 incorporation compared to immunoprecipitates from non-transformed cells. Similar results were obtained using anti-JAK2 immunoprecipitates; however, the level of JAK2 tyrosyl phosphorylation and P-32 incorporation in anti-JAK2 immunoprecipitates were markedly lower than in anti-JAK1 immunoprecipitates. We conclude that JAK1, and possibly JAK2, are constitutively activated in Src-transformed cells, raising the possibility that Janus family kinases contribute to the constitutive activation of Stat3 previously observed in these cells and/or other properties of Src-transformed cells.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; UNIV S FLORIDA, COLL MED, H LEE MOFFIT CANC CTR & RES INST, DEPT BIOCHEM & MOL BIOL, TAMPA, FL 33612 USA	University of Michigan System; University of Michigan; State University System of Florida; University of South Florida			Yu, Chao-Lan/D-1834-2011	Yu, Chao-Lan/0000-0002-9381-6011	NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048283] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652, R01 CA055652] Funding Source: Medline; NIDDK NIH HHS [DK48283] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; EILERS A, 1995, MOL CELL BIOL, V15, P3579; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1989, ONCOGENE RES, V5, P49; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RAZ R, 1994, J BIOL CHEM, V269, P24391; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANZANT G, 1989, EXP HEMATOL, V17, P81; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	33	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2591	2594		10.1074/jbc.272.5.2591	http://dx.doi.org/10.1074/jbc.272.5.2591			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006890	hybrid			2022-12-25	WOS:A1997WE66700003
J	Hama, Y; Li, YT; Li, SC				Hama, Y; Li, YT; Li, SC			Interaction of G(M2) activator protein with glycosphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMIC-HYDROLYSIS; HEXOSAMINIDASE-A; GM2 GANGLIOSIDE; SIALIC-ACID; HUMAN-BRAIN; DEGRADATION; BINDING; GLYCOLIPIDS; SPECIFICITY; SULFATIDE	G(M2) activator protein is a protein cofactor that has been shown to stimulate the enzymatic hydrolysis of both GalNAc and NeuAc from G(M2) (Wu, Y. Y., Lockyer, J. M., Sugiyama, E., Pavlova, N.V., Li, Y.-T., and Li, S.-C. (1994) J. Biol. Chem. 269, 16276-16283). To understand the mechanism by which G(M2) activator stimulates the hydrolysis of G(M2), we examined the interaction of this activator protein with GM(2) as well as with other glycosphingolipids by TLC overlay and Sephacryl S-200 gel filtration. The TLC overlay analysis unveiled the binding specificity of G(M2) activator, which was not previously revealed. Under the conditions optimal for the activator protein to stimulate the hydrolysis of G(M2) by beta-hexosaminidase A, G(M2) activator was found to bind avidly to acidic glycosphingolipids, including gangliosides and sulfated glycosphingolipids, but not to neutral glycosphingolipids. The gangliosides devoid of sialic acids, such as asialo-G(M1) and asialo-G(M2), and the G(M2) derivatives whose carboxyl function in the NeuAc had been modified by methyl esterification or reduction, were only very weakly bound to G(M2) activator. These results indicate that the negatively charged sugar residue or sulfate group in gangliosides is one of the important sites recognized by G(M2) activator. For comparison, we also studied in parallel the complex formation between glycosphingolipids and saposin B, a separate activator protein with broad specificity to stimulate the hydrolysis of various glycosphingolipids. We found that saposin B bound to neutral glycosphingolipids and gan gliosides equally well, and there was an exceptionally strong binding to sulfatide. In contrast to previous reports, we found that G(M2) activator formed complexes with G(M2) and other gangliosides in different proportions depending on the ratio between the activator protein and the ganglioside in the incubation mixture prior to gel filtration. We were not able to detect the specific binding of G(M2) activator to G(M2) when G(M2) was mixed with G(M1) or G(M3). Thus, the specificity or the mode of action of G(M2) activator cannot be simply explained by its interaction with glycosphingolipids based on complex formation. The binding of G(M2) activator to a wide variety of negatively charged glycosphingolipids may indicate that this activator protein has functions other than assisting the enzymatic hydrolysis of G(M2).	TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112	Tulane University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 09626] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACQUOTTI D, 1994, EUR J BIOCHEM, V225, P271, DOI 10.1111/j.1432-1033.1994.00271.x; CANTU L, 1992, CHEM PHYS LIPIDS, V55, P223; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; FISCHER G, 1977, BIOCHIM BIOPHYS ACTA, V481, P561, DOI 10.1016/0005-2744(77)90288-1; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GEOGHEGAN KF, 1981, INT J PEPT PROT RES, V17, P345; HANDA S, 1984, J BIOCHEM-TOKYO, V95, P1323, DOI 10.1093/oxfordjournals.jbchem.a134738; HARRIS G, 1954, CHEM IND-LONDON, P249; HECHTMAN P, 1977, CAN J BIOCHEM CELL B, V55, P315, DOI 10.1139/o77-044; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; LI SC, 1995, J BIOL CHEM, V270, P24246, DOI 10.1074/jbc.270.41.24246; LI SC, 1984, J BIOL CHEM, V259, P5409; LI SC, 1988, J BIOL CHEM, V263, P6588; LI SC, 1981, J BIOL CHEM, V256, P6234; LI SC, 1976, J BIOL CHEM, V251, P1159; LI YT, 1973, J BIOL CHEM, V248, P7512; LI YT, 1984, LYSOSOM BIOL PATHOL, P99; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITSUYAMA T, 1983, J BIOCHEM-TOKYO, V98, P605; NAGARAJAN S, 1992, BIOCHEM J, V282, P807, DOI 10.1042/bj2820807; RADIN NS, 1972, METHOD ENZYMOL, V28, P300; Skipski V P, 1975, Methods Enzymol, V35, P396, DOI 10.1016/0076-6879(75)35178-1; SOEDA S, 1993, J BIOL CHEM, V268, P18519; SONNINO S, 1990, CHEM PHYS LIPIDS, V52, P231, DOI 10.1016/0009-3084(90)90119-C; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; SVENNERHOLM L, 1987, BIOCHIM BIOPHYS ACTA, V24, P601; TANG PW, 1985, BIOCHEM BIOPH RES CO, V132, P474, DOI 10.1016/0006-291X(85)91158-1; UDA Y, 1977, J BIOL CHEM, V252, P5194; VOGEL A, 1991, EUR J BIOCHEM, V200, P591, DOI 10.1111/j.1432-1033.1991.tb16222.x; WENGER DA, 1984, MOL BASIS LYSOSOMAL, P1; WU YY, 1994, J BIOL CHEM, V268, P16276; WYNN CH, 1986, BIOCHEM J, V240, P921, DOI 10.1042/bj2400921; ZHOU B, 1989, J BIOL CHEM, V264, P12272	37	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2828	2833		10.1074/jbc.272.5.2828	http://dx.doi.org/10.1074/jbc.272.5.2828			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006924	hybrid			2022-12-25	WOS:A1997WE66700037
J	Joaquin, M; Salvado, C; Bellosillo, B; Lange, AJ; Gil, J; Tauler, A				Joaquin, M; Salvado, C; Bellosillo, B; Lange, AJ; Gil, J; Tauler, A			Effect of growth factors on the expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in rat-1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE METABOLISM; CHICKEN-EMBRYO FIBROBLASTS; RAS-DEPENDENT ACTIVATION; LYSOPHOSPHATIDIC ACID; PROTEIN-KINASE; MAP KINASE; TRANSCRIPTIONAL ACTIVATION; PHORBOL ESTERS; MESSENGER-RNA	The activation of glycolytic flux is a biochemical characteristic of growing cells. Several reports have demonstrated the role of fructose 2,6-bisphosphate in this process. In this paper we show that the levels of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (6PF2K/Fru-2,6-P(2)ase) mRNA are modulated in response to serum and growth factors and this effect is due to regulation of its transcription rate. The modulation of the expression of this enzyme by growth factors differs according their mitogenic effect; both lysophosphatidic acid and epidermal growth factor, when added alone, increased the mRNA levels, but endothelin had no effect. Furthermore, cAMP, which acts as an antimitogenic signal in Rat-1 fibroblasts, produced a decrease in 6PF2K/ Fru-2,6-P(2)ase mRNA and inhibited the effects of lysophosphatidic acid and epidermal growth factor on 6PF2K/Fru-2,6-P(2)ase expression. PD 098059, a specific inhibitor of the activation of the mitogen-activated protein kinase, was able to prevent the effect of EGF on 6PF2K/Fru-2,6-P(2)ase gene expression. These results imply that activation of mitogen-activated protein kinase is required for the stimulation of the transcription of 6PF2K/Fru-2,6-P(2)ase by EGF.	UNIV BARCELONA,UNIT BIOQUIM,DEPT CIENCIES FISIOL HUMANES & NUTR,E-08028 BARCELONA,SPAIN; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Barcelona; University of Minnesota System; University of Minnesota Twin Cities			Joaquin, Manel/E-2216-2015; Tauler, Albert/D-5183-2014; Joaquin, Manel/O-6533-2019	Joaquin, Manel/0000-0001-8973-5916; Tauler, Albert/0000-0003-0193-0667; Joaquin, Manel/0000-0001-8973-5916; Gil, Joan/0000-0002-3686-3903				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUSEBEL FM, 1994, CURRENT PROTOCOLS MO; BAULIDA J, 1992, BIOCHEM BIOPH RES CO, V183, P1216, DOI 10.1016/S0006-291X(05)80320-1; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BOSCA L, 1985, P NATL ACAD SCI USA, V82, P6440, DOI 10.1073/pnas.82.19.6440; BOSCA L, 1986, BIOCHEM J, V236, P596; Bradford MM, 1976, ANAL BIOCHEM, V112, P195; BRUNI P, 1987, FEBS LETT, V222, P27, DOI 10.1016/0014-5793(87)80185-0; BRUNI P, 1986, BIOCHIM BIOPHYS ACTA, V887, P23, DOI 10.1016/0167-4889(86)90117-5; BRUNI P, 1983, FEBS LETT, V159, P39, DOI 10.1016/0014-5793(83)80412-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASCALES M, 1992, EUR J BIOCHEM, V207, P391, DOI 10.1111/j.1432-1033.1992.tb17062.x; COFFER P, 1994, ONCOGENE, V9, P911; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DALMAU M, 1994, EXP CELL RES, V212, P93, DOI 10.1006/excr.1994.1122; DARVILLE MI, 1995, ONCOGENE, V11, P1509; DARVILLE ML, 1988, P NATL ACAD SCI USA, V86, P6543; DENISPOUXVIEL C, 1990, BIOCHEM J, V268, P465, DOI 10.1042/bj2680465; DIAMOND I, 1978, J BIOL CHEM, V253, P866; DRIEDGER PE, 1977, CANCER RES, V37, P3257; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; GERLACH WL, 1979, NUCLEIC ACIDS RES, V7, P1869, DOI 10.1093/nar/7.7.1869; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAMER MJ, 1990, BIOCHEM J, V269, P685, DOI 10.1042/bj2690685; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; Joaquin M, 1996, BIOCHEM J, V314, P235, DOI 10.1042/bj3140235; KREBS EG, 1986, MECHANISM INSULIN AC, P13; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOJENA M, 1985, BIOCHEM J, V232, P521, DOI 10.1042/bj2320521; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; ROSA JL, 1990, BIOCHEM J, V270, P645, DOI 10.1042/bj2700645; ROUSSEAU GG, 1988, PROGR CANC RES THER, V35, P150; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P945, DOI 10.1101/SQB.1988.053.01.109; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER JA, 1979, J BIOL CHEM, V253, P872; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAULER A, 1988, P NATL ACAD SCI USA, V85, P6642, DOI 10.1073/pnas.85.18.6642; TAYLOR DJ, 1990, BIOCHEM J, V269, P573, DOI 10.1042/bj2690573; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANDIJCK P, 1993, MOL CELL BIOCHEM, V125, P127, DOI 10.1007/BF00936441; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	58	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2846	2851		10.1074/jbc.272.5.2846	http://dx.doi.org/10.1074/jbc.272.5.2846			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006927	Green Published, hybrid			2022-12-25	WOS:A1997WE66700040
J	Liao, YB; Yi, TL; Hoit, BD; Walsh, RA; Karnik, SS; Husain, A				Liao, YB; Yi, TL; Hoit, BD; Walsh, RA; Karnik, SS; Husain, A			Selective reporter expression in mast cells using a chymase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-FORMING CHYMASE; HUMAN HEART; SUBSTRATE-SPECIFICITY; HUMAN PROCHYMASE; CATHEPSIN-G; GENE; TRANSCRIPTION; GATA-2; RAT; DIFFERENTIATION	Primate alpha-chymases are mast cell neutral proteases that are involved in regulating several regulatory peptides including angiotensin II. Because of significant substrate specificity differences among the chymase group of enzymes, animal models that overexpress primate chymases are crucial for delineating the in vivo function of these enzymes. Activation of alpha-prochymase requires processing enzymes and proteoglycans found in mast cell secretory granules. Thus, the development of models overexpressing active primate chymase requires a mast cell-specific promoter. We show that the 571-base pair (bp) 5'-upstream sequence of the baboon chymase gene, which encodes an alpha-chymase, coupled to the prokaryotic lacZ gene allows the targeting of beta-galactosidase to mast cells in transgenic mice. Tissue expression of the transgene is similar to the expression of the endogenous mouse alpha-chymase mouse mast cell protease-5. A mouse mast cell line that endogenously expresses mouse mast cell protease-5 (JKras mast cells) also selectively supports the expression of this transgene. In vitro transcription studies in JKras mast cells shows the critical role of a GATA cis-regulatory motif in baboon chymase promoter, located similar to 430-bp upstream of the transcription start site. These results suggest that the 571-bp domain of the baboon chymase promoter contains most, if not all, of the mast cell-specific region of the promoter. We describe here for the first time a promoter that directs expression of transgenes specifically to mouse mast cells. This promoter should be generally applicable for dominant expression of mast cell regulatory proteins.	CLEVELAND CLIN FDN,RES INST,DEPT MOL CARDIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; UNIV CINCINNATI,MED CTR,DIV CARDIOL,CINCINNATI,OH 45267	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Cincinnati			Husain, Ahsan/J-6861-2012; Karnik, Sadashiva/Y-2477-2019	Husain, Ahsan/0000-0003-3426-3469; Karnik, Sadashiva/0000-0003-0746-2753	NHLBI NIH HHS [HL44201] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044201] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CAUGHEY GH, 1993, GENOMICS, V15, P614, DOI 10.1006/geno.1993.1115; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; CRAIG SS, 1989, LAB INVEST, V60, P147; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; HOIT BD, 1995, J CLIN INVEST, V95, P1519, DOI 10.1172/JCI117824; Itoh H, 1996, BIOCHEM J, V314, P923, DOI 10.1042/bj3140923; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; MURASAWA S, 1993, J BIOL CHEM, V268, P26996; ORKIN SH, 1992, BLOOD, V80, P5575; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sambrook J., 2002, MOL CLONING LAB MANU; Schwartz L.B, 1990, NEUTRAL PROTEASES MA; SCHWARTZ LB, 1993, MAST CELL HLTH DIS, P219; Springman E. B, 1995, MAST CELL PROTEASES, P169; TOLUNAY HE, 1984, MOL CELL BIOL, V4, P17, DOI 10.1128/MCB.4.1.17; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; URATA H, 1991, J BIOL CHEM, V266, P17173; URATA H, 1990, J BIOL CHEM, V265, P22348; URATA H, 1993, J BIOL CHEM, V268, P24318; URATA H, 1993, J CLIN INVEST, V91, P1269, DOI 10.1172/JCI116325; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; ZON LI, 1991, J BIOL CHEM, V266, P22948	33	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2969	2976		10.1074/jbc.272.5.2969	http://dx.doi.org/10.1074/jbc.272.5.2969			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006944	hybrid			2022-12-25	WOS:A1997WE66700057
J	PijuanThompson, V; Gladson, CL				PijuanThompson, V; Gladson, CL			Ligation of integrin alpha(5)beta(1) is required for internalization of vitronectin by integrin alpha(v)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; FIBRONECTIN RECEPTOR; ALPHA-V-BETA-3 INTEGRIN; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; CYTOPLASMIC TAIL; GENE-EXPRESSION; GROWTH-FACTOR; IN-VITRO; ADHESION	Remodeling of the matrix by tumor cells is necessary for tumor invasion. We have shown previously that malignant astrocytomas, in contrast to normal astrocytes, synthesize vitronectin and express integrins alpha(v) beta(3) and alpha(v) beta(5). The activity states of these two integrins are differentially controlled. Thus, we investigated the regulation of the activity of integrins alpha(v) beta(3) and alpha(v) beta(5) with regard to their role in vitronectin internalization in U-251MG astrocytoma cell monolayers adherent to fibronectin, collagen, or laminin in serum-free conditions. Binding of [I-125]vitronectin occurred in a specific, saturable manner that was partially inhibitable by monoclonal antibodies (mAbs) specific for integrins alpha(v) beta(3) or alpha(v) beta(5). Specific, lysosomally-mediated degradation of [I-125]vitronectin was detectable at 1 h and increased over the 24 h assay period. The cell substrate affected the rate of turnover of [I-125]vitronectin, which was 3.0 ng/min for cells plated on fibronectin but 0.35 ng/min for cells plated on collagen. Furthermore, although mAbs specific for either integrin alpha(v) beta(3) or alpha(v) beta(5) inhibited degradation (30%; combined effect 70%) of [I-125]vitronectin by cells plated on fibronectin, only mAb anti-alpha(v) beta(5) inhibited degradation (70-90%) by cells plated on collagen or laminin. To determine the requirement for integrin alpha(5) beta(1) ligation in order for integrin alpha(v) beta(3) to internalize its ligand, cells were plated on mAbs anti-integrin alpha(5) or anti-integrin alpha(3). When plated on mAb anti-alpha(5), mAbs anti-alpha(v) beta(3), and anti-alpha(v) beta(5) both inhibited degradation. However, when plated on mAb anti-alpha(3), mAb anti-alpha(v) beta(3) had no effect whereas mAb anti-alpha(v) beta(5) inhibited degradation. These data indicate that a signal from integrin alpha(5) beta(1) is necessary for integrain alpha(v) beta(3) to internalize vitronectin, whereas integrin alpha(v) beta(5) constitutively internalizes vitronectin.	UNIV ALABAMA,DEPT PATHOL,DIV NEUROPATHOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA59958] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059958] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONFORTI G, 1994, CELL ADHES COMMUN, V1, P279, DOI 10.3109/15419069409097260; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; FAULL RJ, 1995, STEM CELLS, V13, P38, DOI 10.1002/stem.5530130106; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLADSON CL, 1995, J CELL SCI, V108, P947; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GLADSON CL, 1994, INTEGRINS BIOL PROBL, P83; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PANETTI TS, 1995, J BIOL CHEM, V270, P18593, DOI 10.1074/jbc.270.31.18593; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; SCHRAPPE M, 1991, CANCER RES, V51, P4986; SEPP NT, 1994, J INVEST DERMATOL, V103, P295, DOI 10.1111/1523-1747.ep12394617; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	35	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2736	2743		10.1074/jbc.272.5.2736	http://dx.doi.org/10.1074/jbc.272.5.2736			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006912	hybrid			2022-12-25	WOS:A1997WE66700025
J	Roche, E; AssimacopoulosJeannet, F; Witters, LA; Perruchoud, B; Yaney, G; Corkey, B; Asfari, M; Prentki, M				Roche, E; AssimacopoulosJeannet, F; Witters, LA; Perruchoud, B; Yaney, G; Corkey, B; Asfari, M; Prentki, M			Induction by glucose of genes coding for glycolytic enzymes in a pancreatic beta-cell line (INS-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; INDUCED INSULIN RELEASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TRANSCRIPTIONAL CONTROL; TRANSPORTER ISOFORMS; DEPENDENT REGULATION; TRANSGENIC MICE; ISOLATED ISLETS; MESSENGER-RNA; EXPRESSION	Chronic elevation in glucose has pleiotropic effects on the pancreatic beta-cell including a high rate of insulin secretion at low glucose, beta-cell hypertrophy, and hyperplasia. These actions of glucose are expected to be associated with the modulation of the expression of a number of glucose-regulated genes that need to be identified. To further investigate the molecular mechanisms implicated in these adaptation processes to hyperglycemia, we have studied the regulation of genes encoding key glycolytic enzymes in the glucose-responsive beta-cell line INS-1. Glucose (from 5 to 25 mM) induced phosphofructokinase-1 (PFK-1) isoform C, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (4-fold), and L-pyruvate kinase (L-PR) (7-fold) mRNAs. In contrast the expression level of the glucokinase (Gk) and 6-phosphofructo-2-kinase transcripts remained unchanged. Following a 3-day exposure to elevated glucose, a similar induction was observed at the protein level for PFK-1 (isoforms C, M, and L), GAPDH, and L-PK, whereas M-PR expression only increased slightly. The study of the mechanism of GAPDH induction indicated that glucose increased the transcriptional rate of the GAPDH gene but that both transcriptional and post transcriptional effects contributed to GAPDH mRNA accumulation, 2-Deoxyglucose did not mimic the inductive effect of glucose, suggesting that increased glucose metabolism is involved in GAPDH gene induction. These changes in glycolytic enzyme expression were associated with a 2-3-fold increase in insulin secretion at low (25 mM) glucose. The metabolic activity of the cells was also elevated, as indicated by the reduction of the artificial electron acceptor 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium. A marked deposition of glycogen, which was readily mobilized upon lowering of the ambient glucose, and increased DNA replication were also observed in cells exposed to elevated glucose. The results suggest that a coordinated induction of key glycolytic enzymes as well as massive glycogen deposition are implicated in the adaptation process of the beta-cell to hyperglycemia to allow for chronically elevated glucose metabolism, which, in this particular fuel-sensitive cell, is linked to metabolic coupling factor production and cell activation.	UNIV MONTREAL, DEPT NUTR, MOL NUTR UNIT, MONTREAL, PQ H3C 3J7, CANADA; UNIV GENEVA, CTR MED, DEPT BIOCHIM MED, CH-1121 GENEVA 4, SWITZERLAND; DARTMOUTH COLL SCH MED, DEPT MED, HANOVER, NH 03755 USA; DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; BOSTON UNIV, MED CTR, DIABET & METAB UNIT, BOSTON, MA USA; HOP ROBERT DEBRE, INSERM, CJF 9313, F-75019 PARIS, FRANCE	Universite de Montreal; University of Geneva; Dartmouth College; Dartmouth College; Boston University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035914, R37DK035914, R56DK035914, R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35712, DK35914] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASFARI M, 1995, DIABETOLOGIA, V38, P927, DOI 10.1007/s001250050373; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; BRUN T, 1993, J BIOL CHEM, V268, P18905; BURCH PT, 1981, DIABETES, V30, P923, DOI 10.2337/diabetes.30.11.923; CARTIER N, 1992, ONCOGENE, V7, P1413; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; DUKES ID, 1994, J BIOL CHEM, V269, P10979; DUNAWAY GA, 1988, BIOCHEM J, V251, P677, DOI 10.1042/bj2510677; DUNAWAY GA, 1987, BIOCHEM J, V242, P667, DOI 10.1042/bj2420667; EFRAT S, 1994, TRENDS BIOCHEM SCI, V19, P535, DOI 10.1016/0968-0004(94)90056-6; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; FERRER J, 1993, DIABETES, V42, P1273, DOI 10.2337/diabetes.42.9.1273; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; HELLMAN B, 1969, ENDOCRINOLOGY, V84, P1; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; JANJIC D, 1992, DIABETOLOGIA, V35, P482, DOI 10.1007/BF02342448; KLIP A, 1992, DIABETES CARE, V15, P1747, DOI 10.2337/diacare.15.11.1747; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; LIANG Y, 1994, ANNU REV NUTR, V14, P59, DOI 10.1146/annurev.nu.14.070194.000423; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MACDONALD MJ, 1995, DIABETOLOGIA, V38, P125, DOI 10.1007/BF02369367; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P194, DOI 10.1016/0003-9861(89)90100-8; MACDONALD MJ, 1985, MOL CELL BIOCHEM, V68, P115; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MALAISSE WJ, 1976, J BIOL CHEM, V251, P1731; MARIE S, 1993, J BIOL CHEM, V268, P23881; MARYNISSEN G, 1990, METABOLISM, V39, P87, DOI 10.1016/0026-0495(90)90153-4; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MCGARRY JD, 1994, J CELL BIOCHEM, V55, P29, DOI 10.1002/jcb.240550005; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MELLOUL D, 1994, DIABETOLOGIA, V37, pS3, DOI 10.1007/BF00400820; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MHASKAR Y, 1995, DEV BRAIN RES, V85, P54, DOI 10.1016/0165-3806(94)00190-B; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PHILIPPE J, 1991, ENDOCR REV, V12, P252, DOI 10.1210/edrv-12-3-252; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; PURRELLO F, 1993, DIABETES, V42, P199, DOI 10.2337/diabetes.42.1.199; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; SALAS J, 1965, J BIOL CHEM, V240, P1014; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; TAL M, 1992, J BIOL CHEM, V267, P17241; TIEDGE M, 1991, BIOCHEM J, V279, P899, DOI 10.1042/bj2790899; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; TURK J, 1993, DIABETES, V42, P367, DOI 10.2337/diabetes.42.3.367; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; VANSCHAFTINGEN E, 1993, DIABETOLOGIA, V36, P581, DOI 10.1007/BF00404065; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WAEBER G, 1994, J BIOL CHEM, V269, P26912; WERLEN G, 1993, J BIOL CHEM, V268, P16596; YANEY GC, 1995, DIABETES, V44, P1285, DOI 10.2337/diabetes.44.11.1285; YASUDA K, 1992, DIABETES, V41, P76, DOI 10.2337/diabetes.41.1.76; YIN L, 1992, DIABETES, V41, P792; ZAWALICH WS, 1995, DIABETOLOGIA, V38, P986, DOI 10.1007/s001250050382; Zhou YP, 1996, DIABETES, V45, P580, DOI 10.2337/diabetes.45.5.580	80	108	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3091	3098		10.1074/jbc.272.5.3091	http://dx.doi.org/10.1074/jbc.272.5.3091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006960	hybrid			2022-12-25	WOS:A1997WE66700073
J	Barr, AJ; Brass, LF; Manning, DR				Barr, AJ; Brass, LF; Manning, DR			Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells - A direct evaluation of selectivity in receptor center dot G protein coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C ISOZYMES; G-ALPHA-SUBUNITS; HUMAN-PLATELETS; ADENYLATE-CYCLASE; RAT HIPPOCAMPUS; GAMMA-SUBUNITS; BETA-GAMMA; EXPRESSION; THROMBIN; PURIFICATION	The selectivity in coupling of various receptors to GTP-binding regulatory proteins (G proteins) was examined directly by a novel assay entailing the use of proteins overexpressed in Spodoptera frugiperda (Sf9) cells, Activation of G proteins was monitored in membranes prepared from Sf9 cells co-expressing selected pairs of receptors and G proteins (i.e. alpha, beta(1), and gamma(2) subunits), Membranes were incubated with [S-35]guanosine 5'-(3-O-thio)triphosphate (GTP gamma S) +/- an agonist, and the amount of radiolabel bound to the (alpha subunit was quantitated following immunoprecipitation. When expressed without receptor (but with beta(1) gamma(2)), the G protein subunits alpha(z), alpha(12), and alpha(13) did not bind appreciable levels of [S-35]GTP gamma S consistent with a minimal level of GDP/[S-35]GTP gamma S exchange. In contrast, the subunits alpha(s) and alpha(q) bound measurable levels of the nucleotide, Co-expression of the 5-hydroxytryptamine(1A) (5-HT1A) receptor promoted binding of [S-35]GTP gamma S to alpha(z) but not to alpha(12), alpha(13), or alpha(s). Binding to alpha(z) was enhanced by inclusion of serotonin in the assay, Agonist activation of both thrombin and neurokinin-l receptors promoted a modest increase in [S-35]GTP gamma S binding to alpha(z) and more robust increases in binding to alpha(q), alpha(12), and alpha(13). Binding of [S-35]GTP gamma S to alpha(s) was strongly enhanced only by the activated beta(1)-adrenergic receptor, Our data identify interactions of receptors and G proteins directly, without resort to measurements of effector activity, confirm the coupling of the 5-HT1A receptor to G(z) and extend the list of receptors that interact with this unique G protein to the receptors for thrombin and substance P, imply constitutive activity for the 5-HT1A receptor, and demonstrate for the first time that the cloned receptors for thrombin and substance P activate G(12) and G(13).	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania				Barr, Alastair/0000-0001-7738-8419	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH048125] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45181] Funding Source: Medline; NIGMS NIH HHS [GM51196] Funding Source: Medline; NIMH NIH HHS [MH48125] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; COSTA T, 1992, MOL PHARMACOL, V41, P549; COUGHLIN SR, 1994, SEMIN HEMATOL, V31, P270; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; INNIS RB, 1987, EUR J PHARMACOL, V143, P195, DOI 10.1016/0014-2999(87)90533-4; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LANIYONU A, 1988, FEBS LETT, V240, P186, DOI 10.1016/0014-5793(88)80365-X; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LUTHIN DR, 1993, J BIOL CHEM, V268, P5990; MARKSTEIN R, 1986, N-S ARCH PHARMACOL, V333, P335, DOI 10.1007/BF00500006; MATESIC DF, 1989, J BIOL CHEM, V264, P21638; MAZINA KE, 1994, J RECEPTOR RES, V14, P63, DOI 10.3109/10799899409066997; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RAYMOND JR, 1992, N-S ARCH PHARMACOL, V346, P127, DOI 10.1007/BF00165293; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SHENKER A, 1987, MOL PHARMACOL, V31, P357; SINGER WD, 1994, J BIOL CHEM, V269, P19796; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; SUN XP, 1993, AM J PHYSIOL, V264, pG774, DOI 10.1152/ajpgi.1993.264.4.G774; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WANG HY, 1993, J PHARMACOL EXP THER, V267, P1002; WANGE RL, 1991, J BIOL CHEM, V266, P11409; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZGOMBICK JM, 1989, MOL PHARMACOL, V35, P484	47	162	164	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2223	2229						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999927				2022-12-25	WOS:A1997WD67900033
J	Uren, A; Yu, JC; Karcaaltincaba, M; Pierce, JH; Heidaran, MA				Uren, A; Yu, JC; Karcaaltincaba, M; Pierce, JH; Heidaran, MA			Oncogenic activation of the alpha PDGFR defines a domain that negatively regulates receptor dimerization	ONCOGENE			English	Article						PDGFR; dimerization; tyrosine kinase; transformation	GROWTH-FACTOR RECEPTORS; FMS PROTO-ONCOGENE; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; LIGAND-BINDING; MONOCLONAL-ANTIBODY; POINT MUTATION; BB BINDING; AA; EXPRESSION	The alpha platelet derived growth factor receptor (alpha PDGFR) extracellular Immunoglobulin (Ig) like domains 1-3 contain major determinants for ligand interaction. We now report that a deletion of Ig-like loop 3, but not Ig-like loop 1 or 2, of the alpha PDGFR causes ligandindependent transformation in NIH3T3 cells. Biochemical analyses of alpha PDGFR mutants lacking Ig-like loop 3 indicate that cellular transformation is mediated by ligand-independent activation of the alpha PDGFR tyrosine kinase activity as determined by receptor autophosphorylation both in vivo and in vitro. Moreover, crosslinking analysis of alpha PDGFR mutants expressed ectopically in NIH3T3 cells indicate that deletion within extracellular domain 3 leads to ligand-independent receptor dimerization. All of these findings suggest that the Ig-like loop 3 of the alpha PDGFR contains the major determinants which inhibit receptor dimerization in the quiescent cells and that the ligand binding induces receptor activation by neutralizing the inhibitory effect of this domain.	NCI,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Karcaaltincaba, Musturay/A-3866-2016	Karcaaltincaba, Musturay/0000-0002-3384-0909				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; FLEMING TP, 1992, ONCOGENE, V7, P1355; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J BIOL CHEM, V269, P10668	25	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					157	162		10.1038/sj.onc.1200810	http://dx.doi.org/10.1038/sj.onc.1200810			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010217				2022-12-25	WOS:A1997WC81800003
J	Kunicki, TJ; Annis, DS; FeldingHabermann, B				Kunicki, TJ; Annis, DS; FeldingHabermann, B			Molecular determinants of Arg-Gly-Asp ligand specificity for beta(3) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; CELL-ADHESION; VITRONECTIN RECEPTOR; VONWILLEBRAND-FACTOR; ATTACHMENT; ANTIBODY; BINDING; ALPHA-V-BETA-3; ALPHA-5-BETA-1; FIBRONECTIN	The Arg-Tyr-Asp (RYD) and Arg-Gly-Asp (RGD) sequences within the third complementarity-determining region of the heavy chain (H3) of murine recombinant Feb molecules OPG2 and AP7, respectively, are responsible for their specific binding to the platelet integrin alpha(IIb)beta(3). In this study, we evaluated the influence of divalent cation composition and single amino acid substitutions at key positions within H3 on the selectivity of these Fab molecules for integrin alpha(IIb)beta(3) versus the vitronectin receptor alpha(v) beta(3). The parent Fab molecule OPG2 (H3 sequence, HPFYRYDGGN) binds selectively to alpha(IIb)beta(3) and not at all to any other RGD-cognitive integrin, particularly alpha(IIb)beta(3), under any divalent cation conditions. The binding of the AP7 Fab molecule (HPFYRGDGGN) to alpha(IIb)beta(3) is not affected by the relative composition of calcium, magnesium or manganese. However, AP7 binding to alpha(v) beta(3), either expressed by M21 cells or as the purified integrin, is supported by manganese and inhibited by calcium. If the flanking asparagine 108 residue within the AP7 H3 loop is replaced by alanine (HPFYRGDGGA), the resulting Fab molecule AP7.4 binds selectively to alpha(v) beta(3) in a cation-dependent manner, but does not bind at all to alpha(IIb)beta(3) under any conditions. AP7.4 binding to alpha(IIb)beta(3) is supported by manganese, completely inhibited by calcium, and largely unaffected by magnesium. This behavior mimics that of the adhesive protein, osteopontin, another ligand that binds preferentially to alpha(v) beta(3). Despite these differences in specificity for alpha(IIb)beta(3) and alpha(v) beta(3), AP7 and AP7.4 remain selective for the beta(3) integrins and do not bind to cell lines that express the RGD-cognitive integrins alpha(v) beta(5) or alpha(5) beta(1). These results confirm that subtle changes in the amino acid composition immediately flanking the RGD or RYD moths can have a profound effect on beta(3) integrin specificity, most likely because they influence the juxtaposition of the arginine and aspartate side chains within the extended RGD loop sequence.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Kunicki, TJ (corresponding author), Scripps Res Inst, DEPT MOL & EXPT MED, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA-67988] Funding Source: Medline; NHLBI NIH HHS [HL-46979] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA067988] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046979] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FURIHATA K, 1987, J CLIN INVEST, V80, P1624, DOI 10.1172/JCI113250; HONDA S, 1995, LEUCOCYTE TYPING, V2, P1293; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; KIMICKI TJ, 1996, J BIOL CHEM, V271, P20315; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; NURDEN AT, 1986, BIOCH PLATELETS, P160; PFAFF M, 1994, J BIOL CHEM, V269, P20233; PFAFF M, 1994, CELL ADHES COMMUN, V2, P491, DOI 10.3109/15419069409014213; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1994, J BIOL CHEM, V269, P960; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919	32	20	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4103	4107		10.1074/jbc.272.7.4103	http://dx.doi.org/10.1074/jbc.272.7.4103			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020120	hybrid			2022-12-25	WOS:A1997WH01900036
J	Pendas, AM; Knauper, V; Puente, XS; Llano, E; Mattei, MG; Apte, S; Murphy, G; LopezOtin, C				Pendas, AM; Knauper, V; Puente, XS; Llano, E; Mattei, MG; Apte, S; Murphy, G; LopezOtin, C			Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN SUBSTRATE-SPECIFICITY; HUMAN NEUTROPHIL COLLAGENASE; IN-SITU HYBRIDIZATION; IV COLLAGENASE; FIBROBLAST COLLAGENASE; HUMAN STROMELYSIN-3; BREAST CARCINOMAS; SEQUENCE-ANALYSIS; CLEAVAGE SITES; STROMAL CELLS	We have cloned a novel member of the matrix metalloproteinase (MMP) family of proteins from a human liver cDNA library, The isolated cDNA contains an open reading frame coding for a polypeptide of 508 amino acids, which has been tentatively called MMP-19. This protein exhibits the domain structure characteristic of previously described MMPs, including a signal sequence, a prodomain with the cysteine residue essential for maintaining the latency of these enzymes, an activation locus with the zinc-binding site, and a COOH-terminal fragment with sequence similarity to hemopexin. However, it lacks a series of structural features distinctive of the diverse MMP subclasses, including the Asp, Tyr, and Gly residues located close to the zinc-binding site in collagenases, the fibronectin-like domain of gelatinases, the transmembrane domain of membrane-type (MT) MMPs, and the furin-activation sequence common to stromelysin-3 and MT-MMPs, In addition, the 9-residue insertion rich in hydrophobic amino acids present at the hinge region in stromelysins is replaced in MMP-19 by a longer insertion very rich in acidic residues. On the basis of these structural characteristics, we propose that MMP-19 does not belong to any of the previously defined MMP-subclasses and may represent the first member of a new MMP subfamily. Chromosomal location of the MMP-19 gene revealed that it maps to chromosome 12q14, which is also a unique location for any MMPs mapped to date. The cDNA encoding a full-length MMP-19 was expressed in Escherichia coli, and after purification and refolding, the recombinant protein was able to degrade synthetic substrates for MMPs. MMP-19 proteolytic activity was abolished by TIMP-2 and EDTA, thus providing additional evidence that the isolated cDNA codes for an authentic MMP. Northern blot analysis of polyadenylated RNAs isolated from a variety of human tissues revealed that MMP-19 is mainly expressed in placenta, lung, pancreas, ovary, spleen, and intestine, suggesting that it may play a specialized role in these tissues.	UNIV OVIEDO,FAC MED,DEPT BIOQUIM & BIOL MOL,E-33006 OVIEDO,SPAIN; STRANGEWAYS RES LAB,DEPT CELL & MOL BIOL,CAMBRIDGE CB1 4RN,ENGLAND; HOP ENFANTS LA TIMONE,INSERM U406,F-13385 MARSEILLE,FRANCE; CLEVELAND CLIN FDN,DEPT BIOMED ENGN,CLEVELAND,OH 44195	University of Oviedo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Cleveland Clinic Foundation			Llano, Elena/K-1723-2014; Pendas, Alberto M/L-1017-2014; López-Otín, Carlos/AAB-2106-2020; Puente, Xosé S./ADB-0672-2022; Llano, Elena/AAS-5517-2021	Llano, Elena/0000-0002-2626-5723; López-Otín, Carlos/0000-0001-6964-1904; Puente, Xosé S./0000-0001-9525-1483; Llano, Elena/0000-0002-2626-5723; Knauper, Vera/0000-0002-3965-9924; Mattei, Marie-Genevieve/0000-0002-6027-7058; Pendas, Alberto M/0000-0001-9264-3721	NIAMS NIH HHS [AR43386] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEVY A, 1992, GENOMICS, V13, P881, DOI 10.1016/0888-7543(92)90175-R; Maniatis T., 1982, MOL CLONING; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MAST AE, 1991, J BIOL CHEM, V266, P15810; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MIGNON C, 1995, GENOMICS, V28, P360, DOI 10.1006/geno.1995.1159; MITCHELL TI, 1993, BIOCHIM BIOPHYS ACTA, V1156, P245, DOI 10.1016/0304-4165(93)90038-A; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1994, J BIOL CHEM, V269, P6632; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; PENDAS AM, 1994, CYTOGENET CELL GENET, V66, P263, DOI 10.1159/000133708; PENDAS AM, 1994, CYTOGENET CELL GENET, V67, P31, DOI 10.1159/000133792; PENDAS AM, 1995, GENOMICS, V26, P615, DOI 10.1016/0888-7543(95)80186-P; Pendas AM, 1996, GENOMICS, V37, P266, DOI 10.1006/geno.1996.0557; Puente XS, 1996, CANCER RES, V56, P944; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STJEAN PL, 1995, ANN HUM GENET, V59, P17; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	53	168	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4281	4286		10.1074/jbc.272.7.4281	http://dx.doi.org/10.1074/jbc.272.7.4281			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020145	hybrid			2022-12-25	WOS:A1997WH01900061
J	Vaandrager, AB; Tilly, BC; Smolenski, A; SchneiderRasp, S; Bot, AGM; Edixhoven, M; Scholte, BJ; Jarchau, T; Walter, U; Lohmann, SM; Poller, WC; deJonge, HR				Vaandrager, AB; Tilly, BC; Smolenski, A; SchneiderRasp, S; Bot, AGM; Edixhoven, M; Scholte, BJ; Jarchau, T; Walter, U; Lohmann, SM; Poller, WC; deJonge, HR			cGMP stimulation of cystic fibrosis transmembrane conductance regulator Cl- channels co-expressed with cGMP-dependent protein kinase type II but not type I beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE ENTEROTOXIN; INTESTINAL ELECTROLYTE TRANSPORT; CYCLIC-GMP; DIARRHEAL DISEASE; CHLORIDE CHANNELS; GUANYLYL CYCLASE; CELL-LINE; ACTIVATION; RAT; CLONING	In order to investigate the involvement of cGMP-dependent protein kinase (cGK) type II in cGMP-provoked intestinal Cl- secretion, cGMP-dependent activation and phosphorylation of cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channels was analyzed after expression of cGK II or cGK I beta in intact cells. An intestinal cell line which stably expresses CFTR (IEC-CF7) but contains no detectable endogenous cGK II was infected with a recombinant adenoviral vector containing the cGK II coding region (Ad-cGK II) resulting in co-expression of active cGK II. In these cells, CFTR was activated by membrane-permeant analogs of cGMP or by the cGMP-elevating hormone atrial natriuretic peptide as measured by I-125(-) efflux assays and whole-cell patch clamp analysis. In contrast, infection with recombinant adenoviruses expressing cGK I beta or luciferase did not convey cGMP sensitivity to CFTR in IEC-CF7 cells. Concordant with the activation of CFTR by only cGK II, infection with Ad-cGK II but not Ad-cGK I beta enabled cGMP analogs to increase CFTR phosphorylation in intact cells. These and other data provide evidence that endogenous cGK II is a key mediator of cGMP-provoked activation of CFTR in cells where both proteins are co-localized, e.g. intestinal epithelial cells. Furthermore, they demonstrate that neither the soluble cGK I beta nor cAMP-dependent protein kinase are able to substitute for cGK II in this cGMP-regulated function.	ERASMUS UNIV ROTTERDAM,FAC MED & HLTH SCI,DEPT CLIN GENET,NL-3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,FAC MED & HLTH SCI,DEPT BIOCHEM,CARDIOVASC RES INST,COEUR,NL-3000 DR ROTTERDAM,NETHERLANDS; MED UNIV CLIN WURZBURG,LAB CLIN BIOCHEM,D-97080 WURZBURG,GERMANY	Erasmus University Rotterdam; Erasmus University Rotterdam; University of Wurzburg			Walter, ulrich/W-2478-2017; Poller, Wolfgang/AAB-2185-2021	Walter, ulrich/0000-0001-6784-2307; Poller, Wolfgang/0000-0002-2805-6634; Vaandrager, Arie/0000-0001-9394-9239; Smolenski, Albert/0000-0001-9210-9406				BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; BIJMAN J, 1993, AM J PHYSIOL, V264, pL229, DOI 10.1152/ajplung.1993.264.3.L229; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; DONG YJ, 1995, EMBO J, V14, P2700, DOI 10.1002/j.1460-2075.1995.tb07270.x; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; FIELD M, 1989, NEW ENGL J MED, V321, P879; FIELD M, 1989, NEW ENGL J MED, V321, P800; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; FORTE LR, 1995, FASEB J, V9, P643, DOI 10.1096/fasebj.9.8.7768356; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; Gambaryan S, 1996, J CLIN INVEST, V98, P662, DOI 10.1172/JCI118837; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KELLEY TJ, 1995, PEDIATR PULM, V12, P184; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Poller W, 1996, GENE THER, V3, P521; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; TIEN XY, 1994, J BIOL CHEM, V269, P51; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager A B, 1994, Adv Pharmacol, V26, P253, DOI 10.1016/S1054-3589(08)60057-5; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; VAANDRAGER AB, 1991, AM J PHYSIOL, V261, pG958, DOI 10.1152/ajpgi.1991.261.6.G958; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; WOLFE L, 1989, J BIOL CHEM, V264, P7734	34	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4195	4200		10.1074/jbc.272.7.4195	http://dx.doi.org/10.1074/jbc.272.7.4195			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020133	hybrid, Green Published			2022-12-25	WOS:A1997WH01900049
J	Bakker, BM; Michels, PAM; Opperdoes, FR; Westerhoff, HV				Bakker, BM; Michels, PAM; Opperdoes, FR; Westerhoff, HV			Glycolysis in bloodstream form Trypanosoma brucei can be understood in terms of the kinetics of the glycolytic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORM; FRUCTOSE-BISPHOSPHATE ALDOLASE; METABOLIC CONTROL ANALYSIS; PYRUVATE-KINASE; SIMULTANEOUS PURIFICATION; SACCHAROMYCES-CEREVISIAE; CARBOHYDRATE-METABOLISM; PLASMA-MEMBRANE; RABBIT MUSCLE; PHOSPHOFRUCTOKINASE	In trypanosomes the first part of glycolysis takes place in specialized microbodies, the glycosomes. Most glycolytic enzymes of Trypanosoma brucei have been purified and characterized kinetically. In this paper a mathematical model of glycolysis in the bloodstream form of this organism is developed on the basis of all available kinetic data. The fluxes and the cytosolic metabolite concentrations as predicted by the model were in accordance with available data as measured in non-growing trypanosomes, both under aerobic and under anaerobic conditions. The model also reproduced the inhibition of anaerobic glycolysis by glycerol, although the amount of glycerol needed to inhibit glycolysis completely was lower than experimentally determined. At low extracellular glucose concentrations the intracellular glucose concentration remained very low, and only at 5 mM of extracellular glucose, free glucose started to accumulate intracellularly, in close agreement with experimental observations. This biphasic relation could be related to the large difference between the affinities of the glucose transporter and hexokinase for intracellular glucose. The calculated intraglycosomal metabolite concentrations demonstrated that enzymes that have been shown to be near-equilibrium in the cytosol must work far from equilibrium in the glycosome in order to maintain the high glycolytic flux in the latter.	VRIJE UNIV AMSTERDAM, BIOCENTRUM AMSTERDAM, NL-1081 HV AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EC SLATER INST BIOCHEM RES, BIOCENTRUM AMSTERDAM, NL-1018 TV AMSTERDAM, NETHERLANDS; UNIV CATHOLIQUE LOUVAIN, INT INST CELLULAR & MOL PATHOL, TROP DIS RES UNIT, B-1200 BRUSSELS, BELGIUM; UNIV CATHOLIQUE LOUVAIN, BIOCHEM LAB, B-1200 BRUSSELS, BELGIUM	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Universite Catholique Louvain; Universite Catholique Louvain			Opperdoes, Frederik R/C-8897-2018; Opperdoes, Fred/N-9922-2019; Michels, Paul A/A-5637-2009; Westerhoff, Hans V/I-5762-2012	Opperdoes, Frederik R/0000-0003-1984-3764; Opperdoes, Fred/0000-0003-1984-3764; Michels, Paul A/0000-0003-3726-6104; Westerhoff, Hans V/0000-0002-0443-6114; Bakker, Barbara/0000-0001-6274-3633				Bakker BM, 1995, J BIOENERG BIOMEMBR, V27, P513, DOI 10.1007/BF02110191; BERGMEYER HU, 1974, METHODS ENZYMATIC AN, V1; CALLENS M, 1991, MOL BIOCHEM PARASIT, V47, P19, DOI 10.1016/0166-6851(91)90144-U; CALLENS M, 1991, MOL BIOCHEM PARASIT, V47, P1, DOI 10.1016/0166-6851(91)90142-S; CALLENS M, 1992, MOL BIOCHEM PARASIT, V50, P235, DOI 10.1016/0166-6851(92)90220-E; CORTASSA S, 1994, ENZYME MICROB TECH, V16, P761, DOI 10.1016/0141-0229(94)90033-7; CRONIN CN, 1985, BIOCHEM J, V227, P113, DOI 10.1042/bj2270113; CRONIN CN, 1987, BIOCHEM J, V245, P13, DOI 10.1042/bj2450013; EASTERBY JS, 1981, BIOCHEM J, V199, P155, DOI 10.1042/bj1990155; EISENTHAL R, 1989, BIOCHIM BIOPHYS ACTA, V985, P81, DOI 10.1016/0005-2736(89)90107-7; FAIRLAMB AH, 1977, NATURE, V265, P270, DOI 10.1038/265270a0; FAIRLAMB AH, 1977, EXP PARASITOL, V43, P353, DOI 10.1016/0014-4894(77)90040-6; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GALAZZO JL, 1990, ENZYME MICROB TECH, V12, P162, DOI 10.1016/0141-0229(90)90033-M; GARFINKEL D, 1968, COMPUT BIOMED RES, V2, P68, DOI 10.1016/0010-4809(68)90009-8; HAMMOND DJ, 1980, MOL BIOCHEM PARASIT, V2, P77, DOI 10.1016/0166-6851(80)90033-X; HAMMOND DJ, 1985, J BIOL CHEM, V260, P5646; HANNAERT V, 1994, J BIOENERG BIOMEMBR, V26, P205, DOI 10.1007/BF00763069; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KIAIRA JK, 1994, BIOTECHNOL APPL BIOC, V20, P347, DOI 10.1111/j.1470-8744.1994.tb00322.x; LAMBEIR AM, 1987, EUR J BIOCHEM, V168, P69, DOI 10.1111/j.1432-1033.1987.tb13388.x; LAMBEIR AM, 1991, EUR J BIOCHEM, V198, P429, DOI 10.1111/j.1432-1033.1991.tb16032.x; MARCHAND M, 1989, EUR J BIOCHEM, V184, P455, DOI 10.1111/j.1432-1033.1989.tb15038.x; MICHELS PAM, 1994, J BIOENERG BIOMEMBR, V26, P213, DOI 10.1007/BF00763070; MICHELS PAM, 1988, BIOL CELL, V64, P157, DOI 10.1016/0248-4900(88)90075-5; MISSET O, 1984, EUR J BIOCHEM, V144, P475, DOI 10.1111/j.1432-1033.1984.tb08490.x; MISSET O, 1987, EUR J BIOCHEM, V162, P493, DOI 10.1111/j.1432-1033.1987.tb10667.x; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; NOLAN DP, 1991, EUR J BIOCHEM, V202, P411, DOI 10.1111/j.1432-1033.1991.tb16390.x; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; NWAGWU M, 1982, ACTA TROP, V39, P61; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; RAPOPORT TA, 1974, EUR J BIOCHEM, V42, P107, DOI 10.1111/j.1432-1033.1974.tb03320.x; Rohwer JM, 1996, J THEOR BIOL, V179, P213, DOI 10.1006/jtbi.1996.0062; SAURO HM, 1991, MATH COMPUT MODEL, V15, P15, DOI 10.1016/0895-7177(91)90038-9; SCHUSTER S, 1993, BIOPHYS CHEM, V48, P1, DOI 10.1016/0301-4622(93)80037-J; SEGEL IH, 1975, ENZYME KINETICS, P544; Stein WD, 1986, TRANSPORT DIFFUSION, P237; TERKUILE BH, 1991, J BIOL CHEM, V266, P857; VANSCHAFTINGEN E, 1985, EUR J BIOCHEM, V153, P403, DOI 10.1111/j.1432-1033.1985.tb09316.x; VANSCHAFTINGEN E, 1987, EUR J BIOCHEM, V166, P653; VISSER N, 1981, EUR J BIOCHEM, V118, P521, DOI 10.1111/j.1432-1033.1981.tb05550.x; VISSER N, 1980, EUR J BIOCHEM, V103, P623, DOI 10.1111/j.1432-1033.1980.tb05988.x; VISSER N, 1981, THESIS U AMSTERDAM; Westerhoff H., 1987, THERMODYNAMICS CONTR; WESTERHOFF HV, 1990, NATO ADV SCI I A-LIF, V190, P399; WIEMER EAC, 1995, BIOCHEM J, V312, P479, DOI 10.1042/bj3120479; WIEMER EAC, 1992, BIOCHEM BIOPH RES CO, V184, P1028, DOI 10.1016/0006-291X(92)90694-G	51	165	169	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3207	3215		10.1074/jbc.272.6.3207	http://dx.doi.org/10.1074/jbc.272.6.3207			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013556	Green Published, hybrid			2022-12-25	WOS:A1997WG19200016
J	Dayton, JS; Sumi, M; Nanthakumar, NN; Means, AR				Dayton, JS; Sumi, M; Nanthakumar, NN; Means, AR			Expression of a constitutively active Ca2+/calmodulin-dependent kinase in Aspergillus nidulans spores prevents germination and entry into the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIMA PROTEIN-KINASE; S-PHASE; FISSION YEAST; CALMODULIN; MITOSIS; CALCIUM; GENE; IDENTIFICATION; PHOSPHATASE; ACTIVATION	The unique gene for Ca2+/calmodulin-dependent protein kinase (CaMK) has been shown to be essential in Aspergillus nidulans. Disruption of the gene prevents entry of spores into the nuclear division cycle. Here we show that expression of a constitutively active form of CaMK also prevents spores from entering the first S phase in response to a germinating stimulus. Expression of the constitutively active kinase induces premature activation of NIME(cyclin B)/NIMX(cdc2) in G(0)/G(1). As NIMX(cdc2) is present in spores, the elevation of maturation promotion factor activity may be secondary to the early production of NIME(cyclin B) or post-translation modification of maturation promotion factor. The expression of the constitutively active CaMK also results in the appearance of NIMA kinase activity within 1 h of the germinating signal. These results support the contention that the activities of maturation promotion factor and NIMA are coincidentally regulated in A. nidulans and suggest that the unscheduled appearance of one or both of these activities may be sufficient to prevent A, nidulans spores from entering into DNA synthesis.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [GM33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BARTELT DC, 1988, P NATL ACAD SCI USA, V85, P3279, DOI 10.1073/pnas.85.10.3279; BERGEN LG, 1983, J BACTERIOL, V156, P155, DOI 10.1128/JB.156.1.155-160.1983; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; Dayton JS, 1996, MOL BIOL CELL, V7, P1511, DOI 10.1091/mbc.7.10.1511; DOONAN JH, 1991, J BIOL CHEM, V266, P18889; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; HARRIS SD, 1994, GENETICS, V136, P517; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; JAMES SW, 1995, J CELL SCI, V108, P3485; KORNSTEIN LB, 1992, GENE, V113, P75, DOI 10.1016/0378-1119(92)90671-B; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; LU KP, 1992, MOL ENDOCRINOL, V6, P365, DOI 10.1210/me.6.3.365; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1994, J BIOL CHEM, V269, P6603; LU KP, 1993, METH MOL G, V2, P255; Martin-Castellanos C, 1996, EMBO J, V15, P839, DOI 10.1002/j.1460-2075.1996.tb00419.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OCONNELL MJ, 1992, EMBO J, V11, P2139, DOI 10.1002/j.1460-2075.1992.tb05273.x; OLSEN DB, 1990, P NATL ACAD SCI USA, V87, P1451, DOI 10.1073/pnas.87.4.1451; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1994, J CELL SCI, V107, P1519; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; RASMUSSEN C, 1994, EMBO J, V13, P2545, DOI 10.1002/j.1460-2075.1994.tb06544.x; RASMUSSEN C, 1994, MOL BIOL CELL, V5, P785, DOI 10.1091/mbc.5.7.785; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SU TT, 1995, CELL, V81, P825, DOI 10.1016/0092-8674(95)90000-4; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	43	25	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3223	3230		10.1074/jbc.272.6.3223	http://dx.doi.org/10.1074/jbc.272.6.3223			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013558	hybrid			2022-12-25	WOS:A1997WG19200018
J	Trawick, JD; Wang, SL; Bell, D; Davis, RA				Trawick, JD; Wang, SL; Bell, D; Davis, RA			Transcriptional induction of cholesterol 7 alpha-hydroxylase by dexamethasone in L35 hepatoma cells requires sulfhydryl reducing agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; BILE-ACID SYNTHESIS; NF-KAPPA-B; CULTURED RAT HEPATOCYTES; RATE-LIMITING ENZYME; DNA-BINDING; ENDOPLASMIC-RETICULUM; DOWN-REGULATION; GLUTATHIONE; RECEPTOR	It is known that hepatic levels of reduced glutathione correlate with the activity of the liver-specific enzyme cholesterol-7 alpha-hydroxylase. We examined the possibility that sulfhydryl reducing agents activate transcription of cholesterol 7 alpha-hydroxylase. Adding dithiothreitol (DTT, 1 mM) and dexamethasone to L35 hepatoma cells increased the content of 7 alpha-hydroxylase mRNA 3-fold above the levels observed with dexamethasone alone. Without dexamethasone, DTT had no affect. The addition of reduced glutathione to L35 cells demonstrated a similar potentiation of expression dependent on dexamethasone. Nuclear run-on assays showed that in the presence of both dexamethasone and DTT, the transcription of the 7 alpha-hydroxylase gene was clearly increased. In contrast, by itself, dexamethasone did not cause a detectable increase in the transcription of the 7 alpha-hydroxylase gene. Dexamethasone and DTT did not affect the transcription of p-actin, suggesting a selective induction of the 7 alpha-hydroxylase gene. DTT reversed repression of 7 alpha-hydroxylase expression by insulin but not the repression by phorbol ester. Our data show for the first time that the sulfhydryl redox potential of the hepatocyte (i.e. level of reduced glutathione) has a marked influence on the transcription and expression of the liver-specific gene 7 alpha-hydroxylase.	SAN DIEGO STATE UNIV,DEPT BIOL,MAMMALIAN CELL & MOL BIOL LAB,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOL BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University; California State University System; San Diego State University					NHLBI NIH HHS [HL52005] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052005] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; AUSUBEL FM, CURRENT PROTOCOLS MO, V1; BARKER CW, 1994, J BIOL CHEM, V269, P3985; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DAVIS RA, 1983, J BIOL CHEM, V258, P3661; DAVIS RA, 1992, MOL GENETICS CORONAR, V14, P208; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DUELAND S, 1992, J BIOL CHEM, V267, P22695; Feingold KR, 1996, J LIPID RES, V37, P223; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HASSAN AS, 1988, BIOCHIM BIOPHYS ACTA, V963, P131, DOI 10.1016/0005-2760(88)90274-3; HASSAN AS, 1992, BIOCHEM PHARMACOL, V44, P1475, DOI 10.1016/0006-2952(92)90553-U; HASSAN AS, 1984, STEROIDS, V44, P373, DOI 10.1016/S0039-128X(84)80028-8; HASSAN AS, 1993, BIOCHEM PHARMACOL, V46, P555, DOI 10.1016/0006-2952(93)90536-6; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JONES MP, 1993, J LIPID RES, V34, P885; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MYANT NB, 1977, J LIPID RES, V18, P135; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PANDAK WM, 1994, HEPATOLOGY, V19, P941, DOI 10.1016/0270-9139(94)90295-X; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PRINCEN HMG, 1989, BIOCHEM J, V262, P341, DOI 10.1042/bj2620341; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SHRECK R, 1991, EMBO J, V10, P2247; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEPHAN ZF, 1987, J BIOL CHEM, V262, P6069; STRAVITZ RT, 1995, J LIPID RES, V36, P1359; STRAVITZ RT, 1993, J BIOL CHEM, V268, P13987; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; Trawick JD, 1996, J LIPID RES, V37, P588; TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E	42	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3099	3102		10.1074/jbc.272.5.3099	http://dx.doi.org/10.1074/jbc.272.5.3099			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006961	hybrid			2022-12-25	WOS:A1997WE66700074
J	Hoshi, M; Takashima, A; Murayama, M; Yasutake, K; Yoshida, N; Ishiguro, K; Hoshino, T; Imahori, K				Hoshi, M; Takashima, A; Murayama, M; Yasutake, K; Yoshida, N; Ishiguro, K; Hoshino, T; Imahori, K			Nontoxic amyloid beta peptide (1-42) suppresses acetylcholine synthesis - Possible role in cholinergic dysfunction in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-I; GLYCOGEN-SYNTHASE KINASE-3-BETA; SENILE DEMENTIA; ACETYLTRANSFERASE ACTIVITY; BASAL FOREBRAIN; BRAIN-TISSUE; A-BETA; NEURONS; ABNORMALITIES; NEUROTOXICITY	We show here that amyloid beta peptide(1-42) (A beta(1-42)) may play a key role in the pathogenesis of the cholinergic dysfunction seen in Alzheimer's disease (AD), in addition to its putative role in amyloid plaque formation. A beta(1-42) freshly solubilized in water (non-aged A beta(1-42)), which was not neurotoxic without preaggregation, suppressed acetylcholine (ACE) synthesis in cholinergic neurons at very low concentrations (10-100 nM), although non-aged A beta(1-40) was ineffective. Non-aged A beta(1-42) impaired pyruvate dehydrogenase (PDH) activity by activating mitochondrial tau protein kinase I/glycogen synthase kinase-3 beta, as we have already shown in hippocampal neurons (Hoshi, M., Takashima, A. Noguchi, K., Murayama, M., Sato, M., Hondo, S., Saitoh, Y., Tshiguro, K., Hoshino, T., and Imahori, K. (1996) Proc. Natl. Acad. Sci. U. S. A 93, 2719-2723). Neither choline acetyltransferase activity nor choline metabolism was affected. Therefore, the major cause of reduced ACh synthesis was considered to be an inadequate supply of acetyl-CoA owing to PDH impairment. Soluble A beta(1-42) increases specifically in AD brain (Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., and Roher, A. E. (1996) J. Biol. Chem. 271, 4077-4081). This increase in soluble A beta(1-42) may disturb cholinergic function, leading to the deterioration of memory and cognitive function that is characteristic of AD.			Hoshi, M (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BIRD TD, 1983, ANN NEUROL, V14, P284, DOI 10.1002/ana.410140306; BOWEN DM, 1976, BRAIN, V99, P459, DOI 10.1093/brain/99.3.459; DAVIES P, 1976, LANCET, V2, P1403; DEKOSKY ST, 1992, ANN NEUROL, V32, P625; Geula C, 1996, CEREB CORTEX, V6, P165, DOI 10.1093/cercor/6.2.165; GIBSON GE, 1975, BIOCHEM J, V148, P17, DOI 10.1042/bj1480017; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HOSHI M, 1995, J BIOCHEM-TOKYO, V118, P683, DOI 10.1093/oxfordjournals.jbchem.a124965; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; Kuo YM, 1996, J BIOL CHEM, V271, P4077; LEHERICY S, 1993, J COMP NEUROL, V330, P15, DOI 10.1002/cne.903300103; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MARCHBANKS RM, 1981, J NEUROCHEM, V36, P379, DOI 10.1111/j.1471-4159.1981.tb01605.x; MARCHBANKS RM, 1977, SYNAPSES, P81; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; PERRY EK, 1977, J NEUROL SCI, V34, P247, DOI 10.1016/0022-510X(77)90073-9; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POTTER PE, 1983, J NEUROCHEM, V41, P188, DOI 10.1111/j.1471-4159.1983.tb13668.x; ROSSOR MN, 1982, BRAIN, V105, P313, DOI 10.1093/brain/105.2.313; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAKASHIMA A, 1995, NEUROSCI LETT, V198, P83, DOI 10.1016/0304-3940(95)11964-X; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WILCOCK GK, 1982, J NEUROL SCI, V57, P407, DOI 10.1016/0022-510X(82)90045-4; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; WOOD PL, 1983, J NEUROL SCI, V62, P211, DOI 10.1016/0022-510X(83)90200-9; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8	41	138	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2038	2041		10.1074/jbc.272.4.2038	http://dx.doi.org/10.1074/jbc.272.4.2038			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999897				2022-12-25	WOS:A1997WD67900003
J	Zahedi, K				Zahedi, K			Characterization of the binding of serum amyloid P to laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; GLOMERULAR BASEMENT-MEMBRANE; C4B-BINDING PROTEIN; BIOLOGICAL-ACTIVITY; HEPARAN-SULFATE; MESSENGER-RNA; IV COLLAGEN; COMPONENT; FIBRONECTIN; RECEPTOR	Serum amyloid P (SAP) is a member of the pentraxin family. These are evolutionarily conserved proteins made up of five noncovalently bound identical subunits that are arranged in a flat pentameric disc. Although a variety of activities have been attributed to SAP and other pentraxins, their biological functions remain unclear. In humans SAP is a constitutive serum protein that is synthesized by hepatocytes. It is encoded by a single copy gene on chromosome 1. SAP is a component of all amyloid plaques and is also a normal component of a number of basement membranes including the glomerular basement membrane. The association and distribution of SAP within the glomerular basement membrane are altered or completely disrupted in a number of nephritides (e.g. Alport's Syndrome, type II membranoproliferative glomerulonephritis, and membranous glomerulonephritis). In the present study the binding of SAP to laminin was characterized. SAP binds to human laminin and merosin as well as mouse and rat laminins. The binding of SAP to mouse laminin is saturable and calcium dependent. The K-d of this interaction is 2.74 x 10(-7) m, with a SAP/laminin molar ratio of 1:7.1. Competition binding assays indicate that the binding of SAP to laminin is inhibited by both SAP and its analog, C-reactive protein, as well as phosphatidylethanolamine. In turbidity assays SAP enhanced the polymerization of laminin in a concentration-dependent manner. However, SAP did not alter the ability of laminin to serve as a cell adhesion substrate. Previous observations indicating that SAP binds to extracellular matrix components such as type IV collagen, proteoglycans, and fibronectin in concert with the data presented here suggest that SAP may play an important role in determining the structure of those basement membranes with which it is associated.	UNIV CINCINNATI, COLL MED, DEPT PEDIAT, CINCINNATI, OH 45229 USA	University System of Ohio; University of Cincinnati	Zahedi, K (corresponding author), CHILDRENS HOSP RES FDN, DIV NEPHROL, TCHRF-5, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.		Zahedi, Kamyar/AAQ-3428-2021					ALMUTLAQ H, 1993, HISTOCHEM J, V25, P219, DOI 10.1007/BF00163818; CABANA VG, 1982, J IMMUNOL, V128, P2342; CHARONIS AS, 1983, MICROVASC RES, V26, P108, DOI 10.1016/0026-2862(83)90059-6; CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DE FRUTOS PG, 1995, J BIOL CHEM, V270, P26950, DOI 10.1074/jbc.270.45.26950; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DYCK RF, 1980, LANCET, V2, P607; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; HAMAZAKI H, 1988, BIOCHEM BIOPH RES CO, V150, P212, DOI 10.1016/0006-291X(88)90507-4; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; LAURIE GW, 1989, J CELL BIOL, V109, P1351, DOI 10.1083/jcb.109.3.1351; LE PT, 1982, J IMMUNOL, V129, P665; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; LOVELESS RW, 1992, EMBO J, V11, P813, DOI 10.1002/j.1460-2075.1992.tb05118.x; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MANTZOURANIS EC, 1985, J BIOL CHEM, V260, P7752; MELVIN T, 1986, AM J PATHOL, V125, P460; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PEPYS MB, 1978, CLIN EXP IMMUNOL, V32, P119; PEPYS MB, 1994, P NATL ACAD SCI USA, V91, P5602, DOI 10.1073/pnas.91.12.5602; PEPYS MB, 1978, NATURE, V273, P168, DOI 10.1038/273168a0; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; POTEMPA LA, 1985, J BIOL CHEM, V260, P2142; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SCHWALBE RA, 1992, BIOCHEMISTRY-US, V31, P4907, DOI 10.1021/bi00135a023; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; SWANSON SJ, 1989, J CELL BIOCHEM, V40, P121, DOI 10.1002/jcb.240400112; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TSENG J, 1986, IMMUNOL INVEST, V15, P749, DOI 10.3109/08820138609036360; WILLIAMS EC, 1992, J LAB CLIN MED, V120, P159; YING SC, 1993, J IMMUNOL, V150, P169; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; Zahedi K, 1996, J BIOL CHEM, V271, P14897, DOI 10.1074/jbc.271.25.14897	46	30	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2143	2148						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999915				2022-12-25	WOS:A1997WD67900021
J	Zhang, WL; Lu, Q; Xie, ZJ; Mellgren, RL				Zhang, WL; Lu, Q; Xie, ZJ; Mellgren, RL			Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: Evidence that cleavage of p53 by a calpain-like protease is necessary for G(1) to S-phase transition	ONCOGENE			English	Article						calpain; p53; cell proliferation; p21Waf1; peptide diazomethyl ketones	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; UBIQUITIN PATHWAY; MU-CALPAIN; C-JUN; PROGRESSION; DEGRADATION; CALPASTATIN; CIP1; G1	The effect of a calpain-selective cell permeant inhibitor, benzyloxycarbonyl Leu-Leu-Tyr diazomethylketone (ZLLY-CHN2), on the serum-stimulated growth of WI-38 human fibroblasts has been investigated, Only cell permeant protease inhibitors with activity against calpains prevented progression into S-phase, Protein blotting experiments indicated that p53 immunoreactivity increased in late G(1) cells treated with ZLLY-CHN2. The content of p21(Waf1/Cip1) CDK inhibitor also increased, providing a mechanism for the observed failure to enter S-phase, Further studies indicated that p53 could be degraded by a ZLLY-CHN2-sensitive protease immediately prior to S-phase, but that proteolysis did not occur after this critical time point, Chelation of extracellular Ca2+ by addition of EGTA inhibited the p53 degradation, Consistent with proteolysis of p53 in late G(1) phase, mu-calpain immunoreactivity transiently accumulated in ceh nuclei at this time, ZLLY-CHN, did not appear to increase p53 mRNA in WI-38 cells, Purified mu-calpain required only 1 to 3 mu M Ca2+ to proteolyze p53 in WI-38 cell lysates. These results indicate that ZLLY-CHN, inhibits progression of WI-38 cells into S-phase by inactivating a calpain-like protease that is responsible for proteolysis of constitutively expressed p53 in late G(1).	MED COLL OHIO,DEPT THERAPEUT & PHARMACOL,TOLEDO,OH 43699						NHLBI NIH HHS [HL36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARTER R, 1991, ONCOGENE, V6, P229; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P236; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANA X, 1995, ONCOGENE, V11, P211; HARPER JW, 1993, CELL, V75, P805; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Hsu HL, 1996, J CELL SCI, V109, P277; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LU Q, 1996, IN PRESS ARCH BIOCH; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARCH KL, 1993, CIRC RES, V72, P413, DOI 10.1161/01.RES.72.2.413; Mellgren RL, 1996, J BIOL CHEM, V271, P15568, DOI 10.1074/jbc.271.26.15568; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MINSHULL J, 1989, J CELL SCI S, V12, P77; MURACHI T, 1981, BIOCHEM INT, V2, P651; MURRAY AW, 1989, J CELL SCI S, V12, P65; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; WAHL M, 1993, MOL BIOL CELL, V4, P293, DOI 10.1091/mbc.4.3.293; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825	34	64	64	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					255	263		10.1038/sj.onc.1200841	http://dx.doi.org/10.1038/sj.onc.1200841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018111				2022-12-25	WOS:A1997WD51600001
J	Rao, G; Rekhtman, N; Cheng, GH; Krasikov, T; Skoultchi, AI				Rao, G; Rekhtman, N; Cheng, GH; Krasikov, T; Skoultchi, AI			Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation	ONCOGENE			English	Article						PU1; Spi-1; MEL cells; c-myc; c-myb; differentiation	C-MYC ONCOGENE; VIRUS-INDUCED ERYTHROLEUKEMIA; MOUSE ERYTHROLEUKEMIA; FRIEND-ERYTHROLEUKEMIA; ERYTHROID-DIFFERENTIATION; ERYTHROPOIETIN RECEPTOR; PUTATIVE ONCOGENE; GENE-EXPRESSION; MESSENGER-RNA; P53 GENE	Murine erythroleukemia (MEL) cells are transformed erythroid precursors that are blocked from completing the late stages of erythroid differentiation. A frequent event in the generation of these malignant cells is deregulation of the hematopoietic-specific transcription factor PU.1 (Spi-1) by retroviral insertion of the spleen-focus-forming virus component of Friend virus. During chemically induced reinitiation of MEL cell terminal differentiation, expression of PU.1 is rapidly downregulated, suggesting that PU.1 might interfere with processes required for terminal differentiation of erythroid precursors. To investigate the role of PU.1 in erythroid differentiation we transfected MEL cells with a PU.1 cDNA controlled by the eucaryotic translation elongation factor EF1 alpha promoter. Deregulated expression of PU.1 blocked chemically induced differentiation and terminal cell division. Deregulated expression of two other protooncogenes, c-myc and c-myb, also has been shown to block MEL differentiation, We present evidence that PU.1 inhibits terminal differentiation at an earlier step than c-Myc and c-Myb. Thus reinitiation of MEL cell terminal differentiation appears to be controlled by an ordered program of turning off several protooncogenes. Down-regulation of PU.1 may be a very early step in this program.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330, R37CA016368] Funding Source: NIH RePORTER; NCI NIH HHS [2P30CA13330, 5R37CA16368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONG YH, 1995, MOL CELL BIOL, V15, P1889; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FRIEDMAN EA, 1978, P NATL ACAD SCI USA, V75, P3813, DOI 10.1073/pnas.75.8.3813; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GAMBARI R, 1978, P NATL ACAD SCI USA, V75, P3801, DOI 10.1073/pnas.75.8.3801; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Harlow E., 1988, ANTIBODIES LAB MANUA; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCLEOD DL, 1974, BLOOD, V44, P517, DOI 10.1182/blood.V44.4.517.517; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROUGEON F, 1977, GENE, V1, P229, DOI 10.1016/0378-1119(77)90047-6; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SOEIRO R, 1969, J MOL BIOL, V44, P551, DOI 10.1016/0022-2836(69)90379-9; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	54	89	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					123	131		10.1038/sj.onc.1200807	http://dx.doi.org/10.1038/sj.onc.1200807			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010239				2022-12-25	WOS:A1997WB76000012
J	Gangopadhyay, SB; Peacock, JW; Benchimol, S				Gangopadhyay, SB; Peacock, JW; Benchimol, S			A transcript exhibiting homology to endogenous rat retroviral-like elements is regulated by p53	ONCOGENE			English	Article						p53; differential display; RAL retroviral-like elements	WILD-TYPE P53; PROTEIN; GENE; EXPRESSION; GROWTH; CELLS; CHECKPOINT; SEQUENCES; APOPTOSIS; BINDING	Rat embryo fibroblasts transformed with HPV-16 E7 and the Ha-ras oncogene (ER clones) fall into two distinct groups based on their endogenous p53 status, wild-type or mutant, We have taken advantage of such clones in order to study the p53 target genes by the differential display method of RNA fingerprinting, We have identified a cDNA clone, clone 16, that recognises a large transcript on Northern blots. The clone 16 transcript is overexpressed in ER cell lines that express wild-type p53 compared with ER cell lines that express mutant p53. Similar to the waf1/p21 gene, which is transcriptionally activated in cells treated with ionizing radiation in a p53-dependent manner, the clone transcript was also induced in response to irradiation, The sequence of clone 16 exhibits a high homology to two members of RAL retroviral-like elements.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X				BRISTOW RG, 1994, ONCOGENE, V9, P1527; BUSSEMAKERS MJG, 1992, BIOCHEM BIOPH RES CO, V182, P318, DOI 10.1016/S0006-291X(05)80147-0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; HARPER JW, 1993, CELL, V75, P805; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakamuta M, 1989, Virus Genes, V3, P69, DOI 10.1007/BF00301988; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; PEACOCK JW, 1994, EMBO J, V13, P1084, DOI 10.1002/j.1460-2075.1994.tb06357.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUZUKI N, 1986, NUCLEIC ACIDS RES, V14, P9271, DOI 10.1093/nar/14.23.9271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	28	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2731	2735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000148				2022-12-25	WOS:A1996VZ65400024
J	Han, IS; Ramamurthy, N; Yun, JH; Schaller, U; Meyerhoff, ME; Yang, VC				Han, IS; Ramamurthy, N; Yun, JH; Schaller, U; Meyerhoff, ME; Yang, VC			Selective monitoring of peptidase activities with synthetic polypeptide substrates and polyion-sensitive membrane electrode detection	FASEB JOURNAL			English	Article						polycationic sensor; electrochemical potential; chymotrypsin; renin	BIOANALYTICAL APPLICATIONS; ELECTROCHEMICAL SENSOR; HEPARIN	A novel method to monitor specific peptidase activities in biological samples as complex as undiluted plasma/blood is described. The approach is based on the design of synthetic polypeptide substrates in which di- or triarginine sequences are linked to each, other via one or more other amino acids recognized specifically by the peptidase to be determined. Detection of chymotrypsin and renin activities using synthetic substrates P4 (F-R-R-R-F-V-R-R-F-NH2) and P5 (R-R-R-L-L-R-R-L-L-R-R-R), respectively, serves to demonstrate the principles of this new assay system. A polyion-sensitive membrane electrode, prepared by doping polymer films with dinonyhlaphthalene-sulfonate (DNNS), is shown to exhibit significant nonequilibrium electromotive force (EMF) responses toward these and other polycationic substrates at er levels under physiological conditions: The same electrode, however, exhibits much smaller total EMF response toward the shorter fragments of the synthetic peptides generated by peptidase activity; hence, the addition of peptidase to a solution containing the synthetic substrate yields a change in electrode EMF response, the rate of which is proportional to the activity of peptidase present. Other synthetic polycationic peptides as ell as natural polycationic peptides (e.,., protamine) that lack specific cleavage sites for chymotrypsin and renin, yet are detected by the DNNS-based membrane electrode, do not elicit any significant change in EMF response in the presence of the peptidases, confirming the feasibility and utility of the proposed bioanalytical method.	UNIV MICHIGAN,COLL PHARM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055461, R01HL038353, R29HL038353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028882] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55461, HL38353] Funding Source: Medline; NIGMS NIH HHS [GM-28882] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett A. J., 1980, MAMMALIAN PROTEASES, VI; BARRETT AJ, 1980, MAMMALIAN PROTEASES, V2; DUPONT, 1991, INSTRUCTION MANUAL; FU B, 1995, MACROMOLECULES, V28, P5834, DOI 10.1021/ma00121a021; FU B, 1994, ANAL CHEM, V66, P2250, DOI 10.1021/ac00086a009; HARRELL JB, 1969, ANAL CHEM, V41, P1459, DOI 10.1021/ac60280a026; MA SC, 1993, ANAL CHEM, V65, P2078, DOI 10.1021/ac00063a024; MA SC, 1992, ANAL CHEM, V64, P694, DOI 10.1021/ac00030a023; SCHALLER U, 1994, ANAL CHEM, V66, P391, DOI 10.1021/ac00075a013; SLATER EE, 1981, METHOD ENZYMOL, V80, P427; TELTINGDIAZ M, 1994, ANAL CHEM, V66, P576, DOI 10.1021/ac00076a025; Wahr JA, 1996, J CARDIOTHOR VASC AN, V10, P447, DOI 10.1016/S1053-0770(05)80002-3; YUN JH, 1995, ANAL BIOCHEM, V224, P212, DOI 10.1006/abio.1995.1032; YUN JH, 1995, ASAIO J, V41, P661; 1992, NOM COMM INT UN BIOC, P371	15	33	36	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1621	1626		10.1096/fasebj.10.14.9002554	http://dx.doi.org/10.1096/fasebj.10.14.9002554			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002554	Green Submitted			2022-12-25	WOS:A1996WC86900008
J	Hong, SH; Ryu, KS; Oh, MS; Ji, I; Ji, TH				Hong, SH; Ryu, KS; Oh, MS; Ji, I; Ji, TH			Roles of transmembrane prolines and proline-induced kinks of the lutropin/choriogonadotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; HORMONE-BINDING; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; IDENTIFICATION; ACTIVATION; SEQUENCE; PROTEINS; SUBUNITS; MUTATION	The lutropin/choriogonadotropin receptor is a seven-helix transmembrane (TM) receptor, A unique feature of TM helices is the content of Pro, which generally is absent in alpha helices of globular proteins, Because Pro disrupts helices and introduces a similar to 26 degrees kink, it has been speculated that Pro plays a crucial role in the structure of TM helices, exoloops, and cytoloops of TM receptors. To examine the roles of the five TM Pros of the lutropin/choriogonadotropin receptor, these residues were individually substituted, Mutant receptors were examined for surface expression, hormone binding, and cAMP induction, Surface expression was monitored after introducing the flag epitope into the receptors. Flag epitopes slightly affected cAMP induction but not hormone binding or surface expression of receptors as monitored by immunofluorescence microscopy and I-125-anti-flag antibody, The results indicate that Pro(479) in TM 4 and pro(598) in TM 7 play important yet contrasting roles. pro(479) is crucial for hormone binding at the cell surface but not after solubilization of the receptor. This is more likely due to the Pro side chain than the Pro-induced kink. pro(598) is important for surface expression. The kinks of pro(463) of TM 4, Pro(562) of TM 6, or pro(591) of TM 7 are not important because the substitution of Phe for these residues did not significantly impact surface expression, hormone binding, and cAMP induction.	UNIV WYOMING,DEPT MOL BIOL,LARAMIE,WY 82071	University of Wyoming					NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; GU WX, 1995, ENDOCRINOLOGY, V136, P3146, DOI 10.1210/en.136.7.3146; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HUANG JN, 1995, J BIOL CHEM, V270, P30023; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1991, J BIOL CHEM, V266, P13076; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI L, 1991, ENDOCRINOLOGY, V128, P2648; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; PRIKETT K, 1989, BIOTECHNIQUES, V7, P580; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; STEIN SA, 1994, MOL ENDOCRINOL, V8, P129, DOI 10.1210/me.8.2.129; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; XIE YB, 1990, J BIOL CHEM, V265, P21411	25	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4166	4171		10.1074/jbc.272.7.4166	http://dx.doi.org/10.1074/jbc.272.7.4166			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020129	hybrid			2022-12-25	WOS:A1997WH01900045
J	Yet, SF; Pellacani, A; Patterson, C; Tan, L; Folta, SC; Foster, L; Lee, WS; Hsieh, CM; Perrella, MA				Yet, SF; Pellacani, A; Patterson, C; Tan, L; Folta, SC; Foster, L; Lee, WS; Hsieh, CM; Perrella, MA			Induction of heme oxygenase-1 expression in vascular smooth muscle cells - A link to endotoxic shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CARBON-MONOXIDE; SEPTIC SHOCK; ZINC-PROTOPORPHYRIN; SELECTIVE INHIBITOR; MESSENGER-RNA; RAT; ENDOTHELIUM; PHYSIOLOGY; RESPONSES	Endotoxic shock is a life-threatening consequence of severe Gram-negative infection characterized by vascular smooth muscle cell relaxation and severe hypotension, The production of nitric oxide (NO), through the inducible NO synthase pathway, has been implicated as a major contributor in this process, We now demonstrate that heme oxygenase (HO), an enzyme that generates carbon monoxide (GO) in the course of heme metabolism, may also be involved in the hemodynamic compromise of endotoxic shock, Inducible HO (HO-1) mRNA levels are dramatically increased in aortic tissue from rats receiving endotoxin, and this increase in vascular HO-1 message is associated with an 8.9-fold increase in HO enzyme activity in vivo. Immunocytochemical staining localizes an increase in HO-1 protein within smooth muscle cells of both large (aorta) and small (arterioles) blood vessels, Furthermore, zinc protoporphyrin TX, an inhibitor of HO activity, abrogates endotoxin-induced hypotension in rats, Studies performed in rat vascular smooth muscle cells in vitro show that the induction of HO-1 mRNA is regulated at the level of gene transcription, and this induction is independent of NO production, Taken together, these studies suggest that the up-regulation of HO-1, and the subsequent production of CO, contributes to the reduction in vascular tone during endotoxic shock.	HARVARD UNIV,SCH PUBL ADM,CARDIOVASC BIOL LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003194] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8HL03194] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLA G, 1992, J BIOL CHEM, V267, P18148; COOK MN, 1995, CAN J PHYSIOL PHARM, V73, P515, DOI 10.1139/y95-065; Durante W., 1996, FASEB Journal, V10, pA303; EPSTEIN FH, 1993, NEW ENGL J MED, V328, P106; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRUNDEMAR L, 1995, ACTA PHYSIOL SCAND, V153, P203, DOI 10.1111/j.1748-1716.1995.tb09852.x; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; JOHNSON RA, 1995, HYPERTENSION, V25, P166, DOI 10.1161/01.HYP.25.2.166; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LEE WS, 1990, P NATL ACAD SCI USA, V87, P5163, DOI 10.1073/pnas.87.13.5163; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MAINES MD, 1977, J BIOL CHEM, V252, P5900; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Palmer R M, 1993, Curr Opin Nephrol Hypertens, V2, P122, DOI 10.1097/00041552-199301000-00018; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, P NATL ACAD SCI USA, V93, P2054, DOI 10.1073/pnas.93.5.2054; PHAAS JA, 1993, AM J PHYSIOL, V264, pF411; Raju VS, 1996, J PHARMACOL EXP THER, V277, P1814; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACTER BA, 1988, SEMIN HEMATOL, V25, P349; STOCKER R, 1987, SCIENCE, V235, P1042; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795; ZYGMUNT PM, 1994, ACTA PHYSIOL SCAND, V152, P137, DOI 10.1111/j.1748-1716.1994.tb09793.x	36	162	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4295	4301		10.1074/jbc.272.7.4295	http://dx.doi.org/10.1074/jbc.272.7.4295			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020147	hybrid			2022-12-25	WOS:A1997WH01900063
J	Barlat, I; Maurier, F; Duchesne, M; Guitard, E; Tocque, B; Schweighoffer, F				Barlat, I; Maurier, F; Duchesne, M; Guitard, E; Tocque, B; Schweighoffer, F			A role for Sam68 in cell cycle progression antagonized by a spliced variant within the KH domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC FAMILY; TYROSINE KINASES; BINDING-PROTEIN; NUCLEIC-ACID; C-SRC; RNA; ASSOCIATION; P62; PHOSPHORYLATION; RECEPTOR	Sam68 is the main tyrosine-phosphorylated and Src-associated protein in mitotic cells. Sam68 exhibits a conserved functional KH (hnRNPK homology) RNA binding domain and binds single strand nucleic acids. Tyrosine phosphorylation mediates the interaction of Sam68 with many SH3- and SH2-containing proteins and negatively regulates its nucleic acid binding properties. But the function and the impact of Sam68 on cell signaling and cell proliferation remains elusive. We report here the identification of a natural isoform of Sam68 with a deletion within the KH domain. This isoform, called Sam68 Delta KH, is specifically expressed at growth arrest upon confluency in normal cells. In cells that do not enter quiescence at confluency such as Src-transformed cells, no recruitment of Sam68 Delta KH is observed. Transfected Sam68 Delta KH inhibits serum-induced DNA synthesis and cyclin D1 expression. Sam68 overcomes these effects, suggesting that isoforms of Sam68 are involved, through KH domain signaling, in cell proliferation, and more precisely in G(1)/S transition.	RHONE POULENC RORER,GENE MED DEPT,F-94403 VITRY SUR SEINE,FRANCE	Sanofi-Aventis								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; NEET K, 1995, MOL CELL BIOL, V15, P4908; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	22	80	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3129	3132		10.1074/jbc.272.6.3129	http://dx.doi.org/10.1074/jbc.272.6.3129			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013542	hybrid			2022-12-25	WOS:A1997WG19200002
J	Bornancin, F; Parker, PJ				Bornancin, F; Parker, PJ			Phosphorylation of protein kinase C-zeta on serine 657 controls the accumulation of active enzyme and contributes to its phosphatase-resistant state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMISSIVE ACTIVATION; CATALYTIC SUBUNIT; ALPHA; EXPRESSION; DOMAIN; BRAIN; SITE	Serine 657 in protein kinase C-alpha (PKC alpha) is a site of phosphorylation on expression of the recombinant protein in mammalian cells. To define the function of this phosphorylation, PKC alpha species with mutations of this site were investigated. The alanine mutant, S657A PKC alpha, displayed slow phosphate accumulation in pulse-chase experiments, indicating a rate-limiting role in the initial phase of phosphorylation. Consistent with this, the aspartic acid mutant, S657D PKC alpha, showed an increased rate of phosphate accumulation. Both the S657D and S657A PKC alpha mutants were slow to accumulate as fully phosphorylated forms during a second phase of phosphorylation. This latter property is shown to correlate with an increased phosphatase sensitivity and decreased protein kinase activity for these two PKC alpha mutants. It is further shown that once fully phosphorylated, the S657D PKC alpha mutant displays WT PKC alpha properties with respect to thermal stability and phosphatase sensitivity in vitro and in vivo; in contrast, the S657A PKC alpha mutant remains sensitive. The properties of the Ser-657 site PKC alpha mutants define functional roles for this phosphorylation in both the accumulation of phosphate on PKC alpha as well as in its agonist-induced dephosphorylation. These results are discussed in the context of a working model of PKC alpha behavior, providing insight into the workings of other kinases with equivalent sites of phosphorylation.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Bornancin, Frederic/AAA-2888-2021; Parker, Peter j/D-5192-2013	Bornancin, Frederic/0000-0002-0152-6720; parker, peter/0000-0002-6218-2933				ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; ALESSI DR, 1996, IN PRESS EMBO J; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; ORR JW, 1994, J BIOL CHEM, V269, P27715; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807	26	166	169	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3544	3549		10.1074/jbc.272.6.3544	http://dx.doi.org/10.1074/jbc.272.6.3544			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013603	hybrid			2022-12-25	WOS:A1997WG19200063
J	DeStrooper, B; Beullens, M; Contreras, B; Levesque, L; Craessaerts, K; Cordell, B; Moechars, D; Bollen, M; Fraser, P; StGeorgeHyslop, P; VanLeuven, F				DeStrooper, B; Beullens, M; Contreras, B; Levesque, L; Craessaerts, K; Cordell, B; Moechars, D; Bollen, M; Fraser, P; StGeorgeHyslop, P; VanLeuven, F			Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ENDOPLASMIC-RETICULUM; MISSENSE MUTATIONS; APOLIPOPROTEIN-E; GENE; SECRETION; CLEAVAGE; PATHWAY; EXPRESSION; ANTIBODIES	Presenilins 1 and 2 are unglycosylated proteins with apparent molecular mass of 45 and 50 kDa, respectively, in transfected COS-1 and Chinese hamster ovary cells. They colocalize with proteins from the endoplasmic reticulum and the Gels apparatus in transfected and untransfected cells. In COS-1 cells low amounts of intact endogeneous presenilin 1 migrating at 45 kDa are detected together with relative larger amounts of presenilin 1 fragments migrating between 18 and 30 kDa. The presenilins have a strong tendency to form aggregates (mass of 100-250 kDa) in SDS-polyacrylamide gel electrophoresis, which can be partially resolved when denatured by SDS at 37 degrees C instead of 95 degrees C. Sulfation, glycosaminoglycan modification, or acylation of the presenilins was not observed, but both proteins are posttranslationally phosphorylated on serine residues. The mutations Ala-246 --> Glu or Cys-410 --> Tyr that cause Alzheimer's disease do not interfere with the biosynthesis or phosphorylation of presenilin 1. Finally, using low concentrations of digitonin to selectively permeabilize the cell membrane but not the endoplasmic reticulum membrane, it is demonstrated that the two major hydrophilic domains of presenilin 1 are oriented to the cytoplasm. The current investigation documents the posttranslational modifications and subcellular localization of the presenilins and indicates that postulated interactions with amyloid precursor protein metabolism should occur in the early compartments of the biosynthetic pathway.	KATHOLIEKE UNIV LEUVEN,EXPT GENET GRP,B-3000 LOUVAIN,BELGIUM; KATHOLIEKE UNIV LEUVEN,MOL ONCOL GRP,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM; KATHOLIEKE UNIV LEUVEN,BIOCHEM LAB,B-3000 LOUVAIN,BELGIUM; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,DEPT MED NEUROL & MED BIOPHYS,TORONTO,ON M5S 1A8,CANADA; SCIOS INC,SUNNYVALE,CA 94043	KU Leuven; KU Leuven; KU Leuven; University of Toronto; Scios			de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012	De Strooper, Bart/0000-0001-5455-5819; St George-Hyslop, Peter/0000-0003-0796-7209				*ALZH DIS COLL GRO, 1995, NAT GENET, V11, P219; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CHECLER F, 1995, J NEUROCHEM, V65, P1431; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; DeStrooper B, 1995, J BIOL CHEM, V270, P30310, DOI 10.1074/jbc.270.51.30310; Elder GA, 1996, J NEUROSCI RES, V45, P308; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOSIK KS, 1994, J CELL BIOL, V127, P1501, DOI 10.1083/jcb.127.6.1501; KOVACS DM, 1996, NAT MED, V2, P1; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; LORIES V, 1989, J BIOL CHEM, V264, P7009; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Moussaoui S, 1996, FEBS LETT, V383, P219, DOI 10.1016/0014-5793(96)00250-5; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PASQUALE V, 1996, SCIENCE, V271, P521; REBECK GW, 1993, NEURON, V11, P575; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SLUNT HH, 1995, AMYLOID, V2, P188, DOI 10.3109/13506129509036925; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Van Broeckhoven C, 1995, NAT GENET, V11, P230; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; WISNIEWSKI T, 1995, LANCET, V346, P1366, DOI 10.1016/S0140-6736(95)92379-9	50	249	254	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3590	3598		10.1074/jbc.272.6.3590	http://dx.doi.org/10.1074/jbc.272.6.3590			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013610	hybrid			2022-12-25	WOS:A1997WG19200070
J	Koller, J; Muller, UF; Schmid, B; Missel, A; Kruft, V; Stuart, K; Goringer, HU				Koller, J; Muller, UF; Schmid, B; Missel, A; Kruft, V; Stuart, K; Goringer, HU			Trypanosoma brucei gBP21 - An arginine-rich mitochondrial protein that binds to guide RNA with high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RIBONUCLEOPROTEIN COMPLEXES; ESCHERICHIA-COLI; IN-VITRO; LEISHMANIA-TARENTOLAE; CRITHIDIA-FASCICULATA; P HOLOENZYME; MOLECULES; LIGASE; RECOGNITION	RNA editing in Trypanosoma brucei is a mitochondrial RNA processing reaction that results in the insertion and deletion of uridylate residues into otherwise untranslatable mRNAs. The process is directed by guide RNAs which function to specify the edited sequence, RNA editing in vitro requires mitochondrial protein extracts and guide RNAs have been identified as part of high molecular weight ribonucleoprotein complexes. Within the complexes, the RNAs are in close contact with several mitochondrial proteins and here we describe the isolation and cloning of a gRNA-interacting poly-peptide from Trypanosoma brucei. The protein was named gBP21 for guide RNA-binding protein of 21 kDa. gBP21 shows no homology to proteins in other organisms, it is arginine-rich and binds to gRNA molecules with a dissociation constant in the nanomolar range. The protein does not discriminate for differences in the primary structures of gRNAs and thus likely binds to higher order structural features common to all gRNA molecules. gBP21 binding does not perturb the overall structure of gRNAs but the gRNA/gBP21 ribonucleoprotein complex is more stable than naked guide RNAs. Although the protein is arginine-rich, the free amino acid or an arginine-rich peptide were not able to inhibit the association to the RNAs, In contrast, the gRNA-gBP21 complex formation was sensitive to potassium and ammonium cations, thus indicating a contribution of ionic contacts to the binding.	LMU MUNCHEN, MPI BIOCHEM, GENZENTRUM, MOL BIOL LAB, D-82152 MARTINSRIED, GERMANY; PE APPL BIOSYST, D-64331 WEITERSTADT, GERMANY; SEATTLE BIOMED RES INST, SEATTLE, WA 98109 USA; UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA	Max Planck Society; University of Munich; Thermo Fisher Scientific; Applied Biosystems; Center for Infectious Disease Research; University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM42188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1992, MOL BIOL REP, V16, P217, DOI 10.1007/BF00419661; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINGAUD F, 1995, MOL BIOCHEM PARASIT, V71, P65, DOI 10.1016/0166-6851(95)00023-T; BRUN R, 1979, ACTA TROP, V36, P289; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corell RA, 1996, MOL CELL BIOL, V16, P1410; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; FRECH GC, 1995, EMBO J, V14, P178, DOI 10.1002/j.1460-2075.1995.tb06988.x; GORINGER HU, 1995, PARASITOL TODAY, V11, P265, DOI 10.1016/0169-4758(95)80209-6; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; GRAY DM, 1981, BIOPOLYMERS, V20, P1337, DOI 10.1002/bip.1981.360200702; Green CJ, 1996, NUCLEIC ACIDS RES, V24, P1497, DOI 10.1093/nar/24.8.1497; Greenbaum NL, 1996, STRUCTURE, V4, P5, DOI 10.1016/S0969-2126(96)00003-2; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HIRUMI H, 1994, PARASITOL TODAY, V10, P80, DOI 10.1016/0169-4758(94)90402-2; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; KARN J, 1994, RNA PROTEIN INTERACT, P192; KOLLER J, 1994, NUCLEIC ACIDS RES, V22, P1988, DOI 10.1093/nar/22.11.1988; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEEGWATER P, 1995, EUR J BIOCHEM, V227, P780, DOI 10.1111/j.1432-1033.1995.tb20201.x; MAIZELS RM, 1991, PARASITE ANTIGENS PA, P118; MATTAJ IW, 1995, NAT STRUCT BIOL, V2, P518, DOI 10.1038/nsb0795-518; MCPHERSON MJ, 1992, PCR PRACTICAL APPROA, P171; MISSEL A, 1994, NUCLEIC ACIDS RES, V22, P4050, DOI 10.1093/nar/22.20.4050; Piller KJ, 1996, J BIOL CHEM, V271, P4613, DOI 10.1074/jbc.271.9.4613; PILLER KJ, 1995, MOL CELL BIOL, V15, P2925; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; PRIEST JW, 1995, BBA-MOL CELL RES, V1269, P201, DOI 10.1016/0167-4889(95)00154-6; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; SABATINI R, 1995, J BIOL CHEM, V270, P7233, DOI 10.1074/jbc.270.13.7233; SCHMID B, 1995, NUCLEIC ACIDS RES, V23, P3093, DOI 10.1093/nar/23.16.3093; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; SHU HH, 1995, BBA-GENE STRUCT EXPR, V1261, P349, DOI 10.1016/0167-4781(95)00025-C; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P5394, DOI 10.1021/bi00618a012; STUART K, 1984, J PARASITOL, V70, P747, DOI 10.2307/3281757; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sundquist WI, 1996, NAT STRUCT BIOL, V3, P8, DOI 10.1038/nsb0196-8; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; VIOQUE A, 1988, J MOL BIOL, V202, P835, DOI 10.1016/0022-2836(88)90562-1; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; XING YY, 1995, J MOL BIOL, V249, P319, DOI 10.1006/jmbi.1995.0299	53	84	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3749	3757		10.1074/jbc.272.6.3749	http://dx.doi.org/10.1074/jbc.272.6.3749			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013632	hybrid			2022-12-25	WOS:A1997WG19200092
J	Marchot, P; Prowse, CN; Kanter, J; Camp, S; Ackermann, EJ; Radic, Z; Bougis, PE; Taylor, P				Marchot, P; Prowse, CN; Kanter, J; Camp, S; Ackermann, EJ; Radic, Z; Bougis, PE; Taylor, P			Expression and activity of mutants of fasciculin, a peptidic acetylcholinesterase inhibitor from mamba venom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL SOLUTION STRUCTURE; MOLECULAR-DYNAMICS SIMULATION; PROTEIN-PROTEIN RECOGNITION; SNAKE-VENOM; KAPPA-BUNGAROTOXIN; DENDROASPIS-ANGUSTICEPS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CALCIUM-CHANNEL	Fasciculin, a selective peptidic inhibitor of acetylcholinesterase, is a member of the three-fingered peptide toxin superfamily isolated from snake venoms. The availability of a crystal structure of a fasciculin 2 (Fas2)-acetylcholinesterase complex affords an opportunity to examine in detail the interaction of this toxin with its target site. To this end, we constructed a synthetic fasciculin gene with an appropriate leader peptide far expression and secretion from mammalian cells. Recombinant wild-type Fas2, expressed and amplified in Chinese hamster ovary cells, was purified to homogeneity and found to be identical in composition and biological activities to the venom-derived toxin. Sixteen mutations at positions where the crystal structure of the complex indicates a significant interfacial contact point or determinant of conformation were generated. Two mutants of loop I, T8A/T9A and R11Q, ten mutants of the longest loop II, R24T, K25L, R27W, R28D, H29D, Delta Pro(30), P31R, K32G, M33A, and V34A/L35A, and two mutants of loop III, D45K and K51S, were expressed transiently in human embryonic kidney cells. Inhibitory potencies of the Fas2 mutants toward arouse AChE were established, leased on titration of the mutants with a polyclonal anti-Fas2 serum. The Arg(27), Pro(30), and Pro(31) mutants each lost two or more orders of magnitude in Fas2 activity, suggesting that this subset of three residues, at the tip of loop II, dominates the loop conformation and interaction of Fas2 with the enzyme. The Arg(24), Lys(32), and Met(33) mutants lost about one order of magnitude, suggesting that these residues make moderate contributions to the strength of the complex, whereas the Lys(25), Arg(28), Val(34)-Leu(35), Asp(45), and Lys(51) mutants appeared as active as Fas2. The Thr(8)-Thr(9), Arg(11), and His(29) mutants showed greater ratios of inhibitory activity to immunochemical titer than Fas2. This may reflect immunodominant determinants in these regions or intramolecular rearrangements in conformation that enhance the interaction. Of the many Fas2 residues that lie at the interface with acetylcholinesterase, only a few appear to provide substantial energetic contributions to the high affinity of the complex.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV MEDITERRANEE,FAC MED SECTEUR NORD,INST FED RECH JEAN ROCHE,CNRS,UNITE RECH ASSOCIEE 1455,F-13916 MARSEILLE 20,FRANCE	University of California System; University of California San Diego; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite			MARCHOT, Pascale/AAC-4752-2022; BOUGIS, Pierre E/I-2111-2013	MARCHOT, Pascale/0000-0003-0630-0541; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEM A, 1988, BIOCHIM BIOPHYS ACTA, V968, P340, DOI 10.1016/0167-4889(88)90025-0; ALBRAND JP, 1995, BIOCHEMISTRY-US, V34, P5923, DOI 10.1021/bi00017a022; AXELSEN PH, 1994, PROTEIN SCI, V3, P188; BARAK D, 1994, J BIOL CHEM, V269, P6296; BOUGIS P, 1981, BIOCHEMISTRY-US, V20, P4915, DOI 10.1021/bi00520a017; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; Cervenansky C., 1991, P303; CERVENANSKY C, 1995, EUR J BIOCHEM, V229, P270, DOI 10.1111/j.1432-1033.1995.0270l.x; CERVENANSKY C, 1994, BBA-GEN SUBJECTS, V1199, P1, DOI 10.1016/0304-4165(94)90088-4; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P241; CHIAPPINELLI VA, 1983, BRAIN RES, V277, P9, DOI 10.1016/0006-8993(83)90902-2; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; DRENTH J, 1980, J BIOL CHEM, V255, P2652; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; Dufton M.J., 1991, P259; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Endo T., 1991, P165; FIORDALISI JJ, 1994, BIOCHEMISTRY-US, V33, P12962, DOI 10.1021/bi00248a004; FIORDALISI JJ, 1994, BIOCHEMISTRY-US, V33, P3872, DOI 10.1021/bi00179a011; Fiordalisi JJ, 1996, TOXICON, V34, P213, DOI 10.1016/0041-0101(95)00135-2; FIORDALISI JJ, 1991, BIOCHEMISTRY-US, V30, P10337, DOI 10.1021/bi00106a035; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; GRECO WR, 1979, J BIOL CHEM, V254, P2104; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; Harlow E., 1988, ANTIBODIES LAB MANUA; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KIEFFER B, 1994, BIOCHEMISTRY-US, V33, P4471, DOI 10.1021/bi00181a006; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDU MH, 1989, J BIOL CHEM, V264, P21401; LeDu MH, 1996, ACTA CRYSTALLOGR D, V52, P87, DOI 10.1107/S0907444995007517; LEDU MH, 1992, J BIOL CHEM, V267, P22122; Lee C Y, 1966, Mem Inst Butantan, V33, P555; Lu XJ, 1996, J BIOL CHEM, V271, P289, DOI 10.1074/jbc.271.1.289; Marchot P, 1996, PROTEIN SCI, V5, P672; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; Mebs D., 1991, SNAKE TOXINS, P425; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; OSWALD RE, 1991, BIOCHEMISTRY-US, V30, P4901, DOI 10.1021/bi00234a010; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PILLET L, 1993, J BIOL CHEM, V268, P909; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Rosenberry TL, 1996, BIOCHEMISTRY-US, V35, P685, DOI 10.1021/bi952431d; ROSENTHAL JA, 1994, J BIOL CHEM, V269, P11178; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SEGALAS I, 1995, BIOCHEMISTRY-US, V34, P1248, DOI 10.1021/bi00004a019; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; Straus OH, 1943, J GEN PHYSIOL, V26, P559, DOI 10.1085/jgp.26.6.559; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SUTCLIFFE MJ, 1994, STRUCT BIOL, V1, P802; TAMIYA T, 1985, BIOCHIMIE, V67, P185, DOI 10.1016/S0300-9084(85)80046-8; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; VANDENBORN HKL, 1995, PROTEIN SCI, V4, P703; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WRIGHT CS, 1987, J MOL BIOL, V194, P501, DOI 10.1016/0022-2836(87)90678-4; [No title captured]	70	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3502	3510		10.1074/jbc.272.6.3502	http://dx.doi.org/10.1074/jbc.272.6.3502			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013597	Green Published, hybrid			2022-12-25	WOS:A1997WG19200057
J	Miura, T; Shen, JR; Takahashi, S; Kamo, M; Nakamura, E; Ohta, H; Kamei, A; Inoue, Y; Domae, N; Takio, R; Nakazato, K; Inoue, Y; Enami, I				Miura, T; Shen, JR; Takahashi, S; Kamo, M; Nakamura, E; Ohta, H; Kamei, A; Inoue, Y; Domae, N; Takio, R; Nakazato, K; Inoue, Y; Enami, I			Identification of domains on the extrinsic 33-kDa protein possibly involved in electrostatic interaction with photosystem II complex by means of chemical modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN-EVOLUTION; MANGANESE-STABILIZING PROTEIN; NEAREST-NEIGHBOR RELATIONSHIPS; 33 KDA PROTEIN; EVOLVING COMPLEX; 16-KDA PROTEINS; BINDING-SITE; SPINACH; POLYPEPTIDES; PARTICLES	The extrinsic 33-kDa protein of photosystem II (PSII) was modified with various reagents, and the resulting proteins were checked for the ability to rebind to PSII and to reactivate oxygen evolution, While modification of more than eight carboxyl groups of aspartyl and glutamyl residues with glycine methyl ester did not affect the rebinding and reactivating capabilities, modification of amino groups of lysyl residues with either N-succinimidyl propionate or 2,4,6-trinitrobenzene sulfonic acid or modification of guanidino groups of arginyl residues with 2,3-butanedione resulted in a loss of rebinding and reactivating capabilities of the 33-kDa protein. Moreover, the number of lysyl and arginyl residues susceptible to modification was significantly decreased when the protein was bound to PSII as compared with when it was free in solution, whereas the number of carboxyl groups modified was little affected. These results suggested that positive charges are important for the electrostatic interaction between the extrinsic 33-kDa protein and PSII intrinsic proteins, whereas negative charges on the protein do not contribute to such interaction. By a combination of protease digestion and mass spectroscopic analysis, the domains of lysyl residues accessible to N-succinimidyl propionate or 2,4,6-trinitrobenzene sulfonic acid modification only when the 33-kDa protein is free in solution were determined to be Lys(4), Lys(20), Lys(66)-Lys(76), Lys(101), Lys(105), Lys(130), Lys(159), Lys(186), and Lys(230)-Lys(236). These domains include those previously reported accessible to N-hydroxysuccinimidobiotin only in solution (Frankel and Bricker (1995) Biochemistry 34, 7492-7497), and may be important for the interaction of the 33-kDa protein with PSII intrinsic proteins.	SCI UNIV TOKYO,FAC SCI,DEPT BIOL,SHINJUKU KU,TOKYO 162,JAPAN; SCI UNIV TOKYO,FAC SCI & TECHNOL,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; INST PHYS & CHEM RES,SOLAR ENERGY RES GRP,WAKO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,DIV BIOMOL CHARACTERIZAT,WAKO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,JRDC,PRESTO,WAKO,SAITAMA 35101,JAPAN; SCI UNIV TOKYO,BIOSCI RES INST,NODA,CHIBA 278,JAPAN	Tokyo University of Science; Tokyo University of Science; RIKEN; RIKEN; Japan Science & Technology Agency (JST); RIKEN; Tokyo University of Science			Kamo, Masaharu/S-1280-2019; Dohmae, Naoshi/C-2040-2011; Shen, Jian-Ren/B-2558-2011	Dohmae, Naoshi/0000-0002-5242-9410; Kamo, Masaharu/0000-0001-6791-8754				BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BRICKER TM, 1988, FEBS LETT, V231, P111, DOI 10.1016/0014-5793(88)80713-0; BURNAP RL, 1994, BIOCHEMISTRY-US, V33, P13712, DOI 10.1021/bi00250a023; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; EATONRYE JJ, 1989, BIOCHIM BIOPHYS ACTA, V977, P219, DOI 10.1016/S0005-2728(89)80075-1; ENAMI I, 1991, BIOCHIM BIOPHYS ACTA, V1060, P224, DOI 10.1016/S0005-2728(09)91010-6; ENAMI I, 1987, FEBS LETT, V226, P161, DOI 10.1016/0014-5793(87)80571-9; ENAMI I, 1994, BBA-BIOENERGETICS, V1186, P52, DOI 10.1016/0005-2728(94)90134-1; ENAMI I, 1990, PLANT CELL PHYSIOL, V31, P725; ENAMI I, 1989, BIOCHIM BIOPHYS ACTA, V973, P35, DOI 10.1016/S0005-2728(89)80399-8; ENAMI I, 1984, BIOCHIM BIOPHYS ACTA, V1135, P75; ENAMI L, 1992, PLANT CELL PHYSL, V33, P291; FRANKEL LK, 1992, BIOCHEMISTRY-US, V31, P11059, DOI 10.1021/bi00160a015; FRANKEL LK, 1995, BIOCHEMISTRY-US, V34, P7492, DOI 10.1021/bi00022a024; FRANZEN LG, 1984, BIOCHIM BIOPHYS ACTA, V765, P166, DOI 10.1016/0005-2728(84)90010-0; GHANOTAKIS DF, 1985, PHOTOSYNTH RES, V7, P97, DOI 10.1007/BF00037001; GHANOTAKIS DF, 1984, FEBS LETT, V170, P169, DOI 10.1016/0014-5793(84)81393-9; HOARE DG, 1966, J AM CHEM SOC, V88, P2057, DOI 10.1021/ja00961a045; ISOGAI Y, 1985, FEBS LETT, V187, P240, DOI 10.1016/0014-5793(85)81250-3; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; KUWABARA T, 1986, BIOCHIM BIOPHYS ACTA, V850, P146, DOI 10.1016/0005-2728(86)90019-8; KUWABARA T, 1979, BIOCHIM BIOPHYS ACTA, V581, P228, DOI 10.1016/0005-2795(79)90242-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSAY DG, 1970, BIOCHEM J, V121, P737; MEI R, 1989, BIOCHEMISTRY-US, V28, P5560, DOI 10.1021/bi00439a033; MIYAO M, 1983, BIOCHIM BIOPHYS ACTA, V725, P87, DOI 10.1016/0005-2728(83)90227-X; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; MIYAO M, 1989, BIOCHIM BIOPHYS ACTA, V977, P219; ODOM WR, 1992, BIOCHEMISTRY-US, V31, P5616, DOI 10.1021/bi00139a027; OKUYAMA T, 1960, J BIOCHEM-TOKYO, V47, P454, DOI 10.1093/oxfordjournals.jbchem.a127083; ONO T, 1984, FEBS LETT, V168, P281, DOI 10.1016/0014-5793(84)80263-X; ONO T, 1984, FEBS LETT, V166, P381, DOI 10.1016/0014-5793(84)80117-9; ONO TA, 1983, FEBS LETT, V164, P255, DOI 10.1016/0014-5793(83)80297-X; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SEIDLER A, 1995, PHOTOSYNTHESIS LIGHT, V2, P259; SEIDLER A, 1992, CURRENT RES PHOTOSYN, V2, P409; SHEN JR, 1991, PLANT CELL PHYSIOL, V32, P453, DOI 10.1093/oxfordjournals.pcp.a078101; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; TANAKA S, 1989, BIOCHEMISTRY-US, V28, P7188, DOI 10.1021/bi00444a009; TANAKA S, 1988, PHOTOSYNTH RES, V17, P255, DOI 10.1007/BF00035452; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591	43	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3788	3798		10.1074/jbc.272.6.3788	http://dx.doi.org/10.1074/jbc.272.6.3788			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013637	hybrid			2022-12-25	WOS:A1997WG19200097
J	Kuznetsov, G; Chen, LB; Nigam, SK				Kuznetsov, G; Chen, LB; Nigam, SK			Multiple molecular chaperones complex with misfolded large oligomeric glycoproteins in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; GLUCOSE-REGULATED PROTEINS; N-LINKED OLIGOSACCHARIDES; CHAIN-BINDING-PROTEIN; IMMUNOGLOBULIN-CHAINS; TRANSMEMBRANE PROTEIN; EPITHELIAL-CELLS; HEAT-SHOCK; BIP; THYROGLOBULIN	Thyroglobulin (Tg), the major protein secreted by thyroid epithelial cells and precursor of thyroid hormones, is a large dimeric glycoprotein with multiple disulfide bonds. The folding and assembly of this complex molecule begins in the endoplasmic reticulum (ER) and is Likely to involve a variety of reactions catalyzed by molecular chaperones (Kuznetsov, G., Chen, L. B., and Nigam, S. K. (1994) J. Biol. Chem. 269, 22990-22995). By coimmunoprecipitation in rat thyroid cells, we were able to demonstrate that BiP, grp94, ERp72, and grp170, four proteins believed to function as specific molecular chaperones, complex with Tg during its maturation. The same complex of the four putative chaperones with Tg was observed in cells treated with tunicamycin, indicating that these four ER chaperones stably associate with Tg when it is misfolded/misassembled due to inhibition of its glycosylation. BiP, grp94, and ERp72 were also found to associate with Tg in cells in which misfolding was induced by perturbing ER calcium stores. To determine if the assembly of a complex between the four chaperones and Tg under conditions of misglycosylation was unique to the maturation of this particular secretory protein or a more general phenomenon, adenovirus-transformed rat thyroid cells that do not synthesize Tg were analyzed. In these transformed cells, the only protein these same four chaperones were found to complex with was a protein of approximately 200 kDa. This protein was subsequently identified as thrombospondin, which, like Tg, is a large oligomeric secreted glycoprotein with multiple disulfide bonds. We therefore propose that these ER chaperones complex together with a variety of large oligomeric secretory glycoproteins as they fold and assemble in the ER.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOL BIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049517, R01DK044503] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK49517, DK44503] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ADAMS JC, 1994, MOL BIOL CELL, V5, P423, DOI 10.1091/mbc.5.4.423; ALBERT PR, 1986, AM J PHYSIOL, V251, pC887, DOI 10.1152/ajpcell.1986.251.6.C887; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BUSH KT, 1994, BIOCHEM J, V303, P705, DOI 10.1042/bj3030705; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DOSS RC, 1985, MOL PHARMACOL, V27, P507; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEDMAN RB, 1995, METHOD ENZYMOL, V251, P397, DOI 10.1016/0076-6879(95)51143-1; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROLLMAN EF, 1993, J BIOL CHEM, V268, P3604; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; KIM PS, 1993, AM J PHYSIOL, V265, pC704, DOI 10.1152/ajpcell.1993.265.3.C704; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MORI K, 1993, CELL, V74, P743; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRABAKARAN D, 1993, J BIOL CHEM, V268, P9041; PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314; RONNETT GV, 1981, J BIOL CHEM, V256, P4704; Rowling P J, 1993, Subcell Biochem, V21, P41; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WAGAR G, 1974, ACTA ENDOCRINOL-COP, V77, P64, DOI 10.1530/acta.0.0770064	44	134	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3057	3063		10.1074/jbc.272.5.3057	http://dx.doi.org/10.1074/jbc.272.5.3057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006956	hybrid			2022-12-25	WOS:A1997WE66700069
J	Sanchez, CP; Wunsch, S; Lanzer, M				Sanchez, CP; Wunsch, S; Lanzer, M			Identification of a chloroquine importer in Plasmodium falciparum - Difference in import kinetics are genetically linked with the chloroquine-resistant phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; INFECTED ERYTHROCYTES; DRUG-RESISTANCE; TRANSPORT; MEMBRANE; GENE; INHIBITION; PARASITES; AMILORIDE; REVERSAL	We demonstrate that uptake of the antimalarial drug chloroquine is temperature dependent, saturable, and inhibitable in Plasmodiun falciparum. These features are indicative of carrier mediated transport and suggest that a P. falciparum-encoded protein facilitates chloroquine import. Although both chloroquine-resistant and susceptible parasite isolates exhibit facilitated chloroquine uptake, the kinetics differ. Chloroquine-resistant parasite isolates consistently have an import mechanism with a lower transport activity and a reduced affinity for chloroquine. These differences in uptake kinetics are linked with chloroquine resistance in a genetic cross. These data suggest that changes in chloroquine import kinetics constitute a minimal and necessary event in the generation of the resistant phenotype. Competitive inhibition of chloroquine uptake by amiloride derivatives further suggests that chloroquine import is mediated by a plasmodial Na+/H+ exchanger.	UNIV WURZBURG,ZENTRUM INFEKT FORSCH,D-97070 WURZBURG,GERMANY	University of Wurzburg			Lanzer, Michael/E-9752-2013	Lanzer, Michael/0000-0002-0220-6526				AIKAWA M, 1972, AM J PATHOL, V67, P277; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BOSIA A, 1993, J CELL PHYSIOL, V154, P527, DOI 10.1002/jcp.1041540311; BRAY PG, 1994, MOL BIOCHEM PARASIT, V63, P87, DOI 10.1016/0166-6851(94)90011-6; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; FERRARI V, 1991, BIOCHEM PHARMACOL, V41, P23, DOI 10.1016/0006-2952(91)90006-Q; FERRARI V, 1991, BIOCHEM PHARMACOL, V42, pS167, DOI 10.1016/0006-2952(91)90407-V; FERRARI V, 1990, BIOCHEM PHARMACOL, V39, P753, DOI 10.1016/0006-2952(90)90155-E; FITCH CD, 1970, SCIENCE, V169, P289, DOI 10.1126/science.169.3942.289; FITCH CD, 1973, ANTIMICROB AGENTS CH, V3, P545, DOI 10.1128/AAC.3.5.545; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GINSBURG H, 1991, BIOCHEM PHARMACOL, V41, P1463, DOI 10.1016/0006-2952(91)90562-J; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KIRK K, 1995, BIOCHEM J, V311, P761, DOI 10.1042/bj3110761; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; MARTINEY JA, 1995, J BIOL CHEM, V270, P22393, DOI 10.1074/jbc.270.38.22393; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PEREZ M, 1986, METHOD ENZYMOL, V138, P709; SCHMID A, 1994, J BIOL CHEM, V269, P16706; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; TRAEGER W, 1976, SCIENCE, V193, P673; TSE M, 1993, J MEMBRANE BIOL, V135, P93; VIGNE P, 1983, BIOCHEM BIOPH RES CO, V116, P86, DOI 10.1016/0006-291X(83)90384-4; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784	36	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2652	2658		10.1074/jbc.272.5.2652	http://dx.doi.org/10.1074/jbc.272.5.2652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006900	hybrid			2022-12-25	WOS:A1997WE66700013
J	Li, Q; Cathcart, MK				Li, Q; Cathcart, MK			Selective inhibition of cytosolic phospholipase A(2) in activated human monocytes - Regulation of superoxide anion production and low density lipoprotein oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CALCIUM-INDEPENDENT PHOSPHOLIPASE; SMOOTH-MUSCLE; MACROPHAGE; CELLS; PURIFICATION; RECEPTOR; BIOSYNTHESIS; DISTINCT; OXIDASE	Our previous studies have shown that monocyte activation and release of O-2(radical anion) are required for monocyte-mediated low density lipoprotein (LDL) lipid oxidation. We have also found that intracellular Ca2+ levels and protein kinase C activity are requisite participants in this potentially pathogenic process. In these studies, we further investigated the mechanisms involved in the oxidation of LDL lipids by activated human monocytes, particularly the potential contributions of the cytosolic phospholipase A(2) (cPLA(2)) signaling pathway. The most well-studied cPLA(2), has a molecular mass of 85 kDa and has been reported to be regulated by both Ca2+ and phosphorylation. We found that cPLA(2) protein levels and cPLA(2) enzymatic activity mere induced upon activation of human monocytes by opsonized zymosan, Pharmacologic inhibition of cPLA(2) activity by AA-COOF3, which has been reported to be a specific inhibitor of cPLA(2) as compared with sPLA(2), caused a dose-dependent inhibition of cPLA(2) enzymatic activity and LDL lipid oxidation by activated human monocytes, whereas sPLA(2) activity was not affected. To corroborate these findings, we used specific antisense oligonucleotides to inhibit cPLA(2). We observed that treatment with antisense oligonucleotides caused suppression of both cPLA(2) protein expression and enzymatic activity as well as monocyte-mediated LDL lipid oxidation. Furthermore, antisense oligonucleotide treatment caused a substantial inhibition of O-2(radicl anion) production by activated human monocytes. In parallel experimental groups, cPLA(2) sense oligonucleotides did not affect cPLA(2) protein expression, cPLA(2) enzymatic activity, O-2(radical anion) production, or monoctye-mediated LDL Lipid oxidation. These studies support the proposal that cPLA(2) activity is required for activated monocytes to oxidize LDL Lipids.	CLEVELAND CLIN FDN,DEPT CELL BIOL,RES INST,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051068] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51068] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; BEDWELL S, 1989, BIOCHEM J, V262, P707, DOI 10.1042/bj2620707; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CATCHART MK, 1985, J LEUKOCYTE BIOL, V38, P341; CATHCART MK, 1991, J LIPID RES, V32, P63; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CATHCART MK, 1988, IN VITRO CELL DEV B, V24, P1001; DENNIS EA, 1995, ADV PROSTAG THROMB L, V23, P75; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; ELSAADANI M, 1989, J LIPID RES, V30, P627; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FOLCIK VA, 1993, J LIPID RES, V34, P69; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HENDERSON LM, 1993, EUR J BIOCHEM, V211, P157, DOI 10.1111/j.1432-1033.1993.tb19882.x; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; JAEGER JA, 1989, METHOD ENZYMOL, V183, P281; JOHNSTON RB, 1981, METHODS STUDYING MON, P489; Jones SS, 1996, FASEB J, V10, pL15; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KADRIHASSANI N, 1995, J BIOL CHEM, V270, P15111, DOI 10.1074/jbc.270.25.15111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Q, 1993, J CLIN INVEST, V91, P1499, DOI 10.1172/JCI116355; LI Q, 1994, J BIOL CHEM, V269, P17508; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Locati M, 1996, J BIOL CHEM, V271, P6010, DOI 10.1074/jbc.271.11.6010; MIYAKE R, 1992, BIOCHIM BIOPHYS ACTA, V1165, P167, DOI 10.1016/0005-2760(92)90183-V; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; QUINN MT, 1985, P NATL ACAD SCI USA, V82, P5949, DOI 10.1073/pnas.82.17.5949; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SHIRHATTI V, 1985, ANAL BIOCHEM, V147, P410, DOI 10.1016/0003-2697(85)90290-8; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	46	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2404	2411		10.1074/jbc.272.4.2404	http://dx.doi.org/10.1074/jbc.272.4.2404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999952	hybrid			2022-12-25	WOS:A1997WD67900058
J	McGuire, TF; Sebti, SM				McGuire, TF; Sebti, SM			Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity	ONCOGENE			English	Article						Ras inhibition; lovastatin; geranylgeraniol	CELL-CYCLE PROGRESSION; POSTTRANSLATIONAL MODIFICATIONS; PROTEIN FARNESYLTRANSFERASE; CDC42 GTPASES; GROWTH; BIOSYNTHESIS; MEVALONATE; SUBUNIT; RHO; ISOPRENYLATION	Oncogenic H-Ras requires farnesylation for its transforming activity. Lovastatin inhibits both protein farnesylation and geranylgeranylation by decreasing cellular pools of farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), respectively. Use of lovastatin as a chemotherapeutic agent has been precluded by its significant cytotoxic effects. In this report, we describe a novel approach utilizing a combination of lovastatin and geranylgeraniol (GGOH) to potentiate the ability of lovastatin to block oncogenic H-Ras signaling and concomitantly rescue lovastatin toxicity. GGOH co-treatment with lovastatin enhances inhibition of oncogenic H-Ras processing and constitutive activation of mitogen-activated protein kinase (MAPK), and preserves the processing of geranylgeranyltransferase (GGTase) I and GGTase II protein substrates. Moreover, co-treatment with GGOH significantly (15-fold) attenuates the cytotoxic effects of lovastatin as well as prevents lovastatin-induced cell rounding. These results demonstrate that GGOH potentiates the anti-oncogenic/anti-signaling activity of lovastatin while antagonizing its cytotoxicity. These opposing effects are due to a GGOH metabolite that serves simultaneously as a potent inhibitor for farneslyltransferase as web as a substrate for GGTases I and II.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055823] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BROWN MS, 1980, J LIPID RES, V21, P505; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; CRICK DC, 1994, BIOCHEM BIOPH RES CO, V205, P955, DOI 10.1006/bbrc.1994.2758; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; EPSTEIN WW, 1990, P NATL ACAD SCI USA, V87, P7352, DOI 10.1073/pnas.87.19.7352; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HORI Y, 1991, ONCOGENE, V6, P515; ILLINGWORTH DR, 1989, ARTERIOSCLEROSIS, V9, pI121; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REISS Y, 1992, J BIOL CHEM, V267, P6403; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SUN JZ, 1995, CANCER RES, V55, P4243; VIGANO T, 1995, EUR J PHARM-MOLEC PH, V291, P201, DOI 10.1016/0922-4106(95)90143-4	37	29	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					305	312		10.1038/sj.onc.1200819	http://dx.doi.org/10.1038/sj.onc.1200819			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018116				2022-12-25	WOS:A1997WD51600006
J	Dowell, P; Peterson, VJ; Zabriskie, TM; Leid, M				Dowell, P; Peterson, VJ; Zabriskie, TM; Leid, M			Ligand-induced peroxisome proliferator-activated receptor alpha conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; THYROID-HORMONE RECEPTOR; BETA-OXIDATION PATHWAY; STEROID BINDING DOMAIN; FATTY-ACIDS; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTORS; PROGESTERONE-RECEPTOR; SIGNALING PATHWAYS; CRYSTAL-STRUCTURE	Structurally diverse peroxisome proliferators and related compounds that have been demonstrated to induce the ligand-dependent transcriptional activation function of mouse peroxisome proliferator activated receptor alpha (mPPAR alpha) in transfection experiments were tested for the ability to induce conformational changes within mPPAR alpha in vitro. WY-14,643, 5,8,11,14-eicosatetraynoic acid, LY-171883, and clofibric acid all directly induced mPPAR alpha conformational changes as evidenced by a differential protease sensitivity assay. Carboxyl-terminal truncation mutagenesis of mPPAR alpha differentially affected the ability of these ligands to induce conformational changes suggesting that PPAR ligands may make distinct contacts with the receptor. Direct interaction of peroxisome proliferators and related compounds with, and the resulting conformational alteration(s) in, mPPAR alpha may facilitate interaction of the receptor with transcriptional intermediary factors and/or the general transcription machinery and, thus, may underlie the molecular basis of ligand dependent transcriptional activation mediated by mPPAR alpha.	OREGON STATE UNIV,COLL PHARM,CORVALLIS,OR 97331; OREGON STATE UNIV,PROGRAM MOL & CELLULAR BIOL,CORVALLIS,OR 97331	Oregon State University; Oregon State University					NIEHS NIH HHS [ES00040, ES00210] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES000040, P30ES000210] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BHAT MK, 1993, BIOCHEM BIOPH RES CO, V195, P385, DOI 10.1006/bbrc.1993.2055; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; FRITSCH M, 1993, BIOCHEMISTRY-US, V32, P14000, DOI 10.1021/bi00213a033; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Green S, 1995, MUTAT RES-FUND MOL M, V333, P101, DOI 10.1016/0027-5107(95)00136-0; HSU MH, 1995, MOL PHARMACOL, V48, P559; HUANG Q, 1994, J BIOL CHEM, V269, P8493; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LAKE BG, 1995, ANNU REV PHARMACOL, V35, P483, DOI 10.1146/annurev.pa.35.040195.002411; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; LEWIS DFV, 1993, XENOBIOTICA, V23, P79, DOI 10.3109/00498259309059364; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Miyata KS, 1996, J BIOL CHEM, V271, P9189, DOI 10.1074/jbc.271.16.9189; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; PARKS TD, 1994, ANAL BIOCHEM, V216, P1; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WITZUM JL, 1995, PHARMACOL BASIS THER, P892; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	65	86	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					2013	2020		10.1074/jbc.272.3.2013	http://dx.doi.org/10.1074/jbc.272.3.2013			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999894	hybrid			2022-12-25	WOS:A1997WD05800092
J	Jakubowski, H				Jakubowski, H			Metabolism of homocysteine thiolactone in human cell cultures - Possible mechanism for pathological consequences of elevated homocysteine levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; METHIONINE DEPENDENCY; PROOFREADING INVIVO; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; MALIGNANT-TUMORS; MAMMALIAN-CELLS; AMINO-ACIDS; IN-VIVO; DISEASE	Editing of the non-protein amino acid homocysteine, a frequent type of error-correcting process in amino acid selection for protein synthesis by an aminoacyl-tRNA synthetase, results in formation of a cyclic thioester, homocysteine thiolactone. Here it is shown that human cells in which homocysteine metabolism is deregulated by a mutation in the cystathionine beta-synthase gene and/or by an antifolate drug, aminopterin (which prevents remethylation of homocysteine to methionine by methionine synthase), produce more homocysteine thiolactone, in addition to homocysteine, than unaffected cells. The thiolactone is incorporated into cellular and extracellular proteins, in addition to being secreted and hydrolyzed to homocysteine. Experiments with model proteins and amino acids suggest that the mechanism of incorporation involves acylation of side chain amino groups of lysine residues by the activated carboxyl group of the thiolactone. The metabolic conversion of homocysteine to homocysteine thiolactone and the reactivity of the thiolactone toward proteins may explain pathological consequences of elevated levels of homocysteine such as observed in vascular disease.			Jakubowski, H (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103, USA.		Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409				ANDERSON RF, 1974, INT J RADIAT PHYS CH, V6, P33, DOI 10.1016/0020-7055(74)90033-3; Baernstein HD, 1934, J BIOL CHEM, V106, P451; BLOM HJ, 1995, EUR J CLIN INVEST, V25, P149, DOI 10.1111/j.1365-2362.1995.tb01541.x; BREILLOUT F, 1990, J NATL CANCER I, V82, P1628, DOI 10.1093/jnci/82.20.1628; BUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049; CHRISTENSEN B, 1991, J CELL PHYSIOL, V146, P52, DOI 10.1002/jcp.1041460108; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DONAHUE S, 1974, AM J PATHOL, V77, P167; DUDMAN NPB, 1991, ARTERIOSCLER THROMB, V11, P663, DOI 10.1161/01.ATV.11.3.663; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; FISKERSTRAND T, 1994, CANCER RES, V54, P4899; FOWLER B, 1982, BIOCHIM BIOPHYS ACTA, V721, P201, DOI 10.1016/0167-4889(82)90069-6; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; GOSEKI N, 1992, CANCER, V69, P1865, DOI 10.1002/1097-0142(19920401)69:7<1865::AID-CNCR2820690732>3.0.CO;2-M; GOSS SJ, 1986, J CELL SCI, V82, P309; GUO HY, 1993, CANCER RES, V53, P5676; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HALPERN BC, 1974, P NATL ACAD SCI USA, V71, P1133, DOI 10.1073/pnas.71.4.1133; HARRINGTON CR, 1994, NATURE, V370, P247, DOI 10.1038/370247a0; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1995, J BIOL CHEM, V270, P17672, DOI 10.1074/jbc.270.30.17672; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; KALHOUSE JF, 1993, ARCH BIOCHEM BIOPHYS, V303, P355; KREIS W, 1991, J NATL CANCER I, V83, P725, DOI 10.1093/jnci/83.10.725; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Lubec B, 1996, BBA-MOL BASIS DIS, V1315, P159, DOI 10.1016/0925-4439(95)00119-0; MCCULLY KS, 1989, RES COMMUN CHEM PATH, V63, P301; MUDD SH, 1989, RES COMMUN CHEM PATH, V63, P297; MUDD SH, 1995, METABOLIC MOL BASES, V1, P1279; REFSUM H, 1991, J PHARMACOL EXP THER, V258, P559; Riegel B, 1935, J BIOL CHEM, V112, P149; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SPINDEL E, 1974, BIOCHIM BIOPHYS ACTA, V343, P687, DOI 10.1016/0304-4165(74)90290-6; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; STERN PH, 1984, J CELL PHYSIOL, V119, P29, DOI 10.1002/jcp.1041190106; STERN PH, 1983, J CELL PHYSIOL, V117, P9, DOI 10.1002/jcp.1041170103; STURMAN JA, 1980, J BIOL CHEM, V255, P4763; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UELAND PM, 1986, JNCI-J NATL CANCER I, V77, P283; VIDAL M, 1986, BIOCHIMIE, V68, P723, DOI 10.1016/S0300-9084(86)80166-3; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; White F H Jr, 1972, Methods Enzymol, V25, P541, DOI 10.1016/S0076-6879(72)25052-2	46	248	253	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1935	1942						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999883				2022-12-25	WOS:A1997WD05800081
J	Lawe, DC; Hahn, C; Wong, AJ				Lawe, DC; Hahn, C; Wong, AJ			The Nck SH2/SH3 adaptor protein is present in the nucleus and associates with the nuclear protein SAM68	ONCOGENE			English	Article						Nck; SAM68; SH3 domains; signal transduction; tyrosine kinases	TYROSINE KINASE; SIGNAL-TRANSDUCTION; SH3 DOMAINS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHOLIPASE C-GAMMA-1; BINDING-PROTEIN; SRC; RECEPTOR	SH2/SH3 adaptor proteins are essential components of the signal transduction pathways initiated by tyrosine kinases. Nck is a ubiquitously expressed adaptor protein whose function has been enigmatic. We performed confocal microscopy to localize Nck in NIH3T3 and A431 cells. Surprisingly, Nck was identified in the nucleus as well as the cytoplasm with no visible change in localization due to PDGF or EGF stimulation. Western blot analysis of nuclear and cytosolic fractions confirmed that there was no translocation in response to growth factor and that tyrosine phosphorylation was specific to only cytosolic Nck. Far Western blot analysis with either Nck, the SH2 domain, or the SH3 domains revealed differential binding in nuclear and cytosolic lysates, indicating specific binding partners for each subcellular location. The major target of c-Src during mitosis is SAM68, a RNA-binding protein ordinarily localized to the nucleus. SAM68 was identified as a nuclear specific binding partner of Nck in both nonmitotic and mitotic cells. Several tyrosine kinases can be found in the nucleus but their signal transduction remains undefined. The discovery of an adaptor protein in the nucleus suggests there are signal transduction mechanisms within the nucleus that recapitulate those found in the cytoplasm.	KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; KIMMEL CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University					NATIONAL CANCER INSTITUTE [T32CA009678, R01CA053149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53149, T32-CA09678] Funding Source: Medline; NINDS NIH HHS [NS-31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; FELLER SM, 1995, ONCOGENE, V10, P1465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HU G, 1995, MOL CELL BIOL, V15, P1169; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NERI LM, 1994, CELL MOL BIOL, V40, P619; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAINE PL, 1983, J CELL BIOL, V97, P1240, DOI 10.1083/jcb.97.4.1240; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1992, J BIOL CHEM, V267, P12266; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Romero F, 1996, MOL CELL BIOL, V16, P37; RON D, 1992, BIOTECHNIQUES, V13, P866; RYAN PJ, 1994, DEV BIOL, V166, P101, DOI 10.1006/dbio.1994.1299; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANETTEN RA, 1995, ONCOGENE, V10, P1977; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	54	60	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					223	231		10.1038/sj.onc.1200821	http://dx.doi.org/10.1038/sj.onc.1200821			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010224	Bronze			2022-12-25	WOS:A1997WC81800010
J	Kim, JH; Mynatt, RL; Moore, JW; Woychik, RP; Moustaid, N; Zemel, MB				Kim, JH; Mynatt, RL; Moore, JW; Woychik, RP; Moustaid, N; Zemel, MB			The effects of calcium channel blockade on agouti-induced obesity	FASEB JOURNAL			English	Article						intracellular Ca2+; fatty acid synthase; Ca-2+s channel blockade	FATTY-ACID SYNTHASE; DEHYDROEPIANDROSTERONE-SULFATE LEVELS; CYTOSOLIC FREE CALCIUM; INSULIN-RESISTANCE; RAT-LIVER; ECTOPIC EXPRESSION; GENE-TRANSCRIPTION; HYPERTENSIVE MEN; YELLOW MICE; TRIIODOTHYRONINE	We have previously observed that obese viable yellow (A(vy)/a) mice exhibit increased intracellular Ca2+ ([Ca2+](i)) and fatty acid synthase (FAS) gene expression; further, recombinant agouti protein increases in cultured adipocytes and these effects are inhibited by Ca2+ channel blockade, Accordingly, we determined the effect of Ca2+ channel blockade (nifedipine for 4 wk) on FAS and obesity in transgenic mice expressing the agouti gene in a ubiquitous manner, The transgenic mice initially were significantly heavier (30.5+/-0.6 vs, 27.3+/-0.3 g; P<0.001) and exhibited a 0.81 degrees C lower initial core temperature (B<0,0005), an approximately twofold increase in fat pad weights (P=0,002), a sevenfold increase in adipose FAS activity (P=0,009), and a twofold increase in plasma insulin level (P<0,05) compared to control mice. Nifedipine treatment resulted in an 18% decrease in fat pad weights (P<0.007) and a 74% decrease in adipose FAS activity (P=0.03), normalized circulating insulin levels and insulin sensitivity (P<0,05), and transiently elevated core temperature in the transgenic mice, but was without effect in the control mice, These data suggest that agouti regulates FAS, fat storage, and possibly thermogenesis, at least partially, via a [Ca2+](i)-dependent mechanism, and that Ca2+ channel blockade may partially attenuate agouti-induced obesity.	UNIV TENNESSEE, DEPT NUTR, KNOXVILLE, TN 37996 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory			Mynatt, Randall L/N-1980-2017; Moustaid-Moussa, Naima/B-9067-2014; Woychik, Richard P/C-8345-2019	Mynatt, Randall L/0000-0003-4399-0019; Moustaid-Moussa, Naima/0000-0002-7508-8030; Woychik, Richard P/0000-0001-8196-1732; Zemel, Michael/0000-0003-4104-5750				BARCELLINICOUGET S, 1994, BIOCHEM BIOPH RES CO, V199, P136, DOI 10.1006/bbrc.1994.1205; BEER NA, 1994, J CLIN ENDOCR METAB, V79, P1077, DOI 10.1210/jc.79.4.1077; BEER NA, 1993, J CLIN ENDOCR METAB, V76, P178, DOI 10.1210/jc.76.1.178; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; CHAKRABA.K, 1969, P SOC EXP BIOL MED, V131, P1051, DOI 10.3181/00379727-131-34038; CLARKE SD, 1990, J NUTR, V120, P218, DOI 10.1093/jn/120.2.218; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; DIAMANT S, 1972, EUR J BIOCHEM, V26, P553, DOI 10.1111/j.1432-1033.1972.tb01798.x; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; FERRY WL, 1995, GENETICS, V140, P267; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GUICHARD C, 1992, J LIPID RES, V33, P679; JACKSON IJ, 1991, BIOESSAYS, V13, P439, DOI 10.1002/bies.950130903; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU B, 1994, J BIOL CHEM, V269, P7443; MALAISSE WJ, 1981, BIOCHEM PHARMACOL, V30, P1039, DOI 10.1016/0006-2952(81)90439-1; MALAISSE WJ, 1973, DIABETOLOGIA, V9, P167, DOI 10.1007/BF01219778; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MUSCH K, 1974, BIOCHIM BIOPHYS ACTA, V337, P343, DOI 10.1016/0005-2760(74)90109-X; NESTEL PJ, 1984, J CLIN INVEST, V74, P82, DOI 10.1172/JCI111422; ODIN RS, 1987, BIOCHIM BIOPHYS ACTA, V921, P378; Radin M J, 1993, Obes Res, V1, P433; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; VOLPE JJ, 1974, P NATL ACAD SCI USA, V71, P889, DOI 10.1073/pnas.71.3.889; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WOLF SS, 1994, BIOCHEM BIOPH RES CO, V203, P943, DOI 10.1006/bbrc.1994.2273; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; YOSHIDA T, 1994, INT J OBESITY, V18, P776; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZEMEL MB, 1995, OBES RES, V3, pS338	42	74	80	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1996	10	14					1646	1652		10.1096/fasebj.10.14.9002558	http://dx.doi.org/10.1096/fasebj.10.14.9002558			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002558				2022-12-25	WOS:A1996WC86900012
J	Dolan, M; Horchar, T; Rigatti, B; Hassell, JR				Dolan, M; Horchar, T; Rigatti, B; Hassell, JR			Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN-RECEPTOR; PROTEOGLYCAN CORE PROTEIN; CELL-ADHESION MOLECULES; EPIDERMAL GROWTH-FACTOR; BASEMENT-MEMBRANE; PRECURSOR PROTEIN; LAMININ; CHAIN; ATTACHMENT; SEQUENCE	Perlecan is primarily a heparan sulfate containing proteoglycan found in all basement membranes. Rotary shadowed images of perlecan show it to contain three glycosaminoglycan (GAG) side chains extending from one end of its core protein. Domain I is at the N terminus of perlecan and contains three closely spaced Ser-Gly-Asp sequences that may serve in GAG attachment. We evaluated the serines in these three sequences for GAG attachment by preparing a cDNA construct encoding for the N-terminal half (domains I, II, and III) of perlecan and then a series of constructs containing deletions and mutations within domain I of the domain I/II/III con struct, expressing these constructs in COS-7 cells, and then analyzing the recombinant product for GAG side chains and GAG type, The results showed that all three serine residues in the Ser-Gly-Asp sequences in domain I can accept both chondroitin and heparan sulfate side chains but that a cluster of acidic residues N-terminal to these sequences is the primary determinant responsible for targeting these sites for heparan sulfate, Furthermore, there are two elements that can enhance heparan sulfate synthesis at a targeted site: 1) the presence of a the SEA module in the C-terminal region of domain I and 2) the presence of multiple accepters in close proximity. These results indicate that the proportion of heparan and chondroitin sulfate at any one site in domain I of perlecan is regulated by multiple factors.	UNIV PITTSBURGH,SCH MED,DEPT OPHTHALMOL,OPHTHALMOL RES CTR,EYE & EAR INST,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045380] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM45380] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CHAKRAVARTI S, 1995, J BIOL CHEM, V270, P404, DOI 10.1074/jbc.270.1.404; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; DOEGE K, 1987, J BIOL CHEM, V262, P17757; Hassell John R., 1993, V6, P69; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; IOZZO RV, 1989, ARCH BIOCHEM BIOPHYS, V269, P239, DOI 10.1016/0003-9861(89)90105-7; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KLEIN DJ, 1988, J CELL BIOL, V106, P963, DOI 10.1083/jcb.106.3.963; KOKENYESI R, 1995, BIOCHEM BIOPH RES CO, V211, P252; KOKENYESI R, 1994, J CELL BIOL, V124, P557; LAURIE GW, 1987, AM J ANAT, V181, P320; LEDBETTER SR, 1985, J BIOL CHEM, V260, P8106; LINDAHL U, 1972, GLYCOPROTEINS, VA, P491; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1993, KIDNEY INT, V43, P53, DOI 10.1038/ki.1993.10; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; PAULSSON M, 1987, J MOL BIOL, V197, P197; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; RODEN L, 1966, J BIOL CHEM, V241, P5949; RODEN L, 1985, FED PROC, V44, P373; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127; [No title captured]	27	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4316	4322		10.1074/jbc.272.7.4316	http://dx.doi.org/10.1074/jbc.272.7.4316			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020150	hybrid			2022-12-25	WOS:A1997WH01900066
J	Ishikawa, N; TaniguchiSeto, H; Munakata, Y; Takagi, Y; Shimada, N; Kimura, N				Ishikawa, N; TaniguchiSeto, H; Munakata, Y; Takagi, Y; Shimada, N; Kimura, N			Multiple transcripts for rat nucleoside diphosphate kinase alpha isoform are structurally categorized into two groups that exhibit cell-specific expression and distinct translation potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-METASTASIS; GENE-EXPRESSION; MESSENGER-RNA; DICTYOSTELIUM-DISCOIDEUM; NM23/NDP KINASE; DROSOPHILA; CLONING; AMPLIFICATION; SUPPRESSOR; NM23-H2	Rat nucleoside diphosphate (NDP) kinase is composed of two isoforms (alpha and beta) encoded by independent genes. The mRNAs are expressed ubiquitously; however, the level of expression is tissue-dependent and is also up- or down-regulated under certain conditions, including growth stimulation, differentiation, and tumor metastasis. To address the regulatory mechanisms of gene expression for the rat NDP kinase major isoform alpha (an nm23-H2/PuF homologue), we identified the transcription initiation sites in detail by RNase protection and 5'-rapid amplification of DNA ends and located the core promoter region by chloramphenicol acetyltransferase assay. The transcripts, initiated from an extraordinarily wide range of sites, were categorized into two groups; one transcribed from an upstream region was spliced in the untranslated region (group 1), whereas the other initiated in the downstream region was not (group 2). RNase protection demonstrated that the group 1 mRNA was the dominant form present in all tissues except heart and skeletal muscle. In situ hybridization revealed cell specific expression of these mRNA species, Furthermore, they differed in the translational efficiency (the group 2 alpha > beta > the group 1 alpha). These findings suggest that the regulation of the NDP kinase expression at both transcriptional and posttranscriptional steps could be fundamentally governed by the selection of transcription initiation sites.	TOKYO METROPOLITAN INST GERONTOL,DEPT BIOL MOL,ITABASHI KU,TOKYO 173,JAPAN; TOKYO METROPOLITAN INST GERONTOL,DEPT IMMUNOPATHOL,ITABASHI KU,TOKYO 173,JAPAN	Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology	Ishikawa, N (corresponding author), TOKYO METROPOLITAN INST GERONTOL,DEPT MOL PATHOL,ITABASHI KU,35-2 SAKAECHO,TOKYO 173,JAPAN.							BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CARRASCO D, 1994, CELL BIOL LABORATORY, P466; CHEN HC, 1994, ONCOGENE, V9, P2905; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DOOLEY S, 1994, HUM GENET, V93, P63; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKUCHI T, 1993, GENE, V129, P141; FUKUCHI T, 1994, BBA-PROTEIN STRUCT M, V1205, P113, DOI 10.1016/0167-4838(94)90099-X; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIRZMANN J, 1993, NUCLEIC ACIDS RES, V21, P3597, DOI 10.1093/nar/21.15.3597; ISHIKAWA N, 1992, J BIOL CHEM, V267, P14366; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; NEHLS M, 1993, TRENDS GENET, V9, P336, DOI 10.1016/0168-9525(93)90024-C; OHNEDA K, 1994, FEBS LETT, V348, P273, DOI 10.1016/0014-5793(94)00623-7; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OKABEKADO J, 1995, FEBS LETT, V363, P311, DOI 10.1016/0014-5793(95)00338-A; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; RYU S, 1995, NATURE, V376, P560, DOI 10.1038/376560a0; Schwarz John J., 1993, P93; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TROLL H, 1993, J BIOL CHEM, V268, P25469; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199	44	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3289	3295		10.1074/jbc.272.6.3289	http://dx.doi.org/10.1074/jbc.272.6.3289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013567	hybrid			2022-12-25	WOS:A1997WG19200027
J	Shyue, SK; Ruan, KH; Wang, LH; Wu, KK				Shyue, SK; Ruan, KH; Wang, LH; Wu, KK			Prostacyclin synthase active sites - Identification by molecular modeling-guided site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTED 3-DIMENSIONAL STRUCTURE; PROSTAGLANDIN-H SYNTHASE; THROMBOXANE SYNTHASE; PROTEIN STRUCTURES; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; EXPRESSION; CLONING; HEMOPROTEIN	Prostacyclin synthase (PGIS), a cytochrome P450 enzyme, catalyzes the biosynthesis of a physiologically important molecule, prostacyclin. In this study we have used a molecular modeling-guided site directed mutagenesis to predict the active sites in substrate binding pocket and heme environment of PGIS. A three-dimensional model of PGIS was constructed using P450(BM-3) crystal structure as the template. Our results indicate that residues Ile(67), Val(76), Leu(384), Pro(355), Glu(360), and Asp(364), which were suggested to be located at one side of lining of the substrate binding pocket, are essential for catalytic activity. This region containing beta 1-1, beta 1-2, beta 1-3, and beta 1-4 strands is predicted well by the model, At the heme region, Cys(441) was confirmed to be the proximal axial ligand of heme iron. The conserved Phe and Arg in P450(BM-3) were substituted by Leu(112) and Asp(439) respectively in PGIS. Alteration of Leu(112) to Phe retained the activity, indicating that Leu(112) is a functional substitution for Phe. In contrast, mutant Asp(439) --> Ala exhibited a slight increase in activity. This result implies a difference in the heme region between P450(BM-3) and PGIS, Our results also indicate that stability of PGIS expression is not affected by heme site or active site mutations.	UNIV TEXAS, SCH MED, VASC BIOL RES CTR, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, DIV HEMATOL, HOUSTON, TX 77030 USA	University of Texas System; University of Texas System			Wu, Kenneth Kun-Yu/B-1070-2010; Shyue, Song-Kun/Q-2583-2018	Shyue, Song-Kun/0000-0002-1057-8696	NHLBI NIH HHS [R01 HL-50675] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATES PA, 1989, PROTEIN ENG, V3, P13, DOI 10.1093/protein/3.1.13; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; CLAESSENS M, 1989, PROTEIN ENG, V2, P335, DOI 10.1093/protein/2.5.335; DEWITT DL, 1983, J BIOL CHEM, V258, P3285; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; HAERMANN CA, 1995, STRUCTURE, V2, P41; HARA S, 1994, J BIOL CHEM, V269, P19897; Hatae T, 1996, FEBS LETT, V389, P268, DOI 10.1016/0014-5793(96)00600-X; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYATA A, 1994, BIOCHEM BIOPH RES CO, V200, P1728, DOI 10.1006/bbrc.1994.1652; MONCADA S, 1978, PHARMACOL REV, V30, P293; PEREIRA B, 1994, BIOCHEM BIOPH RES CO, V203, P59, DOI 10.1006/bbrc.1994.2148; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RUAN KH, 1993, J BIOL CHEM, V268, P19483; RUAN KH, 1994, PROTEIN ENG, V7, P1345, DOI 10.1093/protein/7.11.1345; SALMON JA, 1982, METHOD ENZYMOL, V86, P91; SANDUJA SK, 1991, BLOOD, V78, P3178; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; TSAI AL, 1992, J BIOL CHEM, V267, P17753; ULLRICH V, 1984, TRENDS PHARMACOL SCI, V5, P352, DOI 10.1016/0165-6147(84)90467-X; ULLRICH V, 1981, BIOCHEM PHARMACOL, V30, P20330; Wang LH, 1996, J BIOL CHEM, V271, P19970, DOI 10.1074/jbc.271.33.19970; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384; Wu KK, 1996, ANNU REV MED, V47, P315; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	27	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3657	3662		10.1074/jbc.272.6.3657	http://dx.doi.org/10.1074/jbc.272.6.3657			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013619	hybrid			2022-12-25	WOS:A1997WG19200079
J	Bimmler, D; Graf, R; Scheele, GA; Frick, TW				Bimmler, D; Graf, R; Scheele, GA; Frick, TW			Pancreatic stone protein (lithostathine), a physiologically relevant pancreatic calcium carbonate crystal inhibitor?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC CALCIFYING PANCREATITIS; JUICE; RAT; PRECIPITATION; NUCLEATION; EXPRESSION; SECRETIONS; GROWTH; CHAIN; FORMS	Apart from digestive enzymes, pancreatic juice contains several proteins that are not directly involved in digestion. One of these, lithostathine, has been reported to exhibit calcite crystal inhibitor activity in vitro. As pancreatic juice is supersaturated with respect to calcium carbonate, it was hypothesized that lithostathine stabilizes pancreatic juice. Lithostathine is cleaved by trace amounts of trypsin, resulting in a C-terminal polypeptide and an N-terminal undecapeptide, which has been identified as the active site of lithostathine regarding crystal inhibition. We produced rat lithostathine in a baculovirus expression system. In order to test its functional activity, the protein was purified using a nondenaturing multistep procedure. In the low micromolar range, recombinant rat lithostathine in vitro exhibited calcite crystal inhibitor activity, confirming earlier reports. Limited tryptic proteolysis of recombinant lithostathine was performed, and the two cleavage products were separated; the C-terminal polypeptide was precipitated by centrifugation, and the N-terminal undecapeptide was purified by high performance liquid chromatography. Only the C-terminal peptide displayed measurable calcite crystal inhibitory activity. Furthermore, synthetic undecapeptides with identical sequence to the N-terminal undecapeptides of rat or human lithostathine were inactive. However, when tested in the same in vitro assays, other pancreatic or extra-pancreatic proteins show inhibitory activity in the same concentration range as lithostathine, and inorganic phosphate is active as well. Based on these findings it seems unlikely that lithostathine is a physiologically relevant calcite crystal inhibitor. The name 'lithostathine'' is therefore inappropriate, and the protein's key function remains to be elucidated.	HARVARD UNIV,SCH MED,CHARLES A DANA RES INST,LAB CELL & MOL BIOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; BETH ISRAEL HOSP,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Bimmler, D (corresponding author), UNIV SPITAL ZURICH,DEPT CHIRURG,PANKREATITIS FORSCH LAB,CH-8091 ZURICH,SWITZERLAND.			Graf, Rolf/0000-0001-7449-7302				ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; ADRICH Z, 1989, COMP BIOCHEM PHYS B, V93, P793, DOI 10.1016/0305-0491(89)90047-3; AMMANN RW, 1984, GASTROENTEROLOGY, V86, P820; BERNARD JP, 1991, PANCREAS, V6, P162, DOI 10.1097/00006676-199103000-00006; BERNARD JP, 1992, GASTROENTEROLOGY, V103, P1277, DOI 10.1016/0016-5085(92)91516-7; BIMMLER D, 1995, PANCREAS, V11, P63, DOI 10.1097/00006676-199507000-00007; Bockman D E, 1986, Pancreas, V1, P204, DOI 10.1097/00006676-198605000-00002; Dagorn J. C., 1993, P253; DECARO A, 1979, BIOCHEM BIOPH RES CO, V87, P1176, DOI 10.1016/S0006-291X(79)80031-5; DECARO AM, 1989, BIOCHIM BIOPHYS ACTA, V994, P281, DOI 10.1016/0167-4838(89)90305-1; FORSTNER GG, 1989, J PEDIATR GASTR NUTR, V8, P313, DOI 10.1097/00005176-198904000-00009; GROSS J, 1985, J CLIN INVEST, V76, P2115, DOI 10.1172/JCI112216; GUY O, 1983, GASTROENTEROLOGY, V84, P102; HAY DI, 1986, CALCIFIED TISSUE INT, V39, P151, DOI 10.1007/BF02555111; JANOWITZ HD, 1962, CIBA F S EXOCRINE PA, P115; MONTALTO G, 1988, PANCREAS, V3, P263, DOI 10.1097/00006676-198805000-00004; MOORE EW, 1985, J LAB CLIN MED, V106, P611; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULTIGNER L, 1983, BIOCHEM BIOPH RES CO, V110, P69, DOI 10.1016/0006-291X(83)91261-5; REDDY MM, 1977, J CRYST GROWTH, V41, P287, DOI 10.1016/0022-0248(77)90057-4; REDDY MM, 1981, J COLLOID INTERF SCI, V80, P171, DOI 10.1016/0021-9797(81)90173-9; Rinderknecht Heinrich, 1993, P219; ROUIMI P, 1987, FEBS LETT, V216, P195, DOI 10.1016/0014-5793(87)80688-9; ROUQUIER S, 1991, J BIOL CHEM, V266, P786; SARLES H, 1990, GASTROENTEROLOGY, V99, P900, DOI 10.1016/0016-5085(90)90999-H; SEWELL WA, 1975, J PHYSIOL-LONDON, V252, P379, DOI 10.1113/jphysiol.1975.sp011149; WHEELER AP, 1981, SCIENCE, V212, P1397, DOI 10.1126/science.212.4501.1397; YAMADERA K, 1990, PANCREAS, V5, P255, DOI 10.1097/00006676-199005000-00003	28	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3073	3082		10.1074/jbc.272.5.3073	http://dx.doi.org/10.1074/jbc.272.5.3073			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006958	hybrid			2022-12-25	WOS:A1997WE66700071
J	Olakanmi, O; Stokes, JB; Pathan, S; Britigan, BE				Olakanmi, O; Stokes, JB; Pathan, S; Britigan, BE			Polyvalent cationic metals induce the rate of transferrin-independent iron acquisition by HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; FRIEND-ERYTHROLEUKEMIA CELLS; INTRACELLULAR MULTIPLICATION; LEGIONELLA-PNEUMOPHILA; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; FERRIREDUCTASE ACTIVITY; TRANSPORT-SYSTEM; K562 CELLS; BOUND IRON	The trivalent metals iron, aluminum, and gallium greatly increase the rate of iron acquisition from low molecular weight chelates by human myeloid cells. The present study explores the mechanism responsible. Gallium-induced iron acquisition was shown to lead to stable cellular association of iron, the magnitude of which varied with the chelate to which the iron was bound. The majority of this iron initially associated with the plasma membrane. Cellular depletion of ATP did not affect the response to gallium nor did it require the continued presence of extracellular gallium. However, continued cell association of gallium was needed as subsequent cellular exposure to metal chelators resulted in a rapid loss of the ''induced'' phenotype. Other trivalent metals (lanthanum and gadolinium) and tetravalent metals (tin and zirconium) but not divalent metals also induced iron acquisition. Neither enhanced iron reduction nor protein kinase C or tyrosine kinases appeared involved in gallium-mediated induction of iron acquisition. Exposure of HL-60 cells to polyvalent cationic metals results in a dramatic and sustained increase in the rate of iron acquisition from low molecular weight chelating agents. This could be important for the rapid clearance of iron by phagocytes from the extracellular environment at sites of local tissue damage.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; VET ADM MED CTR,RES SERV,IOWA CITY,IA 52246	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025231] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44275] Funding Source: Medline; NIAID NIH HHS [AI28412] Funding Source: Medline; NIDDK NIH HHS [DK25231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABREO K, 1994, KIDNEY INT, V45, P636, DOI 10.1038/ki.1994.85; ABREO K, 1990, KIDNEY INT, V37, P677, DOI 10.1038/ki.1990.33; ALVAREZHERNANDEZ X, 1986, BIOCHIM BIOPHYS ACTA, V886, P214, DOI 10.1016/0167-4889(86)90139-4; AVRUCH J, 1994, BIOCHIM BIOPHYS ACTA, V33, P11850; BACON BR, 1990, HEPATOLOGY, V11, P127, DOI 10.1002/hep.1840110122; BONKOVSKY HL, 1991, AM J MED SCI, V301, P32, DOI 10.1097/00000441-199101000-00006; BYRD TF, 1991, J CLIN INVEST, V88, P1103, DOI 10.1172/JCI115409; BYRD TF, 1991, J CLIN INVEST, V88, P351, DOI 10.1172/JCI115301; BYRD TF, 1989, J CLIN INVEST, V83, P1457, DOI 10.1172/JCI114038; BYRD TF, 1993, J CLIN INVEST, V91, P969, DOI 10.1172/JCI116318; CHITAMBAR CR, 1987, BLOOD, V69, P144; CHITAMBAR CR, 1992, BLOOD, V80, P505; COFFMAN TJ, 1990, J CLIN INVEST, V86, P1030, DOI 10.1172/JCI114805; CUI Y, 1994, J IMMUNOL, V152, P5420; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DEJONG G, 1990, CLIN CHIM ACTA, V190, P1, DOI 10.1016/0009-8981(90)90278-Z; ERNSLEY J, 1991, ELEMENTS; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HAMAZAKI S, 1992, EXP HEMATOL, V20, P436; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; INMAN RS, 1993, J BIOL CHEM, V268, P8521; INMAN RS, 1994, BIOCHEMISTRY-US, V33, P11850, DOI 10.1021/bi00205a022; JOHANSSON A, 1992, ENVIRON RES, V58, P66, DOI 10.1016/S0013-9351(05)80205-1; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; NARASIMHAN J, 1991, ARCH BIOCHEM BIOPHYS, V289, P393, DOI 10.1016/0003-9861(91)90429-M; NARASIMHAN J, 1992, BIOCHEM PHARMACOL, V44, P2403, DOI 10.1016/0006-2952(92)90686-D; OLAKANMI O, 1994, J IMMUNOL, V153, P2691; OLAKANMI O, 1993, J CLIN INVEST, V91, P889, DOI 10.1172/JCI116310; OSHIRO S, 1993, J BIOL CHEM, V268, P21586; QIAN ZM, 1995, BBA-MOL CELL RES, V1269, P205, DOI 10.1016/0167-4889(95)00098-X; QUAIL EA, 1994, J CELL PHYSIOL, V159, P238, DOI 10.1002/jcp.1041590207; RANDELL EW, 1994, J BIOL CHEM, V269, P16046; RICHARDSON D, 1992, J BIOL CHEM, V267, P13972; RICHARDSON DR, 1995, BBA-MOL CELL RES, V1269, P105, DOI 10.1016/0167-4889(95)00096-B; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TAETLE R, 1988, BLOOD, V71, P1590; TESTA U, 1989, J BIOL CHEM, V264, P13181; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; THORSTENSEN K, 1990, BIOCHEM J, V271, P1; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; WARREN L, 1959, J BIOL CHEM, V234, P1971; WEAST C, 1987, CRC HDB CHEM PHYSICS	44	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2599	2606		10.1074/jbc.272.5.2599	http://dx.doi.org/10.1074/jbc.272.5.2599			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006892	hybrid			2022-12-25	WOS:A1997WE66700005
J	Lampi, KJ; Ma, ZX; Shih, M; Shearer, TR; Smith, JB; Smith, DL; David, LL				Lampi, KJ; Ma, ZX; Shih, M; Shearer, TR; Smith, JB; Smith, DL; David, LL			Sequence analysis of beta A3, beta B3, and beta A4 crystallins completes the identification of the major proteins in young human lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-CRYSTALLIN; AMINO-ACID-SEQUENCE; POLYACRYLAMIDE GELS; GENE FAMILY; CATARACT; CALPAIN; BETA-B2-CRYSTALLIN; PEPTIDES	A combination of Edman sequence analysis and mass spectrometry identified the major proteins of the young human lens as alpha A, alpha B, beta A1, beta A3, beta A4, beta B1, beta B2, beta B3, gamma S, gamma C, and gamma D-crystallins and mapped their positions on two-dimensional electrophoretic gels. The primary structures of human beta A1, beta A3, beta A4, and beta B3-crystallin subunits were predicted by determining cDNA sequences. Mass spectrometric analyses of each intact protein as well as the peptides from trypsin-digested proteins confirmed the predicted amino acid sequences and detected a partially degraded form of beta A3/A1 missing either 22 or 4 amino acid residues from its N-terminal extension. These studies were a prerequisite for future studies to determine how human lens proteins are altered during aging and cataract formation.	OREGON HLTH SCI UNIV,DEPT OPHTHALMOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT ORAL MOL BIOL,PORTLAND,OR 97201; UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588	Oregon Health & Science University; Oregon Health & Science University; University of Nebraska System; University of Nebraska Lincoln					NEI NIH HHS [EY07609, EY07755] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007609, R01EY007755, R29EY007755] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AARTS HJM, 1989, J MOL EVOL, V28, P313, DOI 10.1007/BF02103427; ALCALA J, 1988, CURR EYE RES, V7, P353, DOI 10.3109/02713688809031784; BERBERS GAM, 1984, EUR J BIOCHEM, V139, P467, DOI 10.1111/j.1432-1033.1984.tb08029.x; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BONAVENTURA C, 1994, ANAL BIOCHEM, V222, P44, DOI 10.1006/abio.1994.1451; BRAKENHOFF RH, 1990, J MOL BIOL, V216, P519, DOI 10.1016/0022-2836(90)90380-5; CHAMBERS C, 1993, GENE, V133, P295, DOI 10.1016/0378-1119(93)90655-M; COOPER PG, 1993, EUR J BIOCHEM, V213, P321, DOI 10.1111/j.1432-1033.1993.tb17765.x; DATILES MB, 1992, CURR EYE RES, V11, P669, DOI 10.3109/02713689209000740; David LL, 1996, J BIOL CHEM, V271, P4273; DAVID LL, 1993, J BIOL CHEM, V268, P1937; DAVID LL, 1994, INVEST OPHTH VIS SCI, V35, P785; DAVID LL, 1993, FEBS LETT, V324, P265, DOI 10.1016/0014-5793(93)80131-D; DEJONG WW, 1975, FEBS LETT, V58, P310, DOI 10.1016/0014-5793(75)80286-9; DEVRIES ACJ, 1991, EXP EYE RES, V53, P519, DOI 10.1016/0014-4835(91)90169-F; DUNCAN MK, 1995, GENE, V162, P189, DOI 10.1016/0378-1119(95)00363-B; Garland DL, 1996, EXP EYE RES, V62, P285, DOI 10.1006/exer.1996.0034; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HOGG D, 1986, J BIOL CHEM, V261, P2420; KRAMPS JA, 1977, FEBS LETT, V74, P82, DOI 10.1016/0014-5793(77)80757-6; MEDZIHRADSKY KF, 1996, J AM SOC MASS SPECTR, V1, P1; MIESBAUER LR, 1993, PROTEIN SCI, V2, P290; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; RINGENS PJ, 1982, EXP EYE RES, V34, P201, DOI 10.1016/0014-4835(82)90054-9; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SIEZEN RJ, 1987, P NATL ACAD SCI USA, V84, P6088, DOI 10.1073/pnas.84.17.6088; SMITH JB, 1995, BIOCHEM J, V307, P407, DOI 10.1042/bj3070407; Srivastava O. P., 1996, Investigative Ophthalmology and Visual Science, V37, pS421; SWAMY MS, 1991, CURR EYE RES, V10, P213, DOI 10.3109/02713689109003443; THOMSON JA, 1985, EXP EYE RES, V40, P393, DOI 10.1016/0014-4835(85)90152-6; VANRENS GLM, 1991, GENE, V102, P179, DOI 10.1016/0378-1119(91)90149-6	31	162	175	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2268	2275						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999933				2022-12-25	WOS:A1997WD67900039
J	Ying, LH; Morris, BJ; Sigmund, CD				Ying, LH; Morris, BJ; Sigmund, CD			Transactivation of the human renin promoter by the cyclic AMP/protein kinase a pathway is mediated by both cAMP-responsive element binding protein-1 (CREB)-dependent and CREB-independent mechanisms in Calu-6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; GENE-EXPRESSION; JUXTAGLOMERULAR CELLS; REGULATORY ELEMENTS; SOMATOSTATIN GENE; CHORIONIC CELLS; FACTOR-I; AMP; IDENTIFICATION; INDUCTION	We examined the DNA sequence and transcription factor requirements for cAMP-induced transactivation of the human renin promoter using Calu-6 cells that express human renin mRNA endogenously. A series of constructs containing 896 base pairs of human renin 5'-flanking DNA fused to the luciferase gene and containing either the native, a consensus, or a nonfunctional cAMP response element (CRE) mere used to assess DNA sequence requirements mediating the cAMP response. Expression vectors encoding the CREB-1 transcription factor, a dominant negative mutant form of CREB-1, and the catalytic subunit of protein kinase A (PKA) were used to assess transcription factor requirements mediating the cAMP response. Forskolin treatment alone only caused a 2-3-fold activation of the HREN promoter in Calu-6 cells, but nearly a 10-fold activation in JEG-3 cells, which do not express renin but are highly responsive to cAMP. Gel shift assays revealed the binding of five specific DNA-protein complexes consisting of the ATF-I and CREB-1 transcription factors, one of which was an ATF-1 . CREB-1 heterodimer suggesting the potential for regulation of CREB-1 activity by ATF-1. However, over-expression of CREB-1 did not significantly enhance forskolin-induced human renin transcriptional activity. Transfection of both Calu-6 and JEG-3 cells with a PRA expression vector resulted in a 10-fold induction of human renin transcriptional activity in constructs containing the native or consensus CRE and 5-fold activation in a construct containing a nonfunctional CRE. We confirmed that the PKA response has both a CREB-dependent and CREB-independent component by demonstrating that the PKA response was abolished by co-transfection of a dominant negative mutant form of CREB-1 into cells containing the native or consensus CRE construct but not in cells containing the nonfunctional CRE construct. me therefore conclude that the human renin promoter can be transcriptionally activated in a renin expressing cell line through the cAMP-PKA pathway and is mediated by both a CREB-dependent and CREB-independent mechanism.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV SYDNEY,DEPT PHYSIOL,MOL BIOL & HYPERTENS LAB,SYDNEY,NSW 2006,AUSTRALIA	University of Iowa; University of Iowa; University of Sydney			Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048058, R01HL048058] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48058] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BALLERMANN BJ, 1991, KIDNEY, P510; BORENSZTEIN P, 1994, CIRC RES, V74, P764, DOI 10.1161/01.RES.74.5.764; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSON JM, 1994, AM J PHYSIOL, V267, pE260, DOI 10.1152/ajpendo.1994.267.2.E260; BURT DW, 1989, J BIOL CHEM, V264, P7357; Catanzaro Daniel F., 1995, P1589; CATANZARO DF, 1994, KIDNEY INT, V46, P1513, DOI 10.1038/ki.1994.433; Clauser E, 1996, EUR J ENDOCRINOL, V134, P403, DOI 10.1530/eje.0.1340403; DELLABRUNA R, 1995, KIDNEY INT, V47, P1266, DOI 10.1038/ki.1995.181; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; ELLIS MJC, 1995, MOL ENDOCRINOL, V9, P255, DOI 10.1210/me.9.2.255; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; Genest J, 1975, Trans Assoc Am Physicians, V88, P192; Germain S, 1996, BIOCHEM J, V316, P107, DOI 10.1042/bj3160107; GILBERT MT, 1994, J BIOL CHEM, V269, P1; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNS DW, 1990, AM J PHYSIOL, V259, pF882, DOI 10.1152/ajprenal.1990.259.6.F882; Lang JA, 1996, AM J PHYSIOL-RENAL, V271, pF94, DOI 10.1152/ajprenal.1996.271.1.F94; LANG JA, 1995, HYPERTENSION, V25, P704, DOI 10.1161/01.HYP.25.4.704; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LIU F, 1993, J BIOL CHEM, V268, P6714; Marrero MB, 1996, CELL SIGNAL, V8, P21, DOI 10.1016/0898-6568(95)02016-0; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P1163, DOI 10.1093/nar/21.5.1163; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORRIS BJ, 1994, KIDNEY INT, V46, P1516, DOI 10.1038/ki.1994.434; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PINET F, 1988, J CLIN ENDOCR METAB, V67, P1211, DOI 10.1210/jcem-67-6-1211; PINET F, 1987, J CLIN INVEST, V80, P724, DOI 10.1172/JCI113127; PINET F, 1988, P NATL ACAD SCI USA, V82, P8503; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; SMITH DL, 1994, BIOCHEM BIOPH RES CO, V200, P320, DOI 10.1006/bbrc.1994.1451; SUN JD, 1994, CIRC RES, V75, P624, DOI 10.1161/01.RES.75.4.624; TAYLOR GM, 1988, AM J PATHOL, V130, P543; TAYLOR GM, 1988, J HYPERTENS, V6, P845, DOI 10.1097/00004872-198810000-00012; TOYA Y, 1993, KIDNEY INT, V43, P928, DOI 10.1038/ki.1993.130; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	56	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2412	2420						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999953				2022-12-25	WOS:A1997WD67900059
J	Banga, SS; Kim, S; Hubbard, K; Dasgupta, T; Jha, KK; Patsalis, P; Hauptschein, R; Gamberi, B; DallaFavera, R; Kraemer, P; Ozer, HL				Banga, SS; Kim, S; Hubbard, K; Dasgupta, T; Jha, KK; Patsalis, P; Hauptschein, R; Gamberi, B; DallaFavera, R; Kraemer, P; Ozer, HL			SEN6, a locus for SV40-mediated immortalization of human cells, maps to 6q26-27	ONCOGENE			English	Article						immortalization; growth suppressor; SV40, SEN6; senescence	DINUCLEOTIDE REPEAT POLYMORPHISM; HUMAN-DIPLOID FIBROBLASTS; NON-HODGKINS-LYMPHOMA; LARGE T-ANTIGEN; INDEFINITE DIVISION; CELLULAR SENESCENCE; TELOMERASE ACTIVITY; DISTINCT REGIONS; GENETIC-ANALYSIS; SIMIAN VIRUS-40	Normal cells show a Limited lifespan in culture and the phenotype of cellular senescence, Tumors and tumor cell lines have typically overcome this form of growth suppression and grow continuously as immortal cell lines in culture, We have exploited the DNA virus SV40 to study the mechanism by which human fibroblasts overcome senescence and become immortal, Multiple steps have now been identified, including inactivation of cellular growth suppressors through direct interaction with SV40 large T antigen and through mutation of a gene on chromosome 6 (designated SEN6), In this study, we sublocalize the site of SEN6 to 6q26-27 based on molecular genetic analysis, Twelve SV40-immortalized fibroblast cell lines share a deletion in this area based on assessment for loss of heterozygostiy (LOH) for seven informative markers on 6q, Two immortal cell lines (AR5 and HALneo) appeared to have retained separate single copies of chromosome 6 despite the fact that they are both derived from the same preimmortal SV40-transformant and should share the same mutated allele of SEN6 (Hubbard-Smith et al., 1992), Detailed analysis by polymerase chain reaction, restriction fragment length polymorphism and fluorescence in situ hybridization shows, however, that although they differ for 17 markers from the centromere to 6q26, they share AR5 derived sequences (eight markers) distal to 6q26 including the minimal deletion region, further supporting the assignment of SEN6 to this region, Since human tumors including non-Hodgkins lymphoma, mammary carcinoma and ovarian carcinoma show LOH in 6q26-27, inactivation of SEN6 may be responsible for immortalization of these tumors as well.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103; CYPRUS INST NEUROL & GENET,DEPT CYTOGENET,NICOSIA,CYPRUS; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; LOS ALAMOS NATL LAB,CELLULAR & MOL BIOL GRP,LOS ALAMOS,NM	Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; United States Department of Energy (DOE); Los Alamos National Laboratory			Kim, Soo Hyun/ABG-8773-2020; Gamberi, Barbara/AAA-7508-2019	Kim, Soo Hyun/0000-0002-9394-1437; Gamberi, Barbara/0000-0003-3616-5838	NIA NIH HHS [AG04821, AG00378] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG004821, P01AG000378] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Banga SS, 1996, CYTOGENET CELL GENET, V73, P295, DOI 10.1159/000134359; BANGA SS, 1996, AM J HUM GENET; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BRAVARD A, 1992, INT J CANCER, V52, P797, DOI 10.1002/ijc.2910520521; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CASSON AG, 1991, CANCER RES, V51, P4495; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Del Senno L., 1992, Human Molecular Genetics, V1, P354; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FUJII M, 1995, ONCOGENE, V11, P627; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HOFFSCHIR F, 1992, INT J CANCER, V52, P130, DOI 10.1002/ijc.2910520123; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IMAI S, 1994, MOL CELL BIOL, V14, P7182, DOI 10.1128/MCB.14.11.7182; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LITZKAS P, 1984, MOL CELL BIOL, V4, P2549, DOI 10.1128/MCB.4.11.2549; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MITELMAN F, 1991, CATALOG CHROMOSOME A, V1, P393; NEGRINI M, 1994, CANCER RES, V54, P1331; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OFFIT K, 1993, BLOOD, V82, P2157; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; PARASKEVA C, 1989, INT J CANCER, V43, P743, DOI 10.1002/ijc.2910430434; Patsalis PC, 1995, CLIN GENET, V48, P275; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PURRELLO M, 1994, GENOMICS, V22, P94, DOI 10.1006/geno.1994.1349; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; RAY FA, 1992, CANCER GENET CYTOGEN, V59, P39, DOI 10.1016/0165-4608(92)90155-2; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; ROSEN DR, 1995, CYTOGENET CELL GENET, V69, P279, DOI 10.1159/000133979; SAGAWARA O, 1990, SCIENCE, V247, P707; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; SAITO S, 1992, CANCER RES, V52, P5815; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Small MB, 1996, J CELL PHYSIOL, V168, P727, DOI 10.1002/(SICI)1097-4652(199609)168:3<727::AID-JCP26>3.0.CO;2-U; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; TEYSSIER JR, 1992, ANTICANCER RES, V12, P997; TRASK BJ, 1992, METHOD CELL BIOL, V35, P3; VERGNAUD G, 1991, GENOMICS, V11, P135, DOI 10.1016/0888-7543(91)90110-Z; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; WAN MH, 1994, INT J ONCOL, V5, P1043; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; Wiesmuller L, 1996, J VIROL, V70, P737; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	68	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					313	321		10.1038/sj.onc.1200842	http://dx.doi.org/10.1038/sj.onc.1200842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018117				2022-12-25	WOS:A1997WD51600007
J	Fisher, M; Gokhman, I; Pick, U; Zamir, A				Fisher, M; Gokhman, I; Pick, U; Zamir, A			A structurally novel transferrin-like protein accumulates in the plasma membrane of the unicellular green alga Dunaliella salina grown in high salinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM TRANSFERRIN; IRON UPTAKE; LACTOFERRIN; RESOLUTION; MECHANISM; SEQUENCE; SURFACE; CLONING; SALT; RNA	The alga Dunaliella salina is outstanding is its ability to withstand extremely high salinities. To uncover mechanisms underlying salt tolerance, a search was carried out for salt-induced proteins. The level of a plasma membrane 150-kDa protein, p150, was found to increase with rising external salinity (Sadka, A., Himmelhoch, S., and Zamir, A. (1991) Plant Physiol. 95, 822-831). Based on its cDNA-deduced sequence, p150 belongs to the transferrin family of proteins so far identified only in animals. This, to our best knowledge, is the first demonstration of a transferrin-like protein in a photosynthetic organism. Unlike animal transferrins, p150 contains three, rather than two, internal repeats and a COOH-terminal extension including an acidic amino acid cluster. In intact cells p150 is degraded by Pronase, indicating that the protein is extracellularly exposed. The relationship of p150 to iron uptake is supported by the induction of the protein in iron-deficient media and by its radioactive labeling in cells grown with Fe-59. Accumulation of p150 is transcriptionally regulated. It is proposed that p150 acts in iron uptake other than by receptor-mediated endocytosis and that its induction permits the cells to overcome a possible limitation in iron availability under high salinities.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; AVRON M, 1986, TRENDS BIOCHEM SCI, V11, P5, DOI 10.1016/0968-0004(86)90218-5; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BALDWIN GS, 1993, COMP BIOCHEM PHYS B, V106, P203, DOI 10.1016/0305-0491(93)90028-4; BROWN JP, 1982, NATURE, V296, P171, DOI 10.1038/296171a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; Fisher M, 1996, J BIOL CHEM, V271, P17718, DOI 10.1074/jbc.271.30.17718; FISHER M, 1994, PLANT PHYSIOL, V106, P1359, DOI 10.1104/pp.106.4.1359; GOVEZENSKY D, 1989, J BACTERIOL, V171, P5729, DOI 10.1128/jb.171.10.5729-5735.1989; JELTSCH JM, 1982, EUR J BIOCHEM, V122, P291, DOI 10.1111/j.1432-1033.1982.tb05879.x; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8135; KURAMA T, 1995, EUR J BIOCHEM, V228, P229, DOI 10.1111/j.1432-1033.1995.tb20254.x; Kvingedal Ane M., 1993, Molecular Marine Biology and Biotechnology, V2, P233; LERS A, 1990, PLANT PHYSIOL, V93, P389, DOI 10.1104/pp.93.2.389; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORABITO MA, 1994, P NATL ACAD SCI USA, V91, P2478, DOI 10.1073/pnas.91.7.2478; NOWALK JA, 1944, BIOCHEMISTRY-US, V33, P12969; PICK U, 1986, PLANT PHYSIOL, V81, P92, DOI 10.1104/pp.81.1.92; SADKA A, 1991, PLANT PHYSIOL, V95, P822, DOI 10.1104/pp.95.3.822; Sambrook J., 2002, MOL CLONING LAB MANU; THORSTENSEN K, 1990, BIOCHEM J, V271, P1	27	68	94	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1565	1570		10.1074/jbc.272.3.1565	http://dx.doi.org/10.1074/jbc.272.3.1565			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999829	hybrid			2022-12-25	WOS:A1997WD05800027
J	Graves, LM; He, YQ; Lambert, J; Hunter, D; Li, XN; Earp, HS				Graves, LM; He, YQ; Lambert, J; Hunter, D; Li, XN; Earp, HS			An intracellular calcium signal activates p70 but not p90 ribosomal S6 kinase in liver epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; ANGIOTENSIN-II; PHOSPHATIDYLINOSITOL 3-KINASE; MESSENGER-RNA; DEPENDENT ACTIVATION; 3T3 CELLS; C-AKT; RAPAMYCIN	In the rat liver epithelial cell lines GN4 and WB, angiotensin II (Ang II) activates the G(q) class of regulatory G-proteins, increasing intracellular calcium, protein kinase C activity, and protein tyrosine phosphorylation. We compared the ability of Ang II and other compounds that increase intracellular calcium (i.e. the calcium ionophore A23187 and thapsigargin) or protein kinase C activity (the phorbol ester 12-O-tetradecanoylphorbol-13-acetate) to activate p70 ribosomal S6 kinase (p70(S6K)) and p90 ribosomal S6 kinase (p90(RSK)). In GN4 cells, increasing intracellular calcium stimulated p70(S6K) activity in a rapamycin- and wortmannin- sensitive manner, but did not affect p90(RSK) activity. In contrast, 12-O-tetradecanoylphorbol-13-acetate strongly activated p90(RSK) but only weakly stimulated p70(S6K). The ability of calcium to activate p70(S6K) was confirmed by blocking the A23187-dependent activation through chelation of extracellular calcium with EGTA; the effect of thapsigargin was inhibited by the cell permeant chelator bis-(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM). Similarly, BAPTA-AM prevented the activation of p70(S6K) by Ang II, suggesting that this signal was largely calcium-dependent. In contrast, the Ang II-dependent activation of mitogen-activated protein kinase and p90(RSK) was not inhibited but was enhanced by BAPTA-AM. These results show that in GN4 cells, Ang II selectively activates p70(S6K) through effects on calcium, p90(RSK) through effects on protein kinase C. The activation of p70(S6K) by calcium stimuli or Ang II was independent of calmodulin but correlated well with the activation of the recently identified, nonreceptor calcium-dependent tyrosine kinase (CADTK)/PYK-2. Both calcium- and Ang II-dependent activation of p70(S6K) were attenuated by the tyrosine kinase inhibitor genistein, and activation of p70(S6K) was higher in GN4 than WB cells, correlating with the increased ex expression and activation of CADTK/PYK-2 in GN4 cells. In summary, these results demonstrate that intracellular calcium selectively activates p70(S6K) in GN4 cells, consistent with increased CADTK/PYK-2 signaling in these cells.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Graves, LM (corresponding author), UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.		Graves, Lee/AAG-5470-2021		NIGMS NIH HHS [GM54010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BELLACOSA A, 1993, ONCOGENE, V8, P745; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EARP HS, 1995, J BIOL CHEM, V270, P28440; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Huckle William R., 1994, Progress in Growth Factor Research, V5, P177, DOI 10.1016/0955-2235(94)90004-3; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MEIER KE, 1990, J BIOL CHEM, V265, P4635; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SADOSHIMA J, 1995, CIRC RES, V76, P1; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SUSA M, 1992, J BIOL CHEM, V267, P6905; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERAO K, 1970, BIOCHEM BIOPH RES CO, V38, P80, DOI 10.1016/0006-291X(70)91086-7; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WALSH DA, 1991, METHOD ENZYMOL, V201, P304; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YU H, 1996, IN PRESS J BIOL CHEM, V272; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	57	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1920	1928		10.1074/jbc.272.3.1920	http://dx.doi.org/10.1074/jbc.272.3.1920			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999881	Green Published, hybrid			2022-12-25	WOS:A1997WD05800079
J	Nilsson, U; Meshalkina, L; Lindqvist, Y; Schneider, G				Nilsson, U; Meshalkina, L; Lindqvist, Y; Schneider, G			Examination of substrate binding in thiamin diphosphate-dependent transketolase by protein crystallography and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; YEAST TRANSKETOLASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; ACTIVE-SITE; CATALYSIS; COMPLEX; SPECIFICITY; REFINEMENT; ENZYMES	The three-dimensional structure of the quaternary complex of Saccharomyces cerevisiae transketolase, thiamin diphosphate, Ca2+, and the acceptor substrate erythrose-4-phosphate has been determined to 2.4 Angstrom resolution by protein crystallographic methods. Erythrose-4-phosphate was generated by enzymatic cleavage of fructose-6-phosphate. The overall structure of the enzyme in the quaternary complex is very similar to the structure of the holoenzyme; no large conformational changes upon substrate binding were found. The substrate binds in a deep cleft between the two subunits. The phosphate group of the substrate interacts with the side chains of the conserved residues Arg(359), Arg(528), His(469), and Ser(386) at the entrance of this cleft. The aldehyde moiety of the sugar phosphate is located in the vicinity of the C-2 carbon atom of the thiazolium ring of the cofactor. The aldehyde oxygen forms hydrogen bonds to the side chains of the residues His(30) and His(263). One of the hydroxyl groups of the sugar phosphate forms a hydrogen bond to the side chain of Asp(477) The preference of the enzyme for donor substrates with D-three configuration at the C-3 and C-4 positions and for a hydroxylated acceptor substrates can be understood from the pattern of hydrogen bonds between enzyme and substrate. Amino acid replacements by site directed mutagenesis of residues Arg(359), Arg(528), and His(469) at the phosphate binding site yield mutant enzymes with considerable residual catalytic activity but increased K-m values for the donor and in particular acceptor substrate, consistent with a role for these residues in phosphate binding. Replacement of Asp(477) by alanine results in a mutant enzyme impaired in catalytic activity and with increased K-m values for donor and acceptor substrates. These findings suggest a role for this amino acid in substrate binding and catalysis.	KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN; SWEDISH UNIV AGR SCI, DEPT MOL BIOL, S-75124 UPPSALA, SWEDEN	Karolinska Institutet; Swedish University of Agricultural Sciences			Lindqvist, Ylva/F-9009-2010; Meshalkina, Ludmilla/D-8448-2012	Schneider, Gunter/0000-0003-0622-5713; Lindqvist, Ylva/0000-0003-3162-8661				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRESLOW R, 1958, J AM CHEM SOC, V80, P3719, DOI 10.1021/ja01547a064; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; DEMUYNCK C, 1991, TETRAHEDRON LETT, V32, P5085, DOI 10.1016/S0040-4039(00)93434-8; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HEINRICH CP, 1972, BIOCHEM BIOPH RES CO, V49, P1427, DOI 10.1016/0006-291X(72)90498-6; HEINRICH CP, 1971, BIOCHEM BIOPH RES CO, V44, P275, DOI 10.1016/0006-291X(71)90595-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOBORI Y, 1992, J ORG CHEM, V57, P5899, DOI 10.1021/jo00048a023; KOCHETOV GA, 1982, METHOD ENZYMOL, V90, P209; KOCHETOV GA, 1973, BIOCHEM BIOPH RES CO, V54, P1619, DOI 10.1016/0006-291X(73)91172-8; KONIG S, 1994, J BIOL CHEM, V269, P10879; KRAMPITZ LO, 1969, ANNU REV BIOCHEM, V38, P213, DOI 10.1146/annurev.bi.38.070169.001241; KREMER AB, 1980, J BIOL CHEM, V255, P2405; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; NILSSON U, 1993, FEBS LETT, V326, P145, DOI 10.1016/0014-5793(93)81779-Y; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SCHNEIDER G, 1989, J BIOL CHEM, V264, P21619; SCHNEIDER G, 1993, BIOORG CHEM, V21, P109, DOI 10.1006/bioo.1993.1012; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; SUNDSTROM M, 1993, J BIOL CHEM, V268, P24346; USMANOV RA, 1983, BIOCHEMISTRY-MOSCOW+, V48, P478; WIKNER C, 1995, EUR J BIOCHEM, V233, P750, DOI 10.1111/j.1432-1033.1995.750_3.x; WIKNER C, 1994, J BIOL CHEM, V269, P32144	29	103	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1864	1869		10.1074/jbc.272.3.1864	http://dx.doi.org/10.1074/jbc.272.3.1864			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999873	hybrid			2022-12-25	WOS:A1997WD05800071
J	Salvucci, M; Lemoine, A; Azoulay, D; Sebagh, M; Bismuth, H; Reynes, M; May, E; Debuire, B				Salvucci, M; Lemoine, A; Azoulay, D; Sebagh, M; Bismuth, H; Reynes, M; May, E; Debuire, B			Frequent microsatellite instability in post hepatitis B viral cirrhosis	ONCOGENE			English	Article						microsatellite; liver; cirrhosis; HBV; PCR	LIVER-TRANSPLANTATION; GENETIC INSTABILITY; CANCER; POLYMORPHISMS; NEOPLASMS; CARCINOMA; VIRUS	The molecular basis of cirrhosis, the most frequent underlying liver disease in hepatocellular carcinoma, remains unclear, We investigated microsatellite instability at six different loci on chromosomes 2p, 3p, 5q, 9p, 13q and 17p, in DNA from 38 cirrhotic livers of viral (n = 28) and nonviral (n = 10) origin. Sixty percent of the patients exhibited microsatellite alterations in at least one chromosome locus, A striking feature was the close association between genomic instability and cirrhosis linked to hepatitis B viral infection (P<0.01), This high instability may be a clue to the etiology of cancer induced by the hepatitis B virus.	HOP PAUL BROUSSE,SERV BIOCHIM,F-94804 VILLEJUIF,FRANCE; HOP PAUL BROUSSE,CTR HEPATOBILIAIRE,F-94804 VILLEJUIF,FRANCE; HOP PAUL BROUSSE,SERV ANAT PATHOL,F-94804 VILLEJUIF,FRANCE; FAC MED PARIS SUD,FONTENAY ROSES,FRANCE; CEA,UMR 217 CNRS,FONTENAY ROSES,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; CEA			SEBAGH, Mylène/T-7464-2018; Azoulay, Daniel/Q-7887-2018					BEDI GC, 1995, NAT MED, V1, P65, DOI 10.1038/nm0195-65; BOURDON JC, 1995, GASTROENTEROLOGY, V108, P1176, DOI 10.1016/0016-5085(95)90217-1; CHONG JM, 1994, CANCER RES, V54, P4595; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; HAN HJ, 1993, CANCER RES, V53, P5087; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; MARTINSSON T, 1995, CANCER RES, V55, P5681; MERLO A, 1994, CANCER RES, V54, P2098; RISINGER JI, 1995, CANCER RES, V55, P5664; SAMUEL D, 1995, HEPATOLOGY, V21, P333, DOI 10.1016/0270-9139(95)90089-6; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; TAMURA G, 1995, CANCER RES, V55, P1933; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; UCHIDA T, 1995, ONCOGENE, V10, P1019; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YEE CJ, 1994, CANCER RES, V54, P1641	19	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2681	2685						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000142				2022-12-25	WOS:A1996VZ65400018
J	Manie, SN; Beck, ARP; Astier, A; Law, SF; Canty, T; Hirai, H; Druker, BJ; Avraham, H; Haghayeghi, N; Sattler, M; Salgia, R; Griffin, JD; Golemis, EA; Freedman, AS				Manie, SN; Beck, ARP; Astier, A; Law, SF; Canty, T; Hirai, H; Druker, BJ; Avraham, H; Haghayeghi, N; Sattler, M; Salgia, R; Griffin, JD; Golemis, EA; Freedman, AS			Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ADHESION MOLECULE-1; LYMPHOCYTES-B; ACTIVATION; KINASE; VLA-4; CRK; STIMULATION; ASSOCIATION; PRECURSORS	The Crk-associated substrate p130(Cas) (Gas) and the recently described human enhancer of filamentation 1 (HEF1) are two proteins with similar structure (64% amino acid homology), which are thought to act as ''docking'' molecules in intracellular signaling cascades. Both proteins contain an N-terminal Src homology (SH), three domain and a cluster of SH2 binding motifs. Here we show that ligation of either beta 1 integrin or B cell antigen receptor (BCR) on human tonsillar B cells and B cell lines promoted tyrosine phosphorylation of HEF1. In contrast, Cas tyrosine phosphorylation was observed in certain B cell lines but not in tonsillar B cells, indicating a more general role for HEF1 in B cell signaling. Interestingly, pretreatment of tonsillar B cells with cy tochalasin B dramatically reduced both integrin- and BCR-induced HEF1 phosphorylation, suggesting that some component of the BCR-mediated signaling pathway is closely linked with a cytoskeletal reorganization. Both HEF1 and Gas were found to complex with the related adhesion focal tyrosine kinase (RAFTK), and when tyrosine phosphorylated, with the adapter molecule CrkL. In addition, the two molecules were detected in p53/56(Lyn) immunoprecipitates, and Lyn kinase was found to specifically bind the C-terminal proline-rich sequence of Gas in an in vitro binding assay. These associations implicate HEF1 and Gas as important components in a cytoskeleton-linked signaling pathway initiated by ligation of beta 1 integrin or BCR on human B cells.	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; FOX CHASE CANC CTR, CANC RES INST, PHILADELPHIA, PA 19111 USA; UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA; DEACONESS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Fox Chase Cancer Center; University of Tokyo; Oregon Health & Science University			Astier, Anne L/A-1641-2008; Manie, Serge/ABC-8331-2021	Astier, Anne L/0000-0002-0144-3431; Golemis, Erica/0000-0003-3618-3673; manie, serge/0000-0002-9168-1977; Druker, Brian/0000-0001-8331-8206; Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [K08CA060821, R01CA055207, P01CA066996] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996, CA60821, CA55207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BOYER MJ, 1994, ONCOGENE, V9, P349; Burnham MR, 1996, ONCOGENE, V12, P2467; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; FREEDMAN AS, 1993, J IMMUNOL, V150, P1645; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KOOPMAN G, 1991, J EXP MED, V173, P1297, DOI 10.1084/jem.173.6.1297; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; Law SF, 1996, MOL CELL BIOL, V16, P3327; MANIE S, 1996, IN PRESS EXP HEMATOL; Manie SN, 1996, BLOOD, V87, P1855; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MELAMED I, 1991, J IMMUNOL, V147, P1139; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; PATCH LA, 1995, J CELL SCI, V108, P1371; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; RYAN DH, 1992, J IMMUNOL, V149, P3759; RYAN DH, 1990, J IMMUNOL, V145, P477; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; TENHOEVE J, 1994, CANCER RES, V54, P2563; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	108	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4230	4236		10.1074/jbc.272.7.4230	http://dx.doi.org/10.1074/jbc.272.7.4230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020138	hybrid			2022-12-25	WOS:A1997WH01900054
J	Moss, J; Stevens, LA; Cavanaugh, E; Okazaki, IJ; Bortell, R; Kanaitsuka, T; Mordes, JP; Greiner, DL; Rossini, AA				Moss, J; Stevens, LA; Cavanaugh, E; Okazaki, IJ; Bortell, R; Kanaitsuka, T; Mordes, JP; Greiner, DL; Rossini, AA			Characterization of mouse Rt6.1 NAD:arginine ADP-ribosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; AUTOIMMUNE DIABETES-MELLITUS; DIFFERENTIATION MARKER RT6; T-CELL SUBSET; TURKEY ERYTHROCYTES; SKELETAL-MUSCLE; ALLOANTIGEN RT6.1; BB/W RATS; EXPRESSION; RIBOSYLATION	Rat RT6 proteins, and perhaps mouse Rt6, identify a set of immunoregulatory T lymphocytes. Rat RT6.1 (RT6.1) and rat RT6.2 (RT6.2) are NAD glycohydrolases, which catalyze auto-ADP-ribosylation, but not ADP-ribosylation of exogenous proteins. Mouse Rt6.1 (mRt6.1) also catalyzes auto-ADP-ribosylation. The activity of mouse cytotoxic T lymphocytes is reportedly inhibited by ADP-ribosylation of surface proteins, raising the possibility that mRt6 may participate in this process. The reactions catalyzed by mRt6, would, however, need to be more diverse than those of the rat homologues and include the ADP-ribosylation of accepters other than itself. To test this hypothesis, mRt6.1 and rat RT6.2 were synthesized in Sf9 insect cells and rat mammary adenocarcinoma (NMU) cells. mRt6.1, but not rat RT6.2, catalyzed the ADP-ribosylation of guanidino-containing compounds (e.g. agmatine). Unlike RT6.2, mRt6.1 was a weak NAD glycohydrolase. In the presence of agmatine, however, the ratio of [adenine-C-14]ADP-ribosylagmatine formation from [adenine-C-14]NAD to [carbonyl-C-14]nicotinamide formation from [carbonyl-C-14]NAD was similar to 1.0, demonstrating that mRtG.1 is primarily a transferase. ADP-ribosylarginine hydrolase, which preferentially hydrolyzes the alpha-anomer of ADP-ribosylarginine, released [U-C-14]arginine from ADP-ribosyl[U-C-14] arginine synthesized by mRT6.1, consistent with the conclusion that mRt6.1 catalyzes a stereospecific S(n)2-like reaction. Thus, mRt6.1 is an NAD:arginine ADP-ribosyltransferase capable of catalyzing a multiple turnover, stereospecific S(n)2-like reaction.	UNIV MASSACHUSETTS, MED CTR, DIABET DIV, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Moss, J (corresponding author), NHLBI, PULM CRIT CARE MED BRANCH,NIH,RM 6D-03,BLDG 10, 10 CTR DR, MSC 1590, BETHESDA, MD 20892 USA.							BURSTEIN D, 1989, DIABETES, V38, P24, DOI 10.2337/diabetes.38.1.24; CRISA L, 1993, DIABETES, V42, P688, DOI 10.2337/diab.42.5.688; CRISA L, 1992, DIABETES METAB REV, V8, P9, DOI 10.1002/dmr.5610080104; DAVIS T, 1995, GENE, V164, P371, DOI 10.1016/0378-1119(95)00504-Y; FOWELL D, 1993, J EXP MED, V177, P627, DOI 10.1084/jem.177.3.627; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GREINER DL, 1987, J EXP MED, V166, P461, DOI 10.1084/jem.166.2.461; GREINER DL, 1986, J IMMUNOL, V136, P148; HAAG F, 1995, EUR J IMMUNOL, V25, P2355, DOI 10.1002/eji.1830250835; HAAG F, 1990, NUCLEIC ACIDS RES, V18, P1047, DOI 10.1093/nar/18.4.1047; Hollmann C, 1996, MOL IMMUNOL, V33, P807, DOI 10.1016/0161-5890(96)00008-9; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KOCH F, 1986, J EXP MED, V164, P1338, DOI 10.1084/jem.164.4.1338; KOCHNOLTE F, 1995, INT IMMUNOL, V7, P883, DOI 10.1093/intimm/7.5.883; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; KOCHNOLTE F, 1995, IMMUNOGENETICS, V41, P152, DOI 10.1007/BF00182329; KOSUDA LL, 1991, CELL IMMUNOL, V135, P154, DOI 10.1016/0008-8749(91)90262-A; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MOSS J, 1982, J BIOL CHEM, V257, P1660; MOSS J, 1981, P NATL ACAD SCI-BIOL, V78, P4809, DOI 10.1073/pnas.78.8.4809; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; MOSS J, 1980, J BIOL CHEM, V255, P5838; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MOSS J, 1986, BIOCHEMISTRY-US, V25, P5408, DOI 10.1021/bi00367a010; MOSS J, 1992, J BIOL CHEM, V267, P10481; MOSS J, 1985, P NATL ACAD SCI USA, V82, P5603, DOI 10.1073/pnas.82.17.5603; Nemoto E, 1996, J IMMUNOL, V156, P85; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; Okazaki I J, 1996, Adv Pharmacol, V35, P247, DOI 10.1016/S1054-3589(08)60277-X; Okazaki IJ, 1996, BLOOD, V88, P915; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; OPPENHEIMER NJ, 1978, J BIOL CHEM, V253, P4907; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; PROCHAZKA M, 1991, IMMUNOGENETICS, V33, P152, DOI 10.1007/BF00210829; Rigby MR, 1996, J IMMUNOL, V156, P4259; ROSSINI AA, 1995, CLIN IMMUNOL IMMUNOP, V74, P2, DOI 10.1006/clin.1995.1002; ROSSINI AA, 1986, J CLIN INVEST, V77, P1399, DOI 10.1172/JCI112448; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; Wang J, 1996, J IMMUNOL, V156, P2819; WANG J, 1994, J IMMUNOL, V153, P4048; WHALEN BJ, 1994, J AUTOIMMUN, V7, P819, DOI 10.1006/jaut.1994.1065; Zipris D, 1996, J IMMUNOL, V156, P1315; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352; [No title captured]	45	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4342	4346		10.1074/jbc.272.7.4342	http://dx.doi.org/10.1074/jbc.272.7.4342			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020154	hybrid			2022-12-25	WOS:A1997WH01900070
J	Onda, M; Tatsumi, E; Takahashi, N; Hirose, M				Onda, M; Tatsumi, E; Takahashi, N; Hirose, M			Refolding process of ovalbumin from urea-denatured state - Evidence for the involvement of nonproductive side chain interactions in an early intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; DISULFIDE FOLDING PATHWAY; MOLTEN GLOBULE STATE; KINETIC ROLE; REVERSIBLE DENATURATION; HEN OVALBUMIN; ACID; BONDS; RIBONUCLEASE-T1; TRANSITION	Ovalbumin contains one cystine disulfide (Cys(73)-Cys(120)) and four cysteine sulfhydryls (Cys(11), Cys(30), Cys(367), and Cys(382)) in a single polypeptide chain of 385 amino acid residues, The refolding mechanism of ovalbumin was investigated under disulfide-bonded and disulfide-reduced conditions using the denatured protein state, D-A, as the starting protein sample, For the preparation of D-A, the disulfide-intact and disulfide-reduced forms of ovalbumin were denatured by protein incubation in 9 M urea at pH 2.2. When D-A was placed in a refolding buffer, PH 8.2, an intermediate state I-N was produced in either the disulfide-bonded or the disulfide-reduced condition; I-N showed about 60% of the native CD ellipticity at 222 nm and the intrinsic tryptophan fluorescence with the native spectrum peak but with decreased intensity, The formation of I-N as detected by far UV CD ellipticity was quite rapid and finished within a mixing dead time of 20 ms, When D-A was diluted with an acidic buffer, pH 2.2, a partially folded equilibrium intermediate I-A with the structural characteristics equivalent to those of I-N was formed, After the formations of I-N and I-A, the regains in CD ellipticity and tryptophan fluorescence at pH 8.2 followed biphasic kinetics in the disulfide-bonded condition but monophasic kinetics in the disulfide-reduced condition, As unexpected findings, the native disulfide in D-A and I-A underwent nonproductive disulfide rearrangements in the disulfide-bonded condition at an early refolding stage and then was recovered during the subsequent refolding. The integrity of overall refolding was confirmed by the observation that the proteins refolded for 20 h in the disulfide-bonded and disulfide-reduced conditions showed, on differential scanning calorimetry analyses, almost exactly the same denaturation temperatures as their native protein counterparts, These results were consistent with a refolding process for ovalbumin which includes nonproductive side chain-side chain interactions in the early intermediate I-N, which requires subsequent reorganization for the correct refolding.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University				Hirose, Masaaki/0000-0003-2672-4384				BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; CHAN HS, 1994, J CHEM PHYS, V100, P9238, DOI 10.1063/1.466677; CHANG JY, 1995, J BIOL CHEM, V270, P11992, DOI 10.1074/jbc.270.20.11992; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; DARBY NJ, 1995, J MOL BIOL, V249, P463, DOI 10.1006/jmbi.1995.0309; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; FRECH C, 1995, J MOL BIOL, V251, P135, DOI 10.1006/jmbi.1995.0421; GOTO Y, 1982, J MOL BIOL, V156, P911, DOI 10.1016/0022-2836(82)90147-4; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; KOSEKI T, 1988, J BIOCHEM-TOKYO, V103, P425, DOI 10.1093/oxfordjournals.jbchem.a122286; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LEE JY, 1992, J BIOL CHEM, V267, P14753; MUCKE M, 1994, J MOL BIOL, V239, P713, DOI 10.1006/jmbi.1994.1408; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; OOBATAKE M, 1979, J BIOCHEM-TOKYO, V86, P65; PACE CN, 1986, J MOL BIOL, V188, P477, DOI 10.1016/0022-2836(86)90169-5; PACE CN, 1988, J BIOL CHEM, V263, P11820; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RODER H, 1995, NAT STRUCT BIOL, V2, P817, DOI 10.1038/nsb1095-817; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SORENSEN SPL, 1915, COMPT REND TRAV LAB, V12, P12; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846, DOI 10.1093/oxfordjournals.jbchem.a123469; TATSUMI E, 1994, J BIOL CHEM, V269, P28062; THOMPSON EOP, 1978, AUST J BIOL SCI, V31, P433, DOI 10.1071/BI9780433; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1995, NAT STRUCT BIOL, V2, P1123, DOI 10.1038/nsb1295-1123; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; YAMASHITA H, 1993, J BIOL CHEM, V268, P19062; YAMASHITA H, 1995, J BIOL CHEM, V270, P29806; YOUNGMAN KM, 1995, J BIOL CHEM, V270, P19816, DOI 10.1074/jbc.270.34.19816	39	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3973	3979		10.1074/jbc.272.7.3973	http://dx.doi.org/10.1074/jbc.272.7.3973			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020102	hybrid			2022-12-25	WOS:A1997WH01900018
J	Chatterjee, R; Ludden, PW; Shah, VK				Chatterjee, R; Ludden, PW; Shah, VK			Characterization of VNFG, the delta subunit of the vnf-encoded apodinitrogenase from Azotobacter vinelandii - Implications for its role in the formation of functional dinitrogenase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; 2ND ALTERNATIVE NITROGENASE; STRUCTURAL GENES; VANADIUM NITROGENASE; MUTATIONAL ANALYSIS; NUCLEOTIDE-SEQUENCE; VFE PROTEIN; CHROOCOCCUM; PURIFICATION; METALLOCLUSTERS	The vnf-encoded apodinitrogenase (apodinitrogenase 2) from Azotobacter vinelandii is an alpha(2) beta(2) delta(2) hexamer. The delta subunit (the VNFG protein) has been characterized in order to further delineate its function in the nitrogenase 2 enzyme system. Two species of VNFG were observed in cell-free extracts resolved on anoxic native gels; one is composed of VNFG; associated with the VNFDK polypeptides, and the other is a homodimer of the VNFG protein. Both species of VNFG are observed in extracts of A. vinelandii strains that accumulate dinitrogenase 2, whereas extracts of strains impaired in the biosynthetic pathway of the iron-vanadium cofactor (FeV-co) that accumulate apodinitrogenase 2 (a catalytically inactive form of dinitrogenase 2 that lacks FeV-co) exhibit only the VNFG dimer on native gels, FeV-co and nucleotide are required for the stable association of VNFG with the VNFDK polypeptides; this stable association can be correlated with the formation of active dinitrogenase 2. The iron-molybdenum cofactor was unable to replace FeV-co in promoting the stable association of VNFG with VNFDK, FeV-co specifically associates with the VNFG dimer in vitro to form a complex of unknown stoichiometry; combination of this VNFG-FeV-co species with apodinitrogenase 2 results in its reconstitution to dinitrogenase 2. The results presented here suggest that VNFG is required for processing apodinitrogenase 2 to functional dinitrogenase 2.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, COLL AGR & LIFE SCI, CTR STUDY NITROGEN FIXAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; Allen RM, 1996, J BIOL CHEM, V271, P4256; BISHOP PE, 1990, ANNU REV PLANT PHYS, V41, P109; BISHOP PE, 1986, SCIENCE, V232, P92, DOI 10.1126/science.232.4746.92; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; Chatterjee R, 1996, J BIOL CHEM, V271, P6819, DOI 10.1074/jbc.271.12.6819; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; EADY RR, 1987, BIOCHEM J, V244, P197, DOI 10.1042/bj2440197; EADY RR, 1991, ADV INORG CHEM, V36, P77, DOI 10.1016/S0898-8838(08)60037-9; FALLIK E, 1991, J BACTERIOL, V173, P365, DOI 10.1128/jb.173.1.365-371.1991; HALES BJ, 1986, BIOCHEMISTRY-US, V25, P7253, DOI 10.1021/bi00371a001; HALES BJ, 1986, J BIOL CHEM, V261, P5301; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; IMPERIAL J, 1987, J BACTERIOL, V169, P1784, DOI 10.1128/jb.169.4.1784-1786.1987; JOERGER RD, 1986, J BACTERIOL, V168, P673, DOI 10.1128/jb.168.2.673-682.1986; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1989, J BACTERIOL, V171, P1075, DOI 10.1128/jb.171.2.1075-1086.1989; KENNEDY C, 1986, MOL GEN GENET, V205, P318, DOI 10.1007/BF00430445; KENNEDY C, 1992, MOL GEN GENET, V231, P494, DOI 10.1007/BF00292722; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LUQUE F, 1991, MOL GEN GENET, V227, P481, DOI 10.1007/BF00273941; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Premakumar R, 1996, J BACTERIOL, V178, P691, DOI 10.1128/jb.178.3.691-696.1996; RAVI N, 1994, J BIOL CHEM, V269, P20920; ROBSON RL, 1986, NATURE, V322, P388, DOI 10.1038/322388a0; ROBSON RL, 1989, EMBO J, V8, P1217, DOI 10.1002/j.1460-2075.1989.tb03495.x; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; SMITH BE, 1988, BIOCHEM J, V250, P299, DOI 10.1042/bj2500299; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; WOLFINGER ED, 1991, J BACTERIOL, V173, P7565, DOI 10.1128/jb.173.23.7565-7572.1991	39	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3758	3765		10.1074/jbc.272.6.3758	http://dx.doi.org/10.1074/jbc.272.6.3758			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013633	hybrid			2022-12-25	WOS:A1997WG19200093
J	Noguchi, N; Takasawa, S; Nata, K; Tohgo, A; Kato, I; Ikehata, F; Yonekura, H; Okamoto, H				Noguchi, N; Takasawa, S; Nata, K; Tohgo, A; Kato, I; Ikehata, F; Yonekura, H; Okamoto, H			Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca2+ from islet microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL RYANODINE RECEPTOR; PANCREATIC BETA-CELLS; SARCOPLASMIC-RETICULUM; INSULIN-SECRETION; CALCIUM-RELEASE; PROINSULIN SYNTHESIS; MOLECULAR-CLONING; FEET STRUCTURES; ACINAR-CELLS; RAT	Cyclic ADP-ribose (cADPR) is a second messenger for Ca2+ mobilization via the ryanodine receptor (RyR) from islet microsomes for insulin secretion (Takasawa, S., Nata, K., Yonekura, H., and Okamoto, H. (1993) Science 259, 370-373). In the present study, FK506, an immunosuppressant that prolongs allograft survival, as well as cADPR were found to induce the release of Ca2+ from islet microsomes. After islet microsomes were treated with FK506, the Ca2+ release by cADPR from microsomes was reduced. cADPR as well as FK506 bound to FK506-binding protein 12.6 (FKBP12.6), which we also found occurs naturally in islet microsomes. When islet microsomes were treated with cADPR, FKBP12.6 dissociated from the microsomes and moved to the supernatant, releasing Ca2+ from the intracellular stores, The microsomes that were then devoid of FKBP12.6 did not show Ca2+ release by cADPR, These results strongly suggest that cADPR may be the ligand for FKBP12.6 in islet RyR and that the binding of cADPR to FKBP12.6 frees the RyR from FKBP12.6, causing it to release Ca2+.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,SENDAI,MIYAGI 98077,JAPAN	Tohoku University								ARAKAWA H, 1994, BIOCHEM BIOPH RES CO, V200, P836, DOI 10.1006/bbrc.1994.1527; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; FURUYA Y, 1995, GENE, V165, P329, DOI 10.1016/0378-1119(95)00540-M; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GROMADA J, 1995, FEBS LETT, V360, P303, DOI 10.1016/0014-5793(95)00131-R; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; ISLAM MS, 1993, SCIENCE, V262, P584, DOI 10.1126/science.8211188; ITOH N, 1979, EUR J BIOCHEM, V97, P1, DOI 10.1111/j.1432-1033.1979.tb13079.x; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; ITOH N, 1977, FEBS LETT, V80, P111, DOI 10.1016/0014-5793(77)80418-3; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; Masiello P, 1984, Toxicol Pathol, V12, P274; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; NELSON PA, 1991, GENE, V109, P255, DOI 10.1016/0378-1119(91)90617-K; OKAJIMA T, 1993, ANAL BIOCHEM, V211, P293, DOI 10.1006/abio.1993.1272; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; OKAMOTO H, 1995, BIOCHIMIE, V77, P356, DOI 10.1016/0300-9084(96)88146-6; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; SITSAPESAN R, 1995, AM J PHYSIOL-CELL PH, V268, pC1235, DOI 10.1152/ajpcell.1995.268.5.C1235; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TOHGO A, 1994, J BIOL CHEM, V269, P28555; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; YAMAGAMI T, 1985, CANCER RES, V45, P1845	41	162	169	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3133	3136		10.1074/jbc.272.6.3133	http://dx.doi.org/10.1074/jbc.272.6.3133			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013543	hybrid			2022-12-25	WOS:A1997WG19200003
J	Waters, AP; vanSpaendonk, RML; Ramesar, J; Vervenne, RAW; Dirks, RW; Thompson, J; Janse, CJ				Waters, AP; vanSpaendonk, RML; Ramesar, J; Vervenne, RAW; Dirks, RW; Thompson, J; Janse, CJ			Species-specific regulation and switching of transcription between state-specific ribosomal RNA genes in Plasmodium berghei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURES; SEXUAL DEVELOPMENT; MALARIA PARASITES; SURFACE PROTEIN; INVITRO; EXPRESSION; GAMETOCYTOGENESIS; IDENTIFICATION; SCHIZOGONY	Malaria parasites (Plasmodium spp.) differentially express structurally distinct sets of rRNA genes in a stage-specific manner. The four rRNA genes of the rodent malaria parasite, P. berghei, form two classes of 2 units that are genetically unlinked and termed A-type and S-type. Through Northern analysis and in situ hybridization, expression of the units was demonstrated in synchronized parasite preparations covering the developmental pathway from the initiation of the blood-stage asexual cycle to the production of mature ookinetes. A-type units were transcribed in direct response to cell growth in bloodstage asexual parasites yet were differentially regulated during male (inactive) and female (active) gametocytogenesis. S-type expression was not confined solely to the mosquito stages and exhibited a finite period of expression in a subset of bloodstage trophozoites that was significantly elevated in gametocyte-producing parasites, Unlike in the human parasite, P. falciparum, there was no evidence for accumulation of precursor forms of the S-type transcripts in gametocytes. No significant rRNA transcription was observed in cultured, fertilized ookinetes until similar to 20 h of development when S-type transcription was initiated. The results further demonstrate that in Plasmodium the expression of the different rRNA units is linked to developmental progression but in a species-specific manner.	LEIDEN STATE UNIV,DEPT CYTOCHEM & CYTOMETRY,NL-2333 AL LEIDEN,NETHERLANDS; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOL,LONDON SW7 2BB,ENGLAND	Leiden University; Leiden University - Excl LUMC; Imperial College London	Waters, AP (corresponding author), LEIDEN UNIV,DEPT PARASITOL,POSTBUS 9605,NL-2300 RC LEIDEN,NETHERLANDS.		Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Vervenne, Resie/0000-0002-6077-8725; Janse, Chris J/0000-0002-6410-6205				CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; DAME JB, 1983, J BIOL CHEM, V258, P6984; DAME JB, 1984, MOL BIOCHEM PARASIT, V11, P301, DOI 10.1016/0166-6851(84)90074-4; DAME JB, 1984, NUCLEIC ACIDS RES, V12, P5943, DOI 10.1093/nar/12.14.5943; DAME JB, 1983, MOL BIOCHEM PARASIT, V8, P263, DOI 10.1016/0166-6851(83)90048-8; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; ENEA V, 1991, J MOL EVOL, V32, P183, DOI 10.1007/BF02515391; GUNDERSON JH, 1987, SCIENCE, V238, P933, DOI 10.1126/science.3672135; JANSE CJ, 1989, INT J PARASITOL, V19, P509, DOI 10.1016/0020-7519(89)90080-5; JANSE CJ, 1984, INT J PARASITOL, V14, P317, DOI 10.1016/0020-7519(84)90083-3; JANSE CJ, 1985, PARASITOLOGY, V91, P219, DOI 10.1017/S0031182000057322; JANSE CJ, 1985, PARASITOLOGY, V91, P19, DOI 10.1017/S0031182000056481; JANSE CJ, 1994, MOL BIOCHEM PARASIT, V68, P285, DOI 10.1016/0166-6851(94)90173-2; JANSE CJ, 1995, PARASITOL TODAY, V11, P138, DOI 10.1016/0169-4758(95)80133-2; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; LI J, 1994, MOL BIOCHEM PARASIT, V65, P283, DOI 10.1016/0166-6851(94)90079-5; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MCCUTCHAN TF, 1988, MOL BIOCHEM PARASIT, V28, P63, DOI 10.1016/0166-6851(88)90181-8; MCCUTCHAN TF, 1995, PARASITOL TODAY, V11, P134, DOI 10.1016/0169-4758(95)80132-4; MONS B, 1985, PARASITOLOGY, V91, P423, DOI 10.1017/S0031182000062673; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L; Paule Marvin R., 1993, Gene Expression, V3, P1; PONZI M, 1990, MOL BIOCHEM PARASIT, V41, P73, DOI 10.1016/0166-6851(90)90098-7; RAAP AK, 1995, HUM MOL GENET, V4, P529, DOI 10.1093/hmg/4.4.529; Sambrook J., 2002, MOL CLONING LAB MANU; Shaw MK, 1996, EUR J CELL BIOL, V71, P270; SINDEN RE, 1983, ADV PARASIT, V22, P153, DOI 10.1016/S0065-308X(08)60462-5; THOMPSON J, 1994, MOL BIOCHEM PARASIT, V68, P189, DOI 10.1016/0166-6851(94)90164-3; VERVENNE RAW, 1994, MOL BIOCHEM PARASIT, V68, P259, DOI 10.1016/0166-6851(94)90170-8; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WATERS AP, 1989, NATURE, V342, P438, DOI 10.1038/342438a0; WATERS AP, 1993, MOL BIOL EVOL, V10, P914; ZHU JD, 1990, J BIOL CHEM, V265, P12740	33	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3583	3589		10.1074/jbc.272.6.3583	http://dx.doi.org/10.1074/jbc.272.6.3583			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013609	hybrid			2022-12-25	WOS:A1997WG19200069
J	Gether, U; Ballesteros, JA; Seifert, R; SandersBush, E; Weinstein, H; Kobilka, BK				Gether, U; Ballesteros, JA; Seifert, R; SandersBush, E; Weinstein, H; Kobilka, BK			Structural instability of a constitutively active G protein-coupled receptor - Agonist-independent activation due to conformational flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; INTRINSIC ACTIVITY; ANTAGONISTS; MUTATION; RHODOPSIN; MECHANISM; MUTANTS; DOMAIN; MODEL	Mutations in several domains can lead to agonist-independent, constitutive activation of G protein-coupled receptors. However, the nature of the structural and molecular changes that constitutively turn on a G protein-coupled receptor remains unknown. Here we show evidence that a constitutively activated mutant of the beta(2) adrenergic receptor (CAM) is characterized by structural instability and an exaggerated conformational response to ligand binding. The structural instability of CAM could be demonstrated by a 4-fold increase in the rate of denaturation of purified receptor at 37 degrees C as compared with the wild type receptor. Spectroscopic analysis of purified CAM labeled with the conformationally sensitive and cysteine-reactive fluorophore, N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine, further indicated that both agonist and antagonist elicit more profound structural changes in CAM than in the wild type protein. We propose that the mutation that confers constitutive activity to the beta(2) adrenergic receptor removes some stabilizing conformational constraints, allowing CAM to more readily undergo transitions between the inactive and the active states and making the receptor more susceptible to denaturation.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,BECKMAN CTR B157,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305; MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029	Howard Hughes Medical Institute; Stanford University; Stanford University; Icahn School of Medicine at Mount Sinai			WEINSTEIN, HAREL/O-8245-2019; Seifert, Roland/G-3189-2013	WEINSTEIN, HAREL/0000-0003-3473-9818; Kobilka, Brian/0000-0001-5958-3990; Gether, Ulrik/0000-0002-0020-3807	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009083] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00060, DA-09083] Funding Source: Medline; NINDS NIH HHS [R0 1 NS28471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; CERIONE RA, 1994, METHOD ENZYMOL, V237, P409; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; GETHER U, 1995, J BIOL CHEM, V270, P28268; GUAN XM, 1992, J BIOL CHEM, V267, P21995; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; KENAKIN T, 1994, TRENDS PHARMACOL SCI, V15, P408, DOI 10.1016/0165-6147(94)90086-8; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LUO XC, 1994, PROTEIN ENG, V7, P1441, DOI 10.1093/protein/7.12.1441; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SAMAMA P, 1997, IN PRESS P NATL ACAD; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TIBERI M, 1994, J BIOL CHEM, V269, P27925; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021	31	260	270	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2587	2590		10.1074/jbc.272.5.2587	http://dx.doi.org/10.1074/jbc.272.5.2587			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006889	hybrid			2022-12-25	WOS:A1997WE66700002
J	He, M; Bodi, I; Mikala, G; Schwartz, A				He, M; Bodi, I; Mikala, G; Schwartz, A			Motif III S5 of L-type calcium channels is involved in the dihydropyridine binding site - A combined radioligand binding and electrophysiological study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1 SUBUNIT; CA2+ CHANNELS; BETA-SUBUNIT; MOLECULAR DETERMINANTS; RECEPTOR-SITE; SMOOTH-MUSCLE; IDENTIFICATION; EXPRESSION; BLOCK; ALPHA-2-SUBUNIT	The alpha(1) subunit of L-type voltage-dependent Ca2+ channels (alpha(1C)) has been shown to harbor high affinity binding sites for the Ca2+ channel dihydropyridine (DHP) modulators. It has been suggested by a number of investigators that the binding site may be composed of III S6 and IV S6. Evidence with chimeric channels indicated the possible involvement of III S5 in DHP binding. Site-directed mutations were introduced in motif III S5 region of the alpha(1C), changing the amino acids to their counterparts in the DHP-insensitive alpha(1A) channel. The mutant channels were expressed both in HEK 293 cells and in Xenopus oocytes. Equilibrium binding and electrophysiological studies showed that the Thr(1006) to Tyr substitution produced a mutant channel with at least 1000-fold decreased affinity in [H-3](+)isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-(2,6-dimethyl-5-methoxycarbonyl)pyridine-3-carboxylate (PN200-110, isradipine) binding and in sensitivity of R(-)-4(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-5-nitro-3-pyridincarboxylic acid isopropylester (R202-791) in terms of inhibition of current through the L-type voltage-dependent Ca2+ channels. Replacing Gln(1010) with Met resulted in more than a 10-fold decrease in binding affinity for [H-3](+)PN200-110 and in the potency of channel modulation by S202-791. Four additional mutations in this region also lead to a slight but statistically significant increase of K-D values for [H-3](+)PN200-110 binding. The binding and electrophysiological results show that certain residues of the transmembrane segment III S5 are important in contributing to the DHP binding ''pocket'' and are critical for DHP binding and for its calcium channel effect.	UNIV CINCINNATI,INST MOL PHARMACOL & BIOPHYS,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NHLBI NIH HHS [P01-HL22619, 5R37 HL43231, T32 HL07382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, R37HL043231, P01HL022619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLIN T, 1993, CIRC RES, V72, P1337, DOI 10.1161/01.RES.72.6.1337; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FAN Z, 1996, BIOPHYS J, V70, P319; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HE M, 1996, BIOPHYS J, V70, P184; ITAGAKI K, 1992, FEBS LETT, V297, P221, DOI 10.1016/0014-5793(92)80542-O; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; MITTERDORFER J, 1995, BIOCHEMISTRY-US, V34, P9350, DOI 10.1021/bi00029a010; MIYAZAKI J, 1989, GENE, V79, P269; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; QU YS, 1995, P NATL ACAD SCI USA, V92, P11839, DOI 10.1073/pnas.92.25.11839; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SLISH DF, 1989, FEBS LETT, V250, P509, DOI 10.1016/0014-5793(89)80786-0; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRUBING C, 1993, BRIT J PHARMACOL, V108, P884, DOI 10.1111/j.1476-5381.1993.tb13482.x; SUNAMI A, 1996, CIRCULATION S1, V94, P286; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; YATANI A, 1993, CIRC RES, V73, P351, DOI 10.1161/01.RES.73.2.351; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	29	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2629	2633		10.1074/jbc.272.5.2629	http://dx.doi.org/10.1074/jbc.272.5.2629			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006896	hybrid			2022-12-25	WOS:A1997WE66700009
J	Kennedy, K; Gigoux, V; Escrieut, C; Maigret, B; Martinez, J; Moroder, L; Frehel, D; Gully, D; Vaysse, N; Fourmy, D				Kennedy, K; Gigoux, V; Escrieut, C; Maigret, B; Martinez, J; Moroder, L; Frehel, D; Gully, D; Vaysse, N; Fourmy, D			Identification of two amine acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTAGONIST BINDING DOMAINS; RAT PANCREATIC ACINI; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; AGONIST; AFFINITY; CCK; LOCALIZATION; MUTAGENESIS; GASTRIN	A region between residues 38 and 42 of the human cholecystokinin-A (CCK-A) receptor was shown to be involved in the binding of CCK but not in that of JMV 179 and JMV 180, two peptides closely related to CCK (Kennedy, K., Escrieut, C., Dufresne, M., Clerc, P., Vaysse, N., and Fourmy, D. (1995) Biochem. Biophys. Res. Commun. 213, 845-852). In the present study, we have identified the residues of both the receptor and the ligand responsible for this differential binding. Residues Trp-39 and Gln-40 of the receptor were crucial for binding of the C-terminal nonapeptide of CCK as W39F and Q40N mutants demonstrated parallel decreases in both affinity and potency to induce accumulation of inositol phosphates (12.9- and 20.9-fold). The W39F and Q40N mutant receptors bound CCK analogues modified at their C-terminal end, including JMV 179 and JMV 180, as well as the C-terminal amidated heptapeptide of CCK, with identical affinities to the wild-type receptor. In contrast, W39F and Q40N mutants bound CCK octapeptide with the same decreased affinity as the CCK nonapeptide. The modeling of the CCK-A receptor and the docking of the peptide agonists [Thr,Nle]CCK9 and CCK-8 indicated that their N terminus was connected to the receptor through a strong bond network involving Trp-39 and Gln-40 thus confirming experimental data. These first molecular data identifying the agonist binding site of the human CCK-A receptor represent an important step toward the complete delineation of the agonist binding site and the understanding of the molecular mechanisms that govern differential activation of this receptor by CCK-related peptides.	CHU RANGUEIL, INSERM, U151, INST LOUIS BUGNARD, F-31054 TOULOUSE, FRANCE; UNIV NANCY 1, CHIM THEOR LAB, F-54506 VANDOEUVRE LES NANCY, FRANCE; FAC PHARM MONTPELLIER, CNRS, URA 1845, F-34060 MONTPELLIER, FRANCE; MAX PLANCK INST BIOCHEM, D-82143 MARTINSRIED, GERMANY; SANOFI RECH, F-31036 TOULOUSE, FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Max Planck Society; Sanofi-Aventis; Sanofi France			Gigoux, Véronique/AAE-6090-2020; Martinez, Jean/R-9421-2019; Fourmy, Daniel/AAE-3703-2019	Gigoux, Véronique/0000-0003-1408-5335; Martinez, Jean/0000-0002-9267-4621; Fourmy, Daniel/0000-0001-9910-4827; Moroder, Luis/0000-0001-9570-5713				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DESCHENES RJ, 1984, P NATL ACAD SCI-BIOL, V81, P726, DOI 10.1073/pnas.81.3.726; DEWEERTH A, 1993, BIOCHEM BIOPH RES CO, V194, P811, DOI 10.1006/bbrc.1993.1894; FONG TM, 1992, J BIOL CHEM, V267, P25664; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; GULLY D, 1993, EUR J PHARMACOL, V232, P13, DOI 10.1016/0014-2999(93)90722-T; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; JAGERSCHMIDT A, 1995, MOL PHARMACOL, V48, P783; Jagerschmidt A, 1996, EUR J PHARMACOL, V296, P97, DOI 10.1016/0014-2999(95)00676-1; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JOSEPH MP, 1995, J PROTEIN CHEM, V14, P381, DOI 10.1007/BF01886795; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; LABBEJULLIE C, 1995, MOL PHARMACOL, V47, P1050; LIGNON MF, 1987, J BIOL CHEM, V262, P7226; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MIYAKE A, 1995, BIOCHEM BIOPH RES CO, V208, P230, DOI 10.1006/bbrc.1995.1328; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; MORODER L, 1993, Z NATURFORSCH B, V48, P1419; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUTT V, 1967, BIOCHEM BIOPH RES CO, V26, P392, DOI 10.1016/0006-291X(67)90558-X; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; Schwartz TW, 1996, TRENDS PHARMACOL SCI, V17, P213, DOI 10.1016/0165-6147(96)10017-1; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; SILVENTEPOIROT S, 1994, MOL PHARMACOL, V45, P599; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Strosberg A D, 1993, Drug Des Discov, V9, P199; TAKASUKA T, 1994, J BIOL CHEM, V269, P7509; TSUNODA Y, 1995, AM J PHYSIOL-GASTR L, V269, pG435, DOI 10.1152/ajpgi.1995.269.3.G435; ULRICH CD, 1993, BIOCHEM BIOPH RES CO, V193, P204, DOI 10.1006/bbrc.1993.1610; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701; WOODRUFF GN, 1991, ANNU REV PHARMACOL, V31, P469; YULE DI, 1992, J BIOL CHEM, V267, P13830; YULE DY, 1996, AM J PHYSIOL, V265, pG999	42	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2920	2926		10.1074/jbc.272.5.2920	http://dx.doi.org/10.1074/jbc.272.5.2920			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006937	hybrid			2022-12-25	WOS:A1997WE66700050
J	Nagaya, N; Papazian, DM				Nagaya, N; Papazian, DM			Potassium channel alpha and beta subunits assemble in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+-CHANNEL; BREFELDIN-A; RAT-BRAIN; BOVINE BRAIN; IN-VIVO; PROTEIN; TRANSPORT; STOICHIOMETRY; GOLGI; OLIGOSACCHARIDES	We have characterized the maturation of Shaker K+ channel protein and the cellular site of assembly of pore-forming alpha and cytoplasmic beta subunits in a transfected mammalian cell line. Shaker protein is made as a partially glycosylated, immature precursor that is converted to a fully glycosylated, mature product. Shaker protein did not mature when transport from the endoplasmic reticulum (ER) to the Golgi apparatus was blocked. Consistent with this finding, only the immature form was sensitive to digestion with endoglycosidase H. These results indicate that the immature protein is core glycosylated in the ER, whereas the oligosaccharides of the mature protein have been further processed in the Golgi compartment. After inhibiting ER-to-Golgi transport, the oligomeric state of Shaker subunits was assessed by cross-linking in intact cells or by solubilization and sucrose gradient sedimentation. The results indicate that Shaker subunits assemble with each other in the ER. When co-expressed, the Kv beta 2 subunit also associated with Shaker in the ER. Assembly with the beta 2 subunit did not increase the rate or extent of Shaker protein maturation. Our results indicate that the biogenesis of Shaker K+ channels in vivo involves core glycosylation and subunit assembly in the ER, followed by efficient transfer to the Golgi apparatus where the oligosaccharides are modified.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043459] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM043459-11, R01 GM043459-15, R01 GM043459-14, R01 GM043459-12, R01 GM043459-15S1, R01 GM043459, R01 GM043459-09, R01 GM043459-10, R01 GM043459-16, R01 GM043459-13, R01 GM043459-17] Funding Source: Medline; NINDS NIH HHS [NS070115] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; Fra A, 1993, Subcell Biochem, V21, P143; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIN L, 1994, BIOPHYS J, V66, pA106; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; MCCORMACK K, 1993, BIOPHYS J, V65, P1740, DOI 10.1016/S0006-3495(93)81202-5; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROSENBERG RL, 1992, NATURE, V360, P166, DOI 10.1038/360166a0; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; Rowling P J, 1993, Subcell Biochem, V21, P41; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P1295, DOI 10.1021/bi00172a002; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SCHWARZ TL, 1990, NEURON, V4, P119, DOI 10.1016/0896-6273(90)90448-O; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; SMITH MM, 1987, J BIOL CHEM, V262, P4367; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	59	118	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3022	3027		10.1074/jbc.272.5.3022	http://dx.doi.org/10.1074/jbc.272.5.3022			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006951	hybrid			2022-12-25	WOS:A1997WE66700064
J	PlengeTellechea, F; Soler, F; FernandezBelda, F				PlengeTellechea, F; Soler, F; FernandezBelda, F			On the inhibition mechanism of sarcoplasmic or endoplasmic reticulum Ca2+-ATPases by cyclopiazonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; NUCLEOTIDE BINDING-SITES; ADENOSINE 5'-TRIPHOSPHATE; TRANSPORT ATPASES; INFLUX PATHWAY; ATP-BINDING; THAPSIGARGIN; CELLS; MUSCLE; CA-2+-ATPASE	Ca2+-ATPase inhibition by stoichiometric and substoichiometric concentrations of cyclopiazonic acid was studied in sarcoplasmic reticulum preparations from rabbit fast-twitch muscle. The apparent affinity of the nonphosphorylated enzyme for ATP showed a K-d of similar to 3 mu M in the absence of cyclopiazonic acid and similar to 28 mu M in the presence of the drug. Fractional saturation of the enzyme by cyclopiazonic acid was accompanied by the appearance of two ATP-binding populations (enzyme with and without drug) and a progressive increase in the half-maximal concentration for saturating the ATP-binding sites. Enzyme turnover in the presence of stoichiometric concentrations of cyclopiazonic acid dis played lower apparent affinity for ATP and lower maximal hydrolytic activity than in the absence of the drug. When cyclopiazonic acid is in the substoichiometric range, the observed kinetic parameters will correspond to the simultaneous contribution of two different reaction cycles sustained by the enzyme with and without drug. The inhibition could be elicited by adding ATP to allow the enzyme turnover when cyclopiazonic acid was preincubated with the enzyme in the presence of Ca2+. The onset of inhibition during enzyme cycling was observed over a period of seconds, revealing the existence of a low inhibition rate constant, It is concluded that cyclopiazonic acid decreases enzyme affinity for ATP in non-turnover conditions by approximately one order of magnitude. This allows enzyme cycling after drug binding, provided that a high ATP concentration is used. Cyclopiazonic acid and ATP do not compete for the same binding site.	UNIV MURCIA, DEPT BIOQUIM & BIOL MOL A, EDIFICIO VET, E-30071 MURCIA, SPAIN	University of Murcia			PLenge, Luis/AAA-9458-2022					BAUDET S, 1993, CIRC RES, V73, P813, DOI 10.1161/01.RES.73.5.813; BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; Cole R. J., 1986, Diagnosis of mycotoxicoses. A publication based on the symposium on the diagnosis of mycotoxicoses of importance in the United States and Japan, held at Ames, Iowa, October 11-13, 1984, P91; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FALCONE D, 1995, J CELL PHYSIOL, V164, P205, DOI 10.1002/jcp.1041640125; FOSKETT JK, 1992, AM J PHYSIOL, V262, pC656, DOI 10.1152/ajpcell.1992.262.3.C656; GOEGER DE, 1988, BIOCHEM PHARMACOL, V37, P978, DOI 10.1016/0006-2952(88)90195-5; HOLZAPFE.CW, 1968, TETRAHEDRON, V24, P2101, DOI 10.1016/0040-4020(68)88113-X; INESI G, 1994, J MEMBRANE BIOL, V141, P1; KARON BS, 1994, BIOCHEMISTRY-US, V33, P13928, DOI 10.1021/bi00250a048; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON MJ, 1991, J BIOL CHEM, V266, P20856; NORRED WP, 1985, FOOD CHEM TOXICOL, V23, P1069, DOI 10.1016/0278-6915(85)90054-7; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; PASYK E, 1995, AM J PHYSIOL-HEART C, V268, pH138, DOI 10.1152/ajpheart.1995.268.1.H138; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; WATANABE T, 1982, J BIOL CHEM, V257, P1510; Williams J W, 1979, Methods Enzymol, V63, P437	31	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2794	2800		10.1074/jbc.272.5.2794	http://dx.doi.org/10.1074/jbc.272.5.2794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006919	hybrid			2022-12-25	WOS:A1997WE66700032
J	Kundu, GC; Mukherjee, AB				Kundu, GC; Mukherjee, AB			Evidence that porcine pancreatic phospholipase A(2) via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; PLASMINOGEN-ACTIVATOR; MOLECULAR-CLONING; EXPRESSION; LOCALIZATION; INFLAMMATION; RAT	Cellular migration and extracellular matrix (ECM) invasion are some of the critical steps in embryonic implantation, inflammation, mound healing, and cancer metastasis. Extracellular phospholipases A(2) (PLA(2)s), belonging to either group I (PLA(2)-I) or group II (PLA(2)-II), play an essential role in the generation of proinflammatory lipid mediators (e.g. prostaglandins, leukotrienes, etc.). Recent reports indicate that PLA(2)-I, in addition to its digestive function, has receptor-mediated effects. For instance, PLA(2)-I, via its receptor, can induce cell proliferation and airway as well as vascular smooth muscle contraction. Here, we report that both porcine pancreatic and Naja naja PLA(2)s, in a dose-dependent manner, stimulate dramatic invasion of an artificial ECM (Matrigel(TM)) by MH 3T3, mouse fibrosarcoma, and sarcoma cells in vitro, but it has no such effect on lymphoma and mastocytoma cells. That this is a receptor-mediated process is strongly suggested by the following findings. (a) While NIH 3T3, mouse fibrosarcoma, and sarcoma cells, which respond to PLA(2)-I stimulation, express high affinity PLA(2)-I receptor mRNA and protein, this receptor expression is not detectable in nonresponder lymphoma and mastocytoma cells. (b) There is a close correlation between the K-d values for I-I25-PLA(2)-I binding to its receptor and the ED(50) values for PLA(2)-I-induced ECM-invasion. (c) Catalytically inactivated PLA(2)-I is as effective as the active enzyme in stimulating invasion. (d) Suppression of PLA(2)-I receptor expression in responder cells causes inhibition of ECM invasion. (e) Treatment of the same cells with PLA(2)-I receptor-antibody also produces virtually identical effects. Taken together, our results identify a novel receptor-mediated function of PLA(2)-I and raises the possibility that extracellular PLA(2)s play important physiological as well as pathological roles via this receptor. To our knowledge, this is the first report of this novel receptor-mediated effect (i.e. ECM invasion) of PLA(2)-I on normal as well as malignant cancer cells.	NICHHD, SECT DEV GENET, HERITABLE DISORDERS BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Kundu, Gopal C./ABA-9897-2020					ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; BOMALASKI JS, 1991, J IMMUNOL, V146, P3904; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dennis EA, 1983, ENZYMES, P307; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRY MR, 1992, BIOL REPROD, V47, P751, DOI 10.1095/biolreprod47.5.751; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HERTZ J, 1992, CELL, V71, P411; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KISHINO J, 1992, BIOCHEM BIOPH RES CO, V186, P1025, DOI 10.1016/0006-291X(92)90849-G; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, ADV SEC MESS PHOSPH, V28, P81; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; WAITE M, 1988, PHOSPHOLIPASES, P1	37	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2346	2353						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999944				2022-12-25	WOS:A1997WD67900050
J	Ranganathan, G; Vu, D; Kern, PA				Ranganathan, G; Vu, D; Kern, PA			Translational regulation of lipoprotein lipase by epinephrine involves a trans-acting binding protein interacting with the 3' untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT ADIPOCYTES; HUMAN ADIPOSE-TISSUE; GENE-EXPRESSION; ORNITHINE DECARBOXYLASE; 3'-UNTRANSLATED REGION; FERRITIN; CELLS; EFFICIENCY; SECRETION; SEQUENCE	To better characterize the translational regulation of lipoprotein lipase (LPL) by epinephrine, cytoplasmic extracts were prepared from 3T3-L1 adipocytes, 3T3-F442A adipocytes, and other nonadipocyte cell lines (C2 cells, 3T3 fibroblasts, and Chinese hamster ovary cells), After treatment with epinephrine, cell extracts from the adipocytes inhibited LPL translation in an in vitro translation assay, whereas extracts from the C2 cells and 3T3 fibroblasts did not affect LPL translation, To identify the region on the LPL mRNA that controlled translation in vitro translation was carried out using constructs containing different LPL sequences, Specific deletion of the first 50 (1601-1650) nucleotides of the 3' untranslated region (UTR) resulted in a loss of translation inhibition, The addition of LPL 3' UTR to a heterologous reporter gene construct resulted in an inhibition of translation Inhibition of the reporter LPL 3' UTR translation was demonstrated by the addition of epinephrine-treated cell extracts to an in vitro translation assay, as well as by transfection of this construct into 3T3-F442A cells, followed by treatment of the cells with epinephrine. Competition for a trans-acting binding protein was demonstrated by the addition of sense mRNA strands corresponding to the proximal 135 nucleotides of the 3' UTR of LPL, To identify a RNA-binding protein, adipocyte extracts were incubated with P-32-labeled RNA sequences followed by RNase treatment, The epinephrine-treated cell extract protected a fragment of RNA when the RNA included sequences on the proximal 3' UTR of LPL, Cross-linking of this protected fragment and analysis by SDS-poIyacrylamide gel electrophoresis revealed a protein that migrated at about 30 kDa, Thus, the addition of epinephrine to 3T3 adipocytes results in an inhibition of translation through the production of a RNA-binding protein that binds to a region on the proximal 3' UTR of the LPL mRNA.	JOHN L MCCLELLAN MEM VET ADM MED CTR,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039176, R37DK039176, R01DK039176] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39176] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CHNG JL, 1990, SCIENCE, V245, P1003; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; GOLDSTEIN S, 1989, NUCLEIC ACIDS RES, V17, P3959, DOI 10.1093/nar/17.10.3959; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRENS A, 1990, J BIOL CHEM, V265, P11810; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KAHANA C, 1985, J BIOL CHEM, V260, P5390; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MUNRO HN, 1990, J CELL BIOCHEM, V44, P107, DOI 10.1002/jcb.240440205; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; ONG JM, 1988, J BIOL CHEM, V263, P12933; ONG JM, 1989, J BIOL CHEM, V264, P3177; ONG JM, 1992, ENDOCRINOLOGY, V130, P2310, DOI 10.1210/en.130.4.2310; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; RANGANATHAN G, 1995, J BIOL CHEM, V270, P7149, DOI 10.1074/jbc.270.13.7149; ROJAS C, 1990, BIOCHEM J, V271, P11, DOI 10.1042/bj2710011; SAFFARI B, 1992, J LIPID RES, V33, P241; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SIMSOLO RB, 1992, J LIPID RES, V33, P89; SOMMERVILLE J, 1992, BIOESSAYS, V14, P337, DOI 10.1002/bies.950140509; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	31	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2515	2519						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999967				2022-12-25	WOS:A1997WD67900073
J	Gottfried, DS; Juszczak, LJ; Fataliev, NA; Acharya, AS; Hirsch, RE; Friedman, JM				Gottfried, DS; Juszczak, LJ; Fataliev, NA; Acharya, AS; Hirsch, RE; Friedman, JM			Probing the hemoglobin central cavity by direct quantification of effector binding using fluorescence lifetime methods	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED HEMOGLOBIN; LIGAND-BINDING; PROXIMAL HISTIDINE; OXYGEN BINDING; LEAST-SQUARES; DERIVATIVES; REACTIVITY; SPECTROSCOPY; KINETICS; DYNAMICS	Time-resolved fluorescence methods have been used to show that 8-hydroxy-1,3,6-pyrenetrisulfonate (HPT), a fluorescent analog of 2,3-diphosphoglycerate, binds to the central cavity of carboxyhemoglobin A (HbACO) at pH 6.35. A direct quantitative approach, based on the distinctive free and bound HPT fluorescent lifetimes of 5.6 ns and similar to 27 ps, respectively, was developed to measure the binding affinity of this probe. HPT binds to a single site and is displaced by inositol hexaphosphate at a 1:1 mol ratio, indicating that binding occurs at the 2,3-diphosphoglycerate site in the central cavity. Furthermore, the results imply that low pH HbACO exists as an altered R state and not an equilibrium mixture of R and T states. The probe was also used to monitor competitive effector binding and to compare the affinity of the binding site in several cross-bridged HbA derivatives.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Gottfried, DS (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,1300 MORRIS PK AVE,BRONX,NY 10461, USA.			Gottfried, David/0000-0002-2729-2504	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038655] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38655] Funding Source: Medline; NIGMS NIH HHS [GM-44343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM DJ, 1992, BIOCHEMISTRY-US, V31, P9141, DOI 10.1021/bi00153a005; ACHARYA AS, 1996, ARTIF CELLS BLOOD SU, V24, P296; ADAMS ML, 1974, BIOCHEM BIOPH RES CO, V58, P525, DOI 10.1016/S0006-291X(74)80452-3; AMICONI G, 1981, METHOD ENZYMOL, V76, P532; BENESCH R, 1969, NATURE, V221, P618, DOI 10.1038/221618a0; BUCCI E, 1996, ARTIF CELLS BLOOD SU, V24, P310; CAMBELL BF, 1984, J MOL BIOL, V179, P143; CHRISTENSEN SM, 1988, J BIOCHEM BIOPH METH, V17, P143, DOI 10.1016/0165-022X(88)90045-0; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; EISINGER J, 1979, ANAL BIOCHEM, V94, P15, DOI 10.1016/0003-2697(79)90783-8; FINDSEN EW, 1985, SCIENCE, V229, P661, DOI 10.1126/science.4023704; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; Gottfried DS, 1996, J PHYS CHEM-US, V100, P12034, DOI 10.1021/jp9609489; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; HIRSCH RE, 1994, METHOD ENZYMOL, V232, P231; HOLTOM GR, 1990, P SOC PHOTO-OPT INS, V1204, P2, DOI 10.1117/12.17680; Imai K., 1982, ALLOSTERIC EFFECTS H; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KWIATKOWSKI L, 1982, HEMOGLOBIN OXYGEN BI, P403; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; LARSEN RW, 1990, J BIOL CHEM, V265, P4449; MACQUARRIE R, 1971, J BIOL CHEM, V246, P5832; MACQUARRIE R, 1972, J BIOL CHEM, V247, P5686; MARDEN MC, 1986, BIOCHEMISTRY-US, V25, P7591, DOI 10.1021/bi00371a049; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; MURRAY LP, 1988, P NATL ACAD SCI USA, V85, P2151, DOI 10.1073/pnas.85.7.2151; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PERUTZ MF, 1976, BIOCHEMISTRY-US, V15, P378, DOI 10.1021/bi00647a022; POLITI MJ, 1984, J AM CHEM SOC, V106, P265, DOI 10.1021/ja00314a001; POYART C, 1994, METHOD ENZYMOL, V232, P496; SCOTT TW, 1983, FEBS LETT, V158, P69; Vandegriff K D, 1992, Biotechnol Genet Eng Rev, V10, P403; VANDEGRIFF KD, 1989, J BIOL CHEM, V264, P17824; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P17049; WALDER RY, 1994, METHOD ENZYMOL, V231, P274; WARD LD, 1985, METHOD ENZYMOL, V117, P400; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WINSLOW RM, 1995, BLOOD SUBSTITUTES PH; WOLFBEIS OS, 1983, FRESEN Z ANAL CHEM, V314, P119, DOI 10.1007/BF00482235; ZHAO MD, 1993, BIOPHYS J, V64, P1520, DOI 10.1016/S0006-3495(93)81521-2	42	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1571	1578		10.1074/jbc.272.3.1571	http://dx.doi.org/10.1074/jbc.272.3.1571			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999830	hybrid			2022-12-25	WOS:A1997WD05800028
J	MeivarLevy, I; Sabanay, H; Bershadsky, AD; Futerman, AH				MeivarLevy, I; Sabanay, H; Bershadsky, AD; Futerman, AH			The role of sphingolipids in the maintenance of fibroblast morphology - The inhibition of protrusional activity, cell spreading, and cytokinesis induced by fumonisin B-1 can be reversed by ganglioside GM(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-MONILIFORME; REGULATORY ROLE; BIOSYNTHESIS; DISRUPTION; METABOLISM; CERAMIDE; CYCLE; MICROVILLI; MIGRATION; ADHESION	Previous studies demonstrated that inhibition of sphingolipid synthesis by the mycotoxin fumonisin B-1 (FB1) disrupts axonal growth in cultured hippocampal neurons (Harel, R., and Futerman, A. H. (1993) J. Biol. Chem. 268, 14476-14481) by affecting the formation or stabilization of axonal branches (Schwarz, A., Rapaport, E., Hirschberg, K., and Futerman, A.H. (1995) J. Biol. Chem. 270, 10990-10998). We now demonstrate that long term incubation with FB1 affects fibroblast morphology and proliferation. Incubation of Swiss 3T3 cells with FB1 resulted in a decrease in synthesis of ganglioside GM(3), the major glycosphingolipid in 3T3 fibroblasts and of sphingomyelin. The projected cell area of FB1-treated cells was similar to 45% less than control cells. FB1 had no affect on the organization of microtubules or intermediate filaments, but fewer actin-rich stress fibers were observed, and there was a loss of actin-rich lamellipodia at the leading edge. Three other processes involving the actin cytoskeleton, cytokinesis, microvilli formation, and the formation of long processes induced by protein kinase inhibitors, were all disrupted by FB1. All the effects of FB1 on cell morphology could be reversed by addition of ganglioside GM(3) even in the presence of FB1, whereas the bioactive intermediates, sphinganine, sphingosine, and ceramide, were without effect. Finally, FB1 blocked cell proliferation and DNA synthesis in a reversible manner, although ganglioside GM(3) could not reverse the effects of FB1 on cell proliferation. Together, these data suggest that ongoing sphingolipid synthesis is required for the assembly of both new membrane and of the underlying cytoskeleton.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science				Futerman, Anthony/0000-0003-0013-0115; Bershadsky, Alexander/0000-0002-9571-7375				ABBAS HK, 1994, PLANT PHYSIOL, V106, P1085, DOI 10.1104/pp.106.3.1085; ARRO E, 1981, SCAN ELECTRON MICROS, P159; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chigorno V, 1996, J BIOL CHEM, V271, P21738, DOI 10.1074/jbc.271.36.21738; DUNN GA, 1986, J CELL SCI, V83, P313; FURUYA S, 1995, J NEUROCHEM, V65, P1551; FUTERMAN AH, 1995, TRENDS CELL BIOL, V5, P377, DOI 10.1016/S0962-8924(00)89078-9; FUTERMAN AH, 1994, TRENDS GLYCOSCI GLYC, V6, P143; GELDERBLOM WCA, 1995, CARCINOGENESIS, V16, P625, DOI 10.1093/carcin/16.3.625; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1990, J BIOL CHEM, V265, P22137; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAREL R, 1993, J BIOL CHEM, V268, P14476; HEDBERG KK, 1990, EXP CELL RES, V188, P199, DOI 10.1016/0014-4827(90)90160-C; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; KOJIMA N, 1991, Glycobiology, V1, P623, DOI 10.1093/glycob/1.6.623; MEIVARLEVY I, 1994, BIOCHEM J, V303, P377, DOI 10.1042/bj3030377; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; OKADA Y, 1988, FEBS LETT, V235, P25, DOI 10.1016/0014-5793(88)81227-4; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; Sofer A, 1996, J CELL SCI, V109, P2111; STRUM JC, 1995, J BIOL CHEM, V270, P13541, DOI 10.1074/jbc.270.22.13541; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; UEMURA K, 1990, J BIOCHEM-TOKYO, V108, P525; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VOLBERG T, 1994, CELL MOTIL CYTOSKEL, V29, P321, DOI 10.1002/cm.970290405; WANG E, 1991, J BIOL CHEM, V266, P14486; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	39	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1558	1564		10.1074/jbc.272.3.1558	http://dx.doi.org/10.1074/jbc.272.3.1558			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999828	hybrid			2022-12-25	WOS:A1997WD05800026
J	Merchant, AK; Loney, TL; Maybaum, J				Merchant, AK; Loney, TL; Maybaum, J			Expression of wild-type p53 stimulates an increase in both Bax and Bcl-x(L) protein content in HT29 cells	ONCOGENE			English	Article						p53; Bax; Bcl-x; programmed cell death; HT29	CHEMOTHERAPY-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; IN-VIVO; DNA FRAGMENTATION; BCL-2 EXPRESSION; CANCER-CELLS; C-MYC; CYCLE; DEATH; GENE	It has been shown previously that wild-type p53 activity can simultaneously up-regulate Bax, a protein which predisposes cells to programmed cell death (PCD), and down-regulate Bcl-2, a protein which antagonizes PCD. These findings have been interpreted to suggest that correction of the mutant p53 status of some tumor cells may be a means of increasing their sensitivity to chemotherapeutic agents, by increasing their likelihood of undergoing PCD. We show here that when wild-type p53 activity is expressed in HT29 human colon cancer cells by use of a temperature sensitive p53 mutant, Bax levels rise, but so do levels of Bcl-x(L) protein. These observations indicate that Bcl-2 and Bcl-x(L) are regulated differently in response to wild-type p53 activity and that, while correction of mutant p53 phenotype may effectively kill cells having Bcl-2 as their major defense against PCD, this is not necessarily the case in cells using Bcl-x(L) as their primary defense	UNIV MICHIGAN, SCH MED, DEPT PHARMACOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [P01CA042761, R01CA056663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42761, R01-CA56663] Funding Source: Medline; NIGMS NIH HHS [2T32 GM07767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAGWELL CB, 1979, J HISTOCHEM CYTOCHEM, V27, P293, DOI 10.1177/27.1.374589; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; CANMAN CE, 1992, P NATL ACAD SCI USA, V89, P10474, DOI 10.1073/pnas.89.21.10474; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DOLE MG, 1995, CANCER RES, V55, P2576; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FORGUELAFITTE ME, 1989, CANCER RES, V49, P6566; HAGUE A, 1994, ONCOGENE, V9, P3367; HALDAR S, 1994, CANCER RES, V54, P2095; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PARK JR, 1994, BLOOD, V84, P440; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SINICROPE FA, 1995, CANCER RES, V55, P237; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; STEWART N, 1995, ONCOGENE, V10, P109; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tang HYK, 1996, CANCER CHEMOTH PHARM, V37, P486, DOI 10.1007/s002800050416; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WILLINGHAM MC, 1994, J HISTOCHEM CYTOCHEM, V42, P441, DOI 10.1177/42.4.7907352; Wu GS, 1996, CLIN CANCER RES, V2, P623; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZHAN QM, 1994, ONCOGENE, V9, P3743	39	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2631	2637						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000137				2022-12-25	WOS:A1996VZ65400013
J	Emlet, DR; Moscatello, DK; Ludlow, LB; Wong, AJ				Emlet, DR; Moscatello, DK; Ludlow, LB; Wong, AJ			Subsets of epidermal growth factor receptors during activation and endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; CARCINOMA-CELLS A-431; PHOSPHOLIPASE-C-GAMMA; HIGH-AFFINITY BINDING; DIRECT VISUALIZATION; AUTOPHOSPHORYLATION SITES; MULTIVESICULAR BODY; EGF RECEPTOR; SH2 DOMAINS; INTERNALIZATION	Mutation of the autophosphorylation sites of receptor protein-tyrosine kinases alters ligand dependent internalization and down-regulation, indicating a critical role for these sites in receptor processing. Currently, no differences in receptor processing based on an individual autophosphorylation site have been defined. By using a glutathione S-transferase fusion protein containing the are homology 2 domains of phospholipase C-gamma(1) to specifically recognize tyrosine 992 on the EGF receptor (Tyr(P)(992)), we have found differences in this subpopulation of receptors. Following EGF stimulation, the number of Tyr(P)(992) receptors increased 2-fold over receptors identified by an antibody that recognizes activated EGF receptors (alpha-Act. EGFR) in A431 cells. Confocal fluorescence microscopy showed that Tyr(P)(992) receptors underwent endocytosis at a slower rate and did not rapidly concentrate in juxtanuclear bodies. Tyr(P)(992) receptors were associated with more SOS, Ras-GTPase activating protein, phosphatidylinositol 3-kinase, and SHPTP2/syp, but less Grb2, than receptors in the general population, and these receptors were more heavily phosphorylated than the general population of active receptors. These findings suggest that autophosphorylation status is relevant to the endocytosis, degradation, and effector molecule interaction of individual EGF receptors. Further investigations based on phosphorylation status should provide new insights into how receptor protein-tyrosine kinase signaling is regulated.	KIMMEL CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; KIMMEL CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University					NCI NIH HHS [CA-53149, CA-51093] Funding Source: Medline; NINDS NIH HHS [NS-31102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051093, R01CA053149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; NESTEROV A, 1994, ARCH BIOCHEM BIOPHYS, V313, P351, DOI 10.1006/abbi.1994.1398; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLER C, 1994, J BIOL CHEM, V269, P12320; SORKIN A, 1991, J BIOL CHEM, V266, P8355; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; YANG LJ, 1994, J BIOL CHEM, V269, P7156; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4079	4086		10.1074/jbc.272.7.4079	http://dx.doi.org/10.1074/jbc.272.7.4079			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020117	hybrid			2022-12-25	WOS:A1997WH01900033
J	Shayiq, RM				Shayiq, RM			Role of gene overlap in the regulation of mRNA translation for mitochondrial cytochrome P-450c27/25 in the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASE INHIBITOR; BILE-ACID BIOSYNTHESIS; MESSENGER-RNA; ANTISENSE RNA; INTERNAL INITIATION; UNWINDING ACTIVITY; OPPOSITE STRAND; MAMMALIAN-CELLS; TRANSCRIPTION; EXPRESSION	Previously published results have revealed sequence complementarity between the 5'-terminal regions of mRNAs for hepatic mitochondrial cytochrome P-450c27/25 (e27/25) and serine protease inhibitors (SPI) and pre dieted a role for this sequence overlap in both the regulation of c27/25 mRNA transcription and translation. The possibility that c27/25 mRNA forms an RNA duplex with complementary sequences of SPI mRNAs in vivo was demonstrated in the rat liver and COS-1 cells cotransfected with c27/25 and SPI2.1 plasmids. Quantitative evaluation of RNA duplex in COS-1 cells revealed that most of the c27/25 mRNA exists in duplex form when SPI2.1 mRNA was present at 5-10-fold that of c27/25 mRNA, a ratio comparable to that observed between these two RNAs in the liver. In cotransfected COS-1 cells with the same ratio of mRNAs, highly significant inhibition of the c27/25 mRNA translation (66-75%) was ob served, while its transcription remained unaffected. The partial inhibition of c27/25 mRNA translation, even when most of it exists in duplex form, suggests that RNA duplex is undergoing some type of cytoplasmic processing to disengage c27/25 mRNA and make it available for translation. These results imply that abundant endogenous SPI RNAs are able to regulate the c27/25 gene expression.			Shayiq, RM (corresponding author), TEMPLE UNIV,SCH MED,DEPT PHARMACOL,DRUG LIVER UNIT,PHILADELPHIA,PA 19140, USA.							ADDYA S, 1991, BIOCHEMISTRY-US, V30, P8323, DOI 10.1021/bi00098a007; ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; BARTLES JR, 1984, ANAL BIOCHEM, V140, P284, DOI 10.1016/0003-2697(84)90166-0; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; BUNCH TA, 1989, NUCLEIC ACIDS RES, V17, P9761, DOI 10.1093/nar/17.23.9761; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CANCELA L, 1988, HORMONES THEIR ACT 1, P269; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELUCA HF, 1976, ANNU REV BIOCHEM, V45, P631, DOI 10.1146/annurev.bi.45.070176.003215; DELUCA HF, 1980, HARVEY LECT, V75, P333; FRIEDLANDER EJ, 1975, ARCH BIOCHEM BIOPHYS, V170, P731, DOI 10.1016/0003-9861(75)90171-X; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HENERY HL, 1980, VITAMIN D MOL BIOL C, P127; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1992, ANN REV CELL BIOL, V8, P192; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; NELLEN W, 1992, BIOCHEM SOC T, V20, P750, DOI 10.1042/bst0200750; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NIRANJAN BG, 1988, J BIOL CHEM, V263, P575; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; ROSSI V, 1992, NUCLEIC ACIDS RES, V20, P1061, DOI 10.1093/nar/20.5.1061; SAKAKI T, 1992, J BIOL CHEM, V267, P16497; Sambrook J., 2002, MOL CLONING LAB MANU; SHAYIQ RM, 1989, BIOCHEMISTRY-US, V28, P7546, DOI 10.1021/bi00445a008; SHAYIQ RM, 1990, BIOCHEMISTRY-US, V29, P866, DOI 10.1021/bi00456a003; SHAYIQ RM, 1992, J BIOL CHEM, V267, P2421; SPENCER CA, 1986, NATURE, V322, P279, DOI 10.1038/322279a0; SU P, 1990, DNA CELL BIOL, V9, P957; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; USUI E, 1990, FEBS LETT, V274, P175, DOI 10.1016/0014-5793(90)81357-T; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WANG SJ, 1993, NUCLEIC ACIDS RES, V21, P4383, DOI 10.1093/nar/21.18.4383; WIKVALL K, 1993, HDB EXPT PHARM, V105, P705; WILLIAMS T, 1986, NATURE, V322, P275, DOI 10.1038/322275a0; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; YOON JB, 1990, J BIOL CHEM, V265, P19947	56	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4050	4057						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020113				2022-12-25	WOS:A1997WH01900029
J	Ting, YT; Bhat, MK; Wong, R; Cheng, SY				Ting, YT; Bhat, MK; Wong, R; Cheng, SY			Tissue-specific stabilization of the thyroid hormone beta 1 nuclear receptor by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-CAPACITY; CO-REPRESSOR; PROTEIN; ACTIVATION; RAT; PROTEOLYSIS; SEQUENCE; ISOFORMS; KINASE; ACID	The present study evaluated the expression and regulation of endogenous thyroid hormone receptors (TRs) in cultured cells. In COS-1 cells, the endogenous TR, subtype beta 1 (TR beta 1), but not subtype beta 2 or alpha 1, was induced to express by okadaic acid (OA) in a concentration-dependent manner. The induced TR beta 1 had immunoreactivity and partial V8 proteolytic maps similar to those of the transfected and in vitro translated human TR beta 1 (h-TR beta 1). The OA-induced expression of endogenous TR beta 1 was, however, not observed in a variety of other cultured cell lines tested, indicating that the induction was cell type-dependent. TR beta 1 induced by OA was a multisite phosphorylated protein, in which serine and threonine in a ratio of 10:1 were phosphorylated. The induced TR beta 1 was functional as it could mediate the thyroid hormone-dependent transcriptional activity via several thyroid hormone response elements. The induction of endogenous TR beta 1 expression by OA was not accompanied by an increase in mRNA levels but was the result of an increase in the stability of the TR beta 1 protein. This is the first report to indicate that one of the mechanisms by which the TR isoforms are differentially expressed is via the tissue-specific stabilization of the TR isoform proteins. Furthermore, this selective stability of TR beta 1 could be conferred by phosphorylation.	NCI,MOL BIOL LAB,NIH,BETHESDA,MD 20892; NIDDKD,MOL & CELLULAR ENDOCRINOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BHAT MK, 1995, BIOCHEMISTRY-US, V34, P10591, DOI 10.1021/bi00033a034; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P145; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng Sheue-Yann, 1995, Journal of Biomedical Science, V2, P77, DOI 10.1007/BF02253060; CHENG SY, 1991, PROTEIN PHOSPHORYL 2, P110; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KATZ D, 1995, MOL CELL BIOL, V15, P2341; KOERNER D, 1975, J BIOL CHEM, V250, P6417; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; LIN KH, 1991, ENDOCRINOLOGY, V128, P2601, DOI 10.1210/endo-128-5-2601; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; ONATE SA, 1995, SCIENCE, V270, P1354; OPPENHEIMER JH, 1994, EUR J ENDOCRINOL, V130, P15, DOI 10.1530/eje.0.1300015; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; SAMUELS HH, 1974, SCIENCE, V184, P1188, DOI 10.1126/science.184.4142.1188; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WALLACE BG, 1995, J CELL BIOL, V128, P1121, DOI 10.1083/jcb.128.6.1121; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	32	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4129	4134		10.1074/jbc.272.7.4129	http://dx.doi.org/10.1074/jbc.272.7.4129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020124	hybrid			2022-12-25	WOS:A1997WH01900040
J	Yan, SF; Zou, YS; Mendelsohn, M; Gao, Y; Naka, Y; Yan, SD; Pinsky, D; Stern, D				Yan, SF; Zou, YS; Mendelsohn, M; Gao, Y; Naka, Y; Yan, SD; Pinsky, D; Stern, D			Nuclear factor interleukin 6 motifs mediate tissue-specific gene transcription in hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; ENDOTHELIAL GROWTH-FACTOR; NECROSIS FACTOR-ALPHA; INDUCIBLE FACTOR-1; EXPRESSION; INDUCTION; PROMOTER; SIMILARITIES; ACTIVATION; MECHANISM	Activation of transcription at the nuclear factor interleukin 6 (NF-IL-6) DNA binding motif modulates expression of multiple genes important in host adaptive and developmental mechanisms. Studies showing that hypoxia-induced transcription of IL-6 in cultured endothelial cells was due to transcriptional activation by the NF-IL-6 motif in the promoter (Yan, S.-F., Tritto, I., Pinsky, D., Liao, H., Huang, J., Fuller, G., Brett, J., May, L., and Stern, D. (1995) J. Biol. Chem. 270, 11463-11471) led us to prepare transgenic mice using 115- or 14-base pair regions of the promoter encompassing the NF-IL-6 site ligated to the lacZ reporter gene and the basal thymidine kinase promoter. On exposure to hypoxia or induction of ischemia, mice bearing either of the constructs showed prominent expression of the transgene in lung and cardiac vasculature and in the kidney but not in the liver (parenchyma or vasculature). In contrast, transgenic mice bearing a mutationally inactivated NF-IL-6 site showed no increase in transgene expression in hypoxia. Gel retardation assays revealed time-dependent, hypoxia-enhanced nuclear binding activity for the NF-IL-6 site in nuclear extracts of the heart, lung, and kidney but not in the liver; the hypoxia-enhanced band disappeared on addition of antibody to C/EBP beta-NF-IL-6. Consistent with the specificity of hypoxia-mediated activation of C/EBP beta-NF-IL-6, gel retardation assays showed no change in the intensity of the hypoxia-enhanced gel shift band in the presence of excess unlabeled oligonucleotide probes or antibodies related to other transcription factors, including NF kappa B, AP1, cAMP response element-binding protein, SP1, and hypoxia-inducible factor 1. These data indicate that the transcription factor NF-IL-6 is sensitive to environmental oxygen deprivation, and the tissue-specific pattern of gene expression suggests that local mechanisms have an important regulatory effect.	COLUMBIA UNIV COLL PHYS & SURG, DEPT SURG, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University	Yan, SF (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, P&S 11-518, 630 W 168TH ST, NEW YORK, NY 10032 USA.				NHLBI NIH HHS [HL42507, HL50629] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042507, R01HL050629] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; ANDERSON GR, 1989, J BIOL CHEM, V264, P14885; BRETT J, 1993, AM J PATHOL, V143, P1699; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; COSTAGIOMI P, 1990, J BIOL CHEM, V265, P10185; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; KNIGHT S, 1981, CELL, V25, P385; LAYE S, 1994, MOL BRAIN RES, V27, P157, DOI 10.1016/0169-328X(94)90197-X; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MAURY CPJ, 1989, J INTERN MED, V225, P333, DOI 10.1111/j.1365-2796.1989.tb00090.x; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; OGAWA S, 1991, P NATL ACAD SCI USA, V88, P9897, DOI 10.1073/pnas.88.21.9897; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463	26	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4287	4294		10.1074/jbc.272.7.4287	http://dx.doi.org/10.1074/jbc.272.7.4287			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020146	hybrid			2022-12-25	WOS:A1997WH01900062
J	Brown, SE; Martin, SR; Bayley, PM				Brown, SE; Martin, SR; Bayley, PM			Kinetic control of the dissociation pathway of calmodulin-peptide complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; STOPPED-FLOW FLUORESCENCE; BINDING-SITE MUTANTS; CALCIUM-BINDING; GLOBULAR DOMAINS; TARGET PEPTIDES; PROTEIN-KINASE; CA2+ BINDING; MYOSIN; FRAGMENTS	The mechanism of dissociation reactions induced by calcium chelators has been studied for complexes of Drosophila calmodulin with target peptides, including four derived from the skeletal muscle myosin light chain kinase target sequence. Reactions were monitored by fluorescence stopped-flow techniques using a variety of intrinsic probes and the indicator Quin2. For most of the complexes, apparently biphasic kinetics were observed in several fluorescence parameters. The absence of any obvious relationship between dissociation rates and peptide affinities implies kinetic control of the dissociation pathway. A general mechanism for calcium and peptide dissociation was formulated and used in numerical simulation of the experimental data. Unexpectedly, the rate of the slowest step decreases with increasing [peptide]/[calmodulin] ratio. Numerical simulation shows this step could contain a substantial contribution from a reversible relaxation process (involving the species Ca-2-calmodulin-peptide), convolved with the following step (loss of C-terminal calcium ions). The results indicate the potentially key kinetic role of the partially calcium-saturated intermediate species. They show that subtle changes in the peptide sequence can have significant effects on both the dissociation rates and also the dissociation pathway. Both effects could contribute to the variety of regulatory behavior shown by calmodulin with different target enzymes.	NATL INST MED RES, DIV PHYS BIOCHEM, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research			Brown, Susan/C-3123-2009					BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; Bayley P. M., 1996, Biophysical Journal, V70, pA57; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; Brown S. E., 1995, Biophysical Journal, V68, pA403; CHABBERT M, 1991, BIOCHEMISTRY-US, V30, P7615, DOI 10.1021/bi00244a034; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; CRAESCU CT, 1995, J BIOL CHEM, V270, P7088, DOI 10.1074/jbc.270.13.7088; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; FINDLAY WA, 1995, PROTEIN SCI, V4, P2375, DOI 10.1002/pro.5560041116; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAIECH J, 1990, ADV EXP MED BIOL, V269, P43; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; JOHNSON JD, 1981, J BIOL CHEM, V256, P2194; JOHNSON JD, 1993, 11 IUPAB C JUL 1993, P101; KASTURI R, 1993, J BIOL CHEM, V268, P7958; KILHOFFER MC, 1992, BIOCHEMISTRY-US, V31, P8098, DOI 10.1021/bi00149a046; KILHOFFER MC, 1981, BIOCHEMISTRY-US, V20, P4407, DOI 10.1021/bi00518a027; KLEE CB, 1988, CALMODULIN, P33; LINSE S, 1991, J BIOL CHEM, V266, P8050; MALENCIK DA, 1986, BIOCHEM BIOPH RES CO, V135, P1050, DOI 10.1016/0006-291X(86)91034-X; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MARTIN SR, 1992, EUR J BIOCHEM, V205, P1107, DOI 10.1111/j.1432-1033.1992.tb16879.x; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MUKHERJEA P, 1993, BIOCHEM MOL BIOL INT, V29, P555; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3870, DOI 10.1021/bi00636a024; SANYAL G, 1988, BIOCHEMISTRY-US, V27, P6229, DOI 10.1021/bi00417a006; Snyder C. H., 1995, Biophysical Journal, V68, pA164; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; SUKO J, 1985, EUR J BIOCHEM, V153, P451, DOI 10.1111/j.1432-1033.1985.tb09323.x; SUKO J, 1986, EUR J BIOCHEM, V159, P425, DOI 10.1111/j.1432-1033.1986.tb09904.x; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; WINDER SJ, 1993, BIOCHEMISTRY-US, V32, P13327, DOI 10.1021/bi00211a046; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YAZAWA M, 1992, BIOCHEMISTRY-US, V31, P3171, DOI 10.1021/bi00127a018	47	69	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3389	3397		10.1074/jbc.272.6.3389	http://dx.doi.org/10.1074/jbc.272.6.3389			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013581	hybrid			2022-12-25	WOS:A1997WG19200041
J	Huang, WB; Bateman, E				Huang, WB; Bateman, E			Transcription of the Acanthamoeba TATA-binding protein gene - A single transcription factor acts both as an activator and a repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; TBP GENE; CRYSTAL-STRUCTURE; PROMOTER ELEMENT; FACTOR TFIIB; A-T; DNA; CLONING; CASTELLANII; EXPRESSION	Transcription of the Acanthamoeba TATA-binding protein (TBP) gene is regulated by TBP promoter-binding factor (TPBF), a previously described transactivator that binds as a tetramer to the TBP Promoter Element (TPE) and stimulates transcription up to 10-fold in vitro, Here me report that TPBF also functions as a transcription repressor by binding to a negative cis-element, located between the TATA box and the transcription initiation site, The negative element, referred to as the nTPE, is structurally similar to the TPE, and its disruption increases the transcription potency of the TBP promoter, TPBF binds to the nTPE, as demonstrated by mobility shift assays, However, the binding affinity of TPBF for the nTPE is about 10-fold lower than for the TPE. When placed upstream of the TATA box, the nTPE has very little effect on transcription, However, it inhibits transcription when placed at several positions down-stream of the TATA box, Mechanistic studies with the TBP promoter suggest that binding of TPBF to the nTPE not only prevents TBP from binding to the TATA box but also displaces bound TBP, thereby inhibiting further assembly of the preinitiation complex, These results suggest a mechanism in which the cellular TPBF concentration controls the level of TBP gene transcription and show that a single factor can be stimulatory, inhibitory, or neutral depending on the sequence and the context of its binding site.	UNIV VERMONT,MARKEY CTR MOL GENET,DEPT MICROBIOL & MOL GENET,CELL & MOL BIOL PROGRAM,BURLINGTON,VT 05405	University of Vermont					NATIONAL EYE INSTITUTE [R29EY008706, R01EY008706] Funding Source: NIH RePORTER; NEI NIH HHS [EY 08706] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHALUT C, 1995, GENE, V161, P277, DOI 10.1016/0378-1119(95)00209-O; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; Fondell JD, 1996, MOL CELL BIOL, V16, P281; GOODSELL DS, 1994, J MOL BIOL, V239, P79, DOI 10.1006/jmbi.1994.1352; GU BH, 1995, MOL CELL BIOL, V15, P3618; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HU Q, 1996, IN PRESS BIOCH BIOPH; Huang J, 1996, MOL CELL BIOL, V16, P3893; Huang WB, 1996, NUCLEIC ACIDS RES, V24, P1158, DOI 10.1093/nar/24.6.1158; HUANG WB, 1995, J BIOL CHEM, V270, P28839, DOI 10.1074/jbc.270.48.28839; INOSTROZA JA, 1992, CELL, V70, P477; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JENKINS DE, 1994, J GEN VIROL, V75, P2337, DOI 10.1099/0022-1317-75-9-2337; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KIM Y, 1993, NATURE, V6446, P512; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; LANSFORD RD, 1992, P NATL ACAD SCI USA, V89, P5966, DOI 10.1073/pnas.89.13.5966; Lee G, 1996, P NATL ACAD SCI USA, V93, P2570, DOI 10.1073/pnas.93.6.2570; LIU F, 1994, J BIOL CHEM, V269, P18541; LIU F, 1993, NUCLEIC ACIDS RES, V21, P4321, DOI 10.1093/nar/21.18.4321; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; PTASHNE M, 1992, GENETIC SWITCH GENE; PUGH BF, 1992, J BIOL CHEM, V267, P679; QASBA P, 1996, MOL CELL BIOL, V12, P1107; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; SUMITA K, 1993, NUCLEIC ACIDS RES, V21, P2769, DOI 10.1093/nar/21.11.2769; UM M, 1995, MOL CELL BIOL, V15, P5007; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WONG JM, 1992, GENE, V117, P91, DOI 10.1016/0378-1119(92)90494-A; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; ZAWAL L, 1995, ANNU REV BIOCHEM, V64, P533	49	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3852	3859		10.1074/jbc.272.6.3852	http://dx.doi.org/10.1074/jbc.272.6.3852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013645	hybrid			2022-12-25	WOS:A1997WG19200105
J	Iwasaki, T; Suzuki, T; Kon, T; Imai, T; Urushiyama, A; Ohmori, D; Oshima, T				Iwasaki, T; Suzuki, T; Kon, T; Imai, T; Urushiyama, A; Ohmori, D; Oshima, T			Novel zinc-containing ferredoxin family in thermoacidophilic archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; IRON-SULFUR CLUSTERS; SULFOLOBUS-ACIDOCALDARIUS; THERMOPLASMA-ACIDOPHILUM; BACTERIAL FERREDOXINS; THERMOTOGA-MARITIMA; 3FE-4S CLUSTER; ARCHAEBACTERIA; OXIDOREDUCTASE; PURIFICATION	The dicluster-type ferredoxins from the thermoacidophilic archaea such as Thermoplasma acidophilum and Sulfolobus sp. are known to contain an unusually long extension of unknown function in the N-terminal region. Recent x-ray structural analysis of the Sulfolobus ferredoxin has revealed the presence of a novel zinc center, which is coordinated by three histidine ligand residues in the N-terminal region and one aspartate in the ferredoxin core domain. We report here the quantitative metal analyses together with electron paramagnetic resonance and resonance Raman spectra of T. acidophilum ferredoxin, demonstrating the presence of a novel zinc center in addition to one [3Fe-4S] and one [4Fe-4S] cluster (Fe/Zn = 6.8 mol/mol). A phylogenetic tree constructed for several archaeal monocluster and dicluster type ferredoxins suggests that the zinc containing ferredoxins of T. acidophilum and Sulfolobus sp. form an independent subgroup, which is more distantly related to the ferredoxins from the hyperthermophiles than those from the methanogenic archaea, indicating the existence of a novel group of ferredoxins, namely, a ''zinc-containing ferredoxin family'' in the thermoacidophilic archaea. Inspection of the N-terminal extension regions of the archaeal zinc-containing ferredoxins suggested strict conservation of three histidine and one aspartate residues as possible ligands to the novel zinc center.	TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 226,JAPAN; RIKKYO UNIV,DEPT CHEM,TOKYO 171,JAPAN; JUNTENDO UNIV,DEPT CHEM,CHIBA 27016,JAPAN; TOKYO UNIV PHARM & LIFE SCI,DEPT MOL BIOL,TOKYO 19203,JAPAN	Tokyo Institute of Technology; Rikkyo University; Juntendo University; Tokyo University of Pharmacy & Life Sciences	Iwasaki, T (corresponding author), NIPPON MED COLL,DEPT BIOCHEM & MOL BIOL,BUNDESANSTALT MILCHFORSCH,1-1-5 SENDAGI,TOKYO 113,JAPAN.		Kon, Takahide/AAG-6975-2021	Iwasaki, Toshio/0000-0001-9562-4649; Kon, Takahide/0000-0002-1231-7609				ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; BLAMEY JM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P19, DOI 10.1016/0167-4838(93)90190-3; BLAMEY JM, 1994, BIOCHEMISTRY-US, V33, P1000, DOI 10.1021/bi00170a019; BRETON JL, 1995, EUR J BIOCHEM, V233, P937, DOI 10.1111/j.1432-1033.1995.937_3.x; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CZERNUSZEWICZ RS, 1987, J AM CHEM SOC, V109, P7178, DOI 10.1021/ja00257a045; DANSON MJ, 1989, CAN J MICROBIOL, V35, P58, DOI 10.1139/m89-009; DARIMONT B, 1994, EMBO J, V13, P1772, DOI 10.1002/j.1460-2075.1994.tb06445.x; DENDA K, 1990, J BIOL CHEM, V265, P21509; ERIKSSON AE, 1993, PROTEINS, V16, P29, DOI 10.1002/prot.340160104; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FUJII T, 1991, J BIOCHEM, V110, P472, DOI 10.1093/oxfordjournals.jbchem.a123605; FUKUYAMA K, 1989, J MOL BIOL, V210, P383, DOI 10.1016/0022-2836(89)90338-0; IMAI T, 1995, FEBS LETT, V368, P23, DOI 10.1016/0014-5793(95)00601-5; Iwasaki T, 1995, J BIOL CHEM, V270, P30893, DOI 10.1074/jbc.270.52.30893; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; Iwasaki T, 1996, FEMS MICROBIOL LETT, V144, P259; Iwasaki T, 1995, J BIOL CHEM, V270, P30902, DOI 10.1074/jbc.270.52.30902; JOHNSON MK, 1988, J AM CHEM SOC, V105, P6671; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; KERSCHER L, 1982, TRENDS BIOCHEM SCI, V7, P371, DOI 10.1016/0968-0004(82)90118-9; KERSCHER L, 1977, FEBS LETT, V83, P197, DOI 10.1016/0014-5793(77)81004-1; LUBBEN M, 1995, BBA-BIOENERGETICS, V1229, P1, DOI 10.1016/0005-2728(94)00174-4; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MINAMI Y, 1985, J BIOCHEM-TOKYO, V97, P745, DOI 10.1093/oxfordjournals.jbchem.a135114; MORTENSON LE, 1962, BIOCHEM BIOPH RES CO, V7, P448, DOI 10.1016/0006-291X(62)90333-9; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PFEIFER F, 1993, MOL GEN GENET, V239, P66, DOI 10.1007/BF00281602; SATO S, 1981, BIOCHIM BIOPHYS ACTA, V668, P277, DOI 10.1016/0005-2795(81)90035-0; STEIGERWALD VJ, 1992, P NATL ACAD SCI USA, V89, P6929, DOI 10.1073/pnas.89.15.6929; STETTER KO, 1995, ASM NEWS, V61, P285; TEIXEIRA M, 1995, EUR J BIOCHEM, V227, P322, DOI 10.1111/j.1432-1033.1995.tb20392.x; WAKABAYASHI S, 1983, FEBS LETT, V162, P21, DOI 10.1016/0014-5793(83)81041-2; WAKAGI T, 1986, SYST APPL MICROBIOL, V7, P342; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YASUDA M, 1995, APPL ENVIRON MICROB, V61, P3482, DOI 10.1128/AEM.61.9.3482-3485.1995; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	43	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3453	3458		10.1074/jbc.272.6.3453	http://dx.doi.org/10.1074/jbc.272.6.3453			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013590	hybrid			2022-12-25	WOS:A1997WG19200050
J	Ojaniemi, M; Martin, SS; Dolfi, F; Olefsky, JM; Vuori, K				Ojaniemi, M; Martin, SS; Dolfi, F; Olefsky, JM; Vuori, K			The proto-oncogene product p120(cbl) links c-Src and phosphatidylinositol 3'-kinase to the integrin signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MEDIATED TYROSINE PHOSPHORYLATION; EPIDERMAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX; CELL-ADHESION; CBL PROTOONCOGENE; STABLE ASSOCIATION; ANTIGEN RECEPTOR; JURKAT CELLS; SH2 DOMAIN	Integrin-mediated cell adhesion triggers intracellular signaling cascades, including tyrosine phosphorylation of intracellular proteins, We show in this report that p120(cbl) (Cbl), the 120-kDa c-cbl proto-oncogene product, becomes tyrosine-phosphorylated during integrin-mediated macrophage cell adhesion to extracellular matrix substrata and anti-integrin antibodies. This tyrosine phosphorylation does not occur when cells attach to polylysine, to which cells adhere in a nonspecific fashion, It also does not take place when adhesion-induced reorganization of the cytoskeleton is inhibited with cytochalasin D. In contrast to the rapid and transient tyrosine phosphorylation of Cbl by CSF-1 stimulation, tyrosine phosphorylation of Cbl by cell attachment was gradual and persistent, Tyrosine-phosphorylated Cbl was found to form complexes with the SH2 domain-containing signaling proteins Src and phosphatidylinositol 3-kinase; in vitro kinase assays demonstrated that these kinases were active in the Cbl complexes following integrin ligand binding. Furthermore, Cbl was found to translocate to the plasma membrane in response to cell adhesion to fibronectin. These observations suggest that Cbl serves as a docking protein and may transduce signals to downstream signaling pathways following integrin-mediated cell adhesion in macrophages.	LA JOLLA CANC RES CTR, BURNHAM INST, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, LA JOLLA, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA071560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NCI NIH HHS [CA71560] Funding Source: Medline; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andoniou CE, 1996, ONCOGENE, V12, P1981; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CELADA A, 1992, J IMMUNOL, V148, P1102; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LEVESQUE JP, 1991, IMMUNOL TODAY, V12, P258, DOI 10.1016/0167-5699(91)90122-A; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MONDAL K, 1995, BIOCHEM SOC T, V23, P460, DOI 10.1042/bst0230460; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PATCH LA, 1995, J CELL SCI, V108, P1371; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Sattler M, 1996, ONCOGENE, V12, P839; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yan SR, 1995, J INFLAMM, V45, P297; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3780	3787		10.1074/jbc.272.6.3780	http://dx.doi.org/10.1074/jbc.272.6.3780			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013636	hybrid			2022-12-25	WOS:A1997WG19200096
J	Ting, JTL; Balsamo, RA; Ratnayake, C; Huang, AHC				Ting, JTL; Balsamo, RA; Ratnayake, C; Huang, AHC			Oleosin of plant seed oil bodies is correctly targeted to the lipid bodies in transformed yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BAKERS-YEAST; PROTEIN; MAIZE; EXPRESSION; PARTICLES; SURFACE; ISOFORMS; GENES; BODY	Yeast (Saccharomyces cerevisiae) has been used extensively as a heterologous eukaryotic system to study the intracellular targeting of proteins to different organelles. The lipid bodies in yeast have not been previously subjected to such studies. These organelles are functionally equivalent to the subcellular storage oil bodies in plant seeds. A plant oil body has a matrix of oils (triacylglycerols) surrounded by a layer of phospholipids embedded with abundant structural proteins called oleosins. We tested whether plant oleosin could be correctly targeted to the lipid bodies in transformed yeast. The coding region of a maize (Zea mays L.) oleosin gene was incorporated into yeast high copy and low copy number plasmids in which its expression was under the control of GAL1 promoter. Yeast strains transformed with these plasmids produced oleosin when grown in a medium containing galactose but not glucose. The oleosin produced in yeast had a molecular mass slightly higher than that of the native protein in maize. Oleosin accumulated concomitantly with the storage lipids during growth of the transformed yeast, and it was not secreted. Subcellular fractionation of the cell extracts obtained by two different cell breakage procedures revealed that the oleosin was largely restricted to the lipid bodies. Oleosin apparently did not affect the lipid contents and composition of the trans formed yeast lipid bodies but replaced some of the native proteins associated with the organelles. Immunocytochemistry of the transformed yeast cells showed that the oleosin was present mostly on the periphery of the lipid bodies. Oleosin isolated from maize or transformed yeast strain, alone or in the presence of phospholipids or SDS, did not bind to the yeast lipid bodies in vitro. We conclude that plant oleosin is correctly targeted to the lipid bodies in transformed yeast and that yeast may be used as a heterologous system to dissect the intracellular targeting signals in the oleosin.	UNIV CALIF RIVERSIDE, DEPT PLANT SCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside								Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CHAO QM, 1994, J BIOL CHEM, V269, P20866; CHRISTIANSEN K, 1979, BIOCHIM BIOPHYS ACTA, V574, P448, DOI 10.1016/0005-2760(79)90241-8; CLAUSEN MK, 1974, FEBS LETT, V43, P176, DOI 10.1016/0014-5793(74)80994-4; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FAWCETT DW, 1966, ATLAS FINE STRUCTURE, P307; GAL S, 1994, PLANT J, V6, P235, DOI 10.1046/j.1365-313X.1994.6020235.x; GALLIE DR, 1989, PLANT CELL, V1, P301, DOI 10.1105/tpc.1.3.301; GURR MI, 1980, BIOCH PLANTS, V4, P204; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; LEBER R, 1995, BBA-BIOMEMBRANES, V1234, P119, DOI 10.1016/0005-2736(94)00270-Y; LEE K, 1995, PLANT J, V7, P603, DOI 10.1046/j.1365-313X.1995.7040603.x; LEE WS, 1991, P NATL ACAD SCI USA, V88, P6181, DOI 10.1073/pnas.88.14.6181; LI M, 1992, J BIOL CHEM, V267, P8245; OSAFUNE T, 1990, J ELECTRON MICROSC, V39, P372; PAUTOT V, 1991, MOL PLANT MICROBE IN, V4, P284, DOI 10.1094/MPMI-4-284; QU R, 1986, BIOCHEM J, V235, P57, DOI 10.1042/bj2350057; QU R, 1990, J BIOL CHEM, V265, P2238; REID GA, 1991, J GEN MICROBIOL, V137, P1765, DOI 10.1099/00221287-137-8-1765; ROSE MD, 1990, METHODS YEAST GENETI, P119; ROSSENEU M, 1992, STRUCTURE FUNCTION A; ROSSLER PG, 1988, J PHYSIOL-LONDON, V24, P394; RUBIN H, 1976, J CELL BIOL, V70, P374, DOI 10.1083/jcb.70.2.374; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J, 1989, MOL CLONING; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THOYTS PJE, 1995, PLANT MOL BIOL, V29, P403, DOI 10.1007/BF00043664; TZEN JTC, 1990, PLANT PHYSIOL, V94, P1282, DOI 10.1104/pp.94.3.1282; TZEN JTC, 1992, J CELL BIOL, V117, P327, DOI 10.1083/jcb.117.2.327; TZEN JTC, 1992, J BIOL CHEM, V267, P15626; VANCE VB, 1987, J BIOL CHEM, V262, P11275; VANROOIJEN GJH, 1995, PLANT PHYSIOL, V109, P1353, DOI 10.1104/pp.109.4.1353; WANG SM, 1987, J BIOL CHEM, V262, P2270	36	40	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3699	3706		10.1074/jbc.272.6.3699	http://dx.doi.org/10.1074/jbc.272.6.3699			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013626	hybrid			2022-12-25	WOS:A1997WG19200086
J	Berditchevski, F; Tolias, KF; Wong, K; Carpenter, CL; Hemler, ME				Berditchevski, F; Tolias, KF; Wong, K; Carpenter, CL; Hemler, ME			A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION; CELL-ADHESION; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; T-CELLS; ANTIGEN; FIBRONECTIN; ASSOCIATION; EXPRESSION	Enzymatic and immunochemical assays show a phosphatidylinositol 4-kinase in novel and specific complexes with proteins (CD63 and CD81) of the transmembrane 4 superfamily (TM4SF) and an integrin (alpha(3) beta(1)). The size (55 kDa) and other properties of the phosphatidylinositol 4-kinase (PI 4-K) (stimulated by nonionic detergent, inhibited by adenosine, inhibited by monoclonal antibody 4CG5) are consistent with PI 4-K type II. Not only was PI 4-K associated with alpha(3) beta(1)-CD63 complexes in alpha(3)-transfected K562 cells, but also it could be co-purified from CD63 in untransfected K562 cells lacking alpha(3) beta(1). Thus, TM4SF proteins may link PI 4-K activity to the alpha(3) beta(1) integrin. The alpha(5) beta(1) integrin, which does not associate with TM4SF proteins, was not associated with PI 4-K. Notably, alpha(3) beta(1)-CD63-CD81-PI 4-K complexes are located in focal complexes at the cell periphery rather than in focal adhesions. The novel linkage between integrins, transmembrane 4 proteins, and phosphoinositide signaling at the cell periphery may play a key role in cell motility and provides a signaling pathway distinct hom conventional integrin signaling through focal adhesion kinase.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DIV SIGNAL TRANSDUCT,BETH ISRAEL HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Tolias, Kimberley/0000-0002-2092-920X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38903, GM54387] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; AUGER KR, 1992, J BIOL CHEM, V267, P5408; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BISWAS C, 1995, CANCER RES, V55, P434; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FUKUDOME K, 1992, J VIROL, V66, P1384; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HEMLER ME, 1983, J IMMUNOL, V131, P334; HOTTA H, 1988, CANCER RES, V48, P2955; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAI T, 1993, J IMMUNOL, V151, P6470; JULIANO RL, 1993, J CELL BIOL, V120, P557; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; Mannion BA, 1996, J IMMUNOL, V157, P2039; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; Udagawa T, 1996, J BIOL CHEM, V271, P12542, DOI 10.1074/jbc.271.21.12542; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WICE BM, 1995, J BIOL CHEM, V270, P21907, DOI 10.1074/jbc.270.37.21907; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; WONG K, 1994, J BIOL CHEM, V269, P28878; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4	47	219	223	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2595	2598		10.1074/jbc.272.5.2595	http://dx.doi.org/10.1074/jbc.272.5.2595			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006891	hybrid			2022-12-25	WOS:A1997WE66700004
J	Gaudriault, G; Nouel, D; DalFarra, C; Beaudet, A; Vincent, JP				Gaudriault, G; Nouel, D; DalFarra, C; Beaudet, A; Vincent, JP			Receptor-induced internalization of selective peptidic mu and delta opioid ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; SMOOTH-MUSCLE CELLS; AGONIST-INDUCED INTERNALIZATION; OPIATE ENKEPHALIN RECEPTORS; NG108-15 HYBRID-CELLS; DOWN-REGULATION; MEDIATED ENDOCYTOSIS; NEUROBLASTOMA-CELLS; EPITHELIAL-CELLS; BINDING-SITES	The binding and internalization of radioiodinated and fluorescent mu and delta opioid peptides in mammalian cells were quantitatively studied by biochemical techniques and directly visualized by confocal microscopy. The labeled peptides were prepared by inserting either a I-125-Bolton-Hunter group or a fluorescent probe into the C-terminal part of 5-aminopentylamide derivatives of deltorphin-I and [Lys(7)]dermorphin. The purified derivatives kept most of their specificity and selectivity toward delta and mu opioid receptors, respectively. Biochemical and confocal microscopy data showed that both mu and delta opioid peptides were internalized in mammalian cells transfected with the corresponding opioid receptor according to a receptor-mediated mechanism. The internalization process was time- and temperature- dependent and was completely blocked by the endocytosis inhibitor phenylarsine oxyde. Internalization of both delta and mu ligands occurred from a single large cap at one pole of the cell, indicating that polymerization of ligand-receptor complexes preceeded internalization. Finally, green and red fluorescent analogues of deltorphin-I and [Lys(7)]dermorphin, respectively, were found to internalize through partly distinct endocytic pathways in cells co-transfected with mu and delta receptors, suggesting that each of these receptors interacts with distinct proteins mediating intracellular sorting and trafficking.	CNRS,INST PHARMACOL MOL & CELLULAIRE,UPR 411,F-06560 VALBONNE,FRANCE; MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; McGill University								ABOOD ME, 1994, J NEUROSCI RES, V37, P714, DOI 10.1002/jnr.490370605; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; ARVIDSSON U, 1995, J NEUROSCI, V15, P1215; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Befort K, 1996, MOL PHARMACOL, V49, P216; BELCHEVA MM, 1992, MOL PHARMACOL, V42, P445; BENYA RV, 1995, MOL PHARMACOL, V47, P10; CHABRY J, 1993, J BIOL CHEM, V268, P17138; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHANG KJ, 1978, MOL PHARMACOL, V14, P961; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; CHENG PY, 1995, J NEUROSCI, V15, P5976; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; CONE RI, 1991, LIFE SCI, V49, pPL147, DOI 10.1016/0024-3205(91)90396-S; Edwards DA, 1996, P NATL ACAD SCI USA, V93, P1786, DOI 10.1073/pnas.93.5.1786; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; FAURE MP, 1995, J NEUROSCI, V15, P4140; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; GAUDRIAULT G, 1992, PEPTIDES, V13, P1187, DOI 10.1016/0196-9781(92)90027-Z; GAUDRIAULT G, 1997, IN PRESS J NEUROCHEM; GOLDSTEIN A, 1988, P NATL ACAD SCI USA, V85, P7375, DOI 10.1073/pnas.85.19.7375; GOULD GW, 1989, ARCH BIOCHEM BIOPHYS, V268, P264, DOI 10.1016/0003-9861(89)90588-2; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; GUCKER S, 1992, MOL PHARMACOL, V42, P656; HALPERN J, 1981, P NATL ACAD SCI-BIOL, V78, P587, DOI 10.1073/pnas.78.1.587; HAMEL E, 1984, NATURE, V312, P155, DOI 10.1038/312155a0; HAZUM E, 1979, SCIENCE, V206, P1077, DOI 10.1126/science.227058; HAZUM E, 1979, NATURE, V282, P626, DOI 10.1038/282626a0; HAZUM E, 1980, P NATL ACAD SCI-BIOL, V77, P3038, DOI 10.1073/pnas.77.5.3038; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; JOHNSON SM, 1989, PHARMACOL REV, V41, P435; KEITH D, 1995, AM SOC NEUROSCI M, V21, P533; KLOTZ KN, 1994, BIOESSAYS, V16, P193, DOI 10.1002/bies.950160310; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW PY, 1983, MOL PHARMACOL, V24, P413; LUTZ W, 1990, P NATL ACAD SCI USA, V87, P6507, DOI 10.1073/pnas.87.17.6507; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; NEGRI L, 1992, P NATL ACAD SCI USA, V89, P7203, DOI 10.1073/pnas.89.15.7203; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NIXON RA, 1995, TRENDS NEUROSCI, V18, P489, DOI 10.1016/0166-2236(95)92772-I; NOUEL D, 1997, IN PRESS ENDOCRINOLO; PASQUINI F, 1992, J COMP NEUROL, V326, P229, DOI 10.1002/cne.903260206; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; POLLARD JW, 1984, METHOD MOL BIOL, V2, P321; PUTTFARCKEN PS, 1989, LIFE SCI, V45, P1937, DOI 10.1016/0024-3205(89)90548-1; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SCHLESSINGER J, 1980, NATURE, V286, P729, DOI 10.1038/286729a0; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; TOTA MR, 1994, BIOCHEMISTRY-US, V33, P13079, DOI 10.1021/bi00248a017; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; ZADINA JE, 1993, J PHARMACOL EXP THER, V265, P254	62	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2880	2888		10.1074/jbc.272.5.2880	http://dx.doi.org/10.1074/jbc.272.5.2880			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006932	hybrid			2022-12-25	WOS:A1997WE66700045
J	Lin, M; Nielsen, K				Lin, M; Nielsen, K			Binding of the Brucella abortus lipopolysaccharide O-chain fragment to a monoclonal antibody - Quantitative analysis by fluorescence quenching and polarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YERSINIA-ENTEROCOLITICA O-9; ENZYME IMMUNOASSAYS; ANTIGENS; AFFINITY; OLIGOSACCHARIDES; STRAIN-19	An antigenic O-chain polysaccharide fragment derived from Brucella abortus lipopolysaccharide was labeled with 14.8 +/- 1.8 (n = 5) and 52.3 +/- 2.4 (n = 3) mu mol of fluorescein/g of polysaccharide (designated FL(1) and FL(2), respectively) for use in investigating the binding of O-chain to a specific murine antibody YsT9 under equilibrium conditions. Upon binding to YsT9, the fluorescence of FL(1) and FL(2) was quenched 45-57% with no shift in the excitation and emission spectra, and polarization of fluorescence increased by 300-335%. With fluorescence quenching and polarization as sensitive signals for antibody-bound labeled O-chains, the equilibrium constants for binding of FL(1), FL(2), and unlabeled O-chain to YsT9 were determined to be within a similar order (1.5 x 10(7) to 2.0 x 10(7) M(-1)) using a nonlinear curve fitting approach rather than Scatchard analysis. These results indicated that covalent attachment of fluorescein groups to the O-chain did not influence the recognition of the YsT9-defined epitope by the antibody. The reversibility of the O-chain-antibody reaction was also demonstrated by showing a rapid depolarization of the labeled O-chain-antibody complex in the presence of unlabeled O-chain, suggesting that this displacement experiment could be exploited to quantify the Brucella polysaccharide antigen. The study described here provides a useful model for characterization of the complex formation between a carbohydrate-binding protein and a carbohydrate ligand and also for the design of a homogeneous assay system to quantitate antigens or antibodies of clinical interest.			Lin, M (corresponding author), AGR CANADA,ANIM DIS RES INST,3851 FALLOWFIELD RD,NEPEAN,ON K2H 8P9,CANADA.							AHLSTEDT S, 1974, INT ARCH ALLER A IMM, V46, P470, DOI 10.1159/000231150; Aragon V, 1996, J BACTERIOL, V178, P1070, DOI 10.1128/jb.178.4.1070-1079.1996; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BUNDLE DR, 1989, INFECT IMMUN, V57, P2829, DOI 10.1128/IAI.57.9.2829-2836.1989; BUNDLE DR, 1984, INFECT IMMUN, V46, P389, DOI 10.1128/IAI.46.2.389-393.1984; BUNDLE DR, 1989, PURE APPL CHEM, V61, P1171, DOI 10.1351/pac198961071171; CAROFF M, 1984, INFECT IMMUN, V46, P384, DOI 10.1128/IAI.46.2.384-388.1984; CAROFF M, 1984, EUR J BIOCHEM, V139, P195, DOI 10.1111/j.1432-1033.1984.tb07994.x; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; Cherwonogrodzky J. W., 1990, Animal brucellosis., P19; Dandliker W B, 1981, Methods Enzymol, V74 Pt C, P3; DANDLIKER WB, 1977, IMMUNOCHEMISTRY PROT, V1, P232; DIAZ R, 1968, J BACTERIOL, V96, P893, DOI 10.1128/JB.96.4.893-901.1968; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Granath K, 1973, CARBOHYDRATE RES, V2, P375, DOI DOI 10.1016/S0008-6215(00)81824-8; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; HETHERINGTON SV, 1988, J IMMUNOL, V140, P3966; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMET J, 1987, ANN INST PASTEUR IMM, V138, P417, DOI 10.1016/S0769-2625(87)80052-1; LIN M, 1989, ARCH BIOCHEM BIOPHYS, V269, P219, DOI 10.1016/0003-9861(89)90103-3; MEIKLE PJ, 1989, INFECT IMMUN, V57, P2820, DOI 10.1128/IAI.57.9.2820-2828.1989; MONTARAZ JA, 1984, INFECT IMMUN, V51, P961; MULCAHY G, 1992, RES VET SCI, V52, P133, DOI 10.1016/0034-5288(92)90001-I; Nielsen K, 1996, J IMMUNOL METHODS, V195, P161, DOI 10.1016/0022-1759(96)00116-0; Nielsen K., 1994, Genetic Engineer and Biotechnologist, V14, P25; NIELSEN K, 1989, AM J VET RES, V50, P5; NIELSEN K, 1990, VET IMMUNOL IMMUNOP, V24, P373, DOI 10.1016/0165-2427(90)90007-F; PERRY MB, 1990, ADVANCES IN BRUCELLOSIS RESEARCH, P76; Steward M.W., 1983, ANTIBODY AFFINITY TH; STEWARD MW, 1985, J IMMUNOL METHODS, V78, P173, DOI 10.1016/0022-1759(85)90074-2; VORBERG E, 1990, J IMMUNOL METHODS, V132, P81, DOI 10.1016/0022-1759(90)90401-G; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; WEI AP, 1993, ANAL CHEM, V65, P3372, DOI 10.1021/ac00071a007; WU AM, 1987, MOL CELL BIOCHEM, V75, P103; YOUNG WW, 1983, J BIOL CHEM, V258, P4890	35	28	28	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2821	2827		10.1074/jbc.272.5.2821	http://dx.doi.org/10.1074/jbc.272.5.2821			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006923	hybrid			2022-12-25	WOS:A1997WE66700036
J	Mynarcik, DC; Williams, PF; Schaffer, L; Yu, GQ; Whittaker, J				Mynarcik, DC; Williams, PF; Schaffer, L; Yu, GQ; Whittaker, J			Analog binding properties of insulin receptor mutants - Identification of amino acids interacting with the cooh terminus of the B-CHAIN of the insulin molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; SIDE-CHAIN; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; MAIN CHAIN; DOMAIN; LIGAND; SITE; KINASE; DETERMINANTS	Recent studies utilizing alanine scanning mutagenesis have identified a major ligand binding domain of the secreted recombinant insulin receptor composed of two subdomains, one between amino acids 1 and 120 and the other between amino acids 704 and 716. In order to obtain a more detailed characterization of these subdomains, we examined the binding of an insulin superanalog, des-(B25-30)-[His-A8, Asp-B10, Tyr-B25 alpha-carboxamide]insulin, to alanine mutants of the ligand binding determinants of these subdomains. cDNAs encoding mutant secreted recombinant receptors were transiently expressed in 293 EBNA cells, and the binding properties for this analog of the expressed receptors were evaluated. In general des-(B25-30)-[His-A8, Asp-B10, Tyr-B25 alpha-carboxamide]insulin binding correlated with insulin binding, suggesting that both peptides bound to the receptor in a similar manner. Alanine mutations of eight amino acids (Asn(15), Phe(64), Phe(705), Glu(706), Tyr(708), Leu(709) Asn(711), and Phe(714)) of the receptor produced the most profound decreases in affinity for des-(B25-30)-[His-A8, Asp-B10, Tyr-B25 alpha-carboxamide]insulin, suggesting that interactions with these amino acids contributed the major part of the free energy of the ligand-receptor interaction. Mutation of Arg(14) and His(710) to Ala produced receptors with undetectable insulin binding but an affinity for des-(B25-30)-[His-A8, Asp-B10, Tyr-B25 alpha-carboxamide]insulin only 8-23-fold less than for native receptor. Further analog studies were performed to elucidate this paradox. The receptor binding potencies of His-Ag and Asp-B10 insulins for these receptor mutants appeared to parallel their relative potencies for native receptor. In contrast the receptor binding potency of des-(B25-30)-[Tyr-B25 alpha-carboxamide]insulin was disproportionately increased for these mutants when compared with its potency for native receptor.	SUNY STONY BROOK,DEPT PHYSIOL & MED,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT BIOPHYS,STONY BROOK,NY 11794; NOVO NORDISK AS,INSULIN RES,DK-2880 BAGSVAERD,DENMARK	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Novo Nordisk					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42171] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; DREYER K, 1991, DIABETES, V40, P1488; FABRY M, 1992, J BIOL CHEM, V267, P8950; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; NAKAGAWA SH, 1987, J BIOL CHEM, V262, P12054; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; NAKAGAWA SH, 1989, J BIOL CHEM, V264, P272; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SCHWARTZ GP, 1987, P NATL ACAD SCI USA, V84, P6408, DOI 10.1073/pnas.84.18.6408; SIMON J, 1977, ENDOCRINOLOGY, V100, P115, DOI 10.1210/endo-100-1-115; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	35	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2077	2081						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999905				2022-12-25	WOS:A1997WD67900011
J	Spencer, RH; Sokolov, Y; Li, HL; Takenaka, B; Milici, AJ; Aiyar, J; Nguyen, A; Park, H; Jap, BK; Hall, JE; Gutman, GA; Chandy, KG				Spencer, RH; Sokolov, Y; Li, HL; Takenaka, B; Milici, AJ; Aiyar, J; Nguyen, A; Park, H; Jap, BK; Hall, JE; Gutman, GA; Chandy, KG			Purification, visualization, and biophysical characterization of Kv1.3 tetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; SHAKER POTASSIUM CHANNELS; HUMAN LYMPHOCYTE-T; VACCINIA VIRUS; EXPRESSION; PROTEIN; SYSTEM; RECONSTITUTION; CHARYBDOTOXIN; INHIBITOR	The voltage-gated K+ channel of T-lymphocytes, Kv1.3, was heterologously expressed in African Green Monkey kidney cells (CV-1) using a vaccinia virus/T7 hybrid expression system; each infected cell exhibited 10(4) to 5 x 10(5) functional channels on the cell surface. The protein, solubilized with detergent (3-[cholamidopropyl)dimethylammonio]-1-propanesulfonic acid or cholate), was purified to near-homogeneity by a single nickel-chelate chromatography step. The Kv1.3 protein expressed in vaccinia virus-infected cells and its purified counterpart are both modified by a similar to 2-kDa core-sugar moiety, most likely at a conserved N-glycosylation site in the external S1-S2 loop; absence of the sugar does not alter the biophysical properties of the channel nor does it affect expression levels. Purified Kv1.3 has an estimated size of similar to 64 kDa in denaturing SDS-polyacrylamide electrophoresis gels, consistent with its predicted size based on the amino acid sequence. By sucrose gradient sedimentation, purified Kv1.3 is seen primarily as a single peak with an approximate mass of 270 kDa, compatible with its being a homotetrameric complex of the similar to 64-kDa subunits. When reconstituted in the presence of lipid and visualized by negative-staining electron microscopy, the purified Kv1.3 protein forms small crystalline domains consisting of tetramers with dimensions of similar to 65 x 65 Angstrom. The center of each tetramer contains a stained depression which may represent the ion conduction pathway. Functional reconstitution of the Kv1.3 protein into lipid bilayers produces voltage-dependent K+-selective currents that can be blocked by two high affinity peptide antagonists of Kv1.3, margatoxin and stichodactylatoxin.	UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL, IRVINE, CA 92697 USA; UNIV CALIF IRVINE, COLL MED, DEPT MOL GENET, IRVINE, CA 92697 USA; UNIV CALIF IRVINE, COLL MED, DEPT PHYSIOL & BIOPHYS, IRVINE, CA 92697 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA; PFIZER INC, PFIZER CENT RES, GROTON, CT 06340 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Pfizer				Li, Huilin/0000-0001-8085-8928	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024783] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24783] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; Bollag D.M., 1991, PROTEIN METHODS; CAI YC, 1993, J BIOL CHEM, V268, P23720; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P379, DOI 10.1085/jgp.89.3.379; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HALL JE, 1984, BIOPHYS J, V45, P233, DOI 10.1016/S0006-3495(84)84151-X; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HILLE B, 1993, IONIC CHANNELS EXCIT; JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7; JAP BK, 1995, J MOL BIOL, V251, P413, DOI 10.1006/jmbi.1995.0444; KARSCHIN A, 1992, METHOD ENZYMOL, V207, P408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MILICI AJ, 1991, J ELECTRON MICR TECH, V19, P305, DOI 10.1002/jemt.1060190306; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; PENNINGTON MW, 1995, INT J PEPT PROT RES, V46, P354; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; RASBAND W, 1995, NIH IMAGE; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; ROSENBERG RL, 1992, NATURE, V360, P166, DOI 10.1038/360166a0; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P1295, DOI 10.1021/bi00172a002; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SHEN NV, 1993, NEURON, V11, P67; SUN TY, 1994, BIOCHEMISTRY-US, V33, P9992, DOI 10.1021/bi00199a024; ZAMPIGHI GA, 1985, P NATL ACAD SCI USA, V82, P8468, DOI 10.1073/pnas.82.24.8468	39	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2389	2395						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999950				2022-12-25	WOS:A1997WD67900056
J	Takenaga, K; Nakamura, Y; Sakiyama, S				Takenaga, K; Nakamura, Y; Sakiyama, S			Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells	ONCOGENE			English	Article						S100A4; metastasis; invasion; motility; Lewis lung carcinoma	NONMUSCLE MYOSIN; PEL98 PROTEIN; MTS1; MOTILITY; INVASION; P9KA; ADENOCARCINOMA; IDENTIFICATION; TRANSFECTION; INDUCTION	S100A4 (also known as pEL98/mts1/p9Ka/18A2/42A/calvasculin/FSP1/CAPL), a member of S100-related calcium-binding proteins, has been implicated to play a role in metastasis. In the present study, we examined the effect of antisense S100A4 RNA on metastatic potential of Lewis lung carcinoma (LLC) cells. High-metastatic All cells were transfected with the expression vector containing S100A4 cDNA in an inverted (antisense) orientation under the transcriptional control of the mouse metallothionein promoter. Treatment of a stably transfected clone (AS10 cells) with Zn2+ resulted in the suppression of the experimental metastatic ability, which was accompanied with the expression of antisense S100A4 RNA and the suppression of the S100A4 expression at both the mRNA and the protein levels. To further confirm the effect of antisense S100A4 RNA, we established several clones after retroviral transduction with an antisense S100A4 construct. Notably, reduced metastatic potential was also evident in these clones. In the antisense S100A4 RNA-expressing cells, cell motility and in vitro invasiveness were found to be suppressed.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,CHUOH KU,CHIBA 260,JAPAN	Chiba Cancer Center	Takenaga, K (corresponding author), CHIBA CANC CTR,RES INST,DIV CHEMOTHERAPY,CHUOH KU,666-2 NITONA,CHIBA 260,JAPAN.							AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIES BR, 1993, ONCOGENE, V8, P999; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; EPNER DE, 1993, CANCER RES, V53, P1995; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FORD HL, 1995, ONCOGENE, V11, P2067; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KANTOR JD, 1993, CANCER RES, V53, P1971; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMI MS, 1993, ANTICANCER RES, V13, P299; LIOTTA LA, 1988, BREAST CANCER RES TR, V11, P113, DOI 10.1007/BF01805835; LIOTTA LA, 1991, CANCER RES, V51, pS5054; PARKER C, 1994, DNA CELL BIOL, V13, P1021, DOI 10.1089/dna.1994.13.1021; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; TAKENAGA K, 1994, BIOCHEM BIOPH RES CO, V202, P94, DOI 10.1006/bbrc.1994.1898; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; YAMADA KM, 1990, CANCER RES, V50, P4485	29	135	144	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					331	337		10.1038/sj.onc.1200820	http://dx.doi.org/10.1038/sj.onc.1200820			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018119				2022-12-25	WOS:A1997WD51600009
J	Tomida, A; Suzuki, H; Kim, HD; Tsuruo, T				Tomida, A; Suzuki, H; Kim, HD; Tsuruo, T			Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells	ONCOGENE			English	Article						glucose-regulated response; growth arrest; retinoblastoma protein; cyclin D1; p21(WAF1)	MAMMALIAN-CELLS; DEPENDENT KINASES; TUMOR-SUPPRESSOR; P53 PROTEIN; G1 PHASE; GROWTH; INDUCTION; ARREST; P21; ACCUMULATION	Glucose-regulated stress response of cancer cells occurs during the growth of solid tumors and is induced in culture by treatments with various agents, including 2-deoxyglucose, glucosamine, and calcium ionophore A23187. We previously reported that the three stressors commonly induced cell-cycle arrest in the G(1) phase and resistance to antitumor drugs in human cancer A2780 and HT-29 cells. In this study, we investigated the mechanisms of stress-induced G(1) arrest by determining the expression of cell-cycle-regulating proteins. Among G(1) cyclins and cyclin-dependent kinases (cdk) examined, the expression levels of cyclin D1 preferentially decreased in the stressed cells. A time-course study showed that the decrease in cyclin D1 coincided with the appearance of hypophosphorylated retinoblastoma protein (pRb), which is the growth suppressive form. These findings suggest that the stress-induced G(1) arrest is mediated through the down-regulation of cyclin D1-associated kinases (cdk4/6), pRb kinases during G(1) phase. This was also supported by decreased cdk4 expression in stressed HT-29 cells, In addition, p21(WAF1), a cdk inhibitor, was induced in the stressed cells, particularly A23187-treated cells. A23187, compared with the other stressors, caused extreme pRb hypophosphorylation, suggesting that p21(WAf1) is involved in the regulation of pRb phosphorylation in the stressed cells. Our present findings could explain a molecular-based mechanism of a growth-arrested quiescent state and also resistance to chemotherapy of solid tumor cells.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BIOMED RES LAB,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CAI JW, 1993, J CELL PHYSIOL, V154, P229, DOI 10.1002/jcp.1041540204; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1992, SCIENCE, V258, P424; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; SHEN JW, 1989, MOL CELL BIOL, V9, P3284, DOI 10.1128/MCB.9.8.3284; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TOMIDA A, 1996, IN PRESS INT J CANC; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yun J, 1995, ONCOL RES, V7, P583	40	29	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2699	2705						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000144				2022-12-25	WOS:A1996VZ65400020
J	Tucker, RM; Burke, DT				Tucker, RM; Burke, DT			Transgenic mice for the establishment of histidinol-resistant embryonic fibroblast feeder layers	FASEB JOURNAL			English	Article						embryonic stem cells; gene targeting; selectable marker	STEM ES CELLS; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; GENE; LOCUS; SITE; ACTIVATION; SELECTIONS; MUTATIONS; STRATEGY	Gene targeting in mouse embryonic stem cells generates mutations by replacing an endogenous chromosomal region with a copy disrupted by a selectable genetic marker, The most commonly used selectable marker is the bacterial neo(r) gene, which confers resistance in mammalian cells to the antibiotic G418. Use of an alternative selectable marker, the Salmonella typhimurium gene hisD, should provide expanded applications for gene targeting, The hisD gene encodes the protein histidinol dehydrogenase, which catalyzes the conversion of histidinol to the amino acid histidine. Histidinol is toxic to mammalian cells, while histidine is an essential mammalian amino acid, Consequently, growth selection in cultures with media containing histidinol in place of histidine occurs by both histidine starvation and histidinol poisoning, The hisD selection is being tested for potential use in gene targeting experiments with mouse embryonic stem (ES) cells, Currently, most successful gene targeting experiments use primary embryonic fibroblast feeder layers, which assist in the maintenance of the pluripotential state of the embryonic stem cells, To support ES cell stability under histidinol selection, mice transgenic for the S, typhimurium hisD gene have been produced and used to generate embryonic fibroblast feeder cells, The transgenic embryonic fibroblasts survive under a wide range of histidinol-containing growth conditions and support growth of ES cell cultures.	UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan				Burke, David/0000-0002-2564-7949				ASKEW GR, 1993, MOL CELL BIOL, V13, P4115, DOI 10.1128/MCB.13.7.4115; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BAUTISTA D, 1993, J IMMUNOL, V151, P1950; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DETLOFF PJ, 1994, MOL CELL BIOL, V14, P6936, DOI 10.1128/MCB.14.10.6936; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HANSEN BS, 1972, J BIOL CHEM, V247, P3854; HANSON KD, 1995, MOL CELL BIOL, V15, P45, DOI 10.1128/MCB.15.1.45; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HOGAN B, 1986, MANIPULATING MOUSE E; JOHNSON KA, 1995, NUCLEIC ACIDS RES, V23, P1273, DOI 10.1093/nar/23.7.1273; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; LI YP, 1993, MOL CELL BIOL, V13, P6064, DOI 10.1128/MCB.13.10.6064; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NEWMAN EM, 1983, CANCER RES, V43, P4703; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SCORNIK OA, 1980, J BIOL CHEM, V255, P6322; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; VONMELCHNER H, 1990, P NATL ACAD SCI USA, V87, P3733, DOI 10.1073/pnas.87.10.3733; WARBURTON D, 1990, GENOMICS, V6, P358, DOI 10.1016/0888-7543(90)90577-H; WARRINGTON RC, 1994, ANTICANCER RES, V14, P367; WARRINGTON RC, 1989, BRIT J CANCER, V60, P652, DOI 10.1038/bjc.1989.333; ZIMMER A, 1989, NATURE, V338, P150, DOI 10.1038/338150a0	32	3	5	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1996	10	14					1641	1645		10.1096/fasebj.10.14.9002557	http://dx.doi.org/10.1096/fasebj.10.14.9002557			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002557	Green Submitted			2022-12-25	WOS:A1996WC86900011
J	Miyata, S; Liu, BP; Shoda, H; Ohara, T; Yamada, H; Suzuki, K; Kasuga, M				Miyata, S; Liu, BP; Shoda, H; Ohara, T; Yamada, H; Suzuki, K; Kasuga, M			Accumulation of pyrraline-modified albumin in phagocytes due to reduced degradation by lysosomal enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; ADVANCED MAILLARD REACTION; GLUCOSE-MODIFIED PROTEINS; LOW-DENSITY LIPOPROTEINS; INDUCED DIABETIC RAT; HUMAN-SKIN COLLAGEN; IMMUNOCHEMICAL DETECTION; PHYSIOLOGICAL CONDITIONS; MONOCLONAL-ANTIBODY; ENDOCYTIC UPTAKE	Previous studies suggested that the interaction between proteins modified by advanced glycation end products (AGEs) and cells, such as macrophages, may be involved in diabetic angiopathy. Pyrraline is one of the AGEs and known to be elevated in plasma of diabetic rats and humans, and is present in vascular lesions of diabetic and elderly subjects. We examined whether modification of albumin by pyrraline influences its degradation by macrophage-like cell line, P388D(1) cells. Degradation of pyrraline-modified albumin by these cells was diminished, causing accumulation of the albumin in these cells. The susceptibility of pyrraline-modified albumin to lysosomal proteolytic enzymes was reduced by approximately 40% in vitro, while lysosomal activity in the cells per se was not affected. This phenomenon was also observed when human monocytes were used instead of P388D(1) cells. Our results suggest that accumulation of pyrraline-modified albumin in P388D, cells is due to the reduced susceptibility of the protein to lysosomal enzymatic degradation. Such alterations in the interaction between AGEs-modified protein and phagocytes may contribute to angiopathy in elderly subjects and patients with diabetes.			Miyata, S (corresponding author), KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, CHUO KU, 7-5-1 KUSUNOKI CHO, KOBE 650, JAPAN.							Absolom D R, 1986, Methods Enzymol, V132, P95; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; BAGGIOLINI M, 1974, METHOD ENZYMOL, V31, P348; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN M, 1989, J BIOL CHEM, V264, P20947; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; COHEN MP, 1986, DIABETES PROTEIN GLY; DAWE CJ, 1957, AM J PATHOL, V33, P603; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HAYASE F, 1994, BIOSCI BIOTECH BIOCH, V58, P1936, DOI 10.1271/bbb.58.1936; IBERG N, 1986, J BIOL CHEM, V261, P3542; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P2009, DOI 10.1080/00021369.1987.10868313; KIRSCHBAUM B, 1986, CLIN CHEM, V32, P572; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; KOREN HS, 1975, J IMMUNOL, V114, P894; KUME S, 1995, AM J PATHOL, V147, P654; LAPOLLA A, 1995, DIABETOLOGIA, V38, P1076; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MITSUHASHI T, 1993, DIABETES, V42, P826, DOI 10.2337/diabetes.42.6.826; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MONNIER VM, 1989, MAILLARD REACTION AG; MYCEK MJ, 1970, METHOD ENZYMOL, V19, P285; NAKAI N, 1974, ANAL BIOCHEM, V58, P563, DOI 10.1016/0003-2697(74)90225-5; NAKAMURA K, 1992, J CHEM SOC CHEM COMM, P992, DOI 10.1039/c39920000992; NAKAMURA Y, 1993, AM J PATHOL, V143, P1649; NAKAYAMA H, 1993, DIABETES, V42, P345, DOI 10.2337/diabetes.42.2.345; NJOROGE FG, 1987, CARBOHYD RES, V167, P211; ODETTI P, 1992, DIABETES, V41, P153, DOI 10.2337/diabetes.41.2.153; PORTEROOTIN M, 1995, BBA-PROTEIN STRUCT M, V1247, P74, DOI 10.1016/0167-4838(94)00209-Y; SAISHOJI T, 1995, BIOCHEM BIOPH RES CO, V217, P278, DOI 10.1006/bbrc.1995.2775; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; SELL DR, 1989, J BIOL CHEM, V264, P21597; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; STEINBRECHER UP, 1984, DIABETES, V33, P130, DOI 10.2337/diabetes.33.2.130; TANEDA S, 1994, CLIN CHEM, V40, P1766; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; VLASSARA H, 1984, J EXP MED, V160, P197, DOI 10.1084/jem.160.1.197; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; YAMADA H, 1994, J BIOL CHEM, V269, P20275	49	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4037	4042		10.1074/jbc.272.7.4037	http://dx.doi.org/10.1074/jbc.272.7.4037			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020111	hybrid			2022-12-25	WOS:A1997WH01900027
J	Pronin, AN; Benovic, JL				Pronin, AN; Benovic, JL			Regulation of the G protein-coupled receptor kinase GRK5 by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN KINASE; DEPENDENT PHOSPHORYLATION; CARDIAC-FUNCTION; PURIFICATION; FAMILY; ACTIVATION; EXPRESSION; AUTOPHOSPHORYLATION; TRANSDUCTION; MEMBER	G protein-coupled receptor kinases (GRKs) specifically recognize and phosphorylate the hormone-occupied form of numerous G protein-coupled receptors, ultimately resulting in termination of receptor signaling. While little is presently known about the regulation of GRK function, recent studies suggest a role for protein kinase C (PKC) phosphorylation of the beta-adrenergic receptor kinase in membrane association and activation of the kinase. To assess a potential general role for PKC in regulating GRK function, we characterized the ability of PKC to phosphorylate GRK5, a recently identified member of the GRK family, We demonstrate that GRK5 can be rapidly and stoichiometrically phosphorylated by PKC in vitro, Intact cell studies reveal that GRK5 is also phosphorylated when transiently expressed in COS-1 cells following treatment with the PKC activator, phorbol 12-myristate 13-acetate. In vitro analysis reveals two major sites of PKC phosphorylation within the C-terminal 26 amino acids of GRK5, GRK5 phosphorylation by PKC dramatically reduces its ability to phosphorylate both receptor (light-activated rhodopsin) and non-receptor (casein and phosvitin) substrates. Kinetic analysis reveals an similar to 5-fold increased K-m and similar to 3-fold decreased V-max for rhodopsin, with no change in the K-m for ATP, The reduced affinity of PKC-phosphorylated GRK5 for rhodopsin was also evident in a decreased ability to bind to rhodopsin-containing membranes, while direct binding of GRK5 to phospholipids appeared unaltered, These results suggest that PKC might play an important role in modulating the ability of GRK5 to regulate receptor signaling and that GRK phosphorylation by PKC may serve as a disparate mechanism for regulating GRK activity.	THOMAS JEFFERSON UNIV, KIMMEL CANC CTR, DEPT BIOCHEM & MOL PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS CS, 1995, J BIOL CHEM, V270, P23317, DOI 10.1074/jbc.270.40.23317; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Diviani D, 1996, J BIOL CHEM, V271, P5049; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; GOMEZ J, 1992, MOL BIOL RECEPTORS T, P1; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KIM CM, 1993, RECEPTOR, V3, P39; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nagayama Y, 1996, J BIOL CHEM, V271, P10143, DOI 10.1074/jbc.271.17.10143; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROCKMAN HA, 1995, CIRCULATION, V92, P1145; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	41	109	110	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3806	3812		10.1074/jbc.272.6.3806	http://dx.doi.org/10.1074/jbc.272.6.3806			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013639	hybrid			2022-12-25	WOS:A1997WG19200099
J	Cardinaud, B; Sugamori, KS; Coudouel, S; Vincent, JD; Niznik, HB; Vernier, P				Cardinaud, B; Sugamori, KS; Coudouel, S; Vincent, JD; Niznik, HB; Vernier, P			Early emergence of three dopamine D-1 receptor subtypes in vertebrates - Molecular phylogenetic, pharmacological, and functional criteria defining D-1A, D-1B, and D-1C receptors in European eel Anguilla anguilla	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MESSENGER-RNA; D5 RECEPTOR; RAT-BRAIN; CLONING; GENE; DESENSITIZATION; PHOSPHORYLATION; EXPRESSION; SEQUENCES	The existence of dopamine D-1C and D-1D receptors in Xenopus and chicken, respectively, challenged the established duality (D-1A and D-1B) of the dopamine D-1 receptor class in vertebrates. To ascertain the molecular diversity of this gene family in early diverging vertebrates, we isolated four receptor-encoding sequences from the European eel Anguilla anguilla. Molecular phylogeny assigned two receptor sequences (D-1A1 and D-1A2) to the D-1A subtype, and a third receptor to the D-1B subtype. Additional sequence was orthologous to the Xenopus D-1C receptor and to several other previously unclassified fish D-1-like receptors. When expressed in COS-7 cells, eel D-1A and D-1B receptors display affinity profiles for dopaminergic ligands similar to those of other known vertebrate homologues. The D-1C receptor exhibits pharmacological characteristics virtually identical to its Xenopus homologue. Functionally, while all eel D-1 receptors stimulate adenylate cyclase, the eel D-1B receptor exhibits greater constitutive activity than either D-1A or D-1C receptors. Semiquantitative reverse transcription-polymerase chain reaction reveals the differential distribution of D-1A1, D-1A2, D-1B, and D-1C receptor mRNA within the hypothalamic-pituitary axis of the eel brain. Taken together, these data suggest that the D-1A, D-1B, and D-1C receptors arose prior to the evolutionary divergence of fish and tetrapods and exhibit molecular, pharmacological, and functional attributes that unambiguously allow for their classification as distinct D-1 receptor subtypes in the vertebrate phylum.	UNIV TORONTO,DEPT PSYCHIAT,TORONTO,ON M5T 1R8,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON M5T 1R8,CANADA; CLARKE INST PSYCHIAT,MOL NEUROBIOL LAB,TORONTO,ON M5T 1R8,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Cardinaud, B (corresponding author), INST ALFRED FESSARD,CNRS,UPR2212,F-91198 GIF SUR YVETTE,FRANCE.							ANDERSEN LR, 1988, FOCUS, V10, P35; Balavoine G, 1996, NUCLEIC ACIDS RES, V24, P1547, DOI 10.1093/nar/24.8.1547; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BEISCHLAG TV, 1995, BIOCHEMISTRY-US, V34, P5960, DOI 10.1021/bi00017a025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281; DEMCHYSHYN LL, 1995, J BIOL CHEM, V270, P4005, DOI 10.1074/jbc.270.8.4005; FRAIL DE, 1993, MOL PHARMACOL, V44, P1113; FRYXELL KJ, 1995, J MOL EVOL, V41, P85, DOI 10.1007/BF00174044; HALL JM, 1993, TRENDS PHARMACOL SCI, V14, P376, DOI 10.1016/0165-6147(93)90096-3; JARVIE KR, 1993, J RECEPTOR RES, V13, P573, DOI 10.3109/10799899309073680; JENSEN AA, 1995, J NEUROCHEM, V65, P1325, DOI 10.1046/j.1471-4159.1995.65031325.x; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KEEN M, 1991, TRENDS PHARMACOL SCI, V12, P371, DOI 10.1016/0165-6147(91)90606-S; KENAKIN TP, 1992, PHARMACOL REV, V44, P351; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lamers AE, 1996, BBA-GENE STRUCT EXPR, V1308, P17, DOI 10.1016/0167-4781(96)00086-3; MACRAE AD, 1995, GENOMICS, V25, P436, DOI 10.1016/0888-7543(95)80044-M; MANSOUR A, 1991, NEUROSCIENCE, V45, P359, DOI 10.1016/0306-4522(91)90233-E; MEADORWOODRUFF JH, 1992, NEUROSCI LETT, V145, P209, DOI 10.1016/0304-3940(92)90024-2; Meek J, 1994, PHYLOGENY DEV CATECH; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; OHTA T, 1991, J MOL EVOL, V33, P34, DOI 10.1007/BF02100193; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; PARK EH, 1976, SCIENCE, V193, P64, DOI 10.1126/science.935856; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; POWERS DA, 1991, ADV GENET, V29, P119, DOI 10.1016/S0065-2660(08)60108-X; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SUGAMORI KS, 1995, FEBS LETT, V362, P131, DOI 10.1016/0014-5793(95)00224-W; SUGAMORI KS, 1994, P NATL ACAD SCI USA, V91, P10536, DOI 10.1073/pnas.91.22.10536; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TIBERI M, 1994, J BIOL CHEM, V269, P27925; TOMIC M, 1993, BIOCHEM BIOPH RES CO, V191, P1020, DOI 10.1006/bbrc.1993.1319; VERNIER P, 1995, TRENDS PHARMACOL SCI, V16, P375, DOI 10.1016/S0165-6147(00)89078-1; WONG AOL, 1993, ENDOCRINOLOGY, V133, P577, DOI 10.1210/en.133.2.577; ZAMANILLO D, 1995, NEUROSCI LETT, V188, P183, DOI 10.1016/0304-3940(95)11428-Y	37	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2778	2787		10.1074/jbc.272.5.2778	http://dx.doi.org/10.1074/jbc.272.5.2778			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006917	hybrid			2022-12-25	WOS:A1997WE66700030
J	AlShawi, MK; Ketchum, CJ; Nakamoto, RK				AlShawi, MK; Ketchum, CJ; Nakamoto, RK			Energy coupling, turnover, and stability of the F0F1 ATP synthase are dependent on the energy of interaction between gamma and beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; CARBOXYL-TERMINAL REGION; H+-ATPASE; EPSILON-SUBUNIT; CATALYTIC SITES; F1F0-ATP SYNTHASE; PROTON CHANNEL; POLAR LOOP; F1 ATPASE	Replacement of the F0F1 ATP synthase gamma subunit Met-23 with Lys (gamma M23K) perturbs coupling efficiency between transport and catalysis (Shin, K., Nakamoto, R. K., Maeda, M., and Futai, M. (1992) J. Biol Chem. 267, 20835-20839). We demonstrate here that the gamma M23K mutation causes altered interactions between subunits. Binding of delta or epsilon subunits stabilizes the alpha(3) beta(3) gamma complex, which becomes destabilized by the mutation. Significantly, the inhibition of F-1 ATP hydrolysis by the epsilon subunit is no longer relieved when the gamma M23K mutant F-1 is bound to F-0. Steady state Arrhenius analysis reveals that the gamma M23K enzyme has increased activation energies for the catalytic transition state. These results suggest that the mutation causes the formation of additional bonds within the enzyme that must be broken in order to achieve the transition state. Based on the x-ray crystallographic structure of Abrahams et al. (Abrahams, J.P., Leslie, A. G. W., Lutter, R., and Walker, J.E. (1994) Nature 370, 621-628), the additional bond is likely due to gamma M23K forming an ionized hydrogen bond with one of the beta Glu-381 residues. Two second site mutations, gamma Q269R and gamma R242C, suppress the effects of gamma M23K and decrease activation energies for the gamma M23K enzyme. We conclude that gamma M23K is an added function mutation that increases the energy of interaction between gamma and beta subunits. The additional interaction perturbs transmission of conformational information such that epsilon inhibition of ATPase activity is not relieved and coupling efficiency is lowered.	UNIV VIRGINIA, DEPT MOL PHYSIOL & BIOL PHYS, CHARLOTTESVILLE, VA 22906 USA	University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052502, R01GM050957] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07284] Funding Source: Medline; NIGMS NIH HHS [R01-GM50957, R01-GM52502, R01 GM050957] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; BRAGG PD, 1973, ARCH BIOCHEM BIOPHYS, V159, P664, DOI 10.1016/0003-9861(73)90505-5; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUNN SD, 1982, J BIOL CHEM, V257, P7354; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRAGA D, 1994, J BIOL CHEM, V269, P7532; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; HAZARD AL, 1994, J BIOL CHEM, V269, P427; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; JAGENDORF AT, 1991, CELL CULTURE SOMAT B, V7, P225; JEANTEURDEBEUKELAER C, 1995, J BIOL CHEM, V270, P22850; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; NELSON N, 1974, P NATL ACAD SCI USA, V71, P2720, DOI 10.1073/pnas.71.7.2720; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHIN K, 1992, J BIOL CHEM, V267, P20835; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; STERNWEIS PC, 1978, J BIOL CHEM, V253, P3123; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221; [No title captured]	49	60	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2300	2306						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999937				2022-12-25	WOS:A1997WD67900043
J	AsheryPadan, R; Weiss, AM; Feinstein, N; Gruenbaum, Y				AsheryPadan, R; Weiss, AM; Feinstein, N; Gruenbaum, Y			Distinct regions specify the targeting of otefin to the nucleoplasmic side of the nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-B-RECEPTOR; DROSOPHILA-MELANOGASTER; A PRECURSOR; MEMBRANE; PROTEIN; ISOPRENYLATION; ORGANIZATION; BINDING; CLONING; SIGNALS	Otefin is a 45-kDa nuclear envelope protein with no apparent homology to other known proteins. It includes a large hydrophilic domain, a single carboxyl-terminal hydrophobic sequence of 17 amino acids, and a high content of serine and threonine residues. Cytological labeling located otefin on the nucleoplasmic side of the nuclear envelope. Chemical extraction of nuclei from Drosophila embryos revealed that otefin is a peripheral protein whose association with the nuclear envelope is stronger than that of lamin. Deletion mutants of otefin were expressed in order to identify regions that direct otefin to the nuclear envelope. These experiments revealed that the hydrophobic sequence at the carboxyl terminus is essential for correct targeting to the nuclear envelope, whereas additional regions in the hydrophilic domain of otefin are required for its efficient targeting and stabilization in the nuclear envelope.	HEBREW UNIV JERUSALEM,DEPT GENET,INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL; JERUSALEM COLL TECHNOL,DEPT ELECT,IL-91160 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAILER SM, 1991, J CELL BIOL, V114, P389, DOI 10.1083/jcb.114.3.389; Burke B, 1990, CURR OPIN CELL BIOL, V2, P514, DOI 10.1016/0955-0674(90)90136-3; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; FIRMBACHKRAFT I, 1993, J CELL BIOL, V123, P1661, DOI 10.1083/jcb.123.6.1661; FIRMBACHKRAFT I, 1995, J CELL BIOL, V129, P17, DOI 10.1083/jcb.129.1.17; FISHER PA, 1989, J BIOL CHEM, V264, P3464; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; FURUKAWA K, 1995, EMBO J, V14, P1626, DOI 10.1002/j.1460-2075.1995.tb07151.x; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HAREL A, 1989, J CELL SCI, V94, P463; HENNEKES H, 1994, J CELL SCI, V107, P1019; MCGRADY J, 1970, HISTOCHEMISTRY, V23, P180; MILLER KG, 1985, COLD SPRING HARB SYM, V50, P79, DOI 10.1101/SQB.1985.050.01.012; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; NIGG EA, 1992, BIOCHEM SOC T, V20, P500, DOI 10.1042/bst0200500; PADAN R, 1990, J BIOL CHEM, V265, P7808; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; SASSEVILLE AMJ, 1995, J CELL SCI, V108, P273; SINGER SJ, 1974, ANNU REV BIOCHEM, V43, P805, DOI 10.1146/annurev.bi.43.070174.004105; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531	24	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2493	2499						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999964				2022-12-25	WOS:A1997WD67900070
J	Berlanga, JJ; Gualillo, O; Buteau, H; Applanat, M; Kelly, PA; Edery, M				Berlanga, JJ; Gualillo, O; Buteau, H; Applanat, M; Kelly, PA; Edery, M			Prolactin activates tyrosyl phosphorylation of insulin receptor substrate 1 and phosphatidylinositol-3-OH kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; SIGNAL-TRANSDUCTION; MAMMARY-GLAND; CELLS; JAK2; PROLIFERATION; ASSOCIATION; INVITRO	Prolactin (PRL) has been demonstrated to induce tyrosine phosphorylation and activation of the cytoplasmic tyrosine kinase JAK2. The present study represents an initial effort to identify the phosphorylation repertoire of the PRL receptor (PRLR). For this purpose we have modified the rat PRLR cDNA to encode an additional N-terminal epitope specifically designed to allow the rapid purification of the PRLR and associated proteins from transfected cells. The Flag-tagged PRLR was stably expressed in the human 293 cell line. PRL induced tyrosine phosphorylation of proteins of 85, 95, and 185 kDa from 10 to 30 min after PRL stimulation. Immunoblot analysis of immunoprecipitation indicates that p85 corresponds to the 85-kDa regulatory subunit of phosphatidylinositol (PI)-3' kinase, p95 to PRLR, and p185 to insulin receptor substrate 1 (IRS-1). Both PI-3' kinase and IRS-1 appear to associate with PRLR in a PRL-dependent manner. These results thus indicate that kinases other than JAK2, namely PI-3' kinase, are activated by PRL.	FAC MED NECKER ENFANTS MALAD,INSERM,U344,F-75730 PARIS 15,FRANCE; UNIV AUTONOMA MADRID,FAC CIENCIAS,DEPT BIOL MOL,E-28049 MADRID,SPAIN; UNIV NAPLES FEDERICO II,DIPARTIMENTO FARMACOL SPERIMENTALE,I-80131 NAPLES,ITALY; FAC MED NECKER ENFANTS MALAD,INSERM,U344,F-75730 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Autonomous University of Madrid; University of Naples Federico II; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kelly, Paul/A-7951-2008; Berlanga, Juan José/N-1718-2015; Gualillo, Oreste/B-8223-2008	Berlanga, Juan José/0000-0002-2408-6561; Gualillo, Oreste/0000-0002-7154-1328				ARGETSINGER LS, 1995, J BIOL CHEM, V270, P11685; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; BRELJE TC, 1989, ENDOCRINOLOGY, V125, P2392, DOI 10.1210/endo-125-5-2392; BRELJE TC, 1991, ENDOCRINOLOGY, V128, P45, DOI 10.1210/endo-128-1-45; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; JAHN GA, 1991, BIOMED PHARMACOTHER, V45, P15, DOI 10.1016/0753-3322(91)90148-M; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; NICOLL CS, 1985, PROLACTIN BASIC CLIN, P393; RUI H, 1994, J BIOL CHEM, V269, P5364; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SORENSON RL, 1995, ENDOCRINOLOGY, V136, P4092, DOI 10.1210/en.136.9.4092; SORENSON RL, 1987, ENDOCRINOLOGY, V121, P1447, DOI 10.1210/endo-121-4-1447; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; ZHANG WG, 1993, P NATL ACAD SCI USA, V90, P11317, DOI 10.1073/pnas.90.23.11317	19	89	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2050	2052						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999900				2022-12-25	WOS:A1997WD67900006
J	Koishi, R; Kawashima, I; Yoshimura, C; Sugawara, M; Serizawa, N				Koishi, R; Kawashima, I; Yoshimura, C; Sugawara, M; Serizawa, N			Cloning and characterization of a novel oxidoreductase KDRF from a human bone marrow-derived stromal cell line KM-102	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CSF MESSENGER-RNA; GLUTATHIONE-REDUCTASE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; GM-CSF; MOLECULAR CHARACTERIZATION; DISULFIDE OXIDOREDUCTASES; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY	A cDNA clone coding for a novel oxidoreductase was cloned from a human bone marrow-derived stromal cell Line KM-102. We screened a cDNA library constructed from the mRNA of KM-102 cells stimulated with phorbol 12-myristate 13-acetate and calcium ionophore A23187 using a P-32-labeled 15-mer synthetic oligonucleotide (5'-TAAATAAATAAATAA-3') probe. This probe was designed as a complementary sequence to the three reiterated AUUUA sequences, which are contained in the 3'-untranslated regions of cytokine and some proto-oncogene mRNAs and correlate with rapid mRNA turnover, Then, we obtained one cDNA clone, and further sequence analysis revealed that it coded for a new protein exhibiting 30 to similar to 40% homology with glutathione reductase, By fusion protein analysis, this protein showed reducing activities on 2,6-dichlorophenol-indophenol and 5,5'-dithio-bis(2-nitrobenzoic acid) but only a weak reducing activity on oxidized glutathione. Although it lacked a stretch of hydrophobic amino acids in its N terminus, it was secreted by monkey kidney-derived COS-1 cells when we introduced the expression plasmid into them and also secreted by a human lung carcinoma cell Line A549, Northern blot analysis revealed that the mRNA turnover of this protein was regulated by inflammatory stimuli in KM-102 cells, These results show that this protein may have scavenging enzyme properties and has its mRNA expression regulated in a similar fashion to cytokine genes or proto-oncogenes, Thus, we named it KDRF (KM-102-gerived reductase-like factor), and KDRF may play a role in scavenging reactive oxygen intermediates, which are possibly toxic to cells, in response to inflammatory stimuli.	SANKYO CO LTD,BIOMED RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN	Daiichi Sankyo Company Limited								ABOAGYEKWARTENG T, 1992, MOL MICROBIOL, V6, P3089, DOI 10.1111/j.1365-2958.1992.tb01766.x; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ARNOLD HH, 1990, FEBS LETT, V267, P189, DOI 10.1016/0014-5793(90)80922-6; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AUTOR AP, 1982, J BIOL CHEM, V257, P2713; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P5561; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CREISSEN G, 1992, PLANT J, V2, P129; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; DEMPLE B, 1983, NATURE, V304, P466, DOI 10.1038/304466a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; HARIGAYA K, 1985, P NATL ACAD SCI USA, V82, P3477, DOI 10.1073/pnas.82.10.3477; HASS MA, 1982, J BIOL CHEM, V257, P9379; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KARPLUS PA, 1989, EUR J BIOCHEM, V178, P693, DOI 10.1111/j.1432-1033.1989.tb14500.x; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KUBO A, 1993, PLANT CELL PHYSIOL, V34, P1259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; NEGRO A, 1991, EUR J BIOCHEM, V201, P289, DOI 10.1111/j.1432-1033.1991.tb16286.x; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PERHAM RN, 1991, BIOESSAYS, V13, P515, DOI 10.1002/bies.950131005; PERRY ACF, 1991, MOL MICROBIOL, V5, P163, DOI 10.1111/j.1365-2958.1991.tb01837.x; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; UNTUCHTGRAU R, 1981, EUR J BIOCHEM, V120, P407, DOI 10.1111/j.1432-1033.1981.tb05718.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WOODS D, 1984, FOCUS, V6, P1	46	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2570	2577						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999974				2022-12-25	WOS:A1997WD67900080
J	Ohuchi, E; Imai, K; Fujii, Y; Sato, H; Seiki, M; Okada, Y				Ohuchi, E; Imai, K; Fujii, Y; Sato, H; Seiki, M; Okada, Y			Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; SANDWICH ENZYME-IMMUNOASSAY; INTERGLOBULAR DOMAIN; MONOCLONAL-ANTIBODIES; TISSUE INHIBITOR; ACTIVATION; PURIFICATION; PRECURSOR; PROTEOGLYCAN; AGGRECAN	Membrane type 1 matrix metalloproteinase (MT1-MMP) is expressed on cancer cell membranes and activates the zymogen of MMP-2 (gelatinase A). We have recently isolated MT1-MMP complexed with tissue inhibitor of metalloproteinases 2 (TIMP-2) and demonstrated that MT1-MMP exhibits gelatinolytic activity by gelatin zymography (Imai, H., Ohuchi, E., Aoki, T., Nomura, H., Fujii, Y., Sate, H., Seiki, M., and Okada, Y. (1996) Cancer Res. 56, 2707-2710). In the present study, we have further purified to homogeneity a deletion mutant of MT1-MMP lacking the transmembrane domain (Delta MT1) and native MT1-MMP secreted from a human breast carcinoma cell line (MDA-MB-231 cells) and examined their substrate specificities. Both proteinases are active, without any treatment for activation, and digest type I (guinea pig), II (bovine), and III (human) collagens into characteristic 3/4 and 1/4 fragments. The cleavage sites of type I collagen are the Gly(775)/Ile(776) bond for alpha 1(I) chains and the Gly(775)-Leu(776) and Gly(781)-Ile(782) bonds for alpha 2(I) chains. Delta MT1 hydrolyzes type I collagen 6.5- or 4-fold more preferentially than type II or III collagen, whereas MMP-1 (tissue collagenase) digests type III collagen more efficiently than the other two collagens. Quantitative analyses of the activity of Delta MT1 and MMP-1 indicate that Delta MT1 is 5-7.1-fold less efficient at cleaving type I collagen. On the other hand, gelatinolytic activity of Delta MT1 is 8-fold higher than that of MMP-1. Delta MT1 also digests cartilage proteoglycan, fibronectin, vitronectin and laminin-1 as well as alpha(1)-proteinase inhibitor and alpha(2)-macroglobulin. The activity of Delta MT1 on type I collagen is synergistically increased with co-incubation with MMP-2. These results indicate that MT1-MMP is an extracellular matrix-degrading enzyme sharing the substrate specificity with interstitial collagenases, and suggest that MT1-MMP plays a dual role in pathophysiological digestion of extracellular matrix through direct cleavage of the substrates and activation of proMMP-2.	KANAZAWA UNIV,CANC RES INST,DEPT MOL IMMUNOL & PATHOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,CANC RES INST,DEPT MOL ONCOL & VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; FUJI CHEM IND CO LTD,TAKAOKA,TOYAMA 933,JAPAN; FUKUI MED SCH,DEPT CHEM,FUKUI 91011,JAPAN	Kanazawa University; Kanazawa University; University of Fukui			Okada, Yasunori/B-5550-2014; SATO, Hiroshi/D-8454-2015; Seiki, Motoharu/K-9443-2015; Imai, Kazushi/E-7206-2012	Okada, Yasunori/0000-0001-9208-4755; Fujii, Yutaka/0000-0001-6357-3795				BANDA MJ, 1987, METHOD ENZYMOL, V144, P288; BUTTLE DJ, 1993, ARTHRITIS RHEUM, V36, P1709, DOI 10.1002/art.1780361210; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIMOTO N, 1993, CLIN CHIM ACTA, V220, P31, DOI 10.1016/0009-8981(93)90004-N; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Imai K, 1996, CANCER RES, V56, P2707; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; MINAMOTO T, 1988, HUM PATHOL, V19, P815, DOI 10.1016/S0046-8177(88)80265-X; MURPHY G, 1986, PROTEINASES INFLAMMA, P173; NAGASE H, 1980, ANAL BIOCHEM, V107, P385, DOI 10.1016/0003-2697(80)90400-5; NEGASE H, 1997, TXB RHEUMATOLOGY; NOMURA H, 1995, CANCER RES, V55, P3263; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Ruoslahti E, 1978, Ann N Y Acad Sci, V312, P178, DOI 10.1111/j.1749-6632.1978.tb16802.x; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; ZHANG J, 1993, CLIN CHIM ACTA, V219, P1, DOI 10.1016/0009-8981(93)90192-7	35	781	804	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2446	2451		10.1074/jbc.272.4.2446	http://dx.doi.org/10.1074/jbc.272.4.2446			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999957	hybrid			2022-12-25	WOS:A1997WD67900063
J	Zaychikov, E; Denissova, L; Meier, T; Gotte, M; Heumann, H				Zaychikov, E; Denissova, L; Meier, T; Gotte, M; Heumann, H			Influence of Mg2+ and temperature on formation of the transcription bubble	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; LAC UV5 PROMOTER; SINGLE-STRANDED REGIONS; ESCHERICHIA-COLI; OPEN COMPLEXES; CHEMICAL PROBES; START SITE; DNA; INITIATION; TRANSLOCATION	The transcription bubble formed in the binding complex of T7A1 promoter upon Escherichia coli RNA polymerase was analyzed by chemical probes, namely by single-strand specific reagents, to map the unpaired bases in the bubble, and by FeEDTA, to analyze the accessibility of the DNA backbone, The latter probe could also be used as a local hydroxyl radical probe placed close to the Mg2+-binding site in the active center, The data show that the transcription bubble consists of two parts, an Mg2+-dependent part and an Mg2+-independent part, both having individual transition temperatures, The data further suggest that formation of a transcription active open complex is preceded by a transition state complex having enhanced affinity for those Mg2+ ions presumably participating in the formation of the catalytic site, Our data also suggests that the three catalytically active Mg2+ ions in RNA polymerase are functionally not equivalent, One/two of the three Mg2+ ions are responsible for the polymerization, the other two/one for enlargement of the transcription bubble.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society								BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BUCKLE M, 1989, BIOCHEMISTRY-US, V28, P4388, DOI 10.1021/bi00436a040; Chamberlin M.J., 1976, RNA POLYMERASE, P159; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; Gotte M, 1996, FEBS LETT, V390, P226, DOI 10.1016/0014-5793(96)00662-X; Hermann T, 1995, RNA, V1, P1009; HEUMANN H, 1987, BIOCHIM BIOPHYS ACTA, V909, P126, DOI 10.1016/0167-4781(87)90034-0; HEUMANN H, 1988, J MOL BIOL, V210, P115; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KING PA, 1993, NUCLEIC ACIDS RES, V21, P2473, DOI 10.1093/nar/21.10.2473; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; Maniatis T., 1982, MOL CLONING; MEIER T, 1995, NUCLEIC ACIDS RES, V23, P988, DOI 10.1093/nar/23.6.988; MEIER T, 1995, THESIS LUDWIGMAXIMIL; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; PALECEK E, 1992, METHOD ENZYMOL, V212, P139; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; STRANEY DC, 1987, J MOL BIOL, V193, P279, DOI 10.1016/0022-2836(87)90219-1; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; SUH WC, 1992, BIOCHEMISTRY-US, V31, P7815, DOI 10.1021/bi00149a011; THEDERAHN T, 1990, BIOCHEM BIOPH RES CO, V168, P756, DOI 10.1016/0006-291X(90)92386-E; TULLIUS TD, 1987, TRENDS BIOCHEM SCI, V12, P297, DOI 10.1016/0968-0004(87)90145-9; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VONHIPPEL PH, 1982, PROMOTERS STRUCTURE, P3; WALTER G, 1967, EUR J BIOCHEM, V3, P194, DOI 10.1111/j.1432-1033.1967.tb19515.x; WANG JC, 1977, NUCLEIC ACIDS RES, V4, P1225, DOI 10.1093/nar/4.5.1225; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	36	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2259	2267						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999932				2022-12-25	WOS:A1997WD67900038
J	Groblewski, T; Maigret, B; Larguier, R; Lombard, C; Bonnafous, JC; Marie, J				Groblewski, T; Maigret, B; Larguier, R; Lombard, C; Bonnafous, JC; Marie, J			Mutation of Asn(111) in the third transmembrane domain of the AT(1A) angiotensin II receptor induces its constitutive activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; ALPHA-1B-ADRENERGIC RECEPTOR; HORMONE RECEPTOR; ACTIVE MUTANTS; ANTAGONISTS; RHODOPSIN; STATE; OPSIN; CELLS; CONFORMATION	A preliminary model of the rat AT(1A) angiotensin II (AII) receptor (Joseph, M. P., Maigret, B., Bonnafous J.-C., Marie, J., and Scheraga, H. A. (1995) J. Protein Chem. 14, 381-398) has predicted an interaction between Asn(111) located in transmembrane domain (TM) In: and Tyr(292) (TM VII) in the nonactivated receptor; a disruption of this interaction upon AII activation would allow Tyr(292) to interact with the conserved Asp(74) (TM II), The previous verification that Ty(292) is essential for receptor coupling to phospholipase C (Marie, J., Maigret, B., Joseph, M. P., Larguier, R., Nouet, S., Lombard, C., and Bonnafous, J.-C. (1994) J. Biol. Chem. 269, 20815-20818) prompted us to check the possible alterations in receptor properties upon Asn(111)-->Ala mutation. The mutated receptor (N111A) displayed: (i) strong constitutive activity, with amplification of the maximal phospholipase C response to AII; (ii) agonist behavior of the AT(2)-specific ligand CGP 42112A, [Sar(1),Ile(8)]AII, and [Sar(1),Ala(8)]AII, antagonists of the wild-type receptor; (iii) inverse agonism behavior of the non-peptide ligands DuP 753, LF 7-0156, and LF 8-0129. The results are discussed in the light of the allosteric ternary complex models and other described examples of constitutive activation of G protein-coupled receptors.	CCIPE,INSERM,U401,F-34094 MONTPELLIER 05,FRANCE; UNIV NANCY 1,CHIM THEOR LAB,F-54506 VANDOEUVRE NANCY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Lorraine								ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BARKER EL, 1994, J BIOL CHEM, V269, P11867; BONNAFOUS JC, 1988, BIOCHEM J, V253, P765; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAHMY K, 1994, BIOCHEMISTRY-US, V33, P13700, DOI 10.1021/bi00250a021; GROBLEWSKI T, 1995, BIOCHEM BIOPH RES CO, V209, P153, DOI 10.1006/bbrc.1995.1483; GUILLON G, 1988, BIOCHEM J, V253, P765, DOI 10.1042/bj2530765; HEINFLINK M, 1995, MOL ENDOCRINOL, V9, P1455, DOI 10.1210/me.9.11.1455; JOSEPH MP, 1995, J PROTEIN CHEM, V14, P381, DOI 10.1007/BF01886795; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIE J, 1994, J BIOL CHEM, V269, P20815; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Perez DM, 1996, MOL PHARMACOL, V49, P112; REN Q, 1993, J BIOL CHEM, V268, P16483; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; WHITEBREAD SE, 1991, BIOCHEM BIOPH RES CO, V181, P1365, DOI 10.1016/0006-291X(91)92089-3	35	141	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1822	1826		10.1074/jbc.272.3.1822	http://dx.doi.org/10.1074/jbc.272.3.1822			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999867	hybrid			2022-12-25	WOS:A1997WD05800065
J	Ke, SH; Tachias, K; Lamba, D; Bode, W; Madison, EL				Ke, SH; Tachias, K; Lamba, D; Bode, W; Madison, EL			Identification of a hydrophobic exosite on tissue type plasminogen activator that modulates specificity for plasminogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; BOVINE TRYPSINOGEN; STREPTOKINASE; FIBRIN; RESOLUTION; CLEAVAGE; CHAIN	A wide variety of important biological processes, in eluding both the formation and dissolution of blood clots, depend on specific cleavage of individual target proteins by serine proteases. For example, tissue type plasminogen activator (t-PA), a trypsin like enzyme that catalyzes the rate limiting step of the endogenous fibrinolytic cascade, has only one known substrate in vivo, a single peptide bond (Arg(561)-Val(562)) in the proenzyme plasminogen. We have previously suggested that the specificity of t-PA for plasminogen is mediated in part by direct protein-protein interactions between the protease domain of t-PA and plasminogen that are distinct from those occurring within t-PA's active site. We demonstrate in this study that residues 420-423 of t-PA, which form a fully solvent exposed, hydrophobic region of a surface loop mapping near one edge of the active site of t-PA, form, or are essential for the integrity of, an important, secondary site of interaction between t-PA and plasminogen that significantly modulates the rate of plasminogen activation in the absence, but not the presence, of fibrin. Identification of this secondary site of interaction between t-PA and plasminogen provides new insight into molecular details of the evolution of stringent substrate specificity by t-PA and suggests a novel strategy to enhance the fibrin dependence of plasminogen activation by t-PA. While the activity of wild type t-PA is stimulated by fibrin by a factor of approximately 650, the activity of two variants characterized in this study, t-PA/R275E,P422G and t-PA/R275E,P422E, is stimulated by a factor of approximately 39,000 or 61,000, respectively. It is therefore possible that, compared with wild type t-PA, the two variants would display enhanced ''clot selectivity'' in vivo due to reduced activity in the circulation but full activity at a site of fibrin deposition.	SCRIPPS RES INST, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Scripps Research Institute; Max Planck Society			Lamba, Doriano/B-2961-2011; Lamba, Doriano/L-9808-2018	Lamba, Doriano/0000-0001-6859-7868; Lamba, Doriano/0000-0001-6859-7868	NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1982, BIOCHIM BIOPHYS ACTA, V704, P221, DOI 10.1016/0167-4838(82)90149-2; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; Coombs GS, 1996, J BIOL CHEM, V271, P4461; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KOSSIAKOFF AA, 1977, BIOCHEMISTRY-US, V16, P654, DOI 10.1021/bi00623a016; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LIJNEN HR, 1990, THROMB RES, P45; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P33, DOI 10.1016/0268-9499(92)90045-J; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1993, METHOD ENZYMOL, V223, P249; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REDDY KNN, 1988, ENZYME, V40, P79, DOI 10.1159/000469149; SCHICK LA, 1973, BIOCHEMISTRY-US, V12, P4315, DOI 10.1021/bi00746a003; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0; STEITZ TA, 1969, J MOL BIOL, V46, P337, DOI 10.1016/0022-2836(69)90426-4; STRANDBERG L, 1995, J BIOL CHEM, V270, P23444, DOI 10.1074/jbc.270.40.23444; STROUD RM, 1974, J MOL BIOL, V83, P185, DOI 10.1016/0022-2836(74)90387-8; SUMMARIA L, 1974, J BIOL CHEM, V249, P4760; TACHIAS K, 1995, J BIOL CHEM, V270, P18319, DOI 10.1074/jbc.270.31.18319; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; TURK D, 1992, THESIS TU MUNCHEN MU; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; WEENINGVERHOEFF EJD, 1990, PROTEIN ENG, V4, P191, DOI 10.1093/protein/4.2.191; WIMAN B, 1977, EUR J BIOCHEM, V76, P129, DOI 10.1111/j.1432-1033.1977.tb11578.x; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	48	19	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1811	1816		10.1074/jbc.272.3.1811	http://dx.doi.org/10.1074/jbc.272.3.1811			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999865	hybrid			2022-12-25	WOS:A1997WD05800063
J	Parmer, RJ; Mahata, M; Mahata, S; Sebald, MT; OConnor, DT; Miles, LA				Parmer, RJ; Mahata, M; Mahata, S; Sebald, MT; OConnor, DT; Miles, LA			Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway - Catecholamine storage vesicles as a reservoir for the rapid release of t-PA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN GRANULES; HUMAN GROWTH-HORMONE; CHROMOGRANIN-A; CELL-LINE; PC12 CELLS; ENDOTHELIAL-CELLS; PROTEIN; PHEOCHROMOCYTOMA; INHIBITOR; PEPTIDE	Tissue-type plasminogen activator (t-PA) is a serine protease that plays a central role in the regulation of intravascular thrombolysis. The acute release of t-PA in vivo is induced by a variety of stimuli including exercise, trauma, and neural stimulation. These types of stimuli also result in sympathoadrenal activation and exocytotic release of amines and proteins from catecholamine storage vesicles of the adrenal medulla and sympathetic neurons. Therefore, we tested the hypothesis that t-PA is packaged in and released directly from catecholamine storage vesicles, using several chromaffin cell sources including the rat pheochromocytoma PC-12 chromaffin cell line, primary cultures of bovine adrenal chromaffin cells, and human pheochromocytoma. t-PA was expressed in chromaffin cells as detected by Northern blotting, immunoprecipitation of [S-35]Met-labeled t-PA, and specific t-PA enzyme-linked immunosorbent assay of cell homogenates. In addition, chromaffin cell t-PA was enzymatically active by fibrin zymography. To explore the subcellular localization of the expressed t-PA, PC-12 cells were labeled with [H-3]norepinephrine, homogenized, and subjected to sucrose density fractionation. [H-3]Norepinephrine and t-PA antigen were colocalized to the same subcellular fraction with a major peak at 1.4 M sucrose, consistent with the buoyant density of catecholamine storage vesicles. In addition, catecholamine storage vesicle lysates isolated from human pheochromocytoma tumors were enriched approximately 30-fold in t-PA antigen, compared with tumor homogenate. Furthermore, exposure of PC-12 cells or primary bovine adrenal chromaffin cells to chromaffin cell secretagogues (60 mu M nicotine, 55 mM KCl, or 2 mM BaCl2) resulted in co-release of t-PA in parallel with catecholamines. These data demonstrate that t-PA is expressed in chromaffin cells, is sorted into the regulated pathway of secretion, and is co released with catecholamines by chromaffin cell stimulation. Catecholamine storage vesicles may be an important reservoir and sympathoadrenal activation an important physiologic mechanism for the rapid release of t-PA. In addition, expression of t-PA by chromaffin cells suggests a role for this protease in the proteolytic processing of chromaffin cell proteins.	UNIV CALIF SAN DIEGO, CTR GENET MOL, SAN DIEGO, CA 92161 USA; VET ADM MED CTR, SAN DIEGO, CA 92161 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Scripps Research Institute	Parmer, RJ (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED 9111H, SAN DIEGO, CA 92161 USA.		Mahata, Sushil/AAF-8781-2021		NHLBI NIH HHS [HL45934, HL50174, HL50398] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050398, R01HL050174, R01HL045934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANSAL DD, 1992, J CLIN ENDOCR METAB, V74, P266, DOI 10.1210/jc.74.2.266; BIGGS R, 1947, LANCET, V252, P402; BRITTON BJ, 1976, THROMB HAEMOSTASIS, V35, P396, DOI 10.1055/s-0038-1647934; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANDLER WL, 1992, J AM COLL CARDIOL, V19, P1412, DOI 10.1016/0735-1097(92)90596-F; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; COHEN RJ, 1968, LANCET, V2, P1264; COLLEN D, 1991, BLOOD, V78, P3114; DESRUISSEAUGONZALVEZ S, 1993, IN VITRO CELL DEV-AN, V29, P161; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; EIDEN LE, 1987, NATURE, V325, P301, DOI 10.1038/325301a0; EMEIS JJ, 1992, ANN NY ACAD SCI, V667, P249, DOI 10.1111/j.1749-6632.1992.tb51622.x; EMEIS JJ, 1988, TISSUE TYPE PLASMINO, V2, P21; FANTL P, 1948, AUST J EXP BIOL MED, V26, P521, DOI 10.1038/icb.1948.54; Frey U, 1996, J NEUROSCI, V16, P2057; FRIEDMAN GC, 1994, DEV BRAIN RES, V81, P41, DOI 10.1016/0165-3806(94)90066-3; GOMBAU L, 1994, J BIOL CHEM, V269, P3875; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gualandris A, 1996, J NEUROSCI, V16, P2220; HELLE KB, 1994, ACTA PHYSIOL SCAND, V152, P1, DOI 10.1111/j.1748-1716.1994.tb09779.x; HENRY JP, 1994, J EXP BIOL, V196, P251; HIGAZI AAR, 1994, J BIOL CHEM, V269, P25529; HUTTNER WB, 1987, NATURE, V325, P305, DOI 10.1038/325305b0; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KORSANBENGTSEN K, 1974, SCAND J HAEMATOL, V13, P377; KRISTENSEN P, 1986, HISTOCHEMISTRY, V85, P431, DOI 10.1007/BF00982674; KRISTENSEN P, 1985, J CELL BIOL, V101, P305, DOI 10.1083/jcb.101.1.305; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE P, 1991, J NEUROCHEM, V57, P665, DOI 10.1111/j.1471-4159.1991.tb03798.x; LEVINE JD, 1982, BLOOD, V60, P531; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; LOSKUTOFF DJ, 1988, METHOD ENZYMOL, V163, P293; MACFARLANE RG, 1946, LANCET, V251, P862; MANNUCCI PM, 1975, BRIT J HAEMATOL, V30, P81, DOI 10.1111/j.1365-2141.1975.tb00521.x; MEDH RD, 1992, BLOOD, V80, P981; MILES LA, 1988, J BIOL CHEM, V263, P11928; MOONEN G, 1982, NATURE, V298, P753, DOI 10.1038/298753a0; MOORE HPH, 1987, ANN NY ACAD SCI, V493, P50, DOI 10.1111/j.1749-6632.1987.tb27180.x; OBERLECHNER E, 1982, J NEUROCHEM, V38, P615, DOI 10.1111/j.1471-4159.1982.tb08675.x; OCONNOR DT, 1994, ANN NY ACAD SCI, V733, P36, DOI 10.1111/j.1749-6632.1994.tb17254.x; Padro T, 1990, Blood Coagul Fibrinolysis, V1, P601; Parmer R. J., 1994, Fibrinolysis, V8, P53; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PARMER RJ, 1988, J HYPERTENS, V6, P187, DOI 10.1097/00004872-198803000-00002; PATZAK A, 1986, J CELL BIOL, V102, P510, DOI 10.1083/jcb.102.2.510; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; PITTMAN RN, 1995, J NEUROCHEM, V64, P566; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RODA LG, 1980, EXP CELL RES, V128, P103, DOI 10.1016/0014-4827(80)90392-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; SCHNECK SA, 1961, NEUROLOGY, V11, P959, DOI 10.1212/WNL.11.11.959; SCHRAUWEN Y, 1994, FIBRINOLYSIS, V8, P8, DOI 10.1016/0268-9499(94)90230-5; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P5184, DOI 10.1073/pnas.74.11.5184; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SCHWEITZER ES, 1990, J CELL SCI, V96, P375; SEEDS NW, 1992, ANN NY ACAD SCI, V667, P32; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; TAKIYYUDDIN MA, 1990, HYPERTENSION, V15, P237, DOI 10.1161/01.HYP.15.3.237; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; TODD AS, 1959, J PATHOL BACTERIOL, V78, P281, DOI 10.1002/path.1700780131; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; VANDENEIJNDENSCHRAUWEN Y, 1995, BLOOD, V85, P3510, DOI 10.1182/blood.V85.12.3510.bloodjournal85123510; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WARREN BA, 1963, BRIT J EXP PATHOL, V44, P365; Weil-Malherbe H., 1971, METHODS BIOCH ANAL S, P119; WINKLER H, 1976, NEUROSCIENCE, V1, P65, DOI 10.1016/0306-4522(76)90001-4; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7	75	137	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1976	1982		10.1074/jbc.272.3.1976	http://dx.doi.org/10.1074/jbc.272.3.1976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999889	hybrid			2022-12-25	WOS:A1997WD05800087
J	Biesova, Z; Piccoli, C; Wong, WT				Biesova, Z; Piccoli, C; Wong, WT			Isolation and characterization of e3B1, an eps8 binding protein that regulates cell growth	ONCOGENE			English	Article						epidermal growth factor receptor; eps8; SH3 domain; e3B1; signal transduction	TRANSFORMING ACTIVITY; FACTOR RECEPTOR; SUBSTRATE; KINASE; IDENTIFICATION; PROTOONCOGENE; PRODUCT; CLONING; DOMAIN	Eps8, a substrate of receptor tyrosine kinases, is an SH3 domain containing protein that plays an important role in mitogenic signaling. To determine the cellular function of eps8, we used the SH3 domain of eps8 to screen a human fibroblast M426 expression library and identified, a full-length cDNA clone of 3.2 kb. We designated this clone e3B1 for eps8 SH3 domain binding protein 1. Northern analysis revealed that expression of e3B1 mRNA was ubiquitious in human tissues. The e3B1 gene encodes a SH3 domain containing protein. We show that anti-e3B1 antibodies detect three cytosolic protein species of 65, 68 and 72 kDa in cell lysate isolated from asynchronously growing NIH3T3 cells. E3B1 binds to the SH3 domain of eps8 and Abi in vitro. We also demonstrated that e3B1 associates with eps8 in vivo. Phosphatase digestion and phosphoamino acid analysis revealed that p65(e3B1) is a phosphoserine containing protein and p72(e3B1) and p68(e3B1) are hyperserine-phosphorylated form of p65(e3B1). We further determined that the p65(e3B1) was the most abundant in serum-starved NIH/EGFR cells. Time course studies initiated by the addition of epidermal growth factor (EGF) revealed that the p72(e3B1) started to accumulate at 4 h, peaked at 8 h and remained high until 24 h. Finally, we demonstrate that NIH/EGFR fibroblasts overexpressing e3B1 grow more slowly relative to matched controls.	NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MIKI T, 1993, PRACT APPROACH SER, P177; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WONG WT, 1994, ONCOGENE, V9, P3057	23	89	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					233	241		10.1038/sj.onc.1200822	http://dx.doi.org/10.1038/sj.onc.1200822			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010225				2022-12-25	WOS:A1997WC81800011
J	Cao, MY; Dupriez, VJ; Rider, MH; Deggouj, N; Gersdorff, MCH; Rousseau, GG; Tomasi, JP				Cao, MY; Dupriez, VJ; Rider, MH; Deggouj, N; Gersdorff, MCH; Rousseau, GG; Tomasi, JP			Myelin protein Po as a potential autoantigen in autoimmune inner ear disease	FASEB JOURNAL			English	Article						autoimmunity; cochlea; MALDI-TOF; P zero	PERIPHERAL-NERVE MYELIN; GUILLAIN-BARRE-SYNDROME; MARIE-TOOTH DISEASE; AUDITORY EVOKED-POTENTIALS; SENSORINEURAL HEARING-LOSS; MAJOR STRUCTURAL PROTEIN; MOTOR-SENSORY NEUROPATHY; HEREDITARY MOTOR; POLYACRYLAMIDE GELS; DNA-SEQUENCE	We have previously shown that a 30,000 M(r) protein extracted from guinea pig inner ear tissue is recognized by autoantibodies present in the serum of patients suffering front autoimmune inner ear disease, This protein was localized in the modiolus and in the organ of Corti, We have now identified this protein by a combination of microsequencing and matrix-assisted laser desorption ionization time-of-flight mass spectrometry of its tryptic peptides, A partial sequence of the protein Tvas thereby determined, These data and 2-dimensional gel electrophoresis followed by immunoblotting experiments showed that the 30,000 M,inner ear antigen is the major peripheral myelin protein Po, This suggests that protein Po may be an important autoantigen in autoimmune inner ear disease.	UNIV LOUVAIN,SCH MED,LAB AUTOIMMUN,B-1200 BRUSSELS,BELGIUM; UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; UNIV LOUVAIN,SCH MED,DEPT OTORHINOLARYNGOL,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOL PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								ADELMANN M, 1992, NEUROCHEM RES, V17, P887, DOI 10.1007/BF00993264; BENJELLOUNDELLAGI S, 1992, ANN NEUROL, V32, P700; Cao MY, 1996, ANN OTO RHINOL LARYN, V105, P628; CAO MY, 1995, MOL CELL BIOCHEM, V146, P157, DOI 10.1007/BF00944608; CAO MY, 1995, J LARYNGOL OTOL, V109, P20; CELIS JE, 1991, FASEB J, V5, P2200, DOI 10.1096/fasebj.5.8.1827083; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; GARG BP, 1982, NEUROLOGY, V32, P1017, DOI 10.1212/WNL.32.9.1017; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HARRIS JP, 1990, LARYNGOSCOPE, V100, P516; HAYASAKA K, 1991, BIOCHEM BIOPH RES CO, V180, P515, DOI 10.1016/S0006-291X(05)81094-0; Herinckx C., 1995, Acta Oto-Rhino-Laryngologica Belgica, V49, P63; HOJEBERG B, 1991, J NEUROL SCI, V106, P91, DOI 10.1016/0022-510X(91)90200-Q; HUGHES GB, 1984, LARYNGOSCOPE, V94, P758; KHALILISHIRAZI A, 1992, J NEUROL SCI, V111, P200, DOI 10.1016/0022-510X(92)90069-W; KULKENS T, 1993, NAT GENET, V5, P35, DOI 10.1038/ng0993-35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; MILNER P, 1987, J NEUROL SCI, V79, P275, DOI 10.1016/0022-510X(87)90235-8; MOOS M, 1988, J BIOL CHEM, V263, P6005; MUSIEK FE, 1982, ARCH OTOLARYNGOL, V108, P595; NELSON KR, 1988, NEUROLOGY, V38, P1263, DOI 10.1212/WNL.38.8.1263; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; RAGLAN E, 1987, ACTA OTO-LARYNGOL, V103, P50, DOI 10.3109/00016488709134697; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; ROPPER AH, 1986, NEUROLOGY, V36, P587, DOI 10.1212/WNL.36.4.587; SAKAMOTO Y, 1987, J BIOL CHEM, V262, P4208; SATYAMURTI S, 1979, ANN NEUROL, V5, P445, DOI 10.1002/ana.410050506; SCHIFF JA, 1985, NEUROLOGY, V35, P771, DOI 10.1212/WNL.35.5.771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAKSMAN BH, 1955, J EXP MED, V102, P213, DOI 10.1084/jem.102.2.213; YOO TJ, 1982, SCIENCE, V217, P1153, DOI 10.1126/science.7112122; YOU KH, 1991, GENOMICS, V9, P751, DOI 10.1016/0888-7543(91)90370-T; YUKI N, 1993, ANN NEUROL, V33, P655, DOI 10.1002/ana.410330617	36	40	53	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1635	1640		10.1096/fasebj.10.14.9002556	http://dx.doi.org/10.1096/fasebj.10.14.9002556			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002556				2022-12-25	WOS:A1996WC86900010
J	Morris, JA; Dorner, AJ; Edwards, CA; Hendershot, LM; Kaufman, RJ				Morris, JA; Dorner, AJ; Edwards, CA; Hendershot, LM; Kaufman, RJ			Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; SHOCK COGNATE PROTEIN; HAMSTER OVARY CELLS; HEAVY-CHAIN; FACTOR-VIII; MAMMALIAN-CELLS; ATPASE ACTIVITY; TRANSMEMBRANE PROTEIN; PROCOAGULANT ACTIVITY; MOLECULAR CHAPERONES	BiP/GRP78 is a lumenal stress protein of the endoplasmic reticulum (ER) that interacts with polypeptide folding intermediates transiting the secretory compartment, We have studied the secretion and the stress response in Chinese hamster ovary (CHO) cells that overexpress either wild-type immunoglobulin binding protein (BiP) or a BiP deletion molecule (residues 175-201) that can bind peptides and ATP but is defective in ATP hydrolysis and concomitant peptide release. Overexpressed wild-type BiP was localized to the ER and unique vesicles within the nucleus, whereas overexpressed ATPase-defective BiP was localized to the ER and cytoplasmic vesicles but was absent from the nucleus, Compared;with wild-type CHO cells, overexpression of ATPase-defective BiP prevented secretion of factor WI, a coagulation factor that extensively binds BiP in the lumen of the EB Under these conditions factor VIII was stably associated with the ATPase-defective BiP. In contrast, the secretion of monocyte/macrophage colony stimulating factor, a protein that is not detected in association with BiP, was not affected by overexpression of ATPase-defective BiP. These results show that BiP function is not required for secretion of some proteins and suggest that some proteins do not interact with BiP upon transport through the ER. The presence of unfolded protein in the ER induces transcription of BiP and also elicits a general inhibition of protein synthesis, Overexpression of wild-type BiP prevented the stress-mediated transcriptional induction of BiP in response to either calcium ionophore A23187 treatment or tunicamycin treatment. In contrast, overexpression of ATPase-defective BiP did not prevent the stress induction of BiP, showing that the ATPase activity is required to inhibit transcriptional induction, Overexpression of wild-type BiP, but not ATPase-defective BiP, increased survival of cells treated with A23187, The increased survival mediated by overexpressed wild-type BiP correlated with reduced translation inhibition in response to the stress condition, These results indicate that overexpressed BiP alleviated the stress in the ER to prevent BiP transcriptional induction and permit continued translation of cellular mRNAs.	UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; GENET INST INC, CAMBRIDGE, MA 02140 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; St Jude Children's Research Hospital			Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [HL52173, HL53777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053777, R01HL052173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOMER CJ, 1991, CANCER RES, V51, P6574; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAUFMAN RJ, 1992, ANNU REV MED, V43, P325, DOI 10.1146/annurev.med.43.1.325; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KOONG AC, 1994, INT J RADIAT ONCOL, V28, P661, DOI 10.1016/0360-3016(94)90191-0; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MORI K, 1993, CELL, V74, P743; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1993, BLOOD, V81, P2925; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; POLLOK BA, 1987, P NATL ACAD SCI USA, V84, P9199, DOI 10.1073/pnas.84.24.9199; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; PUIG A, 1994, J BIOL CHEM, V269, P25889; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; SUGAWARA S, 1993, CANCER RES, V53, P6001; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WADA I, 1991, J BIOL CHEM, V266, P19599; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	82	289	308	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4327	4334		10.1074/jbc.272.7.4327	http://dx.doi.org/10.1074/jbc.272.7.4327			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020152	hybrid			2022-12-25	WOS:A1997WH01900068
J	Huang, HJS; Nagane, M; Klingbeil, CK; Lin, H; Nishikawa, R; Ji, XD; Huang, CM; Gill, GN; Wiley, HS; Cavenee, WK				Huang, HJS; Nagane, M; Klingbeil, CK; Lin, H; Nishikawa, R; Ji, XD; Huang, CM; Gill, GN; Wiley, HS; Cavenee, WK			The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; HUMAN-BREAST-CARCINOMA; EGF-RECEPTOR; AUTOPHOSPHORYLATION SITES; KINASE-ACTIVITY; SELF-PHOSPHORYLATION; DOWN-REGULATION; POSTENDOCYTIC TRAFFICKING; HUMAN GLIOBLASTOMAS; INDUCED ENDOCYTOSIS	Deregulation of signaling by the epidermal growth factor receptor (EGFR) is common in human malignancy progression. One mutant EGFR (variously named Delta EGFR, de2-7 EGFR, or EGFRvIII), which occurs frequently in human cancers, lacks a portion of the extracellular ligand-binding domain due to genomic deletions that eliminate exons 2 to 7 and confers a dramatic enhancement of brain tumor cell tumorigenicity in vivo. In order to dissect the molecular mechanisms of this activity, we analyzed location, autophosphorylation, and attenuation of the mutant receptors. The mutant receptors were expressed on the cell surface and constitutively autophosphorylated at a significantly decreased level compared with wild-type EGFR activated by ligand treatment. Unlike wild-type EGFR, the constitutively active Delta EGFR were not down-regulated, suggesting that the altered conformation of the mutant did not result in exposure of receptor sequence motifs required for endocytosis and lysosomal sorting. Mutational analysis showed that the enhanced tumorigenicity was dependent on intrinsic tyrosine kinase activity and was mediated through the carboxyl terminus. In contrast with wild-type receptor, mutation of any major tyrosine autophosphorylation site abolished these activities suggesting that the biological functions of Delta EGFR are due to low constitutive activation with mitogenic effects amplified by failure to attenuate signaling by receptor down-regulation.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093; PHARMINGEN INC,SAN DIEGO,CA 92121; UNIV UTAH,SCH MED,DEPT PATHOL,SALT LAKE CITY,UT 84132	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Utah System of Higher Education; University of Utah	Huang, HJS (corresponding author), UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,9500 GILMAN DR,LA JOLLA,CA 92093, USA.			Wiley, Steven/0000-0003-0232-6867	NIDDK NIH HHS [DK13149] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; Cadena Deborah L., 1996, P265, DOI 10.1002/9783527615032.ch9; CADENA DL, 1994, J BIOL CHEM, V269, P260; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Han YC, 1996, CANCER RES, V56, P3859; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HELIN K, 1991, ONCOGENE, V6, P825; HELIN K, 1991, J BIOL CHEM, V266, P8363; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOUCHENS DP, 1978, P S USE ATHYMIC NUDE, P267; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HURTT MR, 1992, J NEUROPATH EXP NEUR, V51, P84, DOI 10.1097/00005072-199201000-00010; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KLINGBEIL CK, 1995, ARCH BIOCHEM BIOPHYS, V316, P745, DOI 10.1006/abbi.1995.1099; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LUND KA, 1990, J BIOL CHEM, V265, P20517; MALDEN LT, 1988, CANCER RES, V48, P2711; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MASUI H, 1991, CANCER RES, V51, P6170; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RO J, 1988, CANCER RES, V48, P161; SCHLEGEL J, 1994, INT J CANCER, V56, P72; SLOTNICK BM, 1975, STEREOTAXIC ATLAS AL, P3; SOLER C, 1994, J BIOL CHEM, V269, P12320; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WELSH JB, 1994, MOL BIOL CELL, V5, P539, DOI 10.1091/mbc.5.5.539; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308	72	465	487	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2927	2935		10.1074/jbc.272.5.2927	http://dx.doi.org/10.1074/jbc.272.5.2927			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006938	hybrid			2022-12-25	WOS:A1997WE66700051
J	Conti, B; Jahng, JW; Tinti, C; Son, JH; Joh, TH				Conti, B; Jahng, JW; Tinti, C; Son, JH; Joh, TH			Induction of interferon-gamma inducing factor in the adrenal cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RESERPINE	Interferon-gamma inducing factor (IGIF) is a recently identified cytokine also called interleukin-1 gamma (IL-1 gamma) or interleukin-1 gamma (IL-18), Its biological activity is pleiotropic, and, so far, it has been shown to induce interferon-gamma production in Th1 cells, to augment the production of granulocyte-macrophage-CSF, and to decrease that of interleukin-10 (IL-10). We first detected newly synthesized IGIF mRNA by differential display in the adrenal gland of reserpine-treated rats and then isolated two transcripts by reverse transcription polymerase chain reaction. They were identified as rat IGIF on the basis of the high homology with mouse: 91% at both the nucleotide and the amino acid level. Subsequently, we investigated the effects of stress on IGIF mRNA levels and found that acute cold stress strongly induced IGIF gene expression. In. situ hybridization analysis showed that IGIF is synthesized in the adrenal cortex, specifically in the zona reticularis and fasciculata that produce glucocorticoids. The presence of IGIF mRNA was also detected in the neurohypophysis although induction by stress was not significant. Our results call for more attention to the role of the adrenal gland as a potential effector of immunomodulation and suggest that IGIF itself might be a secreted neuroimmunomodulator and play an important role in orchestrating the immune system following a stressful experience.			Conti, B (corresponding author), CORNELL UNIV,COLL MED,WM BURKE MED RES INST,MOL NEUROBIOL LAB,785 MAMARONECK AVE,WHITE PLAINS,NY 10605, USA.			Conti, Bruno/0000-0002-9185-5201				Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; JOH TH, 1973, P NATL ACAD SCI USA, V70, P2767, DOI 10.1073/pnas.70.10.2767; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; MUELLER RA, 1969, MOL PHARMACOL, V7, P463; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; NAKAMURA K, 1993, INFECT IMMUN, V61, P64, DOI 10.1128/IAI.61.1.64-70.1993; OKAMURA H, 1995, INFECT IMMUN, V63, P3966, DOI 10.1128/IAI.63.10.3966-3972.1995; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Tingsborg S, 1996, BRAIN RES, V712, P153, DOI 10.1016/0006-8993(95)01525-6; Ushio S, 1996, J IMMUNOL, V156, P4274; WEISER M, 1993, J NEUROSCI, V13, P3472; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X	14	146	161	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2035	2037						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999896				2022-12-25	WOS:A1997WD67900002
J	Lapan, KA; Fay, PJ				Lapan, KA; Fay, PJ			Localization of a factor X interactive site in the A1 subunit of factor VIIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; FACTOR-IXA; FACTOR-VA; A1/A3-C1-C2 DIMER; BINDING-SITE; INACTIVATION; PROTHROMBIN; ANTIBODIES; A2-SUBUNIT	The protein cofactor, factor (F) VIIIa, is required for the efficient conversion of the substrate FX to FXa by the serine protease FIXa. The interaction between human FVIII (and its constituent subunits) and FX was characterized using a solid phase binding assay performed in the absence of phospholipid and FIXa. Saturable binding of FX to heterodimeric FMIII, the FIII heavy chain (contiguous A1-A2 domains), the FVIIIa-derived A1/A3-C1-C2 dimer, and the isolated A1 subunit was observed with estimated K-d values ranging from approximately 1 to 3 mu m. The interaction of FX with FVIII was inhibited by moderate ionic strength and was Ca2+-dependent, consistent with the salt sensitivity observed in a phospholipid-independent FXa generation assay. Negligible binding to FX was observed for the isolated A2 and A3-C1-C2 subunits of FVIIIa, suggesting that the A1 subunit of FVIII contains a primary binding site for FX. A synthetic peptide to the COOH-terminal acidic region of the A1 subunit, designated FVIII337-372, bound FX and effectively competed with A1 for FX binding (K-i = similar to 16 mu m). Cross-linking between the FVIII337-372 peptide and the FX heavy chain was observed following reaction with 1-ethyl-3-[(diethylamino)propyl]carbodiimide. The presence of FX reduced the rate of activated protein C-catalyzed cleavage at Arg(336) by similar to 5-fold. These results identify a primary FX interactive site on the cofactor of the intrinsic FXase.	UNIV ROCHESTER,MED CTR,SCH MED & DENT,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,SCH MED & DENT,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30616, HL38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Carraway K L, 1972, Methods Enzymol, V25, P616, DOI 10.1016/S0076-6879(72)25060-1; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ELDER B, 1993, GENOMICS, V16, P374, DOI 10.1006/geno.1993.1200; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1994, J BIOL CHEM, V269, P20522; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; Gilbert GE, 1996, J BIOL CHEM, V271, P11120, DOI 10.1074/jbc.271.19.11120; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1990, BLOOD, V76, P1; MOSESSON MW, 1990, J CLIN INVEST, V85, P1983, DOI 10.1172/JCI114662; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Regan LM, 1996, J BIOL CHEM, V271, P3982; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; TOOLE JJ, 1984, NATURE, V312, P330; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	39	94	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2082	2088						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999906				2022-12-25	WOS:A1997WD67900012
J	Prieto, PA; Larsen, RD; Cho, M; Rivera, HN; Shilatifard, A; Lowe, JB; Cummings, RD; Smith, DF				Prieto, PA; Larsen, RD; Cho, M; Rivera, HN; Shilatifard, A; Lowe, JB; Cummings, RD; Smith, DF			Expression of human H-type alpha 1,2-fucosyltransferase encoding for blood group H(O) antigen in Chinese hamster ovary cells - Evidence for preferential fucosylation and truncation of polylactosamine sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GDP-L-FUCOSE; D-GALACTOSIDE 2-ALPHA-L-FUCOSYLTRANSFERASE; GROUP ALPHA(1,2)FUCOSYLTRANSFERASE GENE; ASPARAGINE-LINKED OLIGOSACCHARIDES; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; RESPIRATORY-MUCUS GLYCOPROTEINS; 500-MHZ H-1-NMR SPECTROSCOPY; QUANTITATIVE SUGAR ANALYSIS; AFFINITY-CHROMATOGRAPHY	The human H(O) blood group is specified by the structure Fuc alpha 1-2Gal beta 1-R, but the factors regulating expression of this determinant on cell surface glycoconjugates are not well understood. To learn more about the regulation of H blood group expression, cDNA encoding the human H-type GDPFuc:beta-D-galactoside alpha 1,2-fucosyltransferase (alpha 1,2FT) was stably transfected into Chinese hamster ovary (CHO) cells, The new cell line, designated CHO(alpha 1,2)FT, expressed surface neoglycans containing the H antigen. The structures of the fucosylated neoglycans in CHO(alpha 1,2)FT cells and the distribution of these glycans on glycoproteins were characterized. Seventeen percent of the [H-3]Gal-labeled glycopeptides from CHO(alpha 1,2)FT cells bound to the immobilized H blood group-specific lectin Ulex europaeus agglutinin-I (UEA-I), whereas none from parental CHO cells bound to the lectin. The glycopeptides from CHO(alpha 1,2)FT cells binding to UEA-I contained polylactosamine [3Gal beta 1-4GlcNAc beta 1-] with the terminal sequence Fuc alpha 1-2Gal beta 1-4GlcNAc-R. Fucosylation of the polylactosamine sequences on complex-type N-glycans in CHO(alpha 1,2)FT cells caused a decrease in both sialylation and length of polylactosamine. Unexpectedly, only small amounts of terminal fucosylation was found in diantennary complex type N-glycans. The O-glycans and glycolipids were not fucosylated by the H-type alpha 1,2FT. Two major high molecular weight glycoproteins, one of which was shown to be the lysosome-associated membrane glycoprotein LAMP-1, preferentially contained the H-type structure and were bound by immobilized UEA-I. These results demonstrate that in CHO cells the expressed H-type alpha 1,2FT does not indiscriminately fucosylate terminal galactosyl residues in complex-type N-glycans, but it favors glycans containing polylactosamine and dramatically alters their length and sialylation.	UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30602 USA; UNIV MICHIGAN, SCH MED, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, OKLAHOMA CITY, OK 73190 USA	University System of Georgia; University of Georgia; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Oklahoma System; University of Oklahoma Health Sciences Center				Prieto, Pedro/0000-0001-9549-3730	NCI NIH HHS [CA37626] Funding Source: Medline; NHLBI NIH HHS [HL48859] Funding Source: Medline; NIGMS NIH HHS [GM45914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYER TA, 1982, GLYCOCONJUGATES, V3, P25; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BREG J, 1988, EUR J BIOCHEM, V171, P643, DOI 10.1111/j.1432-1033.1988.tb13835.x; BREIMER ME, 1980, BIOCHIM BIOPHYS ACTA, V617, P85, DOI 10.1016/0005-2760(80)90226-X; BREIMER ME, 1981, J BIOL CHEM, V256, P3810; BROCKHAUS M, 1985, VOX SANG, V48, P34, DOI 10.1111/j.1423-0410.1985.tb00142.x; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHESTER MA, 1976, EUR J BIOCHEM, V69, P583, DOI 10.1111/j.1432-1033.1976.tb10944.x; CHILDS RA, 1984, EMBO J, V3, P2227, DOI 10.1002/j.1460-2075.1984.tb02120.x; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; CUMMINGS RD, 1985, J BIOL CHEM, V260, P1944; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DO KY, 1993, J BIOL CHEM, V268, P22028; DO KY, 1994, J BIOL CHEM, V269, P23456; DO KY, 1990, BIOCHEM BIOPH RES CO, V173, P1123, DOI 10.1016/S0006-291X(05)80902-7; DO SI, 1990, J BIOL CHEM, V265, P114; DOARES SH, 1991, CARBOHYD RES, V210, P311, DOI 10.1016/0008-6215(91)80131-6; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FINNE J, 1980, EUR J BIOCHEM, V104, P181, DOI 10.1111/j.1432-1033.1980.tb04414.x; FINNE J, 1982, METHOD ENZYMOL, V83, P269; GINSBURG V, 1972, ADV ENZYMOL RAMB, V36, P131; GOLDSTEIN IJ, 1981, J BIOL CHEM, V256, P3890; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HINDSGAUL O, 1985, CAN J CHEM, V63, P2653, DOI 10.1139/v85-440; HIRONAKA T, 1992, J BIOL CHEM, V267, P8012; HIROTA M, 1992, CARCINOGENESIS, V13, P1829, DOI 10.1093/carcin/13.10.1829; HORMIA M, 1989, J PERIODONTAL RES, V24, P137, DOI 10.1111/j.1600-0765.1989.tb00868.x; HORMIA M, 1983, CELL BIOL INT REP, V7, P467, DOI 10.1016/0309-1651(83)90136-4; ITO N, 1990, HISTOCHEM J, V22, P604, DOI 10.1007/BF01072942; KELLY C, 1984, BIOCHEM J, V220, P221, DOI 10.1042/bj2200221; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KLEIN A, 1988, EUR J BIOCHEM, V171, P631, DOI 10.1111/j.1432-1033.1988.tb13834.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRUSIUS T, 1976, FEBS LETT, V71, P117, DOI 10.1016/0014-5793(76)80911-8; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LABARRIERE N, 1994, CANCER RES, V54, P6275; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE RA, 1988, MOL IMMUNOLOGY COMPL, P331; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEE EU, 1989, J BIOL CHEM, V264, P13848; LHERMITTE M, 1991, Glycobiology, V1, P277, DOI 10.1093/glycob/1.3.277; LI E, 1980, ARCH BIOCHEM BIOPHYS, V199, P393, DOI 10.1016/0003-9861(80)90295-7; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MATSUI T, 1992, J BIOL CHEM, V267, P8723; MATSUI T, 1993, BLOOD, V82, P663; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; NAKAGAWA H, 1980, J BIOL CHEM, V255, P5955; OATES DC, 1977, SOMAT CELL GENET, V3, P561, DOI 10.1007/BF01539066; OGATA S, 1975, J BIOCHEM-TOKYO, V78, P361; PARKER PJ, 1984, J BIOL CHEM, V259, P9906; PEREIRA MEA, 1974, BIOCHEMISTRY-US, V13, P3184, DOI 10.1021/bi00712a029; PETRYNIAK J, 1987, METHOD ENZYMOL, V138, P552; PRIETO PA, 1995, J BIOL CHEM, V270, P29515, DOI 10.1074/jbc.270.49.29515; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SMITH DF, 1987, J BIOL CHEM, V262, P12040; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SPOHR U, 1992, CAN J CHEM, V70, P254, DOI 10.1139/v92-036; STELLNER K, 1973, BIOCHEMISTRY-US, V12, P656, DOI 10.1021/bi00728a014; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; TSUJI T, 1980, BIOCHEM J, V187, P677, DOI 10.1042/bj1870677; VANKEUREN M, 1986, HUM GENET, V74, P34, DOI 10.1007/BF00278782; Watkins W M, 1980, Adv Hum Genet, V10, P1; WATSON E, 1994, GLYCOBIOLOGY, V4, P227, DOI 10.1093/glycob/4.2.227; WU AM, 1988, MOL IMMUNOLOGY COMPL, P351; YARIV J, 1972, METHOD ENZYMOL, V28, P356; ZOPF D, 1988, MOL IMMUNOLOGY COMPL, P657	80	34	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2089	2097						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999907				2022-12-25	WOS:A1997WD67900013
J	AssimacopoulosJeannet, F; Thumelinn, S; Roche, E; Esser, V; McGarry, JD; Prentki, M				AssimacopoulosJeannet, F; Thumelinn, S; Roche, E; Esser, V; McGarry, JD; Prentki, M			Fatty acids rapidly induce the carnitine palmitoyltransferase I gene in the pancreatic beta-cell line INS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-SECRETION; DEPENDENT DIABETES-MELLITUS; LONG-TERM EXPOSURE; ACYL-COA ESTERS; MALONYL-COA; RAT ISLETS; COUPLING FACTORS; GLUCOSE; EXPRESSION; RELEASE	Fatty acids are important metabolic substrates for the pancreatic beta-cell, and long term exposure of pancreatic islets to elevated concentrations of fatty acids results in an alteration of glucose-induced insulin secretion. Previous work suggested that exaggerated fatty acid oxidation may be implicated in this process by a mechanism requiring changes in metabolic enzyme expression. We have therefore studied the regulation of carnitine palmitoyltransferase I (CPT I) gene expression by fatty acids in the pancreatic beta-cell line INS-I since this enzyme catalyzes the limiting step of fatty acid oxidation in various tissues. Palmitate, oleate, and linoleate (0.35 mar) elicited a 4-6-fold increase in CPT I mRNA. The effect was dose-dependent and was similar for saturated and unsaturated fatty acids. It was detectable after 1 h and reached a maximum after 3 h. The induction of CPT I mRNA by fatty acids did not require their oxidation, and 2-bromopalmitate, a nonoxidizable fatty acid, increased CPT I mRNA to the same extent as palmitate. The induction was not prevented by cycloheximide treatment of cells indicating that it was mediated by pre-existing transcription factors. Neither glucose nor pyruvate and various secretagogues had a significant effect except glutamine (7 mM) which slightly induced CPT I mRNA. The half-life of the CPT I transcript was unchanged by fatty acids, and nuclear run on analysis showed a rapid (less than 45 min) and pronounced transcriptional activation of the CPT I gene by fatty acids. The increase in CPT I mRNA was followed by a 2-3-fold increase in CPT I enzymatic activity measured in isolated mitochondria. The increase in activity was time-dependent, detectable after 4 h, and close to maximal after 24 h. Fatty acid oxidation by INS 1 cells, measured at low glucose, was also 2-3 fold higher in cells cultured with fatty acid in comparison with control cells. Long term exposure of INS-1 cells to fatty acid was associated with elevated secretion of insulin at a low (5 mM) concentration of glucose and a decreased effect of higher glucose concentrations. It also resulted in a decreased oxidation of glucose. The results indicate that the CPT I gene is an early response gene induced by fatty acids at the transcriptional level in beta- (INS-1) cells. It is suggested that exaggerated fatty acid oxidation caused by CPT-1 induction is implicated in the process whereby fatty acids alter glucose-induced insulin secretion.	UNIV MONTREAL,DEPT NUTR,MOL NUTR UNIT,MONTREAL,PQ H3C 3J7,CANADA; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	Universite de Montreal; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	AssimacopoulosJeannet, F (corresponding author), UNIV GENEVA,CTR MED,DEPT BIOCHIM MED,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.		Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672	NIDDK NIH HHS [DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BALASSE EO, 1973, DIABETOLOGIA, V9, P145, DOI 10.1007/BF01230695; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BRUN T, 1993, J BIOL CHEM, V268, P18905; Chatelain F, 1996, EUR J BIOCHEM, V235, P789, DOI 10.1111/j.1432-1033.1996.00789.x; CHEN YDI, 1987, J CLIN ENDOCR METAB, V64, P17, DOI 10.1210/jcem-64-1-17; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke SD, 1996, J NUTR, V126, pS1105, DOI 10.1093/jn/126.suppl_4.1105S; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; CRESPIN SR, 1973, J CLIN INVEST, V52, P1979, DOI 10.1172/JCI107382; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; ESSER V, 1993, J BIOL CHEM, V268, P5817; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HERBIN C, 1987, EUR J BIOCHEM, V165, P201, DOI 10.1111/j.1432-1033.1987.tb11212.x; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; LI GD, 1990, BIOCHEM J, V272, P637, DOI 10.1042/bj2720637; LOPASCHUK GD, 1994, J BIOL CHEM, V269, P25871; MALAISSE WJ, 1981, BIOCHIM BIOPHYS ACTA, V677, P39, DOI 10.1016/0304-4165(81)90143-4; MALAISSE WJ, 1984, EXPERIENTIA, V40, P1035, DOI 10.1007/BF01971449; MCGARRY JD, 1991, BIOCHIMIE, V73, P77, DOI 10.1016/0300-9084(91)90078-F; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1990, PROG CLIN BIOL RES, V321, P193; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SAHA AK, 1994, AM J PHYSIOL, V267, pE95, DOI 10.1152/ajpendo.1994.267.1.E95; Sambrook J., 2002, MOL CLONING LAB MANU; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; Stein DT, 1996, J CLIN INVEST, V97, P2728, DOI 10.1172/JCI118727; SUGDEN MC, 1994, FASEB J, V8, P54, DOI 10.1096/fasebj.8.1.8299890; TAMARITRODRIGUEZ J, 1984, BIOCHEM J, V221, P317, DOI 10.1042/bj2210317; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; VARA E, 1988, DIABETOLOGIA, V31, P687, DOI 10.1007/BF00278753; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; WARNOTTE C, 1994, DIABETES, V43, P703, DOI 10.2337/diabetes.43.5.703; WERLEN G, 1993, J BIOL CHEM, V268, P16596; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584; Zhou YP, 1996, DIABETES, V45, P580, DOI 10.2337/diabetes.45.5.580; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394	56	130	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1659	1664		10.1074/jbc.272.3.1659	http://dx.doi.org/10.1074/jbc.272.3.1659			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999842	hybrid			2022-12-25	WOS:A1997WD05800040
J	Cottu, PH; Muzeau, F; Estreicher, A; Flejou, JF; Iggo, R; Thomas, G; Hamelin, R				Cottu, PH; Muzeau, F; Estreicher, A; Flejou, JF; Iggo, R; Thomas, G; Hamelin, R			Inverse correlation between RER(+) status and p53 mutation in colorectal cancer cell lines	ONCOGENE			English	Article						colon cancer; p53 mutations; mismatch repair	NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; REPEATED SEQUENCES; MISMATCH REPAIR; HOMOLOG; TUMORIGENESIS; GENE; RECEPTOR; TUMORS	The high point mutation rate of replication error-prone (RER(+)) cells could theoretically lead to inactivation of the p53 gene by polyclonal mutations, which might explain the conflicting results that have been published on the p53 status of RER(+) colon cancers, To address this issue, we tested the p53 status of 21 human colorectal cancer cell lines, including four showing microsatellite instability (RER(+) phenotype). Denaturing gradient gel electrophoresis (DGGE) followed by sequencing showed that all four RER(+) cell lines were mild type for p53 while 15 of the 17 RER(-) cell lines contained p53 mutations (P=0.001), Eight cell lines (four RER(+) and four RER(-)) were analysed using three complementary methods to test more rigorously the polyclonal mutation hypothesis, (i) Of 87 single-cell clones (seven to 14 per cell line) examined by DGGE, only those derived from known p53 mutant cell lines showed altered profiles, (ii) Antibody DO-7 stained more than 80% of nuclei from the p53 mutant cell lines, but only 15% of nuclei from the RER(+) cell lines, (iii) A yeast functional assay which can simultaneously detect polyclonal mutations at over 500 different sites in the p53 cDNA scored all four RER(+) cell lines as containing only transcriptionally active p53, These data thus do not support the polyclonal mutation hypothesis and instead suggest that mismatch repair deficiency provides a p53-independent pathway for development of colorectal cancers.	INST CURIE,INSERM U434,F-75005 PARIS,FRANCE; FAC XAVIER BICHAT,INSERM U410,PARIS,FRANCE; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Swiss Institute Experimental Cancer Research			Iggo, Richard/G-3546-2014; Cottu, Paul/ABC-8595-2020	Estreicher, Anne/0000-0001-6828-2508				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; HAMELIN R, 1993, ONCOGENE, V8, P2213; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	21	112	113	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2727	2730						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000147				2022-12-25	WOS:A1996VZ65400023
J	White, DW; Kuropatwinski, KK; Devos, R; Baumann, H; Tartaglia, LA				White, DW; Kuropatwinski, KK; Devos, R; Baumann, H; Tartaglia, LA			Leptin receptor (OB-R) signaling - Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE GENE; STIMULATING FACTOR RECEPTOR; ACUTE-PHASE RESPONSE; HEMATOPOIETIN RECEPTORS; OBESE GENE; TRANSDUCTION; CLONING; LIGAND; STAT3	The leptin receptor (OB-R) mediates the weight regulatory effects of the adipocyte secreted hormone leptin (OB), Previously we have shown that the long form of OB-R, expressed predominantly in the hypothalamus, can mediate ligand-induced activation of signal transducer and activator of transcription factors 1, 3, and 5 and stimulate transcription via interleukin-6 and hematopoietin receptor responsive gene elements. Here we report that deletion and tyrosine substitution mutagenesis of OB-R identifies two distinct regions of the intracellular domain important for signaling. In addition, granulocyte-colony stimulatory factor receptor/OB-R and OB-R/granulocyte-colony stimulatory factor receptor chimeras are signaling competent and provide evidence that aggregation of two OB-R intracellular domains is sufficient for ligand-induced receptor activation. However, signaling by full-length OB-R appears to be relatively resistant to dominant negative repression by signaling-incompetent OB-R, suggesting that mechanisms exist to permit signaling by the long form of OB-R even in the pretence of excess naturally occurring short form of OB-R.	ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,BUFFALO,NY 14263; MILLENNIUM PHARMACEUT,CAMBRIDGE,MA 02215; ROCHE RES GENT,B-9000 GHENT,BELGIUM	Roswell Park Cancer Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals					NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BRAND T, 1993, J BIOL CHEM, V268, P11500; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Devos R, 1996, P NATL ACAD SCI USA, V93, P5668, DOI 10.1073/pnas.93.11.5668; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ISHEZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAN JC, 1995, J BIOL CHEM, V270, P12906, DOI 10.1074/jbc.270.21.12906; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; VIGON I, 1993, ONCOGENE, V8, P2607; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEISER R, 1993, MOL CELL BIOL, V13, P7239; WEN DX, 1992, J BIOL CHEM, V267, P2512; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	41	249	261	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4065	4071		10.1074/jbc.272.7.4065	http://dx.doi.org/10.1074/jbc.272.7.4065			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020115	hybrid			2022-12-25	WOS:A1997WH01900031
J	Amann, J; Kidd, VJ; Lahti, JM				Amann, J; Kidd, VJ; Lahti, JM			Characterization of putative human homologues of the yeast chromosome transmission fidelity gene, CHL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; SPLICING FACTOR PRP2; BOX RNA HELICASE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; NUCLEOLAR ANTIGEN; CELL-CYCLE; BINDING PROTEIN; MOLECULAR-CLONING; EXCISION-REPAIR	Helicases are components of numerous protein complexes, including those regulating transcription, translation, DNA replication and repair, splicing, and mitotic chromosome transmission. Helicases unwind double-stranded DNA and RNA homo- and hetero-duplexes. The yeast CHL1 helicase has been linked to maintenance of the high fidelity of chromosome transmission during mitosis. Mutations in this gene result in a 200-fold increase in the rate of aberrant chromosome segregation with a concomitant delay in the cell cycle at G(2)-M, suggesting that CHL1 is required for the maintenance of proper chromosome transmission, Two highly related human cDNA clones encoding proteins which are homologous to the yeast CHL1 gene product have been isolated, Here we show that these two distinct human CHL1-related mRNAs and proteins (hCHLR1 and hCHLR2) are expressed only in proliferating human cell lines, Quiescent normal human fibroblasts stimulated to re-enter the cell cycle by addition of serum begin to express the CHL1-related proteins as the cells enter S phase, concomitant with the expression of proliferating cell nuclear antigen, Furthermore, expression of the CHL1-related mRNAs is lost when human K562 cells cease to proliferate and terminally differentiate in response to phorbol ester treatments. Human hCHLR expression is not extinguished during hemin-induced differentiation of the same cell line, which produces erythrocyte-like cells that continue to proliferate. These experiments are consistent with the requirement of this putative helicase during either S or G(2)-M phase but not G(1). In vitro transcribed and translated hCHLR1 protein binds to both single- and double-stranded DNA, supporting the possibility that these proteins are DNA helicases. Finally, affinity-purified hCHLR1 antisera was used to demonstrate the localization of the hCHLR proteins to the nucleolus by indirect immunofluorescence as well as by cell fractionation.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA	St Jude Children's Research Hospital; University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 44088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; Amann J, 1996, GENOMICS, V32, P260, DOI 10.1006/geno.1996.0113; BALL LA, 1992, J VIROL, V66, P2326, DOI 10.1128/JVI.66.4.2326-2334.1992; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BURATOWSKI S, 1993, SCIENCE, V260, P37, DOI 10.1126/science.8465198; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHATTERJEE A, 1987, CANCER RES, V47, P1123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FONAGY A, 1992, CANCER RES, V52, P5250; FREEMAN JW, 1986, CANCER RES, V46, P3593; FREEMAN JW, 1991, CANCER RES, V51, P1973; FREEMAN JW, 1988, CANCER RES, V48, P1244; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; GILLESPIE DE, 1995, GENE DEV, V9, P2495, DOI 10.1101/gad.9.20.2495; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GOMEZCASARES MT, 1993, LEUKEMIA, V7, P1824; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Hazlewood J, 1989, Cancer Commun, V1, P29; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; KALLAJOKI M, 1991, EMBO J, V10, P3351, DOI 10.1002/j.1460-2075.1991.tb04899.x; Lombard DB, 1996, TRENDS GENET, V12, P283, DOI 10.1016/0168-9525(96)30065-6; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; NAUMOVSKI L, 1987, MOL GEN GENET, V209, P458, DOI 10.1007/BF00331150; OCHS RL, 1988, CANCER RES, V48, P6523; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PEGORARO L, 1980, BLOOD, V55, P859; PLUMPTON M, 1994, EMBO J, V13, P879, DOI 10.1002/j.1460-2075.1994.tb06331.x; Qui H., 1993, GENE DEV, V7, P2161; RIPMASTER TL, 1992, P NATL ACAD SCI USA, V89, P11131, DOI 10.1073/pnas.89.23.11131; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; RUTHERFORD TR, 1979, CELL, V16, P415, DOI 10.1016/0092-8674(79)90017-5; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHER A, 1988, NATURE, V334, P478, DOI 10.1038/334478b0; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TEIGELKAMP S, 1994, EMBO J, V13, P888, DOI 10.1002/j.1460-2075.1994.tb06332.x; TSENG BY, 1989, MOL CELL BIOL, V9, P1940, DOI 10.1128/MCB.9.5.1940; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; XIANG JL, 1994, J BIOL CHEM, V269, P15786; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	69	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3823	3832		10.1074/jbc.272.6.3823	http://dx.doi.org/10.1074/jbc.272.6.3823			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013641	hybrid			2022-12-25	WOS:A1997WG19200101
J	Buyse, G; Voets, T; Tytgat, J; DeGreef, C; Droogmans, G; Nilius, B; Eggermont, J				Buyse, G; Voets, T; Tytgat, J; DeGreef, C; Droogmans, G; Nilius, B; Eggermont, J			Expression of human pI(Cln) and ClC-6 in Xenopus oocytes induces an identical endogenous chloride conductance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL; PROTEIN; CURRENTS; CLONING; CELLS; K+; ACTIVATION; CALCIUM; ISK	pI(Cln) is a protein that induces an outwardly rectifying, nucleotide-sensitive chloride current (I-Cln) when expressed in Xenopus oocytes, but its precise function (plasma membrane anion channel versus cytosolic regulator of a channel) remains controversial. We now report that a chloride current identical to I-Cln is induced when Xenopus oocytes are injected with human ClC-6 RNA. Indeed, both the pI(Cln) and the ClC-6 induced current are outwardly rectifying, they inactivate slowly at positive potentials and have an anion permeability sequence NO3- > I- > Br- > Cl- > gluconate. Cyclamate, NPPB, and extracellular cAMP block the induced currents, The success rate of current expression is significantly increased when the injected Xenopus oocytes are incubated at a higher temperature (24 or 37 degrees C) prior to the analysis. In addition, the I-Cln current was detected in 6.2% of noninjected control Xenopus oocytes. We therefore conclude that the I-Cln current in Xenopus oocytes corresponds to an endogenous conductance that can be activated by expression of structurally unrelated proteins. Furthermore, functional, biochemical, and morphological observations did not support the notion that pI(Cln) resides in the plasma membrane either permanently or transiently after cell swelling. Thus, it is unlikely that pI(Cln) forms the channel that is responsible for the I-Cln current in Xenopus oocytes.	CATHOLIC UNIV LEUVEN,PHYSIOL LAB,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,TOXICOL LAB,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven			Voets, Thomas/E-2466-2012; Voets, Thomas/AAD-4389-2019; Tytgat, Jan/F-1560-2010	Voets, Thomas/0000-0001-5526-5821; Voets, Thomas/0000-0001-5526-5821; Eggermont, Jan/0000-0002-8497-1159; Tytgat, Jan/0000-0003-1778-6022				ABE T, 1993, BIOCHIM BIOPHYS ACTA, V1173, P353, DOI 10.1016/0167-4781(93)90138-4; ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ARELLANO RO, 1995, J PHYSIOL-LONDON, V488, P351, DOI 10.1113/jphysiol.1995.sp020971; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; Buyse G, 1996, BIOCHEM BIOPH RES CO, V218, P822, DOI 10.1006/bbrc.1996.0146; CocaPrados M, 1996, J MEMBRANE BIOL, V150, P197, DOI 10.1007/s002329900044; DEGREEF C, 1995, BIOCHEM J, V307, P713, DOI 10.1042/bj3070713; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; ISHIBASHI K, 1993, BIOCHEM BIOPH RES CO, V192, P561, DOI 10.1006/bbrc.1993.1452; KOWDLEY GC, 1994, J GEN PHYSIOL, V103, P217, DOI 10.1085/jgp.103.2.217; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; NILIUS B, 1996, IN PRESS GEN PHARM, V27; OKADA H, 1995, BBA-BIOMEMBRANES, V1234, P145, DOI 10.1016/0005-2736(95)00015-U; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; Paulmichl Markus, 1996, Biophysical Journal, V70, pA9; Shimbo K, 1995, BIOPHYS J, V69, P1819, DOI 10.1016/S0006-3495(95)80052-4; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Szucs G, 1996, PFLUG ARCH EUR J PHY, V431, P540, DOI 10.1007/s004240050033; Szucs G, 1996, J MEMBRANE BIOL, V149, P189, DOI 10.1007/s002329900019; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; VANDRIESSCHE W, 1993, PFLUG ARCH EUR J PHY, V425, P164, DOI 10.1007/BF00374517; Voets T, 1996, J PHYSIOL-LONDON, V495, P441, DOI 10.1113/jphysiol.1996.sp021605	33	91	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3615	3621		10.1074/jbc.272.6.3615	http://dx.doi.org/10.1074/jbc.272.6.3615			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013613	hybrid			2022-12-25	WOS:A1997WG19200073
J	Cornille, F; Martin, L; Lenoir, C; Cussac, D; Roques, BP; FournieZaluski, MC				Cornille, F; Martin, L; Lenoir, C; Cussac, D; Roques, BP; FournieZaluski, MC			Cooperative exosite-dependent cleavage of synaptobrevin by tetanus toxin light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; INTEGRAL MEMBRANE-PROTEIN; AMINO-ACID SEQUENCE; NEUROTRANSMITTER RELEASE; BOTULINAL NEUROTOXINS; SYNAPTIC VESICLES; SINGLE MUTATION; HEAVY-CHAIN; ZINC; INHIBITION	The light chain (L chain) of tetanus neurotoxin (TeNT) has been shown to have been endowed with zinc endopeptidase activity, selectively directed toward the Gln(76)-Phe(77) bond of synaptobrevin, a vesicle-associated membrane protein (VAMP) critically involved in neuroexocytosis. In previous reports, truncations at the NH2 and COOH terminus of synaptobrevin have shown that the sequence 39-88 of synaptobrevin is the minimum substrate of TeNT, suggesting either the requirement of a well defined three-dimensional structure of synaptobrevin or a role in the mechanism of substrate hydrolysis for residues distal from the cleavage site. In this study, the addition of NH2- and COOH-terminal peptides of synaptobrevin, S 27-55 (S-1) and S 82-93 (S-2), to the synaptobrevin fragment S 56-81 allowed the cleavage of this latter peptide by TeNT to occur. This appears to result from an activation process mediated by the simultaneous binding of S-1 and S-2 with complementary sites present on TeNT as shown by surface plasmon resonance experiments and the determination of kinetic constants. All these results favor an exosite-controlled hydrolysis of synaptobrevin by TeNT, probably involving a conformational change of the toxin. This could account for the high degree of substrate specificity of TeNT and, probably, botulinum neurotoxins.	UNIV PARIS 05,DEPT PHARMACOCHIM MOL & STRUCT,INSERM,U266,CNRS,URA D1500,F-75270 PARIS 06,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			MARTIN, Loïc/E-1627-2011	MARTIN, Loïc/0000-0002-7940-2955				Ashton AC, 1995, J BIOL CHEM, V270, P31386, DOI 10.1074/jbc.270.52.31386; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHANGEUX JP, 1993, BIOESSAYS, V15, P625, DOI 10.1002/bies.950150909; CHAPMAN ER, 1995, NEUROPHARMACOLOGY, V34, P1343, DOI 10.1016/0028-3908(95)00147-X; CORNILLE F, 1994, EUR J BIOCHEM, V222, P173, DOI 10.1111/j.1432-1033.1994.tb18855.x; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; FORAN P, 1994, BIOCHEMISTRY-US, V33, P15365, DOI 10.1021/bi00255a017; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HORIKAWA HPM, 1993, FEBS LETT, V330, P236, DOI 10.1016/0014-5793(93)80281-X; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LI Y, 1994, BIOCHEMISTRY-US, V33, P7014, DOI 10.1021/bi00188a034; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MONOD J, 1965, J MOL BIOL, V12, P118; Pellizzari R, 1996, J BIOL CHEM, V271, P20353, DOI 10.1074/jbc.271.34.20353; ROQUES BP, 1993, PHARMACOL REV, V45, P87; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; ROSSETTO O, 1995, J PHYSIOLOGY-PARIS, V89, P43, DOI 10.1016/0928-4257(96)80550-X; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; Soleilhac JM, 1996, ANAL BIOCHEM, V241, P120, DOI 10.1006/abio.1996.0385; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Wictome M, 1996, FEBS LETT, V386, P133, DOI 10.1016/0014-5793(96)00431-0; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; YAMASAKI S, 1994, P NATL ACAD SCI USA, V91, P4688, DOI 10.1073/pnas.91.11.4688; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; ZHOU LQ, 1995, BIOCHEMISTRY-US, V34, P15175, DOI 10.1021/bi00046a025; [No title captured]; [No title captured]	43	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3459	3464		10.1074/jbc.272.6.3459	http://dx.doi.org/10.1074/jbc.272.6.3459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013591	Green Published, hybrid			2022-12-25	WOS:A1997WG19200051
J	Healy, S; You, XQ; Dodson, M				Healy, S; You, XQ; Dodson, M			Interactions of a subassembly of the herpes simplex virus type 1 helicase-primase with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN-BINDING-PROTEIN; SINGLE-STRANDED-DNA; PRIMER SYNTHESIS; GENE-PRODUCTS; UL52 GENE; COMPLEX; REPLICATION; SEQUENCE; ACID; IDENTIFICATION	The UL5, UL8, and UL52 genes of herpes simplex virus type 1 encode a multisubunit assembly that possesses primase, DNA helicase, and DNA-dependent nucleoside triphosphatase activities. A subassembly consisting of the UL5 and UL52 gene products retains these activities. The nucleoside triphosphatase activity of the UL5/UL52 subassembly is strongly stimulated by both home- and heteropolymeric single-stranded DNA. Double-stranded DNA has little ability to stimulate the ATPase activity. The subassembly binds both double and single-stranded DNA. Nucleotides are not required for DNA-binding. The minimum length of single stranded DNA that is bound and that stimulates enzymatic activity is about 12 nucleotides. The kinetic parameters of the ATPase activity of the subassembly are affected by the length of the oligonucleotide coeffector. The K-m decreases as the coeffector length is increased up to a length of about 20 nucleotides and then remains independent of coeffector length. The first order rate constant for ATPase activity exhibits a quasihyperbolic dependence on the length of the DNA coeffector and is maximal for coeffectors of 20 nucleotides and longer.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721	University of Arizona								BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CARMICHAEL EP, 1989, J VIROL, V63, P591, DOI 10.1128/JVI.63.2.591-599.1989; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DODSON MS, 1993, J BIOL CHEM, V268, P1213; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	29	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3411	3415		10.1074/jbc.272.6.3411	http://dx.doi.org/10.1074/jbc.272.6.3411			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013584	hybrid			2022-12-25	WOS:A1997WG19200044
J	Quadri, LEN; Yan, LZ; Stiles, ME; Vederas, JC				Quadri, LEN; Yan, LZ; Stiles, ME; Vederas, JC			Effect of amino acid substitutions on the activity of carnobacteriocin B2 - Overproduction of the antimicrobial peptide, its engineered variants, and its precursor in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEDIOCOCCUS-ACIDILACTICI PAC1.0; LACTOBACILLUS-SAKE LB706; LEUCONOSTOC-GELIDUM; LEUCOCIN-A; SAKACIN-A; BACTERIOCIN; CLONING; PURIFICATION; EXPRESSION; PISCICOLA	Carnobacteriocin B2, a 48-amino acid antimicrobial peptide containing a YGNGV motif that is produced by the lactic acid bacterium Carnobacterium piscicola LV17B, was overexpressed as fusion with maltose-binding protein in Escherichia coli. This fusion protein was cleaved with Factor Xa to allow isolation of the mature bacteriocin that was identical in all respects to that obtained from C. piscicola. Similar methodology permitted production of the precursor precarnobacteriocin B2 (CbnB2P), which has an 18-amino acid leader, as well as six mutants of the mature peptide: CbnF3 (Tyr(3) --> Phe), CbnS33 (Phe(33) --> Ser), CbnI34 (Val(34) --> Ile), CbnI37 (Val(37) --> Ile), CbnG46 (Arg(46) --> Gly), and Cbn28 (truncated frameshift mutation: (carnobacteriocin B2 1-28) + ELTHL). Examination of these compounds for antimicrobial activity showed that although CbnI34, CbnI37, and CbnG46 were fully active, CbnB2P, CbnF3, CbnS33, Cbn28, and all of the fusion proteins had greatly reduced or no antimicrobial activity. Expression of the immunity protein that protects against the action of the parent carnobacteriocin B2 in a previously sensitive organism also protects against the active mutants. Because carnobacteriocin B2 also acts as an inducer of bacteriocin production in C. piscicola, the ability of the precursor CbnB2P and the mutants to exert this effect was examined. All were able to induce Bac(-) cultures and reestablish the Bac(+) phenotype except for the truncated Cbn28. The results demonstrate that very minor changes in the peptide sequence may drastically alter antimicrobial activity but that the induction of bacteriocin production is much more tolerant of structural modification, especially at the N terminus.	UNIV ALBERTA, DEPT CHEM, EDMONTON, AB T6G 2G2, CANADA; UNIV ALBERTA, DEPT AGR FOOD & NUTR SCI, EDMONTON, AB T6G 2G2, CANADA	University of Alberta; University of Alberta				Vederas, John/0000-0002-2996-0326				AHN C, 1990, APPL ENVIRON MICROB, V56, P2503, DOI 10.1128/AEM.56.8.2503-2510.1990; AXELSSON L, 1995, J BACTERIOL, V177, P2125, DOI 10.1128/jb.177.8.2125-2137.1995; BAQUERO F, 1984, FEMS MICROBIOL LETT, V23, P117; BRAUN V, 1994, ARCH MICROBIOL, V161, P199, DOI 10.1007/s002030050042; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; BUKHTIYAROVA M, 1994, APPL ENVIRON MICROB, V60, P3405, DOI 10.1128/AEM.60.9.3405-3408.1994; CHIKINDAS ML, 1993, APPL ENVIRON MICROB, V59, P3577, DOI 10.1128/AEM.59.11.3577-3584.1993; Fleury Y, 1996, J BIOL CHEM, V271, P14421, DOI 10.1074/jbc.271.24.14421; FREMAUX C, 1995, MICROBIOL-SGM, V141, P1637, DOI 10.1099/13500872-141-7-1637; HASTINGS JW, 1991, J BACTERIOL, V173, P7491, DOI 10.1128/jb.173.23.7491-7500.1991; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HECHARD Y, 1992, J GEN MICROBIOL, V138, P2725, DOI 10.1099/00221287-138-12-2725; HOLCK A, 1992, J GEN MICROBIOL, V138, P2715, DOI 10.1099/00221287-138-12-2715; HOLCK AL, 1994, FEMS MICROBIOL LETT, V115, P143, DOI [10.1111/j.1574-6968.1994.tb06629.x, 10.1016/0378-1097(94)90005-1]; JACK RW, 1995, MICROBIOL REV, V59, P171, DOI 10.1128/MMBR.59.2.171-200.1995; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MARUGG JD, 1992, APPL ENVIRON MICROB, V58, P2360, DOI 10.1128/AEM.58.8.2360-2367.1992; QUADRI LEN, 1995, J BACTERIOL, V177, P1144, DOI 10.1128/JB.177.5.1144-1151.1995; QUADRI LEN, 1994, J BIOL CHEM, V269, P12204; RAO AG, 1995, MOL PLANT MICROBE IN, V8, P6, DOI 10.1094/MPMI-8-0006; SAILER M, 1993, BIOCHEMISTRY-US, V32, P310, DOI 10.1021/bi00052a039; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUCIER L, 1995, J APPL BACTERIOL, V78, P684, DOI 10.1111/j.1365-2672.1995.tb03116.x; TAGG JR, 1976, BACTERIOL REV, V40, P722, DOI 10.1128/MMBR.40.3.722-756.1976; TICHACZEK PS, 1994, MICROBIOL-SGM, V140, P361, DOI 10.1099/13500872-140-2-361; VANBELKUM MJ, 1995, APPL ENVIRON MICROB, V61, P3573, DOI 10.1128/AEM.61.10.3573-3579.1995; VANDENBERGH PA, 1993, FEMS MICROBIOL REV, V12, P221, DOI [10.1016/0168-6445(93)90065-H, 10.1111/j.1574-6976.1993.tb00020.x]; VENEMA K, 1995, MOL MICROBIOL, V17, P515, DOI 10.1111/j.1365-2958.1995.mmi_17030515.x	29	67	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3384	3388		10.1074/jbc.272.6.3384	http://dx.doi.org/10.1074/jbc.272.6.3384			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013580	hybrid			2022-12-25	WOS:A1997WG19200040
J	Sanna, MT; Razynska, A; Karavitis, M; Koley, AP; Friedman, FK; Russu, IM; Brinigar, WS; Fronticelli, C				Sanna, MT; Razynska, A; Karavitis, M; Koley, AP; Friedman, FK; Russu, IM; Brinigar, WS; Fronticelli, C			Assembly of human hemoglobin - Studies with Escherichia coli-expressed alpha-globin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HUMAN ADULT HEMOGLOBIN; CONFORMATIONAL DIFFERENCES; BETA-GLOBINS; PROTON-NMR; ASSIGNMENTS; SEQUENCE	The alpha-globin of human hemoglobin was expressed in Escherichia coli and was refolded with heme in the presence and in the absence of native beta-chains, The functional and structural properties of the expressed alpha-chains were assessed in the isolated state and after assembly into a functional hemoglobin tetramer, The recombinant and native hemoglobins were essentially identical on the basis of sensitivity to effecters (Cl- and 2,3-diphosphaglycerate), Bohr effect, CO binding kinetics, dimer-tetramer association constants, circular dichroism spectra of the heme region, and nuclear magnetic resonance of the residues in the alpha(1) beta(1) and alpha(1) beta(2) interfaces. However, the nuclear magnetic resonance revealed subtle differences in the heme region of the expressed alpha-chain, and the recombinant human normal adult hemoglobin (HbA) exhibited a slightly decreased cooperativity relative to native HbA, These results indicate that subtle conformational changes in the heme pocket can alter hemoglobin cooperativity in the absence of modifications of quaternary interface contacts or protein dynamics, In addition to incorporation into a HbA tetramer, the alpha-globin refolds and incorporates heme in the absence of the partner beta-chain. Although the CO binding kinetics of recombinant alpha-chains were the same as that of native alpha-chains, the ellipticity of the Soret circular dichroism spectrum was decreased and CO binding kinetics revealed an additional faster component. These results show that recombinant alpha-chain assumes alternating conformations in the absence of beta-chain and indicate that the isolated alpha-chain exhibits a higher degree of conformational flexibility than the alpha-chain incorporated into the hemoglobin tetramer. These findings demonstrate the utility of the expressed alpha-globin as a tool for elucidating the role of this chain in hemoglobin structure-function relationships.	UNIV MARYLAND,SCH MED,DEPT BIOCHEM & MOL BIOL,BALTIMORE,MD 21201; NCI,MOL CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892; WESLEYAN UNIV,DEPT MOL BIOL & BIOCHEM,HALL ATWATER SHANKLIN LABS,MIDDLETOWN,CT 06459; TEMPLE UNIV,DEPT CHEM,PHILADELPHIA,PA 19122	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wesleyan University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Friedman, Fred K/D-4208-2016; Friedman, Fred/O-6173-2019	Friedman, Fred/0000-0002-0284-7067	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048517] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL48517] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adair GS, 1925, J BIOL CHEM, V63, P529; AOJULA HS, 1986, BIOCHEM J, V237, P613, DOI 10.1042/bj2370613; BUCCI E, 1993, BIOCHEMISTRY-US, V32, P3519, DOI 10.1021/bi00065a001; BUCCI E, 1965, J BIOL CHEM, V240, pPC551; CHIANCONE E, 1992, J CHROMATOGR, V604, P117, DOI 10.1016/0021-9673(92)85536-3; CRAESCU CT, 1989, EUR J BIOCHEM, V181, P87, DOI 10.1111/j.1432-1033.1989.tb14697.x; DALVIT C, 1985, BIOCHEMISTRY-US, V24, P3398, DOI 10.1021/bi00335a003; DICERA E, 1987, BIOCHEMISTRY-US, V26, P4003, DOI 10.1021/bi00387a039; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; DOYLE ML, 1992, BIOCHEMISTRY-US, V31, P8629, DOI 10.1021/bi00151a033; FANELLI MRR, 1978, EUROPEAN J BIOCH, V92, P253; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; GERACI G, BIOCHEMISTRY-US, V8, P1848; HERNAN RA, 1996, J BIOL CHEM, V270, P26257; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; HSU MC, 1971, J AM CHEM SOC, V93, P3515; ISHIMORI K, 1992, BIOCHEMISTRY-US, V31, P3256, DOI 10.1021/bi00127a030; LEMAR GR, 1983, J MOL BIOL, V168, P887; LINSTROM TR, 1972, NATURE-NEW BIOL, V237, P263; MARKOWITZ A, 1992, ANAL INSTRUM, V20, P213; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; RUSSU IM, 1987, BIOCHIM BIOPHYS ACTA, V914, P40, DOI 10.1016/0167-4838(87)90159-2; SHELTON JB, 1981, J LIQ CHROMATOGR, V4, P1381, DOI 10.1080/01483918108059615; SHEN TJ, 1993, P NATL ACAD SCI USA, V90, P8108, DOI 10.1073/pnas.90.17.8108; TAKAHASHI S, 1980, BIOCHEMISTRY-US, V19, P5196, DOI 10.1021/bi00564a007; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; Vandegriff K D, 1992, Biotechnol Genet Eng Rev, V10, P403; Wyman J., 1990, BINDING LINKAGE; YIP YK, 1972, J BIOL CHEM, V247, P7237; [No title captured]	35	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3478	3486		10.1074/jbc.272.6.3478	http://dx.doi.org/10.1074/jbc.272.6.3478			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013594	hybrid			2022-12-25	WOS:A1997WG19200054
J	Uchiumi, T; Kominami, R				Uchiumi, T; Kominami, R			Binding of mammalian ribosomal protein complex P0 center dot P1 center dot P2 and protein L12 to the GTPase-associated domain of 28 S ribosomal RNA and effect on the accessibility to anti-28 S RNA autoantibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 23S RNA; ANTIBIOTIC THIOSTREPTON; TERTIARY STRUCTURE; SITE; CROSSLINKING; NUCLEOTIDES; ANTIBODIES; POLYMERASE; ANTISERA	We have investigated binding of rat ribosomal proteins to the ''GTPase domain'' of 28 S rRNA and its effect on accessibility to the anti-28 S autoantibody, which recognizes a unique tertiary structure of this RNA domain. Ribosomal protein L12 and P protein complex (P complex) consisting of P0, P1, and P2 both bound to the GTPase domain of rat 28 S rRNA in a buffer containing Mg-2. Chemical footprinting analysis of their binding sites revealed that the P complex mainly protected a conserved internal loop region comprising residues 1855-1861 and 1920-1922, whereas L12 protected an adjacent helix region encompassing residues 1867-1878 and 1887-1899. These sites are close to but distinct from the binding site for anti-28 S antibody determined previously. The bindings of P complex and L12 increased the anti-28 S accessibility, as revealed by gel retardation and quantitative immunoprecipitation analyses. In a Mg2+-eliminated condition, the RNA failed to bind to either anti-28 S or L12 but assembled into a complex under their coexistence. However, the RNA retained a property of binding to the P complex even in the absence of Mg2+, and this binding conferred high anti-28 S accessibility. These results indicated that the bindings of the P complex and L12 to their respective sites influenced the GTPase domain to increase the accessibility to anti-28 S. A possible RNA conformation adjusted by the protein bindings is discussed.	NIIGATA UNIV, SCH MED, DEPT BIOCHEM, NIIGATA 951, JAPAN	Niigata University								BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; CHAN YL, 1983, NUCLEIC ACIDS RES, V11, P7819, DOI 10.1093/nar/11.22.7819; CHU JL, 1991, J EXP MED, V174, P507, DOI 10.1084/jem.174.3.507; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; DIJK J, 1979, NUCLEIC ACIDS RES, V6, P2717, DOI 10.1093/nar/6.8.2717; DRAPER DE, 1995, J MOL BIOL, V249, P231, DOI 10.1006/jmbi.1995.0291; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOUGEL M, 1987, J MOL BIOL, V198, P91, DOI 10.1016/0022-2836(87)90460-8; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; Ogata K, 1979, Methods Enzymol, V59, P502; PADGETT RA, 1983, CELL, V35, P101, DOI 10.1016/0092-8674(83)90212-X; PETTERSSON I, 1979, NUCLEIC ACIDS RES, V6, P2637, DOI 10.1093/nar/6.7.2637; PETTERSSON I, 1976, FEBS LETT, V64, P135, DOI 10.1016/0014-5793(76)80267-0; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; RAUE HA, 1990, STRUCTURE FUNCTION G, P217; REIMER G, 1987, J CLIN INVEST, V79, P65, DOI 10.1172/JCI112809; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; RYAN PC, 1991, J MOL BIOL, V221, P1257, DOI 10.1016/0022-2836(91)80125-E; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMIDT FJ, 1981, J BIOL CHEM, V256, P2301; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SUZUKI K, 1990, BIOCHEM BIOPH RES CO, V172, P35, DOI 10.1016/S0006-291X(05)80169-X; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; THOMPSON J, 1979, EUR J BIOCHEM, V98, P261, DOI 10.1111/j.1432-1033.1979.tb13184.x; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; UCHIUMI T, 1995, J BIOL CHEM, V270, P29889; UCHIUMI T, 1994, EMBO J, V13, P3389, DOI 10.1002/j.1460-2075.1994.tb06641.x; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; UCHIUMI T, 1991, J BIOL CHEM, V266, P2054; VLASSOV VV, 1981, FEBS LETT, V123, P277, DOI 10.1016/0014-5793(81)80307-9; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; XING YY, 1995, J MOL BIOL, V249, P319, DOI 10.1006/jmbi.1995.0299; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o	38	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3302	3308		10.1074/jbc.272.6.3302	http://dx.doi.org/10.1074/jbc.272.6.3302			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013569	hybrid			2022-12-25	WOS:A1997WG19200029
J	Laurance, ME; Kwok, RPS; Huang, MS; Richards, JP; Lundblad, JR; Goodman, RH				Laurance, ME; Kwok, RPS; Huang, MS; Richards, JP; Lundblad, JR; Goodman, RH			Differential activation of viral and cellular promoters by human T-cell lymphotropic virus-1 tax and cAMP-responsive element modulator isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I TRANSCRIPTIONAL ACTIVATOR; LONG TERMINAL REPEAT; DNA-BINDING DOMAIN; CYCLIC-AMP; HTLV-I; TRANSACTIVATOR TAX; PROTEIN CREB; PHOSPHORYLATION; MECHANISM; ENHANCER	We have previously proposed that cAMP-responsive element-binding protein (CREB) activity is stimulated by human T-cell lymphotropic virus-1 (HTLV-1) Tax through two mechanisms that are differentially dependent upon CREB phosphorylation. We have tested this model by examining how Tax affects transcriptional activation mediated by the cAMP-responsive element (CRE) modulator (CREM). The CREM proteins are highly homologous to CREB, particularly in their DNA-binding domains and the kinase-inducible domain (KID), a region that interacts with the coactivator CREB-binding protein (CBP) in a phosphorylation-dependent manner. Despite this similarity, most CREM isoforms are transcriptional repressors. CREM alpha lacks the glutamine-rich domains found in CREB that are essential for transcriptional activation. We show that the normally repressive CREM alpha activates the HTLV-1 and cellular CREs in the presence of Tax; activation of the viral element is phosphorylation-independent, and activation of the cellular CRE is phosphorylation-dependent. CREM Delta(C-G) lacks both the KID and the glutamine-rich regions. This isoform activates the HTLV-1 long terminal repeat in a phosphorylation-independent manner, but does not activate the cellular CRE. This study suggests that Tax, interacting with the basic/zipper region of CREM, recruits CBP to the viral promoter. Tax activation of the cellular CRE depends on the KID and its ability to interact with CBP in a phosphorylation dependent manner.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT INTERNAL MED,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University					NATIONAL CANCER INSTITUTE [K11CA064325] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050014] Funding Source: NIH RePORTER; NCI NIH HHS [K11CA64325] Funding Source: Medline; NHLBI NIH HHS [5-T32-HL07781] Funding Source: Medline; NIDDK NIH HHS [DK50014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUJII M, 1994, J VIROL, V68, P7275, DOI 10.1128/JVI.68.11.7275-7283.1994; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GIAM CZ, 1986, P NATL ACAD SCI USA, V83, P7192, DOI 10.1073/pnas.83.19.7192; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; GORAYA TY, 1995, J BIOL CHEM, V270, P19078, DOI 10.1074/jbc.270.32.19078; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; KWOK RPS, 1994, NATURE, V370, P233; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LORIAUX MM, 1994, J BIOL CHEM, V269, P28839; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; POIESZ BJ, 1992, P NATL ACAD SCI USA, V77, P7414; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	37	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2646	2651		10.1074/jbc.272.5.2646	http://dx.doi.org/10.1074/jbc.272.5.2646			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006899	hybrid			2022-12-25	WOS:A1997WE66700012
J	Vaziri, C; Faller, DV				Vaziri, C; Faller, DV			A benzo[alpha]pyrene-induced cell cycle checkpoint resulting in p53-independent G(1) arrest in 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGING AGENTS; MUTANT P53; ONCOGENES; INDUCTION; RECEPTOR; PROTEIN; BENZO<A>PYRENE; ACTIVATION; EXPRESSION; ADDUCTS	The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor of the basic helix-loop-helix family. Although physiological ligands for the AhR have not been identified, carcinogenic polycyclic aromatic hydrocarbons such as Benzo[a]pyrene (B[a]P) are high affinity AhR ligands that induce nuclear translocation and sequence-specific DNA binding of the AhR. AhR-regulated genes include members of the cytochrome P-450 family that are known to oxidize B[a]P to form genotoxic (DNA-damaging) metabolites. Murine Swiss 3T3 cells express high levels of AhR. Treatment of Swiss 3T3 cells with B[a]P during the G(1) phase of the cell cycle resulted in growth arrest, as shown by inhibition of grow-th factor-stimulated DNA synthesis. By contrast, other murine 3T3 fibroblasts not expressing detectable levels of AhR did not undergo growth arrest in response to B[a]P. The AhR antagonist alpha-naphthoflavone prevented B[a]P-induced growth arrest, further demonstrating that cessation of cell growth was mediated by the activated AhR. A nongenotoxic AhR ligand (2,3,7,8-tetrachlorodibenzo-p-dioxin) did not elicit growth ar rest, showing that ligand activation of the AhR alone was insufficient to block cell cycle progression. However, genomic DNA from B[a]P-treated Swiss 3T3 cells contained covalent adducts, whereas that from 2,3,7,8-tetrachlorodibenzo- p-dioxin-treated cells did not, showing that G(1) arrest correlated with DNA damage resulting from genotoxic B[a]P metabolites. B[a]P-induced DNA damage and growth arrest was coincident with elevated levels of nuclear p53 protein and induction of the p53-regulated mdm-2 proto-oncogene. However, Swiss 3T3 fibroblasts expressing ''dominant negative'' mutant p53, as well as primary fibroblasts from p53-/-''knockout'' mice, also underwent growth arrest in response to B[a]P. Therefore, B[a]P-induced growth arrest occurs via p53-independent mechanisms.	BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118	Boston University					PHS HHS [R01-50459] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1988, ONCOGENE, V3, P313; FRITSCHE M, 1993, ONCOGENE, V8, P307; GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOKA P, 1991, J IMMUNOL, V146, P2417; KRAHN DF, 1977, MUTAT RES, V46, P27, DOI 10.1016/0165-1161(77)90108-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LEONARDO AD, 1994, GENE DEV, V8, P2540; MARNETT LJ, 1987, CARCINOGENESIS, V8, P1365, DOI 10.1093/carcin/8.10.1365; MICHIELI P, 1994, CANCER RES, V54, P3391; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROSSI L, 1983, CARCINOGENESIS, V4, P153, DOI 10.1093/carcin/4.2.153; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINSTEIN IB, 1976, SCIENCE, V193, P592, DOI 10.1126/science.959820; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	31	71	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2762	2769		10.1074/jbc.272.5.2762	http://dx.doi.org/10.1074/jbc.272.5.2762			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006915	hybrid			2022-12-25	WOS:A1997WE66700028
J	Young, WJ; Smith, SM; Chang, CS				Young, WJ; Smith, SM; Chang, CS			Induction of the intronic enhancer of the human ciliary neurotrophic factor receptor (CNTFR alpha) gene by the TR4 orphan receptor - A member of steroid receptor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; RESPONSE ELEMENT; NGFI-B; GENOMIC ORGANIZATION; TRANSCRIPTION FACTOR; THYROID-HORMONE; ACID RECEPTORS; NERVOUS-SYSTEM; MOTOR-NEURONS; COUP-TF	A conserved hormone response element, CNTFR-DR1 (5'-AGGTCAGAGGTCAGG-3'), has been identified in the 5th intron of the alpha component of the ciliary neurotrophic factor receptor (CNTFR alpha) gene for the human TR4 orphan receptor (TR4). Electrophoretic mobility shift assay showed a specific binding with high affinity (K-d = 0.066 nM) between TR4 and the CNTFR-DR1. A reporter gene assay using chloramphenicol acetyltransferase demonstrated that the 5th intron of CNTFR alpha has an enhancer activity which could be induced by TR4 in a dose-dependent manner. Furthermore, our in situ hybridization data showed that abundant TR4 transcripts were detected in adult brain, in regions of cortical and hippocampal neurons, as well as in many developing neural structures, including brain, spinal cord, ganglia (sympathetic and sensory), and neuronal epithelia (retinal, otic, olfactory, and gustatory). The striking similarities in the expression patterns of TR4 and CNTFR alpha in the developing and postnatal nervous systems further support the potential role of TRA in neurogenesis. Collectively, these data suggest that the human CNTFR alpha gene could represent the first identified neural-specific gene induced by TR4.	UNIV WISCONSIN, CTR COMPREHENS CANC, ENDOCRINOL REPROD PHYSIOL PROGRAM, MADISON, WI 53792 USA; UNIV WISCONSIN, DEPT NUTR SCI, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA 55639] Funding Source: Medline; NIDDK NIH HHS [DK 47258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055639, R29CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DASILVA SL, 1995, ENDOCRINOLOGY, V136, P2276; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KIRSCH M, 1994, NEUROSCI LETT, V180, P163, DOI 10.1016/0304-3940(94)90512-6; Klockgether T, 1995, AKTUEL NEUROL, V22, P217, DOI 10.1055/s-2007-1017927; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; LEE HJ, 1995, J BIOL CHEM, V270, P30129; LIN TM, 1995, J BIOL CHEM, V270, P30121; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; Lydon John P., 1992, Gene Expression, V2, P273; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; RAKIC L, 1988, SCAND J REHABIL MED, P15; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCOTT DK, 1995, BIOCHEM J, V310, P483, DOI 10.1042/bj3100483; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; VALENZUELA DM, 1995, GENOMICS, V25, P157, DOI 10.1016/0888-7543(95)80121-2; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YANG YZ, 1995, ENDOCRINOLOGY, V136, P2896, DOI 10.1210/en.136.7.2896	37	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3109	3116		10.1074/jbc.272.5.3109	http://dx.doi.org/10.1074/jbc.272.5.3109			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006963	hybrid			2022-12-25	WOS:A1997WE66700076
J	Abrahamson, SL; Wu, HM; Williams, RE; Der, K; Ottah, N; Little, R; GazzanoSantoro, H; Theofan, G; Bauer, R; Leigh, S; Orme, A; Horwitz, AH; Carroll, SF; Dedrick, RL				Abrahamson, SL; Wu, HM; Williams, RE; Der, K; Ottah, N; Little, R; GazzanoSantoro, H; Theofan, G; Bauer, R; Leigh, S; Orme, A; Horwitz, AH; Carroll, SF; Dedrick, RL			Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein - Implications in biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL FRAGMENT; GRAM-NEGATIVE SEPSIS; LIPID-A BINDING; (LPS)-BINDING PROTEIN; HUMAN NEUTROPHILS; SOLUBLE CD14; LPS; ENDOTOXIN; ACTIVATION; REGION	The physiological response to endotoxin (lipopolysaccharide (LPS)) can be regulated by two closely related LPS-binding proteins, LPS-binding protein (LBP), which potentiates LPS' inflammatory activity via interaction with the monocytic antigen CD14, and bactericidal/permeability-increasing protein (BPI), which neutralizes LPS. Both proteins bind LPS with high affinity sites in their N-terminal domains, whereas interaction between LBP and CD14 is dependent upon the LBP C-terminal domain. We have created fusions of the N- and C-terminal domains from each protein and compared the functional activities and pharmacokinetics of these fusions, the individual N-terminal domains, and the parent proteins. The N-terminal domains of BPI and LEP bound lipid A with their characteristic apparent affinity constants, regardless of the C-terminal fusion partner. In addition, the C-terminal domain of LBP allowed transfer of LPS to CD14 in conjunction with either N-terminal LPS binding domain. Proteins containing a EPI N-terminal domain had greater heparin binding capacities in vitro and were cleared more rapidly from the plasma of whole animals. Taken together, these data better define how closely related proteins such as BPI and LBP can have opposing effects on the body's response to LPS.	XOMA CORP,BERKELEY,CA 94710; XOMA CORP,SANTA MONICA,CA 90404									AMMONS WS, 1994, J INFECT DIS, V170, P1473, DOI 10.1093/infdis/170.6.1473; AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; DAY JR, 1994, J BIOL CHEM, V269, P9388; EVANS TJ, 1995, J INFECT DIS, V171, P153, DOI 10.1093/infdis/171.1.153; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Gibaldi M, 1982, PHARMACOKINETICS REV, V2nd, P45; GRAY PW, 1993, GENOMICS, V15, P188, DOI 10.1006/geno.1993.1030; GRAY PW, 1989, J BIOL CHEM, V264, P9505; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAN JH, 1994, J BIOL CHEM, V269, P8172; Horwitz AH, 1996, PROTEIN EXPRES PURIF, V8, P28, DOI 10.1006/prep.1996.0071; HUANG K, 1995, INFLAMMATION, V19, P389, DOI 10.1007/BF01534395; HUANG K, 1994, SHOCK, V1, P81, DOI 10.1097/00024382-199402000-00001; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KUNG AHC, 1994, BACTERIAL ENDOTOXINS, P255; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LIN Y, 1994, SHOCK, V2, P324, DOI 10.1097/00024382-199411000-00005; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; MARRA MN, 1990, J IMMUNOL, V144, P662; MARRA MN, 1992, J IMMUNOL, V148, P532; MESZAROS K, 1993, J LEUKOCYTE BIOL, V54, P558, DOI 10.1002/jlb.54.6.558; MESZAROS K, 1994, BLOOD, V83, P2516; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OOI CE, 1987, J BIOL CHEM, V262, P14891; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Robinson R R, 1991, Hum Antibodies Hybridomas, V2, P84; ROGY MA, 1994, J CLIN IMMUNOL, V14, P120, DOI 10.1007/BF01541345; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TAYLOR AH, 1995, J BIOL CHEM, V270, P17934, DOI 10.1074/jbc.270.30.17934; THEOFAN G, 1994, J IMMUNOL, V152, P3623; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; VANDERMEER TJ, 1994, J APPL PHYSIOL, V76, P2006, DOI 10.1152/jappl.1994.76.5.2006; VONDERMOHLEN MAM, 1995, J INFECT DIS, V172, P144, DOI 10.1093/infdis/172.1.144; WEISS JK, 1984, J IMMUNOL, V142, P2807; WHITE ML, 1994, J IMMUNOL METHODS, V167, P227, DOI 10.1016/0022-1759(94)90091-4; WILDE CG, 1994, J BIOL CHEM, V269, P17411; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WURFEL MM, 1995, J EXP MED, V181, P1743, DOI 10.1084/jem.181.5.1743; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025	42	56	65	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2149	2155						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999916				2022-12-25	WOS:A1997WD67900022
J	Betz, A; Okamoto, M; Benseler, F; Brose, N				Betz, A; Okamoto, M; Benseler, F; Brose, N			Direct interaction of the rat unc-13 homologue Munc13-1 with the N terminus of syntaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; PHORBOL ESTER RECEPTOR; CAENORHABDITIS-ELEGANS; NEUROTRANSMITTER RELEASE; ACETYLCHOLINE LEVELS; VESICLE DOCKING; BINDING PROTEIN; FUSION; GENE; SYNAPTOBREVIN	unc-13 mutants in Caenorhabditis elegans are characterized by a severe deficit in neurotransmitter release, Their phenotype is similar to that of the C. elegans unc-18 mutation, which is thought to affect synaptic vesicle docking to the active zone. This suggests a crucial role for the unc-13 gene product in the mediation or regulation of synaptic vesicle exocytosis, Munc13-1 is one of three closely related rat homologues of unc-13, Based on the high degree of similarity between unc-13 and Munc13 proteins, it is thought that their essential function has been conserved from C, elegans to mammals. Munc13-1 is a brain-specific peripheral membrane protein with multiple regulatory domains that may mediate diacylglycerol, phospholipid, and calcium binding, In the present study, we demonstrate by three independent methods that the C terminus of Munc13-1 interacts directly with a putative coiled coil domain in the N-terminal part of syntaxin. Syntaxin is a component of the exocytotic synaptic core complex, a heterotrimeric protein complex with an essential role in transmitter release. Through this interaction, Munc13-1 binds to a subpopulation of the exocytotic core complex containing synaptobrevin, SNAP25 (synaptosomal-associated protein of 25 kDa), and syntaxin, but to no other tested syntaxin-interacting or core complex-interacting protein. The site of interaction in syntaxin is similar to the binding site for the unc-18 homologue Munc18, but different from that of all other known syntaxin interactors. These data indicate that unc-13-related proteins may indeed be involved in the mediation or regulation of synaptic vesicle exocytosis by modulating or regulating core complex formation. The similarity between the unc-13 and unc-18 phenotypes is paralleled by the coincidence of the binding sites for Munc13-1 and Munc18 in syntaxin, It is possible that the phenotype of unc-13 and unc-18 mutations is caused by the inability of the respective mutated gene products to bind to syntaxin.	MAX PLANCK INST EXPT MED,ABT MOL NEUROBIOL,D-37075 GOTTINGEN,GERMANY; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BEZ A, 1996, BIOCHEM SOC T, V24, P662; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRENNER S, 1974, GENETICS, V77, P71; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BROSE N, 1994, J BIOL CHEM, V269, P16780; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOSONO R, 1987, J NEUROCHEM, V49, P1820, DOI 10.1111/j.1471-4159.1987.tb02442.x; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; Jorgensen Erik M., 1995, Seminars in Developmental Biology, V6, P207, DOI 10.1016/S1044-5781(06)80030-7; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P10777, DOI 10.1074/jbc.270.18.10777; Kee Y, 1996, J NEUROSCI, V16, P1975; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Rose MD., 1990, METHODS YEAST GENETI; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637	46	229	239	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2520	2526						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999968				2022-12-25	WOS:A1997WD67900074
J	Irmer, H; Hohfeld, J				Irmer, H; Hohfeld, J			Characterization of functional domains of the eukaryotic co-chaperone hip	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; PROTEIN-PROTEIN INTERACTIONS; HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; SIGNAL-TRANSDUCTION; ATPASE ACTIVITY; REACTION CYCLE; HSP70; DNAJ	The homo-oligomeric Rip protein cooperates with the 70-kDa heat shock cognate Hsc70 in the folding of newly synthesized polypeptide chains and in the conformational regulation of signaling molecules known to interact with Hsc70 and Hsp90. In order to further assess the role of Hip during protein biogenesis, a structure-function analysis of the Hip protein was initiated. By employing the yeast two-hybrid system, the Hsc70-binding site of Rip was mapped to a domain comprising multiple tetratricopeptide repeats and flanking charged alpha-helices. Affinity chromatography confirmed direct interaction of isolated Rip fragments and protein fusions bearing this region with the ATPase domain of Hsc70 in an ATP- and salt-dependent manner. Contact of Hip with the ATPase domain appears to be mediated primarily by the positively charged alpha-helix following the tetratricopeptide repeats. Furthermore, a domain required for homo-oligomerization was identified at the extreme amino terminus of Hip.	UNIV HEIDELBERG,ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOHFELD J, 1995, CELL, V83, P589; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; SIKORSKI RS, 1991, COLD SH Q B, V56, P663; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; Ziegelhoffer T, 1996, CURR BIOL, V6, P272, DOI 10.1016/S0960-9822(02)00476-1; [No title captured]	38	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2230	2235						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999928				2022-12-25	WOS:A1997WD67900034
J	Panaretou, C; Domin, J; Cockcroft, S; Waterfield, MD				Panaretou, C; Domin, J; Cockcroft, S; Waterfield, MD			Characterization of p150, an adaptor protein for the human phosphatidylinositol (PtdIns) 5-kinase - Substrate presentation by phosphatedylinositol transfer protein to the p150-PtdIns 3-kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOME-LIKE VACUOLE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; MESSENGER-RNAS; YEAST; TRANSPORT; VPS34; GENE; IDENTIFICATION	Genetic and biochemical studies have shown that the phosphatidylinositol (PtdIns) 3-kinase encoded by the yeast VPS34 gene is required for the efficient sorting and delivery of proteins to the vacuole. A human homologue of the yeast VPS34 gene product has recently been characterized as part of a complex with a cellular protein of 150 kDa (Volinia, S., Dhand, R., Vanhaesebroeck, B., MacDougall, L. H., Stein, R,, Zvelebil, M. J., Domin, J., Panaretou, C,, and Waterfield, M. D. (1995) EMBO J. 14, 3339-3348). Here, cDNA cloning is used to show that the amino acid sequence of this protein, termed p150, is 29.6% identical and 53% similar to the yeast Vps15p protein, an established regulator of Vps34p, Northern blot analysis showed a ubiquitous tissue distribution for p150 similar to that previously observed with PtdIns 3-kinase. Recombinant p150 associated with PtdIns 3-kinase in vitro in a stable manner, resulting in a 2-fold increase in lipid kinase activity. Addition of phosphatidylinositol transfer protein (PI-TP) further stimulated the lipid kinase activity of the p150 . PtdIns 3-kinase complex 3-fold. A PtdIns 3-kinase activity could also be coimmunoprecipitated from human cell lysates using anti-PI-TP antisera. This observation demonstrates that an interaction between a PtdIns 3-kinase and PI-TP occurs in vivo, which further implicates lipid transfer proteins in the regulation of PtdIns 3-kinase activity. These results suggest that the Vps15p . Vps34p complex has been conserved from yeast to man and in both species is involved in protein trafficking.	UCL, SCH MED, LUDWIG INST CANC RES, LONDON W10 8BT, ENGLAND; UNIV LONDON UNIV COLL, DEPT PHYSIOL, LONDON WC1E 6JJ, ENGLAND; UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOL BIOL, LONDON WC1E 6BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London; University of London; University College London			Cockcroft, Shamshad/F-9480-2011	Cockcroft, Shamshad/0000-0002-5731-476X				BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONG ZG, 1994, P NATL ACAD SCI USA, V91, P9617, DOI 10.1073/pnas.91.20.9617; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HUNTER T, 1986, ENZYMES, V17, P191; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Reaves BJ, 1996, J CELL SCI, V109, P749; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Sambrook J., 2002, MOL CLONING LAB MANU; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STACK JH, 1995, ANNU REV CELL DEV BI, V11, P11; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WELTERS P, 1994, P NATL ACAD SCI USA, V91, P11398, DOI 10.1073/pnas.91.24.11398; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; ZHO K, 1995, MOL CELL BIOL, V15, P5645; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	53	174	185	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2477	2485						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999962				2022-12-25	WOS:A1997WD67900068
J	Petrou, C; Chen, LC; Tashjian, AH				Petrou, C; Chen, LC; Tashjian, AH			A receptor-G protein coupling-independent step in the internalization of the thyrotropin-releasing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ANGIOTENSIN-II RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; BINDING PROTEIN; CELLS; SEQUESTRATION; ENDOCYTOSIS; LIGAND; REQUIREMENTS	To determine whether functional receptor-G protein coupling or signaling are required for internalization of the thyrotropin-releasing hormone receptor (TRHR), we compared the endocytosis of G(q)-coupled and uncoupled receptors. A hemagglutinin epitope-tagged TRHR (HA-TRHR) was in the G(q)-coupled state when bound to the agonist, MeTRH, and in a nonsignaling state when bound to the HA antibody (12CA5). 12CA5 did not induce an increase in [Ca2+](i) or inositol phosphates and did not inhibit [H-3]MeTRH binding or MeTRH-induced production of second messengers. Both agonist- and antibody-bound HA-TRRRs were rapidly internalized via the same pathway; internalization was sensitive to hypertonic shock, and both types of internalized receptors were sorted into lysosomes. In addition, the amino acid sequence CNC (positions 335-337) in the C-terminal tail of the TRHR, which is important in ligand-induced receptor internalization as determined by deletion mutagenesis (Nussenzveig, D. R., Heinflink, M., and Gershengorn, M. C. (1993) J. Biol. Chem. 268, 2389-2392), was also important for 12CA5-induced internalization. We expressed two truncated receptors, HA-K338STOP and HA-C335STOP, in GH(1)SC(1) pituitary cells. Both HA-TRHR and HA-K338STOP were localized at the plasma membrane of untreated cells and were translocated to intracellular vesicles after MeTRH or 12CA5 binding; however, HA-C335STOP was internalized and recycled constitutively. The intracellular localization of HA-C335STOP was not altered by MeTRH; however, 12CA5 binding induced the disappearance of internalized HA-C335STOP and caused its localization at the plasma membrane, indicating that constitutively cycling HA-C335STOP cannot be reinternalized after antibody binding. Thus, amino acids 335-337, which are important for the internalization of G(q)-coupled TRHRs, are also required for the sequestration of functionally uncoupled TRHRs, and in addition, they act as an inhibitory signal that prevents constitutive receptor internalization. Specifically, the Cys residues at positions 335 and 337 are important for preventing constitutive TRHR internalization, because a mutant HA-C335S/C337S receptor was sequestered constitutively. me conclude that release from a negative regulatory internalization sequence or domain is important for HA-TRHR internalization and that the role of the CNC sequence in internalization is independent of functional TRHR-G(q) coupling.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOL & CELLULAR TOXICOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 11011] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERT PR, 1984, J BIOL CHEM, V259, P5827; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CLARK RB, 1985, J CYCLIC NUCL PROT, V10, P97; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; HAN BM, 1995, MOL ENDOCRINOL, V9, P1708, DOI 10.1210/me.9.12.1708; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HINKLE PM, 1989, MOL ENDOCRINOL, V3, P1337, DOI 10.1210/mend-3-9-1337; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOSHIYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P551, DOI 10.1016/0006-291X(91)92019-G; LOUMAYE E, 1984, J BIOL CHEM, V259, P2663; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; NUSSENZVEIG DR, 1993, MOL ENDOCRINOL, V7, P1105, DOI 10.1210/me.7.9.1105; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PETROU CP, 1995, BIOCHEM J, V306, P107, DOI 10.1042/bj3060107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLICE LW, 1994, J BIOL CHEM, V269, P21755; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N; ZHAO DY, 1992, ENDOCRINOLOGY, V130, P3529, DOI 10.1210/en.130.6.3529	31	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2326	2333						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999941				2022-12-25	WOS:A1997WD67900047
J	Auethavekiat, V; Abrams, CS; Majerus, PW				Auethavekiat, V; Abrams, CS; Majerus, PW			Phosphorylation of platelet pleckstrin activates inositol polyphosphate 5-phosphatase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HOMOLOGY DOMAIN; ESCHERICHIA-COLI; PH DOMAINS; TRISPHOSPHATE; EXPRESSION; MEMBRANE; BINDING; 1,4,5-TRISPHOSPHATE; IDENTIFICATION	Pleckstrin is the major substrate phosphorylated on serine and threonine in response to stimulation of human platelets by thrombin (Abrams, C. S., Zhao, W., Belmonte, E., and Brass, L. F. (1995) J. Biol. Chem. 270, 23317-23321). We now show that pleckstrin in platelets is in a complex with inositol polyphosphate 5-phosphatase I (5-phosphatase I). This enzyme hydrolyzes the 5-phosphate from inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate and thus serves as a calcium signal-terminating enzyme, since the substrates but not the products mobilize intracellular calcium. Pleckstrin co immunoprecipitates with 5-phosphatase I in homogenates of platelets. Platelet homogenates fractionated by anion exchange chromatography show coelution of pleckstrin and 5-phosphatase I. Fractions containing phosphorylated pleckstrin have 7-fold greater 5-phosphatase activity than those containing unphosphorylated pleckstrin. Mixing experiments with recombinant 5-phosphatase I and pleckstrin in, vitro show that they form a stoichiometric complex. A mutant form of pleckstrin, in which the serine and threonine residues that are phosphorylated by protein kinase C are substituted with glutamic acid (pseudophosphorylated pleckstrin), activates recombinant 5-phosphatase I 2-3-fold while native unphosphorylated pleckstrin does not stimulate the enzyme. Thus pleckstrin functions to terminate calcium signaling in platelets when it is phosphorylated by binding to and activating 5-phosphatase I.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOPHYS,DIV HEMATOL,ST LOUIS,MO 63110; UNIV PENN,SCH MED,DEPT INTERNAL MED,PHILADELPHIA,PA 19104	Washington University (WUSTL); University of Pennsylvania	Auethavekiat, V (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL 54500, HL 16634, HL 55672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, P50HL054500, R01HL055672, R37HL016634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1995, J BIOL CHEM, V270, P23317, DOI 10.1074/jbc.270.40.23317; ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1995, EUR J BIOCHEM, V234, P598, DOI 10.1111/j.1432-1033.1995.598_b.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; LYONS RM, 1975, J CLIN INVEST, V56, P924, DOI 10.1172/JCI108172; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085	24	39	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1786	1790		10.1074/jbc.272.3.1786	http://dx.doi.org/10.1074/jbc.272.3.1786			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999861	hybrid			2022-12-25	WOS:A1997WD05800059
J	Cullen, KE; Sarge, KD				Cullen, KE; Sarge, KD			Characterization of hypothermia-induced cellular stress response in mouse tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK GENE-TRANSCRIPTION; HEAT-SHOCK; DNA-BINDING; COLD SHOCK; HSP70 GENE; EXPRESSION; PROTEIN; ACTIVATION; FACTOR-1; PROTECTION	Cells respond to adverse environmental conditions by expressing heat shock proteins, which serve to protect cells from harmful effects of the stress conditions. In this study we demonstrated that mice subjected to whole body hypothermia induced the cellular stress response, resulting in the increased expression of hsp72 mRNA in brain, heart, kidney, liver, and lung. We performed a detailed analysis of the major parameters of the stress response and found that cold induction of hsp expression is mediated by heat shock factor 1 (HSF1), which is also responsible for heat induction of the cellular stress response. However, there are differences in the mechanisms of HSF1 activation by hypothermia versus hyperthermia, as hypothermia does not cause the hyperphosphorylation of HSF1 that is characteristic of heat-activated HSF1.	UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007436, R29HD032008] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32008, T32-HD07436] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; BURTON V, 1988, MOL CELL BIOL, V8, P3550, DOI 10.1128/MCB.8.8.3550; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; GIARDINA C, 1995, J BIOL CHEM, V270, P10369, DOI 10.1074/jbc.270.18.10369; GOODSON ML, 1995, BIOCHEM BIOPH RES CO, V211, P943, DOI 10.1006/bbrc.1995.1903; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LIU AYC, 1994, J BIOL CHEM, V269, P14768; MATZ JM, 1995, AM J PHYSIOL-REG I, V269, pR38, DOI 10.1152/ajpregu.1995.269.1.R38; Morimoto RI, 1990, STRESS PROTEINS BIOL; NOWAK TS, 1985, J NEUROCHEM, V45, P1635, DOI 10.1111/j.1471-4159.1985.tb07236.x; OCHALSKI SJ, 1993, AGENTS ACTIONS, V39, pC52, DOI 10.1007/BF01972718; SALOTRA P, 1995, FEMS MICROBIOL LETT, V131, P57, DOI 10.1111/j.1574-6968.1995.tb07754.x; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SHUAIB A, 1993, NEUROCHEM RES, V18, P663, DOI 10.1007/BF00966779; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; STOCKMEIER CA, 1992, NEUROPHARMACOLOGY, V31, P1089, DOI 10.1016/0028-3908(92)90003-8; VASS K, 1988, ACTA NEUROPATHOL, V77, P122; WAGNER M, 1985, MOL CELL BIOL, V5, P3560, DOI 10.1128/MCB.5.12.3560; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98	29	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1742	1746		10.1074/jbc.272.3.1742	http://dx.doi.org/10.1074/jbc.272.3.1742			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999855	hybrid			2022-12-25	WOS:A1997WD05800053
J	Meissner, G; Rios, E; Tripathy, A; Pasek, D				Meissner, G; Rios, E; Tripathy, A; Pasek, D			Regulation of skeletal muscle Ca2+ release channel (ryanodine receptor) by Ca2+ and monovalent cations and anions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; CALCIUM-RELEASE; CARDIAC-MUSCLE; CA-2+ RELEASE; BINDING; ACTIVATION; CAFFEINE; PROBE; SITES	The effects of ionic composition and strength on rabbit skeletal muscle Ca2+ release channel (ryanodine receptor) activity were investigated in vesicle-Ca-45(2+) flux, single channel and [H-3]ryanodine binding measurements. In <0.01 mu M Ca2+ media, the highest Ca-45(2+) efflux rate was measured in 0.25 M choline-Cl medium followed by 0.25 M KCl, choline 4-morpholineethanesulfonic acid (Mes), potassium 1,4-piperazinediethanesulfonic acid (Pipes), and K-Mes medium. In all five media, the Ca-45(2+) efflux rates were increased when the free [Ca2+] was raised from <0.01 mu M to 20 mu M and decreased as the free [Ca2+] was further increased to 1 mM. An increase in [KCl] augmented Ca2+-gated single channel activity and [H-3]ryanodine binding. In [H-3]ryanodine binding measurements, bell-shaped Ca2+ activation/inactivation curves were obtained in media containing different monovalent cations (Li+, Na+ K+, Cs+, and choline(+)) and anions (Cl-, Mes(-), and Pipes(-)). In choline-Cl medium, substantial levels of [H-3]ryanodine binding were observed at [Ca2+] <0.01 mu M. Replacement of Cl- by Mes(-) or Pipes(-) reduced [H-3]ryanodine binding levels at all [Ca2+]. In all media, the Ca2+-dependence of [H-3]ryanodine binding could be well described assuming that the skeletal muscle ryanodine receptor possesses cooperatively interacting high-affinity Ca2+ activation and low-affinity Ca2+ inactivation sites. AMP primarily affected [H-3]ryanodine binding by decreasing the apparent affinity of the Ca2+ inactivation site(s) for Ca2+, while caffeine increased the apparent affinity of the Ca2+ activation site for Ca2+. Competition studies indicated that ionic composition affected Ca2+-dependent receptor activity by at least three different mechanisms: (i) competitive binding of Mg2+ and monovalent cations to the Ca2+ activation sites, (ii) binding of divalent cations to the Ca2+ inactivation sites, and (iii) binding of anions to specific anion regulatory sites.	UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599; RUSH UNIV,SCH MED,DEPT PHYSIOL,CHICAGO,IL 60612	University of North Carolina; University of North Carolina Chapel Hill; Rush University	Meissner, G (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NIAMS NIH HHS [AR32808, AR18687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018687, R01AR032808, R37AR032808, R37AR018687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUCK E, 1992, J BIOL CHEM, V267, P23560; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHU A, 1990, MOL PHARMACOL, V37, P735; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FRUEN BR, 1994, J BIOL CHEM, V269, P192; GODT RE, 1988, AM J PHYSIOL, V254, pC591, DOI 10.1152/ajpcell.1988.254.5.C591; GYORKE S, 1994, BIOPHYS J, V66, P1879; HASSELBACH W, 1992, Z NATURFORSCH C, V47, P440; KASAI M, 1995, J BIOCHEM, V117, P251, DOI 10.1093/jb/117.2.251; KIRINO Y, 1983, J BIOCHEM-TOKYO, V94, P1111, DOI 10.1093/oxfordjournals.jbchem.a134454; LAI FA, 1989, J BIOL CHEM, V264, P16776; MA J, 1993, J GEN PHYSIOL, V102, P423, DOI 10.1085/jgp.102.3.423; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; NAGASAKI K, 1983, J BIOCHEM-TOKYO, V94, P1101, DOI 10.1093/oxfordjournals.jbchem.a134453; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OGAWA Y, 1990, J BIOCHEM-TOKYO, V107, P894, DOI 10.1093/oxfordjournals.jbchem.a123144; OTSU K, 1994, J BIOL CHEM, V269, P9413; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SUKHAREVA M, 1994, BIOPHYS J, V67, P751, DOI 10.1016/S0006-3495(94)80536-3; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; TU QA, 1994, BIOPHYS J, V66, pA418; WANG JP, 1993, J BIOL CHEM, V268, P20974	30	139	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1628	1638		10.1074/jbc.272.3.1628	http://dx.doi.org/10.1074/jbc.272.3.1628			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999838	Green Published, hybrid			2022-12-25	WOS:A1997WD05800036
J	Holler, T; Cermak, JM; Blusztajn, JK				Holler, T; Cermak, JM; Blusztajn, JK			Dietary choline supplementation in pregnant rats increases hippocampal phospholipase D activity of the offspring	FASEB JOURNAL			English	Article						development; hippocampus; memory; metabotropic glutamate receptors; phosphatidylcholine	LONG-TERM POTENTIATION; ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; SUBSTRATE-SPECIFICITY; ACTIVATION; MEMORY; SLICES; NUTRITION; MODEL; GRANULOCYTES	Supplementation with choline during pregnancy in rats causes a long-lasting improvement of visuospatial memory of the offspring, The biochemical mechanism of this effect may be related to the function of choline as a precursor of phosphatidylcholine (PC), the substrate of a receptor-stimulated enzyme, phospholipase D (PLD), PLD activation initiates the sequential formation of two intracellular messengers, phosphatidic acid and 1,2-sn-diacylglycerol, We hypothesized that prenatal choline status may cause long-term modulation of PLD-catalyzed PC hydrolysis in the hippocampus, a brain region implicated in visuospatial memory functions, PLD activity was determined in hippocampal slices prelabeled with [H-3]glycerol or [H-3]oleic acid by measuring the PLD-catalyzed formation of [3H]phosphatidylpropanol in the presence of l-propanol, Slices were obtained from male pups born to mothers consuming a control diet, a choline-supplemented diet, or a choline-free diet from days 11 to 17 of pregnancy, The radiolabeling of phospholipid classes was unaffected by the treatments, Prenatal choline supplementation significantly increased basal PLD activity in [H-3]glycerol-labeled slices [by 46% of controls on postnatal day (P) 7 and by 36% on P21], and [H-3] oleate-labeled slices (by 91% on P7), as well as glutamate-stimulated PLD activity in [H-3]oleate-labeled slices (by 60% on P?), Prenatal choline deficiency failed to alter PLD activity, The actions of choline apparently required intact cells because in vitro assays of PLD activity in hippocampal homogenates, using fluorescent NBD-PC as substrate, revealed no differences between groups, The results show that prenatal choline supplementation up-regulates basal and receptor-stimulated PLD activity in the hippocampus during postnatal development.	BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02118	Boston University; Boston University				/0000-0001-8438-3122	NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEHNISCH T, 1993, NEUROSCIENCE, V54, P37, DOI 10.1016/0306-4522(93)90381-O; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOSS V, 1992, J NEUROCHEM, V59, P2340; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Crawford M. A., 1993, Nutrition and Health (Bicester), V9, P81; DANIN M, 1993, METH NEUROSCI, V18, P14; Delong G. Robeert, 1993, American Journal of Clinical Nutrition, V57, p286S, DOI 10.1093/ajcn/57.2.286S; EAGLE H, 1955, J EXP MED, V102, P595, DOI 10.1084/jem.102.5.595; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRICKE R, 1977, J COMP NEUROL, V173, P231, DOI 10.1002/cne.901730203; GRIFFITH WENDELL H., 1939, JOUR BIOL CHEM, V131, P567; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HOLLER T, 1993, J NEUROCHEM, V61, P1569, DOI 10.1111/j.1471-4159.1993.tb13659.x; HOLLER T, 1994, BIOCHEM PHARMACOL, V47, P411, DOI 10.1016/0006-2952(94)90033-7; HORWITZ J, 1993, BIOCHEM J, V295, P793, DOI 10.1042/bj2950793; IZQUIERDO I, 1975, Progress in Neurobiology (Oxford), V5, P37, DOI 10.1016/0301-0082(75)90007-6; KLEIN J, 1995, J NEUROCHEM, V65, P1445; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LEE HC, 1993, P NATL ACAD SCI USA, V90, P10086, DOI 10.1073/pnas.90.21.10086; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LLAHI S, 1992, J BIOL CHEM, V267, P3679; LOY R, 1991, ADV EXP MED BIOL, V295, P373; LOY R, 1977, BRAIN RES, V121, P229, DOI 10.1016/0006-8993(77)90149-4; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Minkwitz H G, 1975, J Hirnforsch, V16, P37; Minkwitz H G, 1976, J Hirnforsch, V17, P255; MOHN H, 1992, J BIOL CHEM, V267, P11131; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTANI S, 1993, BRAIN RES, V613, P1, DOI 10.1016/0006-8993(93)90446-T; OTANI S, 1991, EUR J PHARMACOL, V205, P325, DOI 10.1016/0014-2999(91)90920-L; PAI JK, 1988, J BIOL CHEM, V263, P12472; RIEDER MJ, 1994, CLIN PERINATOL, V21, P483, DOI 10.1016/S0095-5108(18)30328-2; SARRI E, 1995, J NEUROCHEM, V65, P837; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SHEN Y, 1994, PROG NEUROBIOL, V44, P485, DOI 10.1016/0301-0082(94)90008-6; SINGH SC, 1977, ANAT EMBRYOL, V151, P183, DOI 10.1007/BF00297480; THAL LJ, 1992, NEUROBIOL AGING, V13, P67, DOI 10.1016/0197-4580(92)90011-L; WANG P, 1991, J BIOL CHEM, V266, P14877; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	51	51	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1653	1659		10.1096/fasebj.10.14.9002559	http://dx.doi.org/10.1096/fasebj.10.14.9002559			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002559				2022-12-25	WOS:A1996WC86900013
J	Connell, GJ; Byrne, EM; Simpson, L				Connell, GJ; Byrne, EM; Simpson, L			Guide RNA-independent and guide RNA-dependent uridine insertion into cytochrome b mRNA in a mitochondrial lysate from Leishmania tarentolae - Role of RNA secondary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRYPANOSOMA-BRUCEI; KINETOPLASTID PROTOZOA; CRITHIDIA-FASCICULATA; MAXICIRCLE DNA; SUBUNIT-III; IN-VITRO; GENES; GRNA; TRANSCRIPTS	A primer extension assay was used for the detection of uridine insertions occurring in vitro in synthetic preedited cytochrome b mRNA during incubation with a Leishmania tarentolae mitochondrial extract. Two different activities were detected that inserted uridines within the first two editing sites: one that is dependent on the secondary structure of the mRNA but is independent of both exogenous and endogenous guide RNA, and a second that does not put the same structural constraints on the mRNA, but is dependent on the presence of a cognate guide RNA.	UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, MACDONALD RES LABS 6780, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MOL CELLULAR & DEV BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT MED MICROBIOL & IMMUNOL, LOS ANGELES, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIAID NIH HHS [AI09102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1992, P NATL ACAD SCI USA, V89, P11944, DOI 10.1073/pnas.89.24.11944; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; DELACRUZ VF, 1984, J BIOL CHEM, V259, P5136; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FRECH GC, 1995, EMBO J, V14, P178, DOI 10.1002/j.1460-2075.1995.tb06988.x; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PILLER KJ, 1995, MOL CELL BIOL, V15, P2916; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; SIMPSON AM, 1985, NUCLEIC ACIDS RES, V13, P5977, DOI 10.1093/nar/13.16.5977; SIMPSON AM, 1992, J BIOL CHEM, V267, P6782; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1986, INT REV CYTOL, V99, P119; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SIMPSON L, 1972, INT REV CYTOL, V32, P139, DOI 10.1016/S0074-7696(08)60340-X; Simpson L, 1993, RNA EDITING ALTERATI, P53; STUART K, 1993, RNA EDITING ALTERATI, P25; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; SUGISAKI H, 1993, J BIOL CHEM, V268, P887; THIEMANN OH, 1994, EMBO J, V13, P5689, DOI 10.1002/j.1460-2075.1994.tb06907.x; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4212	4218		10.1074/jbc.272.7.4212	http://dx.doi.org/10.1074/jbc.272.7.4212			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020135	hybrid			2022-12-25	WOS:A1997WH01900051
J	Bellagamba, C; Hubaishy, I; Bjorge, JD; Fitzpatrick, SL; Fujita, DJ; Waisman, DM				Bellagamba, C; Hubaishy, I; Bjorge, JD; Fitzpatrick, SL; Fujita, DJ; Waisman, DM			Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PHOSPHOLIPID-BINDING; SRC KINASE; MONOCLONAL-ANTIBODIES; CA-2+ BINDING; PROTEINS; SUBSTRATE; CALPACTIN; CALCIUM; IDENTIFICATION	In the present article we have examined if the interaction of the Ca2+-binding protein, annexin II tetramer (AIIt) with the plasma membrane phospholipids or with the submembranous cytoskeleton, effects the accessibility of the tyrosine phosphorylation site of AIIt. In the presence of Ca2+, pp60(c-src) catalyzed the incorporation of 0.22 +/- 0.05 mol of phosphate/mol of AIIt (mean +/- S.D., n = 5). The Ca2+ dependent binding of AIIt to purified adrenal medulla plasma membrane or phosphatidylserine vesicles stimulated the pp60(c-src)-dependent phosphorylation of AIIt to 0.62 +/- 0.04 mol of phosphate/mol of AIIt (mean +/- S.D., n = 5) or 0.93 +/- 0.07 mol of phosphate/ mol of AIIt (mean +/- S.D., n = 5), respectively. Phosphatidylserine- or phosphatidylinositol-containing vesicles but not vesicles composed of phosphatidylcholine or phosphatidylethanolamine, stimulated the phosphorylation of AIIt. In contrast, the binding of AIIt to F-actin resulted in the incorporation of only 0.04 +/- 0.04 mol of phosphate/mol of AIIt (mean +/- S.D., n = 5). These results suggest that the interaction of AIIt with plasma membrane and not the submembranous cytoskeleton, activates the tyrosine phosphorylation of AIIt by inducing a conformational change in the protein resulting in the enhanced exposure or accessibility of the tyrosine-phosphorylation site.	DEPT MED BIOCHEM,CELL REGULAT RES GRP,CALGARY,AB T2N 4N1,CANADA					Waisman, David/0000-0002-5097-9662				ANAND R, 1993, ONCOGENE, V8, P3013; Bandorowicz Joanna, 1993, Acta Biochimica Polonica, V40, P281; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COOPER JA, 1983, J BIOL CHEM, V258, P1108; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; EVANS TC, 1994, BIOCHEMISTRY-US, V33, P13231, DOI 10.1021/bi00249a009; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GREENBERG ME, 1983, J BIOL CHEM, V258, P8497; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HUBAISHY I, 1995, BIOCHEMISTRY-US, V34, P14527, DOI 10.1021/bi00044a031; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; ISACKE CM, 1986, MOL CELL BIOL, V6, P2745, DOI 10.1128/MCB.6.7.2745; ITO S, 1983, J BIOL CHEM, V258, P4626; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; KAETZEL MA, 1995, NEWS PHYSIOL SCI, V10, P171; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARRIOTT G, 1990, BIOCHEMISTRY-US, V29, P7004, DOI 10.1021/bi00482a008; MARTINEZ R, 1982, MOL CELL BIOL, V2, P653, DOI 10.1128/MCB.2.6.653; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; PIGAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P106, DOI 10.1016/0167-4838(90)90108-R; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SEATON BA, 1990, J BIOL CHEM, V265, P4567; SHADLE PJ, 1985, J BIOL CHEM, V260, P6354; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; THIEL C, 1991, J BIOL CHEM, V266, P14732; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; ZIPPEL R, 1989, EUR J CELL BIOL, V50, P428	41	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3195	3199		10.1074/jbc.272.6.3195	http://dx.doi.org/10.1074/jbc.272.6.3195			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013554	hybrid			2022-12-25	WOS:A1997WG19200014
J	Igarashi, H; Tsuzuki, T; Kakuma, T; Tominaga, Y; Sekiguchi, M				Igarashi, H; Tsuzuki, T; Kakuma, T; Tominaga, Y; Sekiguchi, M			Organization and expression of the mouse MTH1 gene for preventing transversion mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-SYNTHESIS; MUTAGENIC SUBSTRATE; HUMAN-CELLS; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; MAMMALIAN-CELLS; PROTEIN; REPAIR; MUTT; PROMOTER	An enzyme, 8-oxo-7,8-dihydrodeoxyguanosine triphosphatase (8-oxo-dGTPase), is present in various organisms and plays an important role in the control of spontaneous mutagenesis. The enzyme hydrolyzes 8-oxo-dGTP, all oxidized form of dGTP, to 8-oxo-dGMP, thereby preventing the occurrence of A:T to C:G transversion, caused by misincorporation. We isolated the mouse genomic sequence encoding the enzyme and elucidated its structure, The gene, named MTH1 for mutT homologue 1, is composed of at least five exons and spans approximately 9 kilobase pairs, A genomic region containing the pseudogene was also isolated. The promoter region for the gene is GC-rich, contains many AP-1 and AP-2 recognition sequences, and lacks a typical TATA box, Primer extension and S1 mapping analyses revealed the existence of multiple transcription initiation sites, among which a major site was defined as +1. The putative promoter region was placed upstream of the chloramphenicol acetyltransferase reporter gene, and control of expression of the gene was examined by introducing the construct into mouse NIH 3T3 cells, Deletion analysis indicated that a sequence from -321 to +9 carries the basic promoter activity while an adjacent region, spanning from +352 to +525 stimulates the frequency of transcription.	FUKUOKA DENT COLL,DEPT BIOL,SAWARA KU,FUKUOKA 81401,JAPAN; KYUSHU UNIV,MED INST BIOREGULAT,DEPT BIOCHEM,FUKUOKA 81282,JAPAN	Fukuoka Dental College (FDC); Kyushu University								AIBA H, 1981, J BIOL CHEM, V256, P1905; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; ARNHEIM N, 1992, MUTAT RES, V275, P157, DOI 10.1016/0921-8734(92)90020-P; BESSHO T, 1992, BIOCHEM BIOPH RES CO, V188, P372, DOI 10.1016/0006-291X(92)92395-E; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; FINANCSEK I, 1982, GENE, V18, P115; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; HARRISON L, 1995, J BIOL CHEM, V270, P5556, DOI 10.1074/jbc.270.10.5556; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; Iwakuma T, 1996, DNA CELL BIOL, V15, P863, DOI 10.1089/dna.1996.15.863; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Miller J.H., 1972, EXPT MOL GENETICS; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; VIDMAR JJ, 1993, CAN J MICROBIOL, V39, P892, DOI 10.1139/m93-133; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; YEH YC, 1991, J BIOL CHEM, V266, P6480; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191	42	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3766	3772		10.1074/jbc.272.6.3766	http://dx.doi.org/10.1074/jbc.272.6.3766			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013634	hybrid			2022-12-25	WOS:A1997WG19200094
J	Li, Q; Lou, XJ; Peyronneau, MA; Straub, PO; Tukey, RH				Li, Q; Lou, XJ; Peyronneau, MA; Straub, PO; Tukey, RH			Expression and functional domains of rabbit liver UDP-glucuronosyltransferase 2B16 and 2B13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CDNAS; GENE; BILIRUBIN; CLONING	Southern blot analysis has demonstrated that the 5' portion of the rabbit liver dexamethasone-inducible UDP-glucuronosyltransferase (UGT) 2B13 RNA is related in sequence to a family of UGT genes (Tukey, R, H., Pendurthi, U. R., Nguyen, N. T., Green, M. D., and Tephly, T. R. (1993) J. Biol. Chem. 268, 15260-15266). To identify these additional gene transcripts, rabbit liver cDNA libraries were screened with a 5' conserved 330-base pair UGT2B13 cDNA fragment, resulting in She isolation and characterization of several rabbit liver UGT cDNAs. One such clone, called pGT11, encodes a putative glycoprotein that is 78% similar to rabbit UGT2B13. The new UGT has been designated UGT2B16. The UGT2B16 gene is expressed as a single 4200-base RNA transcript that is regulated only in adult rabbits. The predicted NH2-terminal 25 amino acids of UGT2B16 are identical to that of rabbit liver UGT2B13, with the remainder of the protein being 77% similar to UGT2B13, Expressed UGT2B16 protein in COS-1 cells was active to ward 4-hydroxybiphenyl, similar to that of UGT2B13. However, UGT2B16 efficiently conjugated 4-hydroxyestrone and 4-tert-butylphenol, substrates that are not efficiently catalyzed by UGT2B13. To further characterize the structural domains of UGT2B16 and UGT2B13, a series of chimeric cDNAs were constructed that contained portions of both UGT2B16 and UGT2B13. chimeric 2B16(300)2B13(531), which contained the amino-terminal UGT2B16 amino acids 1-300 followed by amino acids 301-531 of UGT2B13, as well as chimeric 2B16(358)2B13(531) and 2B16(434)2B13(531) proteins, catalyzed the glucuronidation of 4-hydroxyestrone, indicating that the carboxyl terminus of UGT2B13 could substitute for those same regions on UGT2B16. However, the replacement of the carboxyl end of UGT2B13 with 2B16(300-531) or 2B16(434-531) dramatically impaired the catalytic function of the chimeric proteins. These results indicate that the carboxyl end of UGT2B13 plays an important role in the functional and possible conformational state of the protein.	UNIV CALIF SAN DIEGO,CTR CANC,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANSAL SK, 1980, ANAL BIOCHEM, V109, P321, DOI 10.1016/0003-2697(80)90655-7; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; BURCHELL B, 1995, ADV DRUG METABOLISM, V18, P608; CLARKE DJ, 1994, CONJUGATION DECONJUG, V1, P3; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; Dutton G., 1980, GLUCURONIDATION DRUG, P3; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KINOSAKI M, 1993, CELL STRUCT FUNCT, V18, P41, DOI 10.1247/csf.18.41; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMB JG, 1994, BIOCHEMISTRY-US, V33, P10513, DOI 10.1021/bi00200a037; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; MACKENZIE PI, 1984, BIOCHEM BIOPH RES CO, V122, P1441, DOI 10.1016/0006-291X(84)91252-X; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; POTENZA CL, 1989, J BIOL CHEM, V264, P16222; RITTER JK, 1992, J BIOL CHEM, V267, P3257; SHEPHERD SRP, 1989, BIOCHEM J, V259, P617, DOI 10.1042/bj2590617; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; TUKEY RH, 1993, J BIOL CHEM, V268, P15260; TUKEY RH, 1990, PRINCIPLES DRUG ACTI, V3, P423	19	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3272	3279		10.1074/jbc.272.6.3272	http://dx.doi.org/10.1074/jbc.272.6.3272			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013565	hybrid			2022-12-25	WOS:A1997WG19200025
J	Paumen, MB; Ishida, Y; Muramatsu, M; Yamamoto, M; Honjo, T				Paumen, MB; Ishida, Y; Muramatsu, M; Yamamoto, M; Honjo, T			Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; ACYL-COA SYNTHETASE; SPHINGOMYELIN PATHWAY; FLOW-CYTOMETRY; FACTOR-ALPHA; RAT-HEART; CERAMIDE; EXPRESSION; PROTEIN	To identify cell death-induced genes, we employed a subtractive hybridization approach and isolated a cDNA encoding a mouse homolog of carnitine palmitoyltransferase I (CPT I), an enzyme that resides at the outer mitochondrial membrane and facilitates passage of long-chain fatty acids into mitochondria for beta-oxidation. Induced expression of CPT I mRNA was observed upon programmed cell death in the murine hematopoietic cell lines LyD9 and WEHI-231. To elucidate the role of CPT I in programmed cell death, we examined the effects of long-chain fatty acids and found that the addition of palmitate or stearate to cultured cells led to activation of a death program with a morphology resembling that of apoptosis. Other naturally occurring fatty acids, including myristate and palmitoleate, had no effect, Since both palmitate and stearate are sphingolipid precursors, the effect of these fatty acids on sphingolipid metabolism was tested, Our results indicate that apoptosis induced by palmitate or stearate is correlated with de novo synthesis of ceramide, Inhibition of CPT I by etomoxir enhanced palmitate-induced cell death and led to a further increase in ceramide synthesis.	KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Honjo, Tasuku/N-4470-2016					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; BARTLETT K, 1984, BIOCHEM SOC T, V12, P688, DOI 10.1042/bst0120688; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Britten R J, 1974, Methods Enzymol, V29, P363; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ESSER V, 1993, J BIOL CHEM, V268, P5817; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GOTTSCHALK AR, 1995, EUR J IMMUNOL, V25, P1032, DOI 10.1002/eji.1830250426; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUBOTA M, 1989, JPN J EXP MED, V59, P59; LANIER LL, 1981, J IMMUNOL, V126, P626; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MURTHY MSR, 1994, BIOCHEM J, V304, P31, DOI 10.1042/bj3040031; MURTHY MSR, 1994, J BIOL CHEM, V269, P18283; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RATHEISER K, 1991, METABOLISM, V40, P1185, DOI 10.1016/0026-0495(91)90214-H; Sambrook J., 2002, MOL CLONING LAB MANU; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; VANVELDHOVEN PP, 1995, BIOCHEM MOL BIOL INT, V36, P21; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG E, 1991, J BIOL CHEM, V266, P14486; WEIS BC, 1994, J BIOL CHEM, V269, P18712; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wyllie A H, 1980, Int Rev Cytol, V68, P251	48	303	307	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3324	3329		10.1074/jbc.272.6.3324	http://dx.doi.org/10.1074/jbc.272.6.3324			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013572	hybrid			2022-12-25	WOS:A1997WG19200032
J	Wood, MW; VanDongen, HMA; VanDongen, AMJ				Wood, MW; VanDongen, HMA; VanDongen, AMJ			An alanine residue in the M3-M4 linker lines the glycine binding pocket of the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GLUTAMATE-RECEPTOR; NMDA RECEPTOR; ACID RECEPTOR; TRANSMEMBRANE TOPOLOGY; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PHOSPHORYLATION; SUBUNIT; SITE	While attempting to map a central region in the M3-M4 linker of the N-methyl-D-aspartate receptor NR1 subunit, we found that mutation of a single position, Ala-714, greatly reduced the apparent affinity for glycine, Proximal N-glycosylation localized this region to the extracellular space. Glycine affinities of additional Ala-714 mutations correlated with side chain volume. Substitution of alanine 714 with cysteine did not alter glycine sensitivity, although this mutant was rapidly inhibited by dithionitrobenzoate. Glycine protected the A714C mutant from modification by dithionitrobenzoate, whereas the co-agonist L-glutamate was ineffective. These experiments place Ala-714 in the glycine binding pocket of the N-methyl-D-aspartate receptor, a determination not predicted by previous structural models based on bacterial periplasmic binding protein homology.	DUKE UNIV,DEPT PHARMACOL,DURHAM,NC 27710	Duke University				VanDongen, Antonius/0000-0002-9923-3407	NIMH NIH HHS [MH11278] Funding Source: Medline; NINDS NIH HHS [NS31557] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031557] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; COLQUHOUN D, 1993, NATURE, V366, P510, DOI 10.1038/366510b0; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FAULSTICH H, 1995, METHOD ENZYMOL, V251, P357, DOI 10.1016/0076-6879(95)51139-3; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KANAREK L, 1965, J BIOL CHEM, V240, P2755; Kashiwagi K, 1996, MOL PHARMACOL, V49, P1131; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP BE, 1979, J BIOL CHEM, V254, P2638; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; Koroshetz WJ, 1996, TRENDS PHARMACOL SCI, V17, P227, DOI 10.1016/0165-6147(96)10020-1; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LESTER RAJ, 1993, J NEUROSCI, V13, P1088; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1989, NATURE, V338, P425, DOI 10.1038/338425a0; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCLAUGHLIN JT, 1995, BIOCHEM J, V310, P765, DOI 10.1042/bj3100765; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MOLNAR E, 1994, J NEUROCHEM, V63, P683; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NAKAZAWA K, 1995, NEURON, V15, P697, DOI 10.1016/0896-6273(95)90157-4; OH BH, 1993, J BIOL CHEM, V268, P11348; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PARTIN KM, 1995, NEURON, V14, P833, DOI 10.1016/0896-6273(95)90227-9; PRIESTLEY T, 1994, MOL PHARMACOL, V46, P1191; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROCHE KW, 1994, J BIOL CHEM, V269, P11679; SEKIGUCHI M, 1994, J BIOL CHEM, V269, P14559; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; TAVERNA FA, 1994, J BIOL CHEM, V269, P14159; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; WAFFORD KA, 1995, MOL PHARMACOL, V47, P374; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; Williams K, 1996, MOL PHARMACOL, V50, P701; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; WO ZGL, 1995, J BIOL CHEM, V270, P2000, DOI 10.1074/jbc.270.5.2000; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; YAKEL JL, 1995, P NATL ACAD SCI USA, V92, P1376, DOI 10.1073/pnas.92.5.1376	60	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3532	3537		10.1074/jbc.272.6.3532	http://dx.doi.org/10.1074/jbc.272.6.3532			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013601	hybrid			2022-12-25	WOS:A1997WG19200061
J	Corsi, D; Galluzzi, L; Lecomte, MC; Magnani, M				Corsi, D; Galluzzi, L; Lecomte, MC; Magnani, M			Identification of alpha-spectrin domains susceptible to ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE MATERIAL PROPERTIES; NF-KAPPA-B; ERYTHROCYTE-MEMBRANE; PLASMA-MEMBRANE; PROTEIN LIGASE; MULTIPLE UBIQUITINATION; DEPENDENT PROTEOLYSIS; MULTIUBIQUITIN CHAIN; PROTEASOME PATHWAY; BETA-SPECTRIN	Previously, we demonstrated that alpha-spectrin is a substrate for the ubiquitin system and that this conjugation is a dynamic process (Corsi, D., Galluzzi, L., Crinelli, R., and Magnani, M. (1995) J. Biol. Chem. 270, 8928-8935). In this study, we mapped the sites of ubiquitination on erythrocyte alpha-spectrin. A peptide map of digested alpha-spectrin, previously submitted to in vitro I-125-ubiquitin conjugation, revealed the presence of four distinct labeled bands with M(r) 40,000, 36,000, 29,000, and 25,500. Western blotting experiments using antibodies against each alpha-spectrin domain revealed that only IgG anti-alpha III domain recognized the I-125-labeled ubiquitin peptide of 29 kDa, whereas the IgG anti-alpha V domain recognized the M(r) 40,000 I-125-ubiquitin-labeled peptide. The other two labeled bands of M(r) 36,000 and M(r) 25,500 were identified as tetra and tri multiubiquitin chains. Ubiquitination of the alpha III and alpha V domains was further confirmed by anti-alpha-spectrin domain immunoaffinity chromatography. Endoprotease Lys C-digested spectrin conjugated previously to I-125-ubiquitin was incubated with antibodies against each trypsin-resistant domain of alpha-spectrin. Gamma counting of the radiolabeled antigen-antibody complexes purified by protein A chromatography showed labeling in the IgG anti-alpha III and anti-alpha V complexes alone. Domain alpha III is not associated with any known function, whereas domain alpha V contains the nucleation site for the association of the alpha and beta chains. Ubiquitination of the latter domain suggests a role for ubiquitin in the modulation of the stability, deformability, and viscoelastic properties of the erythrocyte membrane.	UNIV URBINO, G FORNAINI INST BIOL CHEM, I-61029 URBINO, ITALY; FAC MED BICHAT, INSERM, U409, F-75870 PARIS 18, FRANCE	University of Urbino; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Galluzzi, Luca/G-3969-2012; Magnani, Mauro/A-1919-2008	Galluzzi, Luca/0000-0002-1747-526X; Magnani, Mauro/0000-0001-6456-6626				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BARON MD, 1987, BIOCHEM SOC T, V15, P796, DOI 10.1042/bst0150796; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOND U, 1988, J BIOL CHEM, V263, P2384; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COHEN CM, 1983, SEMIN HEMATOL, V20, P141; COHEN CM, 1992, SEMIN HEMATOL, V29, P244; CORSI D, 1995, J BIOL CHEM, V270, P8928, DOI 10.1074/jbc.270.15.8928; DAVIS J, 1983, J BIOL CHEM, V258, P7757; FERBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FORTIER N, 1988, BLOOD, V71, P1427; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOU D, 1994, J BIOL CHEM, V269, P14244; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HUSAIN A, 1984, BIOCHEM BIOPH RES CO, V122, P1194, DOI 10.1016/0006-291X(84)91218-X; HYBICKI AC, 1988, J CLIN INVEST, V81, P255; JI TH, 1980, J BIOL CHEM, V255, P2990; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1984, CELL, V37, P354, DOI 10.1016/0092-8674(84)90364-7; LECOMTE MC, 1990, BRIT J HAEMATOL, V74, P497, DOI 10.1111/j.1365-2141.1990.tb06341.x; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; LU PW, 1985, J BIOL CHEM, V260, P4958; LUNDBERG S, 1992, BIOCHEMISTRY-US, V31, P5665, DOI 10.1021/bi00139a034; LUTZ HV, 1986, J CARDIOVASC PHAR S8, V8, P576; MANNO S, 1995, J BIOL CHEM, V270, P5659, DOI 10.1074/jbc.270.10.5659; MAYER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1089, P141, DOI 10.1016/0167-4781(91)90002-4; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; NIRMALA PB, 1995, BIOCHEM BIOPH RES CO, V213, P24, DOI 10.1006/bbrc.1995.2093; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEDRONI S, 1993, BIOCHEM J, V294, P8841; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHAEFFER JR, 1983, J BIOL CHEM, V258, P3172; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673; SPEISER S, 1982, J BIOL CHEM, V257, P4122; STJOHN T, 1988, SCIENCE, V231, P8845; TAKAKUWA Y, 1988, J CLIN INVEST, V82, P394, DOI 10.1172/JCI113611; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Varshavsky A., 1988, UBIQUITIN, P287; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WILKINSON KD, 1988, UBIQUITIN, P5; WINKELMANN JC, 1993, BLOOD, V81, P3173; ZIEGENHAGEN R, 1988, BIOL CHEM H-S, V369, P1317, DOI 10.1515/bchm3.1988.369.2.1317; ZIEGENHAGEN R, 1990, FEBS LETT, V271, P71, DOI 10.1016/0014-5793(90)80374-R	64	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2977	2983		10.1074/jbc.272.5.2977	http://dx.doi.org/10.1074/jbc.272.5.2977			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006945	hybrid			2022-12-25	WOS:A1997WE66700058
J	Aizawa, S; Nakano, H; Ishida, T; Horie, R; Nagai, M; Ito, K; Yagita, H; Okumura, K; Inoue, J; Watanabe, T				Aizawa, S; Nakano, H; Ishida, T; Horie, R; Nagai, M; Ito, K; Yagita, H; Okumura, K; Inoue, J; Watanabe, T			Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; CYTOPLASMIC DOMAIN; HODGKINS-DISEASE; HIV EXPRESSION; CD30; FAMILY; PROTEIN; CD40; MOLECULE; LIGAND	Signals emanated from CD30 can activate the nuclear factor kappa B (NF kappa B). The two conserved subdomains, D1 and D2, in the C-terminal cytoplasmic region of CD30 were tested for interaction with two tumor necrosis factor receptor-associated factor (TRAF) proteins with NF kappa B activating capacity, TRAF2 and TRAF5. TRAF5 is the newest member of the TRAF family that binds to lymphotoxin beta receptor and CD40. TRAF5, as well as TRAF2, interacted with the D2 subdomain of CD30 in vitro and in vivo. Deletion analysis by the yeast two-hybrid system revealed that the C-terminal 22 and 30 amino acid residues are dispensable for interaction of TRAF5 and TRAF2 with CD30, respectively. Substitution of alanine for threonine at 463 abolished the interaction with TRAF2. Overexpression of the TRAF domain of TRAF2 or TRAF5 showed a dominant negative effect on CD30-mediated NF kappa B activation. Simultaneous expression of these TRAF domains further suppressed the NF kappa B activation, suggesting an interplay of these TRAF proteins. Expression of TRAF2 and TRAF5 mRNA was demonstrated in T- and B-cell lines that express CD30. Taken together, our results indicate that TRAF2 and TRAF5 directly interact with CD30 and are involved in NF kappa B activation by CD30 signaling.	UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; JAPAN SCI & TECHNOL CORP,CORE RES EVOLUT SCI & TECHNOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo; Juntendo University; Japan Science & Technology Agency (JST)				Nakano, Hiroyasu/0000-0003-4843-1427				AIZAWA S, 1996, IN PRESS GENE AMST; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; BARKER SJ, 1996, ONCOGENE, V12, P1; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BISWAS P, 1995, IMMUNITY, V2, P587; Bowen MA, 1996, J IMMUNOL, V156, P442; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; FALINI B, 1995, BLOOD, V85, P1; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; GRUSS HJ, 1994, BLOOD, V83, P2045; HARPER JW, 1993, CELL, V75, P805; HU HM, 1994, J BIOL CHEM, V269, P30069; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; MAGGI E, 1995, IMMUNITY, V3, P251, DOI 10.1016/1074-7613(95)90094-2; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; NAWROCKI JF, 1988, J IMMUNOL, V141, P672; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PURSCHKE WG, 1994, BIOTECHNIQUES, V16, P264; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4	28	175	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2042	2045						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999898				2022-12-25	WOS:A1997WD67900004
J	Kim, TS; Sundaresh, CS; Feinstein, SI; Dodia, C; Skach, WR; Jain, MK; Nagase, T; Seki, N; Ishikawa, K; Nomura, N; Fisher, AB				Kim, TS; Sundaresh, CS; Feinstein, SI; Dodia, C; Skach, WR; Jain, MK; Nagase, T; Seki, N; Ishikawa, K; Nomura, N; Fisher, AB			Identification of a human cDNA clone for lysosomal type Ca2+-independent phospholipase A(2) and properties of the expressed protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE; ACTIVATING-FACTOR ACETYLHYDROLASE; RAT LUNG; PURIFICATION; GLYCEROPHOSPHOLIPIDS; PHOSPHATIDYLCHOLINE; INHIBITION; CELLS; BRAIN; RNA	A Ca2+-independent phospholipase A(2) (PLA(2)) maximally active at pH 4 and specifically inhibited by the transition-state analogue 1-hexadecyI-3-trifluoroethyl-glycero-sn-2-phosphomethanol (MJ33) was isolated from rat lungs. The sequence for three internal peptides (35 amino acids) was used to identify a 1653-base pair cDNA clone (HA0683) from a human myeloblast cell Line. The deduced protein sequence of 224 amino acids contained a putative motif (GXSXG) for the catalytic site of a serine hydrolase, but showed no significant homology to known phospholipases, Translation of mRNA produced from this clone in both a wheat germ system and Xenopus oocytes showed expression of PLA(2), activity with properties similar to the rat lung enzyme. Apparent kinetic constants for PLA(2) with dipalmitoylphosphatidylcholine as substrate were K-m = 0.25 mar and V-max = 1.89 nmol/h. Activity with alkyl ether phosphatidylcholine as substrate was decreased significantly compared with diacylphosphatidylcholine. Significant lysophospholipase, phospholipase A(1), or 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine acetylhydrolase activity was not observed. Enzyme activity was insensitive to p-bromo-phenacyl bromide, bromoenol lactone, trifluoromethylarachidonoyl ketone, mercaptoethanol, and ATP, but was inhibited by MJ33 and diethyl p-nitrophenyl phosphate, a serine protease inhibitor. SDS-polyacrylamide gel electrophoresis with autoradiography of the translated [S-35]methionine-labeled protein confirmed a molecular mass of 25.8 kDa, in good agreement with the enzyme isolated from rat lung. By Northern blot analysis, mRNA corresponding to this clone was present in both rat lung and isolated rat granular pneumocytes. These results represent the first molecular cloning of a cDNA for the lysosomal type Ca2+-independent phospholipase A(2) group of enzymes.	UNIV PENN,SCH MED,INST ENVIRONM MED,MED CTR,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,INST HUMAN GENE THERAPY,MED CTR,PHILADELPHIA,PA 19104; UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716; KAZUSA DNA RES INST,KISARAZU,CHIBA 292,JAPAN	University of Pennsylvania; University of Pennsylvania; University of Delaware; Kazusa DNA Research Institute					NCI NIH HHS [CA 01614] Funding Source: Medline; NHLBI NIH HHS [HL 19737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; ALLEN G, 1981, SEQUENCING PROTEIN P, P174; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BARTH LG, 1959, J EMBRYOL EXP MORPH, V7, P210; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHANDER A, 1982, BIOCHEM J, V208, P651, DOI 10.1042/bj2080651; CHINOY MR, 1993, AM J PHYSIOL, V264, pL300, DOI 10.1152/ajplung.1993.264.3.L300; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DREWENDA AS, 1993, TRENDS BIOCHEM SCI, V18, P20; FISHER AB, 1992, BIOCHEM J, V288, P407, DOI 10.1042/bj2880407; FISHER AB, 1994, AM J PHYSIOL, V267, pL335, DOI 10.1152/ajplung.1994.267.3.L335; Fisher AB, 1996, J LIPID RES, V37, P1057; FRANSON RC, 1973, J CELL BIOL, V56, P621, DOI 10.1083/jcb.56.3.621; GOLAZ O, 1993, ELECTROPHORESIS, V14, P1223, DOI 10.1002/elps.11501401183; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HEATH MF, 1976, BIOCHIM BIOPHYS ACTA, V441, P443, DOI 10.1016/0005-2760(76)90241-1; HOCHSTRASSER DF, 1992, ELECTROPHORESIS, V13, P992, DOI 10.1002/elps.11501301201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITNICK MA, 1980, CLIN CHEM, V26, P277; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OHTA M, 1972, BIOCHIM BIOPHYS ACTA, V280, P552; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; SLOTBOOM AJ, 1982, PHOSPHOLIPIDS NEW BI, V4, P359; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; WANG R, 1994, BIOCHEM J, V304, P131, DOI 10.1042/bj3040131; WOLF RA, 1985, J BIOL CHEM, V260, P7295	36	111	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2542	2550						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999971				2022-12-25	WOS:A1997WD67900077
J	Shi, DQ; Winston, JH; Blackburn, MR; Datta, SK; Hanten, G; Kellems, RE				Shi, DQ; Winston, JH; Blackburn, MR; Datta, SK; Hanten, G; Kellems, RE			Diverse genetic regulatory motifs required for murine adenosine deaminase gene expression in the placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; ELEMENT-BINDING PROTEIN; RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; DEVELOPMENTAL EXPRESSION; TRANSGENIC MICE; NERVOUS-SYSTEM; ALPHA-SUBUNIT; LACTOGEN-I; TISSUE	Murine adenosine deaminase (ADA) is a ubiquitous purine catabolic enzyme whose expression is subject to developmental and tissue-specific regulation. ADA is enriched in trophoblast cells of the chorioallantoic placenta and is essential for embryonic and fetal development. To begin to understand the genetic pathway controlling Ada gene expression in the placenta, we have identified and characterized a 770-base pair fragment located 5.4 kilobase pairs upstream of the Ada transcription initiation site, which directs reporter gene expression to the placenta of transgenic mice. The expression pattern of the reporter gene reflected that of the endogenous Ada gene in the placenta. Sequence analysis revealed potential binding sites for bHLH and GATA transcription factors. DNase I footprinting defined three protein binding regions, one of which was placenta-specific. Mutations in the potential protein binding sites and footprinting regions resulted in loss of placental expression in transgenic mice. These findings indicate that multiple protein binding motifs are necessary for Ada expression in the placenta.	BAYLOR COLL MED,TEXAS MED CTR,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Blackburn, Michael/0000-0002-1394-9966	NICHD NIH HHS [HD34130, HD07843] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; Blackburn MR, 1996, J BIOL CHEM, V271, P15203, DOI 10.1074/jbc.271.25.15203; BRADY TG, 1965, COMP BIOCHEM PHYSIOL, V14, P101, DOI 10.1016/0010-406X(65)90011-3; BRANDY HJM, 1989, FEBS LETT, V257, P451; Brickner AG, 1995, GENE, V167, P261, DOI 10.1016/0378-1119(95)00673-7; CALZONETTI T, 1995, DEV BIOL, V171, P615, DOI 10.1006/dbio.1995.1309; CAMPBELL WJ, 1991, PLACENTA, V12, P227, DOI 10.1016/0143-4004(91)90004-Y; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; CARSON DA, 1977, P NATL ACAD SCI USA, V74, P5677, DOI 10.1073/pnas.74.12.5677; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARIA TN, 1990, DEV BIOL, V141, P279, DOI 10.1016/0012-1606(90)90384-U; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; FREDERIK.S, 1966, ARCH BIOCHEM BIOPHYS, V113, P383, DOI 10.1016/0003-9861(66)90202-5; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HERSHFIELD MS, 1979, J CLIN INVEST, V63, P807, DOI 10.1172/JCI109367; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HONG L, 1991, BIOL REPROD, V44, P83, DOI 10.1095/biolreprod44.1.83; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; NG YK, 1994, DEVELOPMENT, V120, P3257; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; STEGER DJ, 1993, MOL ENDOCRINOL, V7, P1579, DOI 10.1210/me.7.12.1579; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; ULLMAN B, 1981, J BIOL CHEM, V256, P848; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; Viegas-Pequignot E., 1992, PRACTICAL APPROACHES, P137; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; Winston JH, 1996, SOMAT CELL MOLEC GEN, V22, P261, DOI 10.1007/BF02369566; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; YAMADA K, 1995, J BIOL CHEM, V270, P25064, DOI 10.1074/jbc.270.42.25064; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; ZAHRADKA P, 1989, EXP CELL RES, V185, P8, DOI 10.1016/0014-4827(89)90032-3	56	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2334	2341						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999942	hybrid			2022-12-25	WOS:A1997WD67900048
J	Wu, GD; Lai, EJ; Huang, N; Wen, XM				Wu, GD; Lai, EJ; Huang, N; Wen, XM			Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin-8 promoter - The role of Oct-1 as a transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SUCRASE-ISOMALTASE GENE; POU-DOMAIN; INFLAMMATORY CYTOKINES; EXPRESSION; ASSOCIATIONS; MECHANISMS; ACTIVATION; ENHANCER; COMPLEX	Interleukin-8 (IL-8), a potent neutrophil chemoattractant, can be expressed at high levels by many different cell types after immune stimulation, In contrast, expression of IL-8 in these same cells is virtually absent in the unstimulated state, demonstrating the tight regulation of the IL-8 gene. Although much is known about how this gene is transcriptionally activated after immune stimulation, little is known about the regulation of the IL-8 promoter in the absence of immune activation, In this study we examine how the IL-8 promoter is transcriptionally regulated in the uninduced state and how these mechanisms are altered in response to immune stimulation by IL-1 beta. Electrophoretic mobility shift assay and transfection studies show that the IL-8 promoter is transcriptionally regulated by both positive and negative elements. Although the nuclear factor-kappa B (NF kappa B) element regulates only inducible activity of the IL-8 promoter in response to stimulation with IL-1 beta, the AP-1 and CCAAT/Enhancer-binding Protein (C/EBP) elements influence both basal and inducible activities. In contrast to these three positive regulatory elements, the binding of the ubiquitously expressed POU-homeodomain transcription factor, Oct-1, strongly represses transcriptional activity of the IL-8 promoter by binding independently to an element overlapping that of C/EBP.	UNIV PENN,SCH MED,DEPT INTERNAL MED,DIV GASTROENTEROL,PHILADELPHIA,PA 19104	University of Pennsylvania					NIDDK NIH HHS [DK47709] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047709] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1992, INTERLEUKINS MOL BIO, P299; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2031; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAUSHANSKY K, 1994, J IMMUNOL, V152, P1812; KUNSCH C, 1994, J IMMUNOL, V153, P153; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MATSUSHIMA K, 1992, CHEM IMMUNOL, V51, P236; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Sambrook J., 2002, MOL CLONING LAB MANU; SIBBET GJ, 1995, J VIROL, V69, P4006, DOI 10.1128/JVI.69.7.4006-4011.1995; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THORNTON AJ, 1990, J IMMUNOL, V144, P2609; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WU GD, 1994, J BIOL CHEM, V269, P17080; WU GD, 1992, J BIOL CHEM, V267, P7863; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	31	201	204	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2396	2403						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999951				2022-12-25	WOS:A1997WD67900057
J	Brunton, VG; Ozanne, BW; Paraskeva, C; Frame, MC				Brunton, VG; Ozanne, BW; Paraskeva, C; Frame, MC			A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer	ONCOGENE			English	Article						EGF receptor; c-Src; FAK; colon cancer	PROTEIN-TYROSINE KINASE; CARCINOMA CELL-LINE; FACTOR-ALPHA; FAMILY KINASES; FACTOR EGF; PP60C-SRC; EXPRESSION; ACTIVATION; MIGRATION; PHOSPHORYLATION	We have examined the function of the epidermal growth factor (EGF) receptor, c-Src and focal adhesion kinase (FAK) in the progression of colon cancer using an in vitro progression model. A non-tumorigenic cell line was derived from a premalignant colonic adenoma (PC/AA) from which a clonogenic variant was established (AA/C1). Following sequential treatment with sodium butyrate and the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine an anchorage-independent line was isolated which, with time in culture, became tumorigenic when injected into athymic nude mice (AA/C1/SB10). We have shown that both EGF receptor and FAK protein levels were elevated in the carcinoma cells as compared to the adenoma cells, while the expression and activity of c-Src were unaltered during the adenoma to carcinoma transition. EGP induced the movement of the carcinoma cells into a reconstituted basement membrane which was not seen with the premalignant adenoma cells. This increased motility was accompanied by an EGF-induced increase in c-Src kinase activity, relocalisation of c-Src to the cell periphery and phosphorylation of FAK in the carcinoma cells but not in the adenoma cells. This suggests that c-Src plays a role in the biological behaviour of colonic carcinoma cells induced by migratory factors such as EGF, perhaps acting in conjunction with FAK to regulate focal adhesion turnover and tumour cell motility. Furthermore, although c-Src has been implicated in colonic tumour progression, we demonstrate here that in the adenoma to carcinoma in vitro model c-Src is not the driving force for this progression but co-operates with other molecules in carcinoma development.	UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol	Brunton, VG (corresponding author), BEATSON INST CANC RES,CRC,BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,LANARK,SCOTLAND.							AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARDIELLO F, 1993, INT J CANCER, V54, P952; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHAKRABARTY S, 1995, CLIN EXP METASTAS, V13, P191, DOI 10.1007/BF00132207; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; FUJII K, 1995, EXP CELL RES, V216, P261, DOI 10.1006/excr.1995.1032; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KARAMERIS A, 1993, PATHOL RES PRACT, V189, P133, DOI 10.1016/S0344-0338(11)80082-8; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANNING AM, 1991, ONCOGENE, V6, P1471; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OWENS LV, 1995, CANCER RES, V55, P2752; PLUMB JA, 1989, CANCER RES, V49, P4435; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RAJAGOPAL S, 1995, INT J CANCER, V62, P661, DOI 10.1002/ijc.2910620603; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; SUNDARESHAN P, 1991, CANCER COMMUN, V3, P149, DOI 10.3727/095535491820873380; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; WATKINS LF, 1991, INT J CANCER, V47, P455, DOI 10.1002/ijc.2910470325; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063	48	106	119	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					283	293		10.1038/sj.onc.1200827	http://dx.doi.org/10.1038/sj.onc.1200827			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018114				2022-12-25	WOS:A1997WD51600004
J	Grove, AD; Kessler, FK; Metz, RP; Ritter, JK				Grove, AD; Kessler, FK; Metz, RP; Ritter, JK			Identification of a rat oltipraz-inducible UDP-glucuronosyltransferase (UGT1A7) with activity towards benzo(alpha)pyrene-7,8-dihydrodiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CARCINOGENESIS; HUMAN HEPATOCYTES; PRIMARY CULTURES; MOLECULAR-BASIS; MESSENGER-RNA; GENE-COMPLEX; CELL-LINE; GLUCURONIDATION; BENZO<A>PYRENE; METABOLISM	Previous work has shown that polycyclic aromatic hydrocarbons and oltipraz both induce an unidentified rat liver UDP-glucuronosyltransferase with activity to ward benzo(a)pyrene-7,8 diol, the proximate carcinogenic form of benzo(a)pyrene. Here we report the isolation of a benzo(a)pyrene-7,8-diol transferase-encoding cDNA, LC14, from an adult rat hepatocyte-derived cell line (RALA255-10G LCS-3). The predicted amino acid sequence of LC14 is nearly identical (5 differences out of 531 residues) to that deduced from UGT1A7, recently cloned at the genomic DNA level (Emi, Y., Ikushiro, S., and Kyanagi, T. (1995) J. Biochem. (Tokyo) 117, 392-399). Northern analysis of RNA from female F344 rat liver and LCS-3 cells revealed over a 40-fold and 4.4-fold enhancement by oltipraz treatment, respectively. Benzo(a)pyrene 7,8-diol glucuronidating activity was detected (0.4 nmol/10(6) cells/16 h) in AHH-1 cells transfected with the LC14 expression vector, pMF6-LC14-3. The LC14 encoded transferase exhibited even higher activity to ward certain benzo(a)pyrene phenols, including the major 3 and 9-phenol metabolites (4.1 and 2.8 nmol/10(6) cells/16 h, respectively). The K-m of the enzyme for (-)trans benzo(a)pyrene 7,8-diol and 3-OH-BP was 15.5 and 12.3 mu M, respectively. Northern analyses of total RNA revealed expression of LC14 or LC14 like RNA in all extrahepatic tissues tested. Marked inducibility by oltipraz was observed only in liver and (to a lesser extent) intestine. The results suggest that induction of UGT1A7 may explain the increased glucuronidating activities toward benzo(a)pyrene-7,8 diol and other metabolites that occur following treatment with polycyclic aromatic hydrocarbon-type inducing agents and oltipraz. UGT1A7 appears to represent an important cellular chemoprotective enzyme which mediates conjugation and elimination of toxic benzo(a)pyrene metabolites.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University				Metz, Richard/0000-0002-9876-3385	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES007762] Funding Source: NIH RePORTER; NIEHS NIH HHS [1R29ES07762-01] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOCK KW, 1980, BIOCHEM PHARMACOL, V29, P495, DOI 10.1016/0006-2952(80)90368-8; BOCK KW, 1991, CRIT REV BIOCHEM MOL, V26, P129, DOI 10.3109/10409239109081125; BOCK KW, 1988, BIOCHEM PHARMACOL, V37, P1439, DOI 10.1016/0006-2952(88)90004-4; BOCK KW, 1987, ARCH TOXICOL, V60, P22, DOI 10.1007/BF00296941; BOCK KW, 1984, BIOCH BASIS CHEM CAR, P13; BURKE MD, 1977, J BIOL CHEM, V252, P6424; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU JY, 1981, J CELL BIOL, V89, P216, DOI 10.1083/jcb.89.2.216; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; DAVIES RL, 1989, CARCINOGENESIS, V10, P885, DOI 10.1093/carcin/10.5.885; EGNER PA, 1994, CARCINOGENESIS, V15, P177, DOI 10.1093/carcin/15.2.177; EMI Y, 1995, J BIOCHEM, V117, P392, DOI 10.1093/jb/117.2.392; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOWERSGEARY L, 1995, CARCINOGENESIS, V16, P2707, DOI 10.1093/carcin/16.11.2707; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; HU ZH, 1992, J PHARMACOL EXP THER, V263, P334; HU ZH, 1994, TOXICOL APPL PHARM, V127, P306, DOI 10.1006/taap.1994.1166; International Agency for Research on Cancer,, 1983, IARC MON EV CARC RIS; IYANAGI T, 1991, J BIOL CHEM, V266, P24048; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; JIN CJ, 1993, CARCINOGENESIS, V14, P2637, DOI 10.1093/carcin/14.12.2637; KESSLER FK, 1996, IN PRESS CARCINOGENE; MACKENZIE PI, 1993, CANCER RES, V53, P1529; MONTEITH DK, 1990, XENOBIOTICA, V20, P753, DOI 10.3109/00498259009046890; MONTEITH DK, 1987, CARCINOGENESIS, V8, P983, DOI 10.1093/carcin/8.7.983; MUNZEL PA, 1994, BIOCHEM PHARMACOL, V47, P1445, DOI 10.1016/0006-2952(94)90345-X; NEMOTO N, 1976, BIOCHEM PHARMACOL, V25, P1221, DOI 10.1016/0006-2952(76)90373-7; ORZECHOWSKI A, 1994, CARCINOGENESIS, V15, P1549, DOI 10.1093/carcin/15.8.1549; PENNING TM, 1993, CHEM-BIOL INTERACT, V89, P1, DOI 10.1016/0009-2797(93)03203-7; RAUNIO H, 1995, GENE, V159, P113, DOI 10.1016/0378-1119(94)00448-2; ROBERTSON JA, 1986, J BIOL CHEM, V261, P5794; ROYCHOWDHURY J, 1991, J BIOL CHEM, V266, P18294; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; Sambrook J., 2002, MOL CLONING LAB MANU; THAKKER DR, 1985, BIOACTIVATION FOREIG, P178; VIENNEAU DS, 1995, CANCER RES, V55, P1045	36	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1621	1627		10.1074/jbc.272.3.1621	http://dx.doi.org/10.1074/jbc.272.3.1621			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999837	hybrid			2022-12-25	WOS:A1997WD05800035
J	Tai, KK; Wang, KW; Goldstein, SAN				Tai, KK; Wang, KW; Goldstein, SAN			MinK potassium channels are heteromultimeric complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DEPENDENT K+ CHANNEL; I-SK PROTEIN; XENOPUS-OOCYTES; ISK CHANNEL; PORE; EXPRESSION; MUTATIONS; MEMBRANE; CYSTEINE	MinK is a transmembrane protein of 130 amino acids found in the kidney, heart, and vestibular system of mammals. Its expression in Xenopus laevis oocytes induces a voltage-dependent potassium current similar to that Seen in vivo. Indirect evidence has fueled speculation that function requires association of MinK and another protein endogenous to oocytes and native tissues. In this report, we show that direct covalent modification of an oocyte membrane protein alters properties of the MinK ion conduction pore; modified channels exhibit decreased potassium conduction and increased permeability to sodium and cesium. The modifying reagents, two membrane-impermeant, sulfhydryl-specific methanethiosulfonate derivatives, react only from the extracellular solution at rates that are determined by the conformational state of the channel. These findings indicate that MinK is intimately associated with an oocyte protein whose exposure to the external solution changes during channel gating and which acts with MinK to establish ion conduction pore function.	YALE UNIV,SCH MED,BOYER CTR MOL MED,DEPT PEDIAT,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOL MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06536	Yale University; Yale University			Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; CUI J, 1994, J GEN PHYSIOL, V104, P87, DOI 10.1085/jgp.104.1.87; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; Goldstein SAN, 1996, NEURON, V16, P717, DOI 10.1016/S0896-6273(00)80092-6; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HAUSDORFF SF, 1991, BIOCHEMISTRY-US, V30, P3341, DOI 10.1021/bi00227a025; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HICE RE, 1994, PFLUG ARCH EUR J PHY, V426, P139, DOI 10.1007/BF00374681; Hille B., 1992, IONIC CHANNELS EXCIT; INAGAKI N, 1995, SCIENCE, V270, P1160; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; LIU Y, 1996, NEURON, V16, P85; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MARCUS DC, 1994, AM J PHYSIOL, V267, pC857, DOI 10.1152/ajpcell.1994.267.3.C857; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Shimbo K, 1995, BIOPHYS J, V69, P1819, DOI 10.1016/S0006-3495(95)80052-4; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SWANSON R, 1993, SEMIN NEUROSCI, V5, P117; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TZOUNOPOULOS T, 1995, P NATL ACAD SCI USA, V92, P9593, DOI 10.1073/pnas.92.21.9593; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; VARNUM MD, 1993, P NATL ACAD SCI USA, V90, P11528, DOI 10.1073/pnas.90.24.11528; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4; ZHANG ZJ, 1994, P NATL ACAD SCI USA, V91, P1766, DOI 10.1073/pnas.91.5.1766	43	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1654	1658		10.1074/jbc.272.3.1654	http://dx.doi.org/10.1074/jbc.272.3.1654			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999841	hybrid, Green Published			2022-12-25	WOS:A1997WD05800039
J	Zenklusen, JC; Hodges, LC; Conti, CJ				Zenklusen, JC; Hodges, LC; Conti, CJ			Loss of heterozygosity on murine chromosome 6 in two-stage carcinogenesis: Evidence for a conserved tumor suppressor gene	ONCOGENE			English	Article						human chromosome 7; mitotic recombination; skin tumors; tumor suppressor gene; trisomy	POLYMERASE CHAIN-REACTION; MOUSE SKIN TUMORS; SQUAMOUS-CELL; MICROSATELLITE INSTABILITY; MITOTIC RECOMBINATION; ALLELOTYPE ANALYSIS; MALIGNANT-TUMORS; FREQUENT LOSS; CARCINOMAS; CANCER	We have recently demonstrated that loss of heterozygosity (LOH) at 7q31 is frequent in many kinds of human primary tumors and that introducing a single human chromosome (hchr) 7 into a murine squamous cell carcinoma (SCC)-derived cell line suppresses the malignant phenotype. To investigate whether the putative tumor suppressor gene on hchr 7 is conserved in mice, we studied LOH on mouse chromosome (mchr) 6 in chemically induced SCCs in (C57BL x DBA2) F1 (B6D2F1) females. LOH analysis was performed by polymerase chain reaction amplification of 17 (CA), microsatellite repeats in mchr 6 A1-C3. As expected, all the B6D2F1-derived tumors were informative for all the locus assayed. The highest percentage of LOH in the hchr 7q-homologous segment was found at D6Mit50 (60.0%) and the other markers in this segment had LOH incidences normally distributed around the peak. The high incidence of LOH in the tumors studied suggests that a tumor suppressor gene relevant to the development of epithelial cancers is present on mchr 6 A2. As this segment is homologous with hchr 7q31, these data suggest that the putative tumor suppressor gene is conserved in the two species and explains the suppression of tumorigenicity when a single hchr 7 is introduced to a murine SCC cell line.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV SCI PK RES, SMITHVILLE, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA53123] Funding Source: Medline; PHS HHS [PP 57596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON GM, 1993, AM J HEMATOL, V42, P171, DOI 10.1002/ajh.2830420206; ALDAZ CM, 1986, CANCER GENET CYTOGEN, V20, P223, DOI 10.1016/0165-4608(86)90077-4; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; AN HX, 1995, INT J CANCER, V64, P291, DOI 10.1002/ijc.2910640502; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; ATKIN NB, 1991, CANCER GENET CYTOGEN, V52, P113, DOI 10.1016/0165-4608(91)90061-X; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BOWDEN GT, 1994, CANCER RES, V54, pS1882; Boyd J A, 1991, Basic Life Sci, V57, P183; CANZIAN F, 1994, CANCER RES, V54, P6315; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; CONTI CJ, 1992, PROG CLIN BIOL RES, V376, P85; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; EMERIT I, 1989, MUTAT RES, V214, P97, DOI 10.1016/0027-5107(89)90202-9; HEGI ME, 1994, CANCER RES, V54, P6257; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; KEMP CJ, 1993, CANCER RES, V53, P6022; KERE J, 1989, BLOOD, V73, P230; KIBBELAAR RE, 1993, BLOOD, V82, P904; LEHMAN TA, 1991, ENVIRON HEALTH PERSP, V93, P133, DOI 10.2307/3431181; LOEB LA, 1994, CANCER RES, V54, P5059; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MILLER DR, 1987, CANCER RES, V47, P1935; MIYASAKA K, 1995, MOL CARCINOGEN, V13, P37, DOI 10.1002/mc.2940130107; MORI N, 1989, CANCER RES, V49, P5130; NEUBAUER A, 1992, ONCOGENE, V7, P1019; OHSUMI T, 1995, BIOCHEM BIOPH RES CO, V212, P632, DOI 10.1006/bbrc.1995.2016; OSELLA P, 1992, CANCER GENET CYTOGEN, V59, P73, DOI 10.1016/0165-4608(92)90162-2; SASAKI K, 1995, CANCER RES, V55, P3513; SCHREIBER G, 1990, AM J PATHOL, V137, P653; SHIRAISHI Y, 1985, EMBO J, V4, P2553, DOI 10.1002/j.1460-2075.1985.tb03970.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; *WHIT I MIT CTR GE, 1994, GEN MAP MOUS; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YUSPA SH, 1994, INVEST DERMATOL S, V103, pS90; ZAR JH, 1991, BIOSTAT ANAL, P102; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	45	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					109	114		10.1038/sj.onc.1200806	http://dx.doi.org/10.1038/sj.onc.1200806			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010237				2022-12-25	WOS:A1997WB76000010
J	Beniac, DR; Luckevich, MD; Czarnota, GJ; Tompkins, TA; Ridsdale, RA; Ottensmeyer, FP; Moscarello, MA; Harauz, G				Beniac, DR; Luckevich, MD; Czarnota, GJ; Tompkins, TA; Ridsdale, RA; Ottensmeyer, FP; Moscarello, MA; Harauz, G			Three-dimensional structure of myelin basic protein .1. Reconstruction via angular reconstitution of randomly oriented single particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CENTRAL-NERVOUS-SYSTEM; AMINO ACID SEQUENCE; SECONDARY STRUCTURE; MULTIPLE-SCLEROSIS; AQUEOUS-SOLUTION; CHARGE MICROHETEROGENEITY; NEUTRAL PHOSPHOLIPIDS; PROJECTION DIRECTIONS; MEMBRANE INTERACTIONS; UNILAMELLAR VESICLES	Myelin basic protein (MBP) plays an integral role in the structure and function of the myelin sheath. In humans and cattle, an 18.5-kDa isoform of MBP predominates and exists as a multitude of charge isomers resulting from extensive and varied post-translational modifications. We have purified the least modified isomer (named C1) of the 18.5-kDa isoform of MBP from fresh bovine brain and imaged this protein as negatively stained single particles adsorbed to a lipid monolayer. Under these conditions, MBP/C1 presented diverse projections whose relative orientations were determined using an iterative quaternion-assisted angular reconstitution scheme. In different buffers, one with a low salt and the other with a high salt concentration, the conformation of the protein was slightly different. hn low salt buffer, the three-dimensional reconstruction, solved to a resolution of 4 nm, had an overall ''C'' shape of outer radius 5.5 nm, inner radius 3 nm, overall circumference 15 nm, and height 4.7 nm. The three-dimensional reconstruction of the protein in high salt buffer, solved to a resolution of 2.8 nm, was essentially the same in terms of overall dimensions but had a somewhat more compact architecture. These results are the first structures achieved directly for this unusual macromolecule, which plays a key role in the development of multiple sclerosis.	UNIV GUELPH, DEPT MOL BIOL & GENET, GUELPH, ON N1G 2W1, CANADA; ONTARIO CANC INST, DEPT BIOL MOL & STRUCT, TORONTO, ON M5G 2M9, CANADA; HOSP SICK CHILDREN, DEPT BIOCHEM RES, TORONTO, ON M5G 1X8, CANADA	University of Guelph; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Tompkins, Thomas A./0000-0002-2990-2265; Harauz, George/0000-0002-6114-9947				AFSHARRAD T, 1987, BIOCHIM BIOPHYS ACTA, V915, P101, DOI 10.1016/0167-4838(87)90129-4; ANTHONY JS, 1971, BIOCHIM BIOPHYS ACTA, V243, P429, DOI 10.1016/0005-2795(71)90011-0; AOYAMA K, 1995, ULTRAMICROSCOPY, V57, P345, DOI 10.1016/0304-3991(94)00192-P; BACH D, 1985, BIOCHIM BIOPHYS ACTA, V819, P225, DOI 10.1016/0005-2736(85)90177-4; BazettJones DP, 1996, NUCLEIC ACIDS RES, V24, P321, DOI 10.1093/nar/24.2.321; BELLINI T, 1986, ITAL J BIOCHEM, V35, pA131; BENIAC DR, 1996, IN PRESS SCANNING S, V11; BOGGS JM, 1981, BIOCHEMISTRY-US, V20, P1065, DOI 10.1021/bi00508a004; BOGGS JM, 1977, BIOCHEMISTRY-US, V16, P5420, DOI 10.1021/bi00644a003; BRADY GW, 1981, BIOPHYS J, V34, P345, DOI 10.1016/S0006-3495(81)84853-9; BREMER A, 1992, ULTRAMICROSCOPY, V46, P85, DOI 10.1016/0304-3991(92)90008-8; BRUNNER C, 1989, J NEUROCHEM, V52, P296, DOI 10.1111/j.1471-4159.1989.tb10930.x; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CARNEGIE PR, 1971, BIOCHEM J, V123, P57, DOI 10.1042/bj1230057; CAVATORTA P, 1994, BIOPHYS J, V66, P1174, DOI 10.1016/S0006-3495(94)80899-9; CHAN CK, 1987, BIOCHEM BIOPH RES CO, V152, P1468; CHAN KFJ, 1990, J NEUROSCI RES, V25, P535, DOI 10.1002/jnr.490250410; CHAPMAN BE, 1976, BIOCHEM BIOPH RES CO, V73, P758, DOI 10.1016/0006-291X(76)90874-3; CHEIFETZ S, 1985, BIOCHEMISTRY-US, V24, P1909, DOI 10.1021/bi00329a016; CHOU FCH, 1976, J BIOL CHEM, V251, P2671; CZARNOTA GJ, 1994, J STRUCT BIOL, V113, P35, DOI 10.1006/jsbi.1994.1030; Czarnota GJ, 1996, J BIOL CHEM, V271, P3677; DEBER CM, 1991, CLIN BIOCHEM, V24, P113, DOI 10.1016/0009-9120(91)90421-A; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DEIBLER GE, 1990, PROTEINS, V7, P32, DOI 10.1002/prot.340070104; DEMEL RA, 1973, BIOCHIM BIOPHYS ACTA, V311, P507, DOI 10.1016/0005-2736(73)90126-0; DOBROWOLSKI Z, 1986, EUR J CELL BIOL, V42, P17; EDWARDS AM, 1989, J NEUROSCI RES, V22, P97, DOI 10.1002/jnr.490220113; EPAND RM, 1974, BIOCHEMISTRY-US, V13, P1264, DOI 10.1021/bi00703a032; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EYLAR EH, 1971, J BIOL CHEM, V246, P5770; FARROW NA, 1992, J OPT SOC AM A, V9, P1749, DOI 10.1364/JOSAA.9.001749; FIDELIO GD, 1982, BIOCHEM J, V203, P717, DOI 10.1042/bj2030717; FRANK J, 1989, ELECTRON MICROSC REV, V2, P53, DOI 10.1016/0892-0354(89)90010-5; FRANK J, 1996, 3 DIMENSIONAL ELECT, P104; FRASER PE, 1985, BIOCHEMISTRY-US, V24, P4593, DOI 10.1021/bi00338a017; FRASER PE, 1989, BIOCHIM BIOPHYS ACTA, V983, P23, DOI 10.1016/0005-2736(89)90375-1; GOLDS EE, 1978, J BIOL CHEM, V253, P8162; GOLUBOVICH V P, 1989, Biophysics (English Translation of Biofizika), V34, P395; GOW A, 1989, BIOCHEM J, V257, P535, DOI 10.1042/bj2570535; HARAUZ G, 1988, METHOD ENZYMOL, V164, P35; HARAUZ G, 1986, OPTIK, V73, P146; INOUYE H, 1991, J NEUROSCI RES, V28, P1, DOI 10.1002/jnr.490280102; INOUYE H, 1984, BIOCHIM BIOPHYS ACTA, V776, P197, DOI 10.1016/0005-2736(84)90209-8; JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7; KENIRY MA, 1981, BIOCHIM BIOPHYS ACTA, V668, P107, DOI 10.1016/0005-2795(81)90154-9; KENIRY MA, 1979, BIOCHIM BIOPHYS ACTA, V578, P381, DOI 10.1016/0005-2795(79)90169-7; KIES MW, 1965, ANN NY ACAD SCI, V122, P161; KIRSCHNER DA, 1989, J NEUROCHEM, V53, P1599, DOI 10.1111/j.1471-4159.1989.tb08558.x; Koshy KM, 1996, BBA-PROTEIN STRUCT M, V1293, P23, DOI 10.1016/0167-4838(95)00229-4; KRIGBAUM WR, 1975, BIOCHEMISTRY-US, V14, P2542, DOI 10.1021/bi00682a038; LAMPE PD, 1982, BIOCHIM BIOPHYS ACTA, V693, P320, DOI 10.1016/0005-2736(82)90438-2; MACNAUGHTAN W, 1985, BIOCHIM BIOPHYS ACTA, V818, P132, DOI 10.1016/0005-2736(85)90556-5; MAGGIO B, 1989, CHEM PHYS LIPIDS, V51, P127, DOI 10.1016/0009-3084(89)90046-7; MAGGIO B, 1992, BIOCHIM BIOPHYS ACTA, V1112, P105, DOI 10.1016/0005-2736(92)90260-S; MARTENSON RE, 1986, J NEUROCHEM, V46, P1612, DOI 10.1111/j.1471-4159.1986.tb01784.x; MARTENSON RE, 1981, J NEUROCHEM, V36, P1543, DOI 10.1111/j.1471-4159.1981.tb00598.x; MASTRONARDI FG, 1993, J NEUROSCI RES, V36, P315, DOI 10.1002/jnr.490360309; Mateu L, 1996, J MOL BIOL, V256, P319, DOI 10.1006/jmbi.1996.0088; MCLAURIN J, 1992, J NEUROCHEM, V59, P1414, DOI 10.1111/j.1471-4159.1992.tb08455.x; MCLAURIN J, 1993, J NEUROSCI RES, V35, P618, DOI 10.1002/jnr.490350605; MENDZ GL, 1985, BIOCHEM J, V229, P305, DOI 10.1042/bj2290305; MENDZ GL, 1995, EUR J BIOCHEM, V231, P659, DOI 10.1111/j.1432-1033.1995.0659d.x; MENDZ GL, 1982, BIOCHEM BIOPH RES CO, V105, P1333, DOI 10.1016/0006-291X(82)90933-0; MONFERRAN CG, 1986, MOL CELL BIOCHEM, V70, P131; MOSCARELLO MA, 1986, J NEUROSCI RES, V15, P87, DOI 10.1002/jnr.490150109; MOSCARELLO MA, 1994, J CLIN INVEST, V94, P146, DOI 10.1172/JCI117300; MOSCARELLO MA, 1992, J BIOL CHEM, V267, P9779; MOSCARELLO MA, 1996, CELL BIOL PATHOLOGY; MOSKAITIS JE, 1987, NEUROCHEM RES, V12, P409, DOI 10.1007/BF00972291; NAPOLITANO L, 1967, J CELL BIOL, V34, P817, DOI 10.1083/jcb.34.3.817; NEZIL FA, 1992, BIOPHYS J, V61, P1413, DOI 10.1016/S0006-3495(92)81946-X; PALI T, 1987, BIOCHIM BIOPHYS ACTA, V904, P346, DOI 10.1016/0005-2736(87)90384-1; PEREZGIL J, 1994, J THEOR BIOL, V169, P221, DOI 10.1006/jtbi.1994.1143; PIROLLET F, 1992, BIOCHEMISTRY-US, V31, P8849, DOI 10.1021/bi00152a022; PRICE WS, 1988, BIOCHEMISTRY-US, V27, P8990, DOI 10.1021/bi00425a017; RAMWANI JJ, 1989, BIOCHEMISTRY-US, V28, P6538, DOI 10.1021/bi00442a002; REINL HM, 1993, BIOCHIM BIOPHYS ACTA, V1151, P127, DOI 10.1016/0005-2736(93)90095-H; Ridsdale RA, 1997, J BIOL CHEM, V272, P4269, DOI 10.1074/jbc.272.7.4269; SAAVEDRA RA, 1989, J MOL EVOL, V29, P149, DOI 10.1007/BF02100113; Scheybani T., 1994, SUPRAMOL SCI, V1, P111; SEDZIK J, 1992, NEUROCHEM RES, V17, P157, DOI 10.1007/BF00966794; SMITH R, 1992, J NEUROCHEM, V59, P1589, DOI 10.1111/j.1471-4159.1992.tb10989.x; SMITH R, 1980, BIOCHEMISTRY-US, V19, P1826, DOI 10.1021/bi00550a015; SMITH R, 1982, BIOCHEMISTRY-US, V21, P2697, DOI 10.1021/bi00540a019; SMITH R, 1977, BIOCHIM BIOPHYS ACTA, V491, P581, DOI 10.1016/0005-2795(77)90304-X; Staugaitis SM, 1996, BIOESSAYS, V18, P13, DOI 10.1002/bies.950180106; STONER GL, 1984, J NEUROCHEM, V43, P433, DOI 10.1111/j.1471-4159.1984.tb00919.x; STONER GL, 1990, J NEUROCHEM, V55, P1404, DOI 10.1111/j.1471-4159.1990.tb03153.x; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; Stuart BH, 1996, BIOCHEM MOL BIOL INT, V38, P839; SUREWICZ WK, 1987, BIOCHEMISTRY-US, V26, P3881, DOI 10.1021/bi00387a021; TERBEEST MBA, 1993, EUR J BIOCHEM, V211, P689; TOMPKINS TA, 1993, ARCH BIOCHEM BIOPHYS, V302, P476, DOI 10.1006/abbi.1993.1242; TOMPKINS TA, 1994, BBA-PROTEIN STRUCT M, V1206, P208, DOI 10.1016/0167-4838(94)90210-0; ULMER JB, 1988, PROG NEUROBIOL, V31, P241, DOI 10.1016/0301-0082(88)90036-6; VANGURI P, 1993, J IMMUNOL, V150, P2431; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; VANHEEL M, 1989, OPTIK, V82, P114; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; WOOD DD, 1989, J BIOL CHEM, V264, P5121; Wood DD, 1996, ANN NEUROL, V40, P18, DOI 10.1002/ana.410400106; WOOD DD, 1996, MOL BIOL MULTIPLE SC; YADA RY, 1995, TRENDS FOOD SCI TECH, V6, P265, DOI 10.1016/S0924-2244(00)89111-6	105	70	70	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4261	4268		10.1074/jbc.272.7.4261	http://dx.doi.org/10.1074/jbc.272.7.4261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020142	hybrid			2022-12-25	WOS:A1997WH01900058
J	Durstewitz, G; Terwilliger, NB				Durstewitz, G; Terwilliger, NB			Developmental changes in hemocyanin expression in the Dungeness crab, Cancer magister	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHROPOD HEMOCYANINS; EVOLUTION; CRUSTACEA	The copper-based respiratory protein hemocyanin undergoes a developmental shift in subunit composition and function analogous to that seen in many hemoglobins. We studied hemocyanin gene expression in the Dungeness crab (Cancer magister) by Northern blot analysis. Animals were raised under controlled conditions, and total RNA was isolated from 13 developmental stages as well as from six tissue types in the adult animal. RNA was run on formaldehyde-agarose gels, blotted onto nylon membranes, and probed with P-32-labeled cDNA probes specific for C. magister adult hemocyanin. Results indicate that adult hemocyanin biosynthesis occurs in hepatopancreas tissue only. Analysis of developmental stages shows that expression of adult-type hemocyanin, as indicated by the appearance of hemocyanin subunit 6 mRNA, begins during the sixth juvenile instar.	UNIV OREGON,OREGON INST MARINE BIOL,CHARLESTON,OR 97420; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon; University of Oregon								BAK HJ, 1987, EUR J BIOCHEM, V169, P333, DOI 10.1111/j.1432-1033.1987.tb13616.x; BEINTEMA JJ, 1994, MOL BIOL EVOL, V11, P493; BROWN AC, 1992, BIOL BULL, V182, P270, DOI 10.2307/1542121; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; ELLERTON HD, 1970, BIOCHEMISTRY-US, V9, P2225, DOI 10.1021/bi00813a002; FREEDMAN TB, 1976, J AM CHEM SOC, V98, P2809, DOI 10.1021/ja00426a023; GHIRETTIMAGALDI A, 1977, CELL DIFFER DEV, V6, P167, DOI 10.1016/0045-6039(77)90014-8; GHIRETTIMAGALDI A, 1973, EXPERIENTIA, V29, P1265, DOI 10.1007/BF01935109; HANNECKE R, 1980, INVERTEBRATE DIOXYGE, P503; HEIP J, 1980, BRINE SHRIMP ARTEMIA, V2, P427; Ingermann R.L., 1992, Advances in Comparative and Environmental Physiology, V13, P411; LARSON BA, 1981, BIOCHIM BIOPHYS ACTA, V667, P294, DOI 10.1016/0005-2795(81)90195-1; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; Markl J., 1992, Advances in Comparative and Environmental Physiology, V13, P325; Preaux G., 1986, P485; RAINER J, 1993, COMP BIOCHEM PHYS B, V104, P69, DOI 10.1016/0305-0491(93)90339-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIN K, 1979, J EXP ZOOL, V210, P265, DOI 10.1002/jez.1402100210; SCHONENBERGER N, 1980, CELL TISSUE RES, V205, P397; SENKBEIL EG, 1981, COMP BIOCHEM PHYS B, V68, P163, DOI 10.1016/0305-0491(81)90198-X; Terwilliger N., 1995, American Zoologist, V35, p65A; Terwilliger N.B., 1986, P333; TERWILLIGER NB, 1993, J EXP BIOL, V183, P1; TERWILLIGER NB, 1982, J EXP ZOOL, V221, P181, DOI 10.1002/jez.1402210209; Terwilliger Nora Barclay, 1996, P353; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; VANHOLDE KE, 1982, Q REV BIOPHYS, V15, P1, DOI 10.1017/S0033583500002705; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; WILKINSON M, 1990, NUCLEIC ACIDS RES, V19, P679	29	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4347	4350		10.1074/jbc.272.7.4347	http://dx.doi.org/10.1074/jbc.272.7.4347			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020155	hybrid			2022-12-25	WOS:A1997WH01900071
J	Frostesjo, L; Holm, I; Grahn, B; Page, AW; Bestor, TH; Heby, O				Frostesjo, L; Holm, I; Grahn, B; Page, AW; Bestor, TH; Heby, O			Interference with DNA methyltransferase activity and genome methylation during F9 teratocarcinoma stem cell differentiation induced by polyamine depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; EMBRYONAL CARCINOMA-CELLS; ADENOSYL-L-METHIONINE; ORNITHINE DECARBOXYLASE; IRREVERSIBLE INHIBITION; PLASMINOGEN-ACTIVATOR; MAMMALIAN-CELLS; MESSENGER-RNA; C-MYC; MOUSE	When ornithine decarboxylase, the initial and highly regulated enzyme in polyamine biosynthesis, is irreversibly inactivated by alpha-difluoromethylornithine, F9 teratocarcinoma stem cells are depleted of putrescine and spermidine and as a result differentiate into a cell type which phenotypically resembles the parietal endoderm cells of the early mouse embryo, Simultaneously the level of decarboxylated S-adenosylmethionine (dcAdoMet), the aminopropyl group donor in spermidine and spermine synthesis, increases dramatically, as the aminopropyl group acceptor molecules (putrescine and spermidine) become limiting, When this excessive accumulation of dcAdoMet is prevented by specific inhibition of the AdoMet decarboxylase activity, the differentiative effect is counteracted, despite the fact that the extent of polyamine depletion remains almost identical, Therefore, it may be concluded that dcAdoMet plays an important role in the induction of differentiation, Moreover, this key metabolite acts as a competitive inhibitor of DNA methyltransferase and is therefore capable of interfering with the maintenance methylation of newly replicated DNA. During the course of F9 cell differentiation, the highly methylated genome is gradually demethylated, and its pattern of gene expression is changed, Our present findings, that the DNA remains highly methylated and that the differentiative process is counteracted when the build-up of dcAdoMet is prevented, provide strong evidence for a causative relation between the level of dcAdoMet and the state of DNA methylation as well as cell differentiation.	UMEA UNIV,DEPT CELLULAR & DEV BIOL,S-90187 UMEA,SWEDEN; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; COLUMBIA UNIV,DEPT HUMAN GENET & DEV,NEW YORK,NY 10032	Umea University; Massachusetts Institute of Technology (MIT); Columbia University			Holm, Ingvar/H-4735-2014	Holm, Ingvar/0000-0003-4155-6112				ASK A, 1986, INT J CANCER, V37, P465, DOI 10.1002/ijc.2910370320; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; Borchardt R. T., 1986, BIOL METHYLATION DRU, P227; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DANZIN C, 1990, BIOCHEM PHARMACOL, V40, P1499, DOI 10.1016/0006-2952(90)90446-R; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HEBY O, 1988, PROGR POLYAMINE RES, P291; Hogan B. L. M, 1983, CANCER SURV, V2, P115; Jones PA, 1984, DNA METHYLATION BIOC, P165; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; KRAMER DL, 1990, CANCER RES, V50, P3838; Kredich N M, 1980, Adv Enzyme Regul, V18, P181, DOI 10.1016/0065-2571(80)90015-1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MAMONT PS, 1982, EUR J BIOCHEM, V123, P499; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Matsufuji S, 1996, EMBO J, V15, P1360, DOI 10.1002/j.1460-2075.1996.tb00478.x; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MONK M, 1987, DEVELOPMENT, V99, P371; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; NY T, 1988, DNA-J MOLEC CELL BIO, V7, P671, DOI 10.1089/dna.1988.7.671; OREDSSON SM, 1986, MOL CELL BIOCHEM, V70, P89; OREDSSON SM, 1985, EUR J CELL BIOL, V38, P335; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PALMGREN G, 1990, BIOCHIM BIOPHYS ACTA, V1049, P293, DOI 10.1016/0167-4781(90)90100-G; PEGG AE, 1982, BIOCHEM J, V202, P519, DOI 10.1042/bj2020519; PERSSON L, 1989, BIOCHEM BIOPH RES CO, V160, P1196, DOI 10.1016/S0006-291X(89)80130-5; POULIN R, 1995, BIOCHEM J, V311, P723, DOI 10.1042/bj3110723; Pyronnet S, 1996, CANCER RES, V56, P1742; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; SANFORD JP, 1985, TRENDS GENET, V1, P89, DOI 10.1016/0168-9525(85)90033-2; SCHINDLER J, 1985, J CELL PHYSIOL, V122, P1, DOI 10.1002/jcp.1041220102; SCOTT RH, 1993, TRENDS NEUROSCI, V16, P153, DOI 10.1016/0166-2236(93)90124-5; SEILER N, 1985, J CHROMATOGR, V339, P45, DOI 10.1016/S0378-4347(00)84626-5; SHANTZ LM, 1992, BIOCHEM J, V288, P511, DOI 10.1042/bj2880511; STEVENS LC, 1970, DEV BIOL, V21, P364, DOI 10.1016/0012-1606(70)90130-2; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STJERNBORG L, 1993, EUR J BIOCHEM, V214, P671, DOI 10.1111/j.1432-1033.1993.tb17967.x; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAMORI A, 1995, CANCER RES, V55, P3500; TEUBNER B, 1995, J CELL PHYSIOL, V165, P284, DOI 10.1002/jcp.1041650209; TRASLER JM, 1992, NUCLEIC ACIDS RES, V20, P2541, DOI 10.1093/nar/20.10.2541; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WILLIAMSASHMAN HG, 1972, BIOCHEM BIOPH RES CO, V46, P288, DOI 10.1016/0006-291X(72)90661-4; WOOD L, 1988, FEBS LETT, V227, P5, DOI 10.1016/0014-5793(88)81402-9; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; YOUNG PR, 1984, MOL CELL BIOL, V4, P898, DOI 10.1128/MCB.4.5.898	59	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4359	4366		10.1074/jbc.272.7.4359	http://dx.doi.org/10.1074/jbc.272.7.4359			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020157	hybrid			2022-12-25	WOS:A1997WH01900073
J	IniguezLluhi, JA; Lou, DY; Yamamoto, KR				IniguezLluhi, JA; Lou, DY; Yamamoto, KR			Three amino acid substitutions selectively disrupt the activation but not the repression function of the glucocorticoid receptor N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; TRANSACTIVATION DOMAIN; ESTROGEN-RECEPTOR; JUN ACTIVITY; SMALL REGION; PROTEIN; SUPERFAMILY; YEAST	A 210-amino acid region, termed enh2, near the N terminus of the rat glucocorticoid receptor, is necessary for both transcriptional activation and repression. The mechanism(s) of transcriptional regulation conferred by this region, however, are poorly understood. We screened in Saccharomyces cerevisiae a library of random mutants in the enh2 region of a constitutive glucocorticoid receptor derivative and isolated a series of multiply substituted receptors that are specifically defective in transcriptional activation. Although many substitutions in this area were tolerated, three amino acid substitutions (E219K, F220L, and W234R) within a 16-amino acid region were sufficient to disrupt the enh2 transcriptional activation function both in yeast and in mammalian cells. Although this region is rich in acidic residues, the conserved tryptophan at position 234 appears to be a more critical feature for enh2 activity; hydrophobic but not charged residues were tolerated at this position, Notably, the mutants uncoupled the activation and repression functions of enh2, as the activation defective isolates remained competent for repression of AP-1 at the composite response element plfG.	UNIV CALIF SAN FRANCISCO, DEPT MOL & CELLULAR PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Iniguez-Lluhi, Jorge/0000-0001-7010-089X				ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DETERAWADLEIGH SD, 1994, MOL PHYLOGENET EVOL, V3, P192, DOI 10.1006/mpev.1994.1022; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Eggert M, 1995, J BIOL CHEM, V270, P30755, DOI 10.1074/jbc.270.51.30755; FOLKERS GE, 1995, MOL CELL BIOL, V15, P5868; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MIESFELD R, 1988, UCLA S MOL CELL BIOL, V75, P193; Miller JH., 1972, EXPT MOL GENETICS; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; ONATE SA, 1995, SCIENCE, V270, P1354; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; Shen F, 1996, J BIOL CHEM, V271, P4827; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; YAMAMOTO KR, 1996, IN PRESS HARVEY LECT; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, P1169; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	64	109	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4149	4156		10.1074/jbc.272.7.4149	http://dx.doi.org/10.1074/jbc.272.7.4149			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020127	hybrid			2022-12-25	WOS:A1997WH01900043
J	Vitale, N; Moss, J; Vaughan, M				Vitale, N; Moss, J; Vaughan, M			Interaction of the GTP-binding and GTPase-activating domains of ARD1 involves the effector region of the ADP-ribosylation factor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE; CHOLERA-TOXIN; BREFELDIN-A; PHOSPHOLIPASE-D; AMINO-TERMINUS; BOVINE BRAIN; PROTEIN; GOLGI; ARF; EXPRESSION	ADP-ribosylation factors (ARFs) are a family of similar to 20-kDa guanine nucleotide-binding proteins and members of the Pas superfamily, originally identified and purified by their ability to enhance the ADP-ribosyltransferase activity of cholera toxin and more recently recognized as critical participants in vesicular trafficking pathways and phospholipase D activation. ARD1 is a 64-kDa protein with an 18-kDa carboxyl-terminal ARF domain (p3) and a 46-kDa amino-terminal extension (p5) that is widely expressed in mammalian tissues. Using recombinant proteins, we showed that p5, the aminoterminal domain of ARD1, stimulates the GTPase activity of p3, the ARF domain, and appears to be the GTPase-activating protein (GAP) component of this bifunctional protein, whereas in other members of the Ras superfamily a separate GAP molecule interacts with the effector region of the GTP-binding protein. p5 stimulated the GTPase activity of p3 but not of ARF1, which differs from p3 in several amino acids in the effector domain. After substitution of 7 amino acids from p3 in the appropriate position in ARF1, the chimeric protein ARF1(39-45p3) bound to p5, which increased its GTPase activity. Specifically, after Gly(40) and Thr(45) in the putative effector domain of ARF1 were replaced with the equivalent Asp and Pro, respectively, from p3, functional interaction of the chimeric ARF1 with p5 was increased. Thus, Asp(25) and pro(30) Of the ARF domain (p3) of ARD1 are involved in its functional and physical interaction with the GTPase-activating (p5) domain of ARD1. After deletion of the amino-terminal 15 amino acids from ARF1(39-45p3), its interaction with p5 was essentially equivalent to that of p3, suggesting that the amino terminus of ARF1(39-45p3) may interfere with binding to p5. These results are consistent with the conclusion that the GAP domain of ARD1 interacts with the effector region of the ARF domain and thereby stimulates GTP hydrolysis.			Vitale, N (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,NIH,RM 5N-307,BLDG 10,10 CTR DR,BETHESDA,MD 20892, USA.		Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOTSTEIN D, 1988, COLD SPRING HARB SYM, V53, P629, DOI 10.1101/SQB.1988.053.01.072; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONG JX, 1995, P NATL ACAD SCI USA, V92, P3056, DOI 10.1073/pnas.92.7.3056; HONG JX, 1994, J BIOL CHEM, V269, P9743; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSAI SC, 1988, J BIOL CHEM, V263, P1768; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1993, J BIOL CHEM, V268, P10820; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; WEISS O, 1989, J BIOL CHEM, V264, P21066	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3897	3904		10.1074/jbc.272.7.3897	http://dx.doi.org/10.1074/jbc.272.7.3897			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020091	hybrid			2022-12-25	WOS:A1997WH01900007
J	Juan, LJ; Utley, RT; Vignali, M; Bohm, L; Workman, JL				Juan, LJ; Utley, RT; Vignali, M; Bohm, L; Workman, JL			H1-mediated repression of transcription factor binding to a stably positioned nucleosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; GLUCOCORTICOID RESPONSE ELEMENT; HISTONE AMINO TERMINI; LINKER HISTONES; CHROMATIN TEMPLATES; GAL4 DERIVATIVES; DNA; MOBILITY; LOCATION; INVITRO	Previously, we reported that histone H1 binding to nucleosome cores results in the repression of binding of the basic helix-loop-helix upstream stimulatory factor (USF) (Juan, L.-J., Utley, R. T., Adams, C. C., Vettese-Dadey, M., and Workman, J. L. (1994) EMBO J. 13, 6031-6040). We have tested whether this inhibition resulted from H1-mediated changes in nucleosome positioning (Ura, K., Hayes, J. J., and Wolffe, A. P. (1995) EMBO J. 14, 3752-3765) forcing the USF recognition sequence into less accessible locations within the nucleosome. Nucleosome boundaries were determined by assays combining micrococcal nuclease and restriction endonuclease digestion, A unique pair of boundaries were observed, indicating a single nucleosome translational position. This nucleosome position did not change on H1 or USF binding. Thus, H1 repression of USF binding was independent of nucleosome mobility, indicating an alternative mechanism of H1 repression, H1 repressed USF binding at a site 35 base pairs into the nucleosome core more effectively than at a site near the ''linker'' DNA, suggesting that inhibition by H1 was not simply due to steric occlusion. Instead, these data are consistent with a model by which H1 binding reduces transient dynamic exposure of the DNA from the histone octamer surface (Polach, K. L., and Widom, J. (1995) J. Mol. Biol. 254, 130-149).	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,ALTHOUSE LAB 306,UNIVERSITY PK,PA 16802; PENN STATE UNIV,INTERCOLL GRAD PROGRAM GENET,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIVERSITY PK,PA 16802; UNIV STELLENBOSCH,FAC MED,DEPT RADIOTHERAPY,ZA-7505 TYGERBERG,SOUTH AFRICA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Stellenbosch University			Juan, Li-Jung/H-6631-2015	Vignali, Marissa/0000-0002-7319-3371				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; BOHM EL, 1973, FEBS LETT, V34, P217, DOI 10.1016/0014-5793(73)80797-5; Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; COWMAN MK, 1980, BIOCHEMISTRY-US, V19, P532, DOI 10.1021/bi00544a022; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HOUSSIER C, 1981, NUCLEIC ACIDS RES, V9, P5763, DOI 10.1093/nar/9.21.5763; JUAN LJ, 1993, COLD SPRING HARB SYM, V58, P213, DOI 10.1101/SQB.1993.058.01.026; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LI BY, 1994, J BIOL CHEM, V269, P7756; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Q, 1995, MOL CELL BIOL, V15, P4375; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; LUTTER LC, 1979, NUCLEIC ACIDS RES, V6, P41, DOI 10.1093/nar/6.1.41; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X	41	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3635	3640		10.1074/jbc.272.6.3635	http://dx.doi.org/10.1074/jbc.272.6.3635			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013616	hybrid			2022-12-25	WOS:A1997WG19200076
J	Koley, AP; Buters, JTM; Robinson, RC; Markowitz, A; Friedman, FK				Koley, AP; Buters, JTM; Robinson, RC; Markowitz, A; Friedman, FK			Differential mechanisms of cytochrome P450 inhibition and activation by alpha-naphthoflavone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; NATURALLY-OCCURRING FLAVONOIDS; CDNA-DIRECTED EXPRESSION; HUMAN-LIVER-MICROSOMES; CO BINDING-KINETICS; ENDOPLASMIC-RETICULUM; ACTIVE-SITE; BENZO(A)PYRENE; METABOLISM; ENZYMES	The anticarcinogenicity of some flavonoids has been attributed to modulation of the cytochrome P450 enzymes, which metabolize procarcinogens to their activated forms. However, the mechanism by which flavonoids inhibit some P450-mediated activities while activating others is a longstanding, intriguing question, We employed flash photolysis to measure carbon monoxide binding to P450 as a rapid kinetic technique to probe the interaction of the prototype flavonoid alpha-naphthoflavone with human cytochrome P450s 1A1 and 3A4, whose benzo[a]pyrene hydroxylation activities are respectively inhibited and stimulated by this compound, This flavonoid inhibited P450 1A1 binding to benzo[a]pyrene via a classical competitive mechanism. In contrast, alpha-naphthoflavone stimulated P450 3A4 by selectively binding and activating an otherwise inactive subpopulation of this P450 and promoting benzo[a]pyrene binding to the latter. These data indicate that flavonoids enhance activity by increasing the pool of active P450 molecules within this P450 macrosystem. Activators in other biological systems may similarly exert their effect by expanding the population of active receptor molecules.	NCI, MOL CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA; NIH, BIOMED ENGN & INSTRUMENTAT PROGRAM, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA			Friedman, Fred/O-6173-2019; BUTERS, JEROEN/AAF-6949-2020; Buters, Jeroen T/G-5070-2011; Friedman, Fred K/D-4208-2016	Friedman, Fred/0000-0002-0284-7067; Buters, Jeroen/0000-0003-3581-5472				ALBEN JO, 1993, BIOPHYS J, V65, P1357, DOI 10.1016/S0006-3495(93)81183-4; BAUER E, 1995, CHEM RES TOXICOL, V8, P136, DOI 10.1021/tx00043a018; Bruns RF, 1996, TRENDS PHARMACOL SCI, V17, P189, DOI 10.1016/0165-6147(96)20027-6; BUENING MK, 1981, CANCER RES, V41, P67; BUTERS JTM, 1995, DRUG METAB DISPOS, V23, P696; BUTERS JTM, 1994, DRUG METAB DISPOS, V22, P688; CHAE YH, 1991, CANCER LETT, V60, P15, DOI 10.1016/0304-3835(91)90044-I; CONNEY AH, 1982, CANCER RES, V42, P4875; Das A, 1994, Prog Drug Res, V42, P133; DESCHNER EE, 1991, CARCINOGENESIS, V12, P1193, DOI 10.1093/carcin/12.7.1193; DIAMOND L, 1969, SCIENCE, V166, P1023, DOI 10.1126/science.166.3908.1023; FRIEDMAN FK, 1985, PHARMACOLOGY, V31, P194, DOI 10.1159/000138115; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; HUANG MT, 1983, CARCINOGENESIS, V4, P1631, DOI 10.1093/carcin/4.12.1631; IOANNIDES C, 1993, DRUG METAB REV, V25, P485, DOI 10.3109/03602539308993983; JOHNSON EF, 1988, J BIOL CHEM, V263, P17672; KAPITULNIK J, 1977, CLIN PHARMACOL THER, V22, P475; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; KINOSHIT.N, 1972, P NATL ACAD SCI USA, V69, P824, DOI 10.1073/pnas.69.4.824; KOLEY AP, 1994, BIOCHEMISTRY-US, V33, P2484, DOI 10.1021/bi00175a017; KOLEY AP, 1995, J BIOL CHEM, V270, P5014, DOI 10.1074/jbc.270.10.5014; KOLEY AP, 1995, BIOCHEMISTRY-US, V34, P1942, DOI 10.1021/bi00006a015; KOLEY AP, 1996, IN PRESS ARCH BIOCH; LEMARCHAND L, 1989, JNCI-J NATL CANCER I, V81, P1158, DOI 10.1093/jnci/81.15.1158; MCLEMORE TL, 1990, J NATL CANCER I, V82, P1333, DOI 10.1093/jnci/82.16.1333; MCMANUS ME, 1990, CANCER RES, V50, P3367; MINISCALCO A, 1992, J PHARMACOL EXP THER, V261, P1195; NEBERT DW, 1968, J BIOL CHEM, V243, P6242; NESNOW S, 1979, J MED CHEM, V22, P1244, DOI 10.1021/jm00196a018; PIERPOINT WS, 1986, PLANT FLAVONOIDS BIO, P125; SHIMADA T, 1992, MOL PHARMACOL, V41, P856; SHIMADA T, 1989, CANCER RES, V49, P3218; SHIMADA T, 1989, CANCER RES, V49, P6304; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; SIESS MH, 1989, EUR J DRUG METAB PH, V14, P235, DOI 10.1007/BF03190104; STAVRIC B, 1994, CLIN BIOCHEM, V27, P319, DOI 10.1016/0009-9120(94)00039-5; TSYRLOV IB, 1994, BBA-PROTEIN STRUCT M, V1205, P325, DOI 10.1016/0167-4838(94)90252-6; WATTENBERG LW, 1970, CANCER RES, V30, P1922; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YUN CH, 1992, CANCER RES, V52, P1868	41	125	126	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3149	3152		10.1074/jbc.272.6.3149	http://dx.doi.org/10.1074/jbc.272.6.3149			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013547	hybrid			2022-12-25	WOS:A1997WG19200007
J	Yan, BX; Sun, YQ				Yan, BX; Sun, YQ			Glycine residues provide flexibility for enzyme active sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; 4-HELIX BUNDLE PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; MOLECULAR-STRUCTURE; TRICHODERMA-REESEI; GLOBULAR-PROTEINS; 2.0-A RESOLUTION; DESIGN	The high resolution refined structures of 23 enzymes were analyzed to determine the properties of amino acids involved in active site regions. These regions were found to be rich in G-X-P or Y-X-G oligopeptides, where X and Y are polar and non-polar residues, respectively, that are small and with low polarity. Other regions of the enzyme molecules have significantly fewer of these sequences, These features suggest that glycine residues may provide flexibility necessary for enzyme active sites to change conformation, and the G-X-Y or Y-X-G oligopeptides may be a motif for the formation of enzyme active sites.	BEIJING UNIV,NATL LAB PROT ENGN & PLANT GENET ENGN,CTR LIFE SCI,BEIJING 100871,PEOPLES R CHINA	Peking University	Yan, BX (corresponding author), SHANDONG UNIV,NATL LAB MICROBIAL TECHNOL,INST MICROBIOL,JINAN 250100,PEOPLES R CHINA.							ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BIESECKER G, 1977, NATURE, V266, P328, DOI 10.1038/266328a0; BLOSHAM D, 1981, P NATL ACAD SCI USA, V78, P5381; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; CAMICI G, 1989, J BIOL CHEM, V264, P2560; COLOMBO G, 1986, J BIOL CHEM, V261, P587; CORRAN PH, 1975, NATURE, V255, P609; CRIPPEN GM, 1991, BIOCHEMISTRY-US, V30, P4232, DOI 10.1021/bi00231a018; DEGRADO WF, 1993, NATURE, V365, P488, DOI 10.1038/365488a0; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; FERSHT A, 1985, ENZYME STRUCTURE MEC, P4; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GHADIRI MR, 1994, NATURE, V369, P301, DOI 10.1038/369301a0; GOLDBERG JD, 1994, J MOL BIOL, V236, P1123, DOI 10.1016/0022-2836(94)90016-7; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; JOHNSSON K, 1993, NATURE, V365, P530, DOI 10.1038/365530a0; JONSON KA, 1993, ANNU REV BIOCHEM, V62, P685; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MONGE A, 1994, P NATL ACAD SCI USA, V91, P5027, DOI 10.1073/pnas.91.11.5027; MONTAL M, 1995, ANNU REV BIOPH BIOM, V24, P31, DOI 10.1146/annurev.bb.24.060195.000335; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SCHUMACK M, 1986, BITECHNOL LETT, V8, P397; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; SMYTH DG, 1963, J BIOL CHEM, V238, P227; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAO WS, 1982, MOL BASIS PROTEINS; TSOU CL, 1986, TRENDS BIOCHEM SCI, V11, P427, DOI 10.1016/0968-0004(86)90178-7; TSOU CL, 1993, SCIENCE, V262, P380, DOI 10.1126/science.8211158; TULINSKY A, 1973, J MOL BIOL, V81, P47, DOI 10.1016/0022-2836(73)90246-5; WONG WKR, 1986, GENE, V44, P315; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106	50	131	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3190	3194		10.1074/jbc.272.6.3190	http://dx.doi.org/10.1074/jbc.272.6.3190			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013553	hybrid			2022-12-25	WOS:A1997WG19200013
J	Ye, XJ; Sloboda, RD				Ye, XJ; Sloboda, RD			Molecular characterization of p62, a mitotic apparatus protein required for mitotic progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; DEPENDENT MULTIPROTEIN KINASE; ACETYL-COA CARBOXYLASE; SEA-URCHIN EGGS; CYTOPLASMIC DYNEIN; PHOSPHORYLATION SITES; NUCLEOLAR PROTEIN; BINDING DOMAIN; TAU-PROTEIN; IN-VITRO	A 62-M3a (p62) mitotic apparatus-associated protein is important for the proper progression of mitosis in sea urchin embryos (Dinsmore, J. H., and Sloboda, R. D. (1989) Cell 53, 769-780). We have isolated and characterized a full-length p62 cDNA of 3374 base pairs which encodes an extremely acidic polypeptide of 411 amino acids having a calculated M(r) of 46,388 and a pI of 4.01; p62 is a unique protein with no significant identity to any known proteins, Southern and Northern blot analyses demonstrate that the gene for p62 is present once in the sea urchin genome and the corresponding mRNA is present in unfertilized eggs and in early embryos through and up to the gastrula stage. Sequence analysis suggests certain regions may participate in chromatin association and microtubule binding, an observation that is consistent with previous immunological data (Ye, X., and Sloboda, R. D. (1995) Cell Motil. Cytoskeleton 30, 310-323) as well as data reported herein. Confocal microscopy reveals that duping interphase the protein binds to chromatin in the nuclei of sea urchin eggs, In the germinal vesicles of clam oocytes at prophase of meiosis I, p62 binds to the condensed chromosomes, Currently, truncated clones of p62 are being used to identify the tubulin and chromatin binding domains.	DARTMOUTH COLL, DEPT BIOL SCI, HANOVER, NH 03755 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	Dartmouth College; Marine Biological Laboratory - Woods Hole								AIZAWA H, 1990, J BIOL CHEM, V265, P13849; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BODER GB, 1983, EUR J CELL BIOL, V31, P349; Brinkley BR, 1990, CURR OPIN CELL BIOL, V2, P446, DOI 10.1016/0955-0674(90)90126-Y; BROWNE CL, 1990, EXP CELL RES, V188, P122, DOI 10.1016/0014-4827(90)90286-J; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHANG JH, 1988, J BIOL CHEM, V263, P12824; CHAPIN SJ, 1991, J CELL SCI, V98, P27; CLEVELAND DW, 1990, NATURE, V344, P389, DOI 10.1038/344389a0; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; DINSMORE JH, 1990, ANN NY ACAD SCI, V582, P301; DINSMORE JH, 1989, CELL, V57, P127, DOI 10.1016/0092-8674(89)90178-5; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; GATES RE, 1982, BIOCHEM BIOPH RES CO, V105, P57, DOI 10.1016/S0006-291X(82)80010-7; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; HALE TK, 1989, NUCLEIC ACIDS RES, V17, P10112; HALL FL, 1990, J BIOL CHEM, V265, P6944; HARDIE DG, 1986, EUR J BIOCHEM, V157, P553, DOI 10.1111/j.1432-1033.1986.tb09702.x; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HYMAN AA, 1992, NATURE, V359, P533, DOI 10.1038/359533a0; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; JOHNSTON JA, 1994, CELL MOTIL CYTOSKEL, V29, P280, DOI 10.1002/cm.970290311; JOHNSTON JA, 1992, J CELL BIOL, V119, P843, DOI 10.1083/jcb.119.4.843; KEITH C, 1983, J CELL BIOL, V97, P1918, DOI 10.1083/jcb.97.6.1918; KEITH CH, 1987, CELL MOTIL CYTOSKEL, V7, P1, DOI 10.1002/cm.970070102; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUEHL L, 1986, ARCH BIOCHEM BIOPHYS, V248, P272, DOI 10.1016/0003-9861(86)90424-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LI QW, 1994, J BIOL CHEM, V269, P31777; LISCHWE MA, 1979, LIFE SCI, V25, P701, DOI 10.1016/0024-3205(79)90512-5; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; MARIDOR G, 1990, NUCLEIC ACIDS RES, V18, P1286, DOI 10.1093/nar/18.5.1286; MIDDLETON K, 1994, P NATL ACAD SCI USA, V91, P7212, DOI 10.1073/pnas.91.15.7212; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; SALMON ED, 1982, METHOD CELL BIOL, V25, P69, DOI 10.1016/S0091-679X(08)61421-1; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SHOJI S, 1987, J BIOCHEM-TOKYO, V102, P1113, DOI 10.1093/oxfordjournals.jbchem.a122149; SILVER RB, 1989, DEV BIOL, V131, P11; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; SPURCK TP, 1987, J CELL BIOL, V105, P1691, DOI 10.1083/jcb.105.4.1691; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; STEMPLE DL, 1988, CELL MOTIL CYTOSKEL, V9, P231, DOI 10.1002/cm.970090305; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SUPRENANT KA, 1993, J CELL SCI, V104, P445; VANTARD M, 1985, J CELL BIOL, V101, P488, DOI 10.1083/jcb.101.2.488; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WALKER JM, 1978, NATURE, V271, P281, DOI 10.1038/271281a0; WELSH MJ, 1978, P NATL ACAD SCI USA, V75, P1867, DOI 10.1073/pnas.75.4.1867; WEST RR, 1991, J BIOL CHEM, V266, P21886; WOLNIAK SM, 1983, J CELL BIOL, V96, P598, DOI 10.1083/jcb.96.3.598; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; YE XJ, 1995, CELL MOTIL CYTOSKEL, V30, P310, DOI 10.1002/cm.970300408; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZAVORTINK M, 1983, EXP CELL RES, V149, P375, DOI 10.1016/0014-4827(83)90350-6; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	75	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3606	3614		10.1074/jbc.272.6.3606	http://dx.doi.org/10.1074/jbc.272.6.3606			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013612	hybrid			2022-12-25	WOS:A1997WG19200072
J	Kellokumpu, S; Suokas, M; Risteli, L; Myllyla, R				Kellokumpu, S; Suokas, M; Risteli, L; Myllyla, R			Protein disulfide isomerase and newly synthesized procollagen chains form higher-order structures in the lumen of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; LUMINAL ER PROTEINS; MEMBRANE-PROTEINS; BETA-SUBUNIT; BIP; HYDROXYLASE; AGGREGATION; ASSOCIATION; SECRETION; RETENTION	A number of proteins that act as necessary catalysts for correct protein folding and oligomerization in the endoplasmic reticulum (ER) are known to be retained in the organelle via the KDEL-receptor mediated retrieval mechanism. However, a complementary system that may help to retain these proteins in the organelle lumen has been suggested to exist and likely involves physical protein-protein interactions at the level of endoplasmic reticulum (ER) itself. In this report, we provide both morphological and biochemical evidence in support of this proposal. We show that in collagen-secreting human skin fibroblasts, protein disulfide isomerase and newly synthesized procollagen chains exist predominantly in ''aggregated'' state, and form a reticular-like matrix in the ER lumen in vivo. The size of the aggregates was found to be variable, and may exceed 1.5 million Da. Aggregate formation appeared to be transient and to involve multiple types of protein-protein interactions, including formation of aberrant disulfide bonds. Association of protein disulfide isomerase, on the other hand, was found to require at least partly function-related disulfide bonds. These results support the existence of a reticular like matrix in the ER lumen, and suggest that aggregation may be part of the normal maturation pathway during collagen biosynthesis.	UNIV OULU,DEPT BIOCHEM MED,FIN-90220 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,FIN-90220 OULU,FINLAND	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Kellokumpu, S (corresponding author), UNIV OULU,DEPT ANAT,KAJAANINTIE 52A,FIN-90220 OULU,FINLAND.			Risteli, Leila/0000-0002-5532-5895				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BERG RA, 1979, J BIOL CHEM, V254, P3111; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; FREEDMAN RB, 1994, CURR BIOL, V4, P933, DOI 10.1016/S0960-9822(00)00210-4; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HOYHTYA M, 1984, EUR J BIOCHEM, V141, P477, DOI 10.1111/j.1432-1033.1984.tb08217.x; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KEDERSHA NL, 1985, BIOCHEMISTRY-US, V24, P5952, DOI 10.1021/bi00342a040; KELLOKUMPU S, 1988, SCIENCE, V242, P1308, DOI 10.1126/science.2461589; KELLOKUMPU S, 1994, J BIOL CHEM, V269, P30524; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KOCH GLE, 1987, J CELL SCI, V87, P491; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1989, EMBO J, V8, P3137; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0	48	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2770	2777		10.1074/jbc.272.5.2770	http://dx.doi.org/10.1074/jbc.272.5.2770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006916	hybrid			2022-12-25	WOS:A1997WE66700029
J	Cullen, ME; Patient, RK				Cullen, ME; Patient, RK			GATA-1 DNA binding activity is down-regulated in late S phase in erythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; GLOBIN GENE DOMAIN; REPLICATION; EXPRESSION; DIFFERENTIATION; CHROMATIN; PROMOTER; PROTEIN; LOCUS; ACTIVATION	We have set out to test a model for tissue-specific gene expression that relies on the early replication of expressed genes to sequester limiting activating transcript ion factors. Using an erythroid cell line, we have tested the changes in the DNA binding activity of the lineage-restricted transcription factor GATA-1 through the cell cycle. We find that GATA-1 activity is low in G(1), peaks in mid-S phase, and then decreases in G(2)/M. In contrast, the binding activities of two ubiquitous transcription factors, Oct1 and Sp1, remain high in G(2)/M GATA-1 protein and mRNA vary in a similar manner through the cell cycle, suggesting that the expression of the gene or the stability of its message is regulated. Although a number of transcription factors involved in the control of the cell cycle or DNA replication have been shown to peak in S phase, this is the first example of a lineage-restricted transcription factor displaying S phase-specific DNA binding activity. One interpretation of these data leads to a model in which the peak in GATA-1 DNA binding amplifies the effect of early replication on the activation of erythroid-specific genes at the same time as preventing activation of non-erythroid genes containing GATA-responsive elements. These results may also relate to recent data implicating GATA-1 function in apoptosis and cell cycle progression.	UNIV LONDON KINGS COLL,RANDALL INST,DEV BIOL RES CTR,LONDON WC2B 5RL,ENGLAND	University of London; King's College London								Blobel GA, 1996, MOL CELL BIOL, V16, P1687, DOI 10.1128/mcb.16.4.1687; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BROWN EH, 1987, MOL CELL BIOL, V7, P450, DOI 10.1128/MCB.7.1.450; CALZA RE, 1984, CELL, V36, P689, DOI 10.1016/0092-8674(84)90349-0; CARTER R, 1991, ONCOGENE, V6, P229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON S, 1986, MOL CELL BIOL, V6, P601, DOI 10.1128/MCB.6.2.601; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DHAR V, 1988, MOL CELL BIOL, V8, P4958, DOI 10.1128/MCB.8.11.4958; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; Dubart A, 1996, BLOOD, V87, P3711, DOI 10.1182/blood.V87.9.3711.bloodjournal8793711; ENVER T, 1988, MOL CELL BIOL, V8, P1301, DOI 10.1128/MCB.8.3.1301; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HOLTHUIS J, 1990, SCIENCE, V247, P1454, DOI 10.1126/science.2321007; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEONARD M, 1993, BLOOD, V82, P1071; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; NEAVE B, 1995, MECH DEVELOP, V51, P169, DOI 10.1016/0925-4773(95)00351-7; NEVINS JR, 1992, SCIENCE, V258, P424; ORKIN SH, 1992, BLOOD, V80, P575; PERKINS ND, 1989, NUCLEIC ACIDS RES, V17, P1299, DOI 10.1093/nar/17.4.1299; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PROUDFOOT NJ, 1992, NEW BIOL, V4, P369; SEGIL N, 1991, COLD SPRING HARB SYM, V56, P285; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TATE EH, 1983, CYTOMETRY, V4, P211, DOI 10.1002/cyto.990040304; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; Trudel P, 1996, BIOTECHNIQUES, V20, P684; VILLARREAL LP, 1991, MICROBIOL REV, V55, P512, DOI 10.1128/MMBR.55.3.512-542.1991; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Williams RD, 1996, NUCLEIC ACIDS RES, V24, P549, DOI 10.1093/nar/24.4.549; WILSON AC, 1993, NUCLEIC ACIDS RES, V21, P4296, DOI 10.1093/nar/21.18.4296; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORMINGTON WM, 1982, COLD SPRING HARB SYM, V47, P879; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	44	3	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2464	2469						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999960				2022-12-25	WOS:A1997WD67900066
J	Efrati, E; Tocco, G; Eritja, R; Wilson, SH; Goodman, MF				Efrati, E; Tocco, G; Eritja, R; Wilson, SH; Goodman, MF			Abasic translesion synthesis by DNA polymerase beta violates the ''A-rule'' - Novel types of nucleotide incorporation by human DNA polymerase beta at an abasic lesion in different sequence contexts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISPAIR EXTENSION KINETICS; DEOXYRIBONUCLEIC-ACID; REVERSE-TRANSCRIPTASE; SACCHAROMYCES-CEREVISIAE; FRAMESHIFT MUTAGENESIS; APYRIMIDINIC SITES; INSERTION FIDELITY; CODING PROPERTIES; ESCHERICHIA-COLI; REPAIR SYNTHESIS	The ''A-rule'' reflects the preferred incorporation of dAMP opposite abasic lesions in Escherichia coli in vivo. DNA polymerases (pol) from procaryotic and eucaryotic organisms incorporate nucleotides opposite abasic lesions in accordance with the A-rule. However, recent in vivo data demonstrate that A is not preferentially incorporated opposite abasic lesions in eucaryotes. Purified human DNA polymerases beta and alpha are used to measure the specificity of nucleotide incorporation at a site directed tetrahydrofuran abasic lesion, in 8-sequence contexts, varying upstream and downstream bases adjacent to the lesion. Extension past the lesion is measured in 4 sequence contexts, varying the downstream template base. Pol alpha strongly favors incorporation of dAMP directly opposite the lesion. In marked contrast, pol beta violates the A-rule for incorporation directly opposite the lesion, In addition to incorporation taking place directly opposite the lesion, we also analyze misalignment incorporation directed by a template base downstream from the lesion, Lesion bypass by pol beta occurs predominantly by ''skipping over'' the lesion, by insertion of a nucleotide complementary to an adjacent downstream template site. Misalignment incorporation for pol beta occurs by a novel ''dNTP-stabilized'' mechanism resulting in both deletion and base substitution errors. In contrast, pol alpha shows no propensity for this type of synthesis, The misaligned DNA structures generated during dNTP-stabilized lesion bypass do not conform to misaligned structures reported previously.	EUROPEAN MOL BIOL ORG,D-69012 HEIDELBERG,GERMANY; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	Efrati, E (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,HEDCO MOL BIOL LABS,LOS ANGELES,CA 90089, USA.		Eritja, Ramon/B-5613-2008; Wilson, Samuel H/E-6644-2019	Eritja, Ramon/0000-0001-5383-9334; Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398] Funding Source: NIH RePORTER; NIA NIH HHS [AG11398] Funding Source: Medline; NIEHS NIH HHS [ES06839] Funding Source: Medline; NIGMS NIH HHS [GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CAI H, 1993, J BIOL CHEM, V268, P23567; CHANG LMS, 1972, BIOCHEMISTRY-US, V11, P1264, DOI 10.1021/bi00757a023; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; ERITJA R, 1987, NUCLEOS NUCLEOT, V6, P803, DOI 10.1080/15257778708073426; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GIBBS PEM, 1995, J MOL BIOL, V251, P229, DOI 10.1006/jmbi.1995.0430; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; KAMIYA H, 1992, NUCLEIC ACIDS RES, V20, P4409, DOI 10.1093/nar/20.17.4409; KLINEDINST DK, 1992, MOL CARCINOGEN, V6, P32, DOI 10.1002/mc.2940060107; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; NETO JBC, 1992, J BIOL CHEM, V267, P19718; NETO JBC, 1994, J MOL BIOL, V240, P416, DOI 10.1006/jmbi.1994.1457; NISHIDA C, 1988, J BIOL CHEM, V263, P501; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOBEL RW, 1996, NATURE, V379, P183; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Szekeres ES, 1996, J BACTERIOL, V178, P2559, DOI 10.1128/jb.178.9.2559-2563.1996; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1	52	160	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2559	2569						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999973				2022-12-25	WOS:A1997WD67900079
J	Langston, AW; Thompson, JR; Gudas, LJ				Langston, AW; Thompson, JR; Gudas, LJ			Retinoic acid-responsive enhancers located 3' of the Hox A and Hox B homeobox gene clusters - Functional analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; REGION-SPECIFIC EXPRESSION; CENTRAL-NERVOUS-SYSTEM; RAR DOUBLE MUTANTS; HOMEOTIC GENES; POSITIONAL SPECIFICATION; PROOPIOMELANOCORTIN GENE; XENOPUS-LAEVIS; RECEPTORS RARS; GROWTH-FACTORS	Homeobox genes control the spatial identity and differentiation of tissues in the developing vertebrate embryo. Retinoids are signaling molecules involved in the regulation of Hox genes. We previously identified a 3' enhancer called the RAIDR(5), which contained a DR5 retinoic acid response element (RARE) and was responsible for the retinoic acid (RA)-associated expression of the murine Hoxa-1 gene in teratocarcinoma cells. We demonstrate that a similar enhancer, which contains a DR(5) RARE, is located at a DNase I-hypersensitive site 3' of the murine Hoxb-1 gene. This enhancer, the Hoxb-1 RAIDR(5), regulates the RA responsiveness of the Hoxb-1 gene and is different in location and sequence from the RA-regulated 3' Hoxb-1 enhancers previously described. Several DNA elements within the murine Hoxb-1 RA-inducible RAIDR, enhancer, including the DR(5) RARE, conserved element (CE) 1, and CE2, are conserved in the murine Hoxb-1 RAIDR(5), enhancer, the human homolog of Hoxa-1, and in the chicken Hoxb-1 gene. Gel shifts show that the CE2 sequence TATTTACTCA binds an RA-inducible factor, while UV cross-linking indicates that a 170-kDa protein binds to this sequence. Thus, the Hoxa-1 and Hoxb-1 genes possess 3' enhancers with similar sequences through which their expression and responsiveness to endogenous retinoids are controlled.	CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA	Cornell University					NCI NIH HHS [R01CA39036] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039036] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achkar CC, 1996, P NATL ACAD SCI USA, V93, P4879, DOI 10.1073/pnas.93.10.4879; AGARWAL VR, 1993, MECH DEVELOP, V44, P167, DOI 10.1016/0925-4773(93)90065-6; ANDREW DJ, 1992, NEW BIOL, V4, P5; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Blumberg B, 1996, P NATL ACAD SCI USA, V93, P4873, DOI 10.1073/pnas.93.10.4873; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BREIER G, 1986, EMBO J, V5, P2209, DOI 10.1002/j.1460-2075.1986.tb04486.x; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; COLBERGPOLEY AM, 1985, NATURE, V314, P713, DOI 10.1038/314713a0; CONLON RA, 1992, DEVELOPMENT, V116, P357; DEKKER EJ, 1993, MECH DEVELOP, V40, P3, DOI 10.1016/0925-4773(93)90083-A; DUBOULE D, 1993, ANN GENET-PARIS, V36, P24; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRASCH M, 1995, DEVELOPMENT, V121, P957; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GROSVELD F, 1990, ANN NY ACAD SCI, V612, P152; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; HOLDER N, 1991, DEVELOPMENT, V113, P1159; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; Kaufman T C, 1990, Adv Genet, V27, P309; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KESSEL M, 1993, NEURON, V10, P379, DOI 10.1016/0896-6273(93)90328-O; KESSEL M, 1992, DEVELOPMENT, V115, P487; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEWIS EB, 1992, JAMA-J AM MED ASSOC, V267, P1524, DOI 10.1001/jama.267.11.1524; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MORONI MC, 1993, MECH DEVELOP, V44, P139, DOI 10.1016/0925-4773(93)90063-4; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; OGURA T, 1995, P NATL ACAD SCI USA, V92, P392, DOI 10.1073/pnas.92.2.392; OGURA T, 1995, P NATL ACAD SCI USA, V92, P387, DOI 10.1073/pnas.92.2.387; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; POPPERL H, 1993, MOL CELL BIOL, V13, P257; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SHENEFELT RE, 1972, TERATOLOGY, V5, P103, DOI 10.1002/tera.1420050115; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; SUNDIN O, 1992, DEVELOPMENT, V114, P841; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TABIN CJ, 1992, DEVELOPMENT, V116, P289; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAKAHASHI YI, 1975, J NUTR, V105, P1299, DOI 10.1093/jn/105.10.1299; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TICKLE C, 1991, DEVELOPMENT, P113; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202	80	135	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2167	2175						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999919	hybrid			2022-12-25	WOS:A1997WD67900025
J	Ono, S; Yamakita, Y; Yamashiro, S; Matsudaira, PT; Gnarra, JR; Obinata, T; Matsumura, F				Ono, S; Yamakita, Y; Yamashiro, S; Matsudaira, PT; Gnarra, JR; Obinata, T; Matsumura, F			Identification of an actin binding region and a protein kinase C phospkorylation site on human fascin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; CROSS-LINKING PROTEIN; BUNDLING PROTEIN; CULTURED-CELLS; HOMOLOG; MARCKS; EXPRESSION; FAMILY; PHOSPHOPROTEINS; LOCALIZATION	Fascin is a 5538-kDa actin-bundling protein, the actin binding of which is regulated by phosphorylation (Yamakita, Y., One, S., Matsumura, F., add Yamashiro, S, (1996) J. Biol. Chem. 271, 12632-12638). To understand the mechanism of fascin-actin interactions, we dissected the actin binding region and its regulatory site by phosphorylation of human fascin. First, we found that the C-terminal half constitutes an actin binding domain, Partial digestion of human recombinant fascin with trypsin yielded the C-terminal fragment with molecular masses of 32, 30, and 27 kDa. The 32- and 27-kDa fragments purified as a mixture formed a dimer and bound to F-actin at a saturation ratio of 1 dimer:11 actin molecules with an affinity of 1.4 x 10(6) M(-1). Second, we identified the phosphorylation site of fascin as Ser-39 by sequencing a tryptic phosphopeptide purified by chelating column chromatography followed by C-18 reverse phase high performance liquid chromatography. Pep tide map analyses revealed that the purified peptide represented the major phosphorylation site of in vivo as well as in vitro phosphorylated fascin. The mutation replacing Ser-39 with Ala eliminated the phosphorylation-dependent regulation of actin binding of fascin, indicating that phosphorylation at this site regulates the actin binding ability of fascin.	RUTGERS STATE UNIV,DEPT MOL BIOL & BIOCHEM,NELSON LABS,PISCATAWAY,NJ 08855; CHIBA UNIV,DEPT BIOL,INAGE KU,CHIBA 263,JAPAN; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; NCI,UROL ONCOL SECT,SURG BRANCH,NATL INST HLTH,BETHESDA,MD 20892	Rutgers State University New Brunswick; Chiba University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Yamakita, Yoshihiko/A-3003-2016; Matsudaira, Paul/H-1475-2012; Ono, Shoichiro/A-6475-2015	Matsudaira, Paul/0000-0002-8399-3276; Ono, Shoichiro/0000-0002-4763-0398; Yamashiro, Shigeko/0000-0001-7207-9406; Gnarra, James/0000-0002-6369-3110; Matsumura, Fumio/0000-0002-8204-153X	NCI NIH HHS [R37 CA42742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1995, J CELL SCI, V108, P1977; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; BRYAN J, 1978, J MOL BIOL, V125, P207, DOI 10.1016/0022-2836(78)90345-5; BURGESS DR, 1977, J CELL BIOL, V74, P1032, DOI 10.1083/jcb.74.3.1032; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; DUH FM, 1994, DNA CELL BIOL, V13, P821, DOI 10.1089/dna.1994.13.821; Edwards R. A., 1994, Molecular Biology of the Cell, V5, p398A; EDWARDS RA, 1995, CELL MOTIL CYTOSKEL, V32, P1, DOI 10.1002/cm.970320102; EDWARDS RA, 1995, J BIOL CHEM, V270, P10764, DOI 10.1074/jbc.270.18.10764; GAO ZH, 1992, BIOCHEMISTRY-US, V31, P6126, DOI 10.1021/bi00141a024; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOLTHUIS JCM, 1994, BBA-GENE STRUCT EXPR, V1219, P184, DOI 10.1016/0167-4781(94)90267-4; KANE RE, 1975, J CELL BIOL, V66, P305, DOI 10.1083/jcb.66.2.305; KANE RE, 1976, J CELL BIOL, V71, P704, DOI 10.1083/jcb.71.3.704; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MATSUMURA F, 1983, J BIOL CHEM, V258, P6636; Mohr O. L., 1922, Zeitschrift fuer Induktive Abstammungs und Vererbungslehre Berlin, V28, P1, DOI 10.1007/BF01923368; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; MUSZYNSKA G, 1986, BIOCHEMISTRY-US, V25, P6850, DOI 10.1021/bi00370a018; OTTO JJ, 1979, CELL, V17, P285, DOI 10.1016/0092-8674(79)90154-5; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; OTTO JJ, 1984, DEV BIOL, V101, P263, DOI 10.1016/0012-1606(84)90140-4; OTTO JJ, 1981, CELL MOTIL CYTOSKEL, V1, P179, DOI 10.1002/cm.970010203; OTTO JJ, 1980, CELL MOTIL CYTOSKEL, V1, P31, DOI 10.1002/cm.970010104; OVERTON J, 1967, J MORPHOL, V122, P367, DOI 10.1002/jmor.1051220406; PATERSON J, 1991, GENETICS, V129, P1073; SPUDICH JA, 1979, J MOL BIOL, V129, P319, DOI 10.1016/0022-2836(79)90285-7; TILNEY LG, 1995, J CELL BIOL, V130, P629, DOI 10.1083/jcb.130.3.629; VANDEKERCKHOVE J, 1992, Current Opinion in Cell Biology, V4, P36, DOI 10.1016/0955-0674(92)90056-I; Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632; YAMASHIROMATSUMURA S, 1986, J CELL BIOL, V103, P631, DOI 10.1083/jcb.103.2.631; YAMASHIROMATSUMURA S, 1985, J BIOL CHEM, V260, P5087	40	148	154	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2527	2533						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999969				2022-12-25	WOS:A1997WD67900075
J	Slepushkin, VA; Simoes, S; Dazin, P; Newman, MS; Guo, LS; deLima, MCP; Duzgunes, N				Slepushkin, VA; Simoes, S; Dazin, P; Newman, MS; Guo, LS; deLima, MCP; Duzgunes, N			Sterically stabilized pH-sensitive liposomes - Intracellular delivery of aqueous contents and prolonged circulation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DELIVERY; DRUG-DELIVERY; OLEIC-ACID; PLASMA; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; VESICLES; CELLS; MACROMOLECULES; SYSTEM; INVIVO	Liposomes that destabilize at mildly acidic pH are efficient tools for delivering water-soluble drugs into the cell cytoplasm. However, their use in vivo is limited because of their rapid uptake from circulation by the reticuloendothelial system. Lipid-anchored polyethylene glycol (PEG-PE) prolongs the circulation time of liposomes by steric stabilization. We have found that addition of PEG-PE to the membrane of pH-sensitive liposomes composed of cholesteryl hemisuccinate (CHEMS) and dioleoylphosphatidylethanolamine (DOPE) confers steric stability to these vesicles. This modification significantly decreases the pH-dependent release of a charged water-soluble fluorophore, calcein, from liposomes suspended in buffer or cell culture medium. However, the ability of such liposomes to release calcein intracellularly, measured by a novel flow cytometry technique involving dual fluorescence labeling, remains unaltered. As expected, the release of calcein from liposomes endocytosed by cells is inhibited upon pretreatment of the cells with NH4Cl, an inhibitor of endosome acidification. The unique properties of these liposomes were also demonstrated in vivo. The distribution kinetics of In-111-containing CHEMS/DOPE/PEG-PE liposomes injected intravenously into rats has pharmacokinetic parameters similar to control, non-pH-sensitive, sterically stabilized CHEMS/distearoylphosphatidylcholine/PEG-PE liposomes. In contrast, regular pH-sensitive liposomes lacking the PEG-PE component are cleared rapidly. Sterically stabilized pH-sensitive liposomes may therefore be useful, for the intracellular delivery in vivo of highly negatively charged molecules such as genes, antisense oligonucleotides, and ribozymes for the treatment of various diseases.	UNIV PACIFIC,SCH DENT,DEPT MICROBIOL,SAN FRANCISCO,CA 94115; DI IVANOVSKII INST VIROL,MOSCOW 123098,RUSSIA; UNIV COIMBRA,FAC PHARM,P-3000 COIMBRA,PORTUGAL; UNIV COIMBRA,DEPT BIOCHEM,P-3000 COIMBRA,PORTUGAL; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOPHARMACEUT SCI,SAN FRANCISCO,CA 94143; SEQUUS PHARMACEUT,MENLO PK,CA 94025	University of the Pacific; Russian Academy of Medical Sciences; Gamaleya National Research Center for Epidemiology & Microbiology, RAMS; Universidade de Coimbra; Universidade de Coimbra; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Duzgunes, Nejat/V-5058-2019; Simoes, Sergio/A-3798-2012; de Lima, Maria da Conceição Monteiro/AAS-5602-2021; Duzgunes, Nejat/T-5478-2019	de Lima, Maria da Conceição Monteiro/0000-0003-1844-5027; Simoes, Sergio/0000-0002-8898-7625	NIAID NIH HHS [AI 32399, AI 33833, AI 35231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032399, R01AI033833, U01AI035231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN TM, 1993, BIOCHIM BIOPHYS ACTA, V1150, P9, DOI 10.1016/0005-2736(93)90115-G; ALLEN TM, 1994, ADV DRUG DELIVER REV, V13, P285, DOI 10.1016/0169-409X(94)90016-7; ALLEN TM, 1992, CANCER RES, V52, P2431; ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X; ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5; BAKKERWOUDENBERG IAJM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P318, DOI 10.1016/0925-4439(92)90010-K; BANGHAM AD, 1964, J MOL BIOL, V8, P660, DOI 10.1016/S0022-2836(64)80115-7; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y; CHONN A, 1995, CURR OPIN BIOTECH, V6, P698, DOI 10.1016/0958-1669(95)80115-4; CHU CJ, 1990, PHARM RES-DORDR, V7, P824, DOI 10.1023/A:1015908831507; Collins D., 1995, LIPOSOMES TOOLS BASI, P201; CONNOR J, 1985, J CELL BIOL, V101, P582, DOI 10.1083/jcb.101.2.582; DUZGUNES N, 1991, MEMBRANE FUSION, P713; ELLENS H, 1984, BIOCHEMISTRY-US, V23, P1532, DOI 10.1021/bi00302a029; GRANT CWM, 1989, MAGNET RESON MED, V11, P236, DOI 10.1002/mrm.1910110211; KHIBANOV AL, 1990, FEBS LETT, V268, P235; KONO K, 1994, BBA-BIOMEMBRANES, V1193, P1, DOI 10.1016/0005-2736(94)90325-5; KONOPKA K, 1993, VIROLOGY, V193, P877, DOI 10.1006/viro.1993.1197; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; Lasic DD, 1995, STEALTH LIPOSOMES; LEE KD, 1993, BIOCHEMISTRY-US, V32, P889, DOI 10.1021/bi00054a021; LESERMAN L, 1995, LIPOSOMES TOOLS BASI, P215; LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1127, P249, DOI 10.1016/0005-2760(92)90228-N; LIU D, 1989, BIOCHEM BIOPH RES CO, V162, P326, DOI 10.1016/0006-291X(89)91999-2; LIU DX, 1990, BIOCHIM BIOPHYS ACTA, V1022, P348, DOI 10.1016/0005-2736(90)90284-U; LIU DX, 1989, BIOCHEMISTRY-US, V28, P7700, DOI 10.1021/bi00445a027; Lurquin P.F., 1993, LIPOSOME TECHNOLOGY, V2, P129; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; New R. R. C., 1990, LIPOSOMES PRACTICAL, P71; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8; Singhal A., 1994, GENE THERAPEUTICS ME, P118, DOI 10.1007/978-1-4684-6822-9_7; Slepushkin V. A., 1995, Biophysical Journal, V68, pA216; SMITH JG, 1993, BIOCHIM BIOPHYS ACTA, V1154, P327, DOI 10.1016/0304-4157(93)90004-8; STEWART CC, 1990, FLOW CYTOMETRY, P427; STRAUBINGER RM, 1985, FEBS LETT, V179, P148, DOI 10.1016/0014-5793(85)80210-6; STRAUBINGER RM, 1993, METHOD ENZYMOL, V221, P361, DOI 10.1016/0076-6879(93)21030-C; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; Torchilin VP, 1993, J LIPOSOME RES, V3, P201, DOI DOI 10.3109/08982109309148213]; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VAAGE J, 1994, CANCER, V73, P2366, DOI 10.1002/1097-0142(19940501)73:9<2366::AID-CNCR2820730920>3.0.CO;2-6; VIANI P, 1993, BIOCHIM BIOPHYS ACTA, V1147, P73, DOI 10.1016/0005-2736(93)90317-S; WOODLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1105, P193, DOI 10.1016/0005-2736(92)90194-Q; WOODLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P171, DOI 10.1016/0304-4157(92)90038-C	47	215	231	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2382	2388						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999949				2022-12-25	WOS:A1997WD67900055
J	Tang, ZL; Okamoto, T; Boontrakulpoontawee, P; Katada, T; Otsuka, AJ; Lisanti, MP				Tang, ZL; Okamoto, T; Boontrakulpoontawee, P; Katada, T; Otsuka, AJ; Lisanti, MP			Identification, sequence, and expression of an invertebrate caveolin gene family from the nematode Caenorhabditis elegans - Implications for the molecular evolution of mammalian caveolin genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; TRANS-GOLGI-NETWORK; PLASMA-MEMBRANE; C-ELEGANS; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS; PROTEIN-COMPONENT; VESICLES; VIP21-CAVEOLIN; TYROSINE	Caveolae are vesicular organelles that represent an appendage of the plasma membrane. Caveolin, a 21-24-kDa integral membrane protein, is a principal component of caveolae membranes in vivo. Caveolin has been proposed to function as a plasma membrane scaffolding protein to organize and concentrate signaling molecules within caveolae, including heterotrimeric G proteins (alpha and beta gamma subunits), In this regard, caveolin interacts directly with G(alpha) subunits and can functionally regulate their activity. To date, three cDNAs encoding four subtypes of caveolin have been described in vertebrates. However, evidence for the existence of caveolin proteins in less complex organisms has been lacking. Here, we report the identification, cDNA sequence and genomic organization of the first invertebrate caveolin gene, Cav(ce) (for caveolin from Caenorhabditis elegans). The Cav(ce) gene, located on chromosome TV, consists of two exons interrupted by a 125-nucleotide intron sequence, The region of Cav(ce) that is strictly homologous to mammalian caveolins is encoded by a single exon in Cav(ce). This suggests that mammalian caveolins may have evolved from the second exon of Cav(ce). Cav(ce) is roughly equally related to all three known mammalian caveolins and, thus, could represent a common ancestor. Remarkably, the invertebrate Cav(ce) protein behaves like mammalian caveolins: (i) Cav(ce) forms a high molecular mass oligomer, (ii) assumes a cytoplasmic membrane orientation, and (iii) interacts with G proteins. A 20-residue peptide encoding the predicted Gr protein binding region of Cav(ce) possesses ''GDP dissociation inhibitor like activity'' with the same potency as described earlier for mammalian caveolin-1. Thus, caveolin appears to be structurally and functionally conserved from worms to man. In addition, we find that there are at least two caveolin-related genes expressed in C. el-egans, defining an invertebrate caveolin gene family.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, SCH MED,MASSACHUSETTS GEN HOSP, SHRINERS HOSP CRIPPLED CHILDREN,DEPT ANESTHESIA, BOSTON, MA 02114 USA; ILLINOIS STATE UNIV, DEPT BIOL SCI, NORMAL, IL 61790 USA; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, BUNKYO KU, TOKYO 113, JAPAN	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Illinois State University; University of Tokyo			Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; HENGARTNER MO, 1994, PHILOS T R SOC B, V345, P243, DOI 10.1098/rstb.1994.0100; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; IZUMI T, 1988, ANAT REC, V220, P225, DOI 10.1002/ar.1092200302; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	54	78	86	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2437	2445						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999956	hybrid			2022-12-25	WOS:A1997WD67900062
J	Joseph, SK; Boehning, D; Pierson, S; Nicchitta, CV				Joseph, SK; Boehning, D; Pierson, S; Nicchitta, CV			Membrane insertion, glycosylation, and oligomerization of inositol trisphosphate receptors in a cell-free translation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ONE SIGNAL SEQUENCE; 1,4,5-TRISPHOSPHATE RECEPTOR; K+-CHANNEL; POTASSIUM CHANNEL; FUNCTIONAL-CHARACTERIZATION; LIGAND-BINDING; SUBUNIT; EXPRESSION; CLONING	In order to study the membrane topology, processing, and oligomerization of inositol trisphosphate receptor (IP(3)R) isoforms, we have utilized RNA templates encoding putative transmembrane domains to program a cell-free translation system of rabbit reticulocyte lysates supplemented with canine pancreas microsomes. In the absence of microsomes, translation of the RNA templates encoding all the putative transmembrane domains present in the C-terminal segment of the type I (1TM) and type III (3TM) IP(3)R isoforms resulted in a 62- and 59-kDa polypeptide, respectively. In both cases, an additional band approximately 3 kDa larger was observed upon the addition of microsomes. Both bands in the translation doublet were integrated into microsomal membranes and were full-length translation products, as shown by sedimentation through a sucrose cushion and immunoprecipitation with C-terminal isoform-specific antibodies. With both isoforms, N-glycopeptidase F digestion indicates that the upper band in the doublet corresponds to a glycosylated translation product. A 17-kDa protected fragment was observed after proteinase-K digestion of 1TM translated in the presence of microsomes. The pattern and size of protected fragments was consistent with the current six transmembrane domain model of IP(3)R topology. Cotranslation of both 1TM and 3TM RNA templates in the presence of microsomes followed by immunoprecipitation with isoform specific antibodies revealed coimmunoprecipitation of translation products. This was not observed when the isoforms were translated separately and then mixed, suggesting that heteroligomerization occurs cotranslationally. A construct encoding only the first putative transmembrane domain of the type I isoform was found to be sufficient for integration into membranes but was unable to oligomerize with either 1TM or 3TM. Cotranslation experiments using additional constructs indicate that the major structural determinant for homoligomerization lies between putative transmembrane domain 5 and the C terminus. A second oligomerization domain involved in stabilization of heteroligomers is present within the first four transmembrane domains.	THOMAS JEFFERSON UNIV, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19107 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Jefferson University; Duke University			Boehning, Darren/I-8539-2015	Boehning, Darren/0000-0001-7920-6922	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897, R01DK034804] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK34804, R01-DK47897] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COSTA GL, 1994, NUCLEIC ACIDS RES, V22, P2423, DOI 10.1093/nar/22.12.2423; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRATA M, 1994, MOL PHARMACOL, V45, P271; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1993, METH NEUROSCI, V18, P247; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PONGS O, 1993, J MEMBRANE BIOL, V136, P1; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; ZEHAVI HP, 1996, BIOCHEMISTRY-US, V35, P6828; ZHOU MY, 1995, BIOTECHNIQUES, V19, P34	56	57	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1579	1588		10.1074/jbc.272.3.1579	http://dx.doi.org/10.1074/jbc.272.3.1579			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999831	hybrid			2022-12-25	WOS:A1997WD05800029
J	Paudel, HK				Paudel, HK			The regulatory Ser(262) of microtubule-associated protein tau is phosphorylated by phosphorylase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-LIKE STATE; PROLINE-DIRECTED PHOSPHORYLATION; RABBIT-SKELETAL-MUSCLE; SUBSTRATE-SPECIFICITY; NEURONAL MORPHOLOGY; DYNAMIC INSTABILITY; GLYCOGEN-SYNTHASE; PEPTIDE SUBSTRATE; SYNTHETIC PEPTIDE	Abnormally phosphorylated tan is the major component of paired helical filaments found in the brains of patients suffering from Alzheimer's disease. Therefore, the identification of kinases that phosphorylate tau is of considerable interest. A DEAE-Sepharose column resolved porcine brain extract into five tau kinase activity peaks. Among these peaks, two were completely inhibited by EGTA, indicating that these two activity peaks contained Ca2+-dependent tau kinases. One of the above two Ca2+-dependent tau kinase activity peaks also contained phosphorylase kinase activity. The tau kinase and phosphorylase kinase activities associated with this peak could not be separated from each other by Superose 12 gel filtration, hydroxylapatite, and calmodulin-agarose affinity chromatographies. Phosphorylase kinase, purified from rabbit skeletal muscle, phosphorylated tau to a stoichiometry of 2.1 mol of phosphate/mol of tau and converted tau to a species with a retarded mobility on SDS polyacrylamide gel electrophoresis. The apparent K-m and k(cat) values for tau phosphorylation by muscle phosphorylase kinase were 6.9 mu M and 47.4 min(-1), respectively. As a substrate of muscle phosphorylase kinase, phosphorylase was eight times better than tau. Sequence analyses of tryptic and thermolytic phosphopeptides derived from tau phosphorylated by muscle phosphorylase kinase revealed five phosphorylation sites, Ser(237), Ser(262), Ser(285), Ser(305), and Ser(352). Among these sites, Ser(262) was previously shown to be phosphorylated in human tau from fetal, adult, and Alzheimer's diseased brains (Seubert, P., Mawal-Dewan, M., Barbour, R., Jakes, R., Goedert, M., Johnson, G. V. W., Litersky, J. M., Schenk, D., Lieberburg, I., Trojanowski, J. Q., and Lee, V. M. Y. (1995) J. Biol. Chem. 270, 18917-18922); and its phosphorylation abolished tau's binding to microtubules (Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms, G., Meyer, H. E., Mandelkow, E.-M., and Mandelkow, E. (1995) J. Biol. Chem. 270, 7679-7688). Slot-blot analysis using a monoclonal antibody against muscle phosphorylase kinase and an activity assay using phosphorylase revealed that phosphorylase kinase was present in microtubules extensively purified by repeated cycles of polymerization and depolymerization. Taken together, these results suggest that in neurons, phosphorylase kinase may be one of the kinases that participate in the phosphorylation of tau.	MCGILL UNIV, DEPT NEUROL & NEUROSURG, MONTREAL, PQ H3T 1E2, CANADA	McGill University	Paudel, HK (corresponding author), SIR MORTIMER B DAVIS JEWISH HOSP, LADY DAVIS INST MED RES, BLOOMFIELD CTR RES AGING, MONTREAL, PQ H3T 1E2, CANADA.							ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BOLLEN M, 1987, ARCH BIOCHEM BIOPHYS, V254, P437, DOI 10.1016/0003-9861(87)90122-6; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRECKENRIDGE BM, 1965, J NEUROCHEM, V12, P51, DOI 10.1111/j.1471-4159.1965.tb10251.x; BROWNING M, 1979, SCIENCE, V203, P60, DOI 10.1126/science.214855; BROWNING M, 1979, NATURE, V278, P273, DOI 10.1038/278273a0; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CHENG A, 1985, J BIOL CHEM, V260, P2535; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; DEPAOLIROACH AA, 1979, J BIOL CHEM, V254, P4212; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUMMOND GI, 1970, J NEUROCHEM, V17, P475, DOI 10.1111/j.1471-4159.1970.tb00524.x; EDWARDS C, 1974, J NEUROCHEM, V22, P565, DOI 10.1111/j.1471-4159.1974.tb06896.x; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FOLBERGROVA J, 1977, BRAIN RES, V135, P337, DOI 10.1016/0006-8993(77)91036-8; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GREENWOOD JA, 1994, J BIOL CHEM, V269, P4373; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOWNE D, 1971, J PHYSIOL-LONDON, V212, P503, DOI 10.1113/jphysiol.1971.sp009338; Lee V M, 1992, Curr Opin Neurobiol, V2, P653, DOI 10.1016/0959-4388(92)90034-I; LEW J, 1992, J BIOL CHEM, V267, P13383; Madsen NB, 1986, ENZYMES, V17, P365; MALLER JL, 1978, P NATL ACAD SCI USA, V75, P248, DOI 10.1073/pnas.75.1.248; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MATTSON MP, 1991, MOL CHEM NEUROPATHOL, V15, P117, DOI 10.1007/BF03159951; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MATTSON MP, 1994, ANN NY ACAD SCI, V747, P50; MATUS A, 1994, TRENDS NEUROSCI, V17, P19, DOI 10.1016/0166-2236(94)90030-2; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MEYER WL, 1964, BIOCHEMISTRY-US, V3, P1033, DOI 10.1021/bi00896a004; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; PAUDEL HK, 1991, J BIOL CHEM, V266, P16524; PAUDEL HK, 1993, J BIOL CHEM, V268, P6207; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PELECH SL, 1995, NEUROBIOL AGING, V16, P247, DOI 10.1016/0197-4580(94)00187-6; PETTEGREW JW, 1994, NEUROBIOL AGING, V15, P117, DOI 10.1016/0197-4580(94)90152-X; Pickett-Gies CA., 1986, ENZYMES, V17, P395; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SAITOH T, 1993, ANN NY ACAD SCI, V695, P34, DOI 10.1111/j.1749-6632.1993.tb23023.x; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; SODERLING TR, 1979, P NATL ACAD SCI USA, V76, P2536, DOI 10.1073/pnas.76.6.2536; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WATANABE A, 1993, J BIOL CHEM, V268, P25712	72	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1777	1785						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999860				2022-12-25	WOS:A1997WD05800058
J	Pavloff, N; Pemberton, PA; Potempa, J; Chen, WCA; Pike, RN; Prochazka, V; Kiefer, MC; Travis, J; Barr, PJ				Pavloff, N; Pemberton, PA; Potempa, J; Chen, WCA; Pike, RN; Prochazka, V; Kiefer, MC; Travis, J; Barr, PJ			Molecular cloning and characterization of Porphyromonas gingivalis lysine-specific gingipain - A new member of an emerging family of pathogenic bacterial cysteine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLACK-PIGMENTED BACTEROIDES; STRUCTURAL CHARACTERIZATION; EXTRACELLULAR-MATRIX; ARG-GINGIPAIN; DEGRADATION; PURIFICATION; INHIBITORS; ADHERENCE; FORMS	The proteinases of Porphyromonas gingivalis are key virulence factors in the etiology and progression of periodontal disease. Previous work in our laboratories resulted in the purification of arginine- and lysine-specific cysteine proteinases, designated gingipains, that consist of several tightly associated protein subunits. Recent characterization of arginine-specific gingipain-1 (gingipain R1; RGP-1) revealed that the sequence is unique and that the protein subunits are initially translated as a polyprotein encoding a proteinase domain and multiple adhesin domains (Pavloff, N., Potempa, J., Pike, R. N., Prochazka, V., Kiefer, M. C., Travis, J., and Parr, P. J. (1995) J. Biol. Chem. 270, 1007-1010). We now show that the lysine-specific gingipain (gingipain K; KGP) is also biosynthesized as a polyprotein precursor that contains a proteinase domain that is 22% homologous to the proteinase domain of RGP-1 and multiple adhesin domains. This precursor is similarly processed at distinct sites to yield active KGP. The key catalytic residues in the proteinase domain of KGP are identical to those found in RGP-1, but there are significant differences elsewhere within this domain that likely contribute to the altered substrate specificity of KGP. Independent expression of the proteinase domain in insect cells has shown that KGP does not require the presence of the adhesin domains for correct folding to confer proteolytic activity.	JAGIELLONIAN UNIV,INST MOL BIOL,DEPT MICROBIOL & IMMUNOL,PL-31120 KRAKOW,POLAND; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602	Jagiellonian University; University System of Georgia; University of Georgia	Pavloff, N (corresponding author), LXR BIOTECHNOL INC,1401 MARINA WAY S,RICHMOND,CA 94804, USA.		Prochazka, Vaclav/M-2176-2019	Pike, Robert/0000-0002-2083-0269	NIDCR NIH HHS [DE-09761] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CARLSSON J, 1984, INFECT IMMUN, V43, P644, DOI 10.1128/IAI.43.2.644-648.1984; CARLSSON J, 1984, J MED MICROBIOL, V18, P39, DOI 10.1099/00222615-18-1-39; CIBOROWSKI P, 1994, J BACTERIOL, V176, P4549, DOI 10.1128/JB.176.15.4549-4557.1994; HOLT SC, 1988, SCIENCE, V239, P55, DOI 10.1126/science.3336774; HOWKE D, 1987, APPL BIOSYSTEMS PROT, V28, P1; JOHNSON NW, 1991, MARKERS DIS SUSCEPTI; KILIAN M, 1989, INFECT IMMUN, V57, P1868; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Maniatis T., 1982, MOL CLONING; NILSSON T, 1985, INFECT IMMUN, V50, P467, DOI 10.1128/IAI.50.2.467-471.1985; NISHIKATA M, 1991, BIOCHEM BIOPH RES CO, V178, P336, DOI 10.1016/0006-291X(91)91819-X; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; PIKE R, 1994, J BIOL CHEM, V269, P406; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANSONETTI PJ, 1993, MED MICROBIOL IMMUN, V182, P223, DOI 10.1007/BF00579621; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SHAH HN, 1989, FEMS MICROBIOL LETT, V52, P213; SLOTS J, 1988, J CLIN PERIODONTOL, V15, P85, DOI 10.1111/j.1600-051X.1988.tb00999.x; SMALLEY JW, 1988, ARCH ORAL BIOL, V33, P323, DOI 10.1016/0003-9969(88)90065-9; SUNDQVIST G, 1985, J MED MICROBIOL, V19, P85, DOI 10.1099/00222615-19-1-85; WESTERLUND B, 1993, MOL MICROBIOL, V9, P687, DOI 10.1111/j.1365-2958.1993.tb01729.x; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902	28	106	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1595	1600		10.1074/jbc.272.3.1595	http://dx.doi.org/10.1074/jbc.272.3.1595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999833	hybrid			2022-12-25	WOS:A1997WD05800031
J	Schick, C; Kamachi, Y; Bartuski, AJ; Cataltepe, S; Schechter, NM; Pemberton, PA; Silverman, GA				Schick, C; Kamachi, Y; Bartuski, AJ; Cataltepe, S; Schechter, NM; Pemberton, PA; Silverman, GA			Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL ELASTASE; REACTIVE CENTER LOOP; SERINE PROTEINASES; MOLECULAR-CLONING; ANGIOTENSIN-II; MECHANISM; PROTEASE; SUPERFAMILY; EXPRESSION; ACTIVATION	The squamous cell carcinoma antigen (SCCA) serves as a serological marker for more advanced squamous cell tumors. Molecular cloning of the SCCA genomic region revealed the presence of two tandemly arrayed genes, SCCA1 and SCCA2. Analysis of the primary amino acid sequences shows that both genes are members of the high molecular weight serpin superfamily of serine proteinase inhibitors. Although SCCA1 and SCCA2 are nearly identical in primary structure, the reactive site loop of each inhibitor suggests that they may differ in their specificity for target proteinases. SCCA1 has been shown to be effective against papain-like cysteine proteinases. The purpose of this study was to determine whether SCCA2 inhibited a different family of proteolytic enzymes. Using recombinant DNA techniques, we prepared a fusion protein of glutathione S-transferase and full-length SCCA2. The recombinant SCCA2 was most effective against two chymotrypsin-like proteinases from inflammatory cells, but was ineffective against papain-like cysteine proteinases. Serpin-like inhibition was observed for both human neutrophil cathepsin G and human mast cell chymase. The second order rate constants for these associations were on the order of similar to 1 x 10(5) M(-1) s(-1) and similar to 3 x 10(4) M(-1) s(-1) for cathepsin G and mast cell chymase, respectively. Moreover, SCCA2 formed SDS stable complexes with these proteinases at a stoichiometry of near 1:1. These data showed that SCCA2 is a novel inhibitor of two physiologically important chymotrypsin-like serine proteinases.	HARVARD UNIV, CHILDRENS HOSP,SCH MED,DEPT PEDIAT, JOINT PROGRAM NEONATOL, BOSTON, MA 02115 USA; UNIV PENN, SCH MED, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA; LXR BIOTECHNOL, RICHMOND, CA 94804 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Pennsylvania			Silverman, Gary/AAJ-1269-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028475, R29HD028475] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA069331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042931] Funding Source: NIH RePORTER; NCI NIH HHS [CA69331] Funding Source: Medline; NIAMS NIH HHS [AR42931] Funding Source: Medline; NICHD NIH HHS [HD28475] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAICI A, 1982, SCAND J IMMUNOL, V16, P487, DOI 10.1111/j.1365-3083.1982.tb00750.x; BANGALORE N, 1994, BIOL CHEM H-S, V375, P659, DOI 10.1515/bchm3.1994.375.10.659; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BRUCH M, 1989, EUR J BIOCHEM, V185, P271, DOI 10.1111/j.1432-1033.1989.tb15112.x; CAPODICI C, 1991, AGENTS ACTIONS, V34, P8, DOI 10.1007/BF01993223; CARRELL RW, 1989, MOL BIOL MED, V6, P35; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; CAUGHEY GH, 1989, AM J PHYSIOL, V257, pL39, DOI 10.1152/ajplung.1989.257.2.L39; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHRISTENSEN S, 1995, J BIOL CHEM, V270, P14859, DOI 10.1074/jbc.270.25.14859; CRAIG SS, 1989, IMMUNOL RES, V8, P130, DOI 10.1007/BF02919075; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; FRANCKE U, 1981, CYTOGENET CELL GENET, V31, P24, DOI 10.1159/000131622; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; HASEYAMAZAKI T, 1995, CELL IMMUNOL, V160, P24, DOI 10.1016/0008-8749(95)80005-4; HECK LW, 1990, AM J PATHOL, V136, P1267; HEUSEL JW, 1993, BLOOD, V81, P1614; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; HWANG SR, 1994, P NATL ACAD SCI USA, V91, P9579, DOI 10.1073/pnas.91.20.9579; JALLAT S, 1986, PROTEIN ENG, V1, P29, DOI 10.1093/protein/1.1.29; JANUSZ MJ, 1991, J IMMUNOL, V146, P3922; JOHNSON RJ, 1988, J EXP MED, V168, P1169, DOI 10.1084/jem.168.3.1169; KATO H, 1987, JPN J CANCER RES, V78, P1246; KATO H, 1977, CANCER, V40, P1621, DOI 10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I; KATO H, 1984, JPN J CANCER RES, V75, P433; Kato H., 1992, SEROLOGICAL CANC MAR, P437; KLICKSTEIN LB, 1982, J BIOL CHEM, V257, P5042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAOUAR A, 1994, EUR J BIOCHEM, V223, P617, DOI 10.1111/j.1432-1033.1994.tb19033.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MAISON CM, 1991, J IMMUNOL, V147, P921; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; MOLINO M, 1992, BIOCHEM J, V288, P741, DOI 10.1042/bj2880741; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NADEL JA, 1991, ANN NY ACAD SCI, V629, P319; OKADA Y, 1989, FEBS LETT, V249, P353, DOI 10.1016/0014-5793(89)80657-X; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PATSTON PA, 1994, ANN NY ACAD SCI, V714, P13, DOI 10.1111/j.1749-6632.1994.tb12026.x; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; REILLY CF, 1982, J BIOL CHEM, V257, P8619; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SELAK MA, 1988, BIOCHEM J, V251, P293, DOI 10.1042/bj2510293; SHAFER WM, 1993, INFECT IMMUN, V61, P1900, DOI 10.1128/IAI.61.5.1900-1908.1993; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SILVERMAN GA, 1991, GENOMICS, V9, P219, DOI 10.1016/0888-7543(91)90245-A; SILVERMAN GA, 1993, MOL CELL BIOL, V13, P5469, DOI 10.1128/MCB.13.9.5469; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; SPITZNAGEL JK, 1990, J CLIN INVEST, V86, P1381, DOI 10.1172/JCI114851; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; TAKESHIMA N, 1992, TUMOR BIOL, V13, P338, DOI 10.1159/000217784; TONNESEN MG, 1982, J CLIN INVEST, V69, P25, DOI 10.1172/JCI110437; TRAVIS J, 1990, BIOL CHEM H-S, V371, P3; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652	75	190	196	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1849	1855		10.1074/jbc.272.3.1849	http://dx.doi.org/10.1074/jbc.272.3.1849			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999871	hybrid			2022-12-25	WOS:A1997WD05800069
J	Steinert, PM; Marekov, LN				Steinert, PM; Marekov, LN			Direct evidence that involucrin is a major early isopeptide crosslinked component of the keratinocyte cornified cell envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; CROSS-LINKED ENVELOPE; BULLOUS PEMPHIGOID ANTIGEN; PROLINE-RICH PROTEINS; HUMAN LORICRIN; INTERMEDIATE FILAMENTS; TRANSGLUTAMINASE SUBSTRATE; ELASTASE INHIBITOR; GENE-EXPRESSION; TRANSGENIC MICE	Involucrin was the first protein to be identified as a likely constituent of the insoluble cornified cell envelope lope (CE) of stratified squamous epithelia. However, to date, direct isolation from CEs of involucrin crosslinked by way of the transglutaminase-induced isopeptide bond has not been reported. We have treated human foreskin CEs with methanol/KOH (saponification) to hydrolyze off much of the lipids. By immunogold electron microscopy, this exposed large amounts of involucrin epitopes as well as of desmoplakin, a desmosomal structural protein. About 20% of the total CE protein could be solubilized by proteolytic digestion after saponification, of which involucrin was the most abundant. Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin or, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family. Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links. Many identical peptides were obtained from immature CEs isolated from the inner living cell layers of foreskin epidermis. The multiple crosslinked partners of involucrin provide experimental confirmation that involucrin is an important early scaffold protein in the CE. Further, these data suggest that there is significant redundancy in the structural organization of the CE.			Steinert, PM (corresponding author), NIAMSD,SKIN BIOL LAB,NIH,BLDG 6 ROOM 425,BETHESDA,MD 20892, USA.							ABERNETHY JL, 1977, J BIOL CHEM, V252, P1837; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHANG F, 1993, BIOCHIM BIOPHYS ACTA, V1150, P98, DOI 10.1016/0005-2736(93)90126-K; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; DEVIRAGH PA, 1994, J INVEST DERMATOL, V103, P815, DOI 10.1111/1523-1747.ep12413482; DOWNING DT, 1992, J LIPID RES, V33, P301; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ELIAS PM, 1992, SEMIN DERMATOL, V11, P176; ETOH Y, 1986, BIOCHEM BIOPH RES CO, V136, P51, DOI 10.1016/0006-291X(86)90875-2; FOISNER R, 1994, ACTA HISTOCHEM, V96, P421, DOI 10.1016/S0065-1281(11)80029-2; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Fraser R.D.B., 1972, KERATINS THEIR COMPO; Fujiwara S, 1996, J INVEST DERMATOL, V106, P1125, DOI 10.1111/1523-1747.ep12340171; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; GRECO MA, 1995, J INVEST DERMATOL, V104, P204, DOI 10.1111/1523-1747.ep12612759; GREEN H, 1992, MOL BIOL EVOL, V9, P977; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; GREEN KJ, 1990, CELLULAR MOL BIOL IN, P147; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOHL D, 1991, J BIOL CHEM, V266, P6626; IshidaYamamoto A, 1996, J HISTOCHEM CYTOCHEM, V44, P167, DOI 10.1177/44.2.8609373; Jarnik M, 1996, J CELL SCI, V109, P1381; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1987, NUCLEIC ACIDS RES, V15, P5945, DOI 10.1093/nar/15.15.5945; KLATTE DH, 1989, J CELL BIOL, V109, P3773; LAZO ND, 1995, J INVEST DERMATOL, V105, P296, DOI 10.1111/1523-1747.ep12318985; LEE SC, 1993, J BIOL CHEM, V268, P12164; LIESKA N, 1985, J CELL BIOL, V100, P620; LU CG, 1996, P NATL ACAD SCI USA, V93, P4278; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MING ME, 1993, J INVEST DERMATOL, V100, P578; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; NEGRI AP, 1993, TEXT RES J, V63, P109, DOI 10.1177/004051759306300207; NONOMURA K, 1994, J INVEST DERMATOL, V103, P88, DOI 10.1111/1523-1747.ep12391802; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICHARDS S, 1988, BIOCHEM J, V253, P153, DOI 10.1042/bj2530153; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; ROOP DR, 1984, J BIOL CHEM, V259, P8037; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SCHALKWIJK J, 1991, BIOCHIM BIOPHYS ACTA, V1096, P148, DOI 10.1016/0925-4439(91)90053-C; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; SONNENBERG A, 1990, J CELL SCI, V96, P201; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; STEVEN AC, 1994, J CELL SCI, V107, P693; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; TAKAHASHI M, 1992, FEBS LETT, V308, P79, DOI 10.1016/0014-5793(92)81055-Q; TANAKA T, 1991, J BIOL CHEM, V266, P12555; TARCSA E, 1992, J BIOL CHEM, V267, P25648; WARHOL MJ, 1985, J HISTOCHEM CYTOCHEM, V33, P141, DOI 10.1177/33.2.2578499; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WATT FM, 1994, KERATINOCYTE HDB, P153; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; YONEDA K, 1992, J BIOL CHEM, V267, P18060; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754; ZAHN H, 1994, TEXT RES J, V64, P554, DOI 10.1177/004051759406400910; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238; ZHANG B, 1990, J BIOL CHEM, V265, P2425	76	183	187	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					2021	2030		10.1074/jbc.272.3.2021	http://dx.doi.org/10.1074/jbc.272.3.2021			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999895	hybrid			2022-12-25	WOS:A1997WD05800093
J	Wilson, CA; Payton, MN; Elliott, GS; Buaas, FW; Cajulis, EE; Grosshans, D; Ramos, L; Reese, DM; Slamon, DJ; Calzone, FJ				Wilson, CA; Payton, MN; Elliott, GS; Buaas, FW; Cajulis, EE; Grosshans, D; Ramos, L; Reese, DM; Slamon, DJ; Calzone, FJ			Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-Delta 11b	ONCOGENE			English	Article						BRCA1; subcellular localization; alternative splicing	HUMAN CYTOMEGALO-VIRUS; IMMEDIATE EARLY GENE; BREAST-CANCER; OVARIAN-CANCER; MONOCLONAL-ANTIBODIES; KINETIC-MODEL; MUTATIONS; FAMILIES; PROTEIN; TISSUES	The mechanism of BRCA1 tumor suppression in human breast and ovarian cells is the focus investigation. In this report, full length (230 kDa) introduced into cells with CMV promoter constructs was nuclear when transgene expression was low whereas high expression resulted in cytoplasmic accumulation, aberrant nuclear and cell morphology. A nuclear localization signal (NLS) was mapped to BRCA1 amino acid positions 262-570. We describe a splice variant, BRCA1-Delta 11b, missing the majority of exon 11 including the NLS. Exogenous BRCA1-Delta 11b (110 kDa) was cytoplasmic and, unlike the full-length protein, overexpression of the protein encoded by the variant did not appear to be toxic. RNA probe titrations and RT-PCR demonstrated that BRCA1 and Delta 11b transcripts are coexpressed in a wide variety of cells and tissues. Interestingly, BRCA1-Delta 11b message was greatly reduced or absent in several breast and ovarian tumor lines relative to exon 11 transcripts and a Delta 9,10 splice variant. Taken together our results suggest that full-length BRCA1 and BRCA1-Delta 11b may have distinct roles in cell growth regulation and tumorigenesis.	AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90095 USA	Amgen; University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA36827] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKRIGG A, 1985, VIRUS RES, V2, P107, DOI 10.1016/0168-1702(85)90242-4; BAG J, 1991, TRANSLATION EUKARYOT, P71; BERGMANN JE, 1979, J BIOL CHEM, V254, P1927; Bienstock RJ, 1996, CANCER RES, V56, P2539; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOYD M, 1995, NATURE, V375, P541, DOI 10.1038/375541b0; Bradley A, 1996, NAT GENET, V13, P268, DOI 10.1038/ng0796-268b; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNIG D, 1994, PROG GROWTH FACTOR R, V4, P353; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GALAU GA, 1977, ARCH BIOCHEM BIOPHYS, V179, P584, DOI 10.1016/0003-9861(77)90147-3; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GODEFROYCOLBURN T, 1981, J BIOL CHEM, V256, P1762; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Ithier G, 1996, NEW ENGL J MED, V334, P1198; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Jensen RA, 1996, NAT GENET, V13, P269, DOI 10.1038/ng0796-269; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; Rao VN, 1996, ONCOGENE, V12, P523; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shattuck-Eidens D, 1995, JAMA-J AM MED ASSOC, V273, P535; Slobin L.I., 1991, TRANSLATION EUKARYOT, P149; Sobol A, 1996, CANCER RES, V56, P3216; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264	50	176	181	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					1	16		10.1038/sj.onc.1200924	http://dx.doi.org/10.1038/sj.onc.1200924			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010228				2022-12-25	WOS:A1997WB76000001
J	Bisogno, T; Maurelli, S; Melck, D; DePetrocellis, L; DiMarzo, V				Bisogno, T; Maurelli, S; Melck, D; DePetrocellis, L; DiMarzo, V			Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID RECEPTOR; N-ACYLETHANOLAMINES; ENDOGENOUS LIGAND; RAT-BRAIN; CELLS; NEUROPEPTIDES; MODULATION; HYDROLYSIS; AGONIST; BINDS	Anandamide (arachidonoylethanolamide, AnNH) and palmitoylethanolamide (PEA) have been proposed as the physiological ligands, respectively, of central and peripheral cannabinoid receptors. Both of these receptors are expressed in immune cells, including macrophages and mast cells/basophils, where immunomodulatory and/or anti-inflammatory actions of AnNH and PEA have been recently reported. We now provide biochemical grounds to these actions by showing that the biosynthesis, uptake, and degradation of AnNH and PEA occur in leukocytes. On stimulation with ionomycin, J774 macrophages and RBL-2H3 basophils produced AnNH and PEA, probably through the hydrolysis of the corresponding N-acylphosphatidylethanolamines, also found among endogenous phospholipids. Immunological challenge of RBL-2H3 cells also caused AnNH and PEA release. The chemical structure and the amounts of AnNH and PEA produced upon ionomycin stimulation were determined by means of double radiolabeling experiments and isotope dilution gas chromatography/ electron impact mass spectrometry. Both cell lines rapidly sequestered the two amides from the culture medium through temperature-dependent, saturable and chemically inactivable mechanisms. Once uptaken by basophils, AnNH and PEA compete for the same inactivating enzyme which catalyzes their hydrolysis to ethanolamine. This enzyme was found in both microsomal and 10,000 x g fractions of RBL cell homogenates, and exhibited similar inhibition and temperature/pH dependence profiles but a significantly higher affinity for PEA with respect to neuronal ''anandamide amidohydrolase.'' The finding of biosynthetic and inactivating mechanisms for AnNH and PEA in macrophages and basophils supports the previously proposed role as local modulators of immune/inflammatory reactions for these two long chain acylethanolamides.	CNR,IST CHIM MOL INTERESSE BIOL,I-80072 ARCO,NAPOLI,ITALY; CNR,IST CIBERNET,I-80072 ARCO,NAPOLI,ITALY	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR)			Bisogno, Tiziana/B-7891-2015; Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070				Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; DIMARZO V, 1989, TRENDS PHARMACOL SCI, V10, P91, DOI 10.1016/0165-6147(89)90198-3; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; DIMARZO V, 1995, J DRUG DEV CLIN PR, V7, P199; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; FONTANA A, 1995, PROSTAG LEUKOTR ESS, V53, P301, DOI 10.1016/0952-3278(95)90130-2; GULAYA NM, 1993, BIOCHIM BIOPHYS ACTA, V1152, P280, DOI 10.1016/0005-2736(93)90259-3; HANUS L, 1993, J MED CHEM, V36, P3032, DOI 10.1021/jm00072a026; HERKENHAM M, 1995, CANNABINOID RECEPTOR, P35; HILLARD CJ, 1995, BBA-LIPID LIPID MET, V1257, P249, DOI 10.1016/0005-2760(95)00087-S; Kempe K, 1996, J BIOL CHEM, V271, P17287, DOI 10.1074/jbc.271.29.17287; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Maurelli S, 1995, FEBS LETT, V377, P82, DOI 10.1016/0014-5793(95)01311-3; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; MECHOULAM R, 1994, BIOCHEM PHARMACOL, V48, P1537, DOI 10.1016/0006-2952(94)90197-X; MORLEY JE, 1987, LIFE SCI, V41, P527, DOI 10.1016/0024-3205(87)90405-X; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; ODORISIO MS, 1985, J IMMUNOL, V135, pS792; PAYAN DG, 1984, J IMMUNOL, V132, P1601; PERLIK F, 1973, EXPERIENTIA, V29, P67, DOI 10.1007/BF01913256; RIENDEAU D, 1994, J BIOL CHEM, V269, P15615; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SCHWARZ H, 1994, J NEUROIMMUNOL, V55, P107, DOI 10.1016/0165-5728(94)90152-X; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Stefano GB, 1996, J BIOL CHEM, V271, P19238, DOI 10.1074/jbc.271.32.19238; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823	37	332	339	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3315	3323		10.1074/jbc.272.6.3315	http://dx.doi.org/10.1074/jbc.272.6.3315			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013571	hybrid			2022-12-25	WOS:A1997WG19200031
J	Han, SK; Yoon, ET; Scott, DL; Sigler, PB; Cho, WW				Han, SK; Yoon, ET; Scott, DL; Sigler, PB; Cho, WW			Structural aspects of interfacial adsorption - A crystallographic and site-directed mutagenesis study of the phospholipase A(2) from the venom of Agkistrodon piscivorus piscivorus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIZED MIXED LIPOSOMES; AMINO-ACID-SEQUENCE; TRANSITION-STATE ANALOG; PANCREATIC PHOSPHOLIPASE-A(2); CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; ACTIVE-SITE; X-RAY; BINDING; ASPARTATE-49	Recent genetic and structural studies have shed considerable light on the mechanism by which secretory phospholipases A(2) interact with substrate aggregates. Electrostatic forces play an essential role in optimizing interfacial catalysis. Efficient and productive adsorption of the Class I bovine pancreatic phospholipase A(2) to anionic interfaces is dependent upon the presence of two nonconserved lysine residues at sequence positions 56 and 116, implying that critical components of the adsorption surface differ among enzyme species (Dua, R. Wu, S.-K., and Cho, W. (1995) J. Biol. Chem. 270, 263-268). In an effort to further characterize the protein residues involved in interfacial catalysis, we have determined the high resolution (1.7 Angstrom) x-ray structure of the Class II Asp-49 phospholipase A(2) from the venom of Agkistrodon piscivorus piscivorus, Correlation of the three-dimensional coordinates with kinetic data derived from site-directed mutations near the amino terminus (E6R, K7E, K1OE, K11E, and K16E) and the active site (K54E and K69Y) defines much of the interface topography, Lysine residues at sequence positions 7 and 10 mediate the adsorption of A. p. piscivorus phospholipase A(2) to anionic interfaces but play Little role in the enzyme's interaction with electrically neutral surfaces or in substrate binding. Compared to the native enzyme, the mutant proteins K7E and K1OE demonstrate comparable (20-fold) decreases in affinity and catalysis on polymerized mixed liposomes of 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphocholine and 1,2-bis[12-(lipoyloxy)dodecanoyl]-sn-glycero-3-phosphoglycerol, while the double mutant, K7E/K1OE, shows a more dramatic 500-fold decrease in catalysis and interfacial adsorption, The calculated contributions of Lys-7 and Lys-10 to the free energy of binding of A. p. piscivorus phospholipase A(2) to anionic liposomes (-1.8 kcal/mol at 25 degrees C per lysine) are additive (i.e. -3.7 kcal/mol) and together represent nearly half of the total binding energy, Although both lysine side chains lie exposed at the edge of the proposed interfacial adsorption surface, they are geographically remote from the correspending interfacial determinants for the bovine enzyme. Our results confirm that interfacial adsorption is largely driven by electrostatic forces and demonstrate that the arrangement of the critical charges (e.g. lysines) is species-specific. This variability in the topography of the adsorption surface suggests a corresponding flexibility in the orientation of the active enzyme at the substrate interface.	UNIV ILLINOIS, DEPT CHEM, CHICAGO, IL 60607 USA; YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06511 USA; YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06511 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Yale University; Howard Hughes Medical Institute; Yale University					NIGMS NIH HHS [GM52598, GM24324] Funding Source: Medline; NINDS NIH HHS [NS25867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BELL JD, 1991, METHOD ENZYMOL, V197, P249; BURACK WR, 1994, CHEM PHYS LIPIDS, V73, P209, DOI 10.1016/0009-3084(94)90182-1; CHO WW, 1988, J BIOL CHEM, V263, P11237; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIJKSTRA BW, 1981, NATURE, V289, P604, DOI 10.1038/289604a0; DUA R, 1995, J BIOL CHEM, V270, P263, DOI 10.1074/jbc.270.1.263; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; FLEER EAM, 1981, EUR J BIOCHEM, V113, P283, DOI 10.1111/j.1432-1033.1981.tb05064.x; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; JAIN MK, 1993, BIOCHEMISTRY-US, V32, P11838, DOI 10.1021/bi00095a012; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KATES M, 1986, TECHNIQUES LIPIDOLOG, P115; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUIPERS OP, 1989, SCIENCE, V244, P82, DOI 10.1126/science.2704992; KUIPERS OP, 1990, PROTEIN ENG, V3, P599, DOI 10.1093/protein/3.7.599; LATHROP BK, 1992, PROTEIN EXPRES PURIF, V3, P512, DOI 10.1016/1046-5928(92)90069-9; Lee BI, 1996, BIOCHEMISTRY-US, V35, P4231, DOI 10.1021/bi9524777; LIU XH, 1995, BIOCHEMISTRY-US, V34, P7322, DOI 10.1021/bi00022a005; LUGTIGHEID RB, 1993, EUR J BIOCHEM, V213, P517, DOI 10.1111/j.1432-1033.1993.tb17789.x; MALIWAL BP, 1994, BIOCHEMISTRY-US, V33, P4509, DOI 10.1021/bi00181a010; MARAGANORE JM, 1986, J BIOL CHEM, V261, P4797; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PUJIK WC, 1977, BIOCHIM BIOPHYS ACTA, V492, P254; RANDOLPH A, 1982, J BIOL CHEM, V257, P2155; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1994, BIOPHYS J, V67, P493, DOI 10.1016/S0006-3495(94)80546-6; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHEN Z, 1994, BIOCHEMISTRY-US, V33, P11598, DOI 10.1021/bi00204a022; SHEN Z, 1995, INT J BIOCHEM CELL B, V27, P1009, DOI 10.1016/1357-2725(95)00072-W; SHEN Z, 1995, J LIPID RES, V36, P1147; SNITKO Y, IN PRESS BIOCH J; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; TSAI IH, 1981, TOXICON, V19, P141; WELCHES W, 1993, J PROTEIN CHEM, V12, P187, DOI 10.1007/BF01026040; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; WU SK, 1994, ANAL BIOCHEM, V221, P152, DOI 10.1006/abio.1994.1391; WU SK, 1993, BIOCHEMISTRY-US, V32, P13902, DOI 10.1021/bi00213a020	49	88	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3573	3582		10.1074/jbc.272.6.3573	http://dx.doi.org/10.1074/jbc.272.6.3573			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013608	hybrid			2022-12-25	WOS:A1997WG19200068
J	Routledge, EJ; Sumpter, JP				Routledge, EJ; Sumpter, JP			Structural features of alkylphenolic chemicals associated with estrogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR FUNCTIONS; HORMONE-BINDING; YEAST; BIOMARKER; ASSAY	The ability of certain man-made chemicals to mimic the effects of natural steroid hormones and their potential to disrupt the delicate balance of the endocrine system in animals are of increasing concern, The growing list of reported hormone-mimics includes the alkylphenolic (AP) compounds, a small number of which have been reported to be weakly estrogenic, in their most basic form, APs are composed of an alkyl group, which can vary in size, branching, and position, joined to a phenolic ring, The aim of this project was to identify the important structural features responsible for the estrogenic activity of AP chemicals, This was achieved by incubating APs with different structural features in a medium containing a previously described estrogen-inducible strain of yeast (Saccharomyces cerevisiae) expressing the human estrogen receptor and comparing their activity spectrophotometrically by the resulting color change of the medium. The results were compared to the effects of the main natural estrogen 17 beta-estradiol. The data indicate that both the position (para > meta > ortho) and branching (tertiary > secondary = normal) of the alkyl group affect estrogenicity. Optimal estrogenic activity requires a single tertiary branched alkyl group composed of between 6 and 8 carbons located at the pam position on an otherwise unhindered phenol ring. The results are discussed in relation to the purity and composition of the chemicals tested.			Routledge, EJ (corresponding author), BRUNEL UNIV, DEPT BIOL & BIOCHEM, UXBRIDGE UB8 3PH, MIDDX, ENGLAND.		Routledge, Edwin John/V-2336-2019; sumpter, john/HGB-7584-2022; Routledge, Edwin/AGI-0283-2022	Routledge, Edwin/0000-0001-7695-364X				AHEL M, 1993, ENVIRON POLLUT, V79, P243, DOI 10.1016/0269-7491(93)90096-7; AHEL M, 1994, ARCH ENVIRON CON TOX, V26, P540, DOI 10.1007/BF00214159; Arnold SF, 1996, ENVIRON HEALTH PERSP, V104, P544, DOI 10.2307/3432996; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BHATT BD, 1992, J CHROMATOGR SCI, V30, P203, DOI 10.1093/chromsci/30.6.203; BIRNBAUM LS, 1995, ENVIRON HEALTH PERSP, V103, P89, DOI 10.2307/3432515; BITMAN J, 1970, J AGR FOOD CHEM, V18, P1108, DOI 10.1021/jf60172a019; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; *CHEM MAN ASS, 1991, ALK ETH HUM HLTH ENV; Colborn T. C, 1992, ADV MODERN ENV TOXIC, VXXI; Connor K, 1996, FUND APPL TOXICOL, V30, P93, DOI 10.1006/faat.1996.0046; Cook JW, 1933, NATURE, V131, P56, DOI 10.1038/131056b0; DODDS E. C., 1937, Nature, V139, P627, DOI 10.1038/139627b0; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dodds EC, 1937, NATURE, V140, P772, DOI 10.1038/140772a0; Dodds EC, 1938, NATURE, V142, P34, DOI 10.1038/142034a0; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; Dodds EC, 1938, PROC R SOC SER B-BIO, V125, P222, DOI 10.1098/rspb.1938.0023; DODDS EC, 1937, NATURE, V139, P1068; HEPPELL SA, 1995, ENVIRON HEALTH PERSP, V103, P9, DOI 10.2307/3432500; Jobling S, 1996, ENVIRON TOXICOL CHEM, V15, P194, DOI [10.1002/etc.5620150218, 10.1897/1551-5028(1996)015&lt;0194:IOTGIR&gt;2.3.CO;2]; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; JOBLING S, 1993, AQUAT TOXICOL, V27, P361, DOI 10.1016/0166-445X(93)90064-8; KATZENELLENBOGEN BS, 1993, J STEROID BIOCHEM, V47, P39, DOI 10.1016/0960-0760(93)90055-2; KATZENELLENBOGEN JA, 1995, ENVIRON HEALTH PERSP, V103, P99, DOI 10.2307/3432517; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; LAN NC, 1976, ENDOCRINOLOGY, V98, P220, DOI 10.1210/endo-98-1-220; LEDREAN Y, 1995, MOL CELL ENDOCRINOL, V109, P27, DOI 10.1016/0303-7207(95)03482-M; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MIKSICEK RJ, 1994, J STEROID BIOCHEM, V49, P153, DOI 10.1016/0960-0760(94)90005-1; MUELLER GC, 1978, ENDOCRINOLOGY, V102, P1429, DOI 10.1210/endo-102-5-1429; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; PURVIS IJ, 1991, GENE, V106, P35, DOI 10.1016/0378-1119(91)90563-Q; Routledge EJ, 1996, ENVIRON TOXICOL CHEM, V15, P241, DOI 10.1002/etc.5620150303; Sharpe RM, 1995, ENVIRON HEALTH PERSP, V103, P1136, DOI 10.2307/3432610; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SKIDMORE JR, 1972, J ENDOCRINOL, V52, P289, DOI 10.1677/joe.0.0520289; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.1289/ehp.95103s7113; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; SOTO AM, 1991, ENVIRON HEALTH PERSP, V92, P167, DOI 10.1289/ehp.9192167; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; Talmage S.S., 1994, ENV HUMAN SAFETY MAJ; WALLER CL, 1995, ENVIRON HEALTH PERSP, V103, P702, DOI 10.2307/3432862; WHEELER TF, 1997, IN PRESS J CHROMATOG; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; WHITTEN PL, 1995, J NUTR, V125, pS771, DOI 10.1093/jn/125.3_Suppl.771S; WIESE TE, 1995, STEROIDS, V60, P802, DOI 10.1016/0039-128X(95)00143-E	49	424	456	0	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3280	3288		10.1074/jbc.272.6.3280	http://dx.doi.org/10.1074/jbc.272.6.3280			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013566	Green Published, hybrid			2022-12-25	WOS:A1997WG19200026
J	Verheijen, MHG; Defize, LHK				Verheijen, MHG; Defize, LHK			Parathyroid hormone activates mitogen-activated protein kinase via a cAMP-mediated pathway independent of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE-2; BETA-GAMMA-SUBUNITS; MAP KINASE; PC12 CELLS; DEPENDENT ACTIVATION; CYCLIC-AMP; TYROSINE PHOSPHORYLATION; OSTEOSARCOMA CELLS; PHOSPHOLIPASE-C	In a previous study, we demonstrated that parathyroid hormone (PTH) inhibits mitogen-activated protein (MAP) kinase activation in osteosarcoma cells via a protein kinase A-dependent pathway. Here, we show that PTH can induce a transient activation of MAP kinase as well. This was observed in both Chinese hamster ovary R15 cells stably expressing high levels of rat PTH/PTH related peptide receptor and parietal yolk sac carcinoma cells expressing the receptor endogenously. PTH was a strong activator of adenylate cyclase and phospholipase C in Chinese hamster ovary R15 cells. PTH-induced MAP kinase activation did not depend on activation of G(i), phorbol ester-sensitive protein kinase C, elevated intracellular calcium levels, or release of G beta gamma subunits. It could, however, be mimicked by addition of forskolin or 8-bromo-cAMP to these cells, Prolonged treatment with forskolin caused sustained protein kinase A activity, whereas MAP kinase activity returned to basal levels. Subsequent treatment with PTH or 8-bromo-cAMP did not result in MAP kinase activation, whereas phorbol ester or insulin-induced MAP kinase activation was unaffected. Finally, expression of a dominant negative form of Pas (Ras(Asn-17)), which completely blocked insulin-induced MAP kinase activation, did not affect activation by PTH or cAMP. In conclusion, PTH regulates MAP kinase activity in a cell type-specific fashion. The activation of MAP kinase by PTH is mediated by cAMP and independent of Ras.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)			Verheijen, Mark/GQY-5157-2022; Verheijen, Mark/AAD-8112-2019	Verheijen, Mark/0000-0002-3739-3755				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHAN SD, 1990, MOL ENDOCRINOL, V4, P639; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P221; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUO J, 1995, ENDOCRINOLOGY, V136, P3884, DOI 10.1210/en.136.9.3884; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hazlerigg DG, 1996, ENDOCRINOLOGY, V137, P210, DOI 10.1210/en.137.1.210; HEASLY LE, 1991, MOL PHARMACOL, V35, P331; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIAPI C, 1987, J CELL PHYSIOL, V133, P405, DOI 10.1002/jcp.1041330229; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NANTEL F, 1994, J BIOL CHEM, V269, P13148; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; REID IR, 1987, AM J PHYSIOL, V252, pE45; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDESTOLPE A, 1993, J CELL BIOL, V120, P235, DOI 10.1083/jcb.120.1.235; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; WINITZ S, 1993, J BIOL CHEM, V268, P19196; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	52	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3423	3429		10.1074/jbc.272.6.3423	http://dx.doi.org/10.1074/jbc.272.6.3423			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013586	hybrid			2022-12-25	WOS:A1997WG19200046
J	Ferrier, AF; Lee, M; Anderson, WB; Benvenuto, G; Morrison, DK; Lowy, DR; DeClue, JE				Ferrier, AF; Lee, M; Anderson, WB; Benvenuto, G; Morrison, DK; Lowy, DR; DeClue, JE			Sequential modification of serines 621 and 624 in the Raf-1 carboxyl terminus produces alterations in its electrophoretic mobility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAYS; POLYMERASE CHAIN-REACTION; NIH 3T3 CELLS; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANES; MAMMALIAN-CELLS; ACTIVATION; RAS; REQUIREMENT	The Raf-1 serine/threonine protein kinase plays a central role in many of the mitogenic signaling pathways regulating cell growth and differentiation. The regulation of Raf-1 is complex, and involves protein-protein interactions as well as changes in the phosphorylation state of Raf-1 that are accompanied by alterations in its electrophoretic mobility. We have previously shown that a 33-kDa COOH-terminal, kinase-inactive fragment of Raf-1 underwent a mobility shift in response to the stimulation of cells with serum or phorbol esters. Here we demonstrate that treatment of NIH 3T3 cells or Sf9 cells with hydrogen peroxide (H2O2) also induces the mobility shift of the kinase-inactive Raf-1 fragment. A series of deletion mutants of the Raf-1 COOH terminus were analyzed, and the region required for the mobility shift was localized to a 78-amino acid fragment (residues 566-643). Metabolic labeling revealed that the slower migrating forms of the 33-kDa and of the smaller fragment contained phosphorus. Mutation of a previously characterized phosphorylation site, serine 621, to alanine prevented the mobility shift as well as phosphate incorporation or Src and Ras-dependent kinase activation in Sf9 cells when this mutation was engineered into the full-length Raf-1. Mutation of 621 to aspartate yielded a protein that existed in both the shifted and unshifted forms, demonstrating that a negative charge at 621 was necessary, but not sufficient, for the mobility shift to occur; however, its full-length form was still resistant to activation in the Sf9 system. Additional mutation of nearby serine 624 to alanine blocked the shift, implicating this residue as the site of the second of a two-step modification process leading to the slower migrating form. Co-expression of the 33-kDa fragment with an activated form of mitogen-activated protein kinase kinase in NIH 3T3 led to the appearance of the shifted form in a serum-independent manner. These results demonstrate that a mitogen-activated protein kinase kinase-induced event involving modification of serines 621 and 624 leads to the mobility shift of Raf-1.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NCI,MOL MECHANISMS CARCINOGENESIS LAB,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				BENVENUTO, Giovanna/0000-0001-7155-2935				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BORNER C, 1992, J BIOL CHEM, V267, P12900; BOTTORFF D, 1995, MOL CELL BIOL, V15, P5113; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; OLAH Z, 1995, BIOCHEM BIOPH RES CO, V214, P340, DOI 10.1006/bbrc.1995.2293; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; ORR JW, 1994, J BIOL CHEM, V269, P27715; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SETH A, 1992, J BIOL CHEM, V267, P24796; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SOZERI O, 1992, ONCOGENE, V7, P2259; STEVENSON MA, 1994, CANCER RES, V54, P122; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; UEKI K, 1994, J BIOL CHEM, V269, P15756; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG J, 1994, J BIOL CHEM, V269, P19578	61	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2136	2142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999914				2022-12-25	WOS:A1997WD67900020
J	Sato, T; Aoki, J; Nagai, Y; Dohmae, N; Takio, K; Doi, T; Arai, H; Inoue, K				Sato, T; Aoki, J; Nagai, Y; Dohmae, N; Takio, K; Doi, T; Arai, H; Inoue, K			Serine phospholipid-specific phospholipase A that is secreted from activated platelets - A new member of the lipase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; HUMAN LIPOPROTEIN-LIPASE; EXTRACELLULAR PHOSPHOLIPASE-A2; PROSTAGLANDIN SYNTHESIS; PANCREATIC LIPASE; RAT PLATELETS; CDNA; GENE; LYSOPHOSPHOLIPASE; PURIFICATION	Rat platelets secrete two types of phospholipases upon stimulation; one is type II phospholipase A(2) and the other is serine-phospholipid-selective phospholipase A. In the current study me purified serine-phospholipid-selective phospholipase A and cloned its cDNA. The final preparation, purified hom extracellular medium of activated rat platelets, gave a 55-kDa protein band on SDS-polyacrylamide gel electrophoresis. [H-3]Diisopropyl fluorophosphate, an inhibitor of the enzyme, labeled the 55-kDa protein, suggesting that this polypeptide possesses active serine residues. The cDNA for the enzyme was cloned hom a rat megakaryocyte cDNA library. The predicted 456-amino acid sequence contains a putative short N-terminal signal sequence and a GXSXG sequence, which is a motif of an active serine residue of serine esterase. Amino acid sequence homology analysis revealed that the enzyme shares about 30% homology with mammalian lipases (lipoprotein lipase, hepatic lipase, and pancreatic lipase). Regions surrounding the putative active serine, histidine, and aspartic acid, which may form a ''lipase triad,'' were highly conserved among these enzymes. The recombinant protein, which we expressed in Sf9 insect cells using the baculovirus system, hydrolyzed a fatty acyl residue at the sn-1 position of lysophosphatidylserine and phosphatidylserine, but did not appreciably hydrolyze phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidic acid, and triglyceride. The present enzyme, named phosphatidylserine-phospholipase A(1), is the first phospholipase that exclusively hydrolyses the sn-1 position and has a strict head group specificity for the substrate.	UNIV TOKYO, FAC PHARMACEUT SCI, BUNKYO KU, TOKYO 113, JAPAN; RIKEN, INST PHYS & CHEM RES, DIV BIOMOL CHARACTERIZAT, WAKO, SAITAMA 35101, JAPAN; OSAKA UNIV, FAC PHARMACEUT SCI, SUITA, OSAKA 565, JAPAN	University of Tokyo; RIKEN; Osaka University			Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410				ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEN ZO, 1994, J LIPID RES, V35, P1511; BRAULT D, 1992, GENE, V121, P237, DOI 10.1016/0378-1119(92)90127-B; BUSCA R, 1995, J LIPID RES, V36, P939; CHANG HW, 1986, J BIOCHEM-TOKYO, V100, P1099, DOI 10.1093/oxfordjournals.jbchem.a121791; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DOI T, 1987, MOL CELL BIOL, V7, P898, DOI 10.1128/MCB.7.2.898; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HIGASHI S, 1988, J BIOCHEM-TOKYO, V103, P442, DOI 10.1093/oxfordjournals.jbchem.a122289; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P53, DOI 10.1093/oxfordjournals.jbchem.a121907; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; KIM DK, 1990, J BIOCHEM-TOKYO, V108, P903, DOI 10.1093/oxfordjournals.jbchem.a123311; KOBAYASHI T, 1985, J BIOCHEM-TOKYO, V98, P1017, DOI 10.1093/oxfordjournals.jbchem.a135347; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KOMADA M, 1990, BIOCHEM BIOPH RES CO, V168, P1059, DOI 10.1016/0006-291X(90)91137-H; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; LEE KS, 1994, J BIOL CHEM, V269, P19725; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; VAN TH, 1994, J BIOL CHEM, V269, P4626; VERHEIJ HM, 1991, METHOD ENZYMOL, V197, P214; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YOKOYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1280, DOI 10.1093/oxfordjournals.jbchem.a124856	39	125	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2192	2198						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999922				2022-12-25	WOS:A1997WD67900028
J	Laird, V; High, S				Laird, V; High, S			Discrete cross-linking products identified during membrane protein biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL-ANCHOR SEQUENCES; ER-MEMBRANE; PHOTOCROSS-LINKING; SECRETORY PROTEINS; BOVINE OPSIN; TRANSLOCATION; ENVIRONMENT; INSERTION; ADJACENT	We have investigated the molecular details of the membrane insertion of the multiple-spanning membrane protein opsin. Using heterobifunctional cross linking reagents the endoplasmic reticulum (ER) proteins adjacent to a series of defined translocation intermediates were determined. Once the nascent opsin chain reaches a critical minimum length Sec61 alpha is the major ER component adjacent to the polypeptide. Using a homobifunctional reagent, the cross-linking partners from a single cysteine residue in the nascent chain were analyzed. This approach identified chain length-dependent cross-linking products between nascent opsin and a 21-kDa ribosomal protein, followed by Sec61 beta and finally with Sec61 alpha. Our data support a model where the sequential transmembrane domains of a multiple-spanning membrane protein are integrated at an ER insertion site similar to that mediating the insertion of single-spanning membrane proteins.	UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester				High, Stephen/0000-0002-4532-8152				AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOEL AC, 1996, CELL, V85, P379; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1995, PROG BIOPHYS MOL BIO, V63, P233, DOI 10.1016/0079-6107(95)00005-8; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HIGH S, 1993, J BIOL CHEM, V268, P26745; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Martoglio B, 1996, TRENDS CELL BIOL, V6, P142, DOI 10.1016/0962-8924(96)10001-5; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519	37	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1983	1989		10.1074/jbc.272.3.1983	http://dx.doi.org/10.1074/jbc.272.3.1983			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999890	hybrid			2022-12-25	WOS:A1997WD05800088
J	Bies, J; Wolff, L				Bies, J; Wolff, L			Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway	ONCOGENE			English	Article						c-Myb; proteolytic stability; 26S proteasome; ubiquitin; PEST sequence	NEGATIVE REGULATORY DOMAIN; LEUKEMIA-CELL-LINE; V-MYB; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; PROTEIN-DEGRADATION; TRANS-ACTIVATION; MESSENGER-RNA; GENE; EXPRESSION	c-myb activation by insertional mutagenesis in murine myeloid leukemias can lead to amino (NH2)-terminal or carboxyl (COOH)-terminal truncation of its protein product, We observed that in these leukemias, the steady state level of the protein truncated at the COOH terminus was remarkably higher than that of the protein truncated at the NH2-terminus or full length wild-type protein, To examine the rate of proteolysis of different forms of Myb in a uniform cellular background, the proteins were constitutively expressed in the myeloblast cell line M1, using the retrovirus vector LXSN. In pulse chase experiments, using metabolically S-35-labeled proteins, it was determined that COOH-terminal truncation of c-Myb by 248 aa (CT-c-Myb) substantially increases protein stability, resulting in a t(1/2) of about 140 min, as compared to 50 min for full length c-Myb (FL-c-Myb). In an investigation of the mechanism involved in the in vivo degradation of this short lived transcription factor, inhibitors of the lysosomal (chloroquine), proteasomal (ALLM, ALLN, iactacystin) and calpains (EGTA, E-64d, BAPTA/AM) pathways were utilized, Results of this experiment identified the 26S proteasome as a major pathway responsible for rapid breakdown of the protein in hematopoietic cells, Further experiments carried out in vitro demonstrated that c-Myb cap be ubiquitinated, suggesting that this process may be involved in the targeting of wild-type c-Myb to degradation by the 26S proteasome. In addition, it was demonstrated that CT-c-Myb was less efficiently ubiquitinated than wild-type protein indicating that defects in modification account for its escape from rapid turnover, We speculate that the increased half-life of c-Myb resulting from truncation could contribute to its transforming potential.	NCI,CELLULAR ONCOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; FERRAO P, 1995, ONCOGENE, V11, P1631; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PERRYMAN S, 1991, NUCLEIC ACIDS RES, V19, P6950; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolff L, 1996, CURR TOP MICROBIOL, V211, P191; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	48	60	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					203	212		10.1038/sj.onc.1200828	http://dx.doi.org/10.1038/sj.onc.1200828			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010222				2022-12-25	WOS:A1997WC81800008
J	Thompson, AD; Braun, BS; Arvand, A; Stewart, SD; May, WA; Chen, E; Korenberg, J; Denny, C				Thompson, AD; Braun, BS; Arvand, A; Stewart, SD; May, WA; Chen, E; Korenberg, J; Denny, C			EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene	ONCOGENE			English	Article						SH2 domain; transcription factor; oncogenes; cellular transformation; sarcoma	RNA-BINDING PROTEIN; ROUND-CELL TUMORS; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; EWS GENE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; TRANSLOCATION; FAMILY	The EWS/FLI1 fusion protein is created by the translocation between chromosomes 11 and 22 that appears in most Ewing's sarcomas, This chimeric protein has been demonstrated to be an aberrant transcription factor. Genes up regulated by EWS/FLI1 but not by full-length FLI1 were identified by representational difference analysis (RDA), We have characterized a novel gene, EWS/FLI1 activated transcript 2 (EAT-2) that was cloned from a murine cDNA library using a differentially expressed RDA fragment. EAT-2 expression is seen within 4-8 h of EWS/FLI1 induction, Its expression correlates with transformation of NIH3T3 cells by chimeric proteins related to EWS/FLI1 but not by unrelated genes, EAT-2 is expressed in normal murine tissues and contains a unique but biochemically functional SH2 domain, An homologous sequence in the human genome has been identified and mapped to chromosome 1q22, Human EAT-2 transcripts were identified by reverse transcriptase-polymerase chain reaction (RT-PCR) in Ewing's sarcoma cell tumour cell lines. EAT-2's unique structure and correlation with transformation make it a candidate for playing a role in the transformation of NIH3T3 cells and the oncogenesis of Ewing's sarcoma.	UNIV CALIF LOS ANGELES,SCH MED,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT EXPT PATHOL & LAB MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INTERCAMPUS MED GENET TRAINING PROGRAM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,AHMANSON DEPT PEDIAT,DIV GENET,CEDARS SINAI MED CTR,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA32737, CA09056] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Gotoh N, 1995, ONCOGENE, V11, P2525; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heim S, 1995, CANC CYTOGENETICS; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JEON IS, 1995, ONCOGENE, V10, P1229; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KORNBERG JR, 1995, CYTOGENET CELL GENET, V69, P196; LESSNICK SL, 1995, ONCOGENE, V10, P429; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, NAT GENET, V6, P146; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	50	99	103	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2649	2658						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000139				2022-12-25	WOS:A1996VZ65400015
J	Balmforth, AJ; Lee, AJ; Warburton, P; Donnelly, D; Ball, SG				Balmforth, AJ; Lee, AJ; Warburton, P; Donnelly, D; Ball, SG			The conformational change responsible for AT(1) receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; AT2 BINDING-SITES; ANGIOTENSIN-II; MOLECULAR-CLONING; NONPEPTIDE ANTAGONISTS; ADENYLATE-CYCLASE; TYPE-2 RECEPTOR; EXPRESSION; CELLS	A model of the angiotensin AT(1) receptor and site-directed mutagenesis were used to identify key residues involved in ligand binding. Receptors were stably expressed in human embryonic kidney 293 cells, and their binding properties compared. Wild type receptors exhibited low and high affinity binding sites for peptides, Substitution of Asn(111), situated in the third transmembrane helix, resulted in a significant alteration in ligand binding with only high affinity binding of the peptides, angiotensin II, angiotensin III, and [p-amino-Phe(6)]angiotensin II and a marked loss in the binding affinity of the AT(1) receptor selective non-peptide antagonist losartan. From our model it was apparent that Asn(111) was in close spatial proximity to Asn(295) in the seventh transmembrane helix. Substitution of Asn(295), produced identical changes in the receptor's pharmacological profile. Furthermore, the Ser(111)AT(1)A and Ser(295)AT(1A) mutants did not require the association of a G-protein for high affinity agonist binding. Finally, the Ser(296)AT(1A) mutant maintained higher basal generation of inositol trisphosphate than the wild type, indicating constitutive activation. We propose that substitution of these residues causes the loss of an interaction between transmembrane helices III and VII, which allows the AT(1) receptor to ''relax'' into its active conformation.	UNIV LEEDS,DEPT PHARMACOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds	Balmforth, AJ (corresponding author), UNIV LEEDS,INST CARDIOVASC RES,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.		Donnelly, Dan/O-5374-2015	Donnelly, Dan/0000-0001-6048-6995				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BALMFORTH AJ, 1994, BRIT J PHARMACOL, V112, P277, DOI 10.1111/j.1476-5381.1994.tb13064.x; BOTTARI SP, 1991, EUR J PHARM-MOLEC PH, V207, P157, DOI 10.1016/0922-4106(91)90091-U; BURNS L, 1994, FEBS LETT, V343, P146, DOI 10.1016/0014-5793(94)80307-2; CHANG RSL, 1990, BIOCHEM BIOPH RES CO, V171, P813, DOI 10.1016/0006-291X(90)91218-H; CHIU AT, 1993, REGUL PEPTIDES, V44, P141, DOI 10.1016/0167-0115(93)90237-3; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DONNELLY D, 1994, CURR OPIN STRUC BIOL, V4, P582, DOI 10.1016/S0959-440X(94)90221-6; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; FURATA H, 1992, BIOCHEM BIOPH RES CO, V183, P8; GLOSSMANN H, 1974, J BIOL CHEM, V249, P664; GROBLEWSKI T, 1995, BIOCHEM BIOPH RES CO, V209, P153, DOI 10.1006/bbrc.1995.1483; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; JI H, 1994, J BIOL CHEM, V269, P16533; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V183, P1090, DOI 10.1016/S0006-291X(05)80302-X; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KAMBAYASHI Y, 1994, KIDNEY INT, V46, P1502, DOI 10.1038/ki.1994.430; KENT RS, 1980, MOL PHARMACOL, V17, P14; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEUNG KH, 1992, EUR J PHARM-MOLEC PH, V227, P63, DOI 10.1016/0922-4106(92)90143-J; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MORTON AJ, 1992, MOL BRAIN RES, V13, P53, DOI 10.1016/0169-328X(92)90044-C; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Perez DM, 1996, MOL PHARMACOL, V49, P112; POBINER BF, 1985, J BIOL CHEM, V260, P6200; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROGERS TB, 1986, J PHARMACOL EXP THER, V236, P438; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3; TAKAYANAGI R, 1992, BIOCHEM BIOPH RES CO, V183, P910, DOI 10.1016/0006-291X(92)90570-B; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; TSUZUKI S, 1994, BIOCHEM BIOPH RES CO, V200, P1449, DOI 10.1006/bbrc.1994.1613; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5	46	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4245	4251		10.1074/jbc.272.7.4245	http://dx.doi.org/10.1074/jbc.272.7.4245			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020140	hybrid			2022-12-25	WOS:A1997WH01900056
J	Mehrotra, B; Elliott, JT; Chen, J; Olszewski, JD; Profit, AA; Chaudhary, A; Fukuda, M; Mikoshiba, K; Prestwich, GD				Mehrotra, B; Elliott, JT; Chen, J; Olszewski, JD; Profit, AA; Chaudhary, A; Fukuda, M; Mikoshiba, K; Prestwich, GD			Selective photoaffinity labeling of the inositol polyphosphate binding C2B domains of synaptotagmins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMITTER RELEASE; ANTIBODY INJECTION; BINDING; PROTEIN; RECEPTOR; SYNAPSE; 1,4,5-TRISPHOSPHATE; LIGANDS; FAMILY; BRAIN	Synaptotagmin (Syt) II, a synaptic vesicle protein containing two copies of highly conserved protein kinase C homology regions known as the C2A and C2B domains, acts as a Ca2+ sensor and provides both phospholipid and inositol polyphosphate (IPn) recognition domains important in endo- and exocytosis. Four photoaffinity analogues of IP3, IP4, and IP6 containing a P-1- or P-2-linked 4-benzoyldihydrocinnamidyl (BZDC) photophore were used to label glutathione S-transferase (GST) fusion constructs of the Syt II-C2A and C2B domains. The P-2-linked [H-3]BZDC-IP6 showed efficient, IP6-displaceable labeling of the GST-Syt II-C2B. The rank order of photocovalent modification paralleled the order of competitive displacement: IP6 (P-2-linked) > IP4 > IP3. The P-1-linked [H-3]BZDC-IP6 failed to label the C2B domains. The GST-Syt III-C2B domain, which lacks IP6 binding affinity, also failed to undergo labeling by P-2-linked [H-3]BZDC-IP6. When mixtures of the 32-amino acid basic peptide corresponding to the essential IPn binding region of the Syt II-C2B domain and GST-Syt II-C2B were labeled by a stoichiometric amount of P-2-linked [H-3]BZDC-IP6, the two polypeptides showed equivalent affinity for the photolabel. Although the CD spectrum of this 32-mer at two pH values showed a random coil, the photoaffinity analogue of IP6 appeared to induce a binding-compatible structure in the short peptide.	SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Tokyo			Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 	NINDS NIH HHS [NS29632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABDULLAH M, 1992, J BIOL CHEM, V267, P22340; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chen J, 1996, J LABELLED COMPD RAD, V38, P1113, DOI 10.1002/(SICI)1099-1344(199612)38:12<1113::AID-JLCR925>3.0.CO;2-6; CLARK BA, 1995, THESIS STATE U NEW Y; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Davidsson P, 1996, MOL CHEM NEUROPATHOL, V27, P195, DOI 10.1007/BF02815094; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DORMAN G, 1995, TETRAHEDRON LETT, V36, P8719, DOI 10.1016/0040-4039(95)01893-M; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; ESTEVEZ VA, 1991, J AM CHEM SOC, V113, P9885, DOI 10.1021/ja00026a043; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Irvine R, 1996, CURR BIOL, V6, P537, DOI 10.1016/S0960-9822(02)00536-5; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MARECEK JF, 1991, TETRAHEDRON LETT, V32, P1863, DOI 10.1016/S0040-4039(00)85982-1; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; OLSZEWSKI JD, 1995, BIOCONJUGATE CHEM, V6, P395, DOI 10.1021/bc00034a009; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; PRESTWICH GD, 1991, J AM CHEM SOC, V113, P1822, DOI 10.1021/ja00005a055; PRESTWICK GD, 1996, IN PRESS PHOTOCHEM P; Rothman JE, 1996, PROTEIN SCI, V5, P185; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; ULLRICH B, 1995, NEUROPHARMACOLOGY, V34, P1371, DOI 10.1016/0028-3908(95)00132-P; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	46	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4237	4244		10.1074/jbc.272.7.4237	http://dx.doi.org/10.1074/jbc.272.7.4237			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020139	hybrid			2022-12-25	WOS:A1997WH01900055
J	Nadler, SG; Tritschler, D; Haffar, OK; Blake, J; Bruce, AG; Cleaveland, JS				Nadler, SG; Tritschler, D; Haffar, OK; Blake, J; Bruce, AG; Cleaveland, JS			Differential expression and sequence-specific interaction of karyopherin alpha with nuclear localization sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; ACTIVATING PROTEIN; HUMAN HOMOLOG; TRANSPORT; NUCLEOPORINS; SIGNALS; RAN/TC4; CELLS; IDENTIFICATION; TRANSLOCATION	The process of nuclear protein transport requires the interaction of several different proteins, either directly or indirectly with nuclear localization or targeting sequences (NLS). Recently, a number of karyopherins alpha, or NLS-binding proteins, have been identified. We have found that the karyopherins hSRP1 and hSRP1 alpha are differentially expressed in various leukocyte cell lines and could be induced in normal human peripheral blood lymphocytes, We show that the two karyopherins bind with varied specificities in a sequence specific manner to different NLSs and that the sequence specificity is modulated by other cytosolic proteins. There was a correlation between binding of karyopherins cu to different NLSs and their ability to be imported into the nucleus. Taken together, these data provide evidence for multiple levels of control of the nuclear import process.			Nadler, SG (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.							ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BONIFACI N, 1995, AIDS, V9, P995, DOI 10.1097/00002030-199509000-00003; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CSRMELY P, 1995, BIOCHIM BIOPHYS ACTA, V1241, P425; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; FELDHERR CM, 1993, EXP CELL RES, V205, P179, DOI 10.1006/excr.1993.1073; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Hurt EC, 1996, CELL, V84, P509, DOI 10.1016/S0092-8674(00)81026-0; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; LANFORD RE, 1990, EXP CELL RES, V186, P32, DOI 10.1016/0014-4827(90)90206-P; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; SAITOH H, 1995, J BIOL CHEM, V270, P10658, DOI 10.1074/jbc.270.18.10658; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SIMOS G, 1995, FEBS LETT, V369, P107, DOI 10.1016/0014-5793(95)00674-X; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WHITESIDE ST, 1993, J CELL SCI, V104, P949; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	31	149	150	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4310	4315		10.1074/jbc.272.7.4310	http://dx.doi.org/10.1074/jbc.272.7.4310			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020149	hybrid			2022-12-25	WOS:A1997WH01900065
J	VanLeeuwen, JEM; Kearse, KP				VanLeeuwen, JEM; Kearse, KP			Reglucosylation of N-linked glycans is critical for calnexin assembly with T cell receptor (TCR) alpha proteins but not TCR beta proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LYMPHOMA-CELLS; GLUCOSE-GLYCOPROTEIN GLUCOSYLTRANSFERASE; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; ENDOMANNOSIDASE PATHWAY; MOLECULAR CHAPERONE; UDP-GLC; OLIGOSACCHARIDE; ASSOCIATION; BIOSYNTHESIS	Association of calnexin with newly synthesized glycoproteins involves recognition of monoglucosylated glycans, generated in the endoplasmic reticulum via initial removal of two glucose (Glc) residues from immature glycan chains by glucosidase enzymes (Glc trimming), or addition of a single Glc residue to fully trimmed glycans by glucosyltransferase enzymes (reglucosylation). While it has been established that creation of monoglucosylated glycans is important for chaperone binding, it is unknown if most proteins require both deglucosylation and reglucosylation for calnexin assembly or if initial Glc trimming is sufficient. Here, we studied the deglucosylation and reglucosylation of two related glycoproteins, the alpha and beta subunits of the T cell receptor (TCR) complex, and their assembly with calnexin in BW thymoma cells. Our data demonstrate that TCR alpha/beta glycoproteins undergo multiple cycles of Glc removal and addition within the endoplasmic reticulum and that numerous reglucosylated proteins assemble with calnexin, including TCR alpha/beta glycoproteins. Importantly, the current study shows that TCR beta proteins, but not TCR alpha proteins, effectively associate with calnexin under conditions of functional Glc trimming but impaired reglucosylation. These data demonstrate that reglucosylated proteins associate with lectin-like chaperones in vivo and provide evidence that reglucosylation is of differential importance for the association of individual, indeed similar, glycoproteins with calnexin.	NCI,EXPT IMMUNOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			van Leeuwen, Jeroen/G-3555-2010					BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; CHAPMAN AE, 1988, ARCH BIOCHEM BIOPHYS, V260, P320, DOI 10.1016/0003-9861(88)90456-0; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Fernandez F, 1996, EMBO J, V15, P705, DOI 10.1002/j.1460-2075.1996.tb00406.x; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; GANAN S, 1991, BIOCHEMISTRY-US, V30, P3098, DOI 10.1021/bi00226a017; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; KEARSE KP, 1994, J IMMUNOL METHODS, V167, P75, DOI 10.1016/0022-1759(94)90076-0; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1979, J BIOL CHEM, V254, P1649; KUBO RT, 1989, J IMMUNOL, V142, P2736; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PAN YT, 1992, J BIOL CHEM, V267, P8991; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; REARICK JI, 1981, J BIOL CHEM, V256, P6255; SHIN J, 1993, SCIENCE, V259, P1901, DOI 10.1126/science.8456316; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TROWBRIDGE IS, 1978, CELL, V14, P21, DOI 10.1016/0092-8674(78)90297-0; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; VARKI A, 1994, METHOD ENZYMOL, V230, P16; VARKI A, 1991, FASEB J, V5, P227; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	47	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4179	4186		10.1074/jbc.272.7.4179	http://dx.doi.org/10.1074/jbc.272.7.4179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020131	hybrid			2022-12-25	WOS:A1997WH01900047
J	Ledwith, BJ; Pauley, CJ; Wagner, LK; Rokos, CL; Alberts, DW; Manam, S				Ledwith, BJ; Pauley, CJ; Wagner, LK; Rokos, CL; Alberts, DW; Manam, S			Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ARACHIDONIC-ACID METABOLISM; RAT PERITONEAL-MACROPHAGES; PROTEIN-KINASE-C; FATTY-ACIDS; BETA-OXIDATION; MESSENGER-RNA; DNA-SYNTHESIS; 3T3 CELLS; HEPATOCARCINOGENESIS	Increased expression of cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin synthesis, has been associated with growth regulation and carcinogenesis in several systems, COX-2 is known to be induced by cytokines and the skin tumor promoter 12-tetradecanoylphorbol-13-myristate (TPA). In the present study, we investigated the effects of several non-TPA-type tumor promoters on COX-2 expression in immortalized mouse liver cells. Specifically, we tested peroxisome proliferators (PPs), which are rodent liver tumor promoters that cause gross alterations in cellular lipid metabolism, the rodent liver tumor promoter phenobarbital, and the skin tumor promoters okadaic acid and thapsigargin. The PPs Wy-14643, mono-ethylhexyl phthalate, clofibrate, ciprofibrate ethyl ester, and eicosatetraynoic acid each caused large increases in COX-2 mRNA and protein, with maximal expression seen approximately 10 h after treatment of quiescent cells. COX-2 expression was also induced by thapsigargin, okadaic acid, and calcium ionophore A23187, but not by phenobarbital or the steroid PP dehydroepiandrosterone sulfate. Induction of COX-2 expression generally resulted in increased syn thesis of prostaglandin E(2) (PGE(2)). However, the PPs caused little or no increase in PGE(2) levels, and they inhibited serum-induced PGE(2) synthesis. Unlike nonsteroidal anti-inflammatory drugs, the PPs do not directly inhibit cyclooxygenase enzyme activity in vitro, Thus, PPs regulate prostaglandin metabolism via both positive (COX-2 induction) and inhibitory mechanisms, In summary, the strong induction of COX-2 expression by PPs, thapsigargin, and okadaic acid suggests a possible role for COX-2 in the growth regulatory activity of these non-TPA-type tumor promoters.	MERCK RES LABS,DEPT BIOCHEM TOXICOL,W POINT,PA 19486	Merck & Company	Ledwith, BJ (corresponding author), MERCK RES LABS,DEPT GENET & CELLULAR TOXICOL,WP 45-318,W POINT,PA 19486, USA.							AIZU E, 1990, EUR J PHARMACOL, V182, P19; ASHBY J, 1994, HUM EXP TOXICOL, V13, pS1, DOI 10.1177/096032719401300201; BARDOT O, 1995, BIOCHEM PHARMACOL, V50, P1001, DOI 10.1016/0006-2952(95)00229-S; BAYLY AC, 1993, J CELL SCI, V104, P307; BOJES HK, 1994, TOXICOL APPL PHARM, V126, P233, DOI 10.1006/taap.1994.1112; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CATTLEY RC, 1994, CARCINOGENESIS, V15, P1763, DOI 10.1093/carcin/15.8.1763; CATTLEY RC, 1989, CANCER RES, V49, P3246; CHEN ZY, 1994, CANCER RES, V54, P2622; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; DRAGAN YP, 1992, CARCINOGENESIS, V13, P739, DOI 10.1093/carcin/13.5.739; DuBois RN, 1996, CANCER RES, V56, P733; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FOXWORTHY PS, 1993, TOXICOL APPL PHARM, V118, P271, DOI 10.1006/taap.1993.1033; GRABER R, 1994, J LIPID MEDIAT CELL, V9, P91; GRASLKRAUPP B, 1993, CARCINOGENESIS, V14, P2435, DOI 10.1093/carcin/14.11.2435; Green S, 1995, MUTAT RES-FUND MOL M, V333, P101, DOI 10.1016/0027-5107(95)00136-0; HERSCHMAN HR, 1995, ADV PROSTAG THROMB L, V23, P23; HERSCHMAN HR, 1994, PROG NUCLEIC ACID RE, V47, P113, DOI 10.1016/S0079-6603(08)60251-2; HSIEH LL, 1991, BRIT J CANCER, V64, P815, DOI 10.1038/bjc.1991.406; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLUWE WM, 1994, REGUL TOXICOL PHARM, V20, P170, DOI 10.1006/rtph.1994.1068; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LEDWITH BJ, 1993, MOL CARCINOGEN, V8, P20, DOI 10.1002/mc.2940080107; Ledwith BJ, 1996, CANCER RES, V56, P3257; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MALKI MC, 1990, BIOCHEM BIOPH RES CO, V173, P855; MARKS F, 1991, CARCINOGENESIS, V12, P1491, DOI 10.1093/carcin/12.8.1491; MARSMAN DS, 1988, CANCER RES, V48, P6739; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHUCHI K, 1989, BIOCHIM BIOPHYS ACTA, V1013, P86, DOI 10.1016/0167-4889(89)90132-8; OHUCHI K, 1987, J CANCER RES CLIN, V113, P319, DOI 10.1007/BF00397715; PATEK PQ, 1978, NATURE, V276, P510, DOI 10.1038/276510a0; POPP JA, 1993, PEROXISOMES BIOL IMP, P653; RAO CV, 1995, CANCER RES, V55, P1464; RAO MS, 1992, CANCER RES, V52, P2977; REKKA E, 1994, ARCH TOXICOL, V68, P73, DOI 10.1007/s002040050037; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P433; SANO H, 1995, CANCER RES, V55, P3785; SHACKLETON GL, 1995, TOXICOL APPL PHARM, V130, P294, DOI 10.1006/taap.1995.1034; Subbaramaiah K, 1996, CANCER RES, V56, P4424; TANAKA T, 1993, CANCER LETT, V68, P111, DOI 10.1016/0304-3835(93)90136-W; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WADA N, 1992, FUND APPL TOXICOL, V18, P149, DOI 10.1016/0272-0590(92)90208-Y; WILSON MW, 1995, ARCH TOXICOL, V69, P491, DOI 10.1007/s002040050203; YOKOYAMA Y, 1992, CARCINOGENESIS, V13, P265, DOI 10.1093/carcin/13.2.265; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	54	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3707	3714		10.1074/jbc.272.6.3707	http://dx.doi.org/10.1074/jbc.272.6.3707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013627	hybrid			2022-12-25	WOS:A1997WG19200087
J	Leeuwenburgh, C; Rasmussen, JE; Hsu, FF; Mueller, DM; Pennathur, S; Heinecke, JW				Leeuwenburgh, C; Rasmussen, JE; Hsu, FF; Mueller, DM; Pennathur, S; Heinecke, JW			Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LIPID-PEROXIDATION; APOLIPOPROTEIN-B; MYELOPEROXIDASE; CHOLESTEROL; MACROPHAGES; DITYROSINE; LESIONS; DEGRADATION; PHAGOCYTES	Lipoprotein oxidation has been implicated in the pathogenesis of atherosclerosis. However, the physiologically relevant pathways mediating oxidative damage have not yet been identified, Three potential mechanisms are tyrosyl radical, hydroxyl radical, and redox active metal ions, Tyrosyl radical forms o,o'-dityrosine cross-links in proteins, The highly reactive hydroxyl radical oxidizes phenylalanine residues to o-tyrosine and m-tyrosine, Metal ions oxidize low density lipoprotein (LDL) by poorly understood pathways. To explore the involvement of tyrosyl radical, hydroxyl radical, and metal ions in atherosclerosis, we developed a highly sensitive and quantitative method for measuring levels of o,o'-dityrosine, o-tyrosine, and m-tyrosine in proteins, lipoproteins, and tissue, using stable isotope dilution gas chromatography-mass spectrometry, We showed that o,o'-dityrosine was selectively produced in LDL oxidized with tyrosyl radical, Both a-tyrosine and a,o'-dityrosine were major products when LDL was oxidized with hydroxyl radical, Only o-tyrosine was formed in EDL oxidized with copper, Similar profiles of oxidation products were observed in bovine serum albumin oxidized with the three different systems, Applying these findings to LDL isolated from human atherosclerotic lesions, we detected a 100-fold increase in o,o'-dityrosine levels compared to those in circulating LDL, In striking contrast, levels of o-tyrosine and m-tyrosine were not elevated in LDL isolated from atherosclerotic tissue, Analysis of fatty streaks revealed a similar pattern of oxidation products; compared with normal aortic tissue, there was a selective increase in o,o'-dityrosine with no change in o-tyrosine, The detection of a selective increase of o,o'-dityrosine in LDL isolated from vascular lesions is consistent with the hypothesis that oxidative damage in human atherosclerosis is mediated in part by tyrosyl radical, In contrast, these observations do not support a role for free metal ions as catalysts of LDL oxidation in the artery wall.	WASHINGTON UNIV,SCH MED,DIV ATHEROSCLEROSIS NUTR & LIPID RES,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)				Leeuwenburgh, Christiaan/0000-0003-0826-4257; Hsu, Fong-Fu/0000-0001-5368-0183	NCRR NIH HHS [RR00954] Funding Source: Medline; NIA NIH HHS [R01 AG12293] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012293] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AESCHBACH R, 1976, BIOCHIM BIOPHYS ACTA, V439, P292, DOI 10.1016/0005-2795(76)90064-7; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BROWN MS, 1992, CELL, V71, P187, DOI 10.1016/0092-8674(92)90346-E; DANKS DM, 1989, METABOLIC BASIS INHE, P4417; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; HEINECKE JW, 1987, FREE RADICAL BIO MED, V3, P65, DOI 10.1016/0891-5849(87)90040-2; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KAUR H, 1994, METHOD ENZYMOL, V233, P67; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KRUL ES, 1992, BIOCHEM BIOPH RES CO, V189, P1069, DOI 10.1016/0006-291X(92)92313-M; LAMB DJ, 1995, FEBS LETT, V374, P12, DOI 10.1016/0014-5793(95)01068-P; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; *PATH DET ATH YOUT, 1993, ARTERIOSCLER THROMB, V13, P1291; PENN MS, 1994, ATHEROSCLEROSIS, V108, pS21, DOI 10.1016/0021-9150(94)90150-3; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SMITH LH, 1990, WESTERN J MED, V153, P296; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SWAIN J, 1995, FEBS LETT, V368, P513, DOI 10.1016/0014-5793(95)00726-P; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	40	319	326	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3520	3526		10.1074/jbc.272.6.3520	http://dx.doi.org/10.1074/jbc.272.6.3520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013599	hybrid			2022-12-25	WOS:A1997WG19200059
J	Lussier, G; Larose, L				Lussier, G; Larose, L			A casein kinase I activity is constitutively associated with Nck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAINS; INSULIN-RECEPTOR; GROWTH-FACTOR; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; MONOCLONAL-ANTIBODIES; PROTEIN-SYNTHESIS; TYROSINE KINASE; PHOSPHORYLATION; IRS-1	Nck is a 47-kDa cytosolic protein devoid of intrinsic catalytic activity and consisting of Src homology 2 and 3 (SH2 and SH3) domains organized as follows: SH3-SH3-SH3-SH2. Nck is believed to act as an adaptor protein mediating signal transduction initiated by receptor tyrosine kinases (RTKs). Through its SH2 domain, Nck recognizes a specific phosphotyrosine residue on RTKs or on protein substrates of RTKs like insulin receptor substrate-1, the major substrate of the insulin receptor, and through its SH3 domains it interacts with poorly characterized effector molecules, To identify novel proteins that might interact with Nck, we have used the amino-terminal segment of Nck encompassing its three SH3 domains in the yeast two hybrid system. Among the polypeptides that associate with Nck, we have identified the gamma 2 isoform of the serine/threonine casein kinase I (CKI-gamma 2). In transformed rat hepatocytes overexpressing the insulin receptor (HTC-IR cells), serine/threonine protein kinase activity coimmunoprecipitates with Nck, an interaction mediated mainly by the third SH3 domain of Nck. This kinase activity is not apparently modulated by insulin, nor is it sensitive to staurosporine or heparin, and it does not use GTP as a phosphate donor. However the kinase activity coimmunoprecipitated with Nck is completely abolished by N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, a specific inhibitor of casein kinase I. In an in vitro renaturation gel kinase assay, a protein kinase of 70-75 kDa was detected associated with the SH3 domains of Nck. Far Western analysis demonstrated that the SH3 domains of Nck bound directly to a cytosolic protein of 70-75 kDa. A rabbit polyclonal antibody raised against the C-terminal region of CKI-gamma 2 protein kinase immunoprecipitated a single specific protein of 70-75 kDa from HTC-IR cell lysates and detected CKI-gamma 2 among the proteins coimmunoprecipitated with Nck. These results support an in vivo interaction between Nck and CKI-gamma 2 and suggest that CKI-gamma 2 could be involved in signaling pathways downstream of RTKs.	MCGILL UNIV, POLYPEPTIDE LAB, DIV ENDOCRINOL, DEPT MED, MONTREAL, PQ H3A 2B2, CANADA	McGill University								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BEYAERT R, 1993, CANCER RES, V53, P2623; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BONINI JA, 1995, AM J PHYSIOL-ENDOC M, V269, pE759, DOI 10.1152/ajpendo.1995.269.4.E759; BONINI JA, 1995, BIOCHEM BIOPH RES CO, V212, P933, DOI 10.1006/bbrc.1995.2059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DENSLOW ND, 1996, AM SOC BIOCH MOL BIO, V10, pA112; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FINAN P, 1994, J BIOL CHEM, V269, P13752; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GEER PVD, 1993, PROTEIN PHOSPHORYLAT, V123, P31; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P84, DOI 10.1016/0003-9861(91)90267-M; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HU QJ, 1995, MOL CELL BIOL, V15, P1169; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARINCH AM, 1993, AM J PHYSIOL, V264, pE101, DOI 10.1152/ajpendo.1993.264.1.E101; KARINCH AM, 1993, JOSLINS DIABETES MEL, P116; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LU W, 1996, FDN ADV CANC STUD ON, P337; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLFIELD S, 1992, J BIOCH, V208, P73; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TUAZON PT, 1985, J CELL BIOCHEM, V28, P159, DOI 10.1002/jcb.240280208; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	63	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2688	2694		10.1074/jbc.272.5.2688	http://dx.doi.org/10.1074/jbc.272.5.2688			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006905	hybrid			2022-12-25	WOS:A1997WE66700018
J	Utani, A; Nomizu, M; Yamada, Y				Utani, A; Nomizu, M; Yamada, Y			Fibulin-2 binds to the short arms of laminin-5 and laminin-1 via conserved amino acid sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; DERMAL-EPIDERMAL JUNCTION; BASEMENT-MEMBRANE PROTEIN; EGF-LIKE MOTIF; VII COLLAGEN; BETA-3 CHAIN; INTEGRIN BETA-4; NIDOGEN BINDING; KALININ; MOUSE	Epithelial cell-specific laminin-5, consisting of three chains, alpha 3, beta 3, and gamma 2, is a component of the anchoring filament that traverses the lamina lucida beneath the hemidesmosomes of epidermal cells and functions to link these cells to the basement membrane. We have studied the molecular interaction between laminin-5 and extracellular matrix proteins using recombinant proteins and synthetic peptides. Affinity chromatography assays with recombinant fragments of the laminin gamma 2 short arm identified a 195-kDa binding protein in the conditioned media from the mouse epidermal cell line Pam 212 and from primary dermal fibroblasts. This molecule was identified by Western blotting as fibulin-2, a recently identified extracellular matrix protein. Using deletion mutants and various synthetic peptides in competition assays, the g-amino acid sequence SADFSVHKI (residues 199-207) in domain IV of the gamma 2 chain was defined as a critical site for fibulin-2 binding. An anti-gamma 2 antibody co-immunoprecipitated fibulin-2 from the conditioned media, further confirming the interaction of fibulin-2 with laminin-5. Fibulin-2 was also found to interact with laminin-1 (alpha 1 beta 1 gamma 1) through a region (residues 654-665) of the alpha 1 chain short arm whose sequence is similar to that of the fibulin-2 binding site of the gamma 2 chain. Together these results suggest that fibulin-2 functions to bridge laminin-1 and laminin-5 with other extracellular matrix proteins, providing a linkage between the cell surface and the basement membrane.	NIDR,DEV BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								AUMAILLEY M, 1993, KIDNEY INT, V43, P7, DOI 10.1038/ki.1993.3; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BERNIER SM, 1995, MATRIX BIOL, V14, P447, DOI 10.1016/0945-053X(95)90002-0; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHRISTIANO AM, 1993, NAT GENET, V4, P62, DOI 10.1038/ng0593-62; CHRISTIANO AM, 1994, P NATL ACAD SCI USA, V91, P3549, DOI 10.1073/pnas.91.9.3549; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; EADY RAJ, 1994, J INVEST DERMATOL, V103, pS13, DOI 10.1111/1523-1747.ep12398895; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; FLEISCHMAJER R, 1995, J INVEST DERMATOL, V105, P597, DOI 10.1111/1523-1747.ep12323604; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GAMMON WR, 1993, DERMATOL CLIN, V11, P535, DOI 10.1016/S0733-8635(18)30249-3; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; HILAL L, 1995, HUM MOL GENET, V4, P959; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MARCHISIO PC, 1993, EXP CELL RES, V205, P205, DOI 10.1006/excr.1993.1078; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; Mayer U., 1994, EXTRACELLULAR MATRIX, P389, DOI [10.1016/B978-0-12-775170-2.50017-2, DOI 10.1016/B978-0-12-775170-2.50017-2]; MCGRATH JA, 1995, J INVEST DERMATOL, V104, P467, DOI 10.1111/1523-1747.ep12605904; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; NOMIZU M, 1992, INT J PEPT PROT RES, V40, P72; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; SONNENBERG A, 1993, J CELL SCI, V106, P1083; SUGIYAMA S, 1995, EUR J BIOCHEM, V228, P120, DOI 10.1111/j.1432-1033.1995.0120o.x; UITTO J, 1994, J INVEST DERMATOL, V103, pS39, DOI 10.1111/1523-1747.ep12398967; UTANI A, 1995, LAB INVEST, V72, P300; UTANI A, 1994, J BIOL CHEM, V269, P19167; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; YANCEY KB, 1995, J INVEST DERMATOL, V104, P1008, DOI 10.1111/1523-1747.ep12606244; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YUSPA SH, 1980, CANCER RES, V40, P4694	46	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2814	2820		10.1074/jbc.272.5.2814	http://dx.doi.org/10.1074/jbc.272.5.2814			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006922	hybrid			2022-12-25	WOS:A1997WE66700035
J	Yang, JJ; Krauss, RS				Yang, JJ; Krauss, RS			Extracellular ATP induces anchorage-independent expression of cyclin A and rescues the transformed phenotype of a Ras-resistant mutant cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; GROWTH; PROGRESSION; MITOGEN	Anchorage-independent growth is characteristic of neoplastic cells, but the signal transduction pathways that mediate this phenotype are poorly understood. Several important cell cycle events are dependent on cell-substratum adhesion in non-transformed cells, including activation of G(1) cyclin-dependent kinases and expression of cyclin A; the adhesion requirement of these events is abrogated in Ras-transformed cells. The ER-1-2 mutant rat fibroblast cell line is: 1) resistant to has-mediated, anchorage-independent growth; 2) defective in Ras-mediated, adhesion-independent expression of cyclin A, but not adhesion-independent activation of cyclin-dependent kinases; and 3) rescued for Ras-induced, anchorage-independent growth by ectopic expression of cyclin A We report here that extracellular ATP induces adhesion-independent expression of cyclin A and rescues growth in soft agar by ER-1-2 cells that express Ras. ADP, AMP and the non-hydrolyzable analog adenosine 5'-(beta,gamma-iminodiphosphate) are also effective, but adenosine is not. Adenine nucleotide-induced growth in soft agar is inhibited by reactive blue 2, an antagonist of some P-2 purinoceptors. ATP does not induce adhesion-independent expression of cyclin A in ER-1-2 or control rat fibroblasts that do not express Ras, indicating a requirement for additional Ras-regulated signals for expression of this gene; one such signal may lead to phosphorylation of the retinoblastoma protein, pRB, and related proteins. These results suggest that extracellular ATP could play a role in the multistage carcinogenic process in vivo.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA059474, R29CA059474] Funding Source: NIH RePORTER; NCI NIH HHS [CA59474] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Feinleib JL, 1996, MOL CARCINOGEN, V16, P139; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GONZALEZ FA, 1990, P NATL ACAD SCI USA, V87, P9717, DOI 10.1073/pnas.87.24.9717; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUANG NN, 1993, J BIOL CHEM, V268, P10789; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YANG JJ, 1995, ONCOGENE, V10, P1291; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	26	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					3103	3108		10.1074/jbc.272.5.3103	http://dx.doi.org/10.1074/jbc.272.5.3103			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006962	hybrid			2022-12-25	WOS:A1997WE66700075
J	Bandyopadhyay, D; Kusari, A; Kenner, KA; Liu, F; Chernoff, J; Gustafson, TA; Kusari, J				Bandyopadhyay, D; Kusari, A; Kenner, KA; Liu, F; Chernoff, J; Gustafson, TA; Kusari, J			Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; GROWTH-FACTOR RECEPTOR; STIMULATING FACTOR-I; HUMAN-PLACENTA; PHOSPHOTYROSINE PHOSPHATASE; XENOPUS OOCYTES; KINASE DOMAIN; SPECIFICITY; BINDING; SITE	In response to insulin, protein tyrosine phosphatase 1B (PTPase 1B) dephosphorylates 95- and 160-180-kDa tyrosine phosphorylated (PY) proteins (Kenner, K. A., Anyanwu, E., Olefsky, J. M., and Kusari, J. (1996) J. Biol. Chem. 271, 19810-19816). To characterize these proteins, lysates from control and insulin-treated cells expressing catalytically inactive PTPase 1B (CS) were immunoadsorbed and subsequently immunoblotted using various combinations of phosphotyrosine, PTPase 1B, and insulin receptor (IR) antibodies. Anti-PTPase 1B antibodies coprecipitated a 95-kDa PY protein from insulin-stimulated cells, subsequently identified as the IR beta-subunit. Similarly, anti-IR antibodies coprecipitated the 50-kDa PY-PTPase 1B protein from insulin-treated cells. To identify PTPase 1B tyrosine (Tyr) residues that are phosphorylated in response to insulin, three candidate sites (Tyr(66), Tyr(152), and Tyr(153)) were replaced with phenylalanine. Replacing Tyr(66) or Tyr(152) and Tyr(153) significantly reduced insulin-stimulated PTPase 1B phosphotyrosine content, as well as its association with the IR. Studies using mutant IRs demonstrated that IR autophosphorylation is necessary for the PTPase 1B-IR interaction. These results suggest that PTPase 1B complexes with the autophosphorylated insulin receptor in intact cells, either directly or within a complex involving additional proteins. The interaction requires multiple tyrosine phosphorylation sites within both the receptor and PTPase 1B.	TULANE UNIV, MED CTR, SCH MED, DEPT PHYSIOL, NEW ORLEANS, LA 70112 USA; TULANE UNIV, MED CTR, MOL & CELLULAR BIOL PROGRAM, NEW ORLEANS, LA 70112 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, LA JOLLA, CA 92093 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; UNIV MARYLAND, DEPT PHYSIOL, BALTIMORE, MD 21201 USA	Tulane University; Tulane University; University of California System; University of California San Diego; Fox Chase Cancer Center; University System of Maryland; University of Maryland Baltimore			Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044093, R29DK046490, R01DK050602] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50602, DK 46490, DK44093] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; Dixon JE, 1995, ANN NY ACAD SCI, V766, P18, DOI 10.1111/j.1749-6632.1995.tb26644.x; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FAURE R, 1992, J BIOL CHEM, V267, P11215; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KENNER KA, 1993, J BIOL CHEM, V268, P25455; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V197, P1078, DOI 10.1006/bbrc.1993.2588; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	56	220	228	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1639	1645		10.1074/jbc.272.3.1639	http://dx.doi.org/10.1074/jbc.272.3.1639			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999839	hybrid			2022-12-25	WOS:A1997WD05800037
J	Dahl, JL; Wei, BY; Kadner, RJ				Dahl, JL; Wei, BY; Kadner, RJ			Protein phosphorylation affects binding of the Escherichia coli transcription activator UhpA to the uhpT promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-TRANSPORT-SYSTEM; RESPONSE REGULATOR PROTEIN; BACTERIAL CHEMOTAXIS; BACILLUS-SUBTILIS; RNA-POLYMERASE; SITE; OMPR; SEQUENCE; REGION; GENES	Expression of the Escherichia coli sugar phosphate transporter UhpT is induced by extracellular glucose B-phosphate through a transmembrane signaling process dependent on the sensor kinase UhpB and the UhpT homolog, UhpC. These proteins are thought to regulate the phosphorylation of the transcription activator, UhpA. To examine the effect of protein phosphorylation on the binding of UhpA to target sequences in the uhpT promoter region, the UhpA protein was overexpressed and purified. Purified UhpA was phosphorylated by acetyl phosphate in a reaction that was dependent on Mg2+ and on the presence of aspartate 54, the site of phosphorylation in homologous response regulators. Gel electrophoretic mobility shift and DNase I and hydroxyl radical protection assays showed that UhpA bound specifically to the region of the uhpT promoter extending from -80 to -50 bp, relative to the transcription start site. At higher concentrations of UhpA, binding was extended to the -32 region. Binding to the -64 element exhibited positive cooperativity and was stimulated severalfold by phosphorylation of UhpA, whereas extension to the downstream region was more strongly affected by phosphorylation. The consensus sequences for the high affinity UhpA-binding sites in the -64 element and for the downstream, low affinity sites are proposed. The pattern of in vitro binding by UhpA agreed with the in vivo observations that phosphorylation-independent assembly of the transcription initiation complex can occur at elevated concentrations of UhpA.	UNIV VIRGINIA, SCH MED, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia					NIGMS NIH HHS [GM38681] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAYAMA M, 1995, J MOL BIOL, V250, P11, DOI 10.1006/jmbi.1995.0354; BAIKALOV L, 1996, BIOCHEMISTRY-US, V35, P11053; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DIETZ GW, 1976, ADV ENZYMOL RAMB, V44, P237; DRAPAL N, 1995, MOL MICROBIOL, V16, P597, DOI 10.1111/j.1365-2958.1995.tb02422.x; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HARLOCKER SL, 1995, J BIOL CHEM, V270, P26849, DOI 10.1074/jbc.270.45.26849; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HUANG KJ, 1994, J BACTERIOL, V176, P1309, DOI 10.1128/jb.176.5.1309-1315.1994; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; Kadner R., 1995, TWOCOMPONENT SIGNAL, P263; KADNER RJ, 1994, RES MICROBIOL, V145, P381, DOI 10.1016/0923-2508(94)90085-X; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SF, 1988, J BIOL CHEM, V263, P13700; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; MAEDA S, 1990, J BACTERIOL, V172, P501, DOI 10.1128/JB.172.1.501-503.1990; MALONEY PC, 1990, MICROBIOL REV, V54, P1; McCleary WR, 1996, MOL MICROBIOL, V20, P1155, DOI 10.1111/j.1365-2958.1996.tb02636.x; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; MERKEL TJ, 1992, J BACTERIOL, V174, P2763, DOI 10.1128/JB.174.9.2763-2770.1992; MERKEL TJ, 1995, J BACTERIOL, V177, P1712, DOI 10.1128/jb.177.7.1712-1718.1995; PAO GM, 1994, RES MICROBIOL, V145, P356, DOI 10.1016/0923-2508(94)90082-5; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POGELL BM, 1966, ARCH BIOCHEM BIOPHYS, V116, P406, DOI 10.1016/0003-9861(66)90047-6; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SCHRODER I, 1994, J BACTERIOL, V176, P4985, DOI 10.1128/jb.176.16.4985-4992.1994; SHEER DG, 1991, BIOTECHNIQUES, V11, P526; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WEBBER CA, 1995, MOL MICROBIOL, V15, P883, DOI 10.1111/j.1365-2958.1995.tb02358.x; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WESTON LA, 1987, J BACTERIOL, V169, P3546, DOI 10.1128/jb.169.8.3546-3555.1987; WESTON LA, 1988, J BACTERIOL, V170, P3375, DOI 10.1128/jb.170.8.3375-3383.1988	47	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1910	1919		10.1074/jbc.272.3.1910	http://dx.doi.org/10.1074/jbc.272.3.1910			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999880	hybrid			2022-12-25	WOS:A1997WD05800078
J	Bost, S; Belin, D				Bost, S; Belin, D			prl mutations in the Escherichia coli secG gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; SIGNAL-SEQUENCE; SUPPRESSOR MUTATIONS; CYTOPLASMIC MEMBRANE; ALKALINE-PHOSPHATASE; BETA-LACTAMASE; INNER MEMBRANE; EXPORT; TRANSLOCATION; PEPTIDE	SecG, an integral membrane component of the Escherichia coli preprotein translocase, contributes to the efficiency of the export process by undergoing cycles of topology inversion in the membrane, coupled with the insertion-deinsertion cycles of Seek We have previously identified sec alleles of seca that cause a generalized secretion defect. In this study, by screening mutagenized secG libraries for suppressors of a malE signal sequence mutation, we isolated prl alleles of seca. By analogy with secY/prlA, secA/prlD, and secE/prlG, secG could therefore be called secG/prlH. The prlH mutations affect 13 codons distributed along the secG sequence, and none map to the codons affected by sec mutations. prlH suppressors suppress a variety of signal sequence mutations and they allow export of alkaline phosphatase lacking its entire signal sequence. Although secG was not identified in previous selections for prl mutants, several prlH alleles are as strong as the strongest known prlG alleles of secE. Some prlH alleles can also promote the export of alkaline phosphatase fused to predicted cytoplasmic domains of UhpT, an integral membrane protein. These results support the notion that SecG contributes to signal sequence recognition, and suggest that it may also contribute to the topology of integral membrane proteins.	UNIV GENEVA,DEPT PATHOL,CH-1211 GENEVA,SWITZERLAND	University of Geneva								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; ALLARD JD, 1992, J BIOL CHEM, V267, P17809; ALTMAN E, 1990, J BIOL CHEM, V265, P18154; BANKAITIS VA, 1985, J BACTERIOL, V161, P169, DOI 10.1128/JB.161.1.169-178.1985; BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BOST S, 1995, EMBO J, V14, P4412, DOI 10.1002/j.1460-2075.1995.tb00120.x; BOWDEN GA, 1992, J BACTERIOL, V174, P3407, DOI 10.1128/jb.174.10.3407-3410.1992; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; FLOWER AM, 1994, J BACTERIOL, V176, P5607, DOI 10.1128/JB.176.18.5607-5614.1994; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANADA M, 1994, J BIOL CHEM, V269, P23625; HUIE JL, 1995, J BACTERIOL, V177, P3518, DOI 10.1128/jb.177.12.3518-3526.1995; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; JONES JD, 1990, J BIOENERG BIOMEMBR, V22, P213, DOI 10.1007/BF00763166; KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014; KUMAMOTO CA, 1989, GENE, V75, P167, DOI 10.1016/0378-1119(89)90393-4; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller JH., 1992, EXPT MOL GENETICS; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Nouwen N, 1996, MOL MICROBIOL, V19, P1205, DOI 10.1111/j.1365-2958.1996.tb02466.x; Nouwen N, 1996, P NATL ACAD SCI USA, V93, P5953, DOI 10.1073/pnas.93.12.5953; OLSEN MK, 1993, J BACTERIOL, V175, P7092, DOI 10.1128/jb.175.21.7092-7096.1993; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; PUZISS JW, 1992, J BACTERIOL, V174, P92, DOI 10.1128/jb.174.1.92-101.1992; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; STADER J, 1989, GENE DEV, V3, P1045, DOI 10.1101/gad.3.7.1045; UHLAND K, 1994, J BACTERIOL, V176, P4565, DOI 10.1128/JB.176.15.4565-4571.1994; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P10133, DOI 10.1073/pnas.92.22.10133	55	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4087	4093		10.1074/jbc.272.7.4087	http://dx.doi.org/10.1074/jbc.272.7.4087			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020118	hybrid, Green Published			2022-12-25	WOS:A1997WH01900034
J	Dauplais, M; Lecoq, A; Song, JX; Cotton, J; Jamin, N; Gilquin, B; Roumestand, C; Vita, C; deMedeiros, CLC; Rowan, EG; Harvey, AL; Menez, A				Dauplais, M; Lecoq, A; Song, JX; Cotton, J; Jamin, N; Gilquin, B; Roumestand, C; Vita, C; deMedeiros, CLC; Rowan, EG; Harvey, AL; Menez, A			On the convergent evolution of animal toxins - Conservation of a diad of functional residues in potassium channel-blocking toxins with unrelated structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CA-2+-ACTIVATED K+ CHANNEL; CHARYBDOTOXIN BLOCK; H-1-NMR SPECTRA; BINDING-ENERGY; RIBBON MODELS; SNAKE TOXINS; DENDROTOXIN; SPECTROSCOPY; CONDUCTANCE	BgK is a K+ channel-blocking toxin from the sea anemone Bunodosoma granulifera. It is a 37-residue protein that adopts a novel fold, as determined by NMR and modeling. An alanine-scanning-based analysis revealed the functional importance of five residues, which include a critical lysine and an aromatic residue separated by 6.6 +/- 1.0 Angstrom. The same diad is found in the three known homologous toxins from sea anemones. More strikingly, a similar functional diad is present in all K+ channel-blocking toxins from scorpions, although these toxins adopt a distinct scaffold. Moreover, the functional diads of potassium channel-blocking toxins from sea anemone and scorpions superimpose in the three-dimensional structures. Therefore, toxins that have unrelated structures but similar functions possess conserved key functional residues, organized in an identical topology, suggesting a convergent functional evolution for these small proteins.	CEA,DEPT INGN & ETUD PROT,F-91191 GIF SUR YVETTE,FRANCE; UNIV STRATHCLYDE,DEPT PHYSIOL & PHARMACOL,GLASGOW G1 1XW,LANARK,SCOTLAND	CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Strathclyde			Song, Jianxing/J-3617-2013; Jamin, Nadege/AAA-7067-2021; Song, Jianxing/H-8026-2012	ROUMESTAND, Christian/0000-0002-4082-3293; Rowan, Edward/0000-0002-9960-3308; Song, Jianxing/0000-0003-0224-6322	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANEIROS A, 1993, BIOCHIM BIOPHYS ACTA, V1157, P86, DOI 10.1016/0304-4165(93)90082-J; *BIOS TECHN, 1993, FEL SOFTW; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR VERSION 3 1; CANDIA S, 1992, BIOPHYS J, V63, P583, DOI 10.1016/S0006-3495(92)81630-2; CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DANSE JM, 1994, FEBS LETT, V356, P153, DOI 10.1016/0014-5793(94)01235-0; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Doumenc D., 1995, P27; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; GIANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719, DOI 10.1021/bi00144a011; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HARVEY AL, 1989, BIOCHEM BIOPH RES CO, V163, P394, DOI 10.1016/0006-291X(89)92148-7; HARVEY AL, 1992, TOXICON, V30, P1497, DOI 10.1016/0041-0101(92)90528-D; HARVEY AL, 1991, INT ENCY PHARM THERA, P131; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HURST RS, 1991, MOL PHARMACOL, V40, P572; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Pennington MW, 1996, BIOCHEM BIOPH RES CO, V219, P696, DOI 10.1006/bbrc.1996.0297; PILLET L, 1993, J BIOL CHEM, V268, P909; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; RICHARDSON J, 1981, ADV PROTEIN CHEM, V34, P267; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; STRYER L, 1988, BIOCHEMISTRY-US, P227; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; *TRIP ASS, 1994, SYBYL 6 1; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010	51	298	321	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4302	4309		10.1074/jbc.272.7.4302	http://dx.doi.org/10.1074/jbc.272.7.4302			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020148	hybrid			2022-12-25	WOS:A1997WH01900064
J	Wada, M; Nakanishi, H; Satoh, A; Hirano, H; Obaishi, H; Matsuura, Y; Takai, Y				Wada, M; Nakanishi, H; Satoh, A; Hirano, H; Obaishi, H; Matsuura, Y; Takai, Y			Isolation and characterization of a GDP/GTP exchange protein specific for the Rab3 subfamily Small G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; NUCLEOTIDE EXCHANGE; RAS; PURIFICATION; GTPASES; CELLS; MSS4	The Rab small G protein family, consisting of nearly 30 members, is implicated in intracellular vesicle trafficking. They cycle between the GDP-bound inactive and GTP-bound active forms, and the former is converted to the latter by the action of a GDP/GTP exchange protein (GEP). No GEP specific for each Rab family member or Rab subfamily has been isolated. Here we purified a GEP from rat brain with lipid-modified Rab3A as a substrate. The purified protein was specifically active on Rab3A, Rab3C, and Rab3D of the Rab3 subfamily. Of these subfamily members, Rab3A and Rab3C are implicated in Ca2+-dependent exocytosis, particularly in neurotransmitter release. This GEP (Rab3 GEP) was active on the Lipid-modified form, but not on the lipid-unmodified form. Rab3 GEP showed a minimum molecular mass of about 200 kDa on SDS-polyacrylamide gel electrophoresis. We cloned its cDNA from a rat brain cDNA library and determined its primary structure. The isolated cDNA encoded a protein with a M(r) of 177,982 and 1,602 amino acids, which showed no homology to any known protein. The recombinant protein exhibited GEP activity toward Rab3A, Rab3C, and Rab3D. Northern blot and Western blot analyses indicated that Rab3 GEP was expressed in all the rat tissues examined with the highest expression in brain.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; JCR PHARMACEUT CO LTD,JAPAN SCI & TECHNOL CORP,TAKAI BIOTIMER PROJECT,ERATO,NISHI KU,KOBE 65122,JAPAN; NIH,DEPT VIROL 2,TOKYO 162,JAPAN	Osaka University; Japan Science & Technology Agency (JST); National Institute of Health Sciences - Japan				Nakanishi, Hiroyuki/0000-0002-9765-0266				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HORIUCHI H, 1995, METHOD ENZYMOL, V257, P9; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; LLEDO PM, 1994, TRENDS NEUROSCI, V17, P426, DOI 10.1016/0166-2236(94)90017-5; MIYAZAKI A, 1994, FEBS LETT, V350, P333, DOI 10.1016/0014-5793(94)00804-3; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI T, 1995, METHOD ENZYMOL, V257, P70; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0	24	140	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3875	3878		10.1074/jbc.272.7.3875	http://dx.doi.org/10.1074/jbc.272.7.3875			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020086	hybrid			2022-12-25	WOS:A1997WH01900002
J	Kho, CJ; Huggins, GS; Endege, WO; Hsieh, CM; Lee, ME; Haber, E				Kho, CJ; Huggins, GS; Endege, WO; Hsieh, CM; Lee, ME; Haber, E			Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING; C-JUN; PROTEASOME PATHWAY; IN-VIVO; TRANSCRIPTIONAL REGULATOR; SPECIFICALLY INTERACTS; ENHANCER-BINDING; KAPPA-B; S-PHASE	The helix-loop-helix E2A proteins (E12 and E47) govern cellular growth and differentiation. To identify binding partners that regulate the function of these ubiquitous transcription factors, we screened for proteins that interacted with the C terminus of E12 by the yeast interaction trap, UbcE2A, a rat enzyme that is highly homologous to and functionally complements the yeast ubiquitin-conjugating enzyme UBC9, was identified and cloned, UbcE2A appears to be an E2A-selective ubiquitin-conjugating enzyme because it interacts specifically with a 54-amino acid region in E47-(477-530) distinct from the helix-loop-helix domain. In contrast, most of the UbcE2A protein is required for interaction with an E2A protein. The E2A proteins appear to be degraded by the ubiquitin-proteasome pathway because the E12 half-life of 60 min is extended by the proteasome inhibitor MG132, and E12 is multi-ubiquitinated in vivo, Finally, antisense UbcE2A reduces E12 degradation, By participating in the degradation of the E2A proteins, UbcE2A may regulate cell growth and differentiation.	HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM 53249] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1995, J CELL SCI, V108, P475; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022, DOI 10.1128/MCB.14.5.3022; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Kaiser C., 1994, METHODS YEAST GENETI; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MURRE C, 1991, MOL CELL BIOL, V11, P156; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	55	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3845	3851		10.1074/jbc.272.6.3845	http://dx.doi.org/10.1074/jbc.272.6.3845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013644	hybrid			2022-12-25	WOS:A1997WG19200104
J	Li, DX; Meier, UT; Dobrowolska, G; Krebs, EG				Li, DX; Meier, UT; Dobrowolska, G; Krebs, EG			Specific interaction between casein kinase 2 and the nucleolar protein Nopp140	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; CELLULAR-REGULATION; MOLECULAR-COMPLEX; ALPHA-SUBUNIT; CK2; PHOSPHORYLATION; YEAST; DISSECTION; ASSOCIATE	Casein kinase 2 (CK2) is a multifunctional second messenger-independent protein serine/threonine kinase that phosphorylates many different proteins. To understand the function and regulation of this enzyme, biochemical methods were used to search for CK2-interacting proteins. Using immobilized glutathione S-transferase fusion proteins of CK2, the nucleolar protein Nopp140 was identified as a CK2-associated protein. It was found that Nopp140 binds primarily to the CK2 regulatory subunit, beta. The possible in vivo association of Nopp140 with CK2 was also suggested from a coimmunoprecipitation experiment in which Nopp140 was detected in immunoprecipitates of CK2 prepared from cell extracts, Further studies using an overlay technique with radiolabeled CK2 as a probe revealed a direct CK2-Nopp140 interaction. Using deletion mutants of CK2 beta subunits, the binding region of the CK2 beta subunit to Nopp140 has been mapped, It was found that the NH2-terminal 20 amino acids of CK2 beta are involved. Since Nopp140 has been identified as a nuclear localization sequence-binding protein and has been shown to shuttle between the cytoplasm and the nucleus, the finding of a CK2-Nopp140 interaction could shed light on our understanding of the function and regulation of CK2 and Nopp140.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10467 USA	University of Washington; University of Washington Seattle; Yeshiva University; Albert Einstein College of Medicine				Dobrowolska, Grazyna/0000-0002-2598-9666	NIDDK NIH HHS [DK42528] Funding Source: Medline; NIGMS NIH HHS [GM50725] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050725] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6626; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BOLDYREFF B, 1994, CELL MOL BIOL RES, V40, P391; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; ESPINET C, 1995, YEAST, V11, P25, DOI 10.1002/yea.320110104; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUSK M, 1995, J MOL BIOL, V253, P703, DOI 10.1006/jmbi.1995.0584; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; MARIN O, 1995, FEBS LETT, V363, P111, DOI 10.1016/0014-5793(95)00295-K; Meier UT, 1996, J BIOL CHEM, V271, P19376; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; MEIER UT, 1992, CELL, V70, P127; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PYERIN W, 1994, ADV ENZYME REGUL, V34, P225, DOI 10.1016/0065-2571(94)90018-3; SARNO S, 1995, BIOCHEM BIOPH RES CO, V206, P171, DOI 10.1006/bbrc.1995.1024; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7	39	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3773	3779		10.1074/jbc.272.6.3773	http://dx.doi.org/10.1074/jbc.272.6.3773			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013635	hybrid			2022-12-25	WOS:A1997WG19200095
J	Lin, H; Simon, MN; Black, LW				Lin, H; Simon, MN; Black, LW			Purification and characterization of the small subunit of phage T4 terminase, gp16, required for DNA packaging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-LAMBDA TERMINASE; BACILLUS-SUBTILIS BACTERIOPHAGE-SPP1; SULFATE-POLYACRYLAMIDE GELS; SODIUM DODECYL-SULFATE; ESCHERICHIA-COLI; RNA-POLYMERASE; GENE-PRODUCT; COS DNA; INITIATION; PROTEIN	Phage T4 terminase is an enzyme that binds to the portal protein of proheads and cuts and packages concatemeric DNA. The T4 terminase is composed of two subunits, gene products (gp) 16 and 17. The role of the small subunit, gp16, in T4 DNA packaging is not well characterized, We developed a new purification procedure to obtain large quantities of purified gp16 from an overexpression vector. The pure protein is found in two molecular weight forms, due to specific C-terminal truncation, displays in vitro packaging activity, and binds but does not hydrolyze ATP, gp16 forms specific oligomers, rings, and side-by-side double rings, as judged by native polyacrylamide gel electrophoresis and scanning transmission electron microscopy measurements. The single ring contains about eight monomers, and the rings have a diameter of about 8 nm with a central hole of about 2 nm. A DNA-binding helix-turn-helix motif close to the N terminus of gp16 is predicted. The oligomers do not bind to DNA, but following denaturation and renaturation in the presence of DNA, binding can be demonstrated by gel shift and filter binding assays, gp16 binds to double-stranded DNA but not single-stranded DNA, and appears to bind preferentially to a gene 16-containing DNA sequence.	UNIV MARYLAND, SCH MED, DEPT BIOCHEM, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, MOL & CELL BIOL GRAD PROGRAM, BALTIMORE, MD 21201 USA; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; United States Department of Energy (DOE); Brookhaven National Laboratory					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI011676, R01AI011676, R21AI011676] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01777] Funding Source: Medline; NIAID NIH HHS [AI11676] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY JM, 1992, PROTEIN SCI, V1, P68; BECKER A, 1988, J MOL BIOL, V199, P219, DOI 10.1016/0022-2836(88)90391-9; BHATTACHARYYA SP, 1994, GENE, V146, P67, DOI 10.1016/0378-1119(94)90834-6; BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BLACK LW, 1995, BIOESSAYS, V17, P1025, DOI 10.1002/bies.950171206; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BLACK LW, 1981, VIROLOGY, V113, P336, DOI 10.1016/0042-6822(81)90160-4; CASJENS S, 1992, J MOL BIOL, V227, P1086, DOI 10.1016/0022-2836(92)90523-M; CHAI SH, 1994, VIROLOGY, V202, P930, DOI 10.1006/viro.1994.1415; CHAI SH, 1995, J MOL BIOL, V252, P386, DOI 10.1006/jmbi.1995.0505; DAVIDSON A, 1987, VIROLOGY, V161, P305, DOI 10.1016/0042-6822(87)90122-X; DEBRECENI N, 1970, BIOCHEM BIOPH RES CO, V41, P115, DOI 10.1016/0006-291X(70)90476-6; EPPLER K, 1991, VIROLOGY, V183, P519, DOI 10.1016/0042-6822(91)90981-G; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1983, LAMBDA, V2, P305; FRACKMAN S, 1985, J MOL BIOL, V183, P225, DOI 10.1016/0022-2836(85)90215-3; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; KYPR J, 1986, J MOL BIOL, V191, P139, DOI 10.1016/0022-2836(86)90430-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCNICOL LA, 1977, J MOL BIOL, V116, P261, DOI 10.1016/0022-2836(77)90216-9; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; PARRIS W, 1994, J BIOL CHEM, V269, P13564; POWELL D, 1990, NUCLEIC ACIDS RES, V18, P4005, DOI 10.1093/nar/18.13.4005; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; Sambrook J., 2002, MOL CLONING LAB MANU; SHINDER G, 1988, J VIROL, V62, P387, DOI 10.1128/JVI.62.2.387-392.1988; SKORUPSKI K, 1992, J MOL BIOL, V223, P977, DOI 10.1016/0022-2836(92)90256-J; STREISIN.G, 1967, P NATL ACAD SCI USA, V57, P292, DOI 10.1073/pnas.57.2.292; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOMKA MA, 1993, BIOCHEMISTRY-US, V32, P11992, DOI 10.1021/bi00096a008; VANDERSLICE RW, 1974, VIROLOGY, V60, P265, DOI 10.1016/0042-6822(74)90384-5; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WU CHH, 1995, J MOL BIOL, V247, P523	35	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3495	3501		10.1074/jbc.272.6.3495	http://dx.doi.org/10.1074/jbc.272.6.3495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013596	hybrid			2022-12-25	WOS:A1997WG19200056
J	Mackenzie, LF; Brooke, GS; Cutfield, JF; Sullivan, PA; Withers, SG				Mackenzie, LF; Brooke, GS; Cutfield, JF; Sullivan, PA; Withers, SG			Identification of Glu-330 as the catalytic nucleophile of Candida albicans exo-beta-(1,3)-glucanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE NUCLEOPHILE; TANDEM MASS-SPECTROMETRY; BETA-GLUCOSIDASE; GLYCOSYL HYDROLASES; ACID/BASE CATALYST; GLUTAMATE RESIDUE; MECHANISMS; FAMILIES; MUTAGENESIS; GALACTOSIDASE	The exo-beta-(1,3)-glucanase from Candida albicans hydrolyzes cell wall beta-glucans via a double-displacement mechanism involving a glycosyl enzyme intermediate. Reaction of the enzyme with 2',4'-dinitrophenyl-2-deoxy-2-fluoro-beta-n-glucopyranoside resulted in the time-dependent inactivation of this enzyme via the accumulation of a 2-deoxy-2-fluoro-glycosyl-enzyme intermediate as monitored also by electrospray mass spectrometry, The catalytic competence of this intermediate is demonstrated by its reactivation through hydrolysis (k(react) = 0.0019 min(-1)) and by transglycosylation to benzyl thio-beta-D-glucopyranoside (k(react) = 0.024 min(-1); K-react 56 mM). Peptic digestion of the labeled enzyme followed by tandem mass spectrometric analysis in the neutral loss mode allowed detection of two glycosylated active site peptides, the sequences of which were identified as NVAGEW and NVAGEWSAA. A crucial role for Glu-330 is confirmed by site directed mutagenesis at this site and kinetic analysis of the resultant mutant, The activity of the Glu-330 --> Gln mutant is reduced over 50,000-fold compared to the wild type enzyme. The glutamic acid, identified in the exoglucanase as Glu-330, is completely conserved in this family of enzymes and is hereby identified as the catalytic nucleophile.	UNIV BRITISH COLUMBIA, DEPT CHEM, VANCOUVER, BC V6T 1Z1, CANADA; UNIV OTAGO, DEPT BIOCHEM, DUNEDIN, NEW ZEALAND	University of British Columbia; University of Otago								BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BALLARDIE F, 1973, J CHEM SOC PERK T 1, P2418, DOI 10.1039/p19730002418; BORTOLIGERMAN I, 1995, J MOL BIOL, V246, P82, DOI 10.1006/jmbi.1994.0068; BRUSS ML, 1978, ANAL BIOCHEM, V84, P309, DOI 10.1016/0003-2697(78)90514-6; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CERNY M, 1963, MONATSH CHEM, V94, P290, DOI 10.1007/BF00900251; CESARENI G, 1987, GENETIC ENG, V9, P53; CHAMBERS RS, 1993, FEMS MICROBIOL LETT, V111, P63, DOI [10.1111/j.1574-6968.1993.tb06362.x, 10.1016/0378-1097(93)90183-3]; CHAMBERS RS, 1993, FEBS LETT, V327, P366, DOI 10.1016/0014-5793(93)81022-R; CHAUVAUX S, 1992, J BIOL CHEM, V267, P4472; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; DUCROS V, 1995, STRUCTURE, V3, P939, DOI 10.1016/S0969-2126(01)00228-3; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; JIANG B, 1995, MOL GEN GENET, V248, P260, DOI 10.1007/BF02191592; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LUNAARIAS JP, 1991, YEAST, V7, P833, DOI 10.1002/yea.320070808; MACARRON R, 1993, FEBS LETT, V316, P137, DOI 10.1016/0014-5793(93)81202-B; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MIAO SC, 1994, J BIOL CHEM, V269, P10975; MIAO SC, 1994, BIOCHEMISTRY-US, V33, P7027, DOI 10.1021/bi00189a002; PETERSON GL, 1977, ANAL BIOCHEM, V87, P386; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; Sambrook J., 2002, MOL CLONING LAB MANU; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STAEDTLER P, 1995, EUR J BIOCHEM, V232, P658, DOI 10.1111/j.1432-1033.1995.658zz.x; STREET IP, 1989, BIOCHEMISTRY-US, V28, P1581, DOI 10.1021/bi00430a024; SULLIVAN PA, 1991, FEMS SYMP, V50, P35; TULL D, 1995, ANAL BIOCHEM, V224, P509, DOI 10.1006/abio.1995.1080; WANG Q, 1995, BIOCHEMISTRY-US, V34, P14554, DOI 10.1021/bi00044a034; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; WANG QP, 1993, J BIOL CHEM, V268, P14096; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WITHERS SG, 1987, J AM CHEM SOC, V109, P7530, DOI 10.1021/ja00258a047; WITHERS SG, 1995, PROTEIN SCI, V4, P361; YUAN JM, 1994, BIOCHEM J, V299, P527, DOI 10.1042/bj2990527	45	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3161	3167		10.1074/jbc.272.6.3161	http://dx.doi.org/10.1074/jbc.272.6.3161			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013549	hybrid			2022-12-25	WOS:A1997WG19200009
J	Sastry, SS; Ross, BM; Parraga, A				Sastry, SS; Ross, BM; Parraga, A			Cross-linking of DNA-binding proteins to DNA with psoralen and psoralen furan-side monoadducts - Comparison of action spectra with DNA-DNA cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 RNA-POLYMERASE; ELONGATION COMPLEXES; PHOTOCHEMISTRY; 8-METHOXYPSORALEN; FUROCOUMARINS; TEMPLATE; BIOCHEMISTRY; PHOTOBIOLOGY; ORIENTATION; IRRADIATION	We have developed a novel photocross-linking technique using free 8-methoxypsoralen and DNA furan-side monoadducts plus long wave ultraviolet light (UVA), Both sequence-specific (Max) and nonspecific (RecA and T7 RNA polymerase) DNA-binding proteins were crosslinked. The macroscopic equilibrium binding constant (similar to 10(9) M(-1)) and DNase I footprinting indicated that binding of Max to its cognate sequence (E-box) was unimpaired by 8-methoxypsoralen and that cross-linking occurred in normal complexes, RecA protein and T7 RNA polymerase were cross-linked to a 12-mer DNA furanside monoadduct with WA, Cross-link yields were directly proportional to the WA dose, Cross-links were stable to 8 M urea, 1-10% SDS, commonly used alcohols, and mild acids (5% trichloroacetic acid), The DNA in cross-links was reversed with 254 nm UV (photoreversal) or with hot base (base-catalyzed reversal), consistent with (2 + 2) cycloaddition via the 4',5'-furan of the psoralen. Comparative action spectra for DNA-DNA cross linking and DNA-protein cross-linking revealed that the latter occurred maximally at 300 nm, while the former occurred maximally at 320 nm. This 20-nm blue shift suggested a higher potential energy surface for an excited psoralen participating in protein-DNA crosslinking as compared with DNA-DNA cross-linking, As with DNA-DNA cross-linking, DNA-protein cross linking is a two-photon process, Absorption of the first photon formed a 4',5'-adduct with DNA, which then absorbed a second photon, leading to cross-linking to protein, Based on the action spectra and the known excited states of psoralen, it is suggested that the triplet n,pi* transition localized in the C-2=O of psoralen may be involved in protein-psoralen photoreactions.	ROCKEFELLER UNIV, MOL BIOPHYS LAB, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Sastry, SS (corresponding author), ROCKEFELLER UNIV, GENET MOL LAB, 1230 YORK AVE, BOX 174, NEW YORK, NY 10021 USA.							BENHUR E, 1984, ADV RADIAT BIOL, V11, P131; BENSASSON RV, 1978, PHOTOCHEM PHOTOBIOL, V27, P273, DOI 10.1111/j.1751-1097.1978.tb07600.x; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORDIN F, 1993, PHOTOCHEM PHOTOBIOL, V58, P133, DOI 10.1111/j.1751-1097.1993.tb04914.x; BORDIN F, 1994, J PHOTOCH PHOTOBIO B, V26, P197, DOI 10.1016/1011-1344(94)07040-7; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; BUDOWSKY EI, 1989, PROG NUCLEIC ACID RE, V37, P1; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; COLE RS, 1970, BIOCHIM BIOPHYS ACTA, V217, P30, DOI 10.1016/0005-2787(70)90119-X; DALLACQUA F, 1970, FEBS LETT, V9, P121, DOI 10.1016/0014-5793(70)80330-1; DONG Q, 1984, EMBO J, V13, P200; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DUMOULIN P, 1993, P NATL ACAD SCI USA, V90, P2030, DOI 10.1073/pnas.90.5.2030; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1995, NUCLEIC ACIDS MOL BI, V9, P285; FREDERIKSEN S, 1979, BIOCHIM BIOPHYS ACTA, V563, P343, DOI 10.1016/0005-2787(79)90053-4; GOLDBERG J, 1988, J BACTERIOL, V170, P1245; GRANGER M, 1982, PHOTOCHEM PHOTOBIOL, V36, P175, DOI 10.1111/j.1751-1097.1982.tb04360.x; ISAACS ST, 1977, BIOCHEMISTRY-US, V16, P1058, DOI 10.1021/bi00625a005; JOHNSTON BH, 1981, BIOCHEMISTRY-US, V20, P739, DOI 10.1021/bi00507a012; MANTULIN WW, 1973, J AM CHEM SOC, V95, P5122, DOI 10.1021/ja00797a004; MIDDEN WR, 1988, PSORALEN DNA PHOTOBI, V2, P16; MIRZABEKOV AD, 1989, METHOD ENZYMOL, V170, P386; MIZUNO N, 1972, SUNLIGHT MAN NORMAL, P389; MORLIERE P, 1986, PHOTOCHEM PHOTOBIOL, V44, P425, DOI 10.1111/j.1751-1097.1986.tb04689.x; OU CN, 1978, BIOCHEMISTRY-US, V17, P1047, DOI 10.1021/bi00599a017; PATHAK MA, 1992, J PHOTOCH PHOTOBIO B, V14, P3, DOI 10.1016/1011-1344(92)85080-E; PENDERGRAST PS, 1992, P NATL ACAD SCI USA, V89, P10287, DOI 10.1073/pnas.89.21.10287; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P385; SASTRY S, 1992, ADV ENZYMOL, V66, P85; SASTRY SS, 1993, BIOCHEMISTRY-US, V32, P5526, DOI 10.1021/bi00072a006; Sastry SS, 1996, BIOCHEMISTRY-US, V35, P13519, DOI 10.1021/bi960982d; SASTRY SS, 1991, J MOL BIOL, V221, P1111, DOI 10.1016/0022-2836(91)80115-B; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)90921-R; SCHMITT IM, 1995, J PHOTOCH PHOTOBIO B, V27, P101, DOI 10.1016/1011-1344(94)07101-S; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; SHI YB, 1987, BIOCHEMISTRY-US, V26, P3792, DOI 10.1021/bi00387a009; SHIM SC, 1995, CRC HDB ORGANIC PHOT; SINGH H, 1978, PHOTOCHEM PHOTOBIOL, V28, P539, DOI 10.1111/j.1751-1097.1978.tb06966.x; SONG, 1971, PHOTOCHEM PHOTOBIOL, V14, P512; Song P S, 1984, Natl Cancer Inst Monogr, V66, P15; SONG PS, 1979, PHOTOCHEM PHOTOBIOL, V29, P1177, DOI 10.1111/j.1751-1097.1979.tb07838.x; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SPIELMANN HP, 1995, P NATL ACAD SCI USA, V92, P2345, DOI 10.1073/pnas.92.6.2345; SPIELMANN HP, 1992, P NATL ACAD SCI USA, V89, P4514, DOI 10.1073/pnas.89.10.4514; SPIELMANN HP, 1995, BIOCHEMISTRY-US, V34, P12937, DOI 10.1021/bi00040a004; TESSMAN JW, 1985, BIOCHEMISTRY-US, V24, P1669, DOI 10.1021/bi00328a015; Turro N. J., 1991, MODERN MOL PHOTOCHEM, P31; VERONESE FM, 1981, PHOTOCHEM PHOTOBIOL, V34, P351, DOI 10.1111/j.1751-1097.1981.tb09369.x; VERONESE FM, 1982, PHOTOCHEM PHOTOBIOL, V36, P25, DOI 10.1111/j.1751-1097.1982.tb04335.x; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; YOSHIKAWA K, 1979, PHOTOCHEM PHOTOBIOL, V29, P1127, DOI 10.1111/j.1751-1097.1979.tb07830.x	54	22	25	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3715	3723		10.1074/jbc.272.6.3715	http://dx.doi.org/10.1074/jbc.272.6.3715			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013628	hybrid			2022-12-25	WOS:A1997WG19200088
J	Meyer, SC; Zuerbig, S; Cunningham, CC; Hartwig, JH; Bissell, T; Gardner, K; Fox, JEB				Meyer, SC; Zuerbig, S; Cunningham, CC; Hartwig, JH; Bissell, T; Gardner, K; Fox, JEB			Identification of the region in actin-binding protein that binds to the cytoplasmic domain of glycoprotein Ib(alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IB-IX COMPLEX; MEMBRANE SKELETON; PLATELET MEMBRANE; 2-HYBRID SYSTEM; FILAMIN; ALPHA; EXPRESSION; FRAGMENTS; ABP-280; CELLS	Actin-binding protein (ABP-280) is a component of the submembranous cytoskeleton and interacts with the glycoprotein (GP) Ib(alpha) subunit of the GP Ib-IX complex in platelets. In the present studies, we have identified the binding site for GP Ib(alpha) in ABP-280. A melanoma cell line lacking ABP-280 was stably transfected with the cDNAs coding for GP Ib-IX, then transiently transfected with cDNA coding for various carboxyl-truncates of ABP 280. Immunocapture assays and co-immunoprecipitation experiments from detergent-lysed cells showed that deletion of the carboxyl-terminal repeats 20-24 of ABP-280 had no effect on GP Ib-M binding, but deletion of residues 2099 through 2136 within repeat 19 abolished binding. In the yeast two-hybrid system, an ABP-280 fragment comprising repeats 17-19 bound GP Ib(alpha). Deletion from either end abolished binding. Individual or multiple repeats of ABP-280 were expressed as fusion protein in bacteria and purified; structural folding was evaluated, and binding to GP Ib-IX was assessed. Binding depended on the presence of repeats 17-19. None of the individual repeats were able to bind to GP Ib-IX. These findings demonstrate that residues 1850-2136 comprising repeats 17-19 contain the binding site for GP Ib-IX.	CLEVELAND CLIN FDN,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL FF20,CLEVELAND,OH 44195; CHILDRENS HOSP OAKLAND,RES INST,OAKLAND,CA 94609; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,EXPT MED DIV,BOSTON,MA 02115	Cleveland Clinic Foundation; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030657, R01HL030657, R01HL056252, R37HL030657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657, HL56252] Funding Source: Medline; NIDDK NIH HHS [DK38452] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AAKHUS AM, 1992, THROMB HAEMOSTASIS, V67, P252; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FRITZ C C, 1992, Current Biology, V2, P403, DOI 10.1016/0960-9822(92)90315-2; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; HARTWIG JH, 1994, PROTEIN PROFILE, V1, P711; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; KOTELIANSKY VE, 1982, EUR J BIOCHEM, V121, P553, DOI 10.1111/j.1432-1033.1982.tb05822.x; LEBART MC, 1993, J BIOL CHEM, V268, P5642; LEBART MC, 1994, J BIOL CHEM, V269, P4279; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MEYER S, 1993, J BIOL CHEM, V268, P20555; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; Miller J.H, 1972, EXPT MOL GENETICS, P1; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHARMA CP, 1995, J IMMUNOL, V154, P3461; WEIHING RR, 1988, BIOCHEMISTRY-US, V27, P1865, DOI 10.1021/bi00406a011; WEIHING RR, 1985, CAN J BIOCHEM CELL B, V63, P397, DOI 10.1139/o85-059	40	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2914	2919		10.1074/jbc.272.5.2914	http://dx.doi.org/10.1074/jbc.272.5.2914			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006936	hybrid			2022-12-25	WOS:A1997WE66700049
J	Sultan, AS; Miyoshi, E; Ihara, Y; Nishikawa, A; Tsukada, Y; Taniguchi, N				Sultan, AS; Miyoshi, E; Ihara, Y; Nishikawa, A; Tsukada, Y; Taniguchi, N			Bisecting GlcNAc structures act as negative sorting signals for cell surface glycoproteins in forskolin-treated rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-III; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; GLUTAMYL-TRANSFERASE TRANSPEPTIDASE; ASN-LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; CARBOHYDRATE MOIETIES; SERUM INTERLEUKIN-8; ALPHA-FETOPROTEIN; MOLECULAR-BIOLOGY; MESSENGER-RNA	The bisecting N-acetylglucosamine residue is formed by UDP-N-acetylglucosamine:beta-D-mannoside-beta-1,4-N-acetylglucosaminyltransferase III (GnT-III), a key branching enzyme for N-glycans. We found that forskolin, an adenylyl cyclase activator, markedly enhanced GnT-III at the transcriptional level in various hepatoma cells and hepatocytes, resulting in an increase of bisecting GlcNAc residues in various glycoproteins, as judged from the lectin binding to erythroagglutinating phytohemagglutinin (E-PHA). In whole cell lysates, the E-PHA binding was increased, and leukoagglutinating phytohemagglutinin (L-PHA) binding was decreased at 12 h after forskolin treatment, by time, both GnT-III activity and mRNA had reached the maximum levels. In contrast, the binding capacity as to E-PHA, determined by fluorescence-activated cell sorting on the cell surface, was decreased, suggesting that bisecting GlcNAc structures in certain glycoproteins changed the expression levels of glycoproteins and decreased their sorting on the cell surface. Fractionated organelles of M31 cells showed that the binding capacity as to E-PKA was mainly localized in Gels membranes and lysosomes. This was also supported by a fluorescence microscopy. In order to determine whether or not the bisecting GlcNAc residue acts as a sorting signal for glycoproteins, N-oligosaccharide structures of lysosomal-associated membrane glycoprotein 1 and beta-glucuronidase, gamma-glutamyltranspeptidase, and secretory glycoproteins such as ceruloplasmin and alpha-fetoprotein were measured by E-PHA and L-PHA blotting after immunoprecipitation. The expression levels of lysosomal membrane glycoprotein 1 and gamma-glutamyltranspeptidase on the cell surface were decreased at 12 h after forskolin treatment, indicating that the bisecting GlcNAc structure may act as a negative sorting signal for the cell surface glycoproteins and may alter the characteristics of hepatoma cells. This is the first report on glycoprotein sorting related to a specific structure of oligosaccharides, bisecting GlcNAc.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; SPECIAL REFERENCE LAB, HACHIOJI, TOKYO 192, JAPAN	Osaka University			Taniguchi, Naoyuki/A-7086-2016; Sultan, Prof. Ahmed S/AFH-7788-2022; Nishikawa, Atsushi/E-6766-2013; Taniguchi, Naoyuki/I-4182-2014	Sultan, Prof. Ahmed S/0000-0001-6568-1757; Nishikawa, Atsushi/0000-0003-4325-1160; Taniguchi, Naoyuki/0000-0001-5889-5968				AKASAKI K, 1995, EXP CELL RES, V220, P464, DOI 10.1006/excr.1995.1338; AMOS B, 1990, J BIOL CHEM, V265, P19192; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BABAJKO S, 1995, GROWTH REGULAT, V5, P85; BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHARUK JHM, 1995, EUR J BIOCHEM, V230, P797; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON LA, 1994, BBA-MOL CELL RES, V1221, P1, DOI 10.1016/0167-4889(94)90208-9; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FENSTERMAKER RA, 1989, MOL ENDOCRINOL, V3, P1070, DOI 10.1210/mend-3-7-1070; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FUJITA M, 1985, BIOCHEM BIOPH RES CO, V126, P818, DOI 10.1016/0006-291X(85)90258-X; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HASHIMOTO S, 1984, P NATL ACAD SCI-BIOL, V81, P6637, DOI 10.1073/pnas.81.21.6637; HOLCOMBE RF, 1994, LUPUS, V3, P97, DOI 10.1177/096120339400300207; HOLCOMBE RF, 1993, CLIN IMMUNOL IMMUNOP, V67, P31, DOI 10.1006/clin.1993.1042; HOLLANDE E, 1995, IN VITRO CELL DEV-AN, V31, P227; HUGHES EN, 1981, J BIOL CHEM, V256, P664; IKEDA Y, 1993, J BIOL CHEM, V268, P3980; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; JAMES ER, 1994, NATURE, V372, P55; KOENDERMAN AHL, 1989, EUR J BIOCHEM, V181, P651, DOI 10.1111/j.1432-1033.1989.tb14772.x; KORNFELD R, 1975, J BIOL CHEM, V250, P2614; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LEE N, 1990, J BIOL CHEM, V265, P20476; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; MIYOSHI E, 1995, J BIOL CHEM, V270, P28311; Miyoshi E, 1995, HEPATOLOGY, V22, P1847, DOI 10.1002/hep.1840220634; MIYOSHI E, 1993, CANCER RES, V53, P3899; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; NISHI S, 1972, BIOCHIM BIOPHYS ACTA, V278, P293, DOI 10.1016/0005-2795(72)90234-6; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; *NYC PHARM, 1995, OPT TM CENTR TECHN, V5, P9; OHNO M, 1992, INT J CANCER, V51, P315, DOI 10.1002/ijc.2910510223; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; PREZIOSO JA, 1995, MELANOMA RES, V5, P15, DOI 10.1097/00008390-199502000-00003; QIN YF, 1995, INT J CANCER, V60, P694, DOI 10.1002/ijc.2910600521; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; SOBCZAK J, 1986, BIOCHIMIE, V68, P957, DOI 10.1016/S0300-9084(86)80039-6; TANIGUCHI N, 1985, CANCER RES, V45, P5835; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; TIKKANEN R, 1995, DNA CELL BIOL, V14, P305, DOI 10.1089/dna.1995.14.305; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VOGEL LK, 1993, FEBS LETT, V330, P293, DOI 10.1016/0014-5793(93)80891-W; WOJCZYK B, 1995, BIOCHEMISTRY-US, V34, P2599, DOI 10.1021/bi00008a026; WOLOSKI BMRNJ, 1985, BIOCHEM BIOPH RES CO, V130, P30, DOI 10.1016/0006-291X(85)90377-8; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YOKOSAWA N, 1981, ONCODEV BIOL MED, V2, P165; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	70	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2866	2872		10.1074/jbc.272.5.2866	http://dx.doi.org/10.1074/jbc.272.5.2866			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006930	hybrid			2022-12-25	WOS:A1997WE66700043
J	Horrevoets, AJG; Pannekoek, H; Nesheim, ME				Horrevoets, AJG; Pannekoek, H; Nesheim, ME			Production and characterization of recombinant human plasminogen (S741C-fluorescein) - A novel approach to study zymogen activation without generation of active protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION PROTEINASES; PEPTIDE CHLOROMETHYL KETONES; GLU-PLASMINOGEN; CONFORMATIONAL CHANGE; FLUORESCENCE PROBES; LYS-PLASMINOGEN; BINDING-SITES; FIBRINOLYSIS; THROMBIN; DEGRADATION	A variant of recombinant plasminogen with the plasmin active site serine (S741) replaced by cysteine was produced and labeled with fluorescein at this residue to provide the derivative Plg(S741C-fluorescein). Studies of cleavage, conformation, and fibrin-binding properties of the derivative showed it to be a good model substrate to study plasminogen activation. Both in solution and in a fully polymerized fibrin clot, cleavage of the single chain zymogen to the two-chain ''plasmin'' molecule was accompanied by a 50% quench of fluorescence intensity. This change allows facile, continuous monitoring of the kinetics of cleavage. Measurements of cleavage by single chain t-PA within intact, fully polymerized 3 mu M fibrin yielded apparent k(cat) and K-m values of (0.08 s(-1), 0.52 mu M) and (0.092 s(-1), 0.098 mu M) for [Glu(1)]- and [Lys(78)]Plg(S741C-fluorescein), respectively. These values are similar to those obtained by others with plasma plasminogen. The approach used here might generally be useful in simplifying the analysis of zymogen activation kinetics in cases where the product (protease) has a great influence on its own formation via positive or negative feedback loops.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA; UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,NL-1105 AZ AMSTERDAM,NETHERLANDS	Queens University - Canada; Queens University - Canada; University of Amsterdam; Academic Medical Center Amsterdam								BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BOCK PE, 1996, J BIOL CHEM, V271, P1; CHRISTENSEN U, 1992, BIOCHEM J, V285, P419, DOI 10.1042/bj2850419; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVRIES C, 1990, J BIOL CHEM, V265, P13547; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; HORREVOETS AJG, 1995, J BIOL CHEM, V270, P15770, DOI 10.1074/jbc.270.26.15770; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; LAU HK, 1979, J BIOL CHEM, V254, P8751; LENICH C, 1991, THROMB RES, V64, P69, DOI 10.1016/0049-3848(91)90206-C; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARKUS G, 1979, J BIOL CHEM, V254, P1211; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; SHORE JD, 1992, FIBRINOLYSIS S2, V6, P102; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; SUENSON E, 1981, BIOCHEM J, V197, P619, DOI 10.1042/bj1970619; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395	33	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2176	2182						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999920				2022-12-25	WOS:A1997WD67900026
J	Qin, SF; Minami, Y; Hibi, M; Kurosaki, T; Yamamura, H				Qin, SF; Minami, Y; Hibi, M; Kurosaki, T; Yamamura, H			Syk-dependent and -independent signaling cascades in B cells elicited by osmotic and oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; C-JUN; ANTIGEN RECEPTOR; MAMMALIAN-CELLS; CA2+ MOBILIZATION; GROWTH-FACTOR; HA-RAS; ACTIVATION; PHOSPHORYLATION; TRANSDUCTION	It was found that Syk protein-tyrosine kinase is rapidly activated in B cells after H2O2 treatment (oxidative stress) or increased extracellular NaCI concentration (osmotic stress) as well as in response to B cell receptor activation. In this study we examined the involvement of Syk in responses elicited by these types of extracellular stress, particularly Ca2+ responses and c-Jun aminoterminal kinase (JPK) activation, using a chicken B cell line, DT40, as well as the DT40-derived mutant DT40/Syk(-), which does not express Syk. Osmotic stress evokes increases in [Ca2+](i) by stimulating an extracellular Ca2+ influx in both DT40 and DT40/Syk(-) cells. In comparison, oxidative stress elicits an increase in [Ca2+](i) by stimulating both an extracellular Ca2+ influx and Ca2+ release from internal stores in DT40 cells, but this Ca2+ response is partially abolished in DT40/Syk(-) cells, indicating that the oxidative stress-induced Ca2+ response is at least partly dependent on Syk. Interestingly, the depletion of Ca2+ results in a significantly decreased level of Syk activation in DT40 cells stimulated by oxidative but not osmotic stress. Furthermore, JNK is activated to different extents by these two types of stress. The extent of JNK activation in DT40/Syk(-) cells in response to osmotic stress is comparable to that observed in DT40 cells. Intriguingly, oxidative stress-induced JNK activation is significantly compromised in DT40/Syk(-) cells. Collectively, these results indicate that both the Ca2+ response and JNK. activity induced by oxidative stress are partly dependent on Syk, whereas those induced by osmotic stress are independent of Syk.	KOBE UNIV,SCH MED,DEPT BIOCHEM,CHUO KU,KOBE 650,JAPAN; FUKUI MED SCH,FUKUI 91011,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA 565,JAPAN; KANSAI MED UNIV,MORIGUCHI,OSAKA 570,JAPAN	Kobe University; University of Fukui; Osaka University; Kansai Medical University			Hibi, Masahiko/I-6215-2014; Kurosaki, Tomohiro/D-1306-2009	Hibi, Masahiko/0000-0002-9142-4444; Kurosaki, Tomohiro/0000-0002-6352-304X; Qin, Suofu/0000-0002-3323-8846				BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KEEL BA, 1995, ENDOCRINOLOGY, V136, P1197, DOI 10.1210/en.136.3.1197; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Missiaen L, 1996, J BIOL CHEM, V271, P4601; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; Qin SF, 1996, EUR J BIOCHEM, V236, P443, DOI 10.1111/j.1432-1033.1996.00443.x; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x	51	82	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2098	2103						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999908				2022-12-25	WOS:A1997WD67900014
J	Sawai, H; Okazaki, T; Takeda, Y; Tashima, M; Sawada, H; Okuma, M; Kishi, S; Umehara, H; Domae, N				Sawai, H; Okazaki, T; Takeda, Y; Tashima, M; Sawada, H; Okuma, M; Kishi, S; Umehara, H; Domae, N			Ceramide-induced translocation of protein kinase C-delta and -epsilon to the cytosol - Implications in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CELL-FREE SYSTEM; LEUKEMIA-CELLS; HL-60 CELLS; SPHINGOMYELIN TURNOVER; SIGNAL TRANSDUCTION; BACILLUS-CEREUS; CHO CELLS; ACTIVATION; PATHWAY	Ceramide is now recognized as an intracellular lipid signal mediator, which induces various kinds of cell functions including apoptosis. Ceramide-induced apoptosis was reported to be blocked by 12-O-tetradecanoylphorbol 13-acetate, a protein kinase C (PKC) activator, but its mechanism remained unclear. Therefore, we investigated whether ceramide has any effects on PKC in the induction of apoptosis. We here report that N-acetylsphingosine (synthetic membrane-permeable ceramide) induced translocation of PKC-delta and -epsilon isozymes from the membrane to the cytosol within 5 min in human leukemia cell lines. Treatment with sphingomyelinase, tumor necrosis factor-alpha, or anti-Fas antibody, all of which can induce apoptosis by generating natural ceramide, similarly induced cytosolic translocation of PKC-delta and -epsilon. In Fas-resistant cells anti-Fas antibody did not induce cytosolic translocation of PKC-delta and -epsilon because of no generation of ceramide, whereas N-acetylsphingosine induced apoptosis with cytosolic translocation of PKC-delta and -epsilon. Furthermore, both 12-O-tetradecanoylphorbol 13-acetate and a nonspecific kinase inhibitor, staurosporine, prevented ceramide-induced apoptosis by inhibiting cytosolic translocation of PKC-delta and -epsilon. These data suggest that cytosolic translocation of PKC-delta and -epsilon plays an important role in ceramide-mediated apoptosis.	OSAKA DENT UNIV,DEPT MED,CHUO KU,OSAKA 540,JAPAN; KYOTO UNIV,GRAD SCH MED,DEPT HEMATOL & ONCOL CLIN SCI PATHOL ORGANS,SAKYO KU,KYOTO 606,JAPAN; JAPAN TOBACCO INC,PHARMACEUT BASIC RES LABS,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Kyoto University; Japan Tobacco Inc.								BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CACACE AM, 1993, ONCOGENE, V8, P2095; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; JALAVA A, 1993, J CELL PHYSIOL, V155, P301, DOI 10.1002/jcp.1041550211; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, CANCER RES, V54, P1707; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KIM MY, 1991, J BIOL CHEM, V266, P484; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Nakamura Y, 1996, J IMMUNOL, V156, P256; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P57, DOI 10.1016/0005-2760(95)00010-A; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; STRUM JC, 1994, J BIOL CHEM, V269, P15493; TAMURA H, 1992, J BIOCHEM, V112, P488, DOI 10.1093/oxfordjournals.jbchem.a123926; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1992, CANCER RES, V52, P5604; YAMADA A, 1988, EUR J BIOCHEM, V175, P213, DOI 10.1111/j.1432-1033.1988.tb14186.x	38	169	171	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2452	2458						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999958				2022-12-25	WOS:A1997WD67900064
J	Rojanasakul, Y; Weissman, DN; Shi, XL; Castranova, V; Ma, JKH; Liang, WW				Rojanasakul, Y; Weissman, DN; Shi, XL; Castranova, V; Ma, JKH; Liang, WW			Antisense inhibition of silica-induced tumor necrosis factor in alveolar macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELL PROLIFERATION; MESSENGER-RNA EXPRESSION; FACTOR-ALPHA; PULMONARY FIBROSIS; OLIGONUCLEOTIDES; INVITRO; RELEASE; OLIGODEOXYNUCLEOTIDES; GLYCOPROTEINS; ENDOCYTOSIS	Tumor necrosis factor-alpha (TNF alpha) has been shown to play an important role in the pathogenesis of silicotic fibrosis, In this study, antisense oligonucleotides targeted to TNF alpha mRNA were used to inhibit silica-induced TNF alpha gene expression in alveolar macrophages. To achieve macrophage-specific oligonucleotide delivery, a molecular conjugate consisting of mannosylated polylysine that exploits endocytosis via the macrophage mannose receptor was used. Complexes were formed between the mannosylated polylysine and oligonucleotides and added to the cells in the presence of silica, Enzyme-linked immunoadsorbent assay showed that the complex consisting of the conjugate and antisense oligomer effectively inhibited TNF alpha production, whereas the oligomer alone had much less effect. Reverse transcriptase-polymerase chain reaction analysis revealed that the reduction in TNF alpha secretion was associated with specific ablation of targeted TNF alpha mRNA. The conjugate alone or conjugate complexed with inverted or sense sequence oligonucleotide had no effect. The promoting effect of the conjugate on antisense activity was shown to be due to enhanced cellular uptake of the oligomer via mannose receptor-mediated endocytosis. Cells lacking mannose receptors showed no susceptibility to the conjugate treatment. These results indicate that effective and selective inhibition of macrophage TNF alpha expression can be achieved using the antisense mannosylated polylysine system.	W VIRGINIA UNIV,HLTH SCI CTR,DEPT MED,MORGANTOWN,WV 26506; NIOSH,MORGANTOWN,WV 26505	West Virginia University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Rojanasakul, Y (corresponding author), W VIRGINIA UNIV,DEPT BASIC PHARMACEUT SCI,HLTH SCI CTR,SCH PHARM,POB 9530,MORGANTOWN,WV 26506, USA.		Shi, Xianglin/B-8588-2012	Rojanasakul, Yon/0000-0002-8839-6462	NHLBI NIH HHS [HL54291] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BISSONNETTE E, 1989, INFLAMMATION, V13, P329, DOI 10.1007/BF00914399; BONFILS E, 1992, NUCLEIC ACIDS RES, V20, P4621, DOI 10.1093/nar/20.17.4621; BROWN GP, 1988, AM REV RESPIR DIS, V138, P85, DOI 10.1164/ajrccm/138.1.85; BUNNELL BA, 1992, SOMAT CELL MOLEC GEN, V18, P559, DOI 10.1007/BF01232652; CITRO G, 1994, BRIT J CANCER, V69, P463, DOI 10.1038/bjc.1994.84; CITRO G, 1992, P NATL ACAD SCI USA, V89, P7031, DOI 10.1073/pnas.89.15.7031; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DRISCOLL KE, 1990, AM J RESP CELL MOL, V2, P381, DOI 10.1165/ajrcmb/2.4.381; DRISCOLL KE, 1990, TOXICOL IN VITRO, V4, P284, DOI 10.1016/0887-2333(90)90065-2; DUNCAN R, 1987, BRIT J CANCER, V55, P165, DOI 10.1038/bjc.1987.33; GOSSET P, 1991, AM J RESP CELL MOL, V5, P431, DOI 10.1165/ajrcmb/5.5.431; Juliano R L, 1992, Antisense Res Dev, V2, P165; LEMAIRE I, 1995, PULMONARY FIBROSIS L, V80; Liang WW, 1996, BBA-BIOMEMBRANES, V1279, P227, DOI 10.1016/0005-2736(95)00237-5; MOHR C, 1991, AM J RESP CELL MOL, V5, P395, DOI 10.1165/ajrcmb/5.4.395; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONSIGNY M, 1988, ANAL BIOCHEM, V175, P525, DOI 10.1016/0003-2697(88)90578-7; Nicholson WJ, 1996, AM J RESP CELL MOL, V15, P88, DOI 10.1165/ajrcmb.15.1.8679226; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; ROCHE AC, 1983, J CELL BIOCHEM, V22, P131, DOI 10.1002/jcb.240220302; Rojanasakul YY, 1996, ADV DRUG DELIVER REV, V18, P115, DOI 10.1016/0169-409X(95)00020-8; SAVICI D, 1994, EXP LUNG RES, V20, P613, DOI 10.3109/01902149409031740; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STAHL PD, 1978, P NATL ACAD SCI USA, V75, P1399, DOI 10.1073/pnas.75.3.1399; STAHL PD, 1984, BIOL CELL, V51, P215, DOI 10.1111/j.1768-322X.1984.tb00301.x; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STOREY A, 1991, NUCLEIC ACIDS RES, V19, P4109, DOI 10.1093/nar/19.15.4109; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V83, P4143; WU GY, 1992, J BIOL CHEM, V267, P12436; XXIX McBroom C., 1972, METHODS ENZYMOL, V28, P212; ZHANG Y, 1993, J IMMUNOL, V150, P4188	34	27	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3910	3914		10.1074/jbc.272.7.3910	http://dx.doi.org/10.1074/jbc.272.7.3910			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020093	hybrid, Green Published			2022-12-25	WOS:A1997WH01900009
J	Ronca, F; Chan, SL; Yu, VC				Ronca, F; Chan, SL; Yu, VC			1-(5-isoquinolinesulfonyl)-2-methylpiperazine induces apoptosis in human neuroblastoma cells, SH-SY5Y, through a p53-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; WILD-TYPE P53; SIGNAL-TRANSDUCTION; DNA FRAGMENTATION; GENE-MUTATIONS; RETINOIC ACID; HL-60 CELLS; MUTANT P53; TUMOR; INDUCTION	We have studied the effect of 1-(5-isoquinolinylsuIfonyl)-2-methylpiperazine (H-7), a protein kinase inhibitor, on the regulation of apoptosis in the human neuroblastoma cell line, SH-SY5Y. H-7 (20-100 mu M) induced apoptosis in these cells characterized by DNA fragmentation and chromatin condensation, Immunoblot analyses were performed with specific antibody against BCL-2, BCL-X(S/L), BAX, JUNB, c-JUN, ICH-1(L), c-FOS, RB, CDK-2, and p53, H-7 treatment did not significantly alter the level of these proteins with the exception of p53, H-7, but not staurosporine, caused a dramatic nuclear accumulation of p53, The kinetics of nuclear accumulation of p53 correlates well with the kinetics of induction of apoptosis, The effect of H-7 was further assessed in a group of human cell lines, Only cell lines harboring the wild-type p53 gene were responsive to the stimulatory effect of H-7 on nuclear accumulation of p53, Furthermore, cell. lines carrying a mutated p53 gene were resistant to the cytotoxic effect of H-7, The ability of H-7 in mediating apoptosis in the SH-SY5Y line expressing a dominant negative mutant of p53 was significantly diminished, Taken together, these data strongly suggest that a p53-dependent mechanism contributes to the cytotoxicity of H-7 in human neuroblastoma cells.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Yu, Victor/A-7899-2015; Chan, S.L./X-4154-2018	Yu, Victor/0000-0003-3270-4734; Chan, S.L./0000-0002-3270-0525				BARTEK J, 1990, ONCOGENE, V5, P893; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DOLE MG, 1995, CANCER RES, V55, P2576; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FELIPO V, 1990, J BIOL CHEM, V265, P9599; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; IMAMURA J, 1993, CANCER RES, V53, P4053; JARVIS WD, 1994, CANCER RES, V54, P1707; JEOUNG DI, 1995, BIOCHEM BIOPH RES CO, V214, P361, DOI 10.1006/bbrc.1995.2296; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KOMURO H, 1993, CANCER RES, V53, P5284; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; Lee S, 1993, CURR OPIN CELL BIOL, V5, P286, DOI 10.1016/0955-0674(93)90118-A; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; NEGRINI M, 1994, CANCER RES, V54, P1818; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OJEDA F, 1992, INT J RADIAT BIOL, V61, P663, DOI 10.1080/09553009214551471; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROSS RA, 1985, CANCER RES, V45, P1628; SADEE W, 1987, CANCER RES, V47, P5207; SETO M, 1991, EUR J PHARMACOL, V195, P267, DOI 10.1016/0014-2999(91)90545-2; SHAO H, 1995, CELL IMMUNOL, V164, P11, DOI 10.1006/cimm.1995.1137; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEA TB, 1995, J NEUROCHEM, V65, P517; SHEIKH MS, 1994, ONCOGENE, V9, P3407; STRATTON MR, 1990, ONCOGENE, V5, P1297; TRAGANOS F, 1992, CANCER RES, V52, P6200; VOGAN K, 1993, CANCER RES, V53, P5269; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAGINUMA Y, 1995, BRIT J CANCER, V71, P9, DOI 10.1038/bjc.1995.3; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YU VC, 1986, J BIOL CHEM, V261, P1065; YU VC, 1988, J NEUROCHEM, V51, P1892, DOI 10.1111/j.1471-4159.1988.tb01174.x; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	62	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4252	4260		10.1074/jbc.272.7.4252	http://dx.doi.org/10.1074/jbc.272.7.4252			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020141	hybrid			2022-12-25	WOS:A1997WH01900057
J	Srivastava, IK; Rottenberg, H; Vaidya, AB				Srivastava, IK; Rottenberg, H; Vaidya, AB			Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PLASMODIUM-FALCIPARUM; LIVER MITOCHONDRIA; CYTOCHROME-B; RAT-LIVER; RHODAMINE-123; APOPTOSIS; INVITRO; BERGHEI; 566C80	At present, approaches to studying mitochondrial functions in malarial parasites are quite limited because of the technical difficulties in isolating functional mitochondria in sufficient quantity and purity, We have developed a flow cytometric assay as an alternate means to study mitochondrial functions in intact erythrocytes infected with Plasmodium yoelii, a rodent malaria parasite, By using a very low concentration (2 nM) of a Lipophilic cationic fluorescent probe, 3,3'dihexyloxacarbocyanine iodide, we were able to measure mitochondrial membrane potential(Delta Psi(m)) in Live intact parasitized erythrocytes through flow cytometry, The accumulation of the probe into parasite mitochondria was dependent on the presence of a membrane potential since inclusion of carbonyl cyanide m-chlorophenylhydrazone, a protonophore, dissipated the membrane potential and abolished the probe accumulation. We tested the effect of standard mitochondrial inhibitors such as myxothiazole, antimycin, cyanide and rotenone. All of them except rotenone collapsed the Delta Psi(m), and inhibited respiration. The assay was validated by comparing the EC(50) of these compounds for inhibiting Delta Psi(m) and respiration. This assay was used to investigate the effect of various antimalarial drugs such as chloroquine, tetracycline and a broad spectrum antiparasitic drug atovaquone, We observed that only atovaquone collapsed Delta Psi(m) and inhibited parasite respiration within minutes after drug treatment, Furthermore, atovaquone had no effect on mammalian Delta Psi(m). This suggests that atovaquone, shown to inhibit mitochondrial electron transport, also depolarizes malarial mitochondria with consequent cellular damage and death.	ALLEGHENY UNIV HLTH SCI, MCP, HAHNEMANN SCH MED, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19102 USA; ALLEGHENY UNIV HLTH SCI, MCP, HAHNEMANN SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19102 USA	Drexel University; Drexel University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI028398, R22AI028398, R01AI028398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013779] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI028398, AI28398] Funding Source: Medline; NIA NIH HHS [AG13779] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERTS B, 1994, MOL BIOL CELL, P655; ALDRITT SM, 1989, MOL CELL BIOL, V9, P3614, DOI 10.1128/MCB.9.9.3614; AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; CHANCE B, 1955, NATURE, V175, P1120, DOI 10.1038/1751120a0; CHRISTENSEN ST, 1995, CELL DEATH DIFFER, V2, P301; CORNILLON S, 1994, J CELL SCI, V107, P2691; DAVIES C S, 1989, Acta Leidensia, V58, P115; DAVIES CS, 1993, PARASITOLOGY, V106, P1, DOI 10.1017/S0031182000074746; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DIVO AA, 1985, J PROTOZOOL, V32, P442, DOI 10.1111/j.1550-7408.1985.tb04041.x; ELING W, 1977, B WORLD HEALTH ORGAN, V55, P105; FEAGIN JE, 1992, MOL BIOCHEM PARASIT, V52, P145, DOI 10.1016/0166-6851(92)90046-M; FOWLER RE, 1995, J PARASITOL, V81, P452, DOI 10.2307/3283831; FRY M, 1990, COMP BIOCHEM PHYS B, V96, P775, DOI 10.1016/0305-0491(90)90230-Q; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; FRY M, 1991, PARASITOLOGY, V102, P17, DOI 10.1017/S0031182000060297; GALE EF, 1981, MOL BASIS ANTIBIOTIC, P448; GERO AM, 1984, J PARASITOL, V70, P536, DOI 10.2307/3281402; GUTTERIDGE WE, 1979, BIOCHIM BIOPHYS ACTA, V582, P390, DOI 10.1016/0304-4165(79)90131-4; HAMMOND DJ, 1985, MOL BIOCHEM PARASIT, V14, P97, DOI 10.1016/0166-6851(85)90109-4; HOMEWOOD CA, 1980, MALARIA, V1, P345; HUGHES WT, 1990, ANTIMICROB AGENTS CH, V34, P225, DOI 10.1128/AAC.34.2.225; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KROGSTAD DJ, 1987, NEW ENGL J MED, V317, P542, DOI 10.1056/NEJM198708273170905; KRUNGKRAI J, 1993, EXP PARASITOL, V77, P136, DOI 10.1006/expr.1993.1070; MAI MS, 1983, ARCH BIOCHEM BIOPHYS, V221, P467, DOI 10.1016/0003-9861(83)90165-0; MCNALLY J, 1992, PARASITOLOGY, V105, P355, DOI 10.1017/S0031182000074527; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; MODICANAPOLITANO JS, 1984, BIOCHEM BIOPH RES CO, V118, P717, DOI 10.1016/0006-291X(84)91453-0; OELSHLEGEL FJ, 1975, RED CELL, V2, P1264; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; PRAPUNWATTANA P, 1988, MOL BIOCHEM PARASIT, V27, P119, DOI 10.1016/0166-6851(88)90031-X; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; SCHEIBEL LW, 1970, J PARASITOL, V56, P1054, DOI 10.2307/3277545; SCHEIBEL LW, 1969, MIL MED, V134, P1074; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SUMMERHAYES IC, 1982, P NATL ACAD SCI-BIOL, V79, P5292, DOI 10.1073/pnas.79.17.5292; TANABE K, 1983, J PROTOZOOL, V30, P707, DOI 10.1111/j.1550-7408.1983.tb05347.x; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TERASKI M, 1984, CELL, V38, P1011; TRAGER W, 1986, LIVING TOGETHER BIOL, P147; VAIDYA AB, 1989, MOL BIOCHEM PARASIT, V35, P97, DOI 10.1016/0166-6851(89)90112-6; VAIDYA AB, 1993, MOL BIOCHEM PARASIT, V58, P33, DOI 10.1016/0166-6851(93)90088-F; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Welburn SC, 1996, CELL DEATH DIFFER, V3, P229; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; [No title captured]	55	311	324	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3961	3966		10.1074/jbc.272.7.3961	http://dx.doi.org/10.1074/jbc.272.7.3961			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020100	hybrid			2022-12-25	WOS:A1997WH01900016
J	Orsel, JC; Bartoldus, I; Stegmann, T				Orsel, JC; Bartoldus, I; Stegmann, T			Kinetics of fusion between endoplasmic reticulum vesicles in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTADECYLRHODAMINE DEQUENCHING ASSAY; MEMBRANE-FUSION; PROTEIN-TRANSPORT; RAB GTPASES; NSF; ER; MICROSOMES; MECHANISM; BINDING; EVENTS	The endoplasmic reticulum (ER) is a highly dynamic organelle, continuously undergoing membrane fusion and fission. We have measured homotypic fusion between ER vesicles isolated from Chinese hamster ovary cells kinetically in vitro, using an assay based on the metabolic incorporation of pyrene-labeled fatty acids into the phospholipids of cellular membranes. An increase in pyrene-monomer fluorescence was observed after mixing labeled and unlabeled ER vesicles in the presence of ATP and GTP. The protein, temperature, and nucleotide dependence of the increase indicated that it was caused by membrane fusion rather than molecular transfer of labeled lipids to unlabeled membranes. This assay allowed the first kinetic measurements with virtually nonexchangeable probes of a homotypic membrane fusion event. At 37 degrees C, fusion started off immediately at a rate of 1.14 +/- 0.29%/min and reached a half-maximal level after 56 min. In the presence of guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S), or after treatment of the membranes with N-ethylmaleimide, fusion was reduced but not completely inhibited. Addition of GTP during a fusion reaction immediately accelerated, and GTP gamma S immediately slowed down the fusion reaction. Thus, these kinetic measurements indicate that G-proteins might act to rapidly enhance fusion beyond a basic level.	UNIV BASEL, BIOCTR, DEPT BIOPHYS CHEM, CH-4056 BASEL, SWITZERLAND	University of Basel				Orsel, Joke/0000-0003-0303-4735				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COMERFORD JG, 1991, BIOCHEM J, V280, P335, DOI 10.1042/bj2800335; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; FOLCH J, 1957, J BIOL CHEM, V226, P497; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LEE C, 1989, J CELL BIOL, V109, P2045, DOI 10.1083/jcb.109.5.2045; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ORSEL JG, 1996, MOL DYNAMICS BIOMEMB, V96, P199; PAIEMENT J, 1980, J CELL BIOL, V86, P29, DOI 10.1083/jcb.86.1.29; PAL R, 1988, BIOCHEMISTRY-US, V27, P30, DOI 10.1021/bi00401a006; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SILVERSTEIN SC, 1978, TRANSPORT MACROMOLEC; SILVIUS JR, 1987, BIOCHEMISTRY-US, V26, P4279, DOI 10.1021/bi00388a015; STEGMANN T, 1995, BIOCHEM J, V307, P875, DOI 10.1042/bj3070875; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1993, BIOCHEMISTRY-US, V32, P11330, DOI 10.1021/bi00093a009; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; VANBELLE H, 1972, BIOCHIM BIOPHYS ACTA, V289, P158, DOI 10.1016/0005-2744(72)90118-0; Wallach D. F. H., 1966, METHOD ENZYMOL, V8, P164; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WATKINS JD, 1993, J BIOL CHEM, V268, P5182; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WUNDERLIALLENSPACH H, 1990, BIOCHEMISTRY-US, V29, P1990, DOI 10.1021/bi00460a005	38	11	12	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3369	3375		10.1074/jbc.272.6.3369	http://dx.doi.org/10.1074/jbc.272.6.3369			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013578	hybrid			2022-12-25	WOS:A1997WG19200038
J	Johnsson, K; Froland, WA; Schultz, PG				Johnsson, K; Froland, WA; Schultz, PG			Overexpression, purification, and characterization of the catalase-peroxidase KatG from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISONIAZID RESISTANCE; ESCHERICHIA-COLI; GENE; OXIDATION; MECHANISM; MUTATIONS; TARGET; INHA; ETHIONAMIDE; BACILLUS	Wild-type catalase-peroxidase KatG from Mycobacterium tuberculosis as well as a specific mutant (R463L) frequently found in isoniazid-resistant strains have been overexpressed in Escherichia coli, allowing purification of sufficient quantities of enzyme for physical and kinetic characterization. Optical absorption and EPR spectroscopies indicate that KatG is similar to a growing class of bacterial catalase-peroxidases. Optical and EPR spectra of KatG in the presence of either a strong field or weak field ligand suggest that, like horseradish peroxidase and metmyoglobin, KatG is likely to have a histidine as a proximal ligand. The wild-type enzyme functions as a highly active catalase as well as a broad specificity peroxidase. Wild-type KatG and the R463L mutant of KatG exhibit identical spectroscopic and kinetic properties. Furthermore, both enzymes are equally capable of metabolizing the important antituberculosis drug isoniazid.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT CHEM, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley			johnsson, kai/P-4222-2014	johnsson, kai/0000-0002-8002-1981				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENDRIN F, 1994, BBA-PROTEIN STRUCT M, V1209, P1, DOI 10.1016/0167-4838(94)90129-5; CHUNG H, 1993, THESIS U CALIFORNIA; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DEVI BG, 1975, BIOCHEM J, V149, P187, DOI 10.1042/bj1490187; DIAZ GA, 1974, AM REV RESPIR DIS, V110, P312, DOI 10.1164/arrd.1974.110.3.312; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; Falk J. E., 1964, PORPHYRINS METALLOPO, P804; FORKL H, 1993, EUR J BIOCHEM, V214, P251, DOI 10.1111/j.1432-1033.1993.tb17918.x; Fraaije MW, 1996, EUR J BIOCHEM, V235, P192, DOI 10.1111/j.1432-1033.1996.00192.x; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FUKUMORI Y, 1985, J BIOCHEM-TOKYO, V98, P1055, DOI 10.1093/oxfordjournals.jbchem.a135352; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HILDEBRANDT AG, 1975, ARCH BIOCHEM BIOPHYS, V171, P385, DOI 10.1016/0003-9861(75)90047-8; HILLAR A, 1995, ARCH BIOCHEM BIOPHYS, V323, P438, DOI 10.1006/abbi.1995.0065; HOCHMAN A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P299, DOI 10.1016/0167-4838(91)90544-A; HOCHMAN A, 1987, J BIOL CHEM, V262, P6871; ITO K, 1992, BIOCHEMISTRY-US, V31, P11606, DOI 10.1021/bi00161a046; JACOB GS, 1979, BIOCHEMISTRY-US, V18, P2967, DOI 10.1021/bi00581a009; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; Kaufmann S H, 1993, Trends Microbiol, V1, P2, DOI 10.1016/0966-842X(93)90015-J; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LOEWEN PC, 1990, BIOCHEM CELL BIOL, V68, P1037, DOI 10.1139/o90-153; LOPRASERT S, 1988, J GEN MICROBIOL, V134, P1971; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; MDLULI K, 1996, P US JAP TUB RES C N; MORRIS S, 1995, J INFECT DIS, V171, P954, DOI 10.1093/infdis/171.4.954; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Mutsuda M, 1996, BIOCHEM J, V316, P251, DOI 10.1042/bj3160251; NADLER V, 1986, BIOCHIM BIOPHYS ACTA, V882, P234, DOI 10.1016/0304-4165(86)90160-1; NAGY JM, 1995, BIOCHEM SOC T, V23, pS152, DOI 10.1042/bst023152s; OGURA Y, 1955, ARCH BIOCHEM BIOPHYS, V57, P288, DOI 10.1016/0003-9861(55)90291-5; PALMER G, 1983, IRON PORPHYRINS 2, P43; PRETORIUS GS, 1995, ANTIMICROB AGENTS CH, V39, P2276, DOI 10.1128/AAC.39.10.2276; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; RAKSHIT G, 1974, BIOCHEMISTRY-US, V13, P5317, DOI 10.1021/bi00723a010; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO R, 1978, CYTOCHROME P450; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; WAYNE LG, 1986, ANAL BIOCHEM, V157, P89, DOI 10.1016/0003-2697(86)90200-9; WILSON TM, 1995, MOL MICROBIOL, V15, P1009, DOI 10.1111/j.1365-2958.1995.tb02276.x; YOUN HD, 1995, J BIOL CHEM, V270, P13740, DOI 10.1074/jbc.270.23.13740; YOUNG DB, 1994, CURR BIOL, V4, P351, DOI 10.1016/S0960-9822(00)00077-4; YUMOTO I, 1990, J BIOCHEM, V108, P583, DOI 10.1093/oxfordjournals.jbchem.a123246; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	55	126	131	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2834	2840		10.1074/jbc.272.5.2834	http://dx.doi.org/10.1074/jbc.272.5.2834			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006925	hybrid			2022-12-25	WOS:A1997WE66700038
J	Chiba, A; Matsumura, K; Yamada, H; Inazu, T; Shimizu, T; Kusunoki, S; Kanazawa, I; Kobata, A; Endo, T				Chiba, A; Matsumura, K; Yamada, H; Inazu, T; Shimizu, T; Kusunoki, S; Kanazawa, I; Kobata, A; Endo, T			Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; CHONDROITIN SULFATE PROTEOGLYCAN; AGRIN RECEPTOR; MEMBRANE ORGANIZATION; CARBOHYDRATE MOIETIES; BETA-DYSTROGLYCAN; SUGAR CHAINS; COMPLEX; PROTEIN	alpha-Dystroglycan is a heavily glycosylated protein, which is localized on the Schwann cell membrane as well as the sarcolemma, and links the transmembrane protein beta-dystroglycan to laminin in the extracellular matrix. We have shown previously that sialidase treatment, but not N-glycanase treatment, of bovine peripheral nerve alpha-dystroglycan greatly reduces its binding activity to laminin, suggesting that the sialic acid of O-glycosidically-linked oligosaccharides may be essential for this binding. In this report, we analyzed the structures of the sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan by two methods. O-Glycosidically-linked oligosaccharides were liberated by alkaline-borotritide treatment or by mild hydrazinolysis followed by 2-aminobenzamide-derivatization. Acidic fractions obtained by anion exchange column chromatography that eluted at a position corresponding to monosialylated oligosaccharides were converted to neutral oligosaccharides by exhaustive sialidase digestion. The sialidases from Arthrobacter ureafaciens and from Newcastle disease virus resulted in the same degree of hydrolysis. The neutral oligosaccharide fraction, thus obtained, gave a major peak with a mobility of 3.8-3.9 glucose units upon gel filtration, and its reducing terminus was identified as a mannose derivative. Based on the results of sequential exoglycosidase digestion, lectin column chromatography, and reversed-phase high-performance liquid chromatography, we concluded that the major sialylated O-glycosidically-linked oligosaccharide of the alpha-dystroglycan was a novel O-mannosyl-type oligosaccharide, the structure of which was Sia alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man-Ser/Thr (where Sia is sialic acid). This oligosaccharide constituted at least 66% of the sialylated O-linked sugar chains. Furthermore, a laminin binding inhibition study suggested that the sialyl N-acetyllactosamine moiety of this sugar chain was involved in the interaction of the alpha-dystroglycan with laminin.	TOKYO METROPOLITAN INST GERONTOL,DEPT GLYCOBIOL,ITABASHI KU,TOKYO 173,JAPAN; TEIKYO UNIV,SCH MED,DEPT NEUROL & NEUROSCI,ITABASHI KU,TOKYO 173,JAPAN; NOGUCHI INST,RES DEPT,ITABASHI KU,TOKYO 173,JAPAN; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROL,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Gerontology; Teikyo University; University of Tokyo			Inazu, Toshiyuki/R-1966-2019					BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; CARLSON DM, 1968, J BIOL CHEM, V243, P616; DEYST KA, 1995, J BIOL CHEM, V270, P25956, DOI 10.1074/jbc.270.43.25956; DUBRAY G, 1982, ANAL BIOCHEM, V119, P325, DOI 10.1016/0003-2697(82)90593-0; ENDO T, 1992, J BIOL CHEM, V267, P707; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FINNE J, 1979, J BIOL CHEM, V254, P295; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; GORDON H, 1989, DEV BIOL, V135, P1, DOI 10.1016/0012-1606(89)90152-8; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; INAZU T, 1989, CHEM LETT, P69, DOI 10.1246/cl.1989.69; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MONTREUIL J, 1983, BIOCHEM SOC T, V11, P134, DOI 10.1042/bst0110134; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; Pall EA, 1996, J BIOL CHEM, V271, P3817; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; RAIZADA MK, 1975, J BIOL CHEM, V250, P3310; RICE KG, 1993, BIOCHEMISTRY-US, V32, P7264, DOI 10.1021/bi00079a024; ROSENTHAL AL, 1975, J BIOL CHEM, V250, P5295; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; SMALHEISER NR, 1993, J NEUROSCI RES, V36, P528, DOI 10.1002/jnr.490360505; SPIRO RG, 1980, J BIOL CHEM, V255, P5347; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V105, P742, DOI 10.1093/oxfordjournals.jbchem.a122738; TAKEUCHI M, 1987, J CHROMATOGR, V400, P207, DOI 10.1016/S0021-9673(01)81613-7; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; Wu PG, 1996, J BIOL CHEM, V271, P1470, DOI 10.1074/jbc.271.3.1470; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	50	342	350	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2156	2162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999917				2022-12-25	WOS:A1997WD67900023
J	Innamorati, G; Sadeghi, H; Eberle, AN; Birnbaumer, M				Innamorati, G; Sadeghi, H; Eberle, AN; Birnbaumer, M			Phosphorylation of the V2 vasopressin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ADENYLYL CYCLASE; DESENSITIZATION; HORMONE; KINASE; DNA; SEQUESTRATION; INHIBITORS; RHODOPSIN; ARRESTIN	The V2 vasopressin receptor undergoes Ligand-induced sequestration and desensitization (Birnbaumer, M., Antaramian, A, Themmen, A. P, N., and Gilbert, S. (1992) J, Biol. Chem. 267, 11783-11788). The V2 receptor expressed in transfected cells labeled with [P-32] orthophosphate was phosphorylated following the addition of 100 nM arginine vasopressin (AVP). Phosphorylation was complete 5 min after addition of AVP, and was not stimulated by increased levels of Ca2+ or cAMP. The half-maximal dose of AVP that stimulated phosphorylation was 2.4 +/- 0.4 nM, similar to the receptor K-D of 4.5 +/- 0.4 nM. The role of phosphorylation on receptor desensitization was investigated by studying two vasopressin receptors 14 and 27 amino acids shorter than the wild type receptor, The missing segments were not needed for normal Ligand binding or coupling to G(s), but the last 14 amino acids were required for phosphorylation, The truncated receptors exposed to 100 nM AVP were sequestered and desensitized, The R137H V2R mutant receptor that binds vasopressin with wild type-like affinity and does not couple to G(s) (Rosenthal, FV,, Antaramian, A, Gilbert, S., and Birnbaumer, M. (1993) J. Biol, Chem, 268, 13030-13033) was phosphorylated and subjected to ligand-induced sequestration. These results established that phosphorylation is not essential for sequestration and desensitization of the V2 vasopressin receptor, Furthermore, they revealed that the conformation acquired after ligand occupancy is necessary for receptor phosphorylation and sequestration, while coupling to G(s) is not.	UNIV CALIF LOS ANGELES,SCH MED,DEPT ANESTHESIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Innamorati, Giulio/GVU-1941-2022; Innamorati, Giulio/AAR-6314-2020; Mir-mohammad Sadeghi, Hamid/A-8741-2016	Innamorati, Giulio/0000-0003-0123-8777; Mir-mohammad Sadeghi, Hamid/0000-0002-4834-4502	NIDDK NIH HHS [DK 41-244] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041244] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BIRNBAUMER M, 1992, J BIOL CHEM, V267, P11783; BLIND E, 1995, ENDOCRINOLOGY, V136, P4271, DOI 10.1210/en.136.10.4271; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGA K, 1992, J BIOL CHEM, V267, P2222; HARDEN TK, 1980, SCIENCE, V210, P441, DOI 10.1126/science.6254143; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Innamorati G, 1996, MOL PHARMACOL, V50, P467; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; ORLOFF J, 1962, J CLIN INVEST, V47, P1154; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; SADEGHI HM, 1996, IN PRESS J RECEPT SI; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TSUGA H, 1994, J BIOL CHEM, V269, P32522	27	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2486	2492						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999963				2022-12-25	WOS:A1997WD67900069
J	Kim, JY; Caterina, MJ; Milne, JLS; Lin, KC; Borleis, JA; Devreotes, PN				Kim, JY; Caterina, MJ; Milne, JLS; Lin, KC; Borleis, JA; Devreotes, PN			Random mutagenesis of the cAMP chemoattractant receptor, cAR1, of Dictyostelium - Mutant classes that cause discrete shifts in agonist affinity and lock the receptor in a novel activational intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; LIGAND-INDUCED PHOSPHORYLATION; CYCLIC-AMP RECEPTORS; SIGNALING PATHWAYS; ADENYLYL-CYCLASE; DISCOIDEUM; IDENTIFICATION; BINDING; FAMILY	The cAMP chemoattractant receptor, cAR1, of Dictyostelium transduces extracellular cAMP signals via G protein-dependent and G protein-independent mechanisms. While site directed mutagenesis studies of G protein-coupled receptors have provided a host of information regarding the domains essential for various functions, many mechanistic and structural questions remain to be resolved. We therefore carried out polymerase chain reaction-mediated random mutagenesis over a large part of the cAR1 sequence (from TMIII through the proximal part of the cytoplasmic tail). We devised a rapid screen for loss-of-function mutations based on the essential role of cAR1 in the developmental program of Dictyostelium. Although there were an average of two amino acid substitutions per receptor, similar to 90% of the mutants were able to substitute for wild-type cAR1 when expressed in receptor null cells. About 2% were loss-of-function mutants that expressed wild-type levels of receptor protein. We used biochemical screens to select about 100 of these mutants and chose eight representative mutants for extensive characterization. These fell into distinct classes. One class had a conditional defect in cAMP binding that was reversed by high salt. Another large class had decreased affinity under all conditions. Curiously, the decreases were clustered into three discrete intervals. One of the most interesting class of mutants lost all capacity for signal transduction but was phosphorylated in response to agonist binding. This latter finding suggests that there are at least two activated states of cAR1 that can be recognized by different downstream effecters.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University					NIGMS NIH HHS [GM 34933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1990, SOC GEN PHY, V45, P87; BONNER J T, 1949, Sci Am, V180, P44; BOURNE HR, 1989, NATURE, V337, P504, DOI 10.1038/337504a0; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BRECHLER V, 1994, RECEPTOR CHANNEL, V2, P89; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; CATERINA MJ, 1995, J BIOL CHEM, V270, P8667, DOI 10.1074/jbc.270.15.8667; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CONDEELIS J, 1991, METHOD ENZYMOL, V196, P486; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FISHMAN HA, 1995, P NATL ACAD SCI USA, V92, P7877, DOI 10.1073/pnas.92.17.7877; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HERELD D, 1992, INT REV CYTOL, V137B, P35; HERELD D, 1994, J BIOL CHEM, V269, P7036; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; Kim JY, 1996, CHEM BIOL, V3, P239, DOI 10.1016/S1074-5521(96)90103-9; KIM JY, 1994, J BIOL CHEM, V269, P28724; KLEIN P, 1987, J BIOL CHEM, V262, P358; KLEIN P, 1985, J BIOL CHEM, V260, P1757; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; MILNE JL, 1993, MOL BIOL CELL, V4, P283, DOI 10.1091/mbc.4.3.283; MILNE JLS, 1995, J BIOL CHEM, V270, P5926, DOI 10.1074/jbc.270.11.5926; Milne JLS, 1997, J BIOL CHEM, V272, P2069; MISRAHI M, 1994, ANN ENDOCRINOL-PARIS, V55, P75; PARENT CA, 1995, J BIOL CHEM, V270, P22693, DOI 10.1074/jbc.270.39.22693; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SAXE CL, 1993, GENE DEV, V7, P262, DOI 10.1101/gad.7.2.262; SAXE CL, 1991, DEV GENET, V12, P6, DOI 10.1002/dvg.1020120104; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1989, AM J RESP CELL MOL, V1, P81, DOI 10.1165/ajrcmb/1.2.81; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Strosberg A D, 1993, Drug Des Discov, V9, P199; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; VANHAASTERT PJM, 1989, BIOCHEM J, V258, P577, DOI 10.1042/bj2580577; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667	49	27	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2060	2068						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999903				2022-12-25	WOS:A1997WD67900009
J	Park, HY; Zhuang, P; Nichols, R; Howell, EE				Park, HY; Zhuang, P; Nichols, R; Howell, EE			Mechanistic studies of R67 dihydrofolate reductase - Effects of pH and an H62C mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURES; ACTIVE-SITE; CONSTRUCTION; BINDING; MUTAGENESIS; EQUILIBRIUM; RESISTANCE; BACTERIA; PROTEINS	R67 dihydrofolate reductase (DHFR) is encoded by an R-plasmid, and expression of this enzyme in bacteria confers resistance to the antibacterial drug, trimethoprim, This DHFR variant is not homologous in either sequence or structure with chromosomal DHFRs. The crystal structure of tetrameric R67 DHFR indicates a single active site pore that traverses the length of the molecule (Narayana, N., Matthews, D. A., Howell, E. E., and Xuong, N.-H. (1995) Not. Struct. Biol. 2, 1018-1025), A PH profile of enzyme activity in R67 DHFR displays an acidic pK(a) that is protein concentration-dependent. This pK(a) describes dissociation of active tetramer into two relatively inactive dimers upon protonation of His-62 and the symmetry-related His-162, His-262, and His-362 residues at the dimer-dimer interfaces, Construction of an H62C mutation results in stabilization of the active tetramer via disulfide bond formation at the dimer-dimer interfaces. The oxidized, tetrameric form of H62C R67 DHFR is quite active at pH 7, and a pH profile displays increasing activity at low pH. These results indicate protonated dihydrofolate (pK(a) = 2.59) is the productive substrate and that R67 DHFR does not possess a proton donor.	UNIV TENNESSEE, DEPT CHEM, KNOXVILLE, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville				Howell, Elizabeth/0000-0001-6157-433X	NIGMS NIH HHS [GM35308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM035308, R01GM035308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMYES SGB, 1992, J MED MICROBIOL, V36, P1; AMYES SGB, 1992, J MED MICROBIOL, V36, P4, DOI 10.1099/00222615-36-1-4; BACCANARI D, 1975, BIOCHEMISTRY-US, V14, P5267, DOI 10.1021/bi00695a006; BASRAN J, 1995, BIOCHEMISTRY-US, V34, P2872, DOI 10.1021/bi00009a018; BAYORATH J, 1991, PROTEINS, V11, P263; BAYORATH J, 1991, PROTEINS, V9, P217; BAYORATH J, 1991, P NATL ACAD SCI USA, V88, P6423; BLAKLEY RL, 1960, NATURE, V40, P1684; Bradrick TD, 1996, BIOCHEMISTRY-US, V35, P11414, DOI 10.1021/bi960205d; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CHEN YQ, 1994, BIOCHEMISTRY-US, V33, P7021, DOI 10.1021/bi00189a001; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; Creighton T. E., 1990, PROTEIN STRUCTURE PR, P155; DAVIES JF, 1990, BIOCHEMISTRY-US, V29, P9467, DOI 10.1021/bi00492a021; DUGAS H, 1989, BIOORGANIC CHEM CHEM, P359; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fersht A., 1985, ENZYME STRUCTURE MEC, P65; FIERKE CA, 1987, COLD SPRING HARB SYM, V52, P631, DOI 10.1101/SQB.1987.052.01.072; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; HORECKER BL, 1948, J BIOL CHEM, V175, P385; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; HOWELL EE, 1987, BIOCHEMISTRY-US, V26, P8591, DOI 10.1021/bi00400a015; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; MAHARAJ G, 1990, BIOCHEMISTRY-US, V29, P4554, DOI 10.1021/bi00471a008; MATSUMURA M, 1991, METHOD ENZYMOL, V202, P336; MATTHEWS DA, 1986, BIOCHEMISTRY-US, V25, P4194, DOI 10.1021/bi00363a005; MURPHY DJ, 1989, BIOCHEMISTRY-US, V28, P3025, DOI 10.1021/bi00433a043; NARAYANA N, 1995, NAT STRUCT BIOL, V2, P1018, DOI 10.1038/nsb1195-1018; NICHOLS R, 1993, BIOCHEMISTRY-US, V32, P1695, DOI 10.1021/bi00058a002; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; REECE LJ, 1991, BIOCHEMISTRY-US, V30, P10895, DOI 10.1021/bi00109a013; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SAUER RT, 1986, BIOCHEMISTRY-US, V25, P5992, DOI 10.1021/bi00368a024; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; STONE SR, 1984, BIOCHEMISTRY-US, V23, P2753, DOI 10.1021/bi00307a034; Torchinsky Y, 1981, SULFUR PROTEINS; VILLAFRANCA JE, 1987, BIOCHEMISTRY-US, V26, P2182, DOI 10.1021/bi00382a017; Wong SS., 1991, CHEM PROTEIN CONJUGA, P7; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; ZHUANG P, 1994, BIOCHEMISTRY-US, V33, P4237, DOI 10.1021/bi00180a018	40	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2252	2258						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999931				2022-12-25	WOS:A1997WD67900037
J	Gartenhaus, RB				Gartenhaus, RB			Allelic loss determination in chronic lymphocytic leukemia by immunomagnetic bead sorting and microsatellite marker analysis	ONCOGENE			English	Article						allelic losses; chronic lymphocytic leukemia; microsatellite markers	CELL LUNG-CANCER; LYMPHOBLASTIC-LEUKEMIA; HOMOZYGOUS DELETION; CHROMOSOME-3; LYMPHOMAS; REGION; GENES; ARM	Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. Details of the molecular mechanisms involved in the pathogenesis of this leukemia are unclear at present. In other malignancies tumorigenesis has been shown to proceed via a multistep progression model with a causal relation between the accumulation of genetic abnormalities and more aggressive clinical behavior. The loss of chromosomal segments in malignant cells has proven useful in mapping regions of DNA that contain candidate tumor suppressor genes. The detection of loss of heterozygosity (LOH) has been greatly facilitated by the analysis of highly polymorphic microsatellite markers enabling the identification of submicroscopic losses. Utilizing immunomagnetic bead sorting to separate leukemic from normal cells we identified at least one allelic losses in 8/29 (28%) of analysed CLL cases with a PCR-based assay. On chromosomal arm 3p we have identified homozygous deletions in 3/29 cases at locus D3S1284 residing in the vicinity of the newly described FHIT gene. Several cases of CLL manifested LOH at a locus telomeric to the p15 and p16 tumor suppressor genes, all being early to intermediate stage disease. Our findings suggest that losses at these loci may contribute to the development and/or progression of CLL in at least a subset of cases.			Gartenhaus, RB (corresponding author), ALLEGHENY UNIV HLTH SCI,CTR NEUROVIROL,ONCOL MOL LAB,PHILADELPHIA,PA 19102, USA.							BINET JL, 1977, CANCER-AM CANCER SOC, V40, P855, DOI 10.1002/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Califano J, 1996, CANCER RES, V56, P2488; CHAGANTI SR, 1995, GENE CHROMOSOME CANC, V12, P32, DOI 10.1002/gcc.2870120106; DALY MC, 1993, ONCOGENE, V8, P1721; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENAUX P, 1992, LEUKEMIA, V6, P246; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; Gartenhaus R, 1996, BLOOD, V87, P38; Gartenhaus RB, 1996, J MOL MED-JMM, V74, P143, DOI 10.1007/BF01575446; GIADANO G, 1991, P NATL ACAD SCI USA, V88, P5413; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HANNAMHARRIS A, 1984, P AM ASSOC CANC RES, V25, P157; JULIUSSON G, 1990, NEW ENGL J MED, V323, P710; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MERLO A, 1994, CANCER RES, V54, P640; NOWELL PC, 1988, CANCER GENET CYTOGEN, V33, P155, DOI 10.1016/0165-4608(88)90025-8; OBRIEN S, 1995, BLOOD, V85, P307; OFFIT K, 1994, BLOOD, V83, P2608; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OTSUKI T, 1995, CANCER RES, V55, P1436; PARSA NZ, 1994, GENE CHROMOSOME CANC, V9, P8; RAGHOEBIER S, 1991, BLOOD, V77, P1560; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; RUPPERT JM, 1993, CANCER RES, V53, P5093; SCHENA M, 1992, BLOOD, V79, P2981; SIEBERT R, 1995, BRIT J HAEMATOL, V91, P350, DOI 10.1111/j.1365-2141.1995.tb05302.x; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; Thiagalingam S, 1996, CANCER RES, V56, P2936	32	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					375	378		10.1038/sj.onc.1200867	http://dx.doi.org/10.1038/sj.onc.1200867			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018124				2022-12-25	WOS:A1997WD51600014
J	InoharaOchiai, M; Nakayama, T; Goto, R; Nakao, M; Ueda, T; Shibano, Y				InoharaOchiai, M; Nakayama, T; Goto, R; Nakao, M; Ueda, T; Shibano, Y			Altering substrate specificity of Bacillus sp SAM1606 alpha-glucosidase by comparative site-specific mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; ANGSTROM RESOLUTION; CARBOHYDRASE ACTION; CRYSTAL-STRUCTURE; TAKA-AMYLASE; OLIGO-1,6-GLUCOSIDASE; ENZYMES; GENE; PURIFICATION	The Bacillus sp. SAM1606 alpha-glucosidase with a broad substrate specificity is the only known alpha-glucosidase that can hydrolyze alpha,alpha'-trehalose efficiently. The enzyme exhibits a very high sequence similarity to the oligo 1,6-glucosidases (O16G) of Bacillus thermoglucosidasius and Bacillus cereus which cannot act on trehalose. These three enzymes share 80% identical residues within the conserved regions (CR), which have been suggested to be located near or at the active site of the alpha-amylase family enzymes. To identify by site-specific mutagenesis the critical residues that determine the broad substrate specificity of the SAM1606 enzyme we compared the CR sequences of these three glucosidases and selected five targets to be mutagenized in SAM1606 alpha-glucosidase, Met(76), Arg(81), Ala(116), Gly(273), and Thr(342) These residues have been specifically replaced by in vitro mutagenesis with Asn, Ser, Val, Pro, and Asn, respectively, as in the Bacillus O16G. The 12 mutant enzymes with single and multiple substitutions were expressed and characterized kinetically. The results showed that the 5-fold mutation virtually abolished the affinity of the enzyme for alpha,alpha'-trehalose, whereas the specificity constant for the hydrolysis of isomaltose, a good substrate for both the SAM1606 enzyme and O16G, remained essentially unchanged upon the mutation. This loss in affinity for trehalose was critically governed by a Gly(273) --> Pro substitution, whose effect was specifically enhanced by the Thr(342) --> Asn substitution in the B-fold and quadruple mutants. These results provide evidence for the differential roles of the amino acid residues in the CR in determining the substrate specificity of the alpha-glucosidase.	KOBE GAKUIN UNIV,DEPT NUTR PHYSIOL,NISHI KU,KOBE 65121,JAPAN; SUNTORY RES CTR,SHIMAMOTO,OSAKA 618,JAPAN; BIOMOL ENGN RES INST,SUITA,OSAKA 565,JAPAN	Kobe Gakuin University; Suntory Holdings Ltd								BRAYER GD, 1995, PROTEIN SCI, V4, P1730, DOI 10.1002/pro.5560040908; CASSET F, 1995, EUR J BIOCHEM, V232, P284, DOI 10.1111/j.1432-1033.1995.tb20810.x; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; HEHRE EJ, 1977, BIOCHEMISTRY-US, V16, P1780, DOI 10.1021/bi00628a003; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; KELLY CT, 1983, PROCESS BIOCHEM, V18, P6; KITAHATA S, 1981, J BIOL CHEM, V256, P6017; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; MACGREGOR EA, 1989, BIOCHEM J, V259, P145, DOI 10.1042/bj2590145; MACHIUS M, 1995, J MOL BIOL, V246, P545, DOI 10.1006/jmbi.1994.0106; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; NAKAJIMA R, 1985, J BACTERIOL, V163, P401, DOI 10.1128/JB.163.1.401-406.1985; NAKAO M, 1994, EUR J BIOCHEM, V220, P293, DOI 10.1111/j.1432-1033.1994.tb18625.x; NAKAO M, 1994, APPL MICROBIOL BIOT, V41, P337, DOI [10.1007/s002530050154, 10.1007/BF00221229]; PASERO L, 1986, BIOCHIM BIOPHYS ACTA, V869, P147, DOI 10.1016/0167-4838(86)90289-X; PUTTER J, 1983, METHOD ENZYMAT AN, P286; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; SHIBANO Y, 1985, GENE, V34, P243; SUZUKI Y, 1979, BIOCHIM BIOPHYS ACTA, V566, P62, DOI 10.1016/0005-2744(79)90248-1; SUZUKI Y, 1976, BIOCHIM BIOPHYS ACTA, V445, P386, DOI 10.1016/0005-2744(76)90092-9; SUZUKI Y, 1982, BIOCHIM BIOPHYS ACTA, V704, P476, DOI 10.1016/0167-4838(82)90070-X; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; TAKATA H, 1992, J BIOL CHEM, V267, P18447; TODA H, 1982, P JPN ACAD B-PHYS, V58, P208, DOI 10.2183/pjab.58.208; WATANABE K, 1991, J BIOL CHEM, V266, P24287; WATANABE K, 1994, EUR J BIOCHEM, V226, P277, DOI 10.1111/j.1432-1033.1994.tb20051.x; WATANABE K, 1990, EUR J BIOCHEM, V192, P609, DOI 10.1111/j.1432-1033.1990.tb19267.x; WIEGAND G, 1995, J MOL BIOL, V247, P99, DOI 10.1006/jmbi.1994.0125	32	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1601	1607		10.1074/jbc.272.3.1601	http://dx.doi.org/10.1074/jbc.272.3.1601			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999834	hybrid			2022-12-25	WOS:A1997WD05800032
J	Ouchane, S; Picaud, M; Vernotte, C; ReissHusson, F; Astier, C				Ouchane, S; Picaud, M; Vernotte, C; ReissHusson, F; Astier, C			Pleiotropic effects of puf interposon mutagenesis on carotenoid biosynthesis in Rubrivivax gelatinosus - A new gene organization in purple bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES; RHODOPSEUDOMONAS-CAPSULATA; RHODOCYCLUS-GELATINOSUS; CLUSTER; TRANSCRIPTS; ASSIGNMENT; SEQUENCE; COMPLEX; PROTEIN; CRTE	Rubrivivax gelatinosus mutants affected in the carotenoid biosynthesis pathways were created by interposon mutagenesis within the puf operon. Genetic and biochemical analysis of several constructed mutants suggest that at least crtC is localized downstream of the puf operon and that it is cotranscribed with this operon. Sequence analysis confirmed the genetic data and showed the presence of crtD and crtC genes downstream of the puf operon, a localization different from that known for other purple bacteria. Inactivation of the crtD gene indicated that the two crt genes are cotranscribed and that they are involved not only in the hydroxyspheroidene biosynthesis pathway as in Rhodobacter sphaeroides and R. capsulatus, but also in the spirilloxanthin biosynthesis pathway. Carotenoid genes implicated in the spirilloxanthin biosynthesis pathway were thus identified for the first time. Furthermore, analysis of carotenoid synthesis in the mutants gave genetic evidence that crtD and crtC genes are cotranscribed with the puf operon using the oxygen regulated puf promoter.	UNIV PARIS 06, CTR GENET MOL, CNRS, UPR 9061, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay			Ouchane, Soufian/ABE-2609-2020	Ouchane, Soufian/0000-0002-8161-3866				AGALIDIS I, 1990, PHOTOSYNTH RES, V23, P249, DOI 10.1007/BF00034855; Alberti M, 1995, ANOXYGENIC PHOTOSYNT, P1083; Armstrong GA, 1996, FASEB J, V10, P228, DOI 10.1096/fasebj.10.2.8641556; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1995, ANOXYGENIC PHOTOSYNT, P1135; BAUER CE, 1991, MOL GEN GENET, V228, P433, DOI 10.1007/BF00260637; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; Beatty J. T., 1995, ANOXYGENIC PHOTOSYNT, P1209; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; Britton G., 1993, CAROTENOIDS PHOTOSYN, P96, DOI DOI 10.1007/978-94-011-2124-8_4; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; COOMBER SA, 1990, MOL MICROBIOL, V4, P977, DOI 10.1111/j.1365-2958.1990.tb00670.x; Frank H. A., 1993, CAROTENOIDS PHOTOSYN, P252, DOI [10.1007/978-94-011-2124-8_8, DOI 10.1007/978-94-011-2124-8_8]; GIULIANO G, 1988, MOL GEN GENET, V213, P78, DOI 10.1007/BF00333401; GIULIANO G, 1986, J BIOL CHEM, V261, P2925; GOLDEN SS, 1988, METHOD ENZYMOL, V167, P714; JIRSAKOVA V, 1994, FEBS LETT, V353, P151, DOI 10.1016/0014-5793(94)01033-1; KLUG G, 1995, ANOXYGENIC PHOTOSYNT, P1235; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANG HP, 1995, J BACTERIOL, V177, P2064, DOI 10.1128/jb.177.8.2064-2073.1995; LANG HP, 1994, BIOCHEM J, V298, P197, DOI 10.1042/bj2980197; LANG HP, 1994, J BACTERIOL, V176, P3859, DOI 10.1128/JB.176.13.3859-3869.1994; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; NAGASHIMA KVP, 1994, J BIOL CHEM, V269, P2477; NAGASHIMA KVP, 1993, PHOTOSYNTH RES, V36, P185, DOI 10.1007/BF00033037; Ouchane S, 1996, MOL GEN GENET, V252, P379, DOI 10.1007/BF02173002; OUCHANE S, 1995, FEBS LETT, V374, P130, DOI 10.1016/0014-5793(95)01055-J; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDMANN G, 1992, FEMS MICROBIOL LETT, V90, P253, DOI 10.1111/j.1574-6968.1992.tb05162.x; Schmidt K., 1978, PHOTOSYNTHETIC BACTE, P729; SCOLNIK PA, 1980, J BIOL CHEM, V255, P2427; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; UFFEN RL, 1976, P NATL ACAD SCI USA, V73, P3298, DOI 10.1073/pnas.73.9.3298; WELLINGTON CL, 1991, J BACTERIOL, V173, P1432, DOI 10.1128/jb.173.4.1432-1443.1991; WELLINGTON CL, 1992, CAN J MICROBIOL, V38, P20, DOI 10.1139/m92-003; YEN HC, 1976, J BACTERIOL, V126, P619, DOI 10.1128/JB.126.2.619-629.1976; YILDIZ FH, 1992, MOL MICROBIOL, V6, P2683, DOI 10.1111/j.1365-2958.1992.tb01445.x; ZSEBO KM, 1984, CELL, V37, P937, DOI 10.1016/0092-8674(84)90428-8	40	42	44	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1670	1676		10.1074/jbc.272.3.1670	http://dx.doi.org/10.1074/jbc.272.3.1670			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999844	hybrid			2022-12-25	WOS:A1997WD05800042
J	Wu, XQ; RajBhandary, UL				Wu, XQ; RajBhandary, UL			Effect of the amino acid attached to Escherichia coli initiator tRNA on its affinity for the initiation factor IF2 and on the IF2 dependence of its binding to the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA TRANSFORMYLASE; ELONGATION-FACTOR-TU; FORMYLMETHIONINE TRANSFER-RNA; EUKARYOTIC PROTEIN-SYNTHESIS; TRANSLATIONAL INITIATION; RIBONUCLEIC-ACID; ACCEPTOR STEM; RECOGNITION; SEQUENCE; MUTANTS	We show that the nature of the amino acid in the formylaminoacyl-tRNA influences initiation factor (IF) 2 dependence of its ribosome binding and that this IF2 dependence reflects the relative affinity of the formylaminoacyl-tRNA for the initiation factor IF2. We compared the template-dependent ribosome binding activities, in the presence of initiation factors, of wild type and anticodon sequence mutants of Escherichia coli initiator tRNAs that carry formylmethionine (fMet), formylglutamine (fGln), or formylvaline (fVal). The fGln-tRNA bound less well than fMet-tRNA whereas the fVal-tRNA bound as well as flMet-tRNA. The rate and extent of binding of fGln-tRNA to the ribosome was significantly increased by further addition of purified initiation factor IF2. In contrast, the binding of fVal-tRNA or fMet-tRNA was not affected much by the addition of IF2. Using gel mobility shift assay, we have measured the apparent K-d values of the IF2 . formylaminoacyl-tRNA binary complexes. These are 1.8, 3.5, and 10.5 mu M for fMet-tRNA, fVal-tRNA, and fGln-tRNA, respectively.			Wu, XQ (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017151, R01GM017151, R56GM017151, R37GM017151] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17151] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baron Christian, 1995, P529; BEIER H, 1991, ESSENTIAL MOL BIOL P, V2, P221; BROMBACH M, 1986, MOL GEN GENET, V205, P97, DOI 10.1007/BF02428037; CANONACO MA, 1986, FEBS LETT, V207, P198, DOI 10.1016/0014-5793(86)81488-0; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; GIEGE R, 1973, FEBS LETT, V37, P166, DOI 10.1016/0014-5793(73)80450-8; GIEGE R, 1973, FEBS LETT, V30, P291, DOI 10.1016/0014-5793(73)80672-6; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GUALERZI CO, 1986, FEBS LETT, V202, P1, DOI 10.1016/0014-5793(86)80637-8; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HERSHEY JWB, 1987, CELLULAR MOL BIOL, P613; KNOWLTON RG, 1980, J MOL BIOL, V139, P721, DOI 10.1016/0022-2836(80)90057-1; KOZAK M, 1983, MICROBIOL REV, V47, P1; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LATEANA A, 1993, P NATL ACAD SCI USA, V90, P4161, DOI 10.1073/pnas.90.9.4161; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; LEON M, 1979, EUR J BIOCHEM, V98, P149, DOI 10.1111/j.1432-1033.1979.tb13171.x; Li SH, 1996, J BIOL CHEM, V271, P1022, DOI 10.1074/jbc.271.2.1022; LOCKWOOD A, 1991, P NATL ACAD SCI USA, V69, P3122; LODISH HF, 1970, J MOL BIOL, V50, P689, DOI 10.1016/0022-2836(70)90093-8; MAJUMDAR A, 1976, J BIOL CHEM, V251, P137; MANDAL N, 1992, J BACTERIOL, V174, P7827, DOI 10.1128/JB.174.23.7827-7830.1992; MANGROO D, 1995, J BIOL CHEM, V270, P12203, DOI 10.1074/jbc.270.20.12203; Mangroo D, 1995, BIOCHEM CELL BIOL, V73, P1023, DOI 10.1139/o95-109; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; PETERSEN HU, 1979, BIOCHEM BIOPH RES CO, V91, P1068, DOI 10.1016/0006-291X(79)91989-2; PINGOUD A, 1980, BIOCHEMISTRY-US, V19, P2108, DOI 10.1021/bi00551a017; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; RAJBHANDARY UL, 1969, J BIOL CHEM, V244, P1104; RAJBHANDARY UL, 1967, J BIOL CHEM, V243, P575; RUDLAND PS, 1971, NATURE-NEW BIOL, V231, P76, DOI 10.1038/newbio231076a0; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SPURIO R, 1993, TRANSLATIONAL APPARATUS, P241; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1992, J BACTERIOL, V174, P7819, DOI 10.1128/JB.174.23.7819-7826.1992; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; VARSHNEY U, 1993, P NATL ACAD SCI USA, V90, P2305, DOI 10.1073/pnas.90.6.2305; WAGNER T, 1980, EUR J BIOCHEM, V108, P213, DOI 10.1111/j.1432-1033.1980.tb04714.x; WAGNER T, 1984, J BIOL CHEM, V259, P4706; WU XQ, 1996, EMBO J, V17, P4734; Yusupova G, 1996, BIOCHEMISTRY-US, V35, P2978, DOI 10.1021/bi9519415; ZUCKER FH, 1986, BIOCHEMISTRY-US, V25, P3682, DOI 10.1021/bi00360a031	47	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1891	1895		10.1074/jbc.272.3.1891	http://dx.doi.org/10.1074/jbc.272.3.1891			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999877	hybrid			2022-12-25	WOS:A1997WD05800075
J	Watson, DK; Robinson, L; Hodge, DR; Kola, I; Papas, TS; Seth, A				Watson, DK; Robinson, L; Hodge, DR; Kola, I; Papas, TS; Seth, A			FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements	ONCOGENE			English	Article						ETS; FLI1; EWS-FLI1; Egr1; ternary complex factor (TCF); quaternary complex factor (QCF); CArG box; SRE	EWS/FLI-1 FUSION GENE; DNA-BINDING MOTIF; ETS DOMAIN; C-FOS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; SECONDARY STRUCTURE; ONCOGENIC ACTIVITY; REGULATORY FACTOR; MURINE ETS-1	The ETS gene products are a family of transcriptional regulatory proteins that contain a highly conserved and structurally unique DNA binding domain, termed the ETS domain. Several ETS proteins bind to DNA as monomers, however it has been shown that the DNA binding activity is enhanced or modulated in the presence of other factors. By differential display and whole genome PCR techniques, we have recently shown that the Erg1 gene is a target for ETS proteins. The Egr1 promoter contains multiple ETS binding sites, three of which exist as parts of two serum response elements (SREI and SREII). The SRE is a cis-element that regulates the expression of many growth factor responsive genes. ELK1 and SAP1a have been shown to form ternary complexes with SRF on the SRE located in the c-fos promoter. Similarly, we examined whether the ELK1, SAP1a, FLI1, EWS-FLI1, ETS1, ETS2, PEA3 and PU.1 proteins can form ternary complexes with SRF on the Egr1 SREI and II. Our results demonstrate that indeed ELK1, SAP1a, FLI1 and EWS-FLI1 are able to form ternary complexes with SRF on Egr1 SREs. In addition, ELK1 and SAP1a can also form quarternary complexes on the Egr1 SRE1. However, the proteins ETS1, ETS2, PEA3 and PU.1 were unable to form ternary complexes with SRF on either the Egr1 or c-fos SREs. Our data demonstrate that FLI1 and EWS-FLI1 constitute new members of a subgroup of ETS proteins that can function as ternary complex factors and further implicate a novel function for these ETS transcription factors in the regulation of the Egr1 gene. By amino acid sequence comparison we found that, in fact, 50% of the amino acids present in the B-box of SAP1a and ELK1, which are required for interaction with SRF, are identical to those present in both FLI1 (amino acids 231-248) and EWS-FLI1 proteins. This B-box is not present in ETS1, ETS2, PEA3 or PU.1 and these proteins were unable to form ternary complexes with SRF and Egr1-SREs or c-fos SRE. Furthermore, deletion of 194 amino terminal amino acids of FLI1 did not interfere with its ability to interact with SRF, in fact, this truncation increased the stability of the ternary complex. The FLI1 protein has a unique R-domain located next to the DNA binding region. This R-domain may modulate the interaction with SRF, providing a mechanism that would be unique to FLI1 and EWS-FLI1, thus implicating a novel function for these ETS transcription factors in the regulation of the Egr1 gene.	UNIV TORONTO, MRC, GRP PERIODONTAL PHYSIOL, TORONTO, ON M5S 1B2, CANADA; WOMENS COLL HOSP, LAB MOL PATHOL, TORONTO, ON M5S 1B2, CANADA; MED UNIV S CAROLINA, CTR MOL & STRUCT BIOL, CHARLESTON, SC 29425 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ONCOL MOL LAB, FREDERICK, MD 21702 USA; MONASH UNIV, MOL GENET & DEV GRP, MELBOURNE, VIC 3168, AUSTRALIA	University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Monash University			Kola, Ismail/C-5254-2013					ASCIONE R, 1992, INT J ONCOL, V1, P631; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bhat NK, 1996, INT J ONCOL, V8, P841; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KHARBANDA S, 1994, CELL GROWTH DIFFER, V5, P259; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHNO T, 1993, CANCER RES, V53, P5859; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Qi S., 1992, DNA Sequence, V3, P127, DOI 10.3109/10425179209034008; ROBINSON L, 1995, MIAMI SHORT REPORTS, V6, P76; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; Zhang XK, 1995, HYBRIDOMA, V14, P563, DOI 10.1089/hyb.1995.14.563	49	93	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	1997	14	2					213	221		10.1038/sj.onc.1200839	http://dx.doi.org/10.1038/sj.onc.1200839			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010223				2022-12-25	WOS:A1997WC81800009
J	Gopalkrishnan, RV; Dolle, P; Mattei, MG; LaThangue, NB; Kedinger, C				Gopalkrishnan, RV; Dolle, P; Mattei, MG; LaThangue, NB; Kedinger, C			Genomic structure and developmental expression of the mouse cell cycle regulatory transcription factor DP1	ONCOGENE			English	Article						DP1; E2F; cell cycle; genomic structure; mouse chromosome; in situ hybridisation	E2F FAMILY; FACTOR DRTF1/E2F; IN-VIVO; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; SUPPRESSOR GENES; MAMMALIAN-CELLS; BINDING PROTEIN; MEMBER; DNA	The E2F/DP family of transcription factors play an important role in the control of cell cycle progression. By direct regulatory interactions with the retinoblastoma family of proteins, they integrate extracellular growth promoting signals impinging on the cyclin and cyclin dependent kinase complex during the G(1) phase, with cell cycle progression. This is accomplished by direct transcriptional activation of genes required for nucleotide biosynthesis and DNA replication in the S phase, In addition, these transcription factors also play a role in the control of genes involved in regulating G(1) and S phase progression including, autoregulatory control, as in the case of E2F1 itself, In this report, we describe the characterisation of the genomic locus encoding DP1, a member of this family, The DP1 gene has a TATA-less promoter and transcription initiates at multiple sites. Using transient transfection assays we have delineated sequences in the upstream region which have promoter or enhancer activity. The DP1 gene was localised to mouse chromosome 8 by metaphase chromosome analysis, We describe a dynamic pattern of DP1 expression using in situ hybridisation on cryostat sections of mouse embryos at various stages of development and a variable level of expression by Northern blot analysis of RNA from various adult tissues.	INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; FAC MED TIMONE,INSERM U406,F-13385 MARSEILLE,FRANCE; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOL BIOL,GLASGOW G12 8QQ,LANARK,SCOTLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Glasgow			Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOCCO JL, 1993, ONCOGENE, V8, P2977; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCK V, 1995, ONCOGENE, V11, P31; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Decimo D, 1996, GENE PROBES PRACTICA, P183; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANA X, 1995, ONCOGENE, V11, P211; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MIRONOV VN, 1995, NUCLEIC ACIDS RES, V23, P3359, DOI 10.1093/nar/23.16.3359; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEUMAN E, 1995, MOL CELL BIOL, V15, P4660; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; OSWALD F, 1994, ONCOGENE, V9, P2029; PASTEAU S, 1995, ONCOGENE, V11, P1475; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WU CL, 1995, MOL CELL BIOL, V15, P2536; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	69	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2671	2680						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000141				2022-12-25	WOS:A1996VZ65400017
J	Wang, HL; Xie, ZR; Scott, RE				Wang, HL; Xie, ZR; Scott, RE			JunD phosphorylation, and expression of AP-1 DNA binding activity modulated by serum growth factors in quiescent murine 3T3T cells	ONCOGENE			English	Article						JunD; AP-1; cell proliferation; phosphorylation; transcription factors	C-JUN; PROTEINS; TRANSFORMATION; KINASE; GENE; FOS; ACTIVATION; FAMILY; RAS; DIFFERENTIATION	JunD has been implicated as a negative regulator of cell proliferation, If and how JunD is regulated by growth factors however has not been well investigated, We now report that in quiescent murine 3T3T cells, JunD is present in a hypophosphorylated form, but that when quiescent cells are stimulated to proliferate with serum, JunD undergoes a transient increase in its phosphorylation that occurs within 10 min and persists for up to 4 h, The increase in JunD phosphorylation correlates with the induction of cell proliferation since only those growth factors that promote cell proliferation can induce JunD phosphorylation, Treatment of quiescent 3T3T cells with serum also induces significant decreases in JunD/AP-1 DNA binding activity within 2 h and in JunD expression after 8-48 h, However, both hypophosphorylated and hyperphosphorylated forms of JunD can bind AP-1 DNA, These results suggest that serum growth factors can modulate JunD characteristics in a variety of apparently independent ways to overcome its negative regulatory effect in controlling cell proliferation, These include induction of a transient increase in JunD phosphorylation, repression of JunD AP-1 DNA binding activity and downregulation of JunD expression.	UNIV TENNESSEE,COLL MED,DEPT PATHOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; DIAMOND L, 1977, NATURE, V269, P247, DOI 10.1038/269247a0; GABRIELSEN OS, 1989, NUCLEIC ACIDS RES, V17, P6253, DOI 10.1093/nar/17.15.6253; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOERL BJ, 1989, J CELL PHYSIOL, V139, P68, DOI 10.1002/jcp.1041390111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagarrigue S, 1995, BIOCHEM BIOPH RES CO, V217, P501, DOI 10.1006/bbrc.1995.2804; LASKY SR, 1995, J BIOL CHEM, V270, P19676, DOI 10.1074/jbc.270.34.19676; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; Neyns B, 1996, ONCOGENE, V12, P1247; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REZZONICO R, 1995, ONCOGENE, V11, P1069; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; WANG HL, 1994, P NATL ACAD SCI USA, V91, P4649, DOI 10.1073/pnas.91.11.4649; WANG HL, 1991, CELL GROWTH DIFFER, V2, P645; WANG HL, 1991, J CELL PHYSIOL, V147, P102, DOI 10.1002/jcp.1041470114; Wang HL, 1995, MOL CELL BIOCHEM, V153, P59, DOI 10.1007/BF01075919; YE ZS, 1987, J BIOL CHEM, V262, P6313	37	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2639	2647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000138				2022-12-25	WOS:A1996VZ65400014
J	Aubry, L; Maeda, M; Insall, R; Devreotes, PN; Firtel, RA				Aubry, L; Maeda, M; Insall, R; Devreotes, PN; Firtel, RA			The Dictyostelium mitogen-activated protein kinase ERK2 is regulated by ras and cAMP-dependent protein kinase (PKA) and mediates PKA function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; SIGNALING PATHWAYS; DISCOIDEUM; SUBUNIT; RECEPTOR; ROLES; CELLS; CRAC	The chemoattractant cAMP, acting through serpentine cAMP receptors, results in a rapid and transient stimulation of the Dictyostelium mitogen-activated protein kinase ERK2 activity (1), In this study we show that other pathways required for aggregation, including Ras and cAMP-dependent protein kinase (PKA), are important regulators of ERK2 activation and adaptation. By examining both the level and kinetics of activation and adaptation of ERK2, we show that Ras is a negative regulator of ERK2. Activated Ras or disruption of a Ras GAP gene results in reduced ERK2 activation whereas disruption of putative Ras GEF or expression of dominant negative Res proteins have a more rapid, higher, and extended activation. CRAC, a PH domain-containing protein required for adenylyl cyclase activation, is also required for proper ERK2 adaptation. PKA overexpression results in a more rapid, higher level of activation, whereas pka null cells show a lower level but more extended ERK2 activation. Furthermore, we show that constitutive expression of PKA catalytic subunit bypasses the requirement of ERK2 for aggregation and later development, indicating that PKA lies downstream from ERK2 and that ERK2 may regulate one or more components of the signaling pathway required for mediating PRA function, possibly by directly regulating PKA R or a protein controlling the intracellular level of cAMP.	UNIV CALIF SAN DIEGO,CTR MOL GENET,DEPT BIOL,LA JOLLA,CA 92093; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; UNIV LONDON UNIV COLL,MRC,MOL CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND	University of California System; University of California San Diego; Johns Hopkins University; University of London; University College London			Insall, Robert/G-5611-2011	Insall, Robert/0000-0003-4898-040X; Aubry, Laurence/0000-0001-7640-1706	NIGMS NIH HHS [GM28007, GM37830] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028007, R01GM037830, R37GM028007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DANIEL J, 1994, ONCOGENE, V9, P501; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; FIRTEL RA, 1990, GENE DEV, V4, P18, DOI 10.1101/gad.4.1.18; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; Gaskins C, 1996, GENE DEV, V10, P118, DOI 10.1101/gad.10.1.118; HARWOOD AJ, 1992, DEV BIOL, V149, P90, DOI 10.1016/0012-1606(92)90266-J; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; Insall RH, 1996, CURR BIOL, V6, P719, DOI 10.1016/S0960-9822(09)00453-9; Khosla M, 1996, MOL CELL BIOL, V16, P4156; Knetsch MLW, 1996, EMBO J, V15, P3361, DOI 10.1002/j.1460-2075.1996.tb00701.x; LEE S, 1996, IN PRESS DEVELOPMENT; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; Maeda M, 1996, J BIOL CHEM, V271, P3351; MANN SKO, 1992, P NATL ACAD SCI USA, V89, P10701, DOI 10.1073/pnas.89.22.10701; MANN SKO, 1991, MECH DEVELOP, V35, P89, DOI 10.1016/0925-4773(91)90060-J; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; PAWSON T, 1985, MOL CELL BIOL, V5, P33, DOI 10.1128/MCB.5.1.33; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; SEGALL JE, 1995, J CELL BIOL, V128, P405, DOI 10.1083/jcb.128.3.405; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; VanHaastert PJM, 1995, EXPERIENTIA, V51, P1144	26	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3883	3886		10.1074/jbc.272.7.3883	http://dx.doi.org/10.1074/jbc.272.7.3883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020088	hybrid			2022-12-25	WOS:A1997WH01900004
J	Uberall, F; Giselbrecht, S; Hellbert, K; Fresser, F; Bauer, B; Gschwendt, M; Grunicke, HH; Baier, G				Uberall, F; Giselbrecht, S; Hellbert, K; Fresser, F; Bauer, B; Gschwendt, M; Grunicke, HH; Baier, G			Conventional PKC-alpha, novel PKC-epsilon and PKC-theta, but not atypical PKC-lambda are MARCKS kinases in intact NIH 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; SUBSTRATE MARCKS; C SUBSTRATE; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; 87-KDA PROTEIN; ACTIVATION; ZETA; PHOSPHORYLATION; CELLS	Phosphorylation of myristoylated alanine-rich protein kinase C substrate (MARCKS) in intact cells has been employed as an indicator for activation of protein kinase C (PKC). Specific PKC isoenzymes responsible for MARCKS phosphorylation under physiological conditions, however, remained to be identified, In our present study using stably transfected NIH 3T3 cell clones we demonstrate that expression of constitutively active mutants of either conventional cPKC-alpha or novel nPKC-epsilon increased phosphorylation of endogenous MARCKS in the absence of phorbol 12,13-dibutyrate in intact mouse fibroblasts, implicating that each of these PKC isoforms itself is sufficient to induce enhanced MARCKS phosphorylation, Similarly, ectopic expression of a constitutively active mutant of PKC-theta significantly increased MARCKS phosphorylation compared to vector controls, identifying PKC-theta as a MARCKS kinase, The PKC-specific inhibitor GF 109203X (bisindolylmaleimide I) reduced MARCKS phosphorylation in intact cells at a similar dose-response as enzymatic activity of recombinant isoenzymes cPKC-alpha, nPKC-epsilon, and nPKC-theta in vitro, Consistently, phorbol 12,13-dibutyrate-dependent MARCKS phosphorylation was significantly reduced in cell lines expressing dominant negative mutants of either PKC-alpha K368R or (dominant negative) PKC-epsilon R436R, The fact, that the constitutively active PKC-lambda A119E mutant did not alter the MARCKS phosphorylation underscores the assumption that atypical PKC isoforms are not involved in this process, We conclude that under physiological conditions, conventional cPKC-alpha and novel nPKC-epsilon, but not atypical aPKC-lambda are responsible for MARCKS phosphorylation in intact NIH 3T3 fibroblasts.	GERMAN CANC RES CTR, D-69120 HEIDELBERG, GERMANY; UNIV INNSBRUCK, INST MED BIOL & HUMAN GENET, A-6020 INNSBRUCK, AUSTRIA	Helmholtz Association; German Cancer Research Center (DKFZ); University of Innsbruck	Uberall, F (corresponding author), UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA.		Baier, Gottfried/E-8755-2012	Baier, Gottfried/0000-0002-2085-8325				ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HERGET T, 1994, EUR J BIOCHEM, V225, P549, DOI 10.1111/j.1432-1033.1994.t01-1-00549.x; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; HERGET T, 1994, EUR J BIOCHEM, V225, P539, DOI 10.1111/j.1432-1033.1994.00539.x; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LINDNER D, 1992, J BIOL CHEM, V267, P24; MATINYBARON G, 1993, J BIOL CHEM, V268, P9194; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1990, J BIOL CHEM, V265, P6296; PEARS C, 1991, FEBS LETT, V284, P120, DOI 10.1016/0014-5793(91)80776-Y; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UBERALL F, 1994, CELL SIGNAL, V6, P285, DOI 10.1016/0898-6568(94)90033-7; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YAMAMOTO H, 1995, J NEUROCHEM, V65, P802	40	104	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4072	4078		10.1074/jbc.272.7.4072	http://dx.doi.org/10.1074/jbc.272.7.4072			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020116	hybrid			2022-12-25	WOS:A1997WH01900032
J	Wartmann, M; Hofer, P; Turowski, P; Saltiel, AR; Hynes, NE				Wartmann, M; Hofer, P; Turowski, P; Saltiel, AR; Hynes, NE			Negative modulation of membrane localization of the Raf-1 protein kinase by hyperphosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; IN-VITRO; ACTIVATION; RAS; CELLS; GROWTH; SITES	The serine/threonine-specific protein kinase Raf-l plays a key role in mitogenic signal transduction by coupling Pus to the mitogen-activated protein (MAP) kinase cascade. Pus-mediated translocation to the plasma membrane represents a crucial step in the process of serum-stimulated Raf-l kinase activation. The exact role of the multisite phosphorylation in Raf regulation, however, is not clear. We have previously reported that the mobility shift-associated hyperphosphorylation of Raf correlates with a reduction of serum-stimulated Raf kinase activity (Wartmann, M., and Davis, R. J. (1994) J. Biol. Chem. 269, 6695-6701), Here we show that incubation of serum-starved CHO cells with D609, a purported inhibitor of phosphatidylcholine-specific phospholipase C, also results in a mobility shift of Raf-l that is due to hyperphosphorylation on sites identical to those observed following mitogen stimulation. Subcellular fractionation analyses revealed that D609-induced mobility shift-associated hyperphosphorylation was paralleled by a decreased membrane association of Raf-l. Similar results were obtained in an in vitro reconstitution system. Furthermore, PD98059, a specific inhibitor of activation of the MAP kinase kinase MEK, prevented D6O9-induced Raf hyperphosphorylation and restored the amount of membrane-bound Raf to control levels, Taken together, these data suggest that mobility shift-associated hyperphosphorylation of Raf-l, by virtue of reducing the amount of plasma membrane-bound Raf-l, represents a negative feedback mechanism contributing to the desensitization of the MAP kinase signaling cascade.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	Friedrich Miescher Institute for Biomedical Research; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BORNER C, 1989, J BIOL CHEM, V264, P13902; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LISBONA C, 1994, EUR J IMMUNOL, V24, P2746, DOI 10.1002/eji.1830241126; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTE BM, 1995, ONCOGENE, V10, P167; MCGREW BR, 1992, ONCOGENE, V7, P33; MILLER DG, 1992, J VIROL, V66, P78, DOI 10.1128/JVI.66.1.78-84.1992; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAPP UR, 1991, ONCOGENE, V6, P495; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SOZERI O, 1992, ONCOGENE, V7, P2259; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; TRAVERSE S, 1993, ONCOGENE, V8, P3175; UEKI K, 1994, J BIOL CHEM, V269, P15756; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	68	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3915	3923		10.1074/jbc.272.7.3915	http://dx.doi.org/10.1074/jbc.272.7.3915			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020094	hybrid			2022-12-25	WOS:A1997WH01900010
J	Aghdasi, B; Zhang, JZ; Wu, YL; Reid, MB; Hamilton, SL				Aghdasi, B; Zhang, JZ; Wu, YL; Reid, MB; Hamilton, SL			Multiple classes of sulfhydryls modulate the skeletal muscle Ca2+ release channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; RAPID CALCIUM RELEASE; RYANODINE RECEPTOR; CA-2+ RELEASE; REACTIVE OXYGEN; N-ACETYLCYSTEINE; FREE-RADICALS; NITRIC-OXIDE; FATIGUE; VESICLES	Two sulfhydryl reagents, N-ethylmaleimide (NEM), an alkylating agent, and diamide, an oxidizing agent, were examined for effects on the skeletal muscle Ca2+ release channel. NEM incubated with the channel for increasing periods of time displays three distinct phases in its functional effects on the channel reconstituted into planar lipid bilayers; first it inhibits, then it activates, and finally it again inhibits channel activity. NEM also shows a three-phase effect on the binding of [H-3]ryanodine by first decreasing binding (phase 1), followed by a recovery of the binding (phase 2), and then a final phase of inhibition (phase 3), In contrast, diamide 1) activates the channel, 2) enhances [H-3]ryanodine binding, 3) cross-links subunits within the Ca2+ release channel tetramer, and 4) protects against phase 1 inhibition by NEM. All diamide effects can be reversed by the reducing agent, dithiothreitol. Diamide induces intersubunit dimer formation of both the full-length 565-kDa subunit of the channel and the 400-kDa generated by endogenous calpain digestion, suggesting that the cross-link does not involve sulfhydryls within the N-terminal 170-kDa fragment of the protein. NEM under phase 1 conditions blocks the formation of the intersubunit crosslinks by diamide. In addition, single channels activated by diamide are further activated by the addition of NEM, Diamide either cross-links phase 1 sulfhydryls or causes a conformational change in the Ca2+ release channel which leads to inaccessibility of phase 1 sulfhydryls to NEM alkylation. The data presented here lay the groundwork for mapping the location of one of the sites of subunit-subunit contact in the Ca2+ release channel tetramer and for identifying the functionally important sulfhydryls of this protein.	BAYLOR COLL MED,DEPT MOL PHYSIOL & BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Hamilton, Susan/0000-0003-0241-9369	NHLBI NIH HHS [HL45721] Funding Source: Medline; NIAMS NIH HHS [AR41802] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON JJ, 1983, P NATL ACAD SCI-BIOL, V80, P1526, DOI 10.1073/pnas.80.6.1526; ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750; ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; ABRAMSON JJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P245, DOI 10.1016/0003-9861(88)90633-9; ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; BARCLAY JK, 1991, CAN J PHYSIOL PHARM, V69, P279, DOI 10.1139/y91-043; BINDOLI A, 1983, ARCH BIOCHEM BIOPHYS, V221, P458, DOI 10.1016/0003-9861(83)90164-9; BORASO A, 1994, AM J PHYSIOL, V267, pH1010, DOI 10.1152/ajpheart.1994.267.3.H1010; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CHU A, 1990, MOL PHARMACOL, V37, P735; DIAZ PT, 1993, J APPL PHYSIOL, V75, P540, DOI 10.1152/jappl.1993.75.2.540; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20857; GREGORY JD, 1955, J AM CHEM SOC, V77, P3922, DOI 10.1021/ja01619a073; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; Quinn K. E., 1996, Biophysical Journal, V70, pA389; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; REID MB, 1994, J CLIN INVEST, V94, P2468, DOI 10.1172/JCI117615; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; SHINDOH C, 1990, J APPL PHYSIOL, V68, P2107, DOI 10.1152/jappl.1990.68.5.2107; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WANG K, 1974, J BIOL CHEM, V249, P8005; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; ZORZATO F, 1986, J BIOL CHEM, V261, P3252	39	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3739	3748		10.1074/jbc.272.6.3739	http://dx.doi.org/10.1074/jbc.272.6.3739			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013631	hybrid			2022-12-25	WOS:A1997WG19200091
J	Bose, S; Seetharam, S; Dahms, NM; Seetharam, B				Bose, S; Seetharam, S; Dahms, NM; Seetharam, B			Bipolar functional expression of transcobalamin II receptor in human intestinal epithelial caco-2 Cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC-FACTOR-COBALAMIN; AFFINITY CHROMATOGRAPHY; MEDIATED ENDOCYTOSIS; BRUSH-BORDER; TRANSPORT; PROTEINS; VITAMIN-B12; TRANSCYTOSIS; BINDING; RAT	Transcobalamin II (TC II) receptor is expressed in the apical and basolateral membranes of human intestinal mucosa and in post-confluent human intestinal epithelial Caco-2 cells with a 6-7-fold enrichment in basolateral membranes. Caco-2 cells grown on culture inserts bound (at 5 degrees C) 30 and 180 fmol of the ligand, TC II-[Co-57]cobalamin (Cbl), to the apical and the basolateral surfaces, respectively. Within 5 h at 37 degrees C, all apically bound Cbl was internalized and subsequently transcytosed as TC II-Cbl. In contrast, all basolateral surface-bound Cbl was internalized and retained by the cells, but transferred from TC II to other cellular proteins. Chloroquine or leupeptin had no effect on the apical to basolateral transcytosis of either [Co-57]Cbl or I-125-TC II. In contrast, following basolateral internalization of the Ligand, both chloroquine and leupeptin inhibited She intracellular degradation of I-125-TC II which resulted in secretion of 60-65% of TC II-Cbl complex into the basolateral medium. When I-125-TC II-Cbl was orally administered to rats, intact labeled TC II was detected in the portal blood 4 and 8 h later. These studies suggest that TC II-Cbl is processed when presented to the (a) apical/luminal side by a hitherto unrecognized non-lysosomal pathway in which both TC II and Cbl are transcytosed and (b) basolateral side by the lysosomal pathway in which TC II is degraded and the released Cbl is utilized.	MED COLL WISCONSIN,MACC FUND CTR,DEPT BIOCHEM,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; VET ADM MED CTR,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)				, Santanu/0000-0002-5501-3293	PHS HHS [50052] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN RH, 1972, J BIOL CHEM, V247, P7709; ALLEN RH, 1973, J BIOL CHEM, V248, P3660; BARSHOP BA, 1990, AM J MED GENET, V35, P222, DOI 10.1002/ajmg.1320350216; BATT RM, 1989, AM J PHYSIOL, V257, pG9344; Bose S, 1996, J BIOL CHEM, V271, P4195; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; Bose S, 1996, J BIOL CHEM, V271, P11718, DOI 10.1074/jbc.271.20.11718; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPER BA, 1987, ANNU REV NUTR, V7, P291, DOI 10.1146/annurev.nu.07.070187.001451; DAN N, 1994, J BIOL CHEM, V269, P18849; DIX CJ, 1990, GASTROENTEROLOGY, V98, P1272, DOI 10.1016/0016-5085(90)90344-Z; FENTON WA, 1989, METABOLIC BASIS INHE, P2065; GORDON MM, 1995, AM J PHYSIOL-GASTR L, V268, pG33, DOI 10.1152/ajpgi.1995.268.1.G33; GUEANT JL, 1992, FEBS LETT, V297, P229, DOI 10.1016/0014-5793(92)80544-Q; IDRISS JM, 1991, J BIOL CHEM, V266, P9438; KESSLER M, 1978, BIOCHIM BIOPHYS ACTA, V506, P136, DOI 10.1016/0005-2736(78)90440-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1994, BIOCHEM J, V310, P585; LINDEMANS J, 1986, J EXP CELL RES, V184, P449; MOLITORIS BA, 1985, J MEMBRANE BIOL, V83, P207, DOI 10.1007/BF01868695; PINTO M, 1983, BIOL CELL, V47, P323; RAMANUJAM KS, 1991, J BIOL CHEM, V266, P13135; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RAMANUJAM KS, 1991, BIOCHEM BIOPH RES CO, V179, P543, DOI 10.1016/0006-291X(91)91405-2; RAMANUJAM KS, 1992, BIOCHEM BIOPH RES CO, V182, P439, DOI 10.1016/0006-291X(92)91751-B; RAMASAMY M, 1989, AM J PHYSIOL, V257, pG791, DOI 10.1152/ajpgi.1989.257.5.G791; Rindler Michael J., 1994, P1623; ROBERTSON JA, 1985, GASTROENTEROLOGY, V88, P908, DOI 10.1016/S0016-5085(85)80007-X; RODRIGUEZBOULAN E, 1992, ANN REV CELL BIOL, V8, P258; SEETHARAM B, 1982, ANNU REV NUTR, V2, P343, DOI 10.1146/annurev.nu.02.070182.002015; Seetharam Bellur, 1994, P1997; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; YOUNGDAHLTURNER P, 1978, J CLIN INVEST, V61, P133, DOI 10.1172/JCI108911; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	35	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3538	3543		10.1074/jbc.272.6.3538	http://dx.doi.org/10.1074/jbc.272.6.3538			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013602	hybrid			2022-12-25	WOS:A1997WG19200062
J	Chu, C; Cogswell, J; Kohtz, DS				Chu, C; Cogswell, J; Kohtz, DS			MyoD functions as a transcriptional repressor in proliferating myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; UPSTREAM STIMULATORY FACTOR; FIBROBLAST GROWTH-FACTOR; LOOP-HELIX PROTEINS; DNA-BINDING; CELL-CYCLE; TERMINAL DIFFERENTIATION; NEGATIVE REGULATION; ENHANCER-BINDING; GENE ACTIVATION	The myogenic basic helix-loop-helix (myo-bHLH) proteins are a family of transcriptional regulators expressed in myoblasts and differentiated skeletal muscle, Ectopic expression of myo-bHLH regulators transdetermines some fibroblast cell lines into myoblasts, which exit the cell cycle and differentiate into skeletal muscle when cultured in low mitogen medium. While members of the myo-bHLH family have been shown to function as transcriptional activators in differentiating muscle, the molecular basis of their function in proliferating myoblasts has not been elucidated, In this report, we present evidence that MyoD functions as a transcriptional repressor in myoblasts, We show that transcription from a cyclin B1 promoter construct is repressed in proliferating myoblasts and that repression is mediated by a pair of MyoD binding sites, We also show that transcription from the cyclin B1 promoter is repressed in proliferating C3H10T1/2 cells by ectopic expression of MyoD. These results demonstrate that MyoD can repress transcription of specific genes in proliferating cells, a novel function that may be important to maintenance of the myogenic phenotype and to cell cycle regulation in myoblasts.	CUNY MT SINAI SCH MED,DEPT PATHOL 1194,NEW YORK,NY 10029; GLAXO WELLCOME INC,DEPT CELLULAR SCI,RES TRIANGLE PK,NC 27709	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; GlaxoSmithKline								BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUCKINGHAM M, 1994, CELL, V78, P15, DOI 10.1016/0092-8674(94)90568-1; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HWANG A, 1995, J BIOL CHEM, V270, P28419; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KONIGSBERG IR, 1963, SCIENCE, V140, P1273, DOI 10.1126/science.140.3573.1273; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LINKHART TA, 1980, J SUPRAMOL STR CELL, V14, P483, DOI 10.1002/jss.400140407; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; Sambrook J., 2002, MOL CLONING LAB MANU; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232	63	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3145	3148		10.1074/jbc.272.6.3145	http://dx.doi.org/10.1074/jbc.272.6.3145			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013546	hybrid			2022-12-25	WOS:A1997WG19200006
J	Dekker, N; Tommassen, J; Lustig, A; Rosenbusch, JP; Verheij, HM				Dekker, N; Tommassen, J; Lustig, A; Rosenbusch, JP; Verheij, HM			Dimerization regulates the enzymatic activity of Escherichia coli outer membrane phospholipase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LABEL HEXADECANESULFONYL FLUORIDE; STRUCTURAL GENE; INACTIVATION; MECHANISM; PROTEIN; CELLS; PORIN; PLDA; DISSOCIATION; RESOLUTION	The outer membrane phospholipase A (OMPLA) of Escherichia coli is present in a dormant state in the cell envelope, The enzyme is activated by various processes, which have in common that they perturb the outer membrane. Kinetic experiments, chemical cross-linking, and analytical ultracentrifugation were carried out with purified, detergent-solubilized OMPLA to understand the underlying mechanism that results in activation, Under conditions in which the enzyme displayed full activity, OMPLA was dimeric. High detergent concentrations or very dilute protein concentrations resulted in low specific activity of the enzyme, and under those conditions the enzyme was monomeric, The cofactor Ca2+ was required for dimerization, Covalent modification of the active site serine with hexadecylsulfonylfluoride resulted in stabilization of the dimeric form and a loss of the absolute calcium requirement for dimerization. The results of these experiments provide evidence for dimerization as the molecular mechanism by which the enzymatic activity of OMPLA is regulated, This dimerization probably plays a role in vivo as well. Data from chemical cross-linking on whole cells indicate that OMPLA is present in the outer membrane as a monomer and that activation of the enzyme induces dimerization concurrent with the appearance of enzymatic activity.	UNIV UTRECHT,INST BIOMEMBRANES,DEPT MOL CELL BIOL,NL-3584 CH UTRECHT,NETHERLANDS; UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND; UNIV BASEL,BIOCTR,DEPT MICROBIOL,CH-4056 BASEL,SWITZERLAND	Utrecht University; University of Basel; University of Basel	Dekker, N (corresponding author), UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT ENZYMOL & PROT ENGN,PADUALAAN 8,NL-3584 CH UTRECHT,NETHERLANDS.		Tommassen, Jan/I-1690-2016	Tommassen, Jan/0000-0001-7633-4945				AARSMAN AJ, 1976, BIOORG CHEM, V5, P241, DOI 10.1016/0045-2068(76)90033-X; ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; AUDET A, 1974, BIOCHIM BIOPHYS ACTA, V348, P334, DOI 10.1016/0005-2760(74)90213-6; BLAAUW M, 1995, FEBS LETT, V373, P10, DOI 10.1016/0014-5793(95)01002-V; BROK RGPM, 1994, J BACTERIOL, V176, P861, DOI 10.1128/jb.176.3.861-870.1994; CHERNYAK VY, 1982, ANAL BIOCHEM, V123, P110, DOI 10.1016/0003-2697(82)90630-3; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; CRONAN JE, 1969, VIROLOGY, V38, P241, DOI 10.1016/0042-6822(69)90365-1; DEGEUS P, 1986, EUR J BIOCHEM, V161, P163; DEGEUS P, 1983, MOL GEN GENET, V190, P150, DOI 10.1007/BF00330338; DEKKER N, 1995, EUR J BIOCHEM, V232, P214, DOI 10.1111/j.1432-1033.1995.tb20801.x; ELLIS KJ, 1971, J BIOL CHEM, V246, P6631; HELLER KB, 1978, J BACTERIOL, V134, P1181, DOI 10.1128/JB.134.3.1181-1183.1978; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; HOMMA H, 1984, J BIOCHEM, V96, P1655, DOI 10.1093/oxfordjournals.jbchem.a134997; HOMMA H, 1984, J BIOCHEM-TOKYO, V96, P1645, DOI 10.1093/oxfordjournals.jbchem.a134996; HORREVOETS AJG, 1989, BIOCHEMISTRY-US, V28, P1139, DOI 10.1021/bi00429a031; HORREVOETS AJG, 1991, EUR J BIOCHEM, V198, P247, DOI 10.1111/j.1432-1033.1991.tb16008.x; HORREVOETS AJG, 1991, EUR J BIOCHEM, V198, P255, DOI 10.1111/j.1432-1033.1991.tb16009.x; KHEWGOODALL YS, 1991, ARCH BIOCHEM BIOPHYS, V284, P98, DOI 10.1016/0003-9861(91)90269-O; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LUDWIG B, 1982, J BIOL CHEM, V257, P5576; LUIRINK J, 1986, J GEN MICROBIOL, V132, P825; OTT P, 1982, FEBS LETT, V138, P187, DOI 10.1016/0014-5793(82)80437-7; PATRIARCA P, 1972, BIOCHIM BIOPHYS ACTA, V260, P593, DOI 10.1016/0005-2760(72)90008-2; PAVELICH MJ, 1973, BIOCHEMISTRY-US, V12, P1408, DOI 10.1021/bi00731a022; PHILLIPS DC, 1977, BIOCHEM SOC T, V5, P642, DOI 10.1042/bst0050642; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; PUGSLEY AP, 1984, EMBO J, V3, P2393, DOI 10.1002/j.1460-2075.1984.tb02145.x; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Sackett DL, 1996, J BIOL CHEM, V271, P9987, DOI 10.1074/jbc.271.17.9987; SCANDELLA CJ, 1971, BIOCHEMISTRY-US, V10, P4447, DOI 10.1021/bi00800a015; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SKARE JT, 1993, J BIOL CHEM, V268, P16302; TAMORI Y, 1979, J BIOCHEM, V86, P1129, DOI 10.1093/oxfordjournals.jbchem.a132607; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; VERHEIJ HM, 1980, BIOCHEMISTRY-US, V19, P743, DOI 10.1021/bi00545a021; WECKESSER J, 1984, J BACTERIOL, V159, P199, DOI 10.1128/JB.159.1.199-205.1984; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; ZULAUF M, 1987, METHOD ENZYMOL, V172, P528	43	69	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3179	3184		10.1074/jbc.272.6.3179	http://dx.doi.org/10.1074/jbc.272.6.3179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013551	hybrid			2022-12-25	WOS:A1997WG19200011
J	Lehmann, JM; Kliewer, SA; Moore, LB; SmithOliver, TA; Oliver, BB; Su, JL; Sundseth, SS; Winegar, DA; Blanchard, DE; Spencer, TA; Willson, TM				Lehmann, JM; Kliewer, SA; Moore, LB; SmithOliver, TA; Oliver, BB; Su, JL; Sundseth, SS; Winegar, DA; Blanchard, DE; Spencer, TA; Willson, TM			Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-ALPHA-HYDROXYLASE MESSENGER-RNA; BILE-ACID BIOSYNTHESIS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; THYROID-HORMONE; RETINOIC ACID; SUPERFAMILY; ELEMENTS; 24(S),25-EPOXYCHOLESTEROL; IDENTIFICATION; PROMOTER	Accumulation of cholesterol causes both repression of genes controlling cholesterol biosynthesis and cellular uptake and induction of cholesterol 7 alpha-hydroxylase, which leads to the removal of cholesterol by increased metabolism to bile acids, Here, we report that LXR alpha and LXR beta, two orphan members of the nuclear receptor superfamily, are activated by 24(S),25-epoxycholesterol and 24(S)-hydroxycholesterol at physiologic concentrations. In addition, we have identified an LXR response element in the promoter region of the rat cholesterol 7 alpha-hydroxylase gene, Our data provide evidence for a new hormonal signaling pathway that activates transcription in response to oxysterols and suggest that LXRs play a critical role in the regulation of cholesterol homeostasis.	GLAXO WELLCOME INC,RES & DEV,DEPT METAB DIS,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME INC,RES & DEV,DEPT MOL SCI,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME INC,RES & DEV,DEPT MED CHEM,RES TRIANGLE PK,NC 27709; DARTMOUTH COLL,DEPT CHEM,HANOVER,NH 03755	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Dartmouth College	Lehmann, JM (corresponding author), GLAXO WELLCOME INC,RES & DEV,DEPT MOL ENDOCRINOL,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.		feinstein, doug/M-9414-2019	Sundseth, Scott/0000-0002-3122-4862	NHLBI NIH HHS [HL52069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HOEKMAN MFM, 1993, GENE, V130, P217, DOI 10.1016/0378-1119(93)90422-Y; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Kainu T, 1996, J MOL NEUROSCI, V7, P29, DOI 10.1007/BF02736846; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LI YC, 1990, J BIOL CHEM, V265, P12012; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUND E, 1995, ACCOUNTS CHEM RES, V28, P241, DOI 10.1021/ar00054a001; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MYANT NB, 1977, J LIPID RES, V18, P135; NELSON JA, 1981, J BIOL CHEM, V256, P1067; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SAUCIER SE, 1985, J BIOL CHEM, V260, P4571; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; SPENCER TA, 1994, ACCOUNTS CHEM RES, V27, P83, DOI 10.1021/ar00039a004; SU JL, 1995, HYBRIDOMA, V14, P383, DOI 10.1089/hyb.1995.14.383; TAYLOR FR, 1986, J BIOL CHEM, V261, P5039; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033	32	997	1075	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3137	3140		10.1074/jbc.272.6.3137	http://dx.doi.org/10.1074/jbc.272.6.3137			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013544	hybrid			2022-12-25	WOS:A1997WG19200004
J	Read, MA; Whitley, MZ; Gupta, S; Pierce, JW; Best, J; Davis, RJ; Collins, T				Read, MA; Whitley, MZ; Gupta, S; Pierce, JW; Best, J; Davis, RJ; Collins, T			Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappa B and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; SIGNAL-TRANSDUCTION PATHWAYS; CELL-ADHESION MOLECULE-1; TRANSCRIPTIONAL ACTIVATION; HA-RAS; PHOSPHORYLATION; STRESS; PROMOTER; BINDING; FAMILY	E-selectin expression by endothelium is crucial for leukocyte recruitment during inflammatory responses. Transcriptional regulation of the E-selectin promoter by tumor necrosis factor alpha (TNF alpha) requires multiple nuclear factor-kappa B (NF-kappa B) binding sites and a cAMP-responsive element/activating transcription factor-like binding site designated positive domain II (PDII). Here we characterize the role of the stress-activated family of mitogen-activated protein (MAP) kinases in induced expression of this adhesion molecule. By UV cross-linking and immunoprecipitation, we demonstrated that a heterodimer of transcription factors ATF-2 and c-JUN is constitutively bound to the PDII site. TNF alpha stimulation of endothelial cells induces transient phosphorylation of both ATF-2 and c-JUN and induces marked activation of the c-JUN N-terminal kinase (JNK1) and p38 but not extracellular signal-regulated kinase (ERK1). JNK and p38 are constitutively present in the nucleus, and DNA-bound c-JUN and ATF-2 are stably contacted by JNK and p38, respectively. MAP/ERK kinase kinase 1 (MEKK1), an upstream activator of MAP kinases, increases E-selectin promoter transcription and requires an intact PDII site for maximal induction. MEKK1 can also activate NF-kappa B -dependent gene expression. The effects of dominant interfering forms of the JNK/p38 signaling pathway demonstrate that activation of these kinases is critical for cytokine-induced E-selectin gene expression. Thus, TNF alpha activates two signaling pathways, NF-kappa B and JNK/p38, which are both required for maximal expression of E-selectin.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV VASC RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, PROGRAM MOL MED, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01605 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035716, P01HL036028, R37HL035716] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 36028, HL 35716, HL 45462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; CARLOS TM, 1994, BLOOD, V84, P2068; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAI TN, 1995, ONCOGENE, V10, P849; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DECESARE D, 1995, ONCOGENE, V11, P365; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LENORMAND P, 1993, ADV SEC MESS PHOSPH, V28, P237; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Read MA, 1996, J IMMUNOL, V157, P3472; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; YAN MH, 1994, NATURE, V372, P798; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	75	321	329	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2753	2761		10.1074/jbc.272.5.2753	http://dx.doi.org/10.1074/jbc.272.5.2753			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006914	hybrid			2022-12-25	WOS:A1997WE66700027
J	Kowalski, RJ; Giannakakou, P; Hamel, E				Kowalski, RJ; Giannakakou, P; Hamel, E			Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC INSTABILITY; GUANINE-NUCLEOTIDES; BINDING-SITE; BETA-TUBULIN; AMINO-ACIDS; PROTEINS; ANALOGS; POLYMERIZATION; MECHANISM; 5'-TRIPHOSPHATE	Epothilones A and B, natural products with minimal structural analogy to taxoids, have effects similar to those of paclitaxel (Taxol(R)) in cultured cells and on microtubule protein, but differ from paclitaxel in retaining activity in multidrug-resistant cells. We examined interactions of the epothilones with purified tubulin and additional cell Lines, including a paclitaxel-resistant ovarian carcinoma Line with an altered beta-tubulin. The epothilones, like paclitaxel, induced tubulin to form microtubules at low temperatures and without GTP and/or microtubule-associated proteins. The epothilones are competitive inhibitors of the binding of [H-3]paclitaxel to tubulin polymers. The apparent K-i values for epothilones A and B were 1.4 and 0.7 mu M by Hanes analysis and 0.6 and 0.4 mu M by Dixon analysis. In the paclitaxel-sensitive human cell lines we examined, epothilone B had greater antiproliferative activity than epothilone A or paclitaxel, while epothilone A was usually less active than paclitaxel. A multidrug-resistant colon carcinoma line and the paclitaxel-resistant ovarian line retained sensitivity to the epothilones. With Potorous tridactylis kidney epithelial (PtK2) cells examined by indirect immunofluorescence, microtubule bundles appeared more rapidly following epothilone B treatment, and there were different proportions of various mitotic aberrations following treatment with different drugs.	NCI, FREDERICK CANC RES & DEV CTR, LAB DRUG DISCOVERY RES & DEV, DEV THERAPEUT PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BEHRENS BC, 1987, CANCER RES, V47, P414; BLOKHIN AV, 1995, MOL PHARMACOL, V48, P523; BOLLAG DM, 1995, CANCER RES, V55, P2325; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CORTES JE, 1995, J CLIN ONCOL, V13, P2643, DOI 10.1200/JCO.1995.13.10.2643; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIXON M, 1979, ENZYMES, P332; Gerth K, 1996, J ANTIBIOT, V49, P560, DOI 10.7164/antibiotics.49.560; GROVER S, 1995, BIOCHEMISTRY-US, V34, P3927, DOI 10.1021/bi00012a009; HAMEL E, 1995, ARCH BIOCHEM BIOPHYS, V322, P486, DOI 10.1006/abbi.1995.1492; HAMEL E, 1981, J BIOL CHEM, V256, P1887; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; Hamel E, 1996, MED RES REV, V16, P207, DOI 10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.3.CO;2-I; HAMEL E, 1984, J BIOL CHEM, V259, P2501; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P5314, DOI 10.1021/bi00317a033; Hofle GH, 1996, ANGEW CHEM INT EDIT, V35, P1567, DOI 10.1002/anie.199615671; Hyams J. S., 1994, MICROTUBULES; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KUMAR N, 1981, J BIOL CHEM, V256, P435; LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; TAKOUDJU M, 1988, FEBS LETT, V227, P96, DOI 10.1016/0014-5793(88)80875-5; terHaar E, 1996, BIOORGAN MED CHEM, V4, P1659, DOI 10.1016/0968-0896(96)00158-7; terHaar E, 1996, BIOCHEMISTRY-US, V35, P243, DOI 10.1021/bi9515127; THOMPSON WC, 1981, CELL MOTIL CYTOSKEL, V1, P445, DOI 10.1002/cm.970010405; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598	36	470	505	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2534	2541						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999970				2022-12-25	WOS:A1997WD67900076
J	Warren, RA; Green, FA; Enns, CA				Warren, RA; Green, FA; Enns, CA			Saturation of the endocytic pathway for the transferrin receptor does not affect the endocytosis of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED PITS; DENSITY-LIPOPROTEIN RECEPTOR; LYSOSOMAL ACID-PHOSPHATASE; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; INTERNALIZATION SIGNALS; AMINO-ACID; MANNOSE-6-PHOSPHATE RECEPTOR; MEMBRANE-PROTEIN; MAMMALIAN-CELLS	Cell-surface receptors that undergo clathrin-mediated endocytosis contain short amino acid sequences in their cytoplasmic domain that serve as internalization signals. interactions between these sequences and components of the endocytic machinery should become limiting upon overexpression of the constitutively recycling transferrin receptor (TfR). A tetracycline-responsive system was used to induce overexpression of the TfR up to 20-fold in HeLa cells. Internalization assays indicate the rate of I-125-transferrin uptake per surface TfR is reduced by a factor of 4 in induced cells. Consistent with endocytosis being the rate-limiting step, TfRs shift from an endosomal to more of a plasma membrane distribution with TfR overexpression. The clathrin-associated protein AP-2 has been proposed to interact directly with the cytoplasmic domain of many receptors, yet no changes in the amount or distribution of AP-2 were detected in induced cells. The internalization rate for the epidermal growth factor receptor was also measured, with or without induction of TfR expression. Even though endocytosis of the TfR is saturated in induced cells, I-125-labeled epidermal growth factor continues to be internalized at a rate identical to that seen in uninduced cells. We propose that there are different limiting steps for the endocytosis of these two receptors.	OREGON HLTH SCI UNIV, DEPT CELL & DEV BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40608] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1990, BIOCHEM J, V267, P31, DOI 10.1042/bj2670031; BACALLAO R, 1989, METHOD CELL BIOL, V31, P437; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHANG M P, 1991, Journal of Cell Biology, V115, p186A; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DELALUNA S, 1988, GENE, V62, P121; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ENNS CA, 1983, J CELL BIOL, V97, P579, DOI 10.1083/jcb.97.2.579; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANOVER JA, 1985, J BIOL CHEM, V260, P5938; HOPKINS CR, 1985, J CELL SCI, V3, P139; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCDOWELL EM, 1976, ARCH PATHOL LAB MED, V100, P405; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SOSA MA, 1993, J BIOL CHEM, V268, P12537; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; WILDE A, 1994, J BIOL CHEM, V269, P7131; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648	52	91	92	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2116	2121						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999911				2022-12-25	WOS:A1997WD67900017
J	Yan, K; Gautam, N				Yan, K; Gautam, N			Structural determinants for interaction with three different effectors on the G protein beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNITS; PHOSPHOLIPASE-C; K+ CHANNEL; BINDING; IDENTIFICATION; STIMULATION; ASSOCIATION; ACTIVATION	In the yeast two-hybrid system, a 100-residue fragment (beta 1A) from the N terminus of the beta 1 subunit interacts with domains specific to adenylyl cyclase 2 (AC2), the muscarinic atrial potassium channel (GIRK1), and phospholipase C-beta 2 (PLC-beta 2). Based on the crystal structure of the G protein, beta 1A is composed of an N-terminal alpha helix, a loop, and five beta strands in which the C-terminal four beta strands form a beta sheet, the first of seven sheets that make up the propeller structure of the beta subunit. A mutant of beta 1A (L4P, L7P, and L14P), in which the alpha helix was potentially destroyed, interacted poorly with the G protein gamma subunit but effectively with domains of AC2, GIRK1, and PLC-beta 2. In contrast, another mutant of beta 1A (S72A, D76A, and W82A), in which a network of hydrogen bonds was disrupted, interacted poorly with GIRK1 and PLC-beta 2 domains, but effectively with the gamma subunit and the AC2 domain. These results suggest that the proper folding of the first five beta strands in the G protein beta subunit is a requirement for appropriately positioning residues that interact with GIRK1 and PLC-beta 2. Furthermore, since mutations that potentially disrupted the folding of these beta strands did not affect interaction with AC2, the structural determinants on the G protein beta subunit for interaction with various effecters may be different.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUANG Y, 1996, P NATL ACAD SCI USA, V93, P294; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	27	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2056	2059						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999902				2022-12-25	WOS:A1997WD67900008
J	deMedina, SGD; Chopin, D; ElMarjou, A; Delouvee, A; LaRochelle, WJ; Hoznek, A; Abbou, C; Aaronson, SA; Thiery, JP; Radvanyi, F				deMedina, SGD; Chopin, D; ElMarjou, A; Delouvee, A; LaRochelle, WJ; Hoznek, A; Abbou, C; Aaronson, SA; Thiery, JP; Radvanyi, F			Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas	ONCOGENE			English	Article						bladder; fibroblast growth factor receptor; human; transitional cell carcinoma; tumor progression	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; LIGAND-BINDING SPECIFICITY; FGF RECEPTOR; K-SAM; TARGETED EXPRESSION; HUMAN KERATIN-18; CANCER; MOUSE; CLONING; FAMILY	Growth factors and growth factor receptors are involved in tumor progression, The fibroblast growth factor receptor 2 gene encodes distinct isoforms, The isoforms which bind KGF (keratinocyte growth factor or FGF-7) are called KGF-R or FGFR2b. KGF-R is expressed in different epithelia and is involved in the control of epithelial-mesenchymal interactions. Expression of KGF-R mRNA was examined in normal human bladder and transitional cell carcinoma of the bladder (TCC) by semi-quantitative RT-PCR using TFIID and GAPDH as internal standards, In normal bladder, the KGF-R mRNA was detected in the urothelium but not in the underlying stroma, In TCCs, the level of KGF-R mRNA was generally either normal or low, Eighteen out of 54 TCCs had a KGF-R mRNA level below 30% of that found in normal urothelium, This decrease in KGF-R mRNA was not accompanied by an increase in BEK (FGFR2c) mRNA, the other major splice variant of the fibroblast growth factor receptor 2 gene, Expression of the KGF-R was also monitored by immunohistochemistry using a functional KGF-immunoglobulin chimera, The receptor was uniformly expressed throughout the normal urothelium except for the umbrella cells, Immunoreactivity for KGF-R was found to be negative in tumors with low levels of KGF-R mRNA, while the peritumoral normal urothelium was positive, Among patients with muscle invasive tumors, those exhibiting a low level of HGF-R mRNA had a significantly higher proportion of cancer deaths, Our results suggest that decreased expression of KGF-R can be considered as a marker of tumor progression in muscle invasive TCCs.	INST CURIE, CNRS, UMR 144, F-75248 PARIS 05, FRANCE; CHU HENRI MONDOR, GRP ETUD TUMEURS UROL, CRCHM, F-94010 CRETEIL, FRANCE; CHU HENRI MONDOR, UROL SERV, F-94010 CRETEIL, FRANCE; NCI, NIH, BETHESDA, MD 20892 USA; MT SINAI SCH MED, RUTTENBERG CANC CTR, NEW YORK, NY USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai			Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Radvanyi, Francois/0000-0002-5696-6424; Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DIONNE CA, 1992, CYTOGENET CELL GENET, V60, P34, DOI 10.1159/000133290; EISEMANN A, 1991, ONCOGENE, V6, P1195; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ISHII H, 1995, MOL CELL BIOL, V15, P3664; ITOH H, 1994, CANCER RES, V54, P3237; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNOWLES MA, 1994, CANCER RES, V54, P531; KULESH DA, 1989, GENOMICS, V4, P339, DOI 10.1016/0888-7543(89)90340-6; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LEUBE RE, 1986, DIFFERENTIATION, V33, P69, DOI 10.1111/j.1432-0436.1986.tb00412.x; LI ZL, 1989, GENE, V78, P243; LORENZI MV, 1995, ONCOGENE, V10, P2051; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATTEI MG, 1991, HUM GENET, V87, P84, DOI 10.1007/BF01213098; MELLON K, 1995, J UROLOGY, V153, P919, DOI 10.1016/S0022-5347(01)67604-3; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Mostofi FK, 1973, INT HISTOLOGICAL CLA; Nakagawara A, 1994, Prog Clin Biol Res, V385, P155; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; OSHIMA RG, 1986, DIFFERENTIATION, V33, P61, DOI 10.1111/j.1432-0436.1986.tb00411.x; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SPIESSL B, 1992, ILLUSTRATED GUIDE TN, P214; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	55	75	76	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	1997	14	3					323	330		10.1038/sj.onc.1200830	http://dx.doi.org/10.1038/sj.onc.1200830			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018118				2022-12-25	WOS:A1997WD51600008
J	Datta, R; Kojima, H; Banach, D; Bump, NJ; Talanian, RV; Alnemri, ES; Weichselbaum, RR; Wong, WW; Kufe, DW				Datta, R; Kojima, H; Banach, D; Bump, NJ; Talanian, RV; Alnemri, ES; Weichselbaum, RR; Wong, WW; Kufe, DW			Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INTERNUCLEOSOMAL DNA FRAGMENTATION; TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1-BETA CONVERTING-ENZYME; BACULOVIRUS P35; POLY(ADP-RIBOSE) POLYMERASE; CAENORHABDITIS-ELEGANS; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE	The response of eukaryotic cells to ionizing radiation (IR) includes induction of apoptosis. However, the signals that regulate this response are unknown. The present studies demonstrate that IR treatment of U-937 cells is associated with: (i) internucleosomal DNA fragmentation; (ii) cleavage of poly(ADP-ribose) polymerase; (iii) cleavage of protein kinase C delta; and (iv) induction of an Ac-DEVD-p-nitroanilide cleaving activity. Overexpression of the cowpox protein CrmA blocked tumor necrosis factor (TNF)-induced apoptosis but had no effect on IR-induced DNA fragmentation or cleavage of poly(ADP-ribose) polymerase and protein kinase C delta. By contrast, overexpression of the baculovirus p35 protein blocked both IR and TNF induced apoptosis. The results further demonstrate that the IR-induced proteolytic activity is directly inhibited by the addition of purified recombinant p35, but not by CrmA. We show that the CPP32 protease is sensitive to p35 and not CrmA. We also show that IR induces activation of CPP32 and that this event, like induction of apoptosis, is sensitive to overexpression of p35 and not CrmA. These findings indicate that IR induced apoptosis involves activation of CPP32 and that this CrmA-insensitive apoptotic pathway is distinct from those induced by TNF and certain other stimuli.	BASF BIORES CORP, WORCESTER, MA 01605 USA; KIMMEL CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; UNIV CHICAGO, DEPT RADIAT & CELLULAR ONCOL, CHICAGO, IL 60637 USA	BASF; Jefferson University; University of Chicago	Datta, R (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, 44 BINNEY ST, BOSTON, MA 02115 USA.		Alnemri, Emad S/B-4526-2010		NCI NIH HHS [CA55241] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FANCHEU C, 1995, EMBO J, V14, P1914; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hall E.J., 2019, RADIOBIOLOGY RADIOLO, Veighth; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; MANOME Y, 1993, ONCOL RES, V5, P139; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	60	135	137	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1965	1969		10.1074/jbc.272.3.1965	http://dx.doi.org/10.1074/jbc.272.3.1965			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999887	hybrid			2022-12-25	WOS:A1997WD05800085
J	Hess, JA; Ross, AH; Qiu, RG; Symons, M; Exton, JH				Hess, JA; Ross, AH; Qiu, RG; Symons, M; Exton, JH			Role of rho family proteins in phospholipase D activation by growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; ACTIN STRESS FIBERS; CELL-FREE SYSTEM; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PHOSPHATIDYLCHOLINE BREAKDOWN; RECEPTOR; RAS	Treatment of fibroblasts with growth factors results in activation of phospholipase D (PLD). In order to determine the role of the Rho family of small GTPases in growth factor-mediated PLD activation, we used cells transfected with wild type and mutant Rac1. In response to epidermal growth factor (EGF), PLD activity was greatly increased in Rat1 fibroblasts expressing wild type Rac1 (wtRac1), and completely abrogated in cells expressing dominant negative N17Rac1 consistent with Rac1 mediating the action of this growth factor. In contrast, in cells treated with platelet-derived growth factor (PDGF) or phorbol ester, the wtRac1 cells showed little or no enhancement of PLD activity, and the response was not affected in the N17Rac1 cells, implying that Rac1 played a minimal role in the activation of PLD by PDGF or protein kinase C. Both growth factors produced an attenuated PLD response in cells expressing constitutively active V12Rac1, but these cells showed other changes, including altered morphology, increased basal PLD, and decreased growth factor receptor autophosphorylation. The effects of EGF and PDGF on phosphoinositide phospholipase C activity were not enhanced in cells expressing wtRac1 or inhibited in those expressing N17Rac1. In cells expressing constitutively active V12Rac1, basal phosphoinositide phospholipase C was elevated, but there were no significant effects of EGF or PDGF. We used C3 transferase of Clostridium botulinum, which ADP ribosylates and inactivates RhoA, to investigate the involvement of RhoA in the activation of PLD by PDGF. Cells expressing wtRac1 and N17Rac1 showed a decreased PLD in response to PDGF when treated with C3 transferase, indicating a role for RhoA. In summary, these data indicate a major role for Rac1 in the activation of PLD by EGF, but not PDGP or protein kinase C.	VANDERBILT UNIV,SCH MED,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; ONYX PHARMACEUT,RICHMOND,CA 94806	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University								BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HA KS, 1993, J BIOL CHEM, V268, P10534; HART MJ, 1990, J BIOL CHEM, V265, P5990; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Lowe GM, 1996, BIOCHEM BIOPH RES CO, V220, P484, DOI 10.1006/bbrc.1996.0431; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OLSON SC, 1991, J BIOL CHEM, V266, P17236; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; QUI RG, 1995, NATURE, V374, P457; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SIMPSON CMF, 1987, NEUROCHEMISTRY PRACT, P193; SORKIN A, 1992, J BIOL CHEM, V267, P8672; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Wakelam Michael J. O., 1993, Biochemical Society Transactions, V21, P874; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZUBIAUR M, 1995, J BIOL CHEM, V270, P17221, DOI 10.1074/jbc.270.29.17221	44	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1615	1620		10.1074/jbc.272.3.1615	http://dx.doi.org/10.1074/jbc.272.3.1615			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999836	hybrid			2022-12-25	WOS:A1997WD05800034
J	CollFresno, PM; Batoz, M; Tarquin, S; Birnbaum, D; Coulier, F				CollFresno, PM; Batoz, M; Tarquin, S; Birnbaum, D; Coulier, F			Cytotoxic activity of a diphtheria toxin/FGF6 mitotoxin on human tumour cell lines	ONCOGENE			English	Article						mitotoxin; fibroblast growth factor; tumour cell line; diphtheria toxin	FIBROBLAST GROWTH-FACTOR; FACTOR-PSEUDOMONAS EXOTOXIN; HEPARAN-SULFATE PROTEOGLYCANS; FACTOR-SAPORIN MITOTOXIN; BREAST-CARCINOMA CELLS; CYTO-TOXIC ACTIVITY; PHASE-I TRIAL; FUSION PROTEIN; SIGNAL TRANSDUCTION; MYCOSIS-FUNGOIDES	The FGFs constitute a family of, at least, 12 polypeptides (FGF1 to PGF12) implicated in a number of physiological and pathological processes throughout embryogenesis and adult life. They bind to at least three types of cell surface molecules, including four high affinity transmembrane tyrosine kinase receptors (FGFR1 to FGFR4). In addition to important roles during development, FGF involvement in pathological conditions, including tumour formation, has been suspected, and overexpression of FGFR in tumour specimens is well documented. Diphtheria Toxin/FGF6 (DT/FGF6) mitotoxin has been shown to selectively and effectively target FGFR1-expressing cells. We show here that DT/FGF6 targets myoblasts engineered to express either one of the four FGFR, as well as FGFR-expressing tumour cells.	INSERM,U119,MOL ONCOL LAB,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773; Birnbaum, Daniel/0000-0001-7920-9883				ADELAIDE J, 1988, ONCOGENE, V2, P413; ADNANE J, 1991, ONCOGENE, V6, P659; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BATOZ M, 1995, CELL GROWTH DIFFER, V6, P1143; BEITZ JG, 1992, CANCER RES, V52, P227; BIRNBAUM D, 1991, ANN NY ACAD SCI, V638, P409, DOI 10.1111/j.1749-6632.1991.tb49055.x; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COULIER F, 1996, IN PRESS J MOL EVOL; Coulier Francois, 1994, Progress in Growth Factor Research, V5, P1, DOI 10.1016/0955-2235(94)90014-0; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; FOSS FM, 1994, BLOOD, V84, P1765; GALLAGHER JT, 1994, EUR J CLIN CHEM CLIN, V32, P239; GAWLAK SL, 1993, BIOCONJUGATE CHEM, V4, P483, DOI 10.1021/bc00024a010; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HORLICK RA, 1992, GENE, V120, P291, DOI 10.1016/0378-1119(92)90108-2; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JAYE M, 1987, J BIOL CHEM, V262, P16612; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIHARA A, 1995, CANCER RES, V55, P71; KUZEL TM, 1993, LEUKEMIA LYMPHOMA, V11, P369, DOI 10.3109/10428199309067928; LAPPI DA, 1989, BIOCHEM BIOPH RES CO, V160, P917, DOI 10.1016/0006-291X(89)92522-9; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; LUQMANI YA, 1995, INT J CANCER, V64, P274, DOI 10.1002/ijc.2910640411; MCLESKEY SW, 1994, CANCER RES, V54, P523; MERWIN JR, 1992, CANCER RES, V52, P4995; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Pai L H, 1994, Important Adv Oncol, P3; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PLATANIAS LC, 1994, LEUKEMIA LYMPHOMA, V14, P257, DOI 10.3109/10428199409049676; QUARTO N, 1994, J CELL SCI, V107, P3201; RHOGANI M, 1994, J BIOL CHEM, V269, P3976; Siegall C B, 1990, Semin Cancer Biol, V1, P345; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1994, CANCER-AM CANCER SOC, V74, P1006, DOI 10.1002/1097-0142(19940801)74:3+<1006::AID-CNCR2820741506>3.0.CO;2-V; SIEGALL CB, 1994, BIOCONJUGATE CHEM, V5, P77, DOI 10.1021/bc00025a010; TEPLER I, 1994, CANCER-AM CANCER SOC, V73, P1276, DOI 10.1002/1097-0142(19940215)73:4<1276::AID-CNCR2820730424>3.0.CO;2-D; THEILLET C, 1989, ONCOGENE, V4, P915; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; XERRI L, 1991, AM J PATHOL, V138, P9; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YING WB, 1994, CANCER, V74, P848, DOI 10.1002/1097-0142(19940801)74:3<848::AID-CNCR2820740310>3.0.CO;2-J; ZHOU DJ, 1988, ONCOGENE, V2, P279	50	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					243	247		10.1038/sj.onc.1200826	http://dx.doi.org/10.1038/sj.onc.1200826			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010226				2022-12-25	WOS:A1997WC81800012
J	Lohrum, M; Scheidtmann, KH				Lohrum, M; Scheidtmann, KH			Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes	ONCOGENE			English	Review						tumor suppressor; p53; okadaic acid; phosphorylation; transactivation	TUMOR-SUPPRESSOR PROTEIN; LARGE-T-ANTIGEN; WILD-TYPE P53; DNA-BINDING FUNCTION; CASEIN KINASE-II; TRANSCRIPTIONAL ACTIVATION; OKADAIC ACID; P53-MEDIATED TRANSACTIVATION; CELLULAR PROTEINS; EXCISION-REPAIR	The tumor suppressor protein p53 is phosphorylated at multiple sites in the amino-terminal transactivation domain and at several sites in the carboxy-terminal region. Phosphorylation appears to modulate its DNA binding activity. Here we demonstrate that phosphorylation of p53 also modulates its transcriptional activity. Okadaic acid treatment of cells resulted in enhanced phosphorylation of p53 and concomitantly in enhanced transactivation of an mdm2 promoter-linked luciferase reporter gene. This effect was cell type specific, however, since transactivation was enhanced in rat and mouse fibroblasts but reduced in the human Saos-2 cell line. Moreover, the effect was dependent on the promoter. In rat cells transcription from the mdm2, waf1 (cip1) and bar gene promoters, and the artificial PG13 promoter was enhanced by okadaic acid treatment whereas that from the cyclin G promoter was reduced. When various phosphorylation site mutants of p53 were tested for transactivation of these promoters, they behaved differently. Amino-terminal mutants exhibited reduced transcriptional activities on mdm2, waf1 and cyclin G promoters but enhanced activities with bar and PG13 promoters. On the other hand, a mutant at the cdk phosphorylation site, A313, showed reduced activity with mdm2 and waf1 promoters but enhanced activity with the cyclin G promoter, and finally, mutant A390 exhibited enhanced activity on waf1 and bar promoters, but reduced activity on the cyclin G promoter. These results suggest that phosphorylation of p53 may have different effects on its transcriptional activity, depending on the cellular environment and the particular response element. Moreover, both, amino- and carboxy-terminal phosphorylation sites seem to be involved in modulating the DNA-binding and the transactivation activities.	UNIV BONN,INST GENET,ABT MOL GENET,D-53117 BONN,GERMANY	University of Bonn								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; APPEL K, 1995, ONCOGENE, V11, P1971; APPEL K, 1994, INT J ONCOL, V5, P667; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1994, ONCOGENE, V9, P3249; FORRESTER K, 1995, ONCOGENE, V10, P2103; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUCHS B, 1995, ONCOGENE, V10, P789; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUALBERTO A, 1995, J BIOL CHEM, V270, P16980; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL PA, 1993, ONCOGENE, V8, P203; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARPER JW, 1993, CELL, V75, P805; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hecker D, 1996, ONCOGENE, V12, P953; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JAMAL S, 1995, ONCOGENE, V10, P2095; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO K, 1990, ONCOGENE, V5, P921; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1992, BIOCHEM J, V287, P1; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller BF, 1996, ONCOGENE, V12, P1941; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; OROURKE RW, 1990, ONCOGENE, V5, P1829; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PERREM K, 1995, ONCOGENE, V11, P1299; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1994, INT J ONCOL, V5, P1353; SCHONTHAL A, 1991, ONCOGENE, V6, P423; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHIIO Y, 1993, ONCOGENE, V8, P2059; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STRUZBECHER HW, 1996, EMBO J, V15, P1992; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WAGNER P, 1994, INT J ONCOL, V4, P987; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEISSKER SN, 1992, ONCOGENE, V7, P1921; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YATSUNAMI J, 1993, CANCER RES, V53, P239; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG W, 1994, CANCER RES, V54, P4448; ZHANG W, 1994, ONCOGENE, V9, P2513; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	121	61	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2527	2539						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000127				2022-12-25	WOS:A1996VZ65400003
J	DSilva, I; Heath, MC				DSilva, I; Heath, MC			Purification and characterization of two novel hypersensitive response-inducing specific elicitors produced by the cowpea rust fungus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTIVAR-SPECIFIC ELICITOR; RACE-SPECIFIC ELICITOR; CLADOSPORIUM-FULVUM; AVIRULENCE GENE; POLYACRYLAMIDE GELS; RESISTANCE; NECROSIS; PATHOGEN; PROTEINS; TOBACCO	Two novel elicitor peptides that are produced by the race 1 of the cowpea rust fungus Uromyces vignae and that specifically induce a hypersensitive response (a putative form of programmed cell death) in a resistant cultivar of cowpea (Vigna unguiculata L. Walp) have been purified to homogeneity. Purification steps included gel filtration, anion-exchange chromatography, continuous elution electrophoresis, and reversed-phase C-18 high performance liquid chromatography. The relative molecular masses of the peptide elicitors as deduced from Tricine sodium dodecyl sulfate-polyacrylamide gel electrophoresis were 5600 Da (major) and 5800 Da (minor), respectively. Peptide 1 (major) and the minor copurifying peptide (peptide 2) resolved at the final C-18 high performance liquid chromatography step. The NH2 terminus of peptide 1 was deblocked with anhydrous trifluoroacetic acid prior to sequencing. However, the NH2 terminus of peptide 2 was free. The acidic and hydrophobic peptides show some homology between themselves but do not show any significant similarity with known proteins. The two specific elicitors may be products of two avirulence genes corresponding to the two genes for resistance in the resistant cultivar.	UNIV TORONTO,DEPT BOT,TORONTO,ON M5S 3B2,CANADA	University of Toronto								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CHEN CY, 1993, PHYTOPATHOLOGY, V83, P224, DOI 10.1094/Phyto-83-224; CHEN CY, 1990, PHYSIOL MOL PLANT P, V37, P169, DOI 10.1016/0885-5765(90)90009-M; CHEN CY, 1992, PHYSIOL MOL PLANT P, V40, P23, DOI 10.1016/0885-5765(92)90068-7; CHEN CY, 1994, HOST SPECIFIC TOXIN, P73; CULVER JN, 1991, MOL PLANT MICROBE IN, V4, P458, DOI 10.1094/MPMI-4-458; DeWit PJGM, 1995, ADV BOT RES, V21, P147; DUBRAY G, 1982, ANAL BIOCHEM, V119, P325, DOI 10.1016/0003-2697(82)90593-0; EBEL J, 1994, INT REV CYTOL, V140, P1; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KEEN NT, 1990, MOL PLANT MICROBE IN, V3, P112, DOI 10.1094/MPMI-3-112; Kogel K. H., 1992, V13, P239; KoomanGersmann M, 1996, PLANT CELL, V8, P929, DOI 10.1105/tpc.8.5.929; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; RICCI P, 1989, EUR J BIOCHEM, V183, P555, DOI 10.1111/j.1432-1033.1989.tb21084.x; ROHE M, 1995, EMBO J, V14, P4168, DOI 10.1002/j.1460-2075.1995.tb00090.x; Ryerson DE, 1996, PLANT CELL, V8, P393, DOI 10.1105/tpc.8.3.393; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOTTENSTOMA IMJ, 1988, PHYSIOL MOL PLANT P, V33, P59, DOI 10.1016/0885-5765(88)90043-4; Stakman EC, 1915, J AGRIC RES, V4, P193; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; VANDENACKERVEKEN GFJM, 1993, PLANT PHYSIOL, V103, P91, DOI 10.1104/pp.103.1.91; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X	30	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3924	3927		10.1074/jbc.272.7.3924	http://dx.doi.org/10.1074/jbc.272.7.3924			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020095	hybrid			2022-12-25	WOS:A1997WH01900011
J	Igarashi, K; Saisho, T; Yuguchi, M; Kashiwagi, K				Igarashi, K; Saisho, T; Yuguchi, M; Kashiwagi, K			Molecular mechanism of polyamine stimulation of the synthesis of oligopeptide-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHINE-DALGARNO SEQUENCE; ESCHERICHIA-COLI; ORNITHINE DECARBOXYLASE; BOVINE LYMPHOCYTES; MESSENGER-RNA; SPERMIDINE; TRANSLATION; EXPRESSION; MUTANT; IDENTIFICATION	Polyamine stimulation of the synthesis of oligopeptide binding protein (OppA) was shown to occur mainly at the level of translation by measuring OppA synthesis and its mRNA level, Several artificial oppA genes were constructed by site directed mutagenesis. These synthesize different kinds Of OppA mRNAs: mRNAs differing in the size of 5'-untranslated region; mRNAs having the Shine-Dalgarno (SD) sequence in a different position; mRNAs having different secondary structure in the region of the SD sequence; and fusion mRNAs consisting of the 5'-untranslated region of OppA mRNA and the open reading frame of beta-galactosidase. By measuring the synthesis of OppA or beta-galactosidase from these mRNAs, we found that the 171-nucleotide 5'-untranslated region and 145 nucleotides of the ORF of OppA mRNA are involved in the polyamine stimulation of OppA synthesis. When the secondary structure of the above region of OppA mRNA was analyzed by optimal computer folding, it was shown that the degree of polyamine stimulation of OppA protein synthesis was dependent on the structure of the SD sequence in addition to its position. Loose base pairing of the SD sequence with other regions of the mRNA caused strong polyamine stimulation, while intense base pairing of the SD sequence with other regions of the mRNA resulted in insignificant or weak polyamine stimulation.			Igarashi, K (corresponding author), CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,1-33 YAYOI CHO,CHIBA 263,JAPAN.			Igarashi, Kazuei/0000-0003-3751-3187				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHEN HY, 1994, NUCLEIC ACIDS RES, V22, P4953, DOI 10.1093/nar/22.23.4953; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; ECHANDI G, 1975, BIOCHEM BIOPH RES CO, V67, P1185, DOI 10.1016/0006-291X(75)90798-6; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; FUKUCHI JI, 1995, J BIOL CHEM, V270, P18831, DOI 10.1074/jbc.270.32.18831; GHOSAL D, 1979, NUCLEIC ACIDS RES, V6, P1111, DOI 10.1093/nar/6.3.1111; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IGARASHI K, 1984, CANCER RES, V44, P5332; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; IGARASHI K, 1982, ARCH BIOCHEM BIOPHYS, V219, P438, DOI 10.1016/0003-9861(82)90175-8; IGARASHI K, 1979, EUR J BIOCHEM, V93, P345, DOI 10.1111/j.1432-1033.1979.tb12829.x; IGARASHI K, 1974, J BIOCHEM-TOKYO, V77, P383; ITO K, 1990, J BIOL CHEM, V265, P13036; ITO K, 1986, EUR J BIOCHEM, V156, P505, DOI 10.1111/j.1432-1033.1986.tb09609.x; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1994, BIOCHEM BIOPH RES CO, V200, P591, DOI 10.1006/bbrc.1994.1489; KASHIWAGI K, 1992, J BACTERIOL, V174, P4331, DOI 10.1128/JB.174.13.4331-4337.1992; KASHIWAGI K, 1989, ARCH BIOCHEM BIOPHYS, V268, P379, DOI 10.1016/0003-9861(89)90598-5; LIU JK, 1994, J BACTERIOL, V176, P2513, DOI 10.1128/JB.176.9.2513-2516.1994; MITSUI K, 1984, BIOCHEMISTRY-US, V23, P2679, DOI 10.1021/bi00307a022; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; OGASAWARA T, 1989, J BIOCHEM-TOKYO, V105, P164, DOI 10.1093/oxfordjournals.jbchem.a122633; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; Shimogori T, 1996, BIOCHEM BIOPH RES CO, V223, P544, DOI 10.1006/bbrc.1996.0931; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WATANABE Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P134, DOI 10.1016/0005-2787(81)90078-2; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	37	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4058	4064		10.1074/jbc.272.7.4058	http://dx.doi.org/10.1074/jbc.272.7.4058			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020114	hybrid			2022-12-25	WOS:A1997WH01900030
J	Jiang, JG; Bell, A; Liu, YH; Zarnegar, R				Jiang, JG; Bell, A; Liu, YH; Zarnegar, R			Transcriptional regulation of the hepatocyte growth factor gene by the nuclear receptors chicken ovalbumin upstream promoter transcription factor and estrogen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATION; HEPATOPOIETIN-A; COUP-TF; C-MET; EXPRESSION; IDENTIFICATION; FIBROBLASTS; CELLS; MOTILITY; SEQUENCE	Hepatocyte growth factor (HGF) is a multifunctional cytokine that controls the growth and differentiation of various tissues. Previously, we described the existence of a negative cis-acting regulatory element(s) within the -1- to -0.7-kilobase pair (kb) portion of the 5'-flanking region of the mouse HGF promoter. In the present study, we show that the repressor element is located at posi tion -872 to -860 base pairs and comprises an imperfect estrogen-responsive element 5'-AGGTCAGAAAGACCA-3'. We demonstrate that chicken ovalbumin upstream promoter transcription factor (COUP-TF), a nuclear orphan receptor belonging to the steroid/thyroid hormone receptor superfamily, through binding to this site effectively silences the transcriptional activity of the HGF promoter. We show that estrogen receptor, on the other hand, relieves the repressive action of COUP-TF, resulting in the induction of the HGF promoter. Using mice transgenic for either 2.7 or 0.7 kb of the HGF promoter region Linked to the chloramphenicol acetyltransferase reporter gene, we found that injection of estradiol stimulates HGF promoter activity in tissues such as the mammary gland and ovary of mice harboring 2.7 but not 0.7 kb of the mouse HGF promoter region, Potential involvement of the CCAAT/enhancer-binding protein (C/EBP) family of transcription factors in the regulation of HGF gene expression is also discussed.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,DIV CELLULAR & MOL PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Jiang, Jie-Gen/K-3845-2019	Liu, Youhua/0000-0002-4740-805X	NIEHS NIH HHS [R01ES 06109] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAVAMUDAN B, 1993, BIOCHEM BIOPH RES CO, V195, P346, DOI 10.1006/bbrc.1993.2050; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CONNEELY OM, 1994, MOL BIOL INTELLIGENC, P111; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; GOHDA E, 1992, FEBS LETT, V301, P107, DOI 10.1016/0014-5793(92)80220-B; KADOWAKI Y, 1995, P NATL ACAD SCI USA, V92, P4432, DOI 10.1073/pnas.92.10.4432; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; Leng X, 1996, MOL CELL BIOL, V16, P2332; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LIU Y, 1994, MOL CELL BIOL, V11, P7046; LIU Y, 1994, J BIOL CHEM, V267, P24917; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LIU YH, 1994, MOL CELL ENDOCRINOL, V104, P173, DOI 10.1016/0303-7207(94)90120-1; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1992, P NATL ACAD SCI USA, V89, P3800, DOI 10.1073/pnas.89.9.3800; MATSUMOTO K, 1992, J BIOL CHEM, V267, P24917; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V181, P323, DOI 10.1016/S0006-291X(05)81421-4; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V188, P235; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEREIRA FA, 1995, J STEROID BIOCHEM, V53, P503, DOI 10.1016/0960-0760(95)00097-J; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; QIU YH, 1994, P NATL ACAD SCI USA, V91, P4451, DOI 10.1073/pnas.91.10.4451; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SESLAR SP, 1993, CANCER RES, V53, P1233; TAMURA M, 1993, J BIOL CHEM, V268, P8140; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1989, CANCER RES, V49, P3314	41	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3928	3934		10.1074/jbc.272.7.3928	http://dx.doi.org/10.1074/jbc.272.7.3928			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020096	hybrid			2022-12-25	WOS:A1997WH01900012
J	Kannan, S; DeSantis, M; Lohmeyer, M; Riese, DJ; Smith, GH; Hynes, N; Seno, M; Brandt, R; Bianco, C; Persico, G; Kenney, N; Normanno, N; MartinezLacaci, I; Ciardiello, F; Stern, DF; Gullick, WJ; Salomon, DS				Kannan, S; DeSantis, M; Lohmeyer, M; Riese, DJ; Smith, GH; Hynes, N; Seno, M; Brandt, R; Bianco, C; Persico, G; Kenney, N; Normanno, N; MartinezLacaci, I; Ciardiello, F; Stern, DF; Gullick, WJ; Salomon, DS			Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN BREAST-CANCER; FACTOR RECEPTOR; FAMILY; DIFFERENTIATION; GENE; NEU; AMPHIREGULIN; EXPRESSION; ALPHA	Cripto-1 (CR-1), a recently discovered protein of the epidermal growth factor (EGF) family; was found to interact with a high affinity, saturable binding site(s) on HC-11 mouse mammary epithelial cells and on several different human breast cancer cell lines. This receptor exhibits specificity for CR-1, since other EGF-related peptides including EGF, transforming growth factor cu, heparin-binding EGF-like growth factor, amphiregulin, epiregulin, betacellulin, or heregulin beta 1 that bind to either the EGF receptor or to other type 1 receptor tyrosine kinases such as erb B-3 or erb B-4 fail to compete for binding, Conversely, CR-1 was found not to directly bind to or to activate the tyrosine kinases associated with Shc EGFR, erb B-2, erb B-3, or erb B-4 either alone or in various pairwise combinations which have been ectopically expressed in Ba/F3 mouse pro-B lymphocyte cells. However, exogenous CR-1 could induce an increase in the tyrosine phosphorylation of 185- and 120-kDa proteins and a rapid (within 3-5 min) increase in the tyrosine phosphorylation of the SH2-containing adaptor proteins p66, p52, and p46 She in mouse mammary HC-11 epithelial cells and in human MDA-MB-453 and SKBr-3 breast cancer cells. CR-1 was also found to promote an increase in the association of the adaptor Grb2-guanine nucleotide exchange factor-mouse son of sevenless (mSOS) signaling complex with tyrosine-phosphorylated She in HC-11 cells. Finally, CR-1 was able to increase p42(erk-2) mitogen-activated protein kinase (MAPK) activity in HC-11 cells within 5-10 min of treatment. These data demonstrate that CR-1 can function through a receptor which activates intracellular components in the ras/raf/MEK/MAPK pathway.	NCI,TUMOR IMMUNOL & BIOL LAB,TUMOR GROWTH FACTOR SECT,NIH,BETHESDA,MD 20892; HAMMERSMITH HOSP,ICRF ONCOL UNIT,LONDON,ENGLAND; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; IST INT GENET & BIOFIS,NAPLES,ITALY; GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; UNIV NAPLES,FAC MED & CHIRURG 2,CATTEDRA ONCOL MED 2,I-80131 NAPLES,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Imperial College London; Yale University; Friedrich Miescher Institute for Biomedical Research; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Georgetown University; University of Naples Federico II			Normanno, Nicola/AAT-1107-2021; SENO, Masaharu/B-2092-2011; Riese, David/AAF-3581-2020	SENO, Masaharu/0000-0001-8547-6259; Normanno, Nicola/0000-0002-7158-2605; Lohmeyer, Matt/0000-0001-6401-3183; Riese, David/0000-0002-8823-5802; Ciardiello, Fortunato/0000-0002-3369-4841	NCI NIH HHS [CA-45708] Funding Source: Medline; NICHD NIH HHS [HD-07149] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BRANDT R, 1994, J BIOL CHEM, V269, P17320; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DONO R, 1991, AM J HUM GENET, V49, P555; DUBLIN EA, 1995, INT J ONCOL, V7, P617; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; LIN CQ, 1995, J CELL BIOL, V129, P1115, DOI 10.1083/jcb.129.4.1115; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MUDGE AW, 1993, CURR BIOL, V3, P361, DOI 10.1016/0960-9822(93)90201-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; NORMANNO N, 1993, INT J ONCOL, V2, P903; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELICCI G, 1995, ONCOGENE, V11, P899; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; WATANABE T, 1994, J BIOL CHEM, V269, P9966; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zhang K, 1996, J BIOL CHEM, V271, P3884	38	93	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3330	3335		10.1074/jbc.272.6.3330	http://dx.doi.org/10.1074/jbc.272.6.3330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013573	hybrid			2022-12-25	WOS:A1997WG19200033
J	Lehmann, JM; Lenhard, JM; Oliver, BB; Ringold, GM; Kliewer, SA				Lehmann, JM; Lenhard, JM; Oliver, BB; Ringold, GM; Kliewer, SA			Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES ADIPOCYTE DIFFERENTIATION; EXPRESSION; INDUCTION; CELLS; PROSTACYCLIN; FAMILY; FIBROBLASTS; INSULIN; TISSUE; LIGAND	Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) and cyclooxygenase inhibitor that is frequently used as a research tool to study the process of adipocyte differentiation. Treatment of various preadipocyte cell lines with micromolar concentrations of indomethacin in the presence of insulin promotes their terminal differentiation. However, the molecular basis for the adipogenic actions of indomethacin had remained unclear. In this report, we show that indomethacin binds and activates peroxisome proliferator-activated receptor gamma (PPAR gamma), a ligand-activated transcription factor known to play a pivotal role in adipogenesis. The concentration of indomethacin required to activate PPAR gamma is in good agreement with that required to induce the differentiation of C3H10T1/2 cells to adipocytes. We demonstrate that several other NSAIDs, including fenoprofen, ibuprofen, and flufenamic acid, are also PPAR gamma ligands and induce adipocyte differentiation of C3H10T1/2 cells. Finally, we show that the same NSAIDs that activate PPAR gamma are also efficacious activators of PPAR alpha, a liver-enriched PPAR subtype that plays a key role in peroxisome proliferation. Interestingly, several NSAIDs have been reported to induce peroxisomal activity in hepatocytes both in vitro and in vivo. Our findings define a novel group of PPAR gamma ligands and provide a molecular basis for the biological effects of these drugs on adipogenesis and peroxisome activity.	GLAXO WELLCOME RES & DEV, DEPT MOL ENDOCRINOL, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME RES & DEV, DEPT CELL BIOL, RES TRIANGLE PK, NC 27709 USA; AFFYMAX, SANTA CLARA, CA 95051 USA	GlaxoSmithKline; GlaxoSmithKline								AXELROD L, 1981, DIABETES, V30, P163, DOI 10.2337/diabetes.30.2.163; AYRTON AD, 1991, BIOCHEM PHARMACOL, V42, P109, DOI 10.1016/0006-2952(91)90688-2; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARTY TJ, 1980, PROSTAGLANDINS, V19, P51, DOI 10.1016/0090-6980(80)90153-7; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHRIST EJ, 1970, BIOCHIM BIOPHYS ACTA, V218, P296, DOI 10.1016/0005-2760(70)90148-7; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FOXWORTHY PS, 1993, TOXICOL APPL PHARM, V118, P271, DOI 10.1006/taap.1993.1033; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Greene M. E., 1995, Gene Expression, V4, P281; HIRAGUN A, 1988, J CELL PHYSIOL, V134, P124, DOI 10.1002/jcp.1041340115; HOPKINS NK, 1981, BIOCHIM BIOPHYS ACTA, V663, P457, DOI 10.1016/0005-2760(81)90174-0; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Insel PA, 1996, PHARMACOL BASIS THER, P617; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KNIGHT DM, 1987, MOL ENDOCRINOL, V1, P36, DOI 10.1210/mend-1-1-36; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEPAK NM, 1993, PROSTAGLANDINS, V46, P511, DOI 10.1016/0090-6980(93)90070-N; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEGREL R, 1989, BIOCHEM J, V257, P399, DOI 10.1042/bj2570399; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SPARKS RL, 1991, J CELL PHYSIOL, V146, P101, DOI 10.1002/jcp.1041460114; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VERRANDO P, 1981, BIOCHIM BIOPHYS ACTA, V663, P255, DOI 10.1016/0005-2760(81)90212-5; WILLIAMS IH, 1977, BIOCHEM BIOPH RES CO, V77, P175, DOI 10.1016/S0006-291X(77)80180-0; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	43	992	1042	0	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3406	3410		10.1074/jbc.272.6.3406	http://dx.doi.org/10.1074/jbc.272.6.3406			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013583	hybrid			2022-12-25	WOS:A1997WG19200043
J	Reddy, ST; Herschman, HR				Reddy, ST; Herschman, HR			Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D-2 in activated mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; SECRETORY GRANULE; A(2); RAT; BIOSYNTHESIS; LOCALIZATION; RECEPTOR; DRUGS; IGE	Aggregation of IgE cell surface receptors on MMC-34 cells, a murine mast cell line, induces the synthesis and secretion of prostaglandin D-2 (PGD(2)). Synthesis and secretion of PGD(2) in activated MMC-34 cells occurs in two stages, an early phase that is complete within 30 min after activation and a late phase that reaches a maximum about 6 h after activation. The early and late phases of PGD(2) generation are mediated by prostaglandin synthase 1 (PGS1) and prostaglandin synthase 2 (PGS2), respectively. Arachidonic acid, the substrate for both PGS1 and PGS2, is released from membrane phospholipids by the activation of phospholipases. We now demonstrate that in activated mast cells (i) secretory phospholipase A(2) (PLA(2)) mediates the release of arachidonic acid for early, PGS1-dependent synthesis of PGD(2); (ii) secretory PLA(2) does not play a role in the late, PGS2-dependent synthesis of PGD(2); (iii) cytoplasmic PLA(2) mediates the release of arachidonic acid for late, P0GS2-dependent synthesis of PGD(2); and (iv) a cytoplasmic PLA(2)-dependent step precedes secretory PLA(2) activation and is necessary for optimal PGD(2) production by the secretory PLA(2)/PGS1-dependent early pathway.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,MOL BIOL INST 341A,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MOL & MED PHARMACOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034567, U19AI034567] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34567] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARSUMIAN EL, 1985, CELL IMMUNOL, V90, P131, DOI 10.1016/0008-8749(85)90175-3; CHEN J, 1994, J BIOL CHEM, V269, P23018; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CHOCK SP, 1989, J BIOL CHEM, V264, P2862; CHOCK SP, 1994, BIOCHEM J, V300, P619, DOI 10.1042/bj3000619; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CURRIE S, 1994, BIOCHEM J, V304, P923, DOI 10.1042/bj3040923; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FONTEH AN, 1993, J IMMUNOL, V150, P563; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; KAWATA R, 1995, J IMMUNOL, V155, P818; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; MARSHALL LA, 1991, J RHEUMATOL, V18, P59; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1995, J LIPID MEDIAT CELL, V12, P119, DOI 10.1016/0929-7855(95)00013-G; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; NAKATANI Y, 1994, J IMMUNOL, V153, P796; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; REDDY ST, 1994, J BIOL CHEM, V269, P15473; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHMAUDERCHOCK EA, 1989, J HISTOCHEM CYTOCHEM, V37, P1319, DOI 10.1177/37.9.2504812; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126	33	147	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3231	3237		10.1074/jbc.272.6.3231	http://dx.doi.org/10.1074/jbc.272.6.3231			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013559	hybrid			2022-12-25	WOS:A1997WG19200019
J	Xiao, GH; Falkner, KC; Xie, YQ; Lindahl, RG; Prough, RA				Xiao, GH; Falkner, KC; Xie, YQ; Lindahl, RG; Prough, RA			cAMP-dependent negative regulation of rat aldehyde dehydrogenase class 3 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR AROMATIC-COMPOUNDS; PRIMARY MONOLAYER-CULTURE; PROTEIN-KINASE-C; INDUCIBLE EXPRESSION; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION; HEPATOCYTES; CYTOCHROME-P-450C; IDENTIFICATION; INHIBITION	We investigated the inhibitory effects of intracellular cyclic adenosine monophosphate (cAMP) levels in regulating class 3 aldehyde dehydrogenase (aldh3) gene expression using cultures of primary rat hepatocytes and transient transfection experiments with HepG2 cells. In addition to regulation by an Ah receptor-dependent mechanism, expression of many members of the Ah gene battery have been shown to be negatively regulated. As was seen for the cytochrome P450 (cyp1A1) gene, aldh3 is transcriptionally inducible by polycyclic aromatic hydrocarbons (PAH), and this induction involving function of the arylhydrocarbon (Ah) receptor is inhibited by the protein kinase C (PKC) inhibitors, 1-(5-isoquinoline-sulfonyl)-2-methylpiperaziae di-HCl (H7) and staurosporine, However, PAH induction of ALDH-3 activity, protein, and mRNA was potentiated 2-4-fold by addition of the protein kinase A (PKA) inhibitors, N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide di-HCl (H8) and N-(2-guanidinoethyl)-5-isoquinolinesulfonamide HCl (HA1004). These PKA inhibitors had no effect on the PAH induction of the cyp1A1. Protein kinase A activity of cultured hepatocytes was specifically inhibited by H8 and HA1004 in a concentration-dependent manner, but not by H7, and there was an inverse correlation observed between potentiation of PAH-induced aldh3 gene expression and inhibition of specific PRA activity by the PRA inhibitors. The cAMP analog dibutyryl cAMP, the adenylate cyclase activator forskolin, and the protein phosphatase 1 and 2A inhibitor okadaic acid all dramatically inhibited both PAH induction ansi H8 potentiation of PAH induction of aldh3 expression but had no effect on induction of cyp1A1 expression in cultured hepatocytes. Both basal and PAH-dependent expression of a chloramphenicol acetyltransferase expression plasmid containing approximately 3.5 kilobase pairs of the 5'-flanking region of aldh3 (pALDH3.5CAT) were enhanced 3-4-fold by the PKA inhibitor H8 but not by the PKC inhibitor H7 (>20 mu M). cAMP analogs, activators of PRA activity, or protein phosphatase inhibitors diminished expression of the reporter gene in a manner identical to the native gene in cultured rat hepatocytes. Using deletion analysis of the pALDH3.5CAT construct, we demonstrated the existence of a negative regulatory region in the 5'-flanking region between -1057 and -991 base pairs which appears to be responsible for the cAMP-dependent regulation of this gene under both basal and PAH-induced conditions. At least two apparently independent mechanisms which involve protein phosphorylation regulate aldh3 expression. One involves function of the Ah receptor which requires PKC protein phosphorylation to positively regulate both aldh3 and cyp1A1 gene expression and the other a cAMP-responsive process which allows PKA activity to negatively regulate expression of aldh3 under either basal or inducible conditions.	UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40292; UNIV S DAKOTA,SCH MED,DEPT BIOCHEM & MOL BIOL,VERMILLION,SD 57069	University of Louisville; University of South Dakota			Russell A, Prough/AAH-5907-2020	Prough, Russell/0000-0001-8901-8490	NCI NIH HHS [CA 21103] Funding Source: Medline; NIEHS NIH HHS [R01 ES04244] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; *BIOR, ZET PROB BLOTT MEMBR; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; BJORNSSON OG, 1994, EUR J CLIN INVEST, V24, P137, DOI 10.1111/j.1365-2362.1994.tb00979.x; *BOEHR MANNH BIOCH, RAND PRIM DNA LAB KI; Boesch JS, 1996, J BIOL CHEM, V271, P5150; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUNN TJ, 1988, J BIOL CHEM, V263, P10878; EXTON JH, 1971, J BIOL CHEM, V246, P6166; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GONZALEZ FJ, 1992, PHARMACOGENETICS DRU, P413; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HINES RN, 1985, ARCH BIOCHEM BIOPHYS, V237, P465, DOI 10.1016/0003-9861(85)90300-5; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MIRALLES VJ, 1995, MOL MICROBIOL, V17, P653, DOI 10.1111/j.1365-2958.1995.mmi_17040653.x; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; NEBERT DW, 1990, ENVIRON HEALTH PERSP, V88, P13, DOI 10.2307/3431045; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; Prough R A, 1978, Methods Enzymol, V52, P372; RAYCHAUDHURI B, 1990, MOL ENDOCRINOL, V4, P1773, DOI 10.1210/mend-4-12-1773; REINERS JJ, 1993, ARCH BIOCHEM BIOPHYS, V301, P449, DOI 10.1006/abbi.1993.1170; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SCHUETZ EG, 1986, BIOCHEMISTRY-US, V25, P1124, DOI 10.1021/bi00353a027; *SEIK AM INC, 1990, BIOCH PROD LIF SCI, P63; SIDHU JS, 1995, J BIOL CHEM, V270, P12762, DOI 10.1074/jbc.270.21.12762; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKIMOTO K, 1991, BIOCHEM BIOPH RES CO, V180, P953, DOI 10.1016/S0006-291X(05)81158-1; TAKIMOTO K, 1992, ARCH BIOCHEM BIOPHYS, V298, P492, DOI 10.1016/0003-9861(92)90440-8; TAKIMOTO K, 1994, ARCH BIOCHEM BIOPHYS, V312, P539, DOI 10.1006/abbi.1994.1343; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; XIAO GH, 1995, DRUG METAB DISPOS, V19, P793; Xie YQQ, 1996, NUCLEIC ACIDS RES, V24, P4185, DOI 10.1093/nar/24.21.4185	38	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3238	3245		10.1074/jbc.272.6.3238	http://dx.doi.org/10.1074/jbc.272.6.3238			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9013560	hybrid			2022-12-25	WOS:A1997WG19200020
J	Kourtz, L; Ko, K				Kourtz, L; Ko, K			The early stage of chloroplast protein import involves Com70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ENVELOPE MEMBRANE; HEAT-SHOCK PROTEIN; TRANSIT PEPTIDE; PRECURSOR PROTEIN; THYLAKOID MEMBRANE; TRANSLOCATION; HSP70; MACHINERY; IDENTIFICATION; BINDING	The chloroplast envelope protein Com70 is a hsp70 homolog identified recently as a component of the protein translocation apparatus. The stage of protein import involving Com70 was determined by examining the nature of the association of Com70 with the envelope and its interaction with translocating proteins. Com70 is accessible to thermolysin, but its association with the envelope could not be disrupted by stringent washes. In light of the external membrane-bound location, the involvement of Com70 at the early stage of protein translocation was investigated using a combination of in vitro binding assays, chemical cross-linking, and coimmunoprecipitation. The results provide evidence that Com70 is in close physical proximity to different types of chloroplast protein precursors under conditions supporting binding rather than complete translocation. The formation of cross-linked complexes is dependent on the presence of a typical plastid transit signal and protease-accessible outer envelope components. The close proximity of Com70 and the translocating protein occurs while the protein is still exposed to the cytosol.	QUEENS UNIV, DEPT BIOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada								BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CLINE K, 1985, J BIOL CHEM, V260, P3691; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DRESESWERRINGLOER U, 1991, EUR J BIOCHEM, V195, P361, DOI 10.1111/j.1432-1033.1991.tb15714.x; FINDLAY JBC, 1987, BIOL MEMBRANES PRACT, P179; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; GUERA A, 1993, PLANT MOL BIOL, V23, P309, DOI 10.1007/BF00029007; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; KANG PJ, 1990, NATURE, V348, P610; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KO K, 1992, J BIOL CHEM, V267, P13910; KO K, 1992, J BIOL CHEM, V267, P2986; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; MARSHALL JS, 1992, PLANT PHYSIOL, V100, P1048, DOI 10.1104/pp.100.2.1048; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SCHNELL DJ, 1995, CELL, V83, P521, DOI 10.1016/0092-8674(95)90090-X; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; TSUGEKI R, 1993, FEBS LETT, V320, P198, DOI 10.1016/0014-5793(93)80585-I; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; Wan JX, 1996, J BIOL CHEM, V271, P31227, DOI 10.1074/jbc.271.49.31227; WAN JX, 1995, J BIOL CHEM, V270, P16731, DOI 10.1074/jbc.270.28.16731; WERNERWASHBURNE M, 1983, PLANT PHYSIOL, V73, P569, DOI 10.1104/pp.73.3.569; WU CB, 1993, J BIOL CHEM, V268, P19384; WU CB, 1994, J BIOL CHEM, V269, P32264; YALOVSKY S, 1992, P NATL ACAD SCI USA, V89, P5616, DOI 10.1073/pnas.89.12.5616	44	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	1997	272	5					2808	2813		10.1074/jbc.272.5.2808	http://dx.doi.org/10.1074/jbc.272.5.2808			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WE667	9006921	hybrid			2022-12-25	WOS:A1997WE66700034
J	Bame, KJ; Robson, K				Bame, KJ; Robson, K			Heparanases produce distinct populations of heparan sulfate glycosaminoglycans in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; FLAVOBACTERIUM-HEPARINUM; PROTEOGLYCANS; DEGRADATION; ENDOGLUCURONIDASE; OLIGOSACCHARIDES; DEPOLYMERIZATION; POLYSACCHARIDES; SPECIFICITY; MECHANISMS	Once internalized, cell-associated heparan sulfate proteoglycans are degraded to short glycosaminoglycans by the action of endoglycosidases or heparanases. We have begun to address the question of how many heparanases are responsible for this process by analyzing short heparan sulfate chains produced in vivo by Chinese hamster ovary (CHO) cell heparanases. Short heparan sulfate chains were purified from CHO cells and labeled at the reducing end with [H-3]NaBH4. Hydrolysis of the chains to monosaccharides and analysis of the H-3-sugar alcohols indicate that heparanase activities in CHO cells are endo-beta-glucuronidases. The modification state of the heparanase-derived glycosaminoglycans was examined by treating the [H-3]heparan sulfate chains with nitrous acid or bacterial heparin lyases, which cut the chain at specific sequences, and analyzing the products by P2 gel filtration chromatography. Two populations of short chains were identified that differ in the extent of modification on the nonreducing side of the heparanase cleavage site. One class of chains is unmodified for at least 9 residues from the reducing end, while the other group has a modified domain within 3-7 residues from the heparanase cleavage site. Our results suggest a model of heparanase action where the enzymes recognize differences in sulfate content between modified and unmodified regions and bind to sites that encompass both domains. The enzymes then cleave the glycosaminoglycan at junctions between the modified and unmodified sequences to produce the different populations of short heparan sulfate chains.			Bame, KJ (corresponding author), UNIV MISSOURI,SCH BIOL SCI,DIV MOL BIOL & BIOCHEM,KANSAS CITY,MO 64110, USA.							BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1993, J BIOL CHEM, V268, P19956; BUEE L, 1991, ANAL BIOCHEM, V195, P238, DOI 10.1016/0003-2697(91)90323-L; CONRAD HE, 1980, BIOCHEM J, V191, P355, DOI 10.1042/bj1910355; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407; FRANSSON LA, 1968, ANAL BIOCHEM, V21, P317; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GORDON HT, 1956, ANAL CHEM, V28, P849, DOI 10.1021/ac60113a020; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HOOK M, 1974, BIOCHEM J, V137, P33; IOZZO RV, 1989, J BIOL CHEM, V264, P1888; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN U, 1979, H-S Z PHYSIOL CHEM, V360, P1465, DOI 10.1515/bchm2.1979.360.2.1465; KRESSE H, 1987, ADV ENZYMOL RAMB, V60, P217; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; LASKOV R, 1991, INT J CANCER, V47, P92, DOI 10.1002/ijc.2910470117; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; SCHMIDTCHEN A, 1994, EUR J BIOCHEM, V223, P211, DOI 10.1111/j.1432-1033.1994.tb18985.x; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; THUNBERG L, 1982, J BIOL CHEM, V257, P278; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	40	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2245	2251						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999930				2022-12-25	WOS:A1997WD67900036
J	Nowatzke, WL; Burns, CM; Richardson, JP				Nowatzke, WL; Burns, CM; Richardson, JP			Function of the novel subdomain in the RNA binding domain of transcription termination factor rho from Micrococcus luteus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-PR PROMOTER; CRO MESSENGER-RNA; DEPENDENT TERMINATION; POLYMERASE; PROTEINS; IDENTIFICATION; RECOGNITION; INHIBITORS; GENE	Transcription termination factor Rho from Micrococcus luteus, a high G + C Gram-positive bacterium, contains an unusual extra sequence within its RNA binding domain that is rich in Arg, Glu, and Asp residues and deficient in hydrophobic residues, To determine the role of this extra sequence, we compared the biochemical properties of a variant lacking nearly all the extra sequence, des(60-300) Rho, to that of wild-type M. luteus Rho, The two forms had very similar properties except that the des(60-300) Rho was unable to terminate transcription with Escherichia coli RNA polymerase at the promoter proximal sites used by the wild-type Rho on a lambda cro DNA template but could cause termination at more distal sites and did cause termination at proximal sites when ITP replaced GTP in the reaction mixture, The RNA binding properties of the two forms of this Rho with normal and inosine-substituted RNAs were found to correlate fully with their termination properties. These results indicate that the arginine-rich extra sequence is directly involved in the selection of the termination site and support the hypothesis that the sequence is present in M. luteus Rho to facilitate its binding to M. luteus transcripts, which are likely to have a high degree of base-paired secondary structure because of their high proportion of G residues.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI010142, R01AI010142] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 10142] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADHYA S, 1979, P NATL ACAD SCI USA, V76, P1613, DOI 10.1073/pnas.76.4.1613; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURNS CM, 1995, P NATL ACAD SCI USA, V92, P4738, DOI 10.1073/pnas.92.11.4738; BURNS CM, 1996, THESIS INDIANA U; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHAMBERLIN MJ, 1965, FED PROC, V24, P1446; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; Gomelsky M, 1996, J BACTERIOL, V178, P1946, DOI 10.1128/jb.178.7.1946-1954.1996; HU CC, 1995, J VIROL METHODS, V55, P367, DOI 10.1016/0166-0934(95)00085-1; Ingham CJ, 1996, J BIOL CHEM, V271, P21803, DOI 10.1074/jbc.271.36.21803; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1983, J BIOL CHEM, V258, P9391; LOWERY C, 1977, J BIOL CHEM, V252, P1375; MARTINEZ A, 1993, THESIS INDIANA U; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; QUIRK PG, 1993, J BACTERIOL, V175, P647, DOI 10.1128/JB.175.3.647-654.1993; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011	28	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2207	2211						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999924				2022-12-25	WOS:A1997WD67900030
J	Atouf, F; Czernichow, P; Scharfmann, R				Atouf, F; Czernichow, P; Scharfmann, R			Expression of neuronal traits in pancreatic beta cells - Implication of neuron-restrictive silencing factor/repressor element silencing transcription factor, a neuron-restrictive silencer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FETAL-RAT ISLETS; INSULIN GENE; ENDOCRINE-CELLS; ACID DECARBOXYLASE; BINDING PROTEINS; ALPHA-CELLS; RECEPTORS; LINES; ESTABLISHMENT	Pancreatic beta cells (insulin-producing cells) and neuronal cells share a large number of similarities. Here, we investigate whether the same mechanisms could control the expression of neuronal genes in both neurons and insulin-producing cells. For that purpose, we tested the role of the transcriptional repressor neuron-restrictive silencing factor/repressor element silencing transciption factor (NRSF/REST) in the expression of a battery of neuronal genes in insulin-producing cells. NRSF/REST is a negative regulator of the neuronal fate. It is known to silence neuronal-specific genes in non-neuronal cells. We demonstrate that, as in the case of the neuronal pheochromocytoma cell line PC12, mRNA coding for NRSF/REST is absent from the insulinoma cell line INS-1 and from three other insulin and glucagon producing cell lines. NRSF/REST activity is also absent from insulin-producing cell lines. Transient expression of REST in insulin-producing cell lines is sufficient to silence a reporter gene containing a NRSF/REST binding site, demonstrating the role of NRSF/REST in the expression of neuronal markers in insulin-producing cells. Finally, by searching for the expression of NRSF/REST-regulated genes in insulin-producing cells, we increased the list of the genes expressed in both neurons and insulin-producing cells.	HOP ROBERT DEBRE,INSERM,CJF93 13,F-75019 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			scharfmann, raphael/L-3296-2017	Scharfmann, Raphael/0000-0001-7619-337X				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ASFARI M, 1995, MOL CELL ENDOCRINOL, V107, P209, DOI 10.1016/0303-7207(94)03445-Y; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Atouf F, 1995, J NEUROENDOCRINOL, V7, P957, DOI 10.1111/j.1365-2826.1995.tb00741.x; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GONOI T, 1994, J BIOL CHEM, V269, P16989; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUTTON LA, 1992, J NEUROSCI RES, V32, P375, DOI 10.1002/jnr.490320309; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; MARTINO E, 1980, P NATL ACAD SCI-BIOL, V77, P4345, DOI 10.1073/pnas.77.7.4345; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Neophytou PI, 1996, DIABETES, V45, P127, DOI 10.2337/diabetes.45.2.127; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PHILIPSON LH, 1993, DIABETES, V42, P1372, DOI 10.2337/diabetes.42.9.1372; POLAK M, 1993, P NATL ACAD SCI USA, V90, P5781, DOI 10.1073/pnas.90.12.5781; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; SCHARFMANN R, 1988, ENDOCRINOLOGY, V123, P1329, DOI 10.1210/endo-123-3-1329; SCHARFMANN R, 1993, DIABETES, V42, P1829, DOI 10.2337/diabetes.42.12.1829; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TANAKA M, 1995, DIABETOLOGIA, V38, P381, DOI 10.1007/s001250050296; Tazi A, 1996, J BIOL CHEM, V271, P10154, DOI 10.1074/jbc.271.17.10154; TEITELMAN G, 1987, DEV BIOL, V121, P454, DOI 10.1016/0012-1606(87)90182-5; TEITELMAN G, 1990, DEV BIOL, V142, P368, DOI 10.1016/0012-1606(90)90357-O; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WATANABE T, 1991, CELL TISSUE RES, V263, P131, DOI 10.1007/BF00318408	43	150	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1929	1934		10.1074/jbc.272.3.1929	http://dx.doi.org/10.1074/jbc.272.3.1929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999882	hybrid			2022-12-25	WOS:A1997WD05800080
J	Gasset, M; Laynez, J; Menendez, M; Raussens, V; Goormaghtigh, E				Gasset, M; Laynez, J; Menendez, M; Raussens, V; Goormaghtigh, E			Structural domain organization of gastric H+,K+-ATPase and its rearrangement during the catalytic cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; STATISTICAL MECHANICAL DECONVOLUTION; TRANSMEMBRANE ALPHA-HELICES; THERMAL TRANSITIONS; SARCOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGES; MEMBRANE-PROTEINS; GLYCOPHORIN-A; H+/K+-ATPASE; STABILITY	Differential scanning calorimetry has been used to characterized the thermal denaturation of gastric (H+,K+)-ATPase. The excess heat capacity function of (H+,K+)-ATPase in highly oriented gastric vesicles displays two peaks at 53.9 degrees C (T-m1) and 61.8 degrees C (T-m2). Its thermal denaturation is an irreversible process that does not exhibit kinetic control and can be resolved in two independent two-state processes. They can be as signed to two cooperative domains located in the cytoplasmic loops of the alpha-subunit, according to the disappearance of the endothermic signal upon removal of these regions by proteinase K digestion. Analysis of the thermal-induced unfolding of the enzyme trapped in different catalytic cycle intermediates has allowed us to get insight into the E(1)-E(2) conformational change. In the E(1) forms both transitions are always observed. As T-m1 is shifted to T-m2 by vanadate and ATP interaction, the unfolding mechanism changes from two independent to two sequential two-state transitions, revealing interdomain interactions. Stabilization of the E(2) forms results in the disappearance of the second transition at saturation by K+, Mg2+-ATP, and Mg2+-vanadate as well as in significant changes in T-m2 and Delta H-1. The catalytic domain melts following a process in which intermolecular interactions either in the native or in the unfolded state might be involved. Interestingly, the E(2)-vanadate-K+ form displays intermediate properties between the E(1) and E(2) conformational families.	FREE UNIV BRUSSELS,INST CHIM PHYS MACROMOL INTERFACES,B-1050 BRUSSELS,BELGIUM; CSIC,INST QUIM FIS ROCASOLANO,E-28006 MADRID,SPAIN	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)			Gasset, Maria/K-4339-2012; Gasset, Maria/I-2050-2014; Menendez, Margarita/M-1795-2014	Gasset, Maria/0000-0001-6436-4055; Gasset, Maria/0000-0001-6436-4055; Menendez, Margarita/0000-0002-3267-4443; Goormaghtigh, Erik/0000-0002-2071-2262				BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; BROUILLETTE CG, 1987, BIOCHEMISTRY-US, V26, P7431, DOI 10.1021/bi00397a035; BURZ DS, 1990, BIOPHYS CHEM, V37, P31, DOI 10.1016/0301-4622(90)88005-D; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; CONEJEROLARA F, 1991, BIOCHEMISTRY-US, V30, P2067, DOI 10.1021/bi00222a010; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FALLER LD, 1989, BIOCHEMISTRY-US, V28, P6771, DOI 10.1021/bi00442a034; FALLER LD, 1983, BIOCHEMISTRY-US, V22, P4676, DOI 10.1021/bi00289a011; FALLER LD, 1991, BIOCHEMISTRY-US, V30, P3503, DOI 10.1021/bi00228a022; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3174; FREIRE E, 1978, BIOPOLYMERS, V17, P481, DOI 10.1002/bip.1978.360170213; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GRISHAM CM, 1974, J BIOL CHEM, V249, P6738; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HALTIA T, 1995, BBA-BIOENERGETICS, V1228, P1, DOI 10.1016/0005-2728(94)00161-W; HELMICHDEJONG ML, 1987, BIOCHIM BIOPHYS ACTA, V905, P358, DOI 10.1016/0005-2736(87)90464-0; HERLBERT H, 1992, FEBS LETT, V299, P159; JACKSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P9, DOI 10.1016/0005-2736(83)90391-7; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P8829, DOI 10.1021/bi00152a020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEPOCK JR, 1990, BIOCHEMISTRY-US, V29, P681, DOI 10.1021/bi00455a013; LITMAN BJ, 1979, PHOTOCHEM PHOTOBIOL, V29, P671, DOI 10.1111/j.1751-1097.1979.tb07747.x; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MCLENNAN DH, 1985, NATURE, V316, P696; MERINO JM, 1994, FEBS LETT, V343, P155, DOI 10.1016/0014-5793(94)80309-9; MITCHELL RC, 1988, BIOCHIM BIOPHYS ACTA, V941, P31, DOI 10.1016/0005-2736(88)90210-6; MORIN PE, 1990, BIOCHEMISTRY-US, V29, P781, DOI 10.1021/bi00455a028; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; OIKAWA K, 1985, BIOCHEMISTRY-US, V24, P2843, DOI 10.1021/bi00333a005; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; RABBON EC, 1990, ANN REV PHYSL, V52, P321; RABON E, 1982, BIOCHIM BIOPHYS ACTA, V688, P515, DOI 10.1016/0005-2736(82)90363-7; RAMSAY G, 1990, BIOCHEMISTRY-US, V29, P8677, DOI 10.1021/bi00489a024; RAUSSENS V, 1996, IN PRESS J BIOL CHEM, V271; RIGELL CW, 1987, BIOCHEMISTRY-US, V26, P4366, DOI 10.1021/bi00388a027; ROBERT JC, 1990, BIOCHIM BIOPHYS ACTA, V1024, P167, DOI 10.1016/0005-2736(90)90220-I; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; Sachs G, 1980, Ann N Y Acad Sci, V341, P312, DOI 10.1111/j.1749-6632.1980.tb47181.x; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHNYROV VL, 1993, FEBS LETT, V324, P237, DOI 10.1016/0014-5793(93)81400-T; SHRAKE A, 1990, J BIOL CHEM, V265, P5055; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SOUMARMON A, 1980, J BIOL CHEM, V255, P1682; STANTON MG, 1968, ANAL BIOCHEM, V22, P27, DOI 10.1016/0003-2697(68)90255-8; SWARTS HGP, 1991, BIOCHIM BIOPHYS ACTA, V1070, P283, DOI 10.1016/0005-2736(91)90068-J; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11572, DOI 10.1021/bi00161a041	57	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1608	1614		10.1074/jbc.272.3.1608	http://dx.doi.org/10.1074/jbc.272.3.1608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999835	hybrid			2022-12-25	WOS:A1997WD05800033
J	Joba, W; Hoffmann, W				Joba, W; Hoffmann, W			Similarities of integumentary mucin B.1 from Xenopus laevis and prepro-von Willebrand factor at their amino-terminal regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR VWF; REPETITIVE PROTEIN; MOLECULAR-CLONING; INTESTINAL MUCIN; CDNA; SEQUENCE; DOMAINS; RICH; GLYCOPROTEINS; REQUIREMENTS	Frog integumentary mucin B.1 (FIM-B.1) contains various cysteine-rich modules. In the past, a COOH-terminal ''cystine knot'' motif has been found that is similar to von Willebrand factor; this region is generally known to be responsible for dimerization processes. Furthermore, a ''complement control protein'' motif is present as an internal cysteine-rich domain in FIM-B.1. We characterize here the missing 75% toward the NH2 terminus of the FIM B.1 precursor by molecular cloning. Analogous to prepro-von Willebrand factor, four elements with considerable similarity to D-domains are present (i.e. D1-D2-D'-D3). These domains have been described as essential for the multimerization of von Willebrand factor. Thus, the general structure of FIM-B.1 resembles that of the human mucin MUC2 as well as prepro-von Willebrand factor; these three molecules at least seem to share common structural elements allowing similar multimerization mechanisms.	MAX PLANCK INST PSYCHIAT,NEUROCHEM ABT,D-82152 MARTINSRIED,GERMANY; UNIV MAGDEBURG,INST MOL BIOL & MED CHEM,D-39120 MAGDEBURG,GERMANY	Max Planck Society; Otto von Guericke University			Hoffmann, Werner/AAY-9182-2020	Hoffmann, Werner/0000-0003-0031-9540				ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; AZUMA H, 1993, J BIOL CHEM, V268, P2821; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; CARLSTEDT I, 1984, CIBA F SYMP, V109, P157, DOI 10.1002/9780470720905.ch11; DONG ZG, 1994, J BIOL CHEM, V269, P6753; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FORSTNER JF, 1994, PHYSL GASTROINTESTIN, V2, P1255; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; HOFFMANN W, 1988, FEBS LETT, V237, P178, DOI 10.1016/0014-5793(88)80196-0; Hoffmann W, 1995, BIOCHEM SOC T, V23, P805, DOI 10.1042/bst0230805; HOFFMANN W, 1993, COMP BIOCHEM PHYS B, V105, P465, DOI 10.1016/0305-0491(93)90075-G; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Joba W, 1996, GLYCOCONJUGATE J, V13, P735, DOI 10.1007/BF00702337; JOBA W, 1995, THESIS LUDWIG MAXIMI; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MCCOOL DJ, 1994, BIOCHEM J, V302, P111, DOI 10.1042/bj3020111; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; MEYER D, 1993, THROMB HAEMOSTASIS, V70, P99; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; OHMORI H, 1994, J BIOL CHEM, V269, P17833; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; PROBST JC, 1992, J BIOL CHEM, V267, P6310; SILBERBERG A, 1987, BIORHEOLOGY, V24, P605; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; Troxler RF, 1995, BIOCHEM BIOPH RES CO, V217, P1112, DOI 10.1006/bbrc.1995.2884; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; VERDUGO P, 1990, ANNU REV PHYSIOL, V52, P157, DOI 10.1146/annurev.ph.52.030190.001105; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VERWEIJ CL, 1988, J BIOL CHEM, V263, P7921; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; XU GQ, 1992, J BIOL CHEM, V267, P5401	42	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1805	1810		10.1074/jbc.272.3.1805	http://dx.doi.org/10.1074/jbc.272.3.1805			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999864	hybrid			2022-12-25	WOS:A1997WD05800062
J	Jonscher, KR; Yates, JR				Jonscher, KR; Yates, JR			Matrix-assisted laser desorption ionization/quadrupole ion trap mass spectrometry of peptides - Application to the localization of phosphorylation sites on the P protein from Sendai virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P/C MESSENGER-RNA; INFECTED-CELLS; GENE; RESIDUES	The polymerase-associated phosphoprotein (P protein) from Sendai virus, a murine Paramyxovirus, is reported in the literature to be a highly phosphorylated protein. In vitro studies have detected phosphorylation in different regions of the protein, while a single phosphopeptide (identified as the sole phosphorylation) site) was observed using in vivo techniques. In this work, two phosphorylation sites of the P protein from Sendai virus are localized by a direct approach using matrix-assisted laser desorption ionization/quadrupole ion trap mass spectrometry. A computer-aided approach is used to confirm peptide identification.	UNIV WASHINGTON,DEPT MOL BIOTECHNOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								BYRAPPA S, 1995, VIROLOGY, V208, P408, DOI 10.1006/viro.1995.1169; Byrappa S, 1996, VIROLOGY, V216, P228, DOI 10.1006/viro.1996.0052; CURRAN J, 1990, ENZYME, V44, P244, DOI 10.1159/000468762; CURRAN J, 1991, EMBO J, V10, P3079, DOI 10.1002/j.1460-2075.1991.tb07860.x; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; DILLON PJ, 1989, J VIROL, V63, P974, DOI 10.1128/JVI.63.2.974-977.1989; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GIBSON BW, 1990, METHOD ENZYMOL, V193, P480, DOI 10.1016/0076-6879(90)93434-M; HAMAGUCHI M, 1983, VIROLOGY, V128, P105, DOI 10.1016/0042-6822(83)90322-7; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; HSU CH, 1982, VIROLOGY, V120, P225, DOI 10.1016/0042-6822(82)90020-4; JONSCHER K, 1993, RAPID COMMUN MASS SP, V7, P20, DOI 10.1002/rcm.1290070106; JONSCHER KR, 1993, P 41 ASMS C MASS SPE; JONSCHER KR, 1994, P 42 ASMS C MASS SPE, P216; Kaiser Jr R.E., 1990, RAPID COMMUN MASS SP, V4, P30; Kaiser R. E., 1989, RAPID COMMUN MASS SP, V3, P225; KAISER RE, 1991, INT J MASS SPECTROM, V106, P79, DOI 10.1016/0168-1176(91)85013-C; KINGSBURY D W, 1991, P507; LAMB RA, 1976, VIROLOGY, V69, P116, DOI 10.1016/0042-6822(76)90199-9; MATSUOKA Y, 1991, J VIROL, V65, P3406, DOI 10.1128/JVI.65.6.3406-3410.1991; MORAND KL, 1992, RAPID COMMUN MASS SP, V6, P520, DOI 10.1002/rcm.1290060807; QIN J, 1995, J AM CHEM SOC, V117, P5411, DOI 10.1021/ja00124a045; Qin J, 1996, ANAL CHEM, V68, P1784, DOI 10.1021/ac9511612; QIN J, 1995, P 43 ASMS C MASS SPE, P1100; QIN J, 1995, P 43 ASMS C MASS SPE, P989; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SMALLWOOD S, 1994, VIROLOGY, V202, P154, DOI 10.1006/viro.1994.1331; VIDAL S, 1990, J VIROL, V64, P239, DOI 10.1128/JVI.64.1.239-246.1990; VIDAL S, 1988, J VIROL, V62, P2200, DOI 10.1128/JVI.62.6.2200-2203.1988; WATKINS PJF, 1991, BIOCHEM SOC T, V19, P957, DOI 10.1042/bst0190957	30	44	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1735	1741		10.1074/jbc.272.3.1735	http://dx.doi.org/10.1074/jbc.272.3.1735			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999854	hybrid			2022-12-25	WOS:A1997WD05800052
J	Sullivan, J; Feeley, B; Guerra, J; Boxer, LM				Sullivan, J; Feeley, B; Guerra, J; Boxer, LM			Identification of the major positive regulators of c-myb expression in hematopoietic cells of different lineages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL; BINDING-SITES; MESSENGER-RNA; TRANSCRIPTION FACTOR; NEGATIVE REGULATION; PROMOTER ACTIVITY; GENE PROMOTER; ETS PROTEINS; V-MYB; LINES	The c-myb gene is primarily expressed in hematopoietic cells, and it is overexpressed in many leukemias. The regulation of its expression is of critical importance in hematopoietic cells. We identified the major positive regulatory sites in the 5'-flanking sequence of the human c-myb gene, and we found that the positive regulators differed in cells of different lineages. In the Molt-4 T-cell line, two Ets-like binding sites were required for the expression of c-myb. The 5' site played a minor role in the regulation of c-myb expression, and we demonstrated that a protein of 67 kDa bound to this site. Antibodies against Ets proteins showed no cross reactivity with this protein. We showed that Ets-1 bound to the 3'-regulatory site in the c-myb promoter by electrophoretic mobility shift assay and antibody studies. Both of these Ets like binding sites were nonfunctional in the DHL-9 B-cell line and the K562 myeloid cell line. We identified a novel transcription factor of 50.5 kDa that was required for expression of c-myb in these cell lines.	STANFORD UNIV,SCH MED,DIV HEMATOL,DEPT MED,STANFORD,CA 94305; VET AFFAIRS MED CTR,CTR MOL BIOL MED,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [R01CA071832] Funding Source: NIH RePORTER; NCI NIH HHS [CA71832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JACOBS SM, 1994, ONCOGENE, V9, P227; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KU DH, 1993, J BIOL CHEM, V268, P2255; LEUNG S, 1993, ONCOGENE, V8, P989; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; Phan SC, 1996, MOL CELL BIOL, V16, P2387; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; SALA A, 1994, CANCER RES, V54, P1402; Sala A, 1996, CANCER RES, V56, P1991; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON R, 1988, ONCOGENE, V8, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WOTTON D, 1993, LEUKEMIA S, V2, pS55; ZOBEL A, 1991, ONCOGENE, V6, P1397	39	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1943	1949		10.1074/jbc.272.3.1943	http://dx.doi.org/10.1074/jbc.272.3.1943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999884	hybrid			2022-12-25	WOS:A1997WD05800082
J	Borkhardt, A; Repp, R; Haas, OA; Leis, T; Harbott, J; Kreuder, J; Hammermann, J; Henn, T; Lampert, F				Borkhardt, A; Repp, R; Haas, OA; Leis, T; Harbott, J; Kreuder, J; Hammermann, J; Henn, T; Lampert, F			Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23)	ONCOGENE			English	Article						acute leukemias; MLL-rearrangement; AFX-gene; forkhead domain	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; ALL-1 GENE; CHROMOSOMAL TRANSLOCATIONS; T(10-11) TRANSLOCATION; DROSOPHILA-TRITHORAX; B-MYB; PROTEIN; FAMILY; REARRANGEMENTS	We report the cloning and characterization of the entire AFX gene which fuses to MLL in acute leukemias with a t(X;11)(q13;q23). AFX consists of two exons and encodes for a protein of 501 amino acids. We found that normal B- and T-cells contain similar levels of AFX mRNA and that both the MLL/AFX as well as the AFX/MLL fusion transcripts are present in the cell line and the ANLL sample with a t(X;11)(q13;q23), The single intron of the AFX gene consists of 3706 nucleotides, It contains five simple sequence repeats with lengths of at least 12 bps, a chi-like octamer sequence (GCA/TGGA/TGG) and several immunoglobulin heptamer-like sequences (GATAGTG) that are distributed throughout the entire AFX intron sequence. In the KARPAS 45 cell line the breakpoints occur at nucleotides 2913/2914 of the AFX intron and at nucleotides 4900/4901 of the breakpoint cluster region of the MLL gene, The AFX protein belongs to the forkhead protein family. It is highly homologous to the human FKHR protein, the gene of which is disrupted by the t(2;13)(q35;q14), a chromosome rearrangement characteristic of alveolar rhabdomyosarcomas. It is noteworthy that the t(X;11)(q13;q23) in the KARPAS 45 cell line and in one acute nonlymphoblastic leukemia (ANLL) disrupts the forkhead domain of the AFX protein exactly at the same amino acids as does the t(2;13)(q35;q14) in case of the FKHR protein. In addition, the 5'-part of the AFX protein contains a conserved hexapeptide motif (QIYEWM) that is homologous to the functionally important conserved hexapeptide QIYPWM upstream of the homeobox domain in Hox proteins. This motif mediates the co-operative DNA binding of Pbx family members and Hox proteins and, therefore, plays an important role in physiologic and oncogenic processes. In acute leukemias with t(X;11)(q13;q23), this hexapeptide motif is separated from the remaining forkhead domain within the AFX protein. The predicted amino acid sequence of AFX differs significantly from the partial AFX protein sequence published previously (Genes, Chromosomes and Cancer, 1994, 11, 79-84). This discrepancy can be explained by the occurrence of two sequencing errors in the earlier work at nucleotide number 783 and 844 (loss of a cytosine residue or guanosine residue, respectively) that lead to two reading frame shifts.	UNIV GIESSEN,DEPT PEDIAT HEMATOL & ONCOL,D-35392 GIESSEN,GERMANY; ST ANNA CHILDRENS HOSP,CHILDRENS CANC INST,A-1090 VIENNA,AUSTRIA	Justus Liebig University Giessen; Saint Anna Children's Hospital			Haas, Oskar/AAM-5794-2020					BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; BARLETTA C, 1991, CANCER RES, V51, P3821; BERNARD OA, 1994, ONCOGENE, V9, P1039; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BORKHARDT A, 1994, LEUKEMIA, V8, P549; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHERVINSKY DS, 1995, GENE CHROMOSOME CANC, V14, P76, DOI 10.1002/gcc.2870140114; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; Dreyling M. H., 1995, Blood, V86, p430A; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; HROMAS R, 1993, BLOOD, V81, P2854; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARPAS A, 1977, LEUKEMIA RES, V1, P35, DOI 10.1016/0145-2126(77)90063-7; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; NACHEVA E, 1982, HEREDITAS, V97, P273, DOI 10.1111/j.1601-5223.1982.tb00771.x; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; RIENITZ A, 1989, EMBO J, V8, P2879, DOI 10.1002/j.1460-2075.1989.tb08436.x; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; Sambrock J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	46	198	202	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					195	202		10.1038/sj.onc.1200814	http://dx.doi.org/10.1038/sj.onc.1200814			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010221				2022-12-25	WOS:A1997WC81800007
J	Russo, S; Tato, F; Grossi, M				Russo, S; Tato, F; Grossi, M			Transcriptional down-regulation of myogenin expression is associated with v-ras-induced block of differentiation in unestablished quail muscle cells	ONCOGENE			English	Article						v-ras; oncogenes; transformation; myogenesis; myogenin	MYOBLAST DIFFERENTIATION; POSITIVE AUTOREGULATION; GENE-EXPRESSION; UP-REGULATION; DNA-BINDING; ACTIN GENE; MYOD; TRANSFORMATION; MYC; ONCOGENES	Unestablished quail myoblasts were infected with a retroviral vector encoding the oncogenic form of II-Pas in order to investigate the mechanism by which this oncoprotein interferes with terminal differentiation. Primary quail myogenic cells exhibit the simultaneous expression of the muscle regulatory genes myf-5, MyoD and myogenin in proliferative conditions. v-ras-transformed myoblasts displayed an altered growth control and lost the competence for terminal differentiation. When expression of myogenic regulatory genes was analysed, it was immediately apparent that the difference between normal and v-ras-transformed cells was limited to a severely decreased level of myogenin expression. Forced expression of exogenous myogenin in v-ras-transformed quail myoblasts led to a striking recovery of the competence for terminal differentiation. The present data show that: (i) repression of myogenin expression is linked to the differentiation defective phenotype of quail myoblasts transformed by v-ras as well as other retroviral oncogenes; (ii) correction of the differentiation-defective phenotype of v-uas-transformed myoblasts by exogenous myogenin entailed reactivation of endogenous myogenin and of the E-box-dependent transactivating function. These results strongly indicate that myogenin expression plays a central role in regulating the transition into the terminally differentiated state and that its transcriptional down-regulation represents a nodal step in v-ras-induced block of differentiation.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,ROME,ITALY	Sapienza University Rome			Grossi, Milena/D-2955-2009					ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGNAMI M, 1982, EXP CELL RES, V137, P239, DOI 10.1016/0014-4827(82)90024-6; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; CARUSO M, 1993, ONCOGENE, V8, P267; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; DECHESNE CA, 1994, MOL CELL BIOL, V14, P5474, DOI 10.1128/MCB.14.8.5474; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; ENRIETTO PJ, 1994, SEMIN CANCER BIOL, V5, P91; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GROSSI M, 1991, ONCOGENE, V6, P1767; GROSSI M, 1989, PATHOLOGY GENE EXPRE, P233; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KNIGHT J, 1988, ONCOGENE, V2, P317; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LYONS GE, 1992, SEM DEV BIOL, V3, P243; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; OKAZAKI K, 1966, P NATL ACAD SCI USA, V56, P1484, DOI 10.1073/pnas.56.5.1484; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; TEDESCO D, 1995, J VIROL, V69, P6947, DOI 10.1128/JVI.69.11.6947-6957.1995; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YOON HY, 1994, ONCOGENE, V9, P801; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	56	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					63	73		10.1038/sj.onc.1200805	http://dx.doi.org/10.1038/sj.onc.1200805			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010233				2022-12-25	WOS:A1997WB76000006
J	Cortez, D; Stoica, G; Pierce, JH; Pendergast, AM				Cortez, D; Stoica, G; Pierce, JH; Pendergast, AM			The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway	ONCOGENE			English	Article						BCR-ABL; apoptosis; Ras; tyrosine phosphorylation	HEMATOPOIETIC-CELLS; PC12 CELLS; TRANSFORMATION; DEATH; ONCOGENE; PROLIFERATION; PROTEIN	BCR-ABL is a deregulated tyrosine kinase that is expressed in Philadelphia chromosome (Ph(1)) positive human leukemias, When expressed in hematopoietic cells, BCR-ABL causes cytokine independent proliferation, induces tumorigenic growth and prevents apoptosis in response to cytokine deprivation or DNA damage, One mechanism by which BCR-ABL signals in cells is by activating the small guanine nucleotide binding protein Ras, BCR-ABL-transformed cells have constitutively high levels of active, GTP-bound Ras, Here we use 32D cells that inducibly express a dominant negative Ras protein to define the Ras requirements in BCR-ABL-transformed cells, Dominant negative Ras inhibits BCR-ABL-mediated Ras activation, and induces cell death by an apoptotic mechanism, Therefore, BCR-ABL inhibits apoptosis through activation of a Ras-dependent signaling pathway.	DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM,WASHINGTON,DC 20007; NIH,CELL & MOL BIOL LAB,BETHESDA,MD 20892	Duke University; Duke University; Georgetown University; National Institutes of Health (NIH) - USA				Pendergast, Ann Marie/0000-0002-1250-6880	NATIONAL CANCER INSTITUTE [R01CA061033] Funding Source: NIH RePORTER; NCI NIH HHS [CA61033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; MANDANAS RA, 1993, BLOOD, V82, P1838; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	23	131	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2589	2594						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000132				2022-12-25	WOS:A1996VZ65400008
